<SEC-DOCUMENT>0000950123-24-007062.txt : 20241002
<SEC-HEADER>0000950123-24-007062.hdr.sgml : 20241002
<ACCEPTANCE-DATETIME>20240802171149
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-24-007062
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		23
FILED AS OF DATE:		20240802
<PUBLIC-REL-DATE>20241002
DATE AS OF CHANGE:		20240805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Septerna, Inc.
		CENTRAL INDEX KEY:			0001984086
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				843891440
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-07364
		FILM NUMBER:		241172122

	BUSINESS ADDRESS:	
		STREET 1:		250 EAST GRAND AVENUE, SUITE 65
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-338-3533

	MAIL ADDRESS:	
		STREET 1:		250 EAST GRAND AVENUE, SUITE 65
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on August&nbsp;2,
2024. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information
herein remains confidential. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333&#150;&#8195;&#8195;&#8195; </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Septerna, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">84-3891440</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of<BR>incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Septerna, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>250 East
Grand Avenue </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>South San Francisco, California 94080 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">338-3533</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jeffrey Finer, M.D., Ph.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Septerna, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>250 East
Grand Avenue </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>South San Francisco, California 94080 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">338-3533</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Mitchell S. Bloom</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Deepa M. Rich</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Adam V.
Johnson</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Goodwin Procter LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>601 Marshall Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Redwood
City, California 94063 <FONT STYLE="white-space:nowrap">(650)&nbsp;752-3100</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jeffrey Finer, M.D., Ph.D.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Septerna, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>250 East
Grand Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>South San Francisco, California 94080</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">338-3533</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Denny Won</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Charles S. Kim</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kristin
VanderPas</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dave Peinsipp</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3 Embarcadero
Center, 20th Floor</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Francisco, California 94111</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">693-2000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>Approximate date of commencement of proposed sale to the public</B>: As soon as practicable after the effective date of this registration
statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, as amended, check the following box.&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&#8194;&#9744; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>The registrant
hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant files a further amendment which specifically states that this registration statement shall thereafter become
effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a),
may determine. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the applicable provisions of the Fixing America&#146;s Surface Transportation Act, we are omitting our unaudited financial
statements as of and for the three months ended March&nbsp;31, 2022 and 2023 because they relate to historical periods that we believe will not be required to be included in the registration statement at the time of the first public filing of the
registration statement. We intend to amend this registration statement to include all financial information required by Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act of 1933, as amended (Securities Act), at the date
of such amendment before distributing a preliminary prospectus to investors. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="justify"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus is not complete and may
be changed. We may not sell these securities until the Securities and Exchange Commission declares our registration statement effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these
securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED &#8195;&#8195;&#8195;&#8195;, 2024 </B></FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195;Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g00w02.jpg" ALT="LOGO" STYLE="width:1.93125in;height:0.453125in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This is an
initial public offering of shares of common stock of Septerna, Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are offering &#8195;&#8195;&#8195;&#8195; shares of our common
stock. Prior to this offering, there has been no public market for our common stock. It is currently estimated that the initial public offering price per share will be between $&#8195;&#8195;&#8195;&#8195; and $&#8195;&#8195;&#8195;&#8195;. We
intend to apply to list our common stock on the Nasdaq Global Market under the symbol &#147;SEPN,&#148; and this offering is contingent upon obtaining approval of such listing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; as defined under U.S. federal securities laws and,
as such, we have elected to comply with certain reduced public company reporting requirements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Investing in
our common stock involves a high degree of risk. See the section titled &#147;<A HREF="#tx762905_4">Risk Factors</A>&#148; beginning on page 17. </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">See the section titled &#147;Underwriting&#148; for additional disclosure regarding the underwriting
discounts and commissions and estimated offering expenses. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted the underwriters an option for a period of
30&nbsp;days to purchase up to an additional &#8195;&#8195;&#8195;&#8195; shares of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters expect to deliver
the shares of common stock to purchasers on &#8195; &#8195;&#8195;&#8195;&#8195;, 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B>TD Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B>Cantor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B>Wells&nbsp;Fargo&nbsp;Securities</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus is &#8195;&#8195;&#8195;&#8195;, 2024. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_5">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_7">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_8">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_10">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_13">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_14">Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_15">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_16">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_17">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_18">Shares Eligible For Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_19">Material U.S. Federal Income Tax Considerations For <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_20">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_21">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_22">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_23">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_24">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have not, and the underwriters have not, authorized anyone to provide any information or to make any representation other
than those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can
provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of our common stock offered hereby, but only under circumstances and in jurisdictions where it is
lawful to do so. The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our
common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this
offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform
themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Market data and certain other statistical information used throughout this prospectus are based on independent industry
publications, governmental publications, reports by market research firms, including, but not limited to, Clarivate<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, or other independent sources that we believe to be reliable sources.
Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.
In some cases, we do not expressly refer to the sources from which this data is derived. We are responsible for all of the disclosure contained in this prospectus, and we believe that these sources are reliable. While we are not aware of any
misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on
various factors, including those discussed under the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus. Some data are also based on our good faith estimates. The content of, or accessibility through, the below sources, except
to the extent specifically set forth in this prospectus, does not constitute a portion of this prospectus and is not incorporated herein and any websites are an inactive textual reference only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The source of certain statistical data, estimates, and forecasts contained in this prospectus are the following independent
industry publications or reports: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pokhrel B, Bhusal K.&nbsp;Graves Disease. Treasure Island (FL): StatPearls Publishing; January&nbsp;2024.
Creative Commons Attribution-Non Commercial-No Derivatives 4.0 International License <FONT STYLE="white-space:nowrap">(CC&nbsp;BY-NC-ND&nbsp;4.0)];</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Guillen-Aguinaga, S., et al. Updosing nonsedating antihistamines in patients with chronic spontaneous
urticaria: a systematic review and meta-analysis. British Journal of Dermatology 175.6&nbsp;(2016). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This summary highlights information contained in greater detail elsewhere in this prospectus and does not contain all of
the information that you should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including the sections titled &#147;Risk Factors,&#148; &#147;Special Note Regarding
Forward-Looking Statements,&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and our financial statements and the related notes thereto included elsewhere in this prospectus. Except
where the context otherwise requires or where otherwise indicated, the terms &#147;Septerna,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our company,&#148; &#147;the company,&#148; and &#147;our business&#148; refer to Septerna,
Inc. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule
drug discovery powered by our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development
of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every
organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of all U.S.
Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125&nbsp;billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75%
of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have
been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug
discovery, particularly the development of novel oral small molecules, such as agonists for peptide GPCRs and allosteric modulators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> replicates the natural
structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within
ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen
for, and optimize potential product candidates. Leveraging our platform, we have transformed GPCR oral small molecule drug discovery to an industrialized and iterative structure-based drug design approach to expand the landscape of druggable GPCR
targets with novel oral small molecule medicines for patients. Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is designed to enable us to target certain GPCRs for the first time, uncover novel binding pockets for
validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are advancing a deep portfolio of oral small molecule GPCR-targeted
programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline is summarized in the figure below. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g18s00.jpg" ALT="LOGO" STYLE="width:6.33167in;height:4.40643in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT> is, to our
knowledge, the only clinical-stage, oral small molecule agonist targeting the Parathyroid Hormone 1 Receptor (PTH1R) for the treatment of hypoparathyroidism. We are initiating a Phase 1 clinical trial to assess preliminary safety, tolerability,
pharmacokinetics (PK) and pharmacodynamics (PD) of <FONT STYLE="white-space:nowrap">SEP-786,</FONT> and expect to report initial data from this trial in &#8195;&#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe our team, scientific and technical advisors, and our proprietary Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> uniquely positions us to become the leading GPCR-focused biotechnology company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>GPCRs as Therapeutic Targets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GPCRs are the most targeted drug class due to their significant role in human diseases and their pharmacological tractability.
GPCRs are characterized by their seven transmembrane domains, and function in ternary complexes that form with extracellular ligands and intracellular transducer proteins which modulate cellular signaling pathways in response to ligand binding.
Different GPCRs play vital roles in a variety of physiologic processes of every major organ system, including the central nervous system (CNS), cardiovascular, respiratory, metabolic and urogenital systems, making them key therapeutic targets.
Today, many GPCR-targeted drugs have established market-leading positions across a variety of therapeutic areas, including Ozempic and Wegovy (each marketed by Novo Nordisk) for the treatment of type 2 diabetes (T2D) and obesity, respectively, and
Nurtec ODT (marketed by Pfizer) for the acute treatment of migraine. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Historically, GPCR oral small molecule drug discovery has been highly
concentrated on a small number of targets &#150; despite GPCRs constituting the largest human membrane protein family &#150; as GPCRs are difficult to isolate in their native functional form outside of a cellular context, which has limited the
utilization of modern drug discovery tools and technologies. As a result, about 75% of GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Aims to Unlock the Full Therapeutic
Potential of GPCRs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the past decade, drug discovery across various target classes has been revolutionized by a
variety of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> tools and technologies. These innovations include structure-based drug design, computational docking,
and <FONT STYLE="white-space:nowrap">DNA-encoded</FONT> libraries (DELs). However, the utilization of these technologies has been limited for discovering oral small molecules targeting GPCRs due to the inability to isolate functional native GPCR
proteins outside of a cellular context. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With our proprietary Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>, we can purify GPCRs outside of cells and reconstitute them into fully functional ternary complexes with transducer proteins (e.g., G proteins, beta-arrestins) and ligands (endogenous or synthetic),
all housed within a well-defined lipid bilayer environment (Figure&nbsp;1). These Native Complexes are full-length, properly folded GPCRs that retain their natural structure, function, and dynamics. We then apply state-of-the-art discovery tools and
technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we have transformed GPCR drug discovery, potentially expanding the landscape of
druggable GPCR targets with novel oral small molecule medicines for patients. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g98o86.jpg" ALT="LOGO" STYLE="width:3.70848in;height:2.56168in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure&nbsp;1. </B>Native Complexes consist of full-length, properly folded GPCR
proteins reconstituted with a ligand and/or a transducer protein such as a G protein in a lipid bilayer that mimics the cell membrane. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is powered by a suite of tools and
technologies that we have optimized and integrated into a proprietary and industrialized workflow, and together form an efficient and iterative discovery process for identification and optimization of novel small molecule product candidates
targeting high-value GPCRs, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Native Complex biochemistry and structural biology:</I></B> Our Native Complexes reconstitute native
GPCR function in a purified biochemical format, which enables efficient high-resolution, three-dimensional </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
structure determination using cryogenic electron microscopy (cryo-EM). This can reveal receptor binding pockets that we can target with a range of pharmacologies (agonists, antagonists, and
allosteric modulators) as well as novel insights into mechanisms for GPCR modulation.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Native Complex-driven hit identification and optimization:</I></B> We virtually screen our GPCR
structures against ultra-large-scale computational databases containing billions of candidate molecules to identify the most promising small molecule compounds that bind in pockets on the GPCR structure. We use technologies, including DELs, to
screen billions of candidate molecules simultaneously, and we have developed proprietary technologies to discover and optimize compounds with a variety of modes of action. In addition, we use our proprietary Native Complex biochemical screens in our
hit identification and optimization processes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advanced cellular and in vivo pharmacology models: </I></B>We efficiently evaluate hits and lead
compounds through the integration of advanced cellular and <I>in vivo</I> pharmacology models. Prioritized compounds with desired pharmacologies are then either advanced as potential drug candidates or fed back into the process for additional Native
Complex-driven compound optimization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our oral small molecule drug discovery process, powered by our
proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, is depicted in the figure below. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g15a01.jpg" ALT="LOGO" STYLE="width:5.83333in;height:3.24245in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe we are at the forefront of industrial-scale GPCR drug discovery and development.
Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies to achieve
desired therapeutic effects. Our platform has led to the discovery and development of a pipeline of novel, highly potent and selective oral small molecules, and for our most advanced programs, optimized them into clinical development candidates.
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline and Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our wholly-owned pipeline, summarized in the figure below, is focused initially on three therapeutic areas: endocrinology,
immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women&#146;s health, cardiovascular, and respiratory disease. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g59y26.jpg" ALT="LOGO" STYLE="width:6.25in;height:2.80515in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">SEP-786</FONT> &#150; Oral Small Molecule PTH1R
Agonist for Hypoparathyroidism </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hypoparathyroidism is a rare endocrine disease characterized by insufficient levels
of parathyroid hormone (PTH) that affects approximately 70,000 patients in the United States and approximately 140,000 patients in Europe. Patients with hypoparathyroidism are at risk of both short-term and long-term complications, including muscle
cramps, fatigue, cognitive dysfunction, and life-threatening complications, such as cardiac arrhythmias, seizures, and renal failure. The goal of treatment is to relieve symptoms and restore calcium and phosphate levels to normal. Current standard
of care consists of high-dose calcium supplements and activated vitamin D (calcitriol); however, these therapies do not replace other functions of PTH to restore physiological mineral homeostasis or address all of the symptoms experienced by
patients. Hormone replacement with injectable PTH peptides, either marketed or in clinical development, may improve blood chemistry profiles of patients via PTH1R activation but will require life-long daily injections. We believe there is a
substantial opportunity for an oral small molecule therapy that offers convenience, improved compliance, and potentially superior efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT> is, to our knowledge, the only clinical-stage,
oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism. PTH1R is a historically <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-drug</FONT></FONT> small molecule target, yet we effectively
leveraged our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to discover and optimize <FONT STYLE="white-space:nowrap">SEP-786</FONT> with desired drug-like properties. In preclinical studies, <FONT
STYLE="white-space:nowrap">SEP-786</FONT> has been observed to be generally well-tolerated and has demonstrated potent and selective activation of PTH1R in human, dog, and rat receptor <I>in vitro</I> models. In a preclinical animal model of
hypoparathyroidism, <FONT STYLE="white-space:nowrap">SEP-786</FONT> controlled serum calcium levels within the normal range over a <FONT STYLE="white-space:nowrap">28-day</FONT> dosing period. We have successfully completed Investigational New Drug
(IND)-enabling studies and are initiating a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of <FONT STYLE="white-space:nowrap">SEP-786.</FONT> We expect to report initial data from this trial
in&#8195;&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I></I><B><I><FONT STYLE="white-space:nowrap">SEP-631</FONT> &#150; Oral Small Molecule MRGPRX2 NAM for
CSU and Other Mast Cell Diseases</I></B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chronic spontaneous urticaria (CSU) is a systemic inflammatory skin
disease characterized by the spontaneous and persistent recurrence of itchy, painful hives, known as wheals, on the skin and angioedema, or </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
swelling, that affects approximately 1.5 million patients in the United States. While there is no known trigger, the degranulation of mast cells and release of histamine and other inflammatory
mediators lead to these debilitating symptoms. Patients are treated initially with antihistamines and <FONT STYLE="white-space:nowrap">non-responders</FONT> may be treated with Xolair (omalizumab), an injectable
<FONT STYLE="white-space:nowrap">anti-IgE</FONT> monoclonal antibody. The targeting and blocking of IgE-mediated inflammation can effectively address symptoms; however, only an estimated 36% of these antihistamine-refractory patients respond to
anti-IgE therapy. <FONT STYLE="white-space:nowrap">Mas-related</FONT> <FONT STYLE="white-space:nowrap">G-protein</FONT> coupled receptor member X2 (MRGPRX2) plays an important role in mast cell activation and degranulation. We believe an oral
therapy that inhibits MRGPRX2 could provide a differentiated treatment option for patients with CSU given the selective inhibition of mast cells and potential for combination therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SEP-631</FONT> is a selective, oral small molecule MRGPRX2 negative allosteric modulator
(NAM) that we are developing initially for the treatment of CSU. In preclinical studies, <FONT STYLE="white-space:nowrap">SEP-631</FONT> demonstrated potent and long-lasting inhibition of MRGPRX2 and blocked mediator-induced angioedema in mice
engineered to express the human MRGPRX2 receptor. We have initiated <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies of <FONT STYLE="white-space:nowrap">SEP-631</FONT> and upon completion, we anticipate submitting for regulatory
clearance to initiate a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to CSU, we believe there is a significant opportunity to develop <FONT
STYLE="white-space:nowrap">SEP-631</FONT> for the treatment of other mast cell diseases. MRGPRX2 is highly and uniquely expressed on mast cells that drive multiple prevalent diseases, including allergic asthma, atopic dermatitis, interstitial
cystitis, migraine, and prurigo nodularis. We believe <FONT STYLE="white-space:nowrap">SEP-631</FONT> could offer a novel oral treatment option for these patient populations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I></I><B><I>TSHR Program &#150; Oral Small Molecule TSHR NAM for Graves&#146; Disease and TED</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Graves&#146; disease is one of the most prevalent autoimmune conditions affecting over 2 million patients in the United States
and is the leading cause of hyperthyroidism, resulting in symptoms including anxiety, irritability, tremor, and fatigue. Treatments have remained largely unchanged over the past 70 years, and include anti-thyroid medications, radioactive iodine
therapy to ablate thyroid gland function, and thyroidectomy surgery. These treatment options may initially address the underlying symptoms, but they are not disease-modifying and do not stop disease progression to thyroid eye disease (TED) for
approximately 50% of Graves&#146; disease patients. TED is a serious, progressive and vision-threatening autoimmune condition that can lead to eye bulging, swelling, pain and blurred or double vision. Current treatments for TED, such as TEPEZZA
(teprotumumab-trbw), an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IGF-1R</FONT></FONT> human monoclonal antibody, are designed to help manage symptoms. Despite reaching global sales of $2.0&nbsp;billion in 2022, TEPEZZA
requires several intravenous (IV)&nbsp;infusions over several months and has risks of serious side effects, including hearing loss and metabolic issues, such as increased blood glucose or hyperglycemia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These autoimmune conditions are caused by autoantibodies that bind to and activate the thyroid stimulating hormone receptor
(TSHR) on thyroid cells in the thyroid gland (leading to Graves&#146; disease) and other cells including fibroblasts located behind the eyes (leading to TED). We believe an oral small molecule TSHR NAM could offer a novel disease-modifying treatment
approach that directly addresses the pathobiology of both diseases by blocking TSHR overactivation caused by patients&#146; autoantibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In our preclinical studies, we have demonstrated that a TSHR NAM can reverse hyperthyroidism and proptosis in a novel mouse
model of Graves&#146; disease and inhibits multiple Graves&#146; disease patient TSHR activating autoantibodies in cell-based assays using primary human cells. We are advancing several lead compounds towards selection of a development candidate for <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incretin Programs : Oral Small Molecule Single- and Multi-Incretin Receptor Agonists for
Metabolic Disorders Including Obesity and T2D </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obesity and diabetes are two of the most prevalent diseases in the
world, affecting a combined total of more than 800&nbsp;million people, and are associated with severe health complications, including cardiovascular disease </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and kidney failure, as well as an increased risk of death. Weight reduction is seen as an important treatment goal for patients with either condition. In recent years, several injectable peptide
agonists targeting select metabolic hormone receptors, or incretin receptors, have been approved for the treatment of T2D and obesity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Three incretins play significant roles in glucose metabolism and homeostasis: glucagon-like
<FONT STYLE="white-space:nowrap">peptide-1</FONT> <FONT STYLE="white-space:nowrap">(GLP-1),</FONT> gastric inhibitory polypeptide (GIP), and glucagon. Third-party clinical data with incretin-targeted therapeutics have demonstrated substantial and
sustained reductions in body weight, as well as the ability to lower blood glucose and improve glycated hemoglobin (HbA1c). Global sales in 2023 for Ozempic and Wegovy (semaglutide), and Mounjaro and Zepbound (tirzepatide) were $18.4&nbsp;billion
and $5.3&nbsp;billion, respectively. Despite these advancements in the treatment of obesity and T2D, a number of key limitations remain for the incretin therapeutic class, including tolerability, prolonged titration schemes, injection
administration, and supply challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on unique chemical and structural insights obtained with our Native Complex
Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, we believe we have an opportunity to discover and develop novel, next-generation, oral small molecules as selective single- or multi-acting
<FONT STYLE="white-space:nowrap">GLP-1,</FONT> GIP, glucagon receptor agonists. We are advancing several lead compounds towards selection of one or more development candidates for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Team and Investors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have built a strong values-driven organization, and we are advancing cutting-edge science and rigorously developing a broad
and deep portfolio of GPCR-targeted programs for patients. We were founded by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Robert Lefkowitz, M.D., </B>James B. Duke Professor of Medicine and Professor of Biochemistry and Chemistry
at Duke University and an Investigator of the Howard Hughes Medical Institute. Dr.&nbsp;Lefkowitz is globally recognized for his groundbreaking discoveries that reveal the inner workings of GPCRs, for which he was awarded the 2012 Nobel Prize in
Chemistry and elections to both the National Academy of Sciences and the National Academy of Medicine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Arthur Christopoulos, Ph.D., </B>Professor of Analytical Pharmacology, Dean of the Faculty of
Pharmacy&nbsp;&amp; Pharmaceutical Sciences, and Director of the Neuromedicines Discovery Centre at Monash University in Australia. Dr.&nbsp;Christopoulos is a world-leading expert in GPCR molecular pharmacology and responsible for several seminal
discoveries of allosteric modulation of GPCRs, for which he has been elected to both the Australian Academy of Science and the Australian Academy of Health and Medical Sciences. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Patrick Sexton, Ph.D., D.Sc., </B>Professor, Drug Discovery Biology at Monash University and Director of
the ARC Centre for Cryo-electron Microscopy of Membrane Proteins. Dr.&nbsp;Sexton is an international leader in GPCR biochemistry, pharmacology, and structural biology and his team is at the forefront of using
<FONT STYLE="white-space:nowrap">cryo-EM</FONT> to elucidate the structure and dynamics of GPCRs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Jeffrey Finer, M.D., Ph.D.</B>, our President and Chief Executive Officer. Dr.&nbsp;Finer has more than 35
years of research, clinical and business experience. He has focused his career on breakthrough innovations that have included moving several <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> drugs into
clinical trials, developing novel technology platforms that integrate science and engineering, and new company creation. As a Venture Partner at Third Rock Ventures, LLC (Third Rock Ventures), Dr.&nbsp;Finer was involved in the founding and
launching of multiple biotech companies, including Maze Therapeutics, Inc. and Ambys Medicines, Inc., and served as interim Chief Technology Officer at both. Previously, Dr.&nbsp;Finer spent several years in research and development leadership
positions, including Vice President, Research Technology at Theravance Biopharma, Inc. (Theravance Biopharma), Vice President, Discovery at Five Prime Therapeutics, Inc., and Director, Drug Discovery at Cytokinetics, Incorporated.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we have established a team of experienced biotechnology leaders
with deep expertise in company building, drug discovery and clinical advancement of novel medicines. Our senior leadership team includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Elizabeth (Liz) Bhatt, M.S., M.B.A.</B>, our Chief Operating Officer, who has more than 30&nbsp;years of
strategy, deal-making and company-building experience across a range of biotech and pharmaceutical companies, including Applied Molecular Transport Inc., Achaogen, Inc., Gilead Sciences, Inc., Eli Lilly and Company, and Maxygen, Inc.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Alan Ezekowitz, M.D., D.Phil.</B>, our interim Chief Medical Officer, is an Advisory Partner at Third Rock
Ventures and a leader in the field of developmental immunology with more than 150&nbsp;publications. Dr.&nbsp;Ezekowitz served at the Harvard Medical School as the Charles Wilder Professor of Pediatrics, as the Head of Laboratory for Development
Immunology and Principal of the Cancer Center and later as Chief of Pediatric Services at the Massachusetts General Hospital for Children, and as a director on the Partners Healthcare System board. Previously, Dr.&nbsp;Ezekowitz was the co-founder,
President and Chief Executive Officer of Abide Therapeutics, Inc., which he oversaw through its acquisition by H.&nbsp;Lundbeck A/S, and during his tenure at Merck Research Laboratories, he was responsible for the bone, respiratory, immunology,
inflammation, dermatology, and endocrine franchises. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Samira Shaikhly</B>, our Chief People Officer, is a human resources leader with more than 25&nbsp;years of
experience enabling organizational effectiveness in high-growth companies across multiple human resource disciplines including a 15-year tenure at Gilead Sciences, Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Uwe Klein, Ph.D.</B>, our Senior Vice President, Biological Sciences, has deep expertise in GPCR biology
and over 20&nbsp;years of experience in small molecule drug discovery across a range of biotech and pharmaceutical companies, including MyoKardia, Inc. (acquired by Bristol-Myers Squibb (BMS)). Earlier in his career, Dr.&nbsp;Klein held positions as
Vice President, Biology at Numerate, Inc. (acquired by Valo Health, Inc.) and as Senior Director, Molecular &amp; Cellular Biology at Theravance Biopharma, where he led a team of biologists and two cross-functional project teams in the discovery of
numerous development candidates and several clinical compounds across different therapeutic areas and target classes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Daniel Long, D.Phil.</B>, our Senior Vice President, Drug Discovery, is a highly experienced drug hunter
with a track record of leading high-performing teams that discover drug candidates and advance them through preclinical development to IND and into clinical trials. Dr.&nbsp;Long spent more 20&nbsp;years at Theravance Biopharma, where he held
numerous scientist positions, including as Vice President, Head of Medical Chemistry, Biology and Pharmacology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors is composed of accomplished leaders in the life sciences industry, including our board chairman,
Jeffrey Tong, Ph.D., a Partner at Third Rock Ventures; Abraham Bassan, M.S., a Principal at Samsara BioCapital L.P. (Samsara); Bernard Coulie, M.D., Ph.D., M.B.A., President and Chief Executive Officer of Pliant Therapeutics, Inc.;
Dr.&nbsp;Ezekowitz, an Advisory Partner at Third Rock Ventures; Shalini Sharp, M.B.A., a member of the boards of directors of Neurocrine Biosciences, Inc. and Organon&nbsp;&amp; Co. and former Chief Financial Officer and Executive Vice President at
Ultragenyx Pharmaceuticals Inc.; Jake Simson, Ph.D., a Partner at RA Capital Management, L.P. (RA Capital), and Dr.&nbsp;Finer, our Chief Executive Officer. Further, we have assembled a cross-functional scientific and drug discovery advisory board,
comprised of seasoned drug hunters and leading academic scientists at the forefront of GPCR biology and pharmacology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have raised net proceeds of approximately $224.2&nbsp;million in equity capital from a syndicate of
premier life sciences investors. Potential investors should not consider investments made by our existing investors as a factor when making a decision to purchase shares in this offering since our existing
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
investors likely have different risk tolerances and paid significantly less per share than the price at which the shares are being offered in this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our goal is to develop life-changing GPCR-targeted medicines for patients with significant unmet medical needs. We plan to
achieve this goal by pursuing the following strategies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efficiently advance our portfolio of GPCR-targeted programs, led by SEP-786; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to expand our differentiated GPCR-targeted pipeline focused on indications with significant unmet
needs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximize the potential of our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>
through continued innovation and investment; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Evaluate and selectively execute value-creating strategic partnerships. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Summary of Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investment in our common stock involves substantial risks and uncertainties, and our ability to execute on our business
strategy is subject to a number of risks, which are discussed more fully in the section titled &#147;Risk Factors.&#148; You should carefully consider these risks before making an investment in our common stock. If any of these risks or
uncertainties actually occur, our business, financial condition, or results of operations could be materially and adversely affected. In such case, the trading price of our common stock would likely decline, and you could lose all or part of your
investment. These risks include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history and have incurred significant operating losses since our inception and expect
to incur significant losses for the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will require substantial additional funding in order to finance our
operations. If we are unable to raise additional capital when needed on acceptable terms, or at all, we may be forced to delay, reduce, or terminate certain of our research and product development programs, future commercialization efforts or other
operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are early in our development efforts. We have only recently initiated early clinical studies, and as a
result it will be years before we commercialize a product candidate, if ever. If we are unable to identify and advance product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them,
or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preclinical and clinical drug development is a lengthy and expensive process, with uncertain timelines and
outcomes. If preclinical studies or clinical trials of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our therapeutic candidates or any of our
future therapeutic candidates on a timely basis or at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may encounter substantial delays in the commencement, enrollment or completion of our planned clinical
trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing any product candidates we determine to develop on a timely basis, if at all.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may
be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval,
revocation of marketing </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
authorizations or limitations on the use of our product candidates, any of which would limit the commercial potential of such product candidate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our product candidates are subject to extensive regulation and compliance obligations, which is costly and
time-consuming and which may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could
be made more difficult or rendered impossible by multiple factors outside our control, which could adversely affect our business, operating results and prospects. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is based on
novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory
approval, and we may not be successful in our efforts to expand our development portfolio of product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We currently have no marketing and sales organization and have no experience as a company in commercializing
products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketing, sales or distribution capabilities or enter into agreements with third parties to market and sell our products, we may not be
able to generate product revenue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if any of our current or future product candidates receive marketing approval, such product candidate may
fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face substantial competition, which may result in others discovering, developing or commercializing
products before or more successfully than us. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third-party manufacturers, clinical research organizations (CROs), contract manufacturing
organizations (CMOs), and suppliers to supply, develop and test components of our product candidates. The loss of our third-party manufacturers, CROs, CMOs, or suppliers, their failure to comply with applicable regulatory requirements or to supply
sufficient quantities at acceptable quality levels or prices, or at all, or changes in methods of product candidate manufacturing, development or formulation would materially and adversely affect our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The risks summarized above or described in full elsewhere in this prospectus are not the only risks that we face. Additional
risks and uncertainties not presently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations, and future, growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Corporate and Other Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our
name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California 94080, and our telephone number is (650) <FONT STYLE="white-space:nowrap">338-3533.</FONT> Our website address
is <I>www.septerna.com</I>. The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We have included our website address in this prospectus solely
as an inactive textual reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus includes our trademarks and trade names which are protected under
applicable intellectual property laws and are our property. This prospectus also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
names and service marks referred to in this prospectus may appear without
the&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>,&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>&nbsp;or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the
fullest extent permitted under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#146; trademarks, trade names or service marks
to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended
(JOBS Act). As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to present only two years of audited financial statements, in addition to any required
unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to hold nonbinding advisory votes on executive compensation or to obtain stockholder
approval of any golden parachute arrangements not previously approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley Act); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding
the communication of critical audit matters in the auditor&#146;s report on the financial statements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may take advantage of these exemptions for up to five years or such earlier time that we are no longer an emerging growth
company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.235&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal
year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we
are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission (SEC). We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this
prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock. Additionally, the JOBS Act provides that an emerging growth company can take advantage
of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that
are not emerging growth companies. As a result of this election, our financial statements may not be comparable to those of other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We may
choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a &#147;smaller reporting company&#148; as defined in the Securities Exchange Act of 1934, as amended (Exchange
Act), meaning that the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual
revenue was </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
less than $100.0&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our
shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue was less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our
shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain
disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_2"></A>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have granted the underwriters an option for a period of 30 days to purchase up to &#8195;&#8195;&#8195;&#8195; additional shares of
our common stock from us at the public offering price, less underwriting discounts and commissions on the same terms as set forth in this prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares (or&#8195;&#8195;&#8195;&#8195;shares if the underwriters exercise their option to purchase
additional shares in full). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We estimate that the net proceeds to us from this offering will be approximately $&#8195;&#8195;&#8195;&#8195;million (or approximately
$&#8195;&#8195;&#8195;&#8195;million if the underwriters exercise their option to purchase additional shares in full), assuming an initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the estimated price
range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We currently intend to use the net proceeds from this offering, together with our existing cash and cash
equivalents, as follows: approximately $&#8195;&#8195;&#8195;&#8195; million to advance the continued development of SEP-786, our lead product candidate from our PTH1R program, and additional molecules targeting PTH1R; approximately
$&#8195;&#8195;&#8195;&#8195; million to advance the development of SEP-631, and additional small molecules within our MRGPRX2 program; approximately $&#8195;&#8195;&#8195;&#8195; million for other research and development activities, including our
TSHR and incretin receptor programs, other new GPCR programs, and continued innovation of our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>; and the remainder to fund working capital and general corporate purposes.
See the section titled &#147;Use of Proceeds.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investing in our common stock involves a high degree of risk. You should read the section titled &#147;Risk Factors&#148; and other
information included in this prospectus before investing in our common stock. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq trading symbol </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;SEPN&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this offering is based on
&#8195;&#8195;&#8195;&#8195;&nbsp;shares of our common stock (which includes &#8195;&#8195;&#8195;&#8195; shares of unvested restricted common stock subject to repurchase or forfeiture) outstanding as of June&nbsp;30, 2024, after giving effect to
the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of &#8195;&#8195;&#8195;&#8195;&nbsp;shares of our common stock immediately prior to the completion of this offering, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock issuable upon the exercise of stock options outstanding
as of June&nbsp;30, 2024 under our 2021 Stock Option and Grant Plan, as amended from time to time (2021 Plan), with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195; per share; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock issuable upon the exercise of stock options granted
after June&nbsp;30, 2024 pursuant to the 2021 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock reserved for issuance under the 2021 Plan as of
June&nbsp;30, 2024, which shares will cease to be available for issuance at the time that our 2024 Stock Option and Grant Plan (2024 Plan) becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under
the 2024 Plan, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of our common stock
reserved for future issuance under the 2024 Plan and any shares underlying outstanding stock awards granted under the 2021 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock reserved for future issuance under our 2024 Employee
Stock Purchase Plan (ESPP), which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of our common
stock reserved for future issuance under the ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise indicated, all information in this
prospectus reflects or assumes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">one-for-&#8195;&#8195;&#8195;&#8195;reverse</FONT> stock split of our
capital stock, which we effected on &#8195;&#8195;&#8195;&#8195;, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of all outstanding shares of our convertible preferred stock as of June&nbsp;30, 2024
into an aggregate of &#8195;&#8195;&#8195;&#8195;shares of our common stock immediately prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of unvested restricted common stock subject to repurchase or forfeiture as
of &#8195;&#8195;&#8195;, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding stock options and restricted common stock described above;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase up to an additional
&#8195;&#8195;&#8195;&#8195;shares of our common stock in this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our
amended and restated bylaws, each of which will occur immediately prior to the completion of this offering. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_3"></A>Summary Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables summarize our financial data for Septerna, Inc. You should read the following summary financial data
together with the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes thereto included elsewhere in this prospectus. We have derived
the summary statements of operations and comprehensive (loss) income data for the years ended December&nbsp;31, 2022 and 2023 from our audited financial statements included elsewhere in this prospectus. We have derived the summary statements of
operations and comprehensive (loss) income data for the six months ended June&nbsp;30, 2023 and 2024, and the summary balance sheet data as of June&nbsp;30, 2024, from our unaudited interim condensed financial statements included elsewhere in this
prospectus. Our unaudited interim condensed financial statements were prepared on a basis consistent with our audited financial statements and include, in our opinion, all adjustments of a normal and recurring nature that are necessary for the fair
statement of the financial information set forth in those statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in any future period and our interim results are
not necessarily indicative of results that may be expected for the full year. The summary financial data included in this section are not intended to replace the audited financial statements and the related notes thereto included elsewhere in this
prospectus and are qualified in their entirety by our financial statements and the related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except for share and per share data) </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations and Comprehensive (Loss) Income Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses (income):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,924</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) income from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) income before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income and comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income per share attributable to common stockholders<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing net (loss) income per share attributable to
common stockholders<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,372,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,606,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,372,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,746,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except for share and per share data) </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net (loss) income per share attributable to common stockholders (unaudited)<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares outstanding used in computing net (loss) income per share
attributable to common stockholders (unaudited)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">See Note 13 to our audited financial statements and Note &#8195;&#8195;&#8195;&#8195; to our unaudited
interim condensed financial statements included elsewhere in this prospectus for details on the calculation of basic and diluted net (loss) income per share attributable to common stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The unaudited pro forma basic and diluted net (loss) income per share were computed using the
weighted-average number of shares of common stock outstanding, including the pro forma effect of the automatic conversion of all outstanding shares of convertible preferred stock into shares of common stock as of the beginning of the period.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except for share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The pro forma balance sheet data gives effect to the automatic conversion of all outstanding shares of our
outstanding convertible preferred stock as of June&nbsp;30, 2024 into an aggregate of&#8195;&#8195;&#8195;&#8195;shares of our common stock and the related reclassification of the carrying value of the convertible preferred stock to permanent
equity, each of which will occur immediately prior to the completion of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The pro forma as adjusted balance sheet data gives effect to (i)&nbsp;the pro forma adjustments set forth in
footnote (1)&nbsp;above and (ii)&nbsp;the issuance and sale of&#8195;&#8195;&#8195;&#8195; shares of our common stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of
the estimated price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase or decrease in the assumed initial public
offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the pro forma as adjusted amount of each of our
cash and cash equivalents, working capital, total assets and total stockholders&#146; (deficit) equity by $&#8195;&#8195;&#8195;&#8195; million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus,
remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us, as set forth on the
cover page of this prospectus, would increase or decrease, as applicable, the pro forma as adjusted amount of each of our cash and cash equivalents, working capital, total assets and total stockholders&#146; (deficit) equity by
$&#8195;&#8195;&#8195;&#8195; million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">We define working capital as current assets less current liabilities. See our audited and unaudited financial
statements and the related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties
described below together with all of the other information contained in this prospectus, including our consolidated financial statements and related notes appearing at the end of this prospectus, before deciding to invest in our common stock. If any
of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline and you could lose all or part of your
investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to Limited Operating History, Financial Position and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have a limited operating history and have incurred significant operating losses since our inception and expect to incur significant
losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pharmaceutical product development is a highly speculative undertaking and
involves a substantial degree of risk. We are a clinical-stage biotechnology company with a limited operating history<I>,</I>&nbsp;which may make it difficult to evaluate the success of our business to date and assess our future viability. Since our
inception in December 2019, we have focused primarily on organizing and staffing our company, business planning, establishing our intellectual property portfolio, raising capital, developing our proprietary and structure-based drug discovery
platform, identifying and developing our product candidates, conducting research and preclinical studies, including <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, initiating and conducting clinical trials, and providing general and
administrative support for these operations. Our approach to the discovery and development of product candidates based on our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is unproven, and we do not know whether we
will be able to develop any product candidates that succeed in clinical development or commercially. Further, our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT> is in early clinical development and our other product
candidates and development programs are in preclinical development or in the drug discovery stages. Accordingly, we have not yet completed any clinical trials, demonstrated an ability to successfully obtain regulatory approvals, manufactured a
clinical- or commercial-scale product, or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success
or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we
continue to incur significant research and development and other expenses related to our preclinical and clinical development and ongoing operations. As a result, we are not profitable and have incurred significant losses since our inception, with
the exception of the year ended December&nbsp;31, 2023, and negative cash flows from operating activities and capital expenditures and expect to continue to incur significant and increasing operating losses for at least the next several&nbsp;years.
If our product candidates are not successfully developed and approved, we may never generate any significant revenue. Our net loss was $27.7&nbsp;million for the year ended December&nbsp;31, 2022 and net income was $4.2&nbsp;million for
the&nbsp;year ended December&nbsp;31, 2023, respectively. As of June&nbsp;30, 2024, we had an accumulated deficit of $&#8195;&#8195;&#8195;&#8195;million. Substantially all of our losses have resulted from expenses incurred in connection with our
research and development programs and from general and administrative costs associated with our operations. All of our product candidates will require substantial additional development time and resources before we would be able to apply for or
receive marketing approvals and begin generating revenue from product sales. We expect to continue to incur significant losses for the foreseeable future, and we expect that our expenses will increase substantially as we continue our development of,
seek marketing approval for and potentially commercialize any of our product candidates, recruit and maintain key personnel and seek to identify, assess, acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or develop additional product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we succeed in developing and obtaining marketing approval for one or more of our current or future
product candidates, we may never generate revenue that is significant enough to achieve profitability. If we do </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other
expenditures to develop and market additional product candidates. Our failure to become and remain profitable could decrease the value of our common stock and impair our ability to raise capital, maintain our research and development efforts, expand
our business or continue our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if this offering is successful, we will require substantial additional funding in
order to finance our operations. If we are unable to raise additional capital when needed on acceptable terms, or at all, we may be forced to delay, reduce, or terminate certain of our research and product development programs, future
commercialization efforts or other operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The development of pharmaceutical product candidates, including
conducting preclinical studies and clinical trials, is a very time-consuming, capital-intensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses
to increase in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate and conduct clinical trials of, and seek regulatory approval for, <FONT STYLE="white-space:nowrap">SEP-786</FONT>
and any additional product candidates we may identify. In addition, if we obtain regulatory approval for any product candidates we may identify, we expect to incur significant commercialization expenses related to product sales, marketing,
manufacturing, and distribution to the extent that such sales, marketing, manufacturing, and distribution are not the responsibility of a collaborator. Because the outcome of any clinical trial or preclinical study is highly uncertain, we cannot
reasonably estimate the actual amount of capital necessary to successfully complete the development and commercialization of our product candidates. Other unanticipated costs may also arise. Furthermore, upon the completion of this offering, we
expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on
acceptable terms, we would be forced to delay, reduce, or eliminate our research and product development programs, future commercialization efforts or other operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2024, we had approximately $&#8195;&nbsp;million in cash and cash equivalents. We expect that the net
proceeds from this offering, together with our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into &#8195;&#8195;&#8195;&#8195;. However, we have based this estimate on
assumptions that may prove to be wrong, and our operating plan may change as a result of factors currently unknown to us, and we may need to seek funding sooner than planned. Our future capital requirements will depend on many factors, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and progress of research and development, preclinical and clinical development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number, scope and duration of clinical trials required for regulatory approval of our current or future
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our current or future product candidates in any
jurisdictions in which we or our current or any future collaborators may seek approval for our current or future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of manufacturing clinical and commercial supplies of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales
and distribution, for any of our current or future product candidates for which we receive regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting our patent applications, maintaining and enforcing our patents
and other intellectual property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other
arrangements, and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaboration and license agreements on favorable terms, if at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates
and technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product liability or other lawsuits related to our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our implementation of various computerized informational systems and efforts to enhance operational systems;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of global economic uncertainty and geopolitical tensions, which may exacerbate the magnitude of the
factors discussed above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect our expenses to continue to increase in connection with our ongoing
activities, particularly as we identify, continue the research and development of, initiate preclinical studies and clinical trials of, and seek marketing approval for, product candidates, and we may never generate the necessary data or results
required to obtain regulatory approval and achieve product sales. In addition, our current or future product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we
do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable
terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise
additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common
stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, and possibly
other restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any additional fundraising efforts may divert our management from their <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our product candidates. We have no committed sources of additional capital and, if
we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our current or future product candidates or other
research and development initiatives. Without sufficient funding, our license agreements and any future collaboration agreements may also be terminated if we are unable to meet the payment or other obligations under such agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit,
reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Additionally, if we raise funds through
additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates we develop, or we may have
to grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have never
generated revenue from product sales and may never be profitable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to generate revenue from product
sales and achieve profitability depends on our ability, alone or with collaborative partners, to successfully complete the development of, obtain the regulatory approvals </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
necessary to commercialize and eventually commercialize, product candidates we may identify for development. We may not generate revenues from product sales for many years, if ever. Our ability
to generate future revenues from product sales depends heavily on our or our collaborators&#146; ability to successfully: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify product candidates and successfully complete research and development of any product candidates we
may identify; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance our product candidates through preclinical and clinical development, including as we advance <FONT
STYLE="white-space:nowrap">SEP-786</FONT> into later-stage clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek and obtain regulatory approvals for any product candidates for which we successfully complete clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launch and commercialize any product candidates for which we may obtain regulatory approval by establishing a
sales force, marketing and distribution infrastructure, or alternatively, collaborating with a commercialization partner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">qualify for adequate coverage and reimbursement by government and third-party payors for any product
candidates for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish and maintain supply and manufacturing relationships with third parties that can provide adequate, in
both amount and quality, products and services to support clinical development and the market demand for any product candidates for which we obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop, maintain and enhance a sustainable, scalable, reproducible and transferable manufacturing process for
the product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">address competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and
performing our obligations in such collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive market acceptance by physicians, patients, healthcare payors, and others in the medical community;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive coverage and adequate reimbursement by healthcare payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, protect, enforce, defend and expand our portfolio of intellectual property and other proprietary
rights, including patents, trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">defend against third-party intellectual property claims of infringement, misappropriation or other violation;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, hire and retain qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our expenses could increase beyond expectations if we are required by the FDA, European Medicines Agency (EMA), the competent
authorities of individual European Union (EU) Member States, or other comparable foreign regulatory authorities to perform preclinical studies or clinical trials in addition to those that we currently anticipate. Even if one or more of the product
candidates we may develop are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Additionally, such products may become subject to unfavorable pricing regulations,
third-party reimbursement practices or healthcare reform initiatives. Even if we are able to generate revenues from the sale of any approved product candidates, we may not become profitable and may need to obtain additional funding to continue
operations. Our failure to become and remain profitable may have an adverse effect on the value of our company and depress the market price of our common stock and could impair our ability to raise capital, expand our business, maintain our research
and development efforts, diversify our product candidate pipeline, achieve our strategic objectives or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to Discovery, Development and Regulatory Approval of Product Candidates
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are early in our development efforts. We have only recently initiated early clinical studies, and as a result it will be
years before we commercialize a product candidate, if ever. If we are unable to identify and advance product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience
significant delays in doing so, our business will be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The success of our business depends
primarily upon our ability to identify, develop and commercialize product candidates. We are early in our development efforts and our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT> is in early clinical development and our
other product candidates and development programs are in preclinical development or in the drug discovery stages. We have invested substantially all of our research efforts to date in developing our Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>, identifying potential product candidates and conducting preclinical and clinical studies. As an organization, we have limited experience in conducting and managing clinical trials necessary to
obtain regulatory approvals, and we may be unable to do so for our product candidates. While we have successfully completed <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for <FONT STYLE="white-space:nowrap">SEP-786,</FONT> our lead
product candidate from our PTH1R program, and are initiating a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of <FONT STYLE="white-space:nowrap">SEP-786,</FONT> we have not yet completed any clinical trials for <FONT
STYLE="white-space:nowrap">SEP-786</FONT> or any of our product candidates to date. Additionally, we have a portfolio of targets and programs that are in earlier stages of discovery or preclinical development and may never advance to clinical-stage
development. If we are able to advance these other targets and programs into clinical development, we do not have experience managing multiple clinical trials simultaneously, working with global clinical trials, or working in multiple different
disease indications. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing our product candidates, either alone or with third parties, and we cannot guarantee you that we
will ever obtain regulatory approval for any of our product candidates. Before obtaining regulatory approval for the commercial distribution of our product candidates, we must conduct extensive preclinical tests and clinical trials to demonstrate
the safety and efficacy in humans of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not have the financial resources to continue
development of, or to enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical study results may show the product candidate to be less effective than desired or to have harmful
or problematic side effects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or inconclusive results from our clinical trials or the clinical trials of others for product
candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product-related side effects experienced by patients in our clinical trials or by individuals using product
similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party manufacturers&#146; inability to successfully manufacture our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability of any third-party contract manufacturer to scale up manufacturing of our product candidates and
those of our collaborators to supply the needs of clinical trials or commercial sales; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in submitting INDs or other comparable foreign applications or delays or failures in obtaining the
necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical studies conducted outside of the United States may be affected by tariffs or import/export
restrictions imposed by the United States or other foreign governments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions imposed by the FDA, EMA or other comparable foreign regulatory authorities regarding the scope or
design of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in enrolling patients in our clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">high <FONT STYLE="white-space:nowrap">drop-out</FONT> rates of our clinical trial patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inadequate supply or quality of product candidate components or materials or other supplies necessary for the
conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to obtain alternative sources of supply for which we have a single source for product candidate
components or materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater than anticipated costs of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing costs, formulation issues, pricing or reimbursement issues, or other factors that no longer make
a product candidate economically feasible; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">harmful side effects or inability of our product candidates to meet efficacy endpoints during clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to demonstrate a benefit-risk profile acceptable to the FDA, EMA, or other comparable foreign
regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable FDA, EMA, or other comparable foreign regulatory authority inspection and review of any of the
clinical trial sites or manufacturing facilities used in the testing and manufacture of any of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise
meet their contractual obligations in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional
regulatory oversight around clinical testing generally or with respect to our technology in particular; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">varying interpretations of our data by the FDA, EMA, and similar foreign regulatory authorities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our inability to complete development of, or commercialize our product candidates, or significant
delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Preclinical and clinical drug development is a lengthy and expensive process, with uncertain timelines and outcomes. If preclinical
studies or clinical trials of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our therapeutic candidates or any of our future therapeutic candidates
on a timely basis or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Successful development of pharmaceutical products involves a lengthy and expensive
process, is highly uncertain, and is dependent on numerous factors, many of which are beyond our control. Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial results may show the product candidates to be less effective than expected (for example, a
clinical trial could fail to meet its primary or key secondary endpoint(s)) or have an unacceptable safety or tolerability profile; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to receive the necessary regulatory approvals or a delay in receiving such approvals, which, among
other things, may be caused by patients who fail the trial screening process, slow enrollment in clinical trials, patients dropping out of trials, patients lost to <FONT STYLE="white-space:nowrap">follow-up,</FONT> length of time to achieve trial
endpoints, additional time requirements for data analysis or New Drug Application (NDA) or similar foreign application preparation, discussions with the FDA, EMA or other comparable foreign regulatory authorities, including FDA, EMA or other
comparable foreign regulatory authorities requesting additional preclinical or clinical data (such as long-term toxicology studies), or encountering unexpected safety or manufacturing issues; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical study results may show the product candidate to be less effective than desired or to have harmful <FONT
STYLE="white-space:nowrap">on-target</FONT> or <FONT STYLE="white-space:nowrap">off-target</FONT> side effects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of extensive post-marketing approval requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proprietary rights of others and their competing products and technologies that may prevent our product
candidates from being commercialized. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, the length of time necessary to complete clinical
trials and submit an application for marketing approval for a final decision by a regulatory authority varies significantly from one product candidate to the next and from one country or jurisdiction to the next and may be difficult to predict. Even
if we are successful in obtaining marketing approval, commercial success of any approved products will also depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as
the Medicare and Medicaid programs and managed care organizations in the United States or country-specific governmental organizations in foreign countries, which may be affected by existing and future healthcare reform measures designed to reduce
the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources.
If government and other healthcare payors were not to provide coverage and adequate reimbursement for our products once approved, market acceptance and commercial success would be reduced. Even if we are able to obtain coverage and adequate
reimbursement for our products once approved, there may be features or characteristics of our products, such as dose preparation requirements, that prevent our products from achieving market acceptance by the healthcare or patient communities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if any of our product candidates receive marketing approval, we will be subject to significant regulatory
obligations regarding the submission of safety and other post-marketing information and reports and registration, and will need to continue to comply (or ensure that our third-party providers comply) with current Good Manufacturing Practice (cGMPs)
and Good Clinical Practice (GCPs) for any clinical trials that we conduct post-approval. In addition, there is always the risk that we, a regulatory authority or a third party might identify previously unknown problems with a product post-approval,
such as AEs of unanticipated severity or frequency. Compliance with these requirements is costly, and any failure to comply or other issues with our product candidates post-approval could adversely affect our business, financial condition and
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may encounter substantial delays in the commencement, enrollment or completion of our planned clinical
trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing any product candidates we determine to develop on a timely basis, if at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The risk of failure in developing product candidates is high. It is impossible to predict when or if any product candidate
would prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development, submit an IND or comparable
foreign application to permit initiation of clinical studies, and then conduct extensive clinical trials to demonstrate the safety and efficacy of product candidates in humans. We have not yet completed a clinical trial of any product candidate.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and
studies that support our INDs and other regulatory filings. We cannot be certain of the timely identification of a product candidate or the completion or outcome of our preclinical testing and studies and cannot predict whether the FDA, EMA or other
comparable foreign regulatory authorities will accept our proposed clinical programs or whether the outcome of our preclinical testing and studies will ultimately support the further development of any product candidates. Conducting preclinical
testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. As a result, we cannot be sure
that we will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
be able to submit INDs or other comparable foreign regulatory submissions for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs will
result in the FDA, EMA, or other comparable foreign regulatory authority allowing clinical trials to begin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore,
product candidates are subject to continued preclinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could
impact our ability to continue to conduct our clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical testing is expensive, is difficult to design and
implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage
of testing, which may result from a multitude of factors, including, but not limited to, flaws in trial design, dose selection issues, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other events that may prevent successful enrollment, initiation or timely completion of clinical development include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to generate sufficient preclinical, toxicology or other <I>in vivo</I> or <I>in vitro</I>
data to support the initiation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching a consensus with applicable regulatory authorities on trial design or implementation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining regulatory authorization to commence a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective CROs, other vendors, or clinical trial
sites, the terms of which can be subject to extensive negotiation and may vary significantly among different vendors and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining approval from one or more institutional review boards (IRB) refusing to approve,
suspending or terminating the trial at an investigational site, precluding enrollment of additional participants, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in recruiting suitable patients to participate in our ongoing and planned clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to the clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from trial protocol such as the data collection omission we experienced at a clinical
site as discussed above or dropping out of a trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in manufacturing sufficient quantities of our product candidates for use in clinical trials, or delays
in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in having our product candidates being shipped on time, clearing customs and arriving at clinical trial
sites intact; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in having patients complete participation in a trial or return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">participants choosing an alternative treatment for the indication for which we are developing our product
candidates, or participating in competing clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of AEs or serious adverse events (SAEs) associated with the product candidate that are viewed to
outweigh its potential benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of SAEs in clinical trials of the same class of agents conducted by other companies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a temporary or permanent clinical hold by regulatory authorities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical trial end points that require prolonged periods of clinical observation or analysis of
the resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials producing negative or inconclusive results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a facility manufacturing our product candidates or any of their components being ordered by the FDA or
comparable foreign authorities to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements, or contamination or cross-contaminations of product candidates in the manufacturing process;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials,
not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol or other regulatory requirements or committing fraud; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements, guidance, or feedback from regulatory agencies that require amending or
submitting new clinical protocols or otherwise modifying the design of our clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We could
also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs overseeing the conduct of such trials, by a Data Safety Monitoring Board for such trial or by the FDA, EMA, or other comparable foreign regulatory authorities.
Such regulatory authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical
trial operations or trial site by the FDA, EMA, or other comparable regulatory foreign authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug,
changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to
comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination and approval, which may impact the costs, timing or successful completion of a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks
that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocols as a result of differences in healthcare services or cultural customs, managing additional
administrative burdens associated with foreign regulatory requirements, as well as political, currency exchange and other economic risks relevant to such foreign countries. Investigators and patients may not be able to comply with clinical trial
protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff which in turn could adversely impact our clinical trial operations.
Additionally, we may experience interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments,
employers and others in connection with public health concerns. We may face delays in meeting our anticipated timelines for our ongoing and planned clinical trials, which could adversely affect our business, financial condition, results of
operations and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any inability to successfully complete preclinical and clinical development could result
in additional costs to us or impair our ability to generate revenue from future product sales and regulatory and commercialization milestones. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to
conduct additional testing to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow
our competitors to bring comparable products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Serious adverse events, undesirable side effects or other unexpected properties of our
product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following
marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates, any of which would limit the commercial potential of such product candidate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date, we have not completed the evaluation of any product candidates in human clinical trials. It is impossible to predict
when or if any product candidates we may develop will ultimately prove safe in humans. As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product candidates&#146; use.
Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations, if they occur. In
addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical trials with a broader group of patients, or as use of these product candidates becomes more widespread if they receive marketing approval,
illnesses, injuries, discomforts and other AEs that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by participants. Many times, side effects are only detectable after
investigational product candidates are tested in large-scale, Phase&nbsp;3 trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of our current
or future product candidates has serious or life-threatening side effects or other side effects that outweigh the potential therapeutic benefit, the development of the product candidate may fail or be delayed, or, if the product candidate has
received marketing approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition. In particular, because we are developing our product candidates for chronic indications, the FDA, EMA,
and other comparable foreign regulatory authorities will likely require that our product candidates demonstrate a higher level of safety over a longer period of time than would be the case for product candidates intended for short-term use.
Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed and our ability to generate revenue through their sale may be
delayed or eliminated. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics
that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a
risk-benefit perspective, which may limit the commercial value for the product candidate if approved. We may also be required to modify our trial plans based on findings after we commence our clinical trials. Many compounds that initially showed
promise in early-stage testing have later been found to cause side effects that prevented further development of the compound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if any of our product candidates receive marketing approval, the FDA could require us to include a boxed warning
in our label or adopt a REMS, to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the drug for distribution to patients and a communication plan to health care
practitioners. For example, the FDA required that the product label for NATPARA, an approved, injectable parathyroid hormone product targeting PTH1R for the management of hypoparathyroidism include a boxed warning related to the risk of osteosarcoma
based on rodent carcinogenicity studies and also implemented a REMS Program to ensure patients and prescribers were appropriately counseled on the benefits and risks of the drug. Similarly, the FDA initially included boxed warnings for FORTEO and
TYMLOS, injectable PTH peptides approved for osteoporosis due to the risk of osteosarcoma. While we have not yet conducted carcinogenicity studies for <FONT STYLE="white-space:nowrap">SEP-786,</FONT> because it also targets PTH1R, it is possible
that absent compelling data to the contrary, the FDA, EMA, and other comparable foreign regulatory authorities will similarly require a boxed warning for <FONT STYLE="white-space:nowrap">SEP-786</FONT> if it is approved for marketing. Furthermore,
if we or others later identify undesirable side effects caused by our product candidates, several other potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may suspend or withdraw approvals of such product candidate; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label, including &#147;boxed&#148; warnings, or
issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way a product candidate is administered or conduct additional clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may need to conduct a recall; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be forced to suspend marketing of that product, or decide to remove the product from the marketplace;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product may become less competitive, and our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could
significantly harm our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our product candidates are subject to
extensive regulation and compliance obligations, which is costly and time-consuming and which may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The research, clinical development, testing, quality control, safety, effectiveness, manufacturing, labeling, packaging,
storage, record-keeping, advertising, promotion, marketing, import, export, distribution, post-approval monitoring, and post-approval reporting of our product candidates are subject to extensive regulation by the FDA in the United States and by
comparable foreign regulatory authorities in foreign markets. In the United States, neither we nor any future collaborators are permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining
regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and
patient population. Approval policies or regulations may change, new relevant statutes or regulations may be enacted, and the FDA, EMA and other comparable foreign regulatory authorities have substantial discretion in the drug approval process,
including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our potential future
collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities, that such product candidates are safe and
effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be
sufficient to support approval by the FDA, EMA and other comparable foreign regulatory authorities, which could require us to delay or abandon clinical development plans. In addition, regulatory authorities may require us to conduct further
preclinical studies before evaluating our product candidate in a clinical trial. Once we initiate clinical trials, the FDA, EMA, or other comparable foreign regulatory authorities may require additional clinical trials or suggest changes to our
planned clinical trials, prior to and in support of the approval of a NDA or equivalent foreign marketing application. Changes to data requirements by the FDA, EMA, or other comparable foreign regulatory authorities during the development of our
product candidates may cause the applicable regulatory authorities to require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or regulatory authorities may object to
elements of our clinical development program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA, EMA or other comparable foreign regulatory authorities can delay,
limit or deny approval of a product candidate for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree with the design or implementation of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or ambiguous results from our clinical trials or results may not meet the level of statistical
significance required by the FDA, EMA or other comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or
by individuals using drugs similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety
in the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in
countries where the standard of care is potentially different from that of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a product candidate is safe and effective, and that a product
candidate&#146;s clinical and other benefits outweigh its safety risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree with our interpretation or analysis of data from preclinical studies or clinical
trials; such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States
or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree regarding the formulation, labeling and/or the specifications of our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval may be granted only for indications that are significantly more limited than what we apply for and/or
with other significant restrictions on distribution and use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may find deficiencies in the manufacturing processes, approval policies or facilities of our
third-party manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of such authorities may significantly change in a manner rendering our or
any of our potential future collaborators&#146; clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect
to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising
questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA, EMA, and other comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory
considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing
our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Of the large number of drugs in development, only a small percentage successfully complete the
FDA, EMA, or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product
candidates, which would significantly harm our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Enrollment and retention of patients in clinical trials is an expensive and
time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, which could adversely affect our business, operating results and prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patient enrollment and retention in clinical trials is a significant factor in the timing of clinical trials and depends on
many factors, including the size and nature of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data with respect to the study drug, the number, nature and duration of competing treatments and
ongoing clinical trials of competing drugs for the same indication, the proximity of patients to clinical trial sites and the eligibility criteria for the clinical trial. As we progress our programs we may not be able to initiate or continue
clinical trials for any product candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, EMA, or other comparable foreign authorities, or
as needed to provide appropriate statistical power for a given trial. For certain of our product candidates, the conditions which we may evaluate include rare diseases with limited patient pools from which to draw. In some cases, patient populations
for rare diseases are located at specific academic sites focused on such indications, often with multiple competing clinical trials. Potential patients for any planned clinical trials may not be adequately diagnosed or identified with the diseases
which we are targeting or may not meet the entry criteria for such trials. We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for our planned clinical trials and monitoring such patients
adequately during and after treatment. As noted above, other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from these patient populations, which may make it more difficult to fully enroll our clinical
trials. In addition, the process of finding and diagnosing patients may prove costly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The eligibility criteria of our
clinical trials, once established, may further limit the pool of available trial participants. If the actual number of patients with these diseases is smaller than we anticipate, we may encounter difficulties in enrolling patients in our clinical
trials, thereby delaying or preventing development and approval of our product candidates. Even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to
enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment or retention in our clinical trials for a variety of reasons. Patient enrollment and retention in clinical
trials depends on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population, in particular for rare diseases such as the diseases on which
we are focused initially, and process for identifying patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existing body of safety and efficacy data for the product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same
indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity and availability of clinical trial sites for patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the eligibility criteria for the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the complexity of the trial, including number of office visits, lab tests, patient evaluations, and dosing
regimens; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to adequately monitor patients during a trial, clinicians&#146; and patients&#146; perceptions as
to the potential advantages of the product candidate being studied; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that enrolled patients will drop out of a trial before completing all site visits; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug being studied in
relation to other available therapies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, our efforts to build relationships with patient
communities may not succeed, which could result in delays in patient enrollment in our clinical trials. In addition, any negative results we may report in clinical trials of our product candidate may make it difficult or impossible to recruit and
retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop
our product candidates, or could render further development impossible. Further, if patients drop out of our clinical trials, miss scheduled doses or <FONT STYLE="white-space:nowrap">follow-up</FONT> visits, or otherwise fail to follow clinical
trial protocols, the integrity of data from our clinical trials may be compromised or not accepted by the FDA, EMA, or other comparable foreign regulatory authorities, which would represent a significant setback for the applicable program. In
addition, we may rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to compel their actual
performance. Such delays or failures could adversely affect our business, operating results and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if we receive
regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with
regulatory requirements or experience unanticipated problems with our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any of our product
candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy
and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP
requirements for any clinical trials that we conduct post-approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Manufacturers and manufacturers&#146; facilities are
required to comply with extensive FDA, EMA and other comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing
requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, other marketing application and previous responses to
inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated
uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product
candidate. Certain endpoint data we hope to include in any approved product labeling also may not make it into such labeling, including exploratory or secondary endpoint data such as patient-reported outcome measures. The FDA may also require a risk
evaluation and mitigation strategies (REMS) program as a condition of approval of our product candidates, which could entail requirements for long-term patient <FONT STYLE="white-space:nowrap">follow-up,</FONT> a medication guide, physician
communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, EMA or other comparable foreign regulatory authority approves our
product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not
maintained or if problems occur after the product reaches the market. Later discovery of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
previously unknown problems with our product candidates, including adverse events (AEs) of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes,
or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution
restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or
voluntary product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or
suspension or withdrawal of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention or refusal to permit the import or export of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, under the Food and Drug Omnibus Reform Act (FDORA) sponsors of approved drugs and biologics must provide six
months&#146; notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product&#146;s ability
to be marketed. The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved
label. The policies of the FDA, EMA and other comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. In addition,
the U.S. Supreme Court&#146;s July 2024 decision to overturn established case law giving deference to regulatory agencies&#146; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which the FDA&#146;s
regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes. As a result of the Supreme Court&#146;s decision, the FDA and other agencies may be less inclined to engage in formal regulation and may
rely to a greater degree on informal guidance, which may not always be susceptible to immediate challenge. We cannot predict the likelihood, nature or extent of government regulation or guidance that may arise from future court decisions,
legislation, or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or guidance or the adoption of new requirements, guidance, or policies, or if we are not able to
maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our
therapeutics may be delayed and, as a result, our stock price may decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we estimate the
timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include our expectations regarding the commencement or
completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial or the
initiation of other clinical programs. All of these milestones are and will be based on numerous assumptions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our available capital resources or capital constraints we experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate of progress, costs and results of our clinical trials and research and development activities,
including the extent of scheduling conflicts with participating clinicians and collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our receipt of approvals by the FDA, EMA, and other comparable foreign regulatory authorities and the timing
thereof; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other actions, decisions or rules issued by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to access sufficient, reliable and affordable supplies of materials used to manufacture our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts of our collaborators with respect to the commercialization of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales
and marketing activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Securing product reimbursement </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our
control. If we do not meet these milestones as publicly announced, or at all, the commercialization of our product candidates may be delayed or never achieved and, as a result, our stock price may decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Results of preclinical studies and early clinical trials on any of our product candidates may not be predictive of results of future
clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The outcome of preclinical studies and early clinical trials may not be predictive of the success
of later clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that
we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical trials, including
previously unreported adverse events. In addition, while the animal models used in preclinical studies are designed to be representative of disease states in humans, these preclinical models may not be able to accurately predict the way a product
candidate will affect patients in clinical trials. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. In addition, preclinical and clinical data are often
susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In some instances, there can be significant variability in safety or efficacy results between
different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing
regimen, product formulation and other clinical trial protocols and the rate of dropout among clinical trial patients. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory
approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications
that may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have limited financial and
managerial resources, and to date, we have focused on research programs and product candidates within the endocrinology, immunology and inflammation, neurology and metabolic therapeutic areas, with a particular focus on our lead product candidate, <FONT
STYLE="white-space:nowrap">SEP-786.</FONT> Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we believe could be pursued by
leveraging our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>. As a result, we may forgo or delay pursuit of opportunities with other product candidates or in other therapeutic areas that later prove to have greater
commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential
or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain
sole development and commercialization rights to such product candidate. We must continually assess the potential commercial viability of our research programs and product candidates, and we may decide to pause or discontinue development of any of
our product candidates based upon such assessments, even if we obtain positive data from our product candidates in preclinical studies and clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is based on novel technologies that are
unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval, and we may not be
successful in our efforts to expand our development portfolio of product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A key element of our strategy
is to use our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to overcome the historical limitations of G protein-coupled receptor (GPCR) drug development, including the isolation, purification and
stabilization of GPCRs in their native forms, in order to build a robust and diverse portfolio of potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> oral small molecule therapies that address both well-validated and novel GPCR targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have only recently commenced our first clinical trial of the first candidate developed with our platform. The scientific
research that forms the basis of our efforts to develop product candidates with our platform is still ongoing. We are not aware of any FDA approved therapeutics utilizing the technology underlying our platform. Further, the scientific evidence to
support the feasibility of developing therapeutic treatments based on our platform is both preliminary and limited. As a result, we are exposed to a number of unforeseen risks and it is difficult to predict the types of challenges and risks that we
may encounter during development of our product candidates. For example, we have not yet generated any meaningful clinical data on any of the product candidates being developed using our platform, and our current data is limited to animal models and
preclinical cell lines, the results of which may not translate into humans. Further, relevant animal models and assays may not accurately predict the safety and efficacy of our product candidates in humans, and we may encounter significant
challenges creating appropriate models and assays for demonstrating the safety and purity of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given the novelty of our technology, we intend to work closely with the FDA and comparable foreign regulatory authorities to
perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates; however, due to a lack of comparable experiences, the regulatory pathway with the FDA and comparable regulatory
authorities may be more complex and time-consuming relative to other more well-known therapeutics. Even if we obtain human data to support our product candidates, the FDA or comparable foreign regulatory authorities may lack experience in evaluating
the safety and efficacy of product candidates like those developed using our platform, which could result in a longer than expected regulatory review process, increase our expected development costs, and delay or prevent commercialization of our
product candidates. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although our research and development efforts to date have resulted in a development portfolio of potential programs and
product candidates, we may not be able to discover or identify novel chemical matter to new GPCR targets and thus not be able to develop product candidates to expand our development portfolio. We may also pursue opportunities to acquire or <FONT
STYLE="white-space:nowrap">in-license</FONT> additional businesses, technologies or products, form strategic alliances or create joint ventures with third parties to complement or augment our existing business. However, we may not be able to
identify any product candidates through such acquisition or <FONT STYLE="white-space:nowrap">in-license.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if
we are successful in continuing to build and expand our development portfolio, the potential product candidates that we identify may not be suitable for clinical development. For example, they may be shown to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will be successful in clinical trials or receive marketing approval and achieve market
acceptance. If we do not successfully develop and commercialize product candidates, we will not be able to obtain drug revenues in future periods, which likely would result in significant harm to our financial position and adversely affect our stock
price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Preliminary, topline and interim data from our clinical trials that we announce or publish from time to time may change as
more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may publicly disclose interim, preliminary or topline data from our preclinical studies and planned
clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial.
We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that
we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit
and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously made public. As a result, topline and preliminary data should be viewed with caution until the final data are
available. From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient
enrollment continues and more patient data become available. Adverse differences between topline, preliminary or interim data and final data could significantly harm our business prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations,
conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in
general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or
otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a
particular product, product candidate or our business. If the topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain
approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may develop our current or future product candidates in combination with other therapies, which would expose us to additional risks.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may develop our current or potential future product candidates in combination with one or more currently
approved therapies or therapies in development. Even if any of our current or future product candidates were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to
the risks that the FDA, EMA or other comparable foreign regulatory authorities could revoke approval of the therapy used in combination with any of our product candidates, or safety, efficacy, manufacturing or supply issues could arise with these
existing therapies. In addition, it is possible that existing therapies with which our product candidates are approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify
other combination therapies for our product candidates or our own products being removed from the market or being less successful commercially. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also evaluate our current or future product candidates in combination
with one or more other therapies that have not yet been approved for marketing by the FDA, EMA or other comparable foreign regulatory authorities. We will not be able to market and sell any product candidate in combination with any such unapproved
therapies that do not ultimately obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, we cannot be certain that we will be able to
obtain a steady supply of such therapies for use in developing combinations with our product candidates on commercially reasonable terms or at all. Any failure to obtain such therapies for use in clinical development and the expense of purchasing
therapies in the market may delay our development timelines, increase our costs and jeopardize our ability to develop our product candidates as commercially viable therapies. If the FDA, EMA or other comparable foreign regulatory authorities do not
approve or withdraw their approval of these other therapies, or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies we choose to evaluate in combination with any of our current or future product
candidates, we may be unable to obtain approval of or successfully market any one or all of the current or future product candidates we develop. Additionally, if the third-party providers of therapies or therapies in development used in combination
with our current or future product candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our current or future product candidates, or if the cost of combination therapies are prohibitive, our
development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to Commercialization, Marketing and Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may invest
significant resources to develop these capabilities. If we are unable to establish marketing, sales or distribution capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product
revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no internal sales, marketing or distribution capabilities, nor have we as a company
commercialized a product. If any of our product candidates ultimately receives marketing approval, we will be required to build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize
each such product in the markets that we target, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution
systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales
organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and
marketing team. Furthermore, we are currently developing products for multiple indications in different medical specialties, which will require us to build different sales and marketing capabilities that are tailored to a given product or medical
specialty. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or
external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these
functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market
our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant
additional losses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if any of our current or future product candidates receive marketing approval,
such product candidate may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become
profitable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have never commercialized a product, and even if any of our current or future product candidates
are approved by the appropriate regulatory authorities for marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Historically, several
injectable PTH peptides have been approved by the FDA and other regulatory authorities for treatment of hypoparathyroidism and osteoporosis. However, our lead product candidate is an oral small molecule agonist; to date, no such oral small molecule
in this indication has been approved by the FDA or any other regulatory agency. Market participants with significant influence over acceptance of new treatments, such as clinicians and third-party payors, may not adopt new oral treatments for
hypoparathyroidism or osteoporosis, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our existing or future
collaborators. If our current or future product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of our current or future
product candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications and patient populations for which the product candidate is approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the safety, efficacy and potential advantages compared to alternative treatments and therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of the product as well as competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of our relationships with patient communities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment in relation to alternative treatments and therapies, including any similar generic
treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer such product for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convenience and ease of administration compared to alternative treatments and therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of coverage and adequate reimbursement by third-party payors and government authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inclusion of any REMS program or other restrictions included by the regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of the product together with other medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our
product candidates may require significant resources and may never be successful. Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product
candidates, if approved, to find market acceptance would harm our business and could require us to seek additional financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if we are able to commercialize any product candidate, the third-party payor
coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our ability to market those products and decrease our ability to
generate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The availability and adequacy of coverage and reimbursement by governmental healthcare programs
such as Medicare and Medicaid, private health insurers and other third-party payors in the United States are essential for most patients to be able to afford treatments such as our products or product candidates, if approved. Our ability to achieve
acceptable levels of coverage and reimbursement for drug treatments by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our products, and potentially attract
additional collaboration partners to invest in the development of our product candidates. We cannot be sure that adequate coverage and reimbursement in the United States, the EU, Australia or elsewhere will be available for our products or any
products that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. For more information, see the section titled &#147;Business&#150;Government Regulation&#150;Coverage and Reimbursement.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third-party payors increasingly are challenging prices charged for pharmaceutical products, medical devices and services,
and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug is available. It is possible that a third-party payor may consider our products or product candidates, if approved, and
the generic or biosimilar parent drug as substitutable and only offer to reimburse patients for the generic drug. Even if we show improved efficacy or safety or improved convenience of administration with our products or product candidates, if
approved, pricing of the existing parent drug may limit the amount we will be able to charge for such product. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products or
product candidates, and may not be able to obtain a satisfactory financial return on products that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an
important role in determining the extent to which new drugs, biologics and medical devices will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their
coverage and reimbursement policies for drugs, biologics and medical devices. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our products or product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Outside the United States, international operations are generally subject to extensive governmental price controls and other
market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of our products and product candidates, if approved, and
on related parent drugs. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Many countries, including the EU Member States, established complex and lengthy procedures
to obtain price approvals, coverage and reimbursement. These procedures vary from country to country but are commonly initiated after grant of the related marketing authorization. More particularly, in the EU, potential reductions in prices and
changes in reimbursement levels could be the result of different factors, including reference pricing systems. It could also result from the application of external reference pricing mechanisms, which consist of arbitrage between <FONT
STYLE="white-space:nowrap">low-priced</FONT> and high-priced countries. Reductions in the pricing of our medicinal products in one EU Member State could affect the price in other EU Member States and, thus, have a negative impact on our financial
results. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to
charge for our products or product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue
and profits. As an example, many EU Member States review periodically their decisions concerning the pricing and reimbursement of medicinal products. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
outcome of these reviews cannot be predicted and could have adverse effects on the pricing and reimbursement of our medicinal products in the EU Member States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce
healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our products or product candidates. We expect to
experience pricing pressures in connection with the sale of our products and product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The
downward pressure on healthcare costs in general, particularly prescription drugs, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new
products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We face substantial competition, which may result in others discovering, developing or commercializing products before or
more successfully than us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The biotechnology and pharmaceutical industries are characterized by rapidly advancing
technologies, intense competition, and a strong emphasis on proprietary and novel products and product candidates. While we believe our product candidates, platform, knowledge, experience and scientific personnel provide us with several key
competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Our future success will depend in part on our
ability to maintain a competitive position with our structure-based drug discovery platform. If we fail to stay at the forefront of technological change in utilizing our platform to create and develop product candidates, we may be unable to compete
effectively. Our competitors may render our approach obsolete by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug discovery process that we believe we
derive from our research approach and platform. Several other companies also focus on GPCRs and have platform technologies that are distinct from the Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, including Nxera
Pharma (formerly Sosei Heptares), Structure Therapeutics, Tectonic Therapeutics, and Confo Therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we
face competition with respect to our current product candidates and will face competition with respect to any other product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty
pharmaceutical companies and biotechnology companies worldwide. There are several large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of the
indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative
arrangements for research, development, manufacturing and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are aware of several pharmaceutical
companies that have commenced clinical trials of product candidates or have successfully commercialized products addressing areas that we are targeting. Takeda owns the rights to parathyroid hormone product (brand name NATPARA) for the treatment of
hypoparathyroidism. NATPARA was voluntarily recalled due to manufacturing issues in September 2019 in the United States and is now only available to a limited number of patients through a Special Use Program offered by its manufacturer. In October
2022, Takeda announced manufacturing of all strengths of NATPARA will be discontinued globally by the end of 2024. Ascendis Pharma received regulatory approval for a proprietary once-daily injectable PTH peptide, palopegteriparatide (brand name
YORVIPATH), in Europe and the company has submitted an NDA which is currently under review by the FDA with a PDUFA date of August&nbsp;14, 2024. In March 2024, AstraZeneca acquired Amolyt Pharma, who was developing eneboparatide, a proprietary,
once-daily injectable PTH peptide, for hypoparathyroidism, currently in Phase 3 studies. In addition, we are aware of several academic groups and companies working on making longer-acting agonists of the PTH1R. Other companies and groups are
developing or commercializing therapies for hypoparathyroidism, including Calcilytix (a BridgeBio company), Entera Bio, Extend Biosciences, and MBX Biosciences. Several companies are developing clinical-stage small
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
molecule MRGPRX2 inhibitors, including Escient Pharmaceuticals (acquired by Incyte Pharmaceuticals in April 2024), Evommune, and BioArdis. Further there are several other companies pursuing
therapies for CSU addressing other receptors of interest, such a Genentech, Sanofi, Celldex Therapeutics, Jasper Therapeutics, Acelyrin, Allakos, Novartis, Third Harmonic Bio, and Blueprint Medicines. For TSHR, we are aware that Byondis and
Crinetics are also working on research stage compounds, but they have not yet entered clinical development. In addition several companies are working on other mechanisms to address Graves&#146; disease, such as Immunovant, and TED, including Amgen,
Viridian, Argenx, Roche, Lassen Therapeutics, Tourmaline Bio, Sling Therapeutics, and Acelyrin. There are also several currently approved injectable products targeting incretin receptors for the treatment of obesity or T2D. These include, but are
not limited to, products such as Ozempic and Wegovy (semaglutide, marketed by Novo Nordisk) for T2D and obesity, respectively, Trulicity (dulaglutide, marketed by Eli Lilly and Company) for T2D, and Mounjaro and Zepbound (tirzepatide, marketed by
Eli Lilly and Company) for T2D and obesity, respectively. There are also several injectable peptide products in development pursuing similar indications with similar mechanism of actions along with combination products, including those being
developed by Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Roche, and Viking, among others. In addition, there are oral products such as Rybelsus (semaglutide, marketed by Novo Nordisk) approved for patients with T2D
and other oral products in development for treating obesity or T2D, including those being developed by AstraZeneca, Eli Lilly and Company, Pfizer, Roche, Structure, and Terns. Based on our continuing evaluations of the competitive landscape, we may
decide to reallocate resources and reprioritize our development programs if we determine that a particular product candidate or target indication is no longer commercially viable or advantageous. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of our competitors, either alone or with their collaborators, have significantly greater financial, technical,
manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our
products, the timing and scope of marketing approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior
treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or
noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be
adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more
resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These
third parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary
to, or necessary for, our programs. Any failure to compete effectively could harm our business, financial condition and operating results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the
EU Member States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to seek approval to market our product candidates in both the United States and in
selected foreign jurisdictions, including the EU. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly
those in the EU, the pricing of products is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental
authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement
from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Much like the federal Anti-Kickback Statute prohibition in the United
States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or
advantages to reward improper performance is typically governed by the national anti-bribery laws of EU Member States and the Bribery Act 2010 in the United Kingdom. Infringement of these laws could result in substantial fines and imprisonment. EU
Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or
benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains
applicable in the United Kingdom despite its departure from the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Payments made to physicians in certain EU Member
States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities
of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational
risk, public reprimands, administrative penalties, fines or imprisonment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in some foreign countries,
including some countries in the EU, the proposed pricing for a product must be approved before it may be lawfully marketed. The requirements governing product pricing and reimbursement vary widely from country to country. For example, some EU Member
States have the option to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU Member
States and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. An EU Member State may approve a specific price for the medicinal product or it
may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical trial or other studies that compare the
cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for
pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be
significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels
or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Obtaining and maintaining marketing approval of our product candidates in one jurisdiction does not mean that we will be successful in
obtaining marketing approval of our product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obtaining and maintaining marketing
approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a product candidate, it does
not mean that comparable foreign regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining
marketing approval in one jurisdiction may negatively impact the marketing approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than,
those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United
States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obtaining foreign marketing approvals and establishing and maintaining
compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with
the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed, which would
adversely affect our business, prospects, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our future growth may depend, in part, on
our ability to commercialize products in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets.
We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our product
candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, manufacturing, commercial
sales, pricing and distribution of our product candidates. If we obtain regulatory approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different regulatory requirements for approval of drugs in foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existence of additional third-party patent rights of potential relevance to our business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and
other obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is common; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters
including earthquakes, typhoons, floods and fires; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from pandemics or similar public health crises. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If the market opportunities for any of our product candidates are smaller than we estimate, even assuming approval of a product
candidate, our revenue may be adversely affected, and our business may suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The precise incidence and
prevalence for all the conditions we aim to address with our product candidates are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit
from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may
prove to be incorrect. Further, new information may change the estimated incidence or prevalence of these diseases. The total addressable market across all of our product candidates will ultimately depend upon, among other things, the diagnosis
criteria included in the final label for each of our product candidates approved for sale for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of our product candidates relative to such
alternative treatments, acceptance by the medical community and patient access, drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to
treatment with our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to Business Operation and Industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our
operating results to fall below expectations or any guidance we may provide. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our quarterly and annual operating
results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, degree of success and cost of, and level of investment in, research, development, regulatory
approval and commercialization activities relating to our product candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future
drugs that compete with our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our current and future product candidates, which may vary depending on FDA, EMA or
other comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of our agreements with third-party manufacturers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenditures that we may incur to acquire, develop or commercialize additional product candidates and
technologies or other assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for any of our product candidates, if approved, which may fluctuate significantly and be
difficult to predict; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaborations, licensing or other arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to adequately support future growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of preclinical studies or clinical trials or regulatory approval for our
product candidates or any competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which
we may become involved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions and departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential unforeseen business disruptions that increase our costs or expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effects of macro events, such as inflation, geopolitical conflicts, pandemics, natural disasters and supply
chain issues, on our business and operations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the changing and volatile global economic and political environment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, from time to time, we may enter into license or collaboration agreements or strategic partnerships with other
companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. These upfront and milestone payments may vary significantly from period to period and
any such variance could cause a significant fluctuation in our operating results from one period to the next. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the
expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide
to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may
provide. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could
disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2024, we had &#8195;&#8195;&#8195;&#8195; full-time employees. As we
advance our research and development programs, we may need to further increase the number of our employees and the scope of our operations, particularly in the areas of clinical development, biology, chemistry, manufacturing, general and
administrative matters related to being a public company, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our general and administrative functions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify, recruit, integrate, maintain and motivate additional qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manage our development efforts effectively, including the initiation and conduct of clinical trials for our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish and build a marketing and commercial organization; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improve our operational, financial and management controls, reporting systems and procedures.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future financial performance and our ability to develop, manufacture and commercialize our product
candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, to managing these growth activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and
contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are highly dependent on the services of our senior management team and if we are not able to retain these members of our management
team and recruit and retain additional management, clinical and scientific personnel, our business will be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are highly dependent on our senior management team. In particular, we are highly dependent on the development and management
expertise of Jeffrey Finer, M.D., Ph.D., our Chief Executive Officer, as the other principal members of our management, scientific and clinical team. The employment agreements we have with these officers do not prevent such persons from terminating
their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. In addition, we will need to attract, retain and motivate highly
qualified additional management, clinical and scientific personnel. If we are not able to retain our management and to attract, on terms acceptable to us, additional qualified personnel necessary for the continued development of our business, we may
not be able to sustain our operations or grow. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be able to attract or retain qualified personnel in the future
due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and
other resources, different risk profiles and a longer operating history in the industry than we do. They also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates and consultants than what we have
to offer. If we are unable to attract, retain and motivate high-quality personnel and consultants to accomplish our business objectives, the rate and success at which we can discover and develop product candidates and our business will be limited
and we may experience constraints on our development objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To induce valuable employees to remain at our company,
in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and
may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short
notice. For example, employment of our key employees is <FONT STYLE="white-space:nowrap">at-will,</FONT> which means that any of our employees could leave our employment at any time, with or without notice. In addition, we rely on consultants and
advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under
consulting or advisory contracts with other entities that may limit their availability to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future performance will
also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals
and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future marketing approvals, sales of our product
candidates and our results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our employees, independent contractors, principal investigators, CROs, consultants,
vendors and collaboration partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, vendors and
collaboration partners may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (i)&nbsp;FDA, the national competent
authorities of individual EU Member States, or comparable foreign regulations, including those laws that require the reporting of true, complete and accurate information to the FDA, EMA, or other comparable foreign regulatory authorities;
(ii)&nbsp;manufacturing standards; (iii)&nbsp;U.S. federal and state fraud and abuse and other healthcare laws and regulations, including foreign requirements; or (iv)&nbsp;laws that require the reporting of true and accurate financial information
and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations
may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These activities also include the improper use of information obtained in the
course of clinical trials or falsification of clinical trial data, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third-parties, and
the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in
compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not
successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible
exclusion from participation in Medicare, Medicaid and other U.S. federal or non U.S. healthcare programs, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating
results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The U.S. government has recently made statements and taken certain actions that may lead to potential
changes to U.S. and international trade policies, including imposing several rounds of tariffs and export control and sanctions restrictions affecting certain products manufactured in China. Both China and the United States have each imposed tariffs
indicating the potential for further trade barriers, including the U.S. Commerce Department adding numerous Chinese entities to its Unverified List, which requires U.S. exporters to go through more procedures before exporting goods to such entities.
It is unknown whether and to what extent new tariffs, export controls, or other new laws or regulations will be adopted, or the effect that any such actions would have on us or our industry. Most recently, legislation pending in Congress called the
BIOSECURE Act would, among other things, prohibit U.S. federal government contracts, grants, and loans in connection with biotechnology equipment or services provided or produced by certain named Chinese &#147;biotechnology companies of
concern,&#148; which include WuXi AppTec and WuXi Biologics, or collectively WuXi. See the risk factor titled &#147;Risks Related to Government Regulatory and Legal Requirements&#151;We rely on third-party manufacturers and suppliers to supply
components of our product candidates.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any unfavorable government policies on international trade, such as export
controls, economic, sanctions, capital controls or tariffs, may increase the cost of manufacturing our product candidates and platform materials, affect our ability to commercialize our product candidates if approved, the competitive position of our
product candidates, and import or export of raw materials and finished product candidate used in our preclinical studies and clinical trials, particularly with respect to any product candidates and materials that we import from China, including
pursuant to our service arrangements with WuXi. If any new tariffs, export controls, sanctions, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or, in particular, if either the U.S. or Chinese
government takes retaliatory trade actions due to the recent trade tensions, such changes could have an adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Clinical trial and product liability lawsuits against us could divert our resources, could cause us to incur substantial liabilities and
could limit commercialization of any product candidates we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will face an inherent risk of clinical
trial and product liability exposure related to the testing of any product candidates we may develop in clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. While we currently have not
completed the evaluation of any product candidates in human clinical trials or that have been approved for commercial sale, the future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may
expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product
candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidates that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants and inability to continue clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant time and costs to defend any related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of our management&#146;s time and our resources; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exhaustion of any available insurance and our capital resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any product candidates that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decline in price of our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will need to increase our insurance coverage if we continue to commence clinical trials or if we commence commercialization
of any product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If and when coverage is secured, our
insurance policies may also have various exclusions and we may be subject to a product liability claim for which we have no coverage. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such
indemnification may not be available or adequate should any claim arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets
may not be sufficient to cover such claims and our business operations could be impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we or any contract manufacturers and
suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to numerous foreign, federal, state and local environmental, health and safety laws and regulations, including
those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our
operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or
injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources, including any available insurance. Under certain environmental laws, we could be held responsible
for costs relating to any contamination at our current or past facilities and at third-party facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We could incur
significant costs and liabilities which may adversely affect our financial condition and operating results for failure to comply with such laws and regulations, including, among other things, civil or criminal fines and penalties, property damage
and personal injury claims, costs associated with upgrades to our facilities or changes to our operating procedures, or injunctions limiting or altering our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and
regulations may impair our research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#146; compensation insurance
to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for
environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. In the event of contamination or injury, we could be held liable for damages
or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may incur substantial costs in order to comply with current or future environmental, health
and safety laws and regulations. These current or future laws and regulations, which are becoming increasingly more stringent, may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may
result in substantial fines, penalties or other sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our future ability to utilize our net operating loss carryforwards and certain other
tax attributes may be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have incurred losses and we may never achieve
profitability. To the extent that we continue to generate taxable losses, under current law, our unused U.S. federal net operating losses (NOLs) may be carried forward to offset a portion of future taxable income, if any. Additionally, we continue
to generate business tax credits, including research and development tax credits, which generally may be carried forward to offset a portion of future taxable income, if any, subject to expiration of such credit carryforwards. Under Sections 382 and
383 of the Internal Revenue Code of 1986, as amended (Code), if a corporation undergoes an &#147;ownership change,&#148; generally defined as one or more stockholders or groups of stockholders who own at least 5% of the corporation&#146;s equity
increasing their equity ownership in the aggregate by more than 50 percentage points (by value) over a three-year period, the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and other <FONT
STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. Similar rules may apply under state tax laws. Our prior equity offerings and other
changes in our stock ownership may have resulted in such ownership changes in the past. In addition, we may experience ownership changes in the future as a result of this offering or subsequent shifts in our stock ownership, some of which are
outside of our control. As a result, if we earn net taxable income, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs or other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset U.S. federal
taxable income may be subject to limitations, which could potentially result in increased future tax liability to us and could require us to pay U.S. federal income taxes earlier than would be required if such limitations were not in effect.
Additional limitations on our ability to utilize our NOLs to offset future taxable income may arise as a result of our corporate structure whereby NOLs generated by our subsidiary may not be available to offset taxable income earned by our
subsidiary. There is a risk that due to changes under the tax law, regulatory changes or other unforeseen reasons, our existing NOLs or business tax credits could expire or otherwise be unavailable to offset future income tax liabilities. At the
state level, there may also be periods during which the use of NOLs or business tax credits is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, under Senate Bill 167 enacted by California
in June 2024, generally, there is a suspension of the NOL deduction for tax years beginning on or after January&nbsp;1, 2024, and before January&nbsp;1, 2027 for individual and corporate taxpayers with net business income or modified adjusted gross
income of $1&nbsp;million or more, and a limit of $5&nbsp;million of business credits on the aggregate use of otherwise allowable business tax credits that any individual or corporate taxpayer could claim for tax years beginning on or after
January&nbsp;1, 2024, and before January&nbsp;1, 2027. For these reasons, we may not be able to realize a tax benefit from the use of our NOLs or tax credits, even if we attain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have and may in the future engage in strategic transactions that could impact our liquidity, increase our expenses and present
significant distractions to our management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have and in the future, we may consider strategic transactions,
such as acquisitions of companies, asset purchases, and <FONT STYLE="white-space:nowrap">in-licensing</FONT> or <FONT STYLE="white-space:nowrap">out-licensing</FONT> of products, product candidates or technologies from time to time. Additional
potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction
may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our senior management or business, which
could adversely affect our operations and financial results. For example, these transactions may entail numerous operational and financial risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">up-front,</FONT> milestone and royalty payments, equity investments and
financial support of new research and development candidates including increase of personnel, all of which may be substantial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exposure to unknown liabilities, including potential indemnification claims from a potential <FONT
STYLE="white-space:nowrap">spin-off</FONT> or <FONT STYLE="white-space:nowrap">out-license</FONT> of certain of our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruption of our business and diversion of our management&#146;s time and attention to develop acquired
products, product candidates or technologies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">higher than expected costs in risk-sharing collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">higher-than-expected acquisition and integration costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lower-than-expected benefits, from <FONT STYLE="white-space:nowrap">out-licensing</FONT> or selling our
technology, intellectual property or any of our subsidiaries or, from <FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property or purchasing assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">write-downs of assets or goodwill or impairment charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty and cost in combining or separating the operations and personnel of any acquired or sold businesses
with our existing operations and personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may disagree with our strategic partners about decisions affecting the business, which could result in
litigation or arbitration that increases our expenses, distracts our officers and directors and disrupts the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of the strategic venture, including by
delaying important decisions until the dispute is resolved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategic partners may take actions that we oppose; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategic partners might experience financial distress or become bankrupt; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impairment of relationships with key suppliers or customers of any acquired or sold businesses due to changes
in our senior management and ownership; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to retain key employees of any acquired businesses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, to the extent we enter into a strategic transaction that includes ongoing operations or shared ownership and
management, our strategic partners may take actions that we oppose or we may disagree with our strategic partners about decisions affecting the business, which could result in litigation or arbitration, distract our officers and directors and
otherwise disrupt the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of our business and the business of the strategic partner or entity. Furthermore, to the extent that our directors and
officers serve on the boards of our strategic partners, such directors may be required to abstain from board decision-making in the event of a conflict of interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, although we cannot be certain that we will undertake or successfully complete any transactions of the nature
described above, any transactions that we do complete may be subject to the foregoing or other risks, and could harm our business, results of operations, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are conducting, and will continue to conduct, clinical trials for our current product candidates outside of the United States, and we
may do so for our other product candidates. However, conducting trials outside of the United States exposes us to additional risks, which could materially harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are conducting, and may in the future conduct, certain of our clinical trials at centers outside of the United States. The
acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or another comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. For example,
in cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&nbsp;the data are
applicable to the U.S. population and U.S. medical practice; (ii)&nbsp;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii)&nbsp;the data may be considered valid without the need for
an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other
appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and
well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. If the
FDA, the EMA, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), or other foreign regulatory authorities do not accept any data generated from other jurisdictions, we would likely be required to conduct additional clinical trials,
which would be costly and time consuming, and delay aspects of our development plan, which could harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Conducting trials outside the United States also exposes us to additional risks, including risks associated with: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional foreign regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign exchange fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with foreign manufacturing, customs, shipment and storage requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cultural differences in medical practice and clinical research; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diminished protection of intellectual property in some countries; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruptions or delays in our trials resulting from geopolitical events, such as war or terrorism.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If our information systems or data, or those of third parties with whom we work, are or were compromised, we
could experience adverse consequences from such compromises, such as damage our reputation, significant financial and legal exposure, or other adverse effects to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely on information technology systems that we or third parties with whom<B><I> </I></B>we work, operate to process,
transmit and store electronic information, including sensitive information, in our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations. For example, in connection with our product development
efforts, we may collect and process a variety of personal data, proprietary information, trade secrets, and clinical trial information. As a result, we and the third parties with whom<B><I> </I></B>we work, face a variety of evolving threats that
could cause security incidents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cyberattacks, malicious internet-based activity, online and offline fraud, and other
similar activities could result in the theft or destruction of intellectual property, personal data, or other misappropriation of assets, or otherwise threaten to compromise our confidential or proprietary information and disrupt our operations.
Such threats are increasing in their frequency, sophistication, and intensity, have become increasingly difficult to detect, and come from a variety of sources, including traditional computer &#147;hackers,&#148; threat actors,
&#147;hacktivists,&#148; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyberattacks,
including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities, wrongful conduct by hostile foreign governments and industrial espionage. During times of war and other
major conflicts, we and the third parties upon which we work may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to
produce, sell and distribute our services.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and the third parties with whom<B><I> </I></B>we work are subject to a
variety of evolving threats, including but not limited to the deployment of harmful malware (including as a result of advanced persistent threat intrusions), ransomware,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service,</FONT></FONT> credential stuffing, credential harvesting, social engineering fraud (including through deep fakes, which may be increasingly more difficult to
identify as fake, and phishing attacks), malicious code (such as viruses and worms), personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other
information technology assets, adware, attacks enhanced or facilitated by AI, telecommunications failures, earthquakes, fires, floods, and other similar threats. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our
operations, ability to provide our products or services, loss of sensitive data and income, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for
example, applicable laws or regulations prohibiting such payments.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A successful cyberattack could cause serious negative
consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic
plans. Although we devote resources to protect our information systems, there can be no assurance that our efforts will prevent information cybersecurity incidents or breaches that would result in business, legal, financial or reputational harm to
us, or would have a material adverse effect on our results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Remote work has become
more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in
public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present
in acquired or integrated entities&#146; systems and technologies. Furthermore, we may discover security issues or other constraints not found during due diligence of such acquired or integrated entities, creating additional challenges to integrate
said information systems into our information technology environment and security program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we have implemented
security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate, and remediate known vulnerabilities in our information systems (such as
our hardware and/or software, including that of third parties with whom we work). We may not, however, detect and remediate all such vulnerabilities on a timely basis for various reasons including but not limited to the impact on the functional
operations of affected information systems or the availability of a solution for the impacted technology. While remedial measures and/or patches designed to address identified vulnerabilities are being developed and/or implemented, these
vulnerabilities could be exploited and result in a security incident. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Applicable data privacy and security obligations
may require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead
to adverse consequences. Additionally, laws in all 50 states require businesses to provide notice to customers whose personal data has been disclosed as a result of a data breach. These laws are not consistent, and compliance in the event of a
widespread data breach is difficult and may be costly. We also may be contractually required to notify patients or other counterparties of a cybersecurity incident or breach. Although we may have contractual protections with our service providers,
any actual or perceived cybersecurity incident or breach could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data security and in responding to any such actual or perceived breach.
Any contractual protections we may have from our service providers may not be sufficient to adequately protect us from any such liabilities and losses, and we may be unable to enforce any such contractual protections. In addition to government
regulation, privacy advocates and industry groups have and may in the future propose self-regulatory standards from time to time. These and other industry standards may legally or contractually apply to us, or we may elect to comply with such
standards. Determining whether personal data has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we maintain insurance coverage, we cannot assure that such coverage will be adequate or otherwise protect us from or
adequately mitigate liabilities or damages with respect to claims, costs, expenses, litigation, fines, penalties, business loss, data loss, regulatory actions or material adverse effects arising out of our data protection, privacy, and security
practices, or that such coverage will continue to be available on acceptable terms or at all. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance
policies (including premium increases or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
imposition of large deductible or <FONT STYLE="white-space:nowrap">co-insurance</FONT> requirements), could have an adverse effect on our business. In addition, we cannot be sure that our
existing insurance coverage will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Threat actors and their techniques change frequently, are often sophisticated in nature, and may not be detected until after a
cybersecurity incident has occurred. Any failure to prevent or mitigate cybersecurity incidents, breaches or other improper access to, use of, or disclosure of our clinical data or patients&#146; personal data could result in significant liability
under state (e.g., state breach notification laws), federal (e.g., HIPAA), and foreign (e.g., the GDPR) laws, and may cause a material adverse impact to our reputation, affect our ability to conduct new studies and potentially disrupt our business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our reliance on the computer systems of various third parties with whom we work, including our CROs and
other contractors, introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. We rely on our third-party partners to implement effective security measures and identify and
correct for any such failures, deficiencies or breaches. However, our ability to monitor these third parties&#146; information security practices is limited, and these third parties may not have adequate information security measures in place. While
we may be entitled to damages if the third parties with whom we work fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.<B><I> </I></B>In
addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#146; infrastructure in our supply chain or that of the third parties with whom we work have not been compromised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we or our third-party partners fail to maintain or protect our information technology systems and data integrity
effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party partners could have difficulty preventing, detecting and controlling such cyberattacks and any such attacks
could result in disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on
our business, results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate cybersecurity incidents, breaches or other improper access to or disclosure of such information could have
similarly adverse consequences for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to experiencing a security incident, third parties may gather,
collect, or infer sensitive data about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.
Additionally, sensitive data of the Company could be leaked, disclosed, or revealed as a result of or in connection with our employees&#146;, personnel&#146;s, or vendors&#146; use of generative artificial intelligence technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in
unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties with whom we work. A
security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to provide our services. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to Government Regulatory and Legal Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to
hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ability of the FDA, EMA, and other comparable foreign regulatory authorities to review and approve new products can be
affected by a variety of factors, including government budget and funding levels, ability to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent&nbsp;years as a result.
In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by
necessary government agencies, which would adversely affect our business. For example, over the last several&nbsp;years, the U.S. government shut down several times and certain regulatory agencies, such as the FDA, furloughed critical employees and
ceased critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA, EMA, or other comparable foreign
regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA, EMA, or other comparable foreign regulatory authorities to timely review and process our
regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to obtain orphan drug
designation or exclusivity for our product candidates, and even if we do, that designation may not provide an expedited development or regulatory review or approval process and any orphan drug exclusivity we may receive for approved products may not
prevent the FDA or the EMA from approving other competing products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Orphan Drug Act, the FDA may
designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition. A similar regulatory scheme governs the designation of orphan product candidates by the EMA in the EU. Generally, if a product with an orphan
drug designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA (as applicable) from
approving another marketing authorization application for another similar product candidate for the same orphan therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the EU (which can
be extended to 12 years if the sponsor complies with an agreed-upon pediatric investigation plan). The exclusivity period in the EU can be reduced to six years if at the end of the fifth year it is determined that a product no longer meets the
criteria for orphan designation, including if the product is sufficiently profitable so that market exclusivity is no longer justified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order for the FDA to grant orphan drug exclusivity to one of our product candidates, the agency must find that the product
candidate is indicated for the treatment of a condition or disease that affects fewer than 200,000 individuals in the United States or that affects 200,000 or more individuals in the United States and for which there is no reasonable expectation
that the cost of developing and making the product candidate available for the disease or condition will be recovered from sales of the product in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug
exclusivity does not meet this standard. In the EU, a medicinal product may be designated as orphan if (1)&nbsp;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2)&nbsp;either
(a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b)&nbsp;it is unlikely that the product, without the benefits derived from orphan status, would generate sufficient return in the EU to
justify the necessary investment in its development; and (3)&nbsp;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of
significant benefit to those affected by the condition. Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different product candidates can
be approved for the same condition. In addition, even after an orphan drug is approved, the FDA or the EMA can subsequently approve the same product candidate for the same condition if the FDA or EMA (as applicable) concludes that the later product
candidate is clinically superior in that it is shown to be safer, more effective or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
makes a major contribution to patient care compared with the product that has orphan exclusivity. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for
designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>While we may in the future seek designations for our product candidates with the FDA, EMA and other comparable foreign regulatory
authorities that are intended to confer benefits such as a faster development process, an accelerated regulatory pathway or regulatory exclusivity, there can be no assurance that we will successfully obtain such designations. In addition, even if
one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA, EMA, and other comparable foreign regulatory authorities offer certain designations for product candidates that are
designed to encourage the research and development of product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory authorities,
a potentially accelerated regulatory pathway and priority review. However, there can be no assurance that we will successfully obtain such designations for our product candidates. In addition, while such designations could expedite the development
or approval process, they generally do not change the standards for approval. Even if we obtain such designations for our product candidates, there can be no assurance that we will realize their intended benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, we may seek a Fast Track Designation for one or more of our product candidates. If a product is intended for the
treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad
discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we
may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track Designation if it believes that the designation is no longer supported by data from our clinical
development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the EU, we may seek to participate in the PRIority Medicines (PRIME) scheme for our potential
product candidates. The PRIME scheme is intended to encourage development of product candidates in areas of unmet medical need and provides accelerated assessment of product candidates representing substantial innovation, where the marketing
authorization application will be made through the centralized procedure in the EU. Eligible products must target conditions for which there is an unmet medical need (i.e. no treatment option exists in the European Union or, they can offer a major
therapeutic advantage over existing treatments). Many benefits accrue to sponsors of product candidates with access to the PRIME scheme, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on
clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. There is no guarantee, however, that our potential product candidate would be deemed
eligible for the PRIME scheme and even if we do participate in the PRIME scheme, where during the course of development a product no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn. PRIME eligibility does not
change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may seek Breakthrough Therapy Designation for one or more of our product candidates. A breakthrough therapy is defined as a
drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over
currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication
between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA
are also eligible for accelerated approval and priority review. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Designation as a breakthrough therapy is within the discretion of the FDA.
Accordingly, even if we believe a product candidate we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of Breakthrough Therapy
Designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if
any product candidate we develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even in the absence of obtaining Fast Track and/or Breakthrough Therapy Designations, a sponsor can seek priority review at
the time of submitting a marketing application. The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared
with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement
of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such
applications, and to shorten the FDA&#146;s goal for taking action on a marketing application from ten months to six months. Priority review designation may be rescinded if a product no longer meets the qualifying criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Where appropriate, we may secure approval from the FDA, EMA, or other comparable foreign regulatory authorities through the use of
expedited approval pathways, such as accelerated approval. If we are unable to obtain such approvals, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense
of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, EMA, or other comparable foreign regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we
do not comply with rigorous post-marketing requirements, the FDA, EMA, or other comparable foreign regulatory authorities may seek to withdraw the accelerated approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where possible, we plan to pursue accelerated development strategies in areas of high unmet need. We may seek an accelerated
approval pathway for our one or more of our product candidates from the FDA, EMA, or other comparable foreign regulatory authorities. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA&#146;s
implementing regulations, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the
product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful
in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is
thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably
likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage
but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#146;s agreement to conduct, in a diligent manner, additional post-approval confirmatory
studies to verify and describe the drug&#146;s clinical benefit. Under FDORA, the FDA is permitted to require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a specified time period after
the date of approval for a product granted accelerated approval. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies
in a timely manner, send status updates on such studies to the FDA every 180 days to be publicly posted by the agency, or if such post-approval studies fail to verify the drug&#146;s predicted clinical benefit. The FDA is empowered to take action,
such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to seeking accelerated approval, we would seek feedback from the FDA,
EMA, or other comparable foreign regulatory authorities and would otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to
pursue or submit an NDA or BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent feedback from the FDA, EMA, or other comparable foreign regulatory
authorities, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated
approval, there can be no assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA, EMA, or other comparable foreign regulatory authorities could also require us to conduct further
studies prior to considering our application or granting approval of any type, including, for example, if other products are approved via the accelerated pathway and subsequently converted by FDA to full approval. A failure to obtain accelerated
approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate
and could harm our competitive position in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to stringent and evolving U.S. and foreign laws, rules,
regulations, policies, industry standards, contractual requirements, and other obligations related to data protection, privacy, and security. Our actual or perceived failure to comply with such obligations could adversely affect our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to various data protection, privacy, and security laws, rules, regulations, policies, industry
standards, contractual requirements, and other obligations that apply to our collection, transmission, storage, use, disclosure, transfer, maintenance and other processing of sensitive information, including personal data. The legislative and
regulatory landscape for data protection, privacy, and security continues to evolve across jurisdictions worldwide. For example, in the United States, federal, state, and local governments have enacted numerous data protection, privacy, and security
laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section&nbsp;5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In particular, regulations promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996 (HIPAA), as
amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), and implementing regulations, establish stringent privacy and security standards that limit the use and disclosure of individually identifiable health
information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability
of electronic protected health information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Data protection, privacy, and security obligations remain an evolving
landscape at both the domestic and foreign level, with new laws, rules and regulations coming into effect, posing continued legal and compliance challenges. For example, in the past few years, numerous U.S. states&#151;including California,
Virginia, Colorado, Connecticut, and Utah&#151;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights
concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain data processing activities, such as targeted
advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to conduct our operations. Certain states also impose stricter requirements for processing certain personal data, including
sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, in California, the California Consumer Privacy Act of 2018, as amended by the California Privacy
Rights Act of 2020 (CPRA) (collectively, CCPA), provides for fines of up to $7,500 per intentional violation and allows privacy litigants affected by certain data breaches to recover significant statutory damages. The CCPA and other comprehensive
U.S. state privacy laws exempt some data processed in the context of clinical trials, but these developments may further complicate compliance efforts, and increase legal risk and compliance costs for us, the third parties with whom we work. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Similar laws are being proposed in numerous other states and at the federal
level. Proposed legislation, if enacted, may add additional complexity, variation in requirements, processing restrictions, potential legal risk, require additional investment of resources, impact business strategies, and could result in increased
compliance costs and/or changes in business practices and policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are also states that specifically regulate
consumer health information. For example, Washington has enacted a consumer health privacy law, the My Health My Data Act (MHMD), that regulates the collection and sharing of consumer health information. MHMD places restrictions on processing
consumer health data (including imposing stringent requirements for consents), provides consumers certain rights with respect to their health data, and creates a private right of action to allow individuals to sue for violations of the law, which
further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Outside the United States, an increasing number of laws, regulations, and industry standards govern data protection, privacy,
and security. For example, if we conduct clinical trials in the European Economic Area (EEA) and/or the United Kingdom (U.K.), we may become subject to additional privacy laws in those jurisdictions, such as the EU General Data Protection Regulation
(EU GDPR) and the EU GDPR as incorporated into U.K. domestic law post-Brexit (U.K. GDPR and, together with the EU GDPR, GDPR), both of which impose strict requirements for processing personal data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, under the GDPR, data protection authorities may impose large penalties for violations of the GDPR, including
potential fines of up to &#128;20&nbsp;million (&pound;17.5&nbsp;million GBP) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with
supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> could also result in the imposition of orders to stop data processing
activities, which could have a material adverse effect on our business, financial position, and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, we may be unable to transfer personal data from the EEA, U.K., and other jurisdictions to the U.S. or other countries due to data localization requirements or limitations on cross-border data flows. Although there are various mechanisms
that may be used in some cases to lawfully transfer personal data to the U.S. or other countries, these mechanisms are subject to legal challenges and may not always be available to us. For example, the GDPR requires certain adequate safeguards to
enable the transfer of personal data outside of the EEA or the U.K., in particular to the U.S., such as the EU standard contractual clauses, U.K. International Data Transfer Addendum/Agreement, and the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT>
Data Privacy Framework (Framework) and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework). However, these mechanisms are subject to legal
challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the U.S. If there is no lawful manner for us to transfer personal data from the EEA, the U.K. or other jurisdictions to the
U.S., or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data
processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties,
and injunctions against our processing or transferring of personal data necessary to operate our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore,
if we fail, or are perceived to have failed, to comply with applicable data protection, privacy, and security laws, including applicable HIPAA privacy and security standards, we could face significant administrative, civil and criminal penalties.
For example, HHS has the discretion to impose significant penalties, and such enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In
addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
data protection, privacy, or security of the personal data of state residents. We cannot be sure how these laws, rules and regulations will be interpreted, enforced, or applied to our operations.
In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws, rules and regulations at the international, federal and state level may be costly and require
ongoing modifications to our policies, procedures and systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we rely on certain third-party vendors to
process certain confidential, sensitive, or personal data on our behalf. Failure by us or our third-party vendors to comply with any of these laws, rules, regulations, contractual requirements, industry standards, or other obligations could result
in notification obligations, enforcement actions, regulatory investigations or inquiries, significant fines, imprisonment of company officials and public censure, litigation and claims for damages by affected individuals, customers or business
partners, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our employees and personnel use generative artificial intelligence technologies to perform their work, and the disclosure and
use of personal data in generative artificial intelligence technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative artificial intelligence.
Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative artificial intelligence, it could make our business less efficient and result in
competitive disadvantages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also make public statements about our use, collection, disclosure, and other processing of
personal data through our privacy policies and information provided on our website. Although we endeavor to comply with our public statements and documentation, we may at times fail to do so or be alleged to have failed to do so. The publication of
our privacy policies and other statements that provide promises and assurances about data protection, privacy, and security can subject us to potential government or legal action if they are found to be deceptive, unfair or misrepresentative of our
actual practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to data protection, privacy, and security laws, we are contractually subject to industry
standards adopted by industry groups and may become subject to such obligations in the future. We are also bound by other contractual obligations related to data protection, privacy, and security, and our efforts to comply with such obligations may
not be successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obligations related to data protection, privacy, and security (and consumers&#146; data privacy
expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions.
Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data
on our behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of these compliance and operational requirements impose significant costs, such as costs related to
organizational changes, implementing additional protection technologies, training employees and engaging consultants and legal advisors, which are likely to increase over time. Our efforts to comply with the evolving data protection, privacy, and
security laws, rules, regulations, and other obligations may be unsuccessful. It is </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">possible that these various obligations may be
interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection, privacy, and security obligations may be unsuccessful. We may need to devote significant resources to
understanding and complying with this changing landscape. In addition, such requirements may require us to modify our data processing practices and policies, utilize management&#146;s time and/or divert resources from other initiatives and projects.
Any actual or perceived failure by us or our third-party partners to comply with such laws, rules, regulations, and other obligations regarding data protection, privacy, and security could result in significant government-imposed fines or orders
requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, rules or
regulations, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity. Further, any of the foregoing could have a material adverse effect on our business, financial
condition, results of operations or prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Healthcare legislative reform measures may have a negative impact on our business
and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States and some foreign jurisdictions, there have been, and continue to
be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to
profitably sell any product candidates for which we obtain marketing approval. For more information, see the section titled &#147;Business&#150;Government Regulation&#150;Current and Future U.S. Healthcare Reform.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in
healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by
major legislative initiatives. In 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the ACA) was passed, which substantially changed the way healthcare is financed by
both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The continuing
efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand for any of our product candidates, if approved;</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to set a price that we believe is fair for any of our product candidates, if
approved;</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to generate revenues and achieve or maintain profitability;</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of taxes that we are required to pay; and</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of capital.</P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional
activities for pharmaceutical and biologic products. In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S.
Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing
and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2022,
the Inflation Reduction Act of 2022 (IRA) was signed into law. The IRA includes several provisions that may impact our business, depending on how various aspects of the IRA are implemented. Provisions that may impact our business include a $2,000 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cap for Medicare Part D beneficiaries, the imposition of new manufacturer financial liability on most drugs in Medicare Part D, permitting the U.S. government to
negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, requiring companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay until
January&nbsp;1, 2032 the implementation of the HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only
if they have one orphan designation and for which the only approved indication is for that disease or condition. If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug
exemption. The implementation of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#146;s Medicare drug price negotiation program. The effects of the IRA on our business and the
healthcare industry in general is not yet known. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot be sure whether additional legislative changes will be
enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#146;s
approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot predict what healthcare reform initiatives may be adopted in the future. We expect that these and other healthcare
reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government
programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our
drugs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and
state healthcare fraud and abuse laws, false claims laws, other healthcare laws and regulations and health data privacy and security laws and regulations, contractual obligations and self-regulatory schemes. If we are unable to comply, or have not
fully complied, with such laws, we could face substantial penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Healthcare providers and third-party payors
in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal
investigators, consultants, customers and third-party payors may subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal
false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our clinical research, as well as our proposed sales and marketing programs. In addition, we may
be subject to health information privacy and security laws by the federal government, the states and other jurisdictions in which we may conduct our business. For more information, see the section titled &#147;Business&#150;Government
Regulation&#150;Other Healthcare Laws.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of the breadth of these laws and the limited statutory exceptions
and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and
regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the
operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility
that a healthcare company may run afoul of one or more of the requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our operations are found to be in
violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in
government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws and the curtailment or restructuring of our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Legislation or other changes in U.S. tax law may have a material adverse effect on our
business, cash flow, financial condition, or results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The rules dealing with U.S. federal, state,
and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could
adversely affect us or holders of our common stock. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future. For example, under Section&nbsp;174 of the Code, in taxable years
beginning after December&nbsp;31, 2021, expenses that are incurred for research and development in the United States will be capitalized and amortized, which may have an adverse effect on our cash flow. Future changes in tax laws could have a
material adverse effect on our business, cash flow, financial condition or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It cannot be predicted
whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our
stockholders&#146; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. We urge investors to consult with their legal and tax
advisers regarding the implications of potential changes in tax laws on an investment in our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to U.S.
and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could hinder our ability to compete in certain markets. We can face
criminal liability and other serious consequences for violations, which can harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our operations are
subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. Anti-corruption laws generally prohibit us and our employees, officers, CROs, consultants, contractors and other
partners and agents from authorizing, promising, offering, providing, soliciting, or receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. We have direct or
indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> activities to increase over time.
We expect to rely on third parties for research, preclinical studies and clinical trials and/or to obtain necessary permits, licenses, patent registrations and other marketing approvals. We can be held liable for the corrupt or other illegal
activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also subject to U.S. and foreign export controls, trade sanctions, and import laws and regulations. Such laws may
prevent or prohibit the export or provision of certain products and services to countries, governments, and persons targeted by sanctions. Violations of these above laws can result in substantial criminal fines and civil penalties, imprisonment, the
loss of trade privileges, debarment, breach of contract and fraud litigation, reputational harm and other consequences. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related
to Third Party Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may depend on collaborations with third parties for the discovery, development and
commercialization of our product candidates. If any of these collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may in the future seek third-party collaborators for research, development and commercialization of our product candidates.
Pharmaceutical companies are our prior and likely future collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements. If we fail to enter into future collaborations on commercially reasonable terms, or
at all, or such collaborations are not successful, we may not be able to execute our strategy to develop certain targets, product candidates or disease areas that we believe could benefit from the resources of either larger pharmaceutical companies
or those specialized in a particular area of relevance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect to any future collaboration agreements, we expect to have
limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our current or future product candidates. Moreover, our ability to generate revenues from these arrangements will
depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Collaborations involving our current or future product candidates may pose the following risks to us: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to
these collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to
continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors such as an acquisition that diverts
resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our current or future product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators with marketing and distribution rights to one or more products may not commit sufficient
resources to the marketing and distribution of such product or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary
information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to
litigation and potential liability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between the collaborators and us that result in the delay or termination of the research,
development or commercialization of our current or future product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue
further development or commercialization of the applicable product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result of the
foregoing, any future collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. If a future collaborator of ours were to be involved in a business combination, the
continued pursuit and emphasis on our current or future product development or commercialization program could be delayed, diminished or terminated. Any failure to successfully develop or commercialize our product candidates pursuant to any future
collaboration agreements could have a material and adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, to the extent that any of our future collaborators were to terminate a collaboration agreement, we may be forced to
independently develop these product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and defending intellectual property rights, or, in certain instances, abandon product candidates
altogether, any of which could result in a change to our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely on third-party manufacturers, CROs, CMOs, and suppliers to supply, develop and
test components of our product candidates. The loss of our third-party manufacturers, CROs, CMOs, or suppliers, their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or
prices, or at all, or changes in methods of product candidate manufacturing, development or formulation would materially and adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not own or operate facilities for drug manufacturing, storage, distribution or quality testing. We currently rely, and
may continue to rely, on third-party contract manufacturers, including in China, to manufacture and test bulk drug substances, drug products, raw materials, samples, components, or other materials and reports. Reliance on third-party manufacturers
may expose us to different risks than if we were to manufacture product candidates ourselves. There can be no assurance that our preclinical and clinical development product supplies will not be limited, interrupted, terminated or of satisfactory
quality or continue to be available at acceptable prices. In addition, any replacement of our manufacturer could require significant effort and expertise because there may be a limited number of qualified replacements.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The manufacturing process for a product candidate is subject to FDA, EMA and foreign regulatory authority review. In some
cases, we, and our suppliers and manufacturers, some of which may be our sole source of supply, must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to
comply with regulatory standards, such as cGMPs. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the FDA, EMA, and other comparable
foreign regulatory authorities. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA, and other comparable foreign regulatory authorities,
we may not be able to rely on their manufacturing facilities for the manufacture of elements of our product candidates. Moreover, we do not control the manufacturing process at our contract manufacturers and are completely dependent on them for
compliance with current regulatory requirements. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations in relation to quality, timing or otherwise, or if our supply of components or other
materials becomes limited or interrupted for other reasons, we may be forced to enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology
required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such to another third party.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in
order to enable us, or to have another third party, manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that
comply with quality standards and with all applicable regulations and guidelines; and we may be required to repeat some of the development program. The delays associated with the verification of a new manufacturer could negatively affect our ability
to develop product candidates in a timely manner or within budget.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to continue to rely on third-party
manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations
in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. Any manufacturing facilities used to produce our products will be subject to periodic review and inspection by the
FDA and foreign regulatory authorities, including for continued compliance with cGMP requirements, quality control, quality assurance and corresponding maintenance of records and documents. If we are unable to obtain or maintain third-party
manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#146;s failure to execute on our manufacturing
requirements, comply with cGMPs or maintain a compliance status acceptable to the FDA or foreign regulatory authorities could adversely affect our business in a number of ways, including:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay in the progress on certain research programs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to initiate or continue clinical trials of product candidates under development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of the cooperation of existing or future collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to cease distribution or to recall batches of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of approval to market and commercialize a product candidate, an inability to meet commercial
demands for our therapeutics. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, our contract manufacturers may experience manufacturing
difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our contract manufacturers were to encounter any of these difficulties, our ability to provide our product candidates to patients in
preclinical and clinical trials, or to provide product for treatment of patients once approved, would be jeopardized.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, we currently rely on foreign CROs and CMOs, including WuXi AppTec (HongKong) Limited, for manufacturing and development activities and will likely continue to rely on foreign CROs and CMOs in the future. Foreign CMOs may be subject to U.S.
legislation, sanctions, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our
ability to secure significant commitments from governments to purchase our potential therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, if enacted,
legislation pending in Congress known as the BIOSECURE Act would prohibit U.S. federal agencies from entering into or renewing a contract with any company that uses biotechnology equipment or services produced or provided by a &#147;biotechnology
company of concern&#148; in the performance of that contract. It would also prohibit loans or grant funding from U.S. federal agencies to entities that use any biotechnology equipment or services produced or provided by a &#147;biotechnology company
of concern&#148; in the performance of the government grant or loan. The effects of this legislation, if enacted, is unknown; however, it could have the downstream effect of restricting the ability of pharmaceutical companies that enter into
contracts with or receive funding from U.S. federal agencies from purchasing services or equipment from certain Chinese biotechnology companies, including those that are specifically named in the proposed BIOSECURE Act, as well as supply chain
disruptions or delays. The current version of the BIOSECURE Act introduced in the House of Representatives names WuXi Biologics and WuXi AppTec as &#147;biotechnology companies of concern&#148; and includes a grandfathering provision allowing
biotechnology equipment and services provided or produced by named &#147;biotechnology companies of concern&#148; under a contract or agreement entered into before the effective date until January&nbsp;1, 2032.<B></B><B>&nbsp;</B>Depending on
whether the BIOSECURE Act becomes law, what the final language of the BIOSECURE Act includes, and how the law is interpreted by U.S. federal agencies, we could be potentially restricted from pursuing U.S. federal government business or government
reimbursement for our products in the future if we continue to use WuXi Biologics, WuXi AppTec or other suppliers or partners identified as &#147;biotechnology companies of concern&#148; beyond this grandfathering period. In addition to the
BIOSECURE Act, any additional executive action, legislative action, or potential sanctions with China could materially impact our work with WuXi STA. U.S. executive agencies have the ability to designate entities and individuals on various
governmental prohibited and restricted parties lists. Depending on the designation, potential consequences can range from a comprehensive prohibition on all transactions or dealings with designated parties, or a limited prohibition on certain types
of activities, such as exports and financing activities, with designated parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, the pharmaceutical
industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting pharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China which
could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#146;s public health, economic, political, and social conditions and the uncertainty around China&#146;s relationship
with other governments, such as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the U.S. and the United Kingdom, or U.K., could also negatively impact our ability to manufacture our product candidates for our planned clinical trials or have an adverse effect on our ability
to secure government funding, which could adversely affect our financial condition and cause us to delay our clinical development programs. Any of the foregoing factors could have a material adverse effect on our business, results of operations, or
financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, as product candidates progress through preclinical and clinical trials to marketing
approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and
achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of current or future
clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of
our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We
may in the future enter into collaboration agreements and strategic alliances to maximize the potential of our structure-based drug discovery platform and product candidates, and we may not realize the anticipated benefits of such collaborations or
alliances. We expect to form collaborations in the future with respect to our product candidates, but may be unable to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and
commercialization plans. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Part of our business strategy is to explore additional collaborations with third parties
to further utilize our platform capabilities on additional novel GPCR targets and to leverage partners additional disease biology understanding, development and commercial expertise, regional insights or other complementary capabilities to existing
or future Septerna programs. We may therefore form or seek further strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our
development and commercialization efforts with respect to our structure-based drug discovery platform or our current or future product candidates that we may develop. These transactions can entail numerous operational and financial risks, including
exposure to unknown liabilities, disruption of our business and diversion of our management&#146;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt
or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses,
difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in
management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into acquisition or license agreements or strategic partnerships, we may not be able to realize the benefit of such transactions if
we are unable to successfully integrate them with our existing operations and company culture. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or other anticipated benefits that led us to
enter into the arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development collaborations are subject to numerous risks, which may include the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a
collaboration, and may not commit sufficient efforts and resources, or may misapply those efforts and resources causing delays or termination of the research; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of our structure-based drug discovery platform
or collaboration product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results or changes in their strategic focus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay, provide insufficient resources to, or modify or stop clinical trials for
collaboration product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could develop or acquire products outside of the collaboration that compete directly or
indirectly with our products or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual
property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between us and a collaborator that cause the delay or termination of the research,
development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital and personnel
to pursue further development or commercialization of our structure-based drug discovery platform or the applicable product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our
products that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we could face significant competition in seeking appropriate strategic partners and the negotiation process is
time-consuming, expensive, and complex. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our structure-based drug discovery platform or product candidates because they may be deemed
to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate their desired safety and efficacy profile. If and when we collaborate with a
third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party. Our ability to reach a definitive agreement for a
collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of our technologies,
product candidates and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive
than the one with us for our product candidate. We may also be restricted under any license agreements from entering into additional agreements on certain terms or at all with other potential collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result of these risks, we may not be able to realize the benefit of any future collaborations or licensing agreements we
may enter into. In addition, we may face regulatory obstacles in completing such transactions. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development
programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our
own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do
not have sufficient funds, we may not be able to further develop our structure-based drug discovery platform or product candidates or bring them to market and generate revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we may sometimes collaborate with academic institutions to accelerate our preclinical research or development
under written agreements with these institutions. If collaborations occur, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Regardless of such
option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our
ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our products require specific constituents to work effectively and efficiently, and rights to those constituents are, and in
the future may be, held by others. We may also seek to <FONT STYLE="white-space:nowrap">in-license</FONT> third-party technologies to enhance our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>. We may be unable to <FONT
STYLE="white-space:nowrap">in-license</FONT> any rights from constituents, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable
cost or on reasonable terms, which could harm our business. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In
that event, we may be required to expend significant time and resources to develop or license replacement technology in order to establish or maintain our competitive position in the market. Any delays in entering into new collaborations or
strategic partnership agreements related to our product candidates or our structure-based drug discovery platform could delay the development and commercialization of our product candidates in certain geographies or limit our ability to discover and
develop new product candidates, which could harm our business prospects, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The
manufacturing of our product candidates is complex, and our third-party manufacturers may encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product
candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our products for patients, if approved, could be delayed or stopped. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The process of manufacturing pharmaceuticals is complex, time-consuming, highly regulated and subject to multiple risks. Our
contract manufacturers must comply with legal requirements, cGMPs and guidelines for the manufacturing of pharmaceuticals used in clinical trials and, if approved, marketed products. Our contract manufacturers may have limited experience in the
manufacturing of cGMP batches.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Manufacturing pharmaceuticals is highly susceptible to product loss due to contamination,
equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal
manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at our third-party manufacturers&#146; facilities, such facilities may need
to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including,
among others, cost overruns, potential problems with process <FONT STYLE="white-space:nowrap">scale-up,</FONT> process reproducibility, stability issues, compliance with cGMPs, lot consistency and timely availability of raw materials. Even if we or
our future collaborators obtain regulatory approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities,
to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization,
commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and prospects.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Scaling up a pharmaceutical manufacturing process is a difficult and uncertain task, and our third-party manufacturers may not
have the necessary capabilities to complete the implementation, manufacturing and development process. If we are unable to adequately validate or <FONT STYLE="white-space:nowrap">scale-up</FONT> the manufacturing process at our current
manufacturers&#146; facilities, we will need to transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If we are able to adequately validate and <FONT STYLE="white-space:nowrap">scale-up</FONT> the
manufacturing process for our product candidates with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms
acceptable to us.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot assure that any stability or other issues relating to the
manufacture of any of our current or future product candidates will not occur in the future. If our third-party manufacturers were to encounter any of these difficulties, our ability to provide any product candidates to patients in planned clinical
trials and products to patients, once approved, would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical
trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product
candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and
incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of
our supply chain could adversely affect our business and delay or impede the development and commercialization of any of our product candidates or products, if approved, and could have an adverse effect on our business, prospects, financial
condition and results of operations.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As part of our process development efforts, we also may make changes to the
manufacturing processes at various points during development, for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they
will not achieve their intended objectives, and any of these changes could cause our current or future product candidates to perform differently and affect the results of our current or future clinical trials. In some circumstances, changes in the
manufacturing process may require us to perform <I>ex vivo</I> comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical
development may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third
parties perform in an unsatisfactory manner, it may harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not currently have the ability to
independently conduct preclinical studies or clinical trials required to develop our product candidates. We intend to rely on CROs, clinical trial sites and other third parties to ensure the proper and timely conduct of our preclinical studies and
clinical trials, and we expect to have limited influence over their actual performance. We intend to rely upon CROs and others for the execution of future nonclinical studies and to monitor, manage and report data for our clinical trials. We expect
to control only certain aspects of our CROs&#146; and others&#146; activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies or clinical trials are conducted in accordance with the applicable protocol, legal,
regulatory and scientific standards and our reliance on the CROs and others does not relieve us of our regulatory responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, our CROs and other third parties we might engage will be required to comply with good laboratory practices (GLPs) and
GCPs, which are regulations and guidelines enforced by the FDA, EMA, and other comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of our product candidates that are in preclinical
and clinical development. The regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we will rely on CROs and others to conduct
<FONT STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and
applicable laws and regulations, and our reliance on the CROs and others does not relieve us of our regulatory responsibilities. If we, our CROs and other third parties we engage fail to comply with GCPs, the clinical data generated in our clinical
trials may be deemed unreliable and the FDA, EMA, or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs or others fail to comply
with these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
regulations or fail to recruit a sufficient number of participants, we may be required to repeat clinical trials, which would delay the regulatory approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we will have agreements governing their activities, our CROs and other third parties we engage will not be our
employees, and we will not control whether or not they devote sufficient time and resources to our future nonclinical and clinical programs. These CROs and others may also have relationships with other commercial entities, including our competitors,
for whom they may also be conducting clinical trials, or other drug development activities which could harm our business. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs and others,
which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. In addition, certain of our agreements with CROs and other third parties currently or will provide for monetary and
other limitations on their liability. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the preclinical or clinical data they obtain is compromised
due to the failure to adhere to our protocols or regulatory requirements or for any other reasons, our preclinical or clinical programs may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully
commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be
delayed, decreased or eliminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our relationship with these CROs terminates, we may not be able to enter into
arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO
commences work. As a result, delays occur, which can negatively impact our ability to meet our desired development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter
challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time
to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal
investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself
may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our current and future product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We currently depend and in the future may continue to depend on single- or limited-source suppliers for some of the components and
materials used in the product candidates we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently depend and in the future may continue to
depend on single- or limited-source suppliers for some of the components and materials used in any product candidates we may develop. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or
supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes and
finished goods could expose us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or
unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to
establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results
of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we have to switch to a replacement supplier, the manufacture and delivery
of any product candidates we may develop could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers, if required, may not be accomplished quickly or at all. If we are able
to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source
components and materials used in our therapeutics, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair
our ability to meet the demand for our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to obtain, maintain, defend and enforce patent or other intellectual property protection for our current or any future
product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate that we will file additional patent applications both in the United States and in other jurisdictions, as
appropriate. However, we cannot predict: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if and when any patents will issue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree and scope of protection any issued patents will afford us against competitors, including whether
third parties will find ways to invalidate or otherwise circumvent our patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether others will apply for or obtain patents claiming aspects similar to those covered by our patents and
patent applications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we will need to initiate litigation or administrative proceedings to defend our patent rights, which
may be costly whether we win or lose; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the patent applications that we own, or may <FONT STYLE="white-space:nowrap">in-license,</FONT> will
result in issued patents with claims that cover our current or future product candidates or uses thereof in the United States or in foreign jurisdictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely, and may in the future rely, upon a combination of patent, trade secret and trademark protection for our current and
any future product candidates and proprietary technologies to prevent third parties from exploiting our achievements, thus eroding our competitive position in our market. These legal measures afford only limited protection, and competitors or others
may gain access to or use our intellectual property and proprietary information. Our success depends in large part on our ability to obtain, maintain, expand, enforce, and defend the scope, ownership or control, validity and enforceability of our
intellectual property protection in the United States and other countries with respect to our current and any future product candidates and other proprietary technologies we may develop. Our commercial success depends in large part on our ability to
obtain and maintain patent protection in the United States and other jurisdictions with respect to our current and any future product candidates. We seek to protect our proprietary position by filing patent applications in the United States and
abroad related to our current and future development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a
reasonable cost or in a timely manner, including as a result of factors impacting our, our licensors&#146; or governmental patent offices&#146; operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is possible that we will fail to identify patentable aspects of our research and development output before it is too late
to obtain patent protection. The patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover our current or any future product candidates in the United States or
in foreign jurisdictions. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been or will be found, which unknown prior art can invalidate a patent or prevent a patent from
issuing from a pending patent application. Even if patents do issue and even if such patents cover our current or any future product candidates, third parties may challenge their scope, validity, or enforceability,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to&nbsp;us could deprive
us of rights necessary for the successful commercialization of any current or future product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate
under patent protection could be reduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the patent applications we hold or have
<FONT STYLE="white-space:nowrap">in-licensed</FONT> with respect to our product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for current or any future product
candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future drug products. Any such outcome could have a negative effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Composition of matter patents for pharmaceutical products provide intellectual property protection for those types of
products, as such patents provide protection without regard to any method of use. We cannot be certain, however, that the claims in our pending patent applications covering the composition of matter of any of our current or future product candidates
will be considered patentable by the U.S. Patent and Trademark Office (USPTO), or by patent offices in foreign jurisdictions, or that the claims in any of our patents that may issue will be considered valid and enforceable by courts in the United
States or foreign jurisdictions. Method of use patents protect the use of a product for the specified method. We cannot be certain, however, that the claims in our pending patent applications covering methods of use of our current or future product
candidates will be considered patentable by the USPTO, or by patent offices in foreign jurisdictions, or that the claims in any of our patents that may issue will be considered valid and enforceable by courts in the United States or foreign
jurisdictions. Further, this type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not
actively promote their product for our targeted indications, once approved for therapeutic use by FDA. or counterpart foreign regulatory authorities, physicians may prescribe these products
<FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> for those uses that are covered by our method of use patents. Although <FONT STYLE="white-space:nowrap">off-label</FONT> prescriptions may infringe or contribute to the infringement of
method of use patents, the practice is common and such infringement is difficult to prevent or enforce against. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign jurisdictions may
not protect our rights to the same extent as the laws of the United States. Patent applications in the United States and certain other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we
cannot know with certainty whether we were the first to file for patent protection. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications
may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies or products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in either the patent laws or interpretation of the patent laws in the United States and other jurisdictions may
diminish the value of our patents or narrow the scope of our patent protection. These changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all
of which could have a negative effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, we may be subject to a third-party <FONT
STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the USPTO or another patent office or become involved in opposition, derivation, reexamination, <I>inter partes</I> review (IPR), post-grant review (PGR) or interference
proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our
technology or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights or obtaining a costly license from a third party. In addition, if
the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize our current or future product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The issuance of a patent is not conclusive as to its inventorship, scope,
validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims
being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology, products or methods, or limit the duration of the patent protection
of our technology, products or methods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, patents have a limited lifespan. In the United States, if all
maintenance fees are paid timely, the natural expiration of a patent is generally 20 years from the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. Various extensions may be available; however,
the life of a patent, and the protection it affords, is limited. For instance, a patent term extension based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and
any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not necessarily extend to all claims, but instead only to claims that read on the product as approved.
Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due
diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term
extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products
following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be
reduced, possibly materially. In addition, although upon issuance in the United States a patent&#146;s term can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by
the patent applicant during patent prosecution. Without patent protection for our current or future product candidates, including once the patent life has expired even if patents covering our product candidates are obtained, we may be open to
competition from generic versions of such drugs. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates
are commercialized. Even if patents covering our current or future product candidates are obtained, once the patent term has expired for a product, we may be open to competition from generic medications. As a result, our owned and licensed patent
portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we have or obtain patents covering our products or methods, we may still be barred from making, using and selling such
products or methods because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering compositions, products or methods that are similar or identical to ours, which could materially affect our
ability to successfully develop our technology or to successfully commercialize any approved products alone or with collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patent applications in the United States and elsewhere are generally published approximately 18 months after the earliest
filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our methods and current or future product candidates could have been filed by others
without our knowledge. Additionally, pending claims in patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies or related products. These patent
applications may have priority over patent applications filed by us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be subject to claims challenging the inventorship or
ownership of our patents and other intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may be subject to claims that former employees,
collaborators or other third parties have an interest in our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property as an inventor, <FONT STYLE="white-space:nowrap">co-inventor,</FONT>
owner or <FONT STYLE="white-space:nowrap">co-owner.</FONT> For example, we or our licensors may have inventorship or ownership disputes arise from conflicting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
obligations of employees, consultants or others who are involved in developing our current or future product candidates. Litigation may be necessary to defend against these and other claims
challenging inventorship or our or our licensors&#146; ownership of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, we
may be required to pay monetary damages and we may also lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our current or future product candidates. Even if we are
successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results
of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are sued for infringing intellectual property rights of third parties, such litigation could be
costly and time consuming and could prevent or delay us from developing or commercializing our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our current or future product
candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed or misappropriated their intellectual property. Litigation or other legal proceedings relating to
intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our
technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive
these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development
activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such
litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or
other proceedings could have a material adverse effect on our ability to compete in the marketplace.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is a
substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with
respect to our current or future product candidates. We cannot be certain that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. Third parties may assert
infringement claims against us based on existing or future intellectual property rights. In the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued
patents. If we are found to infringe a third party&#146;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively,
we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license
on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In addition, we
could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our investigational products or force
us to cease some of our business operations, which could materially harm our business.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be aware of patents that
have already been issued and that a third party, for example, a competitor in the fields in which we are developing our product candidates, might assert are infringed by our current or future product candidates, including claims to compositions,
formulations, methods of manufacture or methods of use or treatment that cover our product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates
and other proprietary technologies we may develop, could be found to be infringed by one or more of our current or future product candidates. In addition, because patent applications can take many years to issue, there may be currently pending
patent applications that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
may later result in issued patents that our current or future product candidates may infringe. Our competitors in both the United States and abroad, many of which have substantially greater
resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to
make, use and sell our current or future product candidates. The pharmaceutical and biotechnology industries have produced a considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover
various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our current or
future product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For
example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and there is no assurance that a court of competent jurisdiction would
invalidate the claims of any such U.S. patent. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings,
which could have a material adverse effect on our business and operations. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during litigation. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may choose to challenge the enforceability or validity of claims in a third party&#146;s U.S. patent by requesting that the
USPTO review the patent claims in an <I>ex parte</I> <FONT STYLE="white-space:nowrap">re-examination,</FONT> IPR or PGR proceeding. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third
party&#146;s patent in patent opposition proceedings in the European Patent Office (EPO), or other foreign patent office. The costs of these opposition proceedings could be substantial and may consume our time or other resources. If we fail to
obtain a favorable result at the USPTO, EPO or other patent office, then we may be exposed to litigation by a third party alleging that the patent may be infringed by our current or future product candidates or proprietary technologies.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are found to infringe a third-party&#146;s intellectual property rights, we could be forced, including by court order,
to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third-party in order to use the infringing technology and continue developing,
manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we
are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, and could divert the time and attention of our technical
personnel and management, cause development delays, and/or require us to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be possible on a cost-effective basis, any of which could materially harm our business.
In the event of a successful claim of infringement against us, we may have to pay substantial monetary damages, including treble damages and attorneys&#146; fees for willful infringement, pay royalties and other fees, redesign our infringing drug or
obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our
technology licensed from various third parties may be subject to retained rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future licensors may retain
certain rights under the relevant agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make
customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights
to our licensed technology in the event of misuse. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the United States federal government retains certain rights in
inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act (Bayh-Dole Act). The federal government retains a &#147;nonexclusive, nontransferable, irrevocable, <FONT STYLE="white-space:nowrap">paid-up</FONT>
license&#148; for its own benefit. The Bayh-Dole Act also provides federal agencies with <FONT STYLE="white-space:nowrap">&#147;march-in</FONT> rights.&#148; <FONT STYLE="white-space:nowrap">March-in</FONT> rights allow the government, in specified
circumstances, to require the contractor or successors in title to the patent to grant a &#147;nonexclusive, partially exclusive, or exclusive license&#148; to a &#147;responsible applicant or applicants.&#148; If the patent owner refuses to do so,
the government may grant the license itself. We sometimes collaborate with academic institutions to accelerate our preclinical research or development, creating a risk that federal funds may be commingled. Therefore, we cannot be sure that any
intellectual property co-developed from a collaboration with an academic institution will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we <FONT STYLE="white-space:nowrap">co-own</FONT> or license in technology
which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration date of a third-party
patent, which might adversely affect our ability to develop and market our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we have reviewed
certain third-party patents and patent filings that we believe may be relevant to our product candidates, we have not conducted a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">freedom-to-operate</FONT></FONT> search or analysis
for any of our current or future product candidates, and we may not be aware of patents or pending or future patent applications that, if issued, would block us from commercializing our product candidates. Thus, we cannot guarantee that our current
or future product candidates, or our commercialization thereof, do not and will not infringe any third party&#146;s intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot guarantee that any patent searches or analyses that are performed, including the identification of relevant patents,
the scope of patent claims or the expiration dates of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is
relevant to or necessary for the commercialization of our current or future product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#146;s
prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our future products. We may incorrectly determine that our products are
not covered by a third-party patent or may incorrectly predict whether a third-party&#146;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we
consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our
future products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One aspect of the determination of patentability of our inventions depends on the scope and content of
the &#147;prior art,&#148; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability
of our patent claims or, if issued, affect the validity or enforceability of a patent claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The landscape of
intellectual property related to our current or future product candidates and future products is constantly changing. Therefore, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or
their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to
operate, is highly uncertain. Because patent applications in the United States and certain other jurisdictions are confidential for typically a period of at least 18 months after their priority date, or may not be published at all, we cannot be
certain that we were the first to file any patent application related to our current or future product candidates. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, for U.S. applications in which all claims are entitled to a
priority date before March&nbsp;16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For
U.S. applications containing a claim not entitled to priority before March&nbsp;16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to
the U.S. patent laws, including new procedures for challenging pending patent applications and issued patents. Should we fail to win an interference challenge, a third party may obtain rights to intellectual property related to our current or future
product candidates and future products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be successful in obtaining or maintaining necessary rights to our product
candidates through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because our programs may
in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> or use these third-party proprietary rights. We
may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates.
The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider
attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a
competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would&nbsp;allow us to make an appropriate return on our investment or at all. If we
are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could
have a material adverse effect on our business, financial condition, results of operations, and prospects.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we
normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our product candidates, there may be times when the filing and prosecution activities for patents and patent applications relating to
our product candidates are controlled by our future licensors or collaboration partners. If any of our future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent
with the best interests of our business, including by payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to
develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of
patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our future licensors and their counsel that took place prior to the date upon
which we assumed control over patent prosecution.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may enter into license agreements in the future with others to
advance our existing or future research or allow commercialization of our current or future product candidates. These licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all
territories in which we may wish to develop or commercialize our technology platform or product candidates in the future.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, subject to the terms of any such license agreements, we may not have the right to control the preparation,
filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. In such an event, we cannot be certain that these patents and patent applications will be
prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our future licensors fail to prosecute, maintain, enforce, and defend such patents or patent applications, or lose
rights to those patents or patent applications, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our current or future product candidates that are subject of such licensed rights could be
adversely affected.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future licensors may rely on third-party consultants or collaborators or on funds from third
parties such that our future licensors are not the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-license.</FONT> If other third parties have ownership rights to our future
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our
competitive position, business, financial conditions, results of operations, and prospects.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is possible that we may be
unable to obtain necessary licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same
technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of
which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and
prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products resulting in either an
injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor
that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patents and other rights to third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to transfer or assign the license; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting
from the joint creation or use of intellectual property by our future licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and
certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual
property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and
prospects. Moreover, if disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and
commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In spite of our best efforts, our future licensors might conclude that we materially breached our license agreements and might
therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If these <FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products<B> </B>identical to ours. This
could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may be required to license technologies relating to our programs from additional third parties to
further develop or commercialize our current or future product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our product candidates, such licenses
may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could
seriously harm our business and operations.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be involved in lawsuits to protect or enforce our patents, which could be
expensive, time consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Competitors may infringe our intellectual property rights. To prevent infringement or unauthorized use, we may be required to
file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our
potential future collaborators were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent is invalid and/or unenforceable in whole or in part.
In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including but
not limited to lack of novelty, obviousness, or insufficient written description or enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information
from the USPTO or made a misleading statement during prosecution.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third parties may also raise similar invalidity claims
before the USPTO or patent offices abroad, even outside the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> PGR, IPR, derivation proceedings, interference proceedings, and equivalent proceedings
in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in loss of rights to, the revocation of, cancellation of or amendment to our patents in such a way that they no longer cover our technology or platform, or any
product candidates that we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of
which we and the patent examiner were unaware during prosecution. There is also no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent
applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a patent claim. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps
all, of the patent protection on our product candidates or other intellectual property that we may develop. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened or questioned, it could
dissuade companies from collaborating with us to&nbsp;license, develop or commercialize our current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of
operations and prospects.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if resolved in our favor, litigation or other legal proceedings relating to our
intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection
with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other
proceedings. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial
adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be
able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could
compromise our ability to compete in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be subject to claims that we or our employees have misappropriated the
intellectual property, including confidential information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets, of a third-party, or claiming ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of our employees, consultants and contractors were previously employed at or engaged by other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and
<FONT STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and contractors do not use the intellectual property, proprietary information, <FONT
STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, we may be subject to claims that we have wrongfully hired an employee from a competitor or that we or these employees, consultants or contractors have used
or disclosed such third-party intellectual property, including <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets or other proprietary information, to us. Litigation may be necessary to defend against these claims. If we fail in
defending any such claims, it may a have negative impact on our business and our ability to develop product candidates or commercialize our technology. In addition to paying substantial monetary damages, we may lose valuable intellectual property
rights or personnel, or access to consultants and contractors. Even if we are successful in defending against such claims, litigation could incur substantial costs and be a distraction to management and scientific personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of
intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in
claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are
successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may license intellectual property rights from third parties. Such licenses may be subject to early termination if we fail to comply
with our obligations in our licenses with third parties, which could result in the loss of rights or technology that are material to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may become a party to licenses that give us rights to third-party intellectual property or technology that is necessary or
useful for our business, and we may enter into additional licenses in the future. Under these license agreements, we are or may become obligated to pay the licensor fees, which may include annual license fees, milestone payments, royalties, a
percentage of revenues associated with the licensed technology and a percentage of sublicensing revenue. These fees may be significant, which could make it difficult for us to achieve or maintain profitability. In addition, under certain of such
agreements, we are or may become required to diligently pursue the development of products using the licensed technology. If we fail to comply with these obligations, including due to our use of the intellectual property licensed to us in an
unauthorized manner, and fail to cure our breach within a specified period of time, the licensor may have the right to terminate the applicable license, in which event we could lose valuable rights and technology that are material to our business,
harming our ability to develop, manufacture and/or commercialize our platform, products or product candidates.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, the agreements under which we license intellectual property or technology to or from third-parties can be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract
interpretation disagreement that may arise could narrow what we believe to be the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could
have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The licensing
and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual
property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical
development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates
that we may seek to acquire. The failure to obtain or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other third-party intellectual property rights at a reasonable cost or on reasonable terms, could
harm our business. If we fail to obtain licenses to necessary third-party intellectual property rights, we may need to cease use of the compositions or methods covered by such third-party intellectual property rights. Furthermore, we may need to
seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are
able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to
develop or license replacement technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Obtaining and maintaining our patent protection depends on compliance with various
procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or
applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future.
We rely on our outside counsel, patent annuity service providers, or our licensing partners to pay these fees due to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. If these fees are not paid to the USPTO or the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies when due, our rights to such patents or patent applications may be abandoned or otherwise materially impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government patent agencies require compliance with
numerous procedural, documentary, and other similar provisions during the patent application process. For example, many jurisdictions, including the U.S. and China, require a foreign filing license before seeking patent protection in a jurisdiction
outside of the jurisdiction of which the inventor is a citizen or in which the invention was made. Each jurisdiction&#146;s laws regarding foreign filing licenses vary and may even conflict. We employ reputable law firms in foreign jurisdictions and
other professionals to help us comply and we are also dependent on any licensors to take the necessary action to comply with these requirements with respect to our intellectual property. In many cases, an inadvertent lapse can be cured by payment of
a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in
partial or complete loss of patent rights in the relevant jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional
<FONT STYLE="white-space:nowrap">non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT
STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to protect our intellectual property rights throughout the world,
which could negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Filing, prosecuting, maintaining, enforcing, and defending patent
applications and patents covering our current and any future product candidates worldwide is prohibitively expensive, so we will pursue patents in a limited number of jurisdictions. Moreover, our intellectual property rights in some jurisdictions
outside the United States can have a different scope and strength than do those in the United States. Consequently, we will not be able to prevent third parties from practicing our inventions in all jurisdictions, or from selling or importing in and
into various jurisdictions products made using our inventions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own product candidates and, further, may export otherwise infringing
product candidates to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. Further, these product candidates may compete with our product candidates in jurisdictions where we
do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many companies have encountered significant problems protecting and defending intellectual property rights in jurisdictions
outside the United States. The legal systems of certain jurisdictions do not favor the enforcement of patents, trade secrets and other intellectual property rights, particularly those relating to pharmaceutical products, which could make it
difficult in those jurisdictions for us to stop the infringement or misappropriation of our patents or other intellectual property rights, including the marketing of competing products in violation of our proprietary rights. Proceedings to enforce
our patents and other intellectual property rights in jurisdictions outside the United States could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, such proceedings could put our
patents at risk of being invalidated, held unenforceable, or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims of infringement or misappropriation against us. We may not
prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our
proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in
intellectual property laws in the United States and around the world. For example, in Europe, a new unitary patent system took effect June&nbsp;1, 2023, which will significantly impact European patents, including those granted before the
introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (UPC). As the UPC is a
new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national
patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single <FONT STYLE="white-space:nowrap">UPC-based</FONT> revocation challenge that, if successful, could invalidate the patent in
all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. Certain jurisdictions, including China and India, have compulsory licensing laws under which a patent owner may be
compelled to grant licenses to third parties under certain circumstances. In those jurisdictions, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party,
which could materially diminish the value of those patents. In addition, many jurisdictions limit the enforceability of patents against government agencies or government contractors. This could limit our potential revenue opportunities. Accordingly,
our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we do not obtain patent term extension and data exclusivity for any product
candidates we may develop, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depending upon the timing, duration and
specifics of any FDA marketing approval of any product candidates we may develop and our technology, one or more U.S. patents that we license or may own in the future may be eligible for limited patent term extension under the Hatch-Waxman
Amendments. Under certain circumstances the Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the term of a
patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. The application for the
extension must be submitted prior to the expiration of the patent for which extension is sought and within 60 days of FDA approval. A patent that covers multiple products for which approval is sought can only be extended in connection with one of
the approvals. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to
expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable patent term extension or the scope of patent protection afforded could be less than we request. In addition, to the extent we wish to
pursue patent term extension based on a patent that we <FONT STYLE="white-space:nowrap">in-license</FONT> from a third party, we would need the cooperation of that third party. If we are unable to obtain patent term extension or the term of any such
extension is less than we request, we may be open earlier than projected to competition from competitive products, including generics or biosimilars following our patent expiration, and our revenue could be reduced earlier than projected. Any of the
foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of our trade secrets and other
proprietary information. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to
protect proprietary information and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> that we elect not to patent (e.g., our Native Complex Platform drug discovery platform), processes for which patents are difficult to enforce, and any
other elements of our current or future product candidates, technology and product discovery, development processes and drug discovery platform that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology
that is not covered by patents. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research,
clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological
achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third
parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Trade secrets, confidential know-how and proprietary information, however, may be difficult to protect. We seek to protect our
trade secrets, confidential know-how and proprietary information, including our proprietary processes and drug discovery platform, in part, by entering into confidentiality agreements with our employees, consultants, outside scientific advisors,
contractors, and collaborators. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. Although we use reasonable efforts to protect our trade secrets, we cannot
provide any assurances that all such agreements have been duly executed, and notwithstanding the existence of a confidentiality agreement our employees, consultants, outside scientific advisors, contractors, and collaborators might intentionally or
inadvertently disclose our trade secret information, including to competitors. In addition, competitors or other third parties may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Despite our efforts, any of these parties may breach the agreements and
disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and
time-consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or
information to compete with us. Furthermore, the laws of some foreign jurisdictions do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in
protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, or misappropriation of our intellectual property by
third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our intellectual property rights do not necessarily protect against all potential threats to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights
have limitations, and may not adequately protect our business. These risks and uncertainties include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make compounds or formulations that are similar to our current or future product
candidates but that are not covered by the claims of any patents, should they issue, that we own or control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or any strategic partners might not have been the first to make the inventions covered by the issued
patents or pending patent applications that we own or control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might not have been the first to file patent applications covering certain of our current or future product
candidates or inventions we own or control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies
without infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pending patent applications that we own or control may not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or control may be held invalid or unenforceable as a result of legal challenges;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in the United States and other jurisdictions
that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in jurisdictions where we do not have patent rights and then use the information learned from such activities to develop
competitive drugs for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest
and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our current or future trademarks or trade names may be challenged,
opposed, infringed, circumvented, invalidated, cancelled, declared generic, determined to be not entitled to registration, or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our
applications by the USPTO or in foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
agencies in many other jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation
proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Trademark litigation could be expensive. In addition, we could be found liable for significant monetary damages, including treble damages,
disgorgement of profits and attorneys&#146; fees, if we are found to have willfully infringed a trademark. We may not be able to protect our exclusive right to trademarks or trade names or may be forced to stop using these names, which we need for
name recognition by potential collaborators or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks or trade names, we may not be able to compete effectively and our business may be adversely
affected. We may license our trademarks or trade names to third parties, such as distributors. Though these agreements may provide guidelines for how our trademarks or trade names may be used, a breach of these agreements or misuse of our trademarks
or tradenames by third parties may jeopardize our rights in or diminish the goodwill associated with our trademarks or trade names. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, any name we have proposed to use with our product candidates in the United States must be approved by the FDA,
regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an
equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify
under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA or equivalent body. Furthermore, in many jurisdictions, owning and maintaining a trademark registration may not provide an adequate
defense against a subsequent infringement claim asserted by the owner of a senior trademark. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be able to
protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks
similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or
trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Furthermore, assertions of potential trademark infringement or possible market confusion may lead to coexistence agreements in order to avoid costly
disputes related to our trademarks. As a consequence, we may be forced to amend the list of goods and services covered by our trademarks more narrowly than as originally filed and intended, which could adversely affect our ability to establish name
recognition. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our
proprietary rights related to trademarks, trade names, domain name or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Rights to improvements to our product candidates may be held by third parties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the course of testing our current or future product candidates, we may enter into agreements with third parties to conduct
clinical testing, which may provide that improvements to our product candidates may be owned solely by a third party or jointly between the parties. If we determine that rights to such improvements owned solely by a third party are necessary to
commercialize our product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to use the improvements and continue developing, manufacturing or marketing the product candidates. However,
we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain such a license, it could be granted on <FONT STYLE="white-space:nowrap">non-exclusive</FONT> terms, thereby giving our
competitors and other third parties access to the same technologies licensed to us. Failure to obtain a license on commercially reasonable terms or at all, or to obtain an exclusive license, could prevent us from commercializing our current or
future product candidates or force us to cease some of our business operations, which could materially harm our business. If we determine that rights to improvements jointly owned between us and a third party are necessary to commercialize our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
product candidates or maintain our competitive advantage, we may need to obtain an exclusive license from such third party. If we are unable to obtain an exclusive license to any such third-party
<FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such improvements, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other parties, including our competitors, and our competitors could
market competing products and technology. In addition, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our intellectual property in order to enforce such intellectual property against other parties, and
such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The use of new and evolving technologies, such as artificial intelligence, in our offerings may present risks and challenges that can
impact our business including by posing security risks to our confidential information, proprietary information, and personal data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Issues in the development and use of artificial intelligence, combined with an uncertain regulatory environment, may result in
reputational harm, liability, or other adverse consequences to our business operations. As with many technological innovations, artificial intelligence presents risks and challenges that could impact our business. We may adopt and integrate
artificial intelligence tools into our processes for specific use cases reviewed by legal and information security. If we enable or offer solutions that draw controversy due to perceived or actual negative societal impact, we may experience brand or
reputational harm, competitive harm or legal liability. The use of certain artificial intelligence technology can give rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property
infringement. Additionally, we expect to see increasing government and supranational regulation related to artificial intelligence use and ethics, which may also significantly increase the burden and cost of research, development and compliance in
this area. For example, several jurisdictions around the globe, including Europe and certain U.S. states, have proposed enacted, or are considering laws governing the development and use of artificial intelligence, such as the EU&#146;s AI Act. We
expect other jurisdictions will adopt similar laws. Additionally, certain privacy laws extend rights to consumers (such as the right to delete certain personal data) and regulate automated decision making, which may be incompatible with our use
artificial intelligence. These obligations may make it harder for us to conduct our business using artificial intelligence, lead to regulatory fines or penalties, require us to change our business practices, retrain our artificial intelligence, or
prevent or limit our use of artificial intelligence. For example, the FTC has required other companies to turn over (or disgorge) valuable insights or trainings generated through the use of artificial intelligence where they allege the company has
violated privacy and consumer protection laws. If we cannot use artificial intelligence or that use is restricted, our business may be less efficient, or we may be at a competitive disadvantage. The rapid evolution of artificial intelligence will
require the application of significant resources to design, develop, test and maintain our products and services to help ensure that artificial intelligence is implemented in accordance with applicable law and regulation and in a socially
responsible manner and to minimize any real or perceived unintended harmful impacts. Our vendors may in turn incorporate artificial intelligence tools into their own offerings, and the providers of these artificial intelligence tools may not meet
existing or rapidly evolving regulatory or industry standards, including with respect to data protection, privacy, and security. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial
intelligence, to engage in illegal activities involving the theft and misuse of personal data, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and
information, cause us to breach applicable laws and regulations, and adversely impact our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to this Offering,
Ownership of Our Common Stock, and Operating as a Public Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We do not know whether an active, liquid and orderly trading
market will develop for our common stock or what the market price of our common stock will be, and, as a result, it may be difficult for you to sell your shares of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there was no public trading market for our common stock. If a market for our common stock does not
develop or is not sustained, it may be difficult for you to sell your shares of our common stock at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations may be below the
expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. An inactive market may also impair our ability to raise capital by selling our common stock and our ability to
acquire other companies, products, or technologies by using our common stock as consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>You will incur immediate and
substantial dilution as a result of this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you purchase common stock in this offering, you will incur
immediate and substantial dilution of approximately $&#8195;&#8195;&#8195;&#8195;per share, representing the difference between the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, the midpoint of the estimated price
range set forth on the cover page of this prospectus, and our pro forma as adjusted net tangible book value per share as of June&nbsp;30, 2024 after giving effect to this offering and the automatic conversion of all outstanding shares of our
preferred stock upon the closing of this offering. That is because the price that you pay will be substantially greater than the pro forma as adjusted net tangible book value per share of the common stock that you acquire. This dilution is due in
large part to the fact that our earlier investors paid substantially less than the initial public offering price when they purchased their shares of our capital stock. You will experience additional dilution if the underwriters exercise their option
to purchase additional shares in this offering, when those holding stock options exercise their right to purchase common stock under our equity incentive plans, upon the vesting of outstanding restricted stock awards or when we otherwise issue
additional shares of our common stock. See the section titled &#147;Dilution&#148; for a further description of the dilution you will experience immediately after this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The market price of our common stock may be volatile, which could result in substantial losses for investors purchasing shares in this
offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial public offering price for our common stock was determined through negotiations with the
underwriters. This initial public offering price may vary from the market price of our common stock after the offering. As a result, you may not be able to sell your common stock at or above the initial public offering price. The market price for
our common stock may be influenced by those factors discussed in this &#147;Risk Factors&#148; section and many others, some of which may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of existing or new competitive product candidates or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement, enrollment, completion and results of preclinical studies and clinical trials for our
current and future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse results or delays, suspensions or terminations in future preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to our current or future product candidates
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing
clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval of our current or future
product candidates or the failure of a regulatory authority to accept data from preclinical studies or clinical trials conducted in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to commercialize our current or future product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure or discontinuation of any of our development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of any preclinical studies, clinical trials or regulatory approvals of product candidates of our
competitors, or announcements about new research programs or product candidates of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement or termination of collaborations for our product development and research programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents or other intellectual property or
proprietary rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any of our research programs, clinical development programs or product
candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations
by securities analysts, if any, that cover our stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our common stock by us, our insiders or other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expiration of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">market&nbsp;stand-off&nbsp;or&nbsp;lock-up&nbsp;agreements;</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to effectively manage our growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated variations in quarterly operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our cash position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide
to the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, political, industry and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the stock market in general, and the market for pharmaceutical companies in particular, have experienced extreme
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual
operating performance. If the market price of our common stock after this offering does not exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment. In the past,
securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#146;s securities. This type of litigation, if instituted, could result in substantial costs and a
diversion of management&#146;s attention and resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have wide discretion in the use of the net proceeds from this offering
and may not use them effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot specify with certainty the particular uses of the net proceeds we will
receive from this offering. Our management will have wide discretion in the application of the net proceeds, including for any of the purposes described in &#147;Use of Proceeds.&#148; Accordingly, you will have to rely upon the judgment of our
management with respect to the use of the proceeds, with only limited information concerning management&#146;s specific intentions. Our management may spend a portion or all of the net proceeds from this offering in ways
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
that our stockholders may not desire or that may not yield a favorable return. The failure by our management to apply these funds effectively could harm our business, financial condition, results
of operations and prospects. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Future sales of our common stock in the public market could cause our stock price to fall. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our stock price could decline as a result of sales of a large number of shares of our common stock after this offering or the
perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering,&#8195;&#8195;&#8195;&#8195;shares of our common stock will be outstanding
(or&#8195;&#8195;&#8195;&#8195;shares of common stock will be outstanding assuming exercise in full of the underwriters&#146; option to purchase additional shares), based on our shares outstanding as of June&nbsp;30, 2024. All shares of our common
stock expected to be sold in this offering will be freely tradable without restriction or further registration under the Securities Act, unless held by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. The
resale of the remaining&#8195;&#8195;&#8195;&#8195;shares, or&#8195;&#8195;&#8195;&#8195;% of our outstanding shares after this offering, is currently prohibited or otherwise restricted as a result of securities law provisions, market standoff
agreements entered into by our stockholders with us or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by our stockholders with the underwriters. However, subject to applicable securities law restrictions and excluding shares
of our restricted stock that will remain unvested, these shares will be able to be sold in the public market beginning 180 days after the date of this prospectus. Shares of our unvested restricted stock subject to repurchase or forfeiture that were
issued and outstanding as of the date of this prospectus will become available for sale immediately upon the vesting of such shares, as applicable, and the expiration of any applicable market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements. Shares issued upon the exercise of stock options pursuant to future awards that may be granted under our equity incentive plans or pursuant to future awards granted under those plans will become
available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, any applicable market <FONT STYLE="white-space:nowrap">stand-off</FONT> and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements
and Rule 144 and Rule 701 under the Securities Act. For more information see the section titled &#147;Shares Eligible for Future Sale&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, the holders of approximately&#8195;&#8195;&#8195;&#8195;shares,
or&#8195;&#8195;&#8195;&#8195;%, of our common stock, will have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may
file for ourselves or other stockholders. We also intend to register the offer and sale of all shares of our common stock that we may issue under our equity compensation plans. Once we register the offer and sale of shares for the holders of
registration rights and shares to be issued under our equity incentive plans, they can be freely sold in the public market upon issuance, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the section titled
&#147;Underwriting&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in the future, we may issue additional
shares of our common stock or other equity or debt securities convertible into common stock in connection with a financing, acquisition, litigation settlement, employee arrangements or otherwise. Any such issuance could result in substantial
dilution to our existing stockholders and could cause our stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are an &#147;emerging growth company&#148; and
a &#147;smaller reporting company,&#148; and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an &#147;emerging growth company&#148; as defined in the JOBS Act. For as long as we continue to be an emerging growth
company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this prospectus and our periodic
reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth
company, we are only required to provide two years of audited financial statements in this prospectus. We could be an emerging growth company for up to five years following the completion of this offering, although circumstances could cause us to
lose that status earlier, including if we are deemed to be a &#147;large accelerated filer,&#148; which occurs when the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds
$700.0&nbsp;million as of the prior June&nbsp;30, or if we have total annual gross revenue of $1.235&nbsp;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following
December&nbsp;31, or if we issue more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during any three-year period before that time, in which case we would no longer be an emerging growth company immediately.
For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the requirements of the Public Company Accounting Oversight Board regarding
the communication of critical audit matters in the auditor&#146;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing only two years of audited financial statements in addition to any required unaudited interim
financial statements and a correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and
stockholder approval of any golden parachute payments not previously approved. In this prospectus, we have not included all of the executive compensation-related information that would be required if we were not an emerging growth company.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even after we no longer qualify as an emerging growth company, we could still qualify as a
&#147;smaller reporting company,&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports
and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market
for our common stock and our share price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the JOBS Act provides that an emerging growth
company can also take advantage of an extended transition period for complying with new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or
revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may continue to be a smaller reporting
company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our
common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most
recently completed fiscal year and our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will incur significant increased costs as a result of operating as a public
company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company.
We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the
Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Global Market (Nasdaq) to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and
maintenance of effective disclosure and financial reporting controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) was enacted. There are
significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#147;say on pay&#148; and proxy access. Recent legislation
permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of this offering. Stockholder activism, the current political environment and the current high level of government
intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial
compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have an adverse effect on our business. The increased
costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more
difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs
we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Insiders will continue to have substantial influence over us after this offering, which could limit your ability to affect the outcome
of key transactions, including a change of control. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After this offering, our directors and executive officers and
their affiliates will beneficially own shares representing approximately&#8195;&#8195;&#8195;&#8195;% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and
all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction.
This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We do not expect to pay any dividends for the foreseeable future. Investors in this offering may never obtain a return on their
investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should not rely on an investment in our common stock to provide dividend income. We do not
anticipate that we will pay any dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any future credit facility may contain terms
prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return
on their investment. As a result, investors seeking cash dividends should not purchase our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we fail to establish and maintain proper and effective internal control over
financial reporting, our operating results and our ability to operate our business could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ensuring that
we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to
<FONT STYLE="white-space:nowrap">be&nbsp;re-evaluated&nbsp;frequently.</FONT> Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements in accordance with generally accepted accounting principles. In connection with this offering, we intend to begin the process of documenting, reviewing and improving our internal controls and procedures for compliance with
Section&nbsp;404 of the Sarbanes-Oxley Act, which will require annual management assessment of the effectiveness of our internal control over financial reporting starting with our second filing of an Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Implementing any appropriate changes to our internal controls may distract our
officers and employees, entail substantial costs to modify our existing processes and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain
that adequacy or consequent inability to produce accurate financial statements on a timely basis could increase our operating costs and harm our business. In addition, investors&#146; perceptions that our internal controls are inadequate or that we
are unable to produce accurate financial statements on a timely basis cause investors to lose confidence in the accuracy and completeness of our financial reports and could cause the market price of our common stock to decline significantly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering, we will become subject to the periodic reporting requirements of the&nbsp;Exchange Act. We
designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the&nbsp;Exchange Act&nbsp;is accumulated and communicated to management, and recorded, processed, summarized
and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These inherent limitations include the realities
that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an
unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future,
we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may in the future discover material weaknesses in our system of internal financial and accounting controls and procedures
that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only
reasonable, not absolute, assurance that the control system&#146;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud
will not occur or that all control issues and instances of fraud will be detected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, and our independent registered
public accounting firm, were not required to perform an evaluation of our internal control over financial reporting as of December&nbsp;31, 2023 in accordance with the provisions of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Sarbanes-Oxley Act. Accordingly, we cannot assure you that we will not in the future identify material weaknesses. Material weaknesses may exist when we become required to report on the
effectiveness of our internal control over financial reporting under Section&nbsp;404 of the Sarbanes-Oxley Act after the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, or if we
are unable to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported financial
information, the market price of our stock could decline, and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Provisions in our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the
effectiveness of our registration statement and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our
stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation
and amended and restated bylaws that will become effective upon the effectiveness of our registration statement and Delaware law contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes
in our management that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. Our amended and restated certificate of incorporation, which will become effective immediately prior
to the closing of this offering, and amended and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this prospectus is a part, include provisions that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize &#147;blank check&#148; preferred stock, which could be issued by our board of directors without
stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create a classified board of directors whose members serve staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">specify that special meetings of our stockholders can be called only by our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit stockholder action by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our
stockholders, including proposed nominations of persons for election to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office,
even though less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our directors may be removed only for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">specify that no stockholder is permitted to cumulate votes at any election of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expressly authorized our board of directors to make, alter, amend or repeal our amended and restated bylaws;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended
and restated certificate of incorporation and amended and restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These provisions, alone or
together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby
depressing the market price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, because we are incorporated in the State of Delaware, we are
governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law (DGCL), which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the
date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has
the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our amended and restated bylaws that became effective upon the effectiveness of this registration statement designate
certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our
directors, officers, or employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated bylaws that became effective upon effectiveness of the
registration statement of which this prospectus forms a part provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for
(i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and employees to us or our
stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws (including the interpretation,
validity or enforceability thereof) or (iv)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine (Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the
Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum
for resolving any complaint asserting a cause or causes of action arising under the Securities Act (Federal Forum Provision). In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any
interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the
rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Delaware Forum Provision and the Federal Forum Provision in our amended and
restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#146; ability to bring a claim in a judicial
forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our
stockholders. In addition, while the Delaware Supreme Court and other state courts have upheld the validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty
as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose
additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or
results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>General Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition, stock price, and results of operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The global credit and financial markets have experienced extreme volatility and disruptions (including as a result
of actual or perceived changes in interest rates, inflation and macroeconomic uncertainties), which has included severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation,
uncertainty about economic stability, global supply chain disruptions, and increases in unemployment rates. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict,
including the ongoing conflicts between Russia and Ukraine, and Israel and Hamas, terrorism, or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may
also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further
deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decrease in the demand for our product
candidates and in our ability to raise additional capital when needed on acceptable terms, if at all. There are also current geopolitical tensions with China that may affect our operations. For example, there has been proposed United States
legislation, such as the bill titled the BIOSECURE Act, that may restrict the ability of United States pharmaceutical companies to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology companies of concern
without losing the ability to contract with, or otherwise receive funding from, the United States government. We continue to assess the legislation as it develops to determine whether it could have an effect on our contractual relationships.
Furthermore, any disruptions to our supply chain as a result of unfavorable global economic conditions, including due to geopolitical conflicts or public health crises, could negatively impact the timely execution of our ongoing and future clinical
trials. In addition, current inflationary trends in the global economy may impact salaries and wages, costs of goods and transportation expenses, among other things, and recent and potential future disruptions in access to bank deposits or lending
commitments due to bank failures may create market and economic instability. We cannot anticipate all of the ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity,
defaults, or <FONT STYLE="white-space:nowrap">non-performance</FONT> by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Actual events involving limited liquidity, defaults,
<FONT STYLE="white-space:nowrap">non-performance</FONT> or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry
generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding
sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect our Company, the financial institutions with which we have
credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types
of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services
industry. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The results of events or concerns that involve one or more of these factors
could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial
assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential or actual breach of statutory, regulatory or contractual obligations, including obligations that
require us to maintain letters of credit or other credit support arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash
management arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, investor concerns regarding the United States or international
financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it
more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial
obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors
described above or other related or similar factors not described above, could have material adverse impacts on our liquidity, our current and/or planned business operations, and our current or projected financial condition and results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead
to losses or defaults by our suppliers, which in turn, could have a material adverse effect on our current and/or planned business operations and our current or projected results of operations and financial condition. For example, a customer may
fail to make payments when due, default under their agreements with us, become insolvent or declare bankruptcy, or a supplier may determine that it will no longer deal with us as a customer. In addition, a customer or supplier could be adversely
affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on the Company, including but not limited to delayed access or loss of access to uninsured deposits or loss of the
ability to draw on existing credit facilities involving a troubled or failed financial institution. Any customer, collaborator or supplier bankruptcy or insolvency, or the failure of any customer or collaborator to make payments when due, or any
breach or default by a customer, collaborator or supplier, or the loss of any significant supplier or collaborator relationships, could result in material losses to the Company and may have a material adverse impact on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to satisfy listing requirements of Nasdaq or obtain or maintain a listing of our common stock on Nasdaq. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If, after listing, we fail to satisfy Nasdaq&#146;s continued listing requirements, such as the corporate governance
requirements or the minimum closing bid price requirement. Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our
common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price
or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Nasdaq&#146;s listing requirements.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock,
the price of our stock could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The trading market for our common stock will rely in part on the research
and reports that industry or financial analysts publish about us or our business. We do not currently have and may never obtain research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or
more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn
could cause our stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may become involved in litigation that could divert management&#146;s attention and harm
our business, and insurance coverage may not be sufficient to cover all costs and damages. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time we
may be subject to litigation claims through the ordinary course of our business operations regarding, but not limited to, securities litigation, employment matters, security of patient and employee personal data, contractual relations with
collaborators and licensors and intellectual property rights. In the past, securities class action litigation has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic
transaction, the announcement of negative events, such as negative results from clinical trials, or periods of volatility in the market price of a company&#146;s securities. These events may also result in or be concurrent with investigations by the
SEC. We may be exposed to such litigation or investigation even if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management&#146;s attention and resources, which could adversely affect our business and cash
resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured
liabilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not carry insurance for all categories of risk that our business may encounter. Some of the
policies we currently maintain include property, general liability, crime insurance, workers&#146; compensation, and directors&#146; and officers&#146;, employment practices and fiduciary liability insurance, clinical trial insurance, transportation
insurance and umbrella insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our
financial position and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our operations are vulnerable to interruption by disasters, terrorist activity,
pandemics and other events beyond our control, which could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our facilities are located in
California. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major flood, power loss, terrorist activity, pandemics or other regional or global disasters and generally do not
have a recovery plan for such events. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The
occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Increased attention to, and evolving expectations for, environmental, climate change, social, and governance initiatives could increase
our costs, harm our reputation, or otherwise adversely impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Companies across industries are facing
increasing scrutiny from a variety of stakeholders related to their environmental, climate change, social, and governance (ESG) and sustainability practices. Expectations regarding voluntary ESG initiatives and disclosures may result in increased
costs (including but not limited to increased costs related to compliance, stakeholder engagement, contracting and insurance), enhanced compliance or disclosure obligations, or other adverse impacts to our business, financial condition, or results
of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we may at times engage in voluntary initiatives (such as voluntary disclosures, certifications, or
goals, among others) to improve the ESG profile of the Company, such initiatives may be costly and may not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
have the desired effect. Moreover, we may not be able to successfully complete such initiatives due to factors that are within or outside of our control. Even if this is not the case, our actions
may subsequently be determined to be insufficient by various stakeholders, and we may be subject to investor or regulator engagement on our ESG efforts, even if such initiatives are currently voluntary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain market participants, including major institutional investors and capital providers, use third-party benchmarks and
scores to assess companies&#146; ESG profiles in making investment or voting decisions. Unfavorable ESG ratings could lead to increased negative investor sentiment towards us, which could negatively impact our share price as well as our access to
and cost of capital. To the extent ESG matters negatively impact our reputation, it may also impede our ability to compete as effectively to attract and retain employees, which may adversely impact our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we expect there will likely be increasing levels of regulation, disclosure-related and otherwise, with respect to
ESG matters. For example, the SEC has issued rules that require companies to provide significantly expanded climate-related disclosures in their periodic reporting, which may require us to incur significant additional costs to comply, including the
implementation of significant additional internal controls processes and procedures regarding matters that have not been subject to such controls in the past, and impose increased oversight obligations on our management and board of directors. These
and other changes in stakeholder expectations will likely lead to increased costs as well as scrutiny that could heighten all of the risks identified in this risk factor. Additionally, our business partners may be subject to similar expectations,
which may augment or create additional risks, including risks that may not be known to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus, including the sections titled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148;
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and &#147;Business,&#148; contains express or implied forward-looking statements that are based on our management&#146;s belief and assumptions
and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial
performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by
these forward-looking statements. Forward-looking statements in this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress, results and costs of conducting our research and development programs and
our current and future preclinical studies and anticipated clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials
will become available, and our current and future programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to demonstrate, and the timing of, preclinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> <I>in vivo</I> and <I>ex vivo </I>for multiple programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance any product candidates that we may identify and successfully complete any clinical
studies, including the manufacture of any such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, scope and likelihood of regulatory filings and approvals, including timing of INDs or comparable
foreign applications, and final FDA approval of our current product candidates or any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, scope or likelihood of foreign regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, and strategic plans for our business, product candidates, and
technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or
otherwise violate any third-party intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to leverage programs within our initial target indications and to progress additional programs to
further develop our pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability of our preclinical studies and clinical trials to demonstrate safety and efficacy of our product
candidates, and other positive results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and enter into future license agreements and collaborations and the potential benefits
of such agreements and collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to rely on third-party manufacturers and successfully manufacture product candidates for
preclinical use, clinical trials and on a larger scale for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to realize the benefits of collaborations for the development and commercialization of current and
future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize any current and future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments related to our proprietary Native Complex
Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations necessary to complete further development and
commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and growth potential of the markets for our current and future product candidates and our ability to
serve those markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the period during which we will remain an emerging growth company under the JOBS
Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of proceeds from this offering, estimates of our expenses, capital requirements, and needs
for additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of global economic and political developments on our business, including rising inflation and
capital market disruptions, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well as the value of our common stock and our ability to access
capital markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ultimate impact of health epidemics, pandemics, and other widespread outbreaks of contagious disease,
including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our clinical trials, our research programs, healthcare systems or the global economy as a whole; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the section titled &#147;Risk Factors.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In some cases, you can identify forward-looking statements by terminology such as
&#147;anticipates,&#148; &#147;believes,&#148; &#147;continue,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148; &#147;should&#148; or the negative
of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in
some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#147;Risk
Factors&#148; and elsewhere in this prospectus. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the
forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration
statement, of which this prospectus forms a part, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. Statements that
contain &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information
forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant
information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any
date subsequent to the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus also contains estimates, projections and other
information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are
assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by
market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their
estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled &#147;Risk
Factors&#148; and elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that the net proceeds to us from the sale of&#8195;&#8195;&#8195;&#8195;shares of our common stock in this
offering will be approximately $&#8195;&#8195;&#8195;&#8195;million (or approximately $&#8195;&#8195;&#8195;&#8195;million if the underwriters exercise their option to purchase additional shares in full), assuming an initial public offering price of
$&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable
by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A $1.00 increase or decrease in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per
share, the estimated midpoint of the estimated price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the net proceeds to us from this offering by $&#8195;&#8195;&#8195;&#8195;million, assuming the
number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase or decrease of
1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease, as applicable net proceeds to us from this offering by $&#8195;&#8195;&#8195;&#8195;million, assuming no
change in the assumed initial public offering price per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. We do not expect that a change in the offering price or the number of shares by these amounts would have a material effect on our intended uses of the net proceeds from this offering, although it may impact the
amount of time prior to which we may need to seek additional capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently intend to use the net proceeds from
this offering, together with our existing cash and cash equivalents, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;&nbsp;million to advance the continued development of SEP-786, our
lead product candidate from our PTH1R program, and additional molecules targeting PTH1R; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;&nbsp;million to advance the development of SEP-631, and additional
small molecules within our MRGPRX2 program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&#8195;&#8195;&#8195;&#8195;&nbsp;million for other research and development activities,
including our TSHR and incretin receptor programs, other new GPCR programs, and continued innovation of our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder to fund working capital and general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2024, we had cash and cash equivalents of $&#8195;&#8195;&#8195;&#8195; million. Based on our current
plans, we believe our existing cash and cash equivalents, together with the net proceeds from this offering, will be sufficient to fund our operations and capital expenditure requirements into&#8195;&#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The expected use of the net proceeds from this offering represents our intentions based upon our current plans and business
conditions, which could change in the future as our plans and business conditions evolve. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this
offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our research and development, the
addition of new programs or changes to plans for existing programs, as well as any collaborations that we may enter into with third parties or strategic opportunities that become available to us, and any unforeseen cash needs. As a result, our
management will retain broad discretion over the allocation of the net proceeds from this offering. We expect the net proceeds from this offering, together with our existing cash and cash equivalents, will not be sufficient for us to advance any of
our programs through regulatory approval, and we will need to raise additional capital to complete the development and potential commercialization of any of our programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our management will retain broad discretion in the application of the net
proceeds we receive from our initial public offering, and investors will be relying on the judgment of our management regarding the application of the net proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital
preservation instruments, including short-term and long-term interest-bearing instruments, investment-grade securities, and direct or guaranteed obligations of the United States government. We cannot predict whether the proceeds invested will yield
a favorable return. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and
any future earnings to fund the development and expansion of our business, and therefore we do not anticipate paying cash dividends on our common stock in the foreseeable future. Any future determination regarding the declaration and payment of
dividends, if any, will be at the discretion of our board of directors, subject to applicable laws, and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements,
business prospects, and other factors our board of directors may deem relevant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our ability to pay cash
dividends on our capital stock in the future may be limited by the terms of any future debt or preferred securities we issue or any credit facilities we enter into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth our cash and cash equivalents and our capitalization as of June 30, 2024: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to (i)&nbsp;the automatic conversion of all outstanding shares of our
convertible preferred stock into an aggregate of&#8195;&#8195;&#8195;&#8195; shares of our common stock and the related reclassification of the carrying value of the convertible preferred stock to permanent equity, each of which will occur
immediately prior to the completion of this offering, and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the completion of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to reflect: (i) the pro forma adjustments set forth above, and (ii) the
issuance and sale of&#8195;&#8195;&#8195;&#8195;shares of our common stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the estimated price range set forth on the
cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pro forma and pro forma as adjusted information below is illustrative only, and our capitalization following the
completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read the information in this table together with the sections titled &#147;Prospectus
Summary&#151;Summary Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes included elsewhere in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;for&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.001 par value; &#8195;&#8195;&#8195;&#8195;shares
authorized;&#8195;&#8195;&#8195;&#8195; shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.001 par value; no shares authorized, issued or outstanding,
actual; &#8195;&#8195;&#8195;&#8195; shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value;&#8195;&#8195;&#8195;&#8195; shares authorized,
&#8195;&#8195;&#8195;&#8195;shares issued and outstanding, actual; &#8195;&#8195;&#8195;&#8195;shares authorized,&#8195;&#8195;&#8195;&#8195; shares issued and outstanding, pro forma; &#8195;&#8195;&#8195;&#8195; shares authorized,
&#8195;&#8195;&#8195;&#8195;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Each $1.00 increase or decrease in the assumed initial public offering price of
$&#8195;&#8195;&#8195;&#8195;per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the pro forma as adjusted amount of each of our cash and cash
equivalents, total stockholders&#146; equity (deficit) and total capitalization by $&#8195;&#8195;&#8195;&#8195;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of this prospectus,
would increase or decrease, as applicable, the pro forma as adjusted amount of each of our cash and cash equivalents, total stockholders&#146; equity (deficit) and total capitalization by $&#8195;&#8195;&#8195;&#8195;million, assuming no change in
the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters exercise their option to purchase additional shares of our common stock in full, our pro forma as adjusted
cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity (deficit), total capitalization, and shares of our common stock outstanding as of June&nbsp;30, 2024 would be
$&#8195;&#8195;&#8195;&#8195;million, $&#8195;&#8195;&#8195;&#8195;million, $&#8195;&#8195;&#8195;&#8195;million, $&#8195;&#8195;&#8195;&#8195;million, and&#8195;&#8195;&#8195;&#8195;shares, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock issued and outstanding, pro forma and pro forma as adjusted, in the table above is
based on&#8195;&#8195;&#8195;&#8195; shares (which includes &#8195;&#8195;&#8195;&#8195;shares of unvested restricted common stock subject to repurchase or forfeiture) of our common stock outstanding as of June&nbsp;30, 2024, after giving effect to
the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of &#8195;&#8195;&#8195;&#8195;&nbsp;shares of our common stock immediately prior to the completion of this offering, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock issuable upon the exercise of stock options outstanding
as of June&nbsp;30, 2024 under the 2021 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock issuable upon the exercise of stock options granted
after June&nbsp;30, 2024 pursuant to the 2021 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock reserved for issuance under the 2021 Plan as of
June&nbsp;30, 2024, which shares will cease to be available for issuance at the time that the 2024 Plan becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock that will become available for future issuance under
the 2024 Plan, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of our common stock
reserved for future issuance under the 2024 Plan and any shares underlying outstanding stock awards granted under the 2021 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock reserved for future issuance under the ESPP, which will
become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of our common stock reserved for future issuance
under the ESPP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the
difference between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our historical net tangible book value (deficit) as of June&nbsp;30, 2024 was $&#8195;&#8195;&#8195;&#8195;&nbsp;million, or
$&#8195;&#8195;&#8195;&#8195; per share of our common stock. Our historical net tangible book deficit per share is the amount of our total tangible assets less our total liabilities and the carrying values of our convertible preferred stock, which
is not included within stockholders&#146; deficit. Our historical net tangible book deficit per share represents historical net tangible book deficit divided by the &#8195;&#8195;&#8195;&#8195;&nbsp;shares (which includes
&#8195;&#8195;&#8195;&#8195;&nbsp;shares of unvested restricted common stock subject to repurchase or forfeiture) of our common stock outstanding as of &#8195;&#8195;&#8195;&#8195;, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our pro forma net tangible book value as of June&nbsp;30, 2024 was $&#8195;&#8195;&#8195;&#8195; million, or
$&#8195;&#8195;&#8195;&#8195; per share of our common stock. Pro forma net tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to the automatic conversion of all outstanding shares
of our convertible preferred stock into an aggregate of &#8195;&#8195;&#8195;&#8195;&nbsp;shares of our common stock immediately prior to the completion of this offering. Pro forma net tangible book value per share represents pro forma net tangible
book value divided by the total number of shares outstanding as of June 30, 2024, after giving effect to the pro forma adjustment described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After giving further effect to the issuance and sale of&nbsp;shares of our common stock in this offering at an assumed initial
public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us, our pro forma as adjusted net tangible book value as of June&nbsp;30, 2024 would have been $&#8195;&#8195;&#8195;&#8195;&nbsp;million, or $&#8195;&#8195;&#8195;&#8195; per share. This amount represents an immediate
increase in pro forma as adjusted net tangible book value per share of $&#8195;&#8195;&#8195;&#8195; to our existing stockholders and immediate dilution of $&#8195;&#8195;&#8195;&#8195; in pro forma as adjusted net tangible book value per share to
new investors purchasing shares of our common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dilution per share to new investors is determined
by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis (without giving
effect to any exercise by the underwriters of their option to purchase additional shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in historical net tangible book value per share as of June&nbsp;30, 2024
attributable to the pro forma adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to new investors
participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The dilution information discussed above is illustrative only and may change based on the
actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of the
estimated price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, our pro forma as adjusted net tangible book value per share after this offering by $&#8195;&#8195;&#8195;&#8195;, and dilution per share
to new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
investors purchasing shares of our common stock in this offering by $&#8195;&#8195;&#8195;&#8195;, assuming that the number of shares of our common stock offered by us, as set forth on the cover
page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase of 1.0&nbsp;million shares in the number of shares offered by us, as set
forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value per share after this offering by $&#8195;&#8195;&#8195;&#8195; and decrease dilution per share to new investors purchasing shares of our
common stock in this offering by $&#8195;&#8195;&#8195;&#8195;, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by
us. Each decrease of 1.0&nbsp;million shares in the number of shares of our common stock offered by us, as set forth on the cover page of this prospectus, would decrease our pro forma as adjusted net tangible book value per share after this offering
by $&#8195;&#8195;&#8195;&#8195; and increase dilution per share to new investors purchasing shares of our common stock in this offering by $&#8195;&#8195;&#8195;&#8195;, assuming no change in the assumed initial public offering price and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the
underwriters exercise in full their option to purchase additional shares, our pro forma as adjusted net tangible book value per share after this offering would be $&#8195;&#8195;&#8195;&#8195;, representing an immediate increase in pro forma as
adjusted net tangible book value per share of $&#8195;&#8195;&#8195;&#8195; to existing stockholders and immediate dilution in pro forma as adjusted net tangible book value per share of $&#8195;&#8195;&#8195;&#8195; to new investors purchasing
common stock in this offering, based on the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table as of June&nbsp;30, 2024 summarizes on the pro forma as adjusted basis described above, the total number
of shares of our common stock purchased from us on an as converted to common stock basis, the total consideration paid or to be paid, and the average price per share paid or to be paid by existing stockholders and by new investors in this offering
at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, before deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us. As the table shows, new investors purchasing shares of our common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Price</B><br><B>Per Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table above assumes no exercise of the underwriters&#146; option to purchase additional
shares in this offering. If the underwriters&#146; option to purchase additional shares is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced to &#8195;&#8195;&#8195;&#8195;% of the total
number of shares of our common stock outstanding after this offering, and the number of shares of our common stock held by new investors purchasing common stock in this offering would be increased to &#8195;&#8195;&#8195;&#8195;% of the total number
of shares of our common stock outstanding after this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing tables and calculations (other than the historical net
tangible book value calculations) are based on &#8195;&#8195;&#8195;&#8195; shares (which includes&#8195;&#8195;&#8195;&#8195; shares of unvested restricted common stock subject to repurchase or forfeiture) of our common stock outstanding as of
June&nbsp;30, 2024, after giving effect to the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of &#8195;&#8195;&#8195;&#8195;&nbsp;shares of our common stock immediately prior to the completion of
this offering, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;shares of our common stock issuable upon the exercise of stock options outstanding
as of June&nbsp;30, 2024 under the 2021 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195; per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;&nbsp;shares of our common stock issuable upon the exercise of stock options
granted after June&nbsp;30, 2024 pursuant to the 2021 Plan, with a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195; per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;&nbsp;shares of our common stock reserved for issuance under the 2021 Plan as of
June&nbsp;30, 2024, which shares will cease to be available for issuance at the time that the 2024 Plan becomes effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;&nbsp;shares of our common stock that will become available for future issuance
under the 2024 Plan, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of our common stock
reserved for future issuance under the 2024 Plan and any shares underlying outstanding stock awards granted under the 2021 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195;&nbsp;shares of our common stock reserved for future issuance under the ESPP,
which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of our common stock reserved for future
issuance under the ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent that new stock options or other equity awards are issued or any
outstanding stock options are exercised, or we issue additional shares of our common stock in the future, there will be further dilution to new investors. In addition, we may choose to raise additional capital because of market conditions or
strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could
result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>You should read the following discussion and analysis of our financial condition and
results of operations together the section titled &#147;Prospectus Summary&#151;Summary Financial Data&#148; and our audited financial statements and related notes included elsewhere in this prospectus. This discussion and other parts of this
prospectus contain forward-looking statements based upon current beliefs, plans, and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements of our plans,
objectives, expectations, intentions, forecasts and projections. Our actual results and the timing of selected events could differ materially from those discussed in these forward-looking statements as a result of several factors including, but not
limited to, those set forth under the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected for any period in the future, and you should
carefully read the section titled &#147;Risk Factors&#148; to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled &#147;Special
Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical-stage biotechnology company pioneering a new era of GPCR oral small molecule drug discovery powered by our
proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of
product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> replicates the natural
structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within
ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen
for, and optimize potential product candidates. Leveraging our platform, we have transformed GPCR oral small molecule drug discovery to an industrialized and iterative structure-based drug design approach to expand the landscape of druggable GPCR
targets with novel oral small molecule medicines for patients. Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> is designed to enable us to target certain GPCRs for the first time, uncover novel binding pockets
for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat
diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline is summarized in the figure below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g59y26.jpg" ALT="LOGO" STYLE="width:6.25in;height:2.80515in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our lead product candidate, SEP-786, is, to our knowledge, the only clinical-stage, oral
small molecule agonist targeting the Parathyroid Hormone 1 Receptor (PTH1R) for the treatment of hypoparathyroidism. We believe our team, scientific and technical advisors, and our proprietary Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> uniquely positions us to become the leading GPCR-focused biotechnology company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were incorporated in Delaware in December 2019 under the name GPCR NewCo, Inc. In June 2021, we changed our name to
Septerna, Inc. We are headquartered in South San Francisco, California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have incurred significant operating losses
since our inception, except for the year ended December&nbsp;31, 2023. Our revenue to date has been generated solely from research services. Since our founding, we have devoted substantially all of our resources to organizing and staffing our
company, business planning, raising capital, developing our proprietary and structure-based drug discovery platform, identifying and discovering our product candidates, establishing our intellectual property portfolio, conducting research and
preclinical studies, including <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, initiating and conducting clinical trials, establishing arrangements with third parties for the manufacture of our product candidates and related raw
materials, and providing general and administrative support for these operations. We have not had any products approved for sale and have not generated any revenue from product sales. Further, we do not expect to generate revenue from product sales
until such time, if ever, that we are able to successfully complete the development and obtain marketing approval for one or more of our product candidates. Our ability to generate product revenue will depend on the successful development and
eventual commercialization of one or more of our product candidates. We have incurred net losses in each year since inception except for the year ended December&nbsp;31, 2023. During the year ended December&nbsp;31, 2023, we recorded a gain on sale
of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset of $47.6&nbsp;million for the sale of an <FONT STYLE="white-space:nowrap">in-progress</FONT> research and development (IPR&amp;D) asset related to a GPCR program and $0.2&nbsp;million in
revenue related to research services resulting in net income of $4.2&nbsp;million for the year then-ended compared to net loss of $27.7&nbsp;million for the year ended December&nbsp;31, 2022. Of the $47.6&nbsp;million gain on sale of <FONT
STYLE="white-space:nowrap">non-financial</FONT> asset, $25.0&nbsp;million was received in cash in September 2023 and $22.6&nbsp;million was received in the first half of 2024. As of December&nbsp;31, 2023, we had an accumulated deficit of
$46.6&nbsp;million. We expect to continue to incur net losses for the foreseeable future. Our net losses may fluctuate significantly from period to period, depending on the timing and expenditures of our operational activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to continue to incur significant and increasing net operating losses for the next several years as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to advance our product candidates through preclinical studies and into clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, hire and retain additional personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operate as a public company, including expenses related to compliance with the rules and regulations of the
SEC and those of any national securities exchange on which our securities are traded, legal, auditing, additional insurance expenses, investor relations activities, and other administrative and professional services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our research and development efforts and expand our pipeline of product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire, discover, validate, and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the manufacture of supplies for our preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implement operational, financial and information management systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make royalty, milestone or other payments under any future, license or collaboration agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially seek to identify, assess, acquire, or <FONT STYLE="white-space:nowrap">in-license</FONT> or
develop new technologies or additional product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially experience any delays, challenges, or other issues associated with the clinical development of our
product candidates, including with respect to our regulatory strategies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursue regulatory approval of product candidates that successfully complete clinical trials; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which
we may obtain marketing approval and related commercial manufacturing <FONT STYLE="white-space:nowrap">build-out.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our net losses may fluctuate significantly from period to period, depending upon the timing of our expenditures on research
and development activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued research and development and other current liabilities in the
statement of cash flows in our audited financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result, we will
require substantial additional funding to further develop our product candidates and support our continuing operations. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a
combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
existing stockholders&#146; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect existing stockholders&#146; rights as common stockholders. Debt financing and
preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring
dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams,
research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit,
reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have historically financed our operations primarily through the issuances of convertible promissory notes and convertible
preferred stock. In November 2021, we entered into a total of $100.0&nbsp;million of Series&nbsp;A convertible preferred stock financing which was divided into two tranches. The initial tranche was completed in November 2021 for net proceeds of
$44.7&nbsp;million, of which $30.0&nbsp;million was received in cash, net of issuance costs, and $14.7&nbsp;million was for the conversion of the then outstanding convertible promissory notes plus accrued interest. In November 2022, we executed the
second tranche for net cash proceeds of $30.0&nbsp;million. The Series&nbsp;A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
convertible preferred stock agreement was subsequently amended to cancel the remaining 25.0&nbsp;million unissued shares of Series&nbsp;A convertible preferred stock in June 2023, upon entering
into the Series&nbsp;B convertible preferred stock financing. In June 2023, we entered into a total of $150.0&nbsp;million of Series&nbsp;B convertible preferred stock financing, which was divided into two tranches of equal amounts. The first
tranche, which was the issuance of $75.0&nbsp;million of Series&nbsp;B convertible preferred stock, was completed in July 2023 for net proceeds of $74.5&nbsp;million. The second tranche, which was for the issuance of the remaining
$75.0&nbsp;million, was completed in May 2024 for net proceeds of $74.9&nbsp;million. Since our inception, we have devoted substantially all of our resources to raising capital, organizing and staffing our company, business and scientific planning,
conducting discovery and research and development activities, establishing and protecting our intellectual property portfolio, developing and progressing our product candidates and preparing for clinical trials, establishing arrangements with third
parties for the manufacture of our product candidates and component materials, engaging in collaboration activities, and providing general and administrative support for these operations. Based on our current plans, we believe our existing cash and
cash equivalents, together with the net proceeds from this offering, will be sufficient to fund our operations and capital expenditure requirements into &#8195;&#8195;&#8195;&#8195;. See the subsection titled &#147;&#151;Liquidity and Capital
Resources&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We use contract research and development organizations to conduct our preclinical works and
clinical trials. Additionally, we utilize third-party contract manufacturing organizations (CMOs), to manufacture and supply our preclinical materials during the development of our product candidates. We expect to use similar contract resources for
the commercialization of our products, at least until our resources and operations are at a scale that justifies investment in internal manufacturing capabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Vertex Asset Purchase and Service Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Asset Purchase Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2023, we entered into an asset purchase agreement with Vertex Pharmaceuticals Incorporated (Vertex) for a total of
$47.6&nbsp;million under which Vertex acquired all of our IPR&amp;D asset related to a GPCR program, including all intellectual property, materials, and compounds associated with the program (Vertex purchase agreement). Of the $47.6&nbsp;million,
$25.0&nbsp;million was received in cash in September 2023 and $22.6&nbsp;million was received in the first half of 2024. Additionally, as part of the agreement, Vertex assumed all claims, counterclaims and credits associated with the program, and we
gave up all rights to the intellectual property. The transfer of the IPR&amp;D asset to Vertex was completed in November 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the same time in September 2023, we entered into a research service agreement with Vertex under which we agreed to perform
certain exploratory research activities for Vertex. See the subsection titled &#147;&#151;Service Agreement&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Vertex purchase agreement also provides for a potential milestone payment payable to us contingent upon achievement of a
certain research milestone. The milestone payment amount is determined based on the timing of achievement of the research milestone. The variable consideration related to this milestone payment was determined to be improbable of receipt at this
time. As a result, the milestone payment was excluded from the transaction price. After the potential milestone payment, we will not receive any other payments or future royalties related to this IPR&amp;D asset. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Service Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the Vertex purchase agreement, we also entered into a research service agreement with Vertex (Vertex service
agreement) under which we agreed to perform certain exploratory research activities for Vertex. The Vertex service agreement is for a <FONT STYLE="white-space:nowrap">two-year</FONT> term, however, Vertex has the ability to terminate the agreement
with a <FONT STYLE="white-space:nowrap">30-day</FONT> notice at any time. As a result, we concluded that the contract duration is 30 days, representing a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT>
service contract. We recognize revenue associated with the Vertex service agreement over the performance period of the research services as the services are provided. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have not generated any revenue from product sales and do not expect to do so in the foreseeable future. Our ability to
generate product revenue, if ever, will depend on the successful development and eventual commercialization of any product candidates that we identify. If we fail to complete the development of any future product candidates in a timely manner or to
obtain regulatory approval for such product candidates, our ability to generate future revenue and our results of operations and financial position would be materially adversely affected. Our revenues to date have been exclusively related to
research services. We recognize revenue as specified research services are performed and the results of the research and development services are provided to the customer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our operating expenses consist of (i)&nbsp;research and development expenses and (ii)&nbsp;general and administrative expenses.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses account for the largest component of our total operating expenses. Research and development
expenses consist primarily of direct and unallocated costs incurred for the research and development of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our research and development expenses consist of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">direct costs, including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external research and development costs related to (i) the production of preclinical materials, including fees
and milestones paid to contract manufacturers and (ii) agreements with contract development organizations, consultants and other third-party contract organizations to conduct our preclinical studies and other research and development activities on
our behalf; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs incurred in connection with laboratory operations, materials and supplies, and other preclinical
studies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unallocated costs, including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related costs, including salaries, benefits and stock-based compensation for employees engaged in
research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external research and development costs, including contract research and development and professional service
fees for consulting and related services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facility-related and office costs, including lease/rent, building-related expenses, facility-related overhead,
and depreciation expense; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other costs, including expenses related to our funded, sponsored research activities and technology licenses,
laboratory operations, information technology (IT)-related expenses. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expense all research and
development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and
third-party service providers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A significant portion of our research and development costs have been external costs,
which we track by stage of development. However, we do not track our unallocated costs on a program specific basis because these costs are deployed across multiple projects and, as such, are not separately classified. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At this time, we cannot reasonably estimate or know the nature, timing, and
estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We expect that our research and development expenses will increase substantially in absolute
dollars for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct clinical
trials, as we seek regulatory approvals for any product candidates that successfully complete clinical trials, and as we incur expenses associated with hiring additional personnel to support our research and development efforts. The process of
conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with
developing product candidates, many of which are outside of our control, including the uncertainty of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and progress of preclinical and clinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of preclinical and clinical programs we decide to pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our current research and development programs and to establish new ones;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing an appropriate safety profile with <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of sites and patients included in the clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the countries in which the clinical trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">per patient trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful patient enrollment in, and the initiation of, clinical trials, as well as drop out or
discontinuation rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successful completion of clinical trials with safety, tolerability and efficacy profiles that are
satisfactory to the FDA, EMA, or any other comparable foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of trials required for regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and terms of any regulatory approvals from applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish collaboration arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the performance of any future collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant and changing government regulation and regulatory guidance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of any business interruptions to our operations or to those of the third parties with whom we work;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching commercial sales of our product candidates, if approved, whether alone or in collaboration with
others; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profile of the product candidates following approval.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any changes in the outcome of any of these variables could mean a significant change in the costs and
timing associated with the development of our product candidates. For example, if the FDA, EMA or any other comparable foreign regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for
the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and
time on the completion of clinical development. We may never obtain regulatory approval for any of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses consist primarily of personnel-related costs, costs related to maintenance and filing of
intellectual property, legal fees related to corporate matters, professional fees paid for accounting, auditing, consulting, tax and investor relations services, insurance costs, general corporate expenses, and
<FONT STYLE="white-space:nowrap">IT-related</FONT> and facility-related costs not otherwise included in research and development expenses. Personnel-related costs include salaries, benefits, and stock-based compensation for our personnel in
executive, legal, finance and accounting, human resources, and other administrative functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that our general
and administrative expenses will increase substantially in absolute dollars for the foreseeable future as we continue to increase our headcount to support our business growth. We also anticipate that we will incur increased expenses as a result of
our preparation of becoming and, ultimately, operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and expenses related to audit, legal, regulatory services associated with maintaining
compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other
Income, Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Interest Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest income consists of interest earned on our cash and cash equivalents during the period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Other Income, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income, net consists primarily of changes in the fair value of our cash equivalents, partially offset by loss on disposal
of our fixed assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Provision for Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to corporate United States federal and state income taxation. As of December&nbsp;31, 2023, we had
$14.6&nbsp;million of federal NOL carryforwards and $28.9&nbsp;million of state NOL carryforwards, available to reduce future taxable income. Of the federal NOL carryforwards, $14.6&nbsp;million will carryforward indefinitely. The state NOL
carryforwards will begin to expire in 2041, if not utilized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;382 of the Code (Section 382) places a
limitation, referred to as the Section 382 limitation, on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. California has similar
rules. When an ownership change occurs, Section&nbsp;382 limits the use of NOLs and credits in subsequent periods based on the annual 382 limitations. The annual 382 limitations may limit the full use of available tax attributes in one year but the
identified ownership changes may not result in expiration of tax attributes for use prior to expiration of their respective carryforward periods. We establish a valuation allowance against all of our net deferred tax assets. We consider all
available evidence, both positive and negative, including but not limited to our historical operating results, income or loss in recent periods, cumulative losses in recent years, forecasted earnings, future taxable income, and significant risk and
uncertainty related to forecasts, and concluded the deferred tax assets are not more likely than not to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we had federal and state research and development tax credits carryforwards of $2.0&nbsp;million and
$1.8&nbsp;million, respectively, as of December&nbsp;31, 2023 available to reduce future income taxes. The federal research and development tax credits will begin to expire in 2041 if not utilized. The state research and development tax credits have
no expiration date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We record liabilities related to uncertain tax positions in accordance with the guidance that
clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#146;s financial statements by prescribing a minimum recognition threshold and measurement attribute for purposes of financial statement recognition and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
measurement of a tax position taken or expected to be taken in a tax return. As of December&nbsp;31, 2022 and 2023, we had unrecognized tax benefits of $1.8&nbsp;million and $2.5&nbsp;million,
respectively, all of which would affect our income tax expense if recognized, before consideration of our valuation allowance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Results
of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Comparison of the Years Ended December&nbsp;31, 2022 and 2023 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our results of operations for each of the periods indicated are summarized in the table below (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8201;&#8195;2022&#8195;&#8201;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8201;&#8195;2023&#8195;&#8201;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating expenses (income):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total operating expenses (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,924</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">(Loss) income from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">(Loss) income before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our revenue of $0.2&nbsp;million for the year ended December&nbsp;31, 2023 was generated from the services provided to Vertex
while no revenue was recorded for the year ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Operating Expenses (Income) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our research and development expenses for the periods indicated by direct and unallocated costs
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PTH1R</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRGPRX2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TSHR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee-related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility-related and office costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expense was $22.0&nbsp;million and
$36.0&nbsp;million for the years ended December&nbsp;31, 2022 and 2023, respectively. The increase was primarily due to (i) $4.0&nbsp;million of higher direct costs attributable to our preclinical programs, (ii)&nbsp;$4.4&nbsp;million of higher
employee-related costs as a result of increased headcount, (iii) $2.7&nbsp;million of higher expenses associated with external research and development costs, and (iv) $1.5&nbsp;million of higher facility-related and office costs as we continue to
expand our office space to accommodate higher occupancy and larger operational activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses were $5.9&nbsp;million and $9.7&nbsp;million for the years ended December&nbsp;31, 2022 and
2023, respectively. The increase was primarily due to (i) $2.2&nbsp;million of higher employee-related costs a result of increased headcount, (ii) $0.9&nbsp;million of higher legal fees, and (iii) $0.8&nbsp;million of higher consulting expenses.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Gain on Sale of <FONT STYLE="white-space:nowrap">Non-Financial</FONT> Asset </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset of $47.6&nbsp;million was attributable to the sale
of our IPR&amp;D asset related to a GPCR program to Vertex during the year ended December&nbsp;31, 2023. No gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset was recorded during the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other Income, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Interest Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest income was $0.3&nbsp;million and $2.8&nbsp;million for the years ended December&nbsp;31, 2022 and 2023, respectively.
The increase was due to higher interest rates and higher balances of our cash and cash equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Other Income, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the year ended December&nbsp;31, 2023, our other income and expense was immaterial. For the year ended December&nbsp;31,
2022, we did not record other income or expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Provision for Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Provision for income taxes of $0.7&nbsp;million for the year ended December&nbsp;31, 2023 was primarily due to the gain on sale
of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset, which resulted in net income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sources of Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have incurred significant operating losses for each year since our inception, except for the year ended December&nbsp;31,
2023. Our revenue to date has been generated solely from research services. Since our founding, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, developing our proprietary
and structure-based drug discovery platform, identifying and discovering our product candidates, establishing our intellectual property portfolio, conducting research and preclinical studies, including IND-enabling studies, initiating and conducting
clinical trials, establishing arrangements with third parties for the manufacture of our product candidates and related raw materials, and providing general and administrative support for these operations. We have not had any products approved for
sale and have not generated any revenue from product sales. Further, we do not expect to generate revenue from product sales until such time, if ever, that we are able to successfully complete the development and obtain marketing approval for one or
more of our product candidates. Our ability to generate product revenue will depend on the successful development and eventual commercialization of one or more of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
We have incurred net losses in each year since inception except for the year ended December&nbsp;31, 2023. During the year ended December&nbsp;31, 2023, we recorded a gain on sale of <FONT
STYLE="white-space:nowrap">non-financial</FONT> asset of $47.6&nbsp;million for the sale of an IPR&amp;D asset related to a GPCR program and $0.2&nbsp;million in revenue related to research services resulting in net income of $4.2&nbsp;million for
the year then-ended compared to net loss of $27.7&nbsp;million for the year ended December&nbsp;31, 2022. Of the $47.6&nbsp;million gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset, $25.0&nbsp;million was received in cash
in September 2023 and $22.6&nbsp;million was received in the first half of 2024. We expect to incur substantial expenses as we operate as a public company, advance our product candidates into clinical development, undergo the regulatory approval
process, engage in other research and development activities to expand our pipeline of product candidates, expand our operations and headcount, maintain and expand our intellectual property portfolio and, if we obtain approval for one or more of our
product candidates, launch commercial activities. Specifically, in the near term we expect to incur substantial expenses relating to initiating and completing our clinical trials and our other product development activities. Furthermore, upon the
completion of this offering, we expect to incur incremental costs associated with operating as a public company, including significant legal, accounting, investor relations, director and officer insurance and other expenses. As of December&nbsp;31,
2023, we had an accumulated deficit of $46.6&nbsp;million. We expect to continue to incur net losses for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have historically financed our operations primarily through the issuances of convertible promissory notes and convertible
preferred stock. In November 2021, we entered into a total of $100.0&nbsp;million of Series A convertible preferred stock financing which was divided into two tranches. The initial tranche was completed in November 2021 for net proceeds of
$44.7&nbsp;million, of which $30.0&nbsp;million was received in cash, net of issuance costs, and $14.7&nbsp;million was for the conversion of the then outstanding convertible promissory notes plus accrued interest. In November 2022, we executed the
second tranche for net cash proceeds of $30.0&nbsp;million. The Series&nbsp;A convertible preferred stock agreement was subsequently amended to cancel the remaining 25.0&nbsp;million unissued shares of Series&nbsp;A convertible preferred stock in
June 2023, upon entering into the Series&nbsp;B convertible preferred stock financing. In June 2023, we entered into a total of $150.0&nbsp;million of Series B convertible preferred stock financing, which was divided into two tranches of equal
amounts. The first tranche, which was the issuance of $75.0&nbsp;million of Series B convertible preferred stock, was completed in July 2023 for net proceeds of $74.5&nbsp;million. The second tranche, which was for the issuance of the remaining
$75.0&nbsp;million, was completed in May 2024 for net proceeds of $74.9&nbsp;million. During the year ended December&nbsp;31, 2023, we recorded a gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset of $47.6&nbsp;million for
the sale of an IPR&amp;D asset related to a GPCR program and $0.2&nbsp;million in revenue related to research services resulting in net income of $4.2&nbsp;million for the year then-ended compared to net loss of $27.7&nbsp;million for the year ended
December&nbsp;31, 2022. Of the $47.6&nbsp;million gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset, $25.0&nbsp;million was received in cash at the closing of the Vertex purchase agreement in September 2023 and
$22.6&nbsp;million was received in the first half of 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our cash flows for the periods indicated (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Net Cash Used in Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in operating activities was $23.3&nbsp;million and $38.7&nbsp;million for the years ended December&nbsp;31, 2022
and 2023, respectively. The net cash used in operating activities for the year ended December&nbsp;31, 2022 was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
due to our net loss of $27.7&nbsp;million, partially offset by $2.6&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> charges for depreciation and amortization, stock-based
compensation and <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease expense, and $1.7&nbsp;million of net change in operating assets and liabilities. The net cash used in operating activities for the year ended December&nbsp;31, 2023
was due to $47.6&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> adjustment related to gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset, partially offset by (i)&nbsp;our net income of $4.2&nbsp;million,
(ii) $3.8&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> charges for depreciation and amortization, stock-based compensation, <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease expense and deferred income tax, and
(iii) $0.9&nbsp;million of net change in operating assets and liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Net Cash (Used in) Provided by Investing Activities
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities of $1.3&nbsp;million for the year ended December&nbsp;31, 2022 was attributable
to purchases of property and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by investing activities of $22.1&nbsp;million for the year
ended December&nbsp;31, 2023 was due to $25.0&nbsp;million proceeds from the sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset, partially offset by $2.9&nbsp;million of purchases of property and equipment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Net Cash Provided by Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing activities was $30.1&nbsp;million and $74.5&nbsp;million for the years ended December&nbsp;31,
2022 and 2023, respectively. Net cash provided by financing activities for the year ended December&nbsp;31, 2022 was primarily due to net proceeds from the sale and issuance of our Series A convertible preferred stock. Net cash provided by financing
activities for the year ended December&nbsp;31, 2023 was primarily due to net proceeds from the sale and issuance of our Series B convertible preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Future Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our primary use of cash is to fund our operations, primarily research and development expenditures. Cash used for operating
expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical
products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical
trials for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses of manufacturing our product candidates for clinical trials and in preparation for marketing
approval and commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we enter into collaborations or other arrangements with additional third parties in order
to further develop our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses of preparing, filing and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses and fees associated with the discovery, acquisition or
<FONT STYLE="white-space:nowrap">in-license</FONT> of additional product candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish additional collaborations on favorable terms, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses required to scale up our clinical, regulatory and manufacturing capabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses of future commercialization activities, if any, including establishing sales, marketing,
manufacturing and distribution capabilities, for any of our product candidates for which we receive marketing approval; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">revenue, if any, received from commercial sales of our product candidates, should any of our product
candidates receive marketing approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will need additional funds to meet operational needs and
capital requirements for clinical trials, other research and development expenditures, and business development activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our product
candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a
combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
existing stockholders&#146; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect existing stockholders&#146; rights as common stockholders. Debt financing and
preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring
dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams,
research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit,
reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have historically financed our operations primarily through the issuances of convertible promissory notes and convertible
preferred stock. In June 2023, we entered into a total of $150.0&nbsp;million of Series B convertible preferred stock financing, which is divided into two tranches of equal amounts. The first tranche, which was the issuance of $75.0&nbsp;million of
Series B convertible preferred stock, was completed in July 2023 for net proceeds of $74.5&nbsp;million. The second tranche, which was the issuance of the remaining $75.0&nbsp;million, was completed in May 2024 for net proceeds of
$74.9&nbsp;million. Since our inception, we have devoted substantially all of our resources to raising capital, organizing and staffing our company, business and scientific planning, conducting discovery and research and development activities,
establishing, maintaining, and protecting our intellectual property portfolio, developing and progressing our product candidates and preparing for clinical trials, establishing arrangements with third parties for the manufacture of our product
candidates and component materials, engaging in collaboration activities, and providing general and administrative support for these operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on our current plans, we believe our existing cash and cash equivalents, together with the net proceeds from this
offering, will be sufficient to fund our operations and capital expenditure requirements into &#8195;&#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Contractual Obligations and Other Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our future cash outflows for contractual obligations as of December&nbsp;31, 2023 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than&nbsp;1<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">1-3&nbsp;Years</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">3-5&nbsp;Years</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations, including interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We lease certain office space in South San Francisco under a lease that expires in July 2032.
See Note 6 to our audited financial statements included elsewhere in this prospectus for more information on our lease obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We enter into contracts in the normal course of business for contract
research services, contract manufacturing services, professional services and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and
not included in the table above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the periods presented we did not have, nor do we currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT>
sheet arrangements as defined under SEC rules and regulations or any holdings in variable interest entities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Critical Accounting
Estimates, Significant Judgments and Use of Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Management&#146;s discussion and analysis of our financial
condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP). The preparation of these financial statements requires
us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses
incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe that the
accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#146;s judgments and estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We generated revenue for the year ended December&nbsp;31, 2023 from service revenue for research activities performed related
to an agreement with Vertex. We consider revenue to be earned when all of the following criteria are met: (i)&nbsp;we have a contract with a customer that creates enforceable rights and obligations; (ii)&nbsp;promised products or services are
identified; (iii)&nbsp;the transaction price, or the amount we expect to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon
resolution of the uncertainty, is determinable; (iv)&nbsp;and we have transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the
unit of account in the contract. The transaction price for the contract is measured as the amount of consideration we expect to receive in exchange for the goods and services expected to be transferred. When a contract contains variable
consideration and the variable consideration is constrained to the extent that it is not probable that it will be received, it is excluded from the transaction price. A contract&#146;s transaction price is allocated to each distinct performance
obligation on a relative standalone selling price basis and recognized as revenue when, or as, control of the distinct good or service is transferred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation is measured based on the estimated grant date fair value of the award and is recognized as expense on
a straight-line basis over the requisite service period (usually the vesting period). Forfeitures are accounted for in the period in which they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In determining the fair value of the options granted, we use the Black Scholes option pricing model and assumptions discussed
below. Each of these inputs is subjective and generally requires significant judgment to determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Fair Value of
Common Stock</I> &#151; See the subsection titled &#147;&#151;Fair Value of Common Stock&#148; below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected Term</I> &#151; The expected term represents the period that our
stock options granted are expected to be outstanding and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term). We have very limited
historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for our stock option grants. We will continue to apply this process until a sufficient amount of historical
information regarding employee exercise patterns and post-vesting employment termination behavior becomes available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected Volatility</I> &#151; Since we are not a public company and have no trading history for our common stock, the
expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen
based on their similar size, life cycle stage and area of specialty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Risk-free Interest Rate</I> &#151; The risk-free
interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected Dividend</I> &#151; We have never paid dividends on our common stock and have no plans to pay dividends on our
common stock. Therefore, we used an expected dividend yield of zero. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We recorded stock-based compensation of
$1.5&nbsp;million and $1.6&nbsp;million for the years ended December&nbsp;31, 2022 and 2023, respectively. As of December&nbsp;31, 2023, total unrecognized stock-based compensation expense related to unvested restricted stock awards and unvested
stock options was $5.2&nbsp;million, which is expected to be recognized over a weighted-average period of 2.9 years. As of December&nbsp;31, 2023, total unrecognized stock-based compensation expense related to unvested restricted stock awards
subject to performance conditions, which were improbable of achievement, was $0.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The intrinsic value of
all outstanding incentive awards as of June&nbsp;30, 2024 was $&#8195;&#8195;&#8195;&#8195; million based on the assumed initial public offering price of $&#8195;&#8195;&#8195;&#8195;per share (the midpoint of the estimated price range set forth on
the cover page of this prospectus), of which $&#8195;&#8195;&#8195;&#8195; million was related to vested stock options and $&#8195;&#8195;&#8195;&#8195; million was related to unvested stock options and restricted stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Fair Value of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Historically, for all periods prior to this offering, the grant-date fair market value of our common stock underlying stock
options has historically been determined by our board of directors with assistance of unrelated third-party valuation specialists. Because there has been no public market for our common stock, our board of directors have exercised reasonable
judgment and considered a number of objective and subjective factors to determine the best estimate of the fair market value, which include important developments in our operations, the prices at which we sold shares of our convertible preferred
stock, the rights, preferences and privileges of our convertible preferred stock relative to those of common stock, actual operating results, financial performance, external market conditions in the life sciences industry, general U.S. market
conditions, equity market conditions of comparable public companies, and the lack of marketability of our common stock. Given the absence of a public trading market for our common stock, our board of directors exercised reasonable judgment and
considered a number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including: our stage of development and material risks related to our business; the progress of our research and
development programs; sales of our preferred stock; the rights, preferences and privileges of our convertible preferred stock relative to those of our common stock; the lack of marketability of our securities; our financial condition and operating
results, including our levels of available capital resources; the likelihood of achieving a liquidity event such as an initial public offering in light of prevailing market conditions; equity market conditions affecting comparable public companies;
the trends, developments and conditions in the life sciences and biotechnology industry sectors; and general U.S. market and economic conditions. Valuations of our common stock were prepared by an unrelated third-party valuation firm in accordance
with the guidance provided by the American Institute of Certified Public Accountants 2013 Practice Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>, referred to as the &#147;Practice Aid.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the Practice Aid, prior to April 2024, the fair value of
our common stock was determined using the Option Pricing Method (OPM) method as we determined the OPM method was the most appropriate method to utilize based on our stage of development and other relevant factors. The OPM uses the preferred
stockholders&#146; liquidation preferences, participation rights, dividend policy, and conversion rights to determine how proceeds from a liquidity event shall be distributed among the various ownership classes at a future date. Starting April 2024,
in accordance with the Practice Aid, we determined the hybrid probability-weighted expected return method (PWERM) method was the most appropriate method for determining the fair value of our common stock based on our stage of development and other
relevant factors. The hybrid PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes with one of those outcomes incorporating the OPM
method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the equity value was determined and allocated to the various classes of equity securities, a discount for
lack of marketability (DLOM) was applied to arrive at the fair value of common stock on a <FONT STYLE="white-space:nowrap">non-marketable</FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A DLOM is applied based on the theory that as an owner of a private company stock, the holder has limited information and
opportunities to sell the stock. A market participant that would purchase this stock would recognize this risk and thereby require a higher rate of return, which would reduce the overall fair market value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The assumptions underlying these valuations represented management&#146;s best estimates, which involved inherent
uncertainties and the application of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially
different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once a public trading market for our common stock has been established in connection with the completion of
this offering, it will no longer be necessary for our board of directors to estimate the fair value of our common stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our common
stock will be determined based on the quoted market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development costs are expensed as incurred. Research and development expenses consist primarily of
employee-related costs, including salaries, benefits, and stock-based compensation for employees engaged in research and development activities, costs related to research activities, preclinical studies, production of preclinical materials,
IT-related costs, allocated overhead costs including facility-related expenses, contract manufacturing, consulting fees, costs related to laboratory operations, and fees paid to other entities that conduct certain research and development activities
on our behalf. Payments made prior to the receipt of goods and services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into various agreements with outsourced contract manufacturing and development vendors. We estimate accrued
research and development expenses as of each balance sheet date based on facts and circumstances known at that time. We periodically confirm the accuracy of our estimates with internal management personnel and external service providers, and makes
adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and
development services provided, but not yet invoiced, are included in accrued expenses on the balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual
accordingly. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See Note 2 to our audited financial statements included elsewhere in this prospectus for more information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Interest Rate Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate
sensitivities. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a
portfolio of investments in a variety of securities of high credit quality and short-term duration, invested in compliance with our policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We had cash and cash equivalents of $30.6&nbsp;million and $88.5&nbsp;million as of December&nbsp;31, 2022 and 2023,
respectively, which consisted primarily of bank deposits and money market funds. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant for us. Due to the
short-term maturities of our cash equivalents, we believe that a hypothetical 100 basis point increase or decrease in interest rates during any of the periods presented would not have had a material effect on our financial statements included
elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Foreign Currency Exchange Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of our employees and our operations are currently located in the United States and our expenses are generally denominated
in U.S. dollars. However, we do use research and development vendors outside of the United States. As such, our expenses are denominated in both U.S. dollars and foreign currencies. Therefore, our operations are and will continue to be subject to
fluctuations in foreign currency exchange rates. To date, foreign currency transaction gains and losses have not been material to our financial statements. We believe that a hypothetical 100 basis point increase or decrease in exchange rates during
any of the periods presented would not have had a material effect on our financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Effects of Inflation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We believe that inflation has not had
a material effect on our financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Emerging Grown Company Status and Smaller
Reporting Company Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We qualify as &#147;emerging growth company&#148; under the JOBS Act, which permits us to
take advantage of an extended transition period to comply with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates for public and
private companies until those standards would otherwise apply to private companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i)&nbsp;are no longer an emerging growth company or
(ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of
public company effective dates. We could be an emerging growth company until the earliest to occur: (i)&nbsp;the last day of the fiscal year in which we have more than $1.235&nbsp;billion in annual gross revenue; (ii)&nbsp;the date we qualify as a
&#147;large accelerated filers&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, with at least $700.0&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT>
(iii)&nbsp;the issuance, in any three-year period, by us of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; or (iv)&nbsp;the last day of the fiscal year ending after the fifth anniversary of
this offering. Even after we no longer qualify as an emerging growth company, we may continue to qualify as a &#147;smaller reporting company,&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements
including reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements, if either (i)&nbsp;the market value of our stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a smaller reporting company as defined in the Exchange Act. We
may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these
scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our
second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule
drug discovery powered by our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development
of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every
organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of all U.S.
Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125&nbsp;billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75%
of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have
been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug
discovery, particularly the development of novel oral small molecules, such as agonists for peptide GPCRs and allosteric modulators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> replicates the natural
structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within
ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen
for, and optimize potential product candidates. Leveraging our platform, we have transformed GPCR oral small molecule drug discovery to an industrialized and iterative structure-based drug design approach to expand the landscape of druggable GPCR
targets with novel oral small molecule medicines for patients. Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is designed to enable us to target certain GPCRs for the first time, uncover novel binding pockets for
validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are advancing a deep portfolio of oral small molecule GPCR-targeted
programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline is summarized in the figure below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g46d29.jpg" ALT="LOGO" STYLE="width:6.33167in;height:4.40643in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our lead product candidate, SEP-786, is, to our knowledge, the only clinical-stage, oral
small molecule agonist targeting the Parathyroid Hormone 1 Receptor (PTH1R) for the treatment of hypoparathyroidism. We are initiating a Phase&nbsp;1 clinical trial to assess preliminary safety, tolerability, pharmacokinetics (PK) and
pharmacodynamics (PD) of SEP-786, and expect to report initial data from this trial in &#8195;&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
believe our team, scientific and technical advisors, and our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> uniquely positions us to become the leading GPCR-focused biotechnology company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>GPCRs as Therapeutic Targets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GPCRs are the most targeted drug class due to their significant role in human diseases and their pharmacological tractability.
GPCRs are characterized by their seven transmembrane domains, and function in ternary complexes that form with extracellular ligands and intracellular transducer proteins which modulate cellular signaling pathways in response to ligand binding.
Different GPCRs play vital roles in a variety of physiologic processes of every major organ system including the central nervous system (CNS), cardiovascular, respiratory, metabolic and urogenital systems, making them key therapeutic targets. Today,
many GPCR-targeted drugs have established market-leading positions across a variety of therapeutic areas, including Ozempic and Wegovy (each marketed by Novo Nordisk) for the treatment of type 2 diabetes (T2D), and obesity, respectively, and Nurtec
ODT (marketed by Pfizer) for the acute treatment of migraine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Historically, GPCR oral small molecule drug discovery has been highly
concentrated on a small number of targets &#150; despite GPCRs constituting the largest human membrane protein family &#150; as GPCRs are difficult to isolate in their native functional form outside of a cellular context, which has limited the
utilization of modern drug discovery tools and technologies. As a result, about 75% of GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Aims to Unlock the Full Therapeutic Potential of GPCRs
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the past decade, drug discovery across various target classes has been revolutionized by a variety of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> tools and technologies. These innovations include structure-based drug design, computational docking, and <FONT
STYLE="white-space:nowrap">DNA-encoded</FONT> libraries (DELs). However, the utilization of these technologies has been limited for discovering oral small molecules targeting GPCRs due to the inability to isolate functional native GPCR proteins
outside of a cellular context. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With our proprietary Native Complex
Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, we can purify GPCRs outside of cells and reconstitute them into fully functional ternary complexes with transducer proteins (e.g., G proteins, beta-arrestins) and ligands (endogenous
or synthetic), all housed within a well-defined lipid bilayer environment (Figure 1). These Native Complexes are full-length, properly folded GPCRs that retain their natural structure, function, and dynamics. We then apply state-of-the-art discovery
tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we have transformed GPCR drug discovery, potentially expanding the
landscape of druggable GPCR targets with novel oral small molecule medicines for patients. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g98o86.jpg" ALT="LOGO" STYLE="width:3.70848in;height:2.56168in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 1. </B>Native Complexes consist of full-length, properly folded GPCR proteins
reconstituted with a ligand and/or a transducer protein such as a G protein in a lipid bilayer that mimics the cell membrane. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is powered by a suite of tools and
technologies that we have optimized and integrated into a proprietary and industrialized workflow, and together form an efficient and iterative discovery process for identification and optimization of novel small molecule product candidates
targeting high-value GPCRs, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Native Complex biochemistry and structural biology:</I></B> Our Native Complexes reconstitute native
GPCR function in a purified biochemical format, which enables efficient high-resolution, three-dimensional structure determination using cryogenic electron microscopy (cryo-EM). This can reveal receptor binding pockets that we can target with a
range of pharmacologies (e.g., agonists, antagonists, and allosteric modulators) as well as novel insights into mechanisms for GPCR modulation.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Native Complex-driven hit identification and optimization:</I></B> We virtually screen our GPCR
structures against ultra-large-scale computational databases containing billions of candidate molecules to identify the most promising small molecule compounds that bind in pockets on the GPCR structure. We use technologies, including DELs, to
screen billions of candidate molecules simultaneously, and we have developed proprietary technologies to discover and optimize compounds with a variety of modes of action. In addition, we use our proprietary Native Complex biochemical screens in our
hit identification and optimization processes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advanced cellular and in vivo pharmacology models: </I></B>We efficiently evaluate hits and lead
compounds through the integration of advanced cellular and <I>in vivo</I> pharmacology models. Prioritized compounds with desired pharmacologies are then either advanced as potential drug candidates or fed back into the process for additional Native
Complex-driven compound optimization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our oral small molecule drug discovery process, powered by our
proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, is depicted in the figure below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g15a01.jpg" ALT="LOGO" STYLE="width:5.83333in;height:3.24245in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe we are at the forefront of industrial-scale GPCR drug discovery and development.
Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies to achieve
desired therapeutic effects. Our platform has led to the discovery and development of a pipeline of novel, highly potent and selective oral small molecules, and for our most advanced programs, optimized them into clinical development candidates.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Pipeline and Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our wholly-owned pipeline, summarized in the figure below, is focused initially on three therapeutic areas: endocrinology,
immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women&#146;s health, cardiovascular, and respiratory disease. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g95p90.jpg" ALT="LOGO" STYLE="width:6.25in;height:2.80515in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">SEP-786</FONT> &#150; Oral Small Molecule PTH1R Agonist for
Hypoparathyroidism </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hypoparathyroidism is a rare endocrine disease characterized by insufficient levels of
parathyroid hormone (PTH) that affects approximately 70,000 patients in the United States and approximately 140,000 patients in Europe. Patients with hypoparathyroidism are at risk of both short-term and long-term complications, including muscle
cramps, fatigue, cognitive dysfunction, and life-threatening complications, such as cardiac arrhythmias, seizures, and renal failure. The goal of treatment is to relieve symptoms and restore calcium and phosphate levels to normal. Current standard
of care consists of high-dose calcium supplements and activated vitamin D (calcitriol); however, these therapies do not replace other functions of PTH to restore physiological mineral homeostasis or address all of the symptoms experienced by
patients. Hormone replacement with injectable PTH peptides, either marketed or in clinical development, may improve blood chemistry profiles of patients via PTH1R activation but will require life-long daily injections. We believe there is a
substantial opportunity for an oral small molecule therapy that offers convenience, improved compliance, and potentially superior efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT> is, to our knowledge, the only clinical-stage,
oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism. PTH1R is a historically <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-drug</FONT></FONT> small molecule target, yet we effectively
leveraged our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to discover and optimize <FONT STYLE="white-space:nowrap">SEP-786</FONT> with desired drug-like properties. In preclinical studies, <FONT
STYLE="white-space:nowrap">SEP-786</FONT> has been observed to be generally well-tolerated and has demonstrated potent and selective activation of PTH1R in human, dog, and rat receptor <I>in vitro</I> models. In a preclinical animal model of
hypoparathyroidism, <FONT STYLE="white-space:nowrap">SEP-786</FONT> controlled serum calcium levels within the normal range over a <FONT STYLE="white-space:nowrap">28-day</FONT> dosing period. We have successfully completed Investigational New Drug
(IND)-enabling studies and are initiating a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of <FONT STYLE="white-space:nowrap">SEP-786.</FONT> We expect to report initial data from this trial
in&#8195;&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">SEP-631</FONT> &#150; Oral Small Molecule MRGPRX2 NAM for CSU and
Other Mast Cell Diseases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chronic spontaneous urticaria (CSU) is a systemic inflammatory skin disease characterized
by the spontaneous and persistent recurrence of itchy, painful hives, known as wheals, on the skin and angioedema, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
swelling, that affects approximately 1.5&nbsp;million patients in the United States. While there is no known trigger, the degranulation of mast cells and release of histamine and other
inflammatory mediators lead to these debilitating symptoms. Patients are treated initially with antihistamines and <FONT STYLE="white-space:nowrap">non-responders</FONT> may be treated with Xolair (omalizumab), an injectable <FONT
STYLE="white-space:nowrap">anti-IgE</FONT> monoclonal antibody. The targeting and blocking of <FONT STYLE="white-space:nowrap">IgE-mediated</FONT> inflammation can effectively address symptoms; however, only an estimated 36% of these antihistamine-
refractory patients respond to <FONT STYLE="white-space:nowrap">anti-IgE</FONT> therapy. <FONT STYLE="white-space:nowrap">Mas-related</FONT> <FONT STYLE="white-space:nowrap">G-protein</FONT> coupled receptor member X2 (MRGPRX2) plays an important
role in mast cell activation and degranulation. We believe an oral therapy that inhibits MRGPRX2 could provide a differentiated treatment option for patients with CSU given the selective inhibition of mast cells and potential for combination
therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SEP-631</FONT> is a selective, oral small molecule MRGPRX2 negative allosteric
modulator (NAM) that we are developing initially for the treatment of CSU. In preclinical studies, <FONT STYLE="white-space:nowrap">SEP-631</FONT> demonstrated potent and long-lasting inhibition of MRGPRX2 and blocked mediator-induced angioedema in
mice engineered to express the human MRGPRX2 receptor. We have initiated <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies of <FONT STYLE="white-space:nowrap">SEP-631</FONT> and upon completion, we anticipate submitting for regulatory
clearance to initiate a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to CSU, we believe there is a significant opportunity to develop <FONT
STYLE="white-space:nowrap">SEP-631</FONT> for the treatment of other mast cell diseases. MRGPRX2 is highly and uniquely expressed on mast cells that drive multiple prevalent diseases, including allergic asthma, atopic dermatitis, interstitial
cystitis, migraine, and prurigo nodularis. We believe <FONT STYLE="white-space:nowrap">SEP-631</FONT> could offer a novel oral treatment option for these patient populations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>TSHR Program &#150; Oral Small Molecule TSHR NAM for Graves&#146; Disease and TED </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Graves&#146; disease is one of the most prevalent autoimmune conditions affecting over 2&nbsp;million patients in the United
States and is the leading cause of hyperthyroidism, resulting in symptoms including anxiety, irritability, tremor, and fatigue. Treatments have remained largely unchanged over the past 70&nbsp;years, and include anti-thyroid medications, radioactive
iodine therapy to ablate thyroid gland function, and thyroidectomy surgery. These treatment options may initially address the underlying symptoms, but they are not disease-modifying and do not stop disease progression to thyroid eye disease (TED)
for approximately 50% of Graves&#146; disease patients. TED is a serious, progressive and vision-threatening autoimmune condition that can lead to eye bulging, swelling, pain and blurred or double vision. Current treatments for TED, such as TEPEZZA
(teprotumumab-trbw), an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IGF-1R</FONT></FONT> human monoclonal antibody, are designed to help manage symptoms. Despite reaching global sales of $2.0&nbsp;billion in 2022, TEPEZZA
requires several intravenous (IV)&nbsp;infusions over several months and has risks of serious side effects, including hearing loss and metabolic issues, such as increased blood glucose or hyperglycemia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These autoimmune conditions are caused by autoantibodies that bind to and activate the thyroid stimulating hormone receptor
(TSHR) on thyroid cells in the thyroid gland (leading to Graves&#146; disease) and other cells including orbital fibroblasts located behind the eyes (leading to TED). We believe an oral small molecule TSHR NAM could offer a novel disease-modifying
treatment approach that directly addresses the pathobiology of both diseases by blocking TSHR overactivation caused by patients&#146; autoantibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In our preclinical studies, we have demonstrated that a TSHR NAM can reverse hyperthyroidism and proptosis in a novel mouse
model of Graves&#146; disease and inhibits multiple Graves&#146; disease patient TSHR activating autoantibodies in cell-based assays using primary human cells. We are advancing several lead compounds towards selection of a development candidate for <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Incretin Programs &#150; Oral Small Molecule Single- and Multi-Incretin
Receptor Agonists for Metabolic Disorders Including Obesity and T2D </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obesity and diabetes are two of the most
prevalent diseases in the world, affecting a combined total of more than 800&nbsp;million people, and are associated with severe health complications, including cardiovascular disease </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and kidney failure, as well as an increased risk of death. Weight reduction is seen as an important treatment goal for patients with either condition. In recent years, several injectable peptide
agonists targeting select metabolic hormone receptors, or incretin receptors, have been approved for the treatment of T2D and obesity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Three incretins play significant roles in glucose metabolism and homeostasis: glucagon-like
<FONT STYLE="white-space:nowrap">peptide-1</FONT> <FONT STYLE="white-space:nowrap">(GLP-1),</FONT> gastric inhibitory polypeptide (GIP), and glucagon. Third-party clinical data with incretin-targeted therapeutics have demonstrated substantial and
sustained reductions in body weight, as well as the ability to lower blood glucose and improve glycated hemoglobin (HbA1c). Global sales in 2023 for Ozempic and Wegovy (semaglutide), and Mounjaro and Zepbound (tirzepatide) were $18.4&nbsp;billion
and $5.3&nbsp;billion, respectively. Despite these advancements in the treatment of obesity and T2D, a number of key limitations remain for the incretin therapeutic class, including tolerability, prolonged titration schemes, injection
administration, and supply challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on unique chemical and structural insights obtained with our Native Complex
Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, we believe we have an opportunity to discover and develop novel, next-generation, oral small molecules as selective single- or multi-acting
<FONT STYLE="white-space:nowrap">GLP-1,</FONT> GIP, glucagon receptor agonists. We are advancing several lead compounds towards selection of one or more development candidates for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Team and Investors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have built a strong values-driven organization, and we are advancing cutting-edge science and rigorously developing a broad
and deep portfolio of GPCR-targeted programs for patients. We were founded by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Robert Lefkowitz, M.D., </B>James B. Duke Professor of Medicine and Professor of Biochemistry and Chemistry
at Duke University and an Investigator of the Howard Hughes Medical Institute. Dr.&nbsp;Lefkowitz is globally recognized for his groundbreaking discoveries that reveal the inner workings of GPCRs, for which he was awarded the 2012 Nobel Prize in
Chemistry and elections to both the National Academy of Sciences and the National Academy of Medicine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Arthur Christopoulos, Ph.D., </B>Professor of Analytical Pharmacology, Dean of the Faculty of
Pharmacy&nbsp;&amp; Pharmaceutical Sciences, and Director of the Neuromedicines Discovery Centre at Monash University in Australia. Dr.&nbsp;Christopoulos is a world-leading expert in GPCR molecular pharmacology and responsible for several seminal
discoveries of allosteric modulation of GPCRs, for which he has been elected to both the Australian Academy of Science and the Australian Academy of Health and Medical Sciences. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Patrick Sexton, Ph.D., D.Sc., </B>Professor, Drug Discovery Biology at Monash University and Director of
the ARC Centre for Cryo-electron Microscopy of Membrane Proteins. Dr.&nbsp;Sexton is an international leader in GPCR biochemistry, pharmacology, and structural biology and his team is at the forefront of using
<FONT STYLE="white-space:nowrap">cryo-EM</FONT> to elucidate the structure and dynamics of GPCRs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Jeffrey Finer, M.D., Ph.D.</B>, our President and Chief Executive Officer. Dr.&nbsp;Finer has more than
35&nbsp;years of research, clinical and business experience. He has focused his career on breakthrough innovations that have included moving several <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> drugs
into clinical trials, developing novel technology platforms that integrate science and engineering, and new company creation. As a Venture Partner at Third Rock Ventures, LLC (Third Rock Ventures), Dr.&nbsp;Finer was involved in the founding and
launching of multiple biotech companies, including Maze Therapeutics, Inc. and Ambys Medicines, Inc., and served as interim Chief Technology Officer at both. Previously, Dr.&nbsp;Finer spent several years in research and development leadership
positions, including Vice President, Research Technology at Theravance Biopharma, Inc. (Theravance Biopharma), Vice President, Discovery at Five Prime Therapeutics, Inc., and Director, Drug Discovery at Cytokinetics, Incorporated.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we have established a team of experienced biotechnology leaders
with deep expertise in company building, drug discovery, and clinical advancement of novel medicines. Our senior leadership team includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Elizabeth (Liz) Bhatt, M.S., M.B.A.</B>, our Chief Operating Officer, who has more than 30&nbsp;years of
strategy, deal-making and company-building experience across a range of biotech and pharmaceutical companies, including Applied Molecular Transport Inc., Achaogen, Inc., Gilead Sciences, Inc., Eli Lilly and Company, and Maxygen, Inc.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Alan Ezekowitz, M.D., D.Phil.</B>, our interim Chief Medical Officer, is an Advisory Partner at Third Rock
Ventures and a leader in the field of developmental immunology with more than 150 publications. Dr.&nbsp;Ezekowitz served at the Harvard Medical School as the Charles Wilder Professor of Pediatrics, as the Head of Laboratory for Development
Immunology and Principal of the Cancer Center and later as Chief of Pediatric Services at the Massachusetts General Hospital for Children, and as a director on the Partners Healthcare System board. Previously, Dr.&nbsp;Ezekowitz was the co-founder,
President and Chief Executive Officer of Abide Therapeutics, Inc., which he oversaw through its acquisition by H.&nbsp;Lundbeck A/S, and during his tenure at Merck Research Laboratories, he was responsible for the bone, respiratory, immunology,
inflammation, dermatology, and endocrine franchises. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Samira Shaikhly</B>, our Chief People Officer, is a human resources leader with more than 25&nbsp;years of
experience enabling organizational effectiveness in high-growth companies across multiple human resource disciplines including a 15-year tenure at Gilead Sciences, Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Uwe Klein, Ph.D.</B>, our Senior Vice President, Biological Sciences, has deep expertise in GPCR biology
and over 20&nbsp;years of experience in small molecule drug discovery across a range of biotech and pharmaceutical companies, including MyoKardia, Inc. (acquired by Bristol-Myers Squibb (BMS)). Earlier in his career, Dr.&nbsp;Klein held positions as
Vice President, Biology at Numerate, Inc. (acquired by Valo Health, Inc.) and as Senior Director, Molecular&nbsp;&amp; Cellular Biology at Theravance Biopharma, where he led a team of biologists and two cross-functional project teams in the
discovery of numerous development candidates and several clinical compounds across different therapeutic areas and target classes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Daniel Long, D.Phil.</B>, our Senior Vice President, Drug Discovery, is a highly experienced drug hunter
with a track record of leading high-performing teams that discover drug candidates and advance them through preclinical development to IND and into clinical trials. Dr.&nbsp;Long spent more 20&nbsp;years at Theravance Biopharma, where he held
numerous scientist positions, including as Vice President, Head of Medical Chemistry, Biology and Pharmacology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors is composed of accomplished leaders in the life sciences industry, including our board chairman,
Jeffrey Tong, Ph.D., a Partner at Third Rock Ventures; Abraham Bassan, M.S., a Principal at Samsara BioCapital L.P. (Samsara); Bernard Coulie, M.D., Ph.D., M.B.A., President and Chief Executive Officer of Pliant Therapeutics, Inc.;
Dr.&nbsp;Ezekowitz, an Advisory Partner at Third Rock Ventures; Shalini Sharp, M.B.A., a member of the boards of directors of Neurocrine Biosciences, Inc. and Organon&nbsp;&amp; Co. and former Chief Financial Officer and Executive Vice President at
Ultragenyx Pharmaceuticals Inc.; Jake Simson, Ph.D., a Partner at RA Capital Management, L.P. (RA Capital), and Dr. Finer, our Chief Executive Officer. Further, we have assembled a cross-functional scientific and drug discovery advisory board,
comprised of seasoned drug hunters and leading academic scientists at the forefront of GPCR biology and pharmacology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have raised net proceeds of approximately $224.2&nbsp;million in equity capital from a syndicate of
premier life sciences investors. Potential investors should not consider investments made by our existing investors as a factor when making a decision to purchase shares in this offering since our existing investors likely have different risk
tolerances and paid significantly less per share than the price at which the shares are being offered in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our goal is to develop life-changing GPCR-targeted medicines for patients with significant unmet medical needs. We plan to
achieve this goal by pursuing the following strategies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Efficiently advance our portfolio of GPCR-targeted programs, led by
<FONT STYLE="white-space:nowrap">SEP-786.</FONT> </B>Our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT> is, to our knowledge, the only clinical-stage, oral small molecule agonist of PTH1R for hypoparathyroidism. We are
initiating a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of <FONT STYLE="white-space:nowrap">SEP-786,</FONT> and we expect to report initial data from this trial in&#8195;&#8195;&#8195; . Our second most advanced
candidate, <FONT STYLE="white-space:nowrap">SEP-631,</FONT> an oral small molecule MRGPRX2 NAM that we are developing initially for the treatment of CSU, is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. We believe <FONT
STYLE="white-space:nowrap">SEP-631</FONT> represents a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pipeline-in-a-product</FONT></FONT></FONT> opportunity to treat multiple mast cell-driven
diseases. We also plan to continue advancing our TSHR and incretin programs toward selection of development candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continue to expand our differentiated GPCR-targeted pipeline focused on indications with significant unmet
needs. </B>We are leveraging our GPCR biology and pharmacology <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to address a diverse range of diseases.
For each of our programs to date, we have advanced from initiation of medicinal chemistry to potent drug-like compounds with activity in animal models in less than one year. We are focused initially on developing our novel GPCR-targeted drug
candidates in three therapeutic areas &#150; endocrinology, immunology and inflammation, and metabolic diseases &#150; and intend to expand into other therapeutic areas. We will continue to focus on indications with well understood biology,
predictive biomarkers for early <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> efficient clinical development pathways, and high unmet medical need. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Maximize the potential of our Native Complex
Platform</B><B><SUP STYLE="font-size:75%; vertical-align:top">TM</SUP></B><B> through continued innovation and investment. </B>We believe our industrial-scale platform positions us at the forefront of GPCR drug discovery and development. We have
thoughtfully integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art,</FONT></FONT></FONT> high-resolution structural biology with large-scale screening and functional testing to
accelerate the discovery and optimization of high-quality lead compounds. In under three years, our platform has allowed us to determine more than 80 high-resolution, three-dimensional GPCR structures with bound small molecules spanning multiple
pharmacological mechanisms, and we have screened over 10&nbsp;billion compounds across our targets which led to the discovery of our existing portfolio of novel compounds. We plan to continually enhance our
<FONT STYLE="white-space:nowrap">in-house</FONT> capabilities, tools, and technologies to further leverage our platform and expand our competitive advantages. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Evaluate and selectively execute value-creating strategic partnerships. </B>We currently own full worldwide
rights across our portfolio, and we intend to build out a commercial presence in select major markets. Our industrialized drug discovery platform has generated, and we believe will continue to generate, numerous novel GPCR-targeted product
candidates, some of which we will independently develop and commercialize, and others that may benefit from a strategic partner&#146;s development and commercial expertise, infrastructure, and financial resources. For example, in September 2023, we
entered into an asset purchase agreement with Vertex Pharmaceuticals Incorporated (Vertex), under which Vertex acquired an undisclosed discovery-stage GPCR program from us and will be solely responsible for continuing the associated research and
development efforts. We intend to explore additional opportunities with partners that we believe will meaningfully enhance the overall potential of our programs and allow us to further leverage our Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Pioneering Approach to Unlock the Full Therapeutic Potential of
GPCRs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe we are at the forefront of industrial scale GPCR drug discovery and development. We have pioneered
technologies that have unlocked GPCRs that have been historically difficult to drug with oral small molecules, which may allow us to access certain high value GPCRs within the approximately 75% of untapped GPCR therapeutic targets. Our GPCR Native
Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is built upon world-class expertise and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
leverages proprietary tools and technologies to overcome the historical limitations of GPCR drug discovery, including the isolation, purification, and stabilization of GPCRs in their native
forms. Our approach has led to the discovery and development of a deep portfolio of novel oral small molecule GPCR-targeted programs that we are advancing into clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>GPCRs as Therapeutic Targets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GPCRs regulate physiological processes in nearly every organ system of the human body and are the most targeted drug class due
to their significant role in human diseases and their pharmacological tractability. Nearly one-third of all <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs in the United States, representing approximately 500 products, target
GPCR-associated pathways. In fact, GPCR-related drugs comprise approximately 27% of global pharmaceutical sales and generated over $125&nbsp;billion in 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GPCRs are proteins that span the cell membrane seven times, and their primary function is to recognize extracellular
substances, or ligands, and transmit signals across the cell membrane to the inside of the cell. Ligand binding induces conformational changes in GPCRs, forming complexes with signal transducers, including G proteins. These transducers interact with
second messengers, modulating various cellular processes. Certain GPCR ligands are capable of activating multiple pathways through different transducers, leading to diverse physiological and pathological effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GPCRs constitute the largest and most diverse family of cell membrane receptors, with around 800 identified members. GPCRs are
key therapeutic targets due to their vital roles in a variety of physiologic processes including immune regulation, nervous system transmission, mood and behavior regulation, sensory transmission, and maintaining cardiovascular and gastrointestinal
homeostasis. Despite the pharmacological and commercial success of GPCR-targeted agents, a majority of GPCR therapeutic targets remain undrugged. Each step in GPCR activation involves subtle conformational changes that have been historically
challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug
discovery, particularly the development of novel oral small molecules, such as agonists for peptide GPCRs and allosteric modulators. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date, drug discovery has been highly concentrated on a small number of
GPCRs. More than 70% of current GPCR-related drugs target only six subfamilies of GPCRs. There are about 400 known <FONT STYLE="white-space:nowrap">non-olfactory</FONT> GPCRs, each represented as a branch on the phylogenetic tree in Figure&nbsp;2
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g01n96.jpg" ALT="LOGO" STYLE="width:4.445in;height:3.3725in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Figure 2.</B> GPCR phylogenetic tree highlighting the number of FDA-approved drugs for each GPCR as of
February 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Today, approximately 75% of potential GPCR therapeutic targets remain undrugged, representing significant
opportunity to address a vast range of therapeutic areas and diseases. And, even for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the past decade, the landscape of drug discovery has been revolutionized by advanced technologies that significantly impact
small molecule drug discovery across various target classes. These innovations include structure-based drug design, computational docking, and <FONT STYLE="white-space:nowrap">DNA-encoded</FONT> libraries (DELs). However, the full potential of these
technologies has remained largely untapped for GPCRs due to challenges with isolating functional native GPCR proteins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, we can purify GPCRs
outside of cells and reconstitute them into fully functional ternary complexes with transducer proteins (e.g., G proteins, beta-arrestins) and ligands (endogenous or synthetic), all housed within a well-defined lipid bilayer environment. These
Native Complexes are full-length, properly folded GPCRs that retain their natural structure, function, and dynamics. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally
design, screen for, and optimize potential product candidates. Leveraging our platform, we have transformed GPCR drug discovery, potentially expanding the landscape of druggable GPCR targets with novel oral small molecule medicines for patients.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is powered by a suite of tools and
technologies that we have optimized and integrated into a proprietary and industrialized workflow, and together form an efficient and iterative discovery </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
process for identification and optimization of novel small molecule drug candidates targeting high-value GPCRs, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Native Complex biochemistry and structural biology:</I></B> Our Native Complexes reconstitute native
GPCR function in a purified biochemical format, which enables efficient high-resolution, three-dimensional structure determination with cryo-EM. This can reveal receptor binding pockets that we can target with a range of pharmacologies (agonists,
antagonists, and allosteric modulators) as well as novel insights into mechanisms for GPCR modulation.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Native Complex-driven hit identification and optimization:</I></B> We virtually screen our GPCR
structures against ultra-large-scale computational databases containing billions of candidate molecules to identify the most promising small molecule compounds that bind in pockets on the GPCR structure. We use technologies, including DELs, to
screen billions of candidate molecules simultaneously, and we have developed proprietary technologies to discover and optimize compounds with a variety of modes of action. In addition, we use our proprietary Native Complex biochemical screens in our
hit identification and optimization processes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advanced cellular and in vivo pharmacology models: </I></B>We efficiently evaluate hits and lead
compounds through the integration of advanced cellular and <I>in vivo</I> pharmacology models. Prioritized compounds with desired pharmacologies are then either advanced as potential drug candidates or fed back into the process for additional Native
Complex-driven compound optimization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our oral small molecule drug discovery process, powered by our
proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, is depicted in the figure below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g15a01.jpg" ALT="LOGO" STYLE="width:5.83333in;height:3.24245in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe we are at the forefront of industrial-scale GPCR drug discovery and development.
Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including
agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. We have successfully applied the technologies of our platform to identify novel, highly potent and selective oral small molecules, and for our most advanced
programs, optimized them into clinical development candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Native Complex Biochemistry and Structural Biology Capabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have developed an industrialized workflow for creating Native Complexes, which involves reconstituting fully functional
GPCRs outside their cellular context. As illustrated in the figure below, our process for creating a Native Complex begins with a human cell expression system that allows us to express GPCRs at high levels. We then extract these GPCRs using
proprietary solubilization and purification protocols that maintain their stability and prevent denaturation. Following extraction, we reconstitute the GPCRs in an artificial lipid bilayer that closely mimics the natural cell membrane. These
reconstituted GPCRs can be combined with ligands and/or separately purified transducers such as G proteins and beta-arrestins. These Native Complexes are modular assemblies, and a variety of different receptor states can be created by using
different combinations of transducers and ligands. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g00b98.jpg" ALT="LOGO" STYLE="width:6.145in;height:1.92855in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once we have isolated a Native Complex, we determine the high-resolution, three-dimensional
structure of the GPCR and a bound compound using cryo-EM. Our <FONT STYLE="white-space:nowrap">in-house</FONT> capabilities, tools, and technologies enable us to identify the precise binding orientation of a drug candidate with exceptional
resolution. After generating the initial Native Complex structure, our advanced technologies enable us to efficiently produce subsequent high-resolution structures. To date, we have successfully determined the structures of over 80 high-resolution,
three-dimensional GPCR structures with bound small molecule ligands spanning multiple mechanisms including agonists, antagonists, and allosteric modulators. Our structure-based drug discovery approach also allows us to uncover novel binding pockets
on validated GPCRs that may offer enhanced therapeutic benefits. In a single lead optimization campaign, we typically generate <FONT STYLE="white-space:nowrap">10-20</FONT> high-resolution structures, and this has allowed us to rapidly iterate and
optimize our compounds efficiently into lead drug candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Native Complex-Driven Hit Identification and Optimization
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once we have determined Native Complex structures and identified binding pockets of interest, we employ
ultra-large scale virtual screening using extensive computational databases of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">make-on-demand</FONT></FONT> compounds. To date, we have screened over 10&nbsp;billion such compounds,
computationally docking them into the binding pockets of our high-resolution, three-dimensional GPCR structures. Upon identifying candidate compounds with optimal binding poses, we proceed to synthesize and test these compounds in functional assays
to evaluate whether they exhibit the desired molecular pharmacology attributes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Separately, we combine our Native
Complexes with DELs to select for GPCR binders with specific functional profiles. DELs are combinatorial libraries of billions of small molecules synthesized with an added DNA barcode, and we leverage next-generation sequencing technologies to
identify high-affinity binders that are optimally suited to modulate specific GPCRs of interest with desired mechanisms of action. We have developed proprietary DEL workflows to discover novel compounds with a wide spectrum of activities including
agonists, antagonists, and allosteric modulators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By integrating these advanced screening techniques into our Native
Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, we have been able to significantly enhance the efficiency and precision of our drug discovery efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Advanced Cellular and In Vivo Pharmacology Models </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon identifying highly potent, novel compounds, we proceed to test these compounds in novel cell-based assays and <I>in
vivo</I> pharmacology models to evaluate whether the compounds exhibit desired drug-like properties. Only the most promising candidates that demonstrate the intended pharmacologic activity move forward into lead optimization campaigns. Other
candidate compounds are fed back into our drug discovery process for additional Native Complex-driven compound optimization. For each of our programs, we have advanced from initiation of medicinal chemistry to potent drug-like compounds with
activity in animal models in less than one year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our proprietary Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> enables iterative structure-based GPCR drug design for what we believe is the first time at scale. Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>&#146;s
integrated approach of combining high-resolution structural insights with large-scale screening and rapid functional testing accelerates the discovery and optimization of new therapeutic compounds. Our industrial-scale platform aims to unlock the
full potential of GPCR therapies and has led to the discovery and development of our pipeline of product candidates focused on treating patients across a variety of therapeutic areas. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Portfolio Opportunities Targeting the Full Breadth of GPCRs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are significant unmet medical needs across numerous GPCR-driven diseases. Our portfolio is focused initially on three
therapeutic areas with the potential to expand to additional therapeutic areas in the future: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Endocrinology</I></B><I>:</I> The endocrine system involves glands that secrete hormones into the
bloodstream that have effects on other tissues. Central to this system are GPCRs, which serve as primary receptors for many circulating hormones. GPCR biology is at the center of endocrine diseases, such as hypoparathyroidism and Graves&#146;
disease, highlighting the urgency for therapeutic interventions targeting GPCR-mediated endocrine disorders. Other endocrine disorders, like osteoporosis, impacts more than 10&nbsp;million older adults in the United States and could benefit from a
small molecule GPCR-directed therapy to help rebuild bone mass. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Immunology</I></B><B><I></I></B><B><I>&nbsp;&amp; inflammation</I></B><I>: </I>GPCRs serve as key
signaling molecules in various cellular processes, including involvement in the regulation of immune responses and the activation of immune cells such as macrophages, T cells, and dendritic cells. Upon activation by extracellular ligands, GPCRs
initiate intracellular signaling cascades that modulate cytokine production, leukocyte trafficking, and inflammatory mediator release. Dysregulation of GPCR signaling pathways is implicated in numerous inflammatory and autoimmune diseases, such as
CSU, making them attractive targets for therapeutic intervention. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Metabolic diseases</I></B><I>: </I>GPCRs are known to regulate various physiological processes such as
energy metabolism, glucose homeostasis, and lipid metabolism. These receptors are involved in sensing nutrients, hormones, and other signaling molecules, thereby influencing appetite, insulin secretion, and lipid storage. Dysregulation of GPCR
signaling pathways is associated with metabolic disorders, such as obesity and T2D. For instance, GPCRs like adrenergic receptors regulate lipolysis and thermogenesis, while receptors such as the <FONT STYLE="white-space:nowrap">GLP-1</FONT>
receptor modulate insulin secretion and satiety. Targeting GPCRs is a clinically and commercially validated approach for the development of therapeutics that manage metabolic disorders, offering the potential to manage glucose levels, promote weight
loss, and improve metabolic health. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Beyond our initial therapeutic areas of focus, we intend to
evaluate opportunities in additional therapeutic areas where GPCRs are directly connected to disease pathology, including in areas of neurology, women&#146;s health, cardiovascular disease, and respiratory disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are advancing a deep portfolio of highly potent and selective oral small molecule GPCR-targeted programs with novel
mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline is focused initially on three therapeutic areas &#150; endocrinology, immunology and inflammation, and
metabolic diseases &#150; and is summarized in the figure below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g95p90.jpg" ALT="LOGO" STYLE="width:6.25in;height:2.80515in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our target selection process considers the validation level of the GPCR and existing
preclinical and/or clinical data demonstrating desired biological outcomes upon target modulation for a variety of different indications. We have prioritized indications with well-defined biomarkers to streamline the path to clinical <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data, high unmet medical need and significant market opportunities. When analogous molecules exist that are approved or in clinical development, we explore
differentiation opportunities and leverage our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to address known limitations. We also leverage regulatory insights from established precedents to guide each program&#146;s
development strategy. As we expand our portfolio of GPCR-targeted programs, we will continue to focus on targets and indications with well understood biology, predictive biomarkers for early <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> efficient clinical development pathways, and high unmet medical need. We are building a deep portfolio comprised of programs that we can independently develop and commercialize upon
regulatory approval, alongside select programs that may benefit from the development and commercial expertise, infrastructure and financial support of a strategic partner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">SEP-786:</FONT> Oral Small Molecule PTH1R for Hypoparathyroidism </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT> is, to our knowledge, the only clinical-stage,
oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism. We discovered and designed <FONT STYLE="white-space:nowrap">SEP-786</FONT> to have potent and selective activation of PTH1R, a GPCR highly involved in blood calcium
control, with an optimized profile that achieves sustained normalization of serum calcium and phosphate upon once-daily or twice-daily oral dosing. Based on promising preclinical data observed to date, we believe
<FONT STYLE="white-space:nowrap">SEP-786</FONT> has the potential to be a differentiated treatment for hypoparathyroidism. We have successfully completed <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and are initiating a Phase 1
clinical trial to assess preliminary safety, tolerability, PK, and PD of <FONT STYLE="white-space:nowrap">SEP-786.</FONT> We expect to report initial data from this trial in &#8195;&#8195;&#8195;&#8195;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Overview of Hypoparathyroidism </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Disease Background and Role of PTH1R </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hypoparathyroidism is a rare endocrine disease characterized by insufficient levels of PTH that affects approximately 70,000
patients in the United States and 140,000 patients in Europe. PTH is a critical hormone for calcium and phosphate homeostasis and functions through the activation of PTH1R. Under normal physiological conditions, PTH is released from the parathyroid
glands when circulating calcium levels are reduced and will act on PTH1R expressed on bone and kidney cells to increase calcium levels (see Figure 3). Most patients with hypoparathyroidism develop the condition following damage to or accidental
removal of the parathyroid glands during thyroid surgery, while other etiologies include autoimmune and genetic disorders. Patients with hypoparathyroidism are at risk of both short-term and long-term complications and comorbidities, such as
tingling or burning of the extremities, muscle cramps and spasms, abdominal pain, abnormal heart rhythm, cataracts, and fatigue and muscle weakness. Chronic hypoparathyroidism is associated with cognitive and emotional symptoms, such as mental
lethargy, inability to concentrate, memory loss or forgetfulness, anxiety and depression. Many patients experience persistent symptoms that negatively impact quality of life and reduce work productivity. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g02n01.jpg" ALT="LOGO" STYLE="width:6.31945in;height:3.90106in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 3. </B>Overview of parathyroid hormone physiology, hypoparathyroidism, and our
strategy to develop an oral small molecule PTH1R agonist to restore calcium homeostasis in patients with hypoparathyroidism. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Current
Treatment Options and Their Limitations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The standard treatment for hypoparathyroidism consists of high-dose calcium
supplements and activated vitamin D (calcitriol) several times a day, which aim to correct serum calcium levels. However, these therapies do not replace other functions of PTH to restore physiological mineral homeostasis, resulting in an increased
risk of physical symptoms, including fatigue, paraesthesia, muscle cramping, tetany, and joint or bone pain, as well as <FONT STYLE="white-space:nowrap">long-term</FONT> complications, such as <FONT STYLE="white-space:nowrap">soft-tissue</FONT>
calcifications and impaired renal function. For some patients with chronic hypoparathyroidism, a managed transition from a high daily calcium intake to a <FONT STYLE="white-space:nowrap">no-</FONT> or
<FONT STYLE="white-space:nowrap">low-calcium</FONT> treatment regimen may reduce adverse events or complications, including kidney stones and hospitalization due </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
to <FONT STYLE="white-space:nowrap">hyper-</FONT> or hypocalcemia. Even among patients on conventional treatments whose serum calcium levels are within the normal range, these side effects limit
the ability of currently available treatments to be safe and effective options for chronic long-term use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Injectable
synthetic PTH peptides have been validated in clinical trials to increase serum calcium and provide a more physiological alternative to conventional therapy. These therapies are designed to sustain PTH in the normal physiological range, thereby more
fully addressing the underlying condition. In 2015, NATPARA (parathyroid hormone) became the first and only <FONT STYLE="white-space:nowrap">FDA-approved</FONT> prescription PTH injection that is taken with calcium and vitamin D to control
hypocalcemia in adults with hypoparathyroidism. Since then, manufacturer Takeda voluntarily recalled NATPARA in the United States due to manufacturing issues and announced that it will discontinue global manufacturing of NATPARA by the end of 2024.
In 2023, palopegteriparatide (marketed as YORVIPATH in the EU by Ascendis Pharma), an investigational prodrug of active PTH <FONT STYLE="white-space:nowrap">(1-34),</FONT> received regulatory approval in the EU, as a hormone replacement therapy
indicated for the treatment of adults with chronic hypoparathyroidism. While hormone replacement with injectable PTH peptides, either marketed or in clinical development, may effectively normalize calcium levels and manage disease complications,
they require life-long daily injections. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Solution: Oral Small Molecule PTH1R Agonist </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our Program Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe there is an unmet need for an oral small molecule PTH1R agonist that offers hypoparathyroidism patients a
convenient, more physiological treatment option. Since conventional therapies, such as calcium and vitamin D, have limitations and do not restore other actions of PTH, such as bone turnover or renal calcium reabsorption, we believe an oral option
that can increase serum calcium and replace the other functions of PTH, is needed for patients. Our potent and selective PTH1R agonist is designed to address all patients with hypoparathyroidism. This includes the most severe patients, who may start
injectable PTH peptide therapy, as well as mild-to-moderate patients who are currently on high doses of calcium and vitamin D and may be less interested in an injectable PTH peptide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> affords us the opportunity to
continuously iterate and optimize additional oral small molecule PTH1R agonists. We may develop additional molecules for hypoparathyroidism or for other indications where PTH1R agonists can address disease pathology, such as osteoporosis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Preclinical Activity of <FONT STYLE="white-space:nowrap">SEP-786</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> was applied to PTH1R and yielded multiple
tractable chemical series of small molecule PTH1R agonists. Iterative structure-based lead optimization yielded our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT> for which we are currently initiating a Phase 1 clinical
trial. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SEP-786</FONT> has demonstrated potent and selective activation of PTH1R in human,
dog, and rat receptor <I>in vitro</I> models. <I>In vivo</I>, <FONT STYLE="white-space:nowrap">SEP-786</FONT> was generally well-tolerated and showed activity in a translational rat thyroparathyroidectomy (TPTx) model of hypoparathyroidism (Figure
4.A). In this model, surgical removal of the parathyroid glands replicates the human disease of hypoparathyroidism with a reduction in serum calcium from the normal range. To assess the activity of PTH1R agonists, compounds are dosed orally for
small molecules or subcutaneously for peptides, which results in dose-dependent increases in serum calcium allowing for an assessment of compound activity and PK/PD relationships. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Single oral doses of <FONT STYLE="white-space:nowrap">SEP-786</FONT> were compared to single subcutaneous doses of a
long-acting PTH peptide <FONT STYLE="white-space:nowrap">(LA-PTH)</FONT> in the TPTx model (Figure 4.B). The 30 mg/kg oral dose of <FONT STYLE="white-space:nowrap">SEP-786</FONT> demonstrated a similar time-dependent increase in serum calcium levels
to a 2 nmol/kg subcutaneous dose of <FONT STYLE="white-space:nowrap">LA-PTH</FONT> with both doses resulting in serum calcium levels exceeding the normal serum calcium range <FONT STYLE="white-space:nowrap">(2.0-2.6</FONT> mmol/L). <FONT
STYLE="white-space:nowrap">SEP-786</FONT> demonstrated dose-dependent serum calcium increase with oral doses of 3 mg/kg and 10 mg/kg resulting in serum calcium levels within the normal range. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In a <FONT STYLE="white-space:nowrap">28-day</FONT> repeat dose study
(Figure 4.C), <FONT STYLE="white-space:nowrap">SEP-786</FONT> at 3 mg/kg dosed orally twice-daily provided sustained increases in serum calcium to within the normal range over the entire <FONT STYLE="white-space:nowrap">28-day</FONT> dosing period.
Effects on phosphate levels, and downstream effects on bone turnover and vitamin D synthesis were also observed. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g10t06.jpg" ALT="LOGO" STYLE="width:5.95833in;height:5.42883in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 4. </B>(A)<B> </B>Rat hypoparathyroidism disease model (thyroid-parathyroidectomy
model, TPTx). (B) Single oral doses of <FONT STYLE="white-space:nowrap">SEP-786</FONT> in the TPTx model show dose-dependent increase in serum calcium. (C)&nbsp;Repeat twice-daily oral dosing of <FONT STYLE="white-space:nowrap">SEP-786</FONT> in the
TPTx model shows sustained calcium control over 28 days of dosing. PO = oral; SC = subcutaneous; BID = twice-daily. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Preclinical
Studies to Support Clinical Advancement of <FONT STYLE="white-space:nowrap">SEP-786</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A translational PK/PD model
for <FONT STYLE="white-space:nowrap">SEP-786</FONT> was developed utilizing the serum calcium PK/PD relationship in TPTx rats and the predicted human PK. We believe this model supports a projection that once-daily or twice-daily oral dosing of <FONT
STYLE="white-space:nowrap">SEP-786</FONT> could lead to control of serum calcium within the normal range in patients with hypoparathyroidism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>In</I><I></I><I>&nbsp;vitro </I>and<I> in vivo </I>safety studies support that
<FONT STYLE="white-space:nowrap">SEP-786</FONT> has a favorable safety pharmacology profile. In <FONT STYLE="white-space:nowrap">28-day,</FONT> repeat, oral dose Good Laboratory Practice (GLP) toxicology studies in rats and dogs, <FONT
STYLE="white-space:nowrap">SEP-786</FONT> was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
generally well-tolerated. At doses significantly higher than projected human efficacious doses, sustained hypercalcemic effects on bone and kidney were observed that are consistent with <FONT
STYLE="white-space:nowrap">on-target</FONT> pharmacology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Clinical Development Plan and Status of
<FONT STYLE="white-space:nowrap">SEP-786</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have submitted a Clinical Trial Notification (CTN) in Australia to
initiate a randomized, placebo-controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) Phase 1 clinical trial in healthy adult participants designed to assess preliminary safety, tolerability, PK, and PD of <FONT
STYLE="white-space:nowrap">SEP-786.</FONT> In the SAD portion of the trial, we plan to evaluate escalating oral doses of <FONT STYLE="white-space:nowrap">SEP-786.</FONT> The MAD portion of the trial will evaluate once-daily and twice-daily oral
dosing of <FONT STYLE="white-space:nowrap">SEP-786</FONT> for five days to evaluate safety and determine the optimal dosing regimen for serum calcium control. Secondary endpoints include PK, serum calcium, urinary calcium, and other biomarkers. We
are initiating the Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">SEP-786</FONT> and expect to report initial data from this trial in &#8195;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">SEP-631:</FONT> Oral Small Molecule MRGPRX2 NAM for CSU and Other Mast Cell Diseases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing <FONT STYLE="white-space:nowrap">SEP-631,</FONT> a selective, oral small molecule MRGPRX2 NAM, initially for
the treatment of CSU. In preclinical studies, <FONT STYLE="white-space:nowrap">SEP-631</FONT> demonstrated potent and long-lasting inhibition of MRGPRX2, which is a highly and uniquely expressed receptor on mast cells and when activated is a key
driver of CSU and other prevalent mast cell diseases. We have initiated <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies of <FONT STYLE="white-space:nowrap">SEP-631</FONT> and upon completion, we anticipate submitting for regulatory
clearance to initiate a clinical trial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Overview of CSU </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Disease Background and Role of MRGPRX2 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CSU is a systemic inflammatory skin disease characterized by the spontaneous and recurrent appearance of itchy, painful hives,
known as wheals, on the skin and angioedema, or swelling, that affects approximately 1.5&nbsp;million patients in the United States. These chronic symptoms, which typically last between two and five years, can interfere with daily living, including
the ability to work, and are frequently associated with psychiatric comorbidities, including depression and anxiety. Some patients with CSU report associated systemic symptoms including headache and fatigue, wheezing, flushing, palpitations, and
gastrointestinal symptoms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While there is no known trigger, the activation and degranulation of mast cells and release of
histamine and other inflammatory mediators lead to these debilitating symptoms of CSU. Two canonical pathways represent the primary mechanisms for activation and degranulation of mast cells: activation of the IgE pathway via receptor cross-linking
by antibodies targeting the high-affinity IgE receptor (Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#101;</FONT>RI) or IgE itself, and activation of an <FONT STYLE="white-space:nowrap">IgE-independent</FONT> pathway via MRGPRX2. As depicted in Figure 5
below, upon activation, mast cells release a plethora of mediators leading to the hallmark symptoms of itching, redness, and swelling. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">MRGPRX2 is highly expressed on the surface of mast cells and plays a critical role in mast cell activation and degranulation.
This receptor is activated by a variety of stimuli, including neuropeptides, antimicrobial peptides, and certain drugs. Upon activation, MRGPRX2 triggers a signaling cascade that leads to the rapid release of
<FONT STYLE="white-space:nowrap">pre-stored</FONT> mediators such as histamine, proteases, and cytokines from mast cell granules. This degranulation process contributes to immediate hypersensitivity reactions and various inflammatory conditions. The
unique ability of MRGPRX2 to respond to a broad range of ligands highlights its importance in host defense mechanisms and its potential as a therapeutic target for treating allergic and inflammatory diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g73h34.jpg" ALT="LOGO" STYLE="width:5.9in;height:3.42444in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 5. </B>Overview of mast cell activation including the <FONT
STYLE="white-space:nowrap">IgE-mediated</FONT> and MRGPRX2-mediated degranulation pathways, physiologic effects of mast cell degranulation, and our strategy to develop a MRGPRX2 NAM to stop MRGPRX2-mediated mast cell degranulation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Current Treatment Options and Their Limitations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patients suffering from CSU are treated initially with antihistamines to control symptoms; however, approximately 37% of
patients are inadequately controlled in this first-line setting. In the antihistamine-refractory setting, patients may be treated with omalizumab (marketed as Xolair by Novartis and Genentech), which is an injectable
<FONT STYLE="white-space:nowrap">anti-IgE</FONT> monoclonal antibody approved by the FDA as an <FONT STYLE="white-space:nowrap">add-on</FONT> therapy for CSU in patients ages 12 years and older. The targeting and blocking of <FONT
STYLE="white-space:nowrap">IgE-mediated</FONT> inflammation can effectively address symptoms; however, only an estimated 36% of these antihistamine-refractory patients respond to <FONT STYLE="white-space:nowrap">anti-IgE</FONT> therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A significant proportion of patients have persistent symptoms with antihistamines and/or Xolair, highlighting substantial need
for additional treatment options. With the expanding knowledge of the pathogenesis of CSU and the role of mast cells, novel therapeutic agents targeting distinct drivers of CSU are in development. We are aware of several new mechanisms, and programs
are being explored in clinical trials, such as <FONT STYLE="white-space:nowrap">anti-Kit</FONT> antibodies barzolvolimab and briquilimimab, Bruton&#146;s tyrosine kinase inhibitor remibrutinib, and antibody to sialic acid-binding immunoglobulin-like
lectin lirentelimab. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Solution: Oral Small Molecule MRGPRX2 NAM </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our Program Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe an oral small molecule that targets MRGPRX2 could provide a differentiated treatment option for patients with CSU.
Our MRGPRX2 NAM program is designed to selectively inhibit mast cells, minimizing the risk of broad immunosuppression, which might be observed with other mechanistic approaches that either eradicate mast cells or inhibit multiple immune cell types.
We believe selective mast cell inhibitors have the potential to be safer treatment alternatives and could be used for both monotherapy and combination therapy. With our NAM, we believe that we may be able to universally block all endogenous MRGPRX2
agonists and provide insurmountable inhibition, which will control patient symptoms and protect against disease flares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing <FONT STYLE="white-space:nowrap">SEP-631</FONT> initially
for the treatment of CSU, as we believe this may provide an efficient path to clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept.</FONT></FONT> There remains a significant unmet need in CSU, since
antihistamine-refractory patients have few oral treatment alternatives. Because multiple diseases are driven by activated mast cells, we believe there is a broad market opportunity to expand into indications across several therapeutic areas, such as
allergic asthma, atopic dermatitis, interstitial cystitis, migraine, and prurigo nodularis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Preclinical Activity of <FONT
STYLE="white-space:nowrap">SEP-631</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SEP-631</FONT> has been demonstrated to
potently block the activation of intracellular signaling in HEK293 cells with overexpressed human MRGPRX2 stimulated by <FONT STYLE="white-space:nowrap">cortistatin-14</FONT> (IC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> = 1.6 nM).
Experiments using a matrix of different concentrations of <FONT STYLE="white-space:nowrap">SEP-631</FONT> versus different concentrations of <FONT STYLE="white-space:nowrap">cortistatin-14</FONT> showed strong suppression of maximal agonist effects
(Figure 6), which we believe demonstrates <FONT STYLE="white-space:nowrap">SEP-631</FONT> has the potential to be an insurmountable NAM. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g35e11.jpg" ALT="LOGO" STYLE="width:4.50415in;height:2.6382in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 6. </B><FONT STYLE="white-space:nowrap">SEP-631</FONT> shows strong negative
allosteric modulation of <FONT STYLE="white-space:nowrap">cortistatin-14</FONT> activation of MRGPRX2 in HEK293 cells expressing MRGPRX2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SEP-631</FONT> can block IP1 accumulation
in HEK293 cells expressing MRGPRX2 in response to activation by several clinically relevant endogenous MRGPRX2 agonists (Figure 7), demonstrating that its inhibitory effect is independent of the activating agonist (i.e., the inhibitor does not show
probe dependence). </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g02n07.jpg" ALT="LOGO" STYLE="width:4.61179in;height:2.47586in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 7. </B><FONT STYLE="white-space:nowrap">SEP-631</FONT> potently inhibits the
activation of MRGPRX2 by a range of endogenous MRGPRX2 agonists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In different <I>in vitro</I> cellular models of mast
cell degranulation, <FONT STYLE="white-space:nowrap">SEP-631</FONT> was shown to be a potent inhibitor of activation and degranulation in LAD2 cells (IC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> = 2.3 nM) and primary human cord
blood-derived mast cells (IC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> = 0.72 nM). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A differentiating
feature of <FONT STYLE="white-space:nowrap">SEP-631</FONT> compared to other third-party MRGPRX2 inhibitors is its long target residence time or slow <FONT STYLE="white-space:nowrap">off-rate</FONT> of inhibition, meaning it takes a long time for
the receptor-ligand complex to dissociate and for the receptor to become activatable again. Two experimental approaches were taken to determine the half-life of the receptor-ligand complex: radioligand binding experiments and one surface plasmon
resonance (SPR) study demonstrated long half-lives of 124&nbsp;minutes (with a standard deviation of 20&nbsp;minutes) and 50 minutes, respectively. Long target residence times of receptor ligands are recognized as being potentially advantageous for
prolonged drug action <I>in vivo</I>, which have been shown to translate to enhanced clinical activity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For
characterization of <FONT STYLE="white-space:nowrap">SEP-631</FONT><I> in vivo</I>, we developed a transgenic <FONT STYLE="white-space:nowrap">knock-in</FONT> (KI) mouse model in which the coding region of the endogenous mouse MRGPRB2 receptor was
replaced with the human MRGPRX2 receptor, due to the low sequence homology shared between the mouse and human orthologs. In this model, MRGPRX2 agonist ligands such as substance P or <FONT STYLE="white-space:nowrap">cortistatin-14</FONT> stimulate
robust plasma extravasation, or edema, when injected into the skin. Extravasation can be quantitated by following the redistribution of Evans Blue dye from the circulation into skin tissue (Figure&nbsp;8.A). In the MRGPRX2 KI mouse model, <FONT
STYLE="white-space:nowrap">SEP-631</FONT> robustly inhibited skin extravasation when dosed orally prior to the <FONT STYLE="white-space:nowrap">cortistatin-14</FONT> challenge, demonstrating complete blockade of skin mast cell degranulation at an
oral dose of 3 mg/kg (Figure&nbsp;8.B). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g99m62.jpg" ALT="LOGO" STYLE="width:5.9575in;height:2.8725in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure&nbsp;8. </B>(A)<B> </B>Human MRGPRX2 KI mouse model of plasma extravasation into
skin. <FONT STYLE="white-space:nowrap">(B)&nbsp;SEP-631</FONT> potently inhibited <FONT STYLE="white-space:nowrap">cortistatin-14</FONT> mediated plasma extravasation into skin in a human MRGPRX2 KI mouse model. PO&nbsp;=&nbsp;oral. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Preclinical Studies to Support Clinical Advancement of <FONT STYLE="white-space:nowrap">SEP-631</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preclinical drug metabolism and PK profile of <FONT STYLE="white-space:nowrap">SEP-631</FONT> across multiple species was
determined to support human PK projections. <FONT STYLE="white-space:nowrap">SEP-631</FONT> has the potential to be highly orally bioavailable with low clearance and a projected half-life consistent with once-daily oral dosing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>In vitro</I> and<I> in vivo </I>safety studies explored to date support that
<FONT STYLE="white-space:nowrap">SEP-631</FONT> has a favorable tolerability profile. In 14-day repeat oral dose non-GLP toxicology in rats and dogs, SEP-631 was generally well tolerated with wide safety margins over projected maximal exposures at
human efficacious doses. We have initiated 28-day GLP toxicology studies in rats and dogs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Clinical Development Plan and Status of <FONT
STYLE="white-space:nowrap">SEP-631</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We plan to develop <FONT STYLE="white-space:nowrap">SEP-631</FONT> initially
for patients with antihistamine-refractory CSU. <FONT STYLE="white-space:nowrap">SEP-631</FONT> is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, and upon completion, we anticipate submitting for regulatory clearance to
initiate a Phase&nbsp;1 clinical trial. The Phase 1 clinical trial is intended to be a SAD/MAD trial in healthy volunteers to assess safety, tolerability, PK, and PD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to CSU, we are evaluating a range of other indications in which aberrant mast cell activation has been
demonstrated to be central to disease pathobiology. Mast cell activation drives multiple prevalent diseases, including allergic asthma, atopic dermatitis, interstitial cystitis, migraine, and prurigo nodularis, and we believe <FONT
STYLE="white-space:nowrap">SEP-631</FONT> could offer a novel oral treatment option for these patient populations. We plan to explore these indications as potential future clinical development opportunities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>TSHR Program: Oral Small Molecule TSHR NAM for Graves&#146; Disease and TED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing a novel, oral small molecule TSHR NAM for the treatment of Graves&#146; disease and TED. We believe our TSHR
NAM could offer a disease-modifying treatment that directly addresses the pathobiology of both diseases by blocking TSHR overactivation caused by patients&#146; autoantibodies. We are advancing several lead compounds towards selection of a
development candidate for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Overview of Graves&#146; Disease and TED </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Disease Background and Role of TSHR </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Graves&#146; disease is one of the most prevalent autoimmune conditions affecting over 2&nbsp;million patients in the United
States and is the leading cause of hyperthyroidism. In Graves&#146; disease, the body produces autoantibodies that bind to and activate TSHR on thyroid cells (Figure&nbsp;9). These autoantibodies stimulate the thyroid gland to produce excess thyroid
hormone, resulting in hyperthyroidism. Thyroid hormones affect many body systems, so symptoms of Graves&#146; disease can be wide ranging. Common symptoms of Graves&#146; disease include anxiety and irritability, tremors, heat sensitivity, weight
loss, rapid or irregular heartbeat, and sleep disturbance. Although Graves&#146; disease may affect anyone, it is more common among women and people younger than age 40. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">TED is a related, yet distinct, vision-threatening autoimmune condition that develops in approximately 50% of Graves&#146;
disease patients. In TED, autoantibodies bind to and activate TSHR on orbital fibroblasts located behind the eyes, thereby resulting in inflammation, orbital fat expansion, and fibrosis. TED is a progressive disease and early diagnosis and treatment
is important to prevent worsening and serious eye damage, including proptosis (eye bulging), strabismus (misalignment of the eyes), and diplopia (blurred or double vision). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g72w39.jpg" ALT="LOGO" STYLE="width:5.934in;height:3.116in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 9. </B>Overview of TSHR physiology, the role of TSHR autoantibodies in the
pathogenesis of Graves&#146; disease and TED, and our strategy to develop a TSHR NAM to reverse the effects of TSHR antibodies as a potential disease-modifying therapy for patients with Graves&#146; disease and TED. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Current Treatment Options and Their Limitations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The most common treatments for Graves&#146; disease have remained largely unchanged over the past 70 years and include
antithyroid drugs, such as methimazole and propylthiouracil, designed to lower the amount of hormone the thyroid makes or block the effects of thyroid hormone on the body, radioactive iodine therapies that aim to destroy overactive thyroid cells,
and thyroidectomy surgery to remove all or part of the thyroid. For many patients, there is a high rate of disease recurrence after treatment with antithyroid drugs, and lifelong hypothyroidism develops after ablation and thyroidectomy. In addition,
these treatment options may initially address the underlying symptoms, but they are not disease-modifying and do not stop disease progression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current treatments for TED depend on disease severity and are designed to help manage symptoms and slow disease progression.
For patients with mild TED, lifestyle changes and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> remedies, such as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
artificial tear drops and selenium supplements, may help with dry eye relief. For severe TED, steroids and/or eye surgery, such as orbital decompression may be considered. Historically, patients
have had to live with TED until the inflammation subsides, after which they are often left with permanent and vision-impairing consequences and may require multiple surgeries that do not completely return the patient to their <FONT
STYLE="white-space:nowrap">pre-disease</FONT> state. In 2020, the FDA approved TEPEZZA (teprotumumab-trbw), an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IGF-1R</FONT></FONT> human monoclonal antibody, for the treatment
of TED based on its ability to decrease proptosis and resolve diplopia in patients. Despite reaching global sales of $2.0&nbsp;billion in 2022, TEPEZZA requires several IV infusions over several months and has risks of serious side effects,
including hearing loss and metabolic issues, such as hyperglycemia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Solution: Oral Small Molecule TSHR NAM </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our Program Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe there is a significant unmet need for a disease-modifying approach that directly addresses the pathobiology of both
Graves&#146; disease and TED<I>. </I>Our highly selective, oral small molecule TSHR NAM program is designed to block the activation of TSHR by autoantibodies and could lead to a universal treatment option for all Graves&#146; disease and TED
patients. Our NAMs are designed to provide insurmountable inhibition, thus potentially providing protection for patients with high serum antibody levels and for patients with polyclonal activating antibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With few innovative, <FONT STYLE="white-space:nowrap">non-surgical</FONT> or ablative treatments, we believe that there is a
significant unmet need in Graves&#146; disease. While treatments exist for TED, they are focused on the most severe patients, so an oral small molecule TSHR NAM, could provide a new option for all TED patients. Because over-stimulation of TSHR is at
the center of Graves&#146; disease and TED, we believe that if we can treat Graves&#146; disease patients early in their disease course with our oral small molecule TSHR NAM, our treatment may be able to prevent the progression to other
manifestations of the disease, such as TED or Graves&#146; dermopathy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Discovery and Preclinical Activity of Oral TSHR NAMs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have used our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to identify multiple tractable
chemical series of oral small molecule TSHR NAMs.&nbsp;Molecular pharmacology studies with TSHR NAMs have demonstrated multiple compound series with high potencies and desired drug-like properties. In cells expressing human TSHR, cAMP signaling
activated by an autoantibody isolated from a Graves&#146; disease patient was significantly inhibited with several of our lead compounds. In addition, our compounds exhibit high selectivity for inhibition of TSHR over a broad set of other GPCRs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An effective treatment for both Graves&#146; disease and TED will require broad inhibition of patient autoantibodies,
which are typically high affinity and present at high titers during active disease. Furthermore, these autoantibodies may bind to different sites on the large extracellular domain of TSHR. We believe a TSHR NAM is the ideal pharmacologic profile to
fully block the activity of all patient autoantibodies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Experiments using a matrix of different concentrations of one of our oral
small molecule TSHR NAMs <FONT STYLE="white-space:nowrap">(SP-1351)</FONT> versus different concentrations of a Graves&#146; disease patient activating autoantibody showed strong suppression of maximal agonist effects on TSHR, even when the agonist
antibody is applied at high concentrations (Figure 10). We believe these results suggest that the antibody cannot overcome the inhibitory effects of our compound, and that our NAM has the potential to exert insurmountable inhibition of TSHR
activation by the autoantibody. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g43d06.jpg" ALT="LOGO" STYLE="width:4.59363in;height:2.49733in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 10. </B><FONT STYLE="white-space:nowrap">SP-1351</FONT> shows strong TSHR NAM in
HEK293 cells stimulated with a Graves&#146; disease patient-derived autoantibodies against TSHR. mAb&nbsp;= monoclonal antibody. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To demonstrate that our TSHR NAM can fully inhibit multiple patient autoantibodies, we assessed the activity of <FONT
STYLE="white-space:nowrap">SP-1351</FONT> against Graves&#146; disease patient-derived polyclonal sera applied to TED patients&#146; orbital fibroblasts. Fibroblast activation by the sera is measured by quantifying hyaluronic acid production by the
cells. <FONT STYLE="white-space:nowrap">SP-1351</FONT> was able to inhibit the activity of 10 out of 10 polyclonal sera samples, each from a different Graves&#146; disease patient (Figure&nbsp;11). This result suggests broad inhibitory activity of
our TSHR NAMs against the diverse range of polyclonal autoantibodies found in Graves&#146; disease patients. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g05g90.jpg" ALT="LOGO" STYLE="width:5.69564in;height:2.12137in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 11. </B><FONT STYLE="white-space:nowrap">SP-1351</FONT> inhibits activation of
primary orbital fibroblasts by all 10 polyclonal serum samples collected from Graves&#146; disease patients. mAb&nbsp;= monoclonal antibody. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To characterize the effects of these oral TSHR NAMs on disease manifestations <I>in vivo</I>, we developed a translational
mouse model of hyperthyroidism (Figure 12.A). Mice chronically treated with a Graves&#146; disease patient-derived TSHR-activating antibody developed multiple manifestations similar to Graves&#146; disease patients
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
including increased plasma thyroid hormone T4 levels (Figure&nbsp;12.B), increased thyroid weight (Figure&nbsp;12.C), and proptosis (Figure&nbsp;12.D). After one week of <FONT
STYLE="white-space:nowrap">SP-1351</FONT> treatment with repeat oral dosing, several of these manifestations showed signs of reversal including normalization of thyroid hormone T4 levels, reduction in thyroid weight, and reduction of proptosis. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g30c65.jpg" ALT="LOGO" STYLE="width:6.005in;height:3.505in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure&nbsp;12. </B>(A)<B> </B>Translational <I>in vivo</I> mouse model of Graves&#146;
disease. (B,C,D) <FONT STYLE="white-space:nowrap">SP-1351</FONT> demonstrates reversal of the hyperthyroid state and proptosis in mice chronically treated with a monoclonal TSHR autoantibody. mAb&nbsp;= monoclonal antibody. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the same mouse model, effects on thyroid tissue were assessed. Thyroid glands of Graves&#146; disease patients are
characterized by follicular hyperplasia and/or hypertrophy, intracellular colloid droplets, follicular colloid reduction and scalloping, increased vascularity and lymphocyte infiltration, all of which manifest in our mouse disease model. After oral
treatment with <FONT STYLE="white-space:nowrap">SP-1351,</FONT> we observed significant reduction in follicular hypertrophy and colloid droplets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Next Steps </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are continuing to optimize multiple early-stage oral small molecule TSHR NAMs, with the goal of advancing lead compounds
towards selection of a development candidate for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. In our preclinical studies, we have identified multiple TSHR NAMs that demonstrated the ability to reverse hyperthyroidism and proptosis
in a novel mouse model of Graves&#146; disease and inhibit of multiple Graves&#146; disease patient TSHR autoantibodies in cell-based assays using primary human cells. We intend to pursue future clinical development of our TSHR NAM program for the
treatment of Graves&#146; disease and TED. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Incretin Programs &#150; Oral Small Molecule Single- and Multi-Incretin Receptor Agonists
for Metabolic Disorders Including Obesity and T2D </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on unique chemical and structural insights obtained with our
Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, we believe we have an opportunity to discover and develop novel, next-generation, oral small molecules as selective single- or multi-acting <FONT
STYLE="white-space:nowrap">GLP-1,</FONT> GIP, glucagon receptor agonists. We are advancing several lead compounds towards selection of one or more development candidates for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Overview of Obesity and T2D </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Disease Background and Role of Incretins </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obesity and diabetes are two of the most prevalent chronic diseases in the world, affecting a combined total of more than
800&nbsp;million people, and are associated with severe health complications, including cardiovascular disease and kidney failure, as well as an increased risk of death. Obesity is defined as having a BMI of greater than or equal to 30 and is
associated with more than 200 comorbidities, including diabetes, which can lead to blindness, limb amputations, and the need for dialysis. Despite increased awareness about obesity as a global epidemic and the advancement of new treatments, no
country has reported a decline in obesity prevalence across its entire population. It is predicted that 1.55&nbsp;billion people will be living with obesity globally by 2030. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">More than 400&nbsp;million people worldwide live with diabetes and approximately 90% of all diabetes cases are T2D, which is a
chronic disease involving sustained high levels of glucose in the bloodstream. Under normal conditions, insulin is produced by the pancreas, enabling glucose to enter cells to provide energy needed for normal tissue and organ function. T2D results
from either the pancreas not producing enough insulin or the body&#146;s cells not responding normally to insulin, known as insulin resistance. Uncontrolled diabetes can lead to severe health complications, such as an increased risk of heart attack,
stroke, neuropathy, kidney failure, limb amputations, and vision loss. The key risk factors for developing T2D include obesity, genetic predisposition, a sedentary lifestyle, or a history of gestational diabetes. Moreover, T2D and obesity are
considered <FONT STYLE="white-space:nowrap">co-morbidities,</FONT> with 90% of people with T2D being overweight or obese. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Incretins (e.g., <FONT STYLE="white-space:nowrap">GLP-1,</FONT> GIP, and glucagon) are a group of metabolic hormones that,
along with their associated receptors, play significant roles in glucose metabolism and homeostasis (Figure&nbsp;13). <FONT STYLE="white-space:nowrap">GLP-1</FONT> and GIP are secreted in the intestinal tract after eating, and subsequently activate
their respective receptors expressed on pancreatic beta cells, to stimulate insulin secretion in a glucose-dependent manner. Glucagon activates its related receptors expressed on pancreatic alpha cells, to counteract the actions of insulin by
stimulating hepatic glucose production and thereby increases blood glucose levels in a glucoregulatory role. The widespread therapeutic effects of <FONT STYLE="white-space:nowrap">GLP-1</FONT> and GIP receptor agonism in patients with diabetes are
well-documented and include slowing of gastric emptying, increased satiety, reduction of food intake, promotion of weight loss, and reduction of cardiovascular disease morbidity and mortality. Moreover, there is a complex interplay between the
actions of <FONT STYLE="white-space:nowrap">GLP-1,</FONT> GIP, and glucagon, and recent clinical data from the triagonist injectable peptide retatrutide (in development by Eli Lilly and Company) indicate there are potential additional efficacy
benefits on weight loss and its maintenance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g78p09.jpg" ALT="LOGO" STYLE="width:4.578in;height:3.138in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure&nbsp;13. </B>Overview of the physiologic effects of <FONT
STYLE="white-space:nowrap">GLP-1,</FONT> GIP, glucagon acting through their respective receptors <FONT STYLE="white-space:nowrap">GLP-1R,</FONT> GIPR, and GCGR, and our strategy to develop oral small molecule single- and multi-incretin receptor
agonists. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Current Treatment Options and Their Limitations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Standard treatment for obesity and T2D is lifestyle change through a combination of diet, exercise, and behavior therapy, and,
in the case of T2D, metformin. According to the 2022 ADA Standards of Medical Care in Diabetes, management of obesity is an important factor in the treatment of diabetes since even a small degree of weight loss can improve blood glucose levels,
resulting in a decreased need for glucose-lowering medications. While lifestyle modifications can produce weight loss, the magnitude required for disease modification is approximately 10% to 15% of total body weight. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In recent years, several injectable peptide agonists targeting incretins have been approved for the treatment of T2D, and, due
to their ability to increase feelings of fullness, decrease appetite, and effectively promote weight loss, for the treatment of obesity. Third-party clinical data with incretin receptor therapeutics have demonstrated substantial and sustained
reductions in body weight, as well as the ability to lower blood glucose and improve glycated hemoglobin (HbA1c). Global sales in 2023 for Ozempic and Wegovy (semaglutide), and Mounjaro and Zepbound (tirzepatide) were $18.4&nbsp;billion and
$5.3&nbsp;billion, respectively. While the benefits of currently <FONT STYLE="white-space:nowrap">marketed&nbsp;GLP-1&nbsp;and&nbsp;dual</FONT> <FONT STYLE="white-space:nowrap">GLP-1/GIP&nbsp;receptor</FONT> agonists are well-documented in patients
with diabetes and obesity, they suffer from several limitations including tolerability, prolonged titration schemes, and injection administration, and supply challenges. The most frequent adverse events
<FONT STYLE="white-space:nowrap">with&nbsp;GLP-1&nbsp;receptor</FONT> agonists <FONT STYLE="white-space:nowrap">are&nbsp;GI-related</FONT> issues,&nbsp;including nausea, vomiting, and diarrhea, which necessitate dose titration protocols to manage
treatment and often contribute to treatment discontinuation. Finally, certain doses of semaglutide and tirzepatide are currently on several global health authorities&#146; drug shortage lists, highlighting the need for additional scalable treatment
options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Beyond currently available treatment options, we are aware of numerous injectable peptides in clinical
development that are exploring the combination of agonist activities at the <FONT STYLE="white-space:nowrap">GLP-1,</FONT> GIP, and glucagon receptor metabolic targets. In addition, orally administered
<FONT STYLE="white-space:nowrap">GLP-1&nbsp;receptor</FONT> small molecules are being clinically evaluated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Solution: Oral
Small Molecule Single- and Multi-Incretin Receptor Agonists </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our Program Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe there remains a significant unmet need in the treatment of diabetes, obesity and other cardiometabolic disorders to
discover and develop products that can deliver the activity of mono- or multi-acting injectable peptide agonists, like semaglutide or tirzepatide, but as oral small molecules. By exploring novel, single-acting or various multi-acting <FONT
STYLE="white-space:nowrap">GLP-1,</FONT> GIP and glucagon receptor agonists, we believe that we have the potential to discover and develop oral products that have the potential to increase patient convenience and compliance, and to improve
tolerability, ultimately expanding the treated population. Given the significant market opportunity, we are leveraging our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to discover novel scaffolds across various
product profiles to explore multiple different treatment options for patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Discovery and Preclinical Activity of Oral Incretin
Receptor Agonists </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have used our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to
identify multiple tractable chemical series of oral small molecule incretin receptor agonists. Structural biology demonstrated that our compounds occupy novel binding sites, distinct from the known orthosteric binding sites occupied by
clinical-stage small molecules, danuglipron and orforglipron. Analysis of the respective binding sites show a high similarity of more than <FONT STYLE="white-space:nowrap">80-90%</FONT> for <FONT STYLE="white-space:nowrap">GLP-1,</FONT> GIP, and
glucagon receptors, in contrast to the modest similarity of approximately <FONT STYLE="white-space:nowrap">40-60%</FONT> at the danuglipron and orforglipron orthosteric sites. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our portfolio of discovery-stage incretin receptor agonists includes several
potent, selective mono-GIPR receptor agonists, dual-GIPR / GCGR agonists, and <FONT STYLE="white-space:nowrap">triple-GLP-1R</FONT> / GIPR / GCGR agonists (Figure 14). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g69v12.jpg" ALT="LOGO" STYLE="width:5.58681in;height:1.54992in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 14. </B>Cell-based assay activity of exemplar incretin receptor agonists: cAMP
readout in recombinant cells overexpressing GIPR, <FONT STYLE="white-space:nowrap">GLP-1R,</FONT> or GCGR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Favorable
physicochemical and <I>in vitro</I> drug metabolism properties of one of our selective mono-GIPR agonists, <FONT STYLE="white-space:nowrap">SP-3561,</FONT> translated into promising PK in mice with low clearance and high oral bioavailability.
Subsequent evaluation of <FONT STYLE="white-space:nowrap">SP-3561</FONT> in an oral-glucose tolerance test (OGTT) in diet-induced obese (DIO) mice (Figure 15.A) demonstrated significant dose-dependent glucose reduction at oral doses of 10 and 30
mg/kg (Figure 15.B,C). DIO mice were fasted overnight, and 30 minutes after oral dosing of <FONT STYLE="white-space:nowrap">SP-3561</FONT> a glucose challenge was administered, and blood glucose levels were monitored for two hours after dosing. At
30 mg/kg, <FONT STYLE="white-space:nowrap">SP-3561</FONT> demonstrated effective glucose control comparable to retatrutide (clinically studied <FONT STYLE="white-space:nowrap">triple-GLP-1R</FONT> / GIPR / GCGR injectable peptide agonist) dosed
subcutaneously (Figure 15.B,C). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g38i22.jpg" ALT="LOGO" STYLE="width:5.6225in;height:3.385in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 15. </B>(A)<B> </B>OGTT model with DIO mice. (B,C)
<FONT STYLE="white-space:nowrap">SP-3561</FONT> improves oral glucose tolerance in the DIO mouse model comparable to retatrutide. PO = oral, SC&nbsp;=&nbsp;subcutaneous. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Next Steps </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have identified potent, selective mono-GIPR agonists, dual-GIPR / GCGR agonists, and
<FONT STYLE="white-space:nowrap">triple-GLP-1R</FONT> / GIPR / GCGR agonists. Exemplars across our portfolio of oral small molecule incretin receptor agonists with favorable PK properties have demonstrated the ability to achieve glucose control in
mouse models of glucose sensitivity. We plan to conduct preclinical studies to assess the utility of these compounds in weight loss models as single agents or in combination with established weight loss agents (e.g.,
<FONT STYLE="white-space:nowrap">GLP-1R</FONT> agonist peptides or small molecules). We are continuing to optimize multiple early-stage oral small molecule incretin receptor agonists, with a goal of advancing lead compounds towards selection of one
or more development candidates for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a
strong emphasis on proprietary and novel products and product candidates. While we believe our product candidates, platform, knowledge, experience and scientific personnel provide us with several key competitive advantages, we face competition from
major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Our future success will depend in part on our ability to maintain a competitive position with
our structure-based drug discovery platform. If we fail to stay at the forefront of technological change in utilizing our platform to create and develop product candidates, we may be unable to compete effectively. Our competitors may render our
approach obsolete by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug discovery process that we believe we derive from our research approach and
platform. Several other companies also focus on GPCRs and have platform technologies that are distinct from our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, including Nxera Pharma (formerly Sosei Heptares),
Structure Therapeutics, Tectonic Therapeutics, and Confo Therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, any product candidates that we
successfully develop and commercialize, including <FONT STYLE="white-space:nowrap">SEP-786</FONT> and <FONT STYLE="white-space:nowrap">SEP-631,</FONT> may compete with existing therapies and new therapies that may become available in the future that
are approved to treat the same diseases for which we may obtain approval for our product candidates. There are several large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of
product candidates for the treatment of the indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent
protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
are aware of pharmaceutical companies that have commenced clinical studies of products or have successfully commercialized products addressing areas that we are targeting. Takeda owns the rights to an injectable parathyroid hormone product (brand
name NATPARA), for the treatment of hypoparathyroidism. NATPARA was voluntarily recalled in September 2019 in the United States due to manufacturing issues and is now only available to a limited number of patients through a Special Use Program
offered by its manufacturer. In October 2022, Takeda announced manufacturing of all strengths of NATPARA will be discontinued globally by the end of 2024. Ascendis Pharma received regulatory approval for a proprietary once-daily injectable PTH
peptide, palopegteriparatide (brand name YORVIPATH), in Europe and submitted a New Drug Application (NDA), which is currently being reviewed by the FDA, with a Prescription Drug User Free Act (PDUFA) date of August&nbsp;14, 2024. In March 2024,
AstraZeneca acquired Amolyt Pharma, who was developing eneboparatide, a proprietary, once-daily injectable PTH peptide, for hypoparathyroidism, currently in Phase 3 trials. In addition, we are aware of several academic groups and companies working
on making longer-acting agonists of PTH1R. Other companies and groups are developing or commercializing therapies for hypoparathyroidism, including Calcilytix (a BridgeBio company), Entera Bio, Extend Biosciences, and MBX Biosciences. Several
companies are developing clinical-stage small molecule MRGPRX2 inhibitors, including Escient Pharmaceuticals (acquired by Incyte Pharmaceuticals in April 2024), Evommune, and BioArdis. Further there are several other companies pursuing therapies for
CSU addressing other receptors of interest, such as Genentech, Sanofi, Celldex </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Therapeutics, Jasper Therapeutics, Acelyrin, Allakos, Novartis, Third Harmonic Bio, and Blueprint Medicines. For TSHR, we are aware that Byondis and Crinetics are also working on research stage
compounds, but they have not yet entered clinical development. In addition several companies are working on other mechanisms to address Graves&#146; disease, such as Immunovant, and TED, including Amgen, Viridian, Argenx, Roche, Lassen Therapeutics,
Tourmaline Bio, Sling Therapeutics, and Acelyrin. There are also several currently approved injectable products targeting incretin receptors for the treatment of obesity or T2D. These include, but are not limited to, products such as Ozempic and
Wegovy (semaglutide, marketed by Novo Nordisk) for T2D and obesity, respectively, Trulicity (dulaglutide, marketed by Eli Lilly and Company) for T2D, and Mounjaro and Zepbound (tirzepatide, marketed by Eli Lilly and Company) for T2D and obesity,
respectively. There are also several injectable peptide products in development pursuing similar indications with similar mechanism of actions along with combination products, including those being developed by Amgen, AstraZeneca, Boehringer
Ingelheim, Eli Lilly and Company, Novo Nordisk, Roche, and Viking, among others. In addition, there are oral products such as Rybelsus (semaglutide, marketed by Novo Nordisk) approved for patients with T2D and other oral products in development for
treating obesity or T2D, including those being developed by AstraZeneca, Eli Lilly and Company, Pfizer, Roche, Structure, and Terns. Based on our continuing evaluations of the competitive landscape, we may decide to reallocate resources and
reprioritize our development programs if we determine that a particular product candidate or target indication is no longer commercially viable or advantageous. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of our competitors, either alone or with their collaborators, have significantly greater financial, technical,
manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our
products, the timing and scope of marketing approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior
treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or
noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be
adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial opportunity could be reduced or eliminated if our competitors develop and
commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other applicable regulatory
approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in
many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that we are pursuing and additional products are expected to
become available on a generic basis over the coming years. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Manufacturing and Supply </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not own or operate manufacturing facilities for the production of our product candidates and currently have no immediate
plans to build our own clinical or commercial scale manufacturing capabilities. We have engaged, and expect to continue to rely on, third-party contract manufacturing organizations (CMOs) to supply our product candidates for use in our preclinical
studies and clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we intend to rely on third-party manufacturers for later-stage development and
commercial manufacturing if our product candidates receive marketing approval. As our current or future product candidates advance through clinical development, we expect to enter into longer-term commercial supply agreements to fulfill and secure
our production needs. While the drug substances used in our product candidates are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
manufactured by more than one supplier, the number of manufacturers is limited. In the event it is necessary or advisable to acquire supplies from an alternative supplier, we might not be able to
obtain them on commercially reasonable terms, if at all. It could also require significant time and expense to redesign our manufacturing processes to work with another company. If we need to change manufacturers during the clinical or development
stage for product candidates or after commercialization for our product candidates, if approved, the FDA, European Medicines Agency (EMA), and other comparable foreign regulatory authorities must approve these new manufacturers in advance, which
will involve testing and additional inspections to ensure compliance with FDA regulations and standards and may require significant lead times and delay. Reliance on third-party manufacturers and CMOs may expose us to different risks than if we were
to manufacture and develop product candidates ourselves. Should any of these manufacturers become unavailable to us for any reason, we believe that there are a number of potential replacements, although we may incur some delay in identifying and
qualifying such replacements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have personnel with extensive technical, manufacturing, analytical, and quality
experience to oversee contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our intellectual property is critical to our business and we strive to protect it, including by pursuing and, once obtained, by
maintaining patent protection in the United States and in selected foreign jurisdictions for our current and future product candidates, new therapeutic approaches and potential indications, and other inventions that are important to our business. We
also rely on the skills, knowledge, and experience of our scientific and technical personnel, as well as that of our advisors, consultants, contractors, and collaborators. To help protect our proprietary
<FONT STYLE="white-space:nowrap">know-how</FONT> that we elect not to patent, such as our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, processes for which patents are difficult to enforce, and any other
elements of our current or future product candidates, technology and product discovery and development processes that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology that is not covered by patents, we
rely on confidentiality and other agreements to protect our interests. We generally require our employees, consultants, scientific advisors and contractors to enter into confidentiality agreements prohibiting the disclosure of our confidential
information and requiring disclosure and assignment to us of their ideas, developments, discoveries and inventions important to our business. In addition, we also plan to rely on regulatory protection based on orphan drug exclusivities, data
exclusivities, and market exclusivities. See the subsection section titled &#147;&#151;Government Regulation&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The patent positions of biotechnology and pharmaceutical companies like us are generally uncertain and can involve complex
legal, scientific, and factual issues. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary
protection from competitors. We also cannot ensure that patents will issue with respect to any patent applications that we may file in the future, nor can we ensure that any of our patents or future patents will be commercially useful in protecting
our current or future product candidates and methods of using or manufacturing the same. In addition, the coverage claimed in a patent application may be significantly reduced before a patent is issued, and its scope can be reinterpreted and even
challenged after issuance. As a result, we cannot guarantee that any of our current or future product candidates, if they obtain required regulatory approvals, will be protectable or remain protected by enforceable patents. Moreover, any patents
that we hold may be challenged, circumvented, or invalidated by third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success will also depend in
part on our ability to operate without infringing the proprietary intellectual property rights of third parties, and in part on our ability to prevent others from infringing our proprietary rights. It is uncertain whether the issuance of any
third-party patent would require us to alter our development or commercial strategies, or our future drugs or processes, obtain licenses, or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary
rights that we may require to develop or commercialize our future drugs may have an adverse impact on us. See &#147;Risk Factors&#151;Risks Related to Intellectual Property&#148; for a more comprehensive description of risks related to our
intellectual property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patent Applications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We generally file patent applications directed to our current or future product candidates in an effort to secure our
intellectual property positions <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> these programs. For our current or future product candidates, we will, in general, initially pursue patent protection
covering compositions of matter and therapeutic methods of use. Throughout the development of our current or future product candidates, we will seek to identify additional means of obtaining patent protection that would potentially enhance
commercial success, including by protecting inventions related to additional methods of use, processes of making, formulations and dosing regimens. The intellectual property portfolios for our current product candidates as of July&nbsp;28, 2024 are
summarized below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Small Molecule Agonists of PTH1R </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We own four patent families directed to certain small molecule agonists of PTH1R and therapeutic methods of using them. As of
July&nbsp;28, 2024, we have two pending Patent Cooperation Treaty (PCT) patent applications, nine pending foreign applications, and two pending United States provisional patent applications. Any patents that may issue from patent applications in
these families (or in the case of provisional applications, if issued from future <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications that we file) are projected to expire between 2043 and 2045, absent any disclaimers or potentially
available patent term extensions or adjustments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Small Molecule Inhibitors of MRGPRX2 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We own one patent family directed to certain small molecule inhibitors of MRGPRX2 and therapeutic methods of using them. As of
July&nbsp;28, 2024, we have one pending PCT patent application and seven pending foreign applications. Any patents that may issue from patent applications in this family (or in the case of provisional applications, if issued from future <FONT
STYLE="white-space:nowrap">non-provisional</FONT> applications that we file) are projected to expire in 2044, absent any disclaimers or potentially available patent term extensions or adjustments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Small Molecule Inhibitors of TSHR </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For our TSHR program, we own two patent families directed to certain small molecule inhibitors of TSHR and therapeutic methods
of using them. As of July&nbsp;28, 2024, we have one pending PCT patent application and one pending United States provisional patent application. Any patents that may issue from patent applications in these families (or in the case of provisional
applications, if issued from future <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications that we file) are projected to expire between 2043 and 2045, absent any disclaimers or potentially available patent term extensions or
adjustments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Small Molecule Agonists of Incretin Receptors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For our incretin programs, we own four patent families directed to certain small molecule single- and multi-incretin agonists,
incretin receptors, and therapeutic methods of using them. As of July&nbsp;28, 2024, we have five pending United States provisional patent applications. Any patents that may issue from patent applications in these families (or in the case of
provisional applications, if issued from future <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications that we file) are projected to expire between 2044 and 2045, absent any disclaimers or potentially available patent term extensions
or adjustments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patent Term Extensions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, the term of a patent covering an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may, in
certain cases, be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years, but cannot extend beyond a total
of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. If one or more of our pending United States
patent applications are issued as United States patents covering our current or future products or their therapeutic use it is possible that the patents may be entitled to patent term extensions. If a therapeutic use of a drug candidate or the drug
candidate itself receives FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved use or drug candidate. We also intend to seek patent term extensions in any other
jurisdictions where available. However, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted and even if granted, the length of such extensions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Trade Secrets&nbsp;&amp; <FONT STYLE="white-space:nowrap">Know-how</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to patent protection, we also rely on trade secrets, trademarks, proprietary information, confidential <FONT
STYLE="white-space:nowrap">know-how,</FONT> and continuing technological innovation to develop and maintain our competitive position. Our trade secrets, proprietary information, and confidential <FONT STYLE="white-space:nowrap">know-how</FONT>
includes our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>. However, trade secrets, proprietary information, and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. We seek to
protect our trade secrets, proprietary information, and confidential <FONT STYLE="white-space:nowrap">know-how,</FONT> in part, using confidentiality agreements with any collaborators, scientific advisors, employees, and consultants and invention
assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors, and collaborators. These agreements may not provide adequate protection. These agreements may also
be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets, proprietary information, and <FONT STYLE="white-space:nowrap">confidential&nbsp;know-how&nbsp;may</FONT> become known or be independently
developed by a third party, or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our current or future products or
obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop substantially the same or similar proprietary information and techniques or may otherwise
gain access to our proprietary information. As a result, we may not be able to meaningfully protect our trade secrets, proprietary information, and confidential <FONT STYLE="white-space:nowrap">know-how.</FONT> For more information regarding the
risks related to our intellectual property, see the section titled &#147;Risk Factors&#151;Risks Related to Intellectual Property.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions,
including the European Union (EU), extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing,
post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with
applicable statutes and regulations, require the expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Review and Approval of
Drugs in the United States </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, the FDA regulates drugs under the U.S. Federal Food, Drug, and
Cosmetic Act (FDCA) and its implementing regulations. The failure to comply with applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety
of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product seizures, total or
partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the U.S. Department of Justice or
other governmental entities. In addition, an applicant may need to recall a product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An applicant seeking approval to market and distribute a new drug product in
the United States must typically undertake the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of nonclinical, or preclinical, laboratory tests, animal studies and formulation studies in
compliance with the FDA&#146;s good laboratory practice (GLP) regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND which must take effect before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an institutional review board (IRB) representing each clinical site before each clinical trial may
be initiated at that site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices
(GCPs) to establish the safety and efficacy of the proposed drug product for each indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation and submission to the FDA of an NDA and payment of user fees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review of the product by an FDA advisory committee, where appropriate or if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which
the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices (cGMP) requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#146;s identity,
strength, quality and purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity
of the clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with any post-approval requirements, including risk evaluation and mitigation strategies (REMS) and
post-approval studies required by the FDA. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Preclinical Studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before an applicant begins testing a compound in humans, the drug candidate enters the preclinical testing stage. Preclinical
studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient (API) and the formulated drug or drug product, as well as<I>&nbsp;in vitro</I>&nbsp;and animal studies to assess
the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Some long-term
preclinical testing, such as animal tests of reproductive adverse effects and carcinogenicity, may continue after the IND is submitted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The IND and IRB Processes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an
investigational clinical trial and a request for FDA authorization to administer such investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of the investigational drug. In an IND,
applicants must submit a protocol for each clinical trial and any subsequent protocol amendments. In addition, an applicant submits the results of the preclinical tests, manufacturing information, analytical data, any available clinical data or
literature and plans for clinical trials, among other things, to the FDA as part of an IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more
proposed clinical trials and places the trial on clinical hold. The FDA also may impose a clinical hold or partial clinical hold after commencement of a clinical trial under an IND. A clinical hold is an order issued by the FDA to the sponsor to
delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. No more than 30 days after imposition of a clinical hold or
partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation (or full investigation in the case of a partial clinical hold)
may only resume after the FDA has notified the sponsor that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the
investigation can proceed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND.
When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study is conducted in accordance with GCP,
including review and approval by an independent ethics committee (IEC) and informed consent from subjects. The GCP requirements are intended to help ensure the protection of human subjects enrolled in <FONT STYLE="white-space:nowrap">non-IND</FONT>
foreign clinical trials, as well as the quality and integrity of the resulting data. FDA must also be able to validate the data from the study through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection if necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must
review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review of the study at least annually. The IRB must review and approve, among other things, the study protocol and
informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical
trial is not being conducted in accordance with the IRB&#146;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a
data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. The FDA or the
sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health
(NIH) for public dissemination on its <I>ClinicalTrials.gov</I> website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Human Clinical Trials in Support of an NDA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified
investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects, or their legal representative, provide their informed consent in writing before their participation in any clinical
trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be
evaluated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1. The drug is initially introduced into healthy human subjects or, in certain indications such as
cancer, patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine maximal dosage.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2. The drug is administered to a limited patient population to identify possible AEs and safety risks,
to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3. The drug is administered to an expanded patient population, generally at geographically dispersed
clinical trial sites, in well-controlled clinical trials to generate enough data to evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for
the labeling of the product. Post-approval studies, often referred to as Phase 4 studies, may be conducted after initial regulatory approval. These studies are used to gain additional experience from the treatment of patients in the intended
therapeutic indication. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Progress reports detailing the results of the clinical trials must be
submitted at least annually to the FDA. In addition, within 15 calendar days after the sponsor determines that the information qualifies for reporting, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected
suspected adverse reactions; findings from other studies or animal or<I>&nbsp;in vitro</I>&nbsp;testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious suspected adverse
reaction over that listed in the protocol or investigator brochure. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial receipt of
the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the
clinical data submitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Concurrent with clinical trials, companies often complete additional animal studies and must
also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process
must be capable of consistently producing quality batches of the drug candidate and, among other things, the applicant must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate
packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Review of an NDA by the FDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and
clinical trials, together with detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product
for one or more indications. Under federal law, the submission of most NDAs is additionally subject to a significant application user fee as well as annual prescription drug product program fees. These fees are typically increased annually. Certain
exceptions and waivers are available for some of these fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA conducts a preliminary review of an NDA within 60
days of its receipt, before accepting the NDA for filing, to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the
application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins
<FONT STYLE="white-space:nowrap">an&nbsp;in-depth&nbsp;substantive</FONT> review. The FDA has agreed to specified performance goals in the review process of NDAs. Applications for drugs containing new molecular entities are meant to be reviewed
within 10 months from the date of filing, and applications for &#147;priority review&#148; products containing new molecular entities are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three
additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During its review of an NDA, the FDA typically will inspect the facility or facilities where the product is or will be
manufactured. These <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections may cover all facilities associated with an NDA, including drug component manufacturing (such as APIs), finished drug product manufacturing, and control testing
laboratories. The FDA will not approve an NDA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization
strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential AEs, and whether the product is a new
molecular entity. REMS can include medication guides, physician communication plans for healthcare professionals, and elements to assure safe use (ETASU). ETASU may include, but are not limited to, special training or certification for prescribing
or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was
not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what
conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Fast Track, Breakthrough Therapy, and Priority Review </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA has a number of programs intended to facilitate and expedite development and review of new drugs if they are intended
to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. Three of these programs are referred to as Fast Track Designation, Breakthrough Therapy Designation, and priority review designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Specifically, the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with
one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater
interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#146;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical
data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However,
the FDA&#146;s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track Designation may be withdrawn by the FDA if the FDA believes that the
designation is no longer supported by data emerging in the clinical trial process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Second, a product may be designated as
a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies,
including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary
project lead for the review team; and taking other steps to design the clinical trials in an efficient manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third, the
FDA may designate an NDA review for a priority review if it is for a product that treats a serious or life-threatening disease or condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be
illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious
outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#146;s goal for taking action on a
marketing application from 10 months to six months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Accelerated Approval Pathway </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful
therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on an intermediate clinical endpoint that can be
measured earlier than an effect on irreversible morbidity or mortality (IMM), and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the
availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic
image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate
clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate
clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for
concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or
intermediate clinical endpoint occurs rapidly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accelerated approval pathway is contingent on a sponsor&#146;s
agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing
compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Under the Food and Drug Omnibus Reform Act of 2022 (FDORA), the FDA is permitted to require, as
appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Sponsors are also required to send updates to the FDA every 180 days on the status of
such studies, including progress toward enrollment targets, and the FDA must promptly post this information publicly. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under
accelerated approval if, for example, the sponsor fails to conduct such studies in a timely manner and send the necessary updates to the FDA, or if a confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the
FDA generally requires, unless otherwise informed by the <FONT STYLE="white-space:nowrap">agency,&nbsp;pre-approval&nbsp;of</FONT> promotional materials for product candidates approved under accelerated regulations, which could adversely impact the
timing of the commercial launch of the product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The FDA&#146;s Decision on an NDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On the basis of the FDA&#146;s evaluation of the NDA and accompanying information, including the results of the inspection of
the manufacturing facilities and select clinical trial sites, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific
indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If a complete response letter is issued,
the applicant may resubmit the NDA to address all of the deficiencies identified in the letter, withdraw the application, or request a hearing. If the applicant resubmits the NDA, the FDA will issue an approval letter only when the deficiencies have
been addressed to the FDA&#146;s satisfaction. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may
decide that the application does not satisfy the regulatory criteria for approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the FDA approves a product, it may limit the approved indications for use
for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#146;s safety or
effectiveness after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can
materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA,
including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, reporting of adverse experiences with the product and applicable product tracking and tracing
requirements. After approval, many changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are annual prescription drug product program fee requirements for
certain marketed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, drug manufacturers and other entities involved in the manufacture and
distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to
the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements
upon the NDA holder and any third-party manufacturers that the NDA holder may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not
maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a
REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the
market or voluntary product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning or untitled letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of
product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may
be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA approved labeling.
The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted
<FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the
distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA), which regulates the distribution of drugs and drug samples at the federal level, and sets
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and
impose requirements to ensure accountability in distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Hatch-Waxman Amendments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request
marketing authorization for a new drug. A Section&nbsp;505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and
efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for
whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#146;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application.
Section&nbsp;505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application (ANDA). An ANDA provides for marketing of a generic drug product that has
the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product, known as a reference listed drug (RLD). ANDAs are termed
&#147;abbreviated&#148; because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is
bioequivalent to, or performs in the same manner as, the innovator drug through<I>&nbsp;in vitro</I>,<I>&nbsp;in vivo</I>, or other testing. The generic version must deliver the same amount of active ingredients into a subject&#146;s bloodstream in
the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">Non-Patent&nbsp;Exclusivity</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Hatch-Waxman Amendments, the FDA may not approve (or in some cases accept) an ANDA or 505(b)(2) application until any
applicable period of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity for the RLD has expired. The FDCA provides a period of five years of <FONT STYLE="white-space:nowrap">non-patent</FONT> data exclusivity for a new drug containing a
new chemical entity (NCE). For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological
or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification,
which states the proposed generic drug will not infringe one or more of the already approved product&#146;s listed patents or that such patents are invalid or unenforceable, in which case the applicant may submit its application four years following
the original product approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDCA also provides for a period of three years of exclusivity for <FONT
STYLE="white-space:nowrap">non-NCE</FONT> drugs if the NDA or a supplement to the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and
are essential to the approval of the application or supplement. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication, but it
generally would not protect the original, unmodified product from generic competition. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug
as of the date of approval of the original drug product; it only prevents FDA from approving such ANDAs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A drug product
can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods for all formulations, dosage forms, and indications of the active moiety and to patent terms. This <FONT
STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection and patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a study, provided that at the time pediatric exclusivity is granted there is not less than nine months of
term remaining. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Hatch-Waxman Patent Certification and <FONT STYLE="white-space:nowrap">the&nbsp;30-Month&nbsp;Stay</FONT>
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In seeking approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent
with claims that cover the applicant&#146;s product or an approved method of using the product. Upon approval, each of the patents listed by the NDA sponsor is published in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence
Evaluations, commonly known as the Orange Book. Upon submission of an ANDA or 505(b)(2) NDA, an applicant is required to certify to the FDA concerning any patents listed for the RLD in the Orange Book that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no patent information on the drug product that is the subject of the application has been submitted to the
FDA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such patent has expired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which such patent expires; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such patent is invalid, unenforceable or will not be infringed upon by the manufacture, use, or sale of the
drug product for which the application is submitted. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, the ANDA or 505(b)(2) NDA cannot be
approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the
listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or
505(b)(2) NDA applicant has provided a paragraph IV certification the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders
may then initiate a patent infringement lawsuit in response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV
certification, the FDA may not approve that application until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was
favorably decided in the applicant&#146;s favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the <FONT STYLE="white-space:nowrap">30-month</FONT> stay. In instances where an
ANDA or 505(b)(2) NDA applicant files a paragraph IV certification, the NDA holder or patent owner(s) regularly take action to trigger the <FONT STYLE="white-space:nowrap">30-month</FONT> stay, recognizing that the related patent litigation may take
many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#146;s decision to initiate patent
litigation. If the drug has NCE exclusivity and the ANDA is submitted four years after approval, the <FONT STYLE="white-space:nowrap">30-month</FONT> stay is extended so that it expires seven and a half years after approval of the innovator drug,
unless the patent expires or there is a decision in the infringement case that is favorable to the ANDA applicant before then. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patent Term Restoration and Extension </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments,
which permits a patent term restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time between
the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date, provided the sponsor acted with diligence. Patent term restoration cannot be used to extend the
remaining term of a patent past a total of 14 years from the product&#146;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the
expiration of the patent in question and within 60 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
days of drug approval. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office (USPTO)
reviews and approves the application for any patent term extension or restoration in consultation with the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Review and Approval
of Medicinal Products in the European Union </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to market any product outside of the United States, a company
must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and
distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the
product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the EU generally follows similar lines as in the United States. It entails satisfactory completion of preclinical studies and adequate
and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires a submission to the relevant competent authorities of a marketing authorization application (MAA) and granting of
a marketing authorization by these authorities before the product can be marketed and sold in the EU. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Clinical Trial Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the EU, an applicant for authorization of a clinical trial must obtain prior approval from the national competent authority
of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the relevant independent ethics committee has issued a favorable opinion. In April
2014, the Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted in the EU. The Clinical Trials Regulation is directly applicable in all the EU Member States and repealed the Clinical Trials Directive 2001/20/EC, as of
January&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in
the EU. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, known as the &#147;Clinical Trials Information System&#148;; a single set of documents to be prepared and submitted for the
application, as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by an elected Reference Member
State, with support of the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (the Member States concerned). Part II is assessed separately by each Member State concerned.
Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure continues to be governed by the national laws of the concerned EU Member State, however
overall related timelines are defined by the Clinical Trials Regulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Marketing Authorization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To obtain a marketing authorization for a product in the EU, an applicant must submit an MAA either under a centralized
procedure administered by the European Medicines Agency (EMA) or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure or mutual recognition procedure) for obtaining a marketing authorization in
multiple EU Member States. A marketing authorization may be granted only to an applicant established in the European Economic Area (EEA) (which is comprised of the EU Member States plus Norway, Iceland and Liechtenstein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid
throughout the EEA. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products,
advanced therapy medicinal products (gene </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
therapy, somatic cell therapy and tissue-engineered products) and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of
HIV, AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for other products containing a new active substance not yet authorized in the EU, or for
products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the centralized procedure, the Committee for Medicinal Products for Human Use (CHMP) established at the EMA is
responsible for conducting the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization.
Under the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions asked by
the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from a public health
perspective and in particular from the point of view of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days, excluding clock stops, but it is possible that the CHMP can revert to the
standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization
should be granted in relation to a medicinal product. Within 67 days from the date of the CHMP opinion, the European Commission will adopt its final decision on the MAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Now that the United Kingdom (which comprises Great Britain and Northern Ireland) (UK) has left the EU, Great Britain is no
longer covered by centralized marketing authorizations (under the Northern Ireland Protocol, centralized marketing authorizations currently continue to be recognized in Northern Ireland). On January&nbsp;1, 2024, a new international recognition
framework was put in place by the Medicines and Healthcare products Regulatory Agency (MHRA), the UK medicines and medical devices regulator, under which the MHRA may have regard to decisions on the approval of marketing authorizations made by the
EMA and certain other regulators when determining an application for the grant of a UK or Great Britain marketing authorization. The MHRA also has the power to have regard to marketing authorizations approved in EU Member States through
decentralized or mutual recognition procedures with a view to more quickly granting a marketing authorization in the UK or Great Britain. For additional information related to the regulatory framework in the UK, please refer to the discussion below
under the section titled &#147;<I> &#151;</I>Brexit&nbsp;and the Regulatory Framework in the United Kingdom.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
decentralized marketing authorization procedure allows an applicant to apply for simultaneous authorization in more than one EU Member State of medicinal products that have not yet been authorized in any EU Member State and that do not fall within
the mandatory scope of the centralized procedure. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The Reference Member State prepares a draft assessment and
drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the Concerned Member States who, within 90 days of receipt, must decide whether to approve the assessment report
and related materials. If a Concerned Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose
decision is binding on all Member States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The mutual recognition procedure is based on the acceptance by the competent
authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of another EU Member State. The holder of a national marketing authorization may submit an application to the competent authority
of an EU Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Pediatric Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the EU, applicants have to
demonstrate compliance with all measures included in an <FONT STYLE="white-space:nowrap">EMA-approved</FONT> Pediatric Investigation Plan (PIP) covering all subsets of the pediatric population, unless the EMA has granted (1)&nbsp;a product-specific
waiver, (2)&nbsp;a class waiver or (3)&nbsp;a deferral for one or more of the measures included in the PIP. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the product for which a marketing
authorization is being sought. Products that are granted a marketing authorization with the results of the pediatric clinical trials conducted in accordance with the PIP are eligible for a <FONT STYLE="white-space:nowrap">six-month</FONT> extension
of the protection under a supplementary protection certificate (SPC), provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to two years before the SPC expires, even
where the trial results are negative. In the case of orphan medicinal products, a <FONT STYLE="white-space:nowrap">two-year</FONT> extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions
and is not automatically available when data in compliance with the PIP are developed and submitted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Data and Market Exclusivity
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the EU, innovative medicinal products approved on the basis of a complete and independent data package qualify for
eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. Data exclusivity prevents applicants for authorization of generics or biosimilars of these innovative products from referencing the
innovator&#146;s preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar (abbreviated) marketing authorization, for a period of eight years from the date on which the reference
product was first authorized in the EU. During an additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic or biosimilar MAA can be submitted, and the innovator&#146;s data may be referenced, but no generic
or biosimilar medicinal product can be placed on the EU market until the expiration of the market exclusivity. The overall <FONT STYLE="white-space:nowrap">10-year</FONT> period will be extended to a maximum of 11 years if, during the first eight
years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit
in comparison with existing therapies. There is no guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if a product is considered to be an innovative
medicinal product so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained a marketing authorization based on an MAA with a complete
and independent data package of pharmaceutical tests, preclinical tests and clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Orphan Designation and Exclusivity
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regulation (EC) No 141/2000 and Regulation (EC) No.&nbsp;847/2000 provide that a product can be designated as an
orphan medicinal product by the European Commission if its sponsor can establish that: (1)&nbsp;the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition, (2)&nbsp;either
(i)&nbsp;such condition affects no more than five in ten thousand persons in the EU when the application is made, or (ii)&nbsp;without the benefits derived from orphan status, it is unlikely that the marketing of the product in the EU would generate
sufficient return to justify the necessary investment in its development and (3)&nbsp;there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method
exists, the product would be of significant benefit to those affected by that condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An orphan designation provides a
number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized EU marketing authorization. Marketing authorization for an orphan medicinal product leads to a
<FONT STYLE="white-space:nowrap">ten-year</FONT> period of market exclusivity being granted. During this market exclusivity period, the EMA, the European Commission or the competent authorities of the EU Member States may only grant a marketing
authorization to a &#147;similar medicinal product&#148; to the authorized orphan product for the same therapeutic indication </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
if: (i)&nbsp;a second applicant can establish that its product, although similar to the authorized orphan product, is safer, more effective or otherwise clinically superior; (ii)&nbsp;the
marketing authorization holder for the authorized orphan product consents to a second orphan medicinal product application; or (iii)&nbsp;the marketing authorization holder for the authorized orphan product cannot supply enough orphan medicinal
product. A &#147;similar medicinal product&#148; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication.
The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation because, for
example, the product is sufficiently profitable not to justify market exclusivity. Orphan designation must be requested before submitting an application for marketing authorization. Orphan designation does not convey any advantage in, or shorten the
duration of, the regulatory review and approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Periods of Authorization and Renewals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A marketing authorization has an initial validity of five years. The marketing authorization may be renewed after five years on
the basis of a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the relevant EU Member State for a nationally authorized product. To this end, the marketing authorization
holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before
the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authorities of the relevant Member States decide, on justified grounds
relating to pharmacovigilance, to proceed with one further five year renewal period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (for centrally-authorized products) or on the market of the
authorizing EU Member State (for nationally-authorized products) within three years after authorization ceases to be valid (the <FONT STYLE="white-space:nowrap">so-called</FONT> sunset clause). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Regulatory Requirements after a Marketing Authorization has been Obtained </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is required to
comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compliance with the EU&#146;s stringent pharmacovigilance or safety reporting rules must be ensured. These
rules can impose post-authorization studies and additional monitoring obligations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The manufacturing of authorized medicinal products, for which a separate manufacturer&#146;s license is
mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive (EU) 2017/1572, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good
Manufacturing Practice. These requirements include compliance with EU cGMP standards when manufacturing medicinal products and APIs, including the manufacture of APIs outside of the EU with the intention to import the APIs into the EU.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The marketing and promotion of authorized products, including industry-sponsored continuing medical education
and advertising directed toward the prescribers of products and/or the general public, are strictly regulated in the EU notably under Directive 2001/83/EC, as amended, and EU Member State laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The aforementioned EU rules are generally applicable in the EEA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Reform of the Regulatory Framework in the European Union </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The European Commission introduced legislative proposals in April 2023 that, if implemented, will replace the current
regulatory framework in the EU for all medicines (including those for rare diseases and for children). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
The European Commission has provided the legislative proposals to the European Parliament and the European Council for their review and approval. In April 2024, the European Parliament adopted
its position on the legislative proposals. Once the European Commission&#146;s legislative proposals are approved (with or without amendment), they will be adopted into EU law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Brexit and the Regulatory Framework in the United Kingdom </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The UK ceased being a Member State of the EU on January&nbsp;31, 2020, and the EU and the UK have concluded a trade and
cooperation agreement (TCA), which was provisionally applicable since January&nbsp;1, 2021 and has been formally applicable since May&nbsp;1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition
of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not provide for wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented previous EU
legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework continues to apply in Northern Ireland). Except in
respect of the EU Clinical Trials Regulation, the regulatory regime in Great Britain therefore aligns in many ways with current EU medicines regulations, however it is possible that these regimes will diverge more significantly in the future now
that Great Britain&#146;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation. However, notwithstanding that there is no wholesale recognition of EU pharmaceutical
legislation under the TCA, under a new international recognition framework which was put in place by the MHRA on January&nbsp;1, 2024, the MHRA may take into account decisions on the approval of marketing authorizations from the EMA (and certain
other regulators) when considering an application for a Great Britain or UK marketing authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;27,
2023, the UK government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#147;Windsor Framework.&#148; This new framework fundamentally
changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the UK. In particular, the MHRA will be responsible for approving all medicinal products destined for the UK market
(i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. A single <FONT STYLE="white-space:nowrap">UK-wide</FONT> marketing authorization will be granted by
the MHRA for all medicinal products to be sold in the UK, enabling products to be sold in a single pack and under a single authorization throughout the UK. The Windsor Framework was approved by the <FONT STYLE="white-space:nowrap">EU-UK</FONT> Joint
Committee on March&nbsp;24, 2023, so the UK government and the EU will enact legislative measures to bring it into law. On June&nbsp;9, 2023, the MHRA announced that the medicines aspects of the Windsor Framework will apply from January&nbsp;1,
2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other Healthcare Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants,
third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws that may affect our ability to operate include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully
soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the
purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to
have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved,
imprisonment, and exclusion from government healthcare programs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws, including the False Claims Act (FCA), which can be enforced
through civil &#147;qui tam&#148; or &#147;whistleblower&#148; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be
presented, claims for payment or approval from Medicare, Medicaid or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money
to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are
deemed to &#147;cause&#148; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or
fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#147;whistleblower&#148; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or
property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or
making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of
violating these statutes without actual knowledge of the statutes or specific intent to violate them in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH),
imposes requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of,
individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended
HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek
attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even when HIPAA/HITECH do not apply, according to the Federal Trade Commission (FTC), failing to take
appropriate steps to keep consumers&#146; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section&nbsp;5(a) of the Federal Trade Commission Act, 15 U.S.C. &#167; 45(a). The FTC expects a
company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce
vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Reconciliation Act (collectively, the ACA) and its implementing regulations, which requires manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare,
Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the Department of Health and Human Services (HHS) information related to payments or other transfers of value made to physicians (defined to
include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed healthcare professionals (i.e., physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered
nurse anesthetists, and certified nurse midwives), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal government price reporting laws, which require us to calculate and report complex pricing metrics in
an accurate and timely manner to government programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims,
consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales, and marketing arrangements as well as submitting claims involving healthcare items or
services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and
marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical
sales representatives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our operations are found to be in violation of any of such laws or any other
governmental regulations that apply, we may be subject to significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity
oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers
performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which
third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product.
Factors payors consider in determining coverage and reimbursement are based on whether the product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors.
Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price
or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost- effectiveness of medical products
and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct
expensive pharmacoeconomic studies in order to demonstrate the medical necessity and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to
purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician
utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a third-party payor&#146;s decision to provide coverage for a product does not imply that an adequate
reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and
reimbursement can differ significantly from payor to payor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The containment of healthcare costs has become a priority of
federal, state and foreign governments, and the prices of products have been a focus in this effort. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting
coverage and the amount of reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States. Governments have shown significant interest in implementing cost-containment programs,
including price controls, restrictions on reimbursement and requirements for substitution of generic products. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by
any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with
predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the
level of reimbursement. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the
government, such as average sales price (ASP) and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by
government healthcare programs. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the
sale of any approved products. Even if we do receive a favorable coverage determination for approved products by third-party payors, coverage policies and third-party payor reimbursement rates may change at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example,
the U.S. Centers for Medicare&nbsp;&amp; Medicaid Services (CMS) may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their commercial products, which has resulted in several U.S. Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing,
review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Congress has indicated that it will continue to seek new legislative measures to
control drug costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Outside the United States, ensuring coverage and adequate payment for a product also involves
challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a
clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be
marketed only after a reimbursement price has been agreed. Some countries may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or
<FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. For example, the EU Member States have the option to restrict the range of products for which their national
health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the
profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions.
Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises
experienced by many countries in the EU. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political,
economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage
between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will
allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Current and Future U.S.
Healthcare Reform </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, there have been a number of legislative and regulatory changes to the
healthcare system that could impact our ability to sell our products profitably. For example, in March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly
affected the pharmaceutical industry. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. For example, the ACA, among other
things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to
23.1% of the average manufacturer price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">required collection of rebates for drugs paid by Medicaid managed care organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">required manufacturers to participate in a coverage gap discount program, under which they must agree to offer
50&nbsp;percent <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part D (later increased to 70%); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposed a <FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or
importers who sell &#147;branded prescription drugs&#148; to specified federal government programs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since its enactment, there have been judicial, administrative, executive, and legislative challenges to certain aspects of the
ACA as well as executive orders related to the ACA&#146;s implementation. For example, President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. In addition, on June&nbsp;17, 2021, the U.S. Supreme
Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. It is unclear how other healthcare reform measures of the Biden administrations or other
efforts, if any, to challenge repeal or replace the ACA, will impact our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There has been increasing legislative
and enforcement interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more
transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, the
Inflation Reduction </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Act of 2022 (IRA), among other things, (i)&nbsp;directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug
manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#147;maximum fair price&#148; for such drugs and biologics under the law and (ii)&nbsp;imposes rebates with
respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the
initial years. These provisions took effect progressively starting in fiscal year 2023. On August&nbsp;29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation
program is currently subject to legal challenges. It is unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further, on December&nbsp;7, 2023, the Biden administration announced an
initiative to control the price of prescription drugs through the use of <FONT STYLE="white-space:nowrap">march-in</FONT> rights under the Bayh-Dole Act. On December&nbsp;8, 2023, the National Institute of Standards and Technology published for
comment a Draft Interagency Guidance Framework for Considering the Exercise of <FONT STYLE="white-space:nowrap">March-In</FONT> Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise
<FONT STYLE="white-space:nowrap">march-in</FONT> rights. While <FONT STYLE="white-space:nowrap">march-in</FONT> rights have not previously been exercised, it is uncertain if that will continue under the new framework. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2020, FDA released its implementing regulations regarding section 804 Importation Programs under the Medicare Prescription
Drug Improvement and Modernization Act of 2003. These regulations provide guidance for states to build and submit importation plans for certain drugs from Canada. On September&nbsp;25, 2020, CMS stated drugs imported by states under this rule will
not be eligible for federal rebates under Section&nbsp;1927 of the Social Security Act and manufacturers would not report these drugs for &#147;best price&#148; or Average Manufacturer Price purposes. Since these drugs are not considered covered
outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. On January&nbsp;5, 2024, the FDA approved Florida&#146;s Section&nbsp;804 Importation Program (SIP) proposal to import certain drugs
from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also
submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, on December&nbsp;2, 2020, HHS published a regulation removing safe harbor protection for price reductions from
pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The IRA delayed implementation of this rule to
January&nbsp;1, 2032. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other legislative and regulatory changes have been proposed and adopted in the United States since
the ACA was enacted: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The U.S. Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to
providers of 2% per fiscal year, and, due to subsequent legislative amendments to the statute, will remain in effect until 2032. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The U.S. American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to
several types of providers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap, currently set at 100%
of a drug&#146;s average manufacturer price, for single source and innovator multiple source drugs, effective January&nbsp;1, 2024. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise
affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The IRA also includes several other provisions that may impact our business to varying degrees, including
provisions that create a $2,000 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cap for Medicare Part D beneficiaries, and impose new manufacturer financial liability on all drugs in Medicare Part D.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Individual states have also been increasingly active in passing legislation and implementing
regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in
some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and
which suppliers will be included in their prescription drug and other health care programs. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and
state governments will pay for healthcare products and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although a number of these and other proposed measures
may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new
legislative measures to control drug costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Data Protection, Privacy, and Security </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of business, we collect, transmit, store, use, disclose, transfer, maintain and otherwise process
sensitive information, including personal data. Accordingly, we are, or may be become, subject to numerous data protection, privacy, and security obligations, including global, federal, state, and local laws, rules, regulations, guidance, industry
standards, external and internal privacy and security policies, contractual requirements and other obligations related to data protection, privacy, and security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These data protection, privacy, and security obligations are evolving and may impose potentially conflicting obligations. Such
obligations may include, without limitation, federal health information privacy laws, state information security and data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., the
Federal Trade Commission Act). In addition, in the past few years, numerous U.S. states have passed, or are in the process of enacting, comprehensive privacy laws, rules, and regulations that impose certain obligations on covered businesses, and
similar laws are being considered in several other states, as well as at the federal level. While these laws exempt some data processed in the context of clinical trials, these developments may further complicate compliance efforts, and are examples
of the increasingly stringent and evolving regulatory frameworks related to personal data processing, as more fully discussed in the section titled &#147;Risk Factors&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, to the extent we collect personal data from individuals outside of the United States, through clinical trials or
otherwise, we are, or may become, subject to foreign data protection, privacy, and security laws, such as the European Union&#146;s General Data Protection Regulation (EU GDPR) and the EU GDPR as incorporated into U.K. domestic law post-Brexit (UK
GDPR). Such foreign data protection, privacy, and security laws impose significant and complex compliance obligations on entities that are subject to those laws, as more fully discussed in the section titled &#147;Risk Factors&#148; included
elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2024, we had full-time employees, of which &#8195;&#8195;&#8195;have M.D. or Ph.D. degrees. Within our
workforce, &#8195;employees are engaged in research and development and &#8195;are engaged in business development, finance, legal, and general management and administration. None of our employees are represented by labor unions or covered by
collective bargaining agreements. We consider our relationship with our employees to be good. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our human capital resources objectives include, as applicable, identifying,
recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of equity-based
compensation awards in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our corporate headquarters are located in South San Francisco, California, where we lease and occupy approximately 44,819
square feet of combined office, research and laboratory space at 250 East Grand Avenue, South San Francisco, California 94080. The current term of our lease expires in July 2032. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that our existing facilities are adequate for our current needs and for the foreseeable future. To meet the future
needs of our business, we may lease additional or alternate space. We believe that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may become involved in or be subject to legal proceedings, claims and litigation arising from the
ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an
adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the name, age and position of each of our executive officers and directors as of the date of
this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Executive Officers and Employee Directors:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jeffrey Finer, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">58</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Executive Officer, President and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Liz Bhatt, M.S., M.B.A.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">57</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Operating Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alan Ezekowitz, M.D., D.Phil.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">70</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim Chief Medical Officer and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Samira Shaikhly</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">54</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief People Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Uwe Klein, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">60</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Senior Vice President, Biological Sciences</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Daniel Long, D.Phil.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">51</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Senior Vice President, Drug Discovery</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jeffrey Tong, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">49</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chairman and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Abraham Bassan, M.S.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">40</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bernard Coulie, M.D., Ph.D., M.B.A.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">58</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shalini Sharp, M.B.A.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">49</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jake Simson, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the audit committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a biographical summary of the experience of our executive officers and directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Executive Officers and Employee Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Jeffrey Finer, M.D., </I></B><B><I>Ph.D</I></B><B><I>.,</I></B> has served as our President since December 2019, and as
Chief Executive Officer and as a member of our board of directors since November 2021. Since 2016, Dr.&nbsp;Finer has served as a Venture Partner at Third Rock Ventures, a healthcare venture firm, where he was involved in the founding and launching
of multiple biotech companies. Prior to joining us, Dr.&nbsp;Finer held positions as interim Chief Technology Officer at Ambys Medicines, Inc., a privately held cell and gene therapy company, from 2017 to May 2019, and at Maze Therapeutics, Inc., a
small-molecule precision medicine company, from 2016 to June 2019. Earlier in his career, Dr.&nbsp;Finer held numerous research and development leadership positions, including as Director, Drug Discovery at Cytokinetics, Incorporated, a
small-molecule biopharmaceutical company, from 1998 to 2007, as Vice President, Discovery at Five Prime Therapeutics, Inc. (acquired by Amgen, Inc. (Nasdaq: AMGN)), a protein therapeutics company, from January 2007 to August 2011, and as Vice
President, Molecular&nbsp;&amp; Cellular Biology and later as Vice President, Research Technology at Theravance Biopharma, Inc. (Nasdaq: TBPH), a publicly traded biopharmaceutical company focused on multiple therapeutic areas, from 2011 to 2016.
Dr.&nbsp;Finer obtained his B.S. in Chemistry and B.S. in Biology from the Massachusetts Institute of Technology and his M.D. and Ph.D. in Biochemistry from Stanford University School of Medicine. Dr.&nbsp;Finer completed residency training in
Internal Medicine at Stanford University School of Medicine, and residency training in Ophthalmology at Massachusetts Eye&nbsp;&amp; Ear Infirmary and Harvard Medical School. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Dr.&nbsp;Finer is qualified to serve on our board of directors based on his extensive experience as a senior
executive in the pharmaceutical industry, his drug development expertise, his research work for both medical and academic institutions, his public company experience, as well as his knowledge of our company based on his role as our President and
Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Liz Bhatt, M.S., M.B.A.,</I></B> has served as our Chief Operating Officer since June
2022. Prior to joining us, Ms.&nbsp;Bhatt held positions as Chief Business&nbsp;&amp; Strategy Officer at Applied Molecular Transport Inc. (merged with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Cyclo Therapeutics, Inc.), a biopharmaceutical company, from September 2019 to May 2022, as Chief Business Officer and later also as Chief Operating Officer of Achaogen, Inc., a publicly held
commercial-stage antibiotics company which declared bankruptcy in April 2019, from September 2017 to June 2019, and in various senior management positions at Gilead Sciences, Inc. (Nasdaq: GILD), a publicly traded biopharmaceutical company focused
on treatments for viral, cancer and inflammatory disease, including Vice President, Corporate Development, from July 2006 to September 2017. Earlier in her career, Ms.&nbsp;Bhatt held numerous corporate development positions across a range of
biotech and pharmaceutical companies, including at Maxygen, Inc. and Eli Lilly and Company. Ms. Bhatt previously served on the board of directors of eFFECTOR Therapeutics, Inc. (f/k/a Locus Walk Acquisition Corporation), a then publicly traded
clinical-stage biopharmaceutical company, from October 2020 to June 2024. Ms.&nbsp;Bhatt obtained her B.A. in Chemistry from Pomona College, her M.S. in Biomedical Sciences from the University of California, San Diego and her M.B.A. from the Kellogg
School of Management at Northwestern University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Alan Ezekowitz, M.D., D.</I></B><B><I>Phil</I></B><B><I>.,</I></B>
has served as our interim Chief Medical Officer since January 2022 and has been a member of our board of directors since December 2022. Dr.&nbsp;Ezekowitz has served as an Advisory Partner at Third Rock Ventures, a leading biotech venture and
company-formation fund, since January 2023, and was previously a Venture Partner at Third Rock Ventures from December 2019 to December 2022. Previously, from November 2011 to June 2019, Dr.&nbsp;Ezekowitz served as the President and Chief Executive
Officer of Abide Therapeutics, Inc., a privately held biopharmaceutical company that he <FONT STYLE="white-space:nowrap">co-founded,</FONT> which he oversaw through its acquisition by H. Lundbeck A/S in 2019. Earlier in his career, from March 2006
to March 2011, Dr.&nbsp;Ezekowitz was the Senior Vice President and Franchise Head at Merck Research Laboratories (Merck), a healthcare company, where he was responsible for the bone, respiratory, immunology, inflammation, dermatology, and endocrine
franchises. Prior to joining Merck, Dr.&nbsp;Ezekowitz served at the Harvard Medical School as the Charles Wilder Professor of Pediatrics from June 1995 to March 2005, as the Head of Laboratory for Development Immunology and Principal of the Cancer
Center and later as Chief of Pediatric Services at the Massachusetts General Hospital for Children from June 1995 to April 2006, and as a director of the Partners Healthcare System from 2000 to 2006. Dr.&nbsp;Ezekowitz currently serves as a member
of the boards of directors of Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a publicly traded small molecule drug discovery company, and Organon&nbsp;&amp; Co., a global healthcare company. Dr.&nbsp;Ezekowitz was honored in 2008 with the establishment
of the R. Alan B. Ezekowitz Professorship in Pediatrics at Harvard Medical School. He was the Principal Investigator of an NIH Program Project Grant that included Jules Hoffman, Charles Janeway and Fotis Kafatos who led to the discovery of the TOLL
receptors and contributed greatly to the understanding of the field of the innate immunity. Dr.&nbsp;Ezekowitz obtained his M.D. from the University of Cape Town in South Africa and his D.Phil. in Cellular and Molecular Biology from the University
of Oxford. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe Dr.&nbsp;Ezekowitz is qualified to serve on our board of directors because of his considerable
qualifications, attributes and skills, including his distinguished scientific background, experience in leadership roles in the biopharmaceutical industry, venture capital experience as well as his service on the boards of directors of numerous
companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Samira Shaikhly</I></B> has served as our Chief People Officer since February 2023. Prior to joining us,
Ms.&nbsp;Shaikhly was the Chief People Officer at Ambys Medicines, Inc. (the IP of which was later acquired by Cytotheryx, Inc.) (Ambys Medicines), a privately held cell and gene therapy company, from April 2022 to November 2022, where she led the
People&nbsp;&amp; Culture function as the company evolved from a research-focused to a development-focused organization. Prior to Ambys Medicines, Ms.&nbsp;Shaikhly held various roles of increasing responsibility, including Global Head of Human
Resources, Corporate Functions Business Partners, at Gilead Sciences, Inc. (Nasdaq: GILD), a publicly traded biopharmaceutical company focused on treatments for viral, cancer and inflammatory disease, from September 2006 to September 2021, where she
was responsible for all general and administrative human resources functions. Earlier in her career, Ms.&nbsp;Shaikhly held human resource roles in the technology and retail sectors. Ms.&nbsp;Shaikhly obtained her B.A. in Communication Arts from the
University of San Francisco and is a certified Executive Coach from New Ventures West. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Uwe Klein, </I></B><B><I>Ph.D</I></B><B><I>.,</I></B> has served as
our Senior Vice President, Biological Sciences since August 2021. Dr.&nbsp;Klein has over 20 years of experience in small molecule drug discovery and deep expertise in GPCR biology. Prior to joining us, Dr.&nbsp;Klein was Vice President, Biology at
MyoKardia, Inc. (acquired by Bristol-Myers Squibb (NYSE: BMY) (BMS)), a clinical-stage biopharmaceutical company targeting therapies for cardiovascular disease, from October 2019 to November 2020, and then Vice President, Biology at BMS following
the acquisition, from November 2020 to March 2021. Earlier in his career, Dr.&nbsp;Klein held positions as Vice President, Biology at Numerate, Inc. (acquired by Valo Health, Inc.), a privately-held dug discovery company applying novel machine
learning algorithms to drug design, from October 2014 to September 2019, and as Senior Director, Molecular&nbsp;&amp; Cellular Biology at Theravance, from September 1998 to October 2014. Dr.&nbsp;Klein obtained his B.S. and M.S. in Chemistry, and
his Ph.D. in Biochemistry, from Goethe University Frankfurt, Germany. He also earned a certificate in Bioinformatics at the University of California, Santa Cruz, and completed his post-doctoral fellowships in Molecular&nbsp;&amp; Cellular Biology
from University of California, San Francisco and Stanford University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Daniel Long,
D.</I></B><B><I>Phil</I></B><B><I>.,</I></B> has served as our Senior Vice President, Drug Discovery since December 2021. Prior to joining us, Dr.&nbsp;Long spent over 20 years, from January 2001 to December 2021, at Theravance Biopharma, Inc.
(Nasdaq: TBPH), a publicly traded biopharmaceutical company focused on chronic obstructive pulmonary disease treatments, where he held numerous scientist positions, including as Vice President, Head of Medical Chemistry, Biology and Pharmacology.
Dr.&nbsp;Long obtained his B.A., M.A. and D. Phil. in Chemistry from the University of Oxford and completed an industrial post-doctoral fellowship at DuPont Pharmaceuticals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Jeffrey Tong, Ph.D., </I></B>has served as a member of our board of directors since December 2019, as Chairman of our
board of directors since November 2021, and previously served as our interim Chief Executive Officer from December 2019 to November 2022. Dr.&nbsp;Tong is currently a Partner at Third Rock Ventures, where he has worked since May 2016. Earlier in his
career, Dr.&nbsp;Tong served as the CEO of Marea Therapeutics, Inc., the Executive Chairman of the board of directors of Delinia, Inc. (acquired by Celgene Corporation) and President and Chief Executive Officer of Nora Therapeutics, Inc., each a
privately held biotechnology company. Prior to that, Dr.&nbsp;Tong was VP of Corporate and Product Development at Infinity Pharmaceuticals, Inc., held a position at McKinsey&nbsp;&amp; Co., and was a founding researcher at the Harvard Bauer Center
for Genomics Research. Dr.&nbsp;Tong has served as a member of the board of directors of Rapport Therapeutics, Inc. (Nasdaq: RAPP), a publicly traded precision small molecule biopharmaceutical company, since December 2022, as well as on the boards
of directors of numerous privately held biotechnology companies. Dr.&nbsp;Tong previously served on the board of directors of Nurix Therapeutics, Inc. (Nasdaq: NRIX), from February 2018 to May 2022. Dr.&nbsp;Tong obtained his A.B. in Biochemical
Sciences from Harvard University, his A.M. and Ph.D. in Chemistry from Harvard Graduate School of Arts and Sciences and his M.M.S. from Harvard Medical School. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Dr.&nbsp;Tong is qualified to serve on our board of directors based on his significant experience building and
leading successful biotechnology companies and his scientific expertise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Abraham Bassan, M.S.,</I></B> has served
as a member of our board of directors since November 2021. Since April 2021, Mr.&nbsp;Bassan has served as a Principal at Samsara, a privately held life science investment firm, where he served as a Vice President from July 2017 to April 2021. Since
May 2022, Mr. Bassan has served as the interim CEO, President and a Director at Link Cell Therapies Inc., a privately held biotechnology company. From February 2021 to May 2022, Mr.&nbsp;Bassan served as President of Cargo Therapeutics, Inc.
(Nasdaq: CRGX), a then privately held clinical-stage cell therapies company (Cargo Therapeutics). Prior to that, from December 2014 to July 2017, Mr.&nbsp;Bassan served as Director of Program Biology at Revolution Medicines, Inc. (Nasdaq: RVMD), a
then privately held oncology company. Prior to that, from September 2012 to September 2014, Mr.&nbsp;Bassan served as the founder and Chief Executive Officer of Aurora Medical, Inc., a privately held molecular diagnostics testing services company.
From 2010 to 2012, Mr.&nbsp;Bassan served as an Associate Director of Program Management at bluebird bio, Inc. (Nasdaq: BLUE) (bluebird bio), a then privately held </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
biotechnology company, where he was the Project Manager for several of the company&#146;s gene therapy programs. Earlier in his career, Mr.&nbsp;Bassan was an Associate at Third Rock Ventures,
where he played a leading role in the firm&#146;s investment in bluebird bio, as well as the ideation of Blueprint Medicines Corporation (Nasdaq: BMPC), a publicly traded precision medicine oncology company. Mr.&nbsp;Bassan currently serves on the
board of directors of Cargo Therapeutics. Mr.&nbsp;Bassan previously served on the board of directors of Graphite Bio, Inc. (merged with LENZ Therapeutics, Inc. (Nasdaq: LENZ)), from June 2020 to March 2024, and on the boards of directors of
numerous privately held biotechnology companies. Mr.&nbsp;Bassan obtained his B.A. in Molecular Biology from Princeton University and his M.S. in Developmental Biology from Stanford University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Mr.&nbsp;Bassan is qualified to serve as a member of our board of directors because of his education and
experience in the life sciences and oncology fields, venture capital experience, as well as his service on the boards of directors of numerous companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Bernard Coulie, M.D., </I></B><B><I>Ph.D</I></B><B><I>., M.B.A.,</I></B> has served as a member of our board of
directors since December 2023. Dr.&nbsp;Coulie has served as the President, Chief Executive Officer and a member of the board of directors of Pliant Therapeutics, Inc. (Nasdaq: PLRX) (Pliant), a publicly traded late-stage biopharmaceutical company,
since February 2016. Prior to joining Pliant, Dr.&nbsp;Coulie <FONT STYLE="white-space:nowrap">co-founded</FONT> ActoGeniX N.V. (ActoGeniX), a biopharmaceutical company, and held roles of increasing responsibility, including as Vice President
R&amp;D, Chief Medical Officer, and Chief Executive Officer, from September 2006 until February 2015, when it was acquired by Intrexon Corporation. Prior to <FONT STYLE="white-space:nowrap">co-founding</FONT> ActoGeniX, Dr.&nbsp;Coulie held various
positions with increasing responsibility in drug discovery and clinical development at Johnson&nbsp;&amp; Johnson Pharmaceutical Research and Development Europe. Earlier in his career, Dr.&nbsp;Coulie was a Staff Physician in the Department of
Gastroenterology and Hepatology at Mayo Clinic, Assistant Professor in Medicine at Mayo Medical School and a Mayo Foundation scholar. Dr.&nbsp;Coulie is currently serving as a director and chairman of Dualyx N.V., a privately held biotechnology
company based in Belgium, and as a member of the board of directors of Charcot-Marie-Tooth Association, a <FONT STYLE="white-space:nowrap">non-profit</FONT> patient advocacy organization dedicated to the development of new drugs to treat
Charcot-Marie-Tooth disease. Dr.&nbsp;Coulie previously served as a director of SQZ Biotechnologies Company (acquired by STEMCELL Technologies Canada Acquisitions, Inc.) from July 2021 to March 2024, Calypso Biotech B.V. (acquired by Novartis AG
(NYSE: NVS)) from February 2019 to January 2024, Myoscience, Inc. (acquired by Pacira BioSciences, Inc.) from June 2016 until March 2019, Biogazelle N.V. (acquired by CellCarta Biosciences Inc.) from July 2015 until November 2018, and ActoGeniX
(acquired by Intrexon Corporation) from April 2010 until February 2015. Dr.&nbsp;Coulie is a board-certified internist and received his M.D. and Ph.D. from the University of Leuven, Belgium and his M.B.A. from the Vlerick Business School, Leuven,
Belgium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe Dr.&nbsp;Coulie is qualified to serve on our board of directors because of his extensive experience
and expertise in operations management and executive leadership at various biopharmaceutical companies, as well as his service on the boards of directors of numerous companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Shalini Sharp, M.B.A., </I></B>has served as a member of our board of directors since January 2024. Prior to joining us,
Ms.&nbsp;Sharp served as Executive Vice President and Chief Financial Officer of Ultragenyx Pharmaceuticals Inc. (Nasdaq: RARE), a publicly traded biopharmaceutical company, from May 2012 to October 2020. Previously, from August 2003 to May 2012,
Ms.&nbsp;Sharp held positions of increasing responsibility at Agenus, Inc. (Nasdaq: AGEN), a publicly traded clinical-stage immune-oncology company, including as Chief Financial Officer, and also served as a member of its board of directors from May
2012 to June 2018. Earlier in her career, Ms.&nbsp;Sharp worked at Elan Pharmaceuticals, McKinsey&nbsp;&amp; Company, and Goldman Sachs. Ms.&nbsp;Sharp currently serves on the boards of directors of Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a
publicly traded biopharmaceutical company, and Organon&nbsp;&amp; Co (Nasdaq: OGN), a publicly traded healthcare company. Ms.&nbsp;Sharp previously served on the board of directors of Mirati Therapeutics, Inc. (acquired by Bristol-Myers Squibb
Company), a then publicly traded commercial-stage oncology company, from March 2021 to January 2024, Sutro Biopharma, Inc. (Nasdaq: STRO), a publicly traded biopharmaceutical company, from November 2018 to November 2023, Precision BioSciences, Inc.
(Nasdaq: DTIL), a publicly traded gene editing company, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
from December 2018 to June 2022 and Panacea Acquisition Corp. (Nasdaq: PANA), a special purpose acquisition company, from June 2020 until the completion of its business combination in February
2021. Ms.&nbsp;Sharp obtained her B.A. in English and American Literature and Languages from Harvard College and her M.B.A. from Harvard Business School. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe Ms.&nbsp;Sharp is qualified to serve on our board of directors because of her extensive experience and expertise in
financial management and executive leadership at various biopharmaceutical companies, as well as her service on the boards of directors of numerous companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Jake Simson, Ph.D.,</I></B> has served as a member of our board of directors since June 2023. Dr.&nbsp;Simson has served
as a Partner at RA Capital, a multi-stage life sciences investment firm, since December 2020. From July 2013 to December 2020, Dr.&nbsp;Simson served as an Associate, Analyst and then a Principal at RA Capital. Dr.&nbsp;Simson currently serves on
the boards of directors of Janux Therapeutics, Inc. (Nasdaq: JANX), a publicly traded immunotherapy company, and Tyra Biosciences, Inc. (Nasdaq: TYRA), a publicly traded precision medicine company, as well as on the boards of directors of numerous
privately-held biotechnology companies. Dr.&nbsp;Simson previously served on the board of directors of Dice Therapeutics, Inc. (Nasdaq: DICE), a publicly traded biopharmaceutical company, from December 2020 until August 2023, when it was acquired by
Eli Lilly and Company. Dr.&nbsp;Simson obtained his S.B. in Materials Science and Engineering from the Massachusetts Institute of Technology and his Ph.D. in Biomedical Engineering from Johns Hopkins University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Dr.&nbsp;Simson is qualified to serve on our board of directors because of his significant industry experience
as an investor in the biopharmaceutical industry and educational background. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are no family relationships among any of our executive officers or directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors currently consists of seven members, each of whom is a member pursuant to the board composition
provisions of our current certificate of incorporation and agreements with our stockholders, which agreements are described in the section titled &#147;Certain Relationships and Related Party Transactions.&#148; These board composition provisions
will terminate upon the completion of this offering. Upon the termination of these provisions, there will be no further contractual obligations regarding the election of our directors. Our nominating and corporate governance committee and our board
of directors may therefore consider a broad range of factors relating to the qualifications and background of nominees. Our nominating and corporate governance committee&#146;s and our board of directors&#146; priority in selecting board members is
identification of persons who will further the interests of our stockholders through their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our
business, understanding of the competitive landscape, professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their
resignation or removal. Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and our amended and restated bylaws, which will become effective upon the effectiveness
of our registration statement of which this prospectus forms a part, also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes
that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a
majority of our directors then in office. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Staggered Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the terms of our amended and restated certificate of incorporation, which will become effective immediately
prior to the completion of this offering, and our amended and restated bylaws, which will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
be effective upon the effectiveness of the registration statement of which this prospectus forms a part, our board of directors will be divided into three staggered classes of directors and each
director will be assigned to one of the three classes. At each annual meeting of the stockholders, one class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of
the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2025 for Class&nbsp;I directors, 2026 for Class&nbsp;II directors and 2027 for Class&nbsp;III
directors. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;I directors will be&#8195;&#8195;&#8195;&#8195; ; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;II directors will be &#8195;&#8195;&#8195;&#8195; ; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;III directors will be &#8195;&#8195;&#8195;&#8195; . </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this
offering, and our amended and restated bylaws, which will be effective upon the effectiveness of the registration statement of which this prospectus forms a part, will provide that the number of our directors shall be fixed from time to time by a
resolution of the majority of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The division of our board of directors into three classes with
staggered three-year terms may delay or prevent stockholder efforts to effect a change of our management or a change in control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to apply to list our common stock on the Nasdaq Global Market. Under the Nasdaq listing rules, independent directors
must comprise a majority of a listed company&#146;s board of directors within one year from the date of listing. In addition, the Nasdaq listing rules require that, subject to specified exceptions, each member of a listed company&#146;s audit,
compensation and nominating and governance committees be independent within one year from the date of listing. Audit committee members must also satisfy additional independence criteria, including those set forth in Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. Under Nasdaq
listing rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment
in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, a member of an audit committee of a listed company may not, other
than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (i)&nbsp;accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its
subsidiaries, other than compensation for board service; or (ii)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10C-1,</FONT>
the board of directors must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#146;s
ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of compensation of the director, including any consulting advisory or other compensatory fee paid
by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, our board of directors undertook a review of the composition of our board of directors and
its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has
determined that all members of our board of directors, except &#8195;&#8195;&#8195;&#8195;are independent directors, including for purposes of Nasdaq and the SEC rules. In making that determination, our board of directors considered the
relationships that each director has with us and all other facts and circumstances our board of directors deemed relevant in determining independence, including the potential deemed beneficial ownership of our capital stock by each director,
including <FONT STYLE="white-space:nowrap">non-employee</FONT> directors that are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
affiliated with certain of our major stockholders. Upon the completion of this offering, we expect that the composition and functioning of our board of directors and each of our committees will
comply with all applicable requirements of Nasdaq and the rules and regulations of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to adopt a policy,
subject to and effective upon the effectiveness of the registration statement of which this prospectus forms a part, that outlines a process for our securityholders to send communications to our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Board Diversity Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to adopt policies and procedures for director candidates for our nominating and corporate governance committee,
subject to and effective upon the effectiveness of the registration statement of which this prospectus forms a part, which will provide that the value of diversity should be considered in determining director candidates, as well as other factors,
such as a candidate&#146;s character, judgment, skills, education, expertise, and absence of conflicts of interest. Our priority in selection of board members will be identification of members who will further the interests of our stockholders
through their established records of professional accomplishment, their ability to contribute positively to the collaborative culture among board members, and their knowledge of our business and understanding of the competitive landscape in which we
operate and adherence to high ethical standards. Our nominating and corporate governance committee and our full board of directors are committed to creating a board of directors with diversity, including diversity of expertise, experience,
background, and gender, and are committed to identifying, recruiting, and advancing candidates offering such diversity in future searches. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Board Leadership Structure and Board&#146;s Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Currently, the role of chairman of our board of directors is separated from the role of Chief Executive Officer. We believe
that separating these positions allows our Chief Executive Officer to focus on our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business, while allowing the chairman to lead our board of directors in its
fundamental role of providing advice to and independent oversight of management. Our board of directors recognizes the time, effort and energy that the Chief Executive Officer is required to devote to his position in the current business
environment, as well as the commitment required to serve as our chairman, particularly as our board of directors&#146; oversight responsibilities continue to grow. While our amended and restated bylaws and corporate governance guidelines do not
require that our chairman and Chief Executive Officer positions be separate, our board of directors believes that having separate positions is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate
governance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Risk is inherent with every business, and how well a business manages risk can ultimately determine its
success. We face a number of risks, including risks relating to our financial condition, development and commercialization activities, operations, strategic direction, and intellectual property as more fully discussed in the section titled
&#147;Risk Factors.&#148; Management is responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of risks we face, while our board of directors, as a whole and through its committees,
has responsibility for the oversight of risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and
functioning as designed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The role of our board of directors in overseeing the management of our risks is conducted
primarily through committees of our board of directors, as disclosed in the descriptions of each of the committees below and in the charters of each of the committees. Our full board of directors (or the appropriate board committee in the case of
risks that are under the purview of a particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing
the management of a particular risk or risks, the chairman of the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables our board of directors and its
committees to coordinate the risk oversight role, particularly with respect to risk interrelationships. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Committees of Our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors will establish an audit committee, a compensation committee and a nominating and corporate governance
committee, each of which will operate pursuant to a charter to be adopted by our board of directors and will be effective upon the effectiveness of the registration statement of which this prospectus forms a part. We believe that the composition and
functioning of all of our committees will comply with the applicable requirements of Nasdaq, the Sarbanes-Oxley Act and SEC rules and regulations that will be applicable to us. We intend to comply with future requirements to the extent they become
applicable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the completion of this offering, the full text of our audit committee charter, compensation
committee charter and nominating and corporate governance committee charter will be posted on our website at <I>www.septerna.com</I>. We do not incorporate the information contained on, or accessible through, our corporate website into this
prospectus, and you should not consider it a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. Our board of directors may establish other committees as it deems necessary or
appropriate from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the effectiveness of the registration statement of which this prospectus forms a part, our audit committee will consist
of&#8195;&#8195;&#8195;&#8195; and will be chaired by&#8195;&#8195;&#8195;&#8195;. The functions of the audit committee will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, approving the compensation of, and assessing the independence of our independent registered public
accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of
management responsible for preparing our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and
quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and
concerns; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending based upon the audit committee&#146;s review and discussions with management and our independent
registered public accounting firm whether our audited financial statements shall be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements
as they relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing all related party transactions for potential conflict of interest situations and approving all such
transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing quarterly earnings releases. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All members of our audit committee will meet the requirements for financial literacy under the applicable rules and
regulations of the SEC and the Nasdaq listing rules. Our board of directors has determined that&#8195;&#8195;&#8195;&#8195;qualifies as an &#147;audit committee financial expert&#148; within the meaning of applicable SEC
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
regulations. In making this determination, our board of directors considered the nature and scope of experience that&#8195;&#8195;&#8195;&#8195;has previously had with public reporting companies,
including service as&#8195;&#8195;&#8195;&#8195;. Our board of directors has determined that all of the directors that will become members of our audit committee upon the effectiveness of the registration statement of which this prospectus forms a
part satisfy the relevant independence requirements for service on the audit committee set forth in the rules of the SEC and the Nasdaq listing rules. Both our independent registered public accounting firm and management will periodically meet
privately with our audit committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the effectiveness of the registration statement of which this prospectus forms a part, our compensation committee will
consist of&#8195;&#8195;&#8195;&#8195; and will be chaired by&#8195;&#8195;&#8195;&#8195;. The functions of the compensation committee will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annually reviewing and recommending to our board of directors the corporate goals and objectives relevant to
the compensation of our Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and
based on such evaluation (i)&nbsp;reviewing and determining the cash compensation of our Chief Executive Officer and (ii)&nbsp;reviewing and approving grants and awards to our Chief Executive Officer under equity-based plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation of our other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and establishing our overall management compensation, philosophy and policy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating and assessing potential and current compensation advisors in accordance with the independence
standards identified in the applicable Nasdaq listing rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving our policies and procedures for the grant of equity-based awards;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the compensation of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing our compensation committee report if and when required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing annually with management our &#147;Compensation Discussion and Analysis,&#148; if and
when required, to be included in our annual proxy statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in
the evaluation of compensation matters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each member of our compensation committee will be a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director, as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, and an outside director, as defined pursuant to Section&nbsp;162(m) of the Internal Revenue
Code of 1986, as amended (Code). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the effectiveness of the registration statement of which this prospectus forms a part, our nominating and corporate
governance committee will consist of&#8195;&#8195;&#8195;&#8195;and will be chaired by&#8195;&#8195;&#8195;&#8195;. The functions of the nominating and corporate governance committee will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to our board of directors criteria for board and committee membership;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees
recommended by stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the composition of our board of directors to ensure that it is composed of members containing the
appropriate skills and expertise to advise us; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying individuals qualified to become members of our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to our board of directors the persons to be nominated for election as directors and to each of
its committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to our board of directors a code of business conduct and ethics and a set of
corporate governance guidelines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the evaluation of our board of directors and management. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the members of our compensation committee is, or has at any time during the prior three years been, one of our officers
or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our board of
directors or compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors intends to adopt, subject to and effective upon the effectiveness of the registration statement of which
this prospectus forms a part, a written code of business conduct and ethics in connection with this offering. The code of business conduct and ethics will apply to all of our directors, officers and employees (including our principal executive
officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions). Upon the completion of this offering, the full text of our code of business conduct and ethics will be posted on our website
at <I>www.septerna.com</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to disclose on our website any future amendments of our code of business conduct
and ethics or waivers that exempt any principal executive officer, principal financial officer, principal accounting officer or controller, persons performing similar functions, or our directors from provisions in the code of business conduct and
ethics. The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We have included our website address in this prospectus solely as an inactive
textual reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Compensation Recovery </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors intends to adopt, subject to and effective upon the effectiveness of the registration statement of which
this prospectus forms a part, a compensation recovery policy that is compliant with the Nasdaq listing rules, as required by the Dodd-Frank Act. The compensation recovery policy will provide that in the event we are required to prepare a restatement
of financial statements due to material noncompliance with any financial reporting requirement under securities laws, we will seek to recover any incentive-based compensation that was based upon the attainment of a financial reporting measure and
that was received by any current or former executive officer during the three-year period preceding the date that the restatement was required if such compensation exceeds the amount that the executive officers would have received based on the
restated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Limitations on Liability and Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As permitted by Delaware law, provisions in our amended and restated certificate of incorporation, which will become effective
immediately prior to the completion of this offering, and our amended and restated bylaws, which will be effective upon the effectiveness of the registration statement of which this prospectus forms a part, limit or eliminate the personal liability
of directors and officers for a breach of their fiduciary duty of care as a director or officer. The duty of care generally requires that, when acting on behalf of the corporation, a director and or officer exercise an informed business judgment
based on all material information reasonably available to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
him or her. Consequently, a director or officer will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director or officer, except for
liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s or officer&#146;s duty of loyalty to us or our stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our directors, unlawful payments of dividends or unlawful stock repurchases, or redemptions as provided in
Section&nbsp;174 of the Delaware General Corporation Law (DGCL); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our officers, any derivative action by or in the right of the corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These limitations of liability do not limit or eliminate our rights or any stockholder&#146;s rights to
seek <FONT STYLE="white-space:nowrap">non-</FONT> monetary relief, such as injunctive relief or rescission. These provisions will not alter a director or officer&#146;s liability under other laws, such as the federal securities laws or other state
or federal laws. Our amended and restated certificate of incorporation that will become effective upon the completion of this offering also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under
Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As permitted by Delaware law, our amended and restated bylaws, which will be effective upon the
effectiveness of the registration statement of which this prospectus forms a part, will provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors, officers, employees and other agents to the fullest extent permitted by law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we must advance expenses to our directors and officers, and may advance expenses to our employees and other
agents, in connection with a legal proceeding to the fullest extent permitted by law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director
or officer, then the liability of our directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated bylaws will also permit us to secure insurance on behalf of any
officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our amended and restated bylaws permit such indemnification. We have obtained such
insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the indemnification that will be provided for in our amended and restated certificate of
incorporation and amended and restated bylaws, we plan to enter into separate indemnification agreements with each of our directors and executive officers, which may be broader than the specific indemnification provisions contained in the DGCL.
These indemnification agreements may require us, among other things, to indemnify our directors and executive officers for some expenses, including attorneys&#146; fees, expenses, judgments, fines and settlement amounts incurred by a director or
executive officer in any action or proceeding arising out of his service as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these provisions and
agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This
description of the indemnification provisions of our amended and restated certificate of incorporation, our amended and restated bylaws and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is
attached as an exhibit to the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being
sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following discussion contains forward-looking statements that are based on our current plans, considerations, expectations
and determinations regarding our future compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in
this discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As an emerging growth company, we have opted to comply with the executive compensation disclosure rules
applicable to &#147;smaller reporting companies,&#148; as such term is defined in the rules promulgated under the Exchange Act. The compensation provided to our named executive officers (NEOs) for the fiscal year ended December&nbsp;31, 2023 is
detailed in the &#147;<I>2023 Summary Compensation Table</I>&#148; and accompanying footnotes and narrative that follow. Our NEOs for the fiscal year ended December&nbsp;31, 2023 consist of our Chief Executive Officer and the two most highly
compensated executive officers (other than our Chief Executive Officer) who were serving as our executive officers on December&nbsp;31, 2023. In addition, while we are required to disclose a total of three NEOs, we are voluntarily including two
additional NEOs, Drs. Long and Klein, given their roles with the Company during the fiscal year ended December&nbsp;31, 2023. Accordingly, our NEOs for the fiscal year ended December&nbsp;31, 2023 are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jeffrey Finer, M.D., Ph.D., our President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Liz Bhatt, M.S., M.B.A., our Chief Operating Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Samira Shaikhly, our Chief People Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Daniel Long, D.Phil., our Senior Vice President, Drug Discovery; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Uwe Klein, Ph.D., our Senior Vice President, Biological Sciences. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date, the compensation of our NEOs has consisted of a combination of base salary, cash bonuses and long-term incentive
compensation in the form of restricted stock awards and stock options. Our NEOs who are full-time employees are eligible to participate in our health and welfare benefit plans and 401(k) plan like all of our full-time employees. As we transition
from a private company to a publicly traded company, we intend to evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances require. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2023 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information regarding compensation awarded to, earned by, and/or paid to our NEOs for services
rendered to us in all capacities during the fiscal year ended December&nbsp;31, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal<BR>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation($)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Finer, M.D., Ph.D.<BR><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">501,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">284,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,347,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,136,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liz Bhatt, M.S., M.B.A.<BR><I>Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">413,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">883,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samira Shaikhly,<I><BR>Chief People
Officer<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">322,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">235,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">742,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Long, D.Phil.,<BR><I>SVP, Drug Discovery</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">369,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212,090</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">646,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Uwe Klein, Ph.D.,<BR><I>SVP, Biological Sciences</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">363,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">578,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts reported consist of (i)&nbsp;for Dr.&nbsp;Finer, Ms.&nbsp;Bhatt, Ms.&nbsp;Shaikhly,
Dr.&nbsp;Long and Dr.&nbsp;Klein, $284,310, $203,270, $132,094, $149,590 and $149,607, respectively, for discretionary annual bonuses earned for the fiscal year ended December&nbsp;31, 2023 and (ii)&nbsp;for Ms.&nbsp;Shaikhly and Dr.&nbsp;Long,
$50,000 and $62,500, respectively, for <FONT STYLE="white-space:nowrap">sign-on</FONT> bonuses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts reported represent the aggregate grant date fair value of stock options awarded to our NEOs
during the fiscal year ended December&nbsp;31, 2023, calculated in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic&nbsp;718, disregarding estimated forfeitures related to service-based
vesting. For a description of the assumptions used in determining these values, see Note&nbsp;10&#151;&#147;<I>Stock-Based Compensation</I>&#148; to our financial statements included elsewhere in this prospectus. The amount reported in this column
reflects the accounting cost for the stock options and does not correspond to the actual economic value that may be received by our NEOs upon the exercise of the stock options or any sale of the underlying shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts reported represent 401(k) matching contributions made by the Company to our NEOs.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Ms.&nbsp;Shaikhly commenced employment with the Company on February&nbsp;1, 2023 and her annual base salary
and annual bonus for 2023 were <FONT STYLE="white-space:nowrap">pro-rated</FONT> accordingly. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Long commenced employment with the Company on October&nbsp;4, 2021 and his <FONT
STYLE="white-space:nowrap">sign-on</FONT> bonus was paid in two tranches: (i) $62,500 within 30 days of January&nbsp;1, 2022 and (ii)&nbsp;$62,500 within 30 days of January&nbsp;1, 2023, subject to his continued employment with the Company through
each such date of payment. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Narrative to the 2023 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2023 Base Salaries </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our NEOs each receive a base salary to compensate them for services rendered to us. The base salary payable to each NEO is
intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role and responsibilities. Base salaries are reviewed annually, typically in connection with our annual performance review process, approved
by our board of directors or the compensation committee of our board of directors (compensation committee), and may be adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities,
performance, and experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From January&nbsp;1, 2023 through October&nbsp;31, 2023, the annual base salaries for
Dr.&nbsp;Finer, Ms.&nbsp;Bhatt and Dr.&nbsp;Klein were $496,375, $409,863, and $362,472, respectively. Ms.&nbsp;Shaikhly commenced employment with us on February&nbsp;1, 2023 and her annual base salary from February&nbsp;1, 2023 through
October&nbsp;31, 2023 was $350,000. Effective November&nbsp;1, 2023, the annual base salaries for Dr.&nbsp;Finer, Ms.&nbsp;Bhatt, Ms.&nbsp;Shaikhly, and Dr.&nbsp;Klein increased to $526,500, $430,200, $357,500, $369,400, respectively.
Dr.&nbsp;Long&#146;s annual base salary for the entire fiscal year ended December&nbsp;31, 2023 was $369,357. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2023 Cash Incentive
Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the fiscal year ended December&nbsp;31, 2023, each of our NEOs was eligible to earn a
discretionary annual bonus based on the Company&#146;s achievement of certain corporate performance objectives, as determined by our board of directors. The 2023 target annual bonuses for Dr. Finer and Ms. Bhatt were 40% and 35%, respectively, and
30% for Ms. Shaikhly, Dr. Long and Dr. Klein, of the applicable NEO&#146;s annual base salary. The corporate performance objectives for our NEOs&#146; 2023 annual bonuses were based on the Company&#146;s achievement of certain program, platform and
finance/business development goals, which were determined to have been achieved at 135% of target. The discretionary annual bonuses received by each NEO with respect to the fiscal year ended December&nbsp;31, 2023 were $284,310, $203,270, $132,094,
$149,590 and $149,607 for Dr.&nbsp;Finer, Ms.&nbsp;Bhatt, Ms.&nbsp;Shaikhly, Dr.&nbsp;Long and Dr.&nbsp;Klein, respectively. Ms.&nbsp;Shaikhly&#146;s 2023 annual bonus was <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on her commencement
of employment with the Company effective February&nbsp;1, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with Ms.&nbsp;Shaikhly&#146;s and
Dr.&nbsp;Long&#146;s commencement of employment, they were also entitled to a $50,000 and $62,500, respectively, <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus payable in 2023, subject to their continued employment with the Company through
the date of payment. For Ms.&nbsp;Shaikhly, her <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus is subject to full repayment if she (i)&nbsp;is terminated by the Company for &#147;cause,&#148; as defined in the Shaikhly Offer Letter (as
defined below) or (ii)&nbsp;resigns from the Company for any reason, in either case prior to the second anniversary of the payment of the <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Equity-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, we
believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. In addition, we believe that equity grants promote
executive retention because they incentivize our executive officers to remain in our employment during the vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, our board of directors periodically reviews the equity incentive compensation of our executive officers and may
grant equity incentive awards to them from time to time. During the fiscal year ended December&nbsp;31, 2023, we granted option awards to our NEOs under the 2021 Plan as described in more detail in the &#147;<I>Outstanding Equity Awards at 2023
Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT></I>&#148; table below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Perquisites or Personal Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Perquisites and other personal benefits are not a significant component of our executive compensation program. Accordingly, we
do not provide perquisites or personal benefits to our NEOs with an aggregate amount equal to or greater than $10,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>401(k) Plan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently maintain a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> 401(k) retirement savings plan
(401(k) plan) for our employees, including our NEOs, who satisfy certain eligibility requirements. Our NEOs are eligible to participate in the 401(k) plan on the same terms as other full-time employees. Our 401(k) plan is intended to qualify for
favorable tax treatment under Section&nbsp;401(a) of the Code and contains a cash or deferred feature that is intended to meet the requirements of Section&nbsp;401(k) of the Code. Our 401(k) plan allows for discretionary matching contributions under
the plan and in 2023, we provided discretionary matching contributions equal to 50% of up to the first 8% of eligible compensation, capped at $3,000 annually per employee. We believe that providing a vehicle for
<FONT STYLE="white-space:nowrap">tax-deferred</FONT> retirement savings though our 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our NEOs, in accordance with our
compensation policies. Other than the 401(k) plan, we do not provide any qualified or <FONT STYLE="white-space:nowrap">non-qualified</FONT> retirement or deferred compensation benefits to our employees, including our NEOs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Executive Employment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into an offer letter with each of our NEOs in connection with his or her employment with us, which set forth
the terms and conditions of his or her employment, as applicable. The material terms of such offer letters are described below. In connection with this offering, we intend to adopt a new executive severance plan, or the Executive Severance Plan,
which will become effective upon the closing of this offering. Each of the NEOs may participate in the Executive Severance Plan. The Executive Severance Plan will provide for certain payments and benefits in the event of a termination of employment,
including an involuntary employment in connection with a change in control of the Company, and will replace the severance provisions in the NEOs&#146; offer letters, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Prior Employment Arrangements in Place During the 2023 Fiscal Year </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Jeffrey Finer, M.D., Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;9, 2022, we entered into an offer letter with Dr.&nbsp;Finer effective as of September&nbsp;13, 2022, for the
position of our Chief Executive Officer (Finer Offer Letter). The Finer Offer Letter provided for Dr.&nbsp;Finer&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, and an initial annual base salary and initial target annual bonus,
each of which has subsequently been increased as described above under &#147;<I>2023 Base Salaries</I>&#148; and &#147;<I>2023 Cash Incentive Compensation</I>.&#148; The Finer Offer Letter also provided for a one-time $100,000 sign on bonus and the
grant of an award of restricted stock. Dr.&nbsp;Finer is eligible to participate in the employee benefit plans generally available to our employees, subject to the terms of those plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Finer Offer Letter provides that in the event that Dr.&nbsp;Finer&#146;s
employment is terminated by the Company without &#147;cause&#148; or he resigns for &#147;good reason&#148; in either case outside a &#147;change of control period&#148; (each as defined in the Finer Offer Letter), subject to Dr.&nbsp;Finer&#146;s
execution and delivery of an irrevocable separation agreement, including a general release of claims in the Company&#146;s favor, he will be entitled to receive (i)&nbsp;base salary continuation for 12 months following termination and
(ii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that the Company would have paid to provide health insurance to Dr.&nbsp;Finer had he remained employed with the Company until the earliest of (A) 12 months following
termination, (B)&nbsp;Dr.&nbsp;Finer becoming eligible for group medical plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Dr.&nbsp;Finer&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the Finer Offer Letter provides that in the event that Dr.&nbsp;Finer&#146;s employment is terminated by the
Company without &#147;cause&#148; or he resigns for &#147;good reason&#148;, in either case within a &#147;change of control period,&#148; subject to Dr.&nbsp;Finer&#146;s execution and delivery of an irrevocable separation agreement, including a
general release of claims in the Company&#146;s favor, in lieu of the payments and benefits described above, he will be entitled to receive (i)&nbsp;base salary continuation for 12 months following termination, (ii)&nbsp;the amount of his
then-current target bonus for the year of termination, (iii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that the Company would have paid to provide health insurance to Dr.&nbsp;Finer had he remained employed with the
Company until the earliest of (A) 12 months following termination, (B)&nbsp;Dr.&nbsp;Finer becoming eligible for group medical plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Dr.&nbsp;Finer&#146;s COBRA health
continuation period, and (iv)&nbsp;accelerated vesting of all time-based stock options and other time-based stock-based awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Finer also entered into a standard form agreement with respect to confidential information, intellectual property
assignment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Liz Bhatt, M.S., M.B.A. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On May&nbsp;20, 2022, the Company entered into an offer letter with Ms.&nbsp;Bhatt effective as of June&nbsp;15, 2022, for the
position of our Chief Operating Officer (Bhatt Offer Letter). The Bhatt Offer Letter provides for Ms.&nbsp;Bhatt&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, and an initial annual base salary and initial target annual bonus,
each of which has subsequently been increased as described above under &#147;<I>2023 Base Salaries</I>&#148; and &#147;<I>2023 Cash Incentive Compensation</I>.&#148; The Bhatt Offer Letter also provided for a one-time $60,000 sign on bonus and the
grant of an award of restricted stock. Ms.&nbsp;Bhatt is eligible to participate in the employee benefit plans generally available to employees, subject to the terms of those plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Bhatt Offer Letter provides that in the event that Ms.&nbsp;Bhatt&#146;s employment is terminated by the Company without
&#147;cause&#148; outside a &#147;change of control period&#148; (each as defined in the Bhatt Offer Letter), subject to Ms.&nbsp;Bhatt&#146;s execution and delivery of an irrevocable separation agreement, including a general release of claims in
the Company&#146;s favor, she will be entitled to receive (i)&nbsp;base salary continuation for nine months following termination and (ii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that the Company would have paid to
provide health insurance to Ms.&nbsp;Bhatt had she remained employed with the Company until the earliest of (A)&nbsp;nine months following termination, (B)&nbsp;Ms.&nbsp;Bhatt becoming eligible for group medical plan benefits under any other
employer&#146;s group health plan or (C)&nbsp;the end of Ms.&nbsp;Bhatt&#146;s COBRA health continuation period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, the Bhatt Offer Letter provided that in the event that Ms.&nbsp;Bhatt&#146;s employment was terminated by the Company without &#147;cause&#148; within a &#147;change of control period,&#148; subject to Ms.&nbsp;Bhatt&#146;s execution and
delivery of an irrevocable separation agreement, including a general release of claims in the Company&#146;s favor, in lieu of the payments and benefits described above, she would have been entitled to receive (i)&nbsp;base salary continuation for
nine months following termination, (ii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that the Company would have paid to provide health insurance to Ms.&nbsp;Bhatt had she remained
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
employed with the Company until the earliest of (A)&nbsp;nine months following termination, (B)&nbsp;Ms.&nbsp;Bhatt becoming eligible for group medical plan benefits under any other
employer&#146;s group health plan or (C)&nbsp;the end of Ms.&nbsp;Bhatt&#146;s COBRA health continuation period, and (iii)&nbsp;accelerated vesting of all time-based stock options and other time-based stock-based awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ms.&nbsp;Bhatt also entered into a standard form agreement with respect to confidential information, intellectual property
assignment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Samira Shaikhly, M.S. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;22, 2022, the Company entered into an offer letter with Ms.&nbsp;Shaikhly effective as of February&nbsp;1,
2023, for the position of our Chief People Officer (Shaikhly Offer Letter). The Shaikhly Offer Letter provides for Ms.&nbsp;Shaikhly&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, and an initial annual base salary and initial
target annual bonus, each of which has subsequently been increased as described above under &#147;<I>2023 Base Salaries</I>&#148; and &#147;<I>2023 Cash Incentive Compensation</I>.&#148; The Shaikhly Offer Letter also provided for the grant of an
award of stock options and a $50,000 <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus subject to full repayment if Ms.&nbsp;Shaikhly (i)&nbsp;is terminated by the Company for &#147;cause&#148; (as defined in the Shaikhly Offer Letter) or
(ii)&nbsp;resigns from the Company for any reason, in either case prior to the second anniversary of the payment of the <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus. Ms.&nbsp;Shaikhly is eligible to participate in the employee benefit plans
generally available to employees, subject to the terms of those plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Shaikhly Offer Letter provides that in the
event that Ms.&nbsp;Shaikhly&#146;s employment is terminated by the Company without &#147;cause&#148; outside a &#147;change of control period&#148; (each as defined in the Shaikhly Offer Letter), subject to Ms.&nbsp;Shaikhly&#146;s execution and
delivery of an irrevocable separation agreement, including a general release of claims in the Company&#146;s favor, she will be entitled to receive (i)&nbsp;base salary continuation for six months following termination and (ii)&nbsp;monthly payments
of the portion of the premiums equal to the amounts that the Company would have paid to provide health insurance to Ms.&nbsp;Shaikhly had she remained employed with the Company until the earliest of (A)&nbsp;six months following termination,
(B)&nbsp;Ms.&nbsp;Shaikhly becoming eligible for group medical plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Ms.&nbsp;Shaikhly&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the Shaikhly Offer Letter provides that in the event that Ms.&nbsp;Shaikhly&#146;s employment is terminated by
the Company without &#147;cause&#148; within a &#147;change of control period,&#148; subject to Ms.&nbsp;Shaikhly&#146;s execution and delivery of an irrevocable separation agreement, including a general release of claims in the Company&#146;s
favor, in lieu of the payments and benefits described above, she will be entitled to receive (i)&nbsp;base salary continuation for six months following termination, (ii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that
the Company would have paid to provide health insurance to Ms.&nbsp;Shaikhly had she remained employed with the Company until the earliest of (A)&nbsp;six months following termination, (B)&nbsp;Ms.&nbsp;Shaikhly becoming eligible for group medical
plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Ms.&nbsp;Shaikhly&#146;s COBRA health continuation period, and (iii)&nbsp;accelerated vesting of all time-based stock options and other time-based stock-based
awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ms.&nbsp;Shaikhly also entered into a standard form agreement with respect to confidential information,
intellectual property assignment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Daniel Long, D.Phil. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;27, 2021, the Company entered into an offer letter with Dr.&nbsp;Long effective as of October&nbsp;4, 2021,
for the position of our Senior Vice President, Drug Discovery (Long Offer Letter). The Long Offer Letter provides for Dr.&nbsp;Long&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, and an initial annual base salary and initial
target annual bonus, each of which has subsequently been increased as described above under &#147;<I>2023 Base Salaries</I>&#148; and &#147;<I>2023 Cash Incentive Compensation</I>.&#148; The Long Offer Letter also provided for the grant of an award
of restricted stock and a <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus subject to two disbursements: (i) $62,500 which was paid within 30 days of January&nbsp;1, 2022 and (ii) $62,500 which was paid within 30 days of January&nbsp;1, 2023,
subject to Dr. Long&#146;s continuous employment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
with the Company through each such date. Dr.&nbsp;Long is eligible to participate in the employee benefit plans generally available to employees, subject to the terms of those plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Long Offer Letter provides that in the event that Dr.&nbsp;Long&#146;s employment is terminated by the Company without
&#147;cause&#148; outside a &#147;change of control period&#148; (each as defined in the Long Offer Letter), subject to Dr.&nbsp;Long&#146;s execution and delivery of an irrevocable separation agreement, including a general release of claims in the
Company&#146;s favor, he will be entitled to receive (i)&nbsp;base salary continuation for six months following termination and (ii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that the Company would have paid to
provide health insurance to Dr.&nbsp;Long had he remained employed with the Company until the earliest of (A) six months following termination, (B)&nbsp;Dr.&nbsp;Long becoming eligible for group medical plan benefits under any other employer&#146;s
group health plan or (C)&nbsp;the end of Dr.&nbsp;Long&#146;s COBRA health continuation period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the Long
Offer Letter provides that in the event that Dr.&nbsp;Long&#146;s employment is terminated by the Company without &#147;cause&#148; within a &#147;change of control period,&#148; subject to Dr.&nbsp;Long&#146;s execution and delivery of an
irrevocable separation agreement, including a general release of claims in the Company&#146;s favor, in lieu of the payments and benefits described above, he will be entitled to receive (i)&nbsp;base salary continuation for six months following
termination, (ii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that the Company would have paid to provide health insurance to Dr.&nbsp;Long had he remained employed with the Company until the earliest of (A)&nbsp;six
months following termination, (B)&nbsp;Dr.&nbsp;Long becoming eligible for group medical plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Dr.&nbsp;Long&#146;s COBRA health continuation period, and
(iii)&nbsp;accelerated vesting of all time-based stock options and other time-based stock-based awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Long
also entered into a standard form agreement with respect to confidential information, intellectual property assignment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Uwe Klein, Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;17, 2021, the Company entered into an offer letter with Dr.&nbsp;Klein effective as of November&nbsp;1, 2021,
for the position of our Senior Vice President, Biological Sciences (Klein Offer Letter). The Klein Offer Letter provides for Dr.&nbsp;Klein&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, and an initial annual base salary and
initial target annual bonus, each of which has subsequently been increased as described above under &#147;<I>2023 Base Salaries</I>&#148; and &#147;<I>2023 Cash Incentive Compensation</I>.&#148; The Klein Offer Letter also provides for the a
one-time $100,000 sign on bonus and, at Dr. Klein&#146;s option, either grant of an award of restricted stock or an award of stock options. Dr.&nbsp;Klein is eligible to participate in the employee benefit plans generally available to employees,
subject to the terms of those plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Klein Offer Letter provides that in the event that Dr.&nbsp;Klein&#146;s
employment is terminated by the Company without &#147;cause&#148; outside a &#147;change of control period&#148; (each as defined in the Klein Offer Letter), subject to Dr.&nbsp;Klein&#146;s execution and delivery of an irrevocable separation
agreement, including a general release of claims in the Company&#146;s favor, he will be entitled to receive (i)&nbsp;base salary continuation for six months following termination and (ii)&nbsp;monthly payments of the portion of the premiums equal
to the amounts that the Company would have paid to provide health insurance to Dr.&nbsp;Klein had he remained employed with the Company until the earliest of (A)&nbsp;six months following termination, (B)&nbsp;Dr.&nbsp;Klein becoming eligible for
group medical plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Dr.&nbsp;Klein&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the Klein Offer Letter provides that in the event that Dr.&nbsp;Klein&#146;s employment is terminated by the
Company without &#147;cause&#148; within a &#147;change of control period,&#148; subject to Dr.&nbsp;Klein&#146;s execution and delivery of an irrevocable separation agreement, including a general release of claims in the Company&#146;s favor, in
lieu of the payments and benefits described above, he will be entitled to receive (i)&nbsp;base salary continuation for six months following termination, (ii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Company would have paid to provide health insurance to Dr.&nbsp;Klein had he remained employed with the Company until the earliest of (A)&nbsp;six months following termination,
(B)&nbsp;Dr.&nbsp;Klein becoming eligible for group medical plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Dr.&nbsp;Klein&#146;s COBRA health continuation period, and (iii)&nbsp;accelerated vesting of all
time-based stock options and other time-based stock-based awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Klein also entered into a standard form
agreement with respect to confidential information, intellectual property assignment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">2023&nbsp;Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information concerning outstanding equity awards held by our NEOs as of December&nbsp;31, 2023.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP> </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options&nbsp;(#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;or<BR>Units&nbsp;of<BR>Stock&nbsp;That<BR>Have&nbsp;Not<BR>Vested&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Value<BR>of Shares or<BR>Units&nbsp;of&nbsp;Stock<BR>That&nbsp;Have&nbsp;Not<BR>Vested
($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Jeffrey Finer, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/13/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/2/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,620,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/12/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/1/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,474</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,569,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/11/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Liz Bhatt, M.S., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/13/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/15/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">937,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">506,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/12/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/1/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,609</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">699,704</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/11/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Samira Shaikhly</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/31/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/1/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151; </TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/30/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/12/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/1/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151; </TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/11/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Daniel Long, D.Phil.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/26/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/2/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">216,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/12/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/1/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/11/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Uwe Klein, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/26/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/12/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/1/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/11/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each equity award is subject to the terms of the 2021 Plan (as described below). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">This amount is based on the fair market value of a share of our common stock equal to $0.54 as of
December&nbsp;31, 2023, as determined by our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The shares underlying the stock option award or restricted stock award, as applicable, vest in 48 equal
monthly installments over a four-year period, commencing on the vesting commencement date, subject to the applicable NEO&#146;s continued service relationship through each applicable vesting date. The award is also subject to certain acceleration of
vesting rights as set forth in the applicable NEO&#146;s Offer Letter, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The shares underlying the stock option award or restricted stock award, as applicable, vest as follows: 25%
of such shares vested on the first anniversary of the vesting commencement date, and the remaining 75% of the shares vest in 36 equal monthly installments over the following three years, subject to the applicable NEO&#146;s continued service
relationship through each applicable vesting date. The award is also subject to certain acceleration of vesting rights as set forth in the applicable NEO&#146;s Offer Letter, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The shares underlying the restricted stock award vest as follows: 25% of such shares vested on
December&nbsp;1, 2022, and the remaining 75% of the shares vest in 36 equal monthly installments over the following three years, subject to the applicable NEO&#146;s continued service relationship through each applicable vesting date. The award is
also subject to certain acceleration of vesting rights as set forth in the applicable NEO&#146;s Offer Letter, as described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Employee Benefit and Equity Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2021 Stock Option and Grant Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2021 Plan was initially approved and adopted by our board of directors and stockholders on October&nbsp;26, 2021 and has
been subsequently amended from time to time thereafter to increase the number of shares reserved </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
for issuance thereunder. Under the 2021 Plan, we have reserved for issuance an aggregate of 36,524,157 shares of our common stock for the issuance of stock options and other equity awards. This
number of shares of our common stock reserved for issuance is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. As of December&nbsp;31, 2023, options to purchase 9,672,202 shares of our common
stock and 6,666,362 shares of our restricted stock were outstanding under the 2021 Plan and 1,961,671 shares of our restricted stock were outstanding from grants made outside of the 2021 Plan. Our board of directors has determined not to make any
further awards under the 2021 Plan following the completion of this offering, but all outstanding awards under the 2021 Plan will continue to be governed by their existing terms. The maximum number of shares that may be issued as incentive stock
options under the 2021 Plan may not exceed 365,241,570 shares. In connection with this offering, we intend to adopt a new incentive equity plan under which we will grant equity-based awards following this offering, as described below under
&#147;<I>2024 Stock Option and Grant Plan</I>.&#148; This summary is not a complete description of all provisions of the 2021 Plan and is qualified in its entirety by reference to the 2021 Plan, which will be filed as an exhibit to the registration
statement of which this prospectus is part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares of our common stock underlying any awards that are forfeited,
cancelled, reacquired by us prior to vesting, satisfied without the issuance of stock or otherwise terminated (other than by exercise), or held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding under the
2021 Plan will be added back to the shares of our common stock available for issuance under the 2021 Plan (or, following the completion of this offering, the 2024 Plan (as defined below)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has acted as administrator of the 2021 Plan. The administrator has full power to, among other things,
select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, to accelerate at any time the exercisability or vesting of any award and to determine the
specific terms and conditions of each award, subject to the provisions of the 2021 Plan. Persons eligible to participate in the 2021 Plan are those full or part-time officers, employees, <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors, consultants, and key persons as selected from time to time by the administrator in its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2021
Plan permits the granting of both options to purchase shares of our common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and options that do not so qualify. The option exercise price of each option will be
determined by the administrator but may not be less than 100% of the fair market value of our common stock on the date of grant, or in the case of an incentive stock option granted to a 10% owner, the exercise price shall not be less than 110% of
the fair market value of our common stock on the date of grant. The term of each option will be fixed by the 2021 Plan administrator and may not exceed ten years from the date of grant, or five years from the date of grant in the case of an
incentive stock option granted to a 10% owner. The 2021 Plan administrator will determine at what time or times each option may be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2021 Plan administrator may award restricted shares of our common stock and restricted stock units to participants subject
to such conditions and restrictions as it may determine. These conditions and restrictions may include continued employment with us through a specified vesting period and/or the achievement of certain performance goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2021 Plan administrator may also grant shares of our common stock that are free from any restrictions under the 2021 Plan.
Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of certain corporate transactions and events, including a reorganization, recapitalization, reclassification,
stock dividend, stock split, reverse stock split, or other similar change to the Company&#146;s capital stock, the 2021 Plan administrator shall make appropriate adjustments to the maximum number of shares reserved for issuance under the 2021 Plan,
the number and kind of securities subject to outstanding awards under the 2021 Plan and the repurchase or exercise price of any outstanding awards under the 2021 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the effective time of a &#147;sale event&#148; (as defined in the 2021
Plan), all outstanding option awards granted under the 2021 Plan shall terminate unless assumed, substituted, or continued by a successor entity. In the event of such termination, individuals holding options will be permitted to exercise such
options within a specified period of time prior to the sale event. In the event of a sale event, all unvested restricted stock awards and restricted stock units (other than those that become vested as a result of the sale event) will be forfeited
unless assumed, substituted, or continued by a successor entity. With respect to individuals holding restricted stock that is forfeited upon a sale event, such restricted stock shall be repurchased by the Company at a price per share equal to the
original per share purchase price paid by the holder for such shares of our restricted stock. In addition, in connection with a sale event, we may make or provide for a cash payment to participants in exchange for the cancellation of their options
(to the extent then vested and exercisable, including by reason of acceleration in connection with such sale event) or outstanding restricted stock or restricted stock units, in an amount equal to the difference between (a)&nbsp;the per share
consideration in the sale event times the number of shares subject to such awards being cancelled and (b)&nbsp;the aggregate exercise price of such outstanding vested and exercisable stock options, as applicable, with any such cash payments in
respect of restricted stock or restricted stock units to be paid at the time of the sale event or upon the later vesting of such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors may amend or discontinue the 2021 Plan and the 2021 Plan administrator may amend or cancel outstanding
awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may adversely affect rights under any outstanding award without the holder&#146;s consent. Certain amendments to the 2021 Plan require the approval of
our stockholders. The 2021 Plan administrator may exercise its discretion to reduce the exercise price of outstanding stock options or to effect repricing through the cancellation of outstanding stock options and grant of replacement awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No awards may be granted under the 2021 Plan after the date that is ten years from the effective date of the 2021 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2024 Stock Option and Grant Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2024 Plan was adopted by our board of directors on&#8195;&#8195;&#8195;&#8195;, 2024, approved by our stockholders
on&#8195;&#8195;&#8195;&#8195;, 2024, and will become effective upon the date immediately preceding the date on which the registration statement of which this prospectus is part is declared effective by the SEC. The 2024 Plan will replace the 2021
Plan as our board of directors has determined not to make additional awards under the 2021 Plan following the completion of this offering. However, the 2021 Plan will continue to govern outstanding equity awards granted thereunder. The 2024 Plan
allows us to make equity-based and cash-based incentive awards to our officers, employees, directors and consultants. The following summary describes the material terms of the 2024 Plan. This summary is not a complete description of all provisions
of the 2024 Plan and is qualified in its entirety by reference to the 2024 Plan, which will be filed as an exhibit to the registration statement to which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have initially reserved &#8195;&#8195;&#8195;&#8195; shares of our common stock for the issuance of awards under the 2024
Plan (Initial Limit). The 2024 Plan provides that the number of shares reserved and available for issuance under the 2024 Plan will automatically increase on January&nbsp;1, 2025 and each January&nbsp;1 thereafter through January&nbsp;1, 2034, by
&#8195;&#8195;&#8195;&#8195;% of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31 or such lesser number of shares as determined by our compensation committee (Annual Increase). The number of shares
reserved under the 2024 Plan is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares we issue under the 2024 Plan will be authorized but unissued shares or shares that we reacquire. The shares of our
common stock underlying any awards under the 2024 Plan and the 2021 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied
without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added back to the shares of our common stock available for issuance under the 2024 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The maximum number of shares of our common stock that may be issued in the
form of incentive stock options shall not exceed the Initial Limit, cumulatively increased on January&nbsp;1, 2025 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or &#8195;&#8195;&#8195;&#8195; shares of our
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The grant date fair value of all awards made under our 2024 Plan and all other cash compensation paid by us
to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director in any calendar year for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director shall not exceed $&#8195;&#8195;&#8195;&#8195;; provided, however, that such
amount shall be $&#8195;&#8195;&#8195;&#8195; for the calendar year in which the applicable <FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2024 Plan will be administered by our compensation committee. Our compensation committee has the full power to select,
from among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination of awards to participants, to accelerate at any time the exercisability or
vesting of any award and to determine the specific terms and conditions of each award, subject to the provisions of the 2024 Plan. Persons eligible to participate in the 2024 Plan will be those full or part-time officers, employees, <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors and consultants as selected from time to time by our compensation committee in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2024 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options
under Section&nbsp;422 of the Code and options that do not so qualify. The option exercise price of each option will be determined by our compensation committee but may not be less than 100% of the closing price of our common stock on the date of
grant (or, if no closing price is reported on that date, the closing price on the immediately preceding date on which a closing price was reported) (110% in the case of certain incentive stock options) unless the option (i)&nbsp;is granted pursuant
to a transaction described in, and in a manner consistent with Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to U.S. income tax, or (iii)&nbsp;complies with or is exempt from Section&nbsp;409A of the Code.
The term of each option will be fixed by our compensation committee and may not exceed ten years from the date of grant (or five years in the case of certain incentive stock options). Our compensation committee will determine at what time or times
each option may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee may award stock appreciation rights under the 2024 Plan subject
to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient to shares of our common stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price of
each stock appreciation right generally may not be less than 100% of the closing price of our common stock on the date of grant (or, if no closing price is reported on that date, the closing price on the immediately preceding date on which a closing
price was reported) unless the share appreciation right (i)&nbsp;is granted pursuant to a transaction described in, and in a manner consistent with Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to U.S.
income tax, or (iii)&nbsp;complies with or is exempt from Section&nbsp;409A of the Code. The term of each stock appreciation right will be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation
committee will determine at what time or times each stock appreciation right may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee
may award restricted shares of our common stock and restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals
and/or continued employment with us through a specified vesting period. Our compensation committee may also grant shares of our common stock that are free from any restrictions under the 2024 Plan. Unrestricted stock may be granted to participants
in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee may grant dividend equivalent rights to participants that entitle the recipient to receive credits
for dividends that would be paid if the recipient had held a specified number of shares of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee may grant cash bonuses under the 2024 Plan to
participants, subject to the achievement of certain performance goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2024 Plan provides that upon the effectiveness
of a &#147;sale event,&#148; as defined in the 2024 Plan, an acquirer or successor entity may assume, continue or substitute outstanding awards under the 2024 Plan. To the extent that awards granted under the 2024 Plan are not assumed or continued
or substituted by the successor entity, upon the effective time of the sale event, such awards shall terminate. In such case, except as may be otherwise provided in the relevant award agreement, all awards with time-based vesting, conditions or
restrictions shall become fully vested and nonforfeitable as of the effective time of the sale event and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection
with a sale event in the administrator&#146;s discretion or to the extent specified in the relevant award agreement. In the event of such termination, (i)&nbsp;individuals holding options and stock appreciation rights will be permitted to exercise
such options and stock appreciation rights (to the extent exercisable) within a specified period of time prior to the sale event or (ii)&nbsp;we may make or provide for a payment, in cash or in kind, to participants holding vested and exercisable
options and stock appreciation rights equal to the difference between the per share consideration payable to our stockholders in the sale event and the exercise price of the options or stock appreciation rights and we may make or provide for a
payment, in cash or in kind, to participants holding other vested awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors may amend or discontinue
the 2024 Plan and our compensation committee may amend or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may adversely affect rights under an award without the holder&#146;s
consent. Certain amendments to the 2024 Plan require the approval of our stockholders. The administrator of the 2024 Plan is specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options and stock
appreciation rights or effect the repricing of such awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants</FONT> without stockholder consent. No awards may be granted under the 2024 Plan after the date that is 10 years from the
effective date of the 2024 Plan. No awards under the 2024 Plan have been made prior to the date of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2024 Employee
Stock Purchase Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ESPP was adopted by our board of directors on &#8195;&#8195;&#8195;&#8195; , 2024,
approved by our stockholders on &#8195;&#8195;&#8195;&#8195;, 2024, and will become effective on the date immediately preceding the date on which the registration statement of which this prospectus forms a part is declared effective by the SEC. The
ESPP is intended to have two components: a component intended to qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code (423 Component) and a component that is not intended to qualify <FONT
STYLE="white-space:nowrap">(Non-423</FONT> Component). Except as otherwise provided, the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component will be operated and administered in the same manner as the 423 Component, except where prohibited by
law. The following summary describes the material terms of the ESPP. This summary is not a complete description of all provisions of the ESPP and is qualified in its entirety by reference to the ESPP, which will be filed as an exhibit to the
registration statement to which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ESPP initially reserves and authorizes the issuance of up
to a total of &#8195;&#8195;&#8195;&#8195;shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase on January&nbsp;1, 2025 and each
January&nbsp;1 thereafter through January&nbsp;1, 2034, by the least of (i)&nbsp;&#8195;&#8195;&#8195;&#8195;shares of our common stock, (ii) &#8195;&#8195;&#8195;&#8195;% of the outstanding number of shares of our common stock on the immediately
preceding December&nbsp;31, or (iii)&nbsp;such lesser number of shares of our common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock
dividend or other change in our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All employees who are customarily employed by us or one of our designated
subsidiaries for more than &#8195;&#8195;&#8195;&#8195;hours per week and who have been employed for at least &#8195;&#8195;&#8195;&#8195;days are eligible to participate in the ESPP. However, any employee who owns 5% or more of the total combined
voting power or value of all classes of our stock will not be eligible to purchase shares of our common stock under the ESPP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may make one or more offerings each year to our employees to purchase
shares under the ESPP. Offerings will usually begin on each &#8195;&#8195;&#8195;&#8195; and&#8195;&#8195;&#8195;&#8195;and will continue for <FONT STYLE="white-space:nowrap">six-month</FONT> periods, referred to as offering periods. Each eligible
employee may elect to participate in any offering by submitting an enrollment form at least 15 business days before the applicable offering date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each employee who is a participant in the ESPP may purchase shares of our common stock by authorizing payroll deductions of up
to &#8195;&#8195;&#8195;&#8195;% of his or her eligible compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares
of our common stock on the last business day of the offering period at a price equal to 85% of the closing price of the shares of our common stock on the first business day or the last business day of the offering period (or, if no closing price is
reported on that date, the closing price on the immediately preceding date on which a closing price was reported), whichever is lower, provided that no more than a number of shares of common stock determined by dividing $25,000 by the fair market
value of our common stock on the offering date of such offering (or such other lesser maximum number of shares as may be established by the administrator) may be purchased by any one employee during any offering period. Under applicable tax rules,
an employee may purchase no more than $25,000 worth of shares of our common stock, valued at the start of the offering period, under the ESPP for each calendar year during which any option granted to the employee is outstanding at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accumulated payroll deductions of any employee who is not a participant on the last day of an offering period will be
refunded. An employee&#146;s rights under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ESPP may be terminated or amended by our board of directors at any time. An amendment that increases the number of shares
of our common stock authorized under the ESPP and certain other amendments require the approval of our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_14"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents the compensation awarded to, earned by, or paid to each person who served as a <FONT
STYLE="white-space:nowrap">non-employee</FONT> member of our board of directors during the fiscal year ended December&nbsp;31, 2023 for their service on our board of directors during the fiscal year ended December&nbsp;31, 2023. Other than as set
forth in the table and described more fully below, we did not pay any compensation, make any equity awards or <FONT STYLE="white-space:nowrap">non-equity</FONT> awards to, or pay any other compensation to any of the
<FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors in 2023. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors affiliated with Samsara, RA Capital Management, and Third Rock Ventures, including
Mr.&nbsp;Bassan and Drs. Simson and Tong, did not receive cash or equity compensation from us for their service as <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. The compensation for the fiscal year ended December&nbsp;31, 2023
received by Dr.&nbsp;Finer, as an NEO of the Company, is presented in the &#147;<I>2023 Summary Compensation Table</I>&#148; above. Dr.&nbsp;Ezekowitz, who is affiliated with Third Rock Ventures, is an executive officer of the Company, but is not an
NEO. Dr.&nbsp;Ezekowitz has been omitted from the table below since he does not receive any compensation for his services as a member of our board of directors. See the section titled &#147;Certain Relationships and Related Person Transactions&#148;
included elsewhere in this prospectus for more information regarding Dr.&nbsp;Ezekowitz&#146;s compensation for the fiscal year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2023 Director Compensation Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or&nbsp;Paid&nbsp;in<BR>Cash($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abraham Bassan, M.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bernard Coulie, M.D., Ph.D.,
M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jake Simson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Tong, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">As of December&nbsp;31, 2023, Dr.&nbsp;Coulie was the only director holding outstanding equity awards and
held options to purchase an aggregate of 250,000 shares of our common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts reported represent the aggregate grant date fair value of the stock options awarded to our
directors during the fiscal year ended December&nbsp;31, 2023, calculated in accordance with FASB ASC Topic 718, disregarding estimated forfeitures related to service-based vesting. For a description of the assumptions used in determining these
values, see Note 10&#151;&#147;<I>Stock-Based Compensation</I>&#148; to our financial statements included elsewhere in this prospectus. The amount reported in this column reflects the accounting cost for the option and does not correspond to the
actual economic value that may be received by our directors upon the exercise of the stock options or any sale of the underlying shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Coulie joined our board of directors on December&nbsp;7, 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Director Engagement Letters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ms.&nbsp;Shalini Sharp joined our board of directors on January&nbsp;18, 2024. We have entered into director engagement letters
with Dr.&nbsp;Coulie and Ms.&nbsp;Sharp. Pursuant to these engagement letters, each such director received an initial stock option grant for the purchase of 250,000 shares of our common stock that vests in 16 equal quarterly installments over four
years, subject to continued service through each applicable vesting date. The stock options are subject to full accelerated vesting upon a &#147;sale event&#148; (as defined in the 2021 Plan). In addition, pursuant to their respective director
engagement letter, Dr.&nbsp;Coulie and Ms.&nbsp;Sharp are each entitled to receive an annual cash retainer of $30,000, payable quarterly. Dr.&nbsp;Coulie&#146;s first payment occurred in January 2024. Each such director is eligible to receive
reimbursement for their reasonable expenses incurred in attending board of directors&#146; meetings in accordance with our generally applicable reimbursement policies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Non-Employee Director Compensation Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, our board of directors intends to adopt a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy, to be effective as of the date on which the registration statement of which this prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
forms a part is declared effective by the SEC. The policy will be designed to enable us to attract and retain, on a long-term basis, highly qualified
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Under the policy, our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will be eligible to receive cash retainers (which will be payable quarterly in arrears and prorated
for partial years of service) and equity awards as set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annual Retainer for Board Membership:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for <FONT STYLE="white-space:nowrap">non-executive</FONT> chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Additional Annual Retainer for Committee Membership:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audit Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Nominating and Corporate Governance Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation
policy will provide that, upon initial election or appointment to our board of directors, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will be granted an equity award consisting of a stock option grant with a value of
$&#8195;&#8195;&#8195;&#8195; (Director Initial Grant). The Director Initial Grant will vest in equal monthly installments over three years following the grant date, subject to continued service through the applicable vesting date. Furthermore, on
the date of each annual meeting of stockholders following the completion of this offering, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who continues as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director following
such meeting will be granted an annual equity award with a value of $&#8195;&#8195;&#8195;&#8195;(Director Annual Grant). The Director Annual Grant will vest in full upon the earlier of (i)&nbsp;the first anniversary of the date of grant or
(ii)&nbsp;the date of the next annual meeting of our stockholders, subject to continued service through the applicable vesting date. If a <FONT STYLE="white-space:nowrap">non-employee</FONT> director joins our board of directors on a date other than
the date of the annual meeting of our stockholders, then in lieu of the Director Annual Grant, such <FONT STYLE="white-space:nowrap">non-employee</FONT> director will be granted a prorated portion of the Director Annual Grant corresponding to such
partial year of service at the next annual meeting of stockholders. The Director Initial Grant and the Director Annual Grant are subject to full accelerated vesting upon the sale of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The aggregate amount of compensation, including both equity compensation and cash compensation, paid to any <FONT
STYLE="white-space:nowrap">non-employee</FONT> director for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director in a calendar year period will not exceed $&#8195;&#8195;&#8195;&#8195; in the first calendar year such individual
becomes a <FONT STYLE="white-space:nowrap">non-employee</FONT> director and $&#8195;&#8195;&#8195;&#8195; in any other calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will reimburse all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
expenses incurred by directors for their attendance at meetings of our board of directors or any committee thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Employee directors will receive no additional compensation for their service as a director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a description of transactions or series of transactions since January&nbsp;1, 2022, to which we were or will
be a party, in which:<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets
at <FONT STYLE="white-space:nowrap">year-end</FONT> for the last two completed fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of our directors, executive officers or holders of more than 5% or more of our outstanding capital stock,
or any immediate family member of, or person sharing the household with, any of these individuals or entities or affiliated entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Compensation arrangements for our named executive officers and our directors are described in the sections titled
&#147;Director Compensation&#148; and &#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Private Placement of Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Series A Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2021 and 2022, we issued and sold an aggregate of 75,000,000 shares of our Series A convertible preferred stock in two
closings, at a purchase price of $1.00 per share, for an aggregate purchase price of $75.0&nbsp;million. Included in this amount was $14.7&nbsp;million of the then outstanding principal and interest on convertible promissory notes issued to Third
Rock Ventures V, L.P. in 2020 and 2021, all of which converted into Series A convertible preferred stock in this financing in accordance with their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of our Series A convertible preferred stock will automatically convert into one share of our common stock
immediately prior to the completion of this offering. The following table summarizes purchases of our Series A convertible preferred stock as described above by related parties: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Stockholder<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;A&nbsp;Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Rock Ventures V, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,250,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samsara BioCapital, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value
Fund<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Additional details regarding these stockholders and their equity holdings are included in the section titled
&#147;Principal Stockholders.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Entities affiliated with Third Rock Ventures beneficially own more than 5% of our outstanding capital stock.
Dr.&nbsp;Tong and Dr.&nbsp;Ezekowitz, members of our board of directors, were designated to our board of directors by Third Rock Ventures and serve as Partner and Advisory Partner at Third Rock Ventures, respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">$26,593,667 of the total purchase price was funded in cash and $14,656,333 was funded by the conversion of
Third Rock Ventures V, L.P.&#146;s convertible promissory notes (inclusive of principal and accrued interest). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Samsara beneficially owns more than 5% of our outstanding capital stock. Mr.&nbsp;Bassan, a member of our
board of directors, was designated to our board of directors by Samsara and is a Principal at Samsara. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents (i) 2,968,200 shares of our Series A convertible preferred stock purchased by Biotechnology Value
Fund II, L.P. (BVF II), (ii) 4,077,015 shares of our Series A convertible preferred stock purchased by Biotechnology Value Fund, L.P. (BVF) and (iii) 454,785 shares of our Series A convertible preferred stock purchased by Biotechnology Value Trading
Fund OS LP (BVF Trading Fund OS and, together with BVF II and BVF, Biotechnology Value Fund). Entities affiliated with Biotechnology Value Fund collectively beneficially own more than 5% of our outstanding capital stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Series B Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2023 and 2024, we issued and sold an aggregate of 121,657,452 shares of our Series B convertible preferred stock at a
purchase price of $1.23297 per share for an aggregate purchase price of $150.0&nbsp;million in multiple closings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each
outstanding share of our Series B convertible preferred stock will convert into one share of our common stock immediately prior to the completion of this offering. The following table summarizes the shares of our Series B convertible preferred stock
issued to our related parties: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Stockholder<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B&nbsp;Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Rock Ventures VI, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,737,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,499,999.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA
Capital<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,331,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,999,999.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,165,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,999,999.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Goldman<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,165,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,999,999.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samsara BioCapital, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,516,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,499,999.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,082,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,499,999.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value
Fund<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,055,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,999,999.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Additional details regarding these stockholders and their equity holdings are included in the section titled
&#147;Principal Stockholders.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Entities affiliated with Third Rock Ventures beneficially own more than 5% of our outstanding capital stock.
Dr.&nbsp;Tong and Dr.&nbsp;Ezekowitz, members of our board of directors, were designated to our board of directors by Third Rock Ventures and serve as Partner and Advisory Partner at Third Rock Ventures, respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents (i) 14,598,896 shares of our Series B convertible preferred stock purchased by RA Capital
Healthcare Fund, L.P. (RA Capital Healthcare) and (ii) 9,732,596 shares of our Series&nbsp;B convertible preferred stock purchased by RA Capital Nexus Fund III, L.P. (RA Capital Nexus and, together with RA Capital Healthcare, RA Capital).
Dr.&nbsp;Simson, a member of our board of directors, was designated to our board of directors by RA Capital and is a Partner at RA Capital. Entities affiliated with RA Capital collectively beneficially own more than 5% of our outstanding capital
stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents (i)&nbsp;2,846,638 shares of our Series B convertible preferred stock purchased by Special
Situations 2022, L.P., (ii)&nbsp;2,233,760 shares of our Series B convertible preferred stock purchased by West Street Life Sciences&nbsp;I, LP, (iii)&nbsp;1,587,908 shares of our Series B convertible preferred stock purchased by WSLS Emp Onshore
Investments, L.P., (iv) 1,560,292 shares of our Series&nbsp;B convertible preferred stock purchased by Broad Street Principal Investments LLC, (v)&nbsp;598,990 shares of our Series&nbsp;B convertible preferred stock purchased by WSLS Emp Offshore
Investments, L.P., (vi)&nbsp;2,129,548 shares of our Series&nbsp;B convertible preferred stock purchased by WSLS Offshore Investments, SLP, and (vii) 1,208,610 shares of our Series&nbsp;B convertible preferred stock purchased by Special Situations
2022 Offshore Holdings II, L.P. (collectively, Goldman). Entities affiliated with Goldman collectively beneficially own more than 5% of our outstanding capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Samsara beneficially owns more than 5% of our outstanding capital stock. Mr.&nbsp;Bassan, a member of our
board of directors, was designated to our board of directors by Samsara and is a Principal at Samsara. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents (i)&nbsp;1,665,002 shares of our Series&nbsp;B convertible preferred stock purchased by
BVF&nbsp;II, (ii)&nbsp;2,196,680 shares of our Series&nbsp;B convertible preferred stock purchased by BVF and (iii)&nbsp;193,566 shares of our Series&nbsp;B convertible preferred stock purchased by BVF Trading Fund OS. Entities affiliated with
Biotechnology Value Fund collectively beneficially own more than 5% of our outstanding capital stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Agreements with Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Financing Agreements with Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with our Series A and B convertible preferred stock financings, we entered into an investors&#146; rights
agreement and stockholders agreement containing registration rights, information rights, voting rights, and rights of first refusal, among other things, with certain holders of our convertible preferred stock and certain holders of our common stock,
including holders of more than 5% of our capital stock and entities with which certain of our directors and officers are affiliated. Pursuant to our amended and restated investors&#146; rights agreement (as amended, the investor rights agreement),
entities affiliated with Biotechnology Value Fund and RA Capital were each granted the right to designate a board observer in a nonvoting capacity, which right will terminate upon the completion of this offering. These agreements will terminate upon
the completion of this offering, except for the registration rights granted under the investor rights agreement, as more fully described in &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Management Rights Letters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with our Series A and B convertible preferred stock financings, we entered into management rights letters with
certain purchasers of our convertible preferred stock, including holders of more than 5% of our capital stock and entities with which certain of our directors or officers are affiliated, pursuant to which such entities were granted
certain&nbsp;management&nbsp;rights, including the right to consult with and advise our management on significant business issues, review our operating plans, examine our books and records and inspect our facilities. These management rights letters
will terminate upon completion of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Side Letter with Goldman </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with our Series B convertible preferred stock financing, we entered into a side letter agreement (Goldman side
letter) with entities affiliated with Goldman Sachs &amp; Co. LLC (Goldman), which collectively hold more than 5% of our outstanding capital stock. Pursuant to the Goldman side letter, Goldman was granted the right to designate a board observer in a
nonvoting capacity, which right will terminate upon the completion of this offering. Certain of our obligations under the Goldman side letter will remain in effect after the completion of this offering, including our obligations to defend, indemnify
and hold Goldman harmless for any damages, liabilities, losses, taxes, fines, penalties and reasonable costs and expenses arising out of third-party or governmental claims related to Goldman&#146;s status as a securityholder, subject to certain
limitations and exceptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Service Agreement with Third Rock Ventures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third Rock Ventures, a beneficial owner of more than 5% of our outstanding capital stock, has provided us with certain
consulting services, including without limitation, business, technical, financial, IT, and scientific advice related to our business pursuant to a service agreement with Third Rock Ventures, dated August&nbsp;25, 2021 (TRV service agreement).
Dr.&nbsp;Finer, our President, Chief Executive Officer and a member of our directors, is a Venture Partner at Third Rock Ventures. In addition, Dr.&nbsp;Tong, a member of our board of directors, and Dr.&nbsp;Ezekowitz, a member of our board of
directors and our interim Chief Medical Officer, were designated to our board of directors by Third Rock Ventures and are each affiliated with Third Rock Ventures. Dr.&nbsp;Ezekowitz did not receive any cash compensation from us for his service as
our interim Chief Medical Officer, as his services were provided to us through the TRV service agreement. For the fiscal years ended December&nbsp;31, 2022 and 2023, we incurred costs totaling $1.3&nbsp;million and $0.3&nbsp;million, respectively,
for the services provided to us by Third Rock Ventures, which included, among other things, the services of Dr.&nbsp;Ezekowitz in his capacity as our interim Chief Medical Officer. Drs. Tong and Ezekowitz did not receive any cash compensation from
us for their services as members of our board of directors. Of the total fees we incurred under the TRV service agreement in the fiscal years ended December&nbsp;31, 2022 and 2023, $253,500 and $239,000, respectively, were attributed to
Dr.&nbsp;Ezekowitz&#146;s support in his capacity as our interim Chief Medical Officer. Additionally, as compensation for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Dr. Ezekowitz&#146;s services as our interim Chief Medical Officer, we granted him options to purchase 100,000&nbsp;shares of our common stock during the year ended December 31, 2022, and 230,000
shares of our common stock during the year ended December 31, 2023, at exercise prices of $0.18 and $0.32 per share, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Employment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into offer letter agreements with certain of our executive officers and granted stock options to our executive
officers, as more fully described in the section titled &#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Equity Grants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted stock options and restricted stock awards to purchase shares of our common stock to certain of our executive
officers and directors. For more information regarding the stock options granted to our executive officers and directors, see the sections titled &#147;Executive Compensation&#148; and &#147;Director Compensation&#148; included elsewhere in this
prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we intend to enter into new agreements to indemnify our directors and executive officers.
These agreements will, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#146; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding,
including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#146;s status as a member of our board of directors to the maximum extent allowed under Delaware law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Policies for Approval of Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors reviews and approves transactions with directors, executive officers, and holders of 5% or more of our
voting securities and their affiliates, each a related party. Prior to this offering, the material facts as to the related party&#146;s relationship or interest in the transaction were disclosed to our board of directors prior to their consideration
of such transaction, and the transaction was not considered approved by our board of directors unless a majority of the directors who are not interested in the transaction approved the transaction. Further, when stockholders are entitled to vote on
a transaction with a related party, the material facts of the related party&#146;s relationship or interest in the transaction were disclosed to the stockholders, who must approve the transaction in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we expect to adopt a written related party transactions policy that will provide that such
transactions must be approved by our audit committee. This policy will become effective upon effectiveness of our registration statement. Pursuant to this policy, the audit committee has the primary responsibility for reviewing and approving or
disapproving &#147;related party transactions,&#148; which are transactions between us and related parties in which the aggregate amount involved exceeds or may be expected to exceed $120,000 (or, if less, 1% of the average of our total assets in a
fiscal year) and in which a related party has or will have a direct or indirect material interest. For purposes of this policy, a related party will be defined as a director, executive officer, nominee for director, or greater than 5% beneficial
owner of our common stock, in each case since the beginning of the most recently completed year, and their immediate family members. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth, as of &#8195;&#8195;&#8195;&#8195;, 2024, information regarding beneficial ownership of our
common stock by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our current directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The information in the following table is calculated based on&#8195;&#8195;&#8195;&#8195; shares
(including&#8195;&#8195;&#8195;&#8195; &#8195; shares of unvested restricted common stock subject to repurchase or forfeiture) of our common stock deemed to be outstanding before this offering and&#8195;&#8195;&#8195;&#8195; shares of our common
stock outstanding after this offering, assuming no exercise by the underwriters of their option to purchase additional shares of our common stock. The number of shares outstanding is based on the number of shares of our common stock outstanding
(including&#8195;&#8195;&#8195;&#8195; shares of unvested restricted common stock subject to repurchase or forfeiture) as of &#8195;&#8195;&#8195;&#8195;, 2024, as adjusted to give effect to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of
&#8195;&#8195;&#8195;&#8195;shares of our common stock immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sale of&#8195;&#8195;&#8195;&#8195; shares of our common stock in this offering (assuming no exercise of
the underwriters&#146; option to purchase additional shares). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each individual or entity shown on the
table has furnished information with respect to beneficial ownership. Except as otherwise indicated below, the address of each officer, director and 5% stockholder listed below is c/o Septerna, Inc., 250 East Grand Avenue, South San Francisco,
California 94080. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have determined beneficial ownership in accordance with the rules of the
SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with
respect to those securities as well as any shares of our common stock that the person has the right to acquire within 60 days of &#8195;&#8195;&#8195;&#8195;, 2024 through the exercise of stock options or other rights. These shares are deemed to be
outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other
person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of</B><br><B>Common&nbsp;Stock<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares</B><br><B>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or Greater Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Third Rock Ventures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA Capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samsara BioCapital, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Goldman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors, Named Executive Officers and Other</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Finer, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liz Bhatt, M.S., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samira Shaikhly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Long, D.Phil.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Uwe Klein, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Tong, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abraham Bassan, M.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bernard Coulie, M.D., Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alan Ezekowitz, M.D., D. Phil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shalini Sharp, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jake Simson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All executive officers and directors as a group</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(11 persons)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>*</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B></B>Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The following description of our capital stock and certain provisions of our amended and restated certificate of
incorporation and amended and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and the amended
and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part. Copies of these documents have been filed with the SEC as exhibits to our registration statement, of which
this prospectus forms a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will be in effect on the completion of this offering. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon filing of our amended and restated certificate of incorporation and the completion of this offering, our authorized
capital stock will consist of &#8195;&#8195;&#8195;&#8195;shares of our common stock, par value $0.001 per share, and shares of preferred stock, par value $0.001 per share, all of which shares of preferred stock will be undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of &#8195;&#8195;&#8195;&#8195;, 2024, there were &#8195;&#8195;&#8195;&#8195;shares of our common stock outstanding
(including shares of unvested restricted common stock subject to repurchase or forfeiture) and held of record by stockholders. This amount assumes the conversion of all outstanding shares of our convertible preferred stock
into&#8195;&#8195;&#8195;&#8195;shares of our common stock, which will occur immediately prior to the completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the
stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose,
subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in
all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Immediately prior to the completion of this offering, all outstanding shares of our convertible preferred stock will be
converted into shares of our common stock. Upon the completion of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to&#8195;&#8195;&#8195;&#8195;shares of preferred stock in one
or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking
fund terms, and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of
common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our
Company or other corporate action. Immediately after completion of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of &#8195;&#8195;&#8195;&#8195;, 2024, &#8195;&#8195;&#8195;&#8195;shares of our common stock were issuable upon the
exercise of outstanding stock options under the 2021 Plan, at a weighted-average exercise price of $&#8195;&#8195;&#8195;&#8195;per share; no shares of our common stock were issuable upon exercise of outstanding stock options outside of our 2021
Plan; and &#8195;&#8195;&#8195;&#8195;shares of our common stock were reserved for future issuance under the 2024 Plan, which will become effective once the registration statement of which this prospectus forms a part is declared effective, as well
as any future automatic annual increases in the number of shares of our common stock reserved for issuance under the 2024 Plan and any shares underlying outstanding stock awards granted under the 2021 Plan that expire or are repurchased, forfeited,
cancelled, or withheld. For additional information regarding terms of our equity incentive plans, see the section titled &#147;Executive Compensation&#151;Employee Benefit and Equity Compensation Plans.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, certain holders of our common stock, including those issuable upon the conversion of our
preferred stock, will be entitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of the investor rights agreement between us and the holders of our preferred stock.
The investor rights agreement includes demand registration rights, short-form registration rights, and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling
expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Beginning six months after the effective date of this registration statement, certain holders of our common stock, including
common stock issuable upon the conversion of shares of our preferred stock upon the completion of this offering, are entitled to demand registration rights. Under the terms of the investor rights agreement, upon the written request of stockholders
holding at least 25% of the securities eligible for registration then outstanding to file a registration statement with respect to at least 25% of the securities eligible for registration then outstanding, having an anticipated aggregate offering
price, net of related fees and expenses, of at least $5.0&nbsp;million, we will be required to file a registration statement within 60 days of such request covering all securities eligible for registration that our stockholders request to be
included in such registration. We are not required to effect any registration pursuant to this provision of the investor rights agreement (a)&nbsp;during the period that is estimated to be 60 days before and 180 days after the effective date of a
registration statement that we initiate, (b)&nbsp;if we have already effected two registrations pursuant to such requests for registration on Form <FONT STYLE="white-space:nowrap">S-1</FONT> or (c)&nbsp;if the initiating holders propose to register
securities that may be immediately registered on Form <FONT STYLE="white-space:nowrap">S-3.</FONT> The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-1</FONT> is further subject to other specified conditions and
limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Short-Form Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the investor rights agreement, if we are eligible to file a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> upon the written request of stockholders holding at least 10% of the securities eligible for registration then outstanding to file a registration statement with respect to securities having an anticipated
aggregate offering price, net of related fees and expenses, of at least $1.0&nbsp;million, we will be required to file a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement within 45 days of such request covering all securities
eligible for registration that our stockholders request to be included in such registration. We are not required to effect any registration pursuant to this provision of the investor rights agreement (a)&nbsp;during the period that is estimated to
be 30 days before and 90 days after the effective date of a registration statement that we initiate or (b)&nbsp;if we have already effected two registrations pursuant to such requests for registration on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> within the twelve month period immediately preceding the date of such request. The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is further subject to other
specified conditions and limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the investor rights agreement, if we register any of our securities either for our own account or for the account
of other security holders, the holders of our common stock, including common stock issuable upon the conversion of our preferred stock, are entitled to include their shares in the registration. Subject to certain exceptions contained in the investor
rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The investor rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify
holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The demand registration rights and short form registration rights granted under the investor rights agreement will terminate on
the earliest to occur of (a)&nbsp;the closing of certain liquidation events, (b)&nbsp;the fifth anniversary of the completion of this offering or (c)&nbsp;at such time after this offering when the holders&#146; shares may be sold without restriction
pursuant to Rule 144 under the Securities Act (Rule 144) or another similar exemption under the Securities Act within a three month period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ordinarily, other than underwriting discounts and commissions, we are generally required to pay all expenses incurred by us
related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel and reasonable fees and disbursements
of a counsel for the selling security holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Anti-Takeover Effects of Our Certificate of Incorporation and Bylaws and Delaware Law
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some provisions of Delaware law, our amended and restated certificate of incorporation and amended and restated bylaws
include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate
with our board of directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Board Composition and Filling Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation provides for the division of our board of directors into three classes
serving staggered three-year terms, with one class being elected each year. Our amended and restated certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the <FONT
STYLE="white-space:nowrap">holders&nbsp;of&nbsp;two-thirds&nbsp;or&nbsp;more</FONT> of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting
from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors
and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>No Written Consent of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation provides that all stockholder actions are required to be taken by a vote
of the stockholders at an annual or special meeting, and that stockholders may not take any action </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our amended and restated bylaws or
removal of directors by our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Meetings of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and amended and restated bylaws provide that only a majority of the
members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our amended and
restated bylaws will limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Advance Notice Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated bylaws establish advance notice procedures with regard to stockholder proposals relating to the
nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures will provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior
to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the
preceding year. Our amended and restated bylaws specify the requirements as to form and content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special
meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Amendment to Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any amendment of our amended and restated certificate of incorporation must first be approved by a majority of our board of
directors, and if required by law or our amended and restated certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class
entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of
the outstanding shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class. Our amended and restated bylaws may be
amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the amended and restated bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled
to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating to notice of stockholder business and nominations and special meetings must be approved by not less than
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as
a class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation provides for &#8195;&#8195;&#8195;&#8195;authorized shares of preferred
stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due
exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder
approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated certificate of
incorporation grants our board of directors broad </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets
available for distribution to holders of shares of our common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in
control of us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;203 of the Delaware General Corporation Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the DGCL. In general,
Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested
stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or
the transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding, for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of
directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;203 defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, lease, pledge, or other disposition involving the interested stockholder of 10% or more of
the assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any
stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, Section&nbsp;203 defines an
interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Choice of Forum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated bylaws will provide that the Court of Chancery of the State of Delaware is the sole and exclusive
forum for the following claims or causes of action under the Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of, or a claim based on, a breach of a
fiduciary duty owed by any of our current or former directors, officers, or other employees or stockholders to us or our stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
provision of the DGCL or our amended and restated certificate of incorporation or amended and restated bylaws (including the interpretation, validity or enforceability thereof) or as to which the
DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">However, Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any
duty or liability created by the Exchange Act or the rules and regulations thereunder. Consequently, this choice of forum provision would not apply to claims or causes of action brought to enforce a duty or liability created by the Exchange Act or
any other claim for which the federal courts have exclusive jurisdiction or the Securities Act. Moreover, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty
or liability created by the Securities Act or the rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our amended and restated
bylaws will provide that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of
any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be
enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or
certified any part of the documents underlying the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While the Delaware courts have determined that such choice
of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in
those other jurisdictions. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, our amended and restated bylaws will provide that any person or entity holding, owning or otherwise acquiring
any interest in any of our securities shall be deemed to have notice of and consented to these provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Limitations on Liability
and Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See the section titled &#147;Management&#151;Limitations on Liability and Indemnification
Agreements&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Stock Exchange Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to apply to list our common stock on the Nasdaq Global Market under the proposed trading symbol &#147;SEPN,&#148; and
this offering is contingent upon obtaining approval of such listing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The transfer agent and registrar for our common stock will be &#8195;&#8195;&#8195;&#8195;. The transfer agent&#146;s address
is &#8195;&#8195;&#8195;&#8195;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of our
common stock, including shares issued on the exercise of outstanding options, in the public market after this offering, or the possibility of these sales or issuances occurring, could adversely affect the prevailing market price for our common stock
or impair our ability to raise equity capital. Although we intend to apply to list our common stock on the Nasdaq Global Market, we cannot assure you that there will be an active public market for our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the completion of this offering, based on our shares outstanding as of June&nbsp;30, 2024, a total of shares of our
common stock will be outstanding, assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options. Of the outstanding shares, all of the shares sold in this offering will be freely tradable,
except that any shares held by our affiliates, as that term is defined in Rule 144 under the Securities Act, may only be sold in compliance with the limitations described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Rule&nbsp;144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements of
Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90 days, an eligible stockholder is entitled to sell such shares without complying with the manner of sale, volume limitation, or notice provisions of Rule 144, subject to
compliance with the public information requirements of Rule 144. To be an eligible stockholder under Rule 144, such stockholder must not be deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days
preceding a sale and must have beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than our affiliates. If such a person has beneficially owned the shares proposed to be
sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such shares without complying with any of the requirements of Rule 144, subject to the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, under Rule 144, as currently in effect,
our affiliates or persons selling shares on behalf of our affiliates are entitled to sell shares on expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. Beginning 90 days after the date of this prospectus,
within any three-month period, such stockholders may sell a number of shares that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately
&#8195;&#8195;&#8195;&#8195;shares immediately after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares of our common stock from us; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on the Nasdaq Global Market during the four calendar
weeks preceding the filing of a notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales under Rule 144 by
our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Rule&nbsp;701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rule 701 under the Securities Act (Rule 701) generally allows a stockholder who was issued shares under a written compensatory
plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days, to sell these shares in reliance on Rule 144, but without being required to comply with the public information, holding period,
volume limitation, or notice provisions of Rule 144. Rule 701 also permits affiliates of our Company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares,
however, are required by that rule to wait until 90 days after the date of this prospectus before selling those shares under Rule 701, subject to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, all of our directors and executive officers, and the holders of substantially all of our securities have entered into <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters and/or are subject to market standoff agreements or other agreements with us, which prevents us and them, subject among other things and subject to certain exceptions, from
selling any of our securities for a period of not less than 180 days from the date of this prospectus without the prior written consent of J.P. Morgan Securities LLC. See the section titled &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, certain holders of our securities will be entitled to various rights with respect to
registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the
registration. See the section titled &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Equity Incentive Plans
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the
Securities Act to register our shares issued or reserved for issuance under our equity incentive plans. The first such registration statement is expected to be filed soon after the date of this prospectus and will automatically become effective upon
filing with the SEC. Accordingly, shares registered under such registration statement will be available for sale in the open market, unless such shares are subject to vesting restrictions with us or the
<FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described above. As of the date of this prospectus, we estimate that such registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> will cover approximately
&#8195;&#8195;&#8195;&#8195;shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_19"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS <FONT
STYLE="white-space:nowrap">FOR&nbsp;NON-U.S.</FONT> HOLDERS OF COMMON STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following discussion is a summary of
material U.S. federal income tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering. This discussion is based on
the Code, Treasury Regulations promulgated thereunder, published rulings and administrative pronouncements of the U.S. Internal Revenue Service (IRS) and judicial decisions, all as in effect on the date hereof. These authorities are subject to
differing interpretations and may change, possibly retroactively, resulting in U.S. federal income tax consequences different from those discussed below. We have not requested, and do not intend to request, a ruling from the IRS with respect to the
statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This discussion is limited to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders who purchase our common stock pursuant
to this offering and who hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion is not a complete analysis of all potential U.S. federal
income tax consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules under Section&nbsp;451(b) of the Code,
and also does not address any U.S. federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax consequences, such as estate or gift tax consequences, or any tax consequences arising under any state, local or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of such <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s particular circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to
special rules under the U.S. federal income tax laws, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens, or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships, S corporations, or other entities or arrangements treated as partnerships, pass-through
entities, or disregarded entities (including hybrid entities) for U.S. federal income tax purposes (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations&#148; within the meaning of Section&nbsp;957(a) of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;passive foreign investment companies&#148; within the meaning of Section&nbsp;1297(a) of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, financial institutions, investment companies, insurance companies, brokers, dealers or traders in
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts or regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that have elected to mark securities to market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations (including private foundations), and
governmental organizations, or international organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquire our common stock through the exercise of employee stock options or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquire our common stock through the exercise of warrants or conversion rights under convertible
instruments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our common stock as &#147;qualified small business stock&#148; under Section&nbsp;1202 of
the Code or &#147;Section&nbsp;1244 stock&#148; under Section&nbsp;1244 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">qualified foreign pension funds as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that elect to apply <FONT STYLE="white-space:nowrap">Section&nbsp;1400Z-2</FONT> of the Code to gains
recognized with respect to shares of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that acquired our common stock in a transaction subject to the gain rollover provisions of the Code
(including Section&nbsp;1045 of the Code); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own, or have owned, actually or constructively, more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who have elected to mark securities to market; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedging or conversion transaction or straddle, or synthetic
security or a constructive sale, or other risk reduction strategy or integrated investment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If an
entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds our common stock, the U.S. federal income tax treatment of a partner in the partnership generally will depend on the status of the partner, the
activities of the partnership and certain determinations made at the partner level. Partnerships holding our common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax
consequences to them of owning and disposing of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND
IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER
ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS OR UNDER ANY APPLICABLE INCOME TAX TREATY. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Definition of <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is any beneficial owner of our
common stock that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or any organization taxable as a corporation for U.S. federal income taxes that is not created
or organized under the laws of the United States, any state thereof, or the District of Columbia; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign trust or estate, the income of which is not subject to U.S. federal income tax on a net income
basis. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As described under &#147;Dividend Policy,&#148; we do not currently anticipate declaring or paying, for the foreseeable future,
any distributions on our capital stock. However, if we were to distribute cash or other property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or
accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and will first be applied against and reduce a
holder&#146;s tax basis in our common stock, but not below zero. Any excess will be treated as gain realized on the sale or other disposition of our common stock and will be treated as described under &#147;&#151;Gain on sale or other taxable
disposition of our common stock&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussions below regarding effectively connected income,
backup withholding and FATCA (as defined below), dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the
dividends or such lower rate specified by an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
applicable income tax treaty. To receive the benefit of a reduced treaty rate, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must furnish us or our withholding agent with a valid IRS
Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> (in the case of individuals) or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the case of entities), or other appropriate form, certifying
such holder&#146;s qualification for the reduced rate. This certification must be provided to us or our withholding agent before the payment of the dividends and must be updated periodically. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder holds our common stock through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to provide
appropriate documentation to the agent, which then will be required to provide certification to us or our withholding agent, either directly or through other intermediaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock in connection with the conduct of a trade
or business in the United States, and dividends paid on our common stock are effectively connected with such holder&#146;s U.S. trade or business (and, if required by an applicable tax treaty, are attributable to such holder&#146;s permanent
establishment or fixed base in the United States), the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be exempt from U.S. federal withholding tax. To claim the exemption, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder generally must furnish a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form), certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
Holder&#146;s conduct of a trade or business within the United States to the applicable withholding agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">However, any
such effectively connected dividends paid on our common stock generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United
States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively
connected earnings and profits for the taxable year, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not provide the required certification on a timely basis, but
that qualify for a reduced treaty rate, may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors
regarding any applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Gain on Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussions below regarding backup withholding and FATCA (as defined below), a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to U.S. federal income tax on any gain realized on the sale or other taxable disposition of our common stock, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
conduct of a trade or business in the United States and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the
United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present
in the United States for a period or periods aggregating 183 days or more during the taxable year of the disposition, and certain other requirements are met; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a &#147;United States real property interest&#148; by reason of our status as a
United States real property holding corporation (USRPHC) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
holding period for our common stock, and our common stock is not &#147;regularly traded&#148; on an established securities market within the meaning of applicable U.S. Treasury regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at
the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an additional branch
profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gain described in the second bullet point above will be subject to U.S.
federal income tax at a flat 30% rate (or such lower rate specified by an applicable income tax treaty), but may be offset by certain U.S.- source capital losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (even though the
individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Determining whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair
market value of our worldwide real property interests and our other trade or business assets. We believe that we are not currently and we do not anticipate becoming a USRPHC for U.S. federal income tax purposes, although there can be no assurance we
will not in the future become a USRPHC. Even if we are treated as a USRPHC, gain realized by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder on a disposition of our common stock will not be subject to U.S. federal income tax so long as
(1)&nbsp;the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder owned, directly, indirectly and constructively, no more than 5% of our common stock at all times within the shorter of (a)&nbsp;the five-year period preceding the disposition or
(b)&nbsp;the holder&#146;s holding period and (2)&nbsp;our common stock is &#147;regularly traded&#148; on an established securities market within the meaning of applicable U.S. Treasury regulations. There can be no assurance that our common stock
qualifies as regularly traded on an established securities market for purposes of the rules described above. Prospective investors are encouraged to consult their own tax advisors regarding the possible consequences to them if we are, or were to
become, a USRPHC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding
any applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Annual reports are required to be filed with the IRS and provided to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder indicating the amount of distributions on our common stock paid to such holder and the amount of any tax withheld with respect to those distributions. These information reporting requirements apply even if no withholding was required (because
the distributions were effectively connected with the holder&#146;s conduct of a U.S. trade or business, or withholding was reduced or eliminated by an applicable income tax treaty) and regardless of whether such distributions constitute dividends.
This information also may be made available under a specific treaty or agreement with the tax authorities in the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is established. Backup withholding, currently at
a 24% rate, generally will not apply to payments to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of distributions on or the gross proceeds of a disposition of our common stock provided the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder furnishes the required certification for its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS
Form <FONT STYLE="white-space:nowrap">W-8BEN-E</FONT> or IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption, and if the payor does not have actual knowledge, or reason to know, that the holder is a U.S.
person who is not an exempt recipient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Backup withholding is not an additional tax. If any amount is withheld under the
backup withholding rules, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder should consult with a U.S. tax advisor regarding the possibility of and procedure for obtaining a refund or a credit against the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Withholding on Foreign
Entities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sections 1471 through 1474 of the Code, which are commonly referred to as FATCA, impose a U.S. federal
withholding tax of 30% on certain payments made to a &#147;foreign financial institution&#148; (as specially defined under these rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to
collect and provide to the U.S. tax authorities substantial information regarding certain U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are
foreign entities with U.S. owners) or an exemption applies. FATCA also generally imposes a U.S. federal withholding tax of 30% on certain payments made to a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (as
specially defined under these rules) unless such entity provides the withholding agent a certification that it does not have any &#147;substantial United States owners&#148; or provides information identifying certain direct and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
indirect U.S. owners of the entity or an exemption applies. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Under certain
circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of such taxes. FATCA currently applies to dividends paid on our common stock and would have applied also to payments of gross proceeds
from the sale or other disposition of our common stock. However, proposed regulations under FATCA provide for the elimination of the federal withholding tax of 30% applicable to gross proceeds of a sale or other disposition of from property of a
type that can produce U.S. source dividends or interest. Under these proposed Treasury Regulations (which may be relied upon by taxpayers prior to finalization), FATCA withholding does not apply to gross proceeds from sales or other dispositions of
our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prospective investors are encouraged to consult with their tax advisors regarding the possible
implications of FATCA on their investment in our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR
REGARDING THE TAX CONSEQUENCES OF OWNING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT AND PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL,
<FONT STYLE="white-space:nowrap">NON-U.S.</FONT> OR U.S. FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are offering the shares of our common stock described in this prospectus through a number of underwriters. J.P. Morgan
Securities LLC, TD Securities (USA) LLC, Cantor Fitzgerald&nbsp;&amp; Co. and Wells Fargo Securities, LLC are acting as joint book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting
agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting
discounts and commissions set forth on the cover page of this prospectus, the number of shares of our common stock listed next to its name in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters are committed to purchase all the shares of our common stock offered by us if
they purchase any shares. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be
terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters propose to offer the common stock directly to the public at the initial public offering
price set forth on the cover page of this prospectus and to certain dealers at that price less a concession not in excess of $&#8195;&#8195;&#8195;&#8195;per share. After the initial offering of the shares to the public, if all of the shares of our
common stock are not sold at the initial public offering price, the underwriters may change the offering price and the other selling terms. Sales of any shares made outside of the United States may be made by affiliates of the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters have an option to buy up to&#8195;&#8195;&#8195;&#8195;additional shares of our common stock from us to cover
sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30 days from the date of this prospectus to exercise this option to purchase additional shares. If any shares are purchased
with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of our common stock are purchased, the underwriters will offer the
additional shares on the same terms as those on which the shares are being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriting fee is equal to the
public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is $&#8195;&#8195;&#8195;&#8195;per share. The following table shows the per share and total underwriting
discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without&nbsp;Option<BR>to Purchase<BR>Additional<BR>Shares Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With&nbsp;Full&nbsp;Option<BR>to Purchase<BR>Additional</B><br><B>Shares Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that the total expenses of this offering, including registration, filing and
listing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $&#8195;&#8195;&#8195;&#8195;. We have agreed to reimburse the underwriters for expenses relating to the
clearance of this offering with the Financial Industry Regulatory Authority, Inc. in an amount up to $&#8195;&#8195;&#8195;&#8195;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A prospectus in electronic format may be made available on the web sites
maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account
holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have agreed that we will not, subject to certain exceptions, (i)&nbsp;offer, pledge, sell, contract to sell, sell any
option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, hedge, lend, or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the SEC a registration
statement under the Securities Act relating to, any shares of our common stock or any securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii)&nbsp;enter into any swap, hedging, or other agreement that
transfers, in whole or in part, any of the economic consequences of ownership of any shares of common stock or any such other securities, or publicly disclose the intention to undertake any of the foregoing (regardless of whether any of these
transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC for a period of 180 days after the date of this
prospectus, other than the shares of our common stock to be sold in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The restrictions on our actions, as
described above, do not apply to certain transactions, including (i)&nbsp;the issuance of shares of our common stock or securities convertible into or exercisable for shares of our common stock pursuant to the conversion or exchange of convertible
or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement of restricted stock units (RSUs) (including net settlement), in each case outstanding on the date of the underwriting agreement and
described in this prospectus; (ii)&nbsp;grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of our common stock or securities convertible into or exercisable or exchangeable for shares of
our common stock (whether upon the exercise of stock options or otherwise) to our employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the closing date of this offering and
described in this prospectus, provided that such recipients enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters; (iii)&nbsp;the issuance of up to 5% of the outstanding shares of our common stock, or
securities convertible into, exercisable for, or which are otherwise exchangeable for, common stock, immediately following the closing date of this offering, in acquisitions or other similar strategic transactions, provided that such recipients
enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters; or (iv)&nbsp;the filing of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted
pursuant to any plan in effect on the date of the underwriting agreement and described in this prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our directors and executive officers, and substantially all of our securityholders (such persons, the <FONT
STYLE="white-space:nowrap">lock-up</FONT> parties) have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each
<FONT STYLE="white-space:nowrap">lock-up</FONT> party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the restricted period), may not and may not cause any of their direct or indirect affiliates to,
without the prior written consent of J.P. Morgan Securities LLC, (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend,
or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including without limitation, our common stock or such other
securities which may be deemed to be beneficially owned by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or
warrant) (collectively with the common stock, the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities), (ii) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences
of ownership of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities,
in cash or otherwise, (iii)&nbsp;make any demand for or exercise any right with respect to the registration of any the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, or (iv)&nbsp;publicly disclose the intention to do any of the
foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such persons or entities have further acknowledged that these undertakings
preclude them from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other
derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party or any other person) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such
transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise. Such persons or entities further confirm that they have furnished
the representatives with the details of any transaction such persons or entities, or any of their respective affiliates, is a party to as of the date hereof, which transaction would have been restricted by the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements if it had been entered into by such persons or entities during the restricted period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The restrictions described in the immediately preceding paragraph and contained in the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between the underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply, subject in certain cases to various conditions, to certain transactions, including
(a)&nbsp;transfers or dispositions of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities: (i)&nbsp;as bona fide gifts or charitable contribution, or for bona fide estate planning purposes, (ii)&nbsp;by will or intestacy or any other
testamentary document, (iii)&nbsp;to any member of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#146;s immediate family or to any trust for the direct or indirect benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or
the immediate family of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a trust, to a trustor, trustee or beneficiary of the trust or to the estate of a trustor, trustee
or beneficiary of such trust, (iv)&nbsp;to a corporation, partnership, limited liability company, investment fund, or other entity (A)&nbsp;of which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party and its immediate family members are the
legal and beneficial owner of all of the outstanding equity securities or similar interests, or (B)&nbsp;controlled by, or under common control or common investment management with, the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or the
immediate family of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, (v)&nbsp;to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i)&nbsp;through (iv) above, (vi)&nbsp;in
the case of a corporation, partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control or common investment management with the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party or its affiliates or (B)&nbsp;as part of a distribution to limited partners, members or stockholders of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party; (vii)&nbsp;by operation of law,
(viii)&nbsp;to us from the <FONT STYLE="white-space:nowrap">lock-up</FONT> party upon death or disability, or if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is an employee of us, upon death, disability or termination of employment of
such employee, (ix)&nbsp;as part of a sale of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities acquired (A)&nbsp;from the underwriters in this offering or (B)&nbsp;in open market transactions after the completion of this offering,
(x)&nbsp;to us in connection with the vesting, settlement or exercise of RSUs, options, warrants or other rights to purchase shares of our common stock (including &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of
exercise price and tax and remittance payments, or (xi)&nbsp;pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction approved by our board of directors and made to all stockholders involving a change in
control, provided that if such transaction is not completed, all such <FONT STYLE="white-space:nowrap">lock-up</FONT> securities would remain subject to the restrictions in the immediately preceding paragraph; (b)&nbsp;exercise of the options,
settlement of RSUs or other equity awards, or the exercise of warrants granted pursuant to plans described in this prospectus, provided that any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities received upon such exercise, vesting or
settlement would be subject to restrictions similar to those in the immediately preceding paragraph; (c)&nbsp;the conversion of outstanding preferred stock, warrants to acquire preferred stock, or convertible securities into shares of our common
stock or warrants to acquire shares of our common stock, provided that any common stock or warrant received upon such conversion would be subject to restrictions similar to those in the immediately preceding paragraph; and (d)&nbsp;the establishment
or amendment by <FONT STYLE="white-space:nowrap">lock-up</FONT> parties of trading plans under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, provided that (1)&nbsp;such plan does not provide for the transfer of <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities during the restricted period and (2)&nbsp;no filing by any party under the Exchange Act or other public announcement shall be made voluntarily in connection with the establishment or amendment of
such trading plans pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1,</FONT> provided that if a filing under the Exchange Act or other public announcement is required, such announcement or filing shall include a statement to the effect that
no transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities may be made under such trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> during the restricted period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">J.P. Morgan Securities LLC, in its sole discretion, may release the
securities subject to any of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters described above, in whole or in part at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to apply to have our common stock approved for listing on the Nasdaq Global Market under the symbol
&#147;SEPN,&#148; and this offering is contingent upon obtaining approval of such listing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this
offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of our common stock in the open market for the purpose of preventing or retarding a decline in the market price of the
common stock while this offering is in progress. These stabilizing transactions may include making short sales of common stock, which involves the sale by the underwriters of a greater number of shares of our common stock than they are required to
purchase in this offering, and purchasing shares of our common stock on the open market to cover positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the
underwriters&#146; option to purchase additional shares referred to above, or may be &#147;naked&#148; shorts, which are short positions in excess of that amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in
whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the
underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open
market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters have advised us that, pursuant to Regulation M of the Securities Act, they may also engage in other
activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing
transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding
a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them
at any time. The underwriters may carry out these transactions on Nasdaq, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our common stock. The initial public offering price will be
determined by negotiations between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of factors including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information set forth in this prospectus and otherwise available to the representatives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our prospects and the history and prospects for the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assessment of our management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our prospects for future earnings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the general condition of the securities markets at the time of this offering; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors deemed relevant by the underwriters and us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither we nor the underwriters can assure investors that an active trading market will develop for shares of our common
stock, or that the shares will trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time
to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees
and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions
in our debt or equity securities or loans, and may do so in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the
securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material
or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction.
Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a
solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in the European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to each Member State of the European Economic Area (each a Relevant State), no shares have been offered or will be
offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in
another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following
exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the
Prospectus Regulation), subject to obtaining the prior consent of the underwriters; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of
the underwriters and to us that it is a &#147;qualified investor&#148; within the meaning of Article 2(e) of the Prospectus Regulation. In the case of any shares being offered to a financial intermediary as that term is used in the Prospectus
Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances
which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters have been obtained to each such
proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this provision, the expression an &#147;offer to the public&#148; in
relation to shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any
shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in
the United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No shares have been offered or will be offered pursuant to the offering to the public in the
United Kingdom prior to the publication of a prospectus in relation to the shares which (i)&nbsp;has been approved by the Financial Conduct Authority or (ii)&nbsp;is to be treated as if it had been approved by the Financial Conduct Authority in
accordance with the transitional provisions in Article 74 (transitional provisions) of the Prospectus Amendment etc (EU Exit) Regulations 2019/1234, except that the shares may be offered to the public in the United Kingdom at any time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus
Regulation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the
UK Prospectus Regulation), subject to obtaining the prior consent of underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in any other circumstances falling within Section&nbsp;86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of the shares shall require us or any underwriter to publish a prospectus pursuant to Section&nbsp;85 of the FSMA
or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the shares in the United Kingdom means the communication in any
form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#147;UK Prospectus Regulation&#148; means
Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus
Regulation)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order) and/or (ii)&nbsp;who are
high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;) or otherwise in
circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this
document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing
Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or
damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the
purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B></B><B><I>Notice to Prospective Investors in Switzerland</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus does not constitute an offer to the public or a solicitation to purchase or invest in any shares. No shares
have been offered or will be offered to the public in Switzerland, except that offers of shares may be made to the public in Switzerland at any time under the following exemptions under the Swiss Financial Services Act (FinSA): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to any person which is a professional client as defined under the FinSA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to fewer than 500 persons (other than professional clients as defined under the FinSA), subject to obtaining
the prior consent of the representatives of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in any other circumstances falling within Article 36 FinSA in connection with Article 44 of the Swiss
Financial Services Ordinance, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of shares shall require the Company or any investment bank to
publish a prospectus pursuant to Article 35 FinSA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been and will not be listed or admitted to trading
on a trading venue in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither this document nor any other offering or marketing material relating to the
shares constitutes a prospectus as such term is understood pursuant to the FinSA and neither this document nor any other offering or marketing material relating to the shares may be publicly distributed or otherwise made publicly available in
Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B></B><B><I>Notice to Prospective Investors in the Dubai International Financial Centre</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This document relates to an Exempt Offer in accordance with the Markets Law, DIFC Law No.&nbsp;1 of 2012, as amended. This
document is intended for distribution only to persons of a type specified in the Markets Law, DIFC Law No.&nbsp;1 of 2012, as amended. It must not be delivered to, or relied on by, any other person. The Dubai Financial Services Authority (DFSA) has
no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for this document. The
securities to which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the
contents of this document you should consult an authorized financial advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to its use in the DIFC, this document is strictly private and
confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be
offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in the United Arab Emirates
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab
Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this
prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central
Bank of the United Arab Emirates, the Securities and Commodities Authority, Financial Services Regulatory Authority (FSRA) or the DFSA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001
(Cth) (Corporations Act); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission (ASIC), as a
disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or
more of the categories of investors, available under section 708 of the Corporations Act (Exempt Investors). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe
for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be distributed in Australia, except where disclosure to investors is not required under Chapter
6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares, you represent and warrant to us that you are an Exempt Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As any offer of shares of our common stock under this prospectus will be made without disclosure in Australia under Chapter
6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies
to that resale. By applying for the shares of our common stock you undertake to us that you will not, for a period of 12 months from the date of issue of the shares, offer, transfer, assign or otherwise alienate those shares of our common stock to
investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and
Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in
Japan, including any corporation or other entity organized under the laws of Japan), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption
from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than
(a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (SFO) of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the
document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong) (CO) or which do not constitute an offer to the public within the meaning of the CO. No advertisement,
invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to
be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to
&#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in
Singapore </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each underwriter has acknowledged that this prospectus has not been registered as a prospectus with the
Monetary Authority of Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell
any shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the
offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289)
of Singapore, as modified or amended from time to time (SFA)) pursuant to Section&nbsp;274 of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the
SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which
is: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest
(howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(c)(ii) of the SFA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and
Securities-based Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Singapore </I><I>SFA Product
Classification</I> &#151; In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless otherwise specified before an offer of shares of our common stock, we have determined, and hereby notify all relevant persons (as defined
in Section&nbsp;309A(1) of the SFA), that the shares of our common stock are &#147;prescribed capital markets products&#148; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT
STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Bermuda </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of
Bermuda which regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are
permitted to do so under applicable Bermuda legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Saudi Arabia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Rules on
the Offer of Securities and Continuing Obligations Regulations as issued by the board of the Saudi Arabian Capital Market Authority (CMA) pursuant to resolution number
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3-123-2017</FONT></FONT> dated 27&nbsp;December 2017, as amended (CMA Regulations). The CMA does not make any representation as to the accuracy or completeness of this document and
expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the
information relating to the securities. If you do not understand the contents of this document, you should consult an authorised financial adviser. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in the British Virgin Islands </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or
subscription by or on behalf of us. The shares may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands) (BVI Companies), but only where the offer will be made to, and received by, the relevant BVI
Company entirely outside of the British Virgin Islands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus will not be circulated or distributed in the PRC and the shares will not be offered or sold, and will not be
offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any residents of the PRC (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan),
except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with
applicable laws and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Korea </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea
and the decrees and regulations thereunder (FSCMA), and the shares have been and will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
offered in Korea as a private placement under the FSCMA. None of the shares may be offered, sold or delivered directly or indirectly, or offered or sold to any person for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of
Korea and the decrees and regulations thereunder (FETL). Furthermore, the purchaser of the shares shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of
the shares. By the purchase of the shares, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares pursuant to the applicable laws and regulations of Korea. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B></B><B><I>Notice to Prospective Investors in Malaysia</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No prospectus or other offering material or document in connection with the offer and sale of the shares has been or will be
registered with the Securities Commission of Malaysia (Commission) for the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with the offer
or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to
persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services Licence; (iii)&nbsp;a person who acquires the shares, as principal, if the offer is on terms that the shares may
only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse exceeds
RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum
in the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with
total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix)
a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other
person as may be specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the shares is made by a holder of a Capital Markets Services License who carries on the business of dealing in
securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to
subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B></B><B><I>Notice to Prospective Investors in Taiwan</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant
securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a
registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares in Taiwan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B></B><B><I>Notice to Prospective Investors in South Africa</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Due to restrictions under the securities laws of South Africa, no &#147;<I>offer to the public</I>&#148; (as such term is
defined in the South African Companies Act, No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted)</FONT> (the South African Companies Act) is being made in connection with the issue of the shares in South Africa.
Accordingly, this document does not, nor is it intended to, constitute a &#147;<I>registered prospectus</I>&#148; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not
been approved by, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and/or filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The shares are not offered, and the offer shall not be
transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions stipulated in section 96 (1) applies: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%" VALIGN="top" ALIGN="left">Section&#8201;96&#8201;(1)&#8201;(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the offer, transfer, sale, renunciation or delivery is to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(i) persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(ii) the South African Public Investment Corporation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(iii) persons or entities regulated by the Reserve Bank of South Africa; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(iv) authorised financial service providers under South African law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(v) financial institutions recognised as such under South African law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(vi) a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorised
portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under South African law); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(vii) any combination of the person in (i)&nbsp;to (vi), or </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%" VALIGN="top" ALIGN="left">Section&#8201;96&#8201;(1)&#8201;(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the total contemplated acquisition cost of the securities, for any single addressee acting as principal is
equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the South African Companies Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Information made available in this prospectus should not be considered as &#147;<I>advice</I>&#148; as defined in the South
African Financial Advisory and Intermediary Services Act, 2002. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Israel </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of our common stock
under the Israeli Securities Law, 5728&#151;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728&#150;1968,
including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the Addressed Investors; or (ii)&nbsp;the offer is made, distributed or directed to certain qualified
investors defined in the First Addendum of the Israeli Securities Law, 5728&#151;1968, subject to certain conditions, or the &#147;Qualified Investors.&#148; The Qualified Investors shall not be taken into account in the count of the Addressed
Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. We have not and will not take any action that would require us to publish a prospectus in accordance with and subject to the Israeli Securities Law,
5728&#151;1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our shares of our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35
Addressed Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Qualified Investors may have to submit written evidence that they meet the definitions set out in of
the First Addendum to the Israeli Securities Law, 5728&#151;1968. In particular, we may request, as a condition to be offered shares of our common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting
on our behalf: (i)&nbsp;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law,
5728&#151;1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728&#151;1968 and the regulations promulgated thereunder in connection with the offer to be
issued shares of our common stock; (iv)&nbsp;that the shares of our common stock that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728&#151;1968 (A) for its own account, (B)&nbsp;for investment purposes only, and (C)&nbsp;not issued
with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&#151;1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed
Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The validity of the shares of our common stock being offered in this prospectus will be passed upon for us by Goodwin Procter
LLP, Redwood City, California. Cooley LLP, San Francisco, California, is representing the underwriters in this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_22"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our financial
statements at December&nbsp;31, 2022 and 2023, and for each of the two years in the period ended December&nbsp;31, 2023, as set forth in their report. We have included our financial statements in the prospectus and elsewhere in the registration
statement in reliance on Ernst&nbsp;
&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_23"></A>WHERE YOU CAN
FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have filed with the SEC a registration statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> (File Number 333-&#8195;&#8195;&#8195;&#8195; ) under the Securities Act with respect to the common stock we are offering by this prospectus. This prospectus, which constitutes part of the registration
statement, does not contain all of the information included in the registration statement. For further information pertaining to us and our common stock, you should refer to the registration statement and to its exhibits. Whenever we make reference
in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other
document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of the offering, we will be subject to the informational requirements of the Exchange Act
and will file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at <I>www.sec.gov</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_24"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Statements as of and for the Years Ended December 2022 and 2023 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_1">Report of Independent Registered Public Accounting Firm (PCAOB ID:42)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_3">Statements of Operations and Comprehensive (Loss) Income</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_4">Statements of Convertible Preferred Stock and Stockholders&#146;Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Septerna,
Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
audited the accompanying balance sheets of Septerna, Inc. (the Company) as of December&nbsp;31, 2022 and 2023, the related statements of operations and comprehensive (loss) income, convertible preferred stock and stockholders&#146; deficit and cash
flows for the years then ended, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at
December&nbsp;31, 2022 and 2023, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of
America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the
amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We
believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San
Mateo, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;2, 2024 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_2"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In
thousands, except for share and per share data) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivable related to sale of <FONT STYLE="white-space:nowrap">non-financial</FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">12,566</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">546</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred stock, $0.001 par value per share; 100,000,000 and 75,000,000
shares authorized at December&nbsp;31, 2022 and 2023, respectively; 75,000,000 shares issued and outstanding as of December&nbsp;31, 2022 and 2023; liquidation preference of $75,000 at December&nbsp;31, 2022 and 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, $0.001 par value per share; no shares authorized issued or
outstanding at December 31, 2022; 121,657,452 shares authorized at December 31, 2023; 60,828,720 shares issued and outstanding as of December&nbsp;31, 2023; liquidation preference of $75,000 at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value per share, 150,000,000 and 260,590,689 shares authorized at
December&nbsp;31, 2022 and 2023, respectively; 27,396,979 shares and 27,279,062 shares issued and outstanding at December&nbsp;31, 2022 and 2023, respectively; 13,153,654 and 8,628,033 shares subject to repurchase as of December&nbsp;31, 2022 and
2023, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_3"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Operations and Comprehensive (Loss) Income </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except for share and per share data) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses (income):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,924</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) income from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) income before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income and comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income per share attributable to common stockholders:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing net (loss) income per share attributable to
common stockholders:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,372,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,606,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,372,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,746,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:85pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_4"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except for share data) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,247,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,080</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series A Convertible Preferred Stock, net of issuance costs of $31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repurchase of unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,396,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B Convertible Preferred Stock, net of issuance costs of $479</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,828,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repurchase of unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(117,917</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,828,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,279,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:130pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_5"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net (loss) income to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(573</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,878</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchases of forfeited restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series A convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series B convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">89,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure for noncash investing and financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
asset obtained in exchange for operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivable related to sale of <FONT STYLE="white-space:nowrap">non-financial</FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment held in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral
part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_6"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.
Organization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Description of the Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Septerna, Inc. (&#147;Septerna&#148; or the &#147;Company&#148;) is a clinical-stage biotechnology company pioneering a new era of G
protein-coupled receptor (&#147;GPCR&#148;) oral small molecule drug discovery powered by its proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>. The Company&#146;s industrial-scale platform aims to unlock the
full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of product candidates focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> replicates the natural
structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as the Company believes, the first time. The Company&#146;s foundational technologies enable it to isolate, purify, and reconstitute full-length, properly folded
GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. The Company then applies
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen
for, and optimize potential product candidates. Leveraging its platform, the Company has transformed GPCR oral small molecule drug discovery to an industrialized and iterative structure-based drug design approach to expand the landscape of druggable
GPCR targets with novel oral small molecule medicines for patients. The Company&#146;s Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> is designed to enable it to target certain GPCRs for the first time, uncover
novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company was incorporated in Delaware in December 2019, under the name GPCR NewCo, Inc. In June 2021, the Company changed its name to
Septerna, Inc. The Company is headquartered in South San Francisco, California. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Capital Resources </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which assumes that the Company
will realize its assets and satisfies its liabilities in the normal course of business. The Company is subject to risks inherent in operating an early-stage biotechnology business. These risks include, but are not limited to, dependence on the
development of marketable products, the ability to attract, retain, and motivate qualified personnel, rapid technological changes and the rapidly evolving nature of the biotechnology industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has historically financed its operations primarily through the issuances of convertible promissory notes and convertible preferred
stock. In November 2021, the Company entered into a total of $100.0&nbsp;million of Series A convertible preferred stock financing which was divided into two tranches. The initial tranche was completed in November 2021 for net proceeds of
$44.7&nbsp;million, of which $30.0&nbsp;million was received in cash, net of issuance costs, and $14.7&nbsp;million was for the conversion of the then outstanding convertible promissory notes plus accrued interest. In November 2022, the Company
executed the second tranche for net cash proceeds of $30.0&nbsp;million. In June 2023, the Company entered into a total of $150.0&nbsp;million of Series B Convertible Preferred Stock financing, which was divided into two tranches of equal amounts.
The first tranche, which was the issuance of $75.0&nbsp;million of Series B Convertible Preferred Stock, was completed in July 2023 for net proceeds of $74.5&nbsp;million (see Note 8). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The second tranche, which is the issuance of the remaining $75.0&nbsp;million, was completed in May 2024 for net proceeds of
$74.9&nbsp;million (see Note 8). Upon issuance of the Series B Convertible Preferred Stock, the Company also amended the Series A Preferred Stock agreement to cancel the remaining 25.0&nbsp;million unissued shares of Series A Convertible Preferred
Stock originally authorized under the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company recorded a gain totaling
$47.6&nbsp;million for the sale of an <FONT STYLE="white-space:nowrap">in-progress</FONT> research and development (&#147;IPR&amp;D&#148;) asset related to a GPCR program (see Note 4) and $0.2&nbsp;million in revenue related to research services
(see Note 5) resulting in net income of $4.2&nbsp;million. Management expects to incur net losses for the foreseeable future as it conducts research and development. To date, none of the Company&#146;s product candidates have been approved by the
U.S. Food and Drug Administration (&#147;FDA&#148;) for commercial sale and, therefore, the Company has not generated any revenue from product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the income generated during the year ended December&nbsp;31, 2023, the Company has experienced net losses from operations and
negative cash flows from operating activities and capital expenditures since inception and had an accumulated deficit of $46.6&nbsp;million as of December&nbsp;31, 2023. The Company believes its cash and cash equivalents of $88.5&nbsp;million as of
December&nbsp;31, 2023, together with (i)&nbsp;the receipt of the remaining $22.6&nbsp;million in the first half of 2024 related to the gain recognized during the year ended December&nbsp;31, 2023 and (ii)&nbsp;the net proceeds from the issuance of
its second tranche of Series B Convertible Preferred Stock of $74.9&nbsp;million received in May 2024 (see Note 8) will be sufficient to fund the Company&#146;s operations for, at least, twelve months from the date of issuance of the financial
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will need substantial additional funding to support its continuing operations and pursue its development
strategy. Until such time as the Company can generate significant revenue from commercial sales of its product candidates, if ever, management may seek additional funding through the issuance of preferred stock or common stock, debt financings, or
licensing arrangements or collaborations/partnerships with other companies. The amount and timing of future funding requirements will depend on many factors, including the pace and results of clinical development efforts for the Company&#146;s
product candidates and other research, development and manufacturing activities. Management may not be able to raise additional capital on terms favorable for or acceptable to the Company, or at all. Any failure to raise capital as and when needed
would compromise the Company&#146;s ability to execute on its business plan and may cause the Company to significantly delay, scale back or discontinue the research and development of some of its programs or curtail any efforts to expand its product
pipelines and will materially harm its business, financial position and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its founding, the Company has
devoted substantially all of its resources to organizing and staffing the Company, business planning, raising capital, developing its proprietary platform and structure-based drug discovery platform, identifying and discovering its product
candidates, establishing its intellectual property portfolio, conducting research and preclinical studies, including Investigational New Drug (IND)-enabling studies, initiating and conducting clinical trials, establishing arrangements with third
parties for the manufacture of its product candidates and related raw materials, and providing general and administrative support for these operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;), stated in U.S. dollars and include all adjustments necessary for the fair
presentation of the Company&#146;s financial statements as of December&nbsp;31, 2022 and 2023, and for the years then ended. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting
Standards Codification and Accounting Standards Updates (&#147;ASUs&#148;), of the Financial Accounting Standards Board (&#147;FASB&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of
Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosures at the date of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the financial statements and reported amounts of expenses during the reporting periods. These estimates form the basis for judgments the Company makes about the carrying values of assets and
liabilities that are not readily apparent from other sources. The Company bases its estimates using historical experience, Company forecasts and future plans, current economic conditions, and information from third-party professionals that
management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other
sources and adjusts those estimates and assumptions when facts and circumstances dictate. Estimates are used in accounting for, among other things, useful lives of property and equipment, the rate used in determining the present value of lease
payments, fair value of assets and liabilities, research and development accruals, the fair value of common stock and stock options, the allocation of a revenue contract&#146;s transaction price to each distinct performance obligation on a relative
standalone selling price basis, uncertain tax positions and the valuation allowance for deferred income tax assets. Actual results may differ from these estimates and assumptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company utilizes estimates and assumptions in determining the fair value of its common stock, including stock-based awards. The Company
has granted stock options at exercise prices that represented the fair value of its common stock on the specific grant dates. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of
Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that
require the Company&#146;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of convertible preferred stock, the superior
rights and preferences of the convertible preferred stock senior to the Company&#146;s common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of the Company, under differing scenarios.
Changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s results can also be affected by economic, political, legislative, regulatory and legal actions. Economic conditions, such as recessionary trends, inflation, interest, changes in regulatory laws and monetary exchange rates, and
government fiscal policies, can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities, the Company could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Reporting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating
segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#147;CODM&#148;), in deciding how to allocate resources to an individual
segment and in assessing performance. The Company&#146;s CODM is its chief executive officer. The Company has determined it operates in one segment. As of December&nbsp;31, 2022 and 2023, all of the Company&#146;s property and equipment was
maintained in the United States. For the year ended December&nbsp;31, 2023, all of the Company&#146;s revenue was generated and incurred in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial
instruments, which potentially subject the Company to a concentration of credit risk, consist primarily of cash and cash equivalents and accounts receivable. The Company invests its cash equivalents in money market funds and limits its credit risk
by placing its cash and cash equivalents with banks and institutions that are highly creditworthy. Such deposits may be in excess of the Federal Deposit Insurance Corporation (&#147;FDIC&#148;) insured limits. The Company is exposed to credit risk
in the event of default by the financial institutions holding its cash and cash equivalents to the extent recorded in the balance sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary focus of the Company&#146;s investment strategy is to preserve capital and meet
liquidity requirements. Management believes that the Company is not exposed to significant credit risk due to the high-credit-quality financial institutions in which those deposits are held. The Company has not experienced any losses on its cash and
cash equivalents since inception. The Company has no significant <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet concentrations of credit risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to all of the risks inherent in an early-stage biotechnology company. These risks include, but are not limited to,
limited management resources, efficacy of product candidates, intense competition, and dependence upon the availability of cash to sustain operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash, Cash Equivalents and Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash
equivalents. Cash equivalents are reported at fair value. At December&nbsp;31, 2022 and 2023, the Company&#146;s cash equivalents are all held in money market funds. As of the balance sheet date, and periodically throughout the year, the Company has
maintained balances in various operating accounts in excess of the FDIC insured limits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash is comprised of cash that is
restricted as to withdrawal or use under the terms of certain contractual agreements. In connection with the Company&#146;s lease agreement (see Note 6), the Company is required to maintain a collateral account to secure a letter of credit issued to
its landlord. The collateral account is classified as restricted cash on the Company&#146;s balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s cash, cash
equivalents and restricted cash consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">89,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable and Other Receivables </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes a receivable when the Company has an unconditional right to payment, which is generally at the time of delivery of
assets, or at the time services are rendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An allowance for expected credit losses over the life of the receivables is reserved for
based on a combination of historical experience, aging analysis, current economic trends and information on specific accounts, with related amounts recorded as a reserve against revenue recognized. The reserve is
<FONT STYLE="white-space:nowrap">re-evaluated</FONT> on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. No allowance for credit losses was recorded during the year
ended December&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the Company&#146;s accounts receivable and other receivable related to sale
of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset balances were entirely attributed to Vertex Pharmaceuticals Incorporated (&#147;Vertex&#148;) (see Note 4 and Note 5). The Company did not have accounts receivable as of
December&nbsp;31, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment is recorded at cost, subject to adjustments for impairments, less accumulated depreciation. The Company depreciates
property and equipment using the straight-line method over the estimated useful lives of the respective assets, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lab equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Furniture and fixtures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Computer Equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Leasehold improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shorter of remaining lease term or estimated useful life</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation or amortization begins at the time the asset is placed in service. Maintenance and repairs that
do not improve or extend the life of the respective asset are charged to expense as incurred. Upon disposal of assets, the cost and related accumulated depreciation is removed from the balance sheet and the resulting gain or loss is reflected in the
statements of operations and comprehensive (loss) income within other income, net. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived assets for impairment, primarily its property and equipment, whenever events or changes in circumstances
indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the undiscounted expected future cash flows the asset is expected to generate over
its remaining life. An impairment loss would be recognized when the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition are less than its carrying amount. Impairment, if
any, is measured as the amount by which the carrying amount of a long-lived asset or asset group exceeds its fair value. There were no impairments of the Company&#146;s long-lived assets for the years ended December&nbsp;31, 2022 and 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for
its leases in accordance with FASB Accounting Standards Codification (&#147;ASC&#148;) 842, <I>Leases</I> (&#147;ASC 842&#148;). The Company adopted ASC 842 on January&nbsp;1, 2021, prior to entering into the lease agreement for its office and
research and development space. At inception of a contract, the Company determines whether an arrangement is or contains a lease. For each lease, the Company determines the classification as either an operating lease or a financing lease. Lease
recognition occurs at the lease commencement date and lease liability amounts are determined based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease only when it is
reasonably certain that the Company will exercise that option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses its incremental borrowing rate based on the information
available at lease commencement date in determining the present value of lease payments if the Company&#146;s leases do not provide an implicit rate. The Company determines its incremental borrowing rate based on the rate of interest that the
Company would have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets represent the Company&#146;s right to use underlying assets for the lease term and operating lease liabilities represent the Company&#146;s obligation to make lease payments under the lease. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets also include any lease payments made prior to the commencement date and exclude lease incentives received. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company elected to apply the practical expedient of combining lease and <FONT
STYLE="white-space:nowrap">non-lease</FONT> components for the real estate lease asset class. Fixed lease payments on operating leases are recognized as lease expense over the expected term of the lease on a straight-line basis. Variable lease
expenses that are not considered fixed are recognized as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company elected the short-term lease practical
expedient that allows the lessee to not record a lease liability and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for all leases with a term of 12 months or less. See Note 6 for additional
information on the Company&#146;s leases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records all shares of convertible preferred stock at their respective fair values on the dates of issuance, less issuance costs. In
the event of a deemed liquidation event, such as a change of control of the Company, proceeds received from the sale of such shares will be distributed in accordance with the liquidation preferences set forth in the Company&#146;s certificate of
incorporation unless the holders of the convertible preferred stock have converted their shares of convertible preferred stock into shares of common stock. Convertible preferred stock is therefore classified outside of stockholders&#146; deficit on
the balance sheet as events triggering redemption are not solely within the Company&#146;s control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not adjusted the
carrying values of its convertible preferred stock to the liquidation preferences because of the uncertainty of whether or when such an event would occur. As of December&nbsp;31, 2022 and 2023, it was not probable that such a redemption would occur.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company generated revenue for the year ended December&nbsp;31, 2023 from service revenue for research activities performed related to an agreement with Vertex (see Note 5). The Company considers revenue to be earned when all of the following
criteria are met: (i)&nbsp;the Company has a contract with a customer that creates enforceable rights and obligations; (ii)&nbsp;promised products or services are identified; (iii)&nbsp;the transaction price, or the amount the Company expects to
receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; (iv)&nbsp;and the Company
has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. The transaction price for the
contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. When a contract contains variable consideration and the variable consideration is constrained to
the extent that it is not probable that it will be received, it is excluded from the transaction price. A contract&#146;s transaction price is allocated to each distinct performance obligation on a relative standalone selling price basis and
recognized as revenue when, or as, control of the distinct good or service is transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023,
the Company&#146;s revenue was entirely attributable to Vertex. The Company did not record revenue during the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale of <FONT STYLE="white-space:nowrap">Non-Financial</FONT> Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of <FONT STYLE="white-space:nowrap">non-financial</FONT> assets that are outside the scope of the Company&#146;s ordinary activities are
accounted for under ASC <FONT STYLE="white-space:nowrap">610-20,</FONT> <I>Other Income - Gains and Losses from the Derecognition of <FONT STYLE="white-space:nowrap">Non-financial</FONT> Assets</I> (&#147;ASC
<FONT STYLE="white-space:nowrap">610-20&#148;).</FONT> Pursuant to ASC <FONT STYLE="white-space:nowrap">610-20,</FONT> the Company applies the guidance in ASC 606, <I>Revenue from Contracts with</I> </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>Customers </I>(&#147;ASC 606&#148;)<I>,</I> to determine if a contract exists, identify the distinct <FONT STYLE="white-space:nowrap">non-financial</FONT> assets, and determine when control
transfers and, therefore, when to derecognize the <FONT STYLE="white-space:nowrap">non-financial</FONT> asset. Additionally, the Company applies the measurement principles of ASC 606 to determine the amount of consideration, if any, to include in
the calculation of the gain or loss for the <FONT STYLE="white-space:nowrap">non-financial</FONT> asset. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development expenses consist primarily of employee-related
costs, including salaries, benefits and stock-based compensation for employees engaged in research and development activities, costs related to research activities, preclinical studies, production of preclinical materials, information
technology-related costs, allocated overhead costs including facility-related expenses, contract manufacturing, consulting fees, costs related to laboratory operations and fees paid to other entities that conduct certain research and development
activities on the Company&#146;s behalf. Payments made prior to the receipt of goods and services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are
rendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into various agreements with outsourced contract manufacturing and development vendors. The Company
estimates accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with internal management personnel and external
service providers, and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The
estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheets. If the actual timing of the performance of services or the level of effort varies from the original
estimates, the Company will adjust the accrual accordingly. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs to secure
and maintain patents covering the Company&#146;s technology and product candidates are expensed as incurred and are classified as general and administrative expenses in the statements of operations and comprehensive (loss) income. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assets
and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would
be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation
techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair
value measurements as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at
the measurement date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities,
unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by
little or no market data. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous
market in which to transact and the market-based risk. The carrying values of the Company&#146;s financial instruments, which include cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate
their fair values due to their relatively short maturities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense related to stock options and restricted stock awards granted to employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> is recognized based on the grant-date fair value of the awards. The fair value of stock options is determined using the Black Scholes option pricing model on the date of grant. The fair value of
restricted stock awards is determined using the estimated fair value of the Company&#146;s common stock on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair
value of the Company&#146;s common stock is determined by the Company&#146;s Board of Directors with the assistance of management and an independent third-party valuation specialist. The valuation methodologies used to determine the fair value of
the Company&#146;s common stock utilize certain assumptions including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. In determining the fair
value of the Company&#146;s common stock, the methodologies used to estimate the enterprise value of the Company were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants
Technical Practice Aid, &#147;<I>Valuation of Privately Held Company Equity Securities Issued as Compensation,&#148;</I> to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require
management judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of convertible preferred stock, the superior rights and
preferences of the convertible preferred stock senior to the Company&#146;s common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of the Company, under different scenarios. Changes to the
key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For stock-based
awards with service conditions only, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting term of the award of four years. For stock-based awards with
vesting criteria subject to the achievement of performance-based conditions, in addition to service conditions, the Company recognizes stock-based compensation expense on an accelerated basis over the vesting period when achievement of the
performance criteria becomes probable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense is recorded within research and development and general and
administrative expenses in the accompanying statements of operations and comprehensive (loss) income based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards
that have vested. Forfeitures are accounted for as they occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> Income Taxes (Topic 740): <I>Simplifying the Accounting for Income
Taxes </I>on January&nbsp;1, 2021, with no impact to the financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company utilizes the asset and liability approach to
account for income taxes. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the financial statement and income tax basis of existing assets and liabilities.
Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates
expected to be in effect in the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not
be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertain tax positions recognized in the financial statements by prescribing a <FONT
STYLE="white-space:nowrap">more-likely-than-not</FONT> threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any
resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related interest and penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive
(Loss) Income </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive (loss) income is defined as the change in equity of a business enterprise during a period from
transactions and other events and circumstances from <FONT STYLE="white-space:nowrap">non-owner</FONT> sources. The Company did not have any other comprehensive income or loss for the periods presented and therefore comprehensive (loss) income was
the same as the Company&#146;s net (loss) income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net (Loss) Income Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net (loss) income per share is computed by dividing the net (loss) income by the weighted-average number of common shares outstanding
during the period, without consideration of potential dilutive securities. Vested restricted stock is treated as outstanding for accounting purposes. Unvested restricted stock is not considered to be outstanding for purposes of the calculation of
basic net (loss) income per share. Diluted net (loss) income per share is computed by dividing the net (loss) income by the sum of the weighted-average number of common shares outstanding during the period plus the potential dilutive effects of
potential dilutive shares outstanding during the period. Potential dilutive securities include stock options, unvested restricted stock and convertible preferred stock. The dilutive effect of stock options and unvested restricted stock is computed
using the treasury stock method and the dilutive effect of convertible preferred stock is calculated using the <FONT STYLE="white-space:nowrap">&#147;if-converted</FONT> method.&#148; For all periods presented in a net loss position, diluted net
loss per share is the same as basic net loss per share since the effect of including potential common shares is anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and
diluted net (loss) income per share attributable to common stockholders is presented in conformity with the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for participating securities. The Company considers all series of its
convertible preferred stock to be participating securities. Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, the net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holders of
its convertible preferred stock do not have a contractual obligation to share in the Company&#146;s losses. Net income is attributed to common stockholders and participating securities based on their participation rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> <I>Financial Instruments &#150; Credit Losses: Measurement
of Credit Losses on Financial Instruments (Topic 326),</I> which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments,
including trade receivables and available for sale debt securities. Topic 326 is effective for annual periods beginning after December&nbsp;15, 2022, and early adoption is permitted. The Company adopted Topic 326 on January&nbsp;1, 2023, and the
adoption did not have a material impact on its financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting Pronouncements Not Yet Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the
Company as of the specified date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-07,</FONT> <I>Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures</I>. ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment
expenses on an interim and annual basis. The ASU is effective for fiscal years beginning after December&nbsp;15, 2023, and interim periods after December&nbsp;5, 2024, with early adoption permitted. The adoption of this standard is not expected to
have a material impact on the Company&#146;s financial statements at adoption date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2023-09,</FONT> <I>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</I>, which enhances the transparency and decision usefulness of income tax disclosures. The standard is intended to improve
income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU is effective for fiscal years
beginning after December&nbsp;15, 2025, on a prospective basis. Early adoption and retrospective reporting are permitted. We are currently evaluating the impact of ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> on our financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company Status and Smaller Reporting Company Status </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). Under the
JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this
extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&nbsp;is no longer an emerging growth company or
(ii)&nbsp;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as
of public company effective dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is also a smaller reporting company as defined in the Securities Exchange Act of 1934, as
amended (the &#147;Exchange Act&#148;). The Company may continue to be a smaller reporting company even after it is no longer an emerging growth company. The Company may take advantage of certain of the scaled disclosures available to smaller
reporting companies and will be able to take advantage of these scaled disclosures for so long as its voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less
than $250.0&nbsp;million measured on the last business day of its second fiscal quarter, or its annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and its voting and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of its second fiscal quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Balance Sheet Components </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash and
cash equivalents consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Money market funds are highly liquid investments and are actively traded. The fair value of the Company&#146;s
money market funds are based on quoted prices in active markets for identical securities. This approach results in the classification of these securities as Level&nbsp;1 of the fair value hierarchy. There were no transfers between Level&nbsp;1, 2,
or 3 for any of the periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prepaid Expenses and Other Current Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense was $0.6&nbsp;million and $0.8&nbsp;million for the years ended
December&nbsp;31, 2022 and 2023, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Expenses and Other Current Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued operating expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income taxes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Gain on Sale of <FONT STYLE="white-space:nowrap">Non-Financial</FONT> Asset </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vertex Asset Sale </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September
2023, the Company entered into an asset purchase agreement with Vertex under which Vertex acquired an IPR&amp;D asset related to a GPCR program, including all intellectual property, materials, and compounds associated with the program (the
&#147;Vertex Purchase Agreement&#148;). Additionally, as part of the agreement, Vertex assumed all claims, counterclaims and credits associated with the program, and the Company gave up all rights to the intellectual property. The transfer of the
IPR&amp;D asset to Vertex was completed in November 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the same time in September 2023, the Company entered into a research service
agreement with Vertex under which the Company agreed to perform certain exploratory research activities for Vertex (the &#147;Vertex Research Service Agreement&#148;) (see Note 5). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the IPR&amp;D asset sale should be accounted for under the guidance at ASC
<FONT STYLE="white-space:nowrap">610-20,</FONT> as this type of transaction did not meet the definition of &#147;ordinary activities&#148; of the Company and Vertex should not be considered a &#147;customer&#148; in this transaction. However, since
both the Vertex Purchase Agreement and the Vertex Research Service Agreement were entered into at the same time with the same counterparty with a single commercial objective, the Company combined the contracts and applied the allocation principles
under ASC 606. The Company identified the performance obligations in both contracts, determined the transaction price and allocated the transaction price to the performance obligations in the contracts based on the estimated standalone selling price
for each performance obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company recorded a gain on sale of <FONT
STYLE="white-space:nowrap">non-financial</FONT> asset of $47.6&nbsp;million for the sale of the IPR&amp;D asset to Vertex on its statements of operations and comprehensive (loss) income. The Company received $25.0&nbsp;million in cash at the closing
of the agreement in September 2023 and recorded the remaining balance of $22.6&nbsp;million in other receivable related to sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset on its balance sheet as of December&nbsp;31, 2023. As of
December&nbsp;31, 2023, the sale of the IPR&amp;D asset was complete and the Company had an unconditional right to the $22.6&nbsp;million. The Company received the payment of $22.6&nbsp;million of this balance in the first half of 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Vertex Purchase Agreement also provides for a potential milestone payment payable to the Company contingent upon achievement of a certain
research milestone. The milestone payment amount is determined based on the timing of achievement of the research milestone. The variable consideration related to this milestone payment was determined to be improbable of receipt at this time. As a
result, the milestone payment was excluded from the transaction price. After the potential milestone payment, the Company will not receive any other payments or future royalties related to this IPR&amp;D asset. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Revenue </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Vertex Research Service Agreement</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As disclosed in Note 4, the Company entered into the Vertex Research Service Agreement in September 2023 under which the Company agreed to
perform certain exploratory research activities for Vertex. Although the Company accounted for the IPR&amp;D asset sale under the guidance at ASC <FONT STYLE="white-space:nowrap">610-20,</FONT> the research services portion of the transaction fell
under the scope of the revenue from contracts with customers guidance, ASC 606. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Vertex Research Service Agreement is for a <FONT
STYLE="white-space:nowrap">two-year</FONT> term, however, Vertex has the ability to terminate the agreement with a <FONT STYLE="white-space:nowrap">30-day</FONT> notice at any time. As a result, the Company concluded that the contract duration is 30
days, representing a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT> service contract. The Company recognizes this service revenue over the performance period of the research services as the services
are provided. The Vertex Research Service Agreement also includes a provision related to additional research services, which the Company concluded met the definition of a customer option under ASC 606. The Company will recognize revenue related to
the customer option if and when it is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company recorded revenue of
$0.2&nbsp;million related to research activities performed in connection with the Vertex Research Service Agreement, which is also included in accounts receivable on the Company&#146;s balance sheet at December&nbsp;31, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Operating Lease</I></B><B>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, the Company entered into an operating lease for 12,560 square feet of office and research and development space at the
Company&#146;s headquarters in South San Francisco, California, which was scheduled to expire in February 2023. In September 2022, the Company amended the lease agreement to include an additional 9,348 square feet of office and research and
development space, increasing the total leased premises to 21,908 square feet (the &#147;Original Leased Space&#148;), which was also scheduled to expire in February 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2022, the Company entered into another lease amendment to extend the lease term of the Original Leased Space (the &#147;Extension
of Original Leased Space&#148;) and lease an additional 22,911 square feet of office and research and development space (the &#147;Additional Leased Space&#148;). Upon completion of the construction of the new office and research and development
space in November 2023, the Additional Leased Space commenced, and the Company relocated its operations to the Additional Leased Space and vacated the Original Leased Space to allow the landlord to renovate it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Renovation of the Original Leased Space was completed in July 2024. Upon completion of the renovation of the Original Leased Space, the lease
of the Original Leased Space commenced, resulting in the total leased premises increasing to 44,819 square feet (the &#147;Leased Space&#148;). The lease term for the Leased Space is for eight years from the commencement date of the Original Leased
Space. The amended lease also includes an option for the Company to extend the lease for an additional eight-year term (the &#147;Extension Option&#148;). As of December&nbsp;31, 2023, it is not probable that the Company will exercise the Extension
Option. As a result, the Company did not include the Extension Option in the calculation of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and lease liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company recorded an operating lease <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and operating lease liability for the Additional Leased Space as the lease commenced in November 2023, when the Company took control of the property. As of December&nbsp;31, 2023, the
entire balance of the operating lease liability associated with the Additional Leased Space was classified as <FONT STYLE="white-space:nowrap">non-current</FONT> as the Company received a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rent abatement for four months in the first year of the lease and, therefore, the operating lease liability will increase over the 12 month-period starting from December&nbsp;31, 2023. For the
year ended December&nbsp;31, 2022, the Company did not recognize a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset or operating lease liability for the minimum rental payments associated with the
Additional Leased Space. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the expenses recognized and cash paid for the Leased Space (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022, the Company recorded an increase of $0.6&nbsp;million in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and operating lease liability related to the Extension of Original Leased Space. In December 2023, the Company recorded a $12.6&nbsp;million <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and $12.6&nbsp;million operating lease liability associated with the Additional Leased Space. These amounts are disclosed in the supplemental information of
noncash activities on the statements of cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the remaining lease term of the Original Leased Space
was approximately 1.0 year. The incremental borrowing rate used for the calculation of the present value of lease payments over the lease term for the Extension of Original Leased Space was approximately 18.8%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the remaining lease term of the Additional Leased Space was approximately 8.5 years. The incremental borrowing
rate used for the calculation of the present value of lease payments over the lease term at the lease commencement date was approximately 12.3%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, future minimum rental payments for operating leases, including for the Original Leased Space, were as follows
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Future<BR>Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: undiscounted lease payments*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total present value of operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:17%;border-bottom:1px solid #000000; width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Related to the Original Leased Space, which was under renovation at December&nbsp;31, 2023 and commenced in July
2024. </P></TD>
<TD WIDTH="18%">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022 and 2023, the Company did not have any finance leases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary
course of business, the Company may be subject to legal proceedings, claims and litigation, as the Company operates in an industry susceptible to patent or other legal claims. The Company accounts for estimated losses with respect to legal
proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnifications </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary
course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or
occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its officers and directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also agreed to indemnify the investors against certain losses, claims or liabilities due to certain statements, omissions or
violations by the Company if Company securities held by the investors are included in a registration statement. The certain statements, omissions or violations that are covered by these include, but are not limited to, (i)&nbsp;any untrue statement
or alleged untrue statement of a material fact contained in the applicable registration statement, (ii)&nbsp;any omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein
not misleading, (iii)&nbsp;any violation or alleged violation by the Company of the Securities Act of 1933, as amended, the Exchange Act, and certain other securities laws. The Company will reimburse the investors for any legal or other expenses
reasonably incurred by them in connection with investigating or defending such losses, claims, damages or liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum
potential amount of future payments that the Company could be required to make under these provisions is not determinable. The Company is not currently aware of any indemnification claims. Accordingly, the Company did not record any liabilities
associated with these indemnification rights and agreements as of December&nbsp;31, 2022 and 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the Company&#146;s convertible preferred stock consisted of the following (in thousands, except for share and per
share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conversion<BR>Price&nbsp;Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, convertible preferred stock consisted of the following (in thousands, except for
share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conversion<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,657,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,828,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.23297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2021, the Company executed a Series A Convertible Preferred Stock financing arrangement that would
provide financing of up to $100.0&nbsp;million over an initial tranche and subsequent callable tranches through the issuance of up to 100.0&nbsp;million shares of Series A Convertible Preferred Stock at an issuance price of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$1.00 per share. In the initial tranche, the Company issued 45.0&nbsp;million shares of Series A Convertible Preferred Stock for net proceeds of $44.7&nbsp;million, of which $30.0&nbsp;million
was received in cash, net of issuance costs, and $14.7&nbsp;million was for the conversion of the then outstanding convertible promissory notes plus accrued interest. The Series A Convertible Preferred Stock financing arrangement represented an
equity financing, per the terms of the outstanding convertible promissory notes, and as such the unpaid principal and accrued interest outstanding of $14.7&nbsp;million was converted into approximately 14.7&nbsp;million shares of Series A
Convertible Preferred Stock. Additionally, in November 2022, the Company executed the second tranche and issued 30.0&nbsp;million shares of Series A Convertible Preferred Stock and received net cash proceeds of $30.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Convertible Preferred Stock Purchase Agreement provided that, upon the fulfillment of certain conditions, each investor would
purchase its pro rata portion of the shares to be issued in additional Series A Convertible Preferred Stock closings. Further, the Company agreed to sell, and issue said shares of Series A Convertible Preferred Stock on the same terms as the first
tranche in the Purchase Agreement. The Company did not separately account for tranche purchase rights described above as they were not freestanding from the associated shares of convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2023, the Company amended and restated its certificate of incorporation to, among other things, increase the authorized number of
shares of the Company&#146;s convertible preferred stock to 196.7&nbsp;million shares, of which 121.7&nbsp;million shares are designated as Series B Convertible Preferred Stock, and to establish the rights, preferences, privileges and restrictions
of the Series B Convertible Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2023, the Company entered into a Series B Convertible Preferred Stock financing
arrangement in which 121,657,452 shares of Series B Convertible Preferred Stock were authorized to be issued at an issuance price of $1.23297 per share over two tranches, for total proceeds of up to $150.0&nbsp;million. In June&nbsp;2023 and
July&nbsp;2023, the Company issued an aggregate of approximately 60.8&nbsp;million shares of Series B Convertible Preferred Stock at an issuance price of $1.23297 per share for net proceeds of $74.5&nbsp;million related to the first tranche, with a
potential second tranche of additional funding for up to $75.0&nbsp;million based on approval of the Board of Directors and consent of the majority of the holders of the then-outstanding Series B Convertible Preferred Stock. The Series B Convertible
Preferred Stock Purchase Agreement provides that, upon the fulfillment of certain conditions, each investor will purchase its pro rata portion of the shares to be issued in additional Series B Convertible Preferred Stock closings. Further, the
Company agreed to sell, and issue said shares of Series B Convertible Preferred Stock on the same terms as the first tranche in the Purchase Agreement. The Company did not separately account for tranche purchase rights described above as they were
not freestanding from the associated shares of convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance of the Series B Convertible Preferred Stock,
the Company also amended the Series A Convertible Preferred Stock agreement to cancel the remaining 25.0&nbsp;million unissued shares of Series A Convertible Preferred Stock originally authorized under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2024, the Company executed the second tranche of the Series B Convertible Preferred Stock financing arrangement and issued the
remaining approximately 60.8&nbsp;million shares of Series B Convertible Preferred Stock for net proceeds of $74.9&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
rights, privileges, and preferences of the Series A and Series B Convertible Preferred Stock (together, the &#147;Convertible Preferred Stock&#148;) are as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible
Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of the Convertible Preferred Stock is initially convertible, at the option of the holder at any time after all authorized shares of
the Convertible Preferred Stock have been issued or if otherwise approved by the holders representing at least a majority of the then outstanding shares of the Convertible Preferred Stock, including at least one holder that, together with its
affiliates, holds only shares of Series B Convertible Preferred Stock and is a major investor, as defined in the Company&#146;s amended and restated investors&#146; rights agreement (the &#147;Required Vote&#148;), into shares of common stock as
determined by dividing the original issue price by the conversion price in effect at the time of conversion. The Series A Convertible Preferred Stock conversion price is initially $1.00, and the Series B Convertible Preferred Stock conversion<B>
</B>price is initially $1.23297. The conversion prices are subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Convertible Preferred Stock. The conversion prices
are subject to adjustment in the event the Company issues additional shares of common stock without consideration or for a consideration per share less than the conversion price in effect prior to such<B> </B>issuance, unless the Required Vote
determines that no such adjustment shall be made to the conversion price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special mandatory conversion will occur if a convertible
preferred stockholder fails to purchase their agreed upon share, as originally allocated to such holder in the purchase agreement, in additional closings of the Convertible Preferred Stock as defined in the purchase agreement, and such failure is
not cured as specified in the purchase agreement following receipt of the subsequent closing notification. Holders of Series B Convertible Preferred Stock have the option to waive the special mandatory conversion as specified in the purchase
agreement. Upon such event, each share of the Convertible Preferred Stock held by such holder will be automatically converted into that number of shares of common stock equal to 10% of the original issue price divided by the conversion price in
effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mandatory conversion of all outstanding shares of the Convertible Preferred Stock at the then effective conversion rate will also
occur automatically upon (i)&nbsp;consent of holders representing the Required Vote or (ii)&nbsp;the closing of the sale of shares of common stock to the public at a price of at least $1.849455 per share (subject to appropriate adjustment in the
event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a firm commitment underwritten public offering resulting in at least $50.0&nbsp;million in gross proceeds to the Company,
after deducting underwriting discounts and commissions, and in connection with such offering the common stock is listed for trading on the Nasdaq, the New York Stock Exchange or another exchange approved by the board of directors, including the
approval of at least a majority of the Convertible Preferred Stock directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company, other
than dividends on shares of common stock payable in shares of common stock, unless the holders of the Convertible Preferred Stock first receive, or simultaneously receive, a dividend on outstanding shares of the Convertible Preferred Stock in an
amount at least equal to the dividend payable based on the number of shares of common stock at the then conversion rate, such that the calculation should result in the highest preferred stock dividend. The board of directors has not declared any
dividends <FONT STYLE="white-space:nowrap">to-date.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting and Board Representation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of outstanding shares of the Convertible Preferred Stock is entitled to one vote for each share of common stock into which such
shares of preferred stock are convertible and shall vote together with the holders of common stock as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis, except as provided by law or by the other
provisions of the Company&#146;s certificate of incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of shares of Series A Convertible Preferred Stock, exclusively and as a separate
class, are entitled to elect three directors of the Company. The holders of shares of Series B Convertible Preferred Stock, exclusively and as a separate class, are entitled to elect one director of the Company. The holders of record of the shares
of common stock and any other class or series of voting stock (including the Convertible Preferred Stock), as a single class, are entitled to elect the remaining directors. The size of the board shall be set and remain at seven directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Protective Provisions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time
when shares of the Convertible Preferred Stock are outstanding, the Company shall first obtain the approval of the Required Vote, voting separately as a class, with respect to the following actions: (i)&nbsp;consummation of a liquidation,
dissolution or winding up of the Company, or effect any&nbsp;merger, acquisition or consolidation or any other deemed liquidation event, (ii)&nbsp;amend, alter or repeal any provision of the Company&#146;s certificate of incorporation or bylaws,
(iii)&nbsp;create, authorize, issue or obligate the Company to issue shares of any equity security or increase the authorized number of shares of the Convertible Preferred Stock or of any additional class or series of stock unless it ranks junior to
the Convertible Preferred Stock, (iv)&nbsp;reclassify, alter or amend any existing security of the Company that is pari passu with the Convertible Preferred Stock, or is junior with the Convertible Preferred Stock , in respect of the distribution of
assets on the liquidation, dissolution or winding up of the Company, the payment of dividends or rights of redemption, if such reclassification alteration or amendment would render such other security senior to the Convertible Preferred Stock, or in
the case of a previously junior security would render such security senior to or pari passu with the Convertible Preferred Stock, (v)&nbsp;pay or declare any dividend, other than dividends on the Convertible Preferred Stock, or make any distribution
on any shares of capital stock prior to the Convertible Preferred Stock, other than common stock or options to acquire common stock repurchased from former employees or consultants in connection with the cessation of their employment/services,
pursuant to the provisions of existing plans or agreements, (vi)&nbsp;create, adopt, amend, terminate or repeal any equity or equity-linked compensation plan, (vii)&nbsp;increase or decrease the authorized number of directors constituting the Board
of Directors, change the number of votes entitled to be cast by any director or directors on any matter, or adopt any provision inconsistent with Article Sixth; (viii)&nbsp;create or hold (or permit any subsidiary to create, or authorize the
creation of, or issue or obligate itself to issue) any shares of capital stock in any subsidiary that is not a wholly-owned subsidiary of the Corporation, or sell, lease, transfer, exclusively license or otherwise dispose of any direct or indirect
subsidiary capital stock or all or substantially all of any direct or indirect subsidiary assets; or (ix)&nbsp;sell, assign, license, pledge or encumber material technology or intellectual property, or enter into or grant any royalty streams related
thereto, other than licenses granted in the ordinary course of business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preference </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution or winding up, or in the event of a deemed liquidation event of the
Company, the holders of shares of the Convertible Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, or out of the consideration payable to stockholders, as
applicable, before any payment shall be made to the holders of common stock, an amount per share equal to the greater of (i)&nbsp;the original issue price, plus any dividends declared but unpaid, or (ii)&nbsp;such amount per share as would have been
payable had all shares of the Convertible Preferred Stock been converted into common stock immediately prior to such event. If, upon the occurrence of such event, the assets of the Company available for distribution to its stockholders are
insufficient to pay the holders of the Convertible Preferred Stock the full amount to which they are entitled, the holders of the Convertible Preferred Stock shall share ratably in any distribution of the assets available for distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Classification</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has classified the Convertible Preferred Stock outside of permanent equity on the balance sheet as these shares can be redeemed
upon the occurrence of certain change in control events that are outside of the Company&#146;s control, including liquidation, sale or transfer of the Company. The Company has not adjusted the carrying values of the convertible preferred stock to
the liquidation preferences of such shares because it is uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of convertible preferred stock, and at the balance sheet
dates these circumstances were not probable. Subsequent adjustments to the carrying values of the liquidation preferences will be made only when it becomes probable that such a liquidation event will occur. As of December&nbsp;31, 2022 and 2023, it
was not probable that such a redemption would occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the Company was authorized to issue 150.0&nbsp;million shares of $0.001 par value common stock. In June 2023, the
Company amended and restated its certificate of incorporation to, among other things, increase the authorized number of shares of common stock of the Company to approximately 260.6&nbsp;million shares. As of December&nbsp;31, 2023, the Company was
authorized to issue approximately 260.6&nbsp;million shares of $0.001 par value common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of common stock are entitled to
dividends when and if declared by the board of directors, subject to the preferences applicable to outstanding shares of the Convertible Preferred Stock. The board of directors has not declared any dividends and the Company has not paid any
dividends. The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company reserved the following shares of common stock, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, for future issuance: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,657,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock outstanding under 2021 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,230,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,666,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock outstanding outside of 2021 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,922,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,961,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options issued and outstanding under 2021 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">385,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,672,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares reserved for future grants under 2021 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,018,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,072,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,556,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">229,030,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Stock Option and Grant Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, the Company adopted the Septerna, Inc. 2021 Stock Option and Grant Plan (the &#147;2021 Plan&#148;), which authorizes the Company to
grant incentive stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, restricted stock awards, unrestricted stock awards and restricted stock units, to officers, employees, directors, consultants, or other key persons
of the Company. The terms of the stock option and restricted stock agreements, including vesting requirements, are determined by the Board of Directors, subject to the provisions of the 2021 Plan. The exercise price of stock options shall not be
less than the estimated fair value of the underlying common stock on the date of grant. Stock option awards expire 10 years from the grant date, or as otherwise determined by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Board of Directors, or in the case of incentive stock options granted to a 10% stockholders, the term is no more than 5 years from the grant date. Additionally, the Company granted and issued
restricted stock awards and allowed the recipients to purchase the unvested restricted stock awards at par value per share. The shares issued for unvested restricted stock awards under the 2021 Plan are subject to repurchase by the Company at the
original issuance price in the event of the holder&#146;s termination of its relationship with the Company. Consideration received for shares associated with the unvested restricted stock awards is initially recorded as a liability and subsequently
reclassified into stockholders&#146; deficit as the related awards vest over the requisite service period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 Plan initially
authorized a total of approximately 20.3&nbsp;million shares reserved for future issuance. In June 2023, the Company amended and restated its certificate of incorporation to, among other things, increase the shares reserved for issuance under the
2021 Plan to approximately 36.5&nbsp;million shares. Approximately 7.0&nbsp;million and 14.1&nbsp;million shares remained available for future issuance under the 2021 Plan as of December&nbsp;31, 2022 and 2023, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Awards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following summarizes restricted stock award activity under the 2021 Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Grant<BR>Date Fair<BR>Value Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,230,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock awards vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,446,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock awards repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(117,917</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,666,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to grants under the 2021 Plan, the Company has also granted restricted stock awards outside of
plan, under the terms of restricted stock purchase agreements and subscription agreements, and unvested shares are subject to repurchase by the Company upon the holder&#146;s termination of its relationship with the Company at the original purchase
price. Consideration received for shares associated with the unvested restricted stock awards is initially recorded as a liability and subsequently reclassified into stockholders&#146; deficit as the related awards vest. The following summarizes
restricted stock award activity outside of the 2021 Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Grant<BR>Date Fair<BR>Value Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,922,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock awards vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(961,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,961,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restricted stock awards generally include a service condition for vesting and vest over four years with a <FONT
STYLE="white-space:nowrap">one-year</FONT> cliff vesting and <FONT STYLE="white-space:nowrap">pro-rata</FONT> monthly vesting thereafter, but some awards vest over different time periods. In addition, some restricted stock awards include vesting
criteria subject to the achievement of performance-based conditions in addition to service conditions, for which the Company periodically assesses the probability that the performance criteria will be met and only recognizes stock-based compensation
expense related to these awards when achievement of the performance criteria becomes probable. The total fair value of shares vested during the year ended December&nbsp;31, 2023 was $1.4&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022 and 2023, $0.1&nbsp;million and $0.1&nbsp;million in other
liabilities on the Company&#146;s balance sheets was related to the unvested shares subject to repurchase of approximately 13.2&nbsp;million and 8.6&nbsp;million shares, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
summarizes stock option activity under the 2021 Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Options<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">385,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,287,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,672,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">708,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,672,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options include a service condition for vesting and most stock options vest over four years with a <FONT
STYLE="white-space:nowrap">one-year</FONT> cliff vesting and <FONT STYLE="white-space:nowrap">pro-rata</FONT> monthly vesting thereafter. The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated
as the difference between the exercise price of the options and the estimated fair value of the Company&#146;s common stock, as determined by the Board of Directors, as of December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fair value of options that vested for the year ended December&nbsp;31, 2023 was $0.2&nbsp;million. The options granted in the
year ended December&nbsp;31, 2023 had a weighted-average per share grant-date fair value of $0.35 and a total grant date fair value of $3.2&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Valuation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
weighted-average assumptions used to value employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> stock option awards granted under the 2021 Plan during the years ended December&nbsp;31, 2022 and 2023, using the Black Scholes option
pricing model, were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.56</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the fair value of the options granted, the Company uses the Black Scholes option pricing model
and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Fair Value of Common Stock &#151; </I>Given the absence of a public trading market for the
Company&#146;s common stock, the Board of Directors, with input from management, determine the fair value of common stock by considering a number of objective and subjective factors including (i)&nbsp;valuations performed by independent third
parties, (ii)&nbsp;important developments in the Company&#146;s operations, (iii)&nbsp;the rights, preferences, and privileges of the Company&#146;s preferred stock relative to those of the Company&#146;s common stock, (iv)&nbsp;actual operating
results and financial performance, including the Company&#146;s levels of available capital resources, (v)&nbsp;the conditions in the capital markets, biotechnology industry and the U.S. economy in general, (vi)&nbsp;the stock price performance and
volatility of comparable public companies and (vii)&nbsp;the lack of marketability of the Company&#146;s common stock, among other factors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Term &#151; </I>The expected term represents the period that the Company&#146;s stock options granted are expected to be
outstanding and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term). The Company has very limited historical information to develop
reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The Company will continue to apply this process until a sufficient amount of historical information regarding
employee exercise patterns and post-vesting employment termination behavior becomes available. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility &#151; </I>Since the
Company is not a public company and has no trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period, where available, equal
to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage and area of specialty. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Risk-free Interest Rate &#151; </I>The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of
grant for periods corresponding with the expected term of the options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Dividend &#151; </I>The Company has never paid
dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Stock-based Compensation Expense</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense for restricted stock awards and stock options recognized in the Company&#146;s statements of operations and
comprehensive (loss) income is presented as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8195;1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;1,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, total unrecognized stock-based compensation expense related to unvested
restricted stock awards and unvested stock options was $5.2&nbsp;million, which is expected to be recognized over a weighted-average period of 2.9 years. As of December&nbsp;31, 2023, total unrecognized stock-based compensation expense related to
unvested restricted stock awards subject to performance conditions, which were improbable of achievement, was $0.3&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the provision for income taxes were as follows for the years ended December&nbsp;31, 2022 and 2023 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2022, the Company had no income tax expense due to operating losses
incurred. For the year ended December&nbsp;31, 2023, the Company recorded income tax expense of $0.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of
the Company&#146;s effective tax rate to the statutory U.S. federal rate is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. federal taxes at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State tax, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State NOL reserve</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;14.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effects of loss and credit carryforwards and
temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The types of temporary differences that give rise to significant portions of the
Company&#146;s deferred income tax assets and liabilities are set out below (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sec 174 capitalized research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets before valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;10,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;21,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,504</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred income tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has established a valuation allowance for the amount of deferred tax assets that are not more
likely than not be realized. Management considered all available evidence, both positive and negative, including but not limited to the Company&#146;s historical operating results, income or loss in recent periods, cumulative losses in recent years,
forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts, and concluded the deferred tax assets are not more likely than not to be realized. The net change in the total valuation allowance for the years
ended December&nbsp;31, 2022 and 2023 was an increase of $10.2&nbsp;million and $1.9&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2023, the Company had $14.6&nbsp;million of federal net operating loss carryforwards and $28.9&nbsp;million of state net operating loss carryforwards, available to reduce future taxable income. Of the federal net operating loss carryforwards,
$14.6&nbsp;million will carryforward indefinitely. The state net operating loss carryforwards will begin to expire in 2041, if not utilized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the Company had federal research and development tax credits carryforward of $2.0&nbsp;million and state
research and development tax credits carryforward of $1.8&nbsp;million, available to reduce future income taxes. The federal research and development tax credits will begin to expire in 2041 if not utilized. The state research and development tax
credits have no expiration date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal Revenue Code section 382 (&#147;IRC Section&nbsp;382&#148;) places a limitation (the
&#147;Section&nbsp;382 Limitation&#148;) on the amount of taxable income that can be offset by net operating loss (&#147;NOL&#148;) carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation.
California has similar rules. When an ownership change occurs, IRC Section&nbsp;382 limits the use of NOLs and credits in subsequent periods based on the annual 382 limitations. The annual 382 limitations may limit the full use of available tax
attributes in one year but the identified ownership changes may not result in expiration of tax attributes for use prior to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expiration of their respective carryforward periods. The Company performed a Section&nbsp;382 analysis through the year ended December&nbsp;31, 2023 and determined there were ownership changes in
2021 and 2023 that resulted in 382 limitations limiting the full use of carryover attributes in 2023. The ownership changes did not result in a reduction of its net operating loss or in its research and development credit carryforwards expiring
unused. Accordingly, none of the tax attributes have been reduced but limited the full use in 2023. If additional ownership change occurs, the utilization of net operating loss and credit carryforwards could be significantly reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions based on tax positions related to current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustment based on tax positions related to prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;1,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;2,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reversal of the uncertain tax benefits would not impact the Company&#146;s effective tax rate as the
Company continues to maintain a full valuation allowance against its deferred tax assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes interest and penalties
related to uncertain tax positions in income tax expense. During the years ended December&nbsp;31, 2022 and 2023, the Company did not recognize accrued interest and penalties related to unrecognized tax benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files income taxes in the U.S. federal jurisdiction, the state of California and various other U.S. states. The Company is not
currently under examination by income tax authorities in federal, state or other jurisdictions. All income tax returns will remain open for examination by the federal, state and foreign authorities for three or four years, from the date of
utilization of any NOLs or credits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Related Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third Rock Ventures </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the
year ended December&nbsp;31, 2022 and 2021, the Company issued a total of approximately 41.3&nbsp;million shares of its Series A Convertible Preferred Stock to Third Rock Ventures VI, L.P. (&#147;TRV&#148;), a holder of more than 5% of the
Company&#146;s outstanding capital stock, during the initial and second tranche closings, for cash proceeds of approximately $26.6&nbsp;million and upon conversion of outstanding convertible promissory notes of $14.7&nbsp;million (see Note&nbsp;8).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company issued a total of approximately 12.4&nbsp;million shares of its Series B
Convertible Preferred Stock to TRV during the first tranche closing, for cash proceeds of $15.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2021, the Company
entered into a service agreement with TRV (the &#147;TRV service agreement&#148;) under which TRV provides consulting services to the Company. For the years ended December&nbsp;31, 2022 and 2023, the Company recorded expense of $1.3&nbsp;million and
$0.3&nbsp;million, respectively, for such services as general </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and administrative expenses in the Company&#146;s statements of operations and comprehensive (loss) income. As of December&nbsp;31, 2022 and 2023, outstanding accounts payable to TRV were
$0.1&nbsp;million and $0.1&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s interim Chief Medical Officer, and also a member of the
Company&#146;s board of directors, was designated to the Company&#146;s board of directors by TRV and is affiliated with TRV. He did not receive any cash compensation from the Company for his service as its interim Chief Medical Officer, as his
services were provided to the Company through the TRV service agreement. Of the total fees the Company incurred under the TRV service agreement for the years ended December&nbsp;31, 2022 and 2023, $0.3&nbsp;million and $0.2&nbsp;million,
respectively, were attributed to services provided as the Company&#146;s interim Chief Medical Officer. Additionally, as compensation for his services as the Company&#146;s interim Chief Medical Officer, the Company granted him options to purchase
100,000 shares of the Company&#146;s common stock during the year ended December&nbsp;31, 2022, and 230,000 shares during the year ended December&nbsp;31, 2023, at exercise prices of $0.18 and $0.32 per share, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>RA Capital </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2023, the Company issued a total of approximately 12.2&nbsp;million shares of its Series B Convertible Preferred Stock to entities affiliated with RA Capital Management, L.P., which collectively hold more than 5% of the
Company&#146;s outstanding capital stock, during the first tranche closing, for cash proceeds of $15.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Samsara BioCapital
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company issued a total of approximately 4.3&nbsp;million shares of its Series B
Convertible Preferred Stock to Samsara BioCapital, L.P., a holder of more than 5% of the Company&#146;s outstanding capital stock, during the first tranche closing, for cash proceeds of $5.2&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Net (Loss) Income Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of the basic and diluted net (loss) income per share (in thousands, except for share and per
share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2022&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2023&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator, basic:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of earnings to participating preferred stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,613</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income applicable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator, basic:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used to compute net (loss) income per common share,
basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,372,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,606,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator, diluted:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of earnings to participating preferred stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income applicable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator, diluted:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used to compute net (loss) income per common share,
basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,372,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,606,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,013,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used to compute net (loss) income per common share,
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,372,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,746,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income per share, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income per share, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Potentially dilutive securities not included in the calculation of diluted net (loss) income per share because
to do so would be anti-dilutive were as follows (in common stock equivalent shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2022&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2023&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,705,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,501,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,933,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total antidilutive securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,886,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,638,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Employee Retirement Benefit Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains a 401(k) retirement savings plan (the &#147;401(k) Plan&#148;) for its employees. The 401(k) Plan allows eligible
employees to make contributions up to the maximum allowable by the Internal Revenue Service (&#147;IRS&#148;). For the year ended December&nbsp;31, 2023, the Company made matching contributions of and recorded contribution expenses of
$0.1&nbsp;million. For the year ended December&nbsp;31, 2022, the Company did not make any matching contributions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated all subsequent events for recognition and measurement purposes through August&nbsp;2, 2024, the date the financial
statements were available for issuance. The Company has concluded that no subsequent events have occurred that require disclosure, except as described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subsequent Financings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May
2024, the Company executed the second tranche of the Series B Convertible Preferred Stock financing arrangement and issued the remaining approximately 60.8&nbsp;million shares of Series B Convertible Preferred Stock, for net proceeds of
$74.9&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officer and Director Equity Awards Modification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May&nbsp;2024, the Company&#146;s board of directors modified the terms of stock option awards for 7.2&nbsp;million shares of the
Company&#146;s common stock granted during the year ended December&nbsp;31, 2023, stock option awards for 4.1&nbsp;million shares of the Company&#146;s common stock granted in 2024 and restricted stock awards for 7.7&nbsp;million shares granted
during the years ended December&nbsp;31, 2022 and 2021 to certain executive officers and members of the Company&#146;s board of directors. Under the modified terms, accelerated vesting provisions were added associated with certain change of control
events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195;Shares
</B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g00w02.jpg" ALT="LOGO" STYLE="width:1.93125in;height:0.453125in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B>&#8195;TD Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B>&#8195;&#8195;Cantor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B>Wells&nbsp;Fargo&nbsp;Securities</B></TD></TR>
</TABLE> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2024 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Through and including&#8195;&#8195;&#8195;&#8195;, 2024 (the 25th day after the date of this prospectus), all dealers that effect
transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to
their unsold allotments or subscriptions. </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except where the context otherwise requires or where otherwise indicated, the terms &#147;Septerna,&#148; &#147;we,&#148;
&#147;us,&#148; &#147;our,&#148; &#147;our company,&#148; &#147;the company,&#148; &#147;registrant&#148; and &#147;our business&#148; refer to Septerna, Inc. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&#8201;13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Other Expenses of Issuance and Distribution. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth all expenses to be paid by us, other than underwriting discounts and commissions, in connection
with this offering. All amounts shown are estimates except for the Securities and Exchange Commission (SEC) registration fee, the Financial Industry Regulatory Authority, Inc. (FINRA) filing fee and the Nasdaq Global Market (Nasdaq) listing fee.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount<BR>to&nbsp;Be&nbsp;Paid</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$&#8195;&#8195;&#8195;&#8194;*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#8195;&#8195;&#8195;&#8195;*</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#8195;&#8195;&#8195;&#8195;*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and mailing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#8195;&#8195;&#8195;&#8195;*</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#8195;&#8195;&#8195;&#8195;*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#8195;&#8195;&#8195;&#8195;*</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#8195;&#8195;&#8195;&#8195;*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#8195;&#8195;&#8195;&#8195;*</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$&#8195;&#8195;&#8194;&#8195;*</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To be provided by amendment. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&#8201;14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Indemnification of Directors and Officers. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;145 of the Delaware General Corporation Law (DGCL) authorizes a corporation to indemnify its directors and
officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The
indemnity may cover expenses (including attorneys&#146; fees) judgments, fines, and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section&nbsp;145
permits corporations to pay expenses (including attorneys&#146; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section&nbsp;145 provides that a corporation has the power
to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the
corporation would have the power to indemnify the director or officer against such liability under Section&nbsp;145. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
will adopt provisions in our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and the amended and restated bylaws, which will become effective upon the effectiveness
of the registration statement of which this prospectus forms a part, that limit or eliminate the personal liability of our directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended.
Consequently, our directors and officers will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as directors or officers, except for liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our directors, any unlawful payments related to dividends or unlawful stock purchases, redemptions or
other distributions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which they derived an improper personal benefit; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our officers, any derivative action by or in the right of the corporation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These limitations of liability do not alter director and officer liability under the federal securities laws and do not affect
the availability of equitable remedies such as an injunction or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our amended and restated bylaws
will provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees
to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will advance reasonable expenses, including attorneys&#146; fees, to our directors and, in the discretion
of our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into indemnification agreements with each of our directors and intend to enter into such agreements with our
executive officers. These agreements provide that we will indemnify each of our directors, our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#146;
fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for
any action or proceeding arising out of that person&#146;s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification,
advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#146;s or officer&#146;s services as a director
referenced herein. Nonetheless, we have agreed in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide
indemnification for the expenses or liabilities incurred by those directors are secondary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also maintain general
liability insurance which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended
(Securities Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriting agreement filed as Exhibit 1.1 to this registration statement provides for
indemnification of us and our directors and officers by the underwriters against certain liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&#8201;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Recent Sales of Unregistered Securities. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Set forth below is information regarding unregistered securities issued by us since&#8195;&#8195;&#8195;&#8195;2021 to the date
of this registration statement. Also included is the consideration received by us for such securities and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Convertible Promissory Notes </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From January 2020 through September 2021, we issued convertible promissory notes to Third Rock Ventures V, L.P. in an
aggregate principal amount of $14.0&nbsp;million. Each of the convertible promissory notes accrued interest at a rate of 6% per year and converted into shares of our Series A convertible preferred stock in November 2021, as further described below.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Convertible Preferred Stock Issuances </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From November 2021 through November 2022, we issued and sold an aggregate of 75,000,000 shares of our Series A convertible preferred stock in
two closings, at a purchase price of $1.00 per share, for an aggregate purchase price of $75.0&nbsp;million. Included in this amount was $14.7&nbsp;million of the then outstanding principal and interest on convertible promissory notes issued to
Third Rock Ventures V, L.P. in 2020 and 2021, all of which converted into shares of our Series A convertible preferred stock in this financing in accordance with their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From June 2023 through May 2024, we issued and sold an aggregate of 121,657,452 shares of our Series B convertible preferred stock at a
purchase price of $1.23297 per share for an aggregate purchase price of $150.0&nbsp;million in multiple closings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offers, sales and
issuances of the securities described above were deemed to be exempt under Section&nbsp;4(a)(2) of the Securities Act or Rule 506 of Regulation D under the Securities Act as a transaction by an issuer not involving a public offering. The recipients
of securities in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these
transactions. Each of the recipients of securities in these transactions was an accredited investor within the meaning of Rule 501 of Regulation D under the Securities Act and had adequate access, through employment, business or other relationships,
to information about us. No underwriters were involved in these transactions. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Grants and Exercises of Stock Options and Restricted Common Stock </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through &#8195;&#8195;&#8195;, 2024, we have granted stock options to purchase an aggregate of &#8195;&#8195; shares of our common stock, with
exercise prices ranging from $&#8195;&#8195; to $&#8195;&#8195; per share, to our employees, directors and consultants pursuant to our 2021 Stock Option and Grant Plan, as amended from time to time (2021 Plan). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through &#8195;&#8195;&#8195;, 2024, we have granted an aggregate of &#8195;&#8195; shares of restricted common stock to our employees,
consultants and other service providers under the 2021 Plan and an additional &#8195;&#8195; shares to our advisors and <FONT STYLE="white-space:nowrap">co-founders</FONT> outside of the 2021 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuances of the securities under the 2021 Plan described above were deemed to be exempt from registration under Rule 701 promulgated
under the Securities Act as transactions under compensatory benefit plans and contracts relating to compensation, or under Section&nbsp;4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering. The recipients of
such securities were our directors, employees or bona fide consultants and received the securities under our equity incentive plans. Appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of
securities in these transactions had adequate access, through employment, business or other relationships, to information about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
issuance of the securities described above to advisors and <FONT STYLE="white-space:nowrap">co-founders</FONT> outside of the 2021 Plan were deemed exempt from registration pursuant to Section&nbsp;4(a)(2) of the Securities Act as transactions by an
issuer not involving a public offering. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&#8201;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits and Financial Statement Schedules. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Amended and Restated Certificate of Incorporation of the Registrant, to be in effect immediately prior to the
completion of this offering</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.3*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bylaws of the Registrant, as currently in effect</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.4*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Amended and Restated Bylaws of the Registrant, to be in effect as of the effectiveness of the registration
statement of which this prospectus forms a part</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.1*+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amended and Restated Investors&#146; Rights Agreement, by and among the Registrant and certain of its stockholders, dated
as of June&nbsp;28, 2023</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Specimen Common Stock Certificate</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;5.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Opinion of Goodwin Procter LLP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.1*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2021 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.2*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2024 Stock Option and Grant Plan and forms of award agreements thereunder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.3*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2024 Employee Stock Purchase Plan</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.4*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Indemnification Agreement, by and between the Registrant and each of its directors</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.5*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Indemnification Agreement, by and between the Registrant and each of its executive officers</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.6*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.7*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Employment Agreement, by and between the Registrant and Jeffrey Finer, to be in effect upon the completion of this
offering</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.8*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Employment Agreement, by and between the Registrant and Liz Bhatt, to be in effect upon the completion of this
offering</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.9*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Employment Agreement, by and between the Registrant and Samira Shaikhly, to be in effect upon the completion of this
offering</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.10*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Employment Agreement, by and between the Registrant and Uwe Klein, to be in effect upon the completion of this
offering</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.11*#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Employment Agreement, by and between the Registrant and Daniel Long, to be in effect upon the completion of this
offering</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.12*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lease Agreement, by and between the Registrant and Britannia Pointe Grant Limited Partnership, dated as of April&nbsp;20,
2021, as amended by the First Amendment to Lease Agreement dated as of September&nbsp;14, 2022, Second Amendment to Lease Agreement dated as of September&nbsp;23, 2022, Third Amendment to Lease Agreement dated as of December&nbsp;22, 2022, and
Fourth Amendment to Lease Agreement dated as of December&nbsp;12, 2023</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;10.13*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Service Agreement, by and between the Registrant and Third Rock Ventures, LLC, dated as of August&nbsp;25,
2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;21.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subsidiaries of the Registrant</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;23.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consent of Independent Registered Public Accounting Firm</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;23.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consent of Goodwin Procter LLP (included in Exhibit 5.1)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;24.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Power of Attorney (included on signature page)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Filing Fee Table</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Indicates a management contract or any compensatory plan, contract or arrangement </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements Schedules </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&#8201;17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Undertakings. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates
in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the
opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of
expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby
undertakes that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) For purposes of determining any liability under the Securities Act, the information omitted from a form of prospectus
filed as part of this registration statement in reliance upon Rule&nbsp;430A and contained in the form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this registration statement as of the time it was declared effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) For the purpose of determining any liability under the
Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_25"></A><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration
statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, California, on the&#8195;&#8195;&#8195;&#8195;day
of&#8195;&#8195;&#8195;&#8195;, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">SEPTERNA, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jeffrey Finer, M.D., Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">President, Chief Executive Officer and Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_26"></A>POWER OF ATTORNEY AND SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each individual whose signature appears below hereby constitutes and appoints Jeffrey Finer, M.D., Ph.D. and Liz Bhatt, M.S.,
M.B.A., and each of them singly (with full power to each of them to act alone) as such person&#146;s true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent with full power of
substitution and resubstitution, for such person in such person&#146;s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any registration
statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended), and to file the same, with all exhibits thereto, and all documents in connection therewith, with the
Securities and Exchange Commission granting unto each said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent full power and authority to do and perform each and every act and thing requisite
and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement and power of attorney has
been signed by the following person in the capacities and on the date indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jeffrey Finer, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">President and Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(principal executive officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Liz Bhatt, M.S., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chief Operating Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(principal financial officer and principal accounting officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jeffrey Tong, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chairman and Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Abraham Bassan, M.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Bernard Coulie, M.D., Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Alan Ezekowitz, M.D., D.Phil.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Shalini Sharp, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&#8195;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jake Simson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2024</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g762905g00b98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g00b98.jpg
M_]C_X  02D9)1@ ! 0$!] 'T  #_[1<@4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'].
M4?         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !].4>  $  0'T
MY1X  0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!$0      !     "
M   "0    D      .$))300>       $     #A"24T$&@     #00    8
M             \8   P&    !@!G #  , !B #D .     $
M             0             ,!@   \8                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   \8     4F=H=&QO;F<   P&
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   /&     %)G:'1L;VYG   ,!@    -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $    !3A"24T$#      ,YP    $
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M "  4 !H &\ = !O ', : !O '     4 $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P "  ,@ P #( -     $ .$))300B      $R34T *@    @
M!P$2  ,    !  $   $:  4    !    8@$;  4    !    :@$H  ,    !
M  (   $Q  (    ?    <@$R  (    4    D8=I  0    !    J    -0
M  'U     0   ?4    !061O8F4@4&AO=&]S:&]P(#(U+C @*%=I;F1O=W,I
M #(P,C0Z,#@Z,#(@,#DZ-#<Z,#,       .@ 0 #     ?__  "@ @ $
M 0  # :@ P $     0   \8         !@$#  ,    !  8   $:  4    !
M   !(@$;  4    !   !*@$H  ,    !  (   (!  0    !   !,@("  0
M   !              !(     0   $@    !.$))30/]       (
M  #_X0$Z17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    ?    <@$R  (    4
M    D8=I  0    !    J    -0   'U     0   ?4    !061O8F4@4&AO
M=&]S:&]P(#(U+C @*%=I;F1O=W,I #(P,C0Z,#@Z,#(@,#DZ-#<Z,#,
M  .@ 0 #     ?__  "@ @ $     0  # :@ P $     0   \8
M!@$#  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !
M  (   (!  0    !   !,@("  0    !              !(     0   $@
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M*"@H*"@H*"@H*"@H*/_  !$( D,'- ,!(@ "$0$#$0'_Q  <  $  @(# 0
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M\H+W0-K+?.U\!YR>"/7"OZ=HKWZX1W1O231=<$S)XA)$X.8<X(^.%V*B1$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MLL>=GE\"J#46>YVXR1B-^"" 2"1Z8(75CS5O''$LK4FK+MFHJBWQ/:V4.!&
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MU(V,;6[.&^ XZ*/=6/CEH0!D!Q./_*5D0/B%MB,K=KVAP'/JDD(V.H<ZOCC
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MSUT3OT2=I^!5O7*UI.X$1$7$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MX4=0'1CR:\9^\'ZUNU>>?P3-N=2#/O?F<#T]Y>AE\_U4:RR[*?E$1%SKB(B
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M[G"]U!3,M=5](/I6AK"?5GT3T^*]3INMQXJ128<V3%:TS+0C87QL#8WQR1@
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M6[A\LG'[U*&=62]]&QCG'NPY1[YQ2R_F>,\%8=WKO8H8N\^BZ9S3\MRB+O=
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M*J];,9XR6G(#@#]:Y4KW$R#<=O?. _KA<D\\M6Q-,4T'L3*MC<S29!<?#G&
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M<X$;=@W'<M$0J45$^!SSDG#MBR*=U4)^[CD.W(SGPR<*4H8N_EKHGX!.US?
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M- #H3@XZ\K$HH]MYE9^LP%)\#M@=(!+M/.%SC)J*R)N6C8P]!RLVDHWD/.,
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MYG<!@2<9:[YC[EY66D]-?U<?CWATUF,D=MGF:@ODT56R5LSVS-+1R,Y\"/\
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MW#F_:N)JN$\<;Q&<D9</%0-Q9MU7;QNR&PR$%9YJ>(N?%0]RG_\ U+0.\XI
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M;,_H^("C;;6/,$NU[O>D=D^:GA$QUQNL3?=<2TY'!QA0MOH":9HA<'%Q<2?
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M/D'.D/V*W*HT+8K5349;[YB +AGJ[:&DJV1/;)&U[#EK@"%"7)$1 1$0$1$
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MQMJ+J 3U;!_Q?P4;3$(O2^FY+DYM15 QT@/SD^'IZK8T,3(8FQQ-#6-& T=
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MA[JJ4^8'"G.S^MJJ34UO;3Y+^^;AOB3GHIOLOTH_4-VFCJV.CHHF;GR #.?
M ^JW;8M%6.R50JJ*B;[4!@2R'<X?#R7#DRQ&XEZ>'#:8BRQHB+B>@(B("(B
MB*FZH[0[18:LTCBZHJ@<%C"  ?(E3$3/A:M9M.JPP^V2CIH.SR^5,438Y]C/
M?;P>9&@_9E:7L6HHJ.T11O)Q&W:TL&>/#HNSM?U_<=1Q&A@/LUNRT.A8_=WA
MSG+C]7'HJ?1^S6F"/O:S+W-W;">,_!>QT>&+89BWRY^HK;'>(GX66UZTCJ=1
M"#!B9@!CG\%S\_8K#?;M'ADE;,&QY#<D^O@M.UE3%5WYDD  !<.@ZE=]W=+.
MZ%A<YQS@9*BV"/5K6&M*;P6R3[-\FM@@HA'$P%K1@84-;8&5]QE=.3L P&9Q
MDJD6VLO-OI(Q55$!A#1M+QEP'ASD#I]RQ]/ZL;!=JMD[WNB>=XD'@< 'CRX5
M,G3VI6;,:3%[16&PZZ*FCE#:9FQSG $>'DL^>VTGL3G,>]TP YSY<CA4&XZJ
MBWQNI6F;#@7.<,<>04DS4M&^+<RI#2>D9!SGR7-%OETVZ;)',0LU%23RT[7.
M<R-K7AV7=3A=-/3-CJVQO+"6Y._"QK)<WU%/$ZH#0&CWVM.>?)<Y:V@95[O:
M&M(X+2[@%7CF=0QG':/,+M:*4V^-@#W'+7. =X;G;BK'W\'LFTM:7>96NHM6
MT<53&:J=LK. [8X.=A?-;:[LU%0&>PU#JJ5YY@(VF(>>5RWK,RVIBO,<0O=+
M155RD(A&(0[#GD\!76&,10LC;]%@#0O+6D.UB]T-Y;WLC9*)[LN@<<C'D#X'
MU7I^UUT-RMU/6TKMT,[ ]I]"J6K,>5LF*V/RR41%5F(B("(B M,?A%W6J@H:
M"E@+C1%Y]IV.(Y/T0['AC<MSGHO*_:K<YI]85=NH:J1X:W:YY) ;("[<#Y\8
M7=]GT[LN_ACFG5=*()J*.=[6,#]C3W3W$D9\L>2D;%4F6H>^!C8XA'A_'&[/
M@L%E+34#HS,"^J+#EF-P<5)6-TT-5W9H710/C+@W.><YRO:R_DEQSX2C*@XV
MS1Y8!@G'*YQO:]^]C';AQP.,>J[#6-><21$-(R,^)7;1/=/5,:Z:GB:3DN>[
M ^:\M1;*'4MOHJ2"G,54&,:&AQ8,?'JK-#(R:)DD3@Z-XRUPZ$*C06F&:1L3
M+Q1.+W?1;U/H.5=+>QD5'%'$ &,&T #'1<>2M8YAK69]V0B(L5A=L,\D7T'<
M>1Z+J1!(Q5[3Q*W'J%DLJ(G_ $7M^?"A432W<GE]4&R1[/HO</@5VMK)F_I9
M^(4:3W&JJ<U%BJ6M&7, >/D?X96LEM USG-+7L:YI&"%K"^N_%5PD@DC?L^E
M&X='-5ZSI2W/A\7U8 N<&WD29\L?WKFVXT[NKBWXM*MN%-,M%B^WTW_B_P"Z
M?X+Y^,:;]<_U2FS3+18@N%-^N?ZI7T5]-_XO^Z?X)LTRD6(ZXTP'#R[X-*X_
MC.GQTDS_ */]Z;@TS44?^-8\'\V_/R76Z[>[[L.#ZNS^Y-PG2410[KI*2=K&
M ?,KI=7U+O\ O,? !1W&D\N$DT4?TY&M/D3RJ\^:5_TY'N\.7%=:=R=)V2X4
M[,X<7G^:%C274\]U$!ZN.5%HHW)ID2UD\HPZ0X\AQ]RQT7=24LU7,(J:)TDA
M\&C*A+I4I9[%6W1P,$9;#GF5_#1_%6FQ:.CBVS70B1_41-^B/B?%6YC&QL#&
M-#6@8  P @BK'8*2TL!8WO*C',KAS\O)2Z(H!$1 1$0<9)&1M+I'M8T=2XX"
MH^J7T,E6:JBG8^5P#)6LSSZYZ+LUE4S,J&1U+G"G!W#C@GG]RJO?GO&F3W6<
MXP.JZ\6+7U;9VM[,^HKI'4\4(VF.(_FI#R6^F?)2NF+G[+4M+LB"8AKQY'P<
MJ]"1!4]TYV6.YP6^*[8HS#,^-^-D@SNZ8] MIK$QI6);87UK2YP:T$N/  \5
MU:&I:J_6V,L S$>ZED<> 1^_&#\ULFT62FMS0X#O)_&1P^[R7GVCMG4NFE)M
MRA+#IISG-GN+<-'+8O$_'^"M[0&M :  .  B*CIK6*^!$1%A$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!"0 2>@Y18EWD[FTULN<;('
MNS\&E3$;G0\<UDDMZUE=Z_O2T354K\X!R"XX'/H0%+RS4Y9(]S6L:.< %Q:,
M[>3GS(58T[5-9*^-S'.DD.0<9Z*5N5L944<O<&*(./>'=AI=D@'Y#!X7U&M1
M$0\_WY0(=!^,V/B#>[C(+@1P<'XJS53Y*RD8^W3F-\;G EC?I>.2<\=<*CTX
M[N3#LC:Y7RF,,-.?9P.Z/+0WWLC./''.!\U:/")C2I7:.KA(;5.D/'!))!&>
M<?-)*F*>TPQR2!LT&6L:<G<"<\?7]BD]25D<]/L+"UP/NMP!CS*J[0-P\\JL
MS,2FL;A*4USFAB$8:U^.&Y'0?\Y4W2.EJX0*J%S(\  M&.OCC'*Q;"QK8^]8
MUKI6$GWL>&,87"ZW>27+&QMA8X $-<3CGR^2TGCRIK?A"]VTU.S( SC*M%OM
M]/3Q^T1R'>.=QXP!TYRJE&QTTA#>O53$=-4!@:)>@ V[\CA4KRM9DV>1U/KN
MSSQ$[FU\):[S]]J]O+Q-9QWFK+ WWLNKX< G.,R-7ME>1]IQJ\.KIYW B(O,
M;B(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#A)%'(
M,2,:\?SAE?8XV1C$;&M'DT87)$$+J2W25,;9Z<;I8Q@M'Z051=(]I+7 @C@@
MK9"Z)Z.FG.9H(GGS<T$H-'=H53#245/55+PUC7%N3XG&<?8H+1MT?<*"1\C-
MCV2$%I\&GEOV%7_\(JW1N[.Q)#$Q@IZJ-^&C'!RW]ZTGINLDM\D1;M$$A$;V
MAV>GBO6Z;!ZN"9CRYKW[;\MK13EHVOD(XZ+"J:EKF\-R023SU4.V\TGA5QQ$
M.Q^=&TCXJ&NNHHHHG&C=[1*6.<"P^ZT#Q)\?@L_3MO6D[A8*6JC[ZHB:1WL3
M@'CXC(^PK9%O$,U!!(23N8"O-%DO4U!<9*JL>YU/5D[Y#XN!Z_+*WWI>M;4V
M*EDB>U["W <TY!Y5.IQVQ>%L<Q9':RB;#7,D8/S<HY^(6'IZ-C99)L R-P!G
MR4CK3:VRRU4QPRG(>YWD.G\%K?3&K6R:@EB+G-@J&M;$#^B1_'E3AI;)29CV
M1:8K.FV'U8Q@N;G.<^!4-<JMFP#Z7)+@/!8IJ^#^<R22#A=&[OF$') YQC]Z
MCD1HB$]SB=+RUN7%I^S[UL2*VNEMD530NW[FY=&>H/HM7&ZP1WYE*7<20DLD
M!SN>#RW["MF:.KM]I+"?H/(_>JY8M2(E-=3*!K9S&YS)=[7 \M/"A]XDN$+W
M'.WKSU\EL2N9!4Y[Z&-Y\W-R5C6W1]%<G5#V0N88V9;M<0"[P'WK.,T>ZW:A
MHJ\-:,/)^:5%4UX(.X\' !SRLJ:P4V"UDDL;QQSSA1539JZ'/<.9,WTX*M&2
MLH[98\ ADJXP6;@UV_PZ^2EY:OAV. //A5&Y_C*W/IG.MM6^&23:^1D3G-8/
M,D<=<*2HQ4UT@C@A' P78P!\5I/C?LK"2E$TL(>SH[P)ZJ)D;4OJ060/)Z9'
M*M(I)8Z=K,AQ:,<!=<5#52.<806XZGD#X**S6W$23N&3IFF=1-?45+FB5S<-
M;GZ(7.JF#Y<YR3PL<4-8#CNW.)'1HRI*V:<N53*USZ=T;!SF3A4M'9,S,IB>
M[PE--0>T71NYNZ-K3NSTQC'[UGU^F9 \NHI&EA_0><$?-3=GML=NIRQIW2.Y
M>_S_ +EG+D;*A2Z9JGO'M#V1L\<'<5::.FBI*=L,#=K!]OJNY$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 6/6T-+71]W64\<S/)[<X60B>!C
MT5%34,9CHX(H6$Y(8T#*R$1!YZ[9*L2:JJV.;RW:P?(#G[2JE9(6.W/< 3G'
M*VGVWV2EDGI:V$AM;*=KQY@#@K7EMIA3M+#R1R2O1P<UB7B=7/;>8=DE+'*W
MD#ZES@A9'#L#  /(+N "'HNAP]T^'")@&<=%R/ ]$8X8/*XSO#8R<]!U4G,R
MXM<,KHJYVL:3D9/"X0OW9SRNN&T7"[UD<-#32S!SL':"4F8K&Y=&/%-K:=#Z
MJ0LVQQN=\ K-V;Z6J+[>625D+_8F',O4#'EGS*VKI/0-MME!&;C315581E^\
M9:T^0'3YJX4\$5-$(Z>)D48Z-8T- ^07#DZF;1J'J8NDBL[ET6NVT=KINXM]
M.R"+.2&CJ?,GQ66B+C=O@1$0$1$!%K?4_:M06>XNI:>F-2&.VOD[S:,^..#]
M:RX>U*RNIVRRQ5+"?  .'UY5NR6OHWUO2>UIJ.GTY9Y*B5P[]X(A9YN\_@%Y
M8O54ZKKGU)=O<XY<3SRKOVNZIH=15L#Z":0Q1Q@!KACWLG/[EK@3.:'M&-KN
MO"WQUU#T.FQ=E=^\NNK8V>G+&9#R,Y/FNEU,^\0& 1R>V0LS@#.1_!=X?M/F
MLJVU4E'6,J8,;V^8X(\EVX,_I_3/,,^KZ/U_JK.K0K-KH)17%TK"P1DYSQSY
M+,NS9 Z)S&N./$>:O+KW;YY.]JK<TO\ ' !RN4VIJ2-N*&W11^FT 'XX'*OZ
MD1DB^W/&&_HSA[9W/[*5<:MTFG6LJ'O]I[SC/BW"A;.TNF>['Z/52E[B=6US
MYW%K&/.2Q@P&_ +E00MW=W&WC[U.?J*VC5?=3I>CO2^[\:9=/0S3,W#W6GIG
MQ6=16\12;Y"78Z<+/@RV,-#3@<!=\0!6%:0]ZN.' .(!VN(X\/%8KJ?O"002
M#R>5FR1^0X"^ GG 5YC:\UB?+!=2M&1T)XX6'4V83O<[>\>"F',R04:2,#&1
MYJO9"O9"(IK+#&0X@EPY!<>BV;H+M,.E;?-;KE ^IIF O@+" 6'KM.?#[E2G
MQN<WJH&]PO W#C')'FJ9,<37PRS8:VKJ8;]TKVTV^Z5S8+C3-I8W' D8\NVG
M^<,=/5;:C>V1C7L<',<,@@Y!"\&T52*6J;+@D#J 5ZB["]5?C>S.MD[BZ2E8
M'PDGDQGP^1^\+BO37,/*ZC!%.:MHHB+-R"(B M1W?L<;6ZCJ:F"Y-I[942.F
M=$(]TC2[EP:2<8Y.,],K;B+7%FOBF9I*MJ1;RUV.QS1[1&8Z*H9(QH;WC:E^
M3ZGE0%V[&S3.[^P7:3:P$FGJV!VX<\!XY^Q;C17CJLT?[E9Q5GV>;)=/W*(C
M-/'+X9C>.!\\+';9*UGNMH).FWJWI]:VSJ>WFAN3RT8AER]G[PHA3&>SDG'J
M=-?T]@K9IXVNI'1!KA[[B, >?!5^B8(HVL;T:,+DBI?)-_)%="(BS2(B("(B
M B(@*(U)9F7>BV9#:B/)C=Z^1]"I=$&EZF"6FG?#.PLD8<%I74ML7RQTMWB_
M.C9,![LK>H^/F%0+OIVOMI<YT1EA'22,9'S'4*1#!$1 1$0$1$!$1 1$0$0*
M0H+-7UQ'LU+(YI_2(VM^LH(]<XHWRO#(VN>\\!K1DE7*VZ()PZXU&/YD77ZR
MK7;K91VYFVD@:P]"[JX_$H*79='5%1B2XN[B+]0?3/\ !7:W6^EM\/=TD+8Q
MXGQ/Q*RT4 B(@(B("(B B+Z 2< 9/H@ZIX8YXRR9C7M/@X96K[U0/I:F:F>,
MF,Y:2<9;X%;LM^GJZLPXQ]S&?TI./LZJ#[7M%P0:*J[M3U3XZZ@9WA>0-LC,
MX+"/GQZK;!;5NV?=,XK6C;3M34P=V'%X?)&T?FQRXJ,FNTE4_P!EB8^GD8"6
MO)'TAYJ+G:9^ZK*,2&0\EK6X:T#P)"[*JF-4P9C93RX,K]Q/O ]#GR7NTP5K
MYY8Q&FSNQC6;[#J62ANQ;';[AC?/N_-LEQ[KLGH".#\EZ38YKVAS'!S2,@@Y
M!7BBWTMSDIX.ZA-:VH:&0QAI))W$<>>"%Z([":&]45LN#+M%4T]&71^SPSC&
MUV#O+1X#Z/S!7!U^"O\ U8G4_#JP7G\K:"(B\ETB(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B H'7M0:71-^F!P6T4N#Z["%/*H=K
MSW,[-=0EG7V8CY$@%:8HW>L?K"+>)>8=.D0VTR4\8=(,%Q=XYR/(\=5U72[O
M$;MD7=!P#3AP(Y:,<8/BTKMTO'5-HI#WI8QQ;LYZ_5Z++N<<,MO?%(7"3.2Y
MI.TL'CCTPOI;0\^.%#B<Z1SGNY).3PK99:6OA;WQ=^9:/H/<1CCCCPZJN4KF
MMCX+2&2YZ\GY?)6ZCJ(ZNF>*:5HF#-Q! SU/]WDK5_*3/+%U%- ZAV%AY)(+
MG$\[<?6JBR-WNO\ T22 IB^VNKA9'42N#XWMR' C@ XZ?-15,XE[&D<-5?,I
MCB.%BL%)40XGD!]F?PX>/!'3USA1>I)6FXOV-VC \<^'FK(YS*ZC;'33%K]Q
M&&_+KT56NEOGII'OF #3R#NSGI_%6MX176V+03.BG:YK=Q\O-6(U3A$'"%QS
MXN(^OKE5^W2]Q5!SVG &>GIU5D;7PF/P<?I<Y!.3XG/FJTGCRF_ED:/@]H[2
M-.,+BXNK8CCR <#^XKV>O(_9#1^U]K-D/T@USY2?]%CCGGY+UPO'^TI_U(AT
MX/RB(B\YN(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@I?;+3LJ.S6^A^/<A[P9\VD$+R;;+D8B(P&M:0YI(&>"%ZN[;.\_
M)E?.Y:2>[;NQ^KN&?L7DRST?M=5%"6N#7GEV,G SG"]O[,G6*?W<F>(F5HAF
MBJZ.(^U,=O?S$?I' ZKO%+30T8E;W<LK '<YPQI&/> QG"ZZ.A9222101=X[
M!8#+&"X,SQD'H?59%3/+3PU4<<A; 8FO:W9N#L#J3X=.B[YYX8J-<(H:*JFI
MW,$X:'-;("1DGH<+T_\ @]4L$_9C1]]"R0B>7Z3<_I+S3?9XYJBI=(YLE22U
MS7PN'=@ >]QY]%Z-_!DKQ4]GTM/QOI:M[3\" X?>5YW7Q_I\?+?#YY7+M$MD
M,_9_?Z>&%C,T<C@&MQRT%P^Y>,:7:'.(<\2@>Z6G&#GS^&5[JOD7?V6X0GD2
M4\C/K:0O#]NIHY*LB=Q9&UX#B!G S@J/LR=UM"<_$[6>._7*D@BC$D$@ #BV
M6-Q+23C)(ZC S\UGLO-=54\+Y71P,RUKVDY&#G)\P.GBLRG#:2WT=5%'"VI8
MS: \AWN$D#C]RCZ\NIYYX*0LE$;!.=^!G#<G&>" !T79&+'$[TQ[IF-(/44F
MR)DHE>9H)@QDC, !N,\?4MI=B-=5:EHKC$UC>_IBPOYP' Y&1]2TI?*QM8\O
M:(RYWODM;M()'T?DMN_@HRD7V^Q$Y!IXW?4[^]<_6Q%L<S\-,/$MP4VG*V1X
M[[9$SQ).3]BM5OHXJ&F;#".!R2>I/FLE%X;K1=RLE+7/,AS'*>KF^/Q"PX-+
MP-?F6=\C?(#&58$0=<,,<$38HF!L8X "A[EIV"HD=+3N$$CN7 #W25.(@J\&
MEG;QW]2W9Y,;S]JL5)2PTD B@8&L'VKN1   Z (B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@T]VH/E%^D;)G9ANW/EC^.5
M2"X;@<]5OG5FFH+_ $P#B(ZA@PU^.H\BM>L[-;G[1ASH0S(]\OX^K&5Z&'-3
MMU,Z>1U'27MDFT<[4HN 7?/2D4^]CB78SA;5A[.:/,;JBLF>0!N#6@9/IY*=
M_P $K+[)[/[$S&,;\^_\<J9ZJD>$X_L^T;[GGZ@@FJ:EE/&TN?(=K<<X)5MI
M.S2_SW#N*SN(J0$%TP?NR/0=5M"S:/M5IJQ4TT;W2M^B7NR&_ 85A663JIF?
MH=.+HXB/K\JS#H:P1T<-.:%KN[ ]_)#G'S..JL%'204<#(:6)D431@-:,87<
MBY9M:?,NN*Q'B!$156$1$!$1 4)K*[1VC3]5.YX;*YACB'B7'I_%3:T-VYW*
MKDO,E-&YW<T[&@!I^CGDGYJU*]TZ:X,???36=^CD%>7R!W=N^B<]5B23=Y"T
M.?MV#:&#/(\U]GGEGC8V9V[9P">JQ7M.<^*ZWLQ&G;D%H\_-<2.?)<,EH^"%
MXD82#@A$DA:U<HG>[A8K@XE=P! &>41$NTO&.JQG2>]Z+L<S<,K'?M;E0B9)
M,R$!O+O12EKI709DD^D?#R7;9(HW1;L#<5)R,;W> .BVI3W:TQ_[GP$!OD5Q
MCX)PN#7C&"1GU7.$@N/B%JV<@\DD8*>\ 3CY+M&,HX<%$Z8P<9">G"Y1.VOP
MY<3[I/H%\@]\Y!SA0ADO<,+!KH>\C/F.2N^8O9SU"[&!KV$@YRI\D\\*%44<
MGM+HXFEQZ@#R6\/P9[35"NJ[@X.;3Q1NB<<\%Y(X^0&?F%J6_P #F.,L0(VG
MKZ*^=@.J:NDU5!;=Y=351[M[!T/D?B%Q9:ZW#S>IK/;,0]1(B+E>2(B("(B
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MP1N__@,__(U;.1!K5NC;J>H@'QD_N7?%HBO(_.3T[?@2?W+8:(*1!H4\&>N
M\PR/]Y*D:?1EMCQWKIICZNP/L5F1!@4EGM])@P4<+7#](MR?K*SQQT1$!$1
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M"DHJV:6ECWL+R3M+F@9( QGSY7+4'-M<X[&2- '4'T^YR[9YAE'"PW#LYO\
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MWM0"99G#H'NZ@>@Z*V+YS-:+7F8=U8U B(LTB(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MK3^CZVKJ[13.[^<X#Y7;S&W]5I\!]JMZ*DY;S$QORM%8@1$6:PB(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B(.F2DIY9!)+3PO>.0YS 2/FNY$05?M-N$=OT3<W2=9HS T>KN/NR?DO
M'5>1/7.,)#MY\/->N^URS27G1-;'!(&2T_\ C#23C.T'(^HKR3;:*4UK YI
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M  KS.B?AF+YG^_P>O9Z8_*?I+]JG_9Y?^%/RGZ2_:I_V>7_A7F=$_#,7S/\
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M  KS.B?AF+YG^_P>O9Z8_*?I+]JG_9Y?^%/RH:2_:I_V>7_A7F=$_#,7S/\
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MJ@]BEF_%FC8ZF1N)J]YG/'Z/1OV<_-7Y<V6D4O-:SO2]9W&Y$1%FL(B("(B
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MG&=V01XC@)@K3[O>)GZ=^?\ !:9[XUY6?\(&[4LK;;;89625$;W2RAISLXP
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M(P022WXK)J.Q-W?.]FO8$)/ ?!EV/7!PK_H?1EOTE2R-I"^:JFQWM1(!DCR
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M2W)H'0D.CYZR6&NDJC4-:TA\8;MP2?/U476=E5!6ZEJ;K65LLL=1,^5]/W8
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MW1[(V\N<?I/=XN)\U*+@ZOJYSSJ/RML>.*1^HB(N-H(B(*AVN?YN[Q_HQ_\
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MB B(@(B("(B B(@(B("(B B(@+A%#'$7F-C6&1VYY QN/F5S1 1$0$1$!$1
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M[P,<''BK5H:.L_$YFN%%344LSR]L4$0CPWPW >*BWCE-?/"PHB+-H(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("C=2_Y.W3^BR?V
M2I)1NI?\G;I_19/[)4PB?#66G/\ HB#1]Y'NPS=[13GPYD?M)_Y\%<-6_P#2
MFI+'96\QAYK*@?S&?1!^)RH:VVPW3L>AA8,S1LDFC\]S9''[LCYK-[-7SWBH
MK[_6-_.2-92QY\ UHW8^)6D_*D?"-T?=#9M#7VN8 9(JJ38#T+C@#[2L^S:/
M==K5#<+Q=+@^X5+!*'LF+1'GD #ZE':3M;KQH2_4,>!+)52;,]-PP1]H4A9=
M<4MKM$-#>J>K@N5*P1&'NB3)@8!;\4G?.D1KW=-KU/76W3^HH+A+[376A_=L
MF=^GN.UI/GR%D6;2,U;:8+E57>X"\3QB=LHE.UA(R!M\1TX6':M.5]VL&I*F
MKB--57=XDBB?P6AI+FY\LDX659];P6^T0T%PI*MMWIHQ#[,(B3(X# P?7A/V
M3'ZHO2G>Q=F^I][B)FRS;B./>V#*ONDG%VF+6YQ)<:9A))SG@*E:(IZBY:%U
M%!M_QJHGF&T_KEHX^M=]@UI#3V"FMD='6/O,,0@;3"+JX< D^ 46C>]%9TB;
M5(^7L?N[I7N>[O2,N.3])BM4M)<JW1ED@ME8RBC=!#[1.7%KFQ[!G:?/ZE5+
M0US.Q^\-</>$S@?ZS%EZK9,=,Z2?-'/)9F11&L9#G)&UN,^F-RF?/\HCPZ-4
MT5GLUM?5V;4,_P"-(B"UHK.\,G/.0%G:\JZRKM.E9:>9T-552L]YAQASFCGZ
MRHO4578*G3U7!I:SF1^P&6H$! A8#DDN/.>%(7UXEM&A'L.09HNGP:I^#Y7/
M3VG:>R22R05-9/)*T!YGE+P2/''F5PUO=Y+)INKK8 ._: R,GH'$XS\E.J U
MW:9;UIBKI*;F<X>QOZQ:<X^:RCF>6DQJ.$#3Z)EJ+0VJFNUQ-YDC$HF$Y#6O
M(R!CR\%U7NY7Z.V6*RS2"GN]>\QS3QN!+6 @;@1XD'/'D5W4VOJ6"TLIYZ6K
M;>(XQ'[+W)RYX&/J6%=J"_BV6&^UC'55SH93+/"Q@#N[<1Q@#J /M]%I&]\J
M<>S*O6DG6:TS7&S72X,KZ5AE<Z28N;*!R00L#5UWJKIIO2]=1O,%34U+1[IX
M#^1]60LZ^:UI;O9Y[?9*>KJ;C5,,0B[HCN\\$N^"PM1VU]HLFC:&0@R0UL8>
M1TW$Y/VE(W[HG7LXZPL<VF+;#>;?=:^2OCF:)'2R[FR9]/+/@NW4NG)Z'3LM
M[_&]>Z[1-;,Y_>X822,@#P'/"E^US_)!W^OC^\K-UU_D%</]0W[PHB9X3,1R
MKVMZVMK+%I:HI)#%5U,T9!!P-Q;]V5W7S2DUHM$UUMMUN!N=*WOI)'RES9<<
MNR/+JH[5<TM/I/1LM.PR3,DB<Q@_2(;P/FI*_:QAN]HGM=GI:R2YU;#"871%
MIBSP[<?AE3&^-(XYVQM37'\;46BZX@!TU6QS@/!W /VY7/5UW97:M_$U7='6
MRUT\8?.]C]CI7'D-S\Q]JZ]2VXVJAT70D@NAJF-<1TW<$_:NW4E*VR:T=>JZ
MWBNM-7$(Y3W0D[EPP,X/P'UE(T<HV>Y6[3=RH*C3U[?5TLDHCJ:22;O!M/Z0
MST4[K".HL%YI]2T)D?2DB.MA!."T_I ?5\\+#-TH;S<Z*DTI9Z25N\.J:F6C
M:&1L^KJLG5$\FI]01:;H7$44!$M?*WI@=&9_YY^">Z?9V:1CJ=1WF74E;WD=
M(W,=# 3Q@<;R/'Q^?P"O*H.F9I-*ZCDT[6.<:"I)EH)7>&>K,_\ //Q5^5+>
M5J^!$156$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$056_VFMJ]96&N
MIX=]+2[^^?N:-N>G!.3\E:D13,HB-"(BA(B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B M7?A!?Y+V_\ I8_L.6T5'WJS6^]T[(+K2QU,3';VM?G .,9X^*UP9(Q9
M(O/LK>.Z)A3>PK_(5O\ 29/W+82PK1:J*STGLMLIV4]/N+MC,XR>I6:HS7C)
M>;1[E8U$0J_:?2RUF@[Q# TND[H/P!U#7!Q^P%:F['-86S31N4%XD?#%4;'L
MD#"\ MSD$#)YR%Z!(!!!&054:OLXTM55CJF2UL$CG;BUDCF,)_T0<+HP9\=<
M=L62)U/PI>DS:+5:-[3-01ZEU(ZOI8I&4@C$4)D&"\-SD_62MH]K'^:JB^-/
M_95QK='Z?K64[*FTTKV0,[N)H;M#&YS@ >JS[C9K?<K<R@KJ6.:D9MVQ.S@8
MZ+2W5TGT^V.*HC'/._=0>P#_ "3J_P"EN_LM6)^$-_V':OZ0[^RMDV:SV^RT
MSJ>U4L=-"YV\M9G!/GS\%QO5DMM[BCBNU)'51QNW,:_/!\^%E'45CJ/6UPMV
M3V=JJ=C_ /FXIOC+_:*U?V+?YQ(O]7+]R] VRV4=KH6T=!3L@I6YQ&WH,]5'
MVK2=CM5:*RW6V&GJ0"!(W.<'KXJ]>JK'J<?F_P#J/3GZ?T:^_"'_ .S+-_KI
M/[(4EI^TOO?8C#;X1F66G>8QGJYLKG ?6 KQ>[%;+Y'$R[4<=4R(DL#\^Z3U
MZ+)MM#36VBBI*&%L--$"&1MZ-R<_>53[Q$8JTCS$[3V?5,S[M"=DNKJ725=<
M:&^-E@AG<W+]A)B>W((('/C]BG-2]JE?57^"ET<&S0. 8.]AR97D^ ."!T6Q
MK]HG3]]J/:+C;HWSGZ4C"8W.^):1GYKEI_1MAL$QFMEOCCGZ"5Y+W#X%V<?)
M;6ZC!:TY)K,V^/96*7B.V)X:G[>FW#V^RFLP8_9,$L!#.^R=^/EM65;M6:-M
M>CV1VZW-?>7T_=%AI\O[TMQN+R.1GG@Y]%M^]6B@O5$:6Z4L=1 3G:\=#Y@]
M0?@H:RZ"TW9ZQM516UG?M.6NE>Z3:?,;B<'U45ZK'.**7B>/CQ)..W=,PU1^
M#^X-UC6-<0'&A> #XGO(U@=K(]D[3)YI&D,S#+\0 .GU+>ENTK9+;</;J&W0
MP5?/YQF0>>OBN&H])V743XWW>B;-+&-K9 XL=CRR"#A6CK:>OZFIU,:1Z4]G
M:@-2:DMNI.SW44]HF=-%#"6.<YA;S@'H>?%5#\'?_K=Z_P!7'][EL^UZ3LML
MM-3;:2B:VBJ?Y:-SG.W^'))RN^R:=M-C=*ZTT,5*Z4 /+,^]CIU6/KXZXKXJ
MQ//A;LF;1:6AY99NSWM.EJ)H'/IFRN< !C?"_P#5]1GZPKIKKM1L]5IJII++
M)+/5U<9C.Z-S!$#P<YZG'EE;(O=CMM[IQ#=:.&I8/H[V\M^!ZCY*!HNS;2M'
M4-FCM;7N:<@2R.D;]1)"U^\X<G;?+$]T?\H[+1N*SPJW8)I^>BH:R[U4;H_:
M@V. .&"6#DN^!./J5'[/?\[$']*F^YR]'M:&-#6@-:!@ # "A*+25BH;B*^D
MML$58'%PE;G.3U/7U*K7K(F<EK1^:#TO$1[*YVX_Y!S?TB+[RL7L"_R*J/Z:
M_P#L,5]NUKHKO1FEN5.RHIR0XL?G&1T7&S6B@LM*ZFM=,RF@<\O+&9P7$ 9Y
M^ 6,9X]#TO?>U^V>_N9R(BYEQ$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$18%UN]':WTK*V0L=4R"*+#2<N\N.B#/18$EWHX
M[U%:GR$5LL7?-9M."WGG/3]$K/0$18%NN]'<:NMIJ20OFHW]W,"TC:[GSZ]$
M&>B+ M=WH[G+5QT<A>^DD[J4%I&'>7/7H@ST7">5D$,DLAPR-I<X^0 R5CVF
MXTUVH(ZRA>7T\F=KBTMS@XZ%!EHN$\K(())9#AD;2YQ\@!DJ(=J>UML;+N9W
M>P/=L#^[=G.<=,9ZA-&TTB^,<'L:]O+7#(7U 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 10%
M9K"RT=T%NFJ\U>\1[&,<[#CX9 QE3ZG6D;V(B*$B(B B(@(BZ&U=.ZL=2MFC
M-2UN]T8=ES6^9'@@[T6!1W>CK+E5T$$A=54F.]:6D8STYZ%9Z B(@JNNK36W
M22RFAA[T4]:R67WFMVM'4\GGY*U(BG?LC0B(H2(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("+6SXKE>M?7F@CO=?14].UKV-A><=&\8SZKOOEFOUAMLUSH=1UE4:8=X^&H
M]YKFCKU/DK=OZJ]WZ-A(H6UZAI*BRVRNK)8Z8UH:UK7' +SP6CYY69;[O;[B
M^5M#603NB^F&/!VJ-2G<,Y%$'4UD%3[.;I2=[G;M[P=?CT6?6UM-0TKJFKG9
M%3MQF1QX&>B:-LA%%2ZCL\-2*>6YTK)CCW3(/%9E=74M!2&JK)XX:<8S(X\<
M]$TG;)11,MZMM2ZIHH+G3BK$;LAK\N9P>?EU7#2/NV&'==/QG@NS5$GWN3YD
M].B:1M,HH@:ELIJO9Q=*0S9V[>\'7RRL37-^%BL,\T,T3*US?\7:_G<<@' \
M< Y34^#<+$BA],WBGNEE@J&U4<SV1M[]P/T7[03GR7S_  IL7?=U^-J/?G&.
M\'W]$U)N$RBQ:ZX4E!2>U5E1'#3\#O''W>>G*PI=2V6*6:.2YTH?#_*-WCW>
M<)HVET7""6.>&.:%X?%(T/8YO1P/(*Z*&X4E?WWL=1'-W+S')L.=KAX*$LI%
MCU];36^F=45LS(86D O>< 9. L*74=GBJO9I+G2MGR!L,@SE3HVE46-7U]+;
MZ4U-;/'# "!O><#GHNFFO5MJ:Y]%3UT$E4S.8FO!<,=5&C;/1159J*ST508*
MJY4L4PX+'2#(^/DNZXW2EH[5)7/J(1 &Y;(79:3X<CS*G4HVST58T!J$7VS1
MNJ:F*2XC<Z:-G!8-Y#>/AA2-5J2S4M28*BYTL<P."TR#(/JFIWHW&MI9%QCD
M9+&U\3VO8X9#FG((^*C*G4=FIJDT]1<Z5DP."TR#(/JHTG:51<>]C[KO=[>[
MQNWYXQYY45#J6RS5(IXKI2.F)P&B0<E-&TNBJ':=6U-#9*.2BJ)8)'5L;"Z-
MQ:2TAV1QX<!62ON-';H&RU]3%3L/ =(X#)]%.D;9:+!MEWM]TW?B^L@J"WZ0
MC>"1\EG*$B(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B J/VE_];TU_3V_N5X5'[2_^MZ:_I[?W*U?*MO"1J[GW?:#16WV2E=WE&9?
M:"S\ZWE_NAWEQ]I46S5MYK+Y<[5:[;3S3TT[F-D>XM8U@.,NYY)],+G</\[M
ML_\ MQ_M2+CH.>%NJ]6P%S1.ZKW@'JYH+NGPS]JMJ-;1N=I'3VI*N>\RV:^T
M;*2XM9WC#&[,<K?3_GP*XZ=O4<MSU*)Z:EIHJ&8ATL3-KI -V7//B>%@7ES:
MKM2LL=,0^2E@>Z?;^B"#@'ZQ]:B*2*2=G:''""Z1TC\ =3RY-0C<IJAU+J*[
M1.K[39J=UL#CL$TA;+*!UV^"Q^RFH%7/J*H#',$M9OVNZMSDX*G= 54$VCK:
MZ)[=L4(9)S]%PZY4/V9315%=J::G(=$^MW-(\0=W*>TICS"WWG_LBN_U#_[)
M6NM"72_OTS3P6.V4\D-/N#Y:EY;WCLDX: ?7JMBWG_LBN_U#_P"R57.RNHAE
MT92,B<W=$7MD ZM.XGGY%1'Y4SY9%DU*V[V6XR2TP@K:)KVU%-)R X _6#@_
M:JIJ&O\ QGV50U1IH*;?.W\U W:P8>1P%EV)S:J^:WK*8[J5T9C#QT<X-.<?
M45#U'^9JD_I _P#4*M$:E69X7B_:@EM,%LI*&D-7<:P!L4><-& .7'R_O47<
M-3Z@L)@J+_;*/V![PQTE-(2YF?/)]%W:@OMPBN5IL=F,$5551![IYQD-;CP'
MGP56.TF@N5'8V.N]_-8]\K0RF;$(VG@Y.!UQ^]16(]R9\KO<;]44&K[=;9XH
MO8*V,[)>=PD&>#SCR\/%<]77R>TFW4]!%%+6UM0(8VR9P!XG@CID+![2J)]1
MIUEPI?\ K-OD;4QN'D#S]G/R6!8:ENJ-;"YM&:2WTK!'Y=Y(,GZLD?)1$1K:
M=SX2M[U)5LO(LUAHV5EQ:P/F=([;'$/7ZQ]:Z[=J2X4UY@M>I:&&FEJ<^SSP
M.+HWD>'/0JM4UOJ*GM$OU,V[5%LGDVR,[H#\ZWCCGRR/M67=;-%37VS0W;45
M?5U1G$D$)B#L$$=>> ?-3J/"-SY2%=JF[G55;9+704T\L;6NC>\EH:, DO.?
M7P7?7ZCN]*^W6UMOIY+[5-<]S!(>ZC:"><]3P%C6%H/:C?W$<BG9@_U5W:OH
M;5=[]14,]54T5X$9?3SQ<#'/&?'QX"<;3SIVT&HKM37VEMFHJ""%U6#W,],X
MN82/ Y_YY5N6NW5=_P!*WFV4U?<H[I15LPA >W$K><9\_'S*V(JVA-9$1%58
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M717FI;13&A;&^J#3W;9"0TN\,X\%WH@U=V>BZNO]W>:6@=&:O%8]V=S#D\,]
M,^:FZ?4][O<T[]-6VF?0PO+!/5O+>\(_5 *QM#,?+/K&./Z;ZI[6_$[L*0[*
M:B&31]-!&1WT#WLE9XM=O)Y^1"TGWEG7X9>F-2NNKZRCK:4T=TH_Y6$G((\P
M?+^(4'I[56H[_3F6WVRA+(G[)7R/<T'T;SUQ]Z^T+VUG:C=)J0AT4%%W<KV]
M-W'&?^>BR>R  :3=@=:F0G[$F(B-IB9GAQFU9=Y-17&SVVVP5%1 X=VXN+6M
M;CWG/.?,C&,+JI]97=M?/9ZJSL=>P1W3(G_FBW&2XDG@ +MTG_G"U5__ "_N
M2+_.Y-_0!]X3CX1S\LFR:DN?^$;;+J"A@IZB6,R0O@<2UP&>.3Z'ZERKM172
MJO55;-.V^&=]*!WT]2\M8"? 8Z_W%8FHO\YFG/\ 4R?<Y<(;K?=27JYTMHK*
M>W4E#+W3G.C[R1YR1G!\."FH\IW[,VRZDN1U!^);]0PT]6^(RPOA<2QX&?/X
M'ZE7+%+?ORB70MIZ#VES(Q4M+G;6QY;RWUQA?:*":E[4[;#5W5URJ&T[][W
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MD?$?458E1]&?Y;ZM_P!:S]ZO"K:.5J\P(B*J1$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MEE[MK_B%9T3<FH1MGLE!9Z%U);X1%&_Z9SESCYD^*:?LU-8K?['1&0Q;R_\
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M7,      < !$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
*1$0$1$!$1!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g762905g00w02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g00w02.jpg
M_]C_X  02D9)1@ ! 0$!0 %   #_[18&4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $X< 5H  QLE1QP"   "   < E  "')R,SDS-3,S' (% "U-:6-R;W-O
M9G0@5V]R9" M(%!R;VIE8W0@2F%G=6%R("T@1%)3(%,M,2YD;V,X0DE-!"4
M     !"E;&ZR*0O_4Y\P:E[UG=6I.$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'0
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !0     $  0%
M     0 !.$))300F       .             #^    X0DE-! T       0
M  !:.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!$0      !     "
M   "0    D      .$))300>       $     #A"24T$&@     #00    8
M             )$   )J    !@!G #  , !W #  ,@    $
M             0             ":@   )$                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   )$     4F=H=&QO;F<   )J
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   "1     %)G:'1L;VYG   ":@    -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $    !#A"24T$#      +8     $
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MRJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9.$))300A      !7     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #0    ! #A"24T$(@
M   !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    'P   'X!,@ "    %    )T!.P "
M    "0   +&':0 $     0   +P   #H   !0     $   %      4%D;V)E
M(%!H;W1O<VAO<" R-2XW("A7:6YD;W=S*0 R,#(T.C W.C(W(#$Q.C4V.C$R
M ')R,SDS-3,S      .@ 0 #     ?__  "@ @ $     0   FJ@ P $
M 0   )$         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0%.17AI9@
M34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M=@$H  ,    !  (   $Q  (    ?    ?@$R  (    4    G0$[  (    )
M    L8=I  0    !    O    .@   %      0   4     !061O8F4@4&AO
M=&]S:&]P(#(U+C<@*%=I;F1O=W,I #(P,C0Z,#<Z,C<@,3$Z-38Z,3( <G(S
M.3,U,S,      Z !  ,    !__\  * "  0    !   ":J #  0    !
MD0         & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^
M 2@  P    $  @   @$ !     $   %& @( !     $              $@
M   !    2     '_X4(2:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \
M/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z
M:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X
M.GAM<'1K/2)!9&]B92!835 @0V]R92 Y+C$M8S P,B W.2YD8F$S9&$S+" R
M,#(S+S$R+S$S+3 U.C V.C0Y(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN
M<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A
M>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @(" @(" @("!X;6QN<SIX
M;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @
M(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12
M968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M95)E9B,B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B"B @(" @(" @
M(" @('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C O
M(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^
M"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC
M<F]S;V9T(%=O<F0@+2!0<F]J96-T($IA9W5A<B M($124R!3+3$N9&]C/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT
M:71L93X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/G)R,SDS-3,S/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R
M/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R-"TP-RTR-U0Q,3HU,CHU
M,BLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O
M<E1O;VP^4%-C<FEP=#4N9&QL(%9E<G-I;VX@-2XR+C(\+WAM<#I#<F5A=&]R
M5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C0M,#<M,C=4,3$Z
M-38Z,3(K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE
M=&%D871A1&%T93XR,#(T+3 W+3(W5#$Q.C4V.C$R*S U.C,P/"]X;7 Z365T
M861A=&%$871E/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES
M=&EL;&5R(#$P+C N," H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @
M(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C(Q
M-&,T93$Q+6$P8S,M-C<T-BUB8S)A+64W,V,Y.3AC8S1B,3PO>&UP34TZ1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#ID
M-S<P-&$Y-BUE-S$X+3@Y-&0M.#5D9BTR-68R-6,S9C$Q,3 \+WAM<$U-.DEN
M<W1A;F-E240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO<&1F('1O(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C@R-S S
M8C X+60V.60M-CDT,"TY,S8T+3,P9&,R-#,Y9&,X-#PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-"TP-RTR
M-U0Q,3HU-3HU,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(U+C<@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IA8C<R8C%A."TQ9F-E+30U
M-#$M.64R,BTP9CEB,&(T.60V,C0\+W-T179T.FEN<W1A;F-E240^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C0M,#<M,C=4,3$Z-38Z,3(K
M,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS
M;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R-2XW("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O
M;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T
M;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC
M871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V
M=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#ID-S<P-&$Y-BUE-S$X+3@Y-&0M.#5D9BTR-68R-6,S9C$Q,3 \+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C0M,#<M,C=4,3$Z-38Z,3(K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<" R-2XW("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z9F$U-C)B,C,M-C,V,"TT.#,W
M+6(Q8V8M-61F,C@R9C W.3@V/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI
M:60Z86(W,F(Q83@M,69C92TT-30Q+3EE,C(M,&8Y8C!B-#ED-C(T/"]S=%)E
M9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YU
M=6ED.F9A-38R8C(S+38S-C M-#@S-RUB,6-F+35D9C(X,F8P-SDX-CPO<W12
M968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#YU=6ED.F9A-38R8C(S+38S-C M-#@S-RUB,6-F+35D9C(X,F8P
M-SDX-CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM
M<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D
M93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" @(" \=&EF9CI/<FEE
M;G1A=&EO;CXQ/"]T:69F.D]R:65N=&%T:6]N/@H@(" @(" @(" \=&EF9CI8
M4F5S;VQU=&EO;CXS,C O,3PO=&EF9CI84F5S;VQU=&EO;CX*(" @(" @(" @
M/'1I9F8Z65)E<V]L=71I;VX^,S(P+S$\+W1I9F8Z65)E<V]L=71I;VX^"B @
M(" @(" @(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO
M;E5N:70^"B @(" @(" @(#QE>&EF.D-O;&]R4W!A8V4^-C4U,S4\+V5X:68Z
M0V]L;W)3<&%C93X*(" @(" @(" @/&5X:68Z4&EX96Q81&EM96YS:6]N/C8Q
M.#PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF.E!I>&5L
M641I;65N<VEO;CXQ-#4\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N
M9#TB=R(_/O_; $, !@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06
M%AH=)1\:&R,<%A8@+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*
M$R@:%AHH*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*/_  !$( (@"0P,!(@ "$0$#$0'_Q  =  $!  ,!  ,!
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M9.7?;[33_I*C!=^W*'RV3?PT_7(KFLT%-5,IQ[K_ -%PLDY890:(BPRP$1$
M$1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$
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MRJVY;;7UUG?(Z!CS&3(PM.HZ"LZN0[F/Z"U/C;NH+H>79/;,4M,EPN\XCC'
MQ@X72._9:.4K$NIX;G7#KU+$99CEF;) !).@"U6_[0<8L+W1W"[4XF'''&=^
M[\ ILVA;5KWE-1+#3SOH;5KHR"([TN'VR./J7/'.+G$N))/&2M&C:6UFU_9"
MI7>A4=7M\Q>%Y$%/<)P.5L8;UE>=NZ"QXGAMMS Y]&?]RF-%<6UT>C_)#FR*
MSM6VW$:YP;-45%&X]^B.GXA;_:+S;KQ3B>UUL%5&1KK&\'T*#5[;3=:^T53*
MBV5<U-,TZAT;R$FS:8-?XW@ZKGYEZ(N*[)]LL5W=#:<I>R&X/.\BJ@-['+S!
MW,[T%=J6-=1.B7#-#XR4EE!?$CVQL<^1P:QHU+G'0 +Y4V;H':#45=TEQRU3
MNBHZ<[VI<PZ=E=^SKS!2TVGEJ)\$0E)163JU[VMXA:9G127+W1(TEI%.POT/
MA"Q/;UQ#OE;Y@J446TMJI2ZME?G2*N[>N(=\K?,%.WKB'?*WS!4HHI>%4?,.
M=(N#"LOMF8T$]99S*889.Q.[(S>G70'^:V%<8W+?T0NGCG]#5T+/LRMN&69U
M;<7;^1QWL-.T_#E=S#HYSR+$OHX;W56LCXRS'+-AJ)XJ:(RU$K(HV\;GN#0/
M*5I%WVL8?:Y',ENK9GM.A; TOZE,>;YW>\NK7RW&J<RFWQ['31DMC8.3@Y3T
ME:JM.G:5C-K_  *=WH5<=NF(:_*5OF"G;UQ#OE;Y@J445CPJCYD>=(KZV[8L
M-KG!OZ2=3D]_C+5O5OKZ2XT[9Z"IBJ(7<(?&\.'H4#K,XUDUWQNM956>ME@>
MTZEH.K'=!;Q$)-NT1:_QRZ_,DKGYET(M!V6;1J'-*!L3W,@N\3?[ZGXM]]IO
M0M^6)97*N3C)88]--901%ALLR6VXM:)+A=YQ%$W@:T<+I'<C6CE*C&+D\+N=
M,R2 "2= %K5\SK&K(XMN-XI8Y/V&OWSOP"FC/MK%]RB66"GG=06PDAL$)WI<
M/MNY>I<[<XN)+B23RE;%.TMK-KQ]!$KO0K*HVWX="_>MJ:J3I9 =%^7;UQ#O
ME;Y@J445KPJCYD.=(J[MZXAWRM\P4[>N(=\K?,%2BB[X51\PYTBKNWKB'?*W
MS!7IMNVC%;C<*>CIWU?9IY!&S6$@:DZ!20LW@_TPLOC<?K!1EM="BVLG5;)L
MN9$1>=+)HNV;)SC&$5<\$F\K*C^X@(/"'.UU/D )4<O<Y[W.>XN<XZDGC)7?
M=U34O$EDIM3V,A\FG2.#^:X"O2[96H4\7FRK:\RP%N6,[-<HR*-DM#;7LIWC
M5LTYWC2.C5>?99;:>[9[9J.M#70/F!<UW$[3AT]"M9C&QL:QC0UC1H !H %S
M7:Z6G:C!=6%=?%U9+3=@N4D:NEH&GF[+_P"%\]H3*._T'G#[%4J+,\4O^7X&
M\F)+7:$RCO\ 0></L3M"91W^@\X?8JE1'BE_R_ <F)/FSW8[D&/YC:[I6RT;
MJ>FD+WACR3IH1P<'2J#1%5OU$[Y<4R<8J/1&E;6,UBPO&W5#-'U]0>QTT>O+
MRN/0%'=?65%PK9ZNLE=-43/+WO<=2XE;_MZR$WS/*J*.3?4M"/<\>AX-1\8_
MBN<+T&WZ=4U*3[LK62XF%MF);/<BREK9+90N]S$Z=GE.\9^)XUFMBF"#,<@?
M+6C_ -*HMZ^8$?*G7@9UD_\ E5O3014T#(:>-D4+ &M8P:!H'( EZW<.0^"'
M5G:Z^+JR;Z/<]WA[ :J[443N9K7.2MW/=XC8327:BE/,YKFZJE$67XGJ,]_X
M'<J)$F6X-?\ %7DW>A>R#703L^%&?*%K*OBY4--<J&:CKH63TTS2Q['C4$%1
MAM+Q:3$<KJ[=PFFUW].X\K#Q>4<2UM#KO^1F,NC$V5\/5&'QV\UE@O%-<K=*
MZ*H@<' @\8Y0>@JU,*R2DRK'Z:YT3@0]H$C->&-^G"TJ&EVS<Q9 :6_5MEF>
M[L57'V6-O('MX_0H[EIU97S%W7]!5+#P=EVO]S7(/%G*+E:.U_N:Y!XLY1<H
M;1\*7U.W=PNF8]L:R&^V6DN=)-1B"I9OV![R#IT\"YFK3V1]SBP^+CK*?K]1
M/3P4H>I&N*D^IPCM"91W^@\X?8AV"91I\O0></L52HLGQ2_Y?@=R8D<9%LIR
MRQQNEGMQJ(6C4OIG;_0>#C6C.!:2' @C@(*_H 1J.%3]NA]GT<4/OFLT#6 '
M2MC8-!P\4FGAX#X1TJ]I-R=DN"Q=_,A.K"RB?UV/<\9P^T7IN/U\I-!7/TA+
MCP12\W@=Q>%<<7Z4\SZ>>.:)Q;)&X/:1Q@@ZA:-],;H.$O,5&7"\E^J)]J?=
M$R+QV3K*K_#;P+]B]LN8()J(&N?IR.XG>G52!M3[HF1>.R=96/M47&V:?DO^
MQUW9&K+;< P.YYNZN;:7P,-(&%_97::[[733_I*U)=^W*'RV3?PT_7(M75VR
MIIE./=?^BH+BEAFN]H3*._T'G#[$[0F4=_H/.'V*I46'XI?\OP/Y,3G.R^PS
M[.\)KQD$T#61/?4/?&[4!H'7P*<-I>9569Y%+6RE[*-GP*: G@8SVGC*[5NF
M\B-'8*.R0/TDK']DE /#O&\0\IZE-*T=OJX\ZB?=B['CV4%E+!8+ID%7[FL]
M%+52\9#!P#PGB"^F.VBJOUZH[70-WU14R"-O,.<GH U)5H8/BU!B5AI[=01-
M#FM!FET^%*_E<2G:S6+3+"ZMD:X<1/\ :]@615,;7UM714FHUWI)>1^ 62EW
M/%R#-8KU2.=S&-P"HY%CO<]0WW_@?RHDA91L@RFPPNG]RLKJ=H)<^F.^( Y2
M.-<\(()!!!' 05_0!3?NB\&CM]0S(K7"V."<[VJ8P: /Y':=*OZ+<7;+EV=Q
M4ZL+*.' D$$'0CB(52[ L]_3]I%FN4I=<Z1OP7./#+&--/*%+2S^!7Q^.Y;;
M;DU[FLBE DTY6'@</P5S6:=7UM>?D0A+A9<2A?-'.?EUY<XZDU<O#_\ D5<T
M4C98F2,.K7M#@>@J7\4PV.\9O>+G=HPZWPUDN\C<."5V_/H"R=LL57'*0ZU9
MPD:-C6"Y!D0#[=0/[ ?\:7X#/Q/&MR@V%9/,S434 YQV3_PNY1UC(HVLC 8Q
MHT#6C0 +8,<G[/#*==='!3MW*[O%)(XJH^9./:$RCO\ 0></L3M"91W^@\X?
M8JE1(\4O^7X)<F)SC8_BE9@6,7**]RP<,QJ"Z-VH#0T:]14Z;4LKERS+*NK,
MCC21N,5.PG@:P'C\O&J6VX7%UMV;75\;BU\H;""/M'11TKVVQYLI:B?=B[7C
M$4%GL3Q&\Y54NALM&^;>:;^0\#&>$K!-&^< .,G16WLXL-/CN'VVCIV,:XQ-
MDD<T?'>X:DE6M;JO^-!-+JR-<.)D_-V"Y26@F:@!YNR'V+Y[0F4=_H/.'V*I
M46/XI?\ +\#N3$DBZ[%<NH(R]E-!4M')#*"?P*T&Z6RNM52ZGN5+-33-XVR-
M(5Z.:'-(/$5I62VVW7FGFH;O2Q5$>I'PQPM/.#Q@JQ1NDV\6+/T(RI7D2-CM
MXJK#>:6Y4$A9/ \.&A^,.4'H*MW&[O!?K%0W2D.L-5$)!T<X\AU"D7:)@M5B
MU4Z:$F>UR._NY1QM^R[IZ5VO<QW4U>&U= ]Q<ZBJ-6@\C7\('XAR9N48VU*Z
M'D<J;3X6=;K*F&CI)JFID;'!"PO>]W$UH&I*C/:=FE5F>0RU,CWB@B<64L)X
MF,UXSTE=XW2&0NM>&LMT$A;-<9-X[3O8X3^/ I81M6G2B[GW\@NE^D+]Z*CJ
M*ZI93T4$D\[SHUD;2XGR+Z4\,E1/'# QSY9'!C&M&I<2=  K!V4;/J3#+,PR
MLCFN\PWT\^G"/L-Y@/2KVKU<=-'+ZM]A<(<3.!V?8OE]QC$CZ2*D:>_R '\%
MD^T)E'?Z#SA]BJ5%C/=;V^F!_)B2UVA,H[_0></L6J9[L]NN%0TLMUDIWMJ'
M%K.Q.UX1SJT%PC=4_-MC^]?U*QI-?=;:H2QAD9UQ4<HG59O!_IA9?&X_6"PB
MS>#_ $PLOC<?K!;-GN,1'N7,B(O&%XX;NHK3)-9[9=(VES*>3L3R.0.UX?Q
M4X*[,JLE/D5@K;75_)5#"W?::[T\A\A48YCBURQ2[S4-SA<W>G^[E ^!(WD(
M*]!M=ZE7RGW16MCUR8JV5T]MKZ>MHWF.H@>'L<.0A4%CFZ!HW4[([_;9HY@
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MTH);;HY].\S-/7HM;K\)R:@#C56*X,:WC<(2X#RC57 BL1W:U>\DR+I1_/\
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M=C:^33?$=.B(BW46VK$WD%%1[&31$2"01$0 1$0 1$0 1$0 1$0 1$0 1$0
M1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0
(1$0 1$0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g762905g01n96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g01n96.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_[23.4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 9     !  $!D     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              5%   &\@         !
M                          $             !O(   5%
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   5%     %)G:'1L
M;VYG   &\@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   %10    !29VAT;&]N9P  !O(    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     4X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M      $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%1
M81,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"
MHW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W
M1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%
M,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55
M-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=W
MAY>GM\?_V@ , P$  A$#$0 _ /54R=))2TI2G224M*4IU1ZOU&CIV$Z^ZT4[
MB*V/)9(<_P"B\-N=6VST_P"=]/\ <8B!9H*19/UCZ11COR&WLOKKV^IZ;Z_:
M' ['?I;*_IQL65]:.O.KQ<3'H;;4<X,LL>',!;6[1M6YMGZ1[K7,]7['ZVRK
M_@USV3D=,ZUUT9/4K3;BU8X]S?8\.<7VU5O]!S_396RRW]+4_P!&[_2(W6&]
M5JR&.S*J,?I>%.-17:YOI^G8'4XKL=OK/?<]M WLO_5W^I5_P2L1Q &-[[U+
MT^0C^\M)W98.8<++IOQ7O(!:ZZMH@O82&W-]+=^E:UKO;:NPZ=UW ZB\U4ES
M+FC=Z5@VN+1^>SZ37_V7+R_J53L6[%ZEK8\@[0]^_0#Z1#/=4WWO]G_%K:^K
M&??D=>Q7WUMKKWD>I6STVASF/K95Z?T?TF[\Q2YL(E$S[#\EL9:T^C2E*9[V
M5M+['!C&\N<8 ^92%E9;N#@6D2'2(A461>4I2:YKFAS2"TB01J""G24M*4IT
MDE+)TDDE*22224__T/54DDDE*22224LZ8.T NC0$P)^.J\W^O%>1]H96*L7'
ML&ZS)MI<&C=8[;1]KR;FU.^A99[/_)KTE<5]=.E]1]>W,Z>!:'5^KD,!9ZC/
M2;M;:QMSF,?5^C9ZFS]+7_H_TBFY8@9 3^*V6SR.+E9E>!KCAV/6![O3]Q)+
MOHY+)V>[?_.?HUN8_2NN]8RZ,/-+ZF8=1#'Y&.RS':W:S8S$VNK^U.>ZOV6^
MI;^@8L)G3;ZVF[)N%;['!GIM:+K'.)W,C'L:^A^]Z[OI/4,#(Z?A&Q[ZL8;,
M1F.0^?M+@&NQ+[(=9Z+/9L]VRVNW]+[*E;S2X=8UU]5<7#Y+(ZZ.%UOH?3NE
M=)KL^U^J_'AN-6]HA]@;NLHM]+<YWL'JO_FF5_S5GTUK_5GI6?DY%>=U66VX
MX:]H!WML<X.])[;P][?T3/\ !,_PBULK)Z'EU-Z?D4UV.KVOJQ;&>T/ EFR6
M>FUC=WI^K_-_36A@58U..&8[*JQ)+VT !N_\\PP,]_[RK3S2X*UNS9/9>(BV
M'4&9E@97CUUV5G6T6.<TR"UU1K?7]':[\]9S>G7,L-C>ETAQ[^J9]P<RS>?W
M7,=L^BEU'ZRX+*V,JD^JYS2^S?C-86--KGF_)J;0WT]G^$>KM74'-:#D0W90
M'V1P70W=L?\ N?F?UTR)D([?](6H@7JGP!D-I%=U+*&L ;6RMVX!H'T>!MVJ
MRABYF@<=KG &#I]+Z(U1%&=3:X*22204I))))2DDDDE/_]'U5))))2DQ<T$
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MZ&/NSLFZZ!O%%F=971A5[&>I9N^TXV/^DN>E,"@2>'S_ .]^9=#'(FAN6_\
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J    "  ' 1(
M P    $  0   1H !0    $   !B 1L !0    $   !J 2@  P    $  @
M 3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D    T    9
M   !   !D     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#(T
M.C X.C Q(# S.C$W.C$V   #H $  P    '__P  H ( !     $   ;RH ,
M!     $   5%          8! P #     0 &   !&@ %     0   1X!&P %
M     0   28!*  #     0 "   " 0 $     0   2X" @ $     0
M        2     $   !(     3A"24T#_0      "           _^$!-D5X
M:68  $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %
M 0   &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $
M     0   *0   #0   !D     $   &0     4%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I #(P,C0Z,#@Z,#$@,#,Z,3<Z,38   .@ 0 #     ?__
M  "@ @ $     0  !O*@ P $     0  !44         !@$#  ,    !  8
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M&_-2,$DDLK>*.K&>A(\7'P'3ES7SMJ:6UELA#8S-VUD+#FNWDGD/IT V#1Z
M+T-CV2=1J>XRJ5$E8V3L1U"!:MIS6\:[CQ=J2$CK&\E\;O0@_P -E?-.9AF8
MIN>6=U:B/!/%OOPGP(/B#X+TY0E#4Q4DR64II>K#=U!1K6F<<$CR'MW(W&Q/
MA\%%A9N&O'&Y.O<:P2&$D\!.P/(C^*SE=Q=M2RU+U1TKBSF<F9HB_'ED9ICB
M< 2YI)V._/;A4#IRKB;]22*:E-^AA?):O/D+6PN!]T- Y'YKK7U?:BCH1F&-
MS*AD(!)][B! _ %>-?/UH\''C)L3#-$QQD+C,]I>_G[QVZ]>BYE"I9WZ-YI>
M)7F\P-^JY1<+K,@L3+UQ:Q=R _;B<!\=MQ^>RRUUD_JW[].$_N0E&]=!WW93
M1>#O2$F2>E$]Q/B[A&_YJ=6MM!:JPFG.S/3?TYE*U1YIL+6/=N\C;E[HW/1>
MMCM?TVUVU.'+7F_>KTG ?Z_"O"Y.4F\*N=%T;$1:YB[7\$7#VC'YRLWQ?)3W
M ^/"XE3V#[0-+YN<08_,0&P>0BE#HG_@\ J)4IQU3%TRT(B*A(1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!>;FATK=^8X
M3R_!>BZ_V@^" X[IGW0G=,^Z%W1 =.Z9]T+GNV?="[(@.O=L^Z$[MGW0NR(#
MKW;/NA.[9]T+LB Z]VS[H3NV?="[(@.O=L^Z$[MGW0NR(#KW;/NA.[9]T+LB
M Z]VS[H3NV?="[(@.O=L^Z$[MGW0NR(#KW;/NA.[9]T+LB Z]VS[H3NV?="[
M(@.O=L^Z$[MGW0NR(#KW;/NA.[9]T+LB Z]VS[H3NV?="[(@.O=L^Z$[MGW0
MNR(#KW;/NA.Z9]T+LB Z=TS[H3NF?="[H@.G=,^Z$[IGW0NZ(#IW3/NA.Z9]
MT+NB Z=TS[H3NF?="U1VX5]2W,CA(\!#E7T88YYK9Q]OV<G8#A!=S]=N169H
M/7^GX]/:>QPR5Q]^]$?9VWW&25SN-S=GO\?>:1OY!:<F\.) V7W3/NA.Z9]T
M+26F;>HXM9Z_@U#E'3VXL.V9K('.;#7)#R!&/3[VP)53H'+:>[-],:XIZBS$
MUZ>U#%8J6+3I(IFN>06\))\ K\CTD7/IGNF?="A=98BWEM/6JF)L15;KN%T<
MDL0D9N"#LYI\#MLIIDC3&QSB&EP!V)7$T\4,$D\KVMBC:7N>3R  W)*Q3L[D
MFK\3V8RY>?-WM=R5YK.4=!Q08_BBC8(@0T[[[DG=3.=T.V4Z.K8E[(Z>#O-L
MN9*\N<Z, C8'Q/-:HUSVHY?4=J:#3]N;&84$M;)">&>R/O<75C3X;<R/%4/:
M8O[PW<@9?\X;DO%^/%NO2I[%6J+$W;H,74BF;GSG9WJ5^K]29+%LT[/5RY;R
MR-<S/B ;P^[Y'K^2O_9QI7^:.CZ&&ELFW)7:>*4C8;DDD > &^P6E-#=I^8T
MW9BASEJ?*X4D->9CQ3UQ]X./-X'B#X>*^CZT\5JO%/7D;)#*T/8]IW#FD;@A
M<VT0J4N9,TBU+-';NV?="X<QC6DEHV W7=%RECY0Q,!U;V@V&79Y6_2&1E8Z
M0<W-8'$- W\@ %:H.RJO>U1F*-C(68Z./8Q\,S>'BE+V[@>7@>GDHJ:NW0O:
MU+]),D]ECMNO1&-N_'$\D^[YD$[%6&EVC8]E/$1316!+!)(;4C8QO(WA>V/G
MOSVXA\%[N*KA3HZ6^>5NTYK1N\11M%Z(=G<+ELI=LOJU:L,KJX&W%8D8W<@
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"X^U\ERN/M?) <HB(
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M$7E&P1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %U/UFKLNI^LU =D1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!<?:^2Y7'VOD@.41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!1FIZ,^2T]D:5/V;VB>%T;/:6<<1)'+B'B%)J
ME]H':)BM'M;!('7<K(-XZ4)][;[SST8/4]?#=6A&4G:*NR&[%,P/9OF,KFK5
M[4<-3 1'',QX9AI>%\A:]KN\WVV'U=MNNRG]::$MSZ#QV"PD\UR2K=AG,EV?
M=[FMDXG;NVY\EJ[,=J>L,H]W=6ZN*@)]V.K%Q/ ]7N)W^0"CJ_:!K&D_OF:B
MEDX>9;:A8]GS V_>O16Q[0\\C/E(EZ[0-&Y@]HF6U*W X3+XF2I$S_*5@1B+
M@'O.]%XX[M.R(T[6H:<PV/I/B:6&?=SJK!Q'81-Y.?R\3L-]^JH.8[1\CJVU
M6KZM[F#&1[=VRNUS8)9/OR@DGX \AXJ?;L6@@@C;EMTV5Z>RO2KN(<^!XY,7
MLVXOU#E;V2<?L.D[J(>@8S8;?'=1\FG,/+%W4F.KEGAL-B/F.:P=3Z@EH6&T
ML>R-UHLXWOD!+8FGIR\2=NBA*^ILK4D[RR^*Y7'-[!'P/ \VD'KZ%=D:67-6
M1FY9YDQCL)C:%IU"Q2@<9=S#,YN_>#[I)Z."G,=5EQ#^\P-Z[BY1S!KRDM^;
M';M/X+K+'7RN/86OWBD DCD;U:>H</5=<;;D<Y]6YLVY$.?E(WP>%,H1FKV*
MJ3B[%]T]VI93&.;%JZNRY3Z&_2CV>P?>DC\O5GX*W9RK](QU=7Z+GBGO,CYA
MA]RY#XL/KRY'D0M2CET7I@LMD-)Y!V1P8,D#SQ6\=OLRP/%S?NR>OBN*>S87
MCI]W$T;4UAD;,[.,Q5MZAS4=-Q]GO!N19&[DZ-Y]R1A'@0YH_%2':7H2KK/'
MQ$2^RY2KN:UD#?;?JUP\6GEOX^2B]%6L3E]?WLM@Q$:UG&1RN<P;$R.D._$/
M!WN['Q6QUQUY8*BE#+)#9T\#4N+\SY0S&A]5XB9\5W!6++ =A8I$2QO'F.8<
M/F%CZ4T9J7/VY:%+&FJZN0V6:\X1MB!YC=HW<3MY!?6ZIV9!PNO,9DV\JN3C
M]@L>0>-W1N^?,+JI[?5FG'*]B)P4+2W%29H+&88Z=TUPB[+=LF[D)I6@F81-
MWV]&[NV 5VJ=GVDZEEMBMI[',F:=PX0@[%8^.'TAVEY2SUCQM2.LP_KO)<[\
M@U7!<=:<LDWNS[<_*Q>DKN4NGRR\[FD>V.42:\Q-1HVCJ8]\K0.0!>_AY#X-
M5:"S>V;.XRGVD"22[$\?1K8G"(]XYKQ(X\)#=R#L?%5!NL,1O[S[+&_>=6?M
M^Y>GLN5)%9ZEB*@3;]DR>0:QADGE<P11C[1X?W>:DZ&1IY",OI68IVCKP.W(
M^(ZCYK%J1L_G!>>6@O$4>Q\0#OO^Y=4&LS*:>5C/P>'M/;,Z**2U;<..=[&[
M_+T \%F,I67U7V602.KL.SI WW0?BK=V9VA2FREAVW R)A=OTVXN?Y*6U6!A
MM%YG&4V"P^*-LX Y;F24\(/IMXKEG7?*8;<#6,$HW-<&"40-G=&\0N<6M>1R
M)'4;JMZUD:_%MHD NMNV/ZK6\R1Z]-ELG,W+%[0V(EMB!LC;4C R!G!&P!O1
MH\EJ34<O>YZ5N^[8(FL'Q/,_P6]#GO,K+(JL;GUY15M'](!^C?X2#_'S"R%G
M6:\5F$QS-XF]1Y@^8/@5%R0VJ>^[768!]MH]]H]1X_)=JEAR9C:YS9&\$GF&
M[J6B=Q1L=Y@%0CK,,L$G=R-)X3[O0CY*9@!;#&#X- _)6;3T"/5<+@%=)9HX
M1O+(Q@_6.RKH#T7E+(X/CA@C=-9E.T<3>KCY^@'FO:C5O9-VU&NYD)Y&S.TM
M8/@#S=\E;<+AJ^+8\QETMB0;23R?6=Z>@]%E.JEE$NH\3KI_%#%57![FRVIB
M'3R>#CY#]4>"VEV&98PC):9F=[M,BS3W\87D\3?[KR1\"%0MEF:3N'&]H&G;
M+3L+$KZ$GJV1NX_UF#\5Y^TPQTV;0=F?1"(B\4W"(B (B( B(@"+K(]L;"Z1
MS6M'4N.P"\J]VK9<6U[,,KAU#'AQ'X*;"Y[HNDDL<9:))&,+CLT..VY]%W4
M(B( B(@"(B (ND4T4N_=2,?MR/"X'9=T 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %U/UFKLNI^LU =D1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!<?:^2Y7'VOD@.41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( NI^LU=EU/UFH#LB(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B +C[7R7*X^U\D!RB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M++'OU67*KX7GA)YM<.K7>!"ZHNV3,I+>C#P!WK67_P"<LR._/;^"VYV"3?\
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MB (B( B(@"(B (B( NI^LU=EU/UFH#LB(@"(B (B( B(@"(B (B( B(@"(B
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M2X;]  /-0I5'%9<//P[A:-SVQ&B+6<TAD\Q%.R/V8.=#"1N9BP<3MO@M?9F
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M$0!$1 $1$ 1$0!$1 $1$ 7'VODN5Q]KY(#E$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %H?^43;@RUBECL-&)\UCW&6:5KN
M43'-/Z(^;G<B!Z;K:/:-J;^:^FY+4(#[\[A7J,/1TKM]B?0=3Z!:*IUS#&[O
M)'2SR.,DTKNLCR=W./S_ "7=L5)N7*<#.<LK&LJ[V/BXF;\_K<7UM_'?U4UE
M-#ZA^@XLI)1+,28A8?*7MYL\.6^^QW4WG-,Q7Y7V:<@JW'?6=MNR3]H>?J.?
MQ5PU'1EFT]<?J_'X6.G7QT+,=D*$SC))(WD& .()Y=06[+UZFTOFQXO,P5/5
MFHL#I_):AM/J8BL97,9QR'<-:QG3<D\@L^+16?ESLN&9C9O;H6\<C3R:QGWB
M[H&^JMND-,8C469DKZ>R.6BPK(=\DVVZ.)\IWW;&P ['?S/16.])?S$NKL)9
M96QV5NU*WT=7-AAXJ\;G?HR\$CBVW\?%7GM4E)J/]?-2%35LS3FK-,Y;2]B%
MV5KF%SQQQR-(<R5GCLX<BO <6VX<"/53O:!@[V!PN+IY/)-EM.C>109)Q^R\
M1V )!(W/D/)0#28@V*8%CP .?0_ K>G/%G>Y24;!P)YENSAT(7M7M%@V=U'5
MA_>/\%/T]&:@NX89:MC9'XXL=()N-@!:W?<[$[\MCX**P^+OYG(15<17=8MD
M%S6-('(=22>0'Q5L<&GGH5PL]8I&RMW8=_X+:6F\[4IX*DZ_J.*?&UZ4L,V%
MDKM[QSR#PM9L/>&YWXB=UKW+Z<R&,OQ5,A3?!;E#3&UK@>($[#8@D'FNF=PV
M5T[?-++URR?@#^#B!=PG?8\N1Z%85(PK)*_D6BW'.QYX[)X#(C$8Y^#KXON;
M4;;MWVE[S)'O[Q<T\@".?)=->99N:U5D[;'!]8R=W!P_5[IONL ]-A^:@KL#
M)K0DJ/+;!Y$#_>W\%*3:8S$$#[#Y*+N!O$0PN<=O'8;<_P 5:*C3:N+N2,G0
M6F#JW4=;$.:\N<V1\C_\VUL9X#_IEJ]G0V*LTU2\PQW*SS#.P^#V\C\CU"OO
M8FV+3^NL>RO*Z>/,5I(997?:<P=XT@>'B%L;M3[-6ZF?]*X9\=?-L9PN[PD1
MV6CHUWD1X'UYK@GMG)[0U/1FZIWAD?.TK',>98AN[[3?O#_%<3.$E<21G<M/
M$/XK)RT%K"VC5SE2?'V0=N&=NP/[+A[I'S4;+9@A)E9-$8W?7;Q#GZA>A"<9
M*Z9SN+1(-<'-#AT(W"]=.82?4FI8,%5:_P#I<@=*\#<10CZ[C^[XD+C1V*R6
MJ+)HZ?JNM2,=LZ9WNPQ-/1SG?P&Y6[-.:-B[/,[I^T)W6;.1>^G>G/1SG#B8
M&CP:"W8?'FN7:-HC!.G%\YHO%62D]#;4$3((8XHFAL;&AK0/ !=T1?.':16J
MY_9=,Y6??;NZTCM_[I7GHN#V;2>(AVVX*L8_U0L'M-D[O0F9\W0\ _O$#^*L
M-*,14X(VC8-C:T#Y+;2CUOR7Y,5G6?0O-_@]D1574^=LFZW!:=X9,Q,W=\CA
MNRI']]WKY!4A!S=D7G-05V=-39RU9R'\W]-D')O&]BQU938?$_K'P"D,3I3$
MX_'1574X+182]TMB,2/>\_6>2=^97OIG U<!0]GK<4DKW<<\[SN^9YZN<5*2
MR,BB?)(X-C8"YSCT '4J\JB2P4]/,I"FWSJFOD8L6,Q\ /=4JL8_5B:/X+6G
M;(--Y[3YJU\[A8,U1D[^M&^W&TEP&SF'GRW:2/CLM:=H6O;^L[T\->>6MIYC
MBR&NP\)L ';CD(Y['P'3;JJ='4KL9PM@B#?+A"[]GV&H[5)2LR)5(K)(5YVS
MM=P[M>P\+V'ZS#Y%>O4;*.EQ%5EEEJ"#](P^]&V1S!(/+<=#Y']ZWIH?LMT=
MJ/"TLS#:S-JI.-S6GLAH:X'9S'<#0>1!'5=];:507/7<9QABT-8:0TQ8UCG6
M8NE'_1VN#KM@-]V&/Q&_WG= /7=;(BS.LYLWK"EI6[B:F.TX\,BJRU><C TD
M-XAZ-VYK<>#PV.P5!E+$4XJE5G2.,;#XGS/J5K&[V>:MBU#JBU@\_C:5'/2\
M4X?7<^5C=B/=/0'8E>35VGEY-RR6XWC#"LB.U#VCZBL: QFJ\1+CL70= XSB
MPTROELAQ;W+&[<@>$GB6W-,7Y\II[&WKD+(;%B!DLD;'<0:XC<@'Q6O<EV;Y
MJC@*&&TEG8H,?'3?4L5[\7>,?Q$DRMV')^Y/7DKYH[!1:9TQC<-!*^:.G$(A
M(_J[Q)_%<\W'#S2Z)A$18DA$1 $1$ 4+K/"R:@TW=QD,S8'V&@"1S>(#8@]/
MDII%:,G%J2U1$HJ2<7O,'!4G8W#4J3WB1U>)L9>!L'$#;=5?)Z*F&MJVHL)<
MBIR]+4+HR6S#QZ>)'Y@%79%:-64&VMY65.,DD]Q6,'IF7':QS>:?99)'D&L#
M8@T@LX0!S/CT2?3,DNOX-0^T,[F.H:Q@X3Q$DGGO\U9T4\M.][[K=A')1M;I
MN:\=HC-8?)7)]'9N*E5MO,DE6Q%QL8X^+>OGY#PZJ6T=HUF#DO7,A:=DLI>Y
M6+$C=MQ]T#R_P"MJ*TMIJ25F_=]I6-"$7=(UO!H;4&%DLUM+ZACJ8FP\N[F:
M'C=#OUX#_P#;^*SM)Z CP^+SF.OVA=JY)PY\)#@-B-R?O<]]_-7I%,MJJ25F
M_#@([/3B[I&M*VB=5X^D[$XW5,;,0=VM+X-YHV'J&GY^8^2ZZST[4TQV19.A
M2W>&\+Y)'?6D>7MW)_!;-6)E\;4R^/FHY*$3U90 ^,D@'8[^'P5H[5)R3EI=
M-V2S*/9HX6HZVL:TQ.D=2W--TZ-?4K8L'9KL<6&'>9C7-!+ ?+GMUZ*PYGL_
MJ6=.XS'8RP^C8QKQ)6LM&[@_Q)^)YJX5:\52M%7KL#(8F!C&CP:!L O51+:J
MCE=.V=]%XEH[/!*S1KF?16H<[+5BU;GH+./KR"7N:T' 9'#IQ'ELIZUIB6;7
M]#4+;,;8:U5U<P<!W)/%S!^:M"*KVB;\5IQU+*A!?.!6-'Z:EP.2SUF6RR9N
M2M>T-:UI' .?(^?5,9IF6GKS+:@=98Z*[79"V$-(<TMX>9/R5G15=:;;=]5;
MYW$JE%)+AF$1%D:!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!=3]9J[+J?K-0'9$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 7'VODN5Q]KY(#E$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 :,[5<B<GK\
M5-]X,/7  \#+*-R?B&AO^DJ^!R722=UW.Y^X_<NFR4XW/7A:[@ _!J] O=H1
MP4TCFD[L*-SV*9E:#H2[NY6GCBDV^H__  \PI-=2M2#3;Y!#--%=:(Y&2.:2
M1[I(.QV*Y-BN&[!['?JM]XGY!6FKCGWM46L7%P=[-=#&<?3W]B"?3FIJ]I."
M'V)V)G,ALVGTP+,#:YXV[;O',[L._5=,:S22;,W$HM*J^25MBRSNHH_>9&[J
M3]YWE\%*.8V5A:X->P^!Y@JS:VTW'INQCX676739K-G=)'L6;D[;-/B/55?N
MW,),)V\VGH?\%>$E-8D]2'=.QMO'58;^CZ46:HX<8*KBI!%?9-^FADYEHYG<
M.+NK=BJSI736/RURC4T[G,C4M30D9.28"-C8B!QM:1MON>6Q5'EGXH'L.[3N
M"6GXK)#B.AV6*H2BG:6I;&F;BI8V0=H-!V2B@H8/ 43)39WK9WR-:[8.<6G;
M<N/%MZ!==:8BAJ'3M#(OR,V1M8]YKSRN:8'2L<=V\3>9(!.W5:JPDSH\[4]X
M_I&OB/X;_P %8\]EF8G&R6'-[QY(9''OMQN/0?#Q/H%S2HN,D[Z?/$T4DT=;
M=#%04PRQ%5KP#HX[,V^?FH[&YJC6M-H?2-:>$\H)!*"1^H[^!51G,MZ8V,A+
M[3,?%W-C/1K>@"\W102,(='&YOC[H77&E-K,R;5[HV1I(NQW:'INN [N77N.
M CP#F/#F_+?\U] :SR5J@_!LIR=V;.1BADY;[L.^X_)?(FF[UBIJ#$1OR$D5
M:*R)(7N]XPR;$-YD\F%Q (\!NOIJ[F6:@.D)> Q3C)<-B$]8I6-/$T_->;M=
M)\JI27S,G':#BNSO-@6:\-J%T-J&.:)WUF2-#FGX@J(9I#3<<O>,T_B&R;[\
M0I1@_P"RIQ%Y%VCM->08F/2/:%5EQXX<;FPZ*2$<A%*WW@6^AW/+P4YVDU'V
M=(W)8 39I\-N';KQ,._[MUC]I'Z&MA+H/":V4KDGR:YW"?WJV31MFA?&\ L>
MTM(\P5TRJ/F57K[?@YH4TL=):>_Y/'&6X[^.K6X2'1SQMD:1Y$;K)52[,9'1
MZ>DQDV_?8JQ)2=OY-.[3^!"MI( ))  \2L*D<$W%&U.6."DRI=IIXM/UZ^_.
MS=@BV\]W[_P5K>]D49<]S6,:-RYQV "U7VG:UQ@LXJ#'2,R%BG=;8?'$[=IX
M0=F\0WY[D<ANL6+!:QUT\2YZV_$XLG<5P"TD?L<M_BX_)=BV9NE%U'A6>OL<
M;VE*K)4UB>6GJR>U5VD8V#BH82W%->>> S[$Q0CQ?N/K;>032^H=*8&D^.')
M2VK4SN\LV36E<^9_F?=_ >"L.F='873T/#1J,=,1L^>4<3W?,]!Z!3K8(F_5
MB8/@T+.52BE@@G;K2OX,TA3K-XYM7ZF[>**U_/S!GZCK[_V:$Y_W%5.U/7%.
M70&;AH0Y(330&+B?2E8UH=[I))  Y$K:@ '0 *+U1B(\]IW)8J5W"VW ^'BV
MWX200#\CS6<9TD[X7W_@UPU=\EW?D^/8YXV1M:QDFP  V85[12B0D!KV_M-V
M7I/6LXZ[9QV0C,5ZH_NIF.\QT</0C8@^JX!7TRDI*Z.:S3S.2ME]BVLL9I7!
M:@.H+AK4&Y")L![MS_?DCW+0&@_=W^:UC+*V*,O>?='XGT'JKIJ/3[M*=FFF
M[>7;W-FYG8;MII!WC;PNX6GX- W'GNN+;L+@H/>S6BG>YOK2>M,!JLSMP.19
M9E@V[V(L<Q[ >A+7 ';U63BM38G+9G)8O'7&3W<<6BTQ@.T9.^PWZ$\CTZ+2
M5O(V]0]H64U!V94WSLK8@U72MC[J.:9S]AL2-G%H/%S\ED=@E;(8CM!U%C[.
M&GJN=5KNM22V1(YLH!)>X[<R\EQ]%XSI))LZ;F_41%@2$1$ 1$0!$1 $1$ 1
M%TFE9#"^65P9&QI<YQZ #J4!W1>-.U!=JQ6:DK)H)6\3)&'<.'F%[(U8+,(B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( NI^LU=EU/UFH#LB(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B +C[7R7*X^U\D!R
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/F
M*D.&QE&'JW(V@?\ MG+,"R-3TSC-?:BID;,DF;=C\-Q*-SM\'!P6,"O?I/%!
M,Y7J<KJ5SNL6[>JTHN\N6(H&><C@-_AYJX(^A6=!VGZ>G8W>.W8B8[_K&.Y?
MZO[EWU+D:GT--C&6W7YO;WSL>Z-S17CVX> <7B3X#=OJHK,9O"Y2D^M%DV0V
M 0^"9S7,#)!T/$0/AUZ%0-2R+,/%R#P>%[0=^%WB-_%7I14I9O0K+)%GU=EZ
MN5@P3*G'Q4L?'6EXF[>^.NWF%6;-B*M'QSO#&]!Z_ +'NWA [NHV]Y8=]5GA
M\2?)8<4'Z3OIW=[.?MGP]&CP"Z(1PK#$HW?-G>>U-9&T,#8V>#Y>OQ '\5Y%
MMD_UUN9S?)FS=OP&ZR46F!;RMSPKPD6H'1V++7!Q(<)3N.15X[/)[,.JF6;+
M,GEV5*D\L<,38WNC<6\/& [;?8'QW^"IU>-SK),9 +&[].6Y60ZW9JS16J<T
MU6[ 26/A>6NV/([."RJT8S321>$VGF7O66(=/J.2W:RU0R^RU[,52]'W<\_$
MTD1%D30W?<;>&^X5V@?>&H-)4\_29]*&Z9WF&L&PU(S$[A@#MO>/CX_%:&=>
MLS7/;G6II+9>)/:'2$OXO!W%UW7O=U'J*6:&89W)R31.XHA):>0'<QN.?([$
M\QYK*>S3<4KWLBRFKLVQVBQMRW9Y9LR&]*ZI=+>^R51E>8 MV#8^ ;.;OS.Z
M[Z8ORT[FF,MG&NAF,,$]C@^K.PQ\+9QZMWV>/@50<&_,:]N4<*+M^[8D=PRF
MQ*Z3V9GVWG<[#EOMY[@+Z?S^C\?EM,PX<CNFUHA'6E !=$6MV'RY<QXKAJ5(
M4&J<M'>_0F15I2JQQ1U6:["R,<U[&O806N&X(\0N5KOLSRMS&V9M):@!CO5!
MQ57N/*:+T/CM^[EX%;$7EU:3I2P_&=%&JJL<2_IE8[3(#-HG*.;]:!@G'Q80
M[^"L&/F%BA6F;TDC:\?,;K'S]47<%D:Q&_?5Y&;?%I"U.[M!M/TWB,'IN)]G
M-R0-AD>T$]T0-MA^MRZ] M:5*5:&&.Y^?]&56M&C/%+>O)_DDLYJZGHO6F;
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MB (B( B(@"(B (B( B(@"ZGZS5V74_6:@.R(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( N/M?)<KC[7R0
M'*(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M!GXDE6]36UBNA$4=)/I?L$1%B;!%TCECD<]L;VN<P\+@#OPGR*[H B(@"(B
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M7_CB\ED84J2_R27.>81$7.= 1$0!$1 $11>I\Y3TW@;N7R3BVK5C,CN'J[R
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MDIFOR$D?7;;C/%S(^7"?FM%7-0"6M.QE"<QN81Q.<T=1Y+9<.8IBEIO4^G[
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MLV/FL8^XTLN5)713,/4.W)W^>^_S6?IJK-D]6X.C1'';-Z&78?8:QP<YQ]
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M5<8_+'/2DH4E*7RYG9W-4<%1-K)3=W'OPM &[GN\F@<R5G02":&.1H< ]H<
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MC#&ZS T"Q&PC8\;.0=R\6\UI2PXE*'=[,I4<E&T^]>J-1".Q0NS8O).#KM8
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M=EU/UFH#LB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M,?"!)EK .VS/"('S=L=_(+UDU4QQ&(T31&0G@:(^\'NUJX'(<3O'X#=1&E]
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MW/Y%7U;[1-)N,=^OMV>9AL\&XJ4MRR]^WR[0B(N4Z@B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"ZGZS5V74_6:@.R(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( N/M?)<KC[7R0'*
M(B (B( B(@"(B (B( B(@"(B (B( BP<U/>K8^27%U([EII!$+Y>[#AOSY['
MGLJZW7E6JYL>H,=D,.\G;CL1;P[^D@Y?N6D:4IJ\<_G SE5C!VD[?.)<%4M0
M:?M5<@[.Z8+8\D.<]8\H[C?)WD[R<K%CLE2R< FQUN"U$?M0R!P_)9:B,I4V
M)0C41#Z9S]7/4W20<45F(\%BK)RD@?XM</X^*F%5]2Z<FEMC,:?E;3S48YG;
MW++1]B0>/H>H67I;4<.<BEBDB=4R=8\-FG*??C/GZM/@5><$UCAIY?.)6$VG
M@GKY_GH*CE-"ZC9KG*:AT[G:%,WXHXGQ6*9FV#/7B"S-8:/R>I-%XW'YC,5&
MWJ=V*[/;;!P1N$;G'8-W]WD1SW\%?UJ?^4;DK-72N/H5WOCBR%L13O8=N*-K
M2XL/H[E^"4\52<8K4U>2N5W65W06J>T""QJ+5%>;'5*IK05X62AC92[<O=,/
M<].1\E>NS31$&EGYH8K(Q6M-Y1S9ZT#=W=T2W9VS]]G C;\%\WM8T,X&M:&=
M.$#E^"W-_)LR5A\&>Q#WO?3J2130 G<1B0'=@\ANW?;U7=M6RNC3NI71E"IB
M=C6VLM%9336K)L=1HV<E2:UT]=U2,R/9$YW)KVCF-NF_BK1V7=G>8R6H:.3S
M>/GQV+I2"=K+#>&2P\?5' >;6@\]SUV6V\$/:>TC4L^Y(KP5JS?3<%Q_>%<%
M2KME105/H7BB*45*\NE^#L$44-280Y;Z+&7QYR6^WLHL,[S?RX=]]_1>SLSC
M&9,8UV1IMR!&XK&=HE/]W?=>?9FY5M<Z_&G,U3PU'$6,ME;4)L-@BD;&!&#M
MOQ.Y$[CHJIJCM(R$>(Q.8Q(MUY+\KJC<5-2!D;*T$N.[G-Y;;*-[8;N)RFK*
M$5FA1SU2.)T(^CKS([]:?B/+ZPW;Z>?YQ]736=CT=@G:OTO<U%'!:L/CKFTY
MUJI$]H# 1R#^8Y[GDNJFHQ2=OG:4E'&K/YW$K:[2]:XUN#CET_#<O982NAI]
MV8I6AA',^\1S!W'HNN$U%G=:7+.6P>G1CL]BYO9;.]H-)\>[E8X#B;Y<^6R@
M\=V=:AMG0U3*,R=:O"^X^22O8<)*43R#'&9.H.W+\ELG V]!]F[;&);G*=>Y
M-)WUEUJUQS/>?%Y)Y<O-:<K&&<8IOYP,I4%)8<3^=90M88G7N2N91C\7W^,R
M(]^"]"VY[$XC9Q@+7<AXCDHS.Z#PTVG/9X[>IZ65]F@JODL5)A7D$0 '$QK3
MRY;@;G8K>VJ=2UL/HS(9^L^.W!!7,L3HGAS9">3=B.6Q)'-?*V2R>4S=EUW.
M9&W9M2'B($SF,CW^RQH(#0%KLT77T5K?.DK-2A_*_6O:QM/#8320UK/DLWDJ
M.0QXQ\56./*Q.,H>S;=SC(T#P*O&IY</D,;4LZ<R>,9DL8>\I-BF8 0!SBV!
M^JX<MO@M==B6IYW:A_FWF9#D*EF%TE5]K](^-[=MV<1W):1N>?39;KGTS@IP
M1-AL<_?Q-9F_[EE5PT:EI7NNI^P<:DXVNO%>XTOGZ>H<7%;IR-XRT=[#Q;NB
M=XM</#GNI=:AU1I;(Z+R3M0:/+O9!SL5!N0UO4\O%O7U;X*]:(U=1U5C^]KD
M16HP.^KN<"YA\QYM]5E6H)1Y6EG'RZQ1VAN7)5<I>?2BR(ND\K(())I7!L<;
M2]SCX #<E5FOV@:8L:?L9R'+UW8RN\1R3[G9KCT'SW7,DWH=1/9:U/3QTUBK
M4DNS1C=L$;@'/Y^!/)1>#U;BLO(8(YS6O-^O4M-,4K3^R[;?XA1-SM3T;3[K
MVG.5X^]C;*S<'FUPW!Z+QS69T/G=,G-Y"S4DQS9.Z9<&['M?OMLUPV=OS'1:
MQBK6FGUF<L=[Q?9\_)QE6.T7J%V8KM/T#D9 V_&T<J\IY"8;>!^U^*O;'MD8
MU['!S7#<$="%K#5,]O1> EN7LM6RNF9 (W5\F[ADX7#DULFQ+MQX%<=F6KJ\
M-CZ O230Q%HEQ[[GNO,;N8C))Y[;\B"=PMI474ACCG;R_!A&JJ<\,E9/S_)<
M=4:;9EG17*<QI9BMSKVV#F/U7?>:?+U7CIK4QM678K.1-HYR+DZ$GW9A]^,^
M(/EU"LW7HHG4.GZ.>K".[&1*P\44\9X9(G>;7#F%C&::P3T\OQT&LH-/'#7S
M_/22RP9LK4ARU?&RR%MN>-TD32T[.#>NQZ;^BJ]?-Y'2\S*>JB;-!Q#(<LQN
MS1Y"8?9/ZW0K,UY4DM8:#+8LA]W&O%N!S#OQM'UV@CP<W?\ )2J5I)2T>C^>
M)#JWBW'5:K?\X%J18F)OPY3&5;U5W%#8C;(WX$;K+6+33LS9--707RUVN6:0
MUU8^A&N9BVN[F\Z+W632;_I(QMX?>'0E;W[4]0RZ=TE8EI$?2-IPJU1O_:/Y
M<7]T;N^2T+8Q3'X=U)I+W!NX>[J]_7B/J3OO\5Z7TZ'.<GIH8;1%272M"2CX
M"QICVX-AP[=-O#9<6(8[->6"=H?%(TL<T^(*B-*6S/0->3^MKGA._7;P_#HI
MM>C*.%V,XRQ*YK;(X>]B9#&8)K=0?U<\32]VWDYHY[CSZ%1Q?,T[1U9]G=#)
M&Z-H/Q</RZK:\KVQ1NDD<&L:-RX] %7;]Z-D)RN1:\UV':K6V]Y[CT.WF?#R
M'-:0J2MGH5DE?+4Q]-8.5M,^VES8Y7=Y(SH93X;^31X!6MK6M:&L #6C8 <@
M M>3Y[,V9"]MEM1IYB**,/(^+G#<K)QVJKE.0#*N;9JD[.F:P,?%ZD#D1Y]"
MHE&=KM9$QLB]C<#D2%Z87-6=(Y23+T&NDJR#:_4;TE;_ )QH^^WKZ@;+RC>U
M[ YA#FN ((Z$>:Q<O)W6+MO\HS^?)8R@JBPO>7Q8<S8;=;4]%=E="\Y\<U^^
MUTU6)O,R.D<7!VPZCF/BM=XOM+S5"O8;1Q6/#[9+[<U]SII9W'SX2T ;<@WG
ML/%4-U>S7R%6G>D,D=>#OJX<\NX&N/U #TX>?3[RSAMOMN-TI[+!IXL[LRC>
M-NC3YQ9LGLXR^B+V9J5,WH_$8G)F0&K:A;Q122 [@ D;L=RY;]?-;XQ.*H8B
M&6'&5(JL4LKIWMB;L'/=]9Q]2OCFVSCKR#<AP'$UPZM<.8(]00OHK$ZKR.=T
MQ@:&(=Q9R]1BEM63S;5:YHW>[]8\]@N':]DPR6!Y/P.A5DHW9Z:YO4<OJ&CB
M,>:7TS6)<;\I&]!KAL2S<\WD> Z+76KM=6L';L::T2^.E1HN[NQ?+1)-8FZN
MV)Y>6[B#NMRTM#X&''1U;..KW'C=S[$[ Z61YYEQ=UW)]5\S:^TV=*:QR-&8
M25Z\\SK%.3B(;)&X[[ GJ0=P0K;*J-22I[EQWOYN,\-1-SEKY?..\MVC^U?.
MX?)P,U!;&2Q,L@9,^1@;+""=N,.'(@>(V5B[6'-D[2*[FD%ITQ=<#YC<K3]+
M'3:@R$&$QP[ZY;<(]F>]P,)]Y[MN@ Y[KZ\9A,>YE<VJ56Q/%7]F$LD37.[O
M;8MW(WV/B%7;(TZ-1."W&U-N2S- ]EV@LOG*>A\L^EAL;CL>!9%RJT^U6ASV
M$A^*^D%XTJE>C5CK4H(J]:(<+(HF!C6CR '(+V7!4J.;N:)6-.]N.AKF1GBU
M%@JS[-J./NK=:,;ODC',/:/%PZ;>(/HM%FY7:XMDE9$]O)S)#P.;\0>87VLH
MZU@<1;G[^WBJ$\W^<DKL<[\2%U[/M\J,<#5T9SI*3N?+.D]#9/7%P,H1.KX]
MO.:]*PB-P^XWIQ[[;<NBV]G<O-6&/DO4A0U!A'<;(F\X[E<#9[8W>.XV/#U&
MRVO%&R&,,B8UC!R#6C8#Y*/SV$H9VBZKDH&RLZM=T<P^;3U!1[;RD\519&52
M@W&T'F5?6%F%]O2>=JO:^#V@Q=XWQ9+&0/SV6@-'8+,YFE4ET[B,P,PS*N)S
M M<-=D;9/>!:3SV'_DK;%VO9Q.F<]IB>4RRXON\A0E<-BZ$/#OQ!#A\UL/0^
M&QF%T]!%A(W1T[!-H-=(7^])[QYE*CY*&6?#JU7F*$\4G?)Y7Z]'Y&MKU7+T
M^WC3C\OEC;BL5K+X86-X(X&-V &V_,GJ2N===I6A9\D*UK!QZB= [@,_L['L
M:1U#7O\ K?+DK-VPX6%^FLIJ"O'+],X_'3QUI6/(+&O'OG8=3L"OFN**+V9D
M;6M,7"-@.FRTV39X[1G)Z<#6I-PT-]]GNIL)=UL\:>;'6I9&JUKZ?=B)T$T0
M/+@'@6GD0-CL>?)6'MAQ4-[1UBV\;6*!$\3QUZ[$? C]P7S9I26YB];XG(4F
MRRMJ<4T_ -RV%NW%Q>@W\?-?5.N V]H/,&(AS9:3WM/F.'<*:U/D*T)1?!?.
MPYLITZD&NGO_ #<P>T>T]NB)(83_ $B^8JL8\R]P!_+=8>><_)6*VC,(]S((
MHF#(6&?V,(&P8#]YP!'H% ZOS<LSM&5J<)LW'1BTR$='/X"UA/H"2[Y*_:0P
M#<#C3'))W]^=W?6[)'O2R'J?AY!8M<C33>N;7E?LL$^6J22TR3\[=M_F1*T*
MD%"E#4J1MC@A8&,8T;  +W1>%ZW!0IS6K<C8X(6E[WN.P "XLVSMR2(36V<D
MQ./9!09WV7O.[BG".I<>KCZ-WW*:-TM5TY3<X?I\E8]^U;?S?*\\SS\M_!1N
MC*DV9R$NJLI&YKYV\&/@>/ZB#P=^T[J?DIC4NJ\-IR(NREV..3;=L+2#([X-
MZKI:DOV89O?U\.SS.9.+_>J9+=?AQ[?(G%&YK/8S"0]YD[D4'W6$[O=Z-:.9
M^06L[/:18SSG,Q=CZ+I[D=XR$V;3AZ, X6_,E9V$?0I2"S4TMJ'*Y!W,W+\/
MO$^8<\^[\@I_22C_ ).[\Z>97]7&?^/O_&OD)8=1:MU2S)X^ XS&UXG15;%R
M/WQQ;<4C8R0>([; GP5PT_I+'8>=ULB2[DG_ %[MH\<I^!\!Z!0^0U'JV*NZ
M:II$%H^R^V'/_P!$-_BH7'ZLS.4L^RV<UBL%;/\ R>Q6>)1_ID K5PJSC964
M5P=^^UV9QG3A+.[D^*MW7LC:2I/:]JJQI/2#[- -]OLRMJUW.&X8]V_O$>.P
M!.RR!IK-V0#<U?=>WRK01P@_,;E5_7G9<S-Z;GBK9#(6<K$1/7=<MO>PR-WV
M!'0 [D;[<MUSPA2C)8I770GZV.K'-Z1MUM>ESY[L=Y<MFU=N6K5XGB-B6=QD
MW\P=^7R6^>P;5V0S$61PV7G?:GH-9+#9D=N]\;MQLX^)!;U\=UHV3$9.C>]C
ML8'*0WNG<BJ]Y=^R0-G#U"WQV&:,O8&M>R^9B->[D QC*SOK11-W(XOUB2=Q
MX;!>EMSH\ES;7W%:6*^9M-$1>*= 5-[6(6OTD9I&"2.M9AG>TC<.:'<P1XC8
MJY*"UW5-W1N:KL&[WU).'XAI(_,+6A+#4B^DRK1Q4Y+H)QA!8TMVX2.6WDN5
M&:7N>WZ<QMK<'O:['<O@I-9R6%M,TB\2N@JI3U!;S>I_9L((SAZ9(MW'-XA*
M_;^KC/IN"2L/4N3MY_)R::T]*Z/AV&1O,Z5V'[#2/MGGY;;*UX?&5</CH:./
MB;%7B&S6C\R?,E;853C>6KTZ.GV[S+$ZDK1T7RWOW<3,1$6!L$1$ 1$0!$1
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M=_DLOLLNB]H;&%K@[N6>SDCQX#P_N 5"E[1LO+V,9O*6HJT6H\7,:=V)\>[
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M_9@@>'/]VE.GBS>26IG4GAR6;>GS@2>ELID]1967*-WK:>:TQU8G,''9._\
M6GQ Y<AZJVKK&QD4;8XVAK&@-:T#8 #H%V43DI/)61,(N*LW=A$14+A$1 $1
M$ 1$0!$1 $1$ 1$0!=3]9J[+J?K-0'9$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MA(1$0!$1 %U/UFKLNI^LU =D1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M5OUFE3+WM8W=[@T>9.RP3G1GEDT=47&<;K1GS3K#LFS>G]+Y3*RYRI*VG"9
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M?P]/5?8FF<JS,X*A>:YG%8@9*YK7 \)+02%IMD*M%_<VF12ITFLHHRJN/IU
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MO5]_=FDD?"[;]9O"1O\  JYZ [(68C(0934MJ&_<A/'#6A:1!$[P=N>;S\0
M/)>MCM5NX_366O9C3LU6[CWQ L$H?#,UYV#F2#<';Q^*GLYKR/&ZCPF+CJMG
M^DJTMCO&R#]'P,+MMO79=,]HVB<<+>150BLT7=%IBCVS9#Z'HYW):4F@T_:F
M;"+<=ECB"YW#]3??KZ+<L;VR1M>SFUP#A\"N24''4N=D1%4!$1 $1$ 74_6:
MNRZGZS4!V1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M?<#UYGFNAU4R+'S7)KV)O:L[6'TB\1_27L#JP8[A]BVX.\WVX>HWZ[\^BO\
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M$+U,3;=O-^&GF8.N-.0ZJTQ=Q%AYB[]H,<H&_=O:=VN^1 7S;=T'J^A<-2?
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M^'26G*W\AVIZA^B\2Z2MIVJX.FFV_K/UCZ]>%OS6W<)BJ>%QL-''0MBKQ#8
M=2?$D^)/FO#3&!I:<Q,5#'LX8V<W./-SW>+B?-2J\BO64^9#**^79ZU"@X7G
M4SD]?9!$1<QTA$1 $1$ (!!! (/(@JF]FV]*/,X1_7&W7AG_ %<GOM_(D?)7
M)1U?#UJ^;MY6+O!9M1LCE&_NGAZ';S6D))1E%[_/Y<SE%N2DMWE\L2*(BS-
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MU*[>\E>?V1T'J>2ACC,]J?WLW,_#XT_\AJR?I9!^O(.GP 4MI3 XW&TXK-2
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M<P'?EL/#FOHQ0M33NGZV<ER-7%XZ/+.&[YF1-$O/Q)Z\_/Q4O%+'*7]U(Q_
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M>E',GX4)/\%G*C6D[M,O&M1@L*:L6Q%5!KFD>F,S9^&/D_P79NM:KNF*SO\
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MLKIB2:+!8*"P,ADK$V\F1DV)(#?M!NQ.^P55T1K#V3M+I:JLRV@<U:EKWA)
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ML*:O-V+RH_,YO&X: S92Y#69^N>9^ ZE:*U#VJ9W)A[*9CQE<].Z.\GS>?X
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M$0!$1 $1$ 1$0!$1 $1$ 1$0!<?:^2Y7'VOD@.41$ 1$0!$1 $1$ 1$0!$1
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MS/9( S</8T$ >>^W[UYP4\5J7M!T[@<KE+&4TW#A1/2[^=S1;?Q.!<X@CB(
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M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %Q]KY+E<?:^2 Y1$0!$1
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M#<_66JPU(.,-;K+OT]C)N5.:E/-6>?=K[FP5A,R=9^7EQC7N]KBA;.YO"=N
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M_*NKIV,/UHV.>X?DX!5E03>*I47GY%H[1)+#3IOR\S:5FY6JM+K-B&(#KQO
M_>J'JWM,Q]%XI8:Q7GN.Y.L2;F" >;B.;CZ-W6#5[&,1Q<>0R-ZU)YCA9O\
MB"?S4]1[,]+U-M\?[01_GWE_Y)%;+!WDW+LL)/:IJR2CVW]"DXK6NEL+:??G
MDR&;S<@VDMNA#1\&!Q :WY*1=VL7;IVPNG+4Q/3O-S_L@_O6Q:&GL/0 ]BQ=
M*$CH60M!_'928 '0;*95Z+=\#?6_1$1H5TK8TNI>K-3?3_:7DMA3P=6FP]'N
M: ?]=_\ !9-;0N>U(&OUYEY'11NW94JEH!]7$-V_?\5?<SG\5AF<62O00'P8
M7;O=\&CF?D%7;.H]0Y2%YTQ@'-B/U;61=W0/J(SLX_/93&M-J].*CT_EE948
M)VJ2<NC\+U)S#:?PVG8'''U(:S0/>E<=W?-QYJ.MZWH.L.JX2&QF+H.QCJ-W
M:T_K/.S1^*J3M*ZMR<_>Y\4K_O<0AGLO[AO_ ,MH /S)5DIXS5T$#8:UO3]&
M!O)L<-)Y#1_I!5=."=YS4GU_VWX%U4FUAA'"NK^DO$[_ $=JG-C_ "I?BP]1
MW]A0]^4CR=(X$#^ZI? Z9Q>#<^2A7(L/&TD\CR^1_P 7%8>/Q>I&W8I<AJ"O
M+"UV[H8:08'CRW+CLK*L:DVN;%JW1\S-J<$^=)._3\R"(BP-PB(@"PLQE*>'
MH2W<C.V&O&-RX^/H!XE8.I=1U<(R.,L?:R$W*"G"-Y)#\/ >IY*)QNEILK9;
MD]9=U;M=8:7UH*P/@!]IWF[T6T*:MBGDO%]7N8SJ.^&GF_!=?L5"SJBMJZWM
M?%N3%,=O#BZ4;GRV#X&9PY ?J\7CS5PAO:HM1,CQ&"IXNLT;-.0EW('HR/?]
MZME>"&M$V.O%'%&WD&L:&@?(+4W;SK#(8EM#!X:P^I8N-=-/9C.TC(FG;9A\
M"3X^0*WC-59*G3CW_%ZF4:,HIRG+/H^/PL6_^;&3R._T[J.W(W[5>DUL#/AN
M 7?FL3/18+LWT]>U#6Q3I9*[!QN#RZ5X) ^LXKYGJ"6E;;;H6[=6ZT\0LQSN
M#]_,G?GZ[]5N>[E,IVB]@^2CAJFSG&DU98H1_6/8X>\ ?,;';U6M>A4I6Q2Y
MKX9%Z<:;=TL^G,LV%[339U!1Q&9T[D<18OPNFJ/F<Q[9>%O%M[I.W(%8-3MC
MH7L3AI:&+MV<OEI7,KXV-S2_A:[8O<[HUO(\_CY*DZ)TAE8=;X2_B=+Y;"0U
MHGQWY[]ML@F86$<+6GGS=MT6!H_LYU!I+3N'U7B:-W^<U6T_VS'O(WGKN(;P
M >@W/SW\%S\G3^=IM=FS,SVLUL1E)X+>#R1HU)XJMR\P-[J&5_@ 2"X [C<#
MP^"V6#N 1T6@]73ZIU)KBI-E-'9BSIFA(R6M2C+6":4;?I)=]]P.>PV_BM]\
M6S.)WNC;<[^"RJ122L2CE%YUK$-J!DU:6.:%XW:^-P<TCT(4'JK6> TKW(SN
M2BK23;F./9SWN ZGA:"=O59J+;LB;E@7!^L% 2ZTT[%IQF>?F*@Q+SLVQQ;A
MSON@=2[TVW6'4[0]+6\)<R\&8@-"B1[2\M<'1;D <3".+F2.>RG!+@"V(JII
M[M%TGJ'(-HXC-UK%QS2YL1#F.<!Y<0&_R7;"=H6E<WF1B<3FJ]K($O A8';G
MAWXN9&W+8IADMP+2B(J@(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B +C[7R7*X^U\D!RB(@"(B (B( B(@"(B (J
MU6UOA;&I<I@63R-R6.C[V:-S" YNVY+3X[!8F)[1<!E),(RM)8'TO'-)6,D7
M".&(D/XCX=%;!+@"X(J,SM3TP_'9#(,L6#CZ<PKFR('<$TIZ,C\7'Y+TE[2<
M$[1-_4M226:M4<8GPNC+)1-N (RT]"21^*GDY<!<LV<QGTK1]G]KM5'!P>V6
MM(6/!'J.H]%7OHO5V.&]'-U<G&.D5Z#NW?Z;/XA:.O=J&MKULV8\K#CF;[MJ
MUZS'L:/(EX)<?/F/1;9[*.T8:GK6:><-:MEZ@#GEAX8YHST>W<\N?(CS77*A
M6H0O))KO,&H3=[V9,C5>3H;MSNFK\0;UFH[68]O/EL1^"D<5K# Y1XBJY.N)
M_P#,RN[N0>G">:RI]18>#?OLI39MYRM_Q4!F\YH?(QEN5MXRR/UAQ'\1S62@
MI_P?9[/W*N;A_-=ONO8N8Y]$6I39TE3<7Z=U+E,:_P (Z[)9H_\ 1<QR[P:[
MSE4@0QMS<(.V[:,T$I'X</[E;]'-_;XIK\>)7]9!92\&G^? VN0"-B-PHO(:
M=PV0!]MQ5*8G[3X6[_CMNJ_3UED\A%PT=*93VCQ[\LCC;_>)_@O85=8Y'_C-
M['8F(_9J1F:0?WG\OP"S5*<'FTNWV+NK&:RBWV>]A-H;&5PZ3&W,CBB.>]>X
M\,']TDA5R[G+F'F[FEK2ME9F\A5?4$TA_O1\]_B%96:$QLS^\S,][+2[[[VY
MSP_Z#=F_DK%C\=3QT0BHU8:[!RVC8&K3ETON>+K2\W=^1GR,G]JP]3?DK+S*
M5B-4:OMQGO=)=.CWV.YXO[KF[A23<KJ]_33E!G[>1_P8K:BS=6+>4%X^YK&C
M-+.;\/8JGMNLW=,/AF_M7GG_ '%&93#ZDS32S)X?3$@/VI'R.</@>#<?(J^N
MWX3P[<6W+=5+Z8U53)]NTY%;:#]>A::=_P"Z_8J].;><$D^NWFRE2FEE.3:Z
MO9$%B]*:RQ=OCQ^;I5ZG_LKWRSL'PXQN/D5/^P:Q>/>S6+B_8IN=^]RZG7V.
MK<LQ2R>+(Y$V:Q+1_>9Q!2./U?@,@6BIEJCW.Z-+^$_@5:<JSYTH]MO4K"-%
M<V,NR[\B/^A=5N^OJR)G[&-9_%RBLIV>6LL>+)9X2R;[]Y'CX8WCX/ XA^*V
M"Q[7M#F.#FGQ!W"Y62VB<7=678O8UELU.2M*[[7[E'QVC\[BXC%CM87#'X,M
M5VS@? N.X67[)K2 >YD\1;V_SM=T1/\ HDJVJ$U%JK#:>CWREUD;]MQ$W=SW
M?!HYJ55J5':R;ZE[$.E3IQO=I=;]R,.0UG W])A,59V_S-YS2?D6+'O:VNXJ
M SYK3=NM"WZTC)XWCY;D;JLV.T+4&I975=%8A[6'D;$S02WUZ\(^>Z]\9V76
M<E9%W6>4EMV#S,43SM\"XCE_= 75R,(*]=)="O?S.7EISRH-RZ7:WD+_ &N-
MN%E73&'N6[LG1LK=N'X-;N3^2QHM':NU:\3:KRSJ=0\Q5CZ[>18-FCXG<K9V
M&PN.PM?N,74BK1^/ .9^)ZE2"Q>TPI_X(VZ7F_P:K995/\\K]"R7Y*WIO1."
MT^UII48WV!UGF'&_Y$]/ELK(B$@ DG8#F2N6<Y3=Y.[.N$(P5HJR(K4^:@P.
M'FNS@O>-F11-^M+(>36CXG91VD,"^IC[-C,!L^4R?Z2XXCH".48_5:#LJ7D;
MT^IM;Z?N-<1AH[SH:;=MN^<QA<^7X<@!\UMI=%2+HP4=[S?M\]#"E)5IN6Y9
M+W]OR5#LXE=5J9# SN)GQ-@Q-)/-T3O>C/X';Y*WJF9O_(NOL5D@-JV38<?.
M?^D'O1N/X$?@KFLZV;4^/GO\2]').'#+V\ B(L38(B( B(@"(B (B( B(@"(
MB (B(#6'\H"MWFE:<X;N8;0W/D"UP6D,+8-3+T; .QBGC?\ @X+Z+[8*OM/9
M_DSMN80V4?)P_@2OF@';F.HYH#[*!! (.X/1%':;L^V:?QMC??O:T;_Q:%(H
M B(@*AVEZ4;J;!N[AK1D:V[Z[CX^;"?(_OV6NNR/63<'8EPV;F,%)[B8GS'8
M0/\ %IWZ _O^*WHM*]M6D?9ISJ"A'M#*0+;1]EW0/^?('Y>J]+8ZD:D7LU31
MZ=9YVV4Y4Y+:*>JUZOGS(W+6L0VHFRUIHYHG='QN#@?F%Z.:'#9P!^*T_P!F
M^/PNJ,8Y\1L8O.UMFS24I3&7CP?P\VG?;GRZJX&AK#&;^P92EEH1T9?C[N3Y
M/8-OQ"YJFSJ$G#%9KCE[G13KN<5/#D^&?L6F2C4DW[RK [?KQ1@K#ET]AI=^
M\Q&/?O\ >KL/\%!_SRL8_9NH\%D* '(SQ-$\7QW821^"M&.NU\C2BMTI!+7E
M;Q,> 1N/@>:SE&I3SW&D94ZF6\A9]$:9FW[S!T.?W8@W]RP)NS32DF^V+[O?
M_-S2-_WE<44K:*JTD^\A[/2>L5W(JG_!WI4L:TX:#D-M^)VY^)WYKQ?V::4=
M_P#DL-_9FD'^\KBB?J*J_D^]C]/2_P!%W(H[^RO2SNE2PWX69/\ %>+^R;3)
M'NQW&G_XAQ_>K\BM^KK+^;[ROZ2A_HNXUP_LAP1^I8NL_O@_P7@_L<Q)^KD+
MK?DT_P %LY8F1R5+&PF7(6H:\8\9' *RVS:-%)E7LE!9N*-9R=C%(_U>8LM^
M,32O%W8M']C.RCXU@?\ >6S\-EJ69I^U8V;OZ_$6<?"6@D==MP/Q6<KO;MIB
M[.7@BJV+9Y*Z7B_<TX_L5?\ 8SS3^U4__>6+)V+71_5Y:H[]J!P_BMVHI7U'
M:%_+P1#^G;._X^+-&'L9RX/N9''$>K7C^"#L9RQ^MDL?_HO/\%O-%/\ R6T<
M? K_ ,;L_#Q-'M[%L@?K92B/A"XKT;V*6OMYBJ/A6)_BMV(H_P"2VC_;P1/_
M !NS_P"OBS3#>Q.3QS<0^%3_ />7H.Q/SSH^5,?]Y;C11_R.T?[>")_X[9_]
M?%^YIX=B;/'.N^50?]Y>C>Q6$=<Y+\JS?\5MU%'_ "&T?[>"]B?^/V?_ %\7
M[FG;O8OM6<:68X[ ^JV:$!I]-P=PH.K#:T1-MJ/25.]5:=C:$?%MZAY!!^8"
MW\N'-#FEK@'-/(@C<%7C]0J-8:G.7=Y%)?3Z:SI\U]_F4_26J]+98,CQAK5+
M!^K7DC;$_P"0Z'Y*XJD:D[,\!F>.2*)U"T3OWE<[ GU:>7X;*KBAKW17.A*S
M,8QG/NS[Y:/@=G#Y$JKHTJV=.5GP?N656K1RJ1NN*]C;Z+5N$[1,KJ&\*&.K
MXJC;Z<-Z23WCXAH Z[^!.ZLPP>I+G_K+4IKCQ9CZ[6?ZS@2LI[-*F[5&E\Z#
M6&TQJ*]--_.DMA(:"7$ #Q*@\EJW 8YQ;<R])D@^P)0YWX#FH]F@<,\AV1==
MR3_O6K+W#\ 0/R4WCL'B\:T"CCZT&WBR,;_BJVI+>WX>_D6O5>Y+Q]O,@7ZY
MAF8\XG#9G(D?5=%5+6$_M.V53MZKR^1E<S.37=+TR=N".F][W#UE(V;\@MMH
MKPK4X:0\?Q;P*2HU):S\/S?Q*'I=^A89!)0R&/LW7<W3VK DF)^+SN/DKVQ[
M7L#HW!S2-P0=P5@7L)B[X(N8^K-O]^,$K(Q]*OCZ<56E"R&O$-F1L&P:-]UG
M4E&>:O?I-*490R=K=&1D(B+(U"(B (B.(:"7$ #F24 5,UAK6#&6'8W&RUGY
M(CWY)I R&J/O2'SZ>[U*QLIJ2?/2RT\#:CI8QA++65E(:!YMAWZG];H%'TY>
MSW#2!M9L5ZZ.KF1OLR/=XDG8C<GX+LI4%'.:;?!>IQU:[EE!I+B_3W.=.9?!
MXV:2Q7??U)FI1M-<K5C*3^JT]&M'D"IX9C5&0_\ 5V AI1GI)D+&SA_<:#^]
M<1ZER-E@;A-+7C']E]DQUV?AQ;_DHW4^1UECM.Y/*V)</0AJ5Y)^")KYI#PM
M) W=LWTZ*TE=W:5^EW\%[%8MI6BWV*WB_.Y(R874-H Y35'LT;CSBI0-C^0>
M[<JB=JW9A-+3JY?3WMF1R57=DT=B=TDDT1^YQ'ZP.QV\=RM,Y"Q=S\_M^HK4
ME^[* YSI#LUF_P!EK1R 'P6Q>P[55S%:JJZ>GGDEQ60:\0QR'B,$S6\7ND\^
M$AIY>>RZ94*U"/*)K+<E8TC&FWIWYE#IX[*W;9J4\+E);8=PF(U7M+3^L2-F
MCU*^F.RK2K]):1@I6G-?>E>ZQ9<WH)''?A'H!L-_16]%Q[1M<ZZ2>2-X4U$(
MB+D+A474EVSJC+RZ9PLSX:T6QR5UGV6_YII^\>6_D-UF:QSELVHM/Z=<'9FT
M-WR;;MJ1=#([UY\@IK36#J:?Q,5&D#PMW<^1QW=(\]7./B2NB"Y)<H]=WO['
M/-\JW36BU]O?Y;,QU*OCJ4%.E$V*O"P,8QO0 +3N>R&.TOVX7\IK%H9B[N,;
M%0L31\<;7-+>-H\B?X^JW)=LQ4J<]JR\,@A8Z1[CX- W)_ +YKU1VJ:AU#9>
M[&308W%!Q,$?L[)9)&^#GEX(!(Y[ #JK;/2G6D\.?$UDU!$CE[>)FQ>CM25-
M/38[1]?+326J[H>)I)!:V<M^Z3RW/P\M_?M$SNF\]H?M L:8Q;6B."O'-E(X
MPV.P>^;[H\R.JGNR?M)N9C*1Z=U0VO+//&XU;,<08)2T;ECV] =MR-@ 0//K
MMT5:[81 V"(0'K&&#A_#HE1NE+#-9KIZ259K(^<L?4NXSM$TM_/6VR2O["9,
M'8I4V1"29S&[QOVYN<.6PW.YVZ;KGL<M1X[6.G,;I?+S9NC-#8=D(;%)D4E$
MASB'$C=S"7';8D[[_!?1[X(9.[[R*-W=G=G$T'A/F/)<15X8I'OBAC8]_-SF
MM +OB?%9NK=6L,)ZHB+$L$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %Q]KY+E=?[0?! =D1$ 1$0!$1 $1$ 1$0
M'SEJK3&6M:YUSJ'"0SMRN)D@FK#@/#9B=&X2L'WO='0?Q4/C=(Y'46)[.,47
MWL8R6K>CLS,A<',8Z4DM/EQ#ES7U*BW5=I6M\L18T=I#45G3FAK.G\YIZY):
MPMCV=[J<&^\+B>&RP;$$@D;[;G?8^:A,3I_*9CLQUC#CZUR:L,J+]&>Y&6V;
MS6D.<7[[%QV'([<ROHS8>2  #8<@BK6=TL]18^)0:LW$\D<7V@X[%I\B#T*V
M?V#:-KYC+W\UD,?%-BF0>S0]]'NV60N#BYN_4#;;?S)6ZLAHG3&1O>VWL!C)
M[1.YD?7:2X^O+G\U.UH(:L#(:T4<,+!LUD;0UK1Y !==?ZC*I##%6,50C?/,
MC*^F,%7&T.&QS/A69_@L^&A4A&T-6O&/U(P/X+(1>>YR>K-5",=$<!H'0!<H
MBJ6"(B (B(#A_%P.X-N+;EOTW53-/6<X/'EL/5W_ ,U3>\C\7JVJ%SVI:&%G
MCKV!8FMRMXF5Z\1D>X;[;[#U6M)RO:*N^JYE54;7D[+KL19TSFYP/:]6W1YB
MM R+_%<NT/!+RMYS/V6_=?>('X- 7'TSJ7)[C%8)E&(])LE+PN^/=M!/YI_-
MC+Y @YW4EJ2,]8*+169\.(>\?Q6V*<?NDEU6]###"7VQ;Z[^I@7]-Z&Q)X\N
M:I>/"W8+W'Y$[E53+ZDTI7G?2PFBX\I$ "]S:Q9L?#EP$_-6W/8_!:3HL=C\
M3#9S%I_<U!*.]EDD/B7.W.PZE3VC\#]"8X^T/$^2L'O;=CQD>? ?JCH!Y+55
M8QCCDV^&=O+W,W1E*6"*4>-E?S]C37M-I[^+":+R^-<3N#5GGC'X!H"SL;=[
M2H9-ZU7)/9OR9;8'C\3L5O1$>W)Y8$^N[\Q'86OYOLLO(U)+'VG9MK:\XKXR
M%WUIH7-8X?@XG\-E*Z=[*,31?[1F99,K;<=W][RC)_9YD_,K8R+&6V3MAA:*
MZ,C6.QT[XIWD^G,\Z\$5:%L->)D431LUC&AH ] %Z+AS@UI<>@&Y55=K:"0N
M&/Q&:O;<@Z*H0TG]IQ"PC"4]$=$IQAJRUHJD,UJBW_Q+345=OWKMP-/X-:5S
M[#K&USFS&-H ^%>L9B/F\C]ROR-ON:7;?RN4Y:_VIOLMYV+8J;K.Y-EKT6EL
M7(6S66\=V=AYUX/'X.=R ]%&ZHQ<V)Q$EW,:BS%Z0D1Q5X'BN)I'?58 SS*G
M.S[3?\W\07629,E:/>69'.+COX-W//8#DM(QA3CRE[O=U_@SE.=27)VLM_5^
M>LP,M5@JZQT9CJ<38Z]5EA[6-&P:!&&C]ZNZI]T][VIXV/KW&.DD^'$_;^"N
M"I6>4;\/5FE%9RMQ]$0.N<4_,:9N5Z_*TT":N[[LC3NT_EM\UA:3UQB<Y5KM
M=9;7ON8.*"?>,EWCP[_6&^_16M:\P^#QK\]G=.96G#/#Q^WT^(<V1R'F&GJ-
MG ]/-32PR@XSW9^_H5J8HS4H[\O;U-AHXAH)<0 .I*I?T!G\&2[3N6-NH#N*
M&1)=L/)LO-P^:TAVE:SS&IL_;H639QU"BX0NIQ3$"20#WG/<W;B&_(#HK4ME
M=65H--?-Q?E;?<K/YO/J"*6.9O%#(R1OFT[A=U\>Z?SV0TG=9D</9FC;$>*6
ML9'&*9GVFEI.V^W0]05N#M:[3,GIEVE;>%CB?0R,9LV&R,XG=T. G8^'NN*F
MML<Z4E'6Y:,U)7-Q(M*P]HV?S/:ID--X22E'1[AXJS2Q\0[UK&G<D=0"Y>VE
M=1Z\R.IL]0N7\*8<&\-L\%=P,H+2[W/P\5CR+2NRUS<B*G]DFH;NJ="8_+Y3
MNO:YS(']VWA;[KRT<O@%<%G).+LR0B(H 1$0!$1 $1$!$:OJ>W:6RU7;<RUG
MM ]=BODMOU0OLF5G>1/8>C@0OCVY":UVQ 1L8Y',_ D(#Z8[*K?M>@\2XD;Q
MQ]U_HG;^"MBUOV"61+HR6 G=T%IX^1V(_BMD( B(@"\;E:&Y4FK68VR0RM+'
MM<-P05[(B=@U<^<LE6O]F^MV2UN-\+271$])X2>;"?/^.Q7T!A<G6S&+KWZ,
M@D@G8'-(\/,'U!Y*&[0=+QZHP4D #6W8MWUI#X.\O@>A6J^RC53]-YB;#9E[
MH:4LA;^E.PKR@['??H#X^NWFO5FOUE'&OOCKTH\N#_1UL#^R6G0;Z3IT5<FU
MSIB$'BSM [>#)0X_DL;_ (0,$\;UI;-GR[BL]^_X!>>J%1_Q?<=_+TO]EWEL
M150:T9(-X,!J"4>!%(M!_P!(A<-U/F9M_9])Y#;P,\S(_P#%3R$]Z\41R\-S
M\&6Q%4CDM8S,)AP.-@WZ=]>)(^08J[D,1VAY&;^EW:+:IZP5;+H-_P"\&<7Y
MJT-GO]TDNTK+:+?;%OL9?,KG\5B6DY'(5H#]UT@XC\&]2H/^=]O(.X=.X&]=
M;X3V![-%\=WC<_(*%Q>G<UC7]Y6TYIXS^,TUN260_P!YS"5."SK4#88S!@?_
M !<G_<6G)0CI9];7I[F?*SEK==2?FUZ'7Z(U/E3OE<S'CH#U@QL>S_AWCB?R
M"S,;HK"4IA8?5]MM]?:+A[Z3?XN6-[5K7_FW"?\ U<G_ '%*8*7.R22C.5:$
M$8 [LUIG/)/CONT*LW-1R:2Z&O0M!4W+--OI3]="8: T -  '@$1%RG4$1$
M1$0!$1 %YOL0QRLB?-&V5_U6%P!=\!XKT6C>T*TR;5N7S,-&.W0P1K1WVRRE
MLI=Q;M,#@-V; \QOL[H0KPAC=@;JM7JE1S&V[4$#G_5$D@:7?#<KFQ<K5PTV
M+$,0=]7C>&[_  W6B=.8G!:SUAKN?73A+8IS!E:*S8,?LU;AW#VC<;<MCO\
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MX$CD?D=BL:4E&2;T]#>I'%%I:F<#N-QS"^=>U[0V3QNI+N:QE*:YBKSA+)W
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M^,M%)F,-$!D8V[S0M']>T>(_6'YK0PXFN\6N:?@01_%?9*TYVP:!!;/G\-&
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M](J,:Y@\XG#D/D01^"XMMI8H8UN\OGF5IRP5,.Z7G^5Y&T$1%Y1V!$1 $1$
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M@\!B0/WKMVAC_P#FUH(_K2_P54UE"RLX\.AD=!M)$1>>9A$1 $1$ 1$0!$1
M$1$ 1$0!$1 >%F[5JN8VS9AA<_ZHD>&EWPW1ERJ_ZEF%WP>"L+-Z>Q&<,1R^
M.KVW1;AAE9N6[]=BH5_9OI1QW&);&?..:1G[G+2*A;-ON_)96WEM:X.&[2"/
M0KE4T]F^!']2[*0#RCR$P_WET/9[69_Q7.ZA@^&0D</S*G#3_P!O#\BRXDKJ
M>AGIY8+6G<I#6DA!#JUB'CBFW\R""#_BH:/7%O%/$6LL)9Q@Z>V5P;%=WKNT
M;M^:[_S)R3 ?9]99UGEQO;)^\+@Z5U.(W1MUM/(P\BV?'PR _DM(X+6DUXI^
M1*L2=W%Z8UI3;+)'0R3-O<GB+7/9\'#F%$'3&HL#[^E\\^U7:-A1RN\K=O)L
M@((_-0$O9;FHL@V[C=3PT;.^[GU*/L_'^TUCN$_,*?\ ;]8Z=/\ E*G%J.B#
M_7TAW5D#S,6VQ/P*M:V4))K@_P BW!G:+7K\=((=88:YAG=/:&@SUSZ\;1R^
M:MV.R-+)UQ-CK=>U"?MPR!X_)0N#UA@=1E]2*PQEKH^C;;W<H]"QW58>1[/L
M4^=UK"OL8.^>??8^0QM)_6C'NG\%G*,;VDL+^=OF1EO,72Q.G-:933S]VT;N
M^0Q^XV&Y/Z5@^!(.WD5>UI?M#;JS3]7'Y2^^KE68VTV2*_$TPS-!Y.9(P#;A
M<.1(/DMIZ7SM/4>%KY+'OWBE'-IZL<.K3Z@J:L'93U)DG:Y*HB+G*!$1 %P]
MW"QSO(;KE=)F&2&1@.Q<TC?R0%7[+F_^AU6;_/R2S?B\J/[6]$R:PPT!H21Q
M96D\R5W2?5>"-G,/D#L.?@0K/I?%'"8"CC3*)37CX#(&\/$>I.RE%M.I:JYP
M>_(RI0:IQC+@?*,6@-:27'5AIF=DHZR/GC$7QX]^8^'-7.3.2]BUK3N%FBAN
MU<DY]K*V0UW$QQ(;Q,V/)K1MU!Y!;[6O]::(FU)KK#9"=M>3#P4[%6U&]QXW
M=XT@;#;U\UM/:Y5LJFA:,%'0B1KC4^5GU6S3L.&DCP]EHCDGXR)(#&7;[AW,
M\ATY*'QW:9K!O9S8UAD,9BIJ3H]J\=82!S7]YPETG,^X-B>7HICLP[.<II''
M:MI6K4-EF0]RG)QDNX QS6\>XY<B.FZ]L5H;4-#L?IZ<I9*O1S5<EW>-'>0R
M>^YW [<?5(//DJ7@LLMQ.9A:/U_JC)T\L]E+#9\PUA/4DQ-D-XI"=N[>QSBY
MOGN0.BENSW6F=RFK<IIW4M&C'<IUX[)EHN<YC./^S?N3LX?'P54Q?9]J^CE<
MKJ&G'I_#95]+V2"O0+FPO<3SE?[NVX',#8\P%C]F^5;V>/NU]3Y# RNF!EGG
MI6'V;=B8GK(=NFV_+?DIP*5\"N62;T-](M+9OMUK,)9A,1--Y2VGB,?Z(W/Y
MA4#-]J6J\H',&1]CA=]BJP,/^E];\U:&Q59:Y&L:,F?3F1RN/QL9?D;U:JP<
M]YI6L_>51<WVQ:8QX<VG--D96^$#"&G^\=@OFNS8L79@ZU/-9F=T,CS(X_CN
M59<)V?:GS!;[-B9XHW=)+([INWSY_DNA;%3@KU)>AJJ$8YR9<,WVXYBSNW$8
MZK29]Z8F9_\  #\U0,WJW/9H.&2R]N6)W6(2%L?^B.2V;A.PJR\-?F\O'%YQ
M58R[_6=M^Y7_  ?99I3%%K_HUMR8?;M.,@W_ &3[OY*>7V>E]B^=;&.G#0^8
M\;B;^1>&8VA:M.)Z00N?^X+,S6G<AA'1196-E>S(.+N.\:Y[6^;@#[OP/-?1
M/:'K*AHG&BIC((!DYF_HH(VAK8Q]]P'AY#Q7SK+)=S&3+Y'37+]J3]I\CBN'
M:/JLUS::S[SV?INQ/:%RM56AY_@Q\?CI[]R&K3B?/9E<&L8P<R5]*=G?9W1T
MY5AM7XV6LP1Q.E> 1$?)GE\5U[+= 1:7IBY?:R7,3-]YVVXA'W&_Q/BK^N93
MJU.=5E=G#]1VFC-\EL\4HK?O?;K8(B*QY01$0!5?M#N^SX/V<'WK+@PC]7J?
MX*T+6':!=]JSI@:?<K-#/F>9_@O-^K5^1V:5M7EW_@]#Z71Y7:%P6?SM*96T
MS6N7'.K4A+* 9"QO38=3LI?$WI\9<CLUG<+V<MO!P\CZ*Y=FE+W+=UPZGN6_
M+F?X+SUMIKN^\R./9[G6:-HZ?K#^*\BGL]>6S1VC$VUX+H.?ZS3@MH;I*UM>
MLMN#RL&7I-G@(#AR>S?FP^2D%IO!96?$W6SP'=IY/9OR>/+_ ,5MK%WX,E39
M9K.W8[J#U:?(^J]G8=M6T1M+[D<5*IC6>IE(B+T#4@M9Z<KZGPDE&P>!^_'%
M*!N6/'0_#P/HJ)V>ZGLZ?R#]*ZJ=W+X3PUIY7;#;P;N?LG[)^2VPJ=VCZ,@U
M3C2^%K&9.%I[F0CZP^X[T/GX+KV>K%KD:OVOP?$Y-HI23Y:E]R\5P+%]-8O_
M )RI?]NW_%/IK%_\Y4O^W;_BM5]F7T#DGR834&"Q\>9K;M#I*[6F8#S&WUA^
M?5;$_F9IO_F+'?\ 8-_P45:,*4L,K^ I5JE:..-O$D/IK%_\Y4O^W;_BGTUB
M_P#G*E_V[?\ %1_\S--_\Q8[_L&_X)_,W3?_ #%CO_IV_P""SM2XOP]S2];@
MO$D/IG&?\Y4O^W;_ (I],XS_ )RI?]NW_%8'\S=-_P#,6._[!O\ @G\S=-_\
MQ8[_ .G;_@EJ7%^'N3>MP7C[&?\ 3.,_YRI?]NW_ !7!S>*:-SDZ0'K.W_%8
M/\S=-_\ ,>._[!O^"Y9H_3K3NW!X[?\ ^':?X):EQ?@+UN"\3W?J3!L^OF<:
MWXV6?XK'?K+3C#L<YCR?2=I_<5D,TU@V?4PV.'PK,_P63%B,=%_58^HS]F%H
M_@G[73X#]WH\2'?KK33?_P K0N_8:YW[@O-VO<#_ &<]J7_JZ<SO]U6-M2LW
MZM>$?!@7HUC6_5:T? )>EP??^!:KQ7=^2E#M&QUN<UL)2OY&X.L+8C%M\2_;
M997>ZQR1VCKXW#1'QE<;,GY$-4IF-,8?+GBN4H^^ZB>+>.5I\P]NQ4.,+J7#
M<\+F&Y&LWI4R0][;R$HY_B"M4Z37,5GTY_CO1DXU5][NNC+\]S/3^9AMC?.9
MO*9#?ZT0E[F(_P!QO\2IG$Z>Q&('^3<;5KN\7,C'$?B>J@XM<Q4WMBU-CK>&
ME)X>]E;QUR?20<OQ 5JJ6H+E=D]2:.>%XW:^-P<T_,+.HZJ5I:>'AD:4XTF[
MQU\?',@<MHW&7K)N5>]QF1_]JI.[IY_:VY.^:U5VTYS4F%Q$&G+MN&W%DN(F
MW TQS&%FW$QS=]N>X!(\-UOE:%_E(5GLU!IRV2[NI(9X/0.!:[\2-_P6VR3<
MZD83S723*FHWE')FFKTD3JT,<>P'&T<.VVP&_+983JS"3PES/AT6?E6-,43M
MAN) -_'H5C-!'4[KZ6.F1R,PIZL<?#._>7NB'.:>0>T'FT[>86UZ+814A]F:
MUD!8"QK1L TC<+6-L\-:4[;^Z1MYK9F)B=#BZ<3_ *S(6-/Q#0N:NN=<TAH>
MCL%!?@LV#5C<VNT.DD&S7-!.P]>JM.!P$%6O?GS#9708^*,]RR3WI"_ZH+O_
M #U6/@IZL&+S+;@+VRQQ,;$V0->\\>_+?RVYK/&IH1;L...XZ=J%L5BN^7ZQ
M;R!:[;ELN.<JDKQ6G]?DU2BLSV;B\9D:^/O4H)JS'7F5;%=TG&-G'JUVP_\
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MC<=$1%B;!8.7Q-#,5C7R=2*S$?!XZ? ]0LY%*;3NB&DU9E,_FSE\'[VE,J3
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MD_HJ6+3N+JRF*$W*O$^QM]H!PZ=/Q\5UT-K;,QW-4XK5!ANW<+"; FK  2M
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M1;\"%<L=?J9*HRSC[,-FN_FV2)X<T_,+(D8V1CF2-#F.&Q:X;@A4S(]GN/\
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M[(>SKV/NLYGH=K)]ZM7=_9C[SA][R'A\5M]9T:7\Y'=]5^IJWZ;9]%DVO)=
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MRC/^^DMFJQ=FO%$1VJE)7B[]C+8BJ(UJ[[6F\^W_ /1VG_>7(UO']K YX?\
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M?VE6>[QE:N#SEDW(]&C_ !V7'M]3D]FG)\//(ZMAARFT0CT^691<3P_2E+C
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M8#P._B%;L5FJ.38#5G:7^,;N3A\EW4=KIU7AT?!ZFL:BED2*(BZBX1$0!$1
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M2QZ>U5@;>FLM-L(&67%S9B>@!X1S/AYK1T9HBZ-J(B+(D(B( B(@"(B (B(
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M$V4U7A=;T9KV?]HCL36K6[H[L;">Z>T=-AN-V\QS&_38;N10ZSM:WRXL:[[
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M+)[S9<=HUCN**#?AFN['J[R;^'7YK(PNF,GK3(Q9[7,;H*D9XJ6'W]Q@\'2
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M?=8QHW=([P:T>:U'9N9!F>Q.=U'BY<EJ').<W"X:-X:RO&T;E\A=R!V/C_\
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M ^(YD+(IW=3RQ\=*6K<9YM>QWX\P51;?GAE"5^HCE=UF7M%2QG-30;^T8<2
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M&/$.=C'=[[-N1C]&?VA]DJ=C>R1C7QN#F.&X<T[@A<O8V1CF/:'-<-B"-P5
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M]2[@<D_CR.&>("\_VL!&\,GQ+-M_4%6?.5R"XHB*I(1$0!$1 $1$ 1$0!$1
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MXX[)!Y/D(WY=/'_%;'JUX:E>.O6C;%#&T-8Q@V#0/ +U17G4<LMQ+E<(B*A
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M:@LS\33,PGA89!MNS<\E]!:GT9I[5#HGY[$UKLD0V8^1OO-'EN.>WHO2SI'
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MI&31,DB<'1O:'-<.A!Z%6I2C.&*)S?4]EJ;+7P5."MU:>AI_MVT#D<Y/6SN
M@]IMP1=Q8K!P#I(]R0YN_(N!/3?HM-8C2.HLM=]EH8:[WQ.SG3Q&)D?JYSMA
MM\-U]CHDZ-.;Q269?9?K&T[)2=&FU;I6G40.A=.QZ5TK0Q$3^,P,_2/^\\G=
MQ'H22M-0:IDQ/8_J?5$DO^6<[D)H(B.9#@XQL:/1K&DKZ#6O=.=G%6A=LMR
M;9H5LF[)8Q@<1W3GC=P<WH=G;[?%=,))7<CRW=YFG="9NM1T5KW2E>]);K,I
M.NTYI&.C<_=@$C=G 'D[T\U3[-J^_0#-'F20.I]YF7NW/]086O9S^+C^*^L\
M_HW"9[(1W<E4[RRR!]8/:XMWC>"'-.W7J5@/[-],O,Y=0]Z:BW'/=QG<P-
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MPBE.SN@LBC8;LSPM6=MO,&?-Y <S/?>9!OZ-)V_>KM##'!$V."-D<;>0:P
M?)=T5I3E/[F2Y-ZA%%ZBS^-T[CW7,O:97A'3?FYY\F@<R50N^U/VB;BMWF T
MN_\ M3L+-EOIUX1_YYJ84G)8GDN)*C?/<2^JNT*M0MOQ> @.7S(!+HXC^CA
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MQY+L->)B'_);)+F_ .ZA9<@H:P370L^[YU%<%M5<]!INNT[QW,BS]FRY=OH
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M#$WI;L<@L5)JL\9X7L>-P?5KNA"SD6<::B[QR7 JHV>01$6A8(B( B(@"(B
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M2EW38;;_ )*N%\ 3ZX<UKF[. </(C=5347:-I33F4?CLUF(JMUC6O=$Z-[B
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MB (B( B(@"(B (B( N/M?)<KC[7R0'*(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( N'N:QCG/<&M:-R2=@ N52]=VYLG;JZ5QDA98O
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M>L;9@TQJ3(RL<RM=<!!N-@\,807#TW.WR5R?V1Z(??-LX.,.+N(Q":01;_\
M5AW#\MME=Z]>"M797KQ1Q01MX6QL: UH\@%I0H1HMM.]SR?JGUK]=25)0LKW
M>=SYT[,- Y;5NC--27<E0KX2G;-EL4=3^DDM>>1DW\2KQ>K1?_Q$XT=S'P'#
M2DC@&Q/&MJP0Q01B."-D<8Z-8T #Y!<&"$SB<Q1F8#A$G".(#RW78ZS;;Z_$
M\&Q\W,Q.<M#M3GQ>:;0I0VI3/6-82&<<!/)VXX>7+H5SJ' 4SV6:!S;HWNR
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M/M?)<KC[7R0'*(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M7I767? G8?D L:G.G&/;W?EF]+FTYS[._P#"9TU7O5EQF2;_ ,FL-8\_J/\
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M>^[M(L;+1$7,6"(B (B( B(@"(B (B( B(@"X^U\ERN/M?) <HB( B(@"(B
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M:#[!CJ;3W,3CU>22>?3Y@>2VPBT51I6(L$1%F2$1$ 1$0!$1 $1$ 1$0!$1
M$1$ 77^T'P79=?[0?! =D1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 6/D
M;<="A8MSDB*!AD=MY ;K(6/D16=1G;?=&VJYA;(9' -X3R.Y*AZ%HVNKFJL-
M?[0-:U#EL5D,?B,<][A!$Z/B<X ]22#_  ^"FM#:JS7\Z+>E]6Q0?24,??0V
M(!LV5OKX=#Y#Q4)4T7JK3;'2:&ST-O%R.,L56<@MV/D>A^(V4KHW6N2DU/\
M0&L,3%0R[F;Q3Q_5E \/'\CLN:+::Q73\#W:\85(3Y&,912RME*/2][MOU-A
M6K=:HP.M3Q0M/0R/#?WKTAECFC$D+VR,/1S3N"OGFGE\-G]5YG):QKY&\V*8
MP5:T,3Y(HV [<]NA]/7=3?9WDXL7KFW4P$61&GK4#INZM1/:(I6@GEO\-O\
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M*!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MG)RADTU;-WMEIN2L;4:;45&>::=\E:^>N]ROU$GDVW[^N+&/K9">M7= UTG
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M (B( H75V BU%B#4=,^M8CD;/6LQ_6@F;]5X\]O+Q4TBE.P->B+7<;?9G8S
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 <.&[2
M/1> E</)$0'/>N]%QWSO1$0#OG>B=\[T1$ [YWHAE=Z(B =\[T3OG>B(@'?.
M]%U$SM^C?P1$!R)G>B=\[;P1$!U[]WDW\%SW[]O#\$1 #,[;H/P7(F=MX?@B
M(#D3.]$$SO1$0#OG>BZF9V_0?@B(#D3N]%QW[M_#\$1 .^=Y#\%W@D<]Y#MM
M@-T1 CW1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
>!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g762905g02n01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g02n01.jpg
M_]C_X  02D9)1@ ! 0$!@0&!  #_[1_44&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 8'+ @ !  $!@<L"  $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              7A   )A@    8 9P P
M #( ;@ P #$    !                          $             "88
M  7A                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  7A     %)G:'1L;VYG   )A@    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M.8-?LL^6\3/APE]IS)(^RGPG>V/C_55M"HR:[S8*Y(K=L+NQ(YVH_12)V1F
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MF/R7RNDDI^IC\DQ^2^6DD4/U$8\OQ3:2..?.%\O)(_:M/T?_V3A"24T$(0
M    5P    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  (  R #  ,@ Q
M 0 X0DE-!"(      3)-30 J    "  ' 1(  P    $  0   1H !0    $
M  !B 1L !0    $   !J 2@  P    $  @   3$  @   !\   !R 3(  @
M !0   "1AVD !     $   "H    U    8(    !   !@@    %!9&]B92!0
M:&]T;W-H;W @,C(N," H5VEN9&]W<RD ,C R-#HP.#HP,2 P-CHR,3HP-@
M     Z !  ,    !__\  * "  0    !   )AJ #  0    !   %X0
M   & 0,  P    $ !@   1H !0    $   $B 1L !0    $   $J 2@  P
M  $  @   @$ !     $   $R @( !     $              $@    !
M2     $X0DE- _T       @          /_A 3I%>&EF  !-30 J    "  '
M 1(  P    $  0   1H !0    $   !B 1L !0    $   !J 2@  P    $
M @   3$  @   !\   !R 3(  @   !0   "1AVD !     $   "H    U
M 8(    !   !@@    %!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD
M,C R-#HP.#HP,2 P-CHR,3HP-@       Z !  ,    !__\  * "  0    !
M   )AJ #  0    !   %X0         & 0,  P    $ !@   1H !0    $
M  $B 1L !0    $   $J 2@  P    $  @   @$ !     $   $R @( !
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M*"@H*"@H*"C_P  1" 22!V@# 2(  A$! Q$!_\0 '  !  $% 0$
M      4! P0&!P((_\0 8Q   0,# 00$!P@.!P<"!  / 0 " P0%$08'$B$Q
M$T%18105(C)Q@9$(%D)5H;'1TB,S-#4V4G)T=8*2D[*S%U-68G.4P20W0U2B
MX?!CPB4X1)7Q)H,81:/#TT9DM.)VA*3_Q  : 0$  P$! 0
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MDDA>'@'S7MR#\HRN3[/-)'5E)73U%UK8'0S;@#'DYX9SQ6X;''$[.ZP'JFF
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M B(@(B("(B B(@(B("(B B(@(B("A]8N<S2]S<QQ:X0G!!P0IA0VL_P6N?\
M@E6I[4"/V9O<_2%*Y[G.=OOXN.3YQ6=K5SF:4NCF.+7"$X(."M!TGJ"^6^R0
MT]NLCZRF:7%LP8\Y).3R&%DW[4FH*NS5=/66"2GIY&%KY2QXW!V\0NB<4^)O
M\T)S1U(;KL^;2RRR!THD:'[QRT[QP<JSLWNLT;ZNQ7)SO"Z5QW"\Y);UCU<_
M05([,_P0I?RG_P 141M$M\]!7TFHK<T]+ X"8#D0#P)[NHJ.EK6I/F);:'?3
M:;1T%.YPK*L%D>[S:.L_*O5HM<EFT7/%+(\U3H7R2N+R2'$<AZ."UW3,<NKM
M5RWJKC<VDI"UL+#Q&\.('JYGTA;[?/O-7?X+OF5;?8U3XCF.B],>^"VR5,UQ
MJXG,DW,,?D<N]9E^TY<=+TWC2U7:ID;$1OL>>KMQR([EB:%U71V*URT]5%,]
M[Y"\%@&,86;J/5<FHZ$VNRV^I>^=P#W$=6>7=Z2MY\3G_(;+4:GZ/1+;R&CI
MGQ@-9U=(>'LSE:U8-*5>HZ872^7"HQ4>4R-IXXZCV =@"N:UM[K3L]M]$\Y>
MR5N_CEO8<3\JWC38 T_;0.7@T?\ "%CODKNGG(Y[=*.XZ$KZ>KHZR6HMLK]U
M\;S\A'+.,X(6XZTJ!)HJNJ*=[@U\+7-<TX."0L+:HT'2KR>8E81[5CW EVRG
M)Y^",^<*=\W+:>^Q#:7T<V\V.FKY;G61OEWLM:[@,.(_T5N^6VYZ)?!<*"Y3
M5%,Z0,?'(?D(Y8..:O:2UK0VC3]+0U$-0Z6+>R6 8XN)_P!5:U+>JG60I[99
MZ"<1]('OE>.'KZ@!G/-:?;YYYO9'3:*H;54<%0S@V5@>/6,KC-XKJZXW&Y7Z
MDFE;3TM1&UN'$ #DW'LX^E=%U75ML&C7Q,?B7H131GKR1C/^JQ],:>8-"> 5
M#-V2KC<^3(XASO-]@W?8LL<Q2)M^@V:V5;*^WT]7$<LF8'CUK1-J#7RWFQ4[
M9I(V3.<QQ8XCFY@S\JS=EE?(ZW55KJ06S44F #SW23P]1!4?M2F%/>[!.YI<
M(G.>0.9PYAP/8F.O+ET>3+=LZ9NG<O%<'=1)6/I2NN-EU8[3URJG54+FGHGN
M.2#C>!R>." >"R9=I%(QA=XMK.[>P![5BZ4I*^_:L.HZVG--3!IZ$'X7#=&.
MT8).5;[?+/B=AT&IF934TLTIPR-I<X]P7%J:X7*.NAU+*^3H'UA:6[QQCK&.
MS'#U+?-J%R\$L HX\FHK7B-H'/='$_Z#UJY5Z;#= .M0 ,\</29 YR [Q^7(
M5<4Q2NY\_P"!.WBB;>;--3,G?$VH8-V6/F.((*YSJ?1\EDL\U<VZU,QC+1N'
M@#DX[5MFS2Y>'Z9BC>XF:E<87YY]H^0CV*NTS\$*K\IG\044FU+\GYC6;'H=
M]SM%+6F[U49G9O[HXX^59^TF%]NTI;Z>.>4]&\,+]X@NPT\ULNB?P4MG^"%
M;7?O%3?X_P#H5:MYMDB)]3R;C;"3;J4DDDQ-XGT+3=KTLD=DI#'(]A,_P7$?
M!/8L2DU5J6.EB9%IN1S&L :[<DXC'/DH'6]ZN]SML,=UM#Z&-LF\U[FN&\<'
MAQ4X\4Q>)D;QK"USW32D,E+)**NG8V9FXX@O\GB/2LO0M\%[L<<DCLU4.(YL
M\R<<'>M3-O\ O?3?X3?F7-[R9]%:KDKJ6(OH*UKB6YP-[GCU'CZ"52D<\33S
M\A(:^N%1<[O2:<MDKF2/<'3EIQU9 SV 9)]2S=H,(M^B13TSY&MB=&P'?.2
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MP6^F?NMCC..&3@8[>',J5V/\=/U6?Z\_PA8U?IN]V*[U%PTS(V:*9Q<^ XR
M3DMP>8[,<5?<1>WE(LWW2-5I^F-RL%?5%\."Z/F2,\P!S]!6U1W":X:(FK)8
MWP3OI7[P(+2' $$CV94)2:_?32M@U!:YZ)_(R!IQ^R1GV96S76IAK-+UM12R
M-DADI7N:YIX$;I5+\W2+Q^I#1=E-[>VLEM=3*][9ATD.\2<. \H9[QQ]2Z1<
M:N.@H9ZJ<XCA87N]2Y)0T4HT91WJC!\)MM4YYW1Q+,C.>X'Y"5-ZFO7OGCM-
MHMI/^V[LL^[QW #R/HP3Z@K9,<6ON.WF0C]!7*HN6NY*F>1_V:.1^YO' '#
MQW+K"YK8::.CVHSTT#=V**G+&CL 8Q=*6>?4S&O0@1$6*1$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1$.?ZFJKA>]4^
M(:"J=2P1MS(YIP3PR3PX\B!A*O0E53T_36R[57A<8W@'.+0\]F1R65JO3ER-
MZ;>K!(!5  .C) )(X9X\#D<,*Q!KJKH7-AO]HGIWC@96@@'T _Z$KU*VO-*_
M5]=NL=-[>#>F*,E_KD3$S/2>NM>6M=DMH&\U%WM+Q7,>*JG?T;WN9N[_ %@^
MGJ/H6G6>S5.H;O=FFZ5=/T,Q\U[CG+CW\.2Z7:KE272D%303-EB/ XX$'L(Y
M@^E<TT_>*JT7B\&DMDU>9)B'"+/D8<[G@%1AFTSDG'&IZ=/3XK<36D5PUS6Y
MJ]>O7KTZ=DQ_1_4?V@K?:?I4UJ.&2W:$K(65$KY(*4,Z8N(<2,#.>U19UI=0
M"?>O6G'4-_C_ -"F-:.+]&7)[FECG4^2T\VGAP5+3FF](R^L>G]-*5X:N++/
M#Q.^6?7TGU:?IS2D]YM$-<;S6PF0N&X'N.,$CGGN7NZT%XT;T5=2W.:KI2\-
M>R4D^H@D\^T*_I'5MMM-AIZ.JZ;IF%Q.ZS(XN)5G5&H'ZHBBM=DI)I Z0.>]
MS>SEZ!UDGL75O-.68O'V-^<1K3AUPM>'BV.?^S4=IG>_<G[W8GZG\#N%)=*B
MDB= ,,9G!SQSP(X\5IM?8ZJDU-26?QM5/-0 >FWW#=SO=6?[ORKJELI!0VZF
MI6G>$,;8\]N M)O_ /O/L_Y+/F>L.&SVW-(GI$3IU<=PF/EKDM'VK36)ZSY]
MTC8='U%KNL-9)>:FH;'G,3LX=D$<<E0%SH9[SM KZ!M?4TS T.!8]V!AC>&,
M]ZZ:N8UUPFMFT6X5--1R5D@:&]%'G)!8WCP!4<-ER9;VMOKKIV]4\;P^'!CI
M2(U6;1OOZ3^J1]X%1\?UOM/TK9;;;GV?3LM*ZJEJ7L9([I7GRN.3\B@??G=/
M[,5O_7]1;)#525NGG5,],^EDD@<YT+_.9P/ \E3-.>8B,O;?Y?TVX6G"1:9P
M1.]?_;^W.=(Z>J-06^6I==ZR LDZ/=:]QSP!SS[UGW6PW?35*ZXV^\U$S8L&
M1LA)X=N"2"%AZ&U/26.U34]5%,]TDO2 L (Q@#M[EG7[5;K]1NM=GH:B26H\
MEQ(&=W/8/G/ +LOX_C3&OL;\]:T\K#'"?5HMO_LUY3.]^39_&?C/1DU?'F-[
MZ9YX'!:X YQZUJNS:_N94FUULLCQ-Y4#GN+L.QDMR>WGZELL=N=:M#34;W!S
MXZ9^\1VD$E:9061]PT-#746\*ZDFD<W<YO;O<1Z1S'H[UABKCFEZSVF=1/\
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MU2BQOW=.+V4@B(J-!$1 1$0$1$!$1 1$00>N?P/O'YL_YE ;%>.A(<_U\O\
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MQL@;4/WW[[][CW()I$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M3-=13BK,))#&MW=[=:<\"!W87K;O1FVZ/TI1/<"ZG#HB1UEL;0NGUG^[V?\
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MP<<W;S0[5-'UM6*>.[!CW'#72POC83^41@>M;?5UE-1T;ZNJJ(H:5C=]TKW
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MC $KI:5Y_* (^5ORK9%KVM0&4-#48XT]=!)_U@'YT&PHB("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B(,>X53:.DDG?QW1P':>H+0)Y7SS/EE.\]YR2I?4]>*JI$$1!BBYD=;E
M"KHQUU&T"R+:XLN-*X<Q*WYUCK-LL1ENM,!U/#CZN*O/8;ZB(N1(B(@(B("(
MB B(@(B("CM0S&"TSN8<.(#1ZRI%0FKCBVL';(/]5:D;F!IZFK'>7TCA#4DO
MIR< D\6?]E#(NF8B8U*'26N#VAS2"TC((ZPJK4],W3H)!23N^Q./D./P3V>A
M;8N:U>6=)$1%4$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MN\HD9YZ[B)B9V6X6.G+,Q,1K?Y.5Z,T;>+3H/4#;G--476Y4SVMIW2%^YY!
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M;<QKLMXU-1;?2>R<]]MH]]9TYTTOC4#.YT9W?-W_ #N7)3RXL/\ YD7>K_\
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MB1\37.'>0LE 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 4+J&ZBDB,$#LU#QU?
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M0$1$!$1 1$0$1$!$1 1$0$1$!$5N::.%N9' )$;)G2XA( R2 %$U%T<<B!H
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M+1=B6IV7O2L=#,]HK[>!$Y@&-Z/X+L?(>]3FTJZ5MFT3=*^U$MJXF-W'@9+
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MJS\.M=$T]K6-#?GRMA6#9+=':;9!1Q.<\1CRGNYO<>)<>\E9R B(@(B("(B
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MC@.LJ>8-_&X"[(R,!2FN=,VV>)MPG@:]T4C?)/:YP'#UGDI>@HVT4(C;C?\
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MKB\9[MUJWA:GH%@CGU$P<FW)X_Z&K;%R3.Y2(B* 1$0$1$!$1 1$0$1$!$1
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ML<T8?#(R1AY.8<@^M?'4]'-J62@OU^O]4ZW5/"MJ96E[H)0?*8R-N?)P1@X
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M VC_ ,2;^:];2M6V8?@91_XDW\UR#:41$&K:(^[M3_I23^%JVE:MHC[NU/\
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M'K!YA6Z*EBHJ2*FIVEL,30Q@))P!R&2KR("(B B(@(B("(B B(@(B(-6JO\
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MC@ /L?#&>]?7B^%9J>]TFU.W0ZJ?+)>6W&DZ=TKP]Q\MF[DC@?)PONI 1$1
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M-D<T%O C)X9Y<5XVPWFXNUI7T K)VT<<<;&PL<6MPY@)R!SR2K5RVMJ(_/\
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MM<.L*=;M EI&ROLEALMIK)6ECJJEA/2 'GNY.&K2RJ*;8J6G<PSM6)2UGO\
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MB]6^&9W T]>1"_T%LF%ZJ=G6C;KBMI;52032#>;66YW0/](?&1E;/=;3;KO
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MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M-I1$0$1:/M.UPW1OB4^0[PNK:R8.XEL(\]WS(-TJ9XJ6FEJ*A[8X8FE[WN.
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MM.Y8WO;).[3L1$55!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M.P,CC8, #Z>O*S%"1$1 1$0$1$&NZLODUO,-#;1&ZXU +PZ099#&.;W#KXX
M'63W+4XK;55T[G3W>[2SN\HR"K=$&_DM9@ =V%D76ICK]5W*HA)='3L91[V,
M>6TN<\#MP7#CV^A2UJ@Z.+I3YSQ[ M?9KMAUM;7DLT%VK=/U,%/>ZP5=LF.X
MRLEP'PNZA(> +3R!YYYK+FUW;65+FQT]=-1M=NNKHH@Z =ISG):.L@$*EQIQ
M4TSFD D<0",@]RURN:_Q=4MIV!TG0O#& <"=TX&$K$6ZIM::=(=-BD9+&V2)
MP>QPRUS3D$=J]*'T>:<Z7M?@<KI8! UK7N&"<#!SWY!4I-40P &>6.,'EON
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MCL,P\8.1CCP5-1Z3M]_NUDN-<9Q46BH\)I^C?@%^,>4,<0LR6^VZ+44%CDJ
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M*6,[]32 DLE9UEH/FN X\.?)=0BD;+$R2,Y8\!S3V@KF-SF;3VZJE>,M;&>
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MPM=MH;36=%'42P%\CCN AF,XQUEW>K,<M_U3MFTA?9-,7.UV2BAJ8M^LCW9
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M\C*>HAE?$</:QX<6GOQR0TOHB("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("X7MCL!M5^CNU)]CAK79);PW90.)]8&?:N
MZ+6=H]G\=:1KH&-#IXV]-%PXAS>/#TC(]:VP7Y+PZN#S>%EB?*>DN V.AKK]
M<J:U4TDCNF>207'=:.;GD?*OI+3MFI+!:H:"@9NQ1CBX\WNZW'O*TS8SIT6^
MRFZU,>*NM\S>'%D8Y#U\_8NBJ_$Y>:>6.T-N/XCQ+\E>T?R(B+F>>(B("(B
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M<0 >X#DLF&5U+*S?E<^G>=T[YR6.ZN/9U>G"3 DT1% (B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M9J>'>:O/S4BEYK B(LF0B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("$!P((R#P(*(@HQC8V-8QH:QHP !@ =BJB("(B B(@(B
M("(B B(@*F\W>W=X;W9GBJK0^B$M;4R.\MQF?Y?(GRB/4K5KS#?$6N6^>II1
MB$F:/KB>_P#A)^8\%/TT[*B%LD>0#PP1@@]8*B8T+BCJJY8<Z.D:V5[>#G$X
M:T]G>5>N>\Z%D3'%O2OW7$<]W!)^98XIP&@-: T< !U)$#%?55T@P^2.-O\
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M9O%+,VHC;#74SNCGC:<MSC(<WKW3U>OL5K5\X5I??2>Z:1$5&@B(@(B("(B
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M/<D![00<%I[0>I83G/I"6U1<^'X,V,D=SL?.D2,.>!KO.:#CED<EB/B#6X:
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M 1$0$1$!$1$"(B"B(BD4*(50D $GD.*(:3H0"MUKKB[ '<-7#;V$]D$8#O\
MJ>4TKFKVH:VJW@%M*RCH8W=F(S*X#TF1OL5C8873:%-?(29+A7U=6XGKWIG8
M^0!7-D$C:ZVW^[-R?#[U6/:X];&2F-GR,4+-\1$0$1$!$1 1$0$1$!$1 4+J
MVU372VM\"<QM=32">G<\X;O#@0>X@D>M32P+_=([-:*FOF8Z1L+<AC>;W$X
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M"(B B(@(B("(B B(@(B("(B B(@(B("(B BU_:!75-LT3>ZVAE,-5!2O?'(
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M[M2:C\0ST;Q=>D$70 @DN/+CRQWKH&U&ZZ0FLULM6FJ)@KZ([D]3$W#78&"
M?A<>ON7J8J4I,5K#EXB]IKN.R!T]KG4=G>TTMUJ9(V_\&=YEC/ZI*Z9:+G1:
M\C?-2,;;M30,WS"QWD5( XEG6#_YQYKE^F-*5UWHYKB\LH[-3G%173>9'W #
MBX]P"V34]YTY'-99M$TU125-$,R3O&Z9'#&#C)X\_:IRX*9.E8U;U_\ 7GUX
MF^+K:=U]/_$E>+Q6QTTDE;TE1)"]H+9#Q #N(/L6Z0[0;.:0OF,D<[(Q(^$-
MR1D#K]841K"VNONG6ZDMC6GPRG$E1 T<GC@\CMX@\%S:($34S)N)$)$Y/(,Z
M@>\#'KPLN%I6\3%NZ./R7QS%JSTTWFDVF5#)JJH-"R6GDG :S>W71C& 2>_"
MQZS:%='72J?3P0-,#=V.%X)W@#Y1SZ./H6BPMW*)Y;Q-0\0M'9@@Y/R*^2!5
M3NC)DDIXMUI/PB/)+O4"?8NR,=?1YDY;]MM]L^T.H%R,ESI63020[\;XN!8
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MG7S2-HN,GVZ>F8Z4?BR8P\'O#@0IM 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MF]5=S>XLDEHHHW;ACC< \N',EW9V8ZEK=R9'IO:-=::=[8J&]1"XTY)PUDC
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M:.)(X\201GN5IK*0VV;HY7-C?-C)&=PG@,]V./H5]YBCK:AL#'"I,&&N')Q
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MY;<]9>U]'\=7!2<=X^#UCI+AEO$1LW7'O)Y?^=JW/1$99:ISQW75+RP9X
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M9A82YIQO 'J/ H-J1$1 B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M4%8=!OKFTC90)Q33MC&_CAD$\\87T[M^I9ZS91?(:2&2>9S8R(XVESCB1I.
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MQJQF6]:O3 K[ O#&J^QJSF6U:O3&JZP*C&JZT+.9:Q55H5UH5&A76MPJ[:1
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MK/MD,@+)8SV.8>(6>JS$QTE28F)U(B(H0(B("(B B(@(B("(B B(@(B("(B
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M]C>!/7V+W.UVH;U)3.P;/0/ F']?...Z>UK>&>T^A;*!@8')7]GWM?NX_/\
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MP!.:?4<793Z#J) */2FJ;[,T>=+35;V./:3,0T>Q;#;O?;$QL&F-&V;3U+@
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M./*6MENI+93]!0PMBCSD\22X]I)XD^E7J2GBI*:*GIV".&)H8QHY !74!$1
M1$0$1$!$1 1$0$1$0(B(*(B*10HA1$"H554*0*(B*01$1 B(@*BJJ(*%$*)
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M$\46>6^X!$1.UY%2-[9&AT;@YIY$'(542(B("(B B(@(B("(B B(@(B("(B
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MU'6ZEL<U5<FPB9DI8.B:6@C /(D]JP=9ZNN-FU?:;92,IS35)9TAD:2[B['
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M/S2>Y6Y>FUN3[/-M(HK$=9322F..HA=(.;0\$J^JJ:T(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#7:I@M>K*:JC!$-T'@\_8
M)& ECO21EOL6Q*$UE"Z33U3+&<24I;5,/?&X/^9I'K4Q!*V:".5GFO:'#T$*
MT]8B6ENM8G]'M$159B(B B(@(B("(B B(@(B("(B"S6U,='235,Q#8HF%[B>
MP#*C=+4[VV\UM0#X57.\)DR.+0[S6?JMP/4K>K?LM'2T)Y5M5' [\C.\[Y&E
M3@  P. 0$1$!$1 11FIZ^6V:=N5=3AAFIX'R,#QD9 )&5J6R_7;]3BHI+FV&
M.XQ>6SHQALC.X$GB.OTA3KIM&XWIT!%H%SU?<:;:;26"-E.:&4-WB6G?X@GG
MGN[%ODLL<+"^5[6,',N. FB)V]HK5/4P5+=ZGFCE':QP*]NEC:\,<]H>>32>
M)4)>D5L3Q'>Q+&=WSO*'#TKQ+64T36.DJ(6-?P:7/ SZ$%]%9GJ8(&!\\T<;
M#R<YP *N,<U[0YC@YIX@@Y!1#TBL5%734Q J)XHB>0>\#*O,<U[0YC@YIY$'
M(0$5FHJJ>F \(GBBSRWW 95QCVR-#F.#FGD0<A2*E%9J:JGIL>$3Q19Y;[P/
MG7L2-?$7QN:YN,@@Y!1#VJ%<_P!EFJ[GJ2HO#+H8"VF<SH^CCW< EW/CQY!;
MS45=-3N#9ZB*-QY![P"5.M(B=]5Y$:0X M((/(A69ZJGIRT3SQ1EW(/>!E$K
MR*C2'-!:00>((/ JT^JIXXC))/$V,'!<7C /I07D5OIX>AZ;I8^BQG?WAN^U
M5@FBGC#X9&2,/PF'(1#VJ+5--G4QU'<A>IZ22V .Z!L6-X'>\G../FYYK9:B
MJ@IP/")XHL\M]P&?:@NHJ,>U[ YC@YIY$'(54@4*HJE40$1%,(41$1"B!$"
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M(B B(@(B("(B B(@A=/>16WN,>:*PN'ZS&DJ:4+8?OE?/SH?RVJ:0$1$!$1
M1$0$1$!$1 1$0$1$!:^QF_KR5Q_X=N9CUR.S\RV!04/X<57Z/C_F/5J^;3'Y
M^Y.HB*K,1$0%$:Q_!2[_ )K)_"5+J.U)32UFG[C34[=Z::G>Q@SC)(("M7O"
M^.=6AQ79Y4:OBLT@TS!!)2&3RR]K2=[ [3V87B]RWZ76UD=J>**.JZ6,,$8
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MX67-LGI'V&G?;:F2*[AC']*]YW"[''@/-[B%,:IT&:_1-NL]#,SPFW@&)\G
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M19_ ]3:A-3?;K)^D6?P/4V@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M$I/F\0> /K7/]N.T%\&U?2D=)3WN"&TU;VU#&1.:*P9;]J&?L@^E!]-R2QQ
M&1[6 G WCC*]+@6UO4VEM2Z3TM==11:HM<$MQ?%3PPQB&7?' [[7'S>'!;QK
M7:]I[2&J6V"ZPW!]:^$2L-/!T@>3G=8 #DN.,<NM!T5%S70&V"S:NU%-8'T-
MQM%Y8TO92U\6XZ1HXG'?CCCL&5YU7M@M-GU%46*U6NZW^ZT@WJJ&VP]((!_>
M/;RX=Z#IB+6-G^N+-KJTR5UCED^Q/,4\$S-R6%X^"YJV= 1$0$1$$+8/OE??
MSH?RVJ:4+8?OE?/SH?RVJ:0$1$!$1 1$0$1$!$1 1$0$1$!04/X<57Z/B_F/
M4ZH*'\.*K]'Q_P QZM7S:4[3[DZB(JLQ$1 1$0$1$!%S/W1MUK[-LENU;::N
M:CJV/A#9H7;KAF1H.#Z%REEJN3=ES=4MVJW2GN;:'PL4TM6PMWP,AF.?$\!Z
M4'U$BY)LEVC23;&(M4ZZJ1 *=TD;ZI[=TSM:<-< .9/+AS(2W[?=(U-91Q5<
M%XMU-6N#::LK:,QP2=^]GEWH.MHM&UUM2TWHB\T%MU!+4Q2UD1FCDCBWV!H)
M'$@YYCJ!49H_;5I?4^I66&%ERH+C*,PQU]/T/2\,\./,]0/-!TQ%H>LMJ5BT
MQ>H[,Z*X72\/89#16V SR,;VN /!2.S_ %_8M=TM5+8II1+2/Z.HIJB/HYH7
M<>#FGT'V(-K1$0$1$!$1 1$0$1$!$6E;::^JMFRS4M9;JB2FJX:4NCFB.',.
M1Q!0;JB^3K/M3U-?= Z6T;I"IGK=85T<GAU>]Q<^F9TCB/*ZCNXR3R&.LKH&
MTBS6O2^@M.T6KM3ZEDE%<S-;2OWI)IB#P=GDSL'H0=Q1:'M VH:=T Z@I+L^
MKJ*ZJ8#!2TL722O;R#B,CF1CTKDG](K-6>Z&T>;#6W""W.IW155%.'1%D@Z0
MD/9VXW3[$'TNBY5<MNVDJ&Z72V&.[3W&WS&!]/!2%[I' D$LP>(&.)..86Q[
M.=H^G]H%'536*:5LE*0)Z>H9T<D><X)&>7 \1V(-R1<FKMO6DZ>>L-/3WFNH
M*)_1U%PI*,R4\9_+RM@NNU+35MCTY/+//)17YP91UD4>8<D@8>[/D\_G0;RB
MU;7NNK/HBFH);R:A[ZZH%-3PTT?222//8W(X<O:.U;0QV\QKL%N1G!YA!5$1
M 1$0$1$!$1 1<&VOZAN]NV\[/;;07*JIZ"K+.GIXY"&2YE(.\.OAP6XZFVS:
M5TYJ*ML=Q=7FY4K6GHH:<O,I=R:S!XE!TA%S?2&V33.J*>ZNHA7PU=MB,\]'
M/!NS%@YEK<^5Z.\+CNA=L=+1[6=7W&Y/OU19ZW<%'2MIW/="<CSH\^1UH/JI
M%I&N-IMBTC=*:U53*ZON]0W?CH;? 9I=WM('(*YH;:5I[6,%P=;IYJ:>W9\+
MIJV/H98 .9<T]0[4&YHN22;?=)M,T[*:]RVF&4P/ND="74P=G'GYY<NKK6E>
MZ?VCP^]FCMNG*RX15<SHJQE93M+89(G-)&) >?+@@^D$7#K_ *_TUJ_9%=Y:
MZHU';:*WBE955,5/T4Y<YPQN9/E D<>XJ>&TK2NA=):3CN%7<I*.OIVBFJ9H
MMYY8 /*EX\.?'F@ZFBY78MNNDKOJ2ELV[<Z*>K<&TTM92F*.8DX&"3GB>7!3
M^N]I=BT;7T=NKA65EUJP70T-!#TTSAVEH/ 'CCT'L0;JBT[0.T6QZVDK:>V&
MJIZ^C(%115L713,SU[IZEN* B(@(B(,6Z_>NL_P7_P )6!HS\%+3^;,^99]U
M^]=9_@O_ (2L#1GX*6G\V9\RO_@TC[N?>F41%1F(B("(B B(@(B("(B B(@(
MB((6[??^R_E2_P *FE"W?[_V7\J7^%32 B(@(B("(B B(@(OES;!T5Q]T136
MB[W^LL]FDH(G22Q570AAP_CD\.) 4?42>\S:?I:FV<ZPK]1^&R[E72/J14MW
M,C.=W@!C)[1C*#ZS1<WU_M:MNEM0Q:?HK9<+Y?WM$AHJ%F7,;C.7'T<<8Y*_
ML^VIVK6$ERH_!*RUWFWL,E1;ZQN[*&]H[>KVA!T%%PZE]T1;[A:YJJSZ6OMP
MD@>X5$<$>\V%@^$YXR!GCP[EO6D]ING=1Z'JM4T]0ZGM]&'>%MF&'P.:,EI'
M7S&,<\HANZ+BS-OM V"*YU>E[]3::FEZ-EV?#]CQG <1U#UKLE)415=+#44T
MC98)6"2-[3D.:1D$(+B(BD4*(41 J%55"@HB(I!$1$"(OE*W;5:C1VM=I!JZ
MBIN-:^J$%JH7N<\&3>/(=31D9QSY(F(?5IX D\EXCD9(W>C>U[>UIR%QW9GI
M6^06"]:HVAW.X272Y4LKGTC)"&TL+FY(:SD'X'JX#M7G8[J32&F]D5=>K?6W
M7Q'3U4CI'W+==,9,-\EH;SSPP.W*@T[,J+YDVL[:*/4NS2XP6VAOEHGJ',=1
M5,\1C94!KQO!KQPSCJ717[4++H;26B8]2&L<^YT$;A,QF^&[K&Y+SG/PNK*1
M)IU4JBY78]M]AN&IJ>RW"W7>S2U9Q1RW&#HFSY/#T9X84UKS:9:=)76FM'@E
M?=;W4,Z2.@M\722;O:[LY*=HTWI%S>S;8+%=+)>ZQE'<X:ZS1])6VR6$-J6
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MI+3=K5=[!55OW&ZY0=&R?N!ZCQ'M61JS:K:['J"2Q4%LNM]N\+.DGI[=#O\
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M;]G]1-9*JXU-!65TD\;ZV 0DG=:TEH'-N6\^W/8NNKS'&R*-K(FM8QHP&M&
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MW/8>:S;!8;7IZA%'9*"GHJ8'/1PL#03VGM022(B B(@(B("(B B(@+0=O?\
MN>U7^9G^(+?EBW2WTEUM\]#<:>.IHYV[DL4@RUX["@^,] 0WW9?I[3FTBSQ/
MK[)<XG176GW?M0$KFCCU XR#U'@>:Z9[I&_6_4NSO2%VLU0RHHJF[0N8]IY<
M\@]A!X$+O%#8K70V-MFI*"GBM36.C%*&?8]UQ)(QWDGVJ(CV>Z3CMC+>RP4(
MHF3BI;#N>2)0,;V.W"#BFKJZAT][JBSW+4\D4%LEMC13U%1]KC.XYN<G@/*S
M^TL2[7VQW_W5VEZC3E3354,4'133TY!8^0-D/G#@X@$#/JZE]"ZGTK8]44L=
M/?[935T49RP2MR6'N/4L6VZ%TQ;*JAJ:"QT-/44+2RFD9'AT8.2<'UGVH.+[
M 8HW[<]J+WL:Y[)R&DC) ,KLX]@47I.EG=MDVP4%I;T<LUOE;%'%Y/V0M\G'
M?D_*OHJTZ;L]HN5=<+9;J>FK:YV]4S1MPZ4YSDGTDJM#IRST%YK+M16ZGAN5
M8,3U#&X?)Z2@^3=E=74,V5U=._:!9K%0POECJK;5T39)?*//BX%V>KAW=2WB
MDV>T]X]S--;;3<I;J:>22XV^I%.Z%SG,R=UK22>/E#([5V&Z;-='76Z.N-PT
M[;YJQSMYTCH^+CVGM4IJ@7"CTE<&:8IHW7%E,YE'""&-#\8;W #@?4@^<-D=
MPKMKVTNP76[1RFATI;8@XNXM?5Y\X][B,_J+ZI7.-@>AY]#:$92W(#QM63.J
MZPY!P]V!NYZ\ ?*5T= 1$0$1$!$1 1$0?.6V_P#^8W9GZ8_YQ61IRGAF]UQJ
M!TT3)#'0!S"YN=T[K1D=Z[=<M-6:YWBBNM?;:>HN-'CP>H>W+XL'(P?2O4.G
M;1!?IKW%;Z=EVE9T<E4&^6YO83ZD'!Y6,A]V7$V%K8VR6_+PT8#OL)Y^P>Q8
M^C;[9]*>Z,VBNU/6TULBJ&L,+JH[C7\6D8)[CE=_=INS.U$V_.MU.;P&=&*O
M=^R!N,8SZ%C:BT9IS4=1'/?;-15T\8W6R31@N [,H/G"\-N=#[I2^/;J*CTY
M+6TV_25U=$)(Y(SNX:TN( S@\<]1"F]G5NM$VT/6-VK]8T]^D=:IH;F**@,4
M>YAH<X/#BTG#3RYKNVI=(6#4]/#!?K52UL</"/I69+/0>85_3NF[/INA=1V.
MW4U%3..7,B9C>/+)[4'RS%4'0NBJ^Z[/=?V>ZZ;;*7^)+E"TR$EP!;NDY)Y'
MD,\UL6WJYS:I]SE8+VVVBC,TD,DD,;<-B'E-X=C2<8](7:)]EVBI[FZX3:;M
MSJISM]SNBX%V<YQR6TU5OHZNWOH:JFAEHWLZ-T#V L+>S'8@X/MFU-8=1>YY
MO#;!<Z2M?3140J&P/!,9,C,;PZCP/L*TG:#&R:V;$(Y6-?&\P-<UPR"-YG K
MZ.IMGNDZ6VUUOI[!01T5:6&IA;'Y,I8<MSZ"2LRJT?I^J9;&5%HI)&VS!HPY
MGVC&,;O9R"#BONMX(H8-$3PQ,CF9<MUKVM <!Y)P#V96OZV;<K?[I220W^EL
M$E90,\$KZV$21[N,;@R0!Q!XY7TE?].VC4#:9M[M]/6MII.EA$S<[CNT*UJ;
M2UDU12QT]_ME-711Y+!,S)9GG@]2#B.S"UP5>V^KNWOXI;[=HJ,QU;**A,<3
MV\ ,O#BW(_T7T0HC36F;-IBD=36"VTU#"X[SA"S&\>\\RI= 1$0$1$&+=?O7
M6?X+_P"$K T9^"EI_-F?,L^Z_>NL_P %_P#"5@:,_!2T_FS/F5_\&D?=S[TR
MB(J,Q$1 1$0$1$!$1 1$0$1$!$1!"W?[_P!E_*E_A4TH6[_?^R_E2_PJ:0$1
M$!$1 1$0$1$'RKM==IUONFJ/WY>#^)?%T73"HSN<GXSCO4+K";2/]).D3L7X
M7CP@"846\8BS/6#W9SU8YKZPN6G;-<ZGPBXVJBJI]T-Z2:%KW8'(9([U[MEC
MM5J<YULMM'2.=P+H86L)]8"#Y]BN]%H7W4VHJ_5DS:2ANM"UM)63#$8.[$<;
MQ_(<WTJQHZJBU;[HW5.H]/$U-DIK>Z*2K8#T;G&(-&#UY(..X97T5>;+;+U
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MCD0HM72U+<T!5%4JBJL%>5Z*\I"! B!2(C3?W+6?GL_\PJ545IO[EK/SV?\
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M1$])8VF:]8=HMM=!<J*.JI'[\3QP/6.X]ZR5RW9M=S270T$KST%3Y@ZA)_W
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M\Z'\MJFD!$1 1$0$1$!$1 1$0$1$!$1 4%#^'%5^CXOYCU.J"A_#BJ_1\?\
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M5&8B(@(B("(B B(@(B("(B B(@A;O]_[+^5+_"II0MW^_P#9?RI?X5-("(B
MB(@(B(,)]SHFU4E*ZIB\(C;ONCSQ 417WFGB:XL+07><1S*U;7]!/;KX+E3D
MB.H^$.IP&"#Z1A:I4UE3,<])A;TQQ,;<]L\UW$P[K YCH6.B(,9:"TCK"]KG
M&SB^]%.^W5L[R)2.@+W9 /XH[,_Z+HZRM7EG36EXO&Q$157$1$0(B(*(B*10
MHA1$"H554*0*(B*01$1 B*/NETAH&[OGS$9#!\Y4Q&T3T2"HM#N%_K22[IRP
M=C. 5;#JB87"&GK).D@E<& NYM<>1SV*WASK:GB1O3>BBJ5K&O:N2GM#8X7N
M8Z5W$M.#@?\ @5:QN=+3.HVD]1U[K=:)ZB/'28W69[2H79_<ZZY4U9X=(9FQ
MO :\\^(XA04D]2[1-&VJE=(9)G%A<<G=' <?6KVD[OXKLO1QT_2222.>23ZA
M\RTY?LRRY]VB?)L6J*AP=%3 D,+=]W?Q("U]_FE4N%ZDJJR!M;"V$O&['@'C
M[5Z(X$*8C4(F=RC!=:NU3]+22$#/%AXM=Z0M[TY?*>]T9DB\B9G"2(GBT]O>
M.]<YO#, E8>G[D^TW:"I83N!V[(/QF'G]*M-.:%*WFLZ\G9T5&/:]C7,.6N
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ME5J:V:IMUU$$UQEN%)6TM(^:&=DH!#=YO)P((P<+7M6U^M-562UWZ[T%1;[
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M?)59K3*G^F+:13.IHW.T1IJ8R=/\"X56. ;U%K?_ #F%UW5-\I=-Z=N-XKW
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MJ  05(E;^+4#)]3A_KE9RW#26EX+A0/JKBU^[(<0ACL<!S*VF8CJPK$VZ0T
MUE0QV'V^8N[6/:X>W(5'">N:(Y8#3T^07[[@7/P<X '(9YE=&KM".Z;-!5CH
M3\&8>4WUCG\BRH-"4;0WIZRHD/7N -!^=5YX6\.R,V;Q2.NE5,T$0MAW7'J)
M)&!\BZ$L>@HX*"D93TK R)G(=O>>TK(6<SN=M:QRQI0JBJ510D*\KT5Y2$"!
M$"D1&F_N6L_/9_YA4JHK3?W+6?GL_P#,*E4KV+=V10_='J*)0_='ZI197[M\
M7LI!$14:(34WVZR?I%G\#U-J$U-]NLGZ19_ ]3: B(@(B("(B B(@(B("(B
MB(@T'5=O-)>J,4+-UM:[<#>H/_T'6L^6@JJ":GBWQ*V4AH>.&'=BV6XT,5?
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MJ+C=JJ*DHJ=A?)+(<!H'SGN'$K-) !). .M<+BA=MLUI/)4ND&@;#4=''".
MN52#Y1)'-C>'M[R@]PW+6FUV:3Q/)4:5T5O%@K"S%76CM8#YK>_OYGJW'2&S
M+1&DJN."AMU-+=)(S)TU6[IIY " Y_E=Y&2!UK?6-CIX U@;'%&W  & T!?(
M^O=>:XNNU*>\:,MUV;;::%UOI9X;<Z;>B<X%\C01@DEH([@$'UWP [ O,C&2
MQN9(UKV.&"UPR"%QBQ;*_?+;H+I>];:PJI*B,.<QSQ1ECNL%F[D8[%F2;(;I
M:]^;26OM1453CR6UDC*F,^D%J"7U?L<TEJ*4U<5$ZTW8'>CKK<XPR,=VX' ^
MQ:Q3ZLU7LON,5!M!)NVE'O$5/?XV?9(?Q1.UOLSCUE7Z3:-J;1%TI[9M7M\/
M@,SA%#J"@8?!W./+I1\ ^KU8XKK%;26^_6>2GJHX:VW5D7%IPYDC",@@]8Z\
MH,JEJ(:JGCGI9HYH)&AS)(W!S7 \B".!"N+B6C9ZG91KNGT3<)Y9]*W8N?9*
MF9V332<2Z!SN&<GEU\1VKMJ B(@(B("(B B(@(B("(B#2-I.FKO<A1WG2E>^
MEU#:]YU/&]_V"I:[&]%(WE@@<#S!ZU#V?:_:ZQUCH*R(T.H*VN%!56V?+9*:
M3=))(/-IX8/(Y72ZF-\M/(R*5T,CFD-D: 2P]H!!'M"^>M?; [G67SWSVW6$
MD]WA<R<S75K6@='@CRF-   '8@^B5I.K-IFBK!TE)>KY1.E<TM?2Q9G>0>!!
M:P''H*T"&\ZHVQ5,E)8*F6P:/IST55<8A]FKGXPYL).1N YX^CT+H6C]F&D=
M)Q-%JL\#JC'EU-1]EED/62YW6<=6 @X)L?O&@=!ZHU'>WRW-L-3.Z*W$V^8M
MAICAW/=YD\/0WO7T/I77^EM5#%BOE%52]<._N2C]1V'?(MB?30/BZ-\,3H^6
MZ6 CV+0M8[(-)ZE<:GP$VRZ@[T=?;W=#+&[MX<#ZP@G]?:MHM&6)ETN) @=4
MPT_$X\]X:3ZAD^@%:/=KK<=IUZELFF*B2ETA3/W+C=X3AU4X<X8'=;>&'/'J
M/;R?:?:=95]VT]H+7M]I8[-)4OEI+Z^(XJ7;I#(Y,8 >,D#MSS/-=ZV7Z!ET
M':X[?'J&X7&B8W#*:=D8CC.<DMPW>'$GK0;K30LIZ>*&+/1QM#&Y))P!@<3S
M5Q$0$1$!$1 1$00MA^^5\_.A_+:II0MA^^5\_.A_+:II 1$0$1$!$1 1$0$1
M$!$1 1$0%!0_AQ5?H^/^8]3J@H?PXJOT?'_,>K5\VE.T^Y.HB*K,1"0 23@!
M17ODLGQO;_\ ,,^E!*HHKWR63XXM_P#F&?2GODLGQQ;_ /,,^E!GUE+3UM,^
MGK((JBG?P?'*P.:[CGB#P*N1L9'&UD;6M8T;K6M& !V *,]\ED^.+?\ YAGT
MI[Y+)\<6_P#S#/I09<-NHH*-])#1T\=(_>WH6Q@,=GGEN,<5BVC3UGLSY'VF
MUT=&^0Y<Z"%K"?6 J>^2R?'%O_S#/I3WR63XXM_^89]*#.BHZ:*JFJ8J>%E3
M, ))6L >\#ED\SA1]3IFQU-R%PJ+102UPXB=\#2_/;G"]>^2R?'%O_S#/I3W
MR63XXM_^89]*#,N-!27*D?2W"FAJ:=_G1RL#FGU%8]#8K301T[**V4<#:<ET
M(CA:.C)YEO#@2K?ODLGQQ;_\PSZ4]\ED^.+?_F&?2@I=M-V6\3QSW6TT-7,S
MS7S0M<X>LA2/@\'@W@W0Q^#[FYT6Z-S=QC&.6,=2C_?)9/CBW_YAGTI[Y+)\
M<6__ ##/I05M.G;/:)I9K5:Z*CED\]\$+6$^L!2BBO?)9/CBW_YAGTI[Y+)\
M<6__ ##/I02J**]\ED^.+?\ YAGTI[Y+)\<6_P#S#/I02J**]\ED^.+?_F&?
M2GODLGQQ;_\ ,,^E!*HHKWR63XXM_P#F&?2GODLGQQ;_ /,,^E!*J/HK+;J&
MZ5UQI*.**NK=WPB9H\J7=\W/HRK7ODLGQQ;_ /,,^E/?)9/CBW_YAGTH+E78
M[967>CNE310R7&C#FP5!;Y<8=S /8HB_[/\ 2NH+CX?>;%15=9@ RO9Y1 Y9
MQS]:D_?)9/CBW_YAGTI[Y+)\<6__ ##/I07ZBT6ZIM+K7/14[[<YG1FF,8Z/
M=[-WDH;3N@=+:<K3662QT='5$;O2L9EP'8">7J4E[Y+)\<6__,,^E/?)9/CB
MW_YAGTH,'4VA]-:GJ(ZB_P!FI*Z>-NZV21OE =F1U*1CL5KBL1LT5!3QVHQ&
M$TS&886$8(P.U>/?)9/CBW_YAGTI[Y+)\<6__,,^E!?=;XJ>QOM]OA9%"RG,
M,,;>#6C=P!Z.2YGL[V36@:&LM+K;3]#47BD;(USGX>0#(YP&\#QX%=%]\=D^
M-[?_ )AGTI[Y+)\<6_\ S#/I02$5-!#2MIHH8V4[6[@B#0&AO+&.Q:_0Z#TO
M04UQIZ*QT4$%Q9T=6R-F!,WCP/=Q*D/?)9/CBW_YAGTI[Y+)\<6__,,^E!ZK
M]/VFOLC;/6V^GGMC8VQ-II&98UK1AH'9@+#TQHS3NEG2NT_:*2A?*,/?$SRG
M#LR>.%E>^2R?'%O_ ,PSZ4]\ED^.+?\ YAGTH+UOLUNMU=75E#1Q055<\25,
MK!@RN P"4I;/;Z2ZUESIJ2*.OK QM1.T>5(&C#0?0K/ODLGQQ;_\PSZ4]\ED
M^.+?_F&?2@E445[Y+)\<6_\ S#/I3WR63XXM_P#F&?2@E445[Y+)\<6__,,^
ME/?)9/CBW_YAGTH)50^FM-VS3<=8RT0&(5E0ZJG+GN>7R.QDDDGL7OWR63XX
MM_\ F&?2GODLGQQ;_P#,,^E!YO\ IRV7^2VR72GZ62W53:RF>'%ICD;R.1U=
MW(K6KULETA>*ZKKJRWRBMJI3-)/%4R1OWB,'!#N X<N2V?WR63XXM_\ F&?2
MGODLGQQ;_P#,,^E!AZ:T98=.6*:SVJW11T$Y<9HWDR&4G@=XNR3ZUKD&QG1<
M,D6+=4/IHG])'2OK)70-=G/F%V/4MO\ ?)9/CBW_ .89]*>^2R?'%O\ \PSZ
M4$?K'0]@U>*4WRB,LM*28)HI'121Y['-(..Y5T=HBPZ0%4;'1F*:J.]/-)(Z
M623TN<2<=RS_ 'R63XXM_P#F&?2GODLGQQ;_ /,,^E!YTQIRV:9I*FFLT!@A
MJ*A]5("\NS(\Y<>)[N2Y-IW9?37W5FM9]66JIBBDN72T-2V5T3G,+>.ZYA!+
M>XKK?ODLGQQ;_P#,,^E/?)9/CBW_ .89]*"SI#2MGTC:S;[!1MIJ9SB]_E%S
MGN/6YQR2?2HNU[-],6O4\E_M]O=3W*0O+G,F>&$O!#CN9W>()ZE->^2R?'%O
M_P PSZ4]\ED^.+?_ )AGTH,.W:,L5OTY56&"@:ZU5+GNE@D<7AQ?YW$G*@K+
MLBT?9[G25]-;II)J-P?3">JDE9"1R+6N<0%M/ODLGQQ;_P#,,^E/?)9/CBW_
M .89]*#Q-IJUS:H@U#)3DW:"G-,R;?=@1DY(W<XY]:7#3=LN&HK9?*JG+[E;
M6R,II=]P# \8=P!P>':O?ODLGQQ;_P#,,^E/?)9/CBW_ .89]*"5117ODLGQ
MQ;_\PSZ4]\ED^.+?_F&?2@E47F*1DT3)(GM?&\!S7-.01V@KT@Q;K]ZZS_!?
M_"5@:,_!2T_FS/F6?=?O76?X+_X2L#1GX*6G\V9\RO\ X-(^[GWIE$149B(B
M B(@(B("(B B(@(B("(B"%N_W_LOY4O\*FE"W?[_ -E_*E_A4T@(B("(B B(
M@+1ZO:EI6W:HJM/WNX-M5RA< !6 QQR-/)S7^;@]Y"WA<>VM;(6Z]UI07,2B
MD93T$C3-@/WIPYIA#F$'>;Q?D=G!!UBWU]'<J9M3;JNGJZ=W 2P2"1I]8)"R
M5QRDVIT6C+!-:=2VGP+4M YM/%:[?"=VO)R&24XZV.(/>.OJS:I-.;1-H$8J
M]5WM^E;/.,QVJV "H#>KI)' D'N!]003&V62A@H]--IWTT<AU#2R2!CF@DX?
MEQ^DKI%&*4->ZB$&Z]Q<XQ8P7'F3CK7,*;8!H1K3X;27"X2DY,M57REV>WR2
M!\BQY=B%-:B:C0^IK[8:QO%C?">GA)[VO!./6@Z^M)U?M2T?I*62&]WJ&*J9
MSIV-=))^RT?.M-I-I5^T'<H[3M<IX13R-/@M^H8R8)B!G=>/@O.#U#T8XJ+O
M^B+CMGMU9>[Q!XJHN@<+%2.:&3//P9YW8)PX< SD <XRB'8-%Z@9JG3U/>(*
M2>EI:K+H&SX#WQYX/(ZL\P.S"G%A6.A9;++04$;0UE+3QP- .<!K0/\ 19J"
MB(BD4*(41 J%55"@HB(I!$1$"(HW4=YH]/6*NNURD$=)1Q.FD/7@#D.\\AZ4
M$3M!UO:M$6;PVZ2&2>4]'2T<0WIJF0\FL:.)]/(+G=%HW56TT"OVCU4]HL;W
M!\&GZ-^X7,YCIGCCG!P1S]"R-ENG*C6-X&TC6,+C5S_>:B>?(HZ?.6NQ^.>)
MR>W/HZG?[K!9+-67*K$CHJ:,R%D32Y[R!P:T#FXG@ H3V1>DM.:9TYT]#IJW
MT-+)3%HF$309&EPR-YQX\1QYK872-:?*>!Z2OCW3%VVF7+5-TJ*FFU/:K5>*
MD35L]#;-^2, %K0W>&0T X..SK7:8MAMCJ(FR7#4.JJV=PSTLEP+#[ T82#3
MJ]1%'40NBGC9+$\8<Q[0YI'H*YGJ38S8*RL\:::?/IJ^L)?'66]Q:TGL<SS2
M.T<%A2[+-0V)KI="Z\N]/*""*>Z%M3"X#J/DY"OZ4VF5])J"/3&TJVQV6]2D
MMI:N,_['6XX>0XG@X]A]' \$/<L:6U]>M/WZ#2^U*&&EJILMH;S'PIZSCP#C
MR8\X/ XZN''CUH<1P/!06M]*6O66GZBSWN$R4\GE->W@^)XY/:>HA:1LCU%<
M:"\7#9_JJ4RW>T,#J.K=_P#6TGP'=[F@@'_L5,=$=W5$1%*JB(JA!1$1 5%5
M4*E"BHJJBE A1"D#0]H%!J"BKX-4:5GGJJBCB$=39W.^Q5<())W1U2#)P1SP
M O5CVFV&]W*Q4-!.#57-LQ=!(=V2F=&,ECVGB'9X8[EN-PAGJ**:*DJWT<[V
MX9.QC7F,]H#@0?6OGR\;';_I[6T>N:'45+<'TE0*RK\. IWR,;Y_E ;@RW//
M 43N%HU/=]%K1M<ZST-36^KM.I[Y;NCJHW12TS7]*\@C!RUF2#Z5IL%?J;;#
M+(ZSU53IO0K'&)U0UH;5W#MW"<[K!V\.9Y\AO&EMF6D-,L;XKLE,9AYT]1F:
M1Y[2YV?DPF]]C41W<1V Z@T%H.*[ON%\/C"KG,;)Y*24-%.PG<X[O#>YGU+Z
M*L.HK-J" 36.ZT5>S&3X/,UY;Z0#D>M9$]IMTT1CFM]&^,C!:Z!I'S+G^H-C
ME@J*@7'2[I]-7MF7,J[>\M:X]0>P^21GLPD1,(F8EMNJM44&FIK.VYR,ABN-
M7X()7O#6QDL<X$D]66X]:TUMSNFT>_\ 062>>@T50R@RW&$EDEQE8?M<9YB,
M'FX<\+DVM+3J[:#K*SZ(UO76VU5E#$^2*IW7;ERR0-^, 8+L#S>'7PZE] [/
M=,5FD['!;*F]SW2""-L<39((XQ$!U-+1DCTY2)VG45AM'(81$5V:A5%4JB(%
MY7HKRD($"(%(B--_<M9^>S_S"I516F_N6L_/9_YA4JE>Q;NR*'[H]11*'[H_
M5*+*_=OB]E((B*C1":F^W63](L_@>IM0FIOMUD_2+/X'J;0$1$!$1 1$0%XG
ME9!#)+*X,C8TN<X\@!S*U6YZ_LE+JBATY25#:^\U,NX^FIG!QIV#SGR8\T =
M1XJ-V\W)]NV1ZFFIY-V9]-T+7#JWW!G^J#4=E]$=I.KZO:)?(R^W4\CZ6PTD
MG%D;&DM=-@\"XGK]/8,=M6O:+ME/IG0UJH8@&T]%1L!(&,X;DGYRM"TW>MH6
MM; =3V*MLMMM]09'4-NJ*-\SY(VN+1OR!XP7;O4.M!UY%I%+M!I:325HNFJ:
M2JM-QK@(Q;70N=.Z4><UD>-YW+/+DO-?KBDNFC[A<].7:@H7TDHBJ9KG&YO@
M9SY6_&2#OXY-.,DA!N5?14UPHYJ2N@CJ*69I9)%(T.:X'J(*X[LX=4;/-I%7
MH"JEDDL5>QU;8Y)#DQ\S)#GL'' ^E2]+M!N]!HRW5UXM5745]34[C)(*&1K)
M(#/N,D<W),;W,PX,)/$A1.WRLZ"TZ+U=!#/#+;;M$_=F88WB.0[KVN',9&$'
M:$6L:JUE;[)IZMNE//25[J5G2NIXJE@>]@\[=X\2!D@=>,=:KHG7.GM:4+:G
M3]R@J'8R^#> EC[G,YA!LR(B B(@(B("(B B(@YQM\U#46/9_44]MWC=+O(V
MV4@:<'?E\G(] R5M.A-.4ND])VVS43 UE-$&O<!@O?\ "<>\G*YWM;Q<MKFS
M.T2-#HHZJ6O=WE@X?,5U6^5PMEDN%>X;S:6GDG(SC.ZTN_T00&F-:TFI-5:A
MLU!32OALY9'+69!CDD=G+!WC"VMC6L:&L:&M'( 8 7*/<V48MVR:GN-62)[C
M++<:B1_,EQYD^@!5IMINI+C:)+]9M#2U>GF[SHYC7M9//&"?LC8MP\.!.,H.
MKHH&@U=9*K3%!?Y;C34ELK8VR1354K8AY0SNDN(&>?#N*7^_2TMCBN%AHXKP
M)7-#"RJ;'"&'.9'2<0&#', H)"^6FAOEJJ+;=J:.JHJANY)%(W((^GO7)MF%
M56:#UY5[.;I/)-:I(W5=BJ9B2XQYRZ#/66\<>@K8Z/:Q8C8[/772:EM\]PGZ
M+P>2K9Y#0YS3,''&]%EN0[&"""H';[40TUNT9JZWR,D=07:!S)HB")()@6G#
MNL'(*#9]MFF3J;0%P93@-N5"!744H'E,EC\H8Z^."/6I+9=J7WWZ"LU[<,2U
M,/V4=DC26N^4%;/(P21N8[BUP(/H7)/<WD4EHU79F%W1VR^U$48/4QVZX#VD
MH.NHB("(B B(@(B("(B B+G=3MGT/35,U/->,2PO=&\="\X<#@CEVA!T1<EV
M]UE==?$.A+-,Z&KU).63RL/E14T>'2'AU$<.\9"U.K]T5:[)K.HHYW.NNG9P
MV6&LA8624Q/!S'-/G@8SD8/'K4IIR^T.K_=%Q7*WRMGH:2P--*_=(/EO=O'!
MZ^I!V2PVFBL5GI+9:X&04=+&(XXVC  '^JSERK6$=7J_:A'I*2YUUNL]';A7
MSBAE,4M0]SRUK2\<0T '@.>5(:>LE[T-<[L8ZROO6E&T1J(89Y#45D=0T\8V
M<,N:6\ASSA!T5%SJV;0[IXVLM-J/2D]FIKP_HJ69U6V5S9-TN#)(PT%A(!ZS
MQX+5M*7B6;:A>!9*ZZSE@F8ZENDCVQUDN]D='Y&[$Q@! /$NSZT'2MHFDJ/6
MNDZZS5S0.E;O0RX\J&0<6O:>H@]G5E:[L&U/6ZBT.V"]EQOEIF?;Z[>\XO8<
M GO(QQ[<J5V85]_KK)*_4=*R)XJ)Q'(92Y[@)I  6EC<    \<C!7%;SM*I]
ME6TC:.UEKGK36STLT+&>3&V0Q>47OXXR3G',H/IM%P79IME?/8GW'4E%?:RN
MK972!M#:Y7T\# <-9&X [W+).>9/8NH:+UO1ZLGJ8J.W7BD,#0YSJZB? UV3
MC +AQ/<@VI$1 1$0$1$$+8?OE?/SH?RVJ:4+8?OE?/SH?RVJ:0$1$!$1 1$0
M$1$!$1 1$0$1$!04/X<57Z/B_F/4ZH*'\.*K]'Q?S'JU?-I3M/N3J(BJS",C
M!Y+ \2VOXMHOW#?H6>B# \2VOXMHOW#?H3Q+:_BVB_<-^A9Z(,#Q+:_BVB_<
M-^A/$MK^+:+]PWZ%GH@P/$MK^+:+]PWZ$\2VOXMHOW#?H6>B# \2VOXMHOW#
M?H3Q+:_BVB_<-^A9Z(,#Q+:_BVB_<-^A/$MK^+:+]PWZ%GH@P/$MK^+:+]PW
MZ$\2VOXMHOW#?H6>B# \2VOXMHOW#?H3Q+:_BVB_<-^A9Z(,#Q+:_BVB_<-^
MA/$MK^+:+]PWZ%GH@P/$MK^+:+]PWZ$\2VOXMHOW#?H6>B# \2VOXMHOW#?H
M3Q+:_BVB_<-^A9Z(,#Q+:_BVB_<-^A/$MK^+:+]PWZ%GH@P/$MK^+:+]PWZ$
M\2VOXMHOW#?H6>B# \2VOXMHOW#?H3Q+:_BVB_<-^A9Z(,#Q+:_BVB_<-^A/
M$MK^+:+]PWZ%GH@TXVFW?TA,C\7TG1^*R[=Z%N,],..,+8O$MK^+:+]PWZ%%
M'_>,S]$G^<%LB# \2VOXMHOW#?H3Q+:_BVB_<-^A9Z(,#Q+:_BVB_<-^A/$M
MK^+:+]PWZ%GH@P/$MK^+:+]PWZ$\2VOXMHOW#?H6>B# \2VOXMHOW#?H3Q+:
M_BVB_<-^A9Z(,#Q+:_BVB_<-^A/$MK^+:+]PWZ%GH@P/$MK^+:+]PWZ$\2VO
MXMHOW#?H6>B# \2VOXMHOW#?H3Q+:_BVB_<-^A9Z(,#Q+:_BVB_<-^A/$MK^
M+:+]PWZ%GH@P/$MK^+:+]PWZ$\2VOXMHOW#?H6>B# \2VOXMHOW#?H3Q+:_B
MVB_<-^A9Z(,#Q+:_BVB_<-^A/$MK^+:+]PWZ%GH@P/$MK^+:+]PWZ$\2VOXM
MHOW#?H6>B# \2VOXMHOW#?H3Q+:_BVB_<-^A9Z(,#Q+:_BVB_<-^A/$MK^+:
M+]PSZ%GH@\QL;&QK(VM8QHP&M& !V!>D1!BW7[UUG^"_^$K T9^"EI_-F?,L
M^Z_>NL_P7_PE8&C/P4M/YLSYE?\ P:1]W/O3*(BHS$1$!$1 1$0$1$!$1 1$
M0$1$$+=OO_9?RI?X5-*%N_W_ ++^5+_"II 1$0$1$!$1 6)>+C36BU5EQKY!
M'24D3II7GJ:T$GYE#'6EGDU;#INBJF5EU+7231P.#A3,:.)D(\WF  >)RM-]
MTM53,V:&WTSBV2[5U/;LM/'$CCGY @CMCMEEUC>:C:9J>$NJJPF.STTH!;24
MH.6N']X\>([^U=G4+5S4.CM&RS;NY;K11$[HP"(XV<O3@+G=+J':36Z69JVD
MI[(^BEA\+BLHAD=.^$\0WI0[&_N\?-QE!UY%J5?M L=JM%JK;S.^AFN4(EAH
MGQN=4'@"1T8&>&>/!8>I=9,GT9'?-*W>TLHWR;KZVK!>R,#(W1&""YY=AN[D
M')]2#9-4Z?MVI['5VF\TS*BDJ6%C@YH):2.#FGJ<.8*YQL6N=RL=ZO&SK44T
ME156AO3VZJD.3443B SCUEN0.[EU*0I]H]PI*'2[;Y8+A#<;CGPJ*&BE>(_(
M>X;F <N\D$MY@$YY*&VIO%HVI[-M30$Q.JZ@VJ8/:6DQR D CN)Y=J#LJ+7=
M;ZHATG8W7>III*FBAD:*DQ'+H8R<&3'6!S([%GZ>O]JU%;V5UCN%-74K^4D,
M@=@]AQR/<40DD1%(H40HB!4*JJ%!1$12"(B(%Q_;/*[4VL-): BP8*Z<7"X#
M/.GB).Z>XD'Y%V!<CT_$ZY>Z2U55RN#A:K734D0QRZ0;Y^=)3#JDKZ:W4#Y'
MED%)31%SCR:QC1Q]0 6N;.-7,UQITWF&WS45*^H?'3B8@F6-IX2#L![.Y0/N
MB;A-;]DM[%,0):L,HQ_^4=NGY"IBHK+?LUV;4IJ&N?36NDB@9'$/*F> &AK?
M[SC\Z@;@51<QJ-HU_LO@-7J[1SK79ZJ5D1JXJ\3NIBXX;TK-P8&<#@5OMTOM
MHM+X676ZT%$^;[4VIJ&1E_Y(<1E3"-) K6]>Z/MFM=/3VN[1 Y&]!.WA)3R#
MS7L/405A[0M85FDZ=E5#9FUU$V,R33OK&P!OE !C 6DOD.<AO#ES7NHV@:>I
MM14MFJ;E1PU<T9<YLM0QIA>"T")[2<AYW^ [BAIK^Q34EQJJ2Z:5U,[.H-.R
M^"R2'.:F''V.;CVCKZ^!ZU@;?('6..Q:\H& 5EAJVBH(YRTTAW'M/HSGUE>K
M\/$WNCM-5<.ZQE\M4U#4 #SG1YD:3W\ /0%N6TZVMN^SS4="_&)*&4C/:UI<
M/E">1YMBI9XZFFAJ(7!T4K&R,(ZP1D?.KBTS8Q7/N.RS3-1*_?>:-K"<_BDM
M_P!%N:F$*(G6JHA1$1 5"JJA4H45%544H$*\32LAADEF>&1QM+WN/)H R25I
M?]+.@O[5VO\ >?\ 9-ITW9<BVQ25.JM5:?V>T,LD5/6_[;=7QG!\%:?,SU;Q
M!^11=N]T!8Z75M=9;U/%-;V3?[+>:4[T3XW $![>HC.Z2.'#DI/9O74VH-M&
MM[Q1U+*JECHJ2FII6'+2QP+B0>S(59G:T1KJZO0TE/0T<-)10L@IH6"..-@P
MUK1R "NKE];!7:[V@W^U/O-RM5HL4<#!';Y1$^HED#G%SG8/ !H "DK0;[HF
MBOXO$U;?K-2-CEMTK6]+62;W!T3@T>5@XP<=94Q*NF_%46DV/7%557Z*T7_3
MU78:JHII*JF=-,V9LC68WP=T##@"#A:9LTU-45MXOYL%QJ[XUD0(IKG5"*2>
M0/._4,&X1%'@@!G'.1RPG,<DMOVQ:3.I])RR4&8K[;3X9;JAG![)6<=W//!'
M#V*1V8:F]]^AK5>'C=J)8]RH;RW9F'=>,=7E GUKULWN5VNNE*"IOU(V"H?"
MPA_3!YFR.+BW=&X>[BN$VW:O2;+SK*SFBEKZMM[J'4D(/1QM!))R[L[AQ3>N
MIK<:?3G4BX]HC;):)--4E1J2KJWW6H!FF;!02='%O$EK&8'$!N!G)SQ*Z'I+
M5=KU73U$]F?4/C@>&/,T#HN)&>&\.*M$Q*LUF$Z40JBE47E>BO*0@0(@4B(T
MW]RUGY[/_,*E5%:;^Y:S\]G_ )A4JE>Q;NR*'[H_5*)0_;_4465^[?%[*01$
M5&B$U-]NLGZ19_ ]3:A-3?;K)^D6?P/4V@(B("(B L>X44%QH9Z.LCZ2FG88
MY&9(WFGF,CBLA$'!ZOW.]CH]9TEVM$?3VB20MK+742O :UW-\<@(=D<]TDY[
M5[VQ[)M*6O9G?[A8[,8KA20=/$\5$KR-UP)X%Q'('J7=58KJ6&NHIZ2I8)()
MV&-[2,@M(P0@B;!51:@T315%*_$5=0M+'<\;S/\ NN3[/M?4>S[1=+I/4MON
ML6H;6)(&TT-')*VI\MQ8YCV@M(((Z^M9NQ.Y2:/O%?LROTH%70O=/:Y7'A4T
MSB78;WM[/3V+M&.*#B&L]2:E@HM)S:H>=,0U44DM=<*"A\*DII#C=@&0XQY:
M3EV#Q&%YV16:BU%==<-O-)7W*W3U=--#)>8<23@0@-D(W6CCS P, A=Q(SS1
M!%VW3UHMEM;;Z"W4T%$V3I1"QF&A^<[V.W(RN8^Z7;XQL.G-/1X,UXN\$(8>
MMK7;SCZ %V%[FL:YSR&M:,DDX "XGI&K.TW;#4:CA=G3>F ^DH#_ %]0X8D?
MCL Y'T(-DU5LBTQ6Z?K*2RV"T4E?4,Z)E2Z#/0[QP7@=;@"2!V@*]LXV0Z6T
M+'!-04?A-U8/*N%029''KP.31W!=#1 1$0$1$!$1 1$0$1$''=IH=1[<-FU>
M\8AE,]('?WB.7RKI^J:)]RTQ=Z&'[954<T#?2YC@/G7//=%VRHDTC0ZAH&;]
M9INNCN;6_C,:?+'LX^I=)LERI[Q9Z*XT;P^GJH6S,<.L.&4'+-BT\E_]S[3T
ML&#4LI)Z(M['MRW!^17MF&N].6C9!:G7*YTE/+;:,0U5-)(!(R1@(+"WGG([
M.M1FF*AFR[:G7Z;KBZ/3VIIC6VN4\&15!X21'L)\GY%U&ITCIZJN9N-39+=+
M7$AQG?3M+\CKSA!RV[W^EU'>],,I;!:J"Y.M;J^%]]<X14T3W-!:V($![SP)
M/# ]*C-D6F[?K;2^L+3<ZSI;:V_2.:;6]T$+\-'!@R<,).<9*[=>]/VB^LB9
M>K91US8CF,5$0?NGNSR61;K90VT2BWTD%,)7;\@B8&[SL8R<=> $$11Z/ME/
M;+?12FIJXZ&<5$#ZF7?>'#. 3UM&>7):'[I7%1I.PV:' GN5YI8(V =327$^
M@!H777$-:7.(  R2>I<5L-1)M*VRNO,.\=+:6WX*20CR:FK(W7.'<./'N':@
M[62 "3P 7(O<\#PCW]7)K@Z*KU!,&$=88UHRMUVGZBCTKH.]7:0^5#3N;$!S
M=([R6#]HA1>PO3TNFMF%FHJMN*R1CJFH.,$OD<7G/?@@>I!OB(B B(@(B("(
MB B(@+R8V$Y+&Y]"](@TENS>RU6L:K4U\@9<[FXM93=*W['2QM'!K6\B<DDD
M]O4M5U1T>G?=#Z5NDFY'27NWRVQS^H2L)<P>O> "[ M*VNZ+]^^D)J"FE%-=
M('MJ:&I/_"F:<CCV'&#Z4$=JVRZ@MFOX-6Z7M\-V,M%X!64+ZAL#MT.WF/8]
MW#@200>U1M=:MHFHZ34E9/4-T^^HMQH[=:V5+90V3.3,Z1HP'$9:,<LY4OLC
MU^S5EOEMUT;X'JFV?8;C1OX$/'#?;VM.,]RZ"@X';- 74ZGTE646AZ2Q0VVN
M;/6U,MR;55$PW' D.R26Y.3DY)QPYKOB(@$@ D\ %QK8S'3:NO&T/4553Q5%
MKN]>VE@$C<MEBA:69P>HY6/[H?:;'8[54:9L<SG7JJC_ -JGB!<*"G) =(_'
M'.#@#O\ 1G:MD5YT53:0MEFTI>J.>"FC# #(&2/<3Y3BT\<DY..]!L>C=)V_
M2%)5T5EZ2.W33F>.E<[>; 7><&9XAI/''425L"(@(B("(B B(@A;#]\KY^=#
M^6U32A;#]\KY^=#^6U32 B(@(B("(B B(@(B("(B B(@*"A_#BJ_1\?\QZG5
M!0_AQ5?H^+^8]6KYM*=I]R=1$568B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B#6S_O&9^B7?S@MD7'*N'4S=M4-NCN4OB^:'I^FW!OLI
M][>,>]C\=H';@KL: B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B#%NOWKK/\ !?\ PE8&C/P4M/YLSYEGW7[UUG^"_P#A*P-&?@I:?S9G
MS*_^#2/NY]Z91$5&8B(@(B("(B B(@(B("(B B(@A;O]_P"R_E2_PJ:4+=_O
M_9?RI?X5-("(B B(@*/OUGH[[:I[=<F2/I9AAXCE?$[U.:01[5((@^?[)[GB
MW6+6WA EJ+EIVIC>U\3JE\$],[FT[\;F](.KUYXJSMPV>V#2.DJ+4%CI:J.:
MW7.EJ)3+73S#HP_RO)>\CLXXROH90^L+#!J?2]TLM6=V&NIWPEV,[A(X.]1P
M4&'KRV2:FV>WRW6][727"WRQ0.SP<7L.[Q[#D+FVF]K-HL.@;?9S!6OU904C
M*,6@TLG2/G8T-W<AN,9'//)3.P;4DTMHJ-'7YPCU'IP^!RQD_;H6X#)6]H(X
M>SM74NC9TG2;C=_\;''VH.(:ZU/<J34UHBO]RBT<YUL$C[C!0"K?-*2.D@C>
MX$,#2 >1)RFQK35JU18+^S4=!-<86WJ:>%USBW)22!B1S0  X@YY=:[>]C'@
M![6N .1D97H #. !E!%6[3UIMM)0TM#00PP4+W/IF-'VIQ!!(SUD.=[5RK;Y
M24VH=8;.M,U$73MJ;F:F>+C@PL:=[...,979JF>*FII9ZA[8X8F%[WN. UH&
M23ZEQO99*_:!M)O.T![,6>CC=:+.'#BYH=F24>DDCUXZD&1K;8?INOL;Z+3=
MFHZ&MJ'MC=6/?(XP,SY3FM+O*=C@!WK9=F^RO36@8FOL]*]]P+-V6MF>722=
MO#D!W +>T1"B(BD4*(41 J%55"@HB(I!$1$"Y)I284?NB];TD@(=74%)4QD]
M;6M##\H76UQ[:>':7VM:-UD0? )\V6L.<!HD)W''NR?D1,)'W2E))4[);G+"
MPO?1RQ5>!V,?D_(K6V6J%WV2T=YHV.EI&34=S?N#)$(<'D^H%=(O-NIKQ:*V
MW5K>DI:N%T,@[6N!!^=<JV)W=]CJ*_9KJ.3-SM!=X$^08;5T9/D$=XZQV>@J
M"&T:GVCZ<HK72/I*BFO<]?+'%345-(U[YBXCCCC@#GQ6AZIKZ.YZCUK)!1Z:
MM[J%C::OK+SO3RS 1^3T<6\T,;U @^4>*ZW;-*V"TUCJNV6:WTE4[@988&M=
M[0%<KM.66ON<5QK;515%?%P942PM<]OH)":-N::!T5;M6[.-!W*Z55R;5T5O
M8('4]26!I_&Q@\<<,]BZ8+'0^,:2O?$9*NF@=3LD><DM):27=I\D<5FT=)3T
M-)%2T<,<%-$W=CBC;NM:.P#J6)J"\45@LU9=+K.V"CI8S)(]QQP'4.TGD I1
MMS?5H-P]T/HBCB#B;=;ZFOF(^"UP=&W/K6\;0:Z.VZ%U!5S>9'0S9];"!\I6
MC;$Z"NO5ROFT*]Q.AJ+XX1T$+_.BHFXW >S.,^K/6O?NB*R:ITI1:5MQ)N6I
M*N.CC /FQAP<]Q[@!\J>2?--[#*9U+LETQ&\$.-+OX/]YQ=_JMZ6-;*..WVV
MDHH1B*FA9"WT-: /F62IA65%540(@1$040JJH5*%%155%*#F,%8OBZA_Y*E_
M<M^A92%$M!M&RZPT^IZ[4EUI8;C>JF?I&2/9B*G8  QC(^7  <3DDYY*$M#F
MV'W0]ZI9W;L=_M<-1!PP#)$2TCV KK"YWMETI7WNW6^]:<(9J.PS>&4?#[<!
MQ=$?RL?^943&NR8G?=:KJ+4&E-=WJ]V2QOOMLO44)GAAJ&12T\T>\,@/\YK@
M[JY84?>;?M$O=@OM42;;/52P-I;/%5,WV4[#]E'3#@'O![>&%N.SO6EOUQI]
MEQMY,<S#T553/X/IY1S:X?,>M;,D1LWIQO1^D:RFVD66\T>CY+#:Z>EJ(IY*
MBN$\TCW!NZ7#><<<#CCV\EV0DE"J*8C2LSM;J:B.EIY:BH>&11-,CW$\  ,D
MKD&QJPV[5>BK_<;Y0QUM%J"[5%4R*=N?L8>0T@\QR/$84?[H#:!1;GO)HJT4
M\E8YC+I7 %S**G)X@X^$>6/I74M$U-A9IRW46G+A1U-!30LAAZ*5IR&C'+//
MK4=)E.IB&1I"PQ:7L45HH9YI*&G<_P ';*<NBC+BX1YZPW. 3QQA3!)/,Y1%
M:(4F=J%452J*4"\KTO*0@0(@4B(TW]RUGY[/_,*E5%:;^Y:S\]G_ )A4JE>Q
M;NR*'[H_5*)0_='ZI197[M\7LI!$14:(34WVZR?I%G\#U-J$U-]NLGZ19_ ]
M3: B(@(B("(B H356I[?IF.WR76411UM7'1L>7 !KGYP3D\ACCZ5-KD.W;9Q
M>MI=79[?25E-06>DWIIY9,N<][N #6CL /,CF@B-7VV;;/?J;WM2-MUILDCW
M1ZA:P]+-/@@,IR.; X#>/=P67;MINH-# 6W:Q9YQ''AD5]MT1EIIOR^6Z['^
MO +H&SG24VC;!%:77BIN<$+0V+IHV,Z,#J&Z.7IRMHFBCFB=',QLD;AAS7#(
M(["$&H6W:AH>XQAU-JNS\L[LE4R-P](<05'7W;-H2T1.<[4%)6S X$%"X3R.
M/8 U:KMWT-I6ET34U])I^UPUOA=.TRQ4[6NPZ5H(X#K!72K)HC2UDGZ6T:?M
M=).WB)(J9@>/7C(0<OJAK+;!*:22DJ])Z%?QD=,"RNK6=0QR:T\/5UE7MH%F
MM&RJBI-2:2J[?9JNEB;#+;YY>CBNL31YI XF4#B'8/'GS7;%C5]OHKA'T=PH
MZ>JC'P9XFO'L(0<WV";0W;0K9?ZR;>CDAN+A% XC,<+F-+!\CO6NHK6-/:$T
M_IR]5%SL% RW2U$8CFBI_(B> <@E@X9[ULZ B(@(B("(B B(@(B(+573PU=+
M-35,;98)F&.1CAD.:1@@^I<8V:5\NS35M1L^U#-BV5<AJ-/U<A.[(UQ\J D\
M-X'& .WO"[8M8VA:)M6N;$ZW79CFO8=^FJ8^$M/)U/8>H\O2@O:ZTA:=:V":
MU7N'?B=QCE;@20OZGL/40N8T.I]:[,";?K2VU>I=.Q#=@O-NC,D[&CETS"?E
MSU=:]V;7U^V=5$5DVK1/FHLAE)J&G8712-[)NL.';_\ A78+3=*&[T<=7:ZR
M"KII!ELL+P]I'I"#2;5MFT!<8&RMU-0TY/..J?T3AZ0Y6KUMLT';(=Z.^PW"
M4\&P4 Z=[CV !;+=-#Z6NLIEN.G;34R$Y+Y*5A<3WG"L:7LVC:2HF][=NLL5
M13R&.3P6&,21O',' R"@YO5.UKM=E-'X'5:2T1)]NDF!975C/Q0.36GYNWDN
MO::L=NTS8J2TV>G934-*S<8QHQZ7'M).23UDE2:YUM/LVK]45E+8;)50VK3M
M0PFX7!CSX01G[4P=61U^GUAJE?.[:]M)IJ*@=TNB-.3B6JG:<QUU4.+6-/)S
M6G&?7VA=P41I+3=LTG8J:SV.F;3T5.,-:.)<>MSCUD]94N@(B("(B B(@(B(
M"(B B(@+Y6V_:IUC1WBY4NE=5UE704+&OKVT$ B-#ON#6,?*T\22>0P1UKZ&
MU]2:BK["ZCTE64M#6SO;&^JG!)AC/G.8!S=CEE6]-:%L=@TM)8:>D;/23@^%
M/G >^J<[SGR'X1*#1(=C-%5Z/L#J>OJK5JNAIPYMXI7?9GR.\IW2'F\9/6<J
MU3ZHVI:1(IM2Z5BU12L&&UMG>1*X<LN81Q/#/ #FNS-:&M#6\@,!1.K+T+!8
MJFN;335D[6[L%+ TN?/*<[K !VGKZD'.X]L\E1%,*'9_K2HJH7F*2(4 PQX
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MM:X@\N!*":14:X/:'-(<TC((/ A50$11>J+[1Z:L%;=[FYS:2DCWW[HR3U
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ML\,=6,86';]EU#%74$UTO-YN]-;WB6CI*VI+XHGC@TX^$0.6<HET!$1$"(B
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M3'6ECY'.D;'NM<''.,$E0NGMF$=MT[J73%57>$Z:N;W/I:<,(DI0[SFAV<$
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MJFTU+8*V&JS(S>,H9G(X8P23G*D]J6D)=:Z;CMD%6RD>RKAJ>D>PO!#'AQ&
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M#:ZG<8*I@^#(WGZCP([BI5:[>X9;5<#?*)KY(MS<KJ=HSOL'*1H_&;QX=8]
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MH:&".&,G)#1C>/:3UGO*# M-IE94^,+M(RHN3FX&[GHX >;8P?E)XGY%,HB
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M$%$1%(H40HB!4*JJ%!1$12"(B($1$#J5%5404*(42!0JBJ51 5%544P@1$1
MJ!$" B(@*A5512A145512@0HA2!1$12"\KTO*A 515*HI!4551$"(BD4*HJE
M41 5Y7HKRD($1%(H515*HIA5D4 ^SD]C45ZWLPUSSU\ BPO/5U8XU5E(B*JX
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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&("(B#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g762905g02n07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g02n07.jpg
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M!6@# 2(  A$! Q$!_\0 '  !  (# 0$!              <(! 4& P(!_\0
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MK4?'+&Y'->U>2HJ<%0]3PM])#04--1TK$93T\;8HVI^2UJ81/@0]P@
M
M
M
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M_*9OKE;?!T8UNVJSM1.#5J,=WXF0"[  "
M
M
M
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M_0R!877  0
M
M
M                                                         I1X
M.WMV6GTU/T,A=<I1X.WMV6GTU/T,@6%UP $
M
M
M                                                          ,>
MFKJ2JEECIJJ":2+'2-CD1RLSRRB+PY*0#M/HM=;3=1W6TZ7<VETU:YO%)'OG
MZ)M1,B(K][&5=A5QC&.&>:F;X-FEZ_1VIM9V:[/@?5PQT;G+ Y7,PY)')A51
M.I>P"=HYHI'RLCD8]\2[LC6N158N$7"]BX5%]9]D-;;;FS0%]L.L+6O15%35
M)1W&!JX;60;JKER=;FXPCN:93JX$R1O;)&U[%RUR(J+VH!^@
M      4H\';V[+3Z:GZ&0NN4H\';V[+3Z:GZ&0+"ZX "
M      #7WN\45DI8ZBY3)#%),R!JKUN<N$_S5>Y%-@77Q3<3.@ $4
M
M
M                                                !7/:+JO5FR+6
M5TFM])3UFG+U4+6Q^,1N5K)G-1)&HYJIA<MSA<IC&.LCZGVZWVCU/>[Y06VV
MLJ;JR!DC)4>]K.B:K45N')SSUEB=4[2-%QW6JTQ?63U-7O)')1/MTDR2*J93
M#=U=Y%3BBH<AM'TKLAT720W&_6%4FJ%S#2TTTR/DQSPS?1J(F4SG"!4&PU6J
M]LVMJ"DKYY*EV]A=QF[#2193?=A."<.M>*KA./ O'#&V&)D;$PQC4:B=R$-[
M)=I^SVJJX['IVVNL$\[D;''+"QB3NZDWVJN7=F]Z$)F   (
M   %*/!V]NRT^FI^AD+KE*/!V]NRT^FI^AD"PNN  @
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MJWJREJZ>=Z)E6QRM<J)V\%,D\S&O+V  @
M
M
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M>@E3DO-J];53J5#8F-D
M
M                                           5(VW[2-4W/7UPL&GJ
MROI:*AE6G;#0JYLDKV^R<Y6^<O'.$Y81#A/&]I'NC5_^.I)RN6J=)[/=N%XK
MY:U'I<HFPU\+:>19*.7#7(]%W<.8Y,91%5<KW'8_AWV?>_4GR.;ZH55GQG6+
MZVWMU!-J!U$M5%E*YTRQJN^F/9\,E]2&=5[:]#7&SNH:)ZWBHJ)8HV4LE/)&
MQR](WSE<J)C'/THA,P  ! HUX0GMPZD_K(OH6%Y2C/A!*B[8=2*BY3I(D_\
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MYWG?!AI,AK9/O-G']T !X>P
M
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MWB>SK@ >'L
M
M                               0OI&LT=1[0=9LU0^VPZE6Z.=')<=U
M%6G5C>B2-S^"<.I./+JP2@R[:?6/S*^U+'CJFCQCX2-MN.QYNN9&7:S314M\
MC8D;DEX1U#4Y(Y4Y.3J7LX+U*E>:C8SKZ"I6!=.SO7.$='+&YJ_WM[ 58#;C
M7Z$GT=71++:*B^O;B@;2*Q]0DV?-5%9Q1,\\\,$QTJ2)31)-QEW$W_3CB5XV
M,;!ZJT7BFONLEA2:F<DE/01N1^'IR=(Y.'!>*(F>../4MBP@
M      !2CP=O;LM/IJ?H9"ZY2CP=O;LM/IJ?H9 L+K@ (
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MKXHOI)U7BG$T<O\ +O,1X=[AW]?!6UO*'=G.T]SY&6[4\S<+PBK7<,<L-?\
M6^'M)@C>V2-KXW->QR9:YJY14[44B3:'LO299[GIMJ)*JK)+1]3NO\7V+_-^
M#L.8V<Z^J-,3);;FQS[9OJCD5,/@<J\53M3M;_[7Q-8M&ZMB+37M980'E2U$
M-731U%-(V6"1J.8]BY1R+UH>IB90
M
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MP0                *4>#M[=EI]-3]#(77*4>#M[=EI]-3]#(%A=< !
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MX@(_V/:KFU!:)J2X/5]=1;J+(O.1B\E7O3&%]7:2 89C4Z9HG<;  10
M
M
M     4]VK:%U)JS:SJN;3UIFK889XF2/:YK6H[H6+C+E3*X.:_ QM _DW/\
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M[LKZU4[$UKSN6S2-0  \O0
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M/5E;/)45,M/F261RN<]R.5%557T'8R,;)&YDC4<QR*US53**G8<Y9:*V;/\
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M#*RIN&RK3]57U$U34R1R*^69ZO>[\:].*KQ7@@,?P?O:?TW_ %4GTKP!(0
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MRT^FI^AD+KE*/!V]NRT^FI^AD"PNN  @
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MX\%+;[3Y9H /#V
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MRT^FI^AD NN  @
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M5(B,E15XO;U/]?7W^D[8\3&IT]Q.XV  B@
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MF-]*:!L6]CEG=1,\U^$SP /"NHZ:X4LE+7TT-33281\4S$>QV%SQ1>"\4/<
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M4_0R!877  0
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M>EIG=_-S/UJGK,MOM5VQ5^S.DR@ Q,H
M
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M+R@  $                "E'@[>W9:?34_0R%URE'@[>W9:?34_0R!877
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M+UZ96ENJ  'EZ
M                                  >=1/%3023U,L<,,:*Y\DCD:UJ)
MUJJ\D.0BVI:(DK/%6:GMG2YQE9<,_P :^;\X'9@P(KQ;I;A!0PUL$E5/ ZIC
MC8[>5T2*B*],=67(AG@   !H;QK'3UFJXJ6Y7FBAJY9&Q,I^D1TJN<N$3<3*
M\U[#?                       &LO-_L]CZ+[LW6AM_2YZ/QJ=L6_C&<;R
MIG&4^$UOW_Z0_E38_E\7U@.E!J;7J:Q765([7>K962+^13U3)'? BJ;8
M  ^)XF3P20RIO1R-5CDSC**F%/&V4-/;+;24%#'T5)2Q,@A9E5W6-1$:F5XK
MP1.9D@   ,.\6NDO-NEH;E#TU+*K5>S>5N=UR.3BG'FB*9@
M       "E'@[>W9:?34_0R%URE'@[>W9:?34_0R!877  0
M                                     \*^DAKZ&HI*IB/@G8L;VKUM
M5,*>X$3H5 U399M/W^MME1E70/PUWY[5XM=ZTP8MIKIK7<J6OIL)-3RMD8JI
ME,HN2<=NVE9+E1TEXH(5DJH')!*UB95['+AJ^IRX_O=QCZRV=MI=F-)#1QL=
M<;:BU,KD3*R93\8B+\"IW-0[V/F4M2O5YGL\:2E8KI3WJT4MQHGHZ"H8CV]W
M:B]Z+P]1G$)[ -3HU9]/5;T3>S-2Y[?RV_YIZR;#C\C#.')-7J)V  PJ%.-5
M_P :+Q^F3?MN+CE.=5_QHO'Z9-^VXZ?LVG7-HW\FAS\4Y:16)TU(/T'0R8>B
M-[<'/Q/1B+;W"4_!T_CC7?H+OI&%B"O'@Z_QQKOT%W[;"PYR>?&LNM_"'T?"
MKTX8C>P &DVD#;:]-NME[9>:-JMIZUWGJU,)'*G?W\_2BDF[,M2+J33,<TZI
MXY3KT,_'BY43@[UIQ].3:ZLLL-_L%9;YVHJR,58U_->G%J_"0+L\OE1I#5RP
M5R+#!(_Q:K8_\C"XSZ47YLF6/M5U\88ONV_*5D0 8F4
M                                             #2ZTOOWMZ:KKKXN
MZH6G:F(T7&55R-3*]297B6(F9U#S:T4K-I\0W0( _#G=O>F@_P 3_P!X_#G=
M_>F@_P 3_P!YG]UR?)H_Q3C_ #_V3^1AMVU4^S62"V4,RQUM:[><YBX<R-J\
M5[LKA/4IQ_X<[O[TT'^)_P"\CS5VHJO5%\FN=<C6R/1&MC9G=8U$X(F?6OI5
M3+AXUHMN_AJ\OVECMBFN*>\K0: U$S4^EJ.XHJ=.K>CG:GY,C>#OAYIW*AT1
M5+0.O+AHU*ME'##40U&ZKHY57#7)UICN_P CKOPYW?WIH/\ $_\ >>;\6_5/
M3X9,'M3%Z<>I/=/X( _#G=_>F@_Q/_>>M+MSN/C$?C%HI'0[R;Z1O<CL=V<\
M3Q[KD^3-_%./\_\ 9/0/R-V_&UR(J(Y$7"IA3]-=T   5T\*2^R.U#IG3-34
M/IK-4.;4UJM7&^U9-WCW-1'+Z5[D)OI=*:=AL[+=!9K:MNW$:D70,<UR8YKE
M./I.&V][,9->VFFJK4]C+U0([HFO7#9V+Q5BKU+E,HO+GGGE(8T)M:U/LTK$
MT_JZ@J:F@@PWQ>?+9X&_S'+[)O8B\.Q40*DRQZ!IM ;<[9565JLL]ZI:B)L2
MJJ]#(UJ/5B+^:J-RGH7L)P-!I'4]DUG:XKG8ZF*JB8O%%3$D#\85'(O%JX5?
M2G+*$2^%'/<-/VJUW>Q7F[T%1452P3,@KI6QO3<547<WL(J;O4B<PB>0<_8J
M9+SHBSMKIZM7344#WRQ5,D4CG*Q%5=]CD=G/?Q(6V*W:\+MPU18ZV]W6OMU"
MRJCACK*I\J)N3L:U<.7&<<,]Z@:G;[9[=:MK>BW6RAIJ/IWQ.E2")(T>Y)TX
MJB)Q7CS+/E:/"<DEBVF:*DIXNFG8C'1QYQON29,-SU97@=;J791J[4-/)7UN
MO:R.\*F_'34Z.BI(G=3&HCLHG5O8SUJBA4U @#P?MHE[GU%6Z)UE+)-<:;?2
M":9<R;T:^?&Y?RN"*J+SX+Q7@;F@OK-:[9=0:=O-=406VTQHREM\-0Z!*EZ*
MF^]ZM5%?CJ;G&..."A$S'&[5-=4>A=-OK)G1ON$WXJCIW+QDD7K5.>ZG-5]7
M-4-:NFZZP;0-/3V>XW1=/U"SQ5-!+4R311R)$YS')O*JHBX7AG&43',AOPL;
M%!0ZAL%Q945<M1<5F23II5<V-K%CW6L3\E//=R M.U<M1>U#].5M.GFZ7I:Z
MOIJ^^W65*=RMIZRN?4(Y43>1&H[DY<8SWD<[&VU^TBCO-ZUN^Y/5*KH::E;/
M+34\;$1%7=8Q6Y5%7"JN5X>D"< 01I&^W'2NWNLT/]T*NML54S?IHZN5TKZ=
MW0]+AKW*JXX.3&>SK/WPGKCJ/3]DHZZTZCK*6DJJGQ9]+ UL:M\Q5RDB)O\
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MJU+16FAC6&K9#-;WIF.KB=G>1&JO![4XHY/7DGZ![)(8WQ+F-S45J]W4!]@
M(                %*/!V]NRT^FI^AD+KE*/!V]NRT^FI^AD"PNN  @
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M;VR,:^-R.8Y$5KD7**G:6]=2E)W#] !X>P
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MPY?0BIW8 V/A4U'2;,9(Z:5KUCN,+*AK795B*USD1R=7-B\>U#<[/=&Z(O\
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ME#:+;;W;U!;Z.E=VPPM9^I#-/*EF6>FBE=%)"KVHY8Y41'-[EPJIGUGJ$
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MWD^')N@@  !2CP=O;LM/IJ?H9"ZY2CP=O;LM/IJ?H9 L+K@ (
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M$3[$]73UR26.XRNEDB9TE-(Y<KNIS8J]>."IW9["6#7M&ITV*SU1L !%
M
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M(7<*4>#M[=EI]-3]#(!=< !
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MVR1M?&Y',<B*US5RBIVH8,OG;/B\:?0 ,;(
M
M                                   IKM6U1?-);;M17"P5T]&]9HVN
MW>,<F(F>:YJ\'<^OM)6V;>$':;TD5#JV-EIKUPU*A,K3R+WJO%GKRG>;"QS:
M=O&T?:%I34D5).ZIJH*B&"IQ^,_$,:NXOYR83EQX\#@=I7@ZU5)TM=H>9U7
MF7+03N1)&_T'\G>A<+WJ%=!MEV:62WT=#JW2;&4+HZN!9XZ5V(9HWR-:CFHG
M!%RK>7!44L$4(L6H=265ZZ6J:BJ@H)ZF%E105#5_%N;*UW!KN+%RU.6,E]P
M "   '/7W1.F;]4^,WBQ6ZKJ5YS20IOKZ7<U.A &JL6G+-8(W,LEJHJ!'<'>
M+PM8KO2J)E?6;4 #4:@TS9=0MB2]6VFK'0KF)\C?/C7^:Y.*>I3ZT_IVSZ>A
MDBLENIJ)LJ[TBQ,PZ1>USN;E]*FU       *4>#M[=EI]-3]#(77*4>#M[=E
MI]-3]#(%A=< !
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M^#)7[5=,<_9MM9<'Q!*R>&.:%R/CD:CVN3DJ*F44^S$R@
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MLIYEPRLHZA*B-WS)\&<]P$R P[-<Z*\VRFN-KJ8ZFBJ&;\4K%X.3_+T=1F
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M)U;IEM/=JE]NJZ>GJ(EDCI)7OD1%>B91%8F43/$N,   0
M *4>#M[=EI]-3]#(77*4>#M[=EI]-3]#(%A=< !
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M:CF.:N4<B\45#U>-3MYQSN-2^P >'L
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MIM.P>(VUK5X2U35229>]<)N>M%ZC:>"EJW[JZ1J+!529J[4_,2*O%8'KE/\
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M+S7&43BJ>FP[:+4Z0NS-":RH&T&)>BAF6)(W1R.7@DF.#D=PP_O3*JG% LT
M @     \*^=:6AJ*A&[RQ1NDW<XSA%7'S%:/*@K?Y+T_RQWU"RUQ@=4V^I@8
MJ(Z6)S$5>2*J*A$5C\'G2%/:*2*[Q5-7<&QMZ>9E2YK7/QYVZB8PF>77@#AO
M*@K?Y+T_RQWU!Y4%;_)>G^6.^H2/Y/\ H+W!5_*W_O'D_P"@O<%7\K?^\+V1
M=7^$7>+VR"W4%IAMDM1/&Q:EE0KW-;OIG=3"<53AGO+4$&ZHV(Z+ML%"ZVSR
M6NYRU<3*22HJ'.CDD1=[HUSGFC78Y<<>A9R"                   %*/!V
M]NRT^FI^AD+KE*/!V]NRT^FI^AD"PNN  @
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M]'PRL21CDY*U4RBGJ8F4
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M                "E'@[>W9:?34_0R%URE'@[>W9:?34_0R!877  0
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MCXP\8Y[:EE  QL@
M
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M^\IKX.J__P!Z[3Z:GZ&0+"ZX "
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MHGY/77'S=V#\8YKVHYBHYJIE%1<HJ'Z>7H
M
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M)WUS^9;/E7_":SP<8U;MFL;5YL\8S\1(7<*4>#M[=EI]-3]#(!=< !
M
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M9Z,<4]"DR%;MCL4DFT"W+&BX8DCG+V)N.3]:H61,&2-2SXYW  #&R
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M,A=<I1X.WMV6GTU/T,@6%UP $
M                                .,VIZ1;JG3[_ !:)BW6G\^F<J[N>
M/G,5>Q4^?!V8/>.\X[1:OF!7'9/JZ;2M^=:KHYT5NGD5DK).'02\$WE[.6%^
M'J+'(J*F4XH0EMTT:])EU%;(,QJF*U&]2\D?CYE]2]IN=BVN4NM(RQ723_E\
M#,02._[:-.K^DU/A3T*;_)I&>GO&/]7F.W9*@!#>L-KM?8M2W"V0VREECII-
MQ'O>Y%7@B\32PX+YIF*%[Q2-V<_X1%'0T^I:&HIE:E;40*M0Q$ZD7#'+WKQ3
M^ZAS>R34B:;U?3RSJB4E6GBTZJN$:CE3#O4J)ZLF@U1?*K4=\JKG6X26=W!C
M>3&HF$:G<B&J.G6DSCBEOD^4S<J;<CUJ?">R[@(6V7;3;E=;O9]/UE+3N:K%
MB6I17;ZHR-RHJIRSYJ9)I.9EQ6Q3JSZC#EKFI%Z@ ,3*$=;6M$2:AIX[C:VH
MZY4[-UT?+IF<\)WIQQVY]!(H+$ZG<),;C4J?3PR4\SXIXWQ2L7#F/:J*U>Q4
M4\RVURLMLN:HMQM])5.3@CI8FN5/6J$<[6-"T:V+[HV*ABIYJ-,RQP,W4?'U
MKA.M.>>S/<9HR1/9AG',=V=L;TDEGMBW:J<Q]771IT>XJ.2.)>.,IUKP5?0A
M(Y#^Q+5[$B33UPD1KD574CW+SRN59Z<Y5/7W$P&*^]]V6FM=@ 'EZ
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M<I1X.WMV6GTU/T,@6%UP $
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M^LG32UOGM=@HJ6MG=4UC6;U1,Y<K)*Y=Y[O0KE7"=280V@
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M<I1X.WMV6GTU/T,@6%UP $
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M!(O*5B)['^DB?"B'NT=4=4/%9Z9Z92@ #&R
M
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M+3Z:GZ&0+"ZX "
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MW*F;O))RZ9G+/I3AGTH2&8IC4ZEEB=QN  $4
M
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M34_0R%GOPMZ$_E-0_"[]Q6#P='-7;59U1>#EJ,=_XF0+"[  "
M
M    @#;UIOQ"]17JF9BGKO-EPG!LJ)S_ +R<?2BF5L TUXQ7U%^J69BI\PT^
M4YR*GG.]2+C^]W$MZSL,6I-.5EMEW6ND;F)Z_D2)Q:OP\^Y5/?3%GAL%AHK9
M385E/&C5=CV3N;G>M<J;\\R?=_3^/C]/KLFN[9G!:[V:6W4TKJNG?XC<=U<R
M1M3=E7J5Z?YIQX]9WH-/'DMCGJI.I55FX6C4^@;ETZ>,4NX]&MJH%58I.M$S
MR5.Y4[35:MOKM25,5;54D,5QW=R>:+@V?"(B.5O4[GE4X+PX)CC;B>*.>)\4
M\;)(GIAS'IE')V*BD:ZPV16JZ)+4614MU8O%&)QA<OHYM]7P'2Q\W'DG^;&I
M^;!GX]<U.BWA"6B-5U^DKNVKHU5T+L)/3JN&RM[%[%[%ZAK^[4]]U;<+G1;_
M (O4*QS4>F%3S&HJ+ZT4]]4Z-O6FY)/NE1O\7:[=2IC171.[/.ZO7@YQ6)U'
M2PUIOU(G?PVUJ8+XZ>GO<0_(UX8$B\,'YNN:N4XGK1TE37U3:>CIY:BH?G=C
MB8KG+CCP1.XRS>L6U+Q;D]/\JT3OQ]?LZ?9'[8MD_K7?L.+6%:=E^F[W1:\M
M%15VBX00,D<KY)*=[6M\QW-50LL<7VG:+9(U/P_[;G'C59V  YK.P+Y::.]V
MV6AN,*2T\B<4ZVKU*B]2H5<U3;([)J"NMK*EM0VFDW.D3AGAGEGFG)?06R(6
MVWZ3>VI;?Z&!%A<U&52,;[%W4]>Y>2KW)VF7#:(G4L>2NXVB'>;^<GPC>;^<
MGPAS4W'<$Y!K4W4X)R-K5=;8>SK]DM5T&O[5N2-1)'/C=QQE%8[A\."S!#.P
M_24B5#K_ %\&[&C=RD1[>+E7F].[J3TKV$S&KEF)GLSXXU  #$]@!#.VRHU!
M8KG3W"V76NAM]4FXK(Y51L<B)R1.K*<?2BF7!B]:_1$Z2>R9@5-^_?4WO[<?
MCU'W[ZF]_;C\>IO?PR_XH3J6R!"NQ2JU#?[S/6W*[5TUNHVX5CY55LDCN2+V
MX3*_ 34:6?%Z-^B9VL3L !A4
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MGC">G\3(A=LI1X.WMV6GTU/T,@5=< !
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M-J>CMZ5\?0J[?G<E-'YL:>RZO5Z50GDU<^"V">FT]UB=@ ,*@
M                                                        QKE7
M4ULM]175\S(*2GC6665_)K43*J<13[3$J:9M;2Z1U5-;'IO1U<=$U4>WJ<C-
M_?5J\\XY 2 #2:6U79M4TTDMDK63K$N[-$J*R6%W8]CL.;ZT-V
M          I1X.WMV6GTU/T,A=<I1X.WMV6GTU/T,@6%UP $
M
M           /AT,3G*KHV*J]:M0^P!BU=NHZRFEIZJEAE@D:K7L<Q%14*];1
MMF5?IRHEN=D1]1:T=OHD>5DI^.>/6J)^=\/:6/"IE,+R,N+-;'/9J\GB4Y%=
M6\_-6"U:ALNH8XJ#6\*QRM;N17>G3$J8Y)(G'>3OQG]9YWO0=YL;(+K9)UN5
MN=A\%;0JN\G8JHG%/2F23]?[(Z*[K)6Z?6.AK5RKH,8BE7NQ[%?F[NLBFTWO
M5&SJZ/IU9+3*JY?2U#<Q2=Z?O:ITL/(G7\N?TES/4R<6>GD1N/G'U_\ 6XTC
MM;O=E1(+HGW4I45$_'.5)6IRX.Z_7DE[36TO3=^<R*.K6DJ7<HJI$8JKQX(N
M<+R[>M#A8+KH3:%&C+S RRWI^-Z9JI'ON[G^Q=G^<F36W[8K<((%GL5QAN#,
M*Y(WMZ-RIU87*HOS"\<;-/VXZ+?[?]?LZ&++-HWCGJA8!%14145%1>2H1YJ#
M:S9+'>:NVU5)<7STS]Q[HV,5JKW9>A"<-1JW052F%KK8LGG;CTS')WX7+57D
M:"]7.IO%SJ*^N<UU34.WY%:W"*OH&/V?6N[7G=?R,W+].DV\:9NIKC37;4-Q
MKJ&G6GIJB9TC(UYHB]:]Z\\=Y^Z7N-':M0T%9<Z7QNCADWI(<(N\F%ZEX+A<
M+A>>#2L7#@Y<JIM]<>GT_HYO\2GT-_U[^I6$T_K'1.I;U26N#3:)/.JHQTU'
M#NIAJKQPJKU=AVU5HK354Q&2V.WHB+GS(48OPMPI778][8]E_IO^C<6J.7RX
MC#:/3F=3'S=?BY?6Q]:&=7['6JY]3IF1N[C/BDSE_P!EW^2_"1;)0366X(VZ
M6Q=YBJBPU+7-1V%PO%%1?6BEN#$N=MHKI3+3W&EAJ85_)E8CL=Z=B]YAKR<D
M>9G_ "RS3Y("L:[/KI(UMUM]5:9E1$58YW/ASVY7+D]?PG$:R@M]'J6N@LDO
M2VYBMZ%^]O916HO/TJI,^I-CM+/O2Z?JUIWK_P!A49<SU.3BGKR0?J.V5%GO
M=7;ZU&)40.1K]QV4Y(O!?6=+V?EG)>8F9GLP99M6&O1Z]9^[Z]A\ ZVH8?4M
M\V\T9;(K[J>WVRI>^.*IDW'.CQO)P5>&?03-^!&T>^E?\#/W$4;*O;"L?]?_
M +JEKSD>T,^3%DB*3KLV<$]43M$_X$;1[Z5_P,_</P(VCWTK_@9^XE@'/]\S
M?B9M0B?\"-H]]*_X&?N/B?8A;5B<E/=ZQDG4Y[&N1/4F/UDMFAUKJ2GTO9)*
MZ=.DE5=R&+..D>O)/1UJ6.9G^%B8B%7=36:>P7VLME5QDIW[J.QA'MYM<GI3
M"FK-WJF\5NH+D^X7*1'SN3=\U,(UO'"(G8F33Q-WGHG5UG;Q9HMBZ[?#RQ[B
M>Z5=+;'I;O8:2X5=T6CDJ&=(D/B^_NM7V.5WDYIA?6;7\!C/?]WR3_C-ALFU
M_-<IV66]/1U1NXII\8W\)[%W?CDO7Z><KG'OS<\6GO\ L]5U,;0Q^ QGO^[Y
M)_QC\!C/?]WR3_C)G!Y]^S_B_9ZU"&/P&,]_W?)/^,?@,9[_ +ODG_&3.:F[
M7E]OJ&Q-M5SK$5N]TE+$US4Y\,JY./ M>9R+3J+?LDQ$*I:AM,]CO59;:M/Q
MM/(K%7&$<G4Y.Y4POK-<2WMKI'73H+U!9KI2.A;T53)40M:U6Y\U<HY>.5QZ
MT[".=,6J2\7JFI(Z>HJ&*Y'2MIV[S^C1?.5$X=1VL.7KQ]=OU>4X;"--_<W3
M\EVJ&8J;A[#/-L2<OA7*^C!)YS-/J+Q>".&#3=]9%&U&,:E.S#41,(GLSIFK
ME$7"IGJ4^?SVM>\WM\7N-?  !A4
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M.WMV6GTU/T,A=<I1X.WMV6GTU/T,@6%UP $
M
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MA?R5<?GEAREMM_A&E_K6?K+I'(]I8:8YKT1KRV,%IMO8 #EM@
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MM/IJ?H9"ZY2CP=O;LM/IJ?H9 L+K@ (
M
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M9^LND4OML<CKC2M8URN65B)A.O)= YGM68F:_K_PZO&^( #D-D
M                                                        'A'1
MTT4[IHJ>%DSO9/:Q$<OI4]P                       4H\';V[+3Z:GZ&
M0NN4H\';V[+3Z:GZ&0+"ZX "
M
M        !#'A"ZFZ*FIM/4K_ #I<3U.%_)1?,:OI5,^I"9S55NG+)75+ZBMM
M%OJ*A^-Z26G8]SL)A,JJ9Y&3%:*6ZI:_*Q7RXYI2=;4X!<#[T-.>\%J^21_N
M'WH:<]X+5\DC_<;GOE?DX_\ !K_BA%_@\ZFRVJT[5/Y9J*7*_P"-J?M?XB;#
M4T6FK)0U+*BBL]OIZAG%DD5.QKF\,<%1,FV-/+>+VZH=?BXKX<<8[SO0 #&V
M0KWX1G\:[=^A)^V\L(<IKC0U!K%]*MRJZZ)E.B[C*=S&M55YJN6KQX&QQ<T8
M<G5+!R:WMCF,?E4X%B/P'Z=]WW;XR/Z@_ ?IWW?=OC(_J&Y[UC?/_P *Y'RC
M_*OU#_TR#^L;^LNJ1K;-CMDMMQIJVDN-V;/3R-D8JR1XRBYX^9R)*-?E9XRQ
M6(^#L<##DPTFN0 !IM\.6VBZ6;JFPNIXU:RMA7I*=[N6]UM7N7]W8=2"Q.NZ
M3&^RGU\HZNT3RTM?!)3U+5PK'IA?3WIWFLHY-V3=7DXZ[:[J5-2:NG= _>H:
M/_D\&.3L+YSO6OS(AQ;'.8]KF*K7-7**G-%.KCQ_8U/Q?+\GE3[QU4\53=L?
MT/4ON$-\NT+H:>'SJ:-Z8=([J?CJ1.:=JX)L.:V=:B;J?2E'7*J>,M3HJA$Z
MI&\_AX+ZSI3F7WU3$OI<4UM2+5\2  \,@
M
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M%^Y[U\G9]<>4AHOW/>OD[/K@TF@$+^4AHOW/>OD[/KCRD-%^Y[U\G9]<&DT
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M!Q>SC:/9=H#:];''6Q^);G2^,QM9[/>QC#E_-4[0
M
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M '2R96SP-?8:L]-+_P#=+)@D  0
M                                                  I1X.WMV6GT
MU/T,A=<PZ>UV^GF26GH:6*5.3V0M:Y/6B 9@
M       !$GA1^U-5_I4'[1+9Y5--!51+%4PQS1JN=R1J.3X% @GP/OXG7S]/
M3Z-I/9X4E'34;',I*>&!KERJ1,1J*OJ/<
M     "IOA?\ \>;/_9J?2R%CMF7M<Z6_LNF^B:;JKMU%6/1]71T\[T3".EB:
MY43LXH9$;&11MCC:UC&HC6M:F$1$ZD0#Z
M     *4;/O\ K$TW]L3_ +3RZYAQVNWQU"3QT-*V=%WND;"U'9[<XR!F
M                            $>>$)[3VI/ZN+Z9A(9\3PQ5$3HJB-DL3
MO9,>U'(OI10*W^!K[#5GII?_ +I9,QZ2AI*/>\3I8(-_&]T4:,SCMP9
M
M                    #YED9%&^25[61L17.<Y<(U$YJJ]@'T")M=;=M,:;
M8L=OZ6\U:HNXE/YL*_\ BKP5/Z.\;C8EK>NU]I>LNURIZ>G>RN?!''!G",1C
M%3*JJY7SEX\/0!((-1JS45NTK8:J[WB;HJ2G;E<<7/<O)K4ZU52M-X\)34GW
M0W[;9;;34*KEC*ELDCW-[5<CFI\"?"!:T$=;'-J%'M$MU0GB_B5UI,=/3[V\
MU6KR>Q>M.[J^!210                            UU]OELL-'XU>*Z"C
M@5=UKI785R]C4YN7N3*D%ZZ\)&DHWRTFDK8^JG:JM6IKFK&Q%[H^#E]:M] %
MA0>-#*Z>BIY7XWI(VN7'+*IDX+:_M/HMGU# Q(/';Q5(OB](CL)CEOO7J;GA
MVJOK5 D,$0:OUYJW9_1V>ZZLI+576RMD2*ICH(WQ2TKU;O817/<C^".ZDRJ=
M624K)=*.]VFEN5LG;/1U4:212-ZT7]2]2IU*!F@
M        .9VAZSMNAM.R7:ZJ]Z;R1PP1^SFD7.&IV<E55ZD0Y'1FH]>:WTY]
MWK:W3]II)U?XG3U,,M0^1&JK<O>CVHU,HJ<&KVX E0$/;+ML4FHM43Z6U/;H
M[=?HGR1M6%RK%(]F=YN%RK5X*J<51<?#,(
M     /R1[8XW/D<UC&HJN<Y<(B)UJH'Z"+*[;#2W"_+8M!6J?4MS3._)&](J
M:-$X*Y9%SE$[<87J53N-,IJ-6RR:F?:FN<B='!0,D7HUZ]Y[U\[JY-3U@;L
M                               !51$RO!$*^7O;O55&U"WV'3$=%-9G
MUD-'+4RL<YTJND1KW,5'(B)QPBX7.,]8%@P
M                                                         /F2
M-DL;XY6M?&]%:YKDRBHO-%0KO)X3U*R1[/O6G7=54SXZGU"6]EFMH]?:86\1
M4+J%J3O@Z)TG2+YJ(N<X3M B?PPXHVV#33FL:BLJ)6MPF,)NIP^9#=^"1[6M
M;_:<GT<1I_#$_B]IW]*D_80W'@D>UK6_VG)]'$%^"3M0:8I+_=;34W14GI+<
MY\S*-[$6-\RHB-D=GGNIO83'-V>HU.U^P6V^;/+Y%<H(E\6I):B&5S4S"]C5
M<CFKU<N/:F4.T(DVV76X7Y6;/])MZ:[W%J.KI$7S*2FSQ5Z]6]PX<\>E B)O
M!#HJF375UK8T<E)!0+'([JWGO8K4_P!ER^HMH<ELYT9;-G^F8K91O:Y[G(ZH
MJ9,-=/*N$SW=2(GZUY]:                         !R>T_63-":6?>I:
M)U:ULK(NB;)T:KO*O'.%["'V^$_2JY$^]:?C_P#&I]0"Q+X8WR,>^-CGQY5C
ME:BJW//"]11K;^QL>U_4C6-1J+-&["=JQ,55^$O-&[?C:[&-Y$4HWX0?MPZD
M_K(OH6!87<M7\%T?]2S]E"E.U&]/U!MMK9I7*Z*&XLHXFKR1D;T9A/2J*OK4
MNM:OX+H_ZEG[*%#K] ^EVL5\,J*CV7IZ+G^O4$+->%6Q';*U54RK:Z%4[EPY
M/\S1>"#?):O35YLTSU<V@G9-%E>3947*)W;S%7^\;[PJ?:JD_38?]XX;P-Z=
MZU6J:G"I&C*>//:JK(O^7S@^"S( "                         .;VBZI
M9HS2%=?9*1U6VE5B+"U^XKMYZ-YX7'//(A?RH*7^2T_RU/J ;/PNK/6UND[3
M<:5CY*:@J'^,(U,[J/1$:]>Y%3']Y#CM@.V6ATU:6Z<U2KXJ")SG4M6UJN2/
M>57*QZ)QQE55%3//L)EVG[1[9I31%)<+A1)6376)$@H'JBMDWFHKD>JI[%$<
MF>''*)UD 5>QN[WW1#-8V:GIH)JO>JDLU.UV&0+['HU<JJJJB;V[V*F.P+#L
M=DFAKMJ':C4;0;A2OM]GDJIJVD9+A))^DWMWAU(B.RJKSZLEDRG?@W[0*^P:
MNH]/54SY+/<I>A2)ZYZ&9WL7-[,KA%3OSU%Q   "
M     !%NUO:]#L[O%%02V>2O6I@Z='MJ$CW?.5N,;J]@$I%8_"FVA5/W0^\^
MU3.BIXV-?7N8N%D<Y,MC]")A5[<IV':[.=NU/K35U%8H[#+1NJ4D5)G52/1N
MZQ7<MU/S<<RMNU9\E3M4U/TZKO+<YHTS^:CU:WYD0+"P6PB]Z%T;HZCI:B_V
MN*]5Z)/6.=*F4<OL6*[DFZBHF,\%WB=()8YX62P2,DB>B.:]BHK7(O)45.:$
M'>$WI&TQ[-67"BH*:GJ;;-$UDD4:,7HW+N*U<)Q3*M7U&I\$+459545ZL-5*
M^2FI-RHID<N>C1RJCFIW91%QVJO:!8H !
M 0)J/PC::RZ@N=K=IN:9U%4R4RR)6(W?W'*W.-SAG!N+5MLBN^SK4VI8+.^E
M?:MR-D3YDD1[WX1JJJ(F$153/=D&G1:VKJC4M];HFRS/C:YB37JKC7"T].O*
M)%ZI).7<W*E4Z2FAHMND=+2QMBIX-1I%'&U,(QK:G"(G<B(3CH':SH#3-E6*
MHNU75W6KD6IN%8M')F>=WLEY>Q3DB=2(0"M\H?PM.OW2.^YJWM:[?W%ST73[
M^<<\[O4%A?H&LTQ?:'4MBI;O:9'R4-2BK&Y[%:JHCE:O!>*<44V80
M
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MY417*Y<KZ54V@ 0
M
M
M
M
M
M                . U!M.H*+4WWMV&@J[_?TSOTU(K6LAQSZ21RX;CAVXZ\
M =^".KMM!O.GJ9:S4^BKA2VUO&2IHJJ.KZ).U[4W51.\R=!;3+;KBX7R*P4T
M\M-;8HGMF=YKIW/1_FHU<8QN8RJ\<]76'> B'4^W.WZ6N"4-_P!,:@HJE6[[
M6R,A5'-Y914D5%3@O)3VTUMJI]3LG?8-):EKF0JB2.BBB5K57DBKTF,]P$L
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M;4WZJ5KY,]#31)O2RX_-;V=ZX3O(HC\)RRK5[LFG[BVFS_I$E8K\?T>7S@6
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MN7*Y%7ANJO8=L
M
M
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MRXL,5Y\#G^ ]2_I,/[+BPP)  $
M
M
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MI?TF']EQ88$@ "
M
M
M                                     $2[5]C4>T#4L%W=?'V]T5,V
MG2-M*DF=USG;V=]/SOF  ZS3UAU505]-)==8I<Z*-%1].MKCB=)YJHF7HY53
MCA>7'!UP    "%-N>SR_W_5%DU/IU*>N?;$9O6ZHD1B.W)%?E%7S51>2HJIR
M3GU !O:;:PYN[#<=*7>"MY.BBFII&Y[$=TJ9^!#4ZOTM>MK%9:([M:V6+3U%
M*L[W2SLFJJC*8W6HQ5:Q%3M<O;U !4Q11MBC9'&U&L8B-:B=2(?0 0     "
M-]4Z%U5J*VU]MJ]=;ENJ\M?"RTQHNXJYW=[?SW9ZP ,C9!LV9LYHKE3QW1UP
M\<D9(KG0=%N;J*F/9+GF2
M
(       !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g762905g05g90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g05g90.jpg
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M(^'_V@ , P$  A$#$0 _ .J41$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M> '''B035%K]/"O%BM_W9>Q]R,##4EC=UO2$=T / #D+8("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(L&ZWBVVB(276
MX4E%&>3JB9L8/[R$&<BC5+K[2-5-T5/J>ROD/ -%;'D^3BI'%(R6-LD3VO8X
M9#FG((\J#Z1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MZ%V_!/$[<EA=X6N^0<#D<!X%'M/;(-/VF]4]UJZJ[WJMICFG==:KIA">HM
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MHM-7>JIK"&3P4<TL;NV9CNN:PD'!?X0I5L;[UFE_,(_H03%$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MRLWA@[KAD9_>@]T15!4W^[Z:V_T]KN5PJ)M/7ZF/:D4KLLAF Y-\>\TC'_W
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M6HK;-7OKJ]LC96S2-=&!)('G #01Q:.L\%.40:+66E+1K&S/ME^I1/3D[['
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M()#;J1M#114S9JB=L8P)*B0R2.XYXN/$K)1$!$1 1$0$1$!$1 1$0$1$!$1
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M]7X_VCO(@BVR?O9:5]&4_JVJ5**[)^]EI7T93^K:I4@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M\N>X=>'%X!__ !1+&U]14NB=LFB;Y98(Z2.\S.M]=%"T,9+DM <0.&>[!\K
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M@_<NI]4Y<?LH:8L;F%G+P*UAL+5B.?PSRY-==R*.KKW4;V_?OI'NA[:KZ_\
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M=5);WW"IF>UD%'2W&1TDN3Q( =R Z_(.M7O?[':]06]U#>Z&GKJ5QST<S-X
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MK9C:SPZ\1$7EU\1$0$1$!$1 1$0$1$!$1 1$05IV130[9?6M< 6FJI00>O\
M#-7,G:%)_P"E@_Y873G9#][&K\ZI?7-7-B[7"Z::J*N<*U^9B88W:%)_Z6#_
M )87X^@I-QW_ &6#E^K"RE\O]H[R+J?+H\H5_BGS=:[*.]GI7T93^K:I4HKL
MH[V>E?1E/ZMJE2\BZ(B(@(B((OM4[VFJ_1=3ZIRY(C]HWR!=;[5.]IJOT74^
MJ<N2(_:-\@78X3^_;W5L1X/I$1=E6=)=CMWLZ?SRJ]:Y66JT[';O9T_GE5ZU
MRLM>1N9YW=&GH(B+!(B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("I#LG?
MQ&E_.)_5A7>J0[)W\1I?SB?U86_"ZU&\,*\LJ11$7JE!CW#\CE\@^E=RCD%P
MU</R.7R#Z5W*.07"XKJ4[+>'RR(B+EMXB(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@J[;MLYN.T.@M,%K
MK*2E=1RR/>:C>PX.  QN@^!5(_L;M5R-W7W^UN;X"^4CZJZL1!RHWL;]6,:&
MMU!;&M'("24 ?_BKRV-Z/K]$:0=:;K5PU=0:E\W20EQ;NN#0!W0!ZE.40$1$
M!$1 1$0$1$!$1 1$0:;6OO-OWF$_JW+3[&^]9I?S"/Z%N-:^\V_>83^K<M/L
M;[UFE_,(_H03%$1 1$0$1$!4[V2ON+ISTB?42JXE3O9*^XNG/2)]1*L[6>-V
MG$:5>T^BD41%VGE6'>/<FL^*=]!7:U%^1P?%M^A<4WCW)K/BG?05VM1?D<'Q
M;?H7.QF:'<X5DJW>R(BINH(B("KS;_WJ;Q\93?S$:L-5YM_[U-X^,IOYB-94
M9H1/1S*B(O7N<+JG8OWK-->:-^DKE9=4[%^]9IKS1OTE<?BWZ=_99P_BFB(B
MXRR(B("Q+S[D5WQ#_JE9:Q+S[D5WQ#_JE!Q);/<VE^*9]"R5C6SW-I?BF?0L
ME>NMY(V<ZKK(KZ[&/WM:@]*?Y$2H57UV,?O:U!Z4_P B)<_BFE&_M+=A\TKC
M1$7!6Q$1 1$05K?=L>FK5=J^UU=-=)9J65T$O1TP<PN', [W$*NM5ZNV:5NE
M[Q2VG1T<%QGI)8Z:46:%A9*6$-=O#B,$@Y')0O77O^U1Z2E_P6E78L\-HN6X
MKF9^ZM5?FF9CDN>U;0]F5MFIZFCTD::LA +9X;/"Q[78QD.'$*P=$;2K)K&Z
MS6ZU15\=1%"9W=LPA@+0X-X')ZW!<KJS.QS[XE=Z*?ZV-88K 46;<UQ,IMWI
MJJY2Z11$7*6!$1 1$0<S=D'WS6^BX/63*NU8G9!]\UOHN#UDRKM>DX?^/3W]
M5*]GD4AV;=\G2WGO^6]1Y2'9MWR=+>>_Y;ULQFA5LQM9X=>(B+RZ^(B("(B
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M>LTUYHWZ2N5EU3L7[UFFO-&_25Q^+?IW]EG#^*:(B+C+(B(@+$O/N17?$/\
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M CIW8W96,SC). X>7N@.M+50:RV/76Y4MEL$VI=)5<YJ(64SCTT!/#& ">0
M/ @X!R.(7MJ;5&M]HMHJ-.V31%?9H*T=%4UUTS&UD9/=8!:/[LGGPZT2\.R
MU<R\Z%T@RW&K-LU#4,DF9 W,SXF[I,8'6[+AP\+0OJJU1HRHTVZQG9IJ9E 8
M^C:&V=H<WAC>#M[.]U[W/*D6O-F%14;.+!;--SC[L:=='/1R2=STKVCNAX 2
M>(ZL@#EQ6/+M.U@^UNHH=G-]9J$LZ,/,1[4:_EO])RW<\<?)GK0173E1=G]C
M'J:COE/602T DIX!51.8\P]PYO!W' +B/(,=2F^Q'0^GZ?0.G+G+:Z2>Z2Q,
MK#62QATH>>+<./$ #  '@7S<]/ZI]@J[VV^U4UXU'4T[G%C '%I)&(VX'=8
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M(1$7I%)+MCG?6T[Y:CU#UU>N4-CG?6T[Y:CU#UU>O.<1UY[+MG((B*BVB(B
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M*5CSG>&\2'$9ZCPXGPE="*D=N.TB^6[4%%H[0T3GWRJ:'22L8'O9O9W6,!X
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M.>^3<O1$7KGK3B,C*%KHB+GLA<B[3>^7JGSQOJ8UUTN1=IO?+U3YXWU,:O\
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MLLQ$10"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M=FATL'ISN]$1%06VWV-^]>N]*UOKW*=*"[&_>O7>E:WU[E.EMATJ>@J\V_\
M>IO'QE-_,1JPU7FW_O4WCXRF_F(UE1F@GHYE1$7KW.%:VSGWD6;X@?2JI5K;
M.?>19OB!]*H8S-3W]F^QXI&B(JBPV^R/WQ:O_;I/5N5FJLMD?OBU?^W2>K<K
M-7+N9Y9P+$O/N17?$/\ JE9:Q+S[D5WQ#_JE8#B2V>YM+\4SZ%DK&MGN;2_%
M,^A9*]=;R1LYU7613[9'[GWCSW_*C4!4^V1^Y]X\]_RHU6QF6-_:6VQUE.T1
M%166'+[YM)^EH_5R*\%1\OOFTGZ6C]7(KP7/Q.=E'01$6A+CS77O^U1Z2E_P
M6E6ZUU[_ +5'I*7_  6E7J<)HT[*%S-(I%LT]^<OF#_6,4=4BV:>_.7S!_K&
M*,7I_P#B;.9:Z(BYRVU=^YVCTM0_S+%?"H>_<[1Z6H?YEBOA4,3G94]!$15T
MN9NR#[YK?1<'K)E7:L3L@^^:WT7!ZR95VO2</_'I[^JE>SR+,T][ZK'YU_T.
M6&LS3WOJL?G7_0Y;L3I2QMYH7:B(N8N-;J7WN77S27ZCE<6E/>O9_,X?J!4[
MJ7WN77S27ZCE<6E/>O9_,X?J!4L5UAE2VB(BJI43V3WY7I/_ (OZ(E3"N?LG
MORO2?_%_1$J87H.&:/=3OYA>%7^*;\;']<+W7A5_BF_&Q_7"N7].K:6NC-#H
M!$1<I=%+]B_>WM7[51Z^11!2_8OWM[5^U4>OD53%=(32FJ(BILE:]D/WL:OS
MJE]<U<V+I/LA^]C5^=4OKFKFQ=SA62K=5Q'6!?,GXMWD7TOF3\6[R+JST5X6
M_H7WF6/S.+ZH6\6CT+[S+'YG%]4+>+ATY87Q;O8[^7ZO\_B_EXUI%N]COY?J
M_P _B_EXUHQ.1-*R41%19(OM4[VFJ_1=3ZIRY(C]HWR!=;[5.]IJOT74^J<N
M2(_:-\@78X3^_;W5L1X/I$1=E665LJ]Z3?.9_6.4O40V5>])OG,_K'*7KB0O
M1T%F[.>^3<O1$7KGK"6;LY[Y-R]$1>N>M.(R,H6NB(N>R%R+M-[Y>J?/&^IC
M772Y%VF]\O5/GC?4QJ_PW7[--[(CB(B]$IM_L[]^L/F4WUHU;2J79W[]8?,I
MOK1JVER;^K5_?"%NUD@6IU/[GTWI"B_FHEMEJ=3^Y]-Z0HOYJ):+F2=FR%](
MB+ELQ<L[<.^I=O-Z?ZA74RY9VX=]2[>;T_U"KO#M>._HU7LDH0B(O2*3::.]
M^MF_:E]4Y7*J:T=[];-^U+ZIRN5<O$:E7]\%NUE%H]<^\V]>:2?5*WBT>N?>
M;>O-)/JE5ZLLMD+\IOR:+]@?0O1>=-^31?L#Z%Z+E,Q4AV3OXC2_G$_JPKO5
M(=D[^(TOYQ/ZL+?A=:C>&%>65(HB+U2@Q+I[GS>3_%="#DN>[I[GS>3_ !70
M@Y+G8O4[?]6;.41$59N2O8K[P8//*W^:E4Y4&V*^\&#SRM_FI5.5R9ZRS$1%
M (B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B JHV@S[.[AK^V4^JJQM!J"UOAJ8)GDQLD;O;[6.>1NEN1R.#Q.#Q*
MM=5YM'V3Z7UI4/N-W[8I*\1AIJX)MW#6\MX.RW \@\J#5[0]C6GMH%UCOC*^
M:DJ9F-$DM+NO9.T# =QZ\8&0>0"G.B-*VW1NGH+/9F/%/&2YSY#E\CSS<X^$
M_P" 7)6H1-LNN!^\C:)#7=WW5-3;QQ^T!O1.QXSGQ*;:+[)*MAD@@UC:XYH'
M'!K*,%CP/"6'@[Y"/(B73J+QHJJ&NHX*NDD;+3SQMEBD;R<UPR"/*"O9$"(B
M B(@(B(/F61D43Y)7M9&P%SG.. T#F25I;7J_3EVKC1VR_6NKJ^/X&&J8]Q\
M@!X_(J8[+K4E31VBSV"DE<R.N<^>I#3C?:S :T^(DD_U0HCM?V4T&@M#62^V
M6HJV72&:*.ID,GMGEI=OMQ[4AS>&.H^+*)=8HHSLROTFIM!6.[U!!J*FF;TI
M'7(W+7'^)I4F1#3:U]YM^\PG]6Y:?8WWK-+^81_0MQK7WFW[S"?U;EI]C?>L
MTOYA']"#RVU=ZS4?F_\ U!<UKI3;5WK-1^;_ /4%S6@(B(AT7L$[U-E_;J?Y
MF53]0#8)WJ;+^W4_S,JGZ)%3O9*^XNG/2)]1*KB5.]DK[BZ<](GU$JSM9XW:
M<1I5[3Z*11$7:>585Z]R:SXIWT+HBE_)HOV!]"YWO7N36?%.^A=$4OY-%^P/
MH7,QV:'2P>G.[T1$5!;;?8W[UZ[TK6^O<ITH+L;]Z]=Z5K?7N4Z6V'2IZ"KS
M;_WJ;Q\93?S$:L-5YM_[U-X^,IOYB-949H)Z.941%Z]SA6MLY]Y%F^('TJJ5
M:VSGWD6;X@?2J&,S4]_9OL>*1HB*HL-OLC]\6K_VZ3U;E9JK+9'[XM7_ +=)
MZMRLU<NYGEG L2\^Y%=\0_ZI66L2\^Y%=\0_ZI6 XDMGN;2_%,^A9*QK9[FT
MOQ3/H62O76\D;.=5UD4^V1^Y]X\]_P J-0%3[9'[GWCSW_*C5;&98W]I;;'6
M4[1$5%98<OOFTGZ6C]7(KP5'R^^;2?I:/U<BO!<_$YV4=!$1:$N/-=>_[5'I
M*7_!:5;K77O^U1Z2E_P6E7J<)HT[*%S-(I%LT]^<OF#_ %C%'5(MFGOSE\P?
MZQBC%Z?_ (FSF6NB(N<MM7?N=H]+4/\ ,L5\*A[]SM'I:A_F6*^%0Q.=E3T$
M1%72YF[(/OFM]%P>LF5=JQ.R#[YK?1<'K)E7:])P_P#'I[^JE>SR+,T][ZK'
MYU_T.6&LS3WOJL?G7_0Y;L3I2QMYH7:B(N8N-;J7WN77S27ZCE<6E/>O9_,X
M?J!4[J7WN77S27ZCE<6E/>O9_,X?J!4L5UAE2VB(BJI43V3WY7I/_B_HB5,*
MY^R>_*])_P#%_1$J87H.&:/=3OYA>%7^*;\;']<+W7A5_BF_&Q_7"N7].K:6
MNC-#H!$1<I=%+]B_>WM7[51Z^11!2_8OWM[5^U4>OD53%=(32FJ(BILE:]D/
MWL:OSJE]<U<V+I/LA^]C5^=4OKFKFQ=SA62K=5Q'6!?,GXMWD7TOF3\6[R+J
MST5X6_H7WF6/S.+ZH6\6CT+[S+'YG%]4+>+ATY87Q;O8[^7ZO\_B_EXUI%N]
MCOY?J_S^+^7C6C$Y$TK)1$5%DB^U3O::K]%U/JG+DB/VC?(%UOM4[VFJ_1=3
MZIRY(C]HWR!=CA/[]O=6Q'@^D1%V5996RKWI-\YG]8Y2]1#95[TF^<S^L<I>
MN)"]'06;LY[Y-R]$1>N>L)9NSGODW+T1%ZYZTXC(RA:Z(BY[(7(NTWOEZI\\
M;ZF-==+D7:;WR]4^>-]3&K_#=?LTWLB.(B+T2FW^SOWZP^93?6C5M*I=G?OU
MA\RF^M&K:7)OZM7]\(6[62!:G4_N?3>D*+^:B6V6IU/[GTWI"B_FHEHN9)V;
M(7TB(N6S%RSMP[ZEV\WI_J%=3+EG;AWU+MYO3_4*N\.UX[^C5>R2A"(B](I-
MIH[WZV;]J7U3E<JIK1WOULW[4OJG*Y5R\1J5?WP6[646CUS[S;UYI)]4K>+1
MZY]YMZ\TD^J57JRRV0ORF_)HOV!]"]%YTWY-%^P/H7HN4S%2'9._B-+^<3^K
M"N]4AV3OXC2_G$_JPM^%UJ-X85Y94BB(O5*#$NGN?-Y/\5T(.2Y[NGN?-Y/\
M5T(.2YV+U.W_ %9LY1$15FY*]BOO!@\\K?YJ53E0;8K[P8//*W^:E4Y7)GK+
M,1$4 B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("I#:MLNU1K[6SW-O0H=-,BC#6/E<\;^.Z+8@<9\9(4BVXZ&O^
MMJ&U0Z;N-/0R4LDCY3--)'O @ 8W&G/(\USUM$V<:ST'8X[K>+]!-3R3MIPV
MEK)G.WB'$'#FM&.Y/6B87[H[83H[3VY+5TK[Q5MX])78<S/BC'<X\N5N=K6@
MH]9Z*=9K?%0TU5&^-U-+*S#8 '#>W=T$C+<C \*H2Q[%-?7FS4%SI=1T#(*R
M!E1&V2MJ X->T. .(R,X/A*O[8WI6[Z/T@ZV:@K(:RM-2^7I(97R-W2&X&7@
M'J/4@D&C+1)8-)6>T33-FEH:6.G=(T8#BUH!(\7!;E$1 B(@(B("(B#ESLP(
MW1ZDTU4.'X-U-(T'QM>"?K!3SLI)X_8EB(<")JR ,.>?<N/#Y I/MGV=Q[0M
M.14T4[*:YTCS+2S/!+<D8<QV..#PXCD0/(JADV4;3=4LM5EU==::.Q6XAL;N
MD:\AH&,@-&7.W> +S_BB5M]CW"^#8]IQD@PXQRO'D=,]P_N(6-5:YUQ%4RQP
M[,JJ:-CRUL@NL0WP#P.-WAE6#9[=3VBU4=NH6;E+2Q-AB;X&M&!]"RT0J&]Z
MOUY<K+<*#V,:N/MJGD@W_NK$[=WFEN<;O'&>2P]%ZDUOIS2EJLSMFU?4&BIV
MP&45\;=_ YXP<?O5U(@I+7&HM<:FTG<[,S9O74SJR+HQ*:^-X9Q!SC SR\*J
MQNC=H[N6D)/EF8/^I=@(@XO@LVMI[]4V6+36]<Z>)L\L'3,RUCN .=[']ZV7
MWE;2/@B[YQ']I7A8HWCL@]32%C@PV>G =C@3O#K5G(*0V?7?7>D](T-EDV<U
M=4^F,A,S;C"P.WY'/Y<<8WL<^I2+[^M<?[,*S^U8?]%9J(*R.NM<X.-F%9GT
MK#_HH1M/EV@:VH+=3Q[/9Z%U'4]L;SKC%*'=PYN,=SCVV<^)="(IB9B><(JB
M*HF)Z2X^^\?:/\$7?.(_M)]X^T?X(N^<1_:78*+;]1<\U;Z*Q_%Q9J72NNK=
M8:ZKNVFG4U#'&3+,9F'<:>&<!V>M6'07#:;/0T\U-H>*2"2-KXW]LM&\TC(/
MMO K8VX,=)LHU*UC2YQIN  R3W04BTB"W2EE!!!%%""#^P%KKKFY]ZFRC#VJ
M(Y4PHSMO:E\ XOG3/MIVWM2^ <7SIGVUT2BPY0R^51Y*/T1>]H&F[/+12[-Y
MZJ22JFJ72-N<48S(\OP!@\LXYJ0??WKW_9;4_P!KQ?95H(I;%7_?WKW_ &6U
M/]KQ?96@U_<MH&L-(UMF9LYEHS4.C(F==H'[NY(U_M<#.=W'/K5WHD3R^XX^
M]CG:3\%!\\A^VGL<[2?@H/GD/VUV"BM_77_Y-?RJ/)QW+L\VCQ1/DDTJ Q@+
MG'MN'@!_76WT [:!4Z0MDEATG!6VT1ED-0:N-A>&N()P7@CB#U+J2Z#-LJP/
MU+_JE0/L>6/CV0:?9(US'!LV0X8(_#/6NO%7:\U3*FBFGI"N.AVI_ >G^?1?
M;3H=J?P'I_GT7VUT8BQ^=7YLN4*(T34[1].5MWJJC9YVW)<'1'#+K!$&;C2W
MKWLYRI5]^FT+_9;)_;L'V59J+7,S,\Y%9??IM"_V6R?V[!]E>-9J[:%4T<\'
ML7R-Z6-S-[[N0'&01GVJM-% XZI]FFTB"GCB&E00QH:":R'C@?MKT]CG:3\%
M!\\A^VNP45J,;?B.45,/E4>3C[V.=I/P4'SR'[:]]#4^O*&OOUGMFEX:JMI)
MXY*R-U5&TPE\8W1G>P<AF>!*ZZ58[.8WMVM[3WN8X-=+0[I(X'\$[DL:\5>K
M^U52::*:>D(#T.U/X#T_SZ+[:=!M3^!%-\^B^VNC$6'SJ_-ERASE#1;3?NO:
M:RIT-$]E!5-JNCCN$+2\AKFXR7''MO K!^_/:%_LN?\ V[!]E68BPJJFJ><B
ML_OSVA?[+G_V[!]E/OSVA?[+G_V[!]E68BQ')NH-#;1[KJ&Z7-FD.A%=4NJ.
MB-? _<WNK.\,_N"P?8XVD_!5OSR'[:[ 16:<9>HB*::OM#";=,SSF''_ +'&
MTGX*M^>0_;33=JUGI_7;*&?2W3W:>@<^.D%;$S,6^,OWLD<VXQS78"K&XQO/
M9%6F0,=T8L$@+L<,]*>&4JQ=ZJ.551%NF/O$(=N;0_\ 9\[^UX$W-H?^SYW]
MKP*_T6'S[GFRY0YVKZ':'5FC_P#X"YG:]7!5>ZT!WNCD:_=\6=W&>K*GGWZ;
M0_\ 9:[^WH/LJS46NJN:YYRE67WZ;0_]EKO[>@^RGWZ;0_\ 9:[^WH/LJS46
M(YDVB:>VC:PU.V[LT1VCBE93&)UR@E]JY[M[.6_I\L=2C?L;;2?@NSYY#]M=
M?HK%O%7;=/PTU<H8313,\YAR![&VTGX+L^>0_;6#5Z;UQIJ]6&:X:>CCGGK6
MPTC#4QN$LI! ;D...?,X"[-58[98WOOVSHL8YP;J"$NP,X'A*FK&7JHY341;
MIB><0@?:VU/X$TOSZ+[:=K;4_@32_/HOMKHI%K^=7YL^4.;;A;-J-;05-*_1
M=,UL\3HBX5T60' C/M_&IQ:M2[2*"V4=&-FS)!3PLBW_ +LPC>W6@9QCQ*VD
M6%5=5745?]^&TG_9G'_;4/\ HGWX;2?]F<?]M0_Z*T$6(YTVG6_:1KB2U/.A
MF4)H.EQ_WG#+O[^[XQC&[_>H7[&VTGX+L^>0_;77Z+?;Q-VU'PT3RAC5135]
MYAR![&VTGX+L^>0_;6IU3I#6^GK+-<[W8&4M! ^,OE[9C?@EX X-<3Q. NU5
M6?9(1OEV07ID;'/<7T^ T9/X]BSG&7ZHY34B+=$3T0 4^U(@$:*I<'C^71?;
M7[VMM3^!-+\^B^VNB(?Q3/V0OI:OG5^;/E#G9M)M3<<?>72#RU\?VU(M&5^T
MC36FZ2TC9_#4] 9#TOW7B9O;SW/Y8./;8YJYT6-5=56:167WV;2/]F\']MQ?
MZ)]]FTC_ &;P?VW%_HK-18"CMH4FT?6&F9K.[04-&))8I.E%VBDQN/#L8X<\
M8YJM?8RVD?!J'Y[%]M==HMUK$7+4<J)Y,:J*:NL.1/8RVD?!J'Y[%]M>%;LZ
MVATE%45%1IV%D$,;I)'=N1'#0"2<;W@782U6K03I6\@ DFBF  _8<MOUU_\
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M+0PP2M%)(0'M8 1D#!XA6AH[55JUA:#<[#.^>C$CHM]T;F'>&,C#@#UA03V
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M3@YKP>L$(/=$1 1$0$1$!$1 1$Y("+0TNL]-55T^YM-?[7+7[VZ(&53"\N\
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MI*&^4VO=-W"KD- UN_"TY-*!^>P=;#^</&2<@G$9TM40;>=H< U.^2FI+=;
M[M*"3=$D@< ]S? "7 GKX 9X95YZ)VG:4UI&V*V7"-E6\8-%5 1R^0 \'?U2
M52VU[9U<=GU];K?9^7P4L3^DFAB&>U2>9 ZXCUCJSX.1+7[7-F=3LNJZ/5NB
M:VIBHX9FM<USLOIWGEQ_.8>1!\.#G*Z.V>ZB&K-%VF]A@C=5P[SV#DUX):\#
MQ;P*Y_%^UUMTTX;10T=GHK=',P5U0V;!R.+<L)+@WKX Y(Y\"NA]%Z>I]*Z6
MMMDHWNDBHX@S?<,%[LDN=CJRXDX\:#=(B(@1$0$1$$%VYNB9LFU,9WEK>UL
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MW^*GC9'$R*&-C&-PUK>E8  !R "IW2VU>FT/L6M%KLNY5:EJ3.0S&\VF!E>
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M*WI:B1K^(<1NL!;^<TY>"/&%9.L]46W2&GZB\7F4LIHL -8,OD<>36CK)_\
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MH.8W'FUX .'<,C@3GF&AU'>])6+9@VP[/[O55^H[M-'VU4P1O9//G.\UY(R
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MP;Q#71N+CW3>+20<G!\2#%LNI=I.SIU7H:EHI)JJ23%$3$93'D\70GD6N\?
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M$1 1$0:;5^F;9JVQ5%IO4 EII1P(X.C=U/:>IP_^.16+H'1UKT18([59HR&
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MPNV(?UT?\03MB']='_$%7OL);/O@\/GE1]M/82V??!X?/*C[:"PNV(?UT?\
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M(.04'ZB^998XF%\KVL:.MQP$CD9*P.B>U[3UM.0@^D0G R>2^(IHI@3#(R0
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M1!R%^H"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M#E(6#>'RKU1$&#7V>V7&1LEPMU'52-X-=/ UY'D)"S(XV11M9&UK&-&&M:,
M#P +Z1!AW"U6^Y;OW1H*2KW?:]/"V3'DR"O:DI*>B@$-'!%3PCDR)@8T?(%[
M(@(B(/"NHJ6O@,%=305,).3'-&'MSY"OEMOHVTT=.VDIQ3Q^TB$;=UOD&,!9
M*(/*6F@FC;'+#&^-O)KF@@?(ON-C8V-9&UK6-& UHP %](@UHL%G%5VR+3;^
MV<[W2]K,W\^'.,K9(B# KK-;*^9LU=;:*IE;R?- U[A\I"SF-:QC6,:&M:,
M 8 "_4084]HMM16-JY[?1RU;<;LSX6N>,<L.(RO=U+3NG$SH(C,.4A8-[]Z]
MD08U=04=PBZ*OI:>JB!SN31AX_<0E!;J*W1F.WT=/2QDY+8(FL!^0!9*(/F6
M-DT;HY6-DC<,.:X9!'C"P[?:+;;GN?;[?1TKW<'.@@:PGRX"SD0%5O9'6"Z:
MCV?1T-CHI:VK%;'(8H\9W0U^3Q\H5I(@@VS/3;(=FVG;?J.U0.JZ6#==#51-
M>8W;Q\.<*<,8V-C6,:&L:,!H&  OU$&%+:+;-6MK);?1OK&XQ.Z%ID'];&5[
MFEIS/TY@B,WZS<&]X.?->R(,2X6N@N6Y]T:&EJ]SBSIX6R;ODR."]'T5*^..
M-]-"Z.,88TQ@AH\0ZE[H@      #@ %KX;':H:OMN&V4,=5G/3,IV!^?#O8R
MM@B#YEC9+&62L:]AYM<,@_(OR&&*!FY!&R-G/=8T ?W+[1!XQ4M/%*Z6*")D
MCN;VL )\I7C<+5;[B6&X4%)5&/VAGA:_=\F1P68B#\C8V-C61M#6-& UHP %
M^HB##^Y5O[?[>[0I.W?_ %'0MZ3^+&5[QTT$<SI8X(FRN]L]K ''RE>J(,>N
MH:2OAZ&OI8*F+.=R:,/;GR%*&AI*"'H:"E@IH<YW(8PQO[@LA$'C)2T\DS99
M((G2MQA[F N&.7%>KVM>TM> YKA@@C((7ZB#S@IX:=I;3PQQ G)#&AN?W+\J
M*:"H#140Q2AO+?8'8_>O5$ # P.2QJ^@H[A"(J^DIZJ('.Y-&'C/D(62B#PH
MJ*EH(!#0TT--"#D,AC#&_N"^JJGAJX'P54,<T+QAT<C0YKO*"O5$&)!;:&GI
M>U:>BIHJ;.>B9$UK,^'= PLF.-D3 R-K6,;P#6C "^D00;;?::Z][+KY;K33
M255;.V(1PQ^V=B9CCCY 2M1L,TK-;]E]':M4VEC9V5$KS3U<;7XRXD'!R.2M
M!$'Q!#%3PLAIXV11,&&L8T-:T>(!?-5305<#H:N&*>%WMHY&!S3Y05ZH@Q;?
M;:&W1N9;J.FI&..2V")L8/R +VGIX:AH;40QRM!R ]H=C]Z]$00;:EJ#4FF;
M512Z/T_]V)'O,4D38WNZ(;O<G#.KJ_<JWV#Z U =:7'6VMJ5]-6S;Y@BE #S
M)(>Z?N_F@#+0#X?%QZ!1 6!76:V5\S9JZVT53*WD^:!KW#Y2%GH@_&,;&QK&
M-#6-& T#  7E!2T].YQ@@BB+N98P-S^Y>R(,>NH:2OAZ&NI8*F+.=R:,/;^X
MK]HJ*EH(!#0TT%-"#G<AC#&_N"]T0>,]+3U!::B"*4MY%[ ['[UZ2QLEC,<K
M&O8>;7#(/R+Z1!\0PQ0,W((V1LY[K&@#^Y8M/:+;35;JNGM]'%5.SO31PM:\
M^5P&5FH@\8J6GAE=)%!$R1WMG-8 3Y2D-+3P/<Z""*-SN98P G]R]D0%C5]O
MH[A$(KA24]5&#D,GC:\#Y"%DH@QJ"WT=OB,=OI*>EC)R601M8#\@"]IHHYXG
M131LDC<,.8\9!'C"^T085OM%MMKGNMUOHZ1S_;&"%L9/EP%D5%-!4 "HACE
MY![0['[UZH@_&M#6AK0 T#  Y!8<]HMM16-JZBWT<M4W&[,^%KGC'@<1E9J(
M/%U+3NG$SH(C,.4A8-[]Z]D1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
I$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g762905g10t06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g10t06.jpg
M_]C_X  02D9)1@ ! 0$"KP*O  #_[2/L4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0(5[
MAR@        *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! "KW#E  $  0*O
M<.4  0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!$0      !     "
M   "0    D      .$))300>       $     #A"24T$&@     #00    8
M            #I0  !      !@!G #$ , !T #  -@    $
M             0             0    #I0                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P  #I0     4F=H=&QO;F<  !
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   Z4     %)G:'1L;VYG   0      -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $    !SA"24T$#      9LP    $
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MX$'JE)!T(-#?_(IT2*U_E^"TL#UEY;:?VE2QS&MN(./80QH#6W@SL=L=:_\
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MJWNOOL:V@N+2VRVR_>[U2YWJV>IZEB2D/_.CZM?^6V%_[$U?^E$O^<_U:_\
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M7/J]&PMAQEP (;I],M<\;_\ 1[?Y:JTT959JIJ>*&O+]@VD1)_2N>Q[J]_\
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M)*?_V0 X0DE-!"$      %<    ! 0    \ 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '     4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M "  ,@ P #( -     $ .$))300B      $R34T *@    @ !P$2  ,    !
M  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q  (
M   ?    <@$R  (    4    D8=I  0    !    J    -0   *O     0
M J\    !061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#@Z
M,#$@,30Z,3@Z,C,       .@ 0 #     ?__  "@ @ $     0  $ "@ P $
M     0  #I0         !@$#  ,    !  8   $:  4    !   !(@$;  4
M   !   !*@$H  ,    !  (   (!  0    !   !,@("  0    !
M      !(     0   $@    !.$))30/]       (          #_X0$Z17AI
M9@  34T *@    @ !P$2  ,    !  $   $:  4    !    8@$;  4    !
M    :@$H  ,    !  (   $Q  (    ?    <@$R  (    4    D8=I  0
M   !    J    -0   *O     0   J\    !061O8F4@4&AO=&]S:&]P(#(U
M+C,@*%=I;F1O=W,I #(P,C0Z,#@Z,#$@,30Z,3@Z,C,       .@ 0 #
M ?__  "@ @ $     0  $ "@ P $     0  #I0         !@$#  ,    !
M  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !  (   (!  0
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M*"@H*"@H*/_  !$(!ET&^P,!(@ "$0$#$0'_Q  =  $  @(# 0$
M    !@<%" $"! ,)_\0 :Q   0,# 00#" D." D*! 0'  $" P0%$08'$B$Q
M$T%1"!0B87&!D=$5&#)4DY2AL=(6%R,W0E)35G)UDK*SP3,V56)S=(+A)#1#
M@X2BH\+B)28G-41%8\/3\$9DA94H.&6DM./Q5T=FI?_$ !H! 0 # 0$!
M           ! @,$!0;_Q  Y$0$  @( ! ,&!0,$ @(# 0   0(#$002(3$3
M05$4(C)A<9$%0H&AP3-2L14CT?#A\4-3)&*"DO_:  P# 0 "$0,1 #\ VI
M
M
M
M
M
M  !Y+Q<(+5:JNX5;D;!31.E>OB1,FJ,VV'6KZR2:.[[D2O5S8>]XE:C<\&^Y
MSCJYG1@X6^??+Y*7R13NVY!C-,W>&_Z?H+K38Z.JA;)A%SNJO-OE1<IYC)F$
MQ,3J5XZ@ (
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MHY8W;S7)Y2UL=J];1I$3$O2 "B0
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MS\:'M,IC725@ $
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M                                                          $
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M,>6D[ !Q-
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M3Q&5.&8U.I:@ (
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M[%3J/J       #Y05,%1TG>\T<O1N5C]QR.W7)S1<<E\0'U
M
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M=XWMDC:^-S7L<B*US5RBIVH!V
M
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M5A  Y5P
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M%9F;TM]?L>DPN< '*T
M
M   "+:]U,EBH6PTJM=<:A,1(O%&)UO7]WC ]>I=56^Q)T<SEFK')EE/'Q<OC
M7L3QJ5]=-3WJ[9:L_>-.O^3IEPJ^5W/T8,'2Q/DD?/.]TD\B[SY'KE7*>YK4
M1 MK3R)11N=O2-61Z\W/7>5?.I]$I6(G!J'JP, >-U)&Y.+44Y@9-2.1U)43
M4[DY+&]6_,>H8 R-NU=?*'A)-'6QIU3MX_I)Q].256S7UOF1&W".6CDZU5-]
MGI3C\A E:BGGGCWFN14R0:A*;[5=^7"65KD<QRY:J<E;U?(8:KE6*)7-3*YP
MAVHITFI6(ONXVHQR>3DIR]K7M5KDRU>:&,]WI8YCEB88!]S6*9R.<J[JX7@>
M^-[)6-DC5%:[B?=*&E1SG= Q7+S54R=%IX:=B]$QK,KR0FL]3B(K:GT%=A#Y
M*N3E3J:O.0[7VAX=6.I94JW4U1!EN=W>1S57.,=IFM*6"DTW:6T-#O*F=Y\C
MO=/=VJ98Y0(TY0[(<(>JWT-3<:AL%)&LCU]")VJO4!]]/0NJ+Y1,C3*]*UR^
M1%ROR(7"8'2^GHK-$KY%26K>F'/3DU.Q#/$HF0 !      UMH=35NE=M>L:R
MEM51<Z1SE2JCIVJKXVY14>GD7YS+WV\7#;)7VZRVFT5M'IV&H;/6UE2W=SC*
M*U.K.%5$1%7BO4B$FT3I6]VW;'JJ]UE)T=JK6JD$W2-7?7+5]RBY3DO-"U41
M$Y<#LOFK$Q-8ZZ[LZUGS4?MHH)+1KW3&J:JWR7"PT4:0SQ,9OI%NN<N53E]T
MBIGAEN#KJ[7]9KK3-?9M :?N%3%/"YM153Q=''&S'%K>/%R\L?(I>0:B-3#4
M1$[$,HS1JNXZPMRJ-;3UM5W+TE*M!5,K8Z?<6G="Y)/ GS[G&>29+1V>QOCT
M!IV*5CXI6VVG:YKVJUS52-J*BHO)20@I;)-HU\]IB-3MKKHV]TVRG4%_I-7V
MJL=4U-0LE/7Q0](LS./!%7'/.>'6JHI\]8W?46J=::/O[=.W"DL%-7QI3J^)
M5D<G2-5SWM3.ZBXX>)#8U6HO-$7RG)K/$1-N?EZJ\G32F.Z)HJZ&HTMJ*CHY
MJN&U52OG9$U7*B;S'HJXY)X"IGQH8S:]<I]9:(TC=[;:Z]&RU^^L"PJZ1B(J
MMRJ)GAPY^0OH%:YYK%>G8FF]L;?$>_3EP2-CG/=2R(UJ)E57<7A@KON:Z.KH
MM 3PU])44LO?TCD9/$Z-53<9Q1%1.',M8\%_DN,-FJY+)!!47)C%6"*=RM8]
MW8JI_P"_(4K>>6:>J9CKMKQM5M-UMVTFMLMH?BBU=T.\Q.IR/3>^5%7R*I=V
MIK6VBV:76UVZ)SVPVN6GAC8W+G8B5$1$3FJD2T3IC4MWUK]5NO(*6EJ*:'H*
M*B@<CDCYY<N%7M7K5>/5A"U3;-D^&N]Z_P JUKWE!=AT$U/LOLD53#+!,U)=
MZ.5BL<GV5Z\47B0FYLN6R[:#=+Y3VV>OTW=UWYN@:JNA?G*Y[.*KSX*BEX I
M7/JUIF-Q/>$S3I$>BA-5:@N>UYM-I_3-JJZ6T.E;)65U2S=:U$ZN'#ASQG*J
MB<CV[?;3-!0Z'I[91U$]-0U;8U2&-7[C6HU$SA.'!"[D1$3")A 3X^K1RQJ(
M\CDZ=52[6+%<[;JRT:ZL%(^NFH&]%54L>5<^/PN*(G%>#G(OF7J([K?:95ZU
MTG<;-I+3EUFGGB5E4]\7"%G-R)C.57&"_ B(G),"N:(B.:-S'8FOHBVRNFDI
M-G.G()XWQ2LHH]]DC5:YKL95%1>*&1UC9&:CTQ<K1*_<2KA6-'_>NYHOF5$,
MP8_4-L;>;'76YTTD"5,3H^EC7#F*O)4\BF46][F6UTTIW2VLK]H&R1Z:OVEK
MG655(JQ4DU(Q71S,SX*;V/FZL<,F+V837FMV^W*LU'3)2W*6WO>^!.4+?L:-
M;^CCTDDH*_:KIV!;9)9*2_MB\&&O6H:U7)U;V515\Z(OC7F9K9AHN[VV^W?5
M&KZB":_W)$CZ.#BR"-,>#GK7P6IXD;S7)V7M6M;3TW/I/_=,ZQ,L1LZI*F/;
M)M#6:">**9(UCD<Q41R=K5Y*1/0E]H]DUTO=KU=:ZSON>I66GK88$DZ9G4B.
M7&4Z^'6JY-BSA6H[&\B+CM0YXS=XF.DZ_9?E:[ZGNFHM2[0-%Z@DT[74=AIZ
MYD=,KXE616J]N\^1J>Y1<)C/4A)=H%%5NV[Z)JXJ2>2F;&K7S,C56M7+^:HF
M$YH7(!X_;4=HF#E0?;;3SU6S"^14D,D\RLC5(XVJYRXD:JX1./)")5FC:O4^
MPW3U)2QR0W6AACJ(8I$W%5[45%8N>6<KCQX+E!%,UJ1$1Y3LFL3*F*7:_</8
M]MI=IFYNU:C.BZ!8L1N>G#?7K1.OEY^L^>P*V7>/1^JJ:9L]MN<U4]&2RQ*B
MLD5B>$B*G%$52Z\<<]8)G-'+-:UUM'+/G*E*;:Q56"&2S[1;%5K7Q9;TL437
M,J$ZEPN$7RIE/(?38W9JRKUO?=6Q6N2R66MC2*FHWMW5D]SE^[U)E%7^UP+F
M<UKL;R(N.U#DFV>-3%:ZWW_]$5]9  <ZX
M                                                     4ML01;%
MK[7.F:A%:]M1WW"B]<>\J9\Z/C4NDKK7&FKA3ZXL>L-/4[JBIIU2EN%,Q41T
MU.[*;R95$56Y7AU\.PVQ6C4TGS5M':6/VIZ<O5+J6WZUTK&M57T3.BJ*1,JL
ML>5Y(G%>"JBISY8,;'MWIV)T%5IFYLN"<%@:J+EW9Q1%^0N<XW6[V<)GMP7K
MFK-8KDKO7;KI$UG>XE4VRRQ7NY:TNVNM24?L;+70I3TU$J>$UG@^$[/%.#$3
MCQXKP3@0R>_5FC-N&J+I)9+A74]2B1,Z&-41<M8N47&%Y&QH(C/[TS:.DQHF
MO3HIU-M<SEPS1MZ=Y&JO^Z2>TZFFUGHG4$BV:NMDK8)8&15+%1TF8UPJ<$SQ
M7!.P5M>D_#77ZIBL^<JL[FVEJJ39ST5=33TTW?DJ[DT:L=C#>.%ZBTP"E[\]
MIMZIB-1I\:FDIZK'?-/#-CETC$=CTG%/1TU,Y74]-#$Y4PJL8C57T'W!7<]D
MJ>OM#/>^Z)LZ34TRT%JHNFZ18UW%?ARIAW+.\YOH+A +WOSZCTA$1I2-X]D=
ME^T*[:@CMLUPT[>/"F= F70/YKGJ3CGGP5%[4/%JO5-9M<IX--Z3M55%0R2L
MDK*ZJ;AL2-7*)P54\>,Y4OM4RF%.&M:Q,,:C4[$3!K'$1TM-?>CS_P#"O)Y;
MZ*OVK:*K*JS6"X:;:LMVTXYCZ=B\5E8W=X>-<L:N.OBG68>NVQ5%RM<ELM&F
M[I]4DS.BZ!T7@Q.7@KNW">-$\9=(PF<X3)%<T:U>N]=B:^DH7LATE)H[1T-#
M5.1U=/(M34X7*)(Y$3">1&HA#W)[/=THQT6%BL=OQ([JWE:O#RYF^12V[G42
MTMOJ9Z:F?53QQJYD#%1'2.1.#45>"9(=LHTG5:?MU=7WM6NO]WG6JK%:N49E
M55&(O+AE>76O8B"N3XKVGK/3[FNT)T #G7                   !#-HVO(
M-$+;'5-!-5QUCWM<L3T18T;CCA>?NN64)9;ZR"X4-/64<B24\\;9(WI]TU4R
MBEYQVBL7F.DHW&]/N"*:UUI3Z5K[-2U%'-4+<INA:Z-R(C%RU,KG\HE9$TM$
M1:>TFP %4@        !$W:VIF[06:3[SG6I=%TO?&4W$\!78QSZBU:6OOECM
MU1,Z2P$7^K&G^K_ZE5HYTJ.]^^$J,IN*F,X[24"U)KK?F1.P %4@
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M9D  0                      &1D !D9  9&0 &1E  &1E.T !E.T93M
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MMDQRXIQS'7<2M6VP &2P
M   &1D !D9  #( ^=3(L5-+(U$56,5R(O7A#Z'PKU3O&H_HW?,H&+TIJ.EU#
M1=+#B.H9PEA5<JU?WIXS-FN-LN55::]E712+',Q?,Y.Q>U"\-(:FI=1T/218
MCJHT3IH57BU>U.U"]Z:ZPI2V^DL\ "BX          *<V^0QU5]T523HJPSU
M3XWHBX56N=$B_(I]-FURJ]'ZJJ=$7MZK3.<LENF=P1R*JKA/$[CPZG(J=9QM
MR3.K-!)_\ZOZ\1)MK6DW:BL:5=O16WFW_9J9S.#G8XJSY,IXT0].MZ^#CQW[
M6W^D[Z2PF)YIF.\(QMX_Z_T4O_SO^^PG^NM5TFD;*ZNJVK+*Y=R"!%PLC^SQ
M)VJ49JK63=5-T2M1AMSIJY(JEF,<=YF'>?'IR3?;BQLFI-$-J<=Z.JW))GEC
M?BSGS9+3@_I8\G_[?MU.?O:/D^B:BVG2427.*P6Y*14WTIE:[I=WR;^<X\7F
M);I36D&I-+5ERI(NCK*1CTFIGKQCD1JKA?$N"6E*: 5K=7;26TZ_X*K9'8;[
MG>R_^\YZ\N:EIY8C6NWU7ZUF.KYTFU/5VH+<Q=,Z:9+4Q<*F1&NEC1>I&IE,
M=O%5,]?MI5QL&H[=:Z^T-F?56^.98H%7I>^'93<1.6-Y,=OE/CW-G\1ZY>OV
M0?\ LXSSZEC;+W0NG6O1%1*3>3/:C9E3Y3HM7%XML?)&JQ*D3/+$[?*Y:]UO
MIU]'<-366AAL\\R,<R/*RL1?'O+QQGFG''4>VMUGK:ZQRW#2M@A99F,WXY:U
MOAS-^^1-Y.'B3/E/3W0R(N@4_K<?S.)Q8V-9I2@8U$1B43$1$[-Q#&;TC'7+
MR1N9F/DM$3S<NV*T)K&GU)I!+S4;E,L".;5IGP8W-3+E3Q85%\Y$XM::QU14
M3R:+M%(RUQN5K*JMRG28ZTXHGFXF(V*W&DM.S;4E9<H^EHH*ESI(]U';Z+&Q
M-W"\\\$,C9;]KS4UM94:6M=GM%I55;"Z?*JJ(N.")P^0O.&N.]]1&HGS[1_R
MB+3,1N68T%K:ZUFIZW3&K:."EN\$?2QN@SN2-X93FO'"HJ*B\4SRP1^3AW2D
M7CI?_(4Q-EIKQ1[?[4S4%Q@KZ]U*]9'P,W&M18I,-QA.S/G,O-_^9.#^J_\
MD*:<E:6M-?.DST[(WTU/JE+=4U;]KCM.+24?>C*3I4GW5Z;.ZBXSG&/,?*]W
MO7T%UJHK7INAGHF2*D,KY^+V=2KX284PD2__ (C)D_\ D/\ <0E&TO6T6D[=
M''3,2IO%5X%+3HF55>6\J)QQGJZUX=IA--7I6E8F9B%M])F91"7:#K6GU'26
M.HL=I]D:E4W8HY7/5B+UNPY<<$5?)Q)CK_6K=,14U+24_?\ >ZM=VGI69X]6
M\N..,]76>/9AHR6RLFO5]>M1J&X?9)WOX]$B\=Q/'V^A."$'UI[-2;<6,L,E
M)'<$I6MIW5:98B;BJN."\?=%XIBRY>6(C58W/I,_\(W:L;]6>J-5;0;'2MNE
M_L5OFM;<.G92JJ2Q-[?=+R\_F+*LESI;S:J:XT$G24U0Q'L7YT7QHO!4[4*T
MJ;=M6J()H*BX6)8)&JQZ;GW*IA?N#.[&+=+:=)2T4U;3UB15<B-?3NWF-X-R
MU%\3MXSSTI./FC6X]$UF8G2=@ X6H
M                        "M-L4F]+:X<\DD>J>7=3]RD3A3=B:GB)-M?:
MJ7*WO7W*Q.3SH[^\C4:Y8U4["%X[.QR<' ')P#@#D'"'('9%5.2J,JO,X0
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MUD:F29;.-15UMNL-!$R2II*A^ZL+>*M7[Y.SQF5Z;ZPO2VNB[P 8M@
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M93L3CU"<]/:;7WTGIO\ 0Y)Y->;[;49V4^SV_OD7".I7QIY7>"GRJ02SI_\
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M?),5B.H #%8
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M]:TOUD?0QQ0VQ51LZ2JJO7>PF6XX=:\S7P;Q$SZ1M7FA,P 9+
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M+.4:]$1>'B5%0K?A[TKS3_Z^J8O$SI)P 8+
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MW2$FHZJ.KA26%5W>7%,%XM$N7)@OC[QT?< $L@
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MZ*L6II&HO0NJVHSL^Z_<J%P&?&5BN:T0G'.ZP  YEP
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M<8+H^G>Z>=)&="Y5X8QQRB&<7KX>2-]9F/\ ,IU.ZIZ #D:
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MG!$0Y B(CLB^2U_BD !*@
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MK<M5*U>;5<B81?'NHWSY)L.0,LEYR6F\^:U8U&@ %$@
M
M
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M
M
M
M
M                                              (UM+X: U#_ %*7
M]522D8VG_:^U!_5'_,:8?ZE?K"MOAE$MA]\M5%L\I(:RY4=/,R:7>9+,UBIX
M:JG!5[%0]6U;5>F9]$76C6Z4%542Q;L,44K9';^>"X3.,+QR139'LZTYJ/1D
M=PN]&^:J?-(W?29S<(BX3@BX,9<=-T>S37U%5UM$RNT_.JI&^5B.6)?FWF\_
M&GC/3G'BMQ%IB9YHG>O7Z,8M,4CT69L=AGM.S.A===Z%K6R3HDB85D2N5R9\
MW'SF$AUIK#55142:)M-(VU0O5C:FMRG2JG9Q3T<?*6)=[M14.GJFZ3JDU!'
MLR[B(Y'LQR3MS^\K*R7O7.H;4R?1]ILUHM#GN2!TO-41RHJHB<.>>HY\?^Y-
MLLUCK/GVA>>FJQ+*:(UU>JC5\FF-76^"EN.XKX7PY1KT1,\E5<HJ(JHJ+U$!
MO5?J9NVZ&=MLIENS$5M-2I)ECX]Q^%5V>>[E>KB9*U4=[I-NUA;J6X05U>ZE
MD>KH6[K6-6.7#<83L5?.92[?_F/M.?>_#X&0Z:Q7'>9K$=:3/R4F9F/U6U:9
M:J>VTTMPIVTM8^-%EA:_?1CL<41>L]0!Y$]9=  "
M
M
M
M
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M&M/%94KFVFD2\.A=<$C:D[H?<*_'%4\1[0#GF=SM< !
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MKA4NB>-:9/I 7.#R6>X07:TT5QHU<M-5PLGB5R87=<U%3*>13U@
M
M
M
M
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M?Z9G[-@&Y^S=G1[/=,-[+93?LFDB,#L^_B'IO\VTW[)IG@
M
M
M
M                                                         '#F
MHYJM<B*U4PJ+UH<@"-NT'I1RJJZ<M.5[*5B?N.$T%I1.6G;5\6;ZB2@OXE_6
M4<L>C'VNR6JT[WL7;:*C5R858(&QJJ>-43B9  K,S/64@ (
M     U6N7=,WZDN-53ML5K>R&5\:.5\B*J(JIV^(#:DZRIF)Z?S5-3_;17[\
M7[7\))ZP[NH;ZYCFKI^V<4Q_"2>L!W(_#:3J!/\ Y!_[:,VR-2>X_D67:%?'
MKA%=;G.QY98S;8         :']T+]N/4O]+'^R8;X&AW=#?;CU+_ $L?[)@&
MZ>S_ /B)IS\VTW[)IGC!:!_B+IS\VTW[)IG0
M
M
M
M
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M W4T%_$;3OYNIOV33.F#T%_$?3OYNIOV33.
M
M
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M35;OXSO1/RJHKDPO%,=7#BA8(
M                                              U?NG<Q7&KN%54Q
MZEI$2:5TB-=2NX955Q[HV@ &JB=RS=/QFHOBS_6=D[EJY_C/1_%7?2/GMEVL
MZCOVKY],:$EK(:>GE6G5U$B]/4RM54=A6\4:BHJ(B<\97Q0^:AVPZ7B6ZS.U
M/!%%]D?(L[Y6HB<<O;E4QV[R8 OG8CL=K-G-^N%PJKO!7-J:;H$9'"K%1=Y'
M9RJ^(N0JK8'M1^N#9YZ:YMCBOM"B=.C$PV9B\$D:G5QX*G4N.W"6J
M  -#NZ&^W'J3^EC_ &3#?$T.[H;[<>I/Z6/]DP#=70?\2-._FZG_ &33.&#T
M)_$C3WYNI_V;3.
M
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M/VMP,J-F&JHY$14]C9W<>UK%5/E1"(=RU,^79)1M>JJD=3,QN>S>S^\"VP
M
M                 #K*CEB>C%PY47'E.P U*[EFMMMIV@7JDOZLAO4C%B@D
MG5$5'M<O2,ROW2\/0IM1=[C06RW3U=TJ8(*.-BND?*Y$;NXX\^?D*)VT;!I=
M0WBIOVDIH8JVH7?J*.5=ULC^M[7=2KS5%YKQR5?2[$=I-UJ(Z6X4ZPT[%PDE
M56-<QB=J(BJOH0"0]S4L59MOU!666)T5I6"I<QN,(V)TK=QOS>A3;(@6Q[9M
M1;.K'+3Q3=]7&J5'U53N[J/5,[K6IU-3*^E2>@        #0[NAOMQZD_I8_
MV3#?$T/[H;[<>I/Z6/\ 9, W5T)_$G3WYNI_V;3-F$T+_$G3WYNI_P!FTS8
M
M
M     ,5?[_06&.%]Q=.ULJJC>BIWR\4[=Q%QYS*GGK*VDHFM6LJ8*='>Y661
M&9\F0(Q]<;3_ -_</_MU1] ^5/M-TS4QH^GJ:R5BY1',H)W)P7"\489]VH[(
MSW5YMK?+5,3]Y%ME=[M<>AZ%)KE1,<LDZX=.Q%XS/\8T,[9=86F\US:2@?5N
MG5%=B2CEC3"=JN:B$A/%2W:W5<R14EPI)Y5151D4S7.5$Y\$4]H
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MZ2,X]%$B+A%\:IE<+UJSM+JIH(J6FBIZ=B1PQ,1C&)R:U$PB)Y@/H
M
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M^S:9LP>A/XD:>_-U/^S:9P
M
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MKJYR.J:A&^'+CEE>>/$9(
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M[<>I/Z:/]DP#=70G\2-/?FZG_9-,X8/0?\1]._FZG_9-,X
M                                   ,9?)KO#'$MEHJ2K>JKOI45+H4
M:G5C#'9^0R8 B??VM/Y#LO\ ]R?_ .D8[3FI=77ZS4ESI;#:(Z:I9TC$DN+]
M[&53CB+Q$](?L@^UK8,]5/C_ %E RMGJ=0RU>[=[=;J:FW57?IZMTKL]286-
M/G,V
M                "/ZRU;;-)4,-1=72*LS]R**)$5\BHF5PBJG!$Y^8F(FT
MZA6UHK'-;LSTO\$_R*0?8A]K2U?E3?M7F*^O/8G-7%!<^76QGTR.;.-I5KTY
MI&DMEPI*YT\+Y5586,5N'2.<G-R=2H:^!D]'/[=P_P#?"\@0O2FTBR:ENZ6V
MD2IIZMT;I&,J&M;TB-YHW#ERJ(N?(30SM6:SJ6^/)7)7FI.X  57
M
M
M               +R4"@=>[6]GVG=25EN;I6GNU7!(K:B>.EA1O29\)-YR95
M47FO:1Q=ONBT]QL_A_0@3_=(YL=V=VG4^T+5%FUDE0ZJHE>Y&-E6-7N214<[
MM7J7SEUIW/FS]/\ NZJ7RU<GK \NQ3:58=::AKZ*S:8BL]1#2],^9B1Y>U'M
M3=\%J+S<B^8N,A.A=F&F-$W.>OT]230U,T*P/<^=S\L5R+C"KVM0FP
M   T.[H;[<>I?Z:/]DPWQ-#NZ&^W'J7^FC_9, W5T'_$?3OYNI_V33.&#T)_
M$C3OYNI_V33.
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M;_Q7JOCC?HG"]U/0_BM4_'&_0 V1!K:O=4475I6H^.M^@<>VHI.K2D_QY/H
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MX<'(B[CG+V^#(W]%#8$
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M5X;W-?,G%2X^YIIW4^QJQ;Z8619Y/,LS\?)@"#=UQNJ_1C6_PRU<F[V_Y/\
M?@V'3EQYFOVUN'ZL-ONB]-QHCX+<WONIX\D5V^Y%[/!C;^DAL"
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M&^F@?XC:<_-U-^R:9TCNSB5)MGVF9&\G6RF7_9-)$
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M?(B%F!$PF$X(91FMR33U=$\)CG+7+KK$:  9.H
M
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M+8                                                   %<S[;-
M03R0S7]C)(W*QS5IY>"HN%^Y L94RF%.$8U%RC41?$A6WU\]GGXPL^+R_1";
M<MGGXPL^+R_1 LH$3TAM$TMJ^NEH].W5E94Q1K,^-(GM5&(J)GPD1.:IZ26
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M;0-T=G$+:?9_IF)BJK6VVF1%7^B:2(P6@?XBZ<_-M-^R:9T
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M>;FM\)WE<O%?.ID@99,U\GQ2Z\'"8>'C_;KK_( #)T
M
M
M
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M>Z#^W%J7^F9^S:!NIH#^(NG/S;3?LFF>,#H#^(NG/S;3_LFF>
M      Q][N]/9J5M15QU<D;GHQ$I:62H=G"KQ:QJJB<.?(PGU=VOWE??_L]5
M_P"F2L 0^FVBV*IZ3O=EWE6-ZQO1EJJ5W7)S:O@<T[#(VK5EON=='2T]/=62
MOSA9[941,X)GB]S$:G+K4\6SO^ U!^>JS]<E@2  (   ()4;5-.P3212]^MD
MC<K'-6#"HJ+A4YD[*#VW:=]C;]'=:=N*:OSTB(G!LJ<_2G'RY-^'I2]N6SAX
M_-EPX_$Q>7=D:O7EGFVG6Z^L[X2A@MLU)(JQ^%ON>UR83/+"*2UNU?3KWM9&
MVN>]RHU$;"G%5\YKT>JV5,E'7P5-.UKIHGH]B.;O)O)RX=9W>Q8]/%C\8S[Z
MZ^W_ );:555!1T[YZN:."%B9<^1R-:GE52 :BVKV>@:^.ULDN-0G!%;X$:+^
M4O%?,B^4@U'I35VLIF5%SDFC@7PDEK'*B)^3'U>9$0].I8-!;,J1)M153[M=
MD;EE$BIEZ]7@)[E/&Y50Y8QX<?QSN?2'I^T<7Q/]&G+'K;O]F/J]3:QUA)(R
MBZ>.EPN\RES%&U.O>>J_.I5.J=2VRR(ZGHJF&YW!KE1[8,K!'Y9/NES][E/Y
MQZ;MJW6^U^N]A--T#J.T(N.\:+P(FMSSE?P1?/A.Q"Y]E^P*R:9Z&OU$K+Q=
MFX<C'M_P>)?$U?=*G:[T(+<7;7+CCEA:GX929YL]IO/S[?92^A-ENL-I#X:V
MXR/MUB>N\D\R81R?^''S=Y5PGC4VCV?;.M/:%H^BLM&BU+DQ+638=-)Y78X)
MXDPA+T1&HB-1$1."(@.69F9W+T:UK2.6L:@ !"P     &)O[[XR.+ZGX+;*_
M*])W[*]B)V8W6KDRP A;IMH7W-'I5/+4S_0,;IJ_Z[O]DI+I2VW3<=/4M5S6
M254R.3"JG'#%3J+&(?L>7.S6PK_X"_KN"?)D+%)JE]7_ ,NT]EBI=U>-'/*]
M^>K@YJ)@D  0
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M*YSAO'ARY 5G?-L^LTUS>M/Z:TS27-;?-(Q$9'*]ZL:[&\J([R'/UT-KG_\
M;MOQ:;Z1XMF%934?=(:X=65$,#')4(CI7HU%7I6<.)L$EZM*\KG0K_GV>LD5
M7H+7FT:\:IHJ'46BTMULEWNEJN@E;N8:JIQ<Y4XJB)YSY;8MJFHM(:WMNG].
MV>DN,E92LF8R1DCI'/<][=UJ-<GWB?*7!35U'5.W:6JIYG(F<1R(Y?D4H+:N
MF>Z;T$G_ ,O#^VF('+=J>UGKV=9\E-/ZS)Z:VY5D>HJ.RZ^TS46">J5&QSNW
MFMRJX15:Y$7=SPRBJ7C@H/NO6TKM+V/PF^R25J] U/=JU6KO8\6=WSX OT^%
MPDFAH*F2DB2:H9$YT4:\-]R(N$\ZX/C8^F2RV_OK/?'>\?29Y[VZF?E/:!K]
M)M-VN,5479TWS0RK\SC%W[;3M+L% E;>=$TE#2*](TDGBE:F\N<)Q?XE-E36
M+6,TNV/;53Z:I9I/J;M"JM0YCN#MU?LC^S*KAB+Y^T"Z-E&JKGJC0L-_U%1T
M]N=,KY&-CWD;T*<GKO*JIG#E\F%*XK=MVH;]=JJFV:Z2DN]'3.W75<K7JC_'
MA,;N>K*Y7L0MC6]GEJ]GEZLUEC;%));I*:FC9X*)X"M:U.Q.HK#N8+[9Z'0<
M]HK*BFH+K25<G?,-0](WN553#L.QU)N^+= RNSK:_-=]2IIC6EEDL&H'_P "
MQR.2.;AG&'<6JJ(N.:+CGG"+8>LM46O2%@J+O>Y^BI8N"(U,OD<O)C4ZU7^]
M<(BJ4+MDJZ;56VS1%)I6>.LN-'+&L\].N^V)$E1Z9<G#P41RKY3(=T7*FH-H
MVA-&R/<VDGG;45*(O-'OW$7RHULGI ^?U[->7-K[GIW0$L]A3*LE?%*]SFIS
M7>;A.KJ1<>,LO9'M-MVT6VU#Z>!]%<:142HI'NWE:B\G-7AEJX7J1<IY,^2X
M;7]G^G*EEI==XF][HD2,I87R1QHG#=RU%3@9'16G=&SWJHUEI+HGU%>QS)9J
M:95C?E45V69PBY1.I )P<2/;&QSY'(UC457.5<(B=IR57W2.J7Z<V=5%/2/5
MM==']YQ*U<*C5XO5/-P\X&7V<ZZJ-<7J^RV^EA;IJAE2FIZI57I*B5.+EQR1
MN%3'7Q0K&Y;:];RZTOMCTWI>CN?L=4RP_8HI7OW&/5J.=AWB0N'9;IR+2N@[
M/:HFHCV0-?,N,;TKO"<J^=?D0IW84O\ T^;1?Z2I_P#XE /LW:CM;1<OV=;S
M4Y[M+/G]8E^RG;#!K&\SV&\6R2S7Z)%5*>1RJDF[[I$RB*UR<]U>K/'@I:YK
M9M!Z!O=4:5=97-6L<D'?G1\51<O1V]X^BQGQ 7WJS4MJTI9I;I?:MM-21\,J
MBJY[EY-:B<552D'[=]3Z@JI$T%HBHKJ1BXZ:9CY%7RHS@WR;RGCVDQ/VC]T#
M;M'54KV6:V,1\K&+[I>CZ1Z^545K,]1L3:[=1VJ@AHK;314M)"W=CBB;NM:G
MD H^V;>ZVTW*"AVC:4K+'TO*I8U^ZGCW')E4\:*J^(O*W5M-<:&"LH)V3TL[
M$DBE8N6O:J914,;K#35MU98:JTWB!LM/,U41V$WHW=3VKU.0ISN7+O54-5J;
M1%QEZ1]GJ'N@7CP1'JR1$[$WD14_*4"_0  (3M4VB6O9_8WU-:]LUPE:J4E&
MB^%*[M7L:G6O[R3:B=<F6*O=8F0R75(7+2MG7#%DQX*+XLFLFTO9;<Z70EZU
MCKF[RU^I5Z/=CC=]BA:KT3=Y<>"KP3")XP-@]F.HY]6Z&M5\K(HH:BK8YSV1
M9W45'JWAE57J,;M9VCV_9W9HJFJB6KKZE5;2TC7;JR8YJJX7#4RG''6AXNYT
M^TYIW\B7]L\KC6D<>J>ZIL=IK6])1VZ%CEC=Q:JMC=-Q3QJK47Q(!W7;3M"I
M*-MWN6@=VQXZ1TC8Y6*C.W?7*(GC5N"Y]GNL;;KG3<5XM*O;&KECEB?[N*1,
M9:OI1<]:*A(*B"*IIY8)V-DAE8K'L<F4<U4PJ+YC7WN8T6T:TU]IYCE[WIJA
M'1L5>6Z][%7T;OH0#88 H3:QM9O&BMJU);HW-DLG>\<LU.V%'2/5=[@U>"HJ
MX1/$!?8-<]0ZYVP4=IGU.EEH**QM^RI32,1\D<6>"O3>1WE7AY$,A!MCU%K2
M@M]!LYLK)KT^G22X3U"8AI'<E:F5PN53**J\E3@JYP%^ U]TQM0UI8-HMOTM
MM)I*1$KU:R*:%J(K7/7#%16KNN:KN"\,IDF&V_:G]0-+245KIHZV_5V5AB?E
M6QMSC?<B<5RO!$X9PO'AQ"T@:[LUIM@TY21:AU19*6JL*8?44\36MECC7KPB
MJYN/&B^/!F-@.TV]:\U1J."Z21+0P,2:E8V)&.8U7JB(JISX8 L+:OJY=$:'
MK[W''%-4Q*QD$4JJC7O<Y$PN./+*^8@%=M;OUOU_I33E7;+=_P K0T<D[D5Z
M.B69<.:G'JX\SIW0B.U'JK0VBH7*YM=6]]U+$YI&WAG]'I?01/:FB-[I_2G4
MG24./A% V<!5>V':D[2DD%CTW3MN.J:Q4;% B*Y(D7DYR)S5>I/.O#G(M+UE
M[L6BJB[;1+A3NJHXW5,Z0Q(UE.Q$SN</=+^]<)VJ$R!K;:MIFU'7U;6U&A+/
M106F!ZHQT[$RJ=2*]SL*[''#>1BM0[=-;6R6DL]PMU/:K]#-N56_!O-E:N-U
MS45>'F547J5 +QVK:JNFC+127JAH8*RV0U#6W)KM[I61.5$1[,+C@O#CGFGC
M4EMMKJ>YVZFKJ&5)J6IC;-%(G)S7)E%]"GPNEN@O=AJ;=<&I)3UE.Z&5,8RC
MFX7'9S*C[F6^5#;=?-'7*3?J[!5.CC55YQJYR*GD1S5\SD3J NP
M                                    .'(CFJU>2I@Y &F.EM0UNPS:
M9>:&XV^2IHI,QN9G==)%O*L<K%7@O#]Z<%0^&S/:Q2:+OVKKFEMGJ7W9ROIF
M;R-1B[[W)OKV>$G+L-CJBY[.-I[GVNMEM]PJX7.C2"H18:B-4]TC%7#NK[E<
M'CH=@F@*2L;4):9IMU=Y(YJF1S/1GBGER!67<JZ<KKIJJ[ZUN+%2%4DCB>J8
MZ6:1V7N3Q(F4_M>)3: ^%#1TU!214M#!%3TT349'%$U&M8B=2(G!#[@
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MOC=[J-W6BF7.2U9K.I0  @
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M98(Y,\%5TF&_ZL:@;$@
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MX5OK.>_Z3WU3_")ZP/0#X)6TJ\JF#X1#[-<CFHYJHYJ\45%RB@<@
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M3Q-C;Z$1#U@ 5O'I:ON&VI=25-##1VVW4:T]/*F[TE7(].+G8XX:BX3)9
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M>AFNU##5R4,G34ZRHJI&_AX2)RSP3F90
M                   '#\[CMWW6. &LNO=IFG=F]\KK5L[L%ODO"2.2LN$R
M*_=D555S$7.\Y47GQ1$7AA3OLSVS:IN&FM;72\OIJV6TTL4]-$L*1M17.5JH
MN[A53EUYX$=[F.FMU3M,NZZB;$^],8]].E1C/2[_ -D5$7[K^\D7<^T5!+JO
M:?2W6.%]N5RLG;+[CH^DESGL3 %M[(-I-#M$LDD\47>MRI51M52[V=U5SAS5
MZVKA?)A4\:STU+[FE8H]ME]BL#GK9N@J$9O*O&%)6]&J^/W/I4VT
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MBCFHBHIJW@EV@=85&G*UL50Y\UL>OV2+.=S^<WU=9UY/P_4;I.Y2O7O>%/\
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MZ*&8A1&Q,1J(B(B(B(8Q#)P_P3?(2.P
M
M                                                          &E
MM[=M@2\5W>WU:) L[^C1B5&[N[RXQXL 6)MBV$7"Y:AJ-0:)EB;+4/6:>D?)
MT;DD7BKHW<N*\<+CCZ"L+;L4VCSU,T"6V2D9,N)9):MK6/\ RL.55]"GSWML
MW;K?_P#<!5VS+S^K?S)4 ;-[%=F-/LZLT[9)F55WK-U:F=J8:B)R8S/'"97C
MU^A$L8UX[FQNO4U7<UUI]47>/>2]%[)K+N=)TC.6_P!>-[EU9-AP
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M0M!='/1:UB=!6-1,8F:B;RXZLY1WD<!,P
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MGACZDW)%QC^R]/0AL%3?XO%^2GS&N>S[-9W5.JIX$58X6SH]4ZL;C/G V0
M                                           1S:'<;[:M)UM7I2WL
MN%VCW>BIWM5R.17(CEPBHJX3*XR:I:YU?M$KM9:8JK_8^\[K1R[UNI^\WL29
MZN;PPJJKN*-3@IM[J#4%IT[1I5WRX4U#3JN$?,]&[R]B)S7S%67NBM>U#7NE
MKUI?4=MGAL,J35%/EW2.1)&NRB8Z]W&0,GLDU9KZ_P!VJX=9Z9CM=%'#OQSI
M#)"JORB;N'N7/#*\.6"TS":CU59=-244=[KXZ5]8_HX&N1561W#EA/&GI,V
M           T/[H7[<6H_P"EC_9M-\#1#NA?MQ:C_I6?LV@;;:(_BC8?ZA!^
MS0SY@=$?Q0L/]0@_9M,Z@'(   ! ,;<;_9[94)3W*Z45).K4>D<TS6.W5Z\*
MOB4CFN-4:?J-%:@IZ>^6V6::WU$<;&5+%<]RQN1$1,\55<'GVQZ?;<; RYPL
M1:FAXNPG%8U7CZ.?I*/W$QU'7AX>,M>;;RN+_$;\-DY)KN&QUOU=IE+;2([4
M%I:Y(F(J+5QHJ<$ZLD%VCZX2L5UGT]*LL<F&230\5E5?N&8YIXTYE4[K<\D]
M!>&RC1#;=3PWRZ,1U;*W>IXU3^":O)WY2IZ$-)PTP>_:=N>O&9N._P!G''+'
MG/R>C9CH)EEBCNEYB1UU<F8XUXI3HO\ O=J]7(L)SLJ<.=DX1%4X[WF\\UGK
MX<-,-(I2.C@^%QK:.U4$U=<ZF*EI(6[TDLKD:UJ>52.;1->V705L[YN\V_5/
M3,%'$J=)*ODZD\:FK6J=1:IVM7&2IJ56CL5.[P8D<O0Q?3?_ .^"%:Q-IU#9
M+]I.UZ/6E^H;-8:1RV>GJ.D=4/1=^9R-<W>1/N6HCE7CQ7ARY&/P=] Z*=45
M3;?9H5=(["S5#TY)VN7J3Q%U56RJU24%/%!4S0U4;</FQO)(O:K<\/,>MBO7
MA*Q3)/6?V-*1P>W2M0Q=>:;HD<BS25K)-U%XHUN79^0M:W[):.*=KZ^Y2SQ(
MO&..+<RGERI/Z"TVNWLB;0VZEA6),-<V--Y/[7//C*\3QU)I-,?79I[5.$#E
MRIUR>2.V3C)QDXR!VR,*I\Y$>Z)[8GI'(K51KE;O(U>I<=?D(RZT:M=G=U71
MM\EI3_U E*L+V#"E=S+K&'5U)8UU-1N;/1R573+;$RW<>UN[CI.O>SG/49E;
M/JQ/=:KI5\EJ3_U )2JG&3YP->R"-LTG2RHU$<_=W=Y<<5QU>0[A#D'  Y!P
M  . !R<  #D(BG.ZO6!U!\:JNHJ1JK55E/"B??R(A@*W7NFJ/*/N+97)U0M5
M_P QI7%>_P ,3*)F([RS%ZN4%FM%3<*M<10MWL)S<O4B>-5(SL8JH:C0M-21
M/S+1N?'(G+&7N<GFP[Y%('M+UO!J.&GHK8R9E)&[I'K(B(KW<DX=B<3#: U7
M)I2[/GZ)TU+,S<FB1V,]:*GC3]ZGHTX"TX)F8]YC.;5^G9L4J8!!:;:O895^
MS0UD"KVL1R?(IE:;7^F:A$W;DQB]DC'-^=#BGA<U>]9:Q>L^:2 Q]+?[/5?P
M%SI'Y_\ %3UF0C?%(W,<C'IVM7)C-+1WA:) =MWL4;I Z@YPHP0. ,    .0
M< #D'  Y"'  [9&3J<@<Y.<G4 =LG.3H .^0=<A% [@Z9.<@=@=<@#MD'7)S
MD#D'  Y!P<@!E0< =D<H5<IAR(J=BG4$C&UE@LU;E:JUT4BKS<L+47TIQ,'5
M[.--5"+NTDM.Y>N*9WS+E"7 TKFO7M:16M;LDHG96ANE1%XIF(_YL&$J-EU]
MI7*^AK*67'+=>Z-WS8^4N4(;5XW+'GLW*E.\M?VA? 2XN:G+<D2=/1E3A->Z
MKMK]VX0Y5.JHIE9\V"[450Y=Y%1R(J+S12_M=9^.D2*FHMK3^"5MK8J];HI5
M3Y%1?G,]1;3;%/A)TJ:9>U\>\G^JJDFK=.V6NSWU:Z215YNZ-&N]*<3 UNS;
M3M3E8H9Z55_!2JJ>A<CGX:W>LP,G2:ML-6B=%=*9%7JD=N+_ *V#+05$%0W>
MIYHY6]K'(OS%=5.R2!45:2[2L7J22%'?*BH8>?9C?Z1V]15=-*J<MR16.^5/
MWCP<%OAOKZIZ+BP<8*86GU[9\X]D',;V.Z9O[SM%M"U)0*C*^G8_'/IH58J^
MC ]BM/P6B32Y< J^DVL+E$J[6F.V.7]RI^\S='M+L4^$G2IIU_GQY3Y%4RMP
MF6OD:E-!DQ%%J>R5N.@N=-E>IS]U?E/7<[I26VU3W":5KJ>)N55BYWNQ$\:J
M9>':)U,(>YBF&V/X^H&@1%SB2=/]L\IG4FM;K>IW_9WTU+GP8(G*B8\:]9X+
M)J6\661KK=7SQ,:N>BWE6->W+5X';'X??6YGJ0VH!%-GFKH]5VM[WL2&MIU1
MLT:+PX\G)XEPI*SAO2:6FMNX  J              8?4&G:*^5%MFK6JKJ&=
M)V81/"_FKGJ5<+YC, F)FL[A6U*WCEM&X  0L     .LT3)HGQ2L:^-[5:YK
MDRCD7FBE"7W81<K5>);ILSU)-9I)5RZFDD>UJ<<X1[<JK?YKD7RE^@#7RJV5
M[3]31I1:OUS EK=PDCIE<Y7IV*U&L1WG4N'06CK5HBPQVJRQN2-%WY)9%R^5
M_6YR_P#M$)$ -=KMLIVA4NT:^ZDTC>+70>R$TBM>^15?T;G(["HL:IU)Z#V?
M4?MQ7GK:V)Y__P"27Z *8TKI7:[1Z@M\]]UA;JJV1S-=4P-3*R,SQ:GV).KQ
MH9#6^SJ[W[:_IG5=+443*"V,B;+'*YR2.W9'N7=1&JG)R<U0M<      %4[=
MMGMZV@,LE-:ZBABHZ29TE0E0]S5=G">#AJ]6>SF6E30MIZ>*&-,,C8C&IXD3
M!] !YKG04USM]30U\+)Z2HC=%+&_DYJIA4*'DV0:XTG6S_6TU<E-:Y7J]*2L
M<OV-5\6ZYKE\>$7D; @"E-';'+C/J2'4FTN]^SMSIU18(&JJPQJBY15RB91%
MX[J(B9[2R=?:/MFM].S6B\,=T;EWXI6<'PR(BHCV^-,KPZ\DB &O46S/:U;*
M3V$M&N*9+&U.CC>YSFRM9V)X"N;Y$<63LFV;6_9];)V13.K;I5JCJJMD;A7K
M]ZB=3>:\U554G@ %/=U#IZ2Z[/VW2D:JU5GG2I14YI&O!WH\%?,7"?&LIH:R
MDFI:J-LD$S%CD8[DYJIA4 P^@KXS4>C;/=HW(O?5,Q[\+G#\8<GF<BH039OL
MYN^FMJ.JM25]11/H;HZ988XGN61$?,CTWD5J(G!.I5/=LATI>M#5EZL4Z-J-
M.+,M5;JKI$5S=[&]&YO-.2+GEG/:66   &#UEI:U:PL<UJOE/TU-)X351</C
M<G)S5ZE3^Y>!2\.R#:!I25T&@=;-CMBJJM@JU<W<S_-W7M5?&B(;" "@Z/8=
M?=1W&&LVG:LGNC(5RVDIG.W?&F\J(C47KW6HOC0O*TVZDM-MIJ"VP,IZ.G8D
M<43$PC6H>H 4^RZZLH=OE-9*J_Q5ECK():MM''"Q'01HBHU'KNY3CC"YXEP&
M(H=-VNBU!7WR"F_Y4KFM9-.]ZN7=:F$:F5PU.')#+@8C5NG;?JO3]79[Q$LE
M)4MP[=7#FJBY1S5ZE1<*4E!LMVH:=:ZV:1UO ED15Z)M0KFOC:O4B;CL?V53
MS&P@ JS9?LBI]*W>74%^N,M[U++E5JI<XBRF';N55554X;R]7!$3CG(;8]F5
M+M$M=,B5/>5THU5::HW=YN%QO-<G6BX3CS1?.BV& -=9]E>U>YT#;-=M;TRV
M94W'[LLCGN9V+X"*[AU*[!<>SO1=MT+IR.TVE'.3/233O]W-(J<7+Z$PG4A)
MP *HU#LZNURVW6C6$$]$VV4<;&OC>]R2JJ(].";N/NDZRUP!B-86R:]:3O-L
MIG,9/64<M/&Z151J.<Q6HJXSPXD4V&:)N.@]&RVF[S4LU2^K?4(ZF<YS4:K6
MHB95$7/@KU%A "H-L>S6\:PUGIB[VF:B9!;7-Z=L\CFN5$D1W@X:J+P1>PR6
MUS1^FMH4D-EJ;O24>IZ=JR4N[(U9FM5,JCH\Y<U43/BQE.O-FE/;9MF%WU%J
M&W:IT;<(J&_43$8J/7<Z1&JJM5'(B\>*HJ+P5.'5Q"-VW9+KVZ+':]<:N6HT
MQ Y%?!#4/<^=K>*(JJU.'!/=*N.KM(MW/=HFK:[:9#I]T3>DI7T=')(Y=Q%>
MYZ,551%X81%)-5VC;K?Z%]HN-5;Z&DF;T4U2U\37.:O!>+,KQ\2(6ALBV>TN
MSO3;K?#/WU63OZ6IJ-W=WW8PB(G4B=7E4#T;)-)/T5H2WV:H=$^KCWY*A\2J
MK7/<Y57"JB*N$PG+J(AK;9G>+YMEL.K:.HH&VZA6G66.1[DD7<>KEPB-5.2\
M.);X C6T72=+K325=9JS=:Z5N]!*J?P4J>Y=Z>?B52)[.K-7Z+V>5EEVD5UI
M?:(<PQ5"SKN+ _@L;U>C<<55$\2XZD+1,+K33='JW3-?9+DB][U3-W?1.+'(
MN6N3QHJ(H%%4.R35=EJJBMV4:RI66.O7?8CIE5-W*XXHUS7XY;W!2$[4="KI
M:YZ8I;C<I+OJ:[5B2U52]RJN-YK4:F>.,JO%>>.KD3*T:*VR:%C=:M*7&BKK
M.QSEAWW1X:BJJ^YD3+5Z\(JIE5YDAT-LFO\ 7:PI]7[3+I'77.G5KH*2/"M8
MK5RU55$1$1J\41J<^.0+JK:J"W6Z>JJGI'3TT3I)'KR:UJ*JKZ$*1[F2U35\
MVI]<5L+HY;U6/2!%^\WU>]4[4WE1/["DZVQV;4&I--QV'3K(F17"9L==5/D1
MO00(J*N&\W*O+"=64ZR6:>M%+8;'06J@;NTM'"V%G:J(F,KXUYKXU R
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MU>['6S5-QMT,-/4Q(G2238F9CBB;B(O!>&<JF,%JGB<9:+9=U0  Y
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M9-WRX5<<E/:     \U'<*.MDGCHZNGG?3OZ.9L4B.6-WWKD3DOB4#T@
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MU?I.>EF14WUA<K'(G;T;T_>73H+6=BUO;9+AI^;?1CD9-'(S<EC7J1R?,O%
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M'-<F45.2H<D#V%7E]]V5:?JYG.=,R%:=ZN7*JL;E9GSHU%\Y/
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MYT[(G.1/=.QX2^=<KYS-@
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M*IX@+!!'=%:G9J.BJ$GIGT-UHI.@KJ&1<N@DYIQZVJG%'<E0D0
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MKP5,IQ0]8 \MIMU):+;3T%M@93T=.Q(XHF)A&HAZ@
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MS57_  'WGV2U*9Z&MHG_ )42M^;)X)=E5T:JJUM"_P#)>J?.A'C\+YXI^_\
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M/^%3U$O^I:Q_R72_H'5=)V)?^[*;]$CJGHB/UU*?^3G_  J>HY3:I3==O?\
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MK_HA-$;2V>XUBQ?+,_Z -+E!3?U)[4F>YU53.\LB_0./J<VLM]SJ.B=Y9/\
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M%YHIG"OVP1:6VITT=&G1T.IX95DA:F&MJH41V^B<DWF*N>U6HI8!69V  (
M          #A[MQCG85<)G"<U Y!A?J@9UV^O3^PWZ0^J!GO"N_0;](#- PR
M7]G\GU_Z#?I&9:N6HO+*9
M                   CVMM7VO1ULCJ[JZ5[YI$AIZ:G9OS3O7DUC<\5(E5;
M4+C9XHZW5&BKM:K.YR-=6=-'-T65PBR,;Q:GI LX'SIIXJJGBJ*>1LD,K4>Q
M[5RCFJF45#Z(J*JHBIE.8
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M8C6+_:129@#K&QD<;61M:QC4PUK4PB)V(AV
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MTRC45$3*^8#:H&L&OH[GIK:ELVL27NOJ5B92QSR],]J5"]\*BJYN\O-.''/
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MEU+H;:##H/7E:ZY4]<W>MER>Y555XX:JKQ5%PJ8555%PG%%0"^
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M?FZG_9M,^
M
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M$G6+HW5,#HT?ATBKA51,\T RG==_:RH_SG%^SD+)V9QI'L\TTQJ81+=!^HA
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M:(=T-]N+4?\ 2Q_LV ;H[/\ ^(FG/S=3_LVF>,#H#^(NG?S=3_LVF>
M
M
M                      %Y* O)< 8;=XJ<HTX6AN:JO^$T?P+OI#O"Y^^Z
M3X!WT@#DPU3,,]PWR(85;==%_P"V4N/Z!?I&::BHU$7BJ(!R
M                                                           #
MPWZCGN%DKZ.CJI*2IG@?'%41KAT3E:J(Y/&B\36O3.U+5VS):RR:[LMTNRMF
M5T=7).Y7(G8USD5'M7&4X\,FT1UDC9(F)&-<G8Y,@:K:GNFIMO=UM5KM=CJ;
M38*6;I)JB95<WCPWU7"(JHF]AJ9YKYMH[=1PV^WTM%2MW:>FB;#&WL:U,(GH
M0^[6HUJ(U$1$ZD0Y
M   7@B@=0&J6RN_VK66T=;%J'1.F4[X=,Y9HJ/HY$<U'.XY5<\ER7_'LST3&
MY%;I6S93MI6+\Z&G&HJ?6[=:7"YQP:@;7LJ)-RI9'*CT3*HF'(G+'#AU'NAU
M/M:B:FY6ZJ5/YS)7?.B@;P4-%2V^E934%-#34[$PR*%B,:WR(G!#[FO7<W7W
M75TU1<X=82W:2A91[T??D*L:DF^WDJHG'&]\IL*         -#^Z&^W'J/\
MI8_V3#? T/[H;[<>I/Z6/]DP#=/0/\1M._FZG_9M,Z8+0/\ $;3OYNI_V;3.
M@
M
M
M
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M,Z8+0/\ $;3OYNI_V33.@
M
M
M
M
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M/XBZ<_-U/^R:9XP.@/XBZ<_-M-^R:9X
M
M
M
M
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M5[1[G<Z2KM=/1)20ME1T4JNWLNQCB@%O@
M
M
M  PF<XX@      &OG=D+_P U=/\ ]=?^HI9>P[[4VE_ZFWYU//MAV;MVCVVW
M4<ES=;VTDSI=Y(.EWLIC'NDP2;1=A9IC2ULLL<[JAE%"D*2N;NJ_'7CJ QFT
M+9]9->T]'#?VU"LI'.=%T,NXJ*Y$1<\./)"#+W.&AE3@ES3_ $G_ (2Y@!2J
M]S;HGJDNJ?Z0GT35S:;8J736O+U9K>Z1U+23]'&LBY=C"+Q7SGZ&FA&WA/\
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M#]8J_N,_XR:B_JD?ZX&UH
M
M
M   &BNW.UW";:QJ66&AJI(W5.4<R%RHO@IUHAO4,)V(!A-#,='HK3['M5KVV
M^G:J*F%14C:9L                               T!NUHN3]IM8]+?6*
MQUW>J.Z%V,=,O'.#?X83L                              !CM2(JZ=N
MB-15<M+*B(G-5W%-'-C]GN,6U+3#YJ"KC8VOB<YSX7(B(CNM<&^@
M                      !"]M$<DVRS4T<,;Y)'T;FM:Q%557AR1": #3+N
M8+974VUJBDJ:*IAC2FGRZ2)S4]QVJAN:,
M    J;NH*>>JV4545-#)-(M5"N[&U7+C>[$*T[CZ@JZ34>H75=+/ BTD:(LL
M:MRN_P",VD
M
M                                                      ?&MJH*
M*DGJJN5D-- Q9))'KA&-1,JJ^)$0H>[]TO:H;A-'9M/5]QH85P^J61(N&>:-
MW5X>54\QGNZIO$MLV6RT\#U8ZX5,=,Y4Y[G%ZIY]U$\YW[F:RT<.QZC>ZGC>
MMR?,^HWFHO2)ON8B+VINM3AY0)QL_P!;6?75C;<[',JM1=V:"3A)"_[UR?,O
M)22FI?<W5;['MIO5B@<J4=1WQ#N9ZXGJK5\N$5/.;:
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MU/O6HYJ?^U-U-B7VJ-+?U)@$V
M
M
M    !1?=?4KY=GMOJ&\60W!N]_:8]$)5W.,K)=CFG]S'@),Q?*DSR7:WTW2:
MNTM<+)7\(JJ/=1Z)E8WIQ:]/(J(OR&N%IM.V#9U0UVFK#;4K:"HD<L-5"QLJ
M1JO!7,7*;N<)P>G#F!CMA<:U?=&7*HA\*..6NE5R<L*KFI^LAMX5%W/^RV70
MEOJ;A>U8^_5S4:]K';R01\]S/6JKQ54X<$QVK;H
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MIT;6/2-J2N7>5<.<G/JZP)^
M
M
M
M
M
M
M
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M5!)'25[&.BKVR)NM5SE;X3>I$5.*YY<2Q@
M
M
M
M
M    16^;.])7VXS5]WL%#55LV.DF>SPG81$3*IXD1"5 #1SNBK!:].;2)*"R
M4<5'1]ZQ2)%'G&51<KQ\AM%:MD^AG6VD=)IBW/>L3%<Y6*N5QQ7F:W]U6N=K
M4_BHX/F4W)MJ8MU*G9$SY@*9VMW[9SI2\6VUZGTJM?+'1M2G6*!CFQ1(Y41B
M;SD[%)KK/7UKT1H>W7Q]#42V^98888(=UKF-<Q7-X*N."--?^ZZQ]<.V_FYG
M[20FO=%\-@VG?Z>D_82$B4N[H'1+=/0719JQ9)9%C[Q;$BU#%3FJIO;J)RX[
MW'/EQZ-*[=]$Z@JGTZU=1;)&M5R+<&-C:['/#D<J9\N"$=R+IZV5&D[M=:JA
MIIZQU:M.V66-'*UC8V+A%7EQ<N?,5)M-L=-)MWN%HAC9#2SW&*/<C3=1J/1F
M<(G+W2D#8"Y=T9HFCKWTT3;I61L7'?$%.WHU\:;SD54\Q9NDM36K5EFCNEAJ
MVU-&]5;O85JM<G-KD7BBIE"NMN>F+/;=B5WIK?;J:"*B9"Z#<C1%8J2M3*+S
MRJ*N5Z\J55W.]_J+#LUVD5T#_#HH(YX$7DDBLD1%]*-] %T:\VTZ3T=7R4%7
M/45MPC7$E/1L1ZQKV.<JHB>3*J>;1&W/2.J[E%;F255NK951L3*UB-;(Y>36
MN:JIGRX-;=B]ZTC;-2U5YU\Z>JF9X=.QT*S-=(JY<]_:J=6>M<GJV]ZHT=JF
MYT%QT=!44]<U%95.[W2%DB)Q:[@N=Y.*9QRQV ;M@A^Q_4,NJ=F]BNU4JNJI
M8.CF<O-TC%5CG>=6JOG))>JA:6SU]0SW4,$DB>5&JH&I-_K7;3NZ-HZ15Z6V
MPUC:>-B^YZ"%5<_]+=>OG+#[L7^*-A_KSOV:E<]RG&E7M9GGE3>?'032HJ]3
ME<QN?0Y2Q.[&_BI8$[:UW[-0,?LCVM:5T1LHME)=*F::XMDF5U)31;STS(Y4
M5554:B8QUEDZ VS:5UK<4MU#)4T=P?\ P<%8Q&K+PSX*HJHJ^+**1/N7-)V;
MZW[;Q/;Z>HN%7-(U\TT:/5&-7"-3/).'G*9VDTL&G=O\S;1$RDB@N%--&R)N
M&L548Y<)R3BJ\ -I]INT.V;/:&BJKO3U<[*J18V)3(U5143*JN\J$4N'=!Z,
MHZ6AE:EQJ7U422]%3Q,<^+BJ;K\O1$=PY(JD6[L9?^0].)VU$J_ZJ$D[F/3=
MMI-FM#=.\J=UPK9)7OG=&BOPCU:C4=C./!Y>-0(KW4E''?\ 0&G-5T]-/3JV
M1&+'.S=E;'*U53>3*XPK4X9^Z+.V%:J?JW9O;:RI>KZVGS25+EYN>S'A+XU:
MK57QJ>+ND(&S;';ZKDXQ]"]OB5)F?N52!=QM5/?9=34JJO1Q5$,K4[%<UR+^
MH@&Q(
M
M
M
M                                    -*NZG=G:Y6)][30)_JFYU!PH
M:?\ HV_,1K4>SG2>I+H^XWRRP5E:YJ,=*]ST541,(G!4)6QJ,8UK4PUJ81/$
M!J)W73O^D:WIV6YG[20F_='/3ZQ&FDZUJ*3]A(7!J70FF=35S*R_6>FKJEC$
MC;))G*-157'!>U5/3?=)6*_6BGM=WML-504ZM=%"]51K%:BM3&%ZD54 JKN0
M$_Z-+@O;=)/V414FT'CW3<B)_*M)\T9MMIG3EHTQ;WT-@H8J&E?(LKHX\X5Z
MHB*O%>Q$]!C*S9]I:LU M\JK+32W99&R]\N5V]OMQNKSQPP@&%[H/AL=U+_0
MQ_M6%(]S-9DU)HS:+9=Y&.K:>")KUY-<K9MU?,N#:2]6JAO=KJ+==:=E313H
MC98GYPY$7/5XT0QNE=':?TGWS]3MLAH.^=WI>C5R[^[G&<JO+*^D#4;9346#
M1>MKG9]IEEIGQKB)7U5.DO>\C5X+A47P7(O-/%U$EVAZYTJZ_45IV::/TW='
MR8:Z:2U([?D5>#6-PF?+XS8_5.AM-:J>V2_V:EK)FINI*YJM>B=F\F%P=-+Z
M TMI:=9[#9:2DJ%3'3(U7/QV;SLJ@'OT?;Y;7IFW4=33T5-4QPMZ:*BB2.%L
MB\7(QJ<DRJF0N5-WY;JJF7E-$Z/THJ?O/0 -.>YBD2U;99*&H\&66FJ*1$7[
MYJHY?DC4L/NQUQIC3_\ 7'_J*0S:31KLY[H:W7UB+';:NI96[R)P1KEW9F_*
MY?(Y#9O5.E;)JRE@I]04$5=!"_I(VO<Y$:[&,\%3J A'<RMW=C]H7[Z2=?\
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M@MS95IGZD= V>T/:B5$4*/J/Z5WA/X]>%54\B(!*P
M
M
M                                     =)Y8X(GRSR,CB8F7/>N$1/&
MI$:G:;HZFJ.ADOU*K\X56;SVIYT14+5I:_PQM$S$=TQ!X;/>+=>:;OBTUM/6
M0\E="]'8\O8>XB8F.DI  0
M
M      (MK[0=BUU1TU/J"GDD2G>KXGQ2*Q[%7GQ3J7">@D5OI64-!34D3I'1
MP1MB:Z1V\Y4:F$RO6O#F?<      $/NVSFP7?6M+JBYQ5%3<:5&)"R255B9N
MY5JHSQ*JKY>),
M
M
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MB61K=UR)P553GGM4#<H
M
M
M
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M;L:T_CKZ=?\ ;R%F
M
M
M
M                                                           !
M1=MVI:@J=O\ +HYR47L.VIDB3$2])AL2N]UGM3L+T-3]/*CNZ\J%3W]4)_L'
MFV    "JKOL3LUSVA)JV:Y7!M7WU'5] W<Z/>8J*B<LX7=0M4    *5[K?[5
M\'YQB_4D+J*5[K?[5T/YQB_4D D'<W_:9T[Y)_V\A916O<W_ &F=._DS_MY"
MR@
M
M
M
M                                        :67G4.UZ&ZUB0RZJ;"DS
M]Q$IY%3=WEQCP>6#=,U=N&JMM.C:ZJ[ZMM1<;<R1RL=+2I4,1F5PJOC\+EVJ
M! ?JFVQ+RJ-5_%I/HG9NH]LB\IM6+_HTGT2QK%W3LL3TAU-IM6N1</DHY5:J
M?YM_TBQ]/[=]"7A&-?='VZ9W^3K859CRN3+4](%%;$K'JM^VBTWC4%JNZ*^2
M:2>JJ:9[455B>F7.5.M50W&/!:KM;KK"V>UU]+6PN3A)3RMD3THJGO
M   %*]UO]JZ'\XQ?J2%U%*]UM]JZ+\XQ?JR A(.YP^TSIW\F;]O(645MW.'V
MF=.?DS?MY"R0
M
M
M
M                                                  =.FB_",_20
M[FEM\V,;2I;O72T]KE?#).][%;7Q(BM5RJG!7@;>7FS6.]Q]'>+?;ZYG941,
MDQY,IP*[ONP;0%TWG4]'+;I%^ZI*A43/Y+MY/0B&N_UEMI^?^IZCX_#_ .H=
MV[%-J&/^JI__ +A#_P"H!=6AMA/U'Z^ME\M=_2JHZ9SUD@ECW7JCF.;A%:N%
MYIU(7J:J[&=E^O\ 3^T>SW.]V^6&VP.?TSG5L;TPL;D3P4>JKQ5.HVJ
M    %+=UM]JV+\X1?JR%TE+=UM]JV+\X1?JR A(.YP^TSIS\F;]O(625MW./
MVF=.?DS?MY"R0
M
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MYTTS*BGBGB7,<C4>U>U%3*'T
M                                           !UD54C>K4RY$7">,#
M7G;AMTJ[#>I]/:-2%:N!=RIK7M23<?UL8U>"JG6JYXY3' JJ+:]M2I'=]RW*
ML=#G>7IJ&/HU3]#@GD)7W+-)0W?:)?:^^,CFO$;%GA;,G%'N>O2/1%^Z3Y,J
M;8N1'-5KD147@J+U@5-L*VNLV@Q5%OND$5)?:5G2.;$J]'/'G"N:BJJHJ*J9
M3*\T5.Q+:-3&045F[K.G@TPV-E,M6UKXH/<,5\/V5J(G4BJY<=2^0VS
M    %+=UM]JV/\X1?JO+I*6[K;[5L?YPB_5>"$@[G'[3.G/R9OV\A9)6W<X_
M:9TY^3-^WD+)
M
M                                           (1KE=8-N$2Z:>B471
MIO(QD;G;^5SG?3LQR(SG:4[E/4)_FH$_<$Z2+6%QN5YU'!I&P5+Z-70]\W.O
MB7[)3PJN&LC7JD>J+A>I$R9>Q:&TU9($CHK/1K(ONYYHTEFD7K5SW9<J^<B&
MQSO]-5:Z2^/>^[=\TO2J]&HN[T*;ON>&.?(M,(0B_;/+;*_V1TPV/3]^BRZ*
MKH8TC;(OWLK$3$C%7&45,^,RVA+]-J"Q)-7T[:6YTTKZ6MIVYQ',Q<*B9ZE3
M#D\3D)"4S6NU!]<G5[M*.J&4V_2I4]&QCFK,D*9]TB\=W=S@"Y@5.V7:%GA+
M5>>"'Z)/](^RWL,Q=0/WJU7*J^"U%1O5G=X 9D  "F.ZETVZYZ&BO5*U4K+/
M,DN\WFD;E1'>A=U?,7.>*]VV"[V>NMU6U'05<+X7HO8Y%3]X%0Z^VAH_N>(K
MS!*B5UVIF43<+Q21V6R^=$;)Y\$OV,Z6^I+9G;*!6;E;+%WU4Y3CTKTRJ+Y$
MPW^R4!HS0&KZ_4MDTG?K95,TW:;E+5NGEA5(G-X*J([DJ.W.'Y:FW8&E6QC1
MM_U=77^FM6K:FPU5.]KIXHWR(LRJKD5RHUR<EX<>TLR38+JVHC<RJVD5TC7<
M%:Y)GHJ>/,IVUYLYU9I/7U1K79JR.H2=ROGH4YY=[M-WAOM<O'"+E%7AVGGN
MU^VQ:ZIDLU'IQ=/03)N5%4Y'1+CK\-W%$\3450)#:M!+L_V+Z\MJ7J.Z)-25
M,R[D71I$[H%14]TO%<(>KN3H]S90UWW]=,[]5/W&3IMGR:2V)7W3MI:^LN-1
M05"RO8WPJB=\:IP3T-1/$G6?3N<K+<+#LQI**\44]%6)43/=#,W=<B*[@N/(
M!7G=B-^QZ8=_.G_W#.=U<O\ T86U5Z[C%^RD.G=1Z8OFHX]/I8;755ZPNFZ3
MH&;VYG=QGT*9/ND;#=[]L[MU'9K=4UM5'712.B@8KG(U(Y$5<)U95/2!!.Z!
M21^Q39^]J*L2,A1RIRST'#]YL%H.:&HT38):546%U#"K<=FXA%J[1/U5[&;=
MIVXQK25B4$",65O&"9C$PJIY<HOB52K=*5VUK9M0/T^W2RWNBB<JTTK,R-8B
MKR1S5]SGCA414R!LJ^:-DC6/D8U[O<M5<*OD0UYV)?;ZVA[O/[+CX9#([.=
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M
M                    #5W:_LHU)I_5T^K=GJ53HYGNGD92.Q-3O=G>W43B
MYJY7@F<9QC!!EUQM<N#?8]M3?W/?X"M92*U_'AS1B*GI+"V@]TA<+=J2MM^E
MK902TE+(Z%:BKWWK*YJJBN:C7(B-RG#GGGXB,>V;UA_)EBS_ $,O_J 6#W.^
MR.XZ>N4NI]71='='-5M+3O<CWQ;WNI'JF?"5.")GDJYX\K_-;-DNW;4NK]H%
MJL=RHK3%25:R(]\$4B/3=C<Y,*KU3FU.HV3         %+=UM]JV/\X1?JO+
MI*6[K;[5L?YPB_5>$PD'<X?:9TY^3-^WD+)*V[G#[3.G?R9OV\A9(0
M
M
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M;88U5R00)]TJJGNG97R97M)X
M                                              5,M5.T!RX:J\\
M:F[(+#8],;6]1Z=US2V^21&JE&^X1M<QR;V\CD5W!%<Q47Y#8-MCT$J9;;-,
M*GB@@]1J&EIU7MDUS=ZFF:V>KC57/2:5&-@CWE1K$SU)G&$,^G<Z:ZQ_W6G^
ME+]$#:JU6K2E-<(I;30V.*L;GHWTT439$X+G"M3/+)(C638_L6U7I7:):;S=
MEMZT5*LBR=%.KG>%&YJ83=3K5#9L         4MW6WVK8OSA%^J\NDI7NM_M
M71?G"+]5X(2#N;_M,Z=_)F_;R%E%:]S?]IG3OY,W[>0LH
M
M
M
M
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MLHK7N;_M,:=_)G_;R%E
M
M
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MTO.L+KI7:E06J^21S:<OB;E#/T:-=33IA%C<J<T5<<5X^$G8I98
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MLLK/N;/M,Z>_S_[>0LP
M
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M)]#:ABD1%8^WSHN?Z-Q5_<BS/DV:UC'JJMBN,C6>)%9&OSJH%W
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M -O(6:5CW-*YV,V'RS_MWEG
M
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M_*G_ &SRT"J^YBB='L=M"N=O))).Y$^]3I7)CY/E+4
M
M
M               8&$[  &$[
M !4145%3*+U'FM]OH[; Z&W4E/20N<KU9!&C&JY>:X3K4](
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MWD++
M
M
M
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M"0=S=]IG3WDG_;R%EE:=S=]IG3WDG_;R%E@
M
M
M       ?'ONG3_+Q?IH.^Z;WQ#^FAAY**FZ1Z][Q<U^X0X[QI5YT\/Z" 9I*
MF!>4T7Z:'T:Y'-16JBHO6A@?8^C7_LT/Z"&8H(VQ4D;(VHUJ)P1$PB<2!]P
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M'.1J9<J(G+BH'("KCF   147.%Y  ,IE4RF4Z@ !U8]C\[CFNQSPN<'8
M                                   #J U1VI[*-3:<U;/JG9ZM544L
M\CJA.\7+T].YRJKD1$XN8N5QC/!<*G6M9VRY:_9JBMK[<R]-OU:UT4\D5,[I
M7HN,IA&\.2<L8P36ZLVI;+;S755$VOCM+ZA\K=W%12N:KE7BWBC57S*3'1_=
M-QOZ.'5MG6-V41U30KEOE5CESZ%4#)]SSLEN5DNS]5ZP8YES<UW>U/([>>Q7
M^ZD>OWRHJHB9ZUSQ-@2.Z/UMI[5],LVG[G#5*B9?%G=D9^4Q>*$B
M %*=UQ]J^#\XQ?J2%UE*]UO]J^'\XQ?J2 AGNYL^TSI__/\ [>0LPK'N:E_Z
M&K#XEG_;/+.
M
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M?"+Z@,L#$^R%;[WI_A5^B$N%;[VI_A5^B-ITRP,6E=6K_P!G@^$7U'/?M7^
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MH[^JOP4/Z2@90&+[^JOP4/Z2^H=_57X*'])0,H#%]^U7X.'])1W]5?@H?TE
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MIKZAW]5_@H/TE RH,7WY6?@X/2IS'5UBR-:Z*#"KC*.4#)@
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MKS2?)-+<T;=43@,'(0S6<8.4  Y0[Q?PC?*?,[1_PC?*@&4
M     &%DZ=9'XI)U3>7CX/'Y3I_A*?\ 8IU_1]9G0!@%=4HG^(5'^KZS,4&]
MWI'OL<QW'+7<TXGW
M
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MC&.)/>^M<JO@V[3N/'53?0,,VVZW;JYU^6BL+I74*4/1)52HW=Z3?WL[G//
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M*=4.T?NV^4#*@ D
M
M                                     !51$555$1.M2E^Z%VA7?2$F
MF6:;KX(EJYI.^/ 9)EK=S"<<X3PEY 70#I'-')_!R,?^2Y%.X
M"E.ZX^U=#^<8OU)"ZRE>ZX^U=#^<8OU) /5W.WVGK+^5-^V>6(A77<Z_:>LO
MY4W[9Y8\;<NP!#=6.1->:'3/'IZK]@I,W<RD=?:O<[7]+446'P6B3<9A>$BY
M^R>GW/F+NHY8KA0T]92N1T,[$D8O:BIDWS</;%2MI\U*WBTS$.#@^BQHWW3D
M3SGFGJZ2!/LU7!'^5(B&$1,]EV/NNG;/=ZAL]SMM)53-;N(^6-'*B=F?.I&M
M<Z2TQ1:*O<S;3002K22LBD2)$5)'-5&87MWE0D[]2V&'/2WFWMQS3IVJOSE7
M[8=5TMV[TMMHJF5%)']EE>S.'/Y(GF3/I.GA^'MDR168Z*7O%:[3O36D=)W3
M3UNN#++;G]-3L<Y>B1<.W4WD\J+E".:AU=I_2#JBGT?;Z+V2>G1R311HC&)G
MDJI[I?%R*]LUXU!46QNF[1+.Z&:1SDAB3PERG%,]3>"JO5SR6;HG9=36WHZV
M_JRJJDPJ4Z)F.-?']\OR>4ZIX;%PTS;+._2&?B6O&JHEIW2%]UQ7I=+W/+'2
M/7*S2^Z>G8QO9X^7E+;@L+;'89J32K*:EJU1-V6=JO1RYXJ_'%>&3.)A&HC4
M1$1,(B=0.3/Q-\W2>E?1I2D4^J(=[:Y5/^L+-G^@?ZS&VVR:WH+G=*V.XV=T
ME>]CY$6%^$5C$8F./8A8.3C*F"^T0[UUK(Y&U%PM"PNX2-[V<Y%;UIQ4B.O=
MFSHU?<M--<CVKONI6<T7GEGJ]'86YQ&33#FOAMS4_P#:+5B\:LJ;9_M-?#(R
MU:K<Y%1=QE6],*U>6)/I>GM+0?9[54?9N\*&9)/"W^A8[>SUYQQ(CKO0%)J)
MCZNCW::YHGN\>#+XG>OYR Z4U==]!U[[5>:>:6B:[#H'KX47\Z->2IUXY+XC
MKG%CXJ.?#TMYQ_PRBUL?2W;U3G7UIML%[T9T=OHV(^Z[CD2%J;R+%)P7AQ):
MMFM2<K91(O\ 0,]15FTW7%)67C3\MG>RH@H9&UJNY>'RW5[%1,Y\I;E#50W"
MWT]93.WH9V)(Q?$J9.;+@MCI6UH[M*WBTZ@A@B@B2.")D3$Y-8U&IZ$.W4=C
M@P6=3@[*< <  #E#NAT0Y0#Z(JG.5.B*<Y [94XR<9.,@=LA%.N1D#OO#>.F
M1D#MDX.,G&0.V3C)P$4#DX  )P(%M)T)'?X7U]M8UET8WBWDDR)U+X^Q?,I/
M0BX+XLEL5N>G=%JQ:-2J'9AKN2W5#;%J21S($7HX9I>"PNSC<?GJ\:\O)RF-
MRUE3TFO::PXC=!-&W,Z.]S([BU.S&,>E##;7])T,]GGOT3V4U93HG29X).BJ
MB(B_SN/!?,OBI1LCVO;(URI(U45'9XHJ<CUL?#X>*WECIY3'S]7/-[8_=EMB
MK50XP8?0M]9J33%-6Y3OAOV*=O9(G/T\%\YF53!X]JS2TUMWAT1.XW#C!PIV
M.%*I=0 2"'9#J<H!YKK1>R%$ZG[ZJJ7*HO24TBQO3'C,)]2#E_\ B"_?'%]1
M)CE"$H=2:!AHZBKGIK]?8I:IZ23.;6*F^Y$1J*O#L1$,C1Z8?3544RWZ^3)&
MY'='+5JK78ZE3'%"0(<DH=\\0GB.J'*+@"K=N.I.CI8;#3/\*3$M1A>34]RW
MSKQ\R%-H71?MET]XO%7<*B^?9)WJ_'>O).I/=]280C-PV:NH]0V>UK=-_P!D
M4G7I>]\='T34=RWN.<XYI@]OAN)X?#CBG-^T_P##EO2]IWIC]E.H$L6J(V3O
MW*.L3H9%5>#5^Y=Z>'D538=_,IQVQYR?]^8<G92_\9:]I@FIK72P54Z5$\<:
M,?*C=W?5.&<94X^.R8LMHOCG<^;3%6U8U9ZD4P=^CU"^IB6Q5-MBI]SPVU,+
MGN5V>:*BIPQ@S0.!LA-SMNMJZWU5(^X65K*B)T3G)3ORB.1454\+QG2UVO6E
M!;*2B9<+,L=-$V)KEIGJJHU,)GPO$3G)QQ C=MMMYJ73P:EJ+=5T$L:L=#%3
MJW>\ZN4JW5^E;CH>[QW>PR2]Y-=EDJ<5B7[U_:B]O)2]3K-%'4020SL;)%(U
M6O8Y,HY%YHJ&W#\1;!;<=8GO"MZ1>/FBVB-<6[4MO_PF:&DN,2?98I'HU%_G
M-5>:?,9QUTMC?=7*B3_/M]93.TC9VZS;]PM<7?%L5=Y\3F[ZP^5%YM\?5U]I
MGMF[-$:G8VBN&E[%#=6-Y=Y1HV9$YJWAS[4_]IMGX>O+XV#K7T]%:7G?)?NL
MA+K:UY7*B7_/M]9S[)VY?<W"D=Y)F^LK'2EGT=<=>ZCMJZ>L[H4>BTJ=ZL5J
M;B(UZ)PZUX^DG3=!:3B>CF:;L[7-7*+WG'P7T'-?';'.K+Q,3V9\8.RH"B74
MX.3@#DY0X"$#NTQVH;!1:BHFTMRZ98&OW]V-ZMRO'GZ3((I@M7:E^IZGIWI2
MI4+,Y6X63<QCS*6K::SN.Y,;Z,0[99IG=7$=6B^*=?4830VSRQ7?3D597LJ5
MG=-,Q=V;"89*]J=78U#U?7.<G'V,;\/_ ,)B]):Z?9;%'0K0LFW99I-_I53W
M<KGXQCJWL&L<3F_OE7PZ^B=:;T39].W!U9;$J62N8L:H^97-5%[4\QE[O:;=
M>(.AN=)%4,ZM]O%/(O-"+:<UTEXN\- M D2RY\-)<XPBKRQXB:+UE)R7M;FF
M>J8B(C4*PU!LCI9FNDL=6Z!_5#/X35_M<T^4BLKM:Z!;ESYHJ/.ZURJDL*KX
MLYQ\BE\MSG@4EMLU"ZOO,=H@=_@]%QDPO!TBI^Y.'G4]'A,^3-;P[^]'S8Y*
MUK'-'25>I63I7]^MD<E5TG3)(G!4?G.?23.Q:6U!KR=+C752]ZN<J+4S/WN7
M-&M1?4A!2RMB6HN\;Q)9ZA^(*SPHLKP;(B?O1,>5$/2XGFICFV/O#"FIG4K(
MTQH>RZ>W9((.^*M.<\WA.SXDY)YB4;QT<G$'S=[VO.[3N7;$1$:A'+Q!JMUR
ME=:*RTQT*HFXR>![GHN..5143F8/4-EUM>;+5VV6XV5D52SHW.;3/RB?I$^&
M2J4*[TURC41;A8^"<^]9/I$8U9H"[76AJ;E5244MX;A4921+&V5J=N57PO'U
M\BVAY2^/+?%;GIW1-8M&I59LJUVLCH[#?Y%;.U>CIYI."KCAN.\?9GR<RU7Q
MJB\.15FU30JUB2WNSLQ4L3>GA:G\(B?=I_.[>WR\\?I;6=/>[.VUZFU#6V2>
MF5'1W""=L73-1%3=>YR*F4^7AU\^K-BKFIX^&/K'HSI::3R7_1<*1J.C4JIT
MVEF.7.UV\^1+G"[_ ,LPFDKO9[A;JF6[;5KM33LJI8F,[_B9O1([P'8<S/%N
M.)Q-=+O<U4.8?=M\I7FF)]/OOE*VCVD7&[3JJ[E%-7Q2-E7"\%:UB*O;SZBQ
M8TQ(GE R8
M
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MRHI962PO1'->QV45.U%.\?ND\IX\.ED
M
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M;<J?T#209" 8!-#Z73E8K?\  H>ZT6"T6::26U6VDI)9&[KWPQ(Q7)V*J&1
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MT(GAIY3QN*G';)-L<])=--Q75F0 !SK@
M
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MJ>X3Q6K1%3<:-JIT=2ZL2G63@F? >S*<<IY@):"OJ_6^KJ"*.2KV=3,9)+'
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M)R_1.._XD_R-=\1F^@ NE!3W2BDI*UBO@?C>:CE;R7*<4XD?70%@=_V>9/\
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M&>
M
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MTW9(78Y.3YE3@I)C3GN:J^MTYMBDL4RJC:I)J.HCSPWXT<Y%\J*Q4_M*;C
M#Y5<3IZ2>*.5T+Y&.8V1J95BJF$<F>M.8&JO=&;5*B]7.HTCIR1R4$,G0U<D
M?.HE1<+&G\U%X>-?%SG?<_;'VZ78R_ZFB8Z^/3[! Y4<E*U>O\M?DY=ICI.Y
MAM;Y5D^J:X[ZKO*YT+%55[<Y/4WN<8$7/U97KS(B?O OLQ=TT[9;M4-GNMGM
MU;.UNXDE13,D<C>S+D5<<5X>,[Z;M:62PV^V)43524D+8>FF7+Y-U,97QF1
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MZZNBI66:^PND7'23T3F,;XU<J\$)(
M
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M&/T7<79QK;4B>1T'_IDLH8'4M'! ^>6H=&Q&++,J*]^$YNPB)E?(?<
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MK^C;^NT$,W8;):[)1MAM%NI**-417-IXFQ[R]JX3B9(ZQ_P;?(AV
M
M
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M]C$J<.!G;?0:K970OK[[;)J5KLR116US'/3L1RRKCRX"4E  0
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MO.)[$1.O.\JY,N
M
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MK7#*RLN]9<WO<BH^I1B;GB3=1#+
M   ,-?-,VR]SLFN,=2Z1C=Q%BJYH4QG/)CD1>9F0!$9=G.FY8G1RTU<^-R;K
MFNN52J*G8OV0XCV<Z;BC;'%35T<;$PUK+E4HB)V(B2$O &%LFF+79:AT]O95
M-D<W<7I:R:5,>1[E3SF:
M
M
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MW2<\>0S5AU#!>I98X*.Y4_1M1RNJJ1\+5\2*Y.*@U+,@ (
M
M
M
M
M           !U :V7;N9IJ^YUE6FIF-6HF?+NK2*N-YRKCW7C,?+W+E<C5Z+
M4],J]6]2N3_>,A<>Z?6BN%52_4FC^@E='O>R&,[JJF?X/Q'F=W4[U3P=(M1?
M'</_ .6!@]A.BV6/;;4VN^5JP7BSJZ2")B994M5BHJHJ\?<O:Y$YXSV&W!I[
MLPO=TV@=T52ZBBH^]_"66=L:JYL,38>CXN\?!/*IN$         *5[K;[5T/
MYPB_4D+J*5[K?[5T/YQB_4D!#.]S5]IFP?Y_]N\LTK+N:OM,V#RS_MWEF@
M
M
M
M
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M-@\L_P"WD+-*R[FO[3-@_P _^WD+-
M
M
M
M
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M
M
M
M
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MJ*6[K7[5T7YPB_5>"&>[FW[3.GO)/^WD++*T[F[[3.GO)/\ MY"RP
M
M
M
M
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M:M>%7V2HL)Q_AV^LZ-OUG<F6W6WJG:E0SU@9(&.]G;0G_>M!\89ZSCV?L_\
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M@>@
M
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MI_\ $]'\6?ZRJKCH"JH=J3-%OKXWU#JF.F2J1B[OAHU47=SGAO&_IJ5J/_\
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MLLU3_4)/F*N[C?\ BMJ#^N,_4 C2]RY=.K4U'YZ9WK.OM7+M^,M#\7?ZS:H
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M(V)&QK&IAK41$3Q'(
M
M
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M&9D<;$RYSE8J(B(G-2E^Y1TW>K"[4;KW:JZWI-T/1]\PNCW\;^<93CS0V#
M
M
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MBOA?V+XNQ>L"5@
M
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M2JG%<(B)UJ>71]^U/LVVDT^B]:UCKI9KHYL+'3.65JI(NZU[5=QPJ\'-7AS
MMC0>JK!M=T5/!6TT4CU8D5PH).;'+]TWKPJIEKDXICM0BNRW9)?=![2JZJH;
MLWZEW1KB-RY?4(N=UCF\D<Q<+O=?#'-43(V#8NS3>U%FH=/766@LZL<Z2BCX
MN5RK_!Y7*+&O/CQ3'#J5+A \=XN5)9[55W&XS-AHZ6-TLLCON6HF5_\ Z% 7
M#NF6QU#IJ#255-:4?N-J9JCHU=YD:J(OBRI9>WNSU]\V5WNDM6\ZH:QLRQMY
MR-8Y'.;Z$SYB ;(MI&B*W9?!I[5$M!0+1T_>]12U2(C)VIGPV]JKS5.>]GQ
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M
M
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M;553JYZ*J2JB-C:W.ZU$3FO'G\Q+=-+<UL- M_2G;=5A;WRE/GHT?CCC)D@
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M=S:J.3F]>&4Y(GCQFZ@.E/$V"".&/.Y&U&-WE55PB8XJO%3N
M
M
M                                                'BM%IM]GIW4]
MJHJ>CA<]9',A8C45RKE57'6>T    *\V]:4GU?LXKZ*AC?+7T[FU5/&SG(]N
M4W?.USO/@P^PO9+3:'M\=SNK6SZCG9X;^:4S53BQOC[5\R<.=M@
M                  /C6TE/74DU+60QSTTS%9)'(F6O:O!45#K;Z*FMU'%2
M4%/%34L3=V.*)J-:U.Q$0]     5+W2&B;AK+2=OCLD#JBXTU8U6L1<)N/16
MN5<]2>"N>Q%+: %>['MF5OV?69$1&5%ZJ&IWU5XY_P QG8U/EYKU(EA
M                     #QW6UT-WI%I;I205E,KFO6*9B/;E%RBX7QGL '#
M6HQJ-8B-:B81$3"(AR    % ;<]DMRUIM&LM9:E6.EJH%AK:AR9;3HQ<H[QJ
MY'81.U"XM%:5M>CK!!:;+#T<$?%[UXNE?UO<O6JF=
M         >&X6BWW&IHZBOHJ>IGHWK)3OEC1RQ.[6YY*>X    !KEK[8G6ZK
MVSU%8CGT^GZJ..IJ:GAE'XW71L3M7=1>Q-[S&QH Q^G[+0:?M%-;+13,IJ*G
M;NLC;\JJO6J\U4R
M
M
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M;$MJVL=8:O\ 8R_V>FCH5@?(L\-/)$L:IC&5<Y45%Y8\9?8
M
M
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MZFIE/'Q-3+#>;OJ';-I^Z:@?(ZNJ;E2R>&W=1&+(W=1J=3<<@-[@
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M/;8;G=M52Z0US21TU\8]\<<S&[B.>Q%5S'MSC/!<*G!>SMO4
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MI;W0QNAZ15CEA<N5BD;[IN>OJ5%[%3D!)MQOWK?0$:B<D3T'(
M
M
M                                      $%VZ?:EU/_ %5?UD)T03;H
MN[LEU.O_ ,JJ?ZR 0'N/,_4)=OZ^OZC2;=T&V)VQ[4J3[NZD+%3/WW2-Q\N#
M679+MCJ=G=CK+=3V>&N2>?I]]\RLPNZB8PB+V'JUYM<U+M2H8--T5HCA9/,U
MRP4F])),J>Y1?$B\>75X@)YW/UJH[YL/U%;[[<9[;:)+@O2U$4K8E:U&1JY-
MYR*B(N$1?$I\:J;85I>UST<<3KY4*QR+*W?ED<N.I_!J>5#(:\T'6Z5[FF.T
M0,?+613QUM>D:;V%5<NY=3?!3/8W)"MENN- Z;T?''6:;?7ZL:K]URTS9>F>
MJKN(BJO!,83")Z0._<G*RKUEJ&U2(KK?76N1)87<4<B/:U,^9[D\ZF5[GJIF
MT9MCO>D*I[NBJ'2P-W^&\^)5<QV/&W>])ANY/G;'M7K65")%--0S-:Q4PN]O
ML<K<>1%]!G.Z:MU7I':+9M:69>BEJ-U5?C*)/'PX^5N$QXE \6T%K]I7='4M
MDA59K?1S,IGIU)''X4R^==Y/0;9L:C&-:U$1K4PB)U(:V]R1I^2KJ;YJ^O1S
MYYGK31/=]TJJCY'>G=3TFR8$>U+HVQZFK[=5WVB2L?0*Y8&2.7<178RJMY.Y
M)SX&M>TIJ,[J:U,8B-8VLMZ-1$X(F(S;4U*VE+GNJ[=GDE=;T^2,#;4
M             "N.Z*^T[J+\B+]JPL<KGNB?M.ZBS]Y%^U8!&>Y&^U?4_G*7
M]2,^_=3Z<H[ELTJKN^&-*^V21OCFW?"W'/1CF9[/"SCM0P_<K7VT6W9I4Q7&
MZT%)*EPE=N3U#(UPK(\+A5Y<%.>Z6VB6&79_46.T72BN%;<)(VN;2S-E2.-K
MT>KE5JJB+EJ)CGQ ^&Q74]\I>Y_EDT_;'W:[457)24L"<43>5'[SNU&[ZKCS
M<#%IIS;?<[54W>NU&MND8UTK:-948Y41,XPQNZGG4\VF=07397W.MMN=!!'[
M(7FX.='WPU52-KFKNOQUY;$BIG[XXM.E]H&T+2/U0:AULZCL]1%)-T$2JF6-
MRBY:W#43@O#B!TV=ZYU9KO9]J^SS76J2^6VG;6T=9"NY*]&KET:JW&<XPG7X
M1..Y>UU6ZHT_<;=?*V2KN=!*CVR2NR]\+TX<>:X<B\?&A6O<><-<7IB*BM6W
MKY_LC#RV*XQ;&]N]W@K-YEI>V6/*(J_87ITD6.W"HU%\X$FVFZRU%?-NM%I7
M2]WK*"FADCI7][R*U'.7PI'+VX1<<?O5-F8V[C&MRKL)C*\U-7^Y<M$^HM;7
M_6ER;O.8YS8W+^%E7><J>1O#^T;0@4QMOV>:CV@:HLU)15B4VGH85?.Y[_!;
M+O+Q1B<7.W51$SP3CRXYIC0MDI]-]TK0V>C?(^GHZY\372+ERXB=Q4W.-0[6
MN]W6CE__ %27]FX"<=V/5R,TUIZC:Y4BFJY)')VJQB(GZZEC:/H(5V&VRC5C
M>BEL34<W'!=Z'*^E54K_ +L*W2SZ2LEP8U5CI:MT;\=6^W@OI9\I--(WRG9W
M/]'<^D;T5-9%:Y<_=1QJQ4\N6X JON-*V1*O4U#G["K(9L=CLN3YC9XUI[C6
MVR-CU+<W-5(W.BIVKC@JIO.7YT])LL                !J9HW_ /-Q5?U^
MM_92&U=?1TUQHIZ.N@CJ*:9JLDBD;O-<B]2H:G:;JZ:A[K"LJ*VHAIZ=M?6;
MTDST8U,Q2(F57AS7!LG=-?:3ME+-/5ZCM+6Q-5RM95L>]?$C47*KXD0#6C8K
M&NE.Z.K;'3.7O99:NA5.UC4<]ORQM+ U3+M@U;JVKI+!"_3=C@>Z.*:16MZ5
MJ+A'J["N55YHB(B(GI('L&276&WVY:E;$YE/"ZIKG*B<&])EC6KX\/5?[*GM
MLFN=HFUK5-9;-/W>GL=)"QTRI$FYNQHY&^ZPKG+Q3K1/(!\)]9;0=F6T>W6G
M5%\6ZTDKHW2,<J/9)$]VZJHJHCFJF%]'89FMU=?]"]T&VW7>]5M1IVMG16QU
M$BNC2*9/!5,\D8Y<93[U2J]K&F*O2>NJ.CN5[DO%P?%'/-._.6N5RX;Q55Y)
MGSEO]UKIQTUCL6I8&KOTV*2=4ZFNRYB^9V\G]I )]W1FKZG26SN5UMG?!<JZ
M9M+!*Q<.C3BYSD_LM5,_SD/MW/2WJHV<TERU%<:JNJJ][IHUJ'[RLBSNM3SX
M5?.AK]K_ %7/M=ONA;)0.595IXXZA,*B)4O7$J^1$:BY[%4W#M=##;+;2T-(
MU&4]-$V*-O8UJ83Y@,/M#IKM5Z)O-/IQ[V7:6!64[F/1CD<O8J\N&>)J)M2V
M52Z!T;:Z^ZUG3W>MJE9(R-<QQMW57&>;ESU__P!3=PU[[LE?^:^GT_\ G'_J
M 3#1L,U3W-T4%*BK/)8IV1HG-7*QZ)CSE8]QS<J2GK]2V^>:..JG9#)&QRHB
MO1JO1V.W&\GI+JV)JC=DNF5>J(U*)JJJ\D3*E)0:(V?;3M:W+ZCKU<+37LWI
MY8.]TZ-Z([#GQ<<HF53AX^0$+VMWF&/NAZBYV>=C^]ZVF5)(URBR,:Q'<4\:
M*BF[)H]>]$T-%MNMNDM.RSU3(JBGBFFD5'.<_@^1W!."(F>'5NJ;P@
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M*9SEY(K4<YB>)%7/]H"]0
M
M
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MW:$JY;I55C[K?9D5%JI&[J1HONMU,JN5ZW*N5\7$M$
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M.!^\R!C'NQV[K'+NM7Q\2_M(:;MVD]/TMGLT2QTE.F$WERY[EXJYR]:JO$S
M
M
M
M
M
M
M                                                           #
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g762905g15a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g15a01.jpg
M_]C_X  02D9)1@ ! 0$!0P%#  #_[1LD4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'0]
M0Y         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !0]0Y  $  0%#
MU#D  0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      -!    !@             $&@  !V$    & &< ,0 U &$
M,  Q     0                         !              =A   $&@
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $&@
M  !29VAT;&]N9P  !V$    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    %
M.$))300,     !$(     0   *    !9   !X   IN   !#L !@  ?_8_^T
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M0,YS"6N%1(+3!'S"X+"KS[CZI^TWXXW-=Z=Q:[='M^F_\W=N7>?6C_Q/Y_\
MQ+EYY@8U>7U'&QK9V7VMK>6F##C'MY5C#\A\VASAK+#<Z;76O%_A.@_%R 6[
M*\XDD:'):9 (=;ZFUWL_1"S\Y,,>T.#7U]0WD.=M%[8(;&^/?[&-W?3>]6NM
M=&^KO2,*S-?]KOJK>QGLLK$[@[5N^MOT-G^9^D5VSZI]!JZ<S/>[+:Q[&/\
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M3!$]VKS3J_2,OI.3]GRQN:Z33<![+&_R?W;/])3_ -\5C 11C>I:'.QD)0R
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MDEM5CZP3R0QSF;C_ %MJM=$_Y:P/_#%?Y5++Y)?W2H&W_]+C,K^EY'_'6_\
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MO]6[+;64MZ?TH=/Z:#8S?</>6!WYK/9<U]OY_K>I[T#%^JN=TCKK<SIN38W
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ME))))*?_V3A"24T$(0      5P    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  (  R #  ,@ Q     0 X0DE-!"(      3)-30 J    "  ' 1(  P
M  $  0   1H !0    $   !B 1L !0    $   !J 2@  P    $  @   3$
M @   !\   !R 3(  @   !0   "1AVD !     $   "H    U    40    !
M   !1     %!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD ,C R-#HP
M.#HP,B P.3HS,3HR,        Z !  ,    !__\  * "  0    !   '8: #
M  0    !   $&@         & 0,  P    $ !@   1H !0    $   $B 1L
M!0    $   $J 2@  P    $  @   @$ !     $   $R @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 3I%
M>&EF  !-30 J    "  ' 1(  P    $  0   1H !0    $   !B 1L !0
M  $   !J 2@  P    $  @   3$  @   !\   !R 3(  @   !0   "1AVD
M!     $   "H    U    40    !   !1     %!9&]B92!0:&]T;W-H;W @
M,C(N," H5VEN9&]W<RD ,C R-#HP.#HP,B P.3HS,3HR,        Z !  ,
M   !__\  * "  0    !   '8: #  0    !   $&@         & 0,  P
M  $ !@   1H !0    $   $B 1L !0    $   $J 2@  P    $  @   @$
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M 0$  @,!                 0,"! 4&_\0 .A$!  ("  0#!@4#! $$ P$
M  $" Q$$$B$Q$Q11!3(S05)A%2)Q@:%"L<$C4]'PD31#<N$D1/%B_]H # ,!
M  (1 Q$ /P#U2
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MHO>JI](T>S)0^]53Z1I2P'E<?H?BG$_5_$+I]F2B]ZJGTC1[,E#[U5/I&E+
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M4=8
M
M
M                    0;;-^8]3^]C^L>>CT+MF_,>I_>Q_6//1T^#^'^[S
M/M?X\?I_R  VG+  $  "0   ;32UK;>K]1V^25T39W*U7M3*IA%7^A)-H6@W
M:5@IZFGJ'U5-(NX]SFHU6NZC";UBT5GNMK@O;'.6(Z0@X)KL]T7#JJEKY9JR
M2G6F5,(QB.WLHO;YB&SLZ.>1B+E&N5N?,I,7B9FL?)%L5JTB\]I[/@ S+/;:
MB[W*"AHVHZHF=NM15PA,SKK*N(F9U##!OM9:=?IFZ14,TS9I5A;*YS4PB*JJ
MF$^([]3VFPT%!!+9KVMPJ'/1KXEB5NZW"\<^?"?"8Q>)UKYK9PVCFB>FNZ-
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M\K&I/Q2'<=-)^*0[C0=X
M
M
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MFI'8;%"FXCUSA$X>957X#<4":6O%\EL?>N^FB571Q5B-PKE3/'EPY<%RIC;
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MNW8'[L35<N-SGPZN)1;VJQ[FN14<U<*B]2F?"Q'+*CVI:TY(WVU#@ &TY@
M      7EI#VD?F0HTO+2'M8_,AH\;VJ[GL7O?]O\K&I/Q2'<=-)^)0[C0=X
M
M
M
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M[_M_E8U)^*0[CII/Q2'<:#O
M
M
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M:7EI#VD?F0T>-[5=WV+WO^W^5C4GXI#N.FD_%)YCN-!W@
M
M
M
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M))&Y'HB*N7*KDX95>I#LT'<K36[.:NQ5ETIJ&I?TC56=Z,3PERBIE>)4(,O
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M)^*0[C0=X
M
M
M                          0;;-^8]3^]C^L>>CT+MF_,>I_>1_6//1T^
M#^'^[S/M?X\?I_R  VG+  $  "0 =0
M                "                    $  "0    @   "\M(>UC\R%
M&EY:0]K'YD-'C>U7<]B][_M_E8U)^*0[CII/Q2'<:#O
M
M
M
M"#;9OS'J?WL?UCST>A=LWYCU/[R/ZQYZ.GP?PWF?:_QX_2/\@ -IRP    $
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M2/S(4:7EI#VD?F0T>-[5=SV+WO\ M_E8U)^)0[CII/Q2'<:#O
M
M
M
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MC4GXI#N.FD_%(=QH.\
M
M
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MV_.3I?PR;J)[94Z^Q#C-I*P1^.^N7GN*Y6;V$7D9M!=4JIHH]Q$WVJJ*B]:
M;,  #$N_Y*K/W+_H4RS$N_Y*K/W+_H4FO=AD]R5";1?S3JOVF?60K.W<D+,V
MB_FI5?M,^LA65NY(=6G=Y.WNMHWD<G"<CDO:@.H     0  7EI#VD?F0HTO+
M2/M8_,AH\;VJ[GL7O?\ ;_*QJ3\4AW'32?BD.XT'>
M
M
M                                                          $&
MVS?F/4_O(_K'GH]"[9OS'J?WD?UCST=/@_A_N\S[7^/'Z1_D !M.6
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MI#N-!W@
M
M
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M2\M(>TC\R&CQO]+N>Q>]_P!O\K&I/Q2'<=-)^*0[C0=X
M
M
M
M 0;;-^8]3^\C^L>>CT+MF_,>I_>1_6//1T^#^'^[S/M?X\?I_P @ -IRP
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M\BHO6ABO9=530-:U48C55R)EIVLB6/AG+3MDC;*C<\D5'<#[ ^6-PG#D?0
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M2'M(_,AH\;_2[GL7O?\ ;_*QJ3\4AW'32?BD.XT'>
M
M
M                                                          $&
MVS?F/4_O8_K'GH]"[9OS'J?WD?UCST=/@_A_N\S[7^/^T?Y  ;3E@
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MXI#N.FD_%(=QH.\
M
M
M                                (-MF_,>I_>Q_6//1Z%VS?F/4_O8_
MK'GHZ?!_#_=YGVO\>/T_Y  ;3E@       !)] _YZJ_=I])&"3Z!_P ]5?NT
M^DQOV94[KOT!^3ZG][_1"4$7T!^3ZG][_1"4'(R^_+UW!? J  K;0
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MT7\U*K]IGUD*SMW)"S-HOYJ57[3/K(5G;N2'5IW>3M[K9IR.3AO(Y+VH
M    %Y:0]K'YD*-+RTA[2/S(:/&_TNY[%[W_ &_RL:D_%(=QTTGXI#N-!W@
M
M
M
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MK'YD*-+RTA[2/S(:/&]H=SV+WO\ M_E8U)^*0[CII/Q2'<:#O
M
M
M
M      "#;9OS'J?WL?UCST>A=LWYCU/[V/ZQYZ.GP?PWF?:_QX_2/\@ -IRP
M        [*>LJ:)7NI)71/<F%5O6=9PJ9(TF)TXJ-07I%7=N$R>;!C]\-]]\
M9_F.YT:+U'ST+>PPY%T9=/COAOOOC/\ ,<=\-]]\9_F.SH6]@Z%O81X:?&=?
M?#???*?YCGO@OOOC/\Q]]"WL'0M[!X9XSK[X;[[XS_&@[X;[[XS_ #'9T+>P
M="WL'AGC.OOAOOOC/\P[X;[[XS_&AV="WL.>A;V#PSQG5WPWWWRF^-!WPWWW
MQG^8[.A;V'/0M[!X9XSJ[X;[[XS_ ##OAOOOC/\ ,=G0M[!T+>Q!X9XSK[X;
M[[XS_,.^&^^^,_S'9T+1T+>P>&>,Z^^&^^^,_P P[X;[[Y3_ #'9T+>P="WL
M'AGC.OOAOOOE/\P[X;[[XS_,=G0M[#/HK#6UB9AIG;J_I.3"#D@\7[-9WPWW
MWQG^8=\-]]\9_F)93:)G>F:B>./R-3*F=%HBD1/PM3*Y?(B(8ZAE%Y]$%[X;
M[[XS_&@[X;[[Y3_,6"FBK;C"OJ/YD^PZWZ(H53P)YVKY<*1T3SSZ(%WPWWWQ
MG^8=\-]]\9_F)?/H=R(JT]6UR]CVX-16:9N%*BN6GZ1J=<:Y)B(E'B3'R:?O
MAOOOC/\ ,<IJ&^^^,_S'TL2-<K7-5KDYHJ8"1-[$,N1'B_9\=\-]]\9_F'?#
M???&?YCLZ%O8.A:/#1XSK[X;[[XS_,.^&^^^,_S'9T+>Q!T+>P>&>,Z^^&^^
M^,_S#OAOOOC/\QV="WL'0M[!X9XSK[X;[[Y3_,.^&^^^,_S'9T+>P="W'(>&
M>,Z^^&^^^4_S#OAOOOC/\QV)"WL'0M'AGC.OOAOOOC/\P[X;[[XS_&AV="WL
M'0M[!X9XSK34-]]\I_F'?#???&?YCLZ%O8.A;V#PSQG7WPWWWQG^-!WPWWWR
MG^8[.A;V(.A;V#PSQG7WPW[WQG^8Y[X;[[XS_,=G0M[#CH6]@\,\9C55UNM=
M Z"KK)9878RUV,+@YHXE:ADI$U.H^VM1#**Z8VR;C3E.1R 9J0        O+
M2'M(_,A1I>6D/:1^9#1XW^EW/8O>_P"W^5C4GXI/,=QTTGXI#N-!W@
M
M
M
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M!%W(_,AH\;VJ[GL7O?\ ;_*Q:3\2AW'32?BD.XT'>
M
M
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MK:N!S4ZG)Q:OPF[CS4R=I<7/P67![T=/5@  M:H     !      !  "  $
M'+6JYR-:F57@B(<Q1NED1D;5<Y>"(A-M.:?Z%S9)4WIE^)I5ERQBC<MKA.$O
MQ-M5[?.77IJP)&K99VHZ5>2*GM2U--T*L1JJAC6.S\E<TF=#2MA8G Y5[S>=
MR]5APTP4Y*0R8&[L:(?8!@N
M
M
M                                         =0 &!7T3)XW(K47*%-;
M0=#OIY):ZUQ^#[:2%J?.GV%Z&'6TK96+P0LQY)QSN&OQ'#4XBG+=Y-7R@M/:
M%H=?PE=:XD;(F721-3VWE3RE6N:K7*CD5%3FBG5QY8R1N'E>)X:_#WY;?^7
M +&N          ( <M:KW(UJ*JKU(2.S:;DF<V2K3#>IB<_A*[Y*XXW9L8.&
MR<1;5(:6AH*BM=B"-53K<O)"7V72[&*CYF]+)Y4X)\!*;39,,:UD:-:G)$0F
M%LLJ-1,M0Y^7B;7Z1TAZ'AO9F+#^:W64<MEB5<>!A/,2F@LK6(F6F[IJ-D2<
MD,IJ(G(UG28L%$R-J<$,IK4:G!#D #5:EN7<VW.<U?PTG@,\_:;4KG5EP6MN
MCV-7\%!EC?/UK_YV%F*G-9J<;G\'%,QWEI557.55XJJ\5+#TI:$M]&DLK?\
MU,J97/Z*=A&-(6[U[<4ED:BPP8<[/)5ZD)]6U4-%2R5-4](X8TRYR]1;GO\
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MI*=L3$X(<NUYO.Y>IQ8J8:\E(Z/FCI6Q,1$0RP#%8
M
M
M
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M3YCLLEH1K456DIIH&Q,Q@Y=K3:=R]1CI7'6*UC40XIJ=L34PAW@$,P
M
M
M
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M(B': 0R
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M?)W??./\0FLO$M7R=WWRH0/!IZ'-*W_\0FL_U=J^3N^^/\0FL_$M7R=WWRH
M/!IZ)YI6_P#XA-9^):OD[OOC_$)K+Q+5\G=]\J #P:>B.:5O_P"(36?B6KY.
M[[X_Q":S\2U?)W??*@ \&GH<TK?_ ,0FL_U=J^3N^^/\0FLO$M7R=WWRH /!
MIZ'-*W_\0FLO$M7R=WWQ_B$UGXEJ^3N^^5 !X-/0YI6__B$UGXEJ^3N^^/\
M$)K/Q+5\G=]\J #P:>AS2M__ !":S\2U?)W??'^(36?B6KY.[[Y4 '@T]#FE
M;_\ B$UGXEJ^3N^^/\0FL_$M7R=WWRH /!IZ&Y6__B$UGXEJ^3N^^/\ $)K/
MQ+5\G=]\J #P:>AS2M__ !":S\2U?)W??'^(36?B6KY.[[Y4 '@T]#FE;_\
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MFDJ&RL3"GF\V&V&W)9L1.XW#( !4EPYJ.3"G5ZV9G.$.X <-:C4PAR
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M]Q%@ 6@":VG0R5^AZG4/=#HUA9([UOT.<[G^[>Z_,0HPK>MYF(^0  S
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M"$^I9O==/W7L4LK5MU BO@9N(BM5SUSQYJ:/3NKKOJ/U0%DI;M4,EAH*BI9
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M:ANM?4]OOMWIX%N+*=)DD8W&'H_&4[,]AIO5;?DG2G[<_P!6,V5'_P#"K/\
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MPH&>62>9\LSW/D>N\YSERJJ<U51+55$D]1(Z2:1=YSG+E54ZCO</@KAKJ.Z
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M+"BYZ-K48U5\J)C)TV'4EVL+GK:JQ\"/]LW@YJ_ O TX'AUB.7702.]ZUO\
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MWA;^]C&$7Q%.O0&SNXZUO-QMMOJZ2"6B3+W3J[==X2IPPB]A;'J1/\IJ[_\
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M>,]G M>G<NB]E4=?;8XTN%2C%=*J9XN7G\"&!LFU-<+W<ZNTWJ9:ZFFB<_\
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MLOQ'F\W>L]2UVK=05-WNBLZ>941&,3#6-3@C4\R&D+L5.2L0QF=R  L0
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MOAPIMW  7L0                    @
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M53Z>I;NO;\2IVH=+'DB\.KPO%USQKM/HZ@$X@L;8
M
M                7II3VD?F0HLO32?M(_,AR_:7]/[D+&I/Q2 4GXI <M*B
M?5<_D"P?Q3_J'F(].^JY_(%A_BG_ %#S$=/AOAPIMW  7L0
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M5M?745+4,DJJ)S6U$:9S&KF[S47SIQ-"9FW67?I2N..6L:AF@ AF
M&+<;?3W"G6*I9E.IR<VKVH90)B==D6K%HU/96-\L\UJJ-U_APN]I(B<%\GG(
MS?K1%=J16.PV9O&.3L7["Z[A1Q5U(^"=,M<G/L7M*SNE!+;JQ\$R<E\%W4Y.
MU#=P9IG]7!XKA[<+>,F/M_92LT4E-/)!.U6R,7"HIPA-=;6=:F#U]3-S-$GA
MHGZ3>WX"#QNRAU\=XO7;K<-GC/3FCO\ -]@ S;
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M^(C_ *GGZ%<H>@-N'YBR?Q$?]3S]!R.I1S_9_P +]W><A.0+&\ (
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M5%JX_M.^@U38+A5QTM!>[;4U,F=R**I8]SL)G@B+E>"&7+/HC<-R #%(
M &FU3;.Z%N<L:)T\7A,\O:AN036>6=PPR8XR5FENTJ>5$5%14RG)44JO4-"M
MLO,T*)B)_P"$C_97[.1=NJJ%**[2;B8CE\-ODSS*\V@T236R.K8GAT[N/[*\
M_P"AV.&R=?U</A+3P^?P[?/I_P (2U<H<G7"[+3L-]W@
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M5NGRE0^TEV[9J?\ B$^JX@T"Y0F^TW\BTW\2GU7$'I_:GH.'^&H]G? C]7>
M"UO                   %Z:4]I'YD*++TTG[2/S(<OVE_3^Y"QJ3\4@%)^
M*0'+2HGU7/Y L/\ %/\ J'F(].^JY_(%A_BG_4/,1T^&^'"FW< !>Q
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M,63^(C_J>?H.1Z!VX?F+)_$1_P!3S] =2CF^S_A?NR$ 0%C>
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M=E^C];ZAKHTX)TBJGP\3J;R.WO<;=JEN:L6]7( #(
MVVE/R_2>=WU5-2;;2GY?I/.[ZJF-_=E5G^%;])7GL_\ \[5?NT^DFY"-G_\
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M(#EI41ZKG\@6#^*?]0\QGIWU7/Y L/\ %/\ J'F(Z?#?#A3;N  O8@
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M8IU<D3T<K>:=A XZ^29_2M@5*>-/"PF$4W&E*CUS<:F1D:MBW."XY\2$I2
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MU**F4?.B+Y<+_P#P($[LM4ZLM\<SUWE7/'&,\3-,:VIBBBPF.'(R2$@
M".ZUU?;M)6]M3<7.?)(JI%"S&\]4_IY?*86S_75'K&DJ988'TDE.]&N9(]%S
MGDJ+\!;&&\T\371CS1O27@ J9      :K57Y!J_V4^E#:FJU5^0:O]E/I0RI
M[T*L_P *WZ2H7:;^1:;^(3ZKB#TWM2<;3?R+3?Q*?5<0:G]J>AX?X;5]G? _
M=D  M;P                  !>FD_:1^9"BR]-)^TC\R'+]I?T_N0L:E_%(
M!2?BD!RTJ)]5S^0+#_%/^H>8CT[ZKG\@6#^*?]0\Q'3X;X<*;=P %[$
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MCY&$R5:FKFG=SD>K_C4SF<CN:U$0[..O)2*^D.0 &0
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M+)_$1_U//T!Z!VX?F+)_$1_U//T'(ZM7-]G_  OW9" ("QO
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MS\YN6_T\>G Q1/%<3S3V[_M"3Z6I\JBX)_3-W8T0CFFZ7<8BX)0B81$-)Z
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M/@.OPN/\T1Z.%PU9XGB>>>W?_AJJ)F&F<G(Z*=N&G>=&7>  0
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M93Q'PK?H]6[/?QE=YF?U)D0W9[^-KOV6?U)D<O-[\LO9_P "O[_W  5-P
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MQ$?]3S]!R/0.W#\Q9/XB/^IY^@.I1S?9_P +]V0@"<@6-X
M       .HL[8SJMM%4K8Z^14AG?FF<O)KUYM\R_3YRL0USF/1\;E:]JY1R<T
M4B8VKS8HRTFLO7M+/)2SLFA<K9&+E%0LNQ72.Z422-PDK>$C.Q?L/.^S+64>
MH;>VDK)$2Z0-P]%_]Q/&3^I8MIN,UMJDF@7R.:O)R=AJY<?-'W<KAL]N$R36
M_;Y_\K+N5#!<J"HHZMB/@G8K'M[44T>D]$V?3#Y)+="YT\G!997;SD3L1>I#
M;VFYT]R@WX'>$GMF+S:9QHSN.CO5Y;ZO'5I-2:<IK\ZF=4RS1N@5=U8UQE%Y
MH9MLM-#;(F1T5-%%NIC>1J;R^=>:F<!N>R8I6)YM=1>"<31:FU-06*U/JY9H
MY'JJ-BC:Y%5[EX(GF[5[,FGVN7::T:5WX9.B9/,R&9^%54C=[;&.2^4\ZVZX
MPNU9'*C%FIJ??_!S*[>EWEQO(F.2)A,&=*<W5K<1Q/A?EB.NDBVE2T=\NK;M
M4)):[C0[OKJ1B*U)FKQ;N-ZU\I#[A8UEOE-5,J:A]'6OW$<N))6JK<IEW)25
MZN@66Q3QT,?2OJ)(T=&Y-]6X7VS%ZN'#'(Q+;IZYTLM E)3P1N:B/2*6==Y_
M:[_8J]A?%==(<J<TWCFF6+W,GMEIJ:6T5KJNHIT5[:>:)%<U>UJF?I"6)8HZ
MQ*2>GZ:!&U3Y$QAR+QW4YJAU0U=V6[03U5/3Q-1CJ9C]Y<HKU^<L>S;(J&JA
MI+M3W2J6KD:O3-G3>C>O7A$PJ8ZB)M%>K/'AOEW5IJ?1^H(KC3UU/2U$]NG5
M)Z9J-3I8DSG=D1RIC*87X2^Z5TCJ:)T[$9*K45[47*(O6AS3Q]%!'&KE<K&H
MW>7KPG,YD>V-CGR.1K6IE57J->UIMW=?%AKAWRN7N:QCG/5$:U,JJ]2%<ZFO
M+KE5*R)52EC7P4\9>TS-3:A6LWJ:B<J4_P"D[DK_ .Q&'N1K55R\$-G#CY?S
M6<KCN+\6?"Q]O[NJJFZ*)5;Q>[@U/*9NEK:JO1ST555<JJF)1TSJN?><G#J0
ML"P6](F-7!3EOSS]F_P7#>!3KWGNV]M@2*-.!G'#&[K<(<E3<  !@:A_(%S_
M (:7ZJGEC9+M(BT'#=(Y;:^M]>/C<BMF1F[N[WD7/MCULO%.)U]!#^JC_E0V
M,6:M*S2T;B6%JS,[B7E?7NL*K:E5V^BLNG71U$;EXL7I'N5V.;D1,)PZR0;9
M:"\6>CTK2U[JN>PTM-%#5+3N5$<YN$<BKYDX9/138HVKEK&HOD3!RYK7IAS4
M<G8J9+(XN*S7EKTACX>][EX\UNRR5-MM];I.PU]%:X9.CFK*GCTLBIE&IQ7D
MC7?'U%W;0]13V[2]GD33<%]L<T$:SRN\)&)A,\$3P>')Q:?11[N[T;-WLQP/
MK=:K=W=3=[,<"+<5%N7<=ON1CUOJ\C7]VGKU6TB;-[3>:>[.D15:B^"WR-PJ
MKSQQX$[VU:/O=5:].7IU,ZX55%2MIZ^-B;R\/"WL)S3*N1?@+\;%&U<MC8B]
MJ(?:IE,+R)GC)W$Q'8\/OMYOHM2[/ZZ6DI:#9]455?(J-E@C;Q:O^W"JKOA1
M"0;:](526;3UVT[;71,M*9?1L\)T355'<DSG"HN<9YEVMBC:N6QL1>U$/M4R
MF%Y&/F=6BU8[>L[3R=-2\\:ZVH+K#0%7;;39ZY)71M=73O:G1PM:Y'+A4[51
M$XXYEA[ /],[?^W)]8L%(HT142-B(O/AS/IK4:F&HB)V(AC?-6:<E:ZZ[3%9
MB=S*N_5 ?Z8W']Y%]="J= ;98=*:5IK0ZRR5+X=[\*E0C47*YY;JGIIS4<F'
M(BIV*A\=!#^JC_E0G'GK6GAVKOKON36=[B7G335HOVTS:'3:DNU ^CM,#FO1
M7(J-5&+EK6YYKGFID[2D1WJA]-HJ(J*^CX+^\4]"M1&IAJ(B=B'"QL5R.5C5
M<G6J<3+S7YMZZ:U"/#Z(7MFL]7?-G=TI+=$Z:J3<E9$U,N?NO151$[<9*HT#
MM"=;] R:1CLUPJKU&V:&*.-B;J(]7+EW6F%<O4>C3Y2*-'91C47M1##'FBM.
M2T;Z[3-=SN)><_4_VQUVT[K:UJNX^J@;!GL5S7H<[-=;2;-XJ_36I+37.JFS
M*Z!L#4<KW+U<53*+U*F3T-4TK9:2>&-SH%E8K>DB7=<W*<T5.LJ*FL^U6R3S
MPT=;;;U3JN(YJY<O:G;G@N?.JE\9JY>;FUJ==-_Y8<LUUI$]DU55UNW.YU5R
MIW4M7,D\CX'<X\\4:OE1,(>D"KMEFS^YV6_7+4>IJB*6[5JN560^U;O+ER]G
MP(6B4\5>M[_E^4,L<3$=0 &LL  !7FWF[):]G=:U%Q)6.;2L\N]Q=_\ :CBE
M]E>HVJSN-6/\-.-.J]:=;3?^J7U VKO%!9('Y;1M669$\=R)A%\S?K%+Q224
M\S)H'K'*Q4<US>:*AV.&P_Z/7Y]7,XNL9IFKTY;JN6AJV3PKAS5Y=J=A9EIK
MXKE1LGB7R.;XJ]A0^BM2PW^WMWU:VNB1$FC[5\9/(I-+)=9K75;\:[T3N#V+
MR<GVFMFQ;_5H\)Q,\-?DOV6@#%MU?!<($EIGHY.M.M/.91H3&N[T%;1:-P
M)         #XGFC@B=),]&,:F5503.NLD\K((7RRN1K&)E54K6_W9]TJW.RJ
M0,7$;?)VF9J6_.N+U@IE5M*WX%>O:OD(G=[E3VJADJ:IVZQO).MR]B&[@PS'
M7YN%QO%3FMX6/M_=I];WU+3;^BA7_P!7.BHQ/%3K<5E1QJOA.XJO%3MN-;/>
M+C)5U*KER^"WJ:WJ1#O@CW4.SCIX==?-T^$X>.'QZGO/=VL3"'(!DV0
M                -MI3\OTGG=]534FVTI^7Z3SN^JIC?W959_A6_25Y[/\
M_.U7["?23<A&@/\ .U7[M/I)N>>S>_+7]G? C]P Q+M7Q6RWSU<Z*K(FJY43
MFI5$;;LS$1N7W<*R&@HY:JJ?N0Q-WG+C/ J'7>N.[4#Z&@B<RDWD=TBKASL>
M3L.S6>NX[W:$HZ.&6%7N1SU<J<43J*^WL.PJI\!O8,&OS6[N7Q7%3;\E)Z.N
M?>PJX3'69M%J*ZT+&,I*^>*-BHK6([@F/(84[T5%;C@2+9Y':GWZ*DO-+'4Q
M5/X-BO54W'=7+MY&U;45W,;:^'<S$;TUE7J"NN%Q2JJ)Y/7/#PVKA>!:6S34
MZR4$\5XK7/DZ3\&Z3]%,)P53+N^F],657U4-# M8B9CA>Y7-55Z]W)#I&Q1(
M]8F,A1RJ[=8F$R1BPUXFO;4,>(XBW"9(BL[LL':+17.YV!(+-^%Z5[6R1ICP
MFJO!<KY<&TTE;I+5I^DHYHV1RQM\-&NWD5>M<X(=8]9OM]$RFJ873[GM7(["
MHG89];K=72QK01MZ/'A-D3BJFK/!9M\L1T;_ .(8(KSS/[)R0.X::NSM?P7:
MD?%'3.X22,7BUN,*BHO-5\AM*?65"E!455P_]*R!$5SE7**J]2%&OVF7VCU#
M55M-6RR4TDN]T$J[S$9GDB=7#L*/"O29K,=71X>D<53Q,<]'IH&CT]J>V7JV
MTU5#5P-?,U%6)TB(YJ]F#HN6MK!;;I);ZRX1Q53$17(J+A,]6>TJBLST3R6W
MK38WJ]T5GB1]9+A57",;Q<OP%.WZZ372KEJ)WN<BJJ-3L;U(?5]N2W.YU%4C
MM]CG+NX7*8ZC <YK8\K@Z&'#%(W\U]*<KNT_J2KL,LSZ/=5)<(YCTRG WU7M
M$K:NA2'=;3SYRLD?6A#&1=+4Y<JI"KDWG)U(6*FS.EJ*:.6DN<BM>U'(KHTX
MHIGD\*L[N6Y8G<LW16JKA<:^*CJFLF:K559$3"H3XC6GM(4EEJXZB">9[VLW
M%1V,*O6I)30RS6;;HHM,3/0 !4Q<.:CFJUR(K53"HO)4/%M_Z+N[<?6[6M@]
M<R=&C>2-WEPB? >G]86[5E15336C4-%;+:V/BV2)%<G#BJN5%P41K6Q6>P6:
MEIJ.YP72ZSS*^62%<M8Q$PB)YU.Q[,U29Z[W_P!ZM?-U1JSV&Z7EE0^TT$]6
ME.B++T+=Y6YSCASZE,&HIYJ:9T51$^*5JX<Q[5147RHIZ>V1:7FT_HM4<B0W
M*MS*]7-SN+C#45/)V>52)ZMT&^OG:NI]:TG2LXHDD3&.;GR)A<&U7CZSDM6>
MT?JPG%.MJ)!N=4VFBM%>L%NNT%SC_61-5$3R+GK\Q.=D^S2GU7;*BXW::HAI
MTDZ.)L6$5^/;+E47AR3XS:R9Z8Z>);LPBLS.H5C!%+,_=@8][T178:F5PG%5
M/3FR[:+2:JB;;ZEGK:ZQ1IEBKELR(G%S?+VI_P")(-+:+L>F8W):Z)J2N3#Y
MI/#D<GG7EYDP57M;TY'HZ[V[5.G6^M46HQ+%'P:U_-%1.I%1%14Y',R9\7&S
MX>M3\I716V/\R]C5:J_(-7^RGTH95GKF7.U4E;%[2>)LB?"ABZJ_(-7^RGTH
M<FL:M$2RS_"M^DJ%VF_D6F_B$^JX@]-[4G&TW\BTW\2GU7$'IO:H>@X?X;6]
MG? C]7> "UO                   %Z:3]I'YD*++TTI[2/S(<OVE_3^Y"Q
MJ3\4@%)^*0'+2HGU7/Y L/\ %/\ J'F(].^JY_(%A_BG_4/,1T^&^'"FW< !
M>Q  @   $"             )UL7_ #U9^XD^@@I.MB_YZL_<2?01/93Q'PK?
MH]6[/?QM=YF?]Q,B&[/?QE=YF?\ <3(Y>;WY9>S_ (%?W_N  J;@
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MVX?F+)_$1_U//T!Z!VX?F+)_$1_U//T!U*.;[/\ A?NR$ 0%C>   0
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M'6Q88Q=9[NEPG!5P?FMUM_9S3Q;J&2B8.$3!R9MT
M    -MI3\OTGG=]534FVTI^7Z3SN^JIC?W959_A6_25Y[/\ _.U7[M/I)N0C
M0'^=JOW:?23<\]F]^6O[.^!'[A ]KU;ZWLD$397L=+)R;^EA">$*VH6BON]!
M1QVVFZ9[9%WN*)NICF1AUSQML<1$SCF(4BY45,YPJG0Q^\Y<\TX9)U<]FMXB
MINEBZ*5R(KG(CL*G#D0?H7TZNZ5JH]JX5KD.G2];1TEQYQ6Q^^ZZM%14XY0V
MFGY_6%TI*F.+I5C>BHF.OM)914]JO^B)J*CA2EN%&K97NQO;^>'/L\ACVRWQ
MT,#6M:BR8\)_6I;AIXN]_)3Q.6.'B-3N9;":9\TBOE>Y[EZW+DZID3=5%Q\)
M\*_+L(N,<T.JK?AJ+QSY3?[./6LS;J[+1027*NCI6/CB<_@CW\E4VEYTK6V>
MBFK:F>G6FA;O.<URY^!%3F:9)YX(FU$>&OC\-F.>4XH1C56T>[:@M3K=61P1
MQN7P]QJHN44T>*RY,=HY.TO1^R>"IQL6YX[3ZM9J35$ESI4I*9'Q4JJCI&N5
M/"5.1$ZA%1N<\NH^U?B3CE5ZSJJ)%Y+P:IH7O-YYI>PP</CX;'&+'&HA\1NG
M=)O0;^\GA>!G@=S9ZBJJOPN_+*[FJ\54F.R&Z-MVK(8.CZ6"L:L#TW-[GR5"
M7-LTM3/434% ]VX]6K(R/BA%*[F=L+9>2VM(IIIRQVU6OWT5SUQDW,N4@<N[
ME$Y*=$]/41U20RQ/8].I[=TD>C[91W2MEIKA4+&JL5(V9QOOZN/]#;G5*[47
MMO=D;I4?)&]5>J-3J[2]M$/B?IBAZ%ZO:UFZJKVD TEH6JDN52R[1RP4T2HJ
M8QX:YY)Y"U**D@HJ9E/2QMCA9R:TU.*R5M^6&ODM$]'> #25   Z:VD@KJ26
MFK(F34\J;KXWIE')Y324FB=-4D[)J>R4#)6+EKNB151>U,DA!E%[5C42C42$
M4N>SS3%SN$U=7VWIZF9V\][IY.*^;>P9.L=036>*FI;92^O+O6N5E-!G"</;
M/<O4U.!$+EIC7];"M1WSLAJ%3/K:&/=8B]F]DOPTM'YN?EW_ -^3&TQVUM*Z
M306EJ7'16*A54Y*^/?7Y\DBIX(J>%L5/&R*)J8:QB81/@*,?J?:-I"3%YHG7
M"E:O&16;Z*G[3>7PDJL>V73U;$WNBDU!/UM5JO;\:%F3AL\QO?-'VG:*WKV[
M+-*K]437PP:0IZ-SDZ>IJ$5C>O#4557YT3X3,ONV#3E#1O?;Y7U]3CP(V-5J
M*OE5>17=@LM^VFZJCNE\9+%:V.WMY6X8C,Y1C,\\]I9PO#VQV\;+TB$7O$QR
MU73LXB?#H6QQRHJ/;2LRB^8SM5?D&K_93Z4-G#&R&)D434:QC4:U$ZD0UFJO
MR#5_LI]*&ES<V3F]91FC6*T?:5";3?R+3?Q*?5<0BF]J3?:9^1:;^(3ZKB$4
MWM3O\/\ #:WL[X$?J[P 6MX                   O32GM(_,A19>FD_:1^
M9#E^TOZ?W(6-2_BD I/Q2 Y:5$>JY_(%A_BG_4/,9Z<]5S^;]A_BG_4/,9T^
M&^'"FW< !>Q                   )UL7_/5G[B3Z""DZV+_GJS]Q)]!$]E
M/$?"M^CU;L]_&5WF9_4F1#=GOXRN\S/ZDR.7F]^67L_X%?W_ +@ *FX
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M!$]E/$?"M^CU;L]_&5WF9_4F1#=GOXRN\S/ZDR.7F]^67L_X%?W_ +@ *FX
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M095[PKR^Y;]'F[;A^8LG\1'_ %//T!Z!VX?F+)_$1_U//T'(ZE7-]G_"_=D
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M)QIS5=IU$R1]IJDG;'C>PU6X^-#7OAR4ZVALTSX[]*RWH"+E. *EH
M           !6.V;:%%IFW26RWO1]WJ8\<%_$-7])?+V&WVGZ]I-'VE_1O9+
M=945((.>%\9W8B'D^YU]3=*^>MKYG35,SE>^1Z\54Z'!\+XD\]^S3XGB.3\E
M>[&>YSWN<]RN<Y<JJ\U4^3D'8<Z)<  ,HEP#DX"8EP#D!DX.,'((3$OG=-KI
M6U+=+W308S&CM^3]E/\ S!K"U]E=EZ&B]>2L_"U"\,]3>HU^)R1BQS/S78:\
M]M+(TW:6N5%5OS$_H;:QD:<#6Z<I-R-JX).U,-1#@.BZ&TC&]2':V)K>2'V
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M:F$1#M 3N=:  $                      :K57Y!J_V4^E#:FJU5^0:O\
M93Z4,J>]"K/\*WZ2H3:9^1:;^(3ZKB#TWM2<;3?R-3?Q"?5<0BF]J>AP?#:O
ML[X$?J[P 6MX                   O32GM(_,A19>FD_:1^9#E^TOZ?W(6
M-2?BD I?Q2 Y:5$^JY_(%A_BG_4/,1Z<]5S^0+#_ !3_ *AYC.GPWPX4V[@
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MD_%(#EI41ZKG\@6'^*?]0\QGIWU7/Y L/\4_ZAYB.GPWPX4V[@ +V(
M                          @          (              !
M                        3/0.C);_ #)45.8Z%CN*];U[$.O0>C:C4%4V
M:H:Z.WL7+G8XO\B?:>C=.6*.""*&GB;'$Q$1K43@B&KGS\OY:]V=:[<Z:L<<
M,,4,$361,1$:UJ81$+!M-N;$Q.!Q:+:V)B90W;&HUN$.>M&M1J80Y
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M7R%%W"BGM]7)35<:QRL7"HIW>&XBN:/NAC  V0
M
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M_P Q["TOOROR3_F/,8_4Y95$"W?86E]^5^2?\Q["TOOROR3_ )CS&/U.251
MMWV%I??E?DG_ #'L+2^_"_)/^8\QC]3EE40+=]A:7WY7Y)_S'L+2^_*_)/\
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M-IMZ1,;P1#@\1Q%LUMSV=O!AC#77S=MJHDB8F4-JB83"'#41J80Y-=>
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M'XJ#N-'XJ&[ &D[C1]B#N-'XJ&[ &D[C1]B#N-'XJ&[ &D[C1]B#N-'V(;L
M:3N-'XJ#N-'XJ&[ &D[BQ^+\P[C1^*ANP!I.XT?BH.XT?8ANP!I.XT?BH.XT
M?BH;L :3N-'XJ#N-'XJ&[ &D[C1^*GQ#N-'XJ&[ &D[C1^*@[C1^*ANP!I.X
MT?BH.XT?8ANP!I.XT?8@[C1]B?$;L :1+-&GZ*&736YD:\&FP '#&HU,(<@
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MEFC1?:I\1ETM V+DAG@ B83"
M
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M8(B(F$ ,68
M
M
M
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M16YD34X)P,Z.%C$X(AV%*]PQB-3"(<@
M
M
M
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MR0Y(9/AD36)P0^P
M
M
M
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M*GHX5Y,5ZJ_'E3J)Y9[HYHGLD8/ECT<A]$)
M
M
M
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MBMV$150VL4*,0PWONSB-=B!JM;Q.T A(
M
M
M
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M+3>4]*R-."&0UJ-3@AR0D1$1.
M
M
M
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M."'T
M
M
M
M                                           =4L#9$7*&FN%H9*U4
MW45.PWP5$7F!4]\T7!*]SX4="_KW4X?$85)IME.N&1JJ^,O,MZ6F9(BY0QDM
MT:.SNH3S3K2-1O:&VNQ<LM)106ID:)X)M(J=D:<$0[N1"77%"UB)A#L
M
M
M
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MBK^BASN/P8\/+R1K>UV&TVWM/$7*< ==.N8T.PYJ\
M
M
M                                                          59
MZH+\WK=_%?\ 8XHHO7U0/YO6W^*_['%%'H/9_P "&GF]X !O*@  !U ( " $
M  "0    $ @ )  $ <'()    @   $#@Y" D    !   D       $ $ )
M  0  ) X.>H                 $     "_='KX$7[*%!%^:/\ :1?LH<CV
MIVK^_P#AL</\UC4GXI#N.FD_%(=QR&R
M
M
M                                                *L]4#^;UN_BO
M^QQ11>OJ@?S>MW\5_P!CBBCT'L_X$-/-[P #>5 0      (  $@    ( '!R
M2       "  !(    $     "  0$@            ('!R 2
M@<'(!(           7YH_P!I%^RA09?FC_:1?LH<CVIVK^[8X?YK&I/Q2'<=
M-)^*0[CD-D
M
M
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M4GXI#N.FD_$H=QR&R
M
M
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M[CII/Q2'<<AL@
M
M
M                             "K/5!?F];OXK_L<447KZH'\WK=_%?\
M8XHH]![/^!#3R^\  WE0@"          22#7.I8(8XHKQ4-CC:C&M3'!$X(G
M(C8,;4K;WHVF)F.R3]_^J/?JI_\ M^PZZC7&I*F"2">[U#XI&JUS5QQ1>:<B
M. P\''],?^$\T^KZAEDAD;)"]T<C5RCFKA4\RDBCUSJ:.+HV7FJ1B)CFB_T(
MV#*U*V]Z-HB9CLR*^MJ:^H=/6SR3S.YOD=E3FW7"KMM2D]!4RT\R?I1NPIC
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M7[*%!H7YH_VD7[*'(]J=J_NV.'^:QJ3\4AW'32?BD.XY#9
M
M
M
M   %6>J!_-ZW?Q7_ &.**+U]4#^;UN_BO^QQ11Z#V?\  AIYO>  ;RH !
MD    ! (#@Y)       "$  "0!P<@ @ '!R @!  0.#D   "0       @ (
M0  )     0  )           !U    0  )  ( .#D "_-'^TB_90H,OS1_M(
MOV4.1[4[5_=L</\ -8U)^)0[CII/Q2'<<AL@
M
M
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MEL
M
M
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M;@^@
C                                            _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g762905g18s00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g18s00.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" 4J!VP# 2(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M8&6K&;?#35;:F.(5CZ<MY8P?2DYAMSNX=_7KW*=FN_"_$;=10T=M@R":1O\
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M(B +3^%_V@J/REW[+5F"T_A?]H*C\I=^RU>;U7^V=,7]1F"(B])S"(B (B(
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M;'@5KIZVF:3(\M[ L\.4N+1HG?=[U&XS<*^Y>4)!->***BKVQOCEABE$@:1
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MZQBY&7@G0U-LMT-UEIJ1K#1R#F$CHW:<".O7H2![E7<)R_(+P:N?&\%M4#H
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M1?#.>2P1.YZ6VCS9@WT+P=O/T]/\JC\,XFWW$K1);;:VCDIW2&0><1N<6$@
MZTX=.F_>J5-(^:5\LKB^1[BYSCWDGO*SZ7T<L65REPN/J7)F4HTN>Y]9\1+Z
MZGPZCO-NLE+?:5Q9*62LYPR-S20\#1]@^=5;&<MR>HQ^>Z63"K734&W%^IA3
M\P:-EVB!L#U^PK+L)XI7_%*(4-.8*NA:=LAJ6D]GZ^4@@@>SJ%W9EQ9R#)K?
M)0/%/0T4@U(RF:>:0>HN))U[!I>>/H)Q_P!/2FKYM\?(Z/.G^*RZ^3 [GJLF
M<!K8ISKU=9%RX+U\$'%7+J.5S6RU,LQBW_6+97$@?,=_,LQP3.KIA3JUUIBI
M)#5A@D\X8YVN7FUK3A_:*A'W>L^')+O#*:>N?.ZH#X26\CR23KV=5Z9^DEDG
MEOB25?0YQRJ,8^Q<>*>)WJ#/[H66^KJ(ZVI=-3R11.>'AYWH$#O&]:]BU',F
M'&. D5KNCFBM?3Q4XC)V>T+@XM_R@'Z%1Z#CMD=/2B*II+=52@:$SF.:3[2&
MN ^C2HF89;=\MKFU-YJ _D!$43!RQQ@]_*/^YV5E8,^5PCD22C^M%UPCJ<>6
M;S8+547KR>HJ"B!=4RTC^S:.]Q;*YW+\^M?.L\X#X]=!Q"@JYJ*I@@H62&9\
ML98 2PM#>OCL]WL*O]GN%5:O)X@KK?,Z"J@I^>.1O>#VY5"J>.>2RVXT\=/;
MX:@MY34LC<7#V@$D;^8CV+SXHYIK+#&E3;7R.DG!.+EV2+/>:R&K\I.U,A<'
M&G8(7D?VNR>X_M *K>4B2<_@!\*"/]N14*PY#76;)(;Y"YD]?$]TG-4;<'N<
M""7=03WGQ7?FN55V7W=MQND=/'.V)L($#2UO*"2.A)Z^D5[,?I98\L)=E&CC
M+*I0:[MV;;Q<_F0L_P#=I/\ 33R;/Y%7G\L=_IM639#Q%O%^Q>FL-9#0MHH!
M&&NBC<'GD&ALEQ'Z$PKB+>,/ME30VN&ADAJ)#*\SQN<X'E Z:</ +@_1Y/AW
MB[MV;6:/44NU&M>375Q28A=Z*/D-3%5F4L/BU[&AI/LVPA1MBR^[U63?!=OX
M?6J"Z0%Q)+.S[+EWU+N7I[#X["QS%LDN>,705]GJ##-KE<"-M>W^RX>(6B5'
M'C(I*0QQ4-MBF(UVH8\Z]H!=KZ=IE]'/J2E&*DI>]5_D0S+2DW5'HOMSNUQX
MU8P+_;H+?702P1F.&82@M[0N!)'=W]RY^4Z?_KALP\/-7?ME9?39%<(LGBO\
MLHJ;E'.*CGFZAS@=C8&NGL&E[\YS.XYG64U3=8J6.2",QM%.QS003OKMQ7>/
MII1RPDJI*C#RIPDO+-DQ,_\ [N%;^25?[;UY/)=/_@<A'CVD'ZGK,K?Q$N]!
MA<N,0PT1M\D<D9>Z-QDT\DGKS:\3X+RX%FUSPNMGGM@AECJ&ALT,P):_7<>A
M!!&S]*Y3])DECRQ[R=K[FEFBI1?A$7D5!5T-VJA64T\'--)R]I&6\VG'>M]Z
MBU;>(.<U^;5-)+<*:EIQ2M<V,0!W4.UO9).^Y5)?0Q.3@M:IGGE5[!$1="!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!*5^/7BW4;:NOM5=34KB V
M::!S&$GJ-$C75>&DIIZRICIZ.&2>HD/*R.-I<YQ]0 ZE?2'&N&2?A7:X8&.D
MEDGIFL8T;+B6'0 75@.*VSAECDN1Y2]C;FYG7^L80>Z-GK>?$_-W;)^;'_Z'
M^EK:_$W27D]#]/\ BJ]C [GCMZM5.)[G::^C@+N423T[HVD^K9'?T44K5Q"S
M2OS.\&JJR8J2/;::F!]&-O\ W<?$_P#9>_%.%V2Y+0,K:2GAIZ1XW'+5/Y \
M>L  G7MUI>M9=$%+,TF<M.J50W*,BLN881?,2?'\,4H;!(>5D\3N>-Q]6_ ^
MPZ7HDX?7UN)C(VQT\EL[(3<S)07!N]'T?8>_U:*UUL=*6I4^":)75%212N,V
M&NR2\16RU1MDJI YP#G<K0 "22?#N7/*<>K<8NSK==.Q%4UC7N;$_G#0>[9]
M?C\ZUKCJT7N32ZOL1<$,E1-'#!&Z261P8QC!LN<3H #Q*G/B5E'_ ,.7C_Z'
M)^Y=&%_RPL7Y?!_J-7T;QFSNYX4VTFU04DOG9EY_.&N=KEY=:TX?VBO+ZCU&
M3'DCCQI-LZX\<91<I/@^;;ECUZMD1EN5HN%)$/Z\],]C?I(THM?4/";/YL]9
M<Z"\V^F:^&,.=V8)CD8[8+2UQ/Z^OS+%;IA%36\2+OCN/LC<897NB;(_E 8.
MNMGU @?,IA]6W*4,RTN._L)XDDI0=V4A%HM!P=RRLDK&B"EB\V?R;EFT)#H'
MT- [[^_H-JKX]B=YR&Z34%HI#430G4KFN'9LZZV7=W@=>OP7H6?%*VI+8YO'
M)=B"1:3<N"^6T5(Z=D-)5EHV8J>;;_H(&_F6<RQOBE?'*QS)&$M<UPT6D=X(
M]:UCS0R_T.Q*$H\HX(M#LO!_*[K;F5C:>GI6/;S,CJ9>1[AX= #KY]+QMX79
M1YA<JN:BC@CMY>)A+* [T6AY+?[0T1HCO6/B<-UJ1>G/P4A%:,3P:]950U=7
M:(X7PTSN63GD#3O6^@\>BD+CPOR.W8P^^UT5-#3,8)'Q/EU*UI[MC6M]1TWO
MV*O/C4M+DK(L<FKHHZ*\XIPMR7):!E=1T\-/22=8Y:F3D#QZP "=>W2Z\NX9
MY'B]"ZMKZ>*:C:0'S4TG.&;Z#8T"![=:3XC%JT:E9>G*KK8I2*T8U@MZR.RU
METM<43Z6E<YLG-( [;6AQT/'H0IZAX-9=5VX5?FU-"YS>9L$TW+(?FUH'V$A
M)>HQ0=2DD%CD^$9RBO..\+,IOCJ@143:1D$AB<^K=V8YAT('0D^\#7M4)E^)
M7?$JUE->:<1F0%T<C'<S) ._1]GJ[U8Y\<I:%)61PDE;6Q HBMO"O'_C)G%N
MHWLYJ:-_;S^KLV=2#[SIOSK4YJ$7)\(D5J=(B:[&KY043JNNL]QIZ5NMS2TS
MV,&^@ZD:ZJ(7V==G6W*(+_C+I Z:*%L<XU\@R-)81[1H'Z%\=5]%-0W"HHJE
MG)402.B>T^#@=']2\GH_5OU":DJ:_LSKFQ=.J>QT-:YQ(:TN(!)T-] N*^F\
M>X>2VWA9<+8*&D9D59!+')*' EY+CRCG\!K73N51X0\-:FGRZMER.AI*BFM^
MX2USP\"<M8]IUXCE=X^*B_\ H8FIR_+^I?AY6EY,4<US#I[2TZ!T1KO7%:GQ
MRQ&YT62UM]ECA%NK:ED,):\<V^S\1X?)*CW\'\M97TM(:6GYIPYPD$P+&!NM
MEQUT^4/:5VAZK&X*;DE?\?V,/%)-I(H]LMM==:DT]LHZBLG#2[LX(R]VAWG0
M\.H7-UGN3;I\&.H*H7'8;YJ8G=KLC>N76^[JM)PG'LKPSB(^AMU-;:JZFB=)
MRR3$QF(N'78T0=@="N5MDN<OE!4C[[#3P7$U#.UCIW%S!_ ]-$^S2P_4[RTT
MTE?\]BK'LKYNC,KI:Z^TU#8+I15-'.YO.(ZB(QN+=D;T?#H?H7C7T!QCP:^9
M?GE.;13M["*@C:^HF=R1M/:2=-]Y/L *RK,L OV(L9+=:9CJ5YY6U$#N=F_4
M?$'W@*X/5PRQC;6I]A/%*+>VQ5$5LQO ;YD5CJ+M;(X'4<#GL>7RAIVUH<>G
MN(4)CUGJ[_>*:V6YK'5502&![N4= 2>ON!7?JP=[\<^QSTO;;DCERY7<G-RG
MEWK>NFU;G</;Y#E]-CLT4'PC-%V[6B4<I9U)]+_*5L_%W );AC-LH<5HJ6GI
MZ&1\KXPX,&N7O]IZ>]>?)ZW'"48W_5W.D<,I)OP?-"*?Q+$KQE=6^"RTIE$>
MC)*X\K(]]VW']7>K!D7"3*;'025DM/!5P1MYI#2R<Y8/$EI )^;:[RSXXRT2
MDK,*$FK2V* BD+%9J^_7**@M-,^IJI.YC>FAXDD] /:5H!X'Y:(.T'P<7ZWV
M0J#S>[Y.OTJ9,^/&ZG)(1QREND9>B]UYM5;9;C-072G?35<1T^-_Z"#W$>T+
MPKJFFK1FJ"(BH"(B (B( B(@"(B (B( B(@"(B (B( B(@"T_A?]H*C\I=^R
MU9@M/X7_ &@J/REW[+5YO5?[9TQ?U&8(B+TG,(B( B(@"(B (B( B[*>)\\\
M<,0YI)'!C1ZR3H+3N*_#2DPNR45=15M14F6?L)1*&Z:2TN&M#_E*Y3S0A*,'
MR^#2@Y)M=C+41:JWA?34?#.?)+S65,%:(.WCIFAH: XZC#MC?78/SIES0Q5J
M[[",'*Z,L8YS'!S"6N:=@@Z(*N5%Q0S&C@;#%?)W,:- RL9([Z7 E4M%J>.$
M_P"M)D4G'ADK?\@NV05#9[S7SUDC>C>T=T;[@.@^912(M1BHJD1N]V$5TS?$
M:7&\;QJL\XF?7W2#MY8G:Y8QII&NF_ZWCZBJ6LX\D<D=4>"RBXNF$1%L@1$0
M!%V01/GFCBB:722.#6@>))T%JN3X5A6*TKJ"]7JXNOXI>VY86#LR_1Y6_).@
M2/$^WHN63-'&U%\OP:C!R5F3(BE<7LE3D5^HK51#^&J) WFUT8WO<X^P#972
M4E%6^#*5[(BD6E<5>'U!B-MM];:J^>LAGFD@D,G+IKF]-#0]8<#[EFJQBRQR
MQUPX-2BX.F$1<HV.D>UC 2YQT /$KH9.**R9SBD^(5]+05U1%-6R4XGE;$/1
MBV2 W?B?1W\ZY9%:++;\<LE3;[KYY<ZMA?50-<TMI^@(!UU!Z^/J*YK+&236
M]FM+5WV*VQSF/:]CBUS3L$'1!]:N5'Q0S*D@;#%?)W, T#*QDCOSG E4M%9X
MX3_K29%)QX9*7[(+KD%2V>\U\]9(T:;VCNC?<.X?,HM$6HQ452(W>["(BH"(
MB (B( B(@"(B (KQ9L-I:KAG=\IK:F>*2FF[&")FN60^@-G8WWN\/4J.L0R1
MFVEVV*XM581$6R!$5TR[$*6P8;C=S=43.N%U8970N Y&,T"-=-_UF_I6)9%%
MJ+[E46TWX*6BLV4VBRVVS6.:UW7SZOJH>TK(FN:6T[M-/+TZ[V2.OJ595A)3
M5H-4Z"(BT0(BLV*XE47ZUWFY]O'3T%KA,LSW#;G'E):QH]9UZ^FUF<U!7(J3
M;I%916/!+3:;S>W4^071MLH6Q.>9BYK27 @!HWT\?T* G$8FD$)<8@X\A=WZ
MWTVBDG)Q\"MK.M$1:($1$ 1$0!$7.*-\LK(XFE\CR&M:T;))[@$!P17#B'CM
MOQ:6VVR&6:6\"G;+<-O!9&]PV&- '@/63WA5FU4;[C<Z.BB_XE3,R%OO<X#_
M +K$,BG'6N"N+3H\J*W\4<9H<2R;X*M]3/4M9 R21TVMASMG70>K7TJ$QBUF
M]Y%;;8'%OG50R(N;WM!/4_,-E2.2,H=1<<E<6GI[D6O;9[I6V:N96VNIDIJI
M@(;(SO (T?T*8XBV&CQK+*RTV^HEJ(J8,!DEULN+0XCIZMJM*Q<<D4^S(TXN
MCVWBZUUYKGUETJ9*FJ> '2/[R -!>):C0</K'9K%173/KU-0NK6\\%%2LYI2
MWOV>A\"-].GK7JI,!Q#*XIXL(R&I^$XV%XI:]FN<#U'E'TC>EY_BL45M=+O6
MQTZ4G\S)$7=64TU'5S4U3&8YX7F.1A[VN!T1](72O7R<@B+4[+@6-QX-;,AR
MN]5EO%<]S&-BCYQWNUT#2>H;M<LN6.))R[FHP<N#+$6J4^+\-:N9D$&8UK)9
M#RM=+3EK=GUDL 'SD*H9_B55AM_=;:J1L[',$L,S1H2,)(WKP.P00LP]1"<M
M.Z?NFBRQM*RM(B+N8"*S4F)5$N$5F3SSQPT<4H@ACUM\SRX ^X $G?L[O%,3
MM%EN%LO=3>[KYE+20<]+"US0ZHDTX\H!]H Z>M<WEC3:[;&M#X*RB(NAD(B(
M B*S9)B51CUALMPKYX^VNC#-%3L&RR,!I!<?6>8=/TK+FHM)\LJ3:LK*(K_P
MRPJWY+;KY<;W73T-!;&->Z2)H.^CB[O![@WP]:SDR1Q1U2X$8N3I% 1:@,?X
M8;_E?<O_ **[_P#%J+S_  *&P6FAO=DN;;I8ZQW(R8-Y7,=UT#]!]6B-$+G'
MU,')1=J_*:-/&TK*&B(O08"(B (B( B*Z7_$:6T<.[%?9*B8W&YR._@#KD;&
M.;J/'>@S\Y8ED4&D^Y5%NZ[%+1$6R!%9L*Q*HR<W&5D\=-16Z U%3,\;+6@$
MZ \2>4^([EYL*MEMNV004M\N+;=;RUSI*@N#=::= ;Z;)TN;RQ5^W)I1;KW(
M)%Z;G'3PW*KCHI'2TK)7MA>[O<P$\I/O&EYEM.]S(1$5 1$0!$1 $1$ 1$0!
M$7.*-\LK(XFE\CR&M:T;))[@$!P1;I:N#-FMEIBJ\VOOF<CP-L9*R)C#_9YW
M[YC[M?.OV[\%K5<+1)6X5>S5N:"6L?(R5DA']4/;K1]^_F7B_P#R&"ZO;S6Q
MV^'G1A2*1L]EKKO>H;30P%U?*\QB-Q#=$;WO?=K1^A26=XK/A]WAMM941SU#
MJ=DSS&"&M+B1R@GO[N_HO5U(ZM%[G+2ZOL5Q$1;(30RF]BQ? PN4_P %\O)Y
MML<FM[U]/50J(LJ*CP@VWR$1%H!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!]G5ESMEEQ*CN=Z=&VGI(8Y&N<-GGY-#
ME']H[('O57EDMO&'A[4B!GF]5'([LVO.W03-WR[/J(/7V$^(5:XR7ZSW#AA0
M4M!=;?4U39("Z&&I8]X 8=[:#OHLXX/9@<3RF,U,A;;*S4-2">C>OHO_ ,I/
MT$K\_A]')XGEC>M/;Z'OGE2EH?#("RV9[\RH+-<HW1/=71TL['="W;PUP_6O
MI?BA9+U=J&@H<>O5)9J>/9E#IG0N>!H-#2T?)'7I[EG7&QED?<J+*L:O-JFN
M,$K.WA@JHWN>6G;) T'9(T ?9KU%6&^OQ7BW8K?(Z]0VJZ4VSR2N;S,+M<S2
MTD<PZ#1!_P"X7;/DEE>/,]DKO:Z?R,0BHZH$M7VR9_"2YVC)KM17*OBII7QS
MLEYBXM!='LG1+@1I5OR?+G%>L5O&+5YYF,:YS&GQBD!#@/<[K_F4#G5KP'&,
M/%OHWP7?(2TM9413';7$]7OY7<HUX-._#VE4SA/?78_G=LJB2()7^;3 >+']
M/T'1^96'I^IZ>>F^;6U;KQ\P\FG(K-/X"8TZQ7')[G= &>8/=0]H1T'*>:0_
M0&?2L7RR\27_ "2XW27>ZJ9SV@_U6]S1\PT/F7TAQSN\6/X)604@;%4W67L?
M1Z$['IN/^5NOG"^65W] WF<O42[[?8YYZ@EC78F<+_EA8OR^#_4:OIWBA)A<
M8MWQZ:"-R>;;;*?[/-_P_P#+WKY?Q&6.#*K+-/(R.*.MA>][SIK6B0$DD]P6
MJ^4=>;7=F6'X*N5%6]F9^?S:=LG)ODUOE)UW%3U>)Y/48U;7.Z+BEIQR9/1<
M2L!Q&UU$>(T;I9I.O9Q0O8'N'=SO?UT/G[U3N!UPGNO%F>X5C@ZHJ8IY9".[
M9(/3V+)UHG BX4=MSUE1<JNGI(!32-[2>1L;=G6ALG2UD]+'#AR.-MM<O=DC
ME<YQOA%DXUYU?K=G-1;;5<9J2EI8F-Y(M:>7-YB3Z_E ?,K7B<@P[@/)=K:Q
MGGLD!J2\C>Y'NY6D^OE!'3V+(N,M;2W#B-=JF@J8:JF?V7++#('L=J)H.B.A
MZA7OA+F]CJ\0EQ#+)F4\):^**65W*Q\;B3REW]5P).B?9ZEPRX*]-C<8^&UY
M-PG>25OS1 <*<]R%V=V^GKKG55M-72]C+%/(7@<W<6[^3HZ[E<,ZQRADXZ8T
MXQL#*\">=FNCWQ\QV1[>5H^9=^.XA@^#W/X>J<EAJNP!=3L?*P\NQK8#>KW:
M[M#YEFN6\0YKKQ&I<BHHW,@H'L;31/.B8VDD\WM=MV_?KP1+K9G+ J6EKBMQ
M>B%3>]EU\HK)[M07ZWVNWUM124PIA4.["0L+W%SAU(ZZ'+^E6G![Y6W[@I<Z
MBYRNFJ8J6J@,K_E2!K#HD^)T=;]B\633\/N(]OH[A<+Y';JF!FM.F9%*T'J6
M%KM\VCZM^Q3MEGLDG">]0XPU_P %TM-50,DD[Y2(R7/Z]>I)_P#M+RS<5@AC
MT-23WV.L4];E>S16_)A_D_>ORIO["R++,ZO]_FN,%9<9G6^HEYO-NG(T!VV@
M#PUH>_Q6E^3Q?+3:K!>([I=*&BDDJ&N8VHJ&1EPY>\!Q&UAT<@BK&REH>UL@
M=RGN< >Y?0P8T_4Y927BCSSE_IQ29NM+;N(N1XK1QU]PH<?M<;6N;)S&"5S
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M$1 6C&<QJ<?QV]VFDI87"ZQ]G+.XGF:WE(T/F<[Z4X?YC589=*BMI*:&I[>
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"T_A?]H*C\I=^
MRU9@M/X7_:"H_*7?LM7F]5_MG3%_49@B(O2<PB(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MO[L=.'@IGV+L,_ ,'UDG^Y/L789^ 8/K)/\ <KFB?$9?SO[L=.'@IGV+L,_
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M 8/K)/\ <GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/]R?8NPS\
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MO[L=.'@IGV+L,_ ,'UDG^Y/L789^ 8/K)/\ <KFB?$9?SO[L=.'@IGV+L,_
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M_N3[%V&?@&#ZR3_<KFB?$9?SO[L=.'@IGV+L,_ ,'UDG^Y/L789^ 8/K)/\
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MH):*4.YAT'H$@_,0#\RYI1A5J[!1_)B_F@M?XZ?_ %7+5%E?DQ?S06O\=/\
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M &53Z1K8O*PK>S ;VMI!?KQ/(W]P79@W])S//R&/]4"C@MVO%@L^;<5*.PY
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M03Z]*D<:[GF=R9C,^66&WV:D;<6^;LCJ.VF+O'9!(UH>SKI(8XNDU^N_V!]
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MHK[M6=*:WTC>:63KK?L&^GK/@#HJJMXT3VNKIFYKAUWQZAJ'AD=9)_",!/\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M6VCM\,E*Y[V4T+8PYW0;( []!:G""EH5@O=ENM%>[7!<;54-J:*<%T<K00'
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MU$0?RIJ?R=OZU+H B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MT/=UVKEB<UPJ,8M,UZ88[G)2QNJF%O*6REHYAKPZ[Z+3C4=0)5$19 1$0!%
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M![] _05Z<_XH9DHZ:[^?Y['+'LX;W^Q5,6O]=0\2+A<;?;S<KM42SMIXCO\
MXCW'TCKP YO5[PM#H>(URH,JIK?Q&Q^BIG2:$=2V+TH@3T.R7 MWWZ/3JJIC
MLM/@_&VI%Z_@*5L\S&RN'1K) 2Q_NT1L^&RO=Q^O%OR.^6.BL,\5?41M>QSJ
M=P>"Y[F\K01T)Z'Z5VR0CERQBX[.//@S%N,6[W3X/HQ9AY1%S?0X$*:)Q!K:
MED+M?V0"\_I:/I6DT,;X:*GBD=S/9&UKCZR!U63^4O3ODQ*VSM!+8JT-=[.9
MCNOZ/TKX_HDGZB*?D]>9_P"FRW\(J!MNX=6.-HT9(!.X^LO)=_W"P/AYDU!B
MG$.X7&Z]L:<B>+^";S'9>-=-CU%?1/#B9L^!8^]G=YC$WYPT _I!6!\);307
MGB=<:6ZTD-73\D[^SE;L;#QH_I*]WIFO]=Y.._ZG'(G^#22_%CBI:<GQIUHM
M%)5$RR,>^6H8UH:&G?H@$G9^;IM:/P+LU59L!@97QNBFJ9GU(C<-%K7  ;'A
ML-W\ZL-!AN-V^=L]'8[=%,P[:\0-+FGU@D=%/KR9O4XWBZ.*-*[W.L,<E+7-
M[F)>4]]K+#^.E_4U:5PV_D!CWY##^R%FOE/?:RP_CI?U-6E<-OY 8]^0P_LA
M=,O_ .GC^;_<S#_>D8QY37\I[3^1G]MR]L/'FICACC^+C#RM#=^='KK_ "+Q
M>4U_*>T_D9_;<OH2B_B<'XMOZEWGDQP]/BZD-7/>C$8R>26ET?+>+7IV0\:;
M==7P"G=55C7F(.YN7T==^AZEN?$'A_!FMSM4M=6R04E&UX?%$WTI.8M[B>@[
MO45DU3_2.'^(,_8"^D%CUN5PECGCV_"7!%24E+?<^;+=;:2T>4)34%NA$-)!
M4-9&P==#L5M'%?\ FZO_ .2N_6%D4W])8?E3?] +7>*_\W5__)7?K">I;>7"
MWXC_ '&/:,_J85PFXCT>%6RNI:NAJ*EU1,) Z)S0  W6NJ]V?Y[5<2**FLMA
ML542V<3.(_A'D@$ : Z#TCU)5C\G&WT=?C5Z974E/4--2&D2QA_3D'3JJKF]
MIN'"O-X;I8'OCMU0XOA&R6D;]*%_K'J]A'B%[/\ 1EZF24?QKBWLSC^-8U;_
M  FY<-+!-C6%6ZV59!J8VN?* =@.<XN(^;>OF63\'Y#8>+V06-AU32NFC:WV
MQO):?S>;Z5M6+7RER.PTETH7;AG9LM)ZL=W%I]H/18G@S//O*%N]1%U9!+5/
M<1ZAMGZW!># Y26;J>-_G9WG2T:3Z!1$7S3TA$1 $1$ 1$0!$1 $1$!$0?RI
MJ?R=OZU+J(@_E34_D[?UJ70'PU8\NFPCBY>;S34(KY&555'V)>6;YGN&]@%:
M9_[2]T_^$(__ *4[_8JAPOOMLQSCO=KA>ZR.CHVSUK#*\'0)>[0Z+Z,^S!@7
M_P 34?YK_P#:O?FJU<+V(<:C):F^<$[AD+(WV^KGM-1.UL4AYH7!C]$.Z'8U
MO:P7A$_B!Q$M]QL]'E=916^"1LU573322S$N&FQM/-O7HN.@1X[WT"WW)\CM
M&3\*\LK;!71UM*RWU43I(P0 X0DD=0/ CZ5F/D;C_P GR<__ (>#]EZYP>G'
M)UW!5\1O.5\.>--'BMUO51<J.HJHJ:1DDKGQO;+H->T.)Y7 N!Z>HCJKAY2?
M$2\VJZ4&*8O/+35=5&V2>: ZE/,XM9&T_P!7>B21UZCV[JO%3^E)8/RVV_ML
M77Y24,UBXQV6_31/?2.93SM([G&)_I-'MT&G_,%U45*<6UV![LEX?<0,-P.Z
M7-V5R7&&6D?'<K?(Y\C1&]O*XM+B02W>]Z!Z>/<93R2ZV"W8=EM=5OY*:FE;
M-*[^RUL;B3] 5RXL<2<6DX6W<T%YHJR:Y4;Z>G@AE#I"9&\NRWO;H'9WKN]:
MSKR<K9+>>%G$&V4W_'JXW01_WG0N _20L6Y8GK\@CK7<\\XWY/<&VJ[RV:RT
MNG%D<KF1Q-)/(T\G5[SHGKTZ'NZ!<Y[]F_!++Z*DO]TEO-CJ1S\KY'2-DC!T
M[DYNK'M[]=W4=^UV>2YF%IQBLOMER*IBMLU0]CXY*D]FWF9S-<QQ/R3U&M^U
M=/E,91;LSR/'[+B\S+G/3%[2^F/.U\DI:&L:1T)]'PZ=1[5TI]3IU^$&H\?N
M)<^(XI;OB]*SX0NX+H*C0=V<0 )> ?$\S0-^L^I9Q#PRXDU.*-RAF6W!UU?
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MAKW@!;$B1G*.R!E]AX-VNP9C:LBM=RK154C'BH\X/;.K'/#@Y[W$C3B'> \
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M5;LQM&,3.E?=KDUTD4;&>BQC6O/,YW=H]FX #9VHS.<[&+91BMG-O-4;Y4&
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M]W,YQ]?9N  V51.'N=Y/'Q!J,)SRGHC<1 9Z>KHP0V4 ;ZCU$;ZZ&M$$+/\
M*X<V_P#:,M38:FRB^.I)3;WN:_L6T_\ #Z$G3?/R\_=TWI;CAW:EXLAN&69?
M4V+*L<M$%FGK8KK(8Y*ICB&TP!:-N :=_*]8[E;EEN8YE?\ 'LPX>V1YHG.N
MY$5Q<V,D%X+ XQG8T-N=K8]2]/%+B!76&ZVS&L4H([CE%S]**.4_P<+.OINZ
MCU'Q'1I)]N>FW213246)WJ\<5\)MYOM\=8[[:H=.JZ:E88Y(F>):>4=WKZ^[
M7567/\_?1\(),PQ=\3S(R&2$SLY@ ^1K7!PWWC9'?WA3I/:M[!HZ+$[?>N*V
M96B&]8XRRV>VOC#J>*K!=-4@#Y9Z$-#CO0Z=/7WF8X99Y?<UQC(:1]-1T.76
MEYIW!X/8]H=AKG#J1Z37 @;[NG?I5XFE8+CC696K)+Y?K7:G2R2V:1D-3(YG
M*WM"7@M;OJ=&,@G6O5M6-?,O F+,3Q#S+S.HM 8RZL^&NT:_;SVLO-V'3I_[
MS6]=X5VKLQS/+\VOM@P%UKMU)9'B&JK:YI>]\FR--;H]-M<.[PWOJ M3PU*D
M]B&R(LGQ/*<VM>>4^+9S0TU9%5Q&2GNEOB<& @'H_IH?)([AHZ[P5K"Y2BXE
M"(BR B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B *F\5\K&*8K-- X?"-3_ 4C?'G(ZNU_P HZ^_0\5<E6+[A5MOF2VZ\
MW*:KEEH-&&FYV]B"#O9;R[)WH]_@%UP."FGDX1F=M5$SS#N%N26ZULGILMFM
M-36-;+401TO.0[7<YW.-D;^G:C+_ &:ZXEQ*PZXWF^R7AU1/YN)I(>S,;>8-
M+?E'8_A2?I6^JNYCB-!E;* 7"6IB=13=M$^G<UIYO;L'IT'T+U8_6RE-O)P[
MO9>/N<I84H_AY*)G,D=)QSQ&IN+@RA-.61O?T:)/X0#Y]N9](5ZX@9+2XOC%
M;75$K&S&-S*>,GK)(1Z( ]_4^Q5G-[EC%^R4XAE-*^!S8Q/3ULDC8V[(_JNW
MT/>.O0Z5 XB8[C=LMM/:<=JI;SD%?-'!$9:D3OACWOIKHW9#1W;T3X;76&..
M5XU.U2\;-<W?]S,I.&IQ)&GMLU!Y-=48&D2U6JF30Z\IF:-_F-'S+5>'+Z>3
M [ :-S70BBB;MO\ :#0';]O-O?M4C:[3!1X]2VB1C)::*F;3.:X;:]H;RG8]
MJI+N$MNB=+';+U?;=03$F2CIZK49WW@;'Z]KC/-#,I1FZ_$V:4'"FEVHB75#
M<LXZ4;[>>UH+!3N$TS>K3(>8:!][@/\ *5V\-0+QQ3S:]N',V!XHHG>P'1U\
MT8^E:!B^-VO&+=YE9J801$\SW$[?([UN)[RO/AF)T&)4=53VZ2IF\YG-1))4
M.#GEQ '> .G3U>)27J(:91CX27WMA8W:;\V4CCNXW%^+8[&3S7&X-+@/!HTW
MK^?OYEQXLM%SS;!\>C [(U'G,K!_8:1K]#7J\W/$Z"Y95;;_ %,M2:JWL+(8
M@YO9==]2-;WU]?@$GQ.@GS*GR:66I=7T\!@C87-[)K2'#>M;WZ1\?%,?J(04
M?9/[L2QMM^]?8C+]>K%><FDP>\T,LKYX>V!D $;^FQRG?-S=#U \"L_RVPW#
MA3#'>L6O,YMCIVLEMU4>9KM[/3P/=Z@1ZUIF98/:,K=!-7B>"MI^D-73/Y)6
M#>];Z@C?7J.G@H>AX76X5T%5>KI=[V:=W-%%7U'/&T^OEUU_5[%K#FQP2WV[
MJKLDX2D^/DR!XU5!O,>&V4-<SX4K62O8>]HT&Z/UA^A:Z    - = %5,YP6W
M9>ZCEK)ZNEJJ0DPSTSPUS=Z/B#X@'UJ=L=N9:;334$<\]0V!G+VL[^9[_';C
MXE<,DX2Q0C'E7^ITC%J3;[GN1$7F.@1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$!$0?RIJ?R=OZU+J(@_E34_D[?UJ6>WF8YH<6
M[&MCO'M0&$\#/_/N+/$/)CZ3!/YG"_ULYS_Z8F?2MW55X=8+:\"M5306:2KF
MCJ)S42253VO>7%H&MM:!KT?5XE6:IB[>GEA+WL[1A9SL.G-V-;'M73))2E:X
M!AGD]?\ GF=<0<J=Z3*BL\W@=_R<SG:^@1KGQ0N--B''C%<DKW]E02VVH@G=
MZ^1LA^<[>P?0M&PG$['PUQFII:*JECMXE=535%=*W8) !)< T ::%E/%,V[B
MUQ$QO%[#-'64MOYZFX5].\/9'&[EVQKAT)]$#WN'J*[1:ED;[5^Q"P\"[35W
MVY7;B+?XR*Z[O,=#&[KV%,#H:]^@/<W?]90V(7>ENOE3Y*Z>1G-3T+J2D#C_
M %V&(/ ]O20^[:W)C*6TVH,B8R"BHX=-:T::R-C>X>P +YZX+X+;\]Q"]WJ]
M><05U?=Y*FFK*9_9S0D#>VN][W#7=T]@4C)2U2?' +MY2E_90X#)9*?^%NM[
ME92T\#.KW#G!<=?,&^]P5*S>U?%K*>"]NNSFBAH R)\CCZ G!CYCOU<W*?<M
M,P[A19<>O0O575W&]WEHU'5W.;M71#_E&NA]IV?5I63-,2M&969ULOU-VT'-
MSL<T\KXW>#FN\#U_>I')&%17 )*\W.CLUKJKC<IV4]'3,,DDCCT '_?U#Q6
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M[P" ?<WE'S%2O$'!;9G5'0TEZGK&4]).*AK*=[6A[@"/2VT[&B>[7>K4
M- = %O4E#2@8IY3L8918?65/VOI[Q'YPX]S01O9^9KEK5_O5#8K'5W>XSLCH
MJ:(RN?OO'@!ZR>@ \20OS([';\CLU3:KS3-J:*H;RO8>GM!!\"#U!6<4O RR
MB6FCNE[O]UM5,X.@MU75[@;KN&@!T]VEI.,HI2? *QPN-7:\!SOB-=&&&MO
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MKS;Z_)]0[U5?*HCHI>'<#)B?A(UT7F#6?+=)U#@/'7*3\^EUC)2FDN&J(='
MUCLIS;,<]J&DQU,_F% 7>$+-;U\PC^?F7'"I(&^4WG+)"T5#Z&+L]]Y ;#S
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M #\4U9=P%_G+XJCP^$A_JSK8<>MYM%AMMM,G:FCIHZ?M.7EY^1H;O7AO2JF
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MI6-%4VG:!Y[?14UNHH:.@@CIZ6%H9'%$T-:QH\  O0B* (B( B(@"(B (B(
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MBX -]Y\%^4M3!5Q"6EGBGB/0/C>'#Z0@.U%YX:ZDGG?!#5023L^7&R0%S?>
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MEN?]+*T_X4[_ $Y5I+0G#V8)G/L$J\KSAM5F%U@@P:EA'94;*IT1DEZ;,G0
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MW<UQ-V D,A[W-'-R]_=L'V[77Q5L55<N N#W.CI_.A:::EJ)X=;W$80'$CU
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MUK]"Z8VZBMU_;Z@N_E 99=<;Q"RVJDKHZ6[WB04TM:T\C8V@#M'M/]7JX=?
M$JN18#P<%E\VFR6@DN9;MUR^%@)>T_MAO-R]_AK]Z\?%NU7BMX6X!D=[HY*Z
MHM/))<H)!MSXWAA)>/\ (T._O=?%6NF@X*SV$7<08XRE[/G<QY:)6]/DF/?-
MS>S2+\,%5_0'GX)Y96WO"<KLMUKFW&IL@D@CK [F[>$M>&GF_K?(=U]1"HO
M_A;19_A1K<FK:\TM-+)2T-/3R!C8AOF>_J#LESOT>/36B\):RV7?#,GNMDQ*
M#'J&5DD,,L;]FK:UKO2(T-:WKO(V3ZES\E7^:F/\MF_]*2DXJ3CMN@14-'#;
MO*=L]%2M+8*:Q"&,$[TUK'@?H"LOE+_S.WK\93_ZS%5,VN=-BWE*V.[7N04M
MLJK:8!4OZ,:[TQU/AH\N_5S K]\I'.K%7X#462S7&FN5;4R1R/%'()6PQL>'
M%SW-V!U#1U]:)-S@_D#JXWDM\G3&R.\-H#_]A*]\G!2RW7#)KED$];6Y154A
MJ9+A)4.VR4LYM!OR>4'IHCN]2C^./]'/'/[E#_HE;6?Y*G\B_P#0LN;C%5Y8
M,$X*89%Q*Q"*XYY65MTI:%[J*AI#.YC(V- )>2T@EVW:V3W-'?TU*\':0X?Q
MKRW#;?43OLC*9M7#%*[FY'?P9_5(1OQT-]RF?)2_FK'Y=-^IJ\.+_P!*O+/\
M+9^S3K4I-RG'L#<%A.?BJXB<9(L$=6STN/VZE%77L@=RF=Q .B?5Z;![-N*W
M98-?JR+ /**=?KT3!9+_ $0IQ5N!Y(I &#3CX=8V^X/WX%<L/+KFMBDAE?!.
MEML-)<N&!?9L@I)6N:YU5(8Y6[ZAW,7>_P!1Z@@[4UQ-Q+(<P=8:2KN=-;L<
MC:)+RV"=S'R.UU:TENBSIH;([]D= N7$SBO;<>L49QFMM]XOU5(R.DI(9.W#
MMN&RX,.]:V!UZDA9YQ5J9;QQ0Q"Q\0JHVW'I:%D]3'%(8X'5!#N8%V^[F#6[
M)Z#Q&]KI#7*G+W^9#JXG89PJL^*5LU@N='17ZFC,E+YO<G2R22-ZAI;S.[_6
M-:4]?;O5WSR3Y+A<9735<E'&R21W4O+*@,V3XDAO4^M>+B;2<,<5PBYTV/4-
MHJ;U5T[H:9E.X54S=C1DV2XM ;L[Z=RZHW!WD=GE(.H"#[_/%M;J+WY7()C*
MLNJ\0\G#&ZFUR&*X5E#24<$@[XRZ+9</;RM.O42%[K)P"Q=V/L;D,=777R>/
MGJ*YU2\/;*1U+1O70^L'?BJ_Q%L%7>_)IQ::WQNEGMM+1UI8P;)8(2UVA[ [
MF]P*TO'^*6)W3&8;O+?+?2CL@^>&:=K9(G:ZM+"=D[[M#KX;6&Y*/X/+L%'K
M;%DN-\"LPM645D-;'3PR-H9FR%[S#X!^QT[MCJ=;UX!1N0?T1*?\DI__ -H8
MO;69G=<XX.9]=*VAAI;2ULD5M>UKFOFC!.W.V2#TY1L:&^;U+JN5'/7>23%%
M31NDD;012EH&SRLF:YQ^8 GYE5:K5^9 UCAM_-YBW^%4O^BU9IP-_G5XL?X@
MS_4G4WPXXDXE#PSLDE9?J"FDHJ&*">&68-E:^-@:0&?*/=TT#M53R;;A\+9S
MQ(N7920MK*F*I8R1NG!CWS.;L>XA8TM1G?\ -P5SA-A$&;Y+F<%^J:I]AHKI
M))YC%*8V33/>X<SR.ITU@U[_ '[73#),9XU4F&XE=*ZUV;(:-LE2R.4ES(P9
M"]K7'9!U"0'=XYB.Y7/R;/MIQ"_QAW[3TRO^E7AW^$2?JJEU<WKDNU?L"K\:
M^'5FX=X];LGPWSJW7.CK(V%XJ'OY]AW4\Q/78'=H$$]%]'6^<U5!35!&C+$V
M37JV-K)/*L_FK/Y=#^IRU2P?:*W?DT?[(7";<L:;]P5+C;E51A_#NXW*@<&5
M[RVGIWD;Y7O.N;W@<Q'M 50Q#@;CE;C-/5Y8RKN=]KX6SU%5)4R!S'O&]-T=
M'6^]V]Z^93_E$X_59#PON$5OC=-4TDC*ML;1LO#">8 >)Y2XZ]B]&!\3<7NF
M&4%;4WNWTD\-.QM5#43MC?&]K=.'*3LC8Z$=ZL7)8[AY!6*'XS\)>&F5ON]9
M#7T="[5FD?(7R /=R-#P1T )8=;/]8=VEY.'/""SY)C-+D.=FKO-YNT0JG/E
MJ7M$;7C;0.4CP(/7IX +KN-YO?%[A]G<%#;XFVF&1HM,K&.;)5F-_.003HG3
M0.@'5VO!63@YQ'QZMP*UTMPNM';[C;:9E)4P5<S8G-,8Y>8<Q&P0 >G=W+;U
MJ+:YO>@5S!_/.&W&-N#-K9ZK'+K3FIH&3NYG4[@''0/^1XZ=_HGOVH"VXJ<Q
MX[YU::VLJ8+)SLJ*R&G?R&I+0 QCCW\OI.)]WN(FK/71\0_*)IKU9-SV/'J0
MPNJP#R2/(>!RGWR'7K#25(<+_P"D!Q'_ +L?ZVK3;5OO7[@K'%3#;=PJN^,9
M)A3JBWN?7-IIX.W<]DC3UZ\Q)T0""-ZZCN7J\J;&+7YS8KSV#OA"NK8Z2>3M
M':=&&G0UO0]X4UY5W\F,<_Q9G[#T\JPB''L9J9-B&&[,+W:[O0<?^Q3')MP;
MYW!Y>/>,6K$>"+[78H'048N$<@8Z1SSS'>^KB3X*8P/A):H)+-E]]K:^LR/3
M;A/(^4=F9'-WKEUW-V-=?ZOJZ+P^4=>K;?N#DE99:ZGKJ7S^%G:P/#V\PWL;
M'CU"UVQQB7&J"-WR7TD;3\[ N;G)8U\V#".'N/,XT7:\93F<M146B"J=36^W
M-E<R-@ !V>4[[G-[B-G>TSVQ1\%+[9LGQ":HI['550I;A;GRN?&X$$[',2?D
MM=W[(('@=+T\ [_18--?<'RNIBMM?35KIH'U+A&R9C@!Z+CT_J@CUAW3N7'C
MS?:+/J_'\'Q6IBN57+7-J*F6F<)(X6AKF]7#IT#W$^K7M77\74T_\?TH$MQ)
M(/E"<.B.H,4A_;6VK$>)#0SR@^'+1W"*0#_K6W+SY/Z8_+]RF,\=;Q=;AD>,
MX'8ZR2A?>GE]741G3Q"#K0(\-!Y/KT!W;7=<N &)&R.AL[*NBN\;=P7 5+R_
MM!W%PWRZWWZ ]FE&\<Q-C/$7#,Z=#)+;*)QI*QS&[[)I+NOSA[]>T >*OUXX
MH8A;<>DN_P /6^HB$9?'%#.UTLIUT:& [WX=1T\=+I<E&.C^,AF&.SU_%/@5
M?K/>-SWZTR.C9([J^22,<S"?^8^DPGQ[_%7_ ()Y9%?.%-ON-;,!);XG4]6]
MQ^28A\H^]G*[YU!>3%9JVCPZX7>Y0NAEO-:ZJC8X:/9ZT':]IYB/9H^*R[.*
MFOP.^YQA5KAD,63/AEMX9W-$K]/:/>"YG^4+3BIN4%Y_]!=N$%8[X.SWBG=(
MBY]4Z9U,QW>((@7<H/M(:W_(JYP^H,-S.DFR;BID=%5W>MD?V=%/<>P;31AQ
M '*' CN) [M:]ZVN3"VTW"2?$:$M#_@Q](Q_<'2EAVX^]Y)^=8]P5I>'E5CQ
ML^9VRTT>36Z62*H%QU$^0<Q(.W$ D \I'?Z/M54DU*2_3P#T8C=;9@G%VV6/
M$;[%<\3OC>4TS*H3BDG.P-$$ZZAOO#CO>@5U<0K%-D_E'"R1UD]'25UM9'62
M0$![H "]S0?#F+6CY_'N4Y8:S!ZCBO0V3"<1MEP%,WSB>[4[],I7-V=M(!#M
M::-['4Z\%W2?TL(O\)_])2ZE?>@:%P\X?67 H*^*Q><EM9(U\AGD#R.4: '0
M=.I/SJVO8U["U[0YI[P1L%?JB<LOU'C&.5]YN3B*6CC,C@.]Q[FM'M)( ]Z\
MK;D_<IU93D5HPZPRW&[S1TM%"--8T#;W>#&-\2?5_P!EEG!VUW3+,XN7$J_4
MSJ.&IB\WM=,[O$70<_NT-;\2YQ[M*C8K?,>SK(CE/%+(:%D4,A%!8W//9Q-!
M[WC77W?UM;/306_8_GV)WRX16VR7NCJJMS2601$[(:-G73P 7:47C326_<AC
M^:U-4WCA)4\+&35F4,A[*[1/8WS,L  T]Q<"#T9O7B!H[V%X,HK+Y/Q"QN7C
M/3"VV2"8.HA;VA]*Z;8/\*_F) Z#?L\ -E2_#:ZT>!<6\YM.5S1T$MUJ15TE
M74'D9*PO>X#G/3J'^[;2.]=_E&Y-:<AQ^AQ3'ZB"[WNNK(S%%2/$O9ZWU)&P
M"=ZUZB3W+JOZE&MJY!L]TR"S6F5D=UN]OHI'MYV-J:ED9<WU@.(V%$7W.+-2
M8Q>KI:[G;[C);J5]08Z>I9+U /*#RDZ!.@H^^<+\<R>FM1RBC?6UE#2,I1**
MB2/8 Z_)(WUV5&5G"+'K9B62T.*T+J6LN="^GVZH>\.<.K!Z1.O2TO.EC[LI
M3>%G#"V9QC;<LSYU3=[I=B^1O/.]C86!Q T&D>HG7< 0 %%XCC4V)^4M0VIU
M945='';Y'43ZAW,]D!8_3"?^5W,![ K;P%SNS08+36*^5]-:[O9^>GG@K9!"
M=!QT1S$;T.A]1'N5?L^4T65^4_155JD[:@I[?)2Q3@>C-RM>7.;ZQS.(WXZ7
M>YW-/BF0M6<X'4Y3G3J[-KK3Q812P@4U$RJ=%SR=-F3H .O,=@[T .G59;Q>
MM>"8A34-WX;WF"ER"FJ6_P #15YGYF==D^D[6B!XZ()&BI>:"SY;QWR.AXF5
MICI*'T+;1U%08(7-V-$'8ZENG:!Z[/J4;Q].!6K%X[-A5%;'W%T[):B>B:)3
M#$W8T^7J1MQ;TW[_  6L=J48V_V!?/*%H*F?#\?S2W-#;E9)HJKF:/\ W;^4
MGY@X,^;:NV89Q36[A35971O'+-1-EI=GKVD@ 8/F<X;]Q4S!;J:^X+#;JH!]
M)6V]L+]?V71ZV/IVOE^P&Y9!+CO"BX-?JV7F=U:? P1^D!OYY=>]JY02FJ?;
M^P-YX XV<<X:VX3M(K;ANOJ">_FDT6@^T-#?GVM%7XUH8T-: &@: '@%^KA*
M6IMLH1$60$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 1$'\J:G\G;^M2ZB(/Y4U/Y.
MW]:ET 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M1%\_CMJ_*%+J(OG\=M7Y0B!+HB( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B \5[^U%9^*=^I<[5]JZ/\ $L_9"X7O[45GXIWZESM7
MVKH_Q+/V0@/4B(@.BX4=/<**>CKH63TL[#'+$\;:]IZ$$>I==HME%9[=#06N
MFBI:.'8CAB;IK=DDZ'O)/SKUHE]@15DQVSV.:KEL]MI:*2K?SSNAC#3([J=G
MZ3]*Y/L%J??H[V^WTYNT;.R;5EG\(&Z(UOU=3]*DT5M@K^487CF4NC=D%GI:
MV2,<K9'MT\#U<PT=>S:ZZ+!,7HK/46JEL-OCH*G7;0B($2Z((YB>IT0#U*LB
M*ZG56"&K\6L=PM%):JZUTL]NI2TP4\C-LCY00W0\- D+OO-AM5[\U^%J"GJ_
M-9.U@[5G-V;_ .T/45)(I;!QD8V2-S)&AS' M<#W$%>"PV2V6"A\SLM#!14O
M.7]E"WE;S'O.OF"D44OL"N6[!\9MM]-YM]EHZ:YDN/;Q,Y3MP(=T'3KL^'BO
M'>.&F&WBXOK[CCU#-5O=S/D#2SG/K<&D GWJWHM:Y<V""DQ#'I([;&;+0!EM
M?VE&UL(:(';!VS7<=M!^9>NKL-KK+Q27:JH*>6Y4C2V"I<W;XP=[ /AWGZ5)
M(IJ8(V2PVN2^Q7J2@IW7:*/LF51;_"-9U]$'U>D?I7=>+70WFW2T%UI8JNCE
MUSPRMYFNT01L>\ KV(EL'124E/1T4-'2PLBI88Q%'$T>BU@&@T#U:51JN%6#
MU5::N;&;?VQ/,>5A:TG^Z"&_H5U1%)KA@Z:*EIZ&EBIJ*"*GIHF\L<43 UK!
MZ@!T"@,EP/%\FJFU-\LE'5U+0!VSFEKR!W N;HD>PJRHB;3M @J+$,>H:J@J
M:.S4,%10,,=+)'$&F%IWL-UZ^9V_>5.HB-M\@\5XM5!>J%]%=J*GK:1_RHIX
MP]I/KT?'VJMVCAAA=IKF5E!CE!'4L/,Q[FF3E/K <2 ?<KBB*32I,'&1C9(W
M,D:U[' M<UPV"/40J7)PIP:2M\Z?C%N[7?-H,(9O^X#R_H5V1%)KA@Z&4E/'
M1"DC@B92AG9B%C0U@;K7* .@&EYK%9;;8:$45FHH**D#B_LH6\K>8]YTI!$L
M$7D6/6C(Z(4E]MU-7P \S6S,#N4^MI[P?:%%6[AYB5NME5;Z/'Z".DJ@!.PQ
M\QE ((#B=D@$ ZVK2BJDTJ3!%7/'+/=+/#:KC;J:IML/*(Z>1FV-Y1INA[ I
M+L8^P['D;V7+R<FNG+K6ES12V"/L5DMM@H?,K+1045)S%_90MY6\Q[SKYEP@
ML%J@OL]ZAH*=EUG9V<M4&?PCV].A/J]%OT!2:); 7AO-HM][H'T5XHJ>MI']
M3%/&'MWZ^O<?:O<BG *KCW#S$\=KO/+-8:*FJQ\F;E+W-_NEQ/+\RE,DQNS9
M+2-IK];::OA:=L$S-EA];3WCYE+(M:G=V"LV' <5L+)VVFQ4-/V[#%([L^9S
MF$:+2YVSHCPVO9%BEBAQ^2QQVJE;9Y#MU(&?P9Z\W=[P"II$<F^X.BAHZ>@H
MH*.CA9#2P,$443!IK&@:  ]6E4ZSA;A-97FMJ,:MSJ@NYB0SE:X^LM!Y3]"N
M:**37#!XJFTV^IM#[7-14[K:Z/LC3<@$?)_9Y1TU[%SMUNH[;;HJ"@IHH**)
MO)'"QNFM;Z@/4O4B6P4YO##"FW,7!N,VT5(=S;[+T-^OD^3^A6"W62V6VOKJ
MV@H8*>KKBUU3+&W3I2-Z+CXZV?I4BBKDWRP1MFL-KLKZM]IH*>D=5R=K.8F<
MO:/Z^D?6>I2>PVNHOM/>IJ"G?=:>,Q153F_PC&'F]$'U>D[Z2I)%+8(^^V2V
MW^A\RO5%!6TG,']E,WF;S#N.OG7NBC9#$R.)H;&P!K6CN '<%R12^P"IUSX8
MX7<[@ZMK<<H'U+G<SG-86!Q]9#2 3[PKBBJDUPP=%#24U!214M#3Q4]-$WEC
MBB8&-:/4 .@5:OO#C$+]7.K;KC]#/5..WRAI8YY];BTCF^=6Q$4FMTP>*S6F
MWV6A91VBBIZ*E9U$4$88W?KT/'VKJH;#:Z&[5ESHZ"GAN%9H5%0QNGRZ_M'Q
M4DB6P1E]L-JO\$,-ZH*>MBAD$L;9F<P:\#7,/;U*[;U:+??+?)0WBC@K:.31
M=%,P.:2.X^P^U>Y$M@K<&"8Q#8766.R4?P4Z;MW4Q9S,,F@.;1\= *Q0QLAB
M9%$T,C8T-:T=P [@N2(VWR"!R?#\?RAK!?[125SF#3'R,]-H]0<.H'LVN6,X
ME8,78]M@M-)0\XT]\3/3</47'J1[RIQ$U.JL$;6V&UUMVH[I5T%/-<:0$4]0
M]NWQ ]_*?#O*DD12P=57305E-)3U<,4]/*WE?%*T.:X>H@]"%4*3A9A%)7"L
M@QFW"<'F',PN:#[&DEH^A71%5)KA@ !H    Z !15QQVSW*ZT=SK[;2U%PHR
M#3U$D8+XM'8T?#KU4JB)UP JSDN!8MDM3YQ?+'1U=3K1F+>5Y'@"YNB?G5F1
M$VMT")QW'+-C=*ZFL-MI:"%QVX0L#2\^MQ[S\ZYFPVHWX7HT%/\ "PC[(5?)
M_"<G]G?J4FB6^0%X;U::"]V^2@N])#64<A!?#*WF:X@[&Q[PO<BG *;]B[!_
M_A:U?4!>ZRX+B]CN#*ZT6*@HZQ@(;-#$&N (T>ON5D1:UR?<$-DN+V3)J=D-
M_M=+7L9\@S,VYG]UW>/F*\F,X+C.,3.FL-EHZ.=PT9FMYI->H.=L@>S:LB*:
MG56 B(H"KY%P^Q3(JX5EZL5%55?3<Q:6N=K^T6ZYOGVO=18K8:&OI*VBM%%3
MU=)#YO!+%$&F./KZ+==P](_25-(M:G56"NY/A.-Y3(R2_P!FI*V9@Y6RO;IX
M'JYAHZ]FUQI<%Q>DLT]II[#;V6Z<M,T(A&I"T[!<>\Z(\59$35*JL%4R_*[%
MPYL-#+<V2T]NYA20-IXN<-TTEK=> TTZ]RH7 ZWRY#EF3<1*RB=2LNDG86]D
MC>5W8C0+_GY6#?K#ELE13PU,?9U$4<L>]\LC0X;]Q78T!H :  .@ \%I3J+2
MY8"(BY@(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B("(@_E34_D[?UJ741!_*FI_
M)V_K4N@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M *(OG\=M7Y0I=1%\_CMJ_*$0)=$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0'BO?VHK/Q3OU+G:OM71_B6?LA<+W]J*S\4[]2YVK
M[5T?XEG[(0'J1$0!=;IXFRMB=*P2.[F%PV?F5-XS95-AW#VYW2B(%=IL%.2-
M\LCSKF^8;/S*B8CP/LUTQJEN>4U5RK,BKXFU,M9YTX/A>X<P#?61L=3OJ%TC
M!:=4G0);AWD-VN'&C.K56U\TUNH@WS>!Q]&+J.Y:S)(R-A?(]K&#O<XZ 7SY
MP!M]?:N+V<T-WJWUE93Q-C?4R?*E <.5Q]I;HKKP^SNXW9%?+YE%95.QJAJC
M2T%NAE+&'77;M>/*6DD=27=X TNL\:U-WLDB'T/%(R5@?$]KV'N<T[!7(D $
MD@ =Y*^=<[L!X)W&U9/AU35LLDU2VFN%MDE+V.!!.QOV-=U/4'77J0O5Q\NL
M$^>8I:LEKJRCP>J@,]1)3EP$LFW:#M=2!_!^X.)6%AMJGLP;Y!/#."8)8Y .
MA+' Z^A53B#:,DNKK-\5[Q';13U0DJ^=Y;VT73;!IIWX^I9BWAI8:I]!=N#&
M0TM%<Z:5KI=5[I8WQ^(>T<SM]W0]""=J0\I1\C3@NW<KC=V<W*>G]56,%J23
M_0&V[ \5UF>$3=D98^UUODYAS?0L)\I,W Y9P]ALU2ZEKYJJ6&&8?U'N=$T.
M^;>USS7@=8*##KI=**LNAOU%3258KY:DN?+(QI<>8=W77>.HWWJ+'&DV^2F[
MKK?/$R5L;Y8VR.^2TN )]P6*VSB-<:#R;H,EJ)>VO C=21RO](ND[4QM>=]Y
M#1S'?>1[5UX=P1L]XQJFNN7U-QK\@N$3:F6J\Y<UT+GCF ;ZR-]YWU]BG32M
MR?L#<MC>M]47SUP5H+E:..F6VN\5\UPGI*!L3:B4[=)&'1=F3[>3EVOH59G#
M0ZL%0J[1DC^)5'=(+Q&S&8Z4QS6_G/,^73]/URZ\6^/@K?L;UOJL3O+W?^U7
M8F\QY?@AW3?3Y,RKN46>MR3RD;G9::Y55!155OC\]?3NY7N@#&.+&GPYG!HW
MZM^X].GJJWVLA]%13Q2N<V*6-[F]'!K@2/>NQ?-7&#AU;N&MCH\KPBIKK?<*
M2JC8\&<O$@=OJ=^T#8[B">B^C+94^>VVDJB WMXF2Z'AS %8G!)*2>Q3TDZ'
M5=<L\,/+VLL;.8Z;S. W[E0O* <6\(,D+201%'U'XUBI'#GA#:\FPNV7;.):
MRYW"KI(S #4.8VEAY0(VL#2.O+HG?B>[O)L8)QU28-X7&26.-CGR/:QC>]SC
MH!8KP<KKAC'$/(>'=RKIJZCHXQ56Z68[<V,\IY-^Y[>G<"TZ[U0^'N#GB%E^
M;T%XN-;#8:&Z2S.IZ=X:99GR/#220>C0P^'C[UKHK>WLB'U0"' $$$'N(76V
MHA?*8FRQNE;WL#@2/F6!<4)W89:\2X;XY=WVRGKG.\YN51*&OC@+SLE_0#9+
MN[71H'<5PN'#CAC#9W&PY;245^B9SP7 7EG.91W%PYM:)]0!46)5;?/L#Z$7
M7-40PEHFECC+N@YG ;6*X7Q4K)N!-UR*X%LUWM/-2.>X=)9?1$;R/\[=^O17
MDX?<(;;EN,TN1Y[45UVO%UC%3S/J'-$+'=6ANO80?4-Z Z)TM-ZWP4VR]ROA
MLM?+"XMD93R.:X>!#205F?!2ZWW*>#E5/47.22\S&IA@JYG=6/UIA) [@2#W
M)@^+9)AU#EEIN%9Y[C#8)'VN2:7FF8.4[:1X#1]VV[ ZJM\&R1Y--^(.B*>X
M?Z96E%*+K?=$-<P"WWFU8I1TF3W%ERNT9?VU4QQ<'[>XMZD ]&D#N\%/2S10
ML#II61M/3;G !8)B3W'R2:MQ<[F\SK.N^O\ QI%T\*^%=!FF"6J[YI65]?))
M!V5)3MG,<=-"PEK0T#Q.MD^WYU'C6[D^] ^A 0X @@@]Q"J&(VC)*#*,DJ[Y
M>(ZVU5<P=;Z9KR33,YG$@@M '0M[B>Y9SP-%7C/$O,,&\^GJ[50L;44HF=LQ
M@EO0>K8D&]=-MWT7IX+/)XM\5.=QY6UC>\]!_"2J/'I4M^R!M4LC(F%\KVL8
M.]SCH!(WLD8'QN:]A[G-.P5\[X-8AQLO-ZR3+:JKEL--5.I;?;HY3'&  #LZ
M_P"5S>HZDD]>FE;<?X<77!N(5%4X74/^*=4PMN%#4U!<(SX.8#U)[B/'H1O1
M1XTMF]RFN/>UC2Y[@UH[R3H!<()X9V\T$L<K?6QP</T+(,AX>UF59O<[CQ$N
M368M!IMNHH:LQL(_M/[M'0V?';N_06<9Y18QP[R7'KIPVOK&U9JVQ5=%!7=N
MTQ[_ *VB3H]003XC6E8XE+9/<AJ/&;(+K9\UX;TEKKIJ:FN%T[&JCC.A,SM(
M!RN]FG.^E:RL2X_?S@\)O\8_^JTZVU9FOP1_G<ID_E(Y!=<=Q"UU-CKIJ*HD
MN4<3WQ'1<PL>2/=L#Z%J9GB8YC))8VO?\EKG $^X+%?*WYA@%JY/E_"D>O?V
M<B],O >SW2SOGO\ <;G6Y+/'SR7%\Y]&4C?HM[N4'P]7B%K3%P3;KDALQ( Z
MIW]RPG@[YYQ X(7NQ7FI?/412RT,,\CBYS=-:^,D]YY7'Z %8?)MO\MTX?BV
M5Y<+C99W4,S'_*#0=LW[AMO^0K,L6E/V*:KL;UOJN+Y&,87O>UK!WN)T L5X
M4N=F7%O+LQ>XOM]$[X,M_7T2!T<X?,-__,5(X*8(W.'7YV1U=7+CU'<9.SH(
MY2QDTYUS.>1UZ-#=>_PZ[O22NWQ1#ZACD9*P/B>U[#W.:=@KDOGRZVO[#7$?
M&Y<>J:EN+WV?S6JH)9"]D3]M',-_W@0>_P!$C>BI+B95W+-^*U%P]H+A/;[1
M#3^=7.2G=ROD&M\N_5HM&N[;MD'03I6]GL4VV*HAF<YL4L;W-Z.#7 Z]Z["0
M!U6&9IP6M./XY57K!:BOM5\ML3JF.5E2YW;<@)+3OQ(![M#?>-+QYOEDV8>3
M!/>9],K7F&*HY.@[1E0UI(]6];U[46)2K2]KHAO<L\,3FB66-A=T:'. W[EV
M+#\,X-6G(<3H;GFTU=<KU74L<@E-0YGFK"T<C&-'3T1KO!&UZ>!]TN5GRW)N
M']XK9:X6@B:BGE.W]B2/1)]6GL('ALCNTH\:IZ7=%-DEECA87S2,C8/ZSCH+
M]BECF8'Q/:]A[G-.PL0BX9"]72Z7KC#<XY7R3D4=(RN,=/#%WC1]$^.M=.[9
MV2JI;6V7".-N-T?#Z^BJM-S=V-;21U0GC822 "0?<1O9!!Z]5I8D]D]_T!].
M;&];ZKA'+'+S=E(Q_*='E.]'U+Y\XZ4MPN/&G#K=:JV2BGK*1U.9XSUC8]TC
M7N'MY"Y7.S\+&X)9;_)@-54/OE=3-AA?<)@61N!ZO'*WOZ[Z@]0/#:R\:23;
MY!ITU3! 0)IHHR>X/>!OZ5V@@C8(UZUA%%PCPRCL\<_$>[BHR"9G:5=357/L
M^5YZD-V1L#UG>_T+P\!)HCE.:X;27:2ZXS'$322&7FTQQY3RN'3J':.NFQM7
MI*FT^/8A?<0S>X7SBQE6/SM@BMUIB:V$,'I/<2-N<3[^X*.I,@NKO*.K;&ZO
MF-H9;!,VEWZ ?IGI:]?4K..''#JP5?&?++5-'4FDL[HY:4"=P<'!S3Z1_K?.
MO=F%BJLD\I:JM5+<:FWP3V]@JYJ9W+(80P%S6GPYB&C?M\>X]=$=32\ ^CHY
MXI7N9'+&]S?E!K@2/>NPD Z)"^;.+_#BW<-[!2Y7A%576^XT=3&UY,Y>) [?
M4[\=ZV.X@GHK1Q_I:JMP2P9G;-QW"SR0UHY?"-_*3[].Y#[MKDL2=4]F#:U^
M;'7J.BIV09O2T7"V?+J=S>R?0BH@!/?(\ ,:?\S@#\ZQZ:Q36/R5;K4U;GFX
M71T-?,]Q/-Z<\?+U_N@'WDJ1QWSYHI](&6,2-C,C!(X;#21LCV!?LCV1L+Y'
M-8T=Y<= +".&G"2DO5JQS+LDN=RJ+PYL%7&QL@$3(FZ,<>M;URAN]$+P8K:7
M\;<IOUWR:LJCC%NJ32T-OAE+&.(_K.UX\NB3WDN[P!I7I1WWV7)#Z&BECF8'
MQ/:]A[G-.PJEEMHR2ORG&ZNQWB.BM5)*77"F<\@U+=MT  T@] [O([UDF?8X
M>"M9;,IPNIJX[1)4MIZ^VR2E\;VD$[&_8TC9V0=:\5-\8:@2\5^%,D+SV4M4
MYPT>\%\6E8X]TXO9V#;R=#9[E2>+MXGMW#+(+C9JWLJNGA!CFA<"6'G:._YU
M0^)LU=G7%BW\/J>OGHK-!3>=W(P.Y7R]-\ONT6 >&W;T=!1/%[A);<6P*Z73
M#9ZVA,40;6TQG<^.JAY@#S ^(Z.^9(8XIQU/D%^MC<CRC@C:G6B[^:Y!5TD$
M@KIG$=>8%Q) /> 1W>*OMC@JJ:RT$%QG%16Q4\;)Y@=B20- <[YSLK#<M<6^
M271%I(/F5)U!_P#PK%W<6+O=+7P#Q5ULFJ*>"HAHX:VH@WSLA,.SU\-D ;^;
MQ5Z>K9>6#=&5$#Y71,FC=(WO8' D?,NTG0ZKYVH^'7#7)+&X8#?1#D0CYZ:H
M=7O;-V@ZCG8>H!/>6M&O!6[B?37>W>3S<Z;(*R.KNT%-$R:IA)U(1,P!VR =
MZUL^O:P\:M),IJ\L\4(:9I61AQT.9P&RN;G-:TN<X!HZDDZ 6"8'PAMN8X/:
M[OF5;<:VX5=(SL.6<M92Q<NHVL;W?) )WX_2:]P;Q6LSNDNEDRR\5]3CU@J3
M3PTD<I8)7DG?.[O+6AO0>'-TTM=*-/\ %P0^FXI8YF!\3VO8>YS3L%<E\^8E
M:6\.?*"IL:L=54_ =VH73NII9.8,<&O(^<&,Z/?IQ"^@USG#2]NY1L;UM=8G
MB,QB$K#*!LLYAS#YE@WE"LN,_$CA_2V:L?15M2Z6GCG9WQ\[F,+A[0'$KP<6
M^$UGP[!ZC)L>K+G#?+=)%*:M]27/E+I&M)/J.W;V-+<<2=6^2'T1+/%#R]M*
MR/F.AS. V5V+#\>X4T.>XO29#G%?<*Z]W2G;4-E9-R,IFO&V-C8.@T"._?7:
M\G _+ZRT<*LKDNLSZWXN33-A,CB26AFVLWZN8'7JW[$>)4Z=M%-WFGB@:'3R
MLC:>FWN 'Z5V-(< 6D$'N(7S]PVX;P<1K(W+N(E567.KN+GO@@$SHXX(PX@:
M#>[N.@.FM+LM$57PEXM6C':2NJ:K$[^"V""H?S&GEWKT3_>Y?>'==D;1XEO%
M/=$-\>YK&ESW!K1U))T LK\HO(KA8N'45PQZXR4M0ZMBC[:!PV6EK]C?S!5:
MXT<W%OB]>[)<JVIBQ7'@&/I8'\G;S;T>;YP[KX!O36R56?*!X:TN&8G'68O4
MU<%GFJ6,J[?),9(^?3N21N^H/>#[PMX\<5-*3W!].6U[I+?2O>2Y[HFDD^)(
M78:B$3"(RQB4_P!3F'-]"R3CEF-=C&"6:BLU0VEN5W<RF94N=R]BSE'.X.\#
MU:-^&R?!5R#AIPM^">2KRZEFO3F\SKG\,,$G:?V@WFUK?@=GV^*Q'&FM3*;Q
M=9'16RLDC<6O9"]S2/ AI6=>3G?+GD/#IM=>ZV6MJ_.Y6=K*=GE'+H*%X(Y;
M77K%LIL5WKFW&LL1? VM:_G\XB(>&NYOZW5CO2\01[UZ/)4_FJ;^6S?^E5PT
MQDGY0-A1$7 !$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$1!_*FI_)V_K4NHB#^5-3
M^3M_6I= $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 41?/X[:ORA2ZB+Y_';5^4(@2Z(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@/%>_M16?BG?J7.U?:NC_$L_9"X7O[45GXIWZESM
M7VKH_P 2S]D(#U(B(#-_*%L%3D/"ZYPT$;I:FF<RK;&T;+PP^D![>4N/S+T<
M/.(V.7;!K?737>AI9:>F8RKBGF:QT3VM =L$[UL=#XK0%2;CPIPBXW1UQJ\<
MHW53G<[BWF8UQ]98TAI^<=5UC*+CID#-^"-\@R;C/GMUI [S6IA9V1<-%S 0
MUKM>&P ?G7'@%>:/![EDF#Y+416^MAKW5%.^H<(VSM+0WT7'IW,:X>L.]A6T
MVK&;-:;I57&VVZGI:RI8V.62)O+S-: &C7<  !W>I>7*\*QW+&Q_&&TTU:^,
M:9(X%LC1Z@]I#M>S:T\L6VJV=?H0R+RB+_1Y;'9<(QFHBN-UK*YDD@IW"1L+
M0'#TB.@^5L^H-)/@K5GN56&UY/9\.S&RTTEBK*<.CN-6X&)KP"T#1;Z)! '-
MOIS JXXI@^-XF7NQ^STU'(\<KI6@ND(]7.XEVO9M>_(L>M.24/F=]M]/74V^
M8,F;OE/K![P?:%-<=EV0/G+C+B&"XM9F7O"KMYA?FS,-+3T5;VO:;=U(&RYN
MAL[!UTUXJP<<9*V;'N%\MV:6W%];3NJ01K4I:SFZ>_:TVP<+,+L->RMMF/TL
M=4P\S))'/E+#X%O.3H^T*?OV.VF_FD-XH8JLTDO;0=IO^#?_ &AI;ZRM=Z%&
M3<>?YR.%7^)G_4A6H9__ "$R3_#:G_2<O3=\=M-XKK?67.ABJ:JWR=K2R/WN
M)VP=CYVCZ%[ZRFAK:2>EJHQ+3SL=%(QW<YKAH@^\%<G-5%>"GSC8L=JLE\E!
ME);XW2U<,LM5'&T;+^2=Q( \3R\VAZ]+1>'7%3%:W![=+<+U0T%72TS(JFGJ
M91&]KV- .FGJX'6QK??ZU9+Q1S8?@=;'@EJIC/1L,M-0EKBQ_I<SP ""21S:
MZ]^EDM#FW"&[TT=VRJTT%'D('-5TS[?(291\KN:6NV?[77UKM_N)[;7V(?O!
MG(H<JX^9E>*1KVTL]"!#SC1=&UT36NUX; !^=?0BQ'@515-ZS;*\Y=024%LN
M(936^.1G(7Q-T-@>K3&=W39('<MN7//6JE[!&)7G^E=8O\'=^S,EL_I77?\
MP=O[,2UB7';3+D4-^DH8G7>&+L8ZH[YVLZ^CZOZQ^E(\=M,>127YE#$+O)%V
M+ZKKSEG3T?5X#Z$ZB_2@9OY4_P#-/4?E</ZRM+QC^35I_)(?V F06*V9%;G4
M%[HXZRC<X/,4F]$CN/1>^GACIX(X86AD4;0QC1W  : 6'+\"B4H'E!?S/9)^
M*C_U6+Q<',^Q^OX<6AL]UHJ2IM])'35,51,V-S"QH;S:)[B!L'V^O:]OE!?S
M/9)^*C_U6*(PKAMB.2X'BE?>K'35%9\&4W-*"Z-S]1C7-RD<WS[72.GI_B\D
M(3A=*,QXX95F- UQLE/ V@IYB"!*_3!L?,PGW.:NSR<OY3\2_P#%O_7,MEM5
MMHK10145KI(:2DB&F0PL#6M^8+RV3'+38ZBOGM%#%2RUTG;5+F;W*_9.SO\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M3S>]??M-]6@)=%$>;WK[]IOJT\WO7W[3?5H"711'F]Z^_:;ZM/-[U]^TWU:
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M?XEG[(0'J1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0$1!_*FI_)V_K4NHB#^5-3^3M_6I= $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 41?/X[:ORA2Z
MB+Y_';5^4(@2Z(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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ML52J%URAF1<=L&NU-05%%CX?YI03SQ=D*D]>9[0?ZO-(T#_[@+?EG]*K"_\
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M@N]?6<\8?7-$W911N,;(V!VPT -\/6M1XC_S>Y1_A=5_I/56\F_^9RP?_/\
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MR#AI.*>1TX@N5+#3O@BDB<0/DD!O=ON\0T]X5LXRV&TNXSX UUMHRVXU#C6
MPMU4>FT>GT]+IZU)_9";E6=6JS\-;50UMO8[GN5PJ*(B.-FQ\GY)! !UOO)
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M)+RASN=_R6-!Z#H023Z_#2N_#"RV^QX9;X;7*R>.:,3OJ&_^^>X=7?\ 8#P
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M-KHV-Y27:)]$!?02^6/(Z_E'D7Y)'^VJYA\>29%Q:O\ 8;/?:JWLK)ZJ.HJ
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M:UK#X$D.ZCKT&N]:EBU:%'N@;QL;UL;]2+Y=JN &2T>/OO4.32.R*./MW4[
MX$N V6B7FV7>W6B?I5P\GOBC57_&[O2Y+,Z>MLT/G'G!^5+  =\WK<W7?X['
MCLG$L*TZH.Z!N1('>=(OC_$[9D''?,KG4W:\345NI )"QFW-A#B>2.-FP-Z!
MV[V==[49QJM>2X/76RQ5>05=PMD<;YJ&<N<QX:X@.8[KX%@T-D=>FMD+:],M
M6G5N+/M-%\X^5):ZZFM6/9+;:FIA#&MI*CLI'-'4<T;NA]?.-^T*^WCB$W[
MS\LCD JJB@$;2T]U2[^#.O<_9]P7+I/2FNY3446%>2?:*MN,7&_W&>HF?73=
MC3]J\NU''WD;];B1_E6ZK.2.B3C8!( V3H(""-CJ%\Y9)PPR[+LNN%=GV0PV
MNQMYG4_8U'/&P;]%C6N+0WIU+B.OSJCXA7U& \:+99L>R;X8LU15PT\CHI.:
M*5LA#2"T$MYFD]X/A\RZK I+:6Y+/L5"0-;(ZKY?\K"YUMMS7'WT53-%RTG:
M<K'D-<1(>\ ]5QX@\)L@=AE7F-\RFHJ[Y#"*N:G+2(V-[RQCM].4'P '36AW
MI'"FDW*K!]1(2!WG2Q;R=,SK+APPNE5?ZF6J-GDD';2.YGF%L8> 2>\CTAL^
M&ED^'VG(..V7W.KN]YFH[?2:>6LVYL(<3R1QLV .C3L^SKLE18-WJ=)"S0/*
M9SK),2O5E@QVZ2444].]\C6QL=S$.T#Z0*WRC>Z2D@>\[<YC23ZSI?$?'+&[
MSB5[M]GNUWFNU#%3F2@GE'I-C<[JP[)/0CNV1HC6MZ7VU;_XA3?BF_J6LT5&
M$:]PBA\>[]<\;X;5URLE4ZDKHY86ME:UKB 7@'HX$=R\WD\9'=<HX??"%^K'
M5E9YW+'VCFM:>4!NAIH \2O+Y3W\T-R_'P?Z@52X+O='Y-F2OC<6O;'7%KFG
M1![+O"1BGA^H/H- 01L'87QYP3L&1\0Z"ZV?XQU=OL=/(V:J<PE\DSW@AK.\
M>CIA.MZ]AZ:[<=;>.%7'2@QV"ZS55#454$$C22&31S$ %S-D!PYN_P!8]11^
MGW<=6Z%FR>4?G%UPS%*+X!E;!6UTYB[<M#C&P-)/*#TV>G7WJI8?3<2;?A=R
MRR\93V]ODL=16T\!D[21DAB+HG$.9H:[^A]055\J?$I[7>VY#)=7U$%TGY64
M980(.6-HV#S$'>O4.]6G"L$JL;X.Y+>Y[W)70W;&GR,I71EHI]P%V@2X[[]=
MP[ET2C'$J[^P+!Y,N7WW+K3?9<BN#ZZ2GGC9$YS&MY06DD>B!ZEM!( V2 /:
MOG?R/"X8_DY8 Y_G$6@3H$\CO%>"X<*,HR6^7*Y\3LHAME(#S0.CG#X^I/HM
M#BT,:T:[QL[]Y7/)CB\DE=((^E^_N1?(W"2[UF)\:X,;M>0&[V*>8TY?&_FA
MF!87!P&R X'0V/41W+W^4G=;K;>,5F?9ZJ:.HCI*:2%@>>0R":3EVWN/4#O4
M^'>K3?:Q9]5;&];ZH2 -DZ"^2N,/#6\X=8J7*ZG*ZVX7=U0R.H>>9A8YP)!8
M[FWH$:\._P .Y2=@PC*.+F%?&+(<IJ&%D;HZ&E;'MCNS'*7OT0-N<#LZWX^H
M)T8UJU;"SZB1?.GDD91<K@V]62X54M334L<<]/VKBXQ[)#F@GP^3T\.OK6?8
M)#DF3<3[[8+3?JJW15<E0*FH#W.='"V39#>O0D\HZ$=_JVGP^\DWP+/LP$'>
MCW)L;UOJOB[-K??.#/$.FAQ^^5%1)/ VH8]XT) YSFEKV;(=U:?T>*G>+7#.
M]XKC,.75^4UE=>NV8*G?,WD<[?R'\V^AT.X?-W*_#K;\7/ L^M%^$@=Y ]ZS
M/AK?\@R?@G2W"BEAER-\$L$<M2=-=(Q[F->XZ.SH ]W4K)QP;KJBDJ[GQ,S9
MEKN+GNY#-.V0$?VBYSQWG?HCU?,L1Q*VI.J!]2K(;AQ7JI.-%#A%OHF14[)S
M'55,AYG2?P1?I@[FCNZG9/L6>>3)?[M6WR_XI4W26JM_F,KX'N>9!&YKVLYF
M;.PTA^]>P+.Q@E4>,WQ/^&Y/.NW[+X2[,\V^RY]\O-OV?*7:&"*E)2?"%GU#
MQI9G#[1;QPZ,GGG;GSCD="/X/EZ?\3IW^I6S#1=!BEI&0[^&!3,\[V6D]KKT
MOD^CW^KHL$\H>@K,3X7XA:F7.>>:EG=$^I:71F73"=D;)_25=GYH_#?)ZLM[
M_P"-7NM]/%3B0[YI7M&B?7KJX^O2YN#<%7D&ND@=Y 1?)F"\,<CXKVN7)LBR
M>H@9/(YM.9&&9S^4Z) Y@&-!V !ZCW>,EPORO(N'O%$8)E%:^MH)IFTT9>\O
M$;G@&-[">H:[;06^&_6.IX%NHNVA9]0IL;UL;7R=QXNMYH>.M(+'52QU892^
M;LYSR=H>C=M[CUUWKEQ<X4WC%<:.6SY767&YQ2L\Z<_F:07.UMCN;?1Q'S>K
MN18%M<N19]7HL]X!Y%79-PSMM;=973UL;GT\DSOE2<CM GUG6MGQ6A+C*.EM
M,H41?/X[:ORA2ZB+Y_';5^4+*!+HB( B(@"(B (B( B(@"(B (B( B(@"(B
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M#)6VJ@J)(0&QNEIV/+ .X D=%)- : &@ #H %MY(T]*Y!AGDS?R8S+_%9OV
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M N<':[M$M).M=4A)RFFNP.WR>:>6]SY/G==&6SWNL<RG#NI9 P] #ZMZ;_\
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MWM@M-2'B6G$CW!P>-.ZDD]1ZBK'(E#3[V0Q/R-OM7E'XZG_9>J_Q;_I/8_\
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M8:04E$U[GB(/<_TCWG;B2I5<\DM4FT4*(OG\=M7Y0I=1%\_CMJ_*%A ET1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 >*]_:BL_%
M._4N=J^U='^)9^R%PO?VHK/Q3OU+G:OM71_B6?LA >I%6KMGF+6B\LM-SOM#
M37!Q [&231:3W<Q[F[]I"LH.QL=RK37(/+=KC2VFVU-PN,PAHZ:,RRR$$AK1
MU)T.JHWV:>'W_P 20_43?[%*<8/YKLJ_P^;]DJF<",0QNY\)[!5W+'K/5U4K
M)>>:>BCD>[4SP-N+=GH %TC&.C5(%_Q?.<9RF1T5@O-)63-',8FN+9->OE=H
MZ]NEZ\DR:SXTRD??*UM(VKE$$)<QSN=Y[AZ(/Z5A7&O'[1C.9X74X12T]!D4
MM<&^;40#.=FQHE@Z ;)'=U!/?I6#RG_XCAW^,,_4M+%%N-<,AMJ*!S7+;1AM
MF=<[]4]C #R,:T<SY7?V6CQ/3]ZSO[.<%/''6W3#LEH;+(1RW"6F]#1[B?#7
MN)^=<XXY25I%-B1>&V7>@N=GANM#5Q36Z6/M63AVF\OB23W:Z[WW:ZK,9^-U
M'5UE3'BN,W_(:6F=RRU='3DQCW=Y/SZ2,)2X0-9GE9!!)-*[ECC:7N=Z@!LE
M1N,Y#:LGM8N-BJVU=$7F,2M:YHYAWC3@"J[CN=6?.</NU79GRLD@ADCJ*:=O
M++"[E/1PV>_KHCIT/J*J/DQ54%%P=-563,@IH:J>2221VFL:-$DGU*].HMOE
M V5%3< SZESB6NDL]MN#+;3/,;:^=C613N![F#?,?7W=/'KT4/E/%VVVJ_RV
M*R6JYY%=X?\ C06Z+G$1'>'.]8\= Z\>JG3DW5 TI%0L%XH6K*;K-9YZ2NLU
M]B',Z@N$?9R. ZDM]?3KKH?'6E(<0\_LV"T4$MV=-+4U+BVFI*=O-+,1ZAOH
M.HZGUIHE>FMP3][NU%8[54W*ZSBGHJ=O-+*02&C>NX GO*YVBY4EXME-<+;,
M)Z.I8)(I " YI[CH]5@W$WBI!=^']\M%YQZ]8_6UE/ND\_@+63Z<TD!VAUU[
M->U:EP9_FKQ?\AC_ %+4L;C#4R%R1>2\U\=JM%=<)FO?%20/G>UGRB&-+B!O
MQZ++&\=;774--)CU@OEYK)(S++2TD'.ZF;S$#M"W8!.MZ&^A\%F,)2X137D6
M4V_CGC-;875D<%P-S;-YN+0V+GJGR:[FM!ZCH>OL]?1>C#^,%!>\GCQZ[6:Z
M6"ZS#<$5?'R]IXZ\""0#K8T==ZO2FNP-.157B!GEEP:@BJ+S)(^:=W+3TL#>
M>68_\HV.G=U/3JJ=3\;*2FJZ=N4XQ?\ 'J.I<&Q5E;3D1$GUG0(^;:D<<I*T
M@:VB\5PNM#;K1-=*RJBBM\,7;/G+MM#-;WL=_LUWK*XN.E%4"2MI<4R2>P1N
M(?=(Z7<;0.]WJU\^_8D82EP@:19,GL]\N5TM]JK6U%9;).RJXPQP,3]N&B2
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M1\"#^HH\<HJV@6E$18 1$0!$1 $1$ 1$0!$1 $1=-94,I*2>IE.HX8W2./J
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MB( B(@"(B (B( B(@"(B (B( B(@"(B *(OG\=M7Y0I=1%\_CMJ_*$0)=$1
M$197@V97F[<9,OQZMGC?:[='S4\8B:"T\S!U<.I[SWK48N2;78&J(OGSB)QA
MO.&\8WVR=T<V-P]B9H!$.<-?&"YP=W[!.]?,M]HJJ"NHX*NCE9-33L;)'(P[
M#VD;!'S*RQN*3?<'<BRVUYC>*CC_ 'C%99XS9J:@;/'%V;0X/+(COF[^][E
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M]VAW^O5>%]NJ[1P]Q^WW&%T%93TC(Y8G$$M<!U'3HN<EIQTWW!ZL]_D-D?\
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M::DM!O9HJ/SF"W&0,$LFY"7;/3IR-/\ D7[EUHX@YUD^*WNOQXVZV4-PC,=
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M-?<;M9:A_)6TU94-?V3-CTP21X$GIUZ>.UWVF?'>+EJJA=;7V%712F+D,O\
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M?*OM<M5-'#$+8=OD<&M'\')XE5IJ33_*#>U@6;,%H\J+$ZNC'(^X4H94!O\
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MJX*NEDZLF@D#VN]Q"[*VKIZ&EEJ:V>*GIHAS/EE>&-:/62>@6*!W(L\J>-.
M4]087Y'"YP.BZ.&5[?S@TA7&P7ZU9#0BLL=PIJZFWHOA>'<I]1'>#["M.$EN
MT"210.4YA8,5-,,AN<% :GF['M0?3Y=<VM ]W,/I4$.+V!DZ^,U%]#_W(H2>
MZ0+VBCK%?;5?Z0U5DN-+7P Z+Z>4/#3ZCKN/L*A\AXA8KCMR=;[W>Z:CK&M#
MC%('; /<>@446W20+2BH@XO8&2!\9J+Z'?N5KL=ZME]HA5V6OIJZFWR]I3R!
MX!]1UW'V%5QDN4"010;,ML3\E=CPN4(O31LTCMM>1KFZ;&CTZ]/!3BC37("*
M%HLILM=D%58Z.XPSW6E!=/3Q[<8P-;YCK0[QX]ZZ<FS3',8>QE_O-)12O',V
M)[]O(]?*-G7MTFEW5 L"*$QG++#D\<C[!=:2N$?RVQ/])GO:>H^<*;1IK9@(
MB* (B( B(@"(O'>;I166V3W"Z5#*:B@'-+*_>FC>NNO:0G(/8B\UKKZ6ZV^G
MKK?,V>DJ&"2*5O<]I[B%Z4 1%%6+(K3?I:Z*T5T55)0R]C4!F_X-_4<IV/85
M:!*K'[I@67X[F5WR#AU<K<8KL_M:NWW%KN3GV3S-(]I)\-;/>M@16,W'@&.T
M/#W+,IRJUWKB5<K>ZFM;^VI;;;VN[/GV#MQ(]8'KWK71;$B)*;ER B(L@(B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B *$O&+VR[
MWJVW2NCDDJ[<[FI]/(:T[WO7CU ^A3:+49.+N+(TGR%7*["[+6Y33Y#/3.-S
M@Y>5X>0TEN]$CN)_<%8T2,Y0_I=!I/DC[[9K??K;)07:F94TK^I8[P/@01U!
M]H5.M_"+%:2KCGD@JJML1W'#4SE\;?\ +TV/8=K046X9LD%IC)I$<(R=M$#F
ME[?C&,U-T@H#6-I0W<#'<FF; )WH] #ON6:>;<)[E31W^L=14\TC!--1MJ7
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MM(V!CCM[MESY#ZW./4J91:EFR2CH<G1%"*=I!$1<S01$0!$1 $1$ 1$0!$1
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M5-SBF#AOE>0=<P'>!L>U6#CA_-/D_P"2']877P+M=+:N%>/-I(VM-13-JI7
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MQ$HH_-KGPQK:BN;T,M+([LG'U]&N'_4O!38?GG$?*K/>\Y92V*UVN<3TU%$
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ME96W0S4YD _A&<S_ $A[.H^E:PBCR-W[@(B+F B(@"(B (B( B(@"(B (B(
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M:<0!TZ=!H#Z%6[[P9QBY7>>YT<ESLU9.2Z9]LJ>Q$A)V2000/FTCR1E-RNO
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M+^#PYM31&K\[[;1;KG]'DY>OR._?BKLOF[%[E?+AY2EKCRJCAI;O16Z2EF[
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MD<K1U'>".X[(/<!M3I.ZLIL*+&8,RS#!,GM5LXC/H+C:;I)V$%TI&=F8I.@
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M*GX1\R^!ZP5?+V':=MHM/+OF'+\GOZ]ZF.?X]4F"E<3YJ>#CYPW?5EHC+96
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M$8(!TUO4=Q;X'9<.[1*UY9IGW#*>]95393C-]EL600QB)TS8A(R5H&AS-V/
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MOZU+J(@_E34_D[?UJ70!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 %$7S^.VK\H4NHB^?QVU?E"($NB(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B(#Q7O[45GXIWZESM7VKH_Q+/V0N%[
M^U%9^*=^I<[5]JZ/\2S]D(#U(B("*RJ^T>,X]7WFYN+:2CC,C^7O<>X-'M)(
M ]I6467*N+&34#;_ &6R6*FM$@[2FHZM[NVGC\"'; Z^!/*/'6E)>5&V=W"6
MK,.^1M5 9=?V>;77_,6K1,/?!)B=E?1EIIC10F+E[N7D&OT+M&HPU5=D,0X
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$1!_*FI_)V_K4NHB#^
M5-3^3M_6I= $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 41?/X[:ORA2ZB+Y_';5^4(@2Z(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@/%>_M16?BG?J7.U?:NC_ !+/V0N%[^U%9^*=
M^I<[5]JZ/\2S]D(#U(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 41?/X[:ORA2ZB+Y_';5^4(@2Z(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@/%>_M16?BG?J7.U?:NC_$L_9"X
M7O[45GXIWZESM7VKH_Q+/V0@/4B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@(B#^5-3^3M_6I=1$'\
MJ:G\G;^M2Z (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( HB^?QVU?E"EU$7S^.VK\H1 ET1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 >*]_:BL_%._4N=J^U='^)9^R%PO?VHK/Q3OU
M+G:OM71_B6?LA >I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 1$'\J:G\G;^M2ZB(/Y4U/Y.W]:ET
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!1%\_C
MMJ_*%+J(OG\=M7Y0B!+HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B \5[^U%9^*=^I<[5]JZ/\2S]D+A>_M16?BG?J7.U?:NC_$L
M_9" ]2(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B B(/Y4U/Y.W]:EU$0?RIJ?R=OZU+H B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"B+Y_';5^4*741?/
MX[:ORA$"71$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M/DHI7.:USV%AVTZ/0^T*Z75]@3*(B@"(B (B( B(@"(B (B( B(@"(B (B(
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M=WHN( ;O1/30(((Z[!58N.<YQ7<6<CP[&74;BSLS3S5,8Y**,,:7O.AMQVX
M [ZGN79AV49KBW$VW85F]92W>&XPNDIJN(:>T /().@3\@@@C?<=KLX?@?\
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MCVL\JZ(//*9+1IN_$\I/_8K,?Q)MKLP7+CCD=RQ3AW77:R3-AKHI8FM>Y@>
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M(.SOVK4>+7$*+AW9J.X36Y]>*FH[ ,9*(^7T2[>]'U+"O*T ;Q"L    H&
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MF?#&9&U 8&/D[@1RGN!!)]JU)?+OD^4<N:\7;_F=:PF*F>^6/F_JR2DAC?\
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M,6\KVN[MC?R=*P(LIM.T"-QBTML6.6NTLE,S:&ECIA(6\I>&-#=Z\-Z5=Q#
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MB( B(@"(B (B( B(@"(B *(OG\=M7Y0I=1%\_CMJ_*$0)=$1 $1$ 1$0!$1
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MU#('6V4AK_2!(>TD=6]/5XCUJVYGEMMQ*W,J;FY[I)7<D-/$.:25WJ _[_\
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M>C=#45]UJ?\ @T5*WFD</6?4/T^Q0ENXG.9>J2VY/C]=8G5CN6GEF=S,<=Z
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M<@FD601<8;I7T[[C8L OE?8V[(K"X,<]H[W-9H\P]Q6@X1E=LS.P0W>RR.=
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ML3^UIJF+I) _UCUCUCQ]X!%&?PER.[THMN6Y]6W.S,'HTS*<1F0CY/:.YMN
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MXJTU'9+KC,&-6=E0V>IJ9ZML\AY=C3 WQT3X?./'<::%E/3Q01 B.-@8W?J
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MLD5\?CT+8Z>EGJ6PLBVT?PGI=YYG._0?!6S*KAQ-R'&[E:*G :!D5; ^ O\
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M><RL&I-\P'(3S'K&SN&O2]ZF>-=IO-]X=7*U8Y2^<UU68X^3M&QZ9SASCMQ
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MKG25#GD?P4NAMO0!:GCTMKP#045)O7%7";+<'T-QR&E951NY7LC:^7D/B"6
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MMWJ:ZG@MCHVS"IE>&,+'#;3L^O857MG%G!KG<&T5)D=(:ASN5HD#XVN/J#G
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MHAI*:6HJ96101-+Y)'G36M V23X!>:RW2CO5KI[C:YQ4450WFBE (#AO6]$
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M5IW?W M&^]1_$GC!:LFP>[6K"X:VXUM322><.\W<QE+ &DR.>3X\NP->)[_
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MIA$7@DTVVE2.ZXW"(BA0B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M=M7Y0I=1%\_CMJ_*$0)=$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0'BO?VHK/Q3OU+G:OM71_B6?LA<+W]J*S\4[]2YVK[5T?XE
MG[(0'J1$0!$1 $1$!U34\,Q:9H8Y"WN+V@Z7:B( B(@! (((!![P5UP00P B
M"*.,'J0QH;OZ%V(@"(B ZIJ:"?E[>&.3E[N=H.OI7:  -#H$1 <98V2L+)6-
M>P][7#8*11LB8&1,:Q@[FM&@%R1 %UPP10\W8Q1Q\QV>1H&S[5V(@"(B (B$
M@#9.@@,8XLWK,K]4W+",?Q6JC@JRV%UY>\]@87 %QWR@#O+3U/CH;6I8K9*?
M',<MUGH_^!1PMB!UKF('5Q]I.S\ZE&N:\;:X.'K!VOU;<[2BD#);[8+K-Y1N
M/7J*@G?:8+:^*6J#?08_4W0GU^DWZ5JT<$43GNBB8QSSMQ:T N]Z[$4E)RKV
M 75)3022-DDAC?(WN<YH)'N*[460$1$!^.:'-(< 0>\%&M:QH:P!K1W #2_4
M0!=%?++!0U,U/"9YHXW/9$#KM' $AN_:>B[T0&%4$.2\4L]L=?D.-5-@QVQ/
M-0(*HGFJ)^G+WM;L @>&@ >O5;JB+<YZO9 (B+ .N*GAB>Y\4,;'N^4YK0"?
M>NQ$0!=?81=MVW91]KK7/RCFU[UV(@"(B ZIJ:"<M,\,<A;W<[0=?2NT#0T.
M@1$ 1$0!$1 %ULIX62NE9#&V1WRGAH!/O*[$0!$1 $1$!UPP10 B&)D8)V>1
MH&RNQ$0!=<\$4[>6>*.1O?I[01^E=B(#\:T-:&M #1T  [EC7%F]YE>ZFYX3
MCV*538:SEA-Y<\]@87 %YWRZ'>6GJ?'IM;,BU"6EW5@B<2L=/C6-6VS4?6&C
M@;$':USD=[C[2=GYU+(BC=[L'5#3P0N<888XR[Y18T#?O7:B* KW$6DJ*_ <
MBI**)\U3/;YXXHV#;GN+" ![25"<%K+46WA;8K=>J$PU<#9.>"=@YF$RO(Z'
MV$%7Q%K5^'2 .@Z(B+("ZO-X>V[;L8^V[N?E'-]*[40'@R")\]AN4,+2^62F
MD8UH[R2T@!9_Y/E@K;/PRI[=?[>^FJ14RO,%0SKHNZ'16GHM*51<0&@- #0
M!T "_'L;(WE>UKF^HC:_460 -#0Z!=<=/#$]SXH8V/=\IS6@$^]=B( NIU-
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MTPK::!SBX0OT#TW[.<>T!N^Y5SAOA-LS'BUQ".01.JK?07*5S:4R.:QTKY9
M''1&]!I^E:Z45;;VY(?1ENO%MN5L%RH*^EJ* @N\XCE#H]#OV[>AKQ]2AJ/B
M#B-9<!14N2VF6J<>5K&U+?2/J!WHGW+%N.DEIQV?$L#@F?9L3D>:JO[+G>3&
M9#T\7'KSGQZEOJ7;>KGP*K\<EM=.^BI']F6PU,-!.)HW:Z.Y^3F=UUWD[56%
M-7ON#Z+5=O6<XO9*SS2[7^VTM4.ABDG:'-]XWL?.L7P?B-<XO)ROEQDJ'R7.
MTO-!!.X[=I_((W;\2WM/^D*U\(.%^-MP2VU]ZM5+=+G=(&U=145C!*[^$',
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M!7.,JDI%*KPB_FPQ7_#8/V L_P#)K_CV?_XP[];UM<4;(8VQQ,:R-HTUK1H
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M^E<?\'_[+;5T^:T_G/G/81><:Y>UY!SZ]6^]=RQ.6JO8H1$6 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M 1$'\J:G\G;^M2ZB(/Y4U/Y.W]:ET 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!1%\_CMJ_*%+J(OG\=M7Y0B!+HB( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B \5[^U%9^*=^I<[5]J
MZ/\ $L_9"X7O[45GXIWZESM7VKH_Q+/V0@/4B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@(B#^5-3^
M3M_6I=1$'\J:G\G;^M2Z (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( HB^?QVU?E"EU$7S^.VK\H1 ET1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 >*]_:BL_%._4N=J^U='^)9^R%P
MO?VHK/Q3OU+G:OM71_B6?LA >I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 1$'\J:G\G;^M2ZB(/Y
M4U/Y.W]:ET 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!1%\_CMJ_*%+J(OG\=M7Y0B!+HB( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B \5[^U%9^*=^I<[5]JZ/\2S]D+A>_M16?BG?J
M7.U?:NC_ !+/V0@/4B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@(B#^5-3^3M_6I=1$'\J:G\G;^M2
MZ (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( HB^?
MQVU?E"EU$7S^.VK\H1 ET1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 >*]_:BL_%._4N=J^U='^)9^R%PO?VHK/Q3OU+G:OM71_B
M6?LA >I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M3^3M_6I=1$'\J:G\G;^M2Z (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( HB^?QVU?E"EU$7S^.VK\H1 ET1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 >*]_:BL_%._4N=J^U='^)9^R
M%PO?VHK/Q3OU+G:OM71_B6?LA >I$1 $15N3/<1C>YDF461KVDAS371 @CP^
M4JDWP"R(H*WYCC5QJ&P4&0VBIG<=-CBK(W./N .RIU&FN0$1% $7YS#F#=CF
M(WKQTOU $1$ 1$0!%^!P+BT$$CO'J7BH;O;:^LJZ2AKZ2IJJ1W)40Q2M>^$[
M(T\ [:>A[_44H'N1$0!%X:B[VVGN=/;:BOI8KA4-+H:9\K1+(!O9:TG9'0]W
MJ*]R (OQS@UI<X@-'4D]P7Z@"(B (B( B\-SO%MM3J=MSN%)1NJ7]G")YFQF
M1W]ENSU/4= O<@"(B (B( B(@"+PQW>VR7:6U1U]*^YQ,[22D;*TRL;T](LW
ML#TAUUXA>Y $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1>&CN]MK:ZJHJ.OI9ZRE.JB
M"*5KGQ'_ )F@['SKW( B(@"(B (B( B\+[O;67:.UOKZ5MSD9VC*0RM$KF]?
M2#-[(Z'KKP*]R (B( B(@"(B (B( B\,EWML5VBM<E?2LN<K.TCI'2M$KV]?
M2#-[(]$]=>!07>VF[&U"OI3<PSM#2=JWM0W^UR;WKVZ5I@]R(B@"(B (B( B
M+PPW>VS7::UPU]*^YP,[26D;*TRL;T](LWL#TF]=>(]: ]R(B (B( B(@"+C
M(]D4;I)'-8Q@+G.<=  =Y*\MINE!=Z055IK::MI22T2T\K9&$CO&P=(#V(B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B B(/Y4U/Y.W]:EU$0?RIJ?R=O
MZU+H B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M)3?TK:K_  <?J:KV_P#\@VU5?(\\L&-WRFM5ZK/-:BHIWU+7O:>S#&AQ)+O
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MJIHIJRGN+H8'O:'=D"]Y<6[[B>G7V+U\7J.GMW&_AM<**%D%75U)BGDC'*9
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M5*+2,QRPDZ3+&BJ>:Y]9\.J*6&[MJB^H87L[&,.&@='>R%ZLFS"VXY8*6\7
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M8];G5]ZK8:.E:0WGD.N9Q[F@=Y/L'5>3-<HH,.Q^>\W<3FCA<UKNQ8'.VYP
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M]06'RK2'<*V.:00:^$@CQ]%Z\W#NLIK?Y,#*NOH67"EAI:E\E*]Y8V5O;/\
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M2L+BUQ'?R-:"7 ?VNGSCJIOA=QFI,NO3[#>+;+9KX.8,AD<7-D+>I:-@%K@
M3RD>'>L*\GZNS"WU%[GP>PV^[3EL3*A]5(&NB;MQ ;M[>A(.^_Y(5JK\0XE7
M[B?:<KN&,4M!/!/3NF-+41AI:QPVX@R$D\O3W +<L6-7'];!I_%/B_!AU[@L
M-IM4UYOLK6N["-Q:&<WR1T!+G'OT!W:ZJILX^WBRW&FASC"JNU4TYZ2^FQP'
MB0U[1S:]A"<:^%N25N;,S#":EIN#@PNA$PBE;(QO*',)Z$%H&QOU]^U2JKB?
MGF.5%)'Q%QJGN=/$_P#@S<J 1NWXF.0#EWKQT5(8X2BJ5_7<'UA154-=1P55
M)(V6GG8V6.1O<YKAL$?,NY1&(7NCR/&;;=[:PQTE7"'L8X %G@6G73H01\RE
MUXVJ=%"(B@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B *(OG\=M7Y0I=1
M%\_CMJ_*$0)=$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0'BO?VHK/Q3OU+G:OM71_B6?LA<+W]J*S\4[]2YVK[5T?XEG[(0%:O?
M$K$+)?19[I?::GN&PUT9#B&$]P>X#E;\Y"MS2'-#FD%I&P1XKY#X@\$\SJ^(
M%SEMM&VMHJ^K?41U9F:UK0]Q=Z>SL$;]7771?5>,6U]FQRU6R6;MY*.EBIW2
M_P!LL:&D_H7;)"$4G%V"26$>2PUKH,RYF@_^9^(]CENZPGR5O^!F?^)_]G)#
M_;E] :ME^'V7*[146^[T,$C96D-E#!VD3O!S7=X(_P#OK,O)ANU8RWY%BERE
M,LMAK.RC<3W,+G M'L#F./\ F6URR,BC?)*YK(V N<YQT !WDKYTX&R3UCN*
M^44(<(JN65U*X#O?_"R=/:.=GTJPWQR3]B%SNG%:Y7/(:VS<.L:?D$M"[DJ:
MQ\XB@8[NT">A[CUV-Z.MCJI#"^)LMQR8XQEUDFQ_(2SGAB?()(J@=?D.'CT/
MK'0]=]%E' =W$.GPAS\,H<=FM\M5(Y\E8YXE,G0'FTX> &E8;]BG$S)LMQ>Z
M7REQZFDM-4V9CZ29S7N9SM+@=D[Z-[O:?6NDL<$W';[[@N.?<68L/S:&P3VB
M>L[>C%1"ZG>3)+*YSFMB:SE\2WOWX]WK@ZKC!D6.7*A=G>%R6>S5L@C95,J1
M*8O[P ZZ'770Z!T#I=&3P1S>59BW:M#@RUN> ?6&SZ*]?E9-!X7PD@$BXPZ]
MGHR*1C"XQKD"[<6,I-%->\?P2IJ\8B!>*R>?LWS1COD;'KF#===Z/3JM Q7-
MK5D&$1Y0V3S6W]D^2?MCUAY-\X/NT??T7MJH8X<,F@C8UL3+>6-:!T#1'K2^
M:;/-/'Y)=X[ N =< QY'@PRQ[_3^M9C&.1;*MT@:52<5<KR;MJO!,&EK[/$\
MM%75U+83-KOY6G7Z"5:N&G$BDS.6MM]10SVF_4!_\5;Z@[<T;US-.AL;T#T!
M&QZPICAI!3TW#W&HJ(-$ MT#F\OCM@)/O))/SK+[RUM-Y6-B-#IKJJUN-9R_
MUB&3:W\S(_H"E1E:2J@2]YXR24&9WK&*/'*FXW2E>R*CBIY=FI+F\SB[T=,:
MT=YZ_KUYZ?BY?++D5NMO$'$GV6"X2"."KBJ!*QI) ]+70]XWH['J7BX>0QO\
MI3/I7-!DCIF!I/AOLM_J7+RM0!A5CD '.V[1Z/J_@Y/W!;48:E"N4"]<2\_A
MPR.W4U/;YKK>;E(8J.AA=RF0C6R3HZ'4>![_ 'D4ZX<5<MQ80UF=8,ZAL\D@
M8ZJI*MLQBW_::-_I(4]Q@P&LRN:S73'[JRV9#:I'.I9)/D/WHZ/0Z(Y=]Q\0
M1ZJ-=LUXBXI0O'$7$:"]V-I;VM3 &D:V-.<!MO?K6VMZZ4QQBTJ5O]?H#U^5
M#>*Z? H(J"V><V.K[&H=<VS ",\VV-Y-;/,-'?M5BL>;WNS\)ZN]WK&#1?!=
M+#YM$ZL:[SMG*T<^PWT>_NT5#<?+K0WO@)%<K2-4-2^FDA;R\O*WF^3H=VN[
M7L4YQ+_H\UG^%4__ *%53C&+7<$+:>,=_P @JK;)C6#U==:I3#%4U7.X,9*_
MEYVM=RZY6$Z+CZM] IW*>*%7%E=1C&%8]-D%XIF\U21,(H8/87'O/4;ZCJ=;
MWT4QP1@CI^%&,,A:&M=1M>0/%SB7$_22J2_.9YLTOUOX5851U]=%)RW*Y.<V
M"-\@+OE'IS=>;J3L]=#Q6:BY-*/'\W!ZJ7BU?++D=NM7$+$W6:.X2"*"LAJ!
M+'S$@==;&MD;]+8WW*L^5I<;H;?:Z V@BTLJXYF7'MAI\W)(.RY-;'3KS*"X
MWOSN6DQVHS9MDIJ<W%HIZ6AYG/#M=2YQV-:]15V\K;^0UE_Q:/\ TI5TA%*<
M6ER"_P!OS&IHL,KK_G-I..^:O<'0&<3ES>G*06@;+B= >L*E4G$[.;Q1_"^/
M\.Y9[&071OFK&LFF9_::WOZ^P.]FUY?*XEF;P_MD4;N6&6YL;(? ZCD(!]F^
MOS+WTT_&6"FBAI[5A[(8V!C&M?)H- T /2[M+$8QTZJ6X+MPYSBVYU97UMO;
M)!/ _LJJDFZ20/\ 4?9ZC[_$$"EUG%B\7F_UUMX<XLZ^Q4#^2HK9:@0P\P\&
MD]#W=#OKZM=5#87BN88_<<_R"\QVZ!]RM\TO94$I<!4@%P(;WCO<>_O*G?):
MA@CX34KX0WM9:J9TQ'>7<VAO_*&J.,(W);@H-7E<V3\>\'^$+34V>Z4//!54
M<YYN1VGN!:[^LT@@@_\ WS],K$>)=/ SRA>'D[ T5,L<C9-=Y:WFY=_G.6W+
M.5IJ->"HIG$S/:?":2A:VAFN5UN,O845#"=.E=TWLZ.AU [B=D*EW'BGF.,1
M1U^:X&ZDLSGAKZBEK&2NAV=#F:-_I+58>,6!5.81V>MLMT9;;]:IC+1RR?(<
M3HZ.MD';6D'1\>G542ZYCQ*Q.@E'$#$[??K&S7;U$ :00"/2<!L ;T>K M8X
MQ:5)-_S@A?N+&:6^P\/J:_FU4U]H:F2$Q0S$!CFO:7-?U:[P]GBI/.L\MN%8
MI!=KA&][YPUE-20ZYY7D;#1Z@/$^'OT#FG'^\4%_X#6VZ6=O)05-3 Z)G*&\
M@T\<NAT&B".G3HOSB7J?BUPHIZX T :'L#ODF7;?^X8K'&FE?O\ H"9'%'+[
M73LNN5X!44./NT7U$-0)):=I_K/C[]>O8;_V5EX><0G9?@5PR0VUM*:5TS1
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M+=\K&LUZ1<=#O'>JUQZ_G&X5_P"*'_4A75Q;ACGX[\-F2M#FASG:/K:_8_2
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MI)ZJ0QR0M)Z!PYAT]G7V'713_#+A[<[7DEPRW,Z^&OR6N;V8$ _@J=G3T6[
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M/?)(T/;L:.B-]RHN4Y)1/IL9H;]CYJ)KW.UK:*HY7=@[8&W CO'./TJ^@
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M^%TW,X:+0W?,"/ @@@^Y:ECE'=@G$616CC9!?+/#+8<;N5SN\I<?@^F(?V3
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MX4D_@N8$Z#FL([CX;(W[%(W7BWVY>,(QNY91'$P/FJ:8&.%FQOE#M'F< >H
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M7%IZ$ ]X*KKLIMV9<*+Q>;.YYIIK?4M+)!I\;A&X%KAZPH7R9?YGK1^,J/\
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MDMMN]PIH'7FE:6TDSI"UX'B  1S=_B#W^U9AP;_GFXH_E+/VWKU8_BF59=Q
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MOT'2.<.K21W$+624?Q=]P5S'>(>>W"_6^CN7#RIH:*>=D<U2Y[]1,)T7=6^
MZJ,X#-;6\3>)UQK0'7%E>(&EWRF1]I*-#V>@P?Y0MR6,9%B>06?B#7Y7PQJ;
M;5U%6.2YVJ>4 .?Z^\:/3?4@@[[P2%B,HR3256#K\K.DII>'='4RM;YS!<(Q
M"_Q])KN8#V'0/S!='E%?)X>_XK'_ .E4;C[#G-QQFAN>:-M]MIF5C8*:UTC^
MT+GN:XF1[MD$@-T-$]Y[O'5^,N(WG)6X=\#4HG^#Z]D]3N5K.1@Y=GTB-]QZ
M!=(U!1M^00W';^<WA1_BA_U8%IO$0AO#_)R3H"V5._JG*H\<,(NV4TMEN>,R
MQ-OEEJ?.*=DIY1)LM.MGIO;&GKT[U7[L>*><6.JLEPL-!CU)-$YE54BH;(^8
M:ZQQM#CR\W=L]-'O6$E*,=^/\@@+/4S4GD?3R4Q(>Z.:,D?V75;FN_02M:X,
MT=/1<+<9CI&M:Q]%'*[E'>]XYG'W[)41PUPBHI^#$.)Y53]C++'413QM>UY:
M'RO<TAP)&]$$>U5?&HN)W#NW?%^DQ^DR:V0.<**K95-A<UI)(#@X[T-]WAW;
M(TK*IZHI][!:N(EHL]EQW.+[9J>&'(:FVRBIECD/.1R ;+=Z'0 [ 'K7'R<Z
M*FH^$5C=2M;S5 DFE<!U<\R.!W[@ /F7AX=\/+D^XY%D?$#S>6\7V%U+)2PG
M;(*<@ LWZR T="= =YV5!8W:>(G"YM3:+':*?*<=,KI*0^<MAEAYCL@[^D@
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M#*9N3L/3C;S:Y3S?\3>MCN5X5<6DGY 1$4 1$0!$1 $5'Q7.W7WB#DN,FWB
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MI>+%NPOX/#FU=&:KSOMM%N@\\O)R]?D=^_%%%RX!>$1% $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$1!_*FI_)V_K4NHB#^5-3^3M_6I=
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M?X*R<&L_FS3%:NKN].REN5NF=!5MC!#20-\P'4CQ&O6"KQ9&AMFH&M&@*>,
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MO7>/Z(L?Y!!_KL6TD],MN>P+.,P^)' ;&[M'2/K*DVVDA@A .G/=$-%Q'<T
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M( B(@(B#^5-3^3M_6I=1$'\J:G\G;^M2Z (B( B(@"(B (B( B(@"(B (B(
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M( B(@"(B (B( B(@"(B (B( B(@"(B B(/Y4U/Y.W]:EU$0?RIJ?R=OZU+H
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B("(@_E34_D[?UJ741!_*FI_)V_K4N@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B *(OG\=M7Y0I=1%\_CMJ_*$0)=$1
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M0U$5 QS&3SOJ7@N+MO>=N/7]2D%YLV3J3<CI".E4$1%R-A$1 $1$ 1$0!$1
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MCM;/7N[AT6(9U&+223V]_P"]FG"VK9G_  Z)959'-='U-1FM)&8:CSAX<"P
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M;[P01\RG%3ZOAU89ZFHFA;6T3:AQ=/%1U<D,<A/?MH.OHTN?4A..F6W?;?\
MNS6EIVMR!S_)*6^6&2CH9)FT#;S!;:^<>BQT9=Z8:X'N[@3[5W9]:+;878U7
M6.CIJ&XLN<%-%YM&(S+&\D/C.OE CUJXQXU9X\?-C9;X1:BWD-/HZ(WO>^_>
M^N][WU7@M.$VBW7""M'GE544X(IS653YA #_ & XZ'O[UTCFA%4KI7MY^9EP
MD^2-X>D#(LW!/473?_V-JH@BIJ[AE98JF35)/DG*]X=KT'3R;Z^X]ZTVZX/9
MKE=9KA*VJBGJ &U(IZE\3:@ : >&D;Z=%"9CAU.W&[19K/;W24#;O%-- "2&
MQE[C(?8.OS+ICS0U)WNZ^E*C,H2K[G'*+;0V3+L-FL=)!1U<U4ZE>RG8&=I3
M\A+@X#O#= ]>Y4ZXSU,>#7R"FUV=7E<M//N0Q@QN>-ASA\D$@ GU%:G9,0M=
MHN KHA55%6UACCEJZA\SHF?V6<Q/*/TKOCQ>T,MEQMSJ02T=PG?45$<CBX.>
M\@D^SJ 1KN\%F/J81J]ZK^[97C;OL9_66FYTEZQRI99L>Q]\-;'&):>M#73Q
MG8=#R\C>;8[AZPI'"+-;+_)E=7?J*GK*Y]TGII#4,#G11,T&-:3\D ==A6.U
M81:+=<*>M'GE5/3 BG-95/F$ /\ 8#CH>_O7*ZX59[E<9JV5M5!-4 -J135+
MX6U '0"0-(#NG1)>HBUIMKW^OS_<+&UN1?!=D<>!4S(7]I$VHJ&L?O?,!,_1
M43DM#77#C'30VRZ2VN<60N,T<3)"6]L?1TX:\1U]BOU@LU%8+8RWVN(Q4K'.
M<UG,3HN<7'O]I7XZRT1R!MZ,;OA!M,:0/YCKL^;FUKN[_%<^NEEG-=[_ %-:
M'I4?!F]/0U5-Q&MU!G-TJKFW?G%GF(9% Z5O>'L:/^(/ [\?:NH17*Z<1<ID
M%CMEX?2.BIXV7"?E["(LV.1I8X:=U)*TK(;!;\@IH8+E$YXAE;/$]CRQ\;V]
MSFN'4+QWO$;9=J]M=(:NFKPSLC4T=0^"1[/[+BT]1[UTCZF/+YJO;GVKGN9>
M-]C,*J*MMV%W6VSS4<%OFO4,$L%%5]J*.%[AVD1=H%HWX?\ ,5H-QL..6BXV
M>K@A@MM?$]T-&VF:(^W)8?X-VAZ0T-]?I4I28K9J6P2V6.AC-NFV98WDN,A/
M>YSB=EW=UWOH/4O+9L+M-KN$5;'YY4U$#2RG=5U+YNP:>A# XZ'3IZU)^HC*
M]VN?KM\_\E6-HR[$K;<+QA,U548Y9+@:[MI*FX5=9RS<W,[9)+"6<NN@!Z:V
MI4T++G5\,Z3(:BFN&XZH/>R7M8Z@M8TLV[^MOE&_60KI6\/[%5U%3(65D$-4
M\OJ*:GJY(X9G'O+F ZZ^.M*/S#%8[ID>(T[:%_P11MJ6R& F,0?P8[/1!!:>
M8#6O4NOQ$)RVVY?RV?O_ (,=-I?;^YYY+=14/%..BM]+ RDN%JD=74K(QV3N
M5X#'N9W;ZD*GVNEIV\,</I^RC@I+I=VP7"2,!AFC$LNFO<.I'0#JM:Q_&;=8
MI:B>D;/+5U&A-4U,SII7@=P+G'>AZ@O%28+8::W7"WMI9)+?6N#WTTDSG,80
M2?0!/H=23T7./J8K;?:OTO\ SM\C3QM_J0&9VNWV*^XA66.DIZ&NDN4=(YM-
M&(^U@<#SAP'>!H'KW+KX<6*VUEZRNYUE'#/6PWV=L,LC>8Q<I#AR[[CMQ/16
M>SX;:K7<8Z]OG=761-+(9:RI?.86GO#.8]/UJ3M%GH[2:XT+',-94OJYMN)W
M([6SU[NX=%B6=*&E-WY^II8][9ZZRIAHJ2:IJI6Q4\+"^21QT&M V25AU,Y]
M'D\?$2HM;8\=JJES!&0>>!K@&BK+>X%Q'7V'QV"MDR"R4=_MYH;FV22D+VO?
M&V0L#]'8#M=XWX+U5-%35-!)13P1OI)(S$Z(CT2PC6M>K2SAS1Q)][V?R_R6
M<')_(B<FR>DL=!3S!KJVJJR&45+3^D^I<1TY?9W$N[@%XL.L-=!7U=^R&1DE
M[K6",QQ_\.EA!V(FGQZ]2?$_2>BIX;X_41T#)6UVJ&(PTY%7(#&PDG0(._'7
MNT/!2./8?:[!6OJJ!U:971F,]M522MT2#W.)&^@ZHY8XP<8-V_;_ +%2<K98
M41%YCH$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M/.^5Q[%O.]@#6[UH;+N[O)65Z;;=T]MO=W7]BO)X1N"\+*NK=>I:1U YM"V
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M)U?"-S5!M^:W^ZNK'V?$154U-4R4O:FYQQ\SF'1Z%NQX*]4SWR4T3Y6<DCF
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M5= P1NJ:*0-,C1W!X((=K_[NY<L>Q&GM-RDN=575UTN;X^R%362!QC9O?*P
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MK;M=[E=WT1YJ5E6YO)$[NYM-:.9WM.U+V6R4]IJKI44\DKWW&I-3*'D::[E
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) (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g762905g30c65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g30c65.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_[2"44&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'D
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !D     $  0&0
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             %>@  "6(          0
M                   !              EB   %>@
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   %>@    !29VAT;&]N9P
M"6(    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  !7H     4F=H=&QO;F<   EB     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" != * # 2(  A$! Q$!_]T !  *_\0!/P
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M;W;6?RK$>CI?3<NEMS:)K> Y@=9<=")8[W6_Z,JOG_5_'ZCU=N9>PN:RIK'
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MY_FMK?1_G/TG\W_I/>K"2E))))*<[J_5A@,KIHK^T]0R26XF*TZN=^=98?\
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M &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '  ( !# %, -@    $ .$))300B      $N34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    >    <@$R  (    4    D(=I  0    !    I    -    &0
M 0   9     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-#HP
M.#HP,2 P,SHS,#HP,@   Z !  ,    !__\  * "  0    !   )8J #  0
M   !   %>@         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $
M     $@    !    2     $X0DE- _T       @          /_A 39%>&EF
M  !-30 J    "  ' 1(  P    $  0   1H !0    $   !B 1L !0    $
M  !J 2@  P    $  @   3$  @   !X   !R 3(  @   !0   "0AVD !
M  $   "D    T    9     !   !D     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#(T.C X.C Q(# S.C,P.C R   #H $  P    '__P
MH ( !     $   EBH , !     $   5Z          8! P #     0 &   !
M&@ %     0   1X!&P %     0   28!*  #     0 "   " 0 $     0
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M"@,!(@ "$0$#$0'_Q  =  $  04! 0$             !P(#! 4&" $)_\0
M9!   0,# @,"! X."0$$" (+ 0 " P0%$08A!Q(Q$T$((E%A%!87,C96<8&1
ME+&RT=(5(S,W0E15<G-T=9*ALS0U4E-BDY6DP8(8)$/")CA%8X.BP^'P)42E
M\83B9"=EM,33_\0 &@$! 0$! 0$!              $" P0%!O_$ #<1 0 !
M @0$ P8& P$!  ,!   ! A$#$B$Q!!-!4105804R,W&1H2(T4H&QX4+!\-$C
M<M+QXO_:  P# 0 "$0,1 #\ ]4KG->:QMNBK.VX783/8^01LCA:"]Y/DR0-A
MOU71KSCQHJ)=<<5K)I&A<704SPR4L/1SCF0_]+&_*N_#X<8E=JMHW9JFT)JT
M%K&VZUL[KA:A,QC)#&^.8 /:1Y<$C==(O-W!6KDT3Q6O6DZYSF4]2]T4?:;$
MO:<QG_J83_!>D4XC"C#KM&T[%$WC41$7!H1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$0G R>B BY@\0-'@D'5%DR/\ ^=C^
ME7J/6^EJVJBIJ/4=HGJ)7!D<4=7&YSW'H  =RM9:NPZ%$19!$1 14R2,B8Y\
MCVL8T9+G' "J!R,CH@(B("+'N-?26VCDJ[C4PTM+$ 7S3/#&-WQN3L-U6VJ@
M?!%,V:(PRX[-X<,/STP>_*6%U%B27.ACN<5MDK*=MPEC,K*8R 2.8-BX-ZD;
M=5EH"*U654%%2RU-9-'!3Q-+Y)9'!K6-'4DGH%SOJ@Z/]M-D^.Q_2K$3.PZ=
M%I+5J[3MWK&TEJOMLK*IP)$4%4Q[R!U. <K&U%KK3&G)Q!>KY14M1_=.?S/'
MNM&2/?3+-[6'2(M;8K[:K_1^BK)<*:N@Z%\$@=RGR'R'S%7J.Z4%;5U=+1UM
M//4TC@VHBCD#G1$] X#<>^EI&8BP[M=*"T4GHJZUM-14W,&=K42"-O,>@R>]
M8UYU'9;(81>+M04!F!,?HF=L?.!U(R=TB)D;5%S<.O-)32!D6I[*YYZ 5L>_
M_P RZ*-[)8VOC<U['#+7-.01Y04F)C<5(BP*&]6ROKJJCH;C25-72G$\,4S7
M/B/3#@#D>^I89Z(B BI,C!*(R]HD<,AN=R/+A8M%=*"NJ:JGHJVGGJ*1W)41
MQR!SHG>1P'0[=Z#,1$0$14F1@E$9>WM".8,SN1Y<(*D6)17.AKIZJ"BK*>HF
MI7]G.R*0.=$[^RX#H?,5EH"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MBT=UU?IRTUCJ2Z7VV4=4T NAGJF,> >F03E6(F=AO$7,>J#H_P!M-D^.Q_2M
MO57NUTEJ%SJKC20VXM#Q4OF:(R#T(=G!RF68Z#8(N5LO$32-[K?0=LU!0351
M.&Q]IR%Y\C>;'-[V5OKG=*"U,A?<ZVFI&32"*-T\@8'O/1HSU.W1)IF-)@9B
M(M?3WRU5$==)!<:.1E"XMJG,F:1 1G(?OXN,'JI8;!%S'J@Z/]M-D^.Q_2MQ
M:+U:[S&Z2T7*CKF-]<ZFG;(![O*3A6:9C>!GHBP+O>K99F1/N]QI*%DKN2,U
M$S8P]WD&3N5+7&>B(@(OCWM8QSWN#6M&22< !8===;?0&E%=74U.:IXC@[64
M-[5WD;D[GW$&:B(@(B^2/;&QSY'-:QHR7..  @^HL2MN=#0FE%;64\!JI!#!
MVD@;VKST:W/4GR!9: B(@(B("+ BO5LENTMJBN-(^YQ-YWTC9FF5K=MRW.0-
MQ\*NW.X4=KHI*RYU4%)2QXYYIWAC&Y.!DG;J0K:1E(OD;VR1M?&X.8X M<#D
M$'O7U0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0:_4-U@LEDKKG5G
M$%+$Z1WO=WPKR9H2FUS=[]7ZKTO3]K6NFD$E0]C' /?NX#FVZ'W@5ZIUAIND
MU78IK3<9:F.DF<UTGH=X:YW*<@$D';('P*G1FEK=I"RMM=H$OH</=(3*[F<Y
MQZDG \B]6#C4X5$Z7F?X8JIO+RMKVCUS:KU1ZJU1!V5<)HVQU+6,:"]F[00W
M;HWO[@O66F;Q!?[!0W2E.8:J(2#S'O'O'*QM9:7MVKK(^UW=LAIG/;(#$[E<
MUPZ$'!\I31FF:/25D9:K;-4R4C'N>P5#PXMR<D @#;.3[Y3&QJ<6B+Q:8_@I
MIM+>(B+RMB(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(1D8/1$01!QTTCIVW<*]05EOL5LIJN-D99-#2L8]I,K <$#(V)74:-
MTGIRETW9KC%8;6VMCI(IA,VF8'\_(#S<V,Y\ZP_"$^\]J/\ 1Q?SF+I=,>P:
MU_L^/^6%VS3RXUZHX;2G%2ZZH>S[$:0J9X8ZHT]7,*D!D/C8!!+?&VW/3"S*
MSB;5UMVK:+1>F:J_QT+^SJ:ILPBB#QU8PX/,1[RQ?!S83P[JQ&0U[KE58=Y^
M;JN"X.VFLEM5QMK=<UM@KZ*KE;4T BB&#S>O!=N0?*MS33>K3;YIJF'3?$*T
MWC3ESNLS)[>ZU\S:^EJ0!+3N:,D$=_F\JY:3BK?9;6Z]6_0=PGL 8914/J&L
MD=$/PPS!VQOU7+Z6NE%IN@XC:FMEPN.HIX R*>:J@8V"HE!P'-+3XP'-OL-O
M=5ZMDOE9P^GONHN($%'0ST1D90VV")C?&8<19()[P$C#IB=OY+LGC?JR6^<)
MZ&XV"EDDM-P?&Z2H,O9NB(?@,+>_)!!W[E+>D:RXUUC@FO-M;;:OH8!,)<-'
M0\V!U4 5G_JIVMW<VI82?(.W<O1MKJ8*J@@EI9HYHBP8?&X.!V\H6<2(BFT=
MY6'.0ZQSQ+J-)5%&(B*,5E/4]IGM1D!S>7&Q!SWGHM=8>)%-=N)MVTBRD##1
M1E[*KM<B5PY>9O+C;'-Y3T6EXT2MTYJ+2.LG'DIZ&J=25;@,GLI!Y/\ I/PJ
M/*5KM*6+1?$"L#Q)/<*F6M.,Y9/SXV]QH5IPZ:HOW_E+N_UOKFCN%FUW1W"P
M"OL]C=%!+S5+HQ4R%[<M!:,MY=CU7-\3KS=67CALVTV4^@6OBGI(A5X;._D;
MB(Y&W*,>,<]5;J+9-1>#/>ZZLSZ,N[A<9<]<R2L(_@!\*V6NY8Z>3@Y-.]L<
M+)X^9[C@-^UQ]2MTQ$3IZ_PDK.N-0SV;C/I>XU=JJ)[A)97,;04I[1[I7/=X
M@=ML-\GS+LM+\2*JLU7#IS4VG:JQW*IC,M+S2B5DK1DD9P,'8^5:N]NCF\(O
M3,C"U[3997-<#D>O?N%>U[]^WAY^95_,69B)B(F.G_JI/JZ:"LII::KACFIY
M6EDD<C0YKFGJ"#U"@SC_ *6L%KM&GGVVRVZD=+=HHY##3,87M(=EIP-QYE/"
MB#PDOZETS^V8?D<N>#,YX6=DAV[2EAM4_HJT66V458&EK)H:9C'#(\H&5!N@
M[WI335]OENXCT#(M2RUTDCJZNI^T9+&3XO*XYP,>;&Z]$5;IF4<[J5K7U C<
M8VNZ%V#@'S948:+UC8]=6F6@UO36J"_TTLD-30S-Y0S#B 6\Y.V/(>JN',VF
M^I+-T=I>Q>G*35.B+M1LM4]/V%5040#HI),Y#]G88<8VQY?*N/T;JZQ:7XI\
M1OL_<H*'T161]EVIQS8#LX^$*U:+=9;-QVM-/PZD'H:2GE-X@IY"^&-N/%W/
M0YQL#Y/.MSPSH*.NXI\3/1M)3U')61<O:QA^-G=,KI,6B;]O]HT/'_7NF-1Z
M!%!9+Q2UE6:R%_91DD\H)R?XK8\7V6^3B9PW9>6TKK>1+VPJN7LN7 ]=S;8]
MU9/A+6JWT?#;M:2AI8)/1T YXX6M.,GO 6/Q<MM'=^)W#:@N4#*BCG[5LD3^
MCA@'?X%:+6BWK_!+>:HM_"?[ UWHJ/2[(^R=XU,Z%L@.#CEY#G/N*_X.;Z]_
M"ZA^R)F+!+(*4S9YC!GQ.O=UQYL+G>)W"6V6RV,U!HBU4\%TMCNW=3%O:1U,
M8]<TL=D9QD[?0I+X=ZHHM7Z3H;K;PV-KV!DD+1CL9!LYF/,>GFPN=4_@TU6&
M3K6^QZ:TI=+Q-CEI('2 $XYG=&CWR0H#T?1U6@+MHC4]>^1L6HVO@N9(.TDC
MBZ,NS^<WX"NSX]OJ=1W73FA+9*V.IN4WHJ=Y&1'$S."?-G)QYE@:[X>Z\N^E
M*NGN&JZ2OAIV=O'3-HFQESF#+0' 9!V6L.(IIM,[I*5M;:IM^C[!-=;KVAB8
MX1LCB&7RO/K6-'E.%Q#.*EPMU30R:MTC6V6U5LC8HJUTS9!&YWK>T&!RKB=0
MZF.H.''#[4U47.I[9=(6W,X)Y',P"XCWL^^I4UUK;3UIL5)4U+(;PVJFC934
MD)9(Z5QZ$ ^3JLY,NDQ=;N"%[U#ZO]5V-B$W+0MA;&:T!H@,OW<;=X_!_BMG
M2:LI+)4\2+C9----;:ZIKJPBJ=FK]=E^X(;@9. K\57!3^$1,:F2.G,MCC:Q
MLC@W)YSXH\ZM<+::*LUSQ3IJAO/#-7"-[?*TAX(^!:FUKS'2$AW=7J^@I]!O
MU5NZ@%(*H-!&3D>M]W.WNKG*OB;Z!TYI^IJ++4RWV]LYJ6U4[^9_ERYQ P,;
MYPHIIG55324G"64O[:&].9,1U-"/MH<3T[_X*1^)FI+G0ZMT[I73TM!;)ZR)
MTGV1JX@\1-:".5F=N;8]?*%.7$3;_K%V1;N)EPI]1VZTZOTM4V0W)_9TE0)Q
M-&Y_]DX QU"Y6@O6HCX05T#;'VCA2,@,3JS:.#G;]N&W?L>7S]5H]>0ST.M]
M#4UTUA-?KB;E&]\')&V.!O,W<!HZGSGN7;T-3!3>$A>!431Q=I:(FLYW <QR
MW89ZK66(B\1O R+!J6V6V;B37VVQMIZBUU4CZEPJ'.]&/:">8Y'B9\@6'%Q@
MNE;8V7FTZ)N-9:8XNTJ:D2AH! \?LQC+PW??;HM!;_Z!QN_69_F%=]H-H' V
MV@ 8-F_^F5*HIC68OM_"LNX<2K)1Z$I-5#MYJ2KPVG@8T=K)(21R 9ZY![^Y
M<K?>+UVT[;#5ZAT374 F(%*75 <QY)'BO(;XAQD]#T7 V]YM_#;AA>:H$VFW
MW5SZK R& R/PXCR!=[X1>HK._AO)2,KJ::IK9H33LC>'%V'AQ.W08'5(PZ8J
MB+7O)=+=#/Z*HJ>HY>7M8VR<N<XR,X5Y85C_ *EM_P"KQ_-"S5YY41$4!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M1/-U;0NYJ<>NQG'B@YY.G?CRK)X2\,=):DX5VBJNMGBDK*F)_:5#7.:_/.X
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M/A]J^NU#JC5=NK(X6PVJI$,)8""1EPW_ '0N\6\3#G#G+4D3<1$6%$1$!$1
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MDC$_+S&-IR'. \H&<+%U]8;GPVI:'45GU+=:N7T4R*HAK9 ]D@=D] !Y%O\
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MAM&M[W<;S]BHHZ]@,T%%-S8D!SGEQMU/PJ65Y<>BFBNU$WAJ)O&HB(N*B(B
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MND;'55-3(V-SC@$AS#@GS@8]];NTP\3?L)%IJ6V6REA9#Z%-U,_,>SQR\S6
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MA:PGW<!;%$4O<$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M=-WJNI144=KK)H#N'MC.#[GE0:E%7+%)#*Z.9CXY&G#F/!!!\X*H0$1$!$1
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M2U1H_3%M96TM-4R7IT#6R-+3Z[&X!.P!*CB]7&:[7:KKZD_;:B0R$>3/0#S
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M@<YW=A6('!S0X @ =#U5X5&=F#)4GT%W 8,G94"0DDMVSWJEC XDEV?,KW*
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M\4X?WM5A)6&/+27.'BA8]>V.8<_1XZ.'=[RS91XQV\;^RM?., \VP6H8EK)
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M?"G3.F=+V.>DT=7-K*%\QD>]M2V?#\=,M^1=HM53=F!$111$1 1$0$1$!$1
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M>9)"!E!CO9XX<%\>S))"K(W5;0"HK72@@K[&WG*NR[R8\ZK8T,.R0*9F<L)
M"P>PVRY;0CF;E6)F@-5&J?3\[]DJ<QPX(6:QF2L.XX#<94@:&;!<25KIN4DG
MR+.K"", [K732LA@>7$<V%I7,:JK +?*&NY7@@!<A15SVO:#NX+?7:D=402S
MNSR]RY,$,<2WJMT[-Q#MK6X2>/)(1[I6^B#7LV<"!T4:PSRM(\8_"NELU][
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M2-BM900N>0XL/3('E78VRD,I:'] -@L52W3&EV=IV@?4SCF;XK3U4B6^(4[
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MJDP5<Q]M.1MA6B0*K.5<F>&1.<[9!\HP?'=W*P[[L -O*LNC/_=03L7=%BO
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MUKV %&A5R-7Q@(!6W%.G@RC$6H_SJ?Y)%-RA'P9?N6H_SJ?Y)%-R*(B("(B
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M%Z'Q".;R;JSS 5$F1@$*MQVDSUPL0N/;$'<<B*JA&*:0XW+LJV) 6.]U77/
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M'&G:#/=_WEWT*CUHR:*1[F1R,<YO4!P)"K7EOP37W:\ZZU3J&H@?%0U;"7D
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M4'W&/\T+Q:?ND'Z:/YX7M*#[C'^:%\3VG\2/DW3LK1$7S6A$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$$5ZQVU-6D],M^:%J6CF/,[N6YU<,ZFK >F
M6_-"T^,G)V"\]6[4*7N:-R"<[ *H!W+ER^<A.7=W<OI?RPG(R[R*0U"@R\HP
M1N?(K7. , Y)[E;CYR2Z3;R!7&-'/SANZ"N-F&DNZH26C!W)51W\94D\N7.[
MT%  !.?7*]&!A8[<ODY_>PLF,;(/KMNBM[*IYQE61XQP@O-)Q@=$(P@(#5\/
M3/<@I(*J)P%2T>-U5,SM\-150.Y5MS<N!5<0RW*^.ZJ(,&ZN$X'F7Q@V7QV^
MR@^-WZ+[C=&8 57NH*#G. JATW7S(<_;=5$(*#L-E\:-]U7A?6A!2XX!6*[J
MK\QPK)&0<*P/C-W853V[JF('G5YV,H,<^=8DV2_JLMYWV6.]N7A2XMO;AFZM
M2MYNY9<K/M>W54"/#<D*P,3LP&E6S'EJRI6DMV&RICC/)DJP, #;"OM QAPR
M"J96AKE]+QV61NMC J8P)=NBJ= TQB0=>]72S?/57VL'+RD(-:8VLEYF^MQN
MJ_0X<#)&<#O!5R1G(\CERKL>XV&&HC$BP&&"4<T3CD9[BLED'B\G-XXZ$^3R
M+Y+&'/Y!TQG*^,C=V1<"2YIW]Q2ZOCHRW(?N?*K,T7,#LL^&5LK!S-]Q?)8A
MAR7$[ZIVTO[T?RA1X>]2%JS;3!_^'\H4>$Y.W1:KW2G9;)&=U056[ ZJAQRN
M2J<C=4O=ENQW5,AY6GSJW'LW=+BY$W'KBJP[)PK<;N<*XQN_N*BHDCINOO*0
M,E? ?&PJG$EV%%A7&TNW/<E3((V9/7N7T$[-SC/>K#@)IL..S$%(C)CP[;FW
M7R=X:T1M[ADE7FY+B3ZT=%:P)'.('795%AI!:220!T\ZNQ@2%HS@$9*Q)GN?
M4")@\5O59;OM;=N]213(X$O[FL'<L>AC+G2R]SOPE]>>4.:3Z[97&@Q4PC;T
MZE07)GF3 :,DG^"^/ PXY\4-QE402M$,D_</$ 29XCH"'^Z@IIF99SM.^.4^
M=4ROQ4$=>5N2571%II,C*QY\CMBW<NP%!;=O'OU?M\*HACY;F^4;MABY&_XC
MC_[*L-<Z;!];$S)5Z"/$!'4N/.2@IE813\Y.^>BM/ YW$[;;$*].'/D:P>MQ
ME'@& O[P"M*PH7/;+.]WK7#E!5R5G:-9XV< ;K&I2Y\$;IM@YV%G]DUL3F,S
MENZ"GG[27F !Y J&@=OLJJ'D[-Y'4=5\GQ'('-[T1CU^?1#,G8C&%9&&-D8#
MC/1?:]Q;)%GKE6WM+I&D?VD:A\D/9RQ/Z$=?.L*O8'59>P>*X9/NK-NT9:QA
M"L4S>T@>'=>H5&LZ/5V1N"UQ&Y7SL\GS@K)D;EH"@Q:]K7Q =6G8^9:5K (Y
M&8W!V6\:PGGC<=_7#*UTD8;.UW<>JU Q6QN&.JO]CG?'57XV@DC"N @'E5A&
M&QG*2%=BCR.BK='AQ*N0C95%ET*LR1X6<\85C&2<I U[FEKLJX-PLA\8*HY,
M+4,I=\'08&H?SJ?_ .HID4/>#P,-U![L'_U%,*W&S(B(J"(B B(@\?:GLVM.
M"&M[G==+4[JFPUY)#^Q,D7*23R/ W:X'.#Y%PNCM;:TIM.7'2>EJ.0B[5,DD
MIAIW.F)D :YK3T:,#KUWZJ0[[K3BMPTU%<'5])45EBDJ'NA95Q]M$(RXD8>T
MY;MW$^\I T)X1NDKH60WRF?8JMV 7EO/"X_G-&0/="E,7A9F8EU/@\Z#J=":
M%;!= &W2MD]$5# <B/N:S/E Z^?*D]8MKN5%=:-E7;*N"KIGC+9(7AS3[X64
MM2D"(B@(B("(B B(@(B("(B"$/"]^]8S]=B_Y75^#S]YO2_ZL?GN7*>%[]ZQ
MGZ[%_P KJ_!Y^\WI?]6/SW()$1$0$1$!$1 1$0$1$!$1!@WW^I+C^KR?-*\8
M6O\ JVE_1-^1>S[[_4EQ_5Y/FE>,+7_5M+^B;\B^I[+]ZIFIE(B+[+ B(@+'
MN'] J?T;OD*R%CW#^@5/Z-WR+-7NRL/8FCO8C8_U&#^6U;=:C1WL1L?ZC!_+
M:MNORCH(B("(B B(@(B("(B B(@(B("(B B(@(B("(B HMXB<(:?6>NK3J66
M[RTDEO;&T0-A#@_E>7;DG;JI21.MR_1 _%#@);]5ZIN.I*_4LEN9.&E[# TM
M8&M ]<2/(N#MO@_:1NCJL6[B)#5>A&=I.8HHW"-OE<0[8;%7>*YO7%?C8_0U
M!7"DMEO!#PXGD!:WF>\@>N.X "KX-:'?2Z@XJ:-I:UID]""B94R,VR>8<Q ]
MU2G99]4K<%>$=)PYJZ^MH[U)<VUT36>-$U@ !SD$$Y4K+S9X*-[NMOONHM#W
M:8S1VTN?%EW,(RU_*X-/]DG=>DUJ4$1% 1$0$1$!$1 7FSPV?8_IG]8F^8%Z
M37FSPV?8_IG]8F^8$$\Z']A=@_9]/_+:MTM+H?V%V#]GT_\ +:MT@(B("(B
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M>QK;C7 ,YN4<W.\\SC[S1CX%M>(.F&:JO.D;I2L+Z2:1K:@@=82 \$^\"/\
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M+UPMU-::"2KD@IZB.,<SVT\A<YH'4X('\%W' 2E9'IB^U\3XHZMTSHA*_P#
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M$0$1$$H>#=[,=1?J,'SWKT&O/G@W>S+47ZC!\]Z]!K\YQOQJG2-A$1>51$1
M7DGPHM#ZHAU;7:LH.WGLM0R,/]#2.YJ<L8&GF:.XX)R/?7K9:[[,6F6X/MGV
M0HGUN[74O;-,G3<%F<]%)A8>'.''#RZZ_IR;-JV@CK69,E%432ME:/+C&"/.
M"5KJ#AY>JKBI-HR*X4[;S&][35%[^0EK.8[XYNFR]#\4> K)ZTZBX<3_ &(O
MD1[04T3NSCD=WEA'K#_ J.N"]KU;-Q^H[OJFT7"&H/;BIJ)*5S&%XB+<DXQO
MCR[JQK)T3WP)T-=M!Z8JK=?:V&LJ):@RM?$]S@&D=/&&5)"(K,W01$4!$1 1
M$0$1$!$1 1$00AX7OWK&?KL7_*ZOP>?O-:7_ %8_/<N5\+W[UC/UV+_E=5X/
M/WF]+_JQ^>Y!(B(B B(@(B("(B B(@(B(,&^_P!27']7D^:5XPM?]6TOZ)OR
M+V???ZDN/ZO)\TKQA:_ZMI?T3?D7U/9?O5,U,I$1?98$1$!8]P_H%3^C=\A6
M0L>X?T"I_1N^0K-7NRL/8FCO8E8_U&#^6U;=:C1WL2LGZC!_+:MNORCH(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B*$.+E+Q"EXG6%^DS<AI\-B]%^A
MY (\]H>;(S_9PG6(6VDM?QXX(5NJ;V-2Z1GCBNQ#>W@D?R=HYO1[7=SO=\BC
M!_#CC7=8Q;*Z6X&B&6_;[BWL\=.YV2%VG%^BXNR\0+F_2)O/V%/)V'H>4!GK
M1G SY<KC/L=Q[_M:B_SV_2I3L2GS@3PIBX;VFH?53LJ[S68[>5@PQC1T8W.^
M/*3WJ45!W@[TO$2"ZW<\03<S3F%@I_1<@<.;FWQ@]<*<5J68$1%%$1$!$1 1
M$0%YL\-GV/Z9_6)OF!>DUYL\-GV/Z9_6)OF!!/.A_878/V?3_P MJW2TNA_8
M78/V?3_RVK=("C'7W%"?3&II+136=E9V<$<SI7U/9^N+M@.4_P!E2<O-W&K[
MYM;^I4_RO0=%ZMU?[6X/CQ^HGJW5_M;@^/'ZBBE$'?:OXJ7#4.G*VUBPT\!J
M T=H:TGEPX.Z<GF6X]6ZO]K<'QX_444H@E;U;J_VMP?'C]1/5NK_ &MP?'C]
M112B#TGPRUI)K.@N$\U VBDI*@0%C9>T#LL:[.<#^TNR40^#C_56HOU]O\EB
MEY 6DUQ["M0?L^H_EN6[6DUQ["M0?L^H_EN0>0:/^B0_F-^17E9I/Z)#^8WY
M%>7ZNG9S$1%I!$1!2[[I!^FC^>%[2@^XQ_FA>+7?=(?TT?SPO:4'W&/\T+XG
MM/XD?)NG96B(OFM/.OA*>S:Q?L^7^8U18I3\)7V;6+]GR_S&J+%]3A?AP_+>
MU/S$_L(B+TOGB(B I@\&?^N]1_H*?YTBA]3!X,_]>:C_ $%/\Z1>;BOAOH^R
MOS$?*4^HB+Y;]0(B("(B B(@(B("(B B(@(B(/+5]T!K!VI+Y-3Z=J)X)[A4
M312-FC <QTCB#@NST*P_2#K7VKU7^?%]93MJ/45RH;U4T]/,QL+.7E!C![@>
MJUGILO)Z3Q_Y07NIX_%IBT63+"'/2#K7VKU7QB+ZR>D'6OM7JO\ /B^LID.K
M;N.M1%_EA?!J^[=U0P__  @KYAC>AEA#GI!UK[5ZK_/B^LGI!UK[5ZKXQ%]9
M3(-6W<])X_\ +">FN\CK41?Y03S'&]#+"&_2#K7VKU7^?%]9/2#K7VKU7^?%
M]93)Z;KOT[://Z,)Z;KO_?1_Y83S'&]#+"&_2#K7VKU7^?%]9/2#K7VKU7^?
M%]93'Z;KQU[>/'Z(*GTX7?\ OX_\H)YCB^AE0]Z0=:^U>J_SXOK)Z0=:^U>J
M_P ^+ZREXZSNPZSQ_P"4%3Z=+P3@3,]WL@IYEB^AE1'Z0=:^U>J_SXOK)Z0=
M:^U>J^,1?64NMUA>LY-3'R_H@K@U?>/QB/\ R@IYGBKD0]Z0=:^U>J_SXOK)
MZ0=:^U>J_P ^+ZRF(:ON^-YX\_H@OAUA=Q_X\>/T04\SQ3EH>](.M?:O5?Y\
M7UD](.M?:O5?Y\7UE+?IUO+W$131[?\ N@OL>L;VY_*9HP/+V03S3%7EHC](
M.M?:O5?Y\7UD](.M?:O5?Y\7UE,+M87AK@T31NSW]D%<;JN[XRZHC_RPIYKB
M'+0UZ0=:^U>J_P ^+ZR>D'6OM7JO\^+ZRF4ZMNV<B:/'Z,)Z;KL3M/'_ )83
MS7$.6AKT@ZU]J]5_GQ?63T@ZU]J]5_GQ?64Q^FV\9^[Q_P"6%<&K+KC>HCS^
MC">:XART,>D'6OM7JO\ /B^LGI!UK[5ZK_/B^LIE]-EX)VGC_P H([5MV:/N
M\>?T83S7$.6AKT@ZU]J]5_GQ?63T@ZU]J]5_GQ?64P#5E\=D-GC'_P (*E^L
M;R/%$\?-^B">:XART0^D'6OM7JO\^+ZR>D'6OM7JO\^+ZRE6;6][:\-941>?
M[4%1Z=[Z'GFJ8@/)V34\UQ#EHM](.M?:O5?Y\7UD](.M?:O5?Y\7UE*YUI>P
MW)GC_P H+7U?$.]P@-%1'VAZ?:6J^:XART<>D'6OM7JOC$7UD](.M?:O5?Y\
M7UEWTVOM3AG:>BHF1^4P-6ONG$;53.S]"7" =[B:9I"GFN(U&#,N1](.M?:O
M5?&(OK)Z0=:^U>J^,1?66)?.-VO*:K;Z&J:=K(QE\1I6$OWZC99S^+^NHZNE
MJ?1T+[=,QKW,]!LYF9[LJ^:8IR94>D'6OM7JO\^+ZR>D'6OM7JO\^+ZRZJMX
MDZKCA@JZ>X4[Z-XR\FF;EJRSQ*U)44H?25E.V0?@OA;XR>:8K/*<5Z0=:^U>
MJ_SXOK)Z0=:^U>J_SXOK+MJ?B;J%XY:J5M/*.N(6D'^"NS\1+\UN67.,9\M.
MU7S/%3(X3T@ZU]J]5_GQ?63T@ZU]J]5_GQ?6762<1]71C(K:=[>[$#%B'BMJ
MEI//61-QY:=OT*^98ID<]Z0=:^U>J_SXOK)Z0=:^U>J^,1?670LXLZD)WKX?
MB[5>]534W+D5<)_^ U7S'&3*YCT@ZU]J]5_GQ?63T@ZU]J]5_GQ?679T'%.^
M3;2U4/-Y!"U9YXA7]_W.LA'NPM3S#&]#+"/?2#K7VKU7^?%]9/2#K7VKU7^?
M%]9>FK_6ST=C-3 X";Q-R,]3NN1]-%U_OH_\L)YCC>AEA"?I!UK[5ZK_ #XO
MK)Z0=:^U>J_SXOK*;/31=?[Z/_+">FFZ_P!]'_EA/,,;T,L(3](.M?:O5?Y\
M7UD](.M?:O5?Y\7UE-@U3=>^:/\ RPGIING]_'_EA/,,;T,L(3](.M?:O5?Y
M\7UD](.M?:O5?Y\7UE-?IJNI_P#&C_RPAU5=?[Z/_+">8XWH980IZ0=:^U>J
M_P ^+ZR>D'6OM7JO\^+ZRFDZKNH_\:/_ "POAU7=A_XT?^6$\QQO0RH7](.M
M?:O5?Y\7UD](.M?:O5?Y\7UE,WIMNW]_'_EA6GZRNK3CMXS_ /#"GF.+Z&5#
MWI!UK[5ZK_/B^LGI!UK[5ZKXQ%]92^S5U\DZ31M]V(*^W4]Y \>JC_R@IYGB
MKD0SZ0=:^U>J_P ^+ZR>D'6OM7JO\^+ZRFANJKMG[NS_ "POIU7=1N9H\?HP
MIYIBG+0MZ0=:^U>J_P ^+ZR>D'6OM7JO\^+ZRF-VKKL7'$[&@?\ NPJ#K&\%
MV&S1X\O9A/-,1>6A_P!(.M?:O5?Y\7UD](.M?:O5?Y\7UE+QU?>^UP*B/E/0
M=D%E'5=V  ,\9=^C">:8ARD+^D'6OM7JO\^+ZR>D'6OM7JO\^+ZRF#TWWCF+
M/1,7-Y.R"M5NL;Y$^)K)X\O_ /=!3S7$.6B3T@ZU]J]5_GQ?63T@ZU]J]5_G
MQ?64S2:LNT<>.VC<['7LPJH]4WCL.9T\?-^B">:XART+^D'6OM7JO\^+ZR>D
M'6OM7JO\^+ZRF(:ON_/R=O&3^B"J=JR\<P J(P/T03S7$.6AOT@ZU]J]5_GQ
M?63T@ZU]J]5_GQ?64PRZNO )Y:B,?_""I.KKVZ!G)41\YZGL@GFN(<M$'I!U
MK[5ZK_/B^LGI!UK[5ZK_ #XOK*8':MO37QCT1'RX\;[4-UB2ZWOGC<DT8WV^
MU!/-<0Y:*O2#K7VKU7^?%]9/2#K7VKU7^?%]92J-<WD-!=41#/\ [H+"FUY?
MWU!CAJX@!U/8M*OFF(<I&_I!UK[5ZK_/B^LGI!UK[5ZKXQ%]92.S7FH65KHY
M:N+D(RW[2U1[<.+'$""_55,VNIQ2_P#A.]"L./I3S3$:C!F=EKT@ZU]J]5_G
MQ?63T@ZU]J]5_GQ?66?;>)G$29KQ+<*7G'K?^Z,W6R/$K6\E'VD55 R=OKHW
M4["'>YY$\TQ$G!F'/>D'6OM7JO\ /B^LGI!UK[5ZK_/B^LNPH.*&HJFF#Y*N
M".;&',$33@K,@XB:CDCQZ)B+NXB%H3S3%3EN#](.M?:O5?Y\7UD](.M?:O5?
MY\7UEVL_$35,).:I@'ZNT_\ "Q9>)VJ8QD5<#A^@:%?,\5,CE/2#K7VKU7^?
M%]9/2#K7VKU7^?%]9=)ZK.IAZ^HB;[D#2K@XH:HE:'4M= \]['0-5\RQ4RPY
M?T@ZU]J]5_GQ?63T@ZU]J]5_GQ?677P<4=13GLW5<4,HZAT#<%7QQ'U.WUU5
M$1Y1 W"OF.-Z&6'$^D'6OM7JO\^+ZR>D'6OM7JO\^+ZRD"#B'J%__P"DPG_X
M+5DLU]?CUJ8O\EJ>88WHEH4\!M*W^Q:BO=9?;7)013TL44?/(QW,YKG$^M)\
MH4U+CN'5\K[TRX&XRLD[(L#.5@;C/-GI[@78KR8F).)5-56[0B(N8(B("\A1
MW2@LWA<W:NNU7!1T<<S^>:9X:UN8FXR2O7J\3:QTF-;>$O?[":HT@J)R>U#.
M;'+&T]$CWXLU_C+U/ZJ6A?;99OC3?I3U4M"^VRS?&F_2H1_[*3/;0[XJ/I3_
M +*3/;0[XJ/I1EZ-T_J"TZBI'U5BN-+<*=CN1TE/('M#O)D+9K@N#?#T<.-/
M5-K%>:X33F;M#'R8R.F%WJL@B(H"C3CIQ+EX;6.WUE+10UM35SF)L<KRT  9
M)V]Y26O*7AF79CM3:5MA!>VFC?52,;U/.\-Q[X85)[+#&/A67H GTLVX_P#[
MP_Z%/U]XAT6G>&M/JR\Q\HE@C>VGB.3)(\;,;GW_ '@5!]C\("EH*^EI=2Z(
MCH;6X-8R41?;&LZ<Q#FCFVZX5_PQ+Q%5Z9TI%;I&/M]0]]5&Z/UK@&8;CWG*
MSI!&ZQ#X2.K(1!=KCH^-NG9I.S;,SM!GRALA\4N]Y>B[+JJU7;2$.I:>H#;5
M)3FI,C]NS: 2[F\XP0?<45<1;73Q^"JRG$;0RGM5)*S'<X<AS\)*C+2=ZGA\
M$S4,$;R.2K=3#S,D>,C^)2=+QV2-;>K>W'PC]25]97U.D])MJ;'0GFEGD:][
M@S^T\MV9GWU-/"'B+0\1]..N%)$::K@>(JJF<X.,;\9R#WM/<?,5P'@G6Z!_
M!NMYV-/HRKG[3;J.5K<'X%P7@;U!IM;:HH&N/8OIVD-\[)' 'X"K$6G*=+O6
MJ+F]?ZRM>AK$+O?#,*0S-@^TLYW<SLXV]XJ.?^TIH/\ MW/XJ?I4%KPO?O6,
M_78O^5U?@\_>:TO^K'Y[E!_'[C#I?7.AQ:K&ZL-6*F.7$L!8WE&<[Y4X>#S]
MYO2_ZL?GN02(B(@(B("(B B(@(B("(B#!OO]27']7D^:5XPM7]6TOZ)OR+V?
M??ZDN/ZO)\TKQA:_ZMI?T3?D7U/9?O5,U,I$1?98$1$!8]P_H%3^C=\A60L>
MX?T"I_1N^0K-7NRL/8FCO8E8_P!1@_EM6W6HT=[$;'^HP?RVK;K\HZ"(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B(//_'_C!=;#?(=)Z(9SWJ5K3-,Q
MG:/87>M8QN^7$;[],A1>\\=K+']FI77_ )&@R/#^64-'4\T6^![RWMSNU'H/
MPJJ^Z:H#FT-3E\4Y;S"-KV8:[;N!!"] W'B?HN@M1N$^HK>ZF+2X=G)SN=Y@
MT;Y]Y2/=NL[V<]P#XH>J+8JAE?&R"]4)#:AC/6R ]'M'=YQW%2FO+O@K-==N
M).L[_0P.@M4O,&-Q@ ODYFCW<;KU$M=(E.\"X;BUQ(MG#FQLK:^-U35SN+*:
ME8X!TAQN23T:.\^==RO(GA1SFZ\9M/6J;>GBBA9RYV/:29/\%G>8B.JQM,NI
MTSX3+Y+S2T^J]..ME#5$=G4QR./*TG <0X#(\X7I"&1DT3)8G!\;VAS7 Y!!
MZ%>>/#)MM,W0EBJ&QM;)35?91D#&&EAR/<\4*4>"%>^X\*-,5$IYG^@F,)\O
M*.7_ (6HUB?1)W=PHBXX\9J;AV:2CMT%/<KO*>:2G?(6B*/?QG8[R>@]U=]K
M]EUDT7>6:=,@N[J9PI3$0'=IW8)V"\6\6^&5PT-IJT7345::J^W6ID[=H?SM
MC :#@N_"=DG)Z+*P]O:6N3[SINUW*6-L4E731SN8TY#2YH. ??6S7.\./8!I
MS]GP?,"MZXUU8-$4U-/J6M-)%4O+(B(G/YB!G\$%:JBTRS&SIEYL\-GV/Z9_
M6)OF!=]_V@>'/Y=?\4F^JH2\*#B-IG7%FLD.FK@ZKDI9I7R@POCY06@#UP&>
MBBO5&A_878/V?3_RVK=+2Z']A=@_9]/_ "VK=("\W<:OOFUOZE3_ "O7I%>;
MN-7WS:W]2I_E>@XM$1$$1$!$1%3/X./]5:B_7V_R6*7E$/@X_P!5:B_7V_R6
M*7D!:37'L*U!^SZC^6Y;M:37'L*U!^SZC^6Y!Y!H_P"B0_F-^17E9H_Z)#^8
MWY%>7ZNG9S$1%I!$1!2[[I!^FC^>%[2@^XQ_FA>+3Z^']-'\\+VE!]QC_-"^
M)[3^)'R;IV5HB+YK3SKX2GLVL7[/E_F-46*4_"5]FUB_9\O\QJBQ?4X7X</R
MWM3\Q/["(B]+YXB(@*8/!G_KO4?Z"G^=(H?4P>#/_7>H_P!!3_.D7FXKX;Z/
MLK\Q'RE/J(B^6_4"(B B(@(B("(B B(@(B("(B"*M9.=Z9:T-;GUOS0M+A[N
MIY5NM9NQJ6MQ_A^:%HP[?<K4"X(VM\Y560!N K#IV 8ROC:@'9K2X^3R*#(P
M[N&!YD)#1EQP%9';O[PP)V36DF5_,A"LS,'1V53SR.]:T8\Z^![&_<V9*J/.
MX;^*%%6WDMSS.W\@1H<YN1T\JJ:UH/B^,>_*J/3;8^1!0V( Y<Y?<@;-QA?<
M9&Z- Z!9%+6N/4;*_P F&[!?6,.%\YR 5B9:A:E:0T[X*PCS$GGD+3W#RK)J
M901DG<K%$?C!S]SW+-VH78W8^YC?Y5DL+G;. 'N+$#L>97XGX;S=5FZK[<-*
M^X)/56H3VAYO(L@X#%!\VQU]Y4\CB<CHOD1#I"LAAQD(+0  7P;G9?9'8*I:
M_#CCKA!]<[E(;G<[+Z!XV#NOE,W,CC)[R^RNPXH*)7%HY68R>]6Y?M<1><%V
M%\+@X%Q/18TC'U!PUVP08,3GR/+SMYE5%"^2H8''8E9C(FCFPKL;>SC+^\=$
MA6!>)GNF92TNS^\A?!!$V9KIV![F-[U>CC!J75'X2PKU*(X'-!^VO&%2&JN=
M4ZHAEC:?M8=G 6O94 CD<SE&,8ZK+MM Z.C<^=^[CE8\X8R88(*$-!=Z1HQ6
MEC>>+Q2?,NHMC*>:A@>QD;2!ZWER"L6:-A;''(S+)/7^ZLNT4;X*AT4@PQN[
M?<1J^C91T\?8NB<QKXG^N&, +B)A-:9W.<UTE+S'&_C-4@4[&CM(R>O1:2ZP
M\E28G@%Q_"/0JPRMT=3'7T0<V7F?W$C^"H,W9^+/$TM;W]ZM&V^AFAT?VI^=
MHQ\JN3QNJ(VR1[SL]<T]ZU#*U,R.5A]#2.CD.X'4+3SR5D)+:N)KF_VN@6>#
MEQ#3C^TWSJW*:EC?%Q4P_A0'J5NEEK"Z%Q!:0">XK*C&#UZ=R&B@JF.=0CE>
M/74[^K/<6)&]\3N1P((VP>JZ0RS'@L>)(VX/>MC351+, ] L&*4$>-N%2X%F
M71^M6HM*/4NJO8O_ )?RA< N_P!4;Z6'N1_*%P"R"(,=4+AY<)<,95)"HDF8
MSJ<E6751WY6Y4N,DX5MSVCJ<%8Q=(_8H(7';JEUB%Q\X'095!E+NBKC@#=RJ
MPUC>@4U+V6FM>2JXX@'>.%<YL@XV53.9W4*76.Y@,[U4QO/NJ^R)ZKX3R XZ
MK$K"A^!E8\[R#CN5;W\I+G'+O(M?//EQ[0X66H5/FW+6]W578"2PD#Q5A4SS
M*_EQXOE6;,_DC[-O\%EI]C>#/Y@%\[?FE<\=&JAL;XJ=S&;ERIIXQ%"X2[DH
M*Z!A,\U1+W]%=HQVTIEF&0#AJKA(,!&,!)(R:<!BB742/+9'\W>X85]TA#.5
M8]6PEK7=[6[I1N#X.8;A!:BYO1)<1L5D%V9-QME51L#]QT5.XD 052\H=A(1
M@N\G<OI'*]?<['""V[UKB5BN#3S =5]J'.="YHZY"I8US&%SB.BL$-753-8Q
MP?URL9H#)'.SLX9RKMRY7S1L(W[ROD\38*<>-GF16$?^]UC2'[A:>X4#FUKG
M%O.2?@6PC@DBE9-T#2L^Y-;-AS3DN&Y"1"Q-F-;X8XY1.T<S".4CR+)NMNEE
M@;4T3ACE\9H6-2#LBZ,'9;.BFY>5O/@M[E;,Z[HY=3/I*ST32.><[21$_P 5
MO14/:QLT1/9GUP\BV%ZIC#5NE(!:_O 6(R'L?&C&6NZJP-G1U0J:8@/:<#H>
MJU57/$WF#X"!_:3L6Q/[2$['JOLDC7$-J#R9V:_R^9:I8:]Y@D'VN9HSW%67
M4KHSSQ/(/]H=%3<*"..3)^U..^1T<%BPR.AR&NYF^ZNEF=FUAJ6.')5LYCW.
M;U6PA,D<.6/$D.?6]X6D8]L@'E5^!SHW>*=EJ(1T4!9(<M=R^99D;\[$8Q_%
M:>GG:\>-L5L(G%N,;Y1+I7X/$&*ZX\L7R.4BJ->#!)CO&>YT7R/4E**(B("(
MB HVH^$ELI>*=1KEEPJS7S/+S3D-[,9:&^3/<I)1(TFYTL(K<L\4/W65C/SG
M *CT938SZ)AQY><(+Z+$M]SH;D9Q;ZR"I[!_9R]B\.Y'>0XZ%9: B(@*#>+G
M$/3FEN(]HHM1:1IZN5W92LNTP:3%&7D%S<M)/*<G&5.2Y7B#H&P:\MK*34%)
MVABR89V'EDB)_LD?)T4]5A"/A9ZLTQ>=#VJFMERH*^XFL;-&:>1LCHX@QW,2
M1T!RW;O]Y<=Q:TU<*7P?= 5=;%*)J0NCE#A]S9)S%F?)W!3'I;P<]&6.Z1UT
MXJ[FZ)P?'%5/'9@@Y&6@#F]PJ5[W9[??+146NZTL=303LY)(7C8C_C"6T(G5
MYYUSQ!L5=X,E/1T]RI9+G44--1FD$H[5KVEH?EO48Y25K=':2JI_!-O.(9!4
M51EKXV<N[F,=D;><-)7<4O@T:*@NXJWON$U,'<PI'R^)[A(',1[ZFBEHZ>DH
MHJ.F@CBI8F")D36X:UH&  /)A6=;^J1I;T>;/!GU[8K%PGNU)=[I2TE315$L
MK8II USV.:".4=3OD;+7^!C;9JB^ZHO;XB(.1D#'8V+W.+B ?,,?"I!U#X.&
MB[O=Y*Z'T;;VR.YWT],\",GOP"#R^X%*&D=,6G2-EBM5AI&TU''O@;ESN]SB
M=R3Y58G6\D[6?=5Z9M.J[6+=?Z1E71B1LO9N) YAG!V]TKCO4/X?>UZ#]]WT
MJ244'F'PDN&VE-*</A<+#:(J2K-5''VC7.)Y3G(W*EKP>?O-Z7_5C\]RY3PO
M?O6,_78O^5U?@\_>:TO^K'Y[D$B(B("(B B(@(B("(B B(@P;[_4EQ_5Y/FE
M>,+7_5M+^B;\B]GWW^I+C^KR?-*\86O^K:7]$WY%]3V7[U3-3*1$7V6!$1 6
M/</Z!4_HW?(5D+'N'] J?T;OD6:O=E8>Q-'>Q*Q_J,'\MJVZU&CO8E9/U&#^
M6U;=?E'01$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!Y\XHW30?$+7;
MM#WNFN$-]II!3TMPI(P[#R.8M/\ A'?G;KT6EI/!1@;7%U5JB1U+GI%2!LA'
MNEQ'\%PO'V_&P<<JBY:>IO0%VH7L>ZI:_G;.XL&Y:1L<'!\H6VHO"DU/#$&U
M5DM=0\#=_,]F?>"E.UUJWL]1:'TC:-%6**TV&G[*G:>9SG'+Y'=[G'O*WZAG
M@+Q=N/$FY76FN-KI*%M'$V1KH'N<7$G&^5,RU*0+R/X5E,ZT<6M.WMX=Z'EA
MC<78V!CDW'P8*]<+E^(>AK-KRR&VWV$N:UW/%-&<21.\K3_QT6>L3'18ZPA#
MPN]36NY:)L%);JZFJY:FI]$ 0RAY# P[G'E+@%)V@KA;>'_!K3DVI:IM!3QT
ML37OD!V>\9Q@>ZN2TGX-6F[+>H:^XW&LNS('A\5/,QK&9&XYL>N]SHI,XCZ)
MH->:8-CN4T]/2F5DO-3X#@6]!N",*[1/JF\ZMSIV^6[45I@N=EJF55#-GLY6
M @.P2#U\X*\]^&S_ %%I?]9F^8%.N@M*TFB]+4=BM\TTU-2\W*^;',>9Q<<X
M]U:3BMPSMG$BDM]/=ZNKIF44CI&&G+027#!SD'R*3"PW/#CV :<_9\'S K.O
M-!V'75+2T^I*62HBIGF2,,E<S!(QW+=6*VQV>S4-M@>]\5)"R!CG]2&@ $^?
M99RU5-YF68V1)_V>>'?Y*J/C<GTJ%?"=X;::T+9[+/INCEIY*J:5DI?,Y^0&
M@CJ=NJ]BKS9X;/L?TS^L3?,"BIYT/["[!^SZ?^6U;I:70_L+L'[/I_Y;5ND!
M>;N-7WS:W]2I_E>O2*\W<:OOFUOZE3_*]!Q:(B((B("(B"9_!Q_JK47Z^W^2
MQ2\HA\'#^JM1?K[?Y+%+R*+2:X]A6H/V?4?RW+=K2:X]A6H/V?4?RW(/(-'_
M $2'\QOR*\K-'_1(?S&_(KR_5T[.8B(M((B(*7>O@_31_/"]I0?<8_S0O%I^
MZ0_IH_GA>TH/N,?YH7Q/:?Q(^3=.RM$1?-:>=?"4]FUB_9\O\QJBQ2GX2GLV
ML7[/E_F-46+ZG"_#A^6]J?F)_81$7I?/$1$!3!X,_P#7>H_T%/\ .D4/J8/!
MG_KO4?Z"G^=(O-Q7PWT?97YB/E*?41%\M^H$1$!$1 1$0$1$!$1 1$0$1$$,
M\1*Z.FU+6B0]"WYH4?U6JXQ*8XP%L>-=>(-87,%V WDSO_@"AJMU#0TY);)V
MCSY%+B8;;=VR^,\X*WL%:V1FR\ZTNM)NW#8VN#/+E27I:_.JFLYG@@CIE:$C
M-E<YI"K8T #G6+2Y>&CO68P?VMR$M(K'3#>B^@*D/P-@OA)/?A05$;G=4X\Z
M^8VW*^8/=G"3HJK QE?>T#&95 ![R%:E=OCJN=4K"OM^8]<%6WS<IR=PJ'1$
M]"/A6)5/=&TY&%RF72(NO25#7'IA9,#.U82X[+G#4NDGY6NV;U*SO1QF+8*,
M.<X[%_<%%F)C=E.J8Y9^RC&X.ZS2S+>6/WUB4- 829'.R\]=ELHV^)D=40@
M8W ]]5?=-O(J' @;=56W([D'UC-L^\K@Z87W\$;87UG>B+$HYCA5",-:KG(
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M=L5I*NDABIG![_&=N[=6%B'VNKFL[%K/6%;:V53J9['AO-"[9WF7$726">"
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MZQ-\P+TFO-GAL^Q_3/ZQ-\P()YT/["[!^SZ?^6U;I:70_L+L'[/I_P"6U;I
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MP?RVK;K4:.]B5C_48/Y;5MU^4=!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0%Y \+22JBXMV&2W<WHUE'&Z#E&3S]H[&!WG*]?KSIQST-J2_\8M,7:SVJ
M:JMU*R$33L+<,Q*2<Y/D4M>JGYM1M/\ W5''IOXZ?VKY_I[/J)Z;^.G]J^?Z
M>SZB]I(JR@OP=+UQ NEUO#-?&X&G9"PT_HJF;$.;FWQAHSLIT1%01$4!$1 1
M$0$1$!>;/#9]C^F?UB;Y@7I->;/#9]C^F?UB;Y@03SH?V%V#]GT_\MJW2TNA
M_878/V?3_P MJW2 O-W&K[YM;^I4_P KUZ17F[C5]\VM_4J?Y7H.+1$1!$1
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M ]V%JSG-2GE :!Y%\(RJY .Y? %&;OC<^55-SS!?",]%=B;C&416WJJ^;"^
M*AZB/CW9/5-_*J6C=5=$5]9U53E2U5#R(BGHJ"[=52$#*QRX 'RI"P^OD 5
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M("(B"$/"]^]8S]=B_P"5U?@\_>:TO^K'Y[ERGA>_>L;^NQ?\KJ_!Y^\WI?\
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M_P#&[[/:BN^HZB":"3LX@6EX=)R\P:!D!K0"!LI"\$S6UTK9KQI._54M1)0
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M<B\H_9KPBOQ*I^*4J&]>$5C^A5/Q2E7-Z'JY%AV1U4ZST3KB"*PPL,P( \?
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MX!)ZK=20-;LOA :0%=W+-L*V'=Y&RPJP[8NRJ2.8;+ZX%[CD[*MC<# 04AF
MC1S%7,$[#JOK2&[=Z*K8W V5QH#%\V:S/>J,Y=MT41]D=MLJ6@\J^D+Z/6J*
MI&ZI<54SHK;]T% ZJD;O5UL>&Y*HC;N3WH+@&X20[X"^9P523ER"X#LJ<[JK
M8!4$(+F=E2#G*#HOFP!05 CE533D;+'=L-E<B.&($CNNZI8<#96I7$N.55&?
M%05O?G8KXX9:K;CDH'9:1G=!8E=RD[K%=NXE5SGQCY5;0?2=L+%D;ERO.)[E
M;>4%B9G/$Y@ZK'MKG"4QE9L>SBY8L@#)^=G5++=>F>Z"3QP3GO6-(1*XE_1;
M"J/;P@GJ L7L<M5@NP9X621.C(&.XKG:AL]!,>:,21'O(Z!='*#SX/4*MT+:
MEG9N:-]D6*K.&KZ5\@,],]ISU;CHL"E,T)+VM$L9=RO'D757"WFA<7.;XKO(
ML3['-!$L&0'#=N=E;-YV-V$?*'1D]F=\^=7V@GE)[ELX*1G8=GRX!^58XIG1
ME['=>Y(T8E0 2#MLK;FAIYLX5<8(?V;_ ."2>(>4CQ3WJL*XWX&^ZOM(P%CM
M\4XZL_M*XT<N<G(/12-$E+G ?UM]_.A_\ZE913P' [.]D>6'_P ZE9=J=F1$
M14$1$!$1 1$0$1$!$1 1$0$1$!:K5=FBU#IJZ6>=W)'74SX"X?@\S2,^\MJB
M3%]"-'C#1&J-8\$)+YI^LTQ/5FIDYXGX=R=IRX#VN (>",;#=21X*6@;K9S=
MM4:BII:6IN #*>*9O*_ER7.>0=QDG8'R+T*^-DF.T8UV.G,,X521H2(B("(B
M B(@(B("ACPN/O03?KU/\I4SJ*_"6L%UU)PREM]BH9:ZM-7"\0Q <W*"<E!>
M\&C[R^G?S9?YKU)RX#@+9[A8>%5DMUXI9*2NA;)VD,GKFYD<1GWB%WZ B(@(
MB("(B B(@\DZ._\ 7$N?ZY5?RBO6R\UZ7T1J2E\)^X:@J+/51V5]34/;5D#D
M(=&0#U[RO2B B(@(B("(B B(@B?PH_O,WC])#_,"J\%S[RUC_/G_ )SUG^$+
M9;CJ#A9=+=9:.6LKI'Q%D,?KG8>"?X+[X/=EN.G^%-HMUZI):.NB=,7PR>N;
MF5Q'\"$$C(B("(B B(@(B("(B B(@(B("(B B(@(B("(B O-WA9Z,NM75V?5
MMDII*GT SLJAL3>9S '<S7X&Y&<@^\O2*$!P((!!Z@J66)>+>(FO[SQK;8-.
M673]3#/#+S3<KB\%Y'+D[ -:-SDJ?=>76Y\)^#MM]+]-!6UE *>CY98W.:X8
MPYV&D'N\JDZGHJ6F>Y]/301.=U,<8:3\"NR1LD;RR,:]OD<,A7HB'Y8KKQ?\
M'^4U]-!37FMC<^.)C7,8)(Y#R[.)(R!Y>]07I#BE>- Z$N^AZ[3U3]DGNEC@
M>_+#%SC!!;C)QN1CJO:K&-8T-8T-:.X# 5B6AI)IA++2P/E'1[HP7#WU+;^J
MW0IX*&AZ[2^DZZY7BGDIJNZO8YD,C</;$T'E)'=G).%.:(M3-V8T$1%%$1$!
M$1 1$0>>O#2]@UC_ &C_ /3>I=X6?>WTQ^SH/F!1WX5>E[UJG2%IIM/6V>X5
M$5=VCV0@9:WLW#._G(4F</*.HM^A;!1UL3H:J"AACEC=U:X- (*#H$1$!$1
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M\=N0&U31^&P>7RCN4Q+S%Q[X.U-KKWZWX?MDIZB!_HFJIH#AT;AOVL8_B6_
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M 3Y54@(B("(B @(/0Y4*\?>,D.BJ9]DT^YM1J6=N-F\S:4'HYWE=Y&_#YZ.
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M3<Y!17&G+8ZRC> ]H<.K20<%059O!7ML%W$UWU%55M UW-V#(1&Y_F<[)]_
MW\RDQ,Z$39VW@L.K7<';7Z.YBT2RB#F_N^<X_CE2VL>VT--;:""BH(&04L#!
M''$P8:UH[@%D+4S>68BPB(HHB(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B+@>-]=JJWZ"K)]$0"2O;O*\;R1Q;\SHV][O\ \8*DS;58
MB[OEJK_:V72EE;3S,IKDR)[*>K:QKI*<N&.9N05YQIO"$J[CPNK:5H9!K5G)
M2Q8V$O,>7M6@_A#O'EWZ+E-1\-.(G#N"GUK376:MK6XEK70R.=)%GKSY/VQO
ME*L^NQ'INS](ZRU+P0UQ46'6AFJ[+52F1\F[\Y/W>,GKGJYO_*Z77_!"2^W&
M/6/"JY01FK(JA%VQ8.8_A1/ VR>H/?GW%T-@O6FO"#T.^U7EL5'J*F9S$,QS
MQ/Q]TCSU83U'O%9O@[Z#UAH:>\T5_K(_L()"VEIP[GYSG/:MW\0'O;WG^-MT
MGHE^L.9T=P4U7?\ 4U'>N+5U]&QT>#%2B?M'.(.0'$#E#<[[;E>DF@- #0 !
ML $13T!$1 1$0%\<0T$N( '4E>;N)/%76?#[BTV2]T#3I25O9P0Q[MEBSO('
M?WH/4>3;SK7ZP?>^/.L:JU:3O+*72=OIHI729=RR2/;G#V@@D]V#TP5(F^RV
MLZKPCM%:AJK%0W/1-2^&FM4CJI]OI0&$OR7=LS \9PR=O@6HT+K&R<<](2:0
MUKB#4,;>>*9@Y>T<T;21^1P_";_^!QFA-=:FX*:M=IC7+)YK&YVQ<XO[)I.T
ML)[V^5H_@5UO%3@V;_<*'6?"JHB%14RLF>RGE:QA)/W:-VP!\H5B(MZ2E_JY
MZBX+\5]+SU5KTM?(66FJ<0^6*K[-I!VRYA&0<=>53AP6X84G#FRS,=,*N\5A
M#JNIWP2/P6Y_!'PE=MI^"OIK)10WBJ95W".)K9YV,Y ]X&Y 6P5V-Q$10$1$
M!1AQ3XP6SA[J.S6NXT=3*RM!DGG8-H8LXYA_:.>X=RD]>7?".M3M:<:M(Z8A
M$T// 8WS]F<-#G%Q<,[$ #=2^L+&TIZU+I^P<1]*PTU>16VFH<RHCDA?CFP<
M@@^?H?=*P=9\-+#J;1=/IA\;Z*VTSF.@;3.([,-/3?KMD;YZKSEP_P!9:@X&
MZNDTMK&&1]AD?S!VY# >DL7E:>]O_*]27F)FKM'5,5CNYIX[C3D0U]-A_*'#
MUP__ !E6=KPD;VE GA!\*M%6#APZ\6&FAMU92N8R-T<I<*G)P6G).3WY'D*E
M+P=*NMK>#^GY;D7.D$;F,<[JY@<0TGWACWE%MB\&&;[(P#4FJ'UEJ@=S"G@C
M<TN\V7$AN>_ 7I*W45/;J&"CH860TL#!''&P8#6CH D:1/J3K9D(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B#QAJ'V5ZC_:E5_-<L%9NH?97J/]J57\UR
MPE]NCW8?CN+^/7\Y$1%IYQ$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%T
M%1HW4%/9?LM/:YF6[LQ-VQ<W'(>AQG/>.Y6]$65^H-4VZVM:2R64&7;I&W=Q
M^ %>FG7.UW.[7/1SF-)BHF\[<[%CAREN/,"WX5Y\;&G#F(B'T.#X.G'IFJN;
M=(^;R2BS;Y;9K/=ZRW5((EII#&[/FZ'WQ@^^I'T_PMI/2W'>=6WG[%03-#XV
M#E&&D9',7=Y\@72K$IIB\O+A</B8M4TTQMOZ(K12WZD$+[37W.GU!'44<4;I
M:>2&(.$K0TG<\VQR,+E>'>@ZS6,LTC9A26^#:6H<WFWZ\H'EQOYE(QJ)B9OL
MW/!XT513EUG9QR*7W<*K'=*>I9I;5$=;7P YA<6.!/D\7<>[N%QNBM&2W_5M
M18:Z9]OG@9(9#V?.6N:0",9'EZI&-1,3/8JX/%IJBFV^SDE7#$^::.*)O-)(
MX,:/*2< *7*;A/9Z6YNH+YJ>.&KE>134\?(V1[>YQ!)P3Y%R6L='5&D-74%
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MN#.SJJ=W*\ Y'3((\Q!!72C%IKFT//B\-B8,157&DL%%D45%55TQBH::>IE
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M-N.L9[QT&?(IZX*ZUK==:)IKK<K;+15(/9N>1B.<@#[9'_A/RY5C:4EWB(B
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M#)[;I/\ 3V?73U 9/;=)_I[/KJ^*P^[CY1C^GU_I#"*9_4!D]MTG^GL^NGJ
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M/]/9]=/4!D]MTG^GL^NGBL/N>4<1Z?7^D,(IG]0&3VW2?Z>SZZ>H#)[;I/\
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M,,- 2E:UTF?(>J*LPPOHH7$.ZG*S63!])S.W6-<\O!8SIGJJXV\M*&],(RN
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M:A&]IYCG<Y68QX)6FIW[[K/A>"4$I\(#EEV]V+_S*0U'7!TYCNWYT7_F4BJ
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M7%5PC)*NA@:"OE/&0'%$E21XR^AH7W&'%?<(CYW("A\RI:3E!C5+,N5/9Y8
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M,\ULMT[(XJJ8]G(YS' ]D[O.,>N'<<97H"CI8**DAIJ2)D-/"P,CC8,!K1L
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M$10$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M@GF*E?P8N']?I2PU]XOL9@N=X>)/0Y&##'N0"/*2<X[MDIVMT*MTUHB("(B
MB#?HK58]\5)/)$WFD8QSFCRD X2=!PG%SB-0Z(T]7/IZFBEOK8N:GHI9@TNR
M<<Q'D&YQWX4;Z,UY0\;]!7+1^H)8J/4DD!Y'-'*R9PW;(WKT(&6_ N+\&FCL
M>LM>:DK-:Q07&^OQ+##6@/#LD\Y#7=2-ACN"O>$EP[H]$W&T:GT8'V^:>I[/
MT-3;<DHW:Z,#<=#D#S*;1^+JL;Z=&GTCKK6? ZLJ=.WVT&JMW.7QQ/S@$_A1
M/&Q:>N/D75Z#L^I.+_$^BUOJ6W_8ZQ6[E--'@M[3E)+6MSN=SDNV'<%(' 3B
MQ3\0+>;7>V0QZAI&9>PC:H:#CM&@]#TR/*IC P,#HM;3>6=]A$111$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1!%>M#_Z1UONM^:%HNJW>M!G4M;[K?FA:1WBA8J;B!QRW"H<X1QY=ZX=
M,*H#?*MO8'N\8A<18IXW22=J_.W<LOEYSSO)#!T 5V-H8S?8*C/:M(SRQMW)
M[D:A;V<2YOBY[_(L;F);(V-O*S\(_P!I))G5LPIZ88@'KWCO]Q9?9[<AP&1]
M/.A=KVTQ,C7CH.I/>LR/D Y8QD^=5LC=*<-'*WY5D11,CW[TLLR^4\0:<N53
MFASE=R"?(K6<..$LS=<: QBM'!<,E?7R9"I8,@E!63D8"KCSA6@KC78"BPJ<
M3@HP@A6G.SLC?=05O)]Y6@JGG'54<R"B5V%8#MBJI'#=6\[;(JASMU9F><)*
M["QWOVZH651/\8Y5U^!N%A-.ZO DA0;:CER>4XPKT@SG"PJ-IY<K-:T\J0BA
MI+!D'X5E1O$C2"L>2/+>JM1\S']=EI"H'(\[[%8T@YFK-E;SL)\BP@[E)!0:
MIXQ(<]5AU$>9,XV6UJ8P7Y"PIL=,(L;N;O-$X@OB6%1R8'))U742Q->SE6IF
MI&<Q8!@^5&KL=WBL/>%A2%KLGY%D.#H9>SD!+?+W*S5PO8\/A\9GD"L$[,.:
MC;,T\H))Z$=RTM32RLD$=9&#@\S7-[_,ND@B$H,C'N:_^R.F5;D+W.]#U3<.
M.['8V!]U5(8=#$VKAQ( ]N.21IZ^ZOMKC=2226Z5QYXCXO-U<U7F4DE/5FKB
M)P\<KV?\K.JZ1MP[.IBRVKB;GW6__C*+=];"6 2QC/-UQW*N5H: X'+3Y%;9
M--3ADD0YHG;/;WA9PBBFB,E.=CU:>H5AB883FY!!6MG;RO([ELP.78]W>L:N
M9@972&)>J-5>Q'_IB^4*-W*1]69]*&WDC^4*-7.Y&DN.<),V()'' #.JO1M[
MW*BDAR3(_<'H%=<7<V.Y<[M*<;G/1'L!8JP#ME?'[L.ZD# J'.C>"T^(!D^Z
MM&^F-7;ZN-S@6O=DGR^9;JH#G1&&,Y=)W^98E72MHZ%U+&3D@NSYUEJ$;7JQ
M-N\]#1%Q [4#LV[  '!RNFHK?%13B"F8T<@P0.Y9M)1MIP)H(^>H>,'RA77Q
MOA?SEOV]P^!'2:KLD,9!&7$Y<>Y9]M8V9:>@H*JHF+WDC)[UT]!11T[.49[3
M^UE&+K_8-:W?<JJ$$G&,!5AO+U.3WH2"-U2ZYU530 K;2 JP>NZC"^QP 1\N
M>BQPXY3FP$5>#MBK;W[*P93GJJN;(04.R[97(VB,;HW;<JU/, T[[]R"F:3F
M=@+(IQRM\98=*"[+GJZ^<#9!DEP[BL25^7JICB1LK(;F3=!E#UH]Q8\[=RLD
M# &%:G'4E16+&[((1I VPK<;@'N&%<*BLF,X;E7 [*Q.8!N<K[#."<+4#*YN
MY5-&5;<1C(5+9,.SE5E=+52YHSNJ^;(W*M/=E!9J(\^M6(YF3RD>^LX$X\RL
MR@84&%)1NR2P[*CT.0#S*^9.0G<GSJMDG.,DC"HPXXVL<<G97&B!^SG!7GLC
M<#LL-]OAF=D%S3YBK!#)$3 .YP5I]&P^-RX5R.E,;0.T) [DD8YN^^%1C=D!
ML!LKO9 -'*5]RU["K)$C?6.V1$B\*!AETSUS'_YEWRX#A,2673FZYB_\R[]=
M:=F9$1%4$1$!$1 1$0%KM16BEO\ 8ZZU5[ ^EJXG1/:?(>_WNJV*),7T(T>"
M[#>=9Z)N&H>'EC=(*VX58I/M?KFN!+2Z/R<[<9/<!E>B.'7 #3MKTI+3:NHX
M;M=JYH=4S.+AV1W/+&[.1C/KA@E<OX1'#R\U7$C3&HM&TSY+C52MBDY=A'+&
M>9DCCW#&<G_"O1U#Z(%%3BM[,U79M[7L_6\^-\9[LI&VNZSOHY#AOPST[P_B
MJA8J9QGJ'DOJ)CSR<O<P./1H\BWHTO81=3<Q9;;]D<\WHGT,SM,^7FQG/G6X
M1$$1$!$1!SG$9UY9H>]/TQ*(KPVG<ZG>6\V"-S@>7&<>=>)^&UYXBPFXW31=
M?<*I]*\25E,UYG+N;/CNB=GF&<Y(WRO?:\=:AF?P1\("2X11/-DKN:H,,8SS
M0R$Y:.F[7#;WE(TE>CK]#^$]3.>VCUO:I:69OB.JJ0<S>;.#SQG!;[V?<67Q
M-X:V7BT1JGAQ>;>;P WMVMEPV8CH78R6/&V^-\>^N*T_IB[>$!KNJU#=:=MJ
MTS"[LPZ%K6O> ?6-.#S//5SCL.Y=KI7P;W:?UW3W&+450ZS0Y?RQN,50]W<Q
MQ;MR^4A6U[73;9Q-5H;6#9[9/QCU4RBTS;ZAF&U5:973$$>*QHZD_P!H[@96
M7(RAXG^$+;*S0U(8K;:G0RU=>QO*V41N'C>_CE&=RIVXD\)M.<0:NDJKX:Z.
MHIF]FU]-/RY;G."""/+N!E=%HO2-ET99V6S3U&VFIANXYYGR._M.<=R4CO)/
M9OD1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1!S^O\ 3=/JW1UULM4T%M5"6L)_!>-VN]YP"\6Z/UCK
M2PVFY\.K!'+Z/JZPP@QY,D+LELC6;;9.#S=V%[R7ESC)HJ]VGCII_4&C:5TM
M3<YFR\C=FB5A'/S'N:6G)]]2(UUVE>GR=9HKP<M.4^DC3:LB-=>JG[9+512N
M88#_ &6$'?SDC<KO.%O#"Q\.Z&HCM;75%74G[=5S =H]O<WS >0+N8B\QL,@
M ?@<P!R >]5*HYBEX?Z2I+TZ[TVG;9'<B[F[=L#<AWE'<#YQNNG1$!$1 4><
M?+G?K/PQNU=IB01U<31VD@&7LB)PYS?. >O=U4AJQ7TD5=0U%)4M#X)XW12-
M/>UP((^ J3%X6)M+P[H'B-Q(TS9C=;=/6773\4A9.RI!J&1D;X+MW1YSUR 5
M.F@_"3TS>Q'3ZAAELE8=B][@^G/GY]B/?'OJ)]#:D]0WB?J:RWN.66SO:\=F
MUO,Y^,F$CW0<'W4T1PUN'&?45SU+6P16"PRN=V7H6(-YG#8!K3U_Q.\O16)N
MDQ9V'$W@W75=[;K3A+7PETS^W=%2S\I#R=WQ/&Q![V[?\+56RR:OK]56.^\:
M[_#:K3:YFOIV5LK(C-(W<!K&X'<,N.ZZ[A!P/U#HG64E95:C+;/%XS(J)[F^
MB3Y)&D8 ]SX5U_$O@C9-?:ABN]RN=UIY6L#'10R-+"!Y YIY3Y<)&EK%[WNB
M/AI1TNK/"1K+_HFE?2:=HG&2:5K>5CR6\I  V'.[)QY!E>L5I='Z6M&D++%:
MK!2-IJ2/?&<N>[O<XG<DK=)M%H-YO(B(@(B("(B B(@(B("(B B(@(B("(B
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M'SC+CAJUM662$1,Z^9959*^1N(P0%1!3-@897]?*H+E-"RF@VP'>=6)*C,F
M#E5QQR5+RXY:P=Y5R.F!=D8*#Y UPYG/Z]RRXB7*WV9SN5D1D1M\JHK)Y=@J
M0P[DJV79.5]>\XPH!<#LK,A[AU5UFVY7QS1G/?Y$%+&8&_58=PJ!$TC(RLJ>
M7LXR>]:ED3IY"Y^2,]%&H7*0$MYW;E79,EPRLF&'ECP DC&M&25D:F<8)PLB
MBC\56)B'2X;NMC0QX;NK N<O*U6G/QWK(>-NJPIQY%14Z3+#NL6,GM?,JR,-
M7R%OC[A!DU S'E8S78:<=5G%G,WRK&DCP_ Z(--=1D'RJQ;IBQQ!Z+/J& R$
M.6*R(!QP-T&P9*".JQ*Q^6N'<JXAL%6^$/:<C(0:%U1]LQ@$+.I,'&-@L>MH
M'AY,8*L0ODISB3.WE45T44((SO\ "KK8CW+ HJ_+<=0MI33L>%88E\8P@*X"
M6D'?97@T.&0OO+YEJ$51R9"IGYBW+.JJ\4#R*C??!RK"M762RLV SGS+"%T=
M&2U[?X+:54N,]HW \ZULKZ=^<M&513Z)9,TDYRL=['GH-E\\5I/(K\,NVXPH
M)&X)G[7>0<Y#HNON/4FJ.^#_ "F.ZEHP28L^?9RD1=:-F)W$1%I!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$01WJ>R7*KO]5/3T<DD3BWE<",'Q1YUK?2
M[=^Z@E_>;]*E9%B:(6Z+H]/74#>@D!]UOTKZZP7;! H9?A;]*E!$R0N9$[].
MWEV0*"7W<M^E?6:<NP&]OE_>;]*E=$Y<&9%K-/74#>WR_"WZ50_3UX).+?+C
MW6_2I51,D&9$K].WD AMNE/_ %-^E6X],7GF\:WRX_.;]*EY%.7!F14S3MV:
M?Z!+\+?I51L%W(Q]CY?WF_2I31.7!F1,=-W@_P#L^7X6_2JQIR[8WH)?A;]*
ME9$Y<&9$,NFKSGQ;=*1Y<M^E4^EJ]8Q]C9?WF_2I@1.7!F0Z-,7HG>VS?O-^
ME??2S>OR;-C\YOTJ844Y4&9$1TW>>7 MTOPM^E4C3E['_LZ;]YOTJ7T3E09D
M0>EJ]'<VZ8'W6_2K4VFKX6GEMDQ_ZF_2ID1.5!F0DS2M^;_[+F_>;]*L3:2O
M[G[6N<C\YOTJ=$3E09I0E2Z2OC,\UMF'_4WZ5G-TS>>7!MTP]]OTJ7T3E09I
M1 =-7H@__ETWPM^E4-TQ>@3_ /ELV#_B;]*F)%>5!F0V_3%ZSXMMF_>;]*O-
MTU>2SQK=-GW6_2I>1.7!F0G4:2O;G<S;;,3^<WZ55Z5K[V7]63<WDYF_2IJ1
M.5!F0M%IF_='6N;'EYF_2JGZ6O9(Q;9MO\3?I4SHG+@S(-K-(7V0^+:Y_><W
MZ59;H^_B,M-JGS^<WZ5/")RX,SSS/H?4+Y,BT3@?G,^E6)]#:E+#R6BH_>9]
M*]&HKRX,SS=2Z*U3G$EFJ0 =CEGTK:.T5?I&#GM,_,._F9]*GU$R09GGTZ*U
M"X%IM-1CW6?2L-VA=2LDRRT5&1T(<SZ5Z.1,D&9Y\BT;J,L\>S5#7COYF[_Q
M51T5J%S"3:9PX=!S,^E>@43)!F>>/23J)[<&SU#']Y!9CY52=#:DZ_8F<N'^
M)GTKT2B9(,S2ZAI)JG3Y@AB+Y<,\08SL1E<>VPW,-(] R?"WZ5)2*S3$I=&[
M=/W'J:23W,CZ5]-CN0W%%+[F6_2I'13)!=&%19KR6N[*VRYQMDM^E8#-,7R>
M0.J:*4-_L@M^E2\B<N%S(U;8[C3P\L5NE<[W6_2L*/3EYGG,M112M9W,);]*
ME=$Y<&9&)T[<6LP*&4^^WZ5CC3UXD=A]OE#!YV_2I61.7!F1AZ7KH&\K:&0#
MW6_2JFZ?N;&[44F?=;]*DU$Y<&9&!L%V_$9?A;]*MNL%W/2@E^%OTJ4T3)!F
M1:S3]W'6@E^%OTJH6"['K02_"WZ5*"*<N#,B_P"P%V_$)?A;]*&PW;.?0$OP
MM^E2@B<N#,B>33EXD><V^7'NM^E7(M-7-C<>@9/A;]*E1$Y4&9&3;!<PT_\
M<9?A;]*Q*C3UX.0VW2D>ZWZ5+")RH(J0Y3Z5O/:$OMTH'YS?I6SAT[<VMP:&
M3X6_2I01.7!GE%[]/74C:AE^%OTK%DTU=R=J"7X6_2I:13E09D0G3-Y/_LZ7
MX6_2K\.FKJ#XU!+\+?I4KHKRX,R+CIVZ!AY:&7X6_2L"73=[YCRVZ8^^WZ5,
M")RX,TH4GTI?7'F;;)B?)S-^E6XM)WW)+K7/D_XF_2IO1.7!F0JS2=[;_P"S
M)OWF_2LB/2]YY2#;9@?SF_2IB1.7!F0YZ5KP>MLF_>;]*L5&C+K(2?L;+O\
MXF_2IJ1.7!F06W0]X9XS+=/D=W,WZ5E0Z3OK!_5TW[S?I4U(G+@S(=9IN^M/
M]738_.;]*K.G[YRG%MFS[K?I4OHKD@S(;=IZ_?DN<^^WZ5\;8+^/_94_PM^E
M3*B9(2Z%Y]+WN9N#;)]_.WZ5J)]&:A$A[.U3EOYS/I4_HF2%S//CM&ZD+<-M
M%1^\SZ5]I](ZFB.76B=W_4SZ5Z"1,D&9P_#"VW"WPW#[)T<E*Z0Q\H<1XV.;
-/0GRKN$1:B+19E__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g762905g35e11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g35e11.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H*/_  !$( Q<%1P,!(@ "$0$#$0'_Q  =  $
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M##LMP,'/H/-61TU/;ZK3UMGLK8V6R2GC=3-C;NM;&6C= '5@8X(-DB(B!$1
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MSI6BN-1;[Y4U%EKX TOI[A"6.P1D$%N\TCS%==8KO07VV0W&T5+*JBFST<S
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MX'F"@[-$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M"ZQ9=VNYG3^B++9XP6TS:J?KFJ&AYSW#D/0NF' <$10"+\<X-:7.(#0,DD\
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MM.4^N?W3)[\L'Y%E]8'LJ1].W&2[6:EKY:5U*9V[[8G.WB&GD2<#F./I5=M
MV!VHM24U(X$TS#TLY[&#F/3P'I5F6-#&AK0 T#  Y +I\/RYLT3?)/)YGC^E
MT>CFN'3UVMUGG,\O#K+]1$72><$1$!$1 6%>;K0V6VSW"ZU4=+1PC+Y9#P'4
M!WDG@ .)6:H:VV7%S=HVS2V51Q;);CT\C7?%?(US&LSYM[_F0=U3Z]LSKE1T
M-8VOMLU:<4KJ^DD@9.?Q6N<,;W]DX/<NK4<^$)00UVR>]OE $M(&5,+^MCVO
M'$=A()'I6_V87:>^[/M/W*L<75,](PRN/X3P,%WI(SZ4'3.<&-+G$-:!DDG
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M.\.X@JT^R[4\^K-(4UPKZ9U)<HWNIJR!S2TQS,.'#!XC/ X/+.$'6(B("(B
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MR<_;9#DC(X<  .'#(X<%T]';J*B<YU'1TU.YWQC%$UF?/@+*1 B(@(B("(B
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MY"^_,9_W;E4WP5OOJQ_,IOX5;+67W(7WYC/^[<JF^"M]]6/YE-_"B87*1$1
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B H>VR:O$A-BMLH+0<U3V'
M()ZF9[N9] [5U>U#5WN<M0IZ-[?LG5 B/_\ =MZW_P"@[_,HNV::0=JBY23U
MCG-M],X.D..,KL_$S].3_-<W69[6MZ/AZSU]3TG!]!BQXYXAJ^5*](\Y^>C>
M[)-$^.RLO5VA/BL9S3Q/;PE/XQ_LCJ[3YN,U+YAC9#$R*%C61L :UK1@- Y
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M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 4->$D/\
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MVY:L=K;Q2*KEBI#;:BM9O1MC$0#PTG@T[V>/G4C0ZOT7(S[5?]/;G9XW"/\
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MMLG7U1_3I'KWEMHV-C8UD;0UC0 &@8 '8OU$61Y 1$0$1$!$1 1$0$1$!$1
M1$0%^/>V-CGO<&L:,EQ.  M/JC4MLTU0FINM0(\_$B;Q?(>QK?\ 7DJ^ZVUU
M=M:5C**ECD@HG.#8Z.(EQE.>!=CXQ[N0^M;6GTM\W/I'FB9V2!K?:_343YZ+
M3D;:J<#=\;<?M;7?V1^%Y^ \ZC/3^FK_ *\NTU0"]^^[>FK)\A@X\>/6>/Q1
M]2D'06R!L9%9JP-D.,LHV/.!^FX?L'TJ8**DIZ&ECIJ."."GC&&1QM#6M'<
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M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!>-;4Q4=)-4U#MV&%A>\]@
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MN;(XF045),W,4#1Q<XMY.<YQ/$]0""(Z7PGX'5X;5:8D91$XWXZP.D [=TM
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MUEN%S<V>-5FK6=NS'KZO1:30VX7H\F6(F;VY<HYQ'GMO[_@LHUH:T-: &@8
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M*T#G@SO?&\^B1O'^T.Q<:NWT=#>655ZN-+037:T5D71W6E8X=+(>.)(L_&D
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MHVG[4[M;[2Z!ENL4<$(-3*6,:Z2,2$@ $DG//')H4R[(M&2:%T7!9ZBK;55
MD?-*]@(8'.ZFYXX&!]:):G2N@]!Z O=##2P,9>:L.\5GK7%[WEN,ACB-T.X\
MA@D94DJ)O";K[?1[,JAE5*UEQDGB=08=B02M>"7-ZQAN]Q[^]=5LBU!/JC9S
M8[M6'-5-"62N_&>QSF%WI+2?2B'7HB("(B B(@(B("(B B(@(B("(B#3ZR^Y
M"^_,9_W;E4WP5OOJQ_,IOX5;+67W(7WYC/\ NW*IO@K??5C^93?PHF%RD1$0
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B+XFEC@B?+,]L<3!O.>XX ':2@Q;U<Z>T6V>MK'[L40SWN/4!WDJ"
M:RJNVN-0M#6;\K^$<;?B0L_EVE9FM]25&J;PVEH0]U&Q^Y3Q-YR.Y;Q':>KL
M'I4C:2L=+HO3U16W%S!4;G25,HX[H')@_P#7$^A)F*QO*:UFT]F.K!U-64^@
M="MHJ*4"OE:8XG#@YSS\:3T?R"A."TUM5:*RZQQEU+32,9*\]KL_^6?T@MQ=
M*RX:]U>T0M._.[HX(R>$48[?,,DGSJ=[9IB@H-,&QM9OTSXRR5Q'%Y(XN/?^
MSAV+B32W$,DVCE6.GM>TIFIP#3TI//)>8FWJCYY1Z]Y1QL.T]TDT]\J69;'F
M&GR/POPG>@</25,:PK);(+/::6WTH^TP,# >LGK)[R<GTK-73TN&,&.*/,\3
MULZW4VS>'A[/ 1$6PT!$1 1$0%!OA)_[U8/T)OVL4Y*"_"1DB=6V6-LT9FCC
MD+HL^4 XMP?-Y)5;]';^CO\ XA3W_I*&474Z1T'>]54LU3:X8A3QNW#),_<#
MG=@X<<</I6_]YK5/90?KS_)8>S,O?Y>):3%::7R1$QZT;JT>Q7[VUI_^;^]>
MHD]YK5/90?KS_)3;LXLM5I_1U!;+AT?C,._O=&[>;Q>YPX^8A7I$Q+S?TCUV
MGU&EK3#>+3VHZ>R72HB+*\2(B("(B#A-MM3)3[/JT1$CII(XG$?BEV3^S"K,
MK;:ZL9U%I6X6UA FE9O1$\@]IWF_6,>E5.J8):6HE@J(W1S1.+'L<,%I' @K
MM\,M'=S7QW4L\D1?H!<0&@DG@ %TE6V9?;F_3\=@BF?XB9C+T3!Q>XXP#VC(
MR!VGS*9=EVS&.VMANVH8FR5W!\-,[BV'L+NUW=U>?ELME.@*:Q6V"XW.G;)>
M)FA_VQN?%P>36]CL<SZ%(RXFJUF^^/%RCQGS7B/,1$7-6$1$!$1 1$0$1>-;
M5T]#2R5-9-'!!&"Y\DCL #SH3.W.7J][8V.?(X-8T9<XG  [5 &U?:A]E626
MC3<KFT!&[/4@%IF_LMZPWM/7YN>NVH;1ZG4E8ZW6.6:&TC,9W,M=5$]HY[O8
MWZ>P=1LGV7"$,N^J*8].'!U/1R?@X_">.WL'TK<ICKBCMY.ODXV;4WU=NXT_
M3QGY^98VR#9GTG0WS4<'D<'TM)(/C=CWCL[!Z2IR' <$1:^3).2=Y=+3Z>FG
MIV*"(BQLXHHV_P"F?LA9(KW2LS44/DS8'%T1//\ NGCYB5*Z\ZJ"*JII:>H8
M)(96%CV'DYI&"%EP99PWB\>"MJ]J-E)T6\UK89--ZEKK9)DMB?F)Q_#C/%I^
MCZ\K2-!<X-:"23@ =:]76T6B+1TESYC:=DC[#--?9G5/V0J&9H[;B7CR=*?B
M#T8+O0%91<MLSTX-,:2I*-[0*N0=-4'KZ1W,>@8'H74KS6LS]]EF8Z1T;V*G
M9J(B+49!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 5>M1ZGUO#?*V.2:NIMV
M5P;%%%AK6YX8X<1CKZU85%:MME;5W\5:/=9K3^O7/]6?Y+4Z@N]\N;(6WRHJ
MI6QDF/IFXP3SQP\RM:HC\(7_ '*R_P#$E_8U9*WB9VV8[4F(WW0JB(LK$+H+
M)?M26^A$%HJJV.E#B0V)F6Y//J7/JQ&Q#[A8OG$G[0JWG:%J1O*)O=9K3^O7
M/]6?Y+K-F.H-75VJ8(*Y]744#@[I^GCPU@P<'..!SCSJ:T6*;Q,=&6*3'B(B
M+&R"(B"+*W:]+2UD].-":OE$4CF=)'0DM?@D9!SR.%(UJJA=;/25<E++3BJA
M9*:>H9A\>\ =UXZB,X(6:N1V@3:RIA;I]$4UNK&LD=XY2U3MQTC>&-QV0!U_
M5SXH(]V]:'H;5:#K?3$4=KOEIECG<^G:&-F;O!IRT<,C.<]8R#G@IIH)G5%#
M3S2,W'R1M>YOXI(SA<;);+]K&&GI]56^DM%H9(R::ABJ?&9*IS"'-:]P:&M9
MO $@9)QC(&<[;:"=2-TM4G13:=UZRWHA/C&[GRL;W#..W@@Z-0VW_P#:F?\
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M7>KJ64CX !/3N=E[7]0:/PL]6/\ 0J#]<ZPN>O;Q3P0P/93A^Y2T<9+BYQ/
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M'3][(R3]9(^I;FSDIL6/65U+1,WZRI@IV=LL@:/K4!S:@U-> \-JZ^9I/%L
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MGM711'=UZ^)'-'^CMDEJL\C:F[O%SJA@M:]F[$P_H_A>GAW*26M#6AK0 T<
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MULF*6Y?;J;)X-G:.(_O-'TM':LU<,S2;J[\]EM$1%A6$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MO#(V-XN<XG  [\KHO<AJ3\CW#]65UM+JIP4[/=S+S'&.#QJLW>6S17ERB?\
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M$6'3SA9;A!77B.1@+GS"4D9X^2/)^I1W>KE)<GPNG?&71,Z-HCB;& W).,-
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M6+SS_N9%=U"94\^#CK7Y:S^LO]A/@XZU^6L_K+_85PT0W4\^#CK7Y:S^LO\
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M$!$1 1$0$1$!$1!I]9?<A??F,_[MRJ;X*WWU8_F4W\*M_>*(7*T5U"9.C%5
M^'?QG=WFD9QU\U%.RW8C'H/5+;TR_/KB(7P]":01_&QQSOGL[$2F%$1$"(B
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M[A^IQ5]$)$1$0(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M=Z2MJN1V9:\MNO[!]D;:UT,T3NCJ*9YRZ%^,\^L'J/7YP0NN1 B(@(B("(B
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M>X%=>JP::\'F^VW7M'55%PH_L-1U3:AL['GI9&M=O ;N.#C@ \<#O5GT!$1
M105J_:C'=MK.F-+:>J=^BAN,9KJB)WDS/!_HP1S:.OM/FXSJ@(B("(2 "2<
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M"ND7/;0[/)?]#7VU0#,]522,B':_&6_6 @H7I>E9<-36FDFXLJ*R&)^>L.>
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M&#Q+6N));DC'($XX'FH4VQT=3;]I-\IJZOEN-5'(SI:J5H:Z5QC:2<#@!QP
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MAD_[[I7_ (=3^V-=AX)/WM*S_O*7]W&N/\,G_?=*_P##J?VQKL/!)^]I6?\
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M64TVZ=R9AD+P [EGJ(ZBK46':&RYV^>_5E!46?34<0#):^/=GJ)3Q\AC2?)
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MV.'>#P*(@TON)TK^;-D]0B]E= !@8')$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
/1$0$1$!$1 1$0$1$'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g762905g38i22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g38i22.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_[1\(4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'D
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !D     $  0&0
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             %2@  ",D          0
M                   !              C)   %2@
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   %2@    !29VAT;&]N9P
M",D    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  !4H     4F=H=&QO;F<   C)     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !@ * # 2(  A$! Q$!_]T !  *_\0!/P
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M8Z1=U#*R7/?E7.IH]ME5N**0YQW-]EL_X)[?TFQ'ZS;DU>D:'WL,/GT*#?\
MN?3:#_VWO_[XJV!TOZP4=1JOR^I?:,=C'BQFP-W3&UFWZ/\ PGK?39L]+_#6
M*QURCJ%E3+L3/;T^J@/=D/<T.!; ASB[Z'I[7I:7T2+/0^32%O5VBNHY.6Y[
MPVP6#$K@-VNLV6MW?SCMS:_W_4J5_HUN7:VYV4^YY! :+Z!1 C78UI=ZGN65
M9@]?J]7U.OL9Z#!9;-;1M8=VVQ_[K/T=BT>C=/ZQBY.19U#-^UUV!HK;MCW
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MY1-2%4?\)M=?ZI?U;ZD8V=D,8RQ^6&EK)VPQUM;?IESOHM1/\6?\YU/X8_\
M[L+/R/\ \G6'_P"'#_Y\O6A_BS_G.I_#'_\ =A2D5RV0#I/_ +J*,9,O;D=S
M")/UB__3]3LK9;6ZNQH?6\%KV.$@@B'-<#^\H8N+C8=#,;$J9117(956 UHD
M[CM:W^445))3B=;&;6[>_,IIQ+;\)F.RRISR+1?N>-U+F._3N]#9N_1_\3_/
M*X:>N2V,O%B?=.,_B#]']<_>VJ\0#H1/?[DZ2G$OZAGT=4Q^F69^*V_*8YU;
M#BV[G%NHV;<DU;=C+O4WV?Z+]]7/1ZYN/ZWB[8$?JSYG6?\ M8KVUN[= W>/
M?O\ ^26?U&GKKLBNWIF12RL-VV4Y#"YI,_S@]+9;N_Z]L24T\'J>9G9N7A8_
M4,1]V&[;8QN-=+?S'>IOR6,_G6O_ )M[U<>WK-5;[;<S&#*PYQ(QK##1[O\
MN8[W;54-?UOF6OP&/-?Z0[+"POWW;?1]WJM_0?9_4];U6>I_-+0Z:WJ0HL'4
MS6^XV.VFH0S9ILVM,N;_ &W/24T.DY_4.K80R\//Q+:R2W<S&MVR/^-RJG_1
M+/S5+J.9U/IN+]HRLW%9V$XUVPN#76[7.KR;G5L<VM_OV?\ ;CUL!H:(  'D
MDYK7"' .!['4)*0X>9C9V+7EXK_4HN&ZM\$2./HO#7(Z8  0! ' 3I*0VMQJ
MF/OL8V&-+GNVR8:-W_?5S75\NF_&ZDVAMKOM%.,*&MIL,P76;6;:]OM8_P#,
M75JAU+JC<,UXU#/7SLB1CX[2 3 W.L?);LJK24\I]4[AB=2LNR&6UU&I]6\T
MVQO%E8=7/I_39L?O7GWU7Z/UG%^L?3;<GIV937C95=U[WX]H#*RY^VVS]'[6
M>UWN7K^1U'+P,5N +:LCJQ8ZVZP@5555N<YUF7=H6-IH_E^^Y2Z1EY%SG9!R
M:[\"BL5ORW -=:]FXW6/8&U>AL=[O\)5Z/\ QOZ)*>%^M-.3E=;SKL;&R+:\
MDCT'-HMA^VFO?Z?Z/W[-KMZN_7'U,O\ 9S\>FZQF/C[+G"FR&.)K:&O<:_;N
M<NQP<O.ZEF_:JXIZ928J%E1#[@YG\\QUD>G7N/Z)[?IL]2NVM1R<W+SLS[#T
MPM;723]IRK*R^L/K<S]6K^C79;_I6[OZEGJUJ8YY'@T'ZL4/LX5F3&,D# D@
M2K;PU>0OJR#]2<7IS<;(=FUY1>_'%%N\-]2UV[;Z?[KFJW_B]L.&_,.55=2W
M+^SC'<ZJP-?_ #WN8_9LV?I&>]=3U7J5U-C,' 9ZN=;M,;7.976XFO[1>Y@.
MQFYOM5W$KNJQJJKWMMM8T-=8UOI@QIN%8+MB'OR]N4*%2/$J.,1X:)],1$?X
M+__4]4,P8T/8G42LY[^IC W.RL5N2ZR*[0TBH@N+6L][WN=9L_\ !5H/8RQC
MJ[&A['@AS7"00>6N:5G8WU:Z%B].'3*,-C,-KS8*I<?>9]^]SO4W^_V^_P!B
M2D3?^<P+"^_!+0X.MTL'M!=Z[6Z_X.6^F_\ [=6H^^AC"]]C6L'+BX :#=S_
M %5FM^JO0&R6XC1N;L/N?]'NWZ?YWY_[Z)7]7.BU5V5LQ@&W;#9[GR36'"IP
M=OW,<SU'_024Z)( DF -22H/R,=C&V/M8UCM6N+@ 1&_VG^HW>J%OU<Z)<]S
M[,5I>\DN<"X$DC:?HN"3/JWTAF\-I(8][;0P.< U[ [:ZK:X;/YQ[DE)\JW-
MWXYPWX_HVN L-I=):6N=./Z?MM?_ "/W%4R<CJ#<^]K,S%KH:TFNEQ MW"MK
MCOG^;;7_ $C=^D_1_P CWHV=1C>IBM?TYV=L.UEL5/\ 2AKO>Y^5:RW^TW]]
M5,IC#U/)=^R77.V>[,W$2-C=HJAI?OW_ *)WV;])[-__  :)V"E8^3UES+O5
MS<%Q#'FOTSPX!_N?N^BRNUOO_P""_EJ1R/K *:WU/PK@=+G!SO;[WMLN8Z6L
M]*ENSV;?4^FJ>)7377D.9T)],5NEKB3O_1N:VIHVN_G&?J_M;_X'Z2;,HZ=Z
MS*3T7)?94[=6]H'NK8_=9%OJ.]OZ6S]!;_/?S:"FR_+ZX*FG(R</%<W</I"+
MFAM+FVTOL+O2V[[OIL?_ (+]%_A%N5[]C?4(+X&XMXGOMG\U<WB8N)NJ;5TB
MQN+>YKZKBYS75^HVCU/28!ZF*VOTV?X2K^9M_P +Z=%W2,8UC&L8 UC0 UHT
M  X 24R5?(QFEMUM,495E98,EK YXT]G_&['?X-6$DE/,].Z.S.:238,&QWJ
M9+[ 6WY5P=N:;SM'IXE?^!IJ_P#/OJ+6ZIAUVLQG"FZX8U@<VG'>UG .W>+K
M<>O8SV_G>K_H_P#"+0224XV;U*NZL]/OP[ZG7 -%8MQ6/()]H8W[9[M^QS=G
M^$][$V/US$KJ95CXSS6QL- OQ7>UK3J7.S2YVVNI_P#VVM.S"P[;O7MI8^X-
MV![F@D-/YH)_K*#.E]-KW;,:H;V[7':-6D%FUW]ER2FA@=1H(M=T_I]UC;'F
MU_I68SF[G<N;^N;6[W,_,_POJ_X7U5KL<7,:YS2PN )8Z)!/YKMA>SV_R7*%
M6/12Y[JJVL-AEY:(F$5)3__9 #A"24T$(0      50    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      $N34T *@
M  @ !P$2  ,    !  $   $:  4    !    8@$;  4    !    :@$H  ,
M   !  (   $Q  (    >    <@$R  (    4    D(=I  0    !    I
M -    &0     0   9     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C R-#HP.#HP,2 P,SHS-CHU,P   Z !  ,    !__\  * "  0    !
M   (R: #  0    !   %2@         & 0,  P    $ !@   1H !0    $
M  $> 1L !0    $   $F 2@  P    $  @   @$ !     $   $N @( !
M  $              $@    !    2     $X0DE- _T       @
M /_A 39%>&EF  !-30 J    "  ' 1(  P    $  0   1H !0    $   !B
M 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R 3(  @   !0
M  "0AVD !     $   "D    T    9     !   !D     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#(T.C X.C Q(# S.C,V.C4S   #H $
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MABZ=[F[J)'*UJO3_ (7?)-NT5%3*<4-.)PQCF)KVE6EN;N  YEP
M
M
M
M
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MB@EMM4Q%W8)'*Y)$7@["M3JRG/L+7RX\N'EB-3'8BLQ;:W@ <+0
M
M        5'M UAJZGVF4.EM));=^IH_&$6L:N,HKL\4[F]AT7&^;6-.TDEQN
MEJLMSHH$5\L5&]R2(U.*JG#YSKOO]Y^P?HM_[)"YS>TQ6(Z?1$,%HC5%!K#3
MM->+6KNAERUS'XWHWIP5J]_\,&=-<]G>H%T5HW:=74+6/BM]Q_V9CDRW?<NX
MGH]C[A(M.;+:G4&GZ6^7_4]\34%;"E2DD%0C(X%<F4:C,=6>)%L41,[GH1*Z
M@4/:M;ZIDV8:NI(WK4ZCT_,ZD=5-9Y3V(JITF.MR(BD>LM'IN\VJ*ITGK^Z4
MVL%:U^+C5*QBR<-YKFJW&.?+/4(PSUW)MLR"G]L6KKOI^P:8M#[C2T%SN[DB
MK;@SV$#6HWI'LSR15=V<B#7V736F;3)>-%;1*N>_T^)'15%5TK*O'-JLW>L5
MPS,;-MF2-:EJM10ZCT]%9::*6U2R2)<I'IQC:B-W53C^,>[2-Y9J'3-MNT;=
MQM7 V7=[%7FGNY(#M4GFBVG[,XXI9&1R550CVM<J([A'S3K*4K^;0M4%"5]L
MN.I=OFJ;'%>JVW6U:2GFJ/%GX>YJ1QIN-5<HW*ORJHG4>FT6ZKV=[9+%8K;=
MJ^LLEYIY'/@K9.D=&]K7+E%X=;4]U2_A??KK9M>0*2BHZW:IKO4M+<+K74.G
MK%4>)Q4]%)T2S2(KD<YSL+V?L,]I33&H](WN[T3:^6X:1DI%?3R5<V]/!*B>
MQ3M3G\7?FLXXCO/4VL\&N^P_1TNK])4MVOE\O">*5+XZ.*GJ=QK6M=O*KN&7
M*KE<G/D>>IU+:M<ZMOC=7ZM?9K%;ZAU-0T5//T+IL*J+(Y<+GDG_ ,0OX/68
MWV-MD"*Z-U<FI;SJ.CCI'01VBI;3(]SLK(JIE5QU(59H6_TE)KJ71MOU+)?M
M,76D>V"1TJNFIGXPK=]$3FF?B]+8?HVVLUKJ>J26N62SW'HZ=%J'8<BL5/+3
M[9>/6/"BL3LVM?0=5J*JH[@[5=+%33LK'LIDC3".@3&ZJ\5X\R3&OFD:NI?L
M9VE2OJ)G2QUM6C'J]55J(UN,+U'JT5LXJM9:$M=VOFIKPRNEI6^*,IIMR*G:
MB89E,9<N$157(MCCK,SHVOD%;[ +_<;_ *!22\S+45=)524BS+[)Z-QA5[^.
M/06096KRS,)  5      ,9J:^46F[%67>YO5E)2LWWJG->.$1.]55$])DRFO
M"@>YVE;'2*Y4IZFZ1ME\R(XOCKS6B$26R[;4=:T[;K8DM6G;3*F_3,K&K++*
MQ>**ODKP5,<>![],Z^OMIU53:7VBT4$%;5IBCN%*OU&H=[7"XPO'W>HM.G8V
M*"..-$:QK4:U$3"(B(4]X4;&PZ+M-RB7<KJ.Z1+!(G-JJURKC]5%]!I28O;E
MT=ER HG:A#<;MMETA:*2XU5 VOMSFSO@?NJC,R.?CJ1<-5,DGO.B;I8=(K:=
M(W^2CIIJGI*RLN52KI8H5PBMC=NX3DO/W2OAQJ-SW-K/()M+U7<-.732U/;T
MA5ERKTIIND;E=W'5V*4WKRETQI2U.N6D]>7&34<#FN8Q]9TR3+GBBM1N$]/
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M<]=(VO4 &"P
M
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MU=VN^VC4EXNUGK+8RIH(^ABJ&*BM8BM1J*N,95$SCO+O G+O?3K)H !DD
M
M
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M(T=[%%7EE4X\#+FO^A;=J;U\-5-]6Z3IX%IGUSTI>%1'NHJ,:F?)5$X9])L
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M8PI.
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M.\EEMH:>VT45+11-B@C3#6I_\XJ0%MH:>VT<=+11)%#&F$1.OO5>M5[3T@
M
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M/GR<F>*+W*>O2.I:34EN2HIEW)F\)857RF+\W>3J=;1N-Z9P $)
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M1[<]%I6VFLM%PI(JB.>EJ4XIECE1S7?;-7CQ[B_Q>G+H@ !1(
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MQ>+?M7IUM7N-@-(ZEI-26Y)Z949.U$2:!5\IB_-WF-Z<O6&M+\W26= !FT
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M^Q5MSJ;I2ND>Z>IF21TZN;N^6JIG@BKC&.98A2\Q.HCZ$  ,T@
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M$1.T1&G( $@     $)VP_65-^7C^438A.V'ZRIOR\?RBU/-"MO+*B  =3E
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MQ.W"X53V.)RQCQS:7D\-BG+DB(;*VB%]/::*&9<R1PL8[SHU$4]8!\L^G
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MVG8.$$L<\+)8'MDB>U'->U<HY%Y*BG,S2
M                     J3;?*^MU+H#3R9=37"YI+4,1?9,C5BX7NXK[AR\
M)"Q4U=H&IN4LM0R:WL7HF1R;K';RIG>;U\CKVY,=;]3Z U%NKXO07+HJAZ?:
MLD5B97W%]TSNWB&6JV67J.EC?,]S&[K8VJY5\I.2(=%9UR:_]U5]6&M^E+A8
M]EZMT5<I*>ON$<,LM37U"N2!N[Y2L5>#2$:SM6FM/6.IN5KVCW&74T$2R1.;
M<DF6:1.;5:WEGBG/ADE6UNU7NX;)+!#::>JJ(HO%W5U)3Y226)&<6X3BO''#
MYB.7FKL-PT;<;;H'0%:RNDI7L?43VY(N@;NKO*KURKG8141$YJ7IOO\ ?_VT
M?1D]:ZNOD^R31MS\9JZ2"X21-NU;1(O2Q1X5'.3'+.%7/;A.L\^GK?0>/6VM
MV8:ZGJITJ$\;H+C6JJ31XXKN.1%SRZCWVFNU+;-C^C:JP6Y:^FITZ*Z6Y]/O
M32QHY45&HJ<.2]76A$]94UGUG+0PZ T9=;;J#QACGUJTBTL<#4SG>PN%7D36
M/I[_ /I2SNU#2-#7[;-*P35%>UMV;,Z=8YU:K%:SAN+]KRX]IZ-HVHT9K.W:
M&^B*33UCHJ1DE96],J33)A$2-']JHO\ $R6U]U78]>Z(U.ZWUM?;[>DT=3XI
M$KW,5R(B+CT_$8[6]L?!K6VZ^BTY)?K)<:)D591.IDDF@3#5:_<7/%$1/C3/
M$BL[BN_3^XP55J&SZ NMHK=&ZSGO%NEJ4AK;945*S)NN1?JC>Q4PGQ$JNC:_
M:3M-N]@6[5MNT]9(F)/'1OW'5$CLXR[LX?$8Q]73ZMO=KH=!Z*AH*9)4DK;A
M<;2QC&L3.6(BHO'EQ1<YP96YMK]F^TRZZA]2ZVY:>OD;5J'T3%DDII&9XJSL
M7/;UKV#_ #H8*X:9K-+[9M$4CKK67&UJLBTGCC]^2'")O,WNM.2IV$Q\(ZG<
MW9[ZJP+NU5IK(*J)_6B[^ZJ?_5\1%*S4-?J_:_HROAL=SHK-3ND;#+50JQTB
MJB;SE3[5.2)QXDJ\)"I<NSU+3 BOJ[M60TL3$3*N\K>7Y*>Z1UYZ;/HLFTU:
M5]KHZQJ82HA9*B=F\U%_B>H\MJI$H;91TC5RVGA9$B_BM1/X'J.:5@ $
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ME*;1FEZ6S4DKIDBRZ25R861Z\W8ZO,2,Y[:W.EX  5
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M;!$D<?!J<D(KOZEN7_B[#YS/I\1,%U!$P?0
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MM)6ZNBJG05E8L+D=#'5U+Y(XU3EAO+W<EC M%[1&HD$3"83D "H
M
M
M
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M #!N
M
M
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M=I$1'8 !"0
M
M
M
M            !@       8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                      .'31?[
MQGZR";^A?^*IIGL\T[=M<WVJM]+>IJ1\3%EWI'O<BIG&."G1AP1DB;3.HA6U
MM=&YK9&.7#7M5>Y3D:K:UV<:JT+9EO<6I))HX7M1_12R1O;E>"IQX\2\-BVI
MJS5>@Z6ON?&L9(^"23&.DW5]E[BIZ4&3!%:<];;@BVYU*<@ YU@
M
M
M               ^.<UC5<Y4:U.:JN Y4:U7.5$1$RJJ:O:CU%J':SKF2Q:=
MJWTUHC<Y&HCE8Q8VKQD?CBN>I#;#AG+,]=1'=6UM-G(JNGF<K8JB%[DZFO15
M.XUAU5L9OFD+/+>[)?)*F:E3I96Q-="]&IQ5S515SCL+:V'ZHNVI-+.^B"FJ
M&5U*_<Z>2)6).Q4RCDX<5ZE\V>LODP1%.>EMPB+==3"Q  <RX
M
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M*R:"5J/9)&[>:YJ\E14YH=H
M
M                  >"_P#2>H=PZ'^E\7DW?/NJ:[>"BK/HEOJ.QTBTC-W/
M/V?'^!LNYJ.:K7(BHJ85%ZS6+5&E-2;+=:OU!I6F?56M[W.:C&*]K&N5<QR-
M3CA.I?,=G#3%J7Q[ZSV9VZ3$MF:N>&EI9IZI[8Z>)BOD>[DUJ)E57NP=5MKJ
M.X4S9[=4PU$#N3XG(Y/B-9-5;4]6:VM;K%;;&^G\93<F\78][Y$ZV]R+UEP;
M#]#3:+TQ(VXX]4ZQ_2S-1<I&F,-9GK[?.I3)P_A4W>>OHF+;GHL4 ',N
M
M     /CW(QCG+R1,E>T.U:VU;Z61EIO#;;/5)1>/NA;T+)E?N(U5WL^RX91%
M0L&9%="]J<U:J(53#I.\LV7VFTK1_P"WP7:.IDB21O"-*I9%=G./8\0,_P"N
M10NNCH8K5=I;8RJ\3?=&1-=3ME1=U47RM[".\G.[C).2C[MI._R:CFFL]@FM
M5W=6;_JO0US8Z26/>RKI85=ESMWR53'%>.2\$SA,\5
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M#?7.$1.;@-Q0
M
M     !Q;&QBJK&-:J]B8.0
M    QVHDNJV:J^A]:1+IN_4/&L]%O?XL<3(@"J]W;)[?1W^M\PW=LGM]'?ZW
MS%J "J]W;)[?1W^M\PW=LGM]'?ZWS%J "J]W;)[?1W^M\PW=LGM]'?ZWS%J
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MOF+4 %5[NV3V^CO];YB3:'36R3U7T:NLBP[J=!ZG;^=[/'>WNHEP
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MY<YW>JJJF;  &K=W_ODM_*4__2M-I#5N[_WR6_E*?_I6@;2
M
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MGL6JN5:WVJ*O4F$.JVZ%TU;+NESH;130UC7*YCT;PC5>:L;R:JY7BB)S DH
M
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M_P"E:!M(
M
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M:MI+M>ZU\L71*RNK'2L1,HN41>OAS)P
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MIK^L7S](/^0PS8
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MH\=I?NF'WQ!X[2_=,/OB =X.CQVE^Z8??$.4=1!*[=BFC>[L:Y%4#M
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M\_XH;H&G\-^OVW+:I8YJ2WK16RV/:]58JO; U'(YSG/PF7*J(B(;@
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M>6W2U<L"NKJ9E/)G",9+TG#MSA#U
M
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M>I]47:T6=5GCM\,<KJMJ_4Y%>YR89VHF[S3A[A+@*L]830'WKJ/A<GSCUA-
M?>NH^%R?.6F *L]830'WKJ/A<GSCUA- ?>NH^%R?.6F *L]830'WKJ/A<GSC
MUA- ?>NH^%R?.6F *L]830'WKJ/A<GSCUA- ?>NH^%R?.6F *L]830'WKJ/A
M<GSCUA- ?>NH^%R?.6F *L]830'WKJ/A<GSCUA- ?>NH^%R?.6F *L]830'W
MKJ/A<GSF9TELHTGI2\1W2R4,T-8QKFM>ZH>],*F%X*N"=
M                                             !B=61W2735RCT_(
MV*[.@<E*]V,))U9RBH98 :Y^N+M<TFJIJK1[+I2M]E44[,<./6S*>ZAPH]L6
MS.]5F=5Z4\1KL_5))Z)DB9SUJGE>ZA<>T_6D.@M*R7NHHI:V-DK(NBC>C%7>
M7&<J4)?-OVD+ZS<O.S]:Q/\ UI8G+[N,@7OHO5>B;A"RFTG<K3NJO""FW8US
M^)P7XB8&CR:QV<T]^HKO:]&7>W5%+,V9C(+@SH\M7ENN1>'I-GMEFUFQ;0^G
M@H&S4=QA3??25&-Y6^V:J<'(!88       ,3JS4%!I>P5EXNTO1TM,Q7KVO7
MJ:WM5>2&C.T&NOFI+K0ZOO[.B9=YE2CB5?80QN1$Q_ARJ^=452W?"JJK[<-4
M6FT0VVNKK#3,;520T\+U;,]55%1SFHN,(BHG9O*5?M6UG<]3R6-EQTYZAQVY
MG1T\*,D8CVY3@B.1.6.H"^?"VO<]NV=4-O@D5B7&=&2X7&\QB;RIYLX(5K+9
MA8+=X.UNO=+1M;>6T\%9+5Y7>DWTRYJ]6,.Y=R'BVY7NZZSV3:?OMVM3K9/!
M<)H'0*US<-5B8=Y29XX)[K^ZTR^"O02131N;/;Z6F;A>;\(U4\Z*B^X!'':V
MKG>";TR3R+7K*EJ6;>\I$Z3M_$X'DTGLNL-?X.U?>IZ-KKT^FFK8JM57>9N9
M5&IU8PW'I,0ZSU#?!&2I5B[JW7QWS1])T>?=+(T)>*6+P6*V996(VGMM33/X
M\GJCFHGG57)[H'=X(M\GN.SVIM]1(KTMU0K(LKQ1C_*1/,BJI;-ZU38K'4LI
M[S>*"AG>SI&QU$[6.5N53*(J\LHON%+>!K1R0Z/O54]%2.:K:UBXX+NMPN/2
MI-=J.QRS;1+Y2W2ZU]?334].E,UM.K-U6HYSLKO-7CER@27UPM'_ (3V?X6S
MYS7A]QH[KX7<-;;*J&KI))8-R:%Z/8[%,B+A4[%14)C]*[I;[\WGW8OY"N=,
M:6I=%^$[;[!;YIIZ6DEC5DDV-]=^#?7.$1.;NP#<0         \-VJZJCA8Z
MBMTM>]5PK(Y&,PG;ERH(C:)G4;>/6WUI7?\ -G_L,TWDA!]57>[3:;N4<^G*
MF")T#D=*ZIB5&)CGA'94RB7N]8^M:K^%0_S%N65/$C[_ -)20'10RRSTD4M1
M3NII7)ET+G(Y6+V93@IWE6D=0     .,CV1L5\CFM:G-7+A$.10NT;4U3>+S
M4TK)'LH*>18V1(O!RMX*Y>WCG %K:4KZ2:JO+(JF%[GU[E:C7HJJFXSE[B^X
M20U8C>Z-[7QN5KVKE'-7"H7ELLU%/?+1-#7/62KI'(UTB\WM7.%7OX*!-0
M                  '1</ZA4_DG?L4\>EOK9M/YI%\A#V7#^H5/Y)W[%/'I
M;ZV;3^:1?(0#)@
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M*N>]3L]6;7]\J+W]OS@>\'BCNUNED:R.OI'O<N$:V9JJJ^;)[0
M
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MR\7.PJIZ3+;&]BZ:)OM7?KS715UUE5Z1)"U4CA1RJKERO%57. +D
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MHWHJIYT-9ZB:6HF?-42/EE>N7/>N55?.>BSW*IM-?%644CHY8USP7@Y.Q>U
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M\R':4G6^B0 $
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MGOX.4_Z[OG+) $ MFQW0MLN%/746GZ>.IIWI)&_><NZY.2\5)^
M
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M\45%RBA+Z
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MVDV/;#5ZQKYM(7#H;(Y6] SQN-F/)3/!4SS O@U=V.?WG-5_DZCY;#G]#?A
M??;_ /?1?,87P=(;I#MZNL=[D1]S92SI5NWD=O/WF9XISX@;<@     !A]6:
MAH]+V:2YW)E4^GC<UJMIH'2ORJX3R6_M S *M]?'2WW)?_\ EDIUS[>-(T\3
MI:B&^11-YODMLC43SJH%K JU-N6EE1%2DOZHO7ZF2#U\=+?<E_\ ^5R_,!:0
M.BWU<=?0T]7 CTBGC;(Q)&*UV%3*91>*+W'>
M
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M] &<
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MSUU])_=M3\#E_E G8/#9+K1WNUP7"VR]+2SIO,>K5;GCCDO%#W
M
M                 ^/8V1CF2-1S')A6N3**A] %,:\\'G2^HII*NTN?9*UW
M'Z@U'0JO;T?5Z%0KJ;P=M:4KECMVJ('0(N&_598N'F15-K#B^1C/9O:WSK@#
M6>S^#+5U=0V756IWS-3G' Q7.7_C>O#W"\M#Z"T[HFD6&P6^.%[D1)*A_ERR
M8]L]>/HY$H          &/OUZMNG[9+<+U6PT5%'[*65V$3N[U[B%:>VSZ'O
MUT;;Z.\-CJ7NW8^G8L;9%[&JO "Q0=574P4=+-4U<K(:>%BR22/7#6M1,JJK
MV%=TFV_0-5=_4]E]C:Y7;C9WL<V%R\L(]> %D@^*]J,WU<FYC.]GACM*WJMM
M^@J:\+;GWR-7H[<=.QCG0M=G&%?R_@!9(.JDJ8:REBJ:65DU/*U'QR,7+7-7
MDJ*=H U;N_\ ?);^4I_^E:;2&K=W_ODM_*4__2M VD      #A/*R"&2:9R,
MCC:KG.7DB)S4"O\ :U=974]+8*'+JJN<U7M3VF>">E4^)3P;2-6P;)]GM%'#
M#T]9*U:>'=<C5Z3=XR87GA5SCS'7HZ1M\U7<]5W!6QT-(BI&K^3<)A/<;Q\Z
ME#;==05.KY*F[-8]+=3SL@@1>36KO*W_ (EPJKZ#3'29B;?2&.7-%+5I];?^
MVQ>GM8VFNKY&7.CKY;G5S-Z"H21J-8]555<]..]E24Q;7-#,TRVR/T;7/A3R
MEG6>-)5?UOWL9SP]S@4QIGZY+5^=,_:8U.LFV:]IZRK3A<5(Y8JV>M5OU!8]
M-T%_LL'JGIJX0,JW4=1&DO1M<F51[>I<+C?:2&PV?0.OXE;31.LUW5,NIXY,
M)GEY*+P<GF1.98.QE$79+I%%1%1;7 BHOXB&&UULHH;Q))7V)Z6VZ9W_ ",I
M&]WF3V*]Z&^/B9^LZGUC]7-;AKX.N'K7^&?TE')=E^J]//6326H'O8G'HG/6
M%5]'%J_$?(]?ZZTUAFI;$ZJA;PZ7HU8JX_QMRWXC[I_:->=(UR6;7E+,]K>#
M:I$R_'4O8]._F7';;A0WBA954$\552R)P>Q=Y%-;\1:/G5BT>O\ W#7!DIE^
M7.ICZ>G\D!L.V33EP2-E<L]OF=P7I&[S$7\9/XD]MEUM]TC5]MK::J:G-89$
M=CW#"7W0.FKUO.K+5 V5W%984Z-V?.W&?20*Y[%GTTBSZ9O<]+)[2553_P"M
MN%^(SY>&R=IFL_?K#?>2/NN4%'-K=I^DL>,P+=J*)%RNZDJ*U$YJY,/])C-3
M;9+E<;))0TE#ZFUSU5DTS9,JUO%%1N4RB]_43' 9+3^28F/6)/&B.ZWM%5$,
M]5J3H)HY,71^=QR+CZG'\RDF-/\ 1VI[AI6[MK[>]79X30N7R96]B]_?S-I=
M):FM^J+3'76Z5,+PDB<J;\3NMJH1Q7"6P_F[PIP^2+UU]6; !Q.@
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M>*?&!9(/);;E1W.G2>@J8JB)?MF.R>L
M                                                    :N['/[SF
MJ_R=1\MAM$:N['/[SFJ_R=1\M@&T0  %9[=_[#M'Y^WY#BS"L]N_]A6C\^;\
MAP%197M&5[0 @RO:,KV@ ,KVC*]J@ ,KVGUJKO)QZSX?6\T\X%[;'_L?6S_,
M_>.)D0W8_P#8^MG^9^\<3()
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M[')E'-7**@'(
M *J(BJJX1  *<M^T34FL-I#K;HNWP+IBU5*17*OGX=+A<.:S/?G&,JN,\"S]
M4Q7.;3UPCL$D45U?$J4SY5PUK^I5X*!E 4YLQVB:@;JQVBMI%%'2W]6=)2U,
M28CJFHBYY<,X15RG/CP3!<8                   #5W8Y_><U7^3J/EL-H
MC5W8Y_><U7^3J/EL VB   K/;Q_85H_/V_(<685GMX_L*T?GS?D. J( !
M   'UO-#X?6\T O;8_\ 8^MG^9^\<3(ANQ_['UL_S/EN)D$@
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MT^U=Z"=V'55HO;42BJV=-C*Q/\EZ>A>?H S@
M                  '36,=)1SL9[)T;FIY\*=P IWP7YX(M%W*TN<U+I07.
MI95QK[)%61<*OH_87$5%K_9+55^I)-3:%OLFG[]-_6%;QBGQUN1.OAQYY,#)
MIC;C5-6EEU=:H(EX+41L1'>=,,R@'JVJ3P7';SLWMUOW77.DDEJ*ES.;8<91
MJ_JN]TO$K?99LKI-%U-3=;A6S7C456GU:NGYHG6C$ZD7KZRR
M        &KNQS^\YJO\ )U'RV&T1J[L<_O.:K_)U'RV ;1   5GMW_L*T?G[
M?D.+,*SV[_V':/S]OR' 5$  @     #ZWFA\/K?9)YP+VV/_ &/K9_F?+<3(
MANQ_['UL_P SY;B9!(
M                !6.DOLZ:X_,Z3]A9Q6.D?LZ:X_,Z3Y(%G
M               #P7Z6W0V6NDO:P);&PN6IZ?"Q]'CCO9ZL&JT.UO9_H[44
M]5HK1,<KLJUM9+-T2XZ]QJHJM3W"S/"WK*JGV9,AIE<D%35QLG5/:IQ1%[E5
M$)!LCT)I"ET'9YZ.U6^N=54L<LM5-$V9TCU;EW%R+CCE,)R P&Q;6.A=6ZGN
M5RMMN2WZMK<R3-J%WWO:B(B]&[EC")E$P76:J;8+):=&[:M(U6D8XZ.NJ)&2
M34L"X:U5?N[R-^UWD5R8Y<#:L                   .E])3R/5SX(G.7FJ
ML154UJNL;$\*OH48U(?&Z9.CQY/]31>1LV:SW7^]E_\ YE-_T:&E)GK[(ELB
MVCIF.1S:>%KDY*C$3!W@&>TA%=I-Z]1M,SK%)N550J0Q8Y\>:^A,DEJJB*EI
MI:BHD;'#$U7O>Y<(U$YJI3-MGEVC:V:^IWFVN%%>V)>&(D7@GG<JHOF7N)UT
MVK-NNF:V.Z5Z!CM07"/ZO,W<I&N3V$?6_P [OV)WD4\)C7E1#%3Z'TUOS7FY
MN2.I;$OE-C<F&QIWOSZ$3O+5VAZKH="Z/K+O5(W=@9N00)PZ21>#&)Z<>9"F
M?!NTC57^]7':/J=BRU-;*]:+?XIE7+OO1%ZDPC6]R*)G92O+"U=CN@Z?0&CX
M+<W=?73+TU9,B>SD5.7F1,(GF)/?+HZU4K9FV^OKU<[=Z.BC1[T[U153@9$\
M=TAK9H$;;JJ*EESE7R0](BIV8R@B-RLK?:=J>>Y;/M0T46F=11/GHI&(^:F8
MUC55.;EW^"$F;K21&I_^%-3_  1G\YB=HJ7>WZ,NDEQO=(Z!\2Q]&VBW5D5W
M!&HN_P %4SMOCOM?1055)?Z*2"9B/8Y*#FB_\9KX4<L6W_G]D;^S/6RK6NH(
M:E::HI5D;O=#4-1LC.YR(JX7TGI.FB9/'2QLJYF33HGER,9N(Y>U$RN/=.XQ
M2   >"^6:W7VWR4-XHH*RDD3#HYF(Y/.F>2]Y[P!K5J_87>M+7!]^V5W2HCE
M8[I%H72;KL(N=U'9P]/\+O=-;*^JK9*ZI?5RSMJ72N65JN5N'Y7>3'5QSP/T
MFD_HW>93\W]1_7%=OSR;]XXF!X6R2-SNR2(O<]4+@\&W2='K&Z:CH[C-.Q8J
M2)\,C'9W'*]R9PO!4[BG"\_!)OMLLVL+O#=:Z&DDKZ:**F25VZDCT<Y5:B\L
MX4F+36=PI>E;UFMHW"QY='ZZT*]\VF:Y]?0,5%Z)G'/GB5?V&8T_MHB9/XKJ
MNVRT,S<HZ2)JJB+WL7BGQEPHJ*B*BY13#:ATO9M00[EVH(9U3D_&Z]OF<G$V
M\:M_F1_-Q_A+XO\ ;WU]IZQ^\/59[S;KS3I/:JV"JCPBKT;T54SVIS3TGO*3
MO&R"XVF=:W1EWECD;Y20R/5CN''".3@OF5#HHMI>J=*U$=)K2TR2Q9W>FW=Q
MZIVHJ>2X>#%NN.=_Y(XRV/IQ%>7[]X7F"+:6UY8-2-8VAK6,J7)GQ:;R)$]'
M7Z"4F$UFLZEVTO7)'-6=P  A8          'ENO]EUGY%_R5,?HGZSK%^8P?
MNVF0NO\ 9=9^1?\ )4\&B?K.L7YC!^[::1\N?='U9D*B*BHJ910#-*+WW0.F
M[TCUJ[7 R5RY66!.C?GSH0"OV,5-!4/J=+7Z>E?]JV3+7=R;[53]A<X.C'Q6
M7'TBW12<=9[PHUM]VDZ/W676@6Z4;$XOW>EX9]NWBGI0SMBVU66J>L5XI:BW
M291,XZ1OIPF4]PM54RF%Y&!OVC[#?6*ESME/(_\ WC6[CT_XDPIKX^')\VFO
MO'[*\EJ^6?ZO9:+[:KPQ'6NX4M5E,XCD153SIS0R14%VV*4['K/IV[U-%.BY
M:V155$\SDPY/C,9TFU'22-:YJW:CC]JB3<./7A'C\-CR?*O_ "GH<]H\T+R!
M4-BVV44CT@U!;9Z&;*(YT7EM1>O*+A4^,L2Q:JLE]8BVJY4\[NN-'8>GG:O$
MQR<-EQ>:JU;UMVEF@ 8+@       .BLHZ:MA6&L@BGB7[61J.3XR!WW9?05*
MK+9YWT4W/=7RF9[NM"PP!4+;GK/1Z[MPA=74+<*KG9D:B?CIQ3TDKT_M%LUT
M1K*F1:&H7ANRKY*^9W+W29.:CFJUR(K5YHO6174&@K+>-^1(?%*EW_FP</=;
MR E,;V2,1\;FO8O)6KE%.14<NFM6Z4>LMBK'UE-Q^ILX\.]B\/<,E9-J$72)
M3W^C?2RIAJR1HJIGM5J\4^,"R@>2VW*BN<"36^JBJ(^V-V<>?L/6
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MZWFA\/K?9(!>VQ_['UL_S/EN)D0W8_\ 8^MG^9^\<3()
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MIV1X7MRTF:QK>_\ /[&VL]/?-I6Q&:&EOD'JUIAKMQCT57L1N<KN/]DQ>Y_
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MIZ,EI6._VN^TZ36FN@J6=:,=Y2>=.:&=\5J=X=&'B<6;R3U]/JR8 ,VX
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M/K9_F?O'$R"0
M     -/-;?7OJ/\ 2$WRE-PS3S6WU[ZC_2$WRE/1^%_.GV_9AG\K#  ^@<8
M    $NV0?91T_P#C3?NG$1)=L@^RCI_\:;]TXYN,^1;V:8?/#:X 'R[O
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M.L3FHL3D5?&6<."GBTC<KO'I6S,BLCI(VT<*-?XRQ-Y-Q,+@E=T_LRL_(O\
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M                   !J[L<_O.:K_)U'RV&T1J[L<_O.:K_ "=1\M@&T0
M%9[>/[#M'Y^WY#BS"L]N_P#8=H_/V_(<!40 "      /K?9)YSX?6\T O;8_
M]CZV?YG[QQ,B&['_ +'UL_S/WCB9!(
M        \E3<Z"FE6.IK:6&1$SNR2M:ON*IU>K=J^^=#\(9\X$6UAHBZW^\+
M646L[Q:(>C:Q*6E:S<14YKQ3.5,'ZUM__P#U*U'^K&6+ZMVK[YT/PAGSCU;M
M7WSH?A#/G HYVF-2)M0CTMZX6H.@=;'5W3X9O;R/:W=QV84EGK6W_P#_ %*U
M'^K&=#[G0?3#03^/4O0>H$C>DZ9N[GIF<,YYEF>K=J^^=#\(9\X$3TEH:[V*
M\QUM9K:\W6!K51U+4M9N.RG-<)G@3PQ_JW:OOG0_"&?./5NU??.A^$,^<#(
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MZE52-BT[VHN$55XJF.2*6*8RDT_9J.H9/26BWP3L]C)%3,:YOF5$RADP
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MU6TQNF[!;].VUE%:H&Q1I[)W-SUZW.7K4RH!SS,VG<I  0
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M6O154[RJ=';"=+:3U)17NV5%T?5TBN6-)IT<SBU6KE-U.I2U@
M        &KNQS^\YJO\ )U'RV&T1J[L<_O.:K_)U'RV ;1   5GMX_L.T?G[
M?D.+,*SV\?V%:/S]OR' 5$  @     #ZWV2'P^MYH!>VQ_['UL_S/WCB9$-V
M/_8^MG^9\MQ,@D      1O6U+JBJI:=-'W*WT$[7JLSJRF69'-QP1,*F"(>I
M&US\*=._\M=_,!:8*'UQ=]J>DH;5)5:@L,Z7"NCH6(RW*FZY^?*7RN7 DOJ1
MM<_"G3O_ "UW\P%I@K&FM.U=M3$M1J?3SH4>BO:EM<BJW/%/9=A9R<N/,
M                     #5#:[]DN_?CQ_(0B)+MKOV2[]^/'\AI$3U\'RX?
M(<=_N+^X #9R@    #*:4^NNQ_GT/RT-R33;2GUU6/\ /H?EH;DGF\9YX]GT
M?P?Y-O?](  <CU@T\UM]>^H_TA-\I3<,T\UM]>^H_P!(3?*4]'X7\Z?9AG\K
M#  ^@<8     $NV0?91T_P#C3?NG$1)=L@^RCI_\:;]TXYN,^1;V:8?/#:X
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M64L\DL:-5$8JN8N,+Q3T@;=@  5GMW_L*T?G[?D.+,*SV\?V%:/S]OR' 5$
M @     #ZWFGG/A];[)/.!>VQ_['UL_S/EN)D0W8_P#8^MG^9\MQ,@D  $/V
MA[1+'H&.A??W5")6*Y(NABW_ &.,Y[.:$+^F-T-[>Y?!5^<AWAG_ -6TI^4J
M/V,-80-S_IC=#>WN7P5?G'TQNAO;W+X*OSFF )T-E-K.V/2NJ:;3S+8^LWJ&
M[0UDO20*WZFU'9QQXKQ3@3OZ8W0WM[E\%7YS3 #0W/\ IC=#>WN7P5?G'TQN
MA?;W+X*OSFF &AN?],;H7'L[E\%7YRV;1<(+K:Z2X4BN6GJHFS1JY,+NN3*9
M3S*?FL_V#O,?HCLU^Q]IO]'0?NT($C    IC;1KC4&GM6T5NLE9'34[Z%*A^
M84>JN61S>:]6&H7QX[9+<M>XN<BVLDUBL]-]![K,V'==T_C^_O9X8W=U.7,H
M?UT=9_?>+X*P>NCK/[[Q?!6?,=7X#/Z?W1S0M;<VL_[S27^M\QA+SJ':?:;_
M &*TU'T,.J+P^6.!S$EW6K&S?7>X=A!/71UG]]XO@K#%7/6>I;E=[3<ZNYM=
M5VM\CZ9R4[$1JO;NNRG7P'X#/Z?W.:%U[FUG_>:2_P!;YCUVENTU+G3+='Z8
M6@WTZ=(>EW]SKW<IS*>]='6?WWB^"L/GKHZS^^\7P5@_ 9_3^YN&T0-7?71U
MG]]XO@K#ZFU7643F/==(7HUR9:ZF9AR9Y<")X'-$;F#<-H0?&+EC57FJ'TXT
M@  U0VN_9+OWX\?R&D1)=M=^R7?OQX_D-(B>O@^7#Y#CO]Q?W  ;.4     9
M32GUU6/\^@^6AN2:;:4^NJQ_GT'RT-R3S>,\\>SZ/X/\FWO^D  .1ZP:>:V^
MO?4?Z0F^4IN&:>:V^O?4?Z0F^4IZ/POYT^W[,,_E88 'T#C      EVR#[*.
MG_QIOW3B(DNV0?91T_\ C3?NG'-QGR+>S3#YX;7  ^7=X
M  8/7,5SGT?=XK"Y[;J^G>E,K';KDDQPPJ\@,X#3B^4NVJPVFIN=WNMPI:&G
M;ORRR5C,(GN\^K!TZ9;MJU);8[A::V]/HI$S'+),V-)$[6YYIW@;F@T_T/==
MIB;4+58;_>KA25"2MFDI:Z;<Z>)%X[G##N"+R[%-P
M &MUT_O1._2-+_T)=MVM>I:BODEMNI:>BI5QN0.MK95;_P 2O3/N&OEQHKNG
MA!OI7W>)UU]4*;_;O%$1O]3RGU+>QP3"<^\#:<$7M]HU3#6PR5NJ::IIFNS)
M"EK;&KT[-Y)%QYR4
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MFHY?3@"+;'-+3Z.V=6>S5JM6KA8KYMWDCW.5RIWXSCT$S  &KVQU<^$YJO\
M)U'RV&T)J[L<_O.:K_)U'RV ;1   5GMX_L*T?G[?D.+,*SV\?V%:/SYOR'
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MLBVOH1]P %4@
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M;1&KNQS^\YJO\G4?+8!M$  !6>W?^PK1^?M^0XLPK/;Q_85H_/V_(<!40 "
M     /K?9(?#ZWV2 7ML?^Q];/\ ,^6XF1#=C_V/K9_F?+<3()  !K5X9_\
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M88 'T#C      EVR#[*.G_QIOW3B(DNV0?91T_\ C3?NG'-QGR+>S3#YX;7
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MKRWL ;F@
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M2G_Z5IM(:MW?^^2W\I3_ /2M VD
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M^HHDF&QW[*FE?S]G[%)'Z!@ @
M        -7=CG]YS5?Y.H^6PVB-7=CG]YS5?Y.H^6P#:(  "L]O']A6C\_;\
MAQ9A6>WC^PK1^?M^0X"H@ $      ?6^R3SGP^MYIYP+VV/_ &/K9_F?+<3(
MANQ_['UL_P S]XXF02  #6KPS_ZMI7\I4?L8:PFSWAG_ -6TI^4J/V,-828
M       'Q_L'>8_1'9K]C[3?Z.@_=H?G<_V#O,?HCLU^Q]IO]'0?NT D8 (
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M_P#I6FTAJW=_[Y+?RE/_ -*T#:0
M
M   U*VZ[--8W_:7<[E9K#45=#*V-&2L>Q$7#<+S<BFVH T,]9O:#^"]7[Y%_
M,279CLJUO:MH6GJ^XZ=J8*.FK&22RNDC5&M3/'@XW.
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MF        !\?[!WF/T1V:_8^TW^CH/W:'YW/]@[S'Z([-?L?:;_1T'[M )&
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M                   !JW=_[Y+?RE/_ -*TVD-6[O\ WR6_E*?_ *5H&T@
M
M
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M=W_ODM_*4_\ TK0-I
M
M                                            -7=CG]YS5?Y.H^6P
MVB-7MCG]YS5?Y.H^6P#:$  "L]O']A6C\^;\AQ9A6>WC^PK1^?M^0X"H@ $
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M)%F;'T:+OMSC&5Y><W8
M     !J]L<_O.:K_ "=1\MAM":N['/[SFJ_R=1\M@&T0  %9[>/["M'Y^WY#
MBS"L]O']A6C\^;\AP%1  (      ^M]DA\/K?9(!>VQ_['UL_P SY;B9$-V/
M_8^MG^9\MQ,@D  &M/AG_P!6TK^4J/V,-8C9[PS_ .K:5_*5'[&&L*$P
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M3_XTW[IQS<9\BWLTP^>&UP /EW>
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MM,LB-WMS?8K<XZ\9R1#8[LXCV;6>MH(KF^XI4S)+OOA2+=PW&,(JY)^
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MUV>SV^JD=(MLGZ.)7+E4C<F\C?,G%$ N\
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M<3(UJT)X0FE]/Z7H[;5T%XDGAWMY8XHU:N7*O#+T[3/-\)[2"\[9?4_R8_\
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MF$0[                 !I6_2='?/"4N=BORR,HY[C+(YJ.W5E:J;S6HO\
MB13=0J#;%L9CUI=8;]9+BZU7^)&HLN%5LN[[%<IA6N3'!R 4_M<TU0;+MJ^F
M*O1+9*5TR-E2G217[J[^XJ(KESAR+C"JO$]]I:EN\+YZU2HQ)ZJ9S55>:R0K
MNI[JX)MH+8770ZJI]1:^OTEZK*946&%RN>F\GL5>]V55$YHB8XF>VR;'FZWN
M5+?+-<5M=^IFHU)=U5;(C5RWBBHK7(O)R 5;X32.NFV32]LIL.GQ"Q$3M?*F
M/V&UR<$0HS9EL1K+3JUNJ-:WIUXNL7&)JY?AZ<$>Y[N+E1$X)PP7F
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M)QX<B_M!:4H=%Z7H[);-YT-.BJZ1^-Z1ZKESE[U4"0
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MP="6@"(MV:Z,:JXTS:^/_H(%V:Z,545=,VO*?^@A+@!$EV;:,5%1=,VK'Y!
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MB(B)A$X(
M
M
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ME]/,[P
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M01_BI^P#F
M                                        !0E3?-0['M8RKJ6KJ[UH
MJ[3J]E=(JNDHI'=3N[AR1<8XIQX 6#M2UX_2,-OH;30+==1W1ZQ4%$U<;RIS
M>Y>IJ9X\O.5Q>MHNTK05705>N+59*RV5LJ0I3V^3%0QR]3$WE5^/,J<N*9.6
MW"Z3:<UIH[:3;H$NUFIZ>2G?T+LM1'HNZY'<41%W^"]V.LRFS*SQZCF]<O7-
MQHJN=[%DH:=)4=3VR+GYM_")E>:+W@7+15+:NEBG:R2/?:CMR1NZ]N4SAR=2
M]QW%.^#E55ESBUC=I*BLJ;96W9SJ&6I<YRO8B856JOVO)/07$      =-;51
M45'-55"JV&%BO>J-5RHB<^"<5,'H76=EUM9_5&P5231-=N21N3=?$[L<U>*&
M9N5;2VZ@J*RX31P4D#%?+)(N&M:G-5-5);I=J+5LVO-E.EKU#8I'JM;$L>*>
MN8BY5[6)Q1.?%$X<^U +$U9"_:5M;K]'W.MFI=,V.FCJ:F"&3<=5R/1%1'+[
M1$7_ .9(58-/4,.T]];LEJ*ZVZ>M+56[5Z/=+32JU,K&QG-ZXY\5[>KCV[0;
M?/M"MGK@;,9ZE:^:G\2O-LIWJVH<SAEBXZ^&.7%,*G89*T;48&Z0CTGLZT->
M::\OC6!E/+3XB@5>#GO?S=VY5$SU@7?H;55OUEIZ&\6=TBTDKG,3I&[KLM7'
M%/C])GR(;)M)+HG0EMLLLC9:F)N_4/;[%9'<78[B7@==1/%3023U$C8X8VJY
M[W+A&HG-54HZ7:/KW7%PJ?6KLM'ZATSUC]4[CE&U#D]HBJG#EV]^"5>$A/5T
M^QK43Z!7->L;&O<U<*C%D:COF\RJ2#9.R@CV;:;2TI&E'XA$K=SDJ[J9].<Y
M X[-*G5]58Y':^HZ&DN3958QE(N4<Q/ME\I4X]Q+0N<+CGU%7;#]97G4TVJZ
M'4CX9*ZU7%T#7PMW6[F.")YE1>*\>(%H@        \5KNUONK:AULK:>K;3R
MN@E6%Z.W)&\VKCDJ&"DUK1^N-#H^&&1]<M&^MFDY-C:BM1J=ZKO>C $/U]KN
M\7*]W+1FS^TRW&ZQ0?[96I4)!'1J[DB.5.+L*A']E>OK]I2Y4VC-JT,E)5OP
MVWW&=^^V=/:.D1515[%SUX7OX:9O<&S3;+J:T:F5*>AU#,VMHKC)Y+%7&-QS
MEY)G*>?SF?\ ";BM-;LW?'520+<WSQ);41461TJO:F&=:\%XXZ@+>1<IE.0*
M7V*:IOEMOU3L\UKOR76BITGHZM5ST\'#@JKQRB*GQYY<;H          XRR,
MBC?)*YK(V(KG.<N$1$YJIYK5<J*[4,5;:ZJ&KI)>+)H7H]KN.."H!ZRC-;:R
MU/KYE[L&S&US/IJ23H)[TVK2G1)&KE61JN,\L+QY*619]84M\UE?]-TD,J.M
M,3$GG=P17OX[K4[$14X]I56PJ_4^AK]?-G^IG-HJ]*]]113S*C&53'\MU5QQ
M\G*=N<=0$AV2;1Z^6N^@_:%3NMNJJ9J)&Z;@VL;[9J\E=RY+QZBWRC/"9H*"
M\)I6@M]1'#JR>Y1QT4L:_5(XUSO.7=XHU%W5R2'8CK>Z7Q+GIO5D+HM361R1
MU#L<)F?:O\_[>"]8%I         '1<*VFMU%/65\\=/2P,62661VZUC4XJJJ
M!WG"HFCIX))IGHR*-JO>Y>341,JIQI*F&LIHJFDE9-!*U'LD8[+7(O)44AE'
M?H-H>FM7T%I1\*0OJ+4V5ZXWW]'C>3L3+OB K#5FJ]=;3;?(_9I:*JDM-%5;
MT-S\=; ZK5B\FM=C+<]2]WF)WLBVE_14V6RZCI_4O5U"F[4T4B*Q9$3_ ,QB
M+U=J=7F([X.6K:.BL::#O*);M169[X70389T[=]5WF9YKQX^A>LP>WJUK>]J
M&F8-%5<=/K%D,LKY8'8=&QC5<WI%3EE>"9[>P#8H$!V+ZZDUSI9\UP@\6O%!
M*M)71<L2M1,N1.I%[/.3X
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M_BI^P#F
M                                    5/5R4VQZ&[WR\76^7BBNUP:[
M<>G2,HVN7BY51.'GX9PB(F0,]M3UV_2--;Z*U42W'45UEZ"@H\X1SNMSEZFI
ME/=,1IRVZ_O535VO:51Z=JM.U5.JO;2[V\CE5,,Y]7//N*1C;16RTMTT9M,T
M^QMVL]N5R5'0KO?47X\M.SAE,]2XR6M9]::<O6GVWBCO%&MO<S>=(Z5&='VH
MY%XM5.\"D')4;';C+8[^U;SLRNDBQ,>].D=1.5<*Q_=RS[J<<DLH=@>SZM?'
M<*'Q^2V5.[.VECK7>+R-7BG?C"]O6>3P>[;37K26KJ6LB=<-,UEWG6D2L:K^
MFB7"J[CSXX7/:7514L%#20TM'#'!30L1D<<;=UK6IP1$0#C;J&FMM%#1T$$=
M/2PM1D<4:8:U$ZD/0    'R1[8XW/>N&M155>Q"$:EM=;J:JTY?=-:G?1V^D
MEZ>9D2(^.IB7GU<5X8X]J]9,+DM,E!4>/R,CI58K97/=NM1JIA<KU<S4FNH[
MWLWU2O2)J2DV:4]X;*CHI4SGV64W<YC7/_%CM MW6.I+9M8V3:MM^C*A]171
M,6-8)&K&]58]%Y+U*C5Q_ D&PW5MLU1H"UMM[FQU-#3QTM33<G1/:U$7AV+C
M@I"=?:*FDJX-I6R.IC==5;TLM/3JBQ5T?7P3&7<.*=>.U#%:7TMI3:I)+J+3
M-QN6D=51KNW&GH)-QS'K[)5;A%5%7/%,=_$#YK&@NFG=OT#]F;8'7.OI?&;G
M;WOW(I&H]J*KNQ51<YY\%7KX[%Q[VXU9$1'JB;R(N4R0G9QLWMFB9*RLCJJR
MYWFMQXU<:U^_+)CJSU)W$X X3RL@ADFF<C(HVJ]SEY(B)E5*,=K37NTFZUT>
MS%U%:=/T<BQ>JM='O+4/3@J,3#N'H\ZEJ;1;;67C0E_MUK>K*VIHY8HE3K<K
M5X>GEZ2B-"[9J71^@:#3/T,W)VIJ!JTWB#('-1[T5?*5<9XKQ5,9RJ@6YHFT
M:KN&E[I:=I[[=6K,KH&/I4W>EB5.*NPB(G=P1>'$J:S7746P.Y3VN^TE3=M#
MS2J^FJX&HY]/E>OEA>66KP[.L]U'H#:-M(<M?KO4%3IZAD\J.VT*X5$ZLHCL
M)Z<KYC,[&JR\677>I=GU^N<E[HZ*%D]-4U'E/1CN"L=E5X8QP\_:!W7[PA=,
M+;DBTBE7>KW4)NTU)%3N3#UY;^<<,]F3/;!M%5^D=,U=1?W(M]O%0M;6(CLH
MQ5Y-]"<^]2=V^QVJVS.FMULH:65W!SX(&L<OI1#(       @.VNXZALFC_5G
M2[VJ^W3LJ*N!6HJSTZ>S:GNY\R$^,#3ZGL5RU#<--QUT,MTIHT6>D=P7=<G5
MGV7!>..60*,N%OJM&/I]IVRYKJG35RC;4W6U<_(7BKVIU8RO!%X+W<L._:?1
M>O0_5]CM==>J.>RQL=!2M^JPY5-[>3N5,*3W9J]=GNT2Z;/Z]5]1[DYU?9'R
M<4PN=^'LX8Y?.8?7.B;ELOU:[7VSVB\:H7Y2YVIC>4:JBN6/'%$X9X9PO'EP
M YWC:WLLV@4#;5K"CKJ;CEK*NF<CF.[6NC5513RW*R[/-D%_M%TDM&I+O43L
MWZ25R+.RFX<,(N[Y2\L+E4+PHZ2V:BH;?=:VSQ=.]C)XVUE,WIH5YIG*914,
MV!4&S2T7C4VT"NVAZAH7VR%]-XG:Z*3^D;"JY5[TZE7'+O4M\         "M
M-M-WN>GX;/=41L^EV3+37NE5B*KX941B.SSPU5Y(5S417'8;>&WFP])<]FUT
M>U\M.U=]U(KN*.;G'#"\.U."\<*75!>=.:XIK_8Z:K@K4@5]%708XL54PO!>
M:=CDX93N(/LCG6@DO>S'4Z-J9+8U?%/&/*\;H7YW>Y=U%1JI\P%>V3:E1Z>V
MDZVOEOL]PO=IN$D#_&:%N>C3HF^R1<8Z_<,]=]>;)-JSZ6WW^"MAN*N2*GZ6
MG?'.USEY-='GKZE//]#UXV(:W]4--4-3=]&W>5L5131,5\U,]?8XQQ7'4N,8
M7'/"E]^H]LDN$5R=;:3Q]F594.@;TK<IA?*QE. %#JFA=C.LNAI]/ZENU[F@
MS!5N;T_/E&Q55$3JRJ)P)OL=TS>([K?M9:J@;27>^O:K*-JY\7@:B(UKO\2X
MSS+1          J':W=*FUZPL]/J5(ZK0-[C=;:F%S,)#.Y4W7N<G'CQ\W$M
MR61D43Y)'(UC$5SE7J1.:D'N::<VNZ"N5%;JV*KHYT?$DK4\J&5N41VZO%%1
M>/>@%9VNONFPF_Q6N\22U^SZNDQ25>-Y]$]?M7=W!?VIUH1S9EM5@T0S4K:F
MQ72XVNHO$\Z5]$Q'L;G=3"Y5.I$7GUEF[)K@S6&B[EHW6M.R:[6ERT-=!-Q6
M1B>PD3SICCVH1W1MOONQW6L>G8J&IN^CKU4*M-411[TM-(J<4?CJPB9541,)
MGM0#C57C9+MEO%)!.VNAU _#(G-BDAJ.'4KFY;A._D>2U7[2NRN^W>PZ4TGJ
M*X:EDPQE1/'OK5*O'V:JF&(O8G'!?M/9K937!]?3VZCBK7M5CJAD+6R.:JY5
M%<B9QD]P%>;%-(7#2^GZVIU Z-U]N]4ZNK$CY1N=CR$\W\2PP
M
M                             $-VJZ%CV@:92SS5\E U)FR]*R-)%X=6
M%5"9 "F]EFPRFT#JQM\BOT]<]L#X.B?3-C3RL<<HY>PN0       '36P)54<
M].KMU)8W,WL9QE,9.X :YT/@NT=)64\[=553NAD9(C?$VIG=5%Q[+N-BV-W&
M-;G.$P?0
M                                  "';2M?T&@**WUEUI*R:DJJE*=\
MT#,M@1?MG+^Q.:\28F+U!!:+C;YK9??%9*6J8L;X)WHF^B]G'/N 1/:!M*I=
M/V>V26"F6_76\+NVREIGY2?AE7*Y,X:B=A";?M+N3+HFE]L>G(+=375O1T]3
MSIY,\%8[/#K3BB\%7JYD+K;!5[#]I-FO%6ZHN&B&.DAIY?9NHTE1=YJIPXY3
M.>2IWFP>J-/V+:+I%:6LZ.KMU7&DD%1$O%JJF6O8O;_\4"FJJ&OV(7>1LL<E
MXV9W1^XZ%S>D\15W:BY16KE>'VWGYRJBV(;.+WT5WML$LEMJD25L-/6/Z!^>
MQ$7EW'MV6Z;U1;:.\Z1UK%3733=.Q(J&KD=ET\3L^0J=B)PX\EY9+/HZ6"BI
M8J:DB9#3Q-1C(V)AK43DB(!PMM!2VRAAH[?3Q4U+"U&1Q1-1K6HG4B(>D
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M'.1K5<Y41J)E57J*'N6VK4D\]9==,:/EN.CZ*1T<M<Y5:^3=7#G,3/+/<OH
M]NIJF[;0]K%=HZCO%79K'9:9D]:M(]6353W\F[R<4:G C^H="7?8U42ZOT-7
M5%=:F<;G;:ARJKX\Y5^]UXX\53*9Z^)VWJHJ[A>+?M9V6L]46.B\7NUL=PD<
MU.:;OMD1>I>I%3*9.>H]M3-9Z>JM-Z1T[>)-17&)U*Z&I@1L=/O)NN5SL]60
M.=5>8KAJ:P;3M P3UL=4]ELO5N@;F54=[%7-3.'-7=X]F#8#"+A53OX]1K?8
M]-2[*]K^C;=8JE7P7VEZ*Y4B+O-WF-XRIGDF4S[O4;(@
M
M
M
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M]S6,<]ZHUK4RJKR1"AIJS5FU^NN%1IF_SZ7TC02/ABJXL]+6R-YORBIAG+K
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MIP9G#E3O5,(9O97I.^_1#<M:ZX6-M^N$2004D:Y;1P(N=SSKPSYN\"T
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M,<_'%43L,@!7.SG9[56>[U&I=77+U9U34LZ-9]W$=-'_ +N-.I.\L8
M
M
M
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M-<GP1.<QK=QB(F$\E$+<<YK<;SD3/:H'T
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M5)3:)O.I:>SLEHZ.[);:?,JITZ<E?RX<0+G!TT,_C-%3SJW=66-K\=F4R=P
M   "@+!MNU9J1*M^G=!27&&FF6&22&HX-<G4N>["@7^"CZK;5?=.]'4:WT#<
M[7;GO1GC,3VR(S*\U3)<%KO-!<[)!=Z.I8^W30I.R95PFYC.5SR R *1J]M-
MUO\ <ZJBV8Z5J+\RF7=?62N2*%5[LJGQJA\@VS7S3E;2P;3M(U%EIZER,96T
M[DEB:O\ BPJ\/,JKW 7>#IHJJ"MI(:JDE;+3S,22.1JY1S53**AW
M                              'DNUQI+3;JBON51'34=.Q9))9'8:U$
M*.FVF[0M4I/==GVEV.T["Y6Q2U:?5*O'-S4RG#/#AGEV\#';7KF^Z[6;5IO:
M"LULT0KTDIUB7R*Z3ACI7)Q:W*JF.KTY+8V@:TLFS;2#:J9(VM:Q(J&CA3C*
M['DM:B=76J]@$=L&K$VN;)M0PT=.^@NZT\M'/3*[*LFW.&%YX7../'F53H"[
MW_7MBM>S.@<FGZ>UQ.BO51OHDTK&O5O1QMX*BK]MW\^_IV4;4;?L[MMQDO\
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M[4_4G1MCD=>Z&)TOC]-(^6GC16X<BNZ14SQW>7-2[P
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M,L5'K:IUK(V1MU6F6&25\F6-C1$XHG5A&]7>5TVQ;=45-[56FU[?J'__ "+
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M-55X>;*+@O$H[P4+341Z5O%_JXUC6]5KIHT5,*K454SYLJN"\0
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MC+8%RQ'XXX,H            \,MFMDM>E=+;J)]:G*H= U9$_P"+&3W
M
M           !PFBCFC6.9C9&+S:Y,HIS &/HK);**9):2@IXI43".:Q$5#(
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MM+[J1]&D/U98_:JN[R_XBY=(:<M^D]/4=FL\:LI*9FZU7+ESUZW.7K5>:F8
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M)%$Y?\6&IP\R9+P '10TD%!1P4E'$V&F@8D<<;4PC6HF$1#O
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MA;2_!9/YRPMBVQJMV?:@JKI6:A\>26!8$@BB<QBY5%WG9<N53'#S@7,
M                              !QED9%&^21R-8Q%<YRKA$1.:@<@1WZ
M.-+_ (06SX2WYSU6_5%BN,W14%XH*B7EN1SM5?<R!F         %5$YJ
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MWFX4U%"O!'3R(W/FR>&P:STWJ"=8;+>Z&MF3CN12HKO< SX
M   .NIGBIJ>6>HD;'#$U7O>Y<(UJ)E552I+GX0^AZ.L?!3.NMQ:QVZZ:CHU=
M'GSN5,^@"WP1/0>T+3>N8)'Z=KTFEBXRP2,6.6/SM7J[TRAX-=[5M+Z'ND5O
MU#4U,53)$DS4CIW2)NJJIS3O10)V"H8_")V>.>C5N56Q%7V3J.1$3XBQM*ZF
MLVJ[9ZH:>N$-=2;VXKX\INKV*BX5%\X&8 (]K/6=@T90LJ]27&*BBD54C1R*
MYSU3J1J(JJ!(00316UG1VLJY*&R79'5RY5M/-&Z)[D3LWDPOH)7J"]6_3UGJ
M;I>:EM-04Z(Z656JY&HJHG)$5>:H!D 5KZ^FSG\)8O@\W\A-=,:AM>J+1%=+
M#5MJZ"17-9*C7-151<+P<B+S RH*YU-MJT+IVYOM]?>D?5QNW)&4\3Y4C7_$
MJ)@F.F=16K4]JCN5AKHJVB?P22///L5%XHO<H&5!UU$\5-!)/42-CAC:KGO<
MN$:B<U4P^CM4VK6%G]5+%,^>BZ5T2/<Q695J\<(O4!G   !'XM8V6;64FEX:
MI9+Q'!XQ)$UBJUC>]W+/<9NKJ(:2FEJ*J5D,$35?)(]<-:U.*JJ@=H*OCV];
M/'W/Q)+[A<[J3+3R)$J]F]C_ -BS898YHF2PO;)&]$<US5RCD7DJ*!S
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MNZ<*VFI&,E;G.ZO/=]'(S-+I^STE>ZMI;91Q5;N<K(6H[W<&3
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MBVOJO55+7VK4,38-16E_15+6IA)$RJ;V.W*<<<.SF66
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M5EYW7-IKA<5=%GDJ(KE7'ZV"_
M      !ATTS9DU,NH4MU/ZLK#T"U6XF^K.S/Q9[.!F
M             >2[T$5TM-;;ZA52&KA? ]4Y[KFJU?VFOEAI=I^R""2TVNQ0
MZHTQ%*Y\#HG8F:U555X(N4_55,EY:YI;I6Z0NU/IZK=1W9].[Q:9O-KTXHGI
MQCTE6;,=M=JCM$=EV@5C[3J2WIT%4ZN3=256\-[/:J<T_:!RT[M.TGK;4-NM
MNL=.26B_0R;U''<XE7#_ / Y43"\.M$,!MOO=-IO;WHJ[US)GTU+1R.>V%BO
M>N5>G!$Y\SR;7M1V7:9JC3%DT,U+E=X*UL\E? SR8HDYHK^>.2]G#M,[M'8C
MO"6V>LD1')XI*BHJ9SP>!DZCP@["L#_4^R7^LJ43R(6T3VJY?/C@=.P2RW"S
M0:DUCK&-EGDO-1TK8*AR1I%'G**[>Y*JKA,_Q+HCIH(W;T<,37=K6(BF.U7I
MVVZJL539[W"Z:@J-WI&->K%7"HJ<4X\T0!2:CL=?4-IJ.\6VIGDRC8HJECW.
MX<<(BY7@>6^TM;9[#5+HJU6[U2<Y',A>U(HWKGBKMW''!%;#L5T;IRZ1W6PV
M^:FN<#7]!,M5([<<YJMSA5QUD6V7[2G:?J[KIC:5<I:>ZTE0Y8JJN7"2L5>"
M;W9UIVHH&!H*^Y1;9+17;6Z.6CK43H[6M/NK2,<N>*JBKQRO;S5,DMVEZ-U;
MJ':E9[E87Q4-%24CHDN#U:Y87.WMY49G*KA4P1W:EJ2@VEZFTWIG1S_'Y8*M
M*J>LB3,<3$X+Y79W\LX0E.JM?730^TR&#4K_ /\ "%="B4\[8$^HR(G%%=S7
MBG'N5 ,#JRPZ]V=6Z345KUC6W^GIL.J:2O:JMW.M4\I>'FPIX=NNJXKOH[0M
MZ@@Z2EGJVU:P9XJYJ+EF?/E"0[6MJ&G:_1]99=.5C+S=+M&M+#!1_5%3?X97
M'Q(83:!H&YT6PW3T$,/3W&R/;530L17*J+E7(G;C>3W% SC],[4KQ1^JTFK(
M+76/;TL=KAAS&SK1BNSQ7JSQ,]L6UW6ZLH[E;K_ R"_6B7H*I&)AK^*HCD3M
M\E47_P!SY:-M&BZG3D=QGN\%-,D2.?1R.^K(['L43K[C >#W1UEQN^K=85-,
M^GI;U4[U*U[=U7,1SEWL=G%./G DOA!M1-CNI<(G]%'^]82'9M]C_3GZ/@^0
MA'_"$^PYJ;\E'^]82#9M]C_3GZ/@^0@$C-:MHMYJ=/\ A(07*AM=1=JB&B:C
M:.GSOR9C<BXPB\LYY&RI0ER_O9V[M\1__HO R,FV#5,C',IMF-\2=R88K]_=
M1W5GZGR,'9-(WVRZ VA:HU+&E/>KQ22O\71<K$WRE7.%7&<\NI$-ACRW6@@N
MELJJ"K;OT]3$Z&1O:UR87]H%?^#G%''LDLRQ-:BR+*YZHG-W2.3C[B%E&OFS
M[4K]D5TJ]'ZVZ:*UNF=+;KBK5Z)6KS3S=?<N?.3S4>V?1EIMDE137>"Y5&[]
M3IZ1V^][NI.Y,]8$/LS&4?A67:*B\F.HH-^=K>2N5C%55].%])>Y3>PG3=TG
MNUZUSJ6!T%PO#O\ 9X7HJ.BB5<\EY(N&HG<G>7(
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MZHBIQ"(B<D1/,!#]DVBXM!Z*HK,QS7U")TM3(WD^5V-Y4[N&$[D)@
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M/LG+S5R]ZKE5\YF
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M)4VVQ4%/.G%'LB3*$C
M
M
M
M
M
M                                                       #RW6X
M4MJMU175\J14L#%?(]>I"8B9G4#U K_UWM)?=E1\'<>2Z[9-.06^>2WNGJJI
M&_4X5C5B.7O5>2&\<+FF=<LJ>)7U36]ZCM-DJ:."Z5T5-+5OZ.)KUYKVKV)U
M97AQ,LBHJ(J+E%ZS334%ZKK_ '2:X72=TU1(OH8WJ:U.I$+/V7[56VJD]3-3
MR324T3?]GJ43?<U$^T=UJG8O=@[,OPVU,<6KUGZ_],JYXF=2OP%?^N]I+[LJ
M/>'&<TMK:QZGGF@M-4KYHF[SF/8K%5.U,\SAMP^6L;M6=-HO6>D2D@ ,5D:V
MCZMIM$:/K[[5QK,E.U$CB1<+)(Y<-;GJRJIQ*OM-'MBUA;H+P^_6O3D-0U)8
M*-E.KUW'<6[RY7CC'?Q+!VPZ.DUSH*X66FF;#5OW98'O]COL7>1%[$7&,]62
MH+7M?UCL^HZ>U:]T=63PTK&PMKH,M1Z-3"+G&Z[AWIZ )=H?:%J6VZ]BT1M)
MI:2.XU4:RT%=39:RH1$7R<<>/DNX\.*8P>?:OK?65OVI6;2FCIK=&ZX4O2-\
M;AWDW\OSQSP3#3.:(UYH':7>:.JI((%O]&U74[:Z%K:B-$YK&N5RG'J4K[;-
M?:#37A%:3O%WE6*@I:+>E>C5<J(JR(G!.]4 E"Q;=&(KO&=+O5..[T:IGNYF
M7V/;2Z_5-SNFG=56YEMU/;.,T4>=R1N43>1%SCFG6N<HIXY/"+V>MC<Z.X5<
MST3*1QTKMYR]B9ZS ;"J&XZEVG:GVB5-OGMUMKX_%Z6*=JM=(GD>4G:F&)Q[
M55.H"_BI-I>T>]TNKZ;1F@+?3UVHI&)-/)4*O1TT>,HJIE.I47.>'#GDMLQD
M]NME%65-[2W4_JBD+DDJ(X4Z9[$3.[O8ROL4X=R 4X_:'KS05[ML6TVAMD]D
MN$B0-KZ#+>@>O+>3*YY=B>?@6#MAU=/HO9]<;W0-A?61;C(&RHKF*YST3BB*
MBKP7M*,VG:TEVB:@T_IN_6VIT?9/&6U,E5=V*Q\N$5$1J8PF<]:DT\*N6J73
M.G+;0T=16-JK@Q71PL5V^C,8:JIR5RJB(!X*356WBKI8:FGTI9'0S,21CE<Q
M,M5,HN%GRA:>EK[>:+03KOM&IZ:V5].V22I9"J*QC$5=U4PYW-,=96UQU%MB
ML5L]6)-/V9UGIXT>MNBD<^>.-$Y*N.:(G'&?,>3;!K^EUEX.L]VLZNA;6U,5
M)/"Y4WHW(_+FJOH1?,H'HM.M=JNO(JB[Z,M5IMMB1RMI?'T5TE0B=><I^Q$[
MU)AL<VBU>KGW6S:BH66_4UH?T=7 Q?)?Q5-YJ+RY=J\T[2%Z:UOK";2]OI]G
M&CFU%BMM.R!M75/W/&E8W#EC;V*J<R9['M:VG651=9'62&SZKI'=%<H58WI%
MXXSO81SDRG7R S.TW:+9=!6>2HN%1'+7N3%/0M?]4E=U<$XHG:J\#P["M6W/
M6NA&7>]K!XVZIDCQ"S=:C45,)C)TWS9II^.Z:AU95T[JZ\5$+W1OJ%WF4Z)'
MC#&\DY<^?$P?@F?8BI_SN;]J 7(53M6VCW6SZCMVD=$V^&XZHKV=*B3+]3@C
MX\7)E./!5XJB8]!:QCY+3;&W-;NZWTJW)D:M\:2%JR[N.6]C..X"EJW7VT79
M_74%1M$H+76V&KF;#)54"*UU,JKS7BN4]''M+V@E9/!'-$Y'1R-1[7)UHJ91
M36#:]KVHUO46G2URM-7I2R556Q\UPN\:LZ1K793<1$PGG5?/A#9FUPPT]MI(
M*9Z/@CB8R-R+G>:B81<^8#T@J_PDKK7V;9975EJK:BBJF3PHDU/(K'HBNXIE
M.)#J;9SJK66E(=27W6]UH[K44J5-+2TCU9#3M5N\QJHBIE>65Y^<#8$&LVRZ
M+66UK3\E)>]55MNMEI<M,^6B\F>LDX\7OX<&IA._FO$R^S.OO6A]L5RT+=;Y
M57>T+1+64\E4Y7/C7".YKE>6\BIG'6!L$#6_35'J+;C<[K>:C4EPLFEJ6I=3
M45+0O5CY,<=YRICJ5.*YYXX8/+<6ZST3M6T9IJNU17W&QSU:/II7R.;)+&JH
MCHY>/E;JXQG/!>KD!>6T[4CM):$O-[CW5FI8<Q(Y,HKU5&M3'7Q5"OI==ZIH
M-8[-K+<'TJ.O5'TUQ;T&%Z3"KAO'R<<O0>K;RJWR[:-T9&J_^*7%)ZA,9188
MD5RY[LX,+M;FAH]OVSJ:>1D5/#3S/>]ZX:QK=Y555[$1 +Y!1*WS46V#4ZT^
ME*^ML>B;=-B>Y0.6.6N>G!6QN3BC>?7V*O'"'+:5>+]?-?6W9GHVYU%L8RE2
MHN-P1ROE9'C@F][+.-WCE%57<P+T!K5M)T9JO9GHZX7C36M+Q6471]'6P54C
MG/8CEPDL;LY:J*J=G#MY%W;+JJHKMG6FZJLFDGJ9J"%\DLCE<Y[E:F555YJ!
MYMK^H*[2VSB]WJTK&E=21L=$LC=YN5D:U<IU\%4K'2UUVU:DT];[S;ZO324E
M;$DT220JCMU>U,DW\(S["^J/R,?[UA -ENV_1&G=GM@M%UN,T==1TC(9F-@<
MY&N3FF0/36;2=?;/KW;8]I=NME19*Z1(4KJ!%;T3NM5XKG"<<83.%PI9FTW7
M]NT'IGU4JT\9FF5(Z2EC=Y50]>2)SX8XY*/VJ:PAVV2VC26A:*LJ8$JVU%57
MRPJV.-J(K<YX\,.7*KCDG,R^T&%EU\([0>GJE>DH+?2-D6)Z9:]R(]<X_P"%
MON 9:W4NV;5\"7&>YVS2L#TWX:3H%>_=7BB/XJJ+Y^/<A\H]I.KM!ZBH[1M5
MHZ5]LK'I%3WJD16L1?\ &G'MX\E3BO%"]2LO"/M-/=-D=[6H8USJ1B542JF=
MUS>ST*J>D"S&.1[4<U45JIE%3DJ'T@VPZZ37C95IRLJ7/?,M-T;G/YKNN5N?
MB)R
M
M
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MZ,M%FWD<ZDIVL>Y.MW-?C520
M
M
M
M                                               $1U3LUT?JJJ\9
MOVGZ.JJ>N;"QO=YW-5%7TF3TOI2Q:5I5I].VJEM\3O9="S#G>=R\5]*@ 9L
M #$:DTU9=347BE_ME+7P<T;,Q%5O>B\T]  &$TSLOT7IBM2LLFG:*FJFKELJ
MHZ1S5_PJ]5QZ"9
M
=                                  !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g762905g43d06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g43d06.jpg
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M 0$! 0$           8'" 4$ P(!"?_$ &<0  $# P$$ P<-# <$" 0!#0$
M @,$!1$&!Q(A,1-!40@4(F%Q@9$6%Q@R559TDI6ALM'2%2,V-T)25'63E+&S
M,U-B<H*BP20UT^$T0V-SM,+B\%>$I,,F.&6#XV2C)41&9G:&U/_$ !L! 0$
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M^4'@HEI_2TNC]1"/3L;CIFOWC/1;_@T,P&1)'D^T=C!:.1+2.&41-D1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M1NJ+9=M1Z@;5Q,K(V4=.VF,?2SD_>]XY/6,XY<.)PM#("(B(X&T(AN@=2EQ
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M9"*QC0R1QY-#FN(!/CPIQI[2]OLPJ9 P55?5R.DJJVH:'2S.)ZSC@T#@&C@
M%D#:[9H*C;7<+7H^G!DEJ(F,AIA@-G+6[X&.6'9)[#GL0AMQ5_K7:YI71U[=
M:;Q45/?C8VR/;#"7AH=R!.>>...PA3&YW"&RV.IN%REQ!1P&69_:&MR?X+.V
MBK%L\VBF2ZZIO39-47*=\TM,*LP]'EQW(FAP&]NMW1PRB)]3]T!HFHGCAADN
M3Y9'!C&BD.22< <U:M54P4E++4U<T<%/$TODDE<&M8T<R2> "K2R[#-%V>[4
M=QI*6K-122MFBZ2H+F[S3D$CKXA6>YH<TM< 6GF"$$"N^V'0EK#NGU%2S/'Y
M-,UT^?.P$?.NWH/6%!K:SR72T153*-LSH&.J&!AD+0,N !/#CCCV%9H[K2YP
M5.O:&WP,C#J&C'2N: #O/)=NGR-W3_B*T9LDL?J=V<6"W.;NRMIFRRCK$C_#
M</,7$>9%2Y?B>5D$$DTK@V.-I>YQZ@!DE?M0;;?>/N'LLU#4M=NR24_>T?;O
M2'<X>0.)\R(X]BVV6._OF;8[+J6X&'!D[VH!)N9SC.'<,X/H78UAM)HM*6BG
MN5TLM^[VEA9*YS*08A+C@,D)< UV>KQA0[N3K/WCL[J+B]N)+C5O<#VL8 P?
MY@_TKY]UG>Q0Z!I+4QWWVY53=X=L<?A'_-T:*EFRO:=!M$JKF+=:JFDHZ$,S
M-/(TE[G9P-T<N#2>?8K"51]R]8_N3LP@JWMQ-<YWU)SSW1X#1Y,-S_B5GW6[
M6ZT0":[7"DH83P#ZF9L33YW$(CVHO%:KM;KQ 9[3<*2NA!P9*:9LK0?*TE>U
M 1<2KU?INCJC2U>H;/!4@XZ*6MC:_/9@NRNS'(R6-LD3VO8X9:YIR".T%!^E
M^)G]%"^3=<_<:7;K!EQQU =J_:(*PO>V[2UCKW45X@O%%5M <8IZ)S'8/(X)
MY*=Z7OU%J:PTEXM3GNHJII=&7MW7<'%IR.KB"LC=T1TUXU7<+^TYH8JUUGB\
ML,;2XY_O/?Z%>W<OUG?.R2@CSDTU1/#_ )R__P Z*M=5GJ/;;HVP7NKM5;55
M4E52OZ.4P0%[0[K&<\QR/C!74VKZIJ;%::>VV)O2ZDO$G>EOB'-KC[:4_P!E
M@.<\LXZLK%3K0;AK3[CT$[JE\]<*2.=W$RDOW=_SGCYT(AN?2&LZ'5=LFN%K
MH[FVD8W?9)/2NC$PX_T>?;<NKQ*+WW;-9[!'%)>[#J>WQRDM8ZIMXC#B.H$N
MYJQK=1PV^@IJ.E8&4]/$V*-HZFM& /0%FSNN+C)77_3.GJ7+I QTY8/RG2.#
M&?1=Z4(6Y1[4K564D%33VN]NAF8V1CN]V\6D9!]OV(I98[/36JRV^WQQL+*2
MGC@:<<PQH;_HB(Z:(B#'.U34FL=;[0[U:;(+I-1VZ=]/'1T(>0UK'%I>\-YD
MD9R>W"BOJ*VB^XFI/V4JOG4NK=.[*=JMTJVSFJCOD;7W&BIV[TM+*W);("<-
MP[>.6D@Y.>7!>[V2&B_T:]?N\?\ Q$526@=.ZJM6T;2<^HK9=Z:F-RB:V2KC
M>&;V>67<,\"MK*D8]N5@U/J#3]GLMLJ)IJJX0M<^O@:&Q-S[9N'D[XX8/4KN
M0$1$01$0$1$!$1 1$0$1$!$1!D3NN?QD4'ZLC_F2K4VDOP5LWP*'Z#5EGNN?
MQD4'ZLC_ )DJU-I+\%;-\"A^@U%=5$1$$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$ @$$$9!60-NNQ^KTQ6U-\T_ Z
M>P2N,CXV#+J,GF"/S.P]7(]IT9J[6!L6N='V3[R(;S).R5SP=YNZP;F[QX9>
M0.M3)[&O8YCVAS'#!:1D$=B#+O<^;8:JGN%)I?5%0Z>CF(AHZN0Y="[DUCCU
MM/($\CCJY:C6'MNNF*32^T^IH;"TLAG;'4101_\ 5/?GP&^<9 Z@0M>:YO3]
M.;/[M=9G 5%+1.<#_P!J6X;_ )B$5C7:973ZTVMW4T/WZ2JKA1THSP<&D1,Q
MY< ^=:5KW;27:9BL6G],VVSB.G;2LK)+F)3&P-W<M :,''7QQV*@^YKLAO6U
M:@FD;OQ6]CZU^>T#=;_F<T^9;60E1VR78/!I:Z07K4E9%7W* [\$,(/0Q/\
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M7[K9 6CA[8N(["IGW5.O;E:ZBCTO::B2E944_?-7+&=USVESFM8#U#P23VY
M[57^Q"QUFN]KSKY4QDTM+5.N=5)U!Y<7,;GM+L>8%3_NG;=IV\W^RT<=Q$.K
M9#'2LCP.BZ)[_!,SB?  +B0>)X\L8(#LNT18])=SQ<S<:&F?7S6QT\\\D8+^
M^'M\ !QXC=<YH&.SQE5MW->FI-5W:K?5W2[4]-:#!-"RGGW8W.+R=UP(/ [O
M(8ZU:FMM&;0-=6:AL-SJ;#:[7$6.J9J:669]06C@0TM;@=>[GGCCP4_V<Z(M
MF@[ VV6H/>7.Z2>HD]O,_M/8.H#J])(2E<O5-WCL.F[I=IL;E%323X/66M)
M\YP/.NHJRVZS]^6FQZ6B?B74%SAI7@'B(&N#Y'>;#?2B*JVJ:>DH.YTTO+4
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MYZE?:H:@V!T^F=2Z?O&G[A5UCZ2X125$53N "('PG C'$<.''*OE$$1$!$1
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MF_H,_P 5R>IYOZ#/\5RF'KW7CW,M_I?]:>O=>/<RW^E_UK+ZNR_=AE]9ZO\
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M/G4UW&_FCT+GVB[TETEKXZ!QD91SFGDD \ R  N#3UXS@]AR.HHCHHB("(B
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M?"9*IS@V($8!:UK3GF>L<AS7=1!46Q?9YJ39T*VFFJK174-9(R1^Z^1DD9'
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M/K5>;6MH6IK5M;NTENN(IY;?*^F@D9!&'"(X.XX[OAMSQP[.#Q"XOKX;0??
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M .95"4C)=9ZYWIW8CGE+WGJ9$WJ]  \I5@?/4U4-,[-8Z#<#;E?7=))Q\)L
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M'=S(9I0_&96\@6]H ZNKB>M6ZKJ;3-^'PAAV;CK7%Q[[S;J(B+G>@(B("(B
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M!YC!QXUI!$$1$!$1 5 =U3>9ZQNG]&VP[U7<JALTC >)&]N1M/B+B3_A"O\
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MH<R2-P<UP/(@CF%]$1PM<ZBATKI6XWB=N^::/,<?]9(3AC!Y7$!4OZZ>U?\
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MD9'(ZNF).>(.6Y/]XM77UC-)8-FE!;@YC:B\S=\S-YNZ%H!:/%D[I]/C4VV
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M+ S3>E*"WAN)@P23\<YE=Q=\_#R!2%3-DX[S)HL'<8HK/7K(B(M3K$1$!$1
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M9X&N.>CR2U[1XLAIQVD]JT0J"[E:P5+8=0:IJX711W24,I@X8WF!SG.=Y,D
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MI>2ST,=KM-'00\8Z:%D33VAHQE>M:,V3O+S?S6!?.JGCI::6HG=NQ1,+WN[
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M3>JJ"ZZEOM'+2TU2QU/#&TL,TH.6-)=RX@>",YY+1B B(B"(B B(@(B("(B
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M.<GSKJ(BYIG>=Y>G6L5B*P(B**(B("(HKM$UA3:0LIG>!+6S9930Y]L[M/\
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MZ?ME3WLZ.-KGEV[QEPUH)+G$%@P,\ K<NFV>V:=,$=QTGJ>W6SA%%434 BC
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MB^1Q''R!@])06'#K77,^S:37D8L[*5H=.VTFG>2:<.W2XR[^=[ )Y8QZ%/\
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M,_K+_P"Q,I H1M6O#;!;K3=',+S3UI<UO:XP2AH\F2%MPUFUXB&-IVC=7G=
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M("(B B(@(B("(B B(@SQK_:-9-G6U6NJK##)7559&V.\TC2&1=(T> ]K^.)
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M[N9I3402#\T//A1G'(''D*+#0>R[1DFB[#+25ERENEPGE,L]9+G>?U-;Q).
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MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M=.'3.DJ6CE_Z5+]_GX8P]P'@^8 #S+U:I_WEIG]9?_8F4@4?U3_O+3/ZR_\
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M!$1 1$04EK"DV6:7U-<)-;.IJR[W6H-46RPOE= P@  AN0!P)R>)RII3[,-
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M$(HV[D?>\KWCP> QO-' \3YU.;!KNT6K9[/1MKHX[N^>KZ&GE!C>[I*B0M<
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M08XB9S7Z5_=IRS_3'BM_8IIO[AZ2945,'1UU>>FD)]L&?D ]G#C_ (E8"
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M/!]/:-^HRURYMI]F.31GG)7%,XHWEG_4^H*_4EWEN%SEWY7<&M'!L;>IK1U
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MXN\B]O1Q.#',6ZRX-1VABQQ/#.\OJT@C@NC:KS=;;'44UHJIX>_0(Y&P^VD
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MF@X^=>I:FP1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M(7*L?/"TC'WL!K0?.6N\V%<J_%/#'3P1PT\;(H8VAC&,&&M:.  '4%^T!$1
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MC$8.YN[@Y8YGLX*8;!=H[]>Z=F9<MQMZH"UE1N# E:?:R =6<$$=H\8"^=E
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MV@P</!6-O>[.BZ"LU77QT-NB#JESO"SP:QOYSCU +5V@M(V_25J%-1ELM5(
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M>?<ZW^A_VD]>:\^YUO\ 0_[2=W8[R'KVEZYU!9=85E#;:X14L;8RUG0L=C+
M3Q(SS*B_KG:L]TQ^[Q_97!U3?)]17J>YU44<4LH:"V/.Z-UH'6?$N4MT4C;G
M#5-IWZIGZYVK/=,?N\?V5HJUROGME)-*=Z22%CW'&,D@$K(2US9/]RT'P>/Z
M(6O+$1MLSQS,]7M1$6EM$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!\:V
MG;5T<]-(2&31NC)', C'#TK--=L =8JF2;O.74ML)SN4U2*6KC'B:X%C_2TE
M:<1!G#3NS;91>ZOO$5-XM]U'!UON,W>\X/9NN;X7^$E2WV.NA_\ \Z?O(^RK
M UQ;M,5UH>[64-N=0,_ZVL+6;G]UYP6GR'*SI?-K--HNZ1P;/+]<;Q;6NQ)2
M71AE@:.R*5Q$@\G+QE%3NIV)6K3&I-,7G2_W1DDI[G#WQ%(\2-$63E_  C!
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M-\G.^VO!6TM)1S=%;ZUU;#C/2.A,1SV8)*U9JZ?A^SZ_A)%[>+].KICR(;Y
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M[MK^+)]2>QDO_N[:_BR?4@T1ZO=(>^NP?*,/VD]7ND/?78/E&'[2SO[&2_\
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MG_[MO\%CONJ?QK2_ H?_ #+8E!_T*G_[MO\ !%?9$1$$1$!$1 1$0$1$!$1
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MOFL7=TK^..^?W*?^0Q7^-L^C]-6>U4-75U%3/%2PQR]Z0F1L;@P9:79 R.L
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MP2#%S!.0?],A6@B"K[9L>@MFH:F^T6K=31W:I!$U09H7F0''!P=$01P'#'#
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,$0$1$!$1 1$0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g762905g46d29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g46d29.jpg
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M*"@H*"@H*"@H*"@H*"@H*"C_P  1" 4J!VP# 2(  A$! Q$!_\0 '0 !  ,
M P$! 0            4&!P(#! @!"?_$ &80  $#!  # P8&# P$ P0!%0$
M @,$!081!Q(A$S%!"!0B46%Q%18R@9&3%S535%5S=)*AL;+1(S0V-SA"4G)U
M@K/2,V*BP20EPAA#5H.4PR:CX?#Q8],G2(65M"A$9%=VAL3C_\0 &@$! 0$!
M 0$!              $" P0%!O_$ #<1  (" 0,# @0% P4!  ,! 0 ! A$#
M$B$Q$T%1!&$4<8&1(E*AP? RL=$C,T+A\045-&*")/_:  P# 0 "$0,1 #\
MSA$1?MSXH1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MTDOC7NMU%3<[N1Y9IQ/0['L:Y9_4NC=42N@860EY+&D[Y6[Z#?N6QX5_];W
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M2RJUO=%ZX_T%6.(%?5FFG\U,4.INS/)\@#Y7=WA9DM$S7BO=LKL+[564-##
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M&S<'LQNN4W*M:;/1VVRT\7H>;Q%H[0N&F\W<>F^X!5#%=_\ M(W#8U_#U/\
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M>T+@XM_R@'Z%1Z#CMD=/2B*II+=52@:$SF.:3[2&N ^C2HF89;=\MKFU-YJ
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M+*RTV^HEJ(J8,!DEULN+0XCIZMJM*Q<<D4^S(TXNCVWBZUUYKGUETJ9*FJ>
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M!GF]5'([LVO.W03-WR[/J(/7V$^(5:XR7ZSW#AA04M!=;?4U39("Z&&I8]X
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MZJ9SV@_U6]S1\PT/F7TAQSN\6/X)604@;%4W67L?1Z$['IN/^5NOG"^65W]
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MU*,^SVW3?UH\^91M-!$1>TXA$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MD_O.\?H&_':HZ+C\/CU:JW_G;@WU)55EFQ[+JFQXS>[/2TT)%U:&2SN)YFM
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MR-GO=#<FPLG?2S-F;&\D-<6G8WKVJ/11I-4PG18[YE=1><T&15E/$9>VBE[
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M 8/K)/\ <GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/]R?8NPS\
MP?62?[E<T3XC+^=_=CIP\%,^Q=AGX!@^LD_W)]B[#/P#!]9)_N5S1/B,OYW]
MV.G#P4S[%V&?@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K
M)/\ <GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/]R?8NPS\ P?62
M?[E<T3XC+^=_=CIP\%,^Q=AGX!@^LD_W)]B[#/P#!]9)_N5S1/B,OYW]V.G#
MP4S[%V&?@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/\
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M@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/\ <GV+L,_
M,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/]R?8NPS\ P?62?[E<T3XC+^=_
M=CIP\%,^Q=AGX!@^LD_W)]B[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#Z
MR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/\ <GV+L,_ ,'UD
MG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/]R?8NPS\ P?62?[E<T3XC+^=_=CIP
M\%,^Q=AGX!@^LD_W)]B[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_<
MGV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/\ <GV+L,_ ,'UDG^Y7
M-$^(R_G?W8Z</!3/L789^ 8/K)/]R?8NPS\ P?62?[E<T3XC+^=_=CIP\%,^
MQ=AGX!@^LD_W)]B[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_<HR[\
M-L1@J+>V*R0-;).&O'._J/5\I:,HB^_QNU?E(3XC+^=_=CIP\$']B[#/P#!]
M9)_N3[%V&?@&#ZR3_<KFB?$9?SO[L=.'@IGV+L,_ ,'UDG^Y/L789^ 8/K)/
M]RN:)\1E_._NQTX>"F?8NPS\ P?62?[D^Q=AGX!@^LD_W*YHGQ&7\[^['3AX
M*9]B[#/P#!]9)_N3[%V&?@&#ZR3_ '*YHGQ&7\[^['3AX*9]B[#/P#!]9)_N
M3[%V&?@&#ZR3_<KFB?$9?SO[L=.'@IGV+L,_ ,'UDG^Y/L789^ 8/K)/]RN:
M)\1E_._NQTX>"F?8NPS\ P?62?[D^Q=AGX!@^LD_W*YHGQ&7\[^['3AX*9]B
M[#/P#!]9)_N3[%V&?@&#ZR3_ '*YHGQ&7\[^['3AX*9]B[#/P#!]9)_N3[%V
M&?@&#ZR3_<KFB?$9?SO[L=.'@IGV+L,_ ,'UDG^Y/L789^ 8/K)/]RN:)\1E
M_._NQTX>"F?8NPS\ P?62?[D^Q=AGX!@^LD_W*YHGQ&7\[^['3AX*9]B[#/P
M#!]9)_N3[%V&?@&#ZR3_ '*YHGQ&7\[^['3AX*9]B[#/P#!]9)_N3[%V&?@&
M#ZR3_<KFB?$9?SO[L=.'@IGV+L,_ ,'UDG^Y/L789^ 8/K)/]RN:)\1E_._N
MQTX>"F?8NPS\ P?62?[D^Q=AGX!@^LD_W*YHGQ&7\[^['3AX*#=>&>'PVVJD
MBL<#7LC):>T?T.O[RYV[AEA\MOII)+' Y[XFN<>T?U)']Y6Z]_:BL_%._4N=
MJ^U='^)9^R$^(R_G?W8Z</!5OL789^ 8/K)/]R?8NPS\ P?62?[E<T3XC+^=
M_=CIP\%,^Q=AGX!@^LD_W)]B[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#
MZR3_ ')]B[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_<GV+L,_ ,'U
MDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/]R?8NPS\ P?62?[E<T3XC+^=_=CI
MP\%,^Q=AGX!@^LD_W)]B[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_
M ')]B[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_<GV+L,_ ,'UDG^Y
M7-$^(R_G?W8Z</!3/L789^ 8/K)/]R?8NPS\ P?62?[E<T3XC+^=_=CIP\%,
M^Q=AGX!@^LD_W)]B[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_ ')]
MB[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_<GV+L,_ ,'UDG^Y7-$^
M(R_G?W8Z</!3/L789^ 8/K)/]R?8NPS\ P?62?[E<T3XC+^=_=CIP\%,^Q=A
MGX!@^LD_W)]B[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_ ')]B[#/
MP#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G
M?W8Z</!3/L789^ 8/K)/]R?8NPS\ P?62?[E<T3XC+^=_=CIP\%,^Q=AGX!@
M^LD_W)]B[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_ ')]B[#/P#!]
M9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z
M</!3/L789^ 8/K)/]R?8NPS\ P?62?[E<T3XC+^=_=CIP\%,^Q=AGX!@^LD_
MW)]B[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_ ')]B[#/P#!]9)_N
M5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3
M/L789^ 8/K)/]R?8NPS\ P?62?[E<T3XC+^=_=CIP\%,^Q=AGX!@^LD_W)]B
M[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_ ')]B[#/P#!]9)_N5S1/
MB,OYW]V.G#P4S[%V&?@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L78
M9^ 8/K)/]R?8NPS\ P?62?[E<T3XC+^=_=CIP\%,^Q=AGX!@^LD_W)]B[#/P
M#!]9)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_ ')]B[#/P#!]9)_N5S1/B,OY
MW]V.G#P4S[%V&?@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8
M/K)/]R?8NPS\ P?62?[E<T3XC+^=_=CIP\%,^Q=AGX!@^LD_W)]B[#/P#!]9
M)_N5S1/B,OYW]V.G#P4S[%V&?@&#ZR3_ ')]B[#/P#!]9)_N5S1/B,OYW]V.
MG#P4S[%V&?@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/
M]R?8NPS\ P?62?[E<T3XC+^=_=CIP\%,^Q=AGX!@^LD_W)]B[#/P#!]9)_N5
MS1/B,OYW]V.G#P4S[%V&?@&#ZR3_ ')]B[#/P#!]9)_N5S1/B,OYW]V.G#P4
MS[%V&?@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/]R?8
MNPS\ P?62?[E<T3XC+^=_=CIP\%,^Q=AGX!@^LD_W)]B[#/P#!]9)_N5S1/B
M,OYW]V.G#P4S[%V&?@&#ZR3_ ')]B[#/P#!]9)_N5S1/B,OYW]V.G#P4S[%V
M&?@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/]R?8NPS\
M P?62?[E<T3XC+^=_=CIP\%,^Q=AGX!@^LD_W*1MV$8[;8'0T5KBAC<[G+0]
MQZZ WU/L"L2*//D>SD_N50BN$$1%R-!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!$0?RI
MJ?R=OZU+J(@_E34_D[?UJ70!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 %$7W^-VK\I"EU$7W^-VK\I" ET1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 >*]_:BL_%._4N=J^U='^)9^
MR%PO?VHK/Q3OU+G:OM71_B6?LA >I$1 $7CO-RI;/:JNY7"0QT=)$Z:9X:7<
MK6C9.AU*C\/RNS9A:W7#'JP55*V0Q./*YCFN'@6N ([P5:=6"<1>*]W2DLMI
MJ[E<9#%1TL9EE>&EW*T=YT.I75CE[H,CLM+=K1,9J&I!=%(6%A< 2T]" 1U!
M2G5@DD1% $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$717U<-!0U-95.Y*>GC=+
M([1.FM!).AW] @.]%$8KD5LRJRQ76QSFHH97.:R0QN826G1Z. />%+JM5LP$
M1% $1$ 1$0!$5?Q7,++E5LJ[A9*IU12TLKH97F)S.5[6AQ&G $]"%:;W!8$4
M)B&4VG+[2;E8*EU11B1T7.Z-S/2&MC3@#XA3:--.F B*"M^6V>ORJX8Y2U+G
MW>@C$M1"8G -:>71YB-'Y;>X^*)-\ G41% $1$ 1066999\3AHY;[4NIV5<X
MIX2(G/YGD; ]$'7=WE3JM/D!$10!$7EI;C1U=554U+50S5%*0V>.-X<8B>X.
MUW'IW(#U(B( B(@"(B (B( B(@"(B (B( B@KIEEGM>26RPUM2Z.Z7$%U-$(
MG$/ WOT@-#N/>5.JM- (B* (B( B(@"(B (H*^Y99[%>+1:[G4NBK;K(8J1@
MB<[M' @:V!H=7#O2Y999[;DUMQ^LJ7,NMP:7TT0B<0\#>_2 T/DGO*NE^ 3J
M(B@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B B(/
MY4U/Y.W]:EU$0?RIJ?R=OZU+H B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"B+[_ !NU?E(4NHB^_P ;M7Y2$!+HB( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B \5[^U%9^*=^I<[5]JZ
M/\2S]D+A>_M16?BG?J7.U?:NC_$L_9" PG,/*+ALF855KH;)YW04<[H)IW3\
MCWN:=.+!K6@0=;[_ &+=;/<(+M:J.XT;BZFJX63Q$C1+7 $;'N*Q[+/)ZLM^
MRRHO$=TJJ*"JE,U12QQM=S.)V[D<3Z.SL]Q[ULENHH+;;Z:BHXQ%34T388F#
M^JUHT!] 7;)TZ6CD%:XN?S895_AL_P"P5\W<*[C7\,!CF35#WRXMD;'05FAT
M@D9(]H/O ',/6"X>"^D>+G\V&5?X;/\ L%4OA7C5#EOD[VFS7-NX*F&8!X'I
M1O$\G*\>T'K^A;QR4<;OALA;N+LC)N$^32PO:^-]ND<U[3L.!;T(/J41P,K*
M>W\$;%65TS(*6"GEDEE>=-8T2O))65VK):ZS8#F_#C*W\MTME#-YC(X])H0W
M?*">_0])O_*?^5<[_53T_DBV=L!(;/(V*0C^SV[S^MH6NE^'1[@O+.-%9=73
M3XC@UZO5KA<6FL;_  8?KOY1RG?N[_8%<^'/$"T9W0SR6T34]92NY*FCJ&\L
ML)]H\1T/7V>"E,'H::VX=9*2@:UM-%1Q!G*.A]$'?O)Z_.LFIHVVSRKI8[>
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MPS+<%XQY;B<SA#;;BWX4H>;HUHZEP'N!</\ Y2[^!43LHS'+\_J6DLJZ@T-
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MG +W=+,UQ#:P.Y.T .B6MY3OZ5)8[<\@XBV'([+E>,5.-PSTO8Q3/+G%Y>'
MD @?)Z'YU2K)-Q5X8VV*U?%^ER.QTFQ#)2DF0,V3H:]+Q\6'WJPQI6GS\P:3
MCG$JAR;#:^^6"WUU7541Y);8&ZG#_P"R -[WW@^P^HK)/)VR:N@R?(Z5F.W*
M:*Y73FGJ&#T*(DOZ2=._K^A:5P:R[&LG?>#9;*VR7D2"2XTSH@V1[B3Z1< "
M[J7=X!!/=UZUOR:?MGQ!_P 6/[4BU2C&:KP"T9?Q5IK3D;\>L%EN&17R)O--
M3T8TV$?\SM'1ZCPT-]3M1MHXR%F1T5ES#%[ECE16O$=/+.[GC>XG0ZZ;TV0-
MC>M]=*+ES>UVG.+_ $G#C"ZF^WR23_S.J@E,<?:!SN]Q#A\HN_L@GUZ5(XUW
M/,[DS&9\LL-OLU(VXM\W9'4=M,7>.R"1K0]G720QQ=)K]=_L#Z!S[,[5@]B=
M<[U(_D+NSBAB&Y)G_P!EH^;O/0*B0<9JJE;#5Y/A-ZLUEF(#*^0%[6[[B\<H
M+0?G^=1G%AK;AQZX=VZO ?;V-=.UCODF3F<>[QZQL6P9+1TUPQVYTE>UKJ6:
MFD9*'=W*6G:YU&*5J[*0G#G-Z7-<4-^CIWT%.V1['-F>#RAG>XGNTJ<_C--=
M*RI9A.'W;(J*F>625D1[*,D?V?1._GT?8L]Q2KFH_)+O\E,XM>Z=\1(_LOEC
M:[_I)4]PTO'$6TX+9J6P8+;ZBV^;MDBG-<QIF#O2YR.;H3O:Z=**M^]<D-0X
M=<0K7FT=7%315%#=*,\M5;ZIO++$=ZW[1OI[/$!7)8/B=BSFJXUTF5WG&X+/
M22TSJ:M["JCD#QR'E<0';)V&#_*%O"XY(J+V*4KB+Q&M6$>:T]1%45]VK.E-
M;Z1O-+)UUOV#?3UGP!T556\:)[75TS<UPZ[X]0U#PR.LD_A& G^UZ(U[AL^Q
M16,1LN?E39/+7@/DMU T4C7=>3T8AL?,]WYQ6B\7J*FK^&.3Q5K&NC9033-Y
MO![&ES3[^8!;TPBU%KDAW9]F5+B&'2Y$Z%U=2M,?*V%X'.'N !![M==JFV?C
M.V]Y/16^SXQ=*NUU,[:?X4;TB:\_*_JZ+1UZ\P[NY4"[54]7Y(%$^I<7/:]D
M32?[#:HM;]  'S+>.'%)#0X!CE/3L#(VV^ Z ULE@)/O))/SJN,81=JW;0*G
MD7%J*FR*KL.*X_<<EN=&=5(I/1BA/<07Z/4'IW:WTWM=6,<7V5N54V.Y/CMQ
MQRZ572G%2>9DA\!S:'?K0.B-]-JO6O.Z"@OM[HN%&"U-YD=/S5U;'-V4+Y=G
MKS.#MCO\6[ZD>M53B'7Y=7\0^'-1F%FH+2/A-HI8H)NUD([6+FYR"1_9UKVK
M2Q1>S7Z[_8%RXE_TA>'7XJ3_ -:VU8EQ+_I"\.OQ4G_K6VKED_IC\OW*5#B+
MGMOPBDI#505-;<*Z3LJ2AI6\TDSNG=ZAU'TC0*ILO&>LL\M._,\)O%CMT[Q&
MVL<[M6M)_M#E&O=U/3N*DN,N#7K(:VQ7_$JN&&^V9[GQ1S_(D!(/>01OIX]"
M">H5*O'$G(K;0NH>+?#WM[2YS1+44[>>'8(()!+F$['=S!;QPC**I6_GN0U3
MB+GE'A6.T5YF@=6TM541P-,3PT /:YP?L^&F_I5+NG&Z6&&6Y6K#+U<,<B)Y
MKIHQL<T'1>T%IVWVDCVZ4/Y2=9;[CP7L-59>S^#)JVG=3B-O*T1]E)H >&AT
MUX:6NWNBIZ; Z^BBB:VFBMLD+8P.@:(B ->Y1*,8IM<@H]5QFI:Z"G^)-@NF
M2U+X6S31TS"UM,#_ %9':.G]#T&_>IWAAQ(H<[97P,HJFVW6@<&U-%4?*9LD
M;!Z;Z@@[ (/AW*M^2O310\*898V!LD]7,^1P'5Q!#1^@!1G#\!GE-9ZQ@Y6F
MB8X@>)_@#O\ 2?I5E"'XHI< L^5\5J>V9)+CV.V2X9'>H!S3PT8TR'V.?H]>
MHWTT-ZWOHO#8^,>\FHK%EV,W+'*RM<&4SZ@\\;W$Z WIO>=#8V-GKI1#<XME
MKS&_TG#/":F^7627=SJX93'$9 YW>XAWB7?V03O6U2N,%RS*XW'#JC+K%;[/
M3MN3?-HXI^UF+N9N^8@D:Z#U+4<47LU^N_V!=^-G\[?"O\N=_J1)Q$_I'</O
MR>3]4J<;/YV^%?Y<[_4B3B)_2.X??D\GZI4APOD_W!MJ(B\I0B(@"(B (B(
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M@>\>?CG2UE!Y.^/T5SIS3UM*ZCIYHN=KN5S(W-/5I(/=OH5]!*B\9<*JL\Q
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M?D$'^FU8?PYLMKO7'GB)%>+=1U\4;W.8RIA;(&GM -@.!T5(0B[OL4TQG%_
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M$ 1$0!$1 %$7W^-VK\I"EU$7W^-VK\I" ET1$ 1$0!$1 $1$ 1$0!$1 $1$
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MZ4/[+9\1S.'S$MVMCLMTH[U:J6Y6R=M115+!)%(WN<#^H^SP5EC<=V#V(B+
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M=ZU;E&JV8"(B@"(B (OR1XCC<]QTUH)/N58X=YI0YU:*JYVJ&:.DBJGTS#,
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M0L#.T;T.B  -$'U @@CJI.ARR\2\?[CC#ZEILT-N%0R'LV[#],Z\VM_UCXJ
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MQ7 /'OAL"-]7'_J*GO*7I*BKX1W0TP<[L9(9I /%@>-_1L'YEA548US_ )!
M8Y'Q9S&U1Y%%D=OL<%2.VH[=YHU[71GY/.X@D CQZG77HN_A+GF57_BA?+%E
M#(:46^B].DB8WE;,U\;2\.ULAVR0-D>DM*X>5U-<L%L%50O:Z!]#"!RGY)#
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M7USZZOHY::ODZR5%')V;I#ZW#1:3[=;7=@G";%<*J_/+51R35X!#:JJ?VCV
M]_+T ;[P-J^HG4E6F]@>*]6FAO=LGMUVI8JNBG;RR12#8/[CZB.H65'R=<'-
M;VVKH(M[\W%2.3W;Y>;]*V)$CDE'^E@A8<7M%-BTN.T=&RFM,D#Z<PP^CZ#P
M0[KW[.SU[]KP8%@EDP:GJX,?BFCCJGM?)VLI?L@$#6^[O5I134ZJP5;/,$LF
M<TU)!D$4TD=*]SX^RE+-$C1WKW+E>,'LMWPVGQ>MBF=:8&11L8V4AVH]<OI=
M_@K.B:Y*E? (7#\9MV)6*&T69DC**)SG-;(\O.W'9ZGVE0MFX:8[9\RJ,HHH
M:AMVG?+(][IB6[D)YO1[O$JZ(FJ6^_(*UF^#8_FM)'!D% V=T6^RF:2R2/?J
M<.NO8>GL5,L7 '"+57LJGT]97ECN9L59,'1@^UK6C?N.PM8159)15)@\-YM-
M)=[)5VFL8?,JJ%U/(QAY?0(T0-=W10V!X-9<&HZJFQ^*:.*ID$D@EE+R2!KQ
M5G19U.J!0,XX18EF-:ZMN5%)!7O^74TDG9O?_>&BTGVD;7Y@O"+$\,K16VVC
MEJ*]O1E35O[1[/[HT #[0-K0$6NI*M-[ S#CYE7Q8QJG-;CD-]LU8]T%7'+(
M6",]"SKRG6]'1\" LDQ3(.#-IH6WYELJ8KY&TOCMTQEJ!%(-ZY7$<A\-$]WL
M*^I:NF@K*:2GJX8IZ>0<KXI6!S7#U$'H543PMP<S]M\5[7S[WKL1R_F]WZ%T
MQY(QCI=_0ACGD=V>J9)D%XDC<VD>V.FB>1T>X$N=KW>C]*\OE$<4L;RC%HK'
M9.UJZQM4)7R20NC$'*' @<VMN.]>K6U]-4=+3T-+'344$5/3QCE9%$P,:T>H
M = JY3</,1IKF;C#CMM%:7]IVIA#B';WS 'H#OQ6EFB\CR20H@/)\Q5^*\-Z
M&.JB,5?7$UE0UPT6EVN5I]S0WIX':TA$7"4G)MLH1$60$1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %$7W^-VK\I"EU$7W^-VK\
MI" ET1$ 1$0!$1 %Y;K]JZS\2_\ 9*]2\MU^U=9^)?\ LE5 P#R9,/QV_</Z
MJJO5DM]=4MN$D8EJ(&O<&AD9 V?#J?I5BXS\,,0AX>WFXT-II+96T,)J(IZ9
MO9[</ZI Z$'N^=9MP)L/$"YX?438;E%':;<*Q[7030AY,G*S;MECNFBWQ\%?
M*[A-G.5-CI,YSOSBUAX<^GHX>7M->OHT?.0=>I>R>V1MR_N0A\CNU9>O))BK
M+F]\E41%$9'G9>&508TD^)TT=5/6;C19;1C%HHJ&UWB\FAH(&5<]#3\T4+A&
MWF!<2.H^CVJ1X^VRDLO >OMMMB$-'2BFBB8/!HF9])]JNG"VW4ULX=8Y3T<3
M(XS00R.#1KF>Y@<YQ]I))7-RCHMKNP=^"YE9\VLHN=BG<^(.[.2.1O+)$_OY
M7#W$=VPJODG&&R6J]U%GME!=;]<J<EL\5LI^U$1'>"=]X]F_4JOY/<;*3.^*
M%'3M$=-#<@&1MZ-:.TF'0>'0!=&.9SBN*5MUM?#?&+YD$LE09*J>D:Z5CG]W
M_$.W$=#X:ZD@G:G32DTE8+KA'%NQY3?#9'4UPM-YT2VDN$/9N?H;(&B>NNNC
MI2&>\2+-AE32T57'65UUJAS0T-#%VDKF]1O6QH=#[]'U+&,@O-[O/&[ *Z^8
MT['Y'3".%DDXDDE9S=2[0!&N8]"/$JX\2<<RZR\2X<ZPVA@N^Z44U11R'TV@
M="6C8/4:[NN]]""J\<=2ONO/[@GL<XQV6YWVFLUTMUWL-QJ2&P1W*G[,2D]
M =]Y[NH \%<,QRNT8?9WW._50IZ<'E: .9\CO!K6^)_^XK&I^)V,9'=;70<3
M\2KK+7TTPDII*GG$<3^@YB?1<!O7@1W$]VUY..=PJI>-F)4;+1)?8*.E\[CM
MK'Z[9Y<\D]Q'3LVD]#T:G23DE5 M\'':RM?#+=+#D5LMD[@(Z^IH]1'?<=@G
MI[MK6*.I@K:6&II)F34\S!)')&[F:]I&P0?$+&,@SC*KY9*ZUUW":Z/IJN%T
M3PZI! V-;_X?>.\>Y3WDZT-[M7#IENR.CJ*.HI:J1D,<XT[LCRN!]VW.'S+,
MX)1OCZV#3EA_%%^=Y<;_ &JWTHL6+4$<IJ*Z0GM*X,:26L'0\IUKIT[]D]RW
M!0^9_P C[[^03_Z;ESQRTNZ*4#R7_P":*@_*)_VRM764>2__ #14'Y1/^V5J
MZN;_ ')?,((B+F B(@"(B \5[^U%9^*=^I<[5]JZ/\2S]D+A>_M16?BG?J7.
MU?:NC_$L_9" ]2(B +*<LX+V^Y7^2^XU=Z_&KO*2Z66B/H/)[SR@M()\='1]
M2U9%J,W'= Q>/@=+=:Z";.,RN^0T\+N9E,_<;-^W;G?HT?:M:EM%OELKK0^C
MA-L=#YN:;ETSL]:Y=>K2]R*RR2ERP8[!P:N=G[:FQ#/+O9[3*XN\S[/M>3??
MRNYFZ]^M^TJY<.>'UIP6DJ!;W3U5=5NYZJMJ7<TLQ[^_P&R>GMZ[5P1)9)25
M-@IN*8)#CV99)D$==)/)>GA[X71@"+1)Z'?7O7YQ*P.#.8;3'45TE)\'U0JF
MED8=SD>!V>BN:*:Y7J[@XRQLEB?'*T/C>"US2-@@]X6><+>%-LX?7"ZUE%5R
MU<M: QG:L#>QC!)Y01W[Z;/_ "A:*B*32:7<$)F6+VO+[#/:;W 9:633@6G3
MXW#N>T^!'_VNXK-/L-WT4'P2WB/>18>7L_-.Q]/L^[DY^?NUTUK7L6S(K')*
M*I K&/X3:L>PV;'+,QT%)+%)&^5WI/>Y[=%[CXG]P'<OSAMB$6#XK!9*>K?5
MQQ2/>)7L#2>9V^X*T(HY-[,%,DP.!_%"/-//I!.RE\U\U[,<I&B-\V]^*_:;
M!88.)]5F8KI#//2"E-+V8Y0 &C?-O?\ 5_2KDB:Y?L#/<^X7463WJ"^VVY5E
MBR&$!HKJ/O> -#G;L;Z=-['3H=A0U%P;?77FDN.=93<,F\T=S04TL8BA!]K=
MG?<-ZUOQVM;1:6625)@IO$/!(,SGL4DU;)2?!56*IH9&'=H01Z)V>G<K974X
MJZ*HIBXM$T;HRX>&P1O]*[D6-3I+P"H<.,&IL*Q)]@95/KH'R2/<^1@82'@
MC0/L5>X=\)Y<&R U-MRBXRV;;R+7(W^#VX:V2':)'3KR^"U!%KJ2WWY 6<YQ
MPKI+_?V9#9;K68_D+6\KJRDZB0:UZ;=C9UH=XV._:T9%(R<7:!E5GX/MDO\
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M&WM74KV;IGD=3&!O7LWH?,O-#!<5*4DKX]SHYTZ2LU)%E'"C+JZ[6_*<EO\
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ME51P//HQG4>^7Z7_ $*3QTDNZ5@UA%E/&G*KI%7V3#L0J'0Y#=YFN=,SOIH
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MKO1RC)*NJLUE=HT-DB=RE[/!\QUOKWZ\?8.AU1<)1TNBA$19 1$0!$1 $1$
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M=?0OW"KZ,FQ6UWH4_FPK81-V//S\F_#>AOZ% \</YI\G_)#^L+,.&=9Q+ON
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MND[*28\SV\SG>KT">N^\ *G\></L>.TUGL]MN5UN%_N-4T 5M:Z8LCZC9;T
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MM_Z6M5>X>O9'Y26>-N!#:Z2G;YN'][H_X,]/\H9]"V6QVRGLMFH;71<WFU'
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M]4NFI;?,QD9%(6L<UK7 AK=@@#T0.[N7OL5KI[)9:&UT7-YK1P,IX^<[<6M
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M-^QRT7]]$^\T,=6ZBE[:G[0G^#?TZ]#[!WJ615.N $1% $1$ 1$0!$1 $1$
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M\@(B\T=PHY:EU/'5T[ZAO?$V1I</FWM9!Z47X][6#;W-:/63I?J (N(>TO+
MYO,.\;ZKJJZREHV!]94PP-)T#*\,!^E =Z+C&]DC&OC<U['#8<T[!"&1@<07
MM! V03W#UH#DBZJ6I@JXNTI9XIH]ZYHWAPW[PH[+;W#C>-7.\U+2^*B@=,6
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M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!1%]_C=J_*0I=1%]_C=J_*0@)=$1 $1$
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MQQ[^7TG$^[W$35GKH^(?E$TUZLFY['CU(8758!Y)'D/ Y3[Y#KUAI*D.%_\
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M'0;]G@!LJ7X;76CP+BWG-IRN:.@ENM2*NDJZ@\C)6%[W <YZ=0_W;:1WKO\
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MU'C-D%UL^:\-Z2UUTU-37"Z=C51QG0F9VD Y7>S3G?2M96)<?OYP>$W^,?\
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MY%<+%PZBN&/7&2EJ'5L4?;0.&RTM?L;^8*K7&CFXM\7KW9+E6U,6*X\ Q]+
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M6WV^&"US->V2F;OE<'C3A\X3J12I+P4Q?$?Z(]7^15G^O(M%X%?S2XS^3?\
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MUPE*XI>"F)^5C_(6S_XM%_IR+:A_P_F49D6.VG)*2*EOE#%6T\4@F8R3>FO
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ME$TV17C<5DO5$*5U41Z$3P&C1/AHL83[';\"M=Q7$;#BE/)#CUKIZ%LFN=S
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M21R-#FO:>\$'O"Y=17';@I@^"X/PK9A]!?+O4T-PJ)(&S5536UQZ2$;<"SF
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M\V0<.^*%JI1NHJJN5D0[MOY26CYR OHR@HX+?0T]'11-AIJ>-L44;>YC6C0
M]P"\&/XY:,>;5-LM!%1BJD[:81[]-_K.T62K]P9GY/V;6A^!TECN=;!07>T\
M]//353Q$[0<=$!VM].A]1!VH+)+E3\0N/6*TN.R-K:#']U-55Q'FC#N8.T'#
MH>K6#8\2?4M1R;AMB.35IK+U8J:>K=\J9I=$]_\ >+".;YU,8WC=GQJB-)8;
M=34,!.W"%FB\^MQ[W'VDK74BFY+ED,:Q>X4W#[COEE#D$K:.BR$MJZ.JF/+&
MYW,YW*7'H.KWCKXM]H73Y4N9VB?#HK#;JZGK*ZHJ&32-@>)!%&W?5Q'<22T
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M(&N=])&U[D0   :'0!$1 $1$ 1$0'&1C)&%DC6O8>\.&P5^L:UC0UC0UH&@
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M3S>]??M-]6@)=%$>;WK[]IOJT\WO7W[3?5H"711'F]Z^_:;ZM/-[U]^TWU:
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M-[U]^TWU: ET41YO>OOVF^K7?3Q7%K")ZF%SM]"UFNB D$1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 1$'\J:G\G;^M2ZB(/Y4U/Y.W]:ET 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!1%]_C=J_*0I=1%]_C=J_*0@)
M=$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'BO?V
MHK/Q3OU+G:OM71_B6?LA<+W]J*S\4[]2YVK[5T?XEG[(0'J1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0$1!_*FI_)V_K4NHB#^5-3^3M_6I= $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 41??XW:ORD*741??XW:ORD("71$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!XKW]J*S
M\4[]2YVK[5T?XEG[(7"]_:BL_%._4N=J^U='^)9^R$!ZD1$!^/8U["Q[0YI&
MB"-@KS?!U%]YTWU3?W+U(@.B*CIH7A\-/#&\=SFL *_:NEIZR$PUD$4\)[V2
ML#FGYBNY$!YZ&AI*"(Q4-+!31D[Y(8PP?0%V5-/#50NAJH8YHG?*9(T.:?>"
MNQ$!YJ*WT=#$8J&DIZ:)W>R&-K ?F 7=##'"SDAC9&W>],: %S1 >26UT$U8
MVKFH:62J9\F9T+2\>YVMKT,AB9(^1D;&O?\ *<&@$^\KFB +C+&R:-T<S&R1
MN&G-<-@CVA<D0'DH+90V_G^#Z*EI>?Y781-9OWZ"]$T,4[>6:-DC0=Z>T$;^
M=<T0!>*JM-NJZAM15V^DGG;\F22%KG#W$C:]J)P#KD@AD+#)%&\LZMYF@\ON
M]2_3#$Z9LKHV&5HT'EHY@/>N:( N,C&2QN9(UKV.&BUPV"/<N2(#Q4-IMU!(
MZ2AM])32.^4Z&%K"?>0%ZIH8I@!-&R0 [',T'17-$L'XYH>TM< YI&B"-@A?
MD4;(F!D3&L8.YK1H!<D0'!D,3)'R,C8U[_E.#0"?>5YJRTVZNE9+6T%)42L^
M2^6%KR/<2%[$2P=<E/#(UC9(8W-9\D.:"&^Y?KH8G2ME=&PRM&FO+1L>XKFB
M X=C%VW:]FSM=:Y^4<VO>N:(@.#X8GR-D?&QTC/DN+02/<5^RQLE862L:]A[
MVN&P5R1 ?C6AK0UH :!H =P"XPPQ0@B&-D8)V0QH&RN:(#RU]MH;@UK:^CIJ
MIK?DB>)K]>[87?#%'!$V*"-D<;1IK&-  'L 7-$!P$,0F,HC8)2-%_*.8CWK
M\J((JB%T51$R6)W1S'M#@?>"NQ$!Y:"VT-O:YMOHJ:E:[Y0@B:S?OT%ZD1 >
M**TVZ&L-7#;Z2.J/?,V%H>?\VMKVHB \<%KM]/5/JJ>AI8JE_P J5D+6O=[R
M!M>F.&*(.$<;&!QV[E:!L^LKFB6#A##' SDAC9&W>],: %YZ^V4-P#1<**EJ
M@WY/;Q-?KW;"]:(#A!#'!$V*"-D<31IK&-#0![ %S1$ (!!!&P?!>*CM-NHI
MGS4=!24\S_E/BA:QSO>0%[40'":*.>)T<T;)(W#3F/&P1[0NB@MM#;PX6^BI
MJ4.^4((FLW[]!>I$!U,IH(V/8R&-K'_*:&@!WO7.*-D3 R)C6,'<UHT N2(#
M@(8A,91&P2D:+^4<Q'O7"KI:>L@=#6013PN[XY6!S3\Q7<B \T5!1PT[((J2
MG9 P[;&V,!K3ZP-:"[I88IN7M8V/Y3MO,T'1]BYH@#@'-(< 0>A!\5XZ2U6^
MC$HHZ"D@$O23LH6MY_?H=5[$0'&.-D3 R-C6,'<UHT O)':+;'6&KCM]&RJ)
MV9FPM#R?[VMKVHE@Z^QB[;MNR9VNM<_*.;7O7754-)5N8ZKI8)W,^298P[E]
MV^Y>A$!QEC9+&Z.5C7QN&G-<-@CVA>6AM=OM[GNH*&EI7/\ E&&%K"??H+V(
M@"(B \\=#215+ZF*E@94/^5*V,!SO>>]=53:+;55+:FIM]'-4-[I9(6N</G(
MVO:BM@ZY((I',=)$QSF=6ES02WW>I?O8Q=MVO9L[76N?E'-KWKFB@*EQ1@R>
M7$YGX/5=A>H)&RL;RL/;-&^9GI@CJ#OWA42/B]<FT[8Y>'.1'(@SD+!2GLR_
M7]O6^7?L6T(ND9I*FK!F7 G$+ICEHNURR1K([U>ZLUD\32#V8ZD-.NF]N<?9
ML!:-6T5+70]E6TT%3%W\DT8>WZ"N]%F4G)ZF#HHZ.FHH1#14\-/$.O)$P,;]
M 7.IIX:F%T53%'-$[O9(T.!^8KL19!UQ4\,, @AACCA T(VM :!ZM=R\M)9[
M91SF>CMU'!,>^2*!K7'YP-KW(E@(B( B(@"(B (B( B(@"(B (B( B(@"(B
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M!_R!43-87>X$[/S+'> S68WFG$BPTSY/@FW5 EAC<[FY "\'Y^4-&_'E"\O
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M06#?*=<O>#ZUTEB45?\ X0L-LL]NI.+E]O8R:*6LEH0R6SF1NZ9@$7\*1S;
M]$=2T?+[_74\6XE05W&;(Z2OR.@^ (::..WCSB-L3WGD)Y7;T]VRX=Y/@NG&
MXV2^51F<<C0YC[,QKFGN(+:784-@N(8]+Q^S.W26>B=0T,$4E- 8QR0NU&=M
M'@=D_2MJ*IZO"!OUSN-%:J-]7<ZNGHZ5GRI9Y Q@^<]%&6',,=R"=T%DO=OK
MIVC9BAG:Y^O7R[WKVK ^(>18_>N.-109]<'08Q8X@(:;ED<R><AI/,& G^L?
MF8!XE>'BE>^&$MC9<<!K:>W9/02,EI'4-)+!VFG $'T WN).SZM>*D<%U=[_
M &%GU.J5Q@RGXJX+<ZNFN%-1W4PGS(2N;S/>" >5KOE$ [UU4WA-X=D&(6:[
M2-#9*RDCF>!W!Q:"X#Y]JH>4'::"OX8WFKK*2&:IHH"^FE>W;HG%S02T^&P%
MR@EK2924X0Y'37_"+03=8+A=(Z.)U:&SMDE8]PZ\X!V"2#W^I2M[S3&K%5"E
MO%]MU'4]/X*6=H>-^L;V/G69V(T.#>3X<ELE#3TUUFM,+I)V, =)*[36N=Z]
M%^UW\'.&&/2X10W;(;=!=[M=HA5SSUK>U/I^D .;NZ$;/>23U6Y0C;D^+(:Y
M;J^DN5)'56ZJ@JZ60;9+!('L=[B.B]*P7&*,<../S,9M#Y&X_?Z0U+*5SBYL
M,@#SL;_%N'N<._06]+G..E[<,I&7[(+1C\#9KY<Z.@C>=--1*UG,?9L]?F77
M8,ELF0L>ZQW:BK^3Y8IYFO+?> =CYU@?$.KMEAXZ5ERXD6F>XX_/2LCMKS%V
ML,1 ;OT3T.CS['4]=ZZA6?%[)@60YU:,CX>WRCMM52!WG%OI8NS-2T^!C<6E
MHUL$AIWT]2Z/$E&W_P!$-DKZVEMU))57"IAI::,;?+,\,8T>TGH%$6/,\:OM
M4:6SWVW5E2-_P44[2\Z\0-[(]RPSB]D%ENO&FFL6;7!]+BMH@;-)"UKR)YW-
M#@"& GN<T>X'NVH_B;=^$U;C,D^'5=-;LCHN6:AEHJ.:!SG-(]$GD .QW$]Q
MUU5C@M*[W%F@>53434W#6"2FFDA?\(Q#FC<6G7))TV%KE(X"BA<\Z C!))]B
M^>.,M]ER7R=,;N]3HU%34P&4@:!D#9&N/SD$J7\I3(7T5AQFP&M?045WE KJ
MA@)+8&<@<-#J1Z>R!W\NO%7IN2C#W8-0CS_$9;AYC'DMH=5%W*&"J9U/J!WK
M?L5F7SM45_ :7'G6ELM)&WL^1M4VBG\X#M?+[3DV3OKUZ>S2_>%W$"NI.!63
MU#ZDU-58>>"DG=LDL< (B=]>A/CX !9>':U?U!M%[S3&K'5^:WB_6VCJ?&*6
M=H>/>-['SKWOOMI99_A9]SHFVO0/G9G;V.B=#T]Z[^G?WK*>"_#3'ZC!:*\9
M!;:>[7:[Q^=SSUK>U.GG8 YN[IHD]Y)/53.'<*J?'ZS(Z&>:&MQ&YO;+#:9F
M%XA>"#O9/K'Z&[/19E&"M7P4C/)\SU^36NXMR"]TT]ZGN,A@IG2M:_LA&P@,
MC[^4:=W#UGUJ>X=T%HQB+)ZQN64]TIY*PSU,CYFAM$=GT''F('?XZ[E1?)3L
M%JEQVNO$EOIW72GN4L4-46?PC&=FST0?5Z3OI7=P M\%UI>)-OK&\]-57.6"
M1OK:[G!_6NN2*N5<;$-PH*RFN%)%5T%1#4TLHYHYH7A['CU@CH5T27>W17:*
MUR5]*VY2L[2.E=*T2O;U](,WLCH>OL*RCR;:Z>@MM_PVYO\ _&V"M>QN^FXG
M$Z(]G,''W."C^&-2V_YYG?$2I!DH:,/HJ ^!CC;MQ'JVUK3_ )RN;Q4Y>W\1
M37<@RBQ8Z&?#EWH: O&V-GF:USAZP"=E>FRWFVWND\ZLU?2UU/O7:4\HD /J
M.CT/L7R]PRR/ *^HNF1\4*Z&LR&MJ'<L%532S1PQ=-: :6^L#U #6NJ]]'DV
M)V/C+CE7PUK1\&W>04=RHHHI(XFES@UK@UX'B[?3NY3W;Z[>#E;W^A++SYS/
M_P"U+YOVTO8?!'-V?,>7>N_7<M:MEXMMUDJ66RX4E8^F?V<[8)FO,3NO1P!Z
M'H>A]2R#_P#.N_\ T/\ ]EPM[?B/Y1U53?\ #M>64_:L\&BH&R?GY@_ZP*2C
MJKY V.[7:W6>G;/=J^EH8'O$;9*F5L;2X[T 21UZ'I[%[1U'18IQ$'QSXVXM
MBK/3H+.TW2N'>.;H6M/T,'ND*VM<I1TI>Y2AYE9*&OS[%;A4Y(RW55&YQAMQ
M> :WJ.@!<"=>P%6ZHN]MI[BRWU%?215TD9F93OF:V1S!O;@TG>AH]?85D'%K
M^?+AG^,?^T%#\8+)'DGE!XC9ZB66.EJ[=RS]F\M+XVNF>YFQX.#2/G750U)6
M^Q#8K?G.+7&Y"WT.0VN>L+N5L4=2PEQ]3>O4^Y4?RH:B:FX6R24TTD,GGD(Y
MHW%IUZ7B%!\>>'&+VGAG6W.RVBGM]=;G1/BFIQRN(,C6D./];H[O/7875QOK
M9KEY.EDK:IY?45#:*61Q[W.+-D_2KCA'5&4?(-/;FV-6>EM]'=[_ &VEK#!'
MN*:H:'#;1\H;Z?.K(^2&LMSY(:B,T\L1+9F.!;RD?*!'0CQ6<8MP?Q$8?2T]
MSM,-=6U5.U]36S;=,Z1S=N<U_>WJ>FOTJN>3743CAWDMMEE?+#;ZV>&'F/R6
ME@.A[-[/SE8<(M-Q?!27MMJI,>X&913VC(Q?HVTM7(VNCD!T[LOD@ASNHUZ_
M%<^$>866R<)<8=D=\I*2>:*0M\ZG >\=J\;T3LCVJG<(OZ,>5?BZ[_2"E> 7
M#/'ZGA_17>_6ZGN==<&N<#5L[1L,8<0UK >@Z#>^_JNDDDI:GW(;9;J^DN='
M'5VZJ@JZ60;9-!('L=[B.BI&&VNUV3*LTNC<IAKS42B:JI72MU;@TO)#O2/*
M.I[P/DJD8%2MP'CS<\2MCI&V*ZTGGL%.YQ<(7@;Z;_NO'NY=]R[.#]-#6<4>
M+E+5Q-FIYJIL<D;QL/:7S @^PA8T:4Z>U('MX:<18[OQ*S*ENV043J%M1%36
MF(SL:R1O,\?P?7TR?1ZC9.Q[%LR^>^#6*V*;BMQ 9+:J1S+57QFA!C'_ (<A
M\FN3U?);]"^A%,R2EM[%1X:B\6VGN+:"HN%)%7.B,S:=\S6R&,;V_E)WRC1Z
M]W0J-M6:XS=[B:"UW^V5=;UU#%4-<YVN_0WU^98SQ;L<>2^43BMFJ9)64E7;
M=5 C>6E\;73O<S8\"&Z^==7E&X78L5Q.TWK%[?#:;E2U\<;)J4<A(+7N!/K(
M+00>]:CBBZ3>[(;5<\VQBUW+X/N-_ME-6[T89:AK7-/MZ]/G5@8YKVAS"'-(
MV"#L$+)+SPEQ6GX:W&.2V137-E#).ZXR;,[YPPNYR_OZNZZ[EY>$\%SR;R=Z
M:@IKJ:"LDBFI65KFEQBC;*X>L?U/1!WTZ>I9<(M6GW*7^Y9_B5LJW4M?D=JA
MJ&GE=&ZI;MI]1T>GSJ?MU?27*DCJK=5055+(-LE@D#V.]Q'185;8N"^)X_%;
M+O56.YUD<8;4U(A-3)+)_6(+0XMZ[T >BZO)@K*4Y'G5#8Y)C86SQS44<NP6
M-+I .AZ[Y0T=>O0*O$M+DKV(;'?<SQNP5(IKS?+=15! /92SM#P/66[V I&W
MW>W7&WFOM]?2U-$ 29X96O8 ._;@==%\OX%=L1QN\7R@XNV9S\BFK7R/K:VE
M-0QS#KN'4@;YCL [!'7HM:X58IC-+>+]=<.OD%;8;FP,DM<.G1PGV]=C^MT(
M'1VO!)XE%=_V!%X?Q)AN'&#)Z2X9'0_ D44<5M;YPQL3W$MWRG?IN))]9\%M
M"^>.'>(X_+QUS:AEL]&ZCH&Q24L)C'+"[T3MH\#M?0ZF9135>$5'3655/14T
ME36SQ4]/&.9\LKPQK1ZR3T"@[/F^,7FN\SM5_ME75GH(HJAI<[W#?7YEEO%.
M)V;<9\<PBLEE;8X:<U]7$QQ;VSO2(!U[&@>SF*LF<\&\>O-B9!CM%1V.[4[V
M/I:VFCY"P@C?-R]7=-]_7>BBA%):GR#39YHJ>%\T\C(HF N>][@UK0.\DGN"
MKUMSO%;G<!0T&16JHJR>5L4=2PEQ]3>O7YEB_'B\AE\PW#\JO#H+28&55XJH
M6.'G&B6_);L]3&[0ZZ+@?!=&77#@C<<5JJ&US45%71PDTE13T4[)&R >CMW)
MMPWK?,3_ -UJ.'9-WOX)9J?'V62#A%D4D$CXY&QQZ<QQ!'\,SQ"SOBE5U,7D
MSXU/'43,G=%1;D:\AQW&=[/>NI^2U63^2E=*FXRNFK*8-I)97'9?R31\I/MY
M2W9\3U7YQ6_HOXQ^*H?],K<(Z:3_ # WJBJH:6P4U363QPPQT['22RO#6M'*
M.I)[E%6S/<3N=<*.WY':IZIQY6QLJ6[<?4WKU^99EY0U-7RX%C$T=-45=DII
MX9;G3P$@OB#1K>NX?*&_ D%0L[^#F>V+X,MDE!C=R/+V,TE,()(W ^+MAK]]
M1HN/?ZUSCB36IW_@'T8B\-BI)*"RT-'/5OK9((&1.J7C3I2 !S'VGO7N7 H5
M!XP9Q+AEDIS0QL?<:QSF0EXVU@:!S.(\=;;T]JORS[C-A$^8V2F-N<SX1H7.
M?$QYT)&N YF[\#Z+='V>W:[^EZ?5CU?Z3GDU:'IY,^H[=Q:NUOCNL5RF8V9@
MECB,[(W.:1L:8!H;]1TK!P<XCW.\7F7'LF =7-:XQ3<@8XN;\ICP.F];.]#N
M*H]#G.>X-#%0W2DD=2P 1L974YT&CN#9!K8^<K1>%^=X]E%W,;K+26R_NYI
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M/D,KF![G;<0 3MQ)[@%RCGBO3O%W;LTX/J*9*+ O*7@?#><?KM;88WQ[]K7
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M6'\@9_K/6L>4]_-#<OQ\'^H%;LJX?XQE=P@KL@M;:RJ@8(XY#-(SE:"3K37
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M>6FH:9A@C8(0SJ]VW/(&]-  )<>O?M>N*_'K:_P0^ILUQQF5\.ZZS/ YZFD
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MGDXLWA].SLH)*"<PQ_V6]M$0/F'ZEPOMSI+!Y5,UPNTPIJ.&L:Z25X.FM=
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M:I-HH41??XW:ORD*741??XW:ORD+ )=$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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ML'-)*[^RUOB?T#Q6?_9R@I6Q55ZP_);;9Y2 ROFIO0T>XGNZ>XGYU(XY25I
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M:;\ U!%4^&?QL^+TGQ\[#X6\X=R]CR<O9:;R_)Z;WS*V*-4Z 1$4 1$0!$1
M>*]_:BL_%._4N=J^U='^)9^R%PO?VHK/Q3OU+G:OM71_B6?LA ?(7$7A!FE3
MQ#NKZ*V35]/7U<D\56UPY.5[B1SDGT2-Z._5TVOK3%[?-:<:M5NJINWGI*6*
M"27^VYK "?I"DT77)FED23["BH<8/YKLJ_P^;]DK&>$W!JU9/P^M%XJKW?*:
M:J;(714T[6QMU(YO0%I_L[[UN'$NWU5UX?Y#06^$SU=312Q11@@%[BT@#KT6
M.8+<^*N(8K06*EP.*HAI \-EDJ&ASN9[G==/U_673$WH:BZ=D(W,L$JN"\U-
MFF,7(W%D4K8*B&XQ,>_E=XA^NF]:V-'KWD;"L/E"W".[8SP_N, +8:RXP5#
M>\->SF&_F*\V06#B;Q3-';,FMM%CF/QS-EFY)0^20CV!SB2 3H'0WW[TK+QN
MP^XW2S8A08U;WU$-MKXBYC'-'9Q,;R@]2.X +:DM4=3W!#\4X67KR@L"LUQ
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MXDGIOY1&NXJMIK3?*0//Y5MNI7V''+BYC!6Q7)D#'ZZECFN)'NVT%=_E,?\
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M\_/DU94?B]E;L9Q=[:-Q^%:XFGI6M^4">]X'L!^DA7>1[8XW/D<&L:"7.)T
M!XK!Z2UU/%O-+C=Q6U%!9[:1!0S1#TBX'8(]1_K$]XVT+R^DQQE+7D_ICS^R
M.N632TQY9(9!A+<?X$UM(]@-P!CK:EW>>TYV[&_8W8^D^*TO :[X1PFQU1.W
M/HX^8_\ ,&@'](*HE[X6USK/7!V87ZJ_@7GL992YDA )#2-]Q71PWOWFG FN
MJN?^$M\=3$T_\W5S1]+VKTY5UL5J6IZO[_\ ASA^"6ZK;^QW<&)&UMTS7)IC
M_!5-:6L>?!C>9WZG-^A>/A)<XK5AV5YC<@=5-8^8CQ>!U 'O<\A,?_\ K;\G
M>JJ3Z$U73ROW[97<C3]!:O+D%HGH?)RHX(&'?)%53 #KRODY^ONYF_0NDE&<
MI+M*2C]%_$93:2?A-_<D\9QN]9[0B^Y3>[E1TU5Z=)04$O9-9'X./?O?AXZZ
M[ZZ7HQ6LNF)\2!B-QN51<[;6TYJ**6I=S2QZ#CRD^KT7#Z"-=0KUAU;1U.(6
MJIHY8_-&TD8#@1I@:T @^K6M'W+.\=J/CEQEJ[[0@R6FS4QIHIA\F5Y#AT/^
M9Y]P'K7%3>3J*2J*3^C[?4WI4=+7+/W.[I+=.)E/C-RO=18[**82\\,G9.J9
M#W-YSW#PZ]-M/B0O9'C&18EDMIFQFON-VLM0_DK::LJ&O[)FQZ8)(\"3TZ]/
M':[[3/CO%RU50NMK["KHI3%R&7^'B&AZ0( T"=C1V-A0N'MK\-XIPXE2W2:Y
M6:HIW3=G*>8TOHN(WZCZ([M APZ+:M1<%LXK=-;/WOR9[ZNS?)'<0L>?>.+]
MHM(N]R<*H&L<.UZ4@&]=D/ZI_@^_W*R9==KEC\=DPK&JV>IO==O==5O[22.,
MN)+R3X]'>X-/L71B;A>..N3USB#';J<4L8]3O1:?TM?]*A\QL]NN7'.*DR4O
M;0UE&T4SA(8P7@: YA[0X:]9"VGJE&$^(QOZ_P 9.$Y1[NB=N/#BLH;5/7V_
M+;X^^0QF4325.XY' ;Y2WU'N[S\ZGL/S%]UX9G(:P-;44]/*Z?0T"^,'J/?H
M'7M50SC#\#Q&V><U\-;+,]P;#2QUC^TE)/@-]P]:]>=PT>+<$YJ6V4LU"RLY
M&-@F?S/8Z1P<YKCZ] A<VEFC%.W;V=)?/N:5P;?%(A.'=DR7-L28;ED%PHK9
MVKRU[)'/FJ7[T27$]&-UH-]>U-VA]:>,5#8X;G734%DMC1.UT[M3OY?E/&]$
M[D:>OJ]BT/#[:+/BUJMX;RFGIF,</^;7I'Z=K/>#^[ME>;Y!WB:K\W@=_P H
M)/ZNS4>;7U)?\5Q]704-.E=SC45UWXB9A<[3:KG46K';4[LJB>E/++42;(T'
M>K8=[-#9WL+L9C.189E=HDQZONEWLM3)V=;3U4@D[)NP"_?0=QWT&_1\=KAY
M.KHX['>Z68@7&.X.,['?* Y0!OYP[]*M=)F\-PSV7&[92&JCIXC)4UK)?0A=
MU]'6NIWRCO[R?4F24\<Y8X+\,5_&(I22E)[LMZ(B^:>D(B( B(@"(B (B( B
M(@(B#^5-3^3M_6I=1$'\J:G\G;^M2Z P+@?"W*^*V;9?7CM9::?S6CYNO9M)
M<.GJ(8QH_P Q6^KYZX-W.GP/B5F&)9!*VC=650J**68\K)1MVAL]-N:YI'M!
M'>MOR;([3C-JEN-[K8:6FC:3MSAMY]31WN/L"[YDW/;VHB/Q^-6=^2,R!U!$
M;RR/L6U77F#-$:[]=Q*SKC)@]^KLAM&9X2^,W^U,[/S>30$T>W'0WTWZ;P02
M-AW?L=?9P3O^49<+S?[W(8;%4S%MJI'0L:YK 3MW,!LC6ALD[/-[%XN"G$>L
MO]5>K+F-730Y%1U;F,@Y1%S,  (:/$AP=OQZA$IP;?- \N,<=J(5S;5GMKJL
M;NH(:YTK'=B3ZSL<S1[P1[5J5DL]FH9:FX6:BHX9+@1--44[1NHV2X.+A\KY
M1._:J?QX;C1X?71V3BE,@@?YD7Z[7M]'D[/QWS:WKIK>^BB^!E-=QP*IXINT
M%5)!4>9A_0AA+NS[_#?4>PA)13CJCL" \G/_ ,\S+/\ *G>DVJK.Q@=_RESG
M$?1V:W2IG934TL\S@V*)A>XGP &R?T+$/)/N5MCPRML_;,BO$5=))/32'ED(
M+6@. /4CT=>PA6'C[F]%8,,N%JIJADM]N<1I(*6(\T@#_1<X@=1T)UZSK2N2
M+EETH%>\EB!]=0Y9DM0W^&NMR(V?4W;S^F4_0K]8L3O%%Q"N^07#(JBKMU5&
M8Z>V<SQ%!U;HZ+BW>FGN ^45QX46%F#\,K;1W-\=-)!"ZIK'R.#6QN<2]W,3
MT'*#K?\ RJVVNY45UHVU=KK*>LI7$ALU/()&$@Z.B.G>LY)W*37!3U+)<UXO
M5=GR6NLV.X?=+_-0<HJY8.8,C):':'*QW@1U.EK2ZX8(H3(88V,,CB]Y:T#F
M=ZSZST"YQ:3W5@R.P>4%B-9#(V]BLLE9%T?#/"Z0;]0+ 3]("O.#9739QCT]
MSMD=134CYI((7R ![@WIS@>'4G0Z]WS+VWC%,?O50VHN]CME=.WNDJ*9CW?2
M1M2U-!#2P1P4T4<,,8#61QM#6M \ !W!:DX5^% ^=.,^!XSP_P"&59);*62I
MN]RJ(J45U6_M9R22]VCW#880= =ZWG$+6+)BMHM8 !HZ2* Z];6@$_2"LGXZ
M?^=\1^'6,-])DE8:R=GK8UP_]+9%MQ( ))T MY)-P5]]R!87QRH<FR#B)B5O
MQRT25,-O/GIGJ(W"D$O-TYW]WHA@.@=^EKQ6RV>\VR]0R2V>XT=?%&[D>^FF
M;(&N[]$M)T52,-XA5%UXD9-BEYIZ:BJ+>_=$&D\]1'L[<=GJ>4L=H>!/J6<=
MQ;DEP4I657WBIPZ9%?;_ %UJOMD[5K*J"GA$9B#CKH>5I'J!Z]=;"F_*!R^6
MDX34==8:RHIY;O+ *>:!YCD#'#M-@@[&PT#YUP\I7((?BFW$J#55?+U-%%'2
MQ]7M:) [F(\-EH WW[/J*@,\MA?FW"+!RX2MMT4<U0!U#VQAHZ_-"_Z5V@D]
M,FO/V1#VWG L@K<"GO66Y=>*.OH;<9H:2CF+(J?LX]@2'Y4CSKTG;!V3KP7D
MX84&7<3L)H9<BR.OMUF@YH6.H7<E37$.(YY)#OT1\G6CL@D^M77RC+K\%<);
MSRNY9*OLZ1GMYG#F'YH<K)P\MS,<X=6.DF C%+01NF\-.Y>9Y^DE9UO1?N#-
MN!<URMO$/-,7==JRZ6:V%HADJY"]T;^;6M^']8'6AMN]!0>-566YSQ4S:"SW
M^LMUDBF--)4-D<_L6-=RAL#">5KW<F^;P&SWE2/ "K\VP[.\WK!I]95SU3B?
M%L;72?K>X*<\ENW.IN&KKC.-SW2MEJ7//>X \GZVN/SK4WIU2^2!2+G39)@/
M%ZV8]AE^N%UDNU)SOBNTQF;&YW..T=K7R>3G[M]".NUW<8L4NF#XU#E,>;Y!
M57YM5&QSI)^6*0NV2&QCY(Z$ZV1K8TK#A7_UP>4EEUT/IP6BE;11G^R\\K3^
MELOTIY0__G63X!BK?296W'MYV^IC2UN_H=)]"JD]<5[;@V6TRS3VJCEJVAM1
M)"QTK1W!Q:"1]*]2(O&4(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"B+[_&[5^4A2ZB+[_&[5^4A 2Z(B +">%_](SB
M%^*_]4:W983PO_I&<0OQ7_JC7;%_3+Y?N0C[E9*+(_*5R2T72+M*2KLXC>/$
M?P<6G#U$'1!]84AP5O=;AF45O#3*)=OA<9+54.Z"6,[/*/81MP'@>8> 7.U_
MTLKO_A3?].)6/CO@LV3V*&[V/FCR2SGSBDDCZ/D /,6 ^OIMOM&O$KJY+:$N
M&D"N6/\ I99#_A3/].!<+E_2UM7^&._TI55N!V3RY?QVK+S51=E4S6@,F:.[
MG8(6.(]0):3KPVK)>ZB&E\J^URU4T<,0MAV^1P:T?P<GB56FI-/\H-[6!9LP
M6CRHL3JZ,<C[A2AE0&_U]]I'L_,&_FA;-5Y18:.G?/57JVQ1,&W.?5, 'Z5B
M>)5'V3./TF3T#'NQZPP=A!.YI E?IP&M^LO<[W ;UM<L*:MOB@?0:H?&K-I,
M&PF:X4;&ON,\C:6E#QL"1P)YB/'0:3KUZ5>R;@39<@O]?=JB]WN&:LE=,Z.&
M5@8TGP&VGHJ?QPX?LQ?@_;Z2V2UE?1VZY^<SNJ' OY'AS220!T!+1\Z8X0<E
MO8+!;>$ESN-LCK\ASS(&9'*P2%]/5\L4#SUY0WQ [NA;[-*8X)9==KC57[%L
MIF;4WJQ3=GYTW_\ B(MD!Q]HT.OB'#QVHBP\'.&M\L5/=[<:N6AFC[02>?.T
MT:ZAWJ(\0>Y=W JDPAN0Y#)@U%= :35+-65$@?!,"[8[,[V?D[[AT]ZW)J47
M>_TX!3>&M#E/$"Y9/;*K*KK0V*AN,CI'PS.,\KG$AL37DGE8T,)UW>EW'PEJ
M6"]<+>+>.6:+(+A=L?OA,?85TG.Z-V];![@02T[ &P2"/%2GDR_+SK_&'?\
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M'L.PM51;6225)@XPQ1P1,BA8V.)C0UK&#0:!W #P"I&;<*L3S&J-7=K<65Q
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M!J+=;92YK&5+!VKW!Q;RM:">8DM.M>K?15:/CO:F".JK\<R2AL\I 9<)J/\
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MD5_BQJIO.(2V"EAN#>PFJ*@/F>X]2WET"T= ?F"W#$G2K^?(%Z\H[[=<.O\
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M_P 8=^U(HXJ,9)>P-M1$7F*$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!<99&Q1/DD.F,:7.)\ %R57XGW'X+P"^U(=
MRN\V=$T^IS_0'Z7+6..N2BNY).DV47A)Q&N^4Y=54%U,(I74[YJ<,CY3L/
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M .Z'V;]BJ5EX>YAEU*ZZYUEEZM-9,\F.VVV81,IV[.@=;!/Z=:V24Z=-ZG5
MVQ%C'"&\WN@XE9+@]TO,E\H;= VH@K9^LC=\GH%VR3TD\2>K?F7BS:\5F2\9
M9<,K,EJL;LU-2LD8ZEE$,E;*X-/*'G^\1KK\@]-]UZ3U5?N#=$6.4&.9E@V=
M6:.S72[9'BU<[LZR.OE$CZ0; Y^8Z]>^@ZZ(UW+\S#([_F/$*7!\,N!M=+0Q
M]I=;G&-O9W>@P^!Z@=-'>^H .W3M[/8&R(L&SG&[_P +K+\:L>RV]W)E')&:
MVBND_;1SL<X-.O5U(]O7>^G6Y<5\VJ[-PD?DE@;J>KB@=#(YO-V+9=>F1W;
M/3?39"=.ZTN[!HZ+"*+ +E=,1;?\9XCW^OO;H.V8]M9S4\DFM]GR=[>O31/3
MQ'@M2X<UM]K\/H)LLHS1WH-+*AA ',02 _0Z#8T=>O:DH)*TP65$1<P$1$ 1
M$0!$1 $1$ 1$0!$1 %$7W^-VK\I"EU$7W^-VK\I" ET1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 >*]_:BL_%._4N=J^U='^)9^
MR%PO?VHK/Q3OU+G:OM71_B6?LA >I$1 4?CA_-/D_P"2']868<+LOS/%\"M-
M)+A]9?Z"2 24%50R;TQQ)$<@T2-'8WZO7WK8^)%DJLDP:\V>WNB;55D!CC,K
MB&@['>0#^I<N'5EJ<=P>RVBO=$ZJHZ=L4AB)+21ZB0/U+M&:6.GON0I/"?$;
MX<KO.<9K%'37FY,$,%&QW-YM#TZ$]V]-:/F.^IZ<.#>.W:SY[Q'K+I034U+<
M+@):61X&IF]I,=CYG-^E:VBR\K=^Y3,.-&$72_/LV08I)&S([)+VL#'D!L[=
M@\FSTWL>/0[(\5"UW$3B!7VN2W6WAU<J2]RL[/SF5_\ X>)QZ<X) !]8!.O:
M5M*(LE))JZ!G-@P"NFX4U6,Y;=ZFXU]?&XSU$LKINQ>=%H87=2&EK3[3OUJH
M8ID.></[-%C=UPJMOC:(&*CK;?)S,DCWZ(=IIUKNV='6MCQ6ZHBR<IJP8_@.
M*9+-/EN5Y9&8+O>:9\-/;HY.801\N@#UUS>BP?-U[]#JX8XS>;9P#O%EK[?/
M!=)8*UK*9X',XO80T?.ME15Y6_YX!B^.XQ>:?R::BP3VZ=EX=2U+!2$#G+G3
M/+1\X(*O/"*W5=HX;6"@N5.^GK(*?DEB?WM/,>A5O1261R37O8,EPW';M1\?
M<QO550316NKI&,@J7 <DC@(N@_-/T+]X38]=K3Q)XC5]RH9J>CN%8U]+*\#E
MF;SRG8^9P^E:RB/(VFO:@81:K;E7"+(+Q'9,?GR+$[C.:F*.D=J:F>?#ET2>
MFAW:( .P=A>ZT6[*^('$.T9%D-JGQVPV;;Z:CED_AIY"0=N'30V&D['<W779
M*VE%7E[UOY!\^8U2Y3PJS')M8I6Y!:[O4=O%5T'I2#TG$!PT3_6Z@ZZC8VO#
MQ8M?$'/::VW4XV^AH*"I:8+9VHDJ9-]72O[@ .4#7?Z2^D46EFIZJW)1DO'"
MP7:_W'!9[3;YZEE)<FSU'*/^$S;#MWT'Z%K2(N3E:2\%,T\H:QW+(>&\]!9:
M.6LK'5,3Q%'WD G97JS7$YLCX-/L;H#\(,MT1BC/>)XV AOL)(Y?G6@HJLC2
M278&1>3[C%[MU/>;YE\$L5\N#XH-3:YQ#$P-:?G_ /2$X:8Y=[;QBSRZ5]!-
M!;ZYP--.X#EE]/?1:ZBKRMMOR#'>'N-WBW\=,UO%;;YH;961$4]0X#ED/.P]
M/H*URNI(*^BGI*R)DU-.PQRQO&P]I&B#\R[D693<G8,.X48[DO#K/[I8!0U5
M9A]:\RT]8W1;"[6VEWS>B[IW@'N4UQ5X<W.Y9!1YA@]6RBR>C:&N:\Z94M'0
M GNWK8Z]".AUI:NBV\KU:NX,2CXG<1**/S:Y\,:VHKF]#+2R.[)Q]?1KA_U+
MP4V'YYQ'RJSWO.64MBM=KG$]-11 .E)YFN]9UOE&RX^'1JWQ%>K7]*I@R#C5
MC=WO6=\.:RU4$U52V^O[6JDC U$WM83L_,UWT+7T1<W*TEX 6.OQN\'RE([\
M+?-\#BA[,U>AR<W9$:^E;$B1EIOW < YI#@"#T(/BL(L.)W[AMQ>GEQVVU%9
MAUXT9V0:(IB2==/^0DZ_Y7:[UNZ*PFXVO(,/R3&;_P 3>)D,-_M]3;\(M#B^
M-DOHFM>#K>@=^E^AN^XE:]>K';[S8:FS5],Q]OGB[%T0&@&^&O41T(]6@I)$
ME-NO8&)<)*#+>']PO6,7"V5=RL,7:3VVMC +2=%W)W].;U>#M^O:H6-4_$&V
MYG<,IO& U%YO-0[<4M1)RMIAZF-ZZZ: /@![2OJI%T6;=NN248]:\_XC5-SI
M(*SAT^GII9F,EF[<GLV%P!=\PV5L*(N4I)\*BF3>43CUVR&R6"&R4,U9)!<V
M32MB VU@:X%Q]G4*_P"<4LU=A>04E)&Z6IGM]1%%&WO>YT;@ />2%-(KK=)>
M 4+@3:*^Q<+[/;[O2R4E;"9N>&3Y3=RO(_005 <.L;NM!QASVY7"WRQ6VOT*
M>9X'+*.;KI:XBO4=M^08)8;=EW!Z[72CM-@GR3$JR<U$ I'?PU.X]-%NB3T
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MD[6G:U^F\VVGJ/'JT+OZ;)''D4Y=C&2+E%I%&XJTD=EDP"KC(9#;;A%3<W<
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MM=V[_9%ACTOZ')$1>0ZA$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M9:+*R1M(Q[I/X5_,XN<=DDK,LB:?N"=64^4Y=?@WA/71-=ROKYXJ5OYW.?\
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MO++'P8J[M75EMEHJ>R^<6J.*,\\7*QQ_A-@ ]S>X^M>WX_7O_P!G?XX\]/\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M_P#D<^(?PM_4Y//O-O\ \-VN^SY_F^5[?8FN*?/>P3O"L <-,4T-?^54Q_\
ML35F7!F.27/.+T<!U*^N+6'U.+Y]+8L6M/P#C5IM';=OYA2Q4O:\G+S\C WF
MULZWK>ME5S!,#^*F395=_A+SOX=J14=EV'9]AZ3W:WS'F^7WZ'<N:DOQ>_\
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M1<K+43-ADEM?/VD)/L/?T!\.NM;"O'$_/J3!\?AK3 ^MK:QXAHJ2,Z,SS^D
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M( B(@"(B (B( B(@"(B (B( HB^_QNU?E(4NHB^_QNU?E(0$NB(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(#Q7O[45GXIWZESM7V
MKH_Q+/V0N%[^U%9^*=^I<[5]JZ/\2S]D(#U(B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B("+^,%L^^A^8[]R?&"V??0_,=^Y2/91_<V?0G9
M1_<V?0@([XP6S[Z'YCOW)\8+9]]#\QW[E(]E']S9]"=E']S9]" COC!;/OH?
MF._<GQ@MGWT/S'?N4CV4?W-GT)V4?W-GT(".^,%L^^A^8[]R?&"V??0_,=^Y
M2/91_<V?0G91_<V?0@([XP6S[Z'YCOW)\8+9]]#\QW[E(]E']S9]"=E']S9]
M" COC!;/OH?F._<GQ@MGWT/S'?N4CV4?W-GT)V4?W-GT(".^,%L^^A^8[]R?
M&"V??0_,=^Y2/91_<V?0G91_<V?0@([XP6S[Z'YCOW)\8+9]]#\QW[E(]E']
MS9]"=E']S9]" COC!;/OH?F._<GQ@MGWT/S'?N4CV4?W-GT)V4?W-GT(".^,
M%L^^A^8[]R?&"V??0_,=^Y2/91_<V?0G91_<V?0@([XP6S[Z'YCOW)\8+9]]
M#\QW[E(]E']S9]"=E']S9]" COC!;/OH?F._<GQ@MGWT/S'?N4CV4?W-GT)V
M4?W-GT(".^,%L^^A^8[]R?&"V??0_,=^Y2/91_<V?0G91_<V?0@([XP6S[Z'
MYCOW)\8+9]]#\QW[E(]E']S9]"=E']S9]" COC!;/OH?F._<GQ@MGWT/S'?N
M4CV4?W-GT)V4?W-GT(".^,%L^^A^8[]R?&"V??0_,=^Y2/91_<V?0G91_<V?
M0@([XP6S[Z'YCOW)\8+9]]#\QW[E(]E']S9]"=E']S9]" COC!;/OH?F._<G
MQ@MGWT/S'?N4CV4?W-GT)V4?W-GT(".^,%L^^A^8[]R?&"V??0_,=^Y2/91_
M<V?0G91_<V?0@([XP6S[Z'YCOW)\8+9]]#\QW[E(]E']S9]"=E']S9]" COC
M!;/OH?F._<GQ@MGWT/S'?N4CV4?W-GT)V4?W-GT(".^,%L^^A^8[]R?&"V??
M0_,=^Y2/91_<V?0G91_<V?0@([XP6S[Z'YCOW)\8+9]]#\QW[E(]E']S9]"=
ME']S9]" COC!;/OH?F._<GQ@MGWT/S'?N4CV4?W-GT)V4?W-GT("N17>A;?Y
MZ@SCL70A@=RGJ=^Y27Q@MGWT/S'?N73!&SXSU(Y&Z\W;TU[5+]E']S9]" CO
MC!;/OH?F._<GQ@MGWT/S'?N4CV4?W-GT)V4?W-GT(".^,%L^^A^8[]R?&"V?
M?0_,=^Y2/91_<V?0G91_<V?0@([XP6S[Z'YCOW)\8+9]]#\QW[E(]E']S9]"
M=E']S9]" COC!;/OH?F._<GQ@MGWT/S'?N4CV4?W-GT)V4?W-GT(".^,%L^^
MA^8[]R?&"V??0_,=^Y2/91_<V?0G91_<V?0@([XP6S[Z'YCOW)\8+9]]#\QW
M[E(]E']S9]"=E']S9]" COC!;/OH?F._<GQ@MGWT/S'?N4CV4?W-GT)V4?W-
MGT(".^,%L^^A^8[]R?&"V??0_,=^Y2/91_<V?0G91_<V?0@([XP6S[Z'YCOW
M)\8+9]]#\QW[E(]E']S9]"=E']S9]" COC!;/OH?F._<GQ@MGWT/S'?N4CV4
M?W-GT)V4?W-GT(".^,%L^^A^8[]R?&"V??0_,=^Y2/91_<V?0G91_<V?0@([
MXP6S[Z'YCOW)\8+9]]#\QW[E(]E']S9]"=E']S9]" COC!;/OH?F._<GQ@MG
MWT/S'?N4CV4?W-GT)V4?W-GT(".^,%L^^A^8[]R?&"V??0_,=^Y2/91_<V?0
MG91_<V?0@([XP6S[Z'YCOW)\8+9]]#\QW[E(]E']S9]"=E']S9]" COC!;/O
MH?F._<GQ@MGWT/S'?N4CV4?W-GT)V4?W-GT(".^,%L^^A^8[]R?&"V??0_,=
M^Y2/91_<V?0G91_<V?0@([XP6S[Z'YCOW)\8+9]]#\QW[E(]E']S9]"=E']S
M9]" COC!;/OH?F._<GQ@MGWT/S'?N4CV4?W-GT)V4?W-GT(".^,%L^^A^8[]
MR?&"V??0_,=^Y2/91_<V?0G91_<V?0@([XP6S[Z'YCOW)\8+9]]#\QW[E(]E
M']S9]"=E']S9]" COC!;/OH?F._<GQ@MGWT/S'?N4CV4?W-GT)V4?W-GT(".
M^,%L^^A^8[]R?&"V??0_,=^Y2/91_<V?0G91_<V?0@([XP6S[Z'YCOW)\8+9
M]]#\QW[E(]E']S9]"=E']S9]" COC!;/OH?F._<GQ@MGWT/S'?N4CV4?W-GT
M)V4?W-GT(".^,%L^^A^8[]R?&"V??0_,=^Y2/91_<V?0G91_<V?0@([XP6S[
MZ'YCOW)\8+9]]#\QW[E(]E']S9]"=E']S9]" COC!;/OH?F._<GQ@MGWT/S'
M?N4CV4?W-GT)V4?W-GT(".^,%L^^A^8[]R?&"V??0_,=^Y2/91_<V?0G91_<
MV?0@([XP6S[Z'YCOW)\8+9]]#\QW[E(]E']S9]"=E']S9]" COC!;/OH?F._
M<GQ@MGWT/S'?N4CV4?W-GT)V4?W-GT(".^,%L^^A^8[]RC;M=Z&>HM[HIPYL
M4X>\\IZ#U]RL?91_<V?0HF^1L%5:],:-U(WT0';\8+9]]#\QW[D^,%L^^A^8
M[]RD>RC^YL^A.RC^YL^A 1WQ@MGWT/S'?N3XP6S[Z'YCOW*1[*/[FSZ$[*/[
MFSZ$!'?&"V??0_,=^Y/C!;/OH?F._<I'LH_N;/H3LH_N;/H0$=\8+9]]#\QW
M[D^,%L^^A^8[]RD>RC^YL^A.RC^YL^A 1WQ@MGWT/S'?N3XP6S[Z'YCOW*1[
M*/[FSZ$[*/[FSZ$!'?&"V??0_,=^Y/C!;/OH?F._<I'LH_N;/H3LH_N;/H0$
M=\8+9]]#\QW[D^,%L^^A^8[]RD>RC^YL^A.RC^YL^A 1WQ@MGWT/S'?N3XP6
MS[Z'YCOW*1[*/[FSZ$[*/[FSZ$!'?&"V??0_,=^Y/C!;/OH?F._<I'LH_N;/
MH3LH_N;/H0$=\8+9]]#\QW[D^,%L^^A^8[]RD>RC^YL^A.RC^YL^A 1WQ@MG
MWT/S'?N3XP6S[Z'YCOW*1[*/[FSZ$[*/[FSZ$!'?&"V??0_,=^Y/C!;/OH?F
M._<I'LH_N;/H3LH_N;/H0$=\8+9]]#\QW[D^,%L^^A^8[]RD>RC^YL^A.RC^
MYL^A 1WQ@MGWT/S'?N3XP6S[Z'YCOW*1[*/[FSZ$[*/[FSZ$!'?&"V??0_,=
M^Y/C!;/OH?F._<I'LH_N;/H3LH_N;/H0$)=;W;YK;4Q15(<]\9:T<KNIU[ER
MM]\MT5!31R5(#V1-:X<CNA ]R]EZC8+36$,:#V3O#V+LM4;#;*,EC=]BSP_Y
M0@//\8+9]]#\QW[D^,%L^^A^8[]RD>RC^YL^A.RC^YL^A 1WQ@MGWT/S'?N3
MXP6S[Z'YCOW*1[*/[FSZ$[*/[FSZ$!'?&"V??0_,=^Y/C!;/OH?F._<I'LH_
MN;/H3LH_N;/H0$=\8+9]]#\QW[D^,%L^^A^8[]RD>RC^YL^A.RC^YL^A 1WQ
M@MGWT/S'?N3XP6S[Z'YCOW*1[*/[FSZ$[*/[FSZ$!'?&"V??0_,=^Y/C!;/O
MH?F._<I'LH_N;/H3LH_N;/H0$=\8+9]]#\QW[D^,%L^^A^8[]RD>RC^YL^A.
MRC^YL^A 1WQ@MGWT/S'?N3XP6S[Z'YCOW*1[*/[FSZ$[*/[FSZ$!'?&"V??0
M_,=^Y/C!;/OH?F._<I'LH_N;/H3LH_N;/H0$=\8+9]]#\QW[D^,%L^^A^8[]
MRD>RC^YL^A.RC^YL^A 1WQ@MGWT/S'?N3XP6S[Z'YCOW*1[*/[FSZ$[*/[FS
MZ$!'?&"V??0_,=^Y/C!;/OH?F._<I'LH_N;/H3LH_N;/H0$=\8+9]]#\QW[D
M^,%L^^A^8[]RD>RC^YL^A.RC^YL^A 1WQ@MGWT/S'?N3XP6S[Z'YCOW*1[*/
M[FSZ$[*/[FSZ$!'?&"V??0_,=^Y/C!;/OH?F._<I'LH_N;/H3LH_N;/H0$=\
M8+9]]#\QW[D^,%L^^A^8[]RD>RC^YL^A.RC^YL^A 1WQ@MGWT/S'?N3XP6S[
MZ'YCOW*1[*/[FSZ$[*/[FSZ$!'?&"V??0_,=^Y/C!;/OH?F._<I'LH_N;/H3
MLH_N;/H0$=\8+9]]#\QW[D^,%L^^A^8[]RD>RC^YL^A.RC^YL^A 1WQ@MGWT
M/S'?N3XP6S[Z'YCOW*1[*/[FSZ$[*/[FSZ$!'?&"V??0_,=^Y/C!;/OH?F._
M<I'LH_N;/H3LH_N;/H0$=\8+9]]#\QW[D^,%L^^A^8[]RD>RC^YL^A.RC^YL
M^A 1WQ@MGWT/S'?N3XP6S[Z'YCOW*1[*/[FSZ$[*/[FSZ$!'?&"V??0_,=^Y
M/C!;/OH?F._<I'LH_N;/H3LH_N;/H0$=\8+9]]#\QW[D^,%L^^A^8[]RD>RC
M^YL^A.RC^YL^A 1WQ@MGWT/S'?N3XP6S[Z'YCOW*1[*/[FSZ$[*/[FSZ$!'?
M&"V??0_,=^Y/C!;/OH?F._<I'LH_N;/H3LH_N;/H0$=\8+9]]#\QW[D^,%L^
M^A^8[]RD>RC^YL^A.RC^YL^A 1WQ@MGWT/S'?N3XP6S[Z'YCOW*1[*/[FSZ$
M[*/[FSZ$!'?&"V??0_,=^Y/C!;/OH?F._<I'LH_N;/H3LH_N;/H0$=\8+9]]
M#\QW[D^,%L^^A^8[]RD>RC^YL^A.RC^YL^A 1WQ@MGWT/S'?N3XP6S[Z'YCO
MW*1[*/[FSZ$[*/[FSZ$!'?&"V??0_,=^Y/C!;/OH?F._<I'LH_N;/H3LH_N;
M/H0$=\8+9]]#\QW[D^,%L^^A^8[]RD>RC^YL^A.RC^YL^A 1WQ@MGWT/S'?N
M3XP6S[Z'YCOW*1[*/[FSZ$[*/[FSZ$!'?&"V??0_,=^Y/C!;/OH?F._<I'LH
M_N;/H3LH_N;/H0$=\8+9]]#\QW[D^,%L^^A^8[]RD>RC^YL^A.RC^YL^A 1W
MQ@MGWT/S'?N3XP6S[Z'YCOW*1[*/[FSZ$[*/[FSZ$!'?&"V??0_,=^Y/C!;/
MOH?F._<I'LH_N;/H3LH_N;/H0$=\8+9]]#\QW[D^,%L^^A^8[]RD>RC^YL^A
M.RC^YL^A 1WQ@MGWT/S'?N3XP6S[Z'YCOW*1[*/[FSZ$[*/[FSZ$!'?&"V??
M0_,=^Y/C!;/OH?F._<I'LH_N;/H3LH_N;/H0$=\8+9]]#\QW[D^,%L^^A^8[
M]RD>RC^YL^A.RC^YL^A 1WQ@MGWT/S'?N3XP6S[Z'YCOW*1[*/[FSZ$[*/[F
MSZ$!'?&"V??0_,=^Y/C!;/OH?F._<I'LH_N;/H3LH_N;/H0$=\8+9]]#\QW[
MEWP7:BG8713AS0=;Y3^Y>KLH_N;/H7Z&,'<UH^9 <D1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 1$'\J:G\G;^M2ZB(/Y4U/Y.W]:ET 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!1%]_C=J_*0I=1%]_C=J_*0@)=$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'BO?VHK/Q
M3OU+G:OM71_B6?LA<+W]J*S\4[]2YVK[5T?XEG[(0'J1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$
M1!_*FI_)V_K4NHB#^5-3^3M_6I= $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 41??XW:ORD*741??XW:ORD("71$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!XKW]J*S\4[]2YVK[5T
M?XEG[(7"]_:BL_%._4N=J^U='^)9^R$!ZD1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!$0?RIJ?R=O
MZU+J(@_E34_D[?UJ70!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 %$7W^-VK\I"EU$7W^-VK\I" ET1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 >*]_:BL_%._4N=J^U='^)9^R%PO?
MVHK/Q3OU+G:OM71_B6?LA >I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 1$'\J:G\G;^M2ZB(/Y4U
M/Y.W]:ET 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MQT.@7[B&2VW++'#=[+(^2BE<YK7/86';3H]#[0KI=7V!,HB* (B( B(@"(B
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M[RO)CL_%7/K:V_T5[M^-6VHV^CI!2MF<]F^CG%S2='U^/?H#2\V:T\U1Y*-
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M\-QS';7%%'=<UNS601M+0UG:Z:'O(&NG,X #I[^A417V[C#9;9)>?C+:[K/
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M^0PZ)+B.F]> ]94)!@&?W2%LN3<1ZJEYAS206V!L0;ZP)!R_3I9B]M3I7_.
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M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( HB^_P ;M7Y2%+J(OO\
M&[5^4A 2Z(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@/%>_M16?BG?J7.U?:NC_$L_9"X7O[45GXIWZESM7VKH_Q+/V0@/4B(@"R
MW,.#=NNU\??<=NE;C5[D)=)44)]&0GO):"#L^.B-^(*U)%J,G%V@8N[@G<;S
M+&W-L[O%ZH6.#O-&M,3'$>O;G#]&_:M;LMJH;):Z>W6JFCI:*G;R1Q1C0:/^
MY\23U*]J*RR2ELP?+O";")\DNV87.SWZML5YH[K)%'4TXYVNC<YQ+7LV.8;
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M-WO/K))VO?@^/LQ7%+;9(ZAU2RCC[,2N;REW4G>MG7>IQ%')M4P?CVM>TM>
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MG:G3)HR=\A/@0>H/M.^_8S*XXSQMR2RLQF[L:VV>BR2:6> <[6GISO:2YPZ
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M]<6WOVH&K(OQ@(8T./,X#J=:V5^KS%"(B (B( B(@"(B (B( B(@"(B (B(
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M<OI.T-CH=#2MJIO$A^5T..4L7#RAIY[@V9K"V5S V.$-/]MP'?RA6RB$S:.
M5;FNJ!&T2.:- NUU('O7FEO^+R4[EB,?D[6"JH'OO5VNM7>YB9)JX2@;D/>0
MT@[&_62?:MN16,Y0_I8,%BX19]31.M-+Q%G;8G>B=B3M6L_L@;Z=/ . 6Q4X
MH,1Q2GCK*QL-NME*R)U1.X#T&-#03[3KP\5,+%/*%QO,\LJ[3;\>M0K;'3ZJ
M*EIJHXFS2\Q 8X%X=H-'A_:]86U)Y6E)TB'AJ[CD/&RKDH;)V]EP*-_)45KA
MRRUVCU:T>KV=P\=GT5?\K@M^ <(KQ%9H6TM+14$C(0#U[1P+0XGQ)<X$E4V@
MO'&&WT<-)18%8(*:%@9'%'5,#6-'< .V4KQ6M&899PCIK;%;(/AZLDB-;3PS
ML:R)H)<=.<[1T0P="5MK=*U7S!W>3AC<%AX96ZI$36UMS'G<\FNK@2>0;]0;
MKIZR?6JQP7HH,CXMY[EL\;9/-ZLTE&\C>NI:7#V\C&#W.*V*"BEL^*,HK7$)
M9Z.B$-/'L#G<QFFC9Z#9 [U3> .(7##L&=27R 07.IJY*F=G:->1O31Z320>
MC0>_Q6==J4N[!6.*'_GO'OA]8V^DR@#KC)[-'FZ_4CZ5YLNH(,R\I6T6JK8V
M:@LE *F>)PV"[9<-CU;?%L>Q6;'\3O+N.M_RJ[4@BMGFC:6WO,K'%W1@)T"2
M/DO[P/E+]X<XG>:/BAF^37ZD%.VND;#0N[5CR^$$]=-)UT9'T.EK4HK9\+]6
M")\J:K>["K79:;K476XQ0M;ZP-G]HL5^KHZ3!>&]6V@8V*FM-N>8P!K98PD$
M^TN^DE5;B)B=YR3BGA-7'2!V/VA[JF><RL&I-\P'(3S'K&SN&O2]ZF>-=IO-
M]X=7*U8Y2^<UU68X^3M&QZ9SASCMQ [AKYUG9J,;! ^3#:S;N$]',\:?7U$M
M4=_WN0?H8#\ZU=0^&6GX!Q.SVH@!U'210NU_:#0''Z=J87.<M4FRA$18 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!1%]_C=J_*0I=1%]_C=J_*0@)=$1 $1$ 1$0&$
M^3;_ "LXE_XF/]29;LOG'&[#Q4PO),HJ<=QJWU=-=:UTP?55,?R0]Y:0!*TC
M8?XJ:N#.-F44LEMJ*.RX]33@LEJ8I07\I[]$/>1T]0!]H7IR04I7:KYD1Y^
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M*DR.D-0YW*T2!\;7'U!S@ ?I65&3X0+PBX32QPPOEFD9'$QI<Y[CIK0.\D^
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MYK_1MHA*Z /V272- +FANMDC8WH>*]>)YMCF6B3XO7:GK7QCF?&W;7M'K+7
M'7MTFB25T"Q(B+("(B (H6U959+K=:BV6ZXPSUT <9(6@[;RN#3WC70D*:6I
M1<74E1$T^ BA;OE5DL]Q@H+E<88*V< QPD$N=LZ'</$J:1Q:2;7(33(K*['3
MY)CU;:*MSF0U+ TO;WM((<T_,0"J!0XKQ$MENBM-OR6V"WPM$44KX#VK&#H
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M !NU?E(4NHB^_P ;M7Y2$!+HB( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@,NXGX?F^5W&6@M624EOQ:KB;'4P&/<W_. 0W9!&NG,/$=RT#'+/28_8J&
MTVYA924<38HP>\@>)]I/4^TJ11:<VUI 1$60$1$ 1$0'BO?VHK/Q3OU+G:OM
M71_B6?LA<+W]J*S\4[]2YVK[5T?XEG[(0'Q!Q9J,F^RQ=37OKFW)E8X4087!
MPCYCV79:\-:UK]:^UL6->[&K2;R-7,TD1JA_^%Y!S?IVI!T4;I&R.C87M^2X
MCJ/<5S7;)EUI*N 57BO_ #997_A=1_IN6(<'H.*3N'EN?B55866?<O8LJ@>U
MWVCN;?H_VM^*W#BL-\,\K ZGX,J/]-RK7DU@C@[9 00>:?O_ !SUJ$M.)NNY
M#)YJS-,YRN7!,^R*&P<Q:33,I@/.QW@,<.CMZV-NT?42-+4>+$C.'7!&IHL;
M+Z<0QQT4#P?2;SNTYV_[1!<=^L[3R@,"?E..,NMG:YN0VG^&IWQ]'R,'4L!'
M7?3F;[1[5"T=P?QJX'UU"US&9#3M8V5CO1!G80YKO8'@'KX$GU+=J2C+LGN@
M5;AWFO"O&\2HZ&KMTE57OA::V::W=J9)"/2&S_5!V .[2[^!V06R'C%>K9B7
MG#,7N<!J(:>5A8(IFAI.@>X?+'NUZE.X5QELMBQVFLV=4U;:;Y;8FTTL<E*Y
MW:\@T'#0[R!XZ&^XZ5AX593DN9Y'=;M-0_!^'AO)01SP!LTKN@YN;Q'0D]XV
M0 3HJRM*5K]00'#IOQ(XY9-BKOX.WWIGPC0M\.;JXM;\QD'_ ,L+L>WX\^48
MUO\ Q+5B-/L^+34N_P"X<?\ [$O1Y1=%46IN.YS:XN>ML56T2@=.>%Y[B?5O
MT?\ .5)>3G8YZ'");U<@3=+_ %#Z^9[AZ1:2>3Z>KO\ .LMK3U._'\^@,MO^
M5X[5<=KW5Y^V>JMEHW24%((3+&'M(!+F]QZAQZ]Y(]2ZN+F9X!?[%'4XK2ST
M&2T4L<M)40478'HX;!</4.H]1 ]JMM[DJN%'%R[9)66^HJ\4OS09YX&<YII=
M[VX?WN8^T.Z;(TO9E/&1M];36CA5337.]U,C=S.I"(X&;ZEW,![MGH!L[71<
MIQ6WSV!!<?KG/?\ A%@ER<>SJZVH@E<1TY9'0NWKU=5J]!PWL-ALSVXW;:6E
MO$5')3P5_+J7G<PMYG.[R=]5G_E,Q53,*Q&.M>R6L;<8A,^)O*US^S=S$#P&
M]K;+RVM=:*T6E\;+B87^;NE&V"31Y>8>K>EQE)J$:]P?,G#;+,;X?VY^.\0L
M2EI;F)7]K634;9NV!/0GFZD =!R[![_%:OPBMF'T#\@O6#WEU70UKA+-1,<!
M'3:YB &$!S>\CKX>Y5BP<8;0+/+9^+5$^EO=.]S)XJB@+XYALZ(: 0.G3NT=
M;!.UY>!]HBN7$W)<EQZU36O#ZBF\VIXI&&-L[B6;+6]VMM<>G=S >P=)IM2;
MV_LP4GACG&'B[WO)>($,U??JVI)A#Z7MXX8M#7+OH#UU[ T:[RN[,<WQ1F=8
MWD?#Z">BKX:@,KXV4I@CGA)&]@=-ZY@?>/4%9<$OHX*W2[8QF5)4LLDU2ZIM
M]SCA,C' @#1U[&MZ#9!WTZ[5A9Q*N>;9I:[;PVIG.L\3^:Y7*II?X/DV.C=]
M0=;UW$DCIH$K3?XM26WSV!X^(5,S->/V/XM<]R66WTAK):?>FRO(<>OK'1@]
MV_6K!QNX?V&NX<W:HI+71T=;;:9U33S4T+8W-#!LM]$#;2T$:*BN+E#<<4XC
M63B+;:&:OH:>$TERAA&WMC](<^O5IW?W M&^]1_$GC!:LFP>[6K"X:VXUM32
M2><.\W<QE+ &DR.>3X\NP->)[_ \XJ3TN' +]P%_FBQK\G=_J.5MR7^3EU_)
M)?V"JGP&!'"/&@1H^;N_U'*V9+_)RZ_DDO[!7&?];^948?Y+V%6.KPJ2]W.W
M4U=73U#XF.J8Q((HVZ&F@[ V>8D^U=MIME)C'E1"BLD#*.CN%L=)+!$.6,'E
M)Z-'0#<8/SE6'R6P6\)Z8.!!\ZF[_P"\HNY-/_M76HZ.O@D]?\LB[N3<YI^&
M0X/;\1?*/9(/X.U9;!RGP:*@?]RX#ZU=O$<?'3C9B^)L].WVAOPG7CO&^]K7
M#W!@_P#F*8\H^Q37#!&WBW[;<K#.VOA>T>D&@^G] T[_ "*-\G2FJ+T[),[N
M<?+5WRK<R$'KR0L/<#ZM^C_D"B?X>IW6W\^@(/B7C=+E7E(8[;+B"ZA-M;+/
M&#KM&L=*[E/L) !]BN?&C!+%7\-[L^GME'2U5MI7U-++!"V-T9C!=R@@=Q (
MU_W"HO%F^5>.>418+I144]>8+6#-3P-YGNBW-SEH\2&[=\RDL_XMV[+\9J<;
MP*GKKI>KM&:8L%.Y@@8[H\N)]FQZAO9/16IO0UP"'S;.[G-Y,]CK!/(*ZZ/%
MOGG!])S6&0.._6X1Z/\ >*[,9SGA%9,:@M'P4^H:(@R>2:V<[YG:])SB>O4_
M1X*R9IPLJIN!=NQJVELMVM095,#3H2R^D9&@^WG?KYEQL7'?&X+*R+*H*VVW
MZG8(ZBC=2.+GR :/+TT-GP=K7Z554H_A5[O@$)Y-M\I1FN5V&Q/J'8XX>?4#
M)P08AS!I: ?[X'^7:CO)XPFRY#697<;_ $,-P$%<Z""&H'.R,G9>[E/39]$;
M]BTS@]?<IRB6[7F^T;+?8YI-6RF?#R2EF_E$]Y&M=?$DZZ!5KR6VEMMR[F!'
M_FSN_P!RDI-*;7L"*XVX[9K;GG">DH+7104TMQ$$K&0MU+&V2F:&OZ>D "1U
MWWE>ORJJ"GI>']@HK=!#2P"ZM;''"P,8S<<G<!T'4[7=Y2KI+9?.'N124\TM
MOM%Q,M2Z)N^4<\+P/>1&[6U%\>\CH<OX98O>+-VSJ2>\M#1(SE>.5LK3L=?$
M*PMZ&#4H>&.(T^+.LHL="^$P]FZ9\+3,YVOEE^N;FWUWOHJ#Y,\#;YP@N]GN
M),M&:NHI.4^$;XV$@?.YQ^=;C)_PW>XK%/)*:6X!=0X$?^:R=_XN-<HR;QR;
M?@'=Y-UQFMUMR##KK(&U>/UCVCF.AV3B>H]G,''W."ZN!S797G.89[."89Y_
M@^@+AW1-ULCYA'\_,JMY0;*_"\WDO]E8X,R2VRVVHY/NF@W?OY>37]TK;N&6
M-MQ/!K/9^4":"$&<CQE=Z3_^HGYM+4VE%S7_ "_C",1X 879LBO>8W"_T4-P
M;35[H8(9QS1L+G.+W<IZ;.FC?L4GFUGI,BXT8O@9B['&+71^<NHXR6L<0''7
MT!@]>B[UJ3\F)I:,VV"/_-G=_P ZY<7;==,7XCV3B)::":X45-":6XP0#;VQ
M^D.?7JT[O[@6C?>MN3ZK5]MOL"YYSPWQN^8E66]EGH*61D#C3300-C="\ \I
M! [MZV/%9-:[_57_ ,E&]FOD=+/0GS/M''9<ULD9;L^P. ^96C)^.=CN-@GH
ML-BN%SO];$8:>F92O!C<X:V[IUUO>AO_ +J-K\0J<-\E^[VVN:!<)6"IJ&-.
M^1[I6>CT[]-#0?:"LP3BDI^4"/XBW:KHO)TPNVT$ACDN\5+22.!U_!]GLCYR
M&CW;6MT/#/$Z7&&6,V2BEI>R[-\CX6F5YUU>7ZWS>.]]/!9YD>'UN6^3OBT=
MI8772WTE-64\8Z%Y;'HM'MT21[0%(6SCY8769C+C1W*/)6M$<EJ93.+WS=VF
MG6M$^OJ/4DE)Q_!Y8(OR8+9\"WGB#:^<O\RN#*?G/>[D=*W?SZ7'R=X*FJPO
M/*>@E[*LEKZB.&3>N1YCTT_,=+L\F.2NFO7$*:[PF"X2W%CZB(_U)"Z4N;\Q
MV%Q\G9E?\3\Y%I=''<3<9O-G2MVSM.0<NQZMZ6LG,_H"I<-LMQK ;8['.(.(
MRTES;*_MJR:C;,)@7'1=OKH#H.7F! WXK6N#5GQ&EGOETP6\NJZ*X2M?)1M<
M!'3'J0 P@.;WD=?#W*J6#C#9O@:2S\6J)]+>Z=[F3Q5% 7QS#9T0T @=.G=H
MZV#U71P*M;*WB=DF48[:Y[5B,\'84L<C#&V9Y+"7-;ZMM<>G=S >O2:;4F]O
M[,$?P%Q*U7O,\WN=YHX:XT=Q?'3Q3M#XV.<]Y<[E/3?HM&UUYKA5GD\H^PV:
MGI64MKNE"*BLIJ<=G'+R&5W*6MT-$PLV/G[U9O)N:1=.(.P1N\.[_P"\],K:
M?_:IPXZ.O@B3K\U4CD^I+?M^P/!Y3F+V2UX!27*U6NCH*VEK8F12TL+8G!I#
MNGH@=-@'YEN-IF=46NCFD.WR0L>[WEH*RCRJP7<+"&@D^?0]WN<M3L'VBMWY
M-'^R%QD[QJ_<$7Q"M#;[AMTMLUU-I@GBU-6#7\'&#MV]D#1 (/7N)63VO+N#
M^+6."R4[:2[R11B.5T5M,SZA^NKBXMT23[2/4K5Y2-LNUUX7U<-DCEF>R>.6
MHBB!+I(6[V !WZ/*[7_*J[A?%;A[:,:H*:RT$[+HR%L?P=2T#C.^0#1',!IQ
M)\2>JUCBW#N]^P(SR9ZFG.;YY!:J>IH[4^2.:"DG;RNB',_0+=G1T0/F"\W
M_$K5?N(.>W&]4D5<*&YR,IX9VA\;'/DD+G\IZ$Z:T;7JX 3W \6<Z^'Z1U!=
M:QC:MU*\]6!S^;7S"1JF/)U:1DG$K8(W>#K?]^5=)MK6UX01%\5++;L9XQ\.
M+C8:2&WSUU;V%0*9@C:\<\;>H'39;(X'UKT9C219QY1-NQV[@S6:ST7G3J4G
MT)7D [/YS![FZ\5Z>/+2>)?"D@$@7,[^M@3BE2U^%<4+9Q#HJ&>NM1I_-+G'
M W;XVZ(Y_=KE]FV:)&PI%VEYI@D>/> V*KX<W.NH[924=?;8>WAFIX6QGE:?
M28>4#;2W?3UJT\%/YJ<7_(F+,^*G%NUY3@MUM.%PUMQJ)Z<NJI>P<QE+".KR
MXN\2!H:]??W Z;P5!'"K& 1H^9,6)J2Q5+R"6SZ[R6#"KY=:?7;TE')+'L;'
M.&GE_3I?./"',N'U@L+JG)Z:>X9)6R/EJZB:B[<]7'0:X^SJ?62=^"^E\KL[
M,@QFZVB5_(VMII(.?6^4N:0#\QT5B'#7B%3<.;/\4.(M)4VVKMSWMIZGL'21
MSQEQ<-%HV>I.B!K6O%7%O!I*V""QG*L?AX[VBJP&.>EM5W;YK7TIA,4?:'>G
M-;W#KRGI[?6K?4M^(OE'P3C^#M660&-W@T5 U^DN#?K2I/#,ZON=\06R8W1F
MFPBEC(FJ:FFTZH?U^0? [(Z> !)T2 O9Y1MAEN> FZT&VW*QS-KX7M'I!K3Z
M?T#TO\@6F_QJ+[J@0O$S_P"O3C/BN(,].@M8^%+@WO&QU:UWS!H_^8JEQ:R2
MSU/'6&AS4U$N.66!KFTL<9>V69S _;FCP](;]C=>*N/DZ4]1?)\ESRYQ\M7>
MJHQP#OY(6> /JWIO_P M>3B/37# N+,'$"GM\]PL=93BEN38&\SX= #FUZM-
M80>[8()&PD6HRT>%^H*KQ.S3ACDN(U5+:[?)2W:%G/0S0V_L2R0=0WF']4]W
MJZ[\%M7!F^561<-+%<;@YSZMT)BE>[O>YCBSF/M/+OYU1,IXX6NOM?F7#RGJ
MKID=5ID$8HW:B)/5S@1UT/ ;'KZ+6L49=&8[;QD+X778Q U/8MY6!YZD #U=
MWMTL9-H)-5\P1G%3^;7*O\,J/]-RH7DYX19J?AW0W:KH::KN-R:Z226>,2%K
M XM:QNQT&@/G/N5]XJ?S:Y5_AE1_IN6-\&.+=KQ? K=:\PBK*$1->ZBJ13N?
M'4Q%[NXM'>#MOJZ#JD%)XVH^02=EHX<%\I$6:RL\WM-_H3.ZE9TCC> \[ \.
ML;M>KG(45:,6MV4^4OET5Z@;54-)$VI\W?U9))R1M;S#Q #G%3O#J&MS[BU4
M\0)Z&HHK'1TWFEL%0WE?-L$%VO5ISSZO2 V=%<N'S2/*4SXD'1I&=?J5TMJ_
M- \''*V4U&_#L#QZ".UVR^W(NJF4S>0$<S&]W^;>O^4>I:F>'6)&P_ _Q?M_
MF79]GH0MY^[Y7/KFYO\ FWM5#R@,9NMPIK#DF.4[JJZ8_5><BG:-ND9MKCH=
MY(+&]!X$KH/E!8H;1VC(;B;QR\HMGF[NT[3^SS?)UOQ[_9X+G4I06@$%P3JZ
MJALG$?$*B=\]/89)HZ9SSLAA[5I'NW'O7K<5V>2[A=I=A/P_7T<%77U<LD<;
MYV!_91M=R\K0>[9#B3X["]_"/%[M:\,S+(,C@=377(!+5/@<-.C9RO(YAX$E
M[CKP&E3N G%&@Q#"X[;ED-724#II)**N; Z2*0;]./T03S!VS_F\/'I*Y*6C
MV!8;O04^!^4-CLEAB;24&0PNAJJ6(<L9?LC8:.@Z\A]X/K75D=EM;O*DQ^D=
M;*$TD]L?++"8&<DC^6H/,YNM$[ ZGU+T8W)4\4N+]!E=/15--BUBA+*66H9R
MFIE.^H'O=OV!HWU.EYN+-UCPWCYC.4W:GJ76AMO= Z6&/F]/4S2!W#8YVG6^
MXHKO3WH'=Q(HH\NXWXOA54.3'J&D\[EI8_0:\@/(&AX::QOL!=I:'FG#;&K[
MBE7;66>@I7MA=YM-! V-T+P/1(('=O6QXK/^(WGE%EN*\5\;HJBXVOS1K*R"
M-O\ ""%[7$/(_NO/L!:-KW9)QUL=?89J3#HKA<[_ %D9BIZ5E*\&-[AK;O7K
M>]-WO7SK-3:CH_C!6<:GO^=^3)<*"@=+4W.CF\U !].>)CF/Y=^)Y7:UX\NO
M%<<6X@<-CCL.,Y9C/P+.R 4]1VU"'#FUHOY@.<.WUV1L'Q5GQ[&,MP#@88<<
M9&<F$AK9X#&)3IV@YC1W%P:&^O9! WT7FJ>,7#V_8^QF7VYTER;'RS6^>@,C
MQ)KJ&.(T.O<=@^Y:YNE:OL"PV>RVBQ<#+]28Y>)+O:S;ZR2*=\C7@;B=MHY0
M-#>SH]0254\-M5SO?DHBWV/F-?-'.&,:=&0"J<7,'O:"/;O2X<*+!<;/P6SJ
MIKJ2>AI;C!53T='-OFCC[%P!(/7KT'MY0?%2/#.3(:;R;*&?$6L=>H>WDBC?
M'S\X%0_F: ?ZVMZ]JCVNGW0*UA6?</:''*;&<RQ;X)JH81!5&HH \/<!HO)
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MJ_B]EUSC:UM):X111-:/18&Z8-?-$[Z5W\"Z87J:^9?< )+A65;HHW.ZF-@
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M;G=753F$OKI><L#=]&^KO4E5;2LIW</\WM^;T=?46V"KIS15+J66.I:UK@X
M'8Y7'IU_05PS#.K;C%YLUIGIZNLN=VD[.GIZ1K7. V!S.YG#3=GO]A]16=<)
M:NGQGB%Q5H:Z5L%)3U N/,[H&1DO<3]#FK]X30RY3D=]XHWR)S8-/@M,+_\
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M@$1%@'7%3PQ/<^*&-CW?*<UH!/O78B( NOL(NV[;LH^UUKGY1S:]Z[$0!$1
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M^HE3B+$\\IQ<9=W98P47:"(BXFPB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M]KR#GUZM]Z[EB<M5>Q0B(L (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B("(@_E34_D[?UJ741!_*FI_)V_K4N@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B *(OO\;M7Y2%
M+J(OO\;M7Y2$!+HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B \5[^U%9^*=^I<[5]JZ/\2S]D+A>_M16?BG?J7.U?:NC_$L_9" ]
M2(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B B(/Y4U/Y.W]:EU$0?RIJ?R=OZU+H B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"B+[_ !NU?E(4NHB^_P ;
MM7Y2$!+HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB \5[^U%9^*=^I<[5]JZ/\2S]D+A>_M16?BG?J7.U?:NC_$L_9" ]2(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B B(/Y4U/Y.W]:EU$0?RIJ?R=OZU+H B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"B+[_&[5^4A2ZB+[_&[5^4A 2Z(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/%>_M16?
MBG?J7.U?:NC_ !+/V0N%[^U%9^*=^I<[5]JZ/\2S]D(#U(B( B(@"(B (B(
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M"(^#KE^&'?4-_>GP=<OPP[ZAO[U+H@(CX.N7X8=]0W]Z?!UR_##OJ&_O4NB
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MWJ61 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M=) N*$@=Y5)PKBCBN85IHK1<'-K]%PI:B,Q2. [];Z'W E93Q<XC6V#B[B\
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M*@IVVUD?9&$Q@M>-:)</ZQ/B3WK(."L7Q;XO9WB5"7"TQZK(8M[$1);T'S2
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M4;DE[I,>LU1=+B9!2P<O.6-YCU<&CI[R%YL0R>W99;)*^T&4T[)3">U9RGF
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MM726;'CP2QJ>MOY[?<RH2E-2TU1:51>*UQR>EHZ"CPZF?+5UCWLDD9'S&)H
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M=")A%*V1C>4.83T(+0-C?K[]JE57$_/,<J*2/B+C5/<Z>)_\&;E0"-V_$QR
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MM=2YQV-:]15V\K;^0UE_Q:/_ $I5TA%*<6ER"_V_,:FBPRNO^<VDX[YJ]P=
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M.)7V0M[1O-6 3NC[^8,US=W7HTJM\8PV>S\(*.K^UL\T J ?DGT81U_RN?\
M25]%@   #0"PU&$4VKL%6P7-[9FF,F\6@O CVV:GDZ/B>!LM=^C1\0LXL'&R
M\97;F,Q+#)[A=ALU$?G($%.W>F\TC@ 7'1.NGO*\O!QK:;B?Q5I*'0H&S%W*
MWY+7\\G0?2X?,O?Y),,<?#2KD:T"22Y2<SO$Z9& M.$8*3J^/U!.</.*-1?<
MIJ,7RBQ2V/((HS(V)TG.R4#J='7?KJ.\$ ]5IZP_*@&^55B): "ZUOW[?1J%
MN"YY$E37=%1GW$G+*7'\JPVWU-DIKC)=:SL(ZB5P#J4\\8YF[:>OI ]"/DKH
MXE<4J?!,DM%NK;=)44U=#)*Z:)_IM+=\K&LUZ1<=#O'>JUQZ_G&X5_XH?]2%
M=7%N&.?COPV9*T.:'.=H^MK]C]("Z0A%J-^&0[KOQ9S*Q4[;O?>'D]+8"X!T
MGG0,L;2= N&O1]S@.O3:UZQ76EOEFHKI;WE])5Q-FC<1H\I&^H\#ZU7.,;0[
MA9E(< 1YA*>OK VO#P#)=PAQHG[@X?\ V1RQ)1<-25;E+^B(N("(B *"S3%Z
M#+;));KB" 3SQ2M^5$\=SA]/=XA3J+49.#4H\HC2:IGSY#P[XB8K)+%C%T;+
M2/=O4,XC!]I8_H#[M^]?M+PARO(K@VJS"[AC>XETIGEUZA_5 ^?YE]!(O;_^
M1R\I*_-;G'X>'T*5EV(/J.&4V,V'7,V.*.'MWZV&O:XDG7?T/@LNL_#GB19J
M5U-:;I%20.>9#'#6%H+B -ZUW]!]"^AD7/%ZS)CBXJG;O<U+#&3LQ;'\6XFT
M]\M\USOAEH8ZB-\[//'.YHPX%PUKKTVO1Q%X>7N_\0J2\T'FOF<0AYNTEY7>
M@[9Z:6PHK\;-3UI).JX)T8U3"(B\9V"(B R3*, O-RXLT&14WFWP=#/32.YI
M-/U&1S=->Q:)F%OGNV*W:WTG+YQ54TD4?.=#F+2!LJ71=Y>HG+3?_'@PL:5^
MYFW!3#+IA]'=8KQV'-4R1N9V+^;H =[Z#UKU\7<$^.5HB?1=FR[4I_@7O.@]
MI/I,<?5XCV^\J_(J_4Y'EZW<G3CHT=C-L+Q_*K9P^NM@N3X!4BGDCM\\4YVW
MF:=-)UL:=H@^WV+R\!'7,T-_BNU;-6OIZWS<2/F=*W;1Z7*3X=RTNY4<5PM]
M31U!>(9XW1/+'%K@"-=".XKSV"S4%@M<5OM-.V"EC[FCJ23WDD]23ZUN7J-4
M)IK>3(L=-5V)!4#BAPWI<SCCJ8)FTEVA;R-F+=MD;_9>/U$=V_%7]%PQ998I
M:X.F;E%25,^?8L1XKVZG%OHKE(ZD:.5KHZUNFCV%VG >Y2>&<%ZN.[0W7*[D
M)9HY!-V,#B]SW [!>\^WU?2MO1>J7_T,K344E?A')>GBGON9/QIP*\YA<+9-
M9_-N2GB>Q_;2<IV2"-="I3B7B%SR+ ;99[=V'GE/)"Y_:/Y6Z;&YIT=>LA:(
MBY1]5.*@E_QX-O%%W[E8X9V2KQW"K?:[CV?G4'/S]F[F;U>YPT?<0K.B+A.;
MG)R?+-Q6E4C*.-6!WC,*^V36?S;DIXWL?VTG+U)!&NA]2TVU0/IK71T\NNTB
MA9&[74;#0"O4BZ3S2G".-\(RH)2<EW,.R/A7>Z+.!>\+DI88A(*AC)).3LW[
M])NM=6GU>HD+W<>F7^.S6N[4=;);XX&%E3%!5.872/+=-;K7-K3OF6QJ&O.-
M6N\W.WUUR@,\M"2Z%KG'D#CKTBWN)&NFUZ(>LDYQEDWTG-X534>Y)4 >VAIF
MR[[01M#M]^]=5W2,;)&YDC0YC@6N:1L$>HK]1>*SN89D?!ZZVR\NNF"7 4_4
MN;"Z4QOBWX->.\>PZ^=1M9@G$[(P*6^7'EI=]1-5@L/M+6;W\X7T*B]L?_H9
M4E:3:[M;G!^GCV*3PQX?TV$4E3RU3ZNMJ@WMI".5H#=Z#6_.>I5<XF<*'7VZ
M&]8Y4LH[HXATC'DM;(X=SPX=6N_7[/'647&/JLL<G5O=FWBBXZ:V/GJLP3B=
M?866^\7'=""-]O5AS#KQ(;LN^<+6^'6&4F%V0T=._MZF5P?45!&NT=X #P \
M![_6K4BUF]7DRQT;)>%L2&&,'?<S+BCPLARNI^$[7.RCNV@'EX/9S:[MZZ@C
MU]52SBO%IL'F#;G,:8#E[05S>[^]\M?0*+6/UV2$5!I-+BU=$E@BW?!CO#K@
M])9;O3WB_P!P$]; _M8X8">4/];G'J?=H>\KEQ@X>7O*\HHJ^T^:^;Q4K8G=
MK+RGF#WN[M>IP6P(I\;EZG5;W+T8:=)Q+ Z,L> YI&B"-@A8=)PNR#'\\%XP
M]])YE'+VL<<LI:0T_*C/3N[Q[M>*W-%SP^HGAO3P^34\:G5]C\826-+F\KB.
MHWO17ZB+@;"(B B(/Y4U/Y.W]:]]PA=/;ZF&/7/)$YC=^L@A>"#^5-3^3M_6
MI= 8KY/?#2]X--?_ (Q-I#'71Q,8(9>??*7\V^@_M!53A[P*O=AXFT5UN!HG
M66BJ7S1EDI=(X#F[/T==^^4KZ51=NO.V_(HP_,N&-_NW'"VY72>:?!5//2R/
MYY=2:CUS:;KV>M2G'/A/)G3J2ZV2ICI;[2,[,&0EK)F D@%PZM<"3H^WYQKB
M*+-)--=@?,UVP7C'F5+26;)J^DAMD#VN,SI8_2([G'LQS.(\-ZZ_2MCJ\#B^
MQ548=35<CR^C= VIG)<72'TN=WLYO#P'0*[(DLTI5VH'SIP;P/B7AF14]'-)
M308T:DS5;&S1O;+Z/+MO3G\&^KN"\M;PISS#N(-9?>'LM+/!4OD+1)(UI:Q[
MMECVOT" ==0? 'HOI5%KXB5W2W)1\PYGP:XAY)74=\N=UM]=>7_\6(N[..G:
MT@L:P@:/>[?0=?7O:O'E </+_G]-CQL[*1DM()3.V:;E#2\,T ='?R2MF13K
MRM/P*/F^Y</N+%BM+\<QB]LK,=E:6-!DC9)"QWRF%SAS =3\D_,-Z6@\#.&
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MP'J&MYCW^KIOUZ6W(I'*TJ\ RKB?PO?>>&%LQK&'Q0RVJ2.6G$YT).5KFG9
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M2!C:V;T7#?<2S73UZVKKE&26W&K*^YW.;EIQH,#!MTCCW-:/$E)>GR1:37/
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MWR\O-IO+WDN+0![2%.G*ZH&@(L7KN-U?:>RK+[@5\M]CD<&MK)#Z0![B6%H
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M<H/,.LDG>/!:NNN1JHI> 5/B+GEHP6TBJNCS)4R[;34<766=WJ \!W;/A[]
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MN+/#&X48#:^6M-.\M[W1]I&-'V:>_P"DKJK*6&I\K*D=.P/["V]JS8WIPC<
M?TJ6Q7$,GR;B!2YEQ!@IJ 6]A9;K7#().S)WZ;B"1OKOOV3KN  /O=B5Y/E
MLR<4K?@46_L.W[5N^?E(UR[YOT+:DDM-\)@@O*VJ)X\!ME-"2(ZFY,;)UT'
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MR_U6Z_[C6]'9UI1I2:DG6P)GB-DV-8WF5E%'CDU_S-L'+114Q/-%%IP&W=?
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MJMO(^;EY61LZ>BT?,/5W=W?N[(BSDR2R/5(1BHJD$1%@T$1$ 1$0!$1 $1$
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M>U6,7)T@7A%1^)F=NPJ?'XVV\5OPK6"D),W9]ELCTODG??W=%>$<6DF B(H
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M$ 41??XW:ORD*741??XW:ORD("71$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MCAB:&,8T:#6@:  ]6EV(BY@(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B("(@_E34_D[?UJ741!_*FI_)V_K4N@"(B (B( B(@"(B (B( B(@"(B
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MNY-,82=<H)[S[NGM5"QC.<LI<LJL*S&GM[;]-2OFME?3AP@G<&N(YAZMM/4
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!$0?RIJ?R=OZU+J(@
M_E34_D[?UJ70!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MVQ?@[8;->X;Q75=SOES@(,,USG[7LB.XM&AU'AO>N\+24164G+=@(B+("(B
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MPTNFFK*6J<X4U3#,6_*$;P[7OTLT4[T4#A]^DOU/<Y)8&PFDN$U& UV^81D
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M)U=C-#:J2TEQ$$MS,ADJ #KF#6:Y0=>*L,;FF^R(Y)%]15K$;_6W&KN%LO=
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MQ2%LL<H)/:!_?S;)ZGUKIAP6VMN%%<*FJN59<*.0215-54E[@ ".77<&G?4
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M:[NY(^I@JOLU_>_-?N'C>]?S8@*NT6ZHXOVN2>AII)'6EU07.C!)D9(P-?\
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MA:;!4S55''-+73-Y)*JIF=-*YOJYG'H/<K O/EG%I1CPC<4U;?<(B+D;"(B
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MCAT;_&*HOM4TLC)AL2D!G*7 ]_@[KXKV5T8Q[)LX%@A92ZL;:IL4#0UHE'.
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M[?6\KG[#CL:8W8)ZZ2/ITX^^W]G_ (#R4_Y[&U*N4V2ON6/R7.QVV:M<VH=
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M')4TM/4QQ00&5P9'N)NW  _*UKKX:5=I;%35?!N3(JV6IJ+W30O?3U;YW\\
MCD+6!G70&F_/LK2]-%[:O';SQW)U'X\_H;JBS**FCS'-7T5_YI[?0VRGG92%
MQ;'+)(-ND<!WZ[O4HVZ,-BBSZP4$LOP7%:15P1.>7>;.<UP<QI/4 ZWKP65Z
M:WIO?9_?_P!+U.];&OHL>OV.45DPRS9#1&=M]CDHWOK3,\ODYW-#@[9URGF[
MN[71<[ZZ:^\0[Y2U]@K+[0VQD$<%+'4,CCC+V<Q>YKG#F<>X'P 57IE+=2VW
M_2O?W\CJ-<HUY5C,\GJ+!46FFH;9\(U5QF=#''YP(0"!OO((4=POBNE(V\4=
M?1U%';XIVNH8:BH9-)$QP]*/;7'H".F_ KP\5F5DF086VVRQ0UAKI.R?,PN8
MT\GB 1M3'BBLVA[K_J^PE)Z+1Z[EFM[LM/Y[?\3EI;8QP$U1!71SF($ZYBP
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M)W^.U8:ZCIZ^EDIJV&.>GD&GQR#;7#>]$>*I^(QLBXD9O'$QK(VQV]K6M&@
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MGO4/E+)J$XWB]%4UE\M\U35=O##4-9*]L0!%.YY<.C>;J"=Z 6(^G3EIO?\
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MY[03Z.P==%EX%V>_/';[E61^#2D618+@UOO/#B&MF,S[S74+XA5/F>>0;]
M;T WE;X>OUKOAO,V7V_#[,\N%3+(9[HW?5K:8Z<UW]Z0-1^F5M1EPZ>W_?LP
MLCK=<FG7*I\RMU55<G/V$3I>7>N;E!.M_,J1:LRR:Z6NGN-%A7:TD[!)&X72
M,%S3["T'YE;LD_D[=?R27]ARSS 3G#L)L[;6,=;1FF:(7SF8R!O@7 =-IAA%
MXW)I<][_ &$V]5(O>)9#39-9VU])'+"0]T4L,HT^*1ITYI_^[Q4RLINMCGQ^
MR6+'W7"5SKW=RZY5<7\&9"X%SFMU\GFT!\WM7MN]FHL,R3&*C&XW4;:ZM%#5
M4S'N+)F.:3S%I)ZM(WOVJRP0;_"^;KZ!3:6Z+=BM^%_BN3Q3F#S*NFHM<_-S
M]F0.;N&M[[E-K&(:6<XADETH.8UMGR2IKXP#KG#'#G:?86\WT*U4E:S*<_@J
M:20OMEHH!,"#T=/4-VW?KU'U]A*9/3I-M/97_/K8CDX3Y+ZBQK$,1MM?PL9=
MJM\S[KYO+-%6]LX/IBPNY0P[]$#EZCQZKIK;O<,EJ\4HJ^VU=UII+.VX5%'!
M,V$5$A=R\S]D M'?K?\ 6]2OPJ<FE+B[^GU_P3J[6UR;6BRBQTURMM3D4$-G
MJK18I;7)*REGJ62]E.-C; UQ+6D'W;"\<.+4%/PEAR".687V"W-K8KAVSNT8
MYK.9K =ZY0!R\O=\ZGPT;WEX7W^O^2]1^#3YKW3QY)3V0LD-5-3/J@[0Y0QK
M@WZ=E=UIJZNK%7Y]0.HC%4/BBW(']M&-<LG3NWUZ'J-+.8+=17;B;C]PK:1O
MG-39FUTGI.&IFNCY3W^'=I1)JJEUJN=O9430Q7+,9*&>5CR'-B=RDM!\-ZU\
MY6OATTDN:7]V3J-;LU"^7T6N[62B-.9?A.=T ?S\O9Z87;UKKW:\%-++[UBM
MKQ_,\,DLT1I(Y*R1CZ=LCBQY$3M/T2>O>"?'?50=%')DMSOU==L6K[ZYM=+3
M0/95LC93,8=!C&EX+7>).NNU%Z>$HJ47M7[OWK]1U&FTT;8J??LLN-'E8L-G
ML0N=1YF*QSC6-@ ;SENNK3XZ\?%=_#0W48M'#?6R"I@E?$PRRMD>Z,'T"YS2
M03KH?<JS?8KO-QEY;#54E-4BR N?4Q&1I;VQZ  CKO2SBQ14Y1E3I/Y?H64G
MI31-PYE<*2\6^AR7'I+4ROD["GJ&53*AAD\&NT!R[\%=%E%#'<[IQ!H[7G5?
M&)J!PKK=!2P\D-40/E\Q))<WKZ/O\%XZSM<AS3(C<\<K;_34,[:6GA94LCCI
MP&[)Y7.&W.WOF727IXR>VVUNN.=JM_N961K^?X-C18T^HOM#AIM59YW;X:J]
MQ6^"1]0V2:"ED/5I>TGJ-%NSUT5;_BI9L9N%)<K-*;;+&R1CJ9LI(KO1)#7!
MQZN&M['5<I8%'F7R_G_IM9&^Q=D6#6.BJ;[C/PK58Q=+A>*QKYFW=E=&PQNV
M>4Q@O!:UN@-:\%8:ZCJ[]=^'U)D;Y(YI:2J-9''+KMBUL?0EIT0=;.CW;"W+
MTJBZ<N+OZ*_/M[&5EM71K#CH$GN'51F,WJ#(;'2W6C9(RGJ0YS&R !V@XCKK
MW*D06>BM.>5&/441;9+E:GU$U$'NY(WM>&\S>OH[!T=>*JV/4S(.'>'4-&Z2
MD;?JYL-?-$\M<]@+_1!WZ.] =$7IHN.S\?;?_ >1I\&YHLUO%EHL,R+&*G&X
MW4;:ZN%#54S'N+)F.:3S%I)ZM(WOVKHX=XY0W2[7R\7$2U%717RI92\TK@V$
M!P/1H.NI=UWZ@L=".G7JV^7T\FM;O36YJ*(B\QT"(B (B( B(@"(B C[_>*.
MPVBIN5RD[.F@;MQ V2>X #Q).@%5VY/E4E/Y[#AC_,R.<1OKF-J"WU\FNAU_
M5WM=/& AEOQZ:H_B$-ZIGU1/<(]GJ[V;TK-D4M\9% <=I[?.\D]IYY*Y@ \-
M<H.UZ81C&,6TFW?/L<VVVU?!Y8LRM#\/^,CI7LMX9S.#F^F';Y>37]KFZ:4/
M)EN2QT9N4F'2BV-;VA;YXSSD1]_-V>N_7]7>U4K[>9KQAU#4W"CI:."@R6.&
MMCIM]GR,=ISCOP+C^I;*]S6QN>]P# -DD] %J<(XN8W;??\ P9BW/N0%9F%I
MIL4BR$RODH9FM,(C;M\CG= P-_M;Z:]A]2AY,IRJ&F=73X8\4+1SN8VN8ZH#
M/7R:ZG7]7>U$Y=<K;<#@=SM[V.L'PH!SB,QL#].##H@: <'*ZY'+D,;H/B[3
M6V=I#NV\\E>S7=KEY0=^*:(PJX\WSVKMVW+;=[\>")ON<0TF-V>[VBC-R9=*
MF*F@C,HA/,_>MD@Z((T0O+<<OR.U4<M==,-DCH8!SS207&.5S&#O=RZ&]>]5
M#(+O4W_ <4JX*>DH*HW^**..)I,4;FOD:#KIL;&]+VYQ+E5'%3T>37>CAQZX
M.\UJ:RAI"'Q<W3E=S.]%KNHYAO7J7:.""J+2NWRW>WBCFYO=V:K;ZN&X4-/6
M4K^>GJ(VRQN];7#8/T%=Z\ULHX+?;J6BI!RTU/$V*,;WZ+1H=?<%F^54EHDR
M"M=4X[F=5,7CFFHC)V+^@ZLU(!KYEY,>-9)-=OY[H[2DXHU%0F5Y'2XY0Q35
M$<U145$@AIJ6 ;DGD/<UH_65&\.X:*&DK!06R^6]ID;S-NW-S..N]O,YW11V
M6D1<4\+EJSJE+*J.)SODB8L&OG(Z!:AB74<7PK?V5D<GIL[*O+LCM=,ZOO.)
M.BMC!S3/IZUDTL+/%Q9H;UXZ*F:[*((;ECE/31"I@O1?V<[7Z#&MCYP=:Z['
MN73E]5D5*V5]GHK34V]E.Y\WGDKVN)&]@  @C6N_VJJ?"9O-QX87%T$=.:AU
M0_LH_DL_@3T'L72..,UJTI<\/V;7]C+DXNK\?W-214+AO(XX]DKGO)Y;K6]2
M>X!RJMG=)<\;X<6&IFF;;[DV=]7R/+3*(FEPC+AUT2>ON6%Z;=J^/\-_L7J;
M+8V=%19[%9L2=<ZF@NKK-2RT#^TI8W<P81_[]C22>8=W0:/19WD=-2T.+17>
MR8Y=Z2JIW0R-O=7,(Y9"7M',6\Y<[FWW:UU6L?IED>SY]O\ O^UB61QY1OR+
M.Y+92Y;Q%OM'?F.J:&TP4[::D<\B,F1I<Z0@'J>FMJK5$U1C%LXA0VJLG!BJ
MZ2GAF?(7N@8\-;T)Z^B':!]@4CZ;5LGOM^M?Y#R5O6W^#;4669KC-NPS'&WW
M'FRTUTH9829NU<YU4'/:US9-GTM@D_J7?!C]#D?$K+8[RR2II((Z0MIG2.$9
M<Z,^D0"-D:Z>\J+!%QUJ6WR^7O[EUNZK?^?X-,56S#**JQW.S6^WVKX2J[FZ
M5L;#4B$-Y&AQZD$=Q/T+P\)PZ"W7ZWB61]-;[Q44E,)'%Q9$T-(;L]=#94=Q
M-9729O@S+5-!!6F2K[.2=A>QO\&W>P"-]-JX\45FT2W6_P#9LDIO1:_FY[:_
M-KO98XZK),6DH;89&QRU4-<R?LN8Z!<T '6_%7L'8V.H60Y+%?:N^V_'LYN=
M/'8[@]O9RT-/R-J)&G8A>YQ)9LZUK>UV94^:\<1*VVU5DJ[U;;=2Q&.BAG9%
M'SOV3(X.<.;^R._6ETE@C*JI;-[<5]7S]3*R-7_/[&M(L9DK+[C6)9CV%%56
MNAC;";?%/4,F?3&1P9( 6N) &^8;[E;8\&LEG-LKJ&K?;:V"5A?6.F)=5[Z%
MDG,=.YO_ +RY2P1CS+Y=^R?GW]S:R-\(O*+$+7%+DTUWN-VQ:XWN9]9+##.R
ML9&VF8UV@R-I>"TCOWKJ2O964]UK\9PN@R":HIZEUW\WDD$X,CXN636WL)](
MMZ;WO:V_2).G+^5\_P#!E9;[&QJ+Q^]T]\AJY:5DC64U5)2'M  2YAT2/9M4
MNKLU#C&<X]2V2$T]%>&5%-64C7NY) V/F#];Z.'<3[55:&".QX+?I[0#15=3
M>WVTU+''FBA,P;TV>FAL;[^J1]/&2V?-5]VOV#R-,W)%E^88Y;L+MU#>L;CD
MI*^GJX8WD2N=YVQ[PUS) 3Z6][WW]$M6.4.0<1<NDNXEJ(Z&IIGT\/:N:QCS
M$"7:!&SZ('7V^M86"+CKU;?+W2\^_DNMW5;FH(B+S'4(B( B(@"(B *(Q:P4
MV.6QU#1R321.F?-S2D$[>[9'0#HI=%5)I5V)6]E2NF#P3W>HNEINERL]94Z\
MX-'( R8C^LYC@1OVKT6;#J*VT]R#ZJLK:VX1F*IK:J3GE<W1  .M #?0 *RH
MNCS3:JR:(W=$?C]JAL=EH[92OD?!2QB)CI""X@>O0 44<-H?@K(*#MZGLKU/
M)/.[;>9CG@ AG3NZ>.U9465DDFVGR72N#S4%''1VZGHF;?##$V$<^B7-:-=?
MF"C<4QNEQFEJ:6WS5#J.69TT<$K@6P<W4M9H AOL.U-HIK=-7R*01$62A1&/
MV"FL<ET?2R3/-PK'ULO:$'E>[6PW0'3IX[4NBJDTFEW)7<B[;9*>@O=WND4D
MKI[D8C*UQ'*WLV\HY>F^[OV2HTPV["[7=*J3SRH@K*V2KE:V+M7<\IZM#6CY
M/3Q^<JS(M+([_%QM^A-/@I/"/'C8L8<^:G?35-=,ZI=#)\J)AZ1QGW- Z>!)
M4W8L9H;1C(L3>TJ:'ED:X3Z)>U[B7 Z _M$*;1:GEE.3DWSN(P44D4EO#RF=
M3PT-5>+M566%P<RW2RM,>@=AKG!O,YHZ:!/@%..QNB??JNZR\\CZJC%#) [7
M9F,$GNUO9V1WJ:1'FF^6%"**%5<-*6JM;K5/>[RZT-_X-'VK>6+1V!OEVX#P
M!) 5\:.5H:.X#2_44GEE/^IA14>"L9!AM+=+JVZTE=76JZ!@C=4T4@:9&CN#
MP00[7_W=RY8]B-/:;E)<ZJNKKI<WQ]D*FLD#C&S>^5@  :%943K3TZ;V&A79
M2AP\H19KI:#<KB;;6RMF; 7M(IR).T/)Z/<3W[VK#362GI\CK;RR24U-7#'
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M#2UL+FB5K>4-(=L<K@0!L$*THHLLT[L:%P06-XW!99ZNK?55-?<:OE[>KJ7
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KR2NFN;XWRM>1RM+&\HY>GJ]>U*HI++.7+"BEP$1%S-!$1 $1$ 1$0'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g762905g59y26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g59y26.jpg
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M 2(  A$! Q$!_\0 '  !  (" P$               0&!0<" P@!_\0 8!
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MO)W#>5Q^HC.E:([3^S>G_=#:.LN3+4%ZUW57>@N-+24LLD;F/YUXD9LM:"0
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MG_QY*3H\'BXC,1,8[SY3\?LR--IFSZ<TS;JRZV6KO=PKFAY9%M;,32 <;N&
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M'SI:QFR&O)P..=H YZ@INB[)2<J'*GJZKU=SM3!;9.9IZ,R.8UK=MS0-Q!P
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MU+61-."^GE;( ?.02M-<K)TG7:XM0O=/?;W>&TXV+%1-VF $$Y<!@@]9P<X
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M.*DMU-#2TL0PR*%@8UOH 7:^O$UF(9BK2T7))K"CM,FG;?K9L6FGR;0C-/\
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M4TCS@!S2W# 2<<2<]9^@"F63D@U/;[56:?.LMC34^V33PTX$DFT.!)WM!W9
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MYNVD-*QWK2'*%25UG9LN9;JEP$HRX#9YAVT,CB<8X$J?RPW.Y7NT<FNI:\=
MCF:72RB+;9!(7,.WLGB"&[0:>(&%>#6;1CH;I;2TQRN4ERO]+9[Y9+G8*RL
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M>IEA>6E]1*=T>1U-8'./G(6Q;SK2EM]W=9K;;KA>+E#&'S04+&D0-/#;<X@
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M-?O)LKV:T\2&BNY57VI_WIXD-%=RJOM3_O6RT3C7[R;*]FM/$AHKN55]J?\
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MC]#/\\Y3E!M'Z&?YYR"<B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MB B(@(B("(B B(@(B("(B B(@(B("(B B(@@W7_*_/M_JIR@W7_*_/M_JIR
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MD8.!>-LN.,\ T;PMP:;M%/8+#06JC_04<+86DC>[ WD^<G?]*YVOC2BN>?\
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M 7U 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!0;1^AG^><IR@VC]#/\
M/.03D1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$7QS@UI<X@-
MR2>I!]15[2VK*'4E1714$<[>BD?"D: )&DN <W?P^"K"M6I-)VVCFD3%HS B
M(LJ(B("*%0W#I5=74_1:F(4KFMYV5FRR7(SEAZP.!4U68F.I$Y$4**Z4LMWF
MML;RZJAC$L@ W,!.[)[3_134F)CJ9R(B* B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B H,?ZXF^:'\U.4&/]<3?-#^:0)R
M+!:UU-2:2L3[I7Q3S1MD9$V*  O>Y[L #) \_'J6=&\ D8\RN.6018+1FIZ3
M5EJEN-OAGCIFU$D#3* .<V#@N&"=Q/\ )9U)C$XD$1% 1$0$1$!$1 1%@Z/5
M-LK;7=[C2RODH[9)+%/)LX!=&W+]G/$#AGAD%6(F1G$6,TS>(M06"@NU/#-!
M#61"9D<P >&GAG!(X;^*R:DQCD"(B B+%UMWZ-?;=;!0ULQK&R.-3''F& ,&
M?[QW43P ZTB,C*(BJ%%KNEK](2:AM]LN=73BH-/'!!$'RRXDV"YH!^+G)R3P
M!5B)GH+>B(H"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("B7;]73^C^JEJ)=OU=/Z/ZI T=4\EVHIZF66-E)L2/+AF;J))[%U^*G4G[%
M)[;\%OZ']"S_ $A<EZX^MU([/D3_ .%^GGGS^?\ CS_XJ=2?L4GMOP3Q4ZD_
M8I/;?@O0")XW4]C\$^F]_G_CS_XJ=2?L4GMOP3Q4ZD_8I/;?@O0")XW4]C\$
M^F]_G_CS_P"*G4G[%)[;\$\5.I/V*3VWX+T B>-U/8_!/IO?Y_X\_P#BIU)^
MQ2>V_!/%3J3]BD]M^"] (GC=3V/P3Z;W^?\ CS_XJ=2?L4GMOP3Q4ZD_8I/;
M?@O0")XW4]C\$^F]_G_CS_XJ=2?L4GMOP3Q4ZD_8I/;?@O0")XW4]C\$^F]_
MG_CS_P"*G4G[%)[;\$\5.I/V*3VWX+T B>-U/8_!/IO?Y_X\_P#BIU)^Q2>V
M_!/%3J3]BD]M^"] (GC=3V/P3Z;W^?\ CS_XJ=2?L4GMOP3Q4ZD_8I/;?@O0
M")XW4]C\$^F]_G_CS_XJ=2?L4GMOP3Q4ZD_8I/;?@O0")XW4]C\$^F]_G_CS
M_P"*G4G[%)[;\$\5.I/V*3VWX+T B>-U/8_!/IO?Y_X\_P#BIU)^Q2>V_!=4
M')?J*=KC&RDPUQ:<S=8^A>A5!M'Z&;YYR>-U/9/P3Z;W^?\ C1OBIU)^Q2>V
M_!/%3J3]BD]M^"] (GC=3V7\$^F]_G_CS_XJ=2?L4GMOP3Q4ZD_8I/;?@O0"
M)XW4]C\$^F]_G_CS_P"*G4G[%)[;\$\5.I/V*3VWX+T B>-U/8_!/IO?Y_X\
M_P#BIU)^Q2>V_!/%3J3]BD]M^"] (GC=3V/P3Z;W^?\ CS_XJ=2?L4GMOP3Q
M4ZD_8I/;?@O0")XW4]C\$^F]_G_CS_XJ=2?L4GMOP3Q4ZD_8I/;?@O0")XW4
M]C\$^F]_G_CS_P"*G4G[%)[;\$\5.I/V*3VWX+T B>-U/8_!/IO?Y_X\_P#B
MIU)^Q2>V_!/%3J3]BD]M^"] (GC=3V/P3Z;W^?\ CS_XJ=2?L4GMOP3Q4ZD_
M8I/;?@O0")XW4]C\$^F]_G_CS_XJ=2?L4GMOP3Q4ZD_8I/;?@O0")XW4]C\$
M^F]_G_CS_P"*G4G[%)[;\$\5.I/V*3VWX+T B>-U/8_!/IO?Y_X\_P#BIU)^
MQ2>V_!/%3J3]BD]M^"] (GC=3V/P3Z;W^?\ CSU/R7ZBAV-ME)\-P8,3=9^A
M=OBIU)^Q2>V_!;RNO^5^?;_53D\;J>Q^"?3>_P _\>?_ !4ZD_8I/;?@GBIU
M)^Q2>V_!>@$3QNI['X)]-[_/_'G_ ,5.I/V*3VWX)XJ=2?L4GMOP7H!$\;J>
MQ^"?3>_S_P >?_%3J3]BD]M^">*G4G[%)[;\%Z 1/&ZGL?@GTWO\_P#'G_Q4
MZD_8I/;?@GBIU)^Q2>V_!>@$3QNI['X)]-[_ #_QY_\ %3J3]BD]M^"JVHK'
M6:?N)H;B(Q.&!_P';0P>&_Z%ZI6J-=:(N>I]<.EIPV"A$,;7U$G#._(:.)/[
MO.NVC]7-K?U]'C^M_P#$4T].)T(F;9::8USWM8QI<YQP !DDK8^D.2RON6Q4
MWQSJ"E.\18_O7CT?X?IW^9;/TGHFT:;8U]-#SU9CX53*,O\ HZFCT?O5F6=7
MZV9Y:;I])_X6M?ZOJ.<]D6UT$%LH(:.D#Q!"W9:'O+CCTE2D1>"9SS?>B(K&
M($1$41$0$1$!$1 4.\?JV;Z/YA3%#O'ZMF^C^82!+C^(WT!?5\C^(WT!?4!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%!M'Z&?YYRG*#:/T,_P \Y!.1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%1^4V]1P4]+8F5<5+-
M<G;$LTCPT0P?XG$GMW@=N]7A5:P:<E\*W2[:@CIYZVJ?LQ,^.V&%OQ6C(X]J
M[:,UK.^WDQ>)F-L,)IRIM<'*,VFLE33S44MJ;&.9D#P'QNP <=>RI].ZLU9>
M+IL7&KH+3;YC2L;2/#'S2M^,YSL'<,C 4^Y:>=_:BQW.V14T,=(96U#0-@N:
M]N!C WX*PML;7T!N]9IRNM<UEJJB2I?+4%X=32?_ #-P'PANX9"]&:W_ *J]
M<1U_/]\.6)CE/1!I[]=K.W4\U75OKS0/BH:,.W"21Q."X#_%O;GMP5D+Y;+M
M9=.SWDZ@KY;I3,$TC7N'1W[][.;Q@#J'6H6F-.U%ZY.GF2<QW"NJW7!DTC>+
MP[X)<.PAO[UF+C;-0:D@BM]YCHJ"W;375)IYG2/J #G9;N&RTD=>2M6FL7\N
M4\_TQ_U(B9C]G5>KE<[CJ+3E#:*EU'S],^KJ3C:V6%H R.L@YQG=G"Y6OI5K
MUZ^VMNE;6T9MYJIQ5R!^P[;P"#@8]"RU!9IX]97"ZS\T*<TL=+3-:=X:#M.R
M,;MZA36&XNKM55K'0](KZ=M/1Y>?@-#",NW;MYSU\%RBU<;>6,?>9_QG[-XG
MK[L/27.]U')U5W6CDJ)JJJJ7RLV1MR10<YLD,![&@X]*EZ4D%7<J>IL&H:BO
MH@'-K:6OE+I6;O@EH(RTYX]2EOL5WMUJL#;)4QB>VQ[$U+)(YL53EH#LD=8.
M2,CK7*T66XSZJ=?;E3TE ]M.:=L-.\R&0DYVGNP,^8+4VIMMC'G_ /F/VE(B
M<PQG)[;'2WV_78U]=*&UKJ5O.2 B9L8P"[=OQDXX+8"J_)]:[G9;5+072.G^
M!(Y[)HI"XRESB22"!CJ5H7#ZBV[4GFZ:<8J(B+BV(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@*#'^N)OFA_-3E!C_ %Q-
M\T/YI UMRXRUE9==%62UT\=763W$UPIY)-AL@@;M8<[J!VC]2[=4ZJU[:=.7
M*OK--6FG@@@>YTK;D7%F[B!L[SYE8:C3=;5\JM)J&=T/@RBMKJ>!H<2_GGO^
M$[&, ;)QQ7/E5L%QU1HRJLUI?#'+521-D?*XM C#PYV, []W!=HM'],2SB>:
MBV9M;I'1?)8*>HE@IYZR.&LB:<-DZ2USAM#S.*M;[M67_E(=16ZKDI['I]FW
M<)(W8%14.'P82>L-'PCY]Q4+ES#*?05/36]S6W1M;2BV0@9<^9LC=EH'^G*^
M7.WCD_Y%[R'2\Y<#22R5-23OEJIO@E^>OX3ACS *_P!T9\Y3IR8C0UKU!K;2
MU3>KAJJ[T$=74SS6^.DD#!$S;(:7G&7-W;FY QYRNBS:WOVI=*:+M=#4MIKY
M?.>%37A@)AA@<X/D:WAM.P,=62>&[$RQ:>UU0Z(I-*T3K5%124X9X4=(X301
MO&7MYK&]XVG ': X'<5EKEH2KLTFEZ[1O1G5-B@?2]&JW%C:F)X^%EP!V7YR
M[.,9*LS7/['-%N,-QT-JG2_1K]=;G0W:KZ!4TUQF$QR6DMD8< MP1O W+A01
M7G6&O=70MOUPM^GJ"6*C8RBD#'NE:P%^'$'9&3OQO/P=_'.4I+#>;KJBDU+K
M/H='3VF.1U%;Z60RACG##I9'D#)P-P P/YU#DL9K*+3=3>K%36RLBU#53UQ9
M62NB=32&1S=HX!VVD-:<;BD=,^8S&F=07:@T_K6WU=ZI9*FQU1IZ6YW1^RW9
M< 6\Z0/A.;Z-YP%4+SJ.*U6JEN.G]=7Z\:A,\+#%)&\T=0YS@'-V3&&-;C.,
M'*M]QY,JZ/1=-34=73UM\9=FWJK=5 MAK9LG:8[&<-P0!Z.K*[[[I[6&J;GI
MNHND-JH+=;;C%52T$4[I7/#?\9?L@;NIH'6<G@K$USDQ+EJ6HOE\Y56:?LMV
MGMUNIK7SU;+#@N:Y\F!L@[MO W$\ 2>("Q^IYHK/<:"Q777U71VRFIRYXAF=
M)<JF0N)!D<UA+6 '=@;_ .5STKI^LH-7:KO5P,)-TFA;3ACB2V&)FR,[MQ))
M.%@:6PZIT]J[45;9**TW"GO,S9VU%54.BDIR&XV7 -)<T=0!"S$QT7# :2O\
ML\&OJ.&_W>LL5JI8YZ>NJ08ZN(ECWO:'.:"?B[B6\/3E8:"W3Z:_)WJJCIE;
M45U]@C:VGD>"QKYW_P" 8W%S7Y.2<X5GI= :A;HO75!5UM'+>K[5/ECJ@2UC
MV$- :1CX.X.&-^,A92MTQ?+U9=%T=?34-'':ZZ*IJX8IB\;$((C:T[._.XD;
ML>=:W5B>7?\ 9,2KVHK3>M'6[2,L&I+C)=)*^DMPHF.:VC+",%@CQP ;\8DG
MK]%L@N]30\KEWM]=6/\ !DEGCKXF2.^!%L/+'D=G:5-U1IVMO.M-*5P="+5:
MI)JB9KG';?*6;,>!CJ.3Q5*Y5[1)J7E)T]9[35F.6HHIHKJ8OC1T9>P[SU;1
M#FCTK,3%N4G1%O.I[[4:&U-JVFJZJ!ERECH;%2M.SLLYP,$H'[;_ (1\P'G6
M3U W4.EJ>@>V_P!77ZFOTL=NABE(-)2..]TC(\;]EHQDDDYR>Q6G5VEIKH_2
M=';V4\-IM=?%531DX^!$TAC6C&_>1V<%RY1--5U[9:*ZRS017>T58JZ<5&>:
MEW8<QQ&\ CK"1:.1B55U;17705';;Y2ZFO%R>*R&"LIJZ4215#)';+MAN/@$
M<1C]Z[[MJ^HMFM=:U\L\LEIT]:H6=%#L,?42?#!].,-SU94Z:P:CU;>K5/JR
M&AMMHMD[:IE#2SF=U1.WXKGN+6@-'' !SUKHCY/JNX:>US1W::&.KU!6R312
M1DO$<8V>9#MPX8WA(FO_ +'/R8:\6[4UOY/ZO5U=JBXLO@I35OHP6BC8UPSS
M/-8X@'&UG.=Z^VL5MDL_)1IFW5$M-+5O%75B,X+HV1\[(QWF+GX^A=^HM.Z^
MU3I*&PW(6>A@:Z&.IEAG>]U6QKADCX(V!@9QO).!N&5;)--5<_*;27R0PMM=
M%:W4M.P..V)7/^$[&, ;.[BKNC'/^=C"DZINY&O[I0ZPU!>].6\B-MHFHW\S
M32 M^$Y\@!!=M=3L *3JRNU9;])Z4LXNU/-J.XW)D#:VF)V98!M.VW8 _P .
MSM8X[U)?8M<06"OTU4P6G4%%.9&PW&XU;^<:QY)'.,+7%Q;G=@]0[%.LV@ZV
MW7W11DJ8ZBW:>H)HMMQ(>^>0;.0W'Q0.&_<F:P<V#NM'J.U\H]DL]HU7<JB:
MYTL\MP?6!DD<+&XQ)%&  PYR -XSC.=^<KHUMPM?*M>+&V]7.Z6N&V1U$OA"
M42NCJ'/W!I & 69.%GZ+3M9XS[CJ.K=":3P?'0TC6N)<!M;;R1C=O\Z:0T[6
M6W5.K;S<C"9+K4Q\QS;BXB"-FRS.X8/'<LS:,?HN%N1$7%H1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%$NWZNG]']5+42[?JZ?T?U2!)A_0L_
MTA<EQA_0L_TA<D!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%!M'Z&;YY
MRG*#:/T,WSSD$Y$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$$&Z_P"5
M^?;_ %4Y0;K_ )7Y]O\ 53D!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M%#O'ZMF^C^84Q0[Q^K9OH_F$@2X_B-] 7U?(_B-] 7U 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!0;1^AG^><IR@VC]#/\ /.03D1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 5>JM%Z?JJN2IFML9DD=MO >YK7.[2
MT'9/U*PHM5O:O]LX2:Q/5QC8V.-K(VM8QH#6M:,  =07)$65$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!08_P!<3?-#^:G*#'^N)OFA_-($Y$1!@?['V(ZI=J-UO8^]%H;TE[W.V<-V
M00TG9!P,9 RIU]LU!?K<^@NU.*FC>YKG1.<0"6D$9P1U@+((KF3 B(H.JLIH
MJRDGIJANW!,QT<C<D9:1@C(WC<5U6JWTMIMU-06^%L%)3L$<48)(:T<!OWJ4
MB B(@(B("(B L#I;1]BTJ*GP#;V4KJEP=*_;<]S\< 7.).-_#@L\BN9Z B(H
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"B7;]73^C^JEJ)=OU=/Z/ZI DP_H6?Z0N2XP_H6?Z0N2 B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("@VC]#-\\Y3E!M'Z&;YYR"<B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B"#=?\K\^W^JG*#=?\K\^W^JG("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@*'>/U;-]'\PIBAWC]6S?1_,) EQ_$;Z OJ^
M1_$;Z OJ B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("@VC]#/\\Y3E!M'
MZ&?YYR"<B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("@Q_KB;YH?S4Y08_UQ-\T/YI G(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@*)=OU=/Z/ZJ6HEV_5T_H_JD"3#^A9_I"Y+C#^A9_I"Y("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@*#:/T,WSSE.4&T?H9OGG()R(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B((-U_P K\^W^JG*#=?\ *_/M_JIR
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("AWC]6S?1_,*8H=X_5LWT?S
M"0)<?Q&^@+ZOD?Q&^@+Z@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B H-
MH_0S_/.4Y0;1^AG^><@G(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^
MLIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4
M^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y
M4^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[
MY4^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.
M[Y4^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@
M.[Y4^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.
M@.[Y4^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9
M.@.[Y4^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUE%92.-RDCZ3,"(P=K:WG
M?P684&/]<3?-#^:L(= =WRI]9.@.[Y4^LIR**@] =WRI]9.@.[Y4^LIR((/0
M'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/
M0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((
M/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR(
M(/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR
M((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LI
MR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^L
MIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^
MLIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4
M^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUE'N%&Z.CE>:F=X ^*YVX[UEE$N
MWZNG]']54=45"XQM/2Z@9 W!RY= =WRI]93(?T+/](7)14'H#N^5/K)T!W?*
MGUE.1!!Z [OE3ZR= =WRI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T!W?
M*GUE.1!!Z [OE3ZR= =WRI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T!W
M?*GUE.1!!Z [OE3ZR= =WRI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T!
MW?*GUE.1!!Z [OE3ZR= =WRI]93D00>@.[Y4^LHMNI'21RD5,S,2.&&NX^=9
MA0;1^AF^><JAT!W?*GUDZ [OE3ZRG(HJ#T!W?*GUDZ [OE3ZRG(@@] =WRI]
M9.@.[Y4^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI
M]9.@.[Y4^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WR
MI]9.@.[Y4^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =W
MRI]9.@.[Y4^LIR(,/7TCH^CYJ9G[4K6_"=P\X\ZE= =WRI]9+K_E?GV_U4Y5
M$'H#N^5/K)T!W?*GUE.114'H#N^5/K)T!W?*GUE.1!!Z [OE3ZR= =WRI]93
MD00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T!W?*GUE.1!!Z [OE3ZR= =WRI]9
M3D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T!W?*GUE.1!!Z [OE3ZR= =WRI]
M93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T!W?*GUE.1!!Z [OE3ZRC7*D=%
M12O-3.\#'P7.R#O674.\?JV;Z/YA5'!E XL!Z74\/VE]Z [OE3ZRFQ_$;Z O
MJBH/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^L
MIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^
MLIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4
M^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]91;=2.
MDCE(J9F8D<,-=Q\ZS"@VC]#/\\Y5#H#N^5/K)T!W?*GUE.114'H#N^5/K)T!
MW?*GUE.1!!Z [OE3ZR= =WRI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T
M!W?*GUE.1!!Z [OE3ZR= =WRI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)
MT!W?*GUE.1!!Z [OE3ZR= =WRI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K
M)T!W?*GUE.1!!Z [OE3ZR= =WRI]93D00>@.[Y4^LBG(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("@Q_KB;YH?S4Y08_UQ-\T/YI G(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@*)=OU=/Z/ZJ6HEV_5T_H_JD"3#^A9_I"Y+C#^A9_I"Y("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@*#:/T,WSSE.4&T?H9OGG()R(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B((-U_ROS[?ZJ<H-U_ROS[?ZJ<@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B H=X_5LWT?S"F*'>/U;-]'\PD"7'\1OH
M"^KY'\1OH"^H"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@*#:/T,_SSE.
M4&T?H9_GG()R(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B J9K7E
M'L>DJD4E:Z>HK2T.,%.T.+0>!<20!_-7-:#UK!=]%<IM5J@6H7.WU'PFO>TE
MK,M (R =APQN)ZEZOI-*NK>8MVY1TS[.6K::QF%[TKRLZ>U!<8J!HJJ*JE.S
M&*EH#7NZ@' G?Z<+,:XUQ;-&BC-UBJI.E;>QS#&NQLXSG+A^T%K(ZET1R@7N
M@DO4-;9[FPAL<K'M#'G((#G@9W'@2!Q7=^4R<#3I\\__ .S7ICZ6DZ]*368S
MG,?ZESXD[)MG+/>/'3'=KK[%GOJRP:^M4VBYM3LBK/!\3]AS"QO.9V@WAM8X
MD=:HK.6#3@: =-U>X?(Q_>LSR@7.FO/(G6W&BIC2P5#8WMB<T M_OFC>!NZE
M+_3UBU8FDUS,1U6-2<3.[/)UCEPTQG_X:Z^Q9[ZNND=5VG5=$^HL]09!&0V2
M-[=E\9/#(\_;P6J>3O6VC;5H.BH+X8I*V,2<Y$:-TA.7N(&=G!W$=:X?D^P/
MEU1J&Z4D#Z>SN8YC&NX F0.:W/66M!^OSK6M]+2*7F*S7;TSYI35M,Q&<Y;V
M5-UCRCV#2E6*2ODGGK,!SH*9@<Y@/#:R0!Z,Y5I9<*-[VM95T[G.. !(TDGZ
MUYQT+J.6'6E^N<=DJ+Y=ZA[W011C]&TN)<XG!QNV0-W7A>?Z7Z>-3=:T=/+I
M]V]34VXB/-O?1VKK3JVBDJ+1*\F(@2Q2-V7QD\,CSXXC<JU>.6'3%LN4E'M5
ME48W;#Y:>(.8"..\N&?H!4;DHJ]-7>JO4EMM4MIO+]IM=3.E?G!<<[.\  '=
MN (4/6E/9.3G2M906JRRU9NK)07.^&(\- RYQW[(SD#MRNE='3XTZ<UGVCE^
MO/\ 9)O;9NS#9ECNU%?+9#<+7.V>EE&6O&[T@CJ([%A-<:ZM.CFTPN?/RS5!
M.Q#3AKG@#_$02,#J_P#95=Y#[<ZCY.I>B5T$]152R3#FW9$+RUH#3YQ@$^E:
MNY4]'U>GJ2VU]YNDEQN]=,_GI"26M#0, 9WGCYO0%='Z72MKSIVMRB?UDMJ6
MBFZ(>FVG::'#@1E?20T$D@ ;R2N$'Z%G^D*G<L5VDM')]=)8'%LTX;3,(ZML
MX/\ Y=I>'3I.I>*1YNMK;8RD6C75ON=GO=UIZ>J\'6MSPZ; _O\ 9!)+!GLQ
MQQQ"CZ,Y2++JVZ26^VQUD=0R(R_W[&M#@" <8<=^_P#FL+;+:RV<@<\3&X=+
M:9:AY[3(PN_D0/H6I^3UYT_J'2%YSLP5LLE+*>K.UL'/H#VGZ%]&GTNEJ5U)
MKUB<1^D?\<)U;5FN6]=:\HEFTA<(*.YLJY)Y8N= @8UV&Y(&<N'6"NZXZ[M=
M!H^DU)-%5F@J2T,:UC3(,YQD;6.H]:T;RG..H-6:NN )-/:F14[#V.$C&8^O
MG"K+J_\ [O=A_P!<7_WJ^#TXKIYZS,1/ZQE.-;-O99O'CICNUU]BSWU<-'ZR
ML^K897V>=SI(<<Y#(W9>S/ X[/.%K#2?*7I"V:5MM#<*&>6J@IVQRXI6.#G
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M$1$!$1 1$0$1$!$1 1$0%!C_ %Q-\T/YJ<H,?ZXF^:'\T@2WRQL<&OD8UQX
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M27.EUG0NIKG"]S!30PNV9!C&P=HG!SGCNP5MZ"&*GA;%3QLBB:,-8QH: /,
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MG.[K(W*R\MM/%5\N^AZ>H8V2&44K'L<,AP-2_(*M-9R$6:X4L?A2]WRLN#7
M]-EG#G[(!PP!P(#=^>WSJT:CY.K??]7V345;6UC:VU"(1M86!DA8\O!<-G.\
MG?@A;XM8Q[93;+5OY2=+#/K[144L;7,F(B>,?&;SK1CT;S]:[?RJ(8XJO1;H
MF-8X2S,!:,8:#%@>@+9^M^3RW:OO=GN=?55<,UL=M1-A+0UWP@[X60>L=2Y<
MHO)[;M=/M;KE55=.;>][X^CEHVB[9SG(/[(6::M8VY\LDQU:JY;:>*KY=]#T
M]0QLD,HI6/8X9#@:E^05\_*3I89]?:*BEC:YDQ$3QCXS>=:,>C>?K6U-3\GE
MNU#K.SZDJJJKCJ[9S?-11ENP[8D+QM9!/$]136_)Y;M7WNSW.OJJN&:V.VHF
MPEH:[X0=\+(/6.I*ZM8FOM!,=6L/RJ(8XJO1;HF-8X2S,!:,8:#%@>@*Q\KN
MJ*>CUM8K+:]-VV[:GEV)*:IK6C9I\O.S@[CQ:3Q 'GRK=RB\GMNUT^UNN555
MTYM[WOCZ.6C:+MG.<@_LA1.4?DQM>MJVDN$U556^Z4K0R.JIB,[()(!!["20
M00=ZE=2N*Q;RRN)YM+Z^AU*SE;T0[5U7;)*^2IIS&R@:0V%G/C )(R=^>U6+
ME.:/_P R>CA@8,5-GS_WLJMGB0LSJN@KYKQ>IKM2S"=U;+,'OE<"TM!V@=PV
M=V.TY)W++<I7)9;=<W&CN,];5T%?3,YMLL&#M-!)&0>L$G!!ZUOBTS'Y3"8E
M0/RCP!KC00&X<\?_ %8U$Y21!/\ E(Z>AU!L&U[$/--F^(?CXSG=@R<5L>[\
ME-KNL.F65=QN)=86!D+PYF9<%IR_+?\ ='#"RW*%R?6375)%'=XY(ZB#/,U,
M#@V1F>(W@@CS$?4LUU:UQ'YP8EK7\K&&W-TW99=F)MUZ7LQ$ !YAV';7GP';
M'UJO<N,4U7<.3.*[-+IYJ:-M2U_$N)B#P?I)6P=,\AUCM=X@N-TKZZ\S4Y!A
M95N'-MQPR.O'9G'F5EUSR>6[6%XL]QKZJKAEMCMJ)L):&N^$'?"R#^R."M=6
MM,1GIDQ,M??E7TT$>BK(Z.)C3%7"-FRT#9:8W[AV#X(W>9;CTV2=/6LDY)I8
MO^0+"<H^AJ#7EIIK?<ZFJIXH)Q.UU.6AQ.RYN#M [OA%66@IFT=#3TL9<YD$
M;8VEW$AHQO\ J7&UHFD5:B.;O1$7-1$1 42[?JZ?T?U4M1+M^KI_1_5($F']
M"S_2%R54&O\ 3$0YN2ZQM>SX+AS3]Q'_ (5]\8>EO*\?LI/=73A7],O/XK0]
M<?,+4BJOC#TMY7C]E)[J>,/2WE>/V4GNIPK^F?@\7H>N/F%J157QAZ6\KQ^R
MD]U/&'I;RO'[*3W4X5_3/P>+T/7'S"U(JKXP]+>5X_92>ZGC#TMY7C]E)[J<
M*_IGX/%Z'KCYA:D55\8>EO*\?LI/=3QAZ6\KQ^RD]U.%?TS\'B]#UQ\PM2*J
M^,/2WE>/V4GNIXP]+>5X_92>ZG"OZ9^#Q>AZX^86I%5?&'I;RO'[*3W4\8>E
MO*\?LI/=3A7],_!XO0]<?,+4BJOC#TMY7C]E)[J>,/2WE>/V4GNIPK^F?@\7
MH>N/F%J157QAZ6\KQ^RD]U/&'I;RO'[*3W4X5_3/P>+T/7'S"U(JKXP]+>5X
M_92>ZGC#TMY7C]E)[J<*_IGX/%Z'KCYA:D55\8>EO*\?LI/=3QAZ6\KQ^RD]
MU.%?TS\'B]#UQ\PM2*J^,/2WE>/V4GNIXP]+>5X_92>ZG"OZ9^#Q>AZX^86I
M0;1^AF^><L'XP]+>5X_92>ZHEMU]IF*.4276-I,CG#^[?P]5.%?TS\'B]#UQ
M\PNJ*J^,/2WE>/V4GNIXP]+>5X_92>ZG"OZ9^#Q>AZX^86I%5?&'I;RO'[*3
MW4\8>EO*\?LI/=3A7],_!XO0]<?,+4BJOC#TMY7C]E)[J>,/2WE>/V4GNIPK
M^F?@\7H>N/F%J157QAZ6\KQ^RD]U/&'I;RO'[*3W4X5_3/P>+T/7'S"U(JKX
MP]+>5X_92>ZGC#TMY7C]E)[J<*_IGX/%Z'KCYAE-2:@HM.TL%3<B]L$LPAVV
M-VMDD$Y(XX^#U*?0UE-7TK*BBGCG@>,M?&[(*U+RMZJLM[TY3TUJKFU$[:IL
MA:&.&&AKAG>!VA:YT]J&YZ?JN>M=4^+)^'&=['^EO _S7II])-Z9Z2^9K?\
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MIQ$\=?M!^!:/JG[/,?\ 8K4GD:L]1/[%:D\C5GJ+TXB>.OV@_ M'U3]GF/\
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MJ6DLO0:VXXACIXB^23FB[9;MY)P[#G$XX+,Z=,1'?'_?/_"Q:W5.M^J;[56
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MB B(@(B((-U_ROS[?ZJ<H-U_ROS[?ZJ<@(B("(B B(@(B("(B B(@(B("(B
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M1 1$00;K_E?GV_U4Y0;K_E?GV_U4Y 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M[#D.!X$'K"T%K2_<G-=IRLIK%:XS<Y&AM.8*,QN:_.XYP-WFZUL_D@M]=;-
M6RFNC'QU #W"-_QF-+B6@]FX\.K*Y:_T]=/3WQF)SC$M:>I-K8GG^2XHB+Q.
MPB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@*#'^N)OFA_-3E!C_ %Q-\T/YI QVH]8Z?TU4107VZP44LK=MC9,Y<W.,
M[@L1XUM#_P#Z247_ )ON6IORE):.#E'TA+=6<Y;XV,=4LQG:B$V7C'7NRN?]
MJ>1+R"?LCO>7IKHQ-8G$SGLQNYO1%+/%54T513O$D,K!(QXX.:1D'ZEV+67*
MSKZ7DWCT[!;[=#/25+G1.8<YCC9L !F#QP>OL"KM[Y5]7:8NMMFU5I6FH;'7
MOQ'LS;<S&[LY()&T 0=D@97.-*UHS#6Z&[UB+[J6SV&HHH+O7PTDM8XLIVR9
MS(00,#'^H?6J;RJ<I%1I:XVRR6"W-N=_N&#%$XD,:TG9!.-Y)(/6.!)*U)RJ
MWK45QU3HNDU=98[9<*:JVVN@E#XIF/DCWMWG!!:<C)XA73T9MC/1)MAZD1:S
MY2>4JIL.H*/36F+7X6U%5-#A$YV&1@YQG'$X!/$ #>2L?IKE0O5+J^ETUR@V
M.*TUM;CHT\#]J-Y)P =YXG=D'CN(68TK3&5S#;B+56L^4J[1ZS.D]#6:*ZW>
M)FW4/G?LQQ[@<<1P!&22-Y WE2] :_O%VK[Q9]3V%UMN]NC,A=&"Z"3 X9W@
M'>"-YR#YDX5L9,PV4L10ZEL]=?*JS4E?#+=*4%TU.W.TP @'/UCZUIS2W*]K
M35D+1I[2M+420S!M5*7.YIC'8#<?"!S\8GCNQN6<T/=Z.IY<=56^&R45-50P
MO+ZZ-SS+-\./<X$XZQP'4M3HS7.Y-S;R+1NG>5G5^J'W2BTYI>DJZ^CD.9'3
M;$,;,D#:RX9<2#@ C@5:.2;E*?JZ@O(OE'%;:ZT$=*V7'8V?A9._>,;#LC)4
MMHVK&96+1+92Z:ZK@H**HK*R1L5-3QNEED=P8QH))/H *TK3\JNLM32UU7H3
M24-79J1Y89JEYVY,;]PVF[\8.R-HC([5FJ77U)KSDBU?4Q0.I*ZEMM3'54SG
M9V'&%^"#U@X/U$=2<&T=3=#8UAO5NO\ ;VUUFJXZND<XM$L><$CB-ZR"T=R-
MZFHM(\A+KQ<MIT,%3*&QL^-(\NPUH])_J5U'E6UY#9V:EJ=&4PTR[#]ILIYT
M1D[G9SG'GV,*SHSF8A-S>R+7>I^56U6KDZI-54<;JIM=B.EIR=DF3?EKCOQL
M[+L\>'G50NW*IKG3NFA=M1Z2I(8:K8Z)+'(=EI)SLRMVBX9;M$<-X PI71M*
M[H;S1:CU!RI7*R-T36U=OI/!%]@B?43 NVH'NV2_&_& ' C/85E^4_7U9IF^
M:>LMDHZ>MN5VEV-B8D!C2X-:=W:2?5*G"MR,PV*B#AOXHN:B(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("B7;]73^C^JEJ)=OU=/Z/ZI
M DP_H6?Z0N2XP_H6?Z0N2 B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("@
MVC]#-\\Y3E!M'Z&;YYR"<B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M"#=?\K\^W^JG*#=?\K\^W^JG("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@*'>/U;-]'\PIBAWC]6S?1_,) EQ_$;Z OJ^1_$;Z OJ B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("@VC]#/\\Y3E!M'Z&?YYR"<B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@+7G+W_V<5GST7_.MAH0",$9"Z:5^'>+]
MF;5W1,*WR:_]0=/_ /!1?\JUS3<H-RTS?KI:>46&:KIG._V>5E.S9+03OP,!
MS2,=I!W>C=0&!N7":&*=NS-&R1O8]H(_>NE-:L6M-ZYB?F/REF:3B,3T:"TF
MVGU1RO4EWTG:Y+?:*4;4[Q&&-)V7 G W NR!@>GM64T_&R7\H>]MD8U[>:=N
M<,CXC%NJ.-D3 R-C6-' -& %RP,YP,]J[6^LSG$<L8ZLQHX\_/+2WY2$$45K
ML9BB8PFH?G9:!_A"Z^7)K7ZMT6UX#FE^"",@CG&+=I /$ ^E?" >(!6=/ZO9
M%(Q_;G[EM+.>?7#4W*]HSHU+'J;2L0HKE;_ARBF:&;;!_BP.L=?:,YX*X\F^
MJXM7::AK1LMJX_[JIC'^&0=8\QXCZNI6E?  .  ]"YVU]^G%+1F8Z3_AN*8M
MF'U$1>=L1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0%!C_7$WS0_FIR@Q_KB;YH?S2!H'\HRLI[?RGZ,K*YI?24XCFF
M:&[66-GRX8Z]P.Y6#QR\FWDR7_\ MS/O6Y:BCIJEP=44T,K@, R,#L?6NKP5
M;^X4GL6_<N_$K-8B8Z>[.):'_*$N$%X9R=7"EVC35<KIH]L8.R[FB,CT%9'\
MK ?FY8#U]./_ "%;LDHZ:1L;9*>%S8_B!S 0WT=BY5%-!4M J(8Y0#D"1H=C
MZU*ZN-O+H;>K0O+"Z72W*[I76-9!++9V1,AE>QN=AP+P1Z=E^0.O!5>Y7M:6
MS66K]'26'GIZ"DJ@PU;H71M?(Y\9+!M '< "?]07IRIIX:J!T-3#'-"X8<R1
MH<T^D%=,=NHHX8HHZ.F;%$<QL;$T-9Z!C<K76B,3,<X-K0^N:A^@N7J#5EVI
MII+)70B/GXV;7-GF]@CTC9!QV$X435%Y@Y5^5/2T.DXYYJ&U2":IK'1%@:W;
M:X\=XP&8&<9)7HFH@AJ870U,4<T3MSF2-#FGT@KKH:&DH(C%0TL%-&3G8AC#
M!GT!(UHC$XYQ&#:\_27.+DUY>[W<]21S1VJ[PO,-4V,O VBQW5O."TM(&_@K
MQI'E*EUO>K_26JUDZ?I('%EQ>2TN=L[F[)'$G:/$' WK95;14M=#S5;30U,6
M<[$T8>W/H*^TU+3TL @I8(H81PCC8&M'T#<I;4K:.<<R(PTK^28T?V+O#L;S
M<""?_P"6Q1^3C_O(ZU^8D_YXEO.GIX*9I;3PQQ-)R1&T-!/T(RF@CG=,R&)L
MS_C/# ''TE)U<S:<=3:T9^2V!TC6AZ^EQ?SE6,Y*K;)=[QRP6RG<&2U9E@83
MN <Y\X'T9*]#04T%/M='ABBVCEVPP-SZ<)#300O>^&&*-[SE[F- +O3VJSK9
MFTXZX^QM>=^2#E(M&@=+UNGM60U=#<Z*HD>(N8+C+G&[=P=D'C@8QO7'DTM-
M<>3[E.U+64SZ6FO%%4OIHW#&6B.5Q</-\, 'S%>@ZRUV^ME9+6T-+42,^*^6
M%KRWT$C<I3HV.C,;FM,9&R6D;B.S"3K1SF(ZD5>8+98*W4'Y,S([9$^:>DN+
MZHQ,&7/:TN#@!UX#LX\RS-QY7[#6<D1L<$50Z^34 MW0Q"<-=L;!<'<,=8''
M@,+T)!#%3Q[$$3(F<=EC0T?4%';:K>VM-8V@I!5G?SXA;M^MC*O&B?[H\\FU
MYLU=H*]4'(-8"^FE=5T-2^LJ:<#+HHY,\1YO@Y'5D]A4CE7Y4K=K/DVZ#9Z&
MM,VU#)6/?%B.F /#:SO)=@#S96[^4:S7N]:>,.F+N^UW2*42QR!Q:V0 $%CB
M,[CG/ [P%JJ[Z/Y3M562#3MZ;8J*VB1CYZN+]),6_P")P'$]?!N3V+I2\6Q-
MO*4F,=&8U5IO^TGY.UJCB9M5=%;:>L@P-^61C:'TM+AZ<*J<A\E9KWE%;J.[
M-VF6.W0TL9._,NQL@^D_WCO,2%LK7%JUA1:<MECT VB-(VD-'/+4NV9(VAK6
MM<TYQG&UG<5/Y(-$?V%TDVWSR1S5\TAGJ9(_BEQ  :,[\  #ZSUK&^(TY]S'
M-=T1%YFQ$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!1+
MM^KI_1_52U$NWZNG]']4@28?T+/](7):]=RKV"!QA?#<-J,[!Q$W&1N_:7SQ
MN:>^1N/LF^\NWA]3TO'^(?31_P"\-AHM>>-S3WR-Q]DWWD\;FGOD;C[)OO)X
M?4])^(?3>N&PT6O/&YI[Y&X^R;[R>-S3WR-Q]DWWD\/J>D_$/IO7#8:+7GC<
MT]\C<?9-]Y/&YI[Y&X^R;[R>'U/2?B'TWKAL-%KSQN:>^1N/LF^\GC<T]\C<
M?9-]Y/#ZGI/Q#Z;UPV&JQJ[6-+I>NM\5?#(ZGJ@_,L>\QENSU=8W_P#XK!^-
MS3WR-Q]DWWE0.5+5MOU3);C;65#13B0/YY@;\;9QC!/85TT?IK3?%XY/-]7_
M .2TZZ4SHWB;<OW;WM=RH[K2-J;=4QU$#N#V'/T'L/F*EKRG8[U<+'5BHM=5
M)!)U@'X+AV.' CTK<6D.52AN&Q37UK:&J.X3#]$\_P#V_3N\ZNK]):G.O.&?
MI/\ R^EK?TZG],_9LI%\C>V1C7QN:YCAD.:<@A?5Y'UQ$1 1$0$1$!$1 4&T
M?H9OGG*<H-H_0S?/.03D1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$00
M;K_E?GV_U4Y0;K_E?GV_U4Y 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!0[Q^K9OH_F%,4.\?JV;Z/YA($N/XC?0%]7R/XC?0%]0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 4&T?H9_GG*<H-H_0S_/.03D1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$5'UYJFNLEXM\%OC9)"R)U56M+<NYD.:-
MW9_B6]/3G4MMJS:T5C,KPBP.KKWX*TC676C>QSFQ!T+B,@EQ :?/Q"G"OCH+
M33SWJJ@IW\VWG9)'!C=O&_&?/G<FR<9_0W1G#((HUOKZ2XT_/T%3#4PYQMQ/
M#AGLW+I=>K8VX"@-PI!6DXYCG6[>>S&<Y\RFV>F%S">BC-N%&ZB-8VK@-( 2
M9Q(-C<<'X7#BNFVWJV71[V6ZX4M4]F]S8I0X@=N FV>N#,)Z*LVW55-<=6U=
MIIIZ1T$$+2U[9072R'>0W?O#0#GC]"FV2X&0.Z9<J"H=53R&C%.\?"B;_A'[
M3AOSA:MI6KU2+1/1F473/54]/)#'//%&^9VQ&U[@"\]@'65$J[[:J.K%+57*
MCAJ3_P#*DF:UWU$K$5F>D+,Q#(HBQ^H+M!9+/57"J/\ =PLR&];W< T><G 2
M(FTX@F<<Y9!%4.3^]W6YRW2DOS8F5M*Z)VPQNSLMD9M 'SA23?9QJR[4Q<P6
MZVT+9I?@[^<.7<>S9'!=)T;1::]F8O$Q$K,BKVEKS)+I"BNE^J(('S,,CWN(
MC8 2=GCYL+*VVZ4%TC=);JRGJF-.'&&0.QZ<<%FU)K,^RQ:)3$6-K;]::&J%
M-67*C@J#C^[DF:UV_AN)6-UEJ>&PTU,V.6F-74S1QL;+( &M<<&0C]D8._AY
MTKIVM,1$=2;1$961%"K;M;J*ECJ:RNIH*>0 LDDD :\'?N/6NZCJZ:MIFU%'
M/%/ [A)&\.:?I"SMG&<+F.CO18X7RU%\+&W*C+YFE\8$S?AM&<D;^&X_45TV
MFM?!8V5EYN%"\$EQJ(G!L.R2=G!/FPKLG!NAET42VW.AND;I+=64]4QIPXPR
M!V#Y\<%POU=X,LE?7;LT\#Y!GK(!('UX3;.=OF9C&4Y%5.3:^UE^L,D]SV.E
MQ3NB=L-V1C9:X;O0Y0;QJJL=KNVV.TF/F.<V*I[F[1)QM.:WT-&__4NG MOF
MG9GB1B+=UY18^X7RUVV9L5PN-)32NWADLK6GZB5.;+&Z(2M>TQ%NT'@[L=N>
MQ<IK,<VLPY(JMJ75M%3:;N=99ZZDJJJF:&M;'('X<YP:,@'M*SU)5-',4M34
M1&X&%LCXPX!QZBX-[,K4Z=HC,I%HF<):*-+7TL3YXW3Q\[#'SLD8<-IK.TCC
MA8725ZDJ=(TUVOL\$!FVGESB&,:W:(;O/FPD4F8W+NC.%C10;;=[==&O-NKJ
M:J#/C<U(';/IQP6'LNJJ>[:GN-NIIZ5U/3,9S;VRASIW$9<6[^#>!\Z1IVG/
M+HFZ.7NLR+&NO]H;7="=<Z(5>=GFC,W:SV8SQ\RF5%53TQC%1/%$9';#-MP;
MM'C@9XG<5F:S'DN8=R*-;[A1W&)TM!50U,;7%CG1/#@'#JR%)28F.4KU$1%
M1$0$1$!$1 1$0%!C_7$WS0_FIR@Q_KB;YH?S2!.15W7>J:?25C-=+"^IJ99&
MT]+2Q_'J)G;FL'W]BK;+=RF5=-TV2_6:WU1&TVVLHN<B'8UTI.UGM(^A:BN8
MS*9;&1531&J9;OI:6XZ@I1:*JCDD@K6RG8C8YG%S7._P8WYSVC)PLQ!J&SU%
M;+1P76ADJH8N?DB9.TN9'N^$1G<-XW^<*368Y&63182UZLT]=JTT=LO=MJZH
M9_NH:ECW''' !WK)T]=25%54TU/4PRU%,6B>)CP71%PRW:'$9&\928F%2$49
MEPHWULU&RK@=5P,$DL(D&W&T\"X<0#VE8^VZJL%TKW4-MO5NJJQN<PPU#'OW
M<=P.],2,RBQE[U!:+$R-]ZN='0-D.&=(F:S:]&3O75<;S3NTQ672UU]$^,0/
M?!4F3;AV\$-)+<Y&UC<-_5Q3$C,(L3I&6Y3Z9MDU]#6W.6!LE0UK-D->1DC'
M5C./H5"H;MK+5.I=31Z>NUNH+7:ZWH4?/T?.E[VM&WOR.!_FK%<Y]DRVFBU_
MIC4U]H]9?V5UDRBDJYZ<U5#6T8<UD[6G#FN:>#AQ[,#Z[%;JVIEU%>72W.VR
MVFE8QC8(G RP28R\RGJ\P[$FLP99Y%AK1JJP7BK?2VF]6ZLJ6@DQ05#7NP.)
MP#P79>]1V6Q.C;>;M0T+I/B-J)VL+O. 2IMG.%RRJ+JIZF"HI65-//%+3O;M
MME8\.:YO:"-V%B+?J[3MQN'0:"^VRIK,X$,52QSB?, =_P!"8D9Q%CKU?+58
MX&37FXTE#$\X:ZHE:P./8,G>N^V7&BNE&RKMM73U=*_XLL$@>T_2$Q/42D6%
MHM5Z?KKF;=1WNVSUP)',1U+'/R.(P"LTDQ,=018F]ZDLEB=&V\W:AH7R;V-J
M)VL+AV@$\%*9=*!]L-R974SK>&&0U(E:8MD<3M9QA,2)B+#OU388[C!;WWJW
M-KIPTQ0&H9MOVOBX&>OJ[5*O%WMUEI>DW>NIJ*GSL\Y42A@)[ 3Q*8D3D5'G
MU9)6\H6G+38JJFJ+94T4]=52QXD#XQ\"/9<#N^'G*MEXCKIK941VFHBIJYS<
M12RQ[;6'M+<C*LUQU3*8BT[67#E!I]=6_3+-0VB6>JI7U;YA;L"%C3@9&UOR
M=RRVH;MJK3%LMD%PNM!6W2Z7:"CADBI>;;'$<EY().=P._J6N'[FYLQ%BK1J
M.RWFHGI[3=J&MG@_2,IYVO<WJR0#P4VWUU)<:85%OJ8:J DM$D+P]I(.",CL
M(PL8F%2$6.9?;2^*.1ESHG1R3]&8X3M(=+\F#G>[<=W%=$6J+#+;ZBOCO-N=
M14[^:EJ!4,YMCOV2[. 4Q)EF$6.LE]M5]A?+9KE25T;#A[J>5K]D^?!W*%9*
MVIGN5^GJ;G;:BUP3"*!E.X%U,6-_O&RNZG9(..H)B1GD5 USR@T%'HJ[7#2]
MTM]?<*<QQ1MAE;+B1[PT9 /G/U*]4HE;2PBI<'3A@$C@, NQO/UJS68C,IEV
MHM82WC5NH=>ZCM6FKG04%OLX@C<^HI.>+Y'L+B <CAA9RT6[6M-<89[WJ.UU
M%NC)=-'%0<VYS<'@XNW;\*S3'63*YHNBBK*:NHXZNBJ(:BED&TR:)X<QP[01
MN*AR:AL\=I%T?=:%MM)P*HSMYHG.,!V<'>"%G$JR:*!9KS;;W2FHL]?2UT .
MR7T\H> >PX.XJ743,IZ>6:9VS'&TO<>P 9)4P.Q%J/1=;RB:LTU37VFO=HHX
MJLO=%32T)<0T/+1EP=UX5HY/M65MVGO5IU)3T])?+-(UE3S#CS4C'#+)&YW@
M$ [CPW=N!N=.8S[)$KHBK5AO!IM-R734=ZM,M.^9[XZN"0-@$1=AC=HX!(QC
M/:LI9+Y:KY ^:S7&DKHF'#G4\K7[)[#@[EF:S"Y9%%A:K5>GZ6Z"VU-[ML5>
M2&]'?4L#\G@,9X^992MJZ>AI9*FMGBIZ>,9?+*\,:T=I)W!,2.Y%B;)J6R7U
M\C+-=Z&N?&,O;3SM>6CM(!X+A=]56"SU;*6[7JW4=2\ B*>H:QV#P.">";9S
M@RS*+HGK:6"B=63U,,=(UNV9WO 8&]NUPQYU"LFHK-?>=\"W6BKS%\<4\S7E
MOI .Y,2,HHEV_5T_H_JI:B7;]73^C^JD#1=5R8ZDFJ9I8X*<L>\N;F8<"25U
M^*S4WR%-[<+T##^A9_I"Y+UQ];J1V?(G_P +]///,_/_ !Y\\5FIOD*;VX3Q
M6:F^0IO;A>@T5\;J>R?@GTW>?G_CSYXK-3?(4WMPGBLU-\A3>W"]!HGC=3V/
MP3Z;O/S_ ,>?/%9J;Y"F]N$\5FIOD*;VX7H-$\;J>Q^"?3=Y^?\ CSYXK-3?
M(4WMPGBLU-\A3>W"]!HGC=3V/P3Z;O/S_P >?/%9J;Y"F]N%@=3Z7N6FG4XN
MK(V&<.+-AX=G&,_S"]0K6_*SIJY:DN%F@MD.T&-EYR5QPR,$MXG^@WKIH_5V
MM>(OC#S?5_\ B-/3TIMI9FW+]_R:*5STAR>7;4&Q/*WH- =_/2MWN'^ZWK].
MX+:&D.3:U6/8J*T"OKAOVY&_ 8?]UO\ 4_N5Z5U?K?+3^6?I/_"_^WU$_I_N
M6)TQ8:73ML;0T3YGQ@Y+I7EQ)[<<!Z  LLB+Y\S,SF7Z&E*TK%:QB($1%&A$
M1 1$0$1$!0;1^AF^><IR@VC]#-\\Y!.1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1!!NO\ E?GV_P!5.4&Z_P"5^?;_ %4Y 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!0[Q^K9OH_F%,4.\?JV;Z/YA($N/XC?0%]7R/XC?0%]
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 4&T?H9_GG*<H-H_0S_ #SD
M$Y$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 5(MD$=XY0-2RSM$
ME/3TL=OP>!#P7/'_ +[5=UC;-9J:TR5\E.Z5[ZVH=4RND()VCU# &X=0733O
M%8MWG_;-HS,-:2RROM]MT?5.+ZBFN[*=V>+Z9N7M=]1'U++59K[IRA7-\5MI
MKC':HXXH8:F?FVQE[=HO V79)X9\RML^FK?/J>GOSA(*Z&,QC!&P[<1DC''#
MCUKJN^EZ>ON1N$%976^M>P1R2TD@89&C@' @@X[5Z>/29_3[SU<N';^=E/J)
MKC:I-57:""@HGMHFLDIJ2I$I9-GX,C@ ,'9)ZNI9&XVBT6GDSG?+%"Y_1.=Z
M00.<?.X9:_:XYVB,++UMLIM.Z5KH[?;)+F'@NGA<\F2IVCAY<[!)."3_ "5&
MJ[3;;U%16FPNO54PS,+VU?."&BB!R[ < ,]0X]:Z4M%^?2(G]OU9F-O+S9=U
M/!%9M,Z>%LDN5<RG;6FF,PBB&.+I"0<C:)W8*Y0LJIN4FRQ5%OH*"6FIIIY&
MTDFV2QPV0'G9;U\ K9>].4]SK::M94U5%6P,,;)Z5X:XL/\ A.000N%ITK0V
MR\/N<,U7+620<Q*^>7;YP;0.T<C.=P&[ P."Y<>NV9\YB?F?LUPYS\*II^2"
MDT]JW43(8FO?45!IWAH&&M&RS'9DY7PT/@:RZ GQLN@J8XY/-SS3M?O*L$&A
MZ"&R5MH%9<'6^I<'<T90>: =M8;NW GCQ66U#8Z6^VHV^K=+'#M-<'0N#7-+
M3D8."K.M7=UY9^V,?[(TYPJ$U9)<'WO5;!M4UMIY8+6",@N .W-])&!Y@5"L
M]%6TVD":FQ6J:"J@YZHK:FN =)MC.VXEF[CV[EL6FMM+36IENCA;T-D7,\V=
MX+<8P>W*KT6A*!K8Z>6MN4]MB=M,H)9\PC!R 1C) ["5*Z],3$]/\1^I.G/5
ME-&T]12:7MD%;*R:>.$-,C'[;7#_  D'K&,;U3]45U5?-6P4=!;IKE;;/():
MED3VM#Y\'9:2X@$-[/2MC%O]V6,.P,8!;C=Z%CM/62EL-"ZEHS(\/D=+))*[
M:?(]QWEQP,E<J:L5F;S'/_;=J3,17R5+3=94NY3+CTVWRV]U=0,D$4CVN+BQ
MP;G+21PS]2Q-55..EM:W2/?+<:XT</\ O,!$8Q]!=]2V)56:GJ+Y279SY6U5
M-&^)NR1LN:[CD8^I0(M(V^.SV^V!]2::BJ15-R\;4CPXN^&<;QDGL76-:F8G
M\OM_^0Q.G;I^;!4UNAK=;4UIK&MDH;+;XS# X9:Z0[MLCKP!A=U2*6BY38'4
M8B@:RVR25Y8 UNP"-DNZLYZ^Q9V\Z<I[E715\=354-?&SFQ44KPUSF9SLN!!
M!&?,N=FT[0VN.JV1+4SU?_Q$]2[;DFW8PX]F.H;EGBUQG/EC'\^5V3]U*JH9
M++%=:ZHM]+?-.7*1U5)51$&>)C_3\9HZL<..Y2JB@H*G4VC[;2-Y^CIJ62JV
MI1M.=%LXC!)ZLG@LLW0M&VG-$VXW46LG_P"!Z1_=XSG9SC:V?-E9"JTS2RWR
MCND,]52STT38 R!X:Q\8.0QPQP]&%N=:G?O^V(_7\DBD]E0MOA"X:MOE?#:*
M.X-HY^@P-J*CFQ3M9QV6[)X\<KLHY*BTVK6=R<VAIH'-^!34E0)6PSAA:[.
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M[-=4UTG.23MV=D-)    )   PK%XQS,-90V6XV[DUEH:S2FG64<]+F>YU=V
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M("(B B(@(B("(B B(@(B("(B B(@*'>/U;-]'\PIBAWC]6S?1_,) EQ_$;Z
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M@VC]#/\ /.4Y0;1^AG^><@G(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M 1$0$1$!$1 1$0$1$!$1 4&/]<3?-#^:G*#'^N)OFA_-($Y$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M?'8VCL?^7&/-A;U_IZTTXU*YCGC$LTU)FVV?LN*Q?]H+7X?\""LC-TV.<Z.
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MG<6SRTD(?'&0<$%Q(S@]F5+:,Q;;',BW++9:+6G*/RE45LY-O#NGJP2R5_\
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M-Q>,QP5T'-F3=G P2,XWX*OREJS7E*Q.1$19!$1 1$0$1$!$1 1$0$1$!$1
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M'-.X@C(*[Z&MPIG,9B>4PQ>F[\WG7E&U/I'4\%1X"LM54Z@K2P"I,9#FXP.
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MT3GS#CL-;M$GMW;)(ZU*N%M%HUEIME!65TE75R2FI=-4.>)8VLR=IIW#CNP
M%G38)'7^RUSI8Q3VVE?$R( YVW -)'FP%W26:276,5XEE88(:0T\46#D/+LE
MWU;EKBUCE'3$_,Y_X;)\_97;)0G6;JVZW.JJVTG/OAH8()W1-C8PXV_@G>XG
M/%=O)7!*:2\5U5,ZHGJ*UT?/.XR,C 8TG]Z[*+3=\MD-9;K5<J2*U32/DC>Z
M)QGAVMY:TYV>/6?J6=TC9_ .G:.VE[9'PM.T]HW.<223]935U(VS%9Y3C$>Q
M2LYB9AA.4[_::&TVIO&X7"*)P_W =IQ_<%CK'=_ &E;O#&SG*JFN<]'2P]<D
MCG98!ZV?0"K-=;)+7ZGLUQ=*P4UO;*>:(.7/>,9^C"@46DG1:PJKO45#9*0R
M&>GIP/B2N8UKGGM.&G'I2EZ<.*6_/]<]/@FMMV8_)7M%4#;9JJ]3U,G.NME&
MUM1,?\<TF99'?NQZ %FM'ULU'R>R7>OE>^:1DU:XR.)P,DM SU8 W*5;]+R1
MVS4=/55+3/=YI7F6,'^[:]N&C?QQO6+J=*:@K]+"R5=SH8:>*-D,?1HG R-;
MCXY)[!P WGKZEJUZ:D\Y\X_GRS%;5Z1W8VCBGJ*/0-MJY9)IIYG7*9TCBXX:
M"\9S_KQ]"DZ:H*0:EU3?7OJ#%0SF.,F=Y&6,)DSOWC)W [AU*T16%S-507/G
M&=%IJ'HD,(!RT[62[ZAA8:DTK=Z>Q7ZU=-HS%7OD?%*&.#\R'X6WU<-VY.+6
MT3&<9_S.9-DQY?S#HTOJ*"R:2M<M[EJY:FO$E1EL;Y3@NR.&<#!&%DM3:PIZ
M'1QNU'MF2HS%2LD86N<_)&2T[\#!/T>=62VTK:&WTM)'\2")L3?0T8_HL/46
M&6MU?!=JZ9CZ2CB+:2G /P9#\9[O/U#Z%RWZ=KS:T>_Y^S>+17$-=&OLUOH-
M+1T%=TFOI[BR:J?S;P7E^Z1V7 9ZAZ %==02U%YU93Z>AJ)J:C93&LK'PNV7
MR#:V6QAPW@9WG'4LKK.R.O\ IZHM\,K89GN8Z.1PR&EK@?Z$?2L#> V35XGM
M=UIJ*^4M*V*HCJHR8IHG':&#D<#V+K&I74_JCKS]_P!>C&V:\O+DA3T9LNN+
M?24E;5^"8*:6X2TSYG/V-D%O$G."2-Q/$*5IVRG5%J;>;]55AJ*S,D$<-0^-
ME,S)V0T-(R<;\G*Z-#TC[IJ/4EPK:H7"%S&T+:AK=ECQC,C6 <&@X'$]JG4F
MGM1T-K\#4=UHF6UH,<=2Z)QJ&1GJ SLY'#*M[8_IW8MRY_>2L9YXY,%47BXU
M?)O!3MJGON%37BW0U&T0Z3$FYV1YFX)60U+:W6FOT_/35]=+=ZFX1122OG=L
MOCWEXV/BAN.H!9HZ3CBDTW!1R-9;[2]TCHW;W2/V?@N[,Y))]*FW.S25VIK1
M<7RL%-0-E(BP<N>\8S] 6>-6)_IZ<Y_U"[)QS]F*M<U57ZTU-)!,[FZ."*E@
M:YQV.<+2XG'#<<*JVR*.0PT5PK+I9]8&0%M34RO='.[:WAHSL.:1NQN^E6R+
M2,K[%>J*>M,=5<:M]7TB'.8R2"T><#9_>5PJ+!?+Q)017^KMQI*2=E1M4L3Q
M)*YO#)<<-SUX5KJ4C.)[?:/OGLDUF?)CQ:*>Z\J-8^5]06T-)&]^S.\ 3..1
MC!W#9'Q>!42_F&#4EP=J\7..AE<T4-93RO;!"W' [!W.SUD'ZE9[58Z^AU3=
MZXU%+)07$M<]I:X3-+6[(:#G&%C8].:AI;3/9::XT$]LD#V-FJHGNG8QV<CC
MLN(SN)2NI&?[O*(_V36<=/-9-,P5%/8Z2*KKQ<) S(J@/TC3O:>)SNQOZUDU
M#LUOCM5II*"%SGQT\38PYW$X'%3%X[SFTR[QR@1$65$1$!$1 1$0$1$!$1 1
M$0%!C_7$WS0_FIR@Q_KB;YH?S2!0.4-\='RK<GM=<'!EO#JN!LCOBLF?& S/
M83P'H6PKM<:2T6VHK[C.RGI*=A?)(\X  _\ ?!=&H;';=16N6W7FDCJJ23>6
M/ZB.!!&\'SA5.FY*-/,FA=7376Z4\#@Z&EN%:^:",CAAAW'T'*Z9K,1GR3G#
M6,_/MY(+Q65NU1OUE?@^(.W&.&61I!/I:QQ]!"N_*U:[?;M,Z6LMHI8HJSPK
M2Q6YD;0'1EKLN<.O@-Y\^]7G4FE;3J2.BBO%/S]/2/<]D.UAA)86;P..YQQV
M*!I_0=HLMU;<FR5]=71L,<$MPJGU!IV'BV/:^*.KM\ZWQ(ZL[5"MC=0W?E7U
M;=+;36:JFMLD=! VY2R-=3Q[.<QAK3\8Y.>*R&DYA:;SK746H+E9::A?S-/6
M,MDLCV0SMRTEV6#X1VAPSOXJUZ@T#:+S=I+GSUQM]?,P13S6^K=3F=@X!^./
M\UD:+2=DH]-/L$%OB%ID8620')YS/$N)WDGMSE2;UF%Q+5%3;ZK1>FH-.ZJM
M]%?-"U,[88ZVF)BJ(><?EKI&]>\_&:<^?J6>AGA9RK:GN4@+J/3-BCI<..U@
MN!E.\\3LMP5GZ#DSLE+/1NEJ+M6TU&\24U'65SY8(7-^*6L.[=U9SA9>+2-I
M8R_L,,DC;XXFMVY"=O+=G /4,=BLW@B):ZT[I\S_ ).59%*P.K*^@J*YYQO<
M]Q=(W^35]M%=XR*[3-M:><LMIHZ:XW0\6RU+F QPGMQO<1]"SUS,?)YIEECL
M5MOM\FK&R,I(W;50R-VRUH8]Y_1QC(P.& Y=FEM##3/);-I^FA;45U53O;4E
MLG-\Y+(-EQV^(: <9&_#=PRKNY3/>>28;!18S3%J;8M.VVUL?S@HZ=D.W^V6
M@ N^D[_I62<-II;DC(QD<5YY;:UY&?\ I&OUKJ$[Q<;N^*)W[44(V6']Y6=U
MMJ\V6IIK19J0W/4E:TFFHVG#6MX&65W^%@_?P':,QI73]!IBRPVJTL>RDB+G
M-#W;3B7.+B2>O>57[_R:6.^7^HO-7+<XZ^=C8W/IZQ\0V6@ - '5NSZ5US6;
M9GHSB8A#H;))HZQZ@U5?:T7#4DE&^6HJL88QK&DMBB;U,! \Y.\J5R*6[P5R
M76)DNY\T!JY''K,A+\GZ'!2*7D[LU/8;I:#-<IJ2XAK9^?K'R.PTY :3P\^.
M*Q;>1[3'-MAG?=JBF: .8EN$IC('5@$;DFU9B8F3$P@:7G;JSEENFH* B2SV
MBA%KCJ&_%FF+]MVR>L $CZNU6+E6NE)0:6Z'64$MQ==IV6Z&DCG,//22$X:9
M!O:W<<GZ.M6:TVRBL]OAH;72Q4M)",,BB;AH_P#?:H>J=.V[4]J-!=HWOA#V
MRL?&\L?$]OQ7M<-X(4W1-HGR7')I[E*IK^S3=BTY7T&FZ"FN%?3T=+!0NDDF
MCPX'::2&@8P 3OX^=6:NMM+JCES+*Z)M11V"V,=S3QEO/RO);D<#\$9](!ZE
MGH.3:QMKJ"NJ9;E77&BG;/#5UE8^60%O!N3N#=_  96?M=@H;;>+M=*9K^F7
M1T;JE[W9SL-V6@=@ 6IU(QR3#5E_KY:;6W*+?;8T,ELEBCHF.8,?WK@9-KSE
MN[ZE,K;;9-/_ )/=3S[('MJ+7SSIG@%TU3*S+7YXEVVX8/5@=BV%;M,6RA\,
M\W"9!=YG35@E=MB0N;LEO^G&["K!Y(]-/H'4%0ZYU%""##335KWQT^_/]VTG
M#>S/'!(SO*L7KY^QB6>Y-[7X&T'8: MV7Q4<>V/]\C:=^\E5?3<,5\Y9-5UE
MR:V66R1TU+0QO&1"U["][P.TGK[-RV6    , *KZ@T/:[S=?"G/7"WW(QB)]
M5;JIT#Y&#@UV-Q'[USK;G.?-<*>VNIZ+E:UI<Z)K!0V^Q--Q+!\%U0"7MVNU
MVP"%79J:6V?DXT%)& +E?GQQAV-[W5$VU_R'"VS;]&V.WZ<K+'34>S0UK7MJ
M<O<9)B\8<YSR=HN/;E0J'D_M%);;50.EN%33VRL;6TPJ:ETA9(T8:-_^%HX-
MX!=(U*_M]DQ*I\IMBM]MTII;2=JIHXF5MUIJ=NRT;6RT[3Y">W=O/G*A4[;_
M 'CE@U17VVFL]5+:&PT=.RY2R--.QS-HN8&M.]QSOW'J6TKG8*&Y7JTW2K:]
MU5:W2.IL.PT%[=DDCK..'8L3J+0=IO=U-S,UPM]Q?&(I:BWU3J=\S!P:_'$?
MO4KJ1C$F%+LT]=:;KKW4];4V1KH*$,J::V2R/#:B)KB"_::!M8W*P\C.E*.P
MZ$M#W4T;KA4PMJIYWM!>7/&T!D[Q@'&/3VE9D:(L;-(SZ:@I706N<8E;&\A[
MR2"2Y_$DXWD^A6.&-D,3(HFAL;&AK0.H#@I:^8Q!$-<\N3/"5FL>G6N(-ZNL
M%-)LG>(@=MY^C 6-U[8+7<-:Z"TM!0P,M\+IZR:%C  (V, :T^9SMQ[>M;%N
M=@H;E>K3=*MKW55K,CJ;#L-!>W9<2.O<-W8AL%"=4#4#FO-Q;2=":XN^"V/;
MVCAO;GK2M\1'ZF%"N6P[EG#Z*G8&6&P22[,;0,R2.(:S=U;(R/2J]R7,U/#H
MB6^0T^EYXKGSM96UM=42B23X3MKG,,( : 1C. MO6^P4-!?;K>(&/-=<A&V=
MSG9&(V[+0!U#!58EY*M.232@>$8[=++STELCK'MI'OSDDQ@XX]7!6+UQB?8Q
M+7]QMLM/R/V#3SZJDJF7R\QP0.I'.=&V!\IDPTN .!CLZU<-8SMNFNK=9;-8
M:.XW2TP=.$M=4NBIJ8/.R/@-!VW;LC=NZE:M4Z.M6HZ*@IJL5%,*"02TLE%*
M87PD# V2.&Y1KWH2UW6X4MPZ1<Z*X00"FZ515;XI9(A_A>X?&W[\\4WQ/7W,
M*/9)[C5<M=347SP5'+9K,XU#K?M[(+W AKW.WDAN3P&%*Y':>T,Y-KCJ:YQ0
M/-WDJJRX22-#LL$CQL'/4 WAVDJV6WD]L%L\+]!AJ(C=*;HM4>?<YSVX(+MH
MY.T=HY=G.2H)Y*]-GFXFMKV6]H9MV]E6]M-,YH #GQ@X)W#/:1O5F]9C'Y)B
M6M;'3SU6B.2S3=UVV6ZZ5<T]1&XG$D3'.DBC/:' MW>A7CE?BIVSZ)HJ"*-E
MV-Y@-((V@.CB;DR$8X, QD<."NFI-,6O45LBH;E3GFH7MD@="XQO@>WXKF.;
MO:1YE!T]HBU66YNN8?6W"Z%G-BLN%0Z>5C/V6D[FCT!3B1,Y7'DUM573F+?R
MOZHVL9D\%4[NPQQ\WN_\3P5)M]E8[6F@M*W&-KJ"T63P@8'CX$M3D,R1UEIR
MX>E7QV@;&[3<MC=%.ZWS573)6F4[4DFWMY<>L9 W>92]4Z2MVHY:2HJW55-7
M4A/,5E'.89HP?C .'4>PJ\2/Y^6#"/3TVG*G7\]32N:=1T-((9VQ;0V8GG+0
M_ V2=V[.]83EQGE_LO;;;',Z"&[W6FMU1*TX+8GDEV_JSLX^E6G2VF+9IFFG
MBMD<G.5#^=J*B:0R2SO_ &GO.\E=VI;#;]2V>:V7B#GJ27!(!+2T@Y#FD;P0
M>M8BT1:)7')KCEMLUHDT_IC3M/2T\,U5<X*:DCC: 61YP\C_ '=DC/I"E4U?
M1LY7-57FX3-@MVG[7!1&0@[+.<)D<=W9C"S]NY.+)1W.WW*62XUUPH7ET-36
MU;YGCX) ;D]0R2 ,;]ZRU'I6U4HO8Z.9FWF5TM:V9VV),MV2WS-QNPM;XB,)
MAJ>LIJK0VDZFEN]'1ZAY/*V0R.J8B8ZJ%DSLASQ_CWN&"-_#>-P4F6CNU9RO
M5-+9::UU,.F[=3P44%TFD#6![03*W#7$NW;)<?,KC2\EUAA,$4D]VJ;=3O$D
M-NJ*Z22F80<MPPG>!U Y"R>IM$6N_P!RBN,LE=0W../F166^I=!*8\YV"1Q'
MI5XE4Q*F6F>LMVN=2:FOE19(Q;K3S=QI;5+)(\N!YQCGAS0-K9#@-^>"QM/4
M7>S\GMRO-OL.G;59*J"2N>VMJI:FHF$@R"\XPYSL@ %W6 MGV325FLUCJ+31
MT;31U0=TGG7%[J@N&'%[CO<2.U5X<E&G76YUOJI;M5V\-+(:6HKI'Q4X/R;<
MX!'43G"1>OF8E5+;88[CR8:,TQ'=8:/43(HKQ1Q3QE[)"TN?AXX%OP\8\W J
M0+W4>&;Q-J2Q0T>M[%9JBKIJBDE+H:F'9(R!_J PUV<;^"O5[T19[Q1VR&H%
M3#/;&!E'5TT[HIX0 !N>.T 9RNW3FCK78IJNHB-56UM6T1SU==.Z>61@X,)=
MP;Y@IQ(PN&L="4NH;5R;,K#2Z3DME=3FMK*NNJ9MN8/!<XRD,()WXQD\,*;!
MIYE7R8::T=57^D;?)1TRWR-:Z6*=L;S(T8<!M,#"W<1]!PK/'R4Z;9(UA%Q?
M;62<\VUOK'FC:[.<\UG''?C@L]JG25JU+#2-KXY8YJ-VW2U--*898#PRQS>'
M ;N&X*SJ1E(A3=.5DMPY0J*@UK9*>EU5;:1]11UM%,XP5$+CL.W<?0UV>L[N
MO8MV_5T_H_JL/IK1UML%=/7Q25M;<IV")]975#IY=@'(8">#<[\!9B[?JZ?T
M?U7.TQ,\FHZ),/Z%G^D+DN,/Z%G^D+DL*(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B H-H_0S?/.4Y0;1^AF^><@G(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@@W7_ "OS[?ZJ<H-U_P K\^W^JG("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@*'>/U;-]'\PIBAWC]6S?1_,) EQ_$;Z OJ^1_$;Z OJ
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M(B B(@(B("(B B(@(B("(B B(@(B("@Q_KB;YH?S4Y08_P!<3?-#^:0)R(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M@$;MPV=K.UC9X>=9=>?M-5UYN7*MJ:XZ<H8*NJ)DA9-4O+886!P:''&\DAF
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M60LVN]-WJ6HCMES;.^GA=42_W,C=F-N,N)+1VA:LUS8[54\KNG;%;;;1T].
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M "@*Y])R9U]/!DU%PEBHH@/\1>\9'TM#EC^3V#^Q&OKGHYQQ;Z^%MRMQZMH
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M;=-Z8GED?7W)[FM>QA<9Y]QD>X]0RX;SU8[%>EC*VT,K;S0UU3,]T=%E\-.
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MXK:8SMZ]AQ,LF?07!;X;%&U[WM8P.?\ &(&\^E<\)Q(CI!M:DENE)HWEFO\
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M#5<\M-IB[3T[W1S1TLCV/:<%I#3@A8[2;YW54_/Z5BL@V-TK)(W<YO\ B_!
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MJ&D:6P0,#&YX[NL^=8U<;><8G_'NU3.>N82'RQL.'R,:>PN 1DT3W89(QQ[
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M9P+@<':P,^DK)WZ@I+-J_34]JIXJ9]7(^EGCA8&MECV<[P-QQQ4X%>F>?/\
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M:*+'.R,9GAM. 7R.>&1V(Y8WGL:X%7BWQC/\A-E<L!==*0UU!:8(JVJI9[8
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MBSOMW7;"J.T':"#$)*]M 7;9H6U3Q 3G/Q.S*M,4;(HV1Q-:R-@#6M:,  <
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M,4?.?M;(S]:[$1!UO@B>\/?$QSQP<6@D+L1$'"6&*8 2QL>!PVF@KF    ,
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($1$!$1!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g762905g69v12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g69v12.jpg
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M*"@H*"@H*"C_P  1" '1!HP# 2(  A$! Q$!_\0 '  !  (# 0$!
M      <(! 4& @,!_\0 6!   0," @0'"P@%"P(%! ,!  $" P0%!A$'$A0A
M$Q<Q45*1T@@5055687&3E*'1(C(S-V)S@9(64[&RLR,T-4)4<G1U@L'A.*(8
M)"8VPT/"T_ E1(2C_\0 &@$!  ,! 0$               $" P0%!O_$ #<1
M 0 " @ #! @%! ,! 0$!   ! @,1$B$Q!!1!41,5,E)3<9'P!2(S88$TL<'1
M(T*AX7)$8O_:  P# 0 "$0,1 #\ M2
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MG(1H=.++7-7CI/)G:DTG4KW  ^->P
M      (]T^?5E<?O(?XC2J9:S3Y]65Q^\A_B-*IGT?X3^A/S_P!/.[7[?\
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M.=9!9, 62RR2-EJ^$A1$SWJV)N2NZ\D_$O76+)C]%;?%UY[_ )1.[5MQQK2
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M'[R'^(TJF6LT^?5E<?O(?XC2J9]'^$_H3\_]/.[7[?\   #U',
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M]T^?5E<?O(?XC2J9:S3Y]65Q^\A_B-*IGT?X3^A/S_T\[M?M_P   /4<P
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M<]V(GPQ/BJ]1,FQZZ[M;//D1W@\)2W:K]YC'$3K7W/\ "8Q1Z.;;YH# !Z#
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MU<P >@P                          !>X 'Q#V@
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ME/.C4D?%$Y'NR<CDY7*B;T3P&OH,M<M,D<]1J?\ :G'6:36>7/:/0 >@P
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M(]R9Y^%RHG)S&L]GRUR4O'/4:G_:GI*S6U9Y;1V #T&
M        3[W+W\TQ%]Y!^QY 1/O<O?S3$7WD'['G!^)?TUOX_NV[-^I#NM-?
MU8WS^Y'_ !6E2"V^FOZL;Y_<C_BM*D&/X1^C/S_Q#3M?MQ\@ 'JN4
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M961.1[D7_5DB_@7GL^6N3'>.>HU*(R4FMHGEM'  /1<X
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M4G9'K3)\/[^AW6OO*N]Y[GXNK/4.^ [SW/Q=6>H=\"T7'%@+RDIO52=D<<6
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M4G9''%@+RDIO52=D>M,GP_OZ'=:^\J[WGN?BZL]0[X#O/<_%U9ZAWP+1<<6
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M+RDIO52=D<<6 O*2F]5)V1ZTR?#^_H=UK[RKO>>Y^+JSU#O@.\]S\75GJ'?
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M O*2F]5)V1ZTR?#^_H=UK[RC8 #0
M   OWHM^K7"O^5TW\)I00OWHM^K7"O\ E=-_":<7;/9AICZN5[I?ZH;K][!_
M%:4N+H]TO]4-U^]@_BM*7%NQ^Q_*+]0 '6H
M                                               %G^X]_H3$G^(A
M_=<5@+/]Q[_0F)/\1#^ZXY^U?IRM3J[;NDOJ>O?]^G_CL*5%U>Z2^IZ]_P!^
MG_CL*5%.Q^Q/S3?J  ZU
M                                 LWW'G]&8G^^@_=>5D+-]QY_1F)_
MOH/W7G/VG].5J=7;=TM]4-U^]@_BM*7%T>Z6^J&Z_>P?Q6E+BG8_8GYIOU
M=:@
M                               #JM'."+ACV]3VRTSTL$\4"U#G5+G(
MU6HYK<DR1=_RD)%_\-F*_&=E];+_ /C,[9:5G4RF*S*$ 2YB70)B3#]@K[O6
M7"TR4]'"Z:1L4DBN5$YLV(F?XD96&S7"_P!T@MUGI)*NMF7)D<:;_2J\B(GA
M5=R$UO6T;B28F& "<Z#N;,2S4K9*NZVNFF5,^"S>_+S*J-RZLR/M(.C?$.!9
M8UO-.Q])*[5CJZ=VO$Y>;/)%1?,J)YLR*Y:6G42368<: #1
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MH_I+=/=JNBGVU7-:VG<Y58K415SS1.?P%IM$3$2C3@P 6
M          L_W'O]"8D_Q$/[KBL!9_N/?Z$Q)_B(?W7'/VK].5J=7;=TE]3U
M[_OT_P#'84J+J]TE]3U[_OT_\=A2HIV/V)^:;]0 '6H
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MO.?M/Z<K4ZNV[I;ZH;K][!_%:4N+H]TM]4-U^]@_BM*7%.Q^Q/S3?J  ZU
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MZ.;U@'O?W\?1NV[A."V>17_,U<\\VIE\]#C2U;1:-PC6@ %@
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M4D$/ .J9*6H1S)&QHJZN2Y*BJY,E1%RY4-K5QQK?\*Q,HQ !LJ
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M,,??3_L85OL_]+47W[/WD+(=V'_1F&/OI_V,+VIPY:SY[1$[K*L@ .Q0
M                    +/\ <>_T)B3_ !$/[KBL!9_N/?Z$Q)_B(?W7'/VK
M].5J=7;=TE]3U[_OT_\ '84J+J]TE]3U[_OT_P#'84J*=C]B?FF_4 !UJ
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M[)%7\$\!PP!T5K%8U"DSL !8
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MQ=L]F&F/JY7NE_JANOWL'\5I2XNCW2_U0W7[V#^*TI<6['['\HOU  =:@
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M3E5$7,E?3KI0M>D*DM$5KHJVF=1OD<]:E&HCM9&HF6JY>8B(%YI$S%I\$;\
M %T                        !9_N/?Z$Q)_B(?W7%8"S_ ''O]"8D_P 1
M#^ZXY^U?IRM3J[;NDOJ>O?\ ?I_X["E1=7NDOJ>O?]^G_CL*5%.Q^Q/S3?J
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M*%NT@T]GAM5)6TS*-TKI$J$:FLKD:B9:JKR9+UD2@O-(F8M/@C?@  N@
M                                           !^L<YBYL<K5Y-RY'X
M !^N<YZYO<KEYU7,_             %^]%OU:X5_RNF_A-*"%^]%OU:X5_RN
MF_A-.+MGLPTQ]7*]TO\ 5#=?O8/XK2EQ='NE_JANOWL'\5I2XMV/V/Y1?J
MZU
M               L_P!Q[_0F)/\ $0_NN*P%G^X]_H3$G^(A_=<<_:OTY6IU
M=MW27U/7O^_3_P =A2HNKW27U/7O^_3_ ,=A2HIV/V)^:;]0 '6H
M
M    %F^X\_HS$_WT'[KRLA9ON//Z,Q/]]!^Z\Y^T_IRM3J[;NEOJANOWL'\5
MI2XNCW2WU0W7[V#^*TI<4['[$_--^H #K4
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M>3R@X(4SXB,?^*(?;(NT.(C'_BB'VR+M%S-I;T5&TMZ*CO>3R@X(4SXB,?\
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M>3R@X(4SXB,?^*(?;(NT.(C'_BB'VR+M%S-I;T5&TMZ*CO>3R@X(4SXB,?\
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MF^[;^PXL[2W?S"F^[;^P#Z5/T*F$9M3]"IA$P@
M                                                     RJ/YKO2
M8IE4?S7>D$/=1]"XPC-J/H7&$(
M                                         #)H^1QC&31\C@0]U/T*
MF&9E3]"IAB
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M#!,Z2>#3X-NDU\PI9[I4LC9/64L<[VQYZJ*YJ*J)FJKD;@B8U.D@ (
M                   RJ/YKO28IE4?S7>D$/=1]"XPC-J/H7&$(
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MGNE2R-D]9213O;'GJHYS4543-57+>;@B8U.D@ (
M    R:/D<8QDT?(X$/=3]"IAF94_0J88@
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M  T.G.8T7?5QAC_+:?\ AH=.<MO:E:.@ "J0
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M_P"5,_=I29C+-.YCY0FH #%8                          '*  A(
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MRS14Y6IX#< <4\N?0TP+!:X+)9*"UTCY'T]'"R"-TJHKE:U,D551$3/=S&>
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M?TMX:K[Y;/L_!ZS>"U<LL\M7//\ $Z<$\4HTX['NCNRXWJK;/>5JFOH7*K.
M>UJ2(JHJM?FU<T^3X,N53<XMP]28HPY5V6O?-%25*-:]T"HUZ(UR.3)514Y6
MIX#< <4\N?0TP+#:X;)9*"UTCI'T]' R"-TBHKE:U$1%541$SW<R&> 1U2
M@                        #)H^1QC&31\C@0]U/T*F&9E3]"IAB
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MEC<YO!(U$C3-J:N>?\DWE5>5?PZ8 B9F>J0 $
M    .4 !"0                                  #M+=_,*;[MO[#BSM
M+=_,*;[MO[ /I4_0J81FU/T*F$3"
M                                           #*H_FN])BF51_-=Z0
M0]U'T+C",VH^A<80@
M                                ,FCY'&,9-'R.!#W4_0J89F5/T*F&
M(
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M[-]OW#9OM^X\;0_F:-H?S- XX $)
M   .TMW\PIONV_L.+.TMW\PIONV_L ^E3]"IA&;4_0J81,(
M
M  ,JC^:[TF*95'\UWI!#W4?0N,(S:CZ%QA"
M                                                   R:/D<8QDT
M?(X$/=3]"IAF94_0J88@
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MH:QW4XOH*NGNC8^^-'JJZ1B:J2L=GDN7@5%3?ENWH2,8WI-)X96B=\P %4@
M    =I;OYA3?=M_8<6=I;OYA3?=M_8!]*GZ%3",VI^A4PB80
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M\UWI,4RJ/YKO2"'NH^A<81FU'T+C"$
M Q[A6TMNHI:NX5$5-2Q)K22RN1K6IYU4@J]:6ZF_:1,,6[##ZB"Q/N,<,M4K
M%;MBZ[4<U,_ZJ(Y-W+\I,\MQ>F.;]$3.D^@UN)(+E4V*MAL=5'27-\:I3SR)
MFUCN=4R7]BD7_HSI?\M+3ZA/_P 0K2+>.B93$""M$-\QQ?L=5<5=?H;GA^V.
M='4SQ0,;',]6JC6L7415R7?GS)YTSG47IP3J2)V 'E'L5ZM1S5<G*B+O0HEZ
M!Q&FF[5UCT;W:X6FI?35D/!:DK$3-N<K47E\RJ<MW/N,+M?(;M:\353ZBY4_
M!543Y$1'.AD8BIR(FY-R_P"LTC',TFZ-\])@!K,37:*PX?N-UJ,N#HX'S*B_
MUE1-R?BN2?B0UW/N+<2W_%-VI<27":H9'1LGCB>UJ(W65JHJ9)T7(*XYM6;>
M1OGI/  ,T@                          &31\CC&,FCY' A[J?H5,,S*G
MZ%3#$                               '!Z1])-LPC$ZD@5+A?Y$U8+?
M#\IVLO(K\OFIR;N5? 6K6;3J$;T[P$;: +_<\28(GN%ZJGU54ZNE;KNRW-R:
MJ-3S)FI)*KDF:\@M7AF:R1.P$#UFDZXWK3!8[=8ZA\6'-J6E5[6IJUCD^>N:
M_P!5,T1,O3X2>";TFFM^)$[ #R][6-UGN1J<ZKD42] (N:9IO0K9I TA8HL6
MEBZ,I;A.ZQVV>GDGI4:W5X)4CUDY,]ZNRY>533'CG).H1,Z63!X@E9/#'+"Y
M'QR-1S7)R*B[T4@;N@\?7RSWZGMN&*Z6D2DIMHK7Q(U=[W(UB+FB\FY?]1&.
MDWMPP3.D^ P;%-)462WS3.5\LE/&][E\*JU%53.*)
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M />=EIUP.EVM;K[;(4[XTC<YVL3?-$GA\ZMY?1GYC6TTXXBT>'5$;UR9&@_
M]=A>CK:V\,2*MK$:UL&:*L;&YKO5-V:JO)X,B4"+-!6-G7ZU/M%SF5]RHFYL
M>Y?E2Q<B+YU;N1?,J><E,Y,W%QSQ=5ZZUR  9+      =I;OYA3?=M_8<6=I
M;OYA3?=M_8!]*GZ%3",VI^A4PB80                           :C$.'
M+3B)E(R]T4=9%2R\-'')FK=?)4S5.1=RKN7<;<$Q.N@AF:-D7=-T$<3&LC;:
M-5K6IDB(B.W(ANNZ'L57?-'%0EOC=+-1SLJUC8F:N:U'([)/#DCE7\#3U?\
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MT_X=M5/EP='8TBS3^LJ,?FOXKFOXD]$,UO\ U0V__*E_=>3,8Y9WJ?V6KX@
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MB33-I*M#T36JK2C8U7D1Z) K%_!R(IO\/_\ 4YB3_*V?NPGG!?\ U*8U_P
MS]D!IO4S;QU'^$?LZ+05B#OIHUI-L?J5%KUJ*HU]RLX/DS_T*WJ4AW%4;[QH
MUQ;C*H:NO>KO&VGUN5*>-RM8G^W^E#88XKJO V*L;V"@C>K<411RT2-\$DC]
M5^7-GK2I^#3K--=FBP]H)I+3#EJTCZ:)53^LY,]9WXKFOXDUCAM$Q_VE'@EK
M#7_MVU?X2+]Q#8FNPU_[=M7^$B_<0V)R3U:0  @
M     !R@ (2        '/7S!>';Y.LUTM%--.O+*B*Q[O2YN2K^)T()B9CG
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M-5S7\7+UFU W(UC[!:WWYE[=11+=61\$VIR^6C-^[WJ;, ;V  (
M                RJ/YKO28IE4?S7>D$/=1]"XPC-J/H7&$(
M                   -9=+#:[K74%9<:**HJJ!_"4LCTWQ.S1<T_%K>HV8)
MB== -736"UTU]J;S!0PLNE2S@YJE$^6]N[<OY6]1M -Z  $#65%AM=1?*:\S
MT43[I3,6.&I5/EL:N>:)^9W69%VMM'=[?-0W*G94T<R(DD3^1R(N>_\ %$,L
M$[D:JIP]::FP-LD]##):FL;&E,J?(1K516I^&2&934--36^.@@@8RCCB2%L2
M)\E&(F2-]&6XR0-R-9A^P6O#M&^DLE##14[WK(YD29(KE1$SZD3J%%8+717B
MLNM)1117&K1$GG:GRI$W<O4ALP-R  (                           #)
MH^1QC&31\C@0]U/T*F&9E3]"IAB                              #\<
MU'M5KDS:J9*A^@#6V"QVW#]"M'9:.*CI5>LBQQINUERS7W(;( F9WU&LK[#:
M[A=**XUM%%-742JM/,Y/E1Y\QLP!L?"NI(*ZCGI*R)LM-.Q8Y(W<CFJF2HOX
M'RL]LHK-;H:"UT[*:CAS2.)G(W-55<OQ53, WX#60V&UPWV>]1443;K/&D4E
M2B?+<W=N7\J=0I;!:Z6^55XIZ&&.Z53$CFJ43Y3V[MR_E;U&S W(U5SP[:+I
M<Z*XW"WP5%;1*CJ>9[<W1JBYIE^.\^M]LUNOU M%>*2*KI%<CEBD3<JIR*;
M#<CQ!$R"&.&%J,BC:C&M3D1$3)$/8!
M.4 !"0                                  #M+=_,*;[MO[#BSM+=_,
M*;[MO[ /I4_0J81FU/T*F$3"
M                                       #*H_FN])BF51_-=Z00]U'
MT+C",VH^A<80@
M                            ,FCY'&,9-'R.!#W4_0J89F5/T*F&(
M
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MP,K9X^9>L;/'S+UF+PC^F[K'"/Z;NL#*V>/F7K&SQ\R]9B\(_INZQPC^F[K
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M]9B\(_INZQPC^F[K RMGCYEZQL\?,O68O"/Z;NL<(_INZP.2 !"0
M                          #M+=_,*;[MO[#BSM+=_,*;[MO[ /I4_0J8
M1FU/T*F$3"
M                         #*H_FN])BF51_-=Z00]U'T+C",VH^A<80@
M
M              ,FCY'&,9-'R.!#W4_0J89F5/T*F&(
M
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M*AVM+*U,]Z<B9KS999^'P[O!&D%U?H?EQ/<<I*N@@E;4(F[A)8TW>C6^2O\
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ME76_%$.VT#?5-A[[N3^*\3CU2+F^>G?  R6
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M]B_:3]J(HI?CBU:\I)C7.5F ?&AJHJZC@JJ9VM#,Q)&+EEFBIFA]CA:@
M =I;OYA3?=M_8<6=I;OYA3?=M_8!]*GZ%3",VI^A4PB80
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M  8K                   &51_-=Z3%,JC^:[T@A[J/H7&$9M1]"XPA
M                     \O8U^6NUKLES3-,\EYR'=)OUWZ//]?[29"'])4,
MK]->C^1D;W1LU]9R-543?X5-</M?Q*);WN@5<W1'?M3/DA1<N;AF'&8%T=U.
M-\'6NY8JOESB@6F9'0T5%*D<<$3$U6JJ*BYN5$SS\_5+F-+&S$N%;I9Y'(S:
MX'1M>O(UW*U?P<B*1-@?2/%@*Q189Q]0UU!76Y%BAE;"KXZB-%75U53EYL^3
M++>7QS;@U3KM6>O-G:,[C>,+:1[A@*]7"6YT? ;305,RJKT;DBZN:^#+/=X%
M;NW*3*0WHVI+AB[25<<>UU#/06Q(-EMT4[=5\C=R:^7-EK>;-VY5R.SAQQ%)
MI)GP@MOG;+'#PR5:N34>FHUV2)E]K(KDKNW+KKFF'$X7_P"IW%G"<O>QFIG_
M ':?_D[#39J\5F(]?++9TZ]9,O><GI(I*_"&DFW8]H:*>MMKH-DN<<#=9[&\
MB/RYLM7S9LWY9FIQ[CF/2;:H\*8$IJRJEKI6;74R0JR."-KD=\I5\Z)^"9)F
MJFD5FTUM'3E_XC>MPT.-M;BBT7\-GP6T1:V?-DN7NS++D:Z4,!/N^BZ"QV9-
M:KM3(GT;5W*]8VZN7I5JK^.1I:/3C;H+&R"XVZY-Q1'&D3[?LZHKYD3+<O@1
M5W\Z<RE;1.2L</G)'+JY?#.MP>G/@,]3^7RRY_\ S!)>@#5XI;#J9?-ES]/#
M/,#0Y@RJH,%W9<21*RXX@DDFJXUW.8QZ*B-7F7>Y?-K9> Y3 6+VZ*:6KPIC
MBGJX(J>=[Z&LCA5\<T;ESW9>?-?Q5%RR+7_/$UK^W]M$<NK:X_\ ^H3 G!_2
M;._/+H_RO_),Q#.!(:S'6E*;'-115%'9:*GV6VI4-U7RYHJ*_+F^4]?]2)OR
M4F8RR\M5\H35!6FJU0WO2[@>VU2NV:I8YDJ-<J*YFLJN;FG.F:?B=1I=P=A]
MNC*\;-:*&F?14ZS0/A@:QT:MW[E1,]_(O/F:O2-#*_3C@&1D;W1L:_6<C55$
MWKRJ=KI98Z31MB1D;5<Y:*1$1J9JNXOQ3'!$??-&NK@ZRIEJ^Y>X6H>KY.]K
M&:RKFJHUZ-3W(AS5Q8ZPX.T78U@14[W)'352MY5A?G_MKI_K.C6"7_PO<#P4
MG"[!EJ:JZWTO,;NRX>7$6@"CLTD:I--;$2-')DK96_*9_P!R(7BT5^IU?+33
M-W]J,+X/I'ZW?JL;+4*Q?_ZT?RG+^/*G]TU6%6-C[IW%3(VHUC;3&UK43)$1
M&4VXP- $-RQ!?I;]?89&+:+?#::5)&JBKE\YV_PY)O\ [QM<-PRM[IO%<RQ/
M2)UK8B/5JZJKJTWA_!2-<.Z>4'7FF, '*N                     !DT?(
MXQC)H^1P(>ZGZ%3#,RI^A4PQ                             85\I)ZZ
MS5U+1U+Z2IF@?'%4,7)T3U141R>A<E$#48XL]\O-!#3X=ORV25'JLLS8$E<]
MN62-3-4RW[\TWD7:)W38'TB5N$\1TL4MVNC5J8KNU[G/JD36=D[67S/YMZ;\
M]RGUP=I0?@ZW/L6DN.Y07:D>]&5;XW2I4L555%1WAY<L^3++>>L*P7'2%I8I
ML9R6^HM]@MD"PT:U#=5]0N3LER]+U7--VY$W[SIBLUK,6Z*;WT3'=X:JIM59
M!;JE*2LDB<R&H5FOP3U141V7AR7?D5_Q3:[WH]Q=:L6XOJF8LH4E2!)Y$=&^
MD<N:HYD>>JFY%5/!FG@7)3I;GB2]:.M(=UJL2K<KAA&YY/IYV9RMHW9JNKER
M-3>J9>%$:N_+(T^/L2R:78Z/#.":*KEHEJ&S5EQFB5D4:)GNW^G/P*N2(F9.
M*LUG_P#S),[;32K*R?2UHSF:Y'T\DRNC=X%S>Q45/^TFE^6H[/DR(KTRX1KI
ML/V"Y8:A=/<L-RLEAB1,W21MU<T1/"N;&KEX<E\)K;QIKMUQL$U%A^WW.7$U
M3$L,=%LZZT,BIEFJ^%$5<]W+NY/!7AF]:\/@G>IG;UW+6?Z%7?+Z/OI)J\WT
M<9,IQ>A_"LN$,"4-MJT1*UZNJ*E$7-$D=X/P1&I^!VAGEF+7F837E"OW<XX6
MM5SCOUVNE'#6SPUSJ>!L[$>V),D<Y6M7=FN:;_,9^)+71X>[H3",UEIXJ-M?
M"]M1' U&,>N3T5<DW;TR_%$4V/<SPRPX<OZ31OC5;K(J(]JIFFHP:0X97Z=<
M!2,C>Z-L;]9R-543YW*IO-IG):/V_P *Q')\,;(B]TC@I%3-%H7_ +)S)T-_
M^FL:XQP7(NK##/M]$U?U3\LT3T(L?XYGSQG#*[NC<&2MB>L3:)Z.>C5R3=/R
MJ8.GN.XX<Q):,76&)[ZB2FFMLVHU5^<QVHY<N;6<O^E"(_-$4\X.G-AO_P#4
M=-I6Q<[Y5.VDFM5"[P<'&SY:IYE5&K^*G?Z!OJFP]]W)_%>:U<.NPYW/]=:D
MC7:6VF9\S43-5E>Q7.3S[UR_!#::"HWQ:*; R5CF/2.3-KDR5/Y5Y6\Q-)UY
M_P"".KO  <ZX                          .4 !"0       !415151,T
M\(                          ':6[^84WW;?V'%G:6[^84WW;?V ?2I^A
M4PC-J?H5,(F$                           _,DSSR3-/"?H 'XJ(J9*F
M:'Z !SV)L.OOUQLKYZO@[?;ZE*U].V/Y4TK/H\W9[FHJJJIEOW'0@$[WR'YD
MF:KDF:^$_0"!^*B+EFB+D?H !=Z9*$1$3)-R
M          #*H_FN])BF51_-=Z00]U'T+C",VH^A<80@
M           /Q41>5$4_0 .>3#KY,;+B"LJ^%;#2K2T=,V/52%'*BR.5<_E.
M541/!DG.=""8G70#\1$3D1$]!^@@#\R3//),^<_0 /Q414R5$5/.?H
M                              9-'R.,8R:/D<"'NI^A4PS,J?H5,,0
M                            #\5$7E1%])^@ #\1$1,D3)/,?H 'YDF:
MKDF:^$_0                                        !R@ (2
M                             =I;OYA3?=M_8<6=I;OYA3?=M_8!]*GZ
M%3",VI^A4PB80
M                            95'\UWI,4RJ/YKO2"'NH^A<81FU'T+C"
M$
M                !DT?(XQC)H^1P(>ZGZ%3#,RI^A4PQ
M
M   .4 !"0                                  #M+=_,*;[MO[  /K+
M\Q3X $P@
M                       ^T'(X $/4OT:F. (
M                                                      #ZP<C@
M 0]2_,4^  @
8                            '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g762905g72w39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g72w39.jpg
M_]C_X  02D9)1@ ! 0$!] 'T  #_[1T>4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0']            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             &%@  "Y<          0
M       !              N7   &%@                     !
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M;&]N9P  !A8     4F=H=&QO;F<   N7     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    %.$))300,     !+O     0   *
M  !4   !X   G8   !+3 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !4 * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MSMZS<_HN?G6MNR,'IUEA#O6+K;M==E;6EM3?HU,I][V_U/WT/_FW;8X#(P<
ML@-(9;D?0:T,J8!M:W:S96QS/\)_.J2H]2/Y?X2G5<.MR0&XY&NUWND^#=G_
M )FI4_;07'*%;8(V>F3/)G?N_D[%B6?5W+>\V68'3G.)+G$79 EY+7%_T/)_
M_@?^C5WI'3+,&R^RVC'I?<& NQWVV%T%SOTGVGZ#6;O9M0(C6X^S_P!"0__0
M[GJ?7K<'-LH=HP#=7^KWV$PUKWMWXWJ-=S]+;[%JX5YR<.C(/-U;;#[7,^D
M[^;L_25_U+/>BO;N:6R1(B1H0@?;:*P&WV-KL'M=.@GX_P#224UNI=0ZKB7
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M,?95?_H5?^K/5+NJ59%]M7I/98*\D%T_K'\Z[T@ZBFQ^-]ENQOL]]EMGZ/\
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M[BM_<S^\?\7_ -"8IY1'M]KZP6N\#]R$X$'735>;U9=+7PUC[ /SFW7AITY
M>-Z['ZK.O=TAAN+W?I7BLOF=GMC;N_,W[TS+RQQQXKZUJ*_:Q8^:&3)[8'0F
MQK\O^#%__]3U5)?*J22GZJ27RJDDI^I6;X_1QL_-W>'\G^2G_3_R/Q7RRDBE
M^IOT_P#(_%+]/_(_%?+*22OL?J;]/_(_%+]/_(_%?+*22OL?J;]/_(_%+]/_
M "/Q7RRDDK['ZF_3_P C\4WNW#U>)TCB?Y2^6DDE/U4DOE5)!#]4F5$[O/\
M!?+"22GZE._S_!"=&X;]W(7R^DDA_]D .$))300A      !5     0$    /
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-
M30 J    "  ' 1(  P    $  0   1H !0    $   !B 1L !0    $   !J
M 2@  P    $  @   3$  @   !X   !R 3(  @   !0   "0AVD !     $
M  "D    T    ?0    !   !]     %!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*0 R,#(T.C X.C Q(# X.C0S.C W   #H $  P    '__P  H (
M!     $   N7H , !     $   86          8! P #     0 &   !&@ %
M     0   1X!&P %     0   28!*  #     0 "   " 0 $     0   2X"
M @ $     0              2     $   !(     3A"24T#_0      "
M        _^$!-D5X:68  $U- "H    (  <!$@ #     0 !   !&@ %
M 0   &(!&P %     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "
M    %    )"':0 $     0   *0   #0   !]     $   'T     4%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C0Z,#@Z,#$@,#@Z-#,Z,#<
M  .@ 0 #     ?__  "@ @ $     0  "Y>@ P $     0  !A8
M!@$#  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !
M  (   (!  0    !   !+@("  0    !              !(     0   $@
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M*"@H*"@H_\  $0@#IP;T P$B  (1 0,1 ?_$ !T  0 !!0$! 0
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M*A>ARG9!H.B<QH#I7R/<1S.T1^@#V(,&RZ[N%/?8+/J^UBWU$Y#89V'S'$G
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M>?W 9)\%J'2/2S:;U%0ZPMK"6APAK8V^_:=P)\0,>(:L6CD'2'K]M2 YU@M
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M%N.A+'75#IC!) ]QR>H?L@GPX#U*9M2TSD:UJ.GH*36ME]P!&RL=,.O9 ?-
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M-%4T&FZV>F :*B9\FRR-Y]X"&D'UX69=.G:VBD@DL%GKKG*81-4M]!M,.QQ
M._=QX<-ZM]4UO\3,.QJBU+HWUU;]<VB6KHHWT\\#@RHIY""8R=X(/,'?O[BM
M.J^F66MNM72:.TO6WZ&E_G)XW%H/> &NW=A.,]BI&AJ3::XY@RZ\H:R:GLM]
MK*NEM%Q@JZBE.)F1DY9O(_2"H/HRZ0J#7,%2(*>6CKZ0CKZ:4Y(!R 6GF,@C
M@"%S3Z'#[N]8^/\ _.<KQH3%;[N)K@R[-8=3V6_S54-FN,%9)2D"9L9/F9)
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M'N.%-*B1:8[)>)(V2QNCE8U['##FN&01V$*&I=)Z>I*H5-+8[;#4-.T)&4S
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M/U2IKWA:GWH>[/\ :FB_N&?JA9:Q+/\ :FB_N&?JA9:3W1;O(B(H0(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MKFQ_^+.::N<^2_6A_)/1&[X6_>IC4E9>K#4:1HI+L^HEJ*PLJ9>K:WK6[;<
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M=ZD2%SA@C9!)2!W52-)R3O)!4?MN;N:7#P*E*2'K[7_*:B.*!KRYN[+LJ/\
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MEO\ TP]'>GM=WN'J;]26W4\;!"(R]KC*W>YK7,R'9&3@CD>>Y<YO=+TL]%-
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M_4J?5ZU!^#;9['_ZER)>2I^IZ'^*DQ#KWU>]0?@VV>Q_^I4^KYJ#\&VSV/\
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M]6_*T[3-+;-2W/5MSD\AN-X,V(:+RAT5-,T- V]^]P)SO.[VY2G5ZDUF;?\
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M=(B(H!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!#'[LF_D!_:!3*AC]V3?R
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M07F-@C<9 >KE#3EI)&]KAVC/R+KJ(/FJJZ(.D^^4\=NU!JRGDMC2,M=52RY
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M6,8SXPK[",8SXP[9H&P'2_25*:NOH9HZNEFDC?%+N ZQNXYX%-&1Q5^@M74
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M%L:Q+M;X;I;*FAJ@>IG86.+3@C/,'D1Q![0@RT4/I6X35UK+*XCW1I)#2U8
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MP7B:*.>%\4S&R1/:6N8X9#@>((6JV:633%RAL5:]S[74'9M=0\YV-V?)WGM
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MZFR3.(#7U.'0//=,W+1X.V3W(-F148YKVAS'!S2,@@Y!54!$1 1$0$1$!$1
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M^?:::GDKJX7/3T^!37=N"8LG 9/CV"3MW. .\[J"" 0<@H"(B B(@(B("(B
MB(@(B("(B B(@(B("CM2_<Y=?R27]0J14=J7[G+K^22_J%! =#W]&6G/R1OZ
M2MP6G]#W]&6G/R1OZ2MP0$1$!$1 1$0$1$!$1!#'[LF_D!_:!3*AC]V3?R _
MM IE6MX7OX_ 1$55!$1 1$0$1$!$1 1$00FN*5U9I"\0Q F;R5[XL<=MH+F_
M]0"DK75-KK925<9RRHA9*#W. /[UD/:'L<UPRUPP1W+7.CIQ&DJ2F<<NHGRT
M1_\ T4CHQ\C0@V1$1 1$0$1$!4541 J(BD%155$&L]);'OT)>A%DNZC)Q\$$
M$_)E:_ YCX(W1D%CF@M([,;ET*>)D\$D,S0^*1I8YIX$$8(7*:B*;1\OD-T#
MS:6G%)7X):UG*.0^](X \"%I2?#'5KY3<%.Z;)!PWM*]S4!+' $/!&"TCBLN
MADCEHX9('MDB<T%KF'(/@5>5LJUAI/TO4;9]O,FP#GJR=WAVJ3>UKF;+F@M[
M",A95: *F3':L8K3,SW;SJ7U/OSE'UELH:J,LJ*.![>]@R/ \0L.>QR3T4M+
M#<+J*9PQU)J'/C[LM.=W<I=RF( T0,#/1V0F<<M*1&<N$7O3-Q@<6S1L9"7A
MAG<[S&Y.,NY@>I?1VA=/QZ7TM06J*43=2TE\HX/<XESB.[)W=RU*^P1RC8D8
M'1RM+'CM"V#HPKGU>DX(9WE]10O?22$\?,/FY_PEJMU&M;4I$3V7U[VMC+:^
M2HJJBXV 515*H@HJA%1!I/1AIVX:>=J@W-D;?+[U45L&P\.S$\C9)[#W+&Z-
M=,7*P='-39[DR)E=))5N:UD@<W$CW%N_P(6_JA0RY!#T?7R+HST;34KJ:'4^
MFY14Q1R/S%([:=M1EPY$$;__ )6=/9]5ZRU+I^HU)::2QVJS5(KNKCK&U,E3
M.WT<%H :T'MW[UU!$P9<YIM$557J3I%== R.V:AB@A@D8\.=@0ECB6\B">:@
M[99M;VZP4]@@TOIQ]53M; R^2RL=&8QN#S#L[9=CEGBNPJB83ESO5>F;Y3:A
ML&IM,QT=;<K?2NH:JCE=Y.RIB=C>P[PP@Y('#>.S?GZ5CUC7ZGFNNI6PVFUL
MI^H@M$$XGVGD@F61X&,XR !V^W=41&7(]+6;7.C+?5:;L]JME?;.OD?17.:L
MZOJ6/.?KD6-IQ!)X<5@Q]'FH&]#-)IMS*=UUBN;:EXZT;)8)R[.>&<;\+M*H
MAES?5>F+I2ZZ&JK#:Z&]-J*44E;;ZJ1L1.R<MDC>X$ X&"#_ /$SH>COK:JX
M5M^M]IM<4VRRFH:)C7OB:.)DE &T3V 8"VY:5K7I)L>DZQU'6-JZNK8P2RQ4
MD8>86'WSR2 .(]H[5>FG:\XK&295Z3M-7"^T5JK+#)"V\V>M974K9SB.4CC&
MX\@1S[O6M6U#:==:ON>FI[C9[?::*UW.&JEIVUPFDDP3F3(   &0&\3M=RZ-
MI?4-OU-:8[C:I'N@?C+9&%CV$@$!S3PW$'L(((R%*JLQB<29:9:M/U]-TK7Z
M_2LC]SJRWP4\3@\%Q>P^<"WEXJ-U18]06WI BU9I:BIKH9J+R&LH9IQ X@.V
MFO8\[N['=W[NBKRH1ESC1]AU.[I,N&IM2TU%!!5VL4D=/3S=9U)$C2&$X&T<
M DNQC)P% Z$CU19;#46K1PLEYT\V>7R*[/K-CR9I<26R1XRXM)/ A=E6C7'H
MNTU6UE54".OI&U;R^I@HZZ6"&9QXES&G&_GC")B49]#NQ[>C*FVW%Y=5U)#\
M>G]</G>O!725C6RWTEJMU/06ZGCIZ.G8(XHHQ@-:%DHB5$1$%%0JJH4$K1?8
MS/XYHE%]C,_CFBA>%Y$1 1$0$1$!$1 1$0$1$!:Y7?\ @^J:>N&ZCNFS25'8
MV8?S3O\ $-IA[]A;&L*]6Z.[6JIH9G%C9F8#V^E&[BUX[P<$=X09JBI]1V6"
MJ\FFNU#'/G'5NG:"#[5I%SOE;?\ R#3_ %KZ2I#)'79T)V7M$;M@L:>0>2'
M_!([5E1:?M$%-Y/%:Z(0XQ@PM=GQ)&2KQ7/=G:^)Q#<Z^\VVWTIJ:VOIH8 ,
M[;I!@^';ZEKS.D?3A> ZIJ(XB<">2ED;&?\ $6J$I]-62EF$T%JHV2 Y#NK!
MQX9X*2E\YI:[#FD8(.\$*T4A2=66ZTU1#50,FII62PO&6O8X.!'<0H._:PL]
MDJ6TU74/DJB-KJ:>-TKVCM(;P'BM&?IJW,<\TWE-(UQRYE+4/B83_9!PLBWV
MVCMD;VT,#8MHY>X;W//:7'>5,:2)U^.(=$LUTH[S;XZVVSMGII,X< 1@CB"#
MO!'85FKE-JN=1I.ZU50RGEJK/6N$D\<(R^"3&"]K>8(&\+;8>D#2\H9B\4["
MXXQ(',(\<C=ZU2U)B6E-2+0VE%YC>V2-KXW->QPRUS3D$=H*]*C01$0$1$!$
M1 7/.B@[5XUXX</=R5OL:%T,G R>"YYT)YGLE\N1_P#]A>:N=I[6[> ?D0=#
M1$0$1$!$1 1$0$1$!8-_^T5R_)I/U2LY8-_^T5R_)I/U2IKWA:GWH>[/]J:+
M^X9^J%EK$L_VIHO[AGZH66D]T6[R(B*$"(B B(@(B("(B B(@(B("(B B(@+
M2>DC3T]6REOME@;)>K:21'P-3"<[<1/KR.PCO6[(D3A$QF,.8V"XTEZ@BJ*.
M3;B<<.:1AS'#BUPY$<"%L*@^D+20@KW:FL_7T]0&_P L%+Z1 X3!HW/+??-/
MI-X;P%[T[>'5[74]8V-E=%&R0F-P='/&X>;+&>;3\G!;1.YALVI*L8'P/SR&
M0H8J;J6N? ]K?2(4*X$$@C!"O5:%IR]T<399PU_H@9([5;<O+)'12![#@A7;
MTA*S4T3XRW8:#R(&,*#T_5&T:SH)HSLP7%WDE0WDYV"8W>(((]:GF/VXVNQC
M: .%#7VT>64K_)9##4M<)8G?!D:<M(]85<9B8EK-=U<.K(M7T;JVGOD IJLM
MI;Q$,3TKC@D_"9\)I[EM"YIC'$L1$10"(B B(@+GNJ/Z8M&?DM9^J%T)<]U1
M_3%HS\EK/U0@Z$B(@(B("(B B(@(B("(B B(@(B("(B K%?64]!1S5=;,R&F
MA87R2/. UHXE7UH-XNL-SE=<ZICYK%03B.BIH][KE6!V!@<VM<,-Y%P+N#04
M'BOK9JVIH[C<Z.2665__ (-9#N<YP_X\W80-^_<P=KBMDL%B=25#[E=9Q6WJ
M9NS)/C#(F\>KB;[U@]IXDGDTU9YJ:2:YW=S)KU5@"5S=[86#>(8^QH_ZCDGL
M$Z@(B("(B B*DCBV-S@,D#..U!5%H\-RNM0QU0RK>W:&=EH;LCN (Y*P+U=)
M)0QU>Y@.[(C9\RTC3F5:VW=F_HM>LNH8Y!'2W21L5:7;+78PR7L(/ $]G:MA
M5)B8[KS$QW$1%"!$1!JMYLL]OJ*BYV&%LHGR:ZV.QU=8#Q<W.YLN.?!W!W(B
M.L5U@LE/3RT\SIM*5#^KB>_.W;9,XZJ0'>(]K=OWL.X[L8WM:EJ2W&UU%5>*
M.F\IHJANQ=J ,VA/'C!E:WF]K>(]\W=Q#4&VHM1TO7"V55/9Y*GRJVU,?76B
ML+]KK(\9,)=S<T;P??-[VDK;D!$1 1$0$1$!$1 1$0$1$!$1 1$0%':E^YRZ
M_DDOZA4BH[4OW.77\DE_4*" Z'OZ,M.?DC?TE;@M/Z'OZ,M.?DC?TE;@@(B(
M"(B B(@(B("(B"&/W9-_(#^T"F5#'[LF_D!_:!3*M;PO?Q^ B(JJ"(B B(@(
MB("(B B(@+6M*_R>_:HH>#65C*E@Q[V6)I/_ %M>ME6M?8O2*,;FW"V$G?Q=
M#(/W3?(@V5$1 1$0$1$!$5$0(B*05%540%Y>QLC',D:',<,%KAD$+TB#G>H;
M7]*$[[M:@UMFED8*RC W1$G9ZV/LWXRWFIDC!(5KI/P;)0LE^Q7W&F;49X=7
MM\^[.RKSN)SVK2)S#*8Q/")KH',>Z0;V..?!8+E.U0'42YX;)4$Y:535:<LR
MUN<>L:3Y@QCN*PG+*MD@#Y&'<78(5_#IK'#-E:U[2U[0X=A4$VHJ=+7IURM\
M3JBAJ0&U=*T^<2.#V?C <N84Z\K#KH?*(MD'#@<A1C/$MMD7C$MOL%_MM^IC
M-;*ELNSN?&1LOC/8YIWA2BXE5BHMU:VYVX]5<J7?NW"5HXQN[00NQ6>OBNMJ
MI*^G_FJB)LC1V9'#U<%C>FUSZFG.G.)995%546;,5%540%0JJH5(HB(@HJ*J
MH@(B*$**BJB#ROGGI4T]>J+5-RG]SZNX6JY5$<[7P0==L#&'L< -H'<TC! W
M-/)?0R+?0UIT9F8C*+5W0YST,Z?N-II+S<+I&Z!]SFCDC@>TM>UC&8VGCD]V
M3GAPS@9PN@5,\5- ^:IECAA8,ODD<&M:.TD\%=7*^GT3>Y5G=,POLHJOY;O<
M&M./,<[9R=D':Y'CVX2D>WU,3QE$^[#HUJNUON\+Y;774U9&T[+G02AX![#@
M[EEKYUZ$(I':TMU196 4TK)Y;D8W,(8US!L1OV<;P\M(  ;CEM!V/HL<<*-?
M3C2MMB2LYC*BHOGW7FM;]J&^FEM-PDLFFF/D8;@PEH<(SA[W.;OQG<&CCD<2
M5J>B-=ZHT]&^[UMWDJ+(QY9U%=(Z053@1ED6<EK@#G/ ;L\5O]1O%<S//HCV
ME<X?5I18]NK8+E;J6NI'[=-51,GB=VM< 0?85?7&NHB(H%%0JJH4$K1?8S/X
MYHE%]C,_CFBA>%Y$1 1$0$1$!$1 1$0$1$!1VHKQ3V*SU-QK,F.%N0QOI/<=
MP:.\G<KUVN--:K=45U=((J>!A>]Q_1XG@N;TT%3?JN*]W\$OSUE'1.]"E9Q:
M2.;R,$D\%:M<J7MM6K?%74>I7WJ\LBCEO9$#XF#/DSFCZTTNYY:""?A;(6TN
M41J26*HLM8RK?U$ C+WS#>8]GS@\=X(!'@M0T?TA0:EG\CV9X*X1[9#L;$F,
M;6S@[O \EI$,IG,9;_(]K=SG 'O*MNX*&DWDYWKPR9\+LQNQW<BM(JQFR6=S
M5E_->XI!-$'MY\NQ>7#BIA65A_!8L\4<C7-DC8]KAAP<T'([UEO&Y6'A:596
M9?1YJ""TM^EV[3" QO)H9I78;+$3D,!/OFYQCP71)9HHF;<LC&,^$YP 7(JV
MFAJH715,3)8S[UXR%#NT_:VG)I&NQP#W.<!X G"SGI]TYB6M>LVUQ:'>&D.
M+2"#O!"+G?1#,^(7JV"1QI:69CH(W'/5A[<D#\7(W>M=$7-:NV9AVTOOK%H\
MB(BJN(B((;6ET;9=)W>XN./)Z61[?[6#LCVX4;T4VQUHZ/+#2R#$IIFS2#L<
M_P \_*Y0O2^]UU-ATE <R7FL:9P.(IXCMO/R!=$8UK&-8P -:, #D$%41$!$
M1 1$0$1$!$1 6#?_ +17+\FD_5*SE@W_ .T5R_)I/U2IKWA:GWH>[/\ :FB_
MN&?JA9:Q+/\ :FB_N&?JA9:3W1;O(B(H0(B("(B B(@(B("(B B(@(B("(B
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M/[3CQ\5TI8-CM=+9+126VWQ]72TL8CC;W#F>\\5G("(B B(@(B("(B B(@+
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M0$1$!$1 1$00Q^[)OY ?V@4RH8_=DW\@/[0*95K>%[^/P$1%501$0$1$!$1
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M5JZLMM116:^?RBEE>*>FK0?.:>#62#GV!WM745Q'J&RWVP02'$4EQB+O\.7
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MJXZ>$-%MLD^W+(3DRU&R<-'<W.2>TJU>ZFI,;>4URPHFK:&3.#>"DY7;$;G
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MQN&O7TC79BM\+( .6T?/<?\ J ]2[?H_1C5UXB>T<JWG%7,6L=(\,C:7.)P
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M=7MV:H'X3/T'_N%,1$JV[->^EB@^^+M_ZG4?ZUY?IJWM S/=R20 !<Z@DGD
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M#1'&20&8!W@@[AG?@D9SNSPRJQ:N):>SM,QCLL,FBIJ:2HG?LQ^:XGCO+6G
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M(]BBUXK!IZ<VEO%-"*>FBA;Z,; P> &%<1%R/0$1$!$1 1$0$1$!$1 6!?\
M[17+\FD_5*SU@W_[17+\FD_5*FO>%J?>A[L_VIHO[AGZH66L2S_:FB_N&?JA
M9:3W1;O(B(H0(B("(B B(@(B("$X&3P11.KY)HM*WA]-GKFTDI9CCG8*0-1N
M-=-J^NC$+6QZ>HZD/#SZ59(P[L#E&'<^>%,K!L+(8[#;&4V.I%+%L8YC8&]9
MJUAS3.9Y$144D"M.C8226-.>Y75X*E>(8CZ.(NS@@=@.Y70UK!AK0!W+VY6R
M=REK2'EQ6)+#"YVTZ-I=VX60XJRXJT.JD,.Y3MCIGAW%XV0%KKCQ6?J&IV)Z
M6F@BDJ:V;(BIXAE[_F'>=RRZ'0NH:UK75M516UCN+&-,\@]>0W/M5MT5CET1
MKZ>E&)[M+N( JG8XD E= Z'74VU<F['\K\T[?XG9[?TA:3JBU-LE[J*!D\TX
MC#3UDK@7.RT$G=P\%NO0W$<W28L\WS&!_?O)'Z%;4G.EEMKVBW3[OP=+1$7"
M\@1$0$1$&-34%'2RR24M)3PR2'+W1QAI=XD#>LE$3.1H/2*?_P 3Z5[S5?LP
ML=7.DV!E1J'2T<H):35'(.""(Q@@\BL$/EA:8IW[SYK)\<^6T.1^0_(MM/LY
M]7N\5-SI:>5T1>^25OI,B87EOCCAX%>?)Q<-AE.P5%+6-V]D.V7;0&T'-)Q@
MX&>6\=O&%IH:J*%L$=%,:A@PX.;AA=S<7G<03OR,D]F5N6D: QNAW[45''U8
M?CTY,8/L!/\ F[E>^(CAGIYM.)A@6S2,\M7&^X23>31N#MB38!?ZF_IW>&<$
M;H^FIWRB5\$+I!P>6 D>M7D6$VF>9=5:Q6,0(B*%A4< YI:[>",$*J(.>ZAM
MM1310L<,FG?M1/<<,E;@MQG@UV#P.-_=O4?14T\E;322,$?5N+F1M>'RR$M(
MP TD ;^.?G74N1'(\5B55&Q]%514S8X9)HW,#FMQO((R<+2-28C#&=&)G+19
MIXHP*BMD#8\[,;0"[;/8T#>>&>_&> "RJ*KAK(W/A+O-=LN:YI:YIX[P>XA1
M=[CDBKH9'PR-+(S$Z(-RZ/?G( XM.,9&> ]7O3]+5U%PEDIZ=X:8PPAQP"<Y
M#G?!P,\=YSPW+2,17.6,[IMC"7<[9+1@N<XX:UHR7'L 5ZEJ'T4TCHVQOJ\;
M#BXY9",[V[O2=N&<;AC&=V_P'-CVF4DA<YPV9*L;B\<VQ_!;W\3\J\,:UC U
M@#6C< .2K]Y?[G;NG+5=GSSBGK QLKL]6]@(:_M&"3@\^]>ZU^W4.[!YH4 ]
MNTW<XM<"'-<.+2#D$>!4I3RF:!DCMSG#)\>:C;B6NG;='+U*\11/>>#02HAS
MGR.VI7.+NP$@#N"EY6"2)['<' @J( <"6OW/:<.5ZINO054D)\\NDBY@[R/#
MM\%G10P;0ECCCR=X<T+7A6G)<Z,"')&0=X&>)"EZ"9L<4HD< QA!!/?R]N4F
M"EL\/$E%)'GJ0'Q\FYP1W=A6.YP:[9?ECNQPPL\U\7)LI';LX_2KD=3#,=@.
MWGWKA@GV\4S,&V)1C8S,R5S!M-8T\.9[/9GY%%U=OD\J?7V>9D%:['6-=DPU
M&.4@' ]CQO'/:&Y;<  , 8 [%;D@BD.9(F./:6[U&39PY956:"MJI&VI@M=V
MP9);94'$<O:^-PR,?C-R-_G-!40TOCF$%3#+35!!(BE&"X XRT\'#O:2%UVX
M62W7&GZFMI(Y6 [3<Y!8[X37 Y:>\8*UK55JKGLLU)6-%^M,-<Q[:>;994C#
M'C9$FYKA@[L[)&!O*O76M3XPF*X:BP+)C:ILZ<MU;4&+3EY-/6<3:;TUT<W@
MQY\XCOP\=ZP*^UW6TD^ZMIK(&C_BQ,Z^+QVF9P/[0:M:ZU;&%N,+*B:L2BJ:
M>ISY-/#,1Q$;PXCQQP4C$P\PK3(O0M67$U68FK+B:LY2O0M69$U686$\!E4E
MN5!2/#*BL@9*>$6V"\^#1O/J"SF1*0M69$WDHVE?<:QN;;::@Q\YZW^2QCU.
M&W_T>M8<LU'/(^"IK9]053?-=06AO5TS3\&67./$.>,_!64V2EA<C45#Z2S0
M&X5;#LOV';,,)_\ N2;P/[(R[N4>V?%Q)HG17N_0DL=5/:6T-N/,- .]W<"7
MGF6CADMH*ZX4S(+C)%06Q@PRUVTED>S\&208+AW-#1V[2E::"*EIXX*:*.&"
M,;+(XVAK6CL &X!5B)GN-1EMC*;4[ZBIFDK:^:C!FJ9O2=YYW-'!C1R:-W;D
MY*SVL:WT6@> 5ZNA$^I=DN+2*($$?WA7A['1O+)!AW$$<".T+:N(C#.T>6-5
MREN(V'#CO)[ L:$B*5KFC R [',%5>=J61QYN(]FY>2,^;V_HYE:1'#+/*;M
MT>U(^4\&^:WQY_N'M4@%:I8^KIV-/'&3XG>?E5U8RZ(C$"(B)$1$!$1 1%YE
M?U<4C^.RTN]B"4H)]MO5N/G-X=X66M)#Y<[9FE$GPFO(QX8X+/I+O64^!+BK
MB[\-D'KX'UX\56U)[PIOALZ+$H+A35P(@D^N#THW#9>WQ!_3P66LUQ$477WF
MGIRZ.#^4U W;$9W-_M.X#]/<A,X9E=5Q45.9IW8:-P WEQY #F5JL\TM74&H
MJ<"0C#& Y$;>P=_:>?@ J322U,_7U3P^4;F@##6#L:/W\3\B+6M<<RY[WSQ#
MQ*YS(R6-VGG 8WX3B< >LX6W6^E;144-.T[0C;@N^$>)/K.2M=L\/E%VA!]"
M!IF/CP:/E)_PK:E6\\X7THQ&1$14:M5NS.JN]4/ZP,E'K&S^EJQ8Y'4I?+#.
MZG)WN<" T^(.X^/%2&I,,N$4AX& Y\&NS_[EI;GNJ")9SM/.\ [PWN Y+?3K
MNAR:MMELI_3EP=7]*%.Y\T,Q99IF[40Q_P >/CO*Z6N1Z#.>DQF?P1+^VC77
M%E>-MIAT:5MU8F1$147$1$$,?NR;^0']H%,J&/W9-_(#^T"F5:WA>_C\!$15
M4$1$!$1 1$0$1$!$1 1$0$1$&M:B_DNJM,UHX22S4#_"2,O'_5"WVK95K72%
M]:T\*X<;?505F>QK)&[7_3M+94!<XTG]<BNU1)]DS7.HZTGCEK]EH]30%T=<
M]U)33:7NU7=XHS+8ZU[7UC6^E2R;FF4#FT[MKVJU/1GJ1PEU1>8WLD8'1O:]
MI&06G((7I:,A41$2\E>"O14+3R73459/36$Q4U#3R=5-<9!MY<.+8V<R.&3N
M4KQPE2K3EXDM&IK4\BE?2WVF/O9L4TS3X@;)'B K$T&J9F.DCL%% &;^K?7
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MTDE?.8HG%D3#]=E'O?Q1^,?DX]F=JSMAS7KOMA$Z,@;!TGL:V1TG_A$P)(
M/71[AA=66BTD,=/THV^&!@9&RR3AK1_?QK>EC:<SEO6NV,"(BA81$00Q^[)O
MY ?V@4RH8_=DW\@/[0*95K>%[^/P$1%501$0$1$!$1 1$0$1$!$1 1$01^H:
M 72PW&@=PJJ>2'_,TC]ZM:3KS=-,6JN?Z<]-'([^T6C/RY4JM:T!]9M-9;]V
M:"OJ*?'8W;+V?]+VH-E6BZYO=7-<#I^TNCB<Z'K*VH>P/$<;L@,#3N+G;^/
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M8;JV8G+61M'8[))]?+Y5BB42RRNW[6UO!X@<OD7H*T59S:?"CY?*GN>_. [
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M[A3N>^%K)6.V'MX@' .X]A!!60ZCA/O2/ K$T]3NAMX?("))W&4@\0#N:/\
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M-XD8WCV96H6]\4E!3/IB# Z)I9CALXW+*JNE6UNC9[G4-5< Y@+GL 9'O&\
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MM+=TT.\EO+=S]1/@M=/CNPU9SQ$HNWVNY>0P2&]W".I<T%[9XXI&Y[V[ (\
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MK%RU;&TEELB$Y&[KI#LQ^H<7?(.]:]=KI575_P#*G!L .6T[#YH[S\(^.[L
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MI0TL='2L@BSLM&]QXN/,GO)5]$6+I$1$&ML_I8HO^23_ +>-;LM)9_2Q1?\
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M#U%=?M1(JP!P+2LV[VVFNUNGH:U@?!,W![6GDX=XXJD6V7RUFGM-/:^-!DG
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MUA=X-#3M>K>/:%CY=6U,=40&0-'UMO-_$!Q[-Q.!W^I%65;H6PL;''DLC8&
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M@.EB:X@=F\*Q[A6C\%4'Q=GS((/Z;=.?^8+1\<C_ -2B[]K&QF 4M-?+:73
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M\PL# ]F62O9DEA.<C<X</W+I='4LJJ>.:/@X;P>+3S![P<@J M%EAL%NMM%
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MU6U4=55VB6,_69(I)HSC&26MP/\ *YV[YEC$<.CRKJ**G@HZ:OE/V//$XO\
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M1$!$1 11%XU%;K62R:;K*@<((O.?Z^SQ.%I=TU+<KIM,C<:*E/O8G>>[Q?\
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MR86MH]&-9:G<)7W"X]5,X-;-F64CF,^B/XX+?M#;<E35SL ;3LC;!XN&\ >
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M\O;O&"/E[UX:XU!/5DMA'O@-[O#N[U<B #G;(PT -]BA*XB(B6H:J^[;2?\
M^M_L@IU:GTC#.IM*^<YN^JWM<6G^;',+)M=TE@F9#5R&6!Y#6R/])A/ $\P>
M&>(/;RM%9QE6;1$X;&B(H64>T/8YKP'-<,$'>"% U%BDCR:&8%G**;.[P<-_
MM!\5/HIB<=D36)[M/EIZJ$XEI*@'M8PR#VMRKHM=2^B?4F%_6[;=F$C#M@9R
M<=I)SC\4<UM:*=\J1IQ#2'RLB.)B83V2@L/RX5&U,+CB.1LCN38SM./@!O6\
M(-W!6WH]E'JU&IH)J)M,Y\4A:ZG8UY8TOV7C.0<>(W^*\Q05,O\ ,TE0[O+-
M@>UV%N"*L7F(PF=.)G* H++(Z5LEP$6PT'$+3M9R"/./@3N'M5YNGX [!J:D
MQ\F;0]FUC/RY4RBC,K16(X8]'14]&TBFA:PGB[BYWB3O/K6NW*LFJZF9HE>R
MG8\L:QCBW:P<$DC>=X.[AA;4M7NU')1U$TH8YU+(XOVVC/5D[R'=V<G/#?O[
MYKC/*+YQPC9##31NF?*8&MWF02%F/6"LNTZB&3_*VU=,W^<R?KD0^%VD>._O
MY*/KZ85]$612-!VFO8\><-H'(SVA1<=OK75L ?'"V5NU@LD+B\%I&,8&&[P2
M3PPM9K$QRYZVM$\*5=%5PULC&LBZTL8P]8\-ZLM&-XXEOO@1QSR6R:<MHE%-
M&S+J*F#<R'_BN;P [=^\GARYG$9=K]5R5$4,$;#%'$U[6OV0=DY#3DM=YQV2
M>0&X;^*F[+J,RPL?5':ISYIDV0U\1&XAX&[<>8X>&]1,VVKUBD6GEM"TNYPN
MH:A]/0NBGV3N:XEO5#B&N._EPYXQNYK<QOX<%J-9&Z&X5<3^/6&0'M:XY!_2
M/4J4[M-3LPVQ3N'UVHQ^+$W9^4Y/Z%AUE33T<P9'"ZHJL9P79V1VN<<[(/8-
M_<I-0]=;JEU=+-2]2YLVR7"1Y:6N  Y Y& /XX;1$>7-,SCAF6&[RPSSO$(A
MZO9=-%&_;;(PYWC<,.&#RWX[]V_M(<T.:06D9!',+G-+&VV1O$TL;ZNI=D#@
M#@8 '/ XY[SV@+>+354KZ>&FIZEDKX8VM(X.( QG!WK+4B,\-]&9QRSUK.L?
MMCI/_G,?[*5;,M9UE]L=)?\ .8_V4JS;-X1$4 B(@(B("(B B(@(BP+Y<XK1
M;I*J8%^,-8P<7N/ !!GJ/K+U;*,D55?31N'O3(-KV<5S*Y72ONCW&NJ7N8>$
M,9+8V]V!Q]>5@L8U@PQK6CN&%O70GS+EMU41VAO]=KBBC!;0P3U3^1+>K9[3
MO]@*UBYZCNEQ#FOJ/)H3_P .GRWVNXGU84+)/'&<.+L]@:3^@*VRJ$CL,CE'
MXSV. _03\BTC3I7NRG5U+]N%^-@'FL &3GQ[U*6^-KG$/#2 .!6%2&D8YKZJ
M6L?C?L4T+6@^+GG/R!9,5;21N>?(9Y@1@":8,QW^:"HOFW$0OH[:<VGEG01B
MG$CI"UK2=W@K^01G(QVJ EJ9'.RR)C6]CI2[]P5):B5\;6LCIXB#O< YQ/CE
MV/D6?LK2V]O2/*=;-&[.'MW=ZM>5-,S(XQM;1QGAO4$73N: 96M(YL9O/MR@
MZT-+34S%IX@$-S[ %,:,JSU%6R22-B?(R0[+HSAP[%&VVMH672)U9/%U8<20
M79Y'&0._"B?)XCZ3=O\ MDN_2KC0&C#0 .P#"M&ACRI/4QXAN\VK+:S/5BIG
M/XD1 ]KL+ GUA(<BFMX'89I<?(T']*UA%:-"L,YZF\]DK4ZANL^1Y2R!IY0Q
M@'VNR5%3%U0_;J9))W]LSR_'AG@B+2*5CM#*VI:W>0;L=@71--,ZO3]N:>/4
M,/M&?WKG>,[NU=&T^\26*W.'.GC_ %0L>H\.CI?+/1$7,[!0VL+H;/IVLJF'
M$VSU<7]MVX'U<?4IE<YZ8ZLB"VT;3N<Y\SAX8 _24@<Q))))))/$E;%T>53J
M35U ]A/G%S3WC9.[Y%IU[K#0VZ25F.L.&,SVGFL[H=JYJS4M R=[I'QU+2'.
MXX(.[Y"K95P^J6D. (.0=X18]N.:*('WHV?9N_<LA56@1$0$1$!$1 1$00Q^
M[)OY ?V@4RH8_=DW\@/[0*95K>%[^/P$1%505'>COX*J$9&]!Y]\L6)VQ/.S
MWH=GVCA_':O;GF/: &TX$!H[<\%Y$;F%Y>07O.20,#L4H8MT!DI)]@9.,X[0
M-Y'KX*ETGS:R8,9G:&,S^/N!/M"\33BH+J>D.U*\$;6/-8.&<\_4O%<Z$5='
M2;;6QPCK' NQN;C9^7!_PJ80P6!M+<*FB8X.: V9I^"#N(/K;GU]RMZC+_I?
ME8T[(=LAYQG9C+AMG'<W)5OK6-O-63N;4AIB<??;(W@?I\"5D7.=M-:999&E
MS6M)V0,EW8 .T\/6KXY1',+]-*QKG/+N6[O6-13>6WZ69N!'1Q&!V_B]^RXC
MU #V]RPK1(QUMIFQRMDZN-L;B#[X  CN7BR/FIM05M//%LMJ 9HI.3P,#'B,
M[QX%(CN3*_0-,%?<H8G?R:.<=4WX!+0YS1W9=D=F2%36%.Z:UMN$)/74C728
MY/;CSF^.!N/:%Z@(==+H^/=%UK6X[7M8 X^' >(*C-=5TM#I][&@_P J=Y/D
M^]#@<GV CUI6)FT8/#4Z*83ZOA?2AQ/D[A5%G#&/,VN6<\.:W:&L$<0:YI);
MPPM'T!5P2272F#@:DS=<<<V8 'L.[UK;'#<M[\VESS/.589F1,E9('R,D.3M
M.RO-1;J*LIG-#/,<,9:3D*S)P*4$NS.YA.YPSZU$59S:41I6 4-3>+?M9,-2
M)!GFU[00?D*V!0U\AGIJZ.[6^,RRQLZNH@'&:+.=WXS>([>"DJ"KAKZ.*JI7
M[<,@RT\/4>_DHF$UG*^I.U2,=$^!X!SDX/ @\0HQ95.^GH*2>ZW*9M/0TK2]
M\CN[^/7P5;1F,-*=VOT.AJJTZA956JIB%I<'=:V=V#$WC@?"',9QC&]>+]TK
MZ2TZWR:*IENU1'N(I '-SWO)#?9E<<Z3>DRXZMJ)*6D=)1V1IPRG:<.E_&D(
MX^' =_%<Z*]+2^CYFL3K3^2\3%9]UW*JZ?H=IPI]*0N8<Y,M2,GQ 8K%+TQZ
M7JY +QHQM..<E(]KB/D8?E7$'<%:=S6MNCTH[1\Y3G+ZUT76Z2OYE?I2YM=5
M/;EU)4'9E:!V-._'>,CO6N:]B?3UM<VH8YOUGWPX^;R[0OFN">6EG9/32R0S
M1D.9)&XM<T]H(X+OG1KTA4NNJ:+2VMG-]T20**O&&F5PX-=^-N'<[AQX\6KT
M\Z?O5YA$TB>S>-*3%]=;(I<N='2.P.QP#!GV$CUK<]I0UAL4EG=.^KD9)528
M;Y@\UK03@#.\YSD^KL5-553*:SRM<X"2;$<;#[\D[_5C.>Y<M\7O[K2.()IA
M[A#J7M:^2L=/2YWC9$A<'8^"=_J<I2SUHK(HYMC8=M%CF$YPX'!W\_%:/'4E
M[RYQRX\2I_3U0V&H$37Y$P,NR>3P0' >(+3[5IJ:.VN58E(NJI:+4LD3L.BK
M6@L=S:YH.6^&-_B5EO?Y1>6#T>JBVF#X1<2"?4!_U+&OT+)'T3@ :@5$9AQQ
MSGSO5L[6>Y>LYN\(<=DLA<6?C$D ^S ]JPPLDKGOIHZ5IWSN$9[@023[ 5Z)
M'NDP.(WQ.V!WY&?DPK-*>LNY!.TX4_\ DR[]_P#[5YN1:R4.D:[(B<(G#WK\
M@_H'Z543 _F3M<.]8EK.U"YXSL.=YN>P;OW+*PU\,D;SN((]15NC+64;'/(#
M6@C<,#<2,_(JI78_-D>#Q<=H=^['[ED-X+'<"\&1S2T-'FYX^*O.>R*-[Y'M
M8QHRYSC@ =I*#VHK4FH+9INW/K;Q5QT\ W-SO<\_!:WB3W!:#JKI:IVUGN3H
MFD=?+N\[+71M)A:?5O=ZL#O6+IWHPKKS<6WSI(K77"MXLH6N^MQCL=C=C\5N
M[M)1**EJM3=+U0Z"A;+9=(-=A\KO3J #P_&/XH\T<R5UC2VF[9I>ULH+/3B*
M(;WO.]\KOA.=S/Z.2EH8HX(610L;'$P!K6,& T#@ .2]%(0HB(I%%155$!$1
M0A14540>41%*5$144(%Y7I4045%54045%4JB"B(B"BH554*"5HOL9G\<T2B^
MQF?QS10O"\B(@*C@'-(/ JJ\/<[@P GM*"S3;0BE+O2VB">W&Y1MQ<R1E2UY
M&S&S9V2=VT>9\ 5GLG;"QS)CLN&3V@CM5BWSPRSU&T0.N(V6N]\ ,>OYL*85
M6;CYEN=$"1&"QF!NR"X CUC=ZUCW"&!T6P&.?'LEOGNVAC&, =BNU=!3>Z$,
M<C7NA8PR"-[W.:3G' G&[]ZP;O!%13TTE,UL397]6]C!AKLM)!QV[N/BKTGE
M$PL625WD^'O+@'O8TN.3AKR!D^I1<T3:2MK)HR<LGCED>TG#HY,M(<.!V2,Y
MX@8Y!9=M(Q5-S]<$[BYO9GA[1@^U0-YG9'?L&9S:7ZR*H!Q#<ASMSO\ H)[E
MI%<S,$]FQW.*.6QW RM&8XG2-=S:YH)!'801G*MVMTUT>+@\@C9=%$UNX!NU
MO)[2XM![A@=N:ZBE@ATQ7=>]NQ+ ]@W[W%P( ':<X7/[/JBX62G--"(98B26
M,ESYA.\X(XC.3A6II6U(G:B9Q+<==WJBMEHJ:':;)6U$1:V,;R [(VCV#CXX
MPN3V< QSO_XAE<''PX*MXK:JXW!TLSP^KJ7;W8PUH Y#L 6124[:: 1M)<<Y
M<X\R>:UMIQIUV^?+'4ME,Z.NA9>746PTQS[LYWAS03G]*W:5N,KE4CWT%9#5
MTQV9&.VAV9"ZI!*:FA@G<P,=+&UY;G.,C.,K.T8YAG7F)A@5)P"L>WS$3R,S
MYI;E7JS<"L:@ #99,^<3L^ 6M8X<VI.)8FJ7.901U+!M&DGCJ,#F&NW_ "$K
M9(WLEC;)&X.C> YKAS!X%0%5*"US7 %I&"#S"\Z'E)H:REVB8Z2I=%$"<EK-
MQ ]62HU*8C*>GU8M,U;&IBV31N@;&" ]O$=O>H=58XL<'-.' Y!6%HS#LK;;
M*YT@3.@T9=W,&2Z'JSW!Q#2?82M3Z/ZAC[1)3 C;ADSCN/ ^W*WVX0MNECK*
M<-#O*('Q[)^$6D?I7&]$2/AO]'$]SHG.<896G=OP1@CQ 32[3"=7O$NV4+BZ
MDB+N.%&7&4OJG ^BS< IAC0Q@:W@!@*)N<#F3&0#S'\^PK.DQN7O$[7(-0VZ
MHM]PEZ]OF2O<]CV^BX$Y]O<MATAJ"&U:7K Q[9*^6KD=%#@G&0T;3NP;B>];
M-<Z""Y4CZ>I;EIWM=S:[D0N86]K:2I@HK@U\1;,V.1I!&T-K#L'GD9776*W^
M]X8Z<;9RG7U\U94&IJY722/PWK",-[FMY=NY9U-(=IK6M>Y[CAK6-))/< ND
MW:*DBM3X*B.,4C8SMMV<-# -^[P6BZ&.+DX/:3(:7(<>(PYN?;D>Q7KKYI.(
M[-\89UON%PH970M/5.D)?U=1"2<D[RW!&1G?C?O/+*V2Q$RVKKWDNJ9)"9R1
M@[8.",<@,# [.WBJ.^V=K/ B<^=V?6W[O7P5WRAELJZJ*MVFQ32NECD#26NV
MMY;NX$<,=F%RVMN\)B,,>C83%64HKC3B,N8R,Q^>UI&6X?V>HD<.2V"VU,#[
M7&=ML0B8&N:XX+"!P(Y+7Z"O;)63U<=/4^2[(C;(&;B&EV78SG&3CAR*FZNG
MAG?1B2.)[),N#]D$N  (&>S>3ZEG:$PI9PT23]6-EAPX-[BY^-W+=A9[W/;5
MP%@#W.#FX<<8X'/R?*K-72QQ"&2E:V"0O:S+&@;0)&XC@>95\0]14MD,CY'-
M:=HG&X9[!_&Y5[I[,J&+J]I[R'2GB['R#N7J'?&''B[>5[) &20 K40.\M.&
M'@%5*ZB(B1$1 6!J @6*Y9^]I/U2L]1^H/M)<<_>TF/\I4U[K4^]#S82UU!
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MLT7='(YH]@.%/LR-6&U36VAF>7RT=.]YXN,8R?6O45%30Q21T\$4+9!AW5L
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MWSPYKF[O#)*FNABS-C@JIHF;$;L4T?<T><\_JCQ*#K5O!%'%GB6[7MWK(0#
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MM>)G3T;62DG.UNP<]Y'%0&E1/;M04T$\3A,]CH9&O&-W';!YC+>/XRR]+?\
MAVH*ZTL'\EGC\MIVC@PYQ(T=V2"M@G^LW:BE>,QO:^ 'L>XM<!Z]@CQPK1;;
MFOJUKS$2O75KHYH)@PR,BE;*]C/2(&>'>#@XYXPKMXD8:.*J8[;I@1,7MW^:
M6G!^59-6W9DVN[.Y1T3";';(<@-JWM) Y,.U)LCU !5B<<IE<H0^@LD4DS0U
MT<8 83O)Y#QX>M9=JA<Y\3W"3JJ>%L,.VTM)./.=@\.0W]ZK. Z[QL=PC@VF
M#O)(<?$# _Q'M6?%N;D\%293AYNH>12M@/UYCC*T#GL@_IR!ZU(4[8WP!S"7
M"1N2X\3E85OC'DD-0[)FF:'.<3V[\#L'<K]"3$[R9V]H!=&>[.\'PR%4>QET
MY9)@B-HQV$G._P"19(W!8M'O@:X^D[SG>/-9/-J)>D1%"1$1 4?J XLEP[Z:
M4?\ 25(*.U!CW%N.?O:3]4J:]X6I]Z%NC#?<BWF0?6Q%&7>&PLBEDQ3->]V!
ML;1<3P':O%L^U-%GAU#/U0K#AM4E/#P$I#=_)N\_H&%,]U;=Y>(@(K0'OB)8
MV(ES<>ENW[N_]ZC+B_R:W48J'@PM?$)7<1C&XGNVME3]=.*>GD>1EL;2X@<\
M<E'26OK[0RE>[>6!KB.1'9ZPD*K5TIVU= ^-^,/:6^&>?JXK5!$Z6'ZXW$K2
M6/'XP.#ZLK:K899+)"ZH+3(/-+AP=@D9'CC*C*BF-/6M+3F"J>00>+),9R.X
M[)]?BMM*^V<(E!VNC9+?&"1H>V"(RXQD!^0&D^K:QX=RV"XU3*"WU-9-Z$$;
MI#GG@</7P7BRQ-9%5 _SWE#^L[>/F_\ 1LK#UI+'!I^:24;6R]CPSX6R=HC_
M "M<?4HO;?8[0Y>)Y[A,;A72F6JG:"2>#&G>&M'(!9-%4^1U<51M.:(W!SBW
MCCG\BP;>PQT4+7<=D'PYX7JL);3/P,YW>"UB/#CF74#-'+$V2)[7QO&6N:=Q
M"BZUXP5JVAZU['U-(=HQN'6 \FG@?;N]BG*R7<=ZF*XG#IZ>N[EB>7&EF+@-
MIIW$++EJ&R1A[#EKAD+7ZV3CS*S(@Z&CC8_<X#>.Q:S&(>WI:?#-TJ\-O-WA
M!P'B*8-[3@AQ^0+9USRMN'N1<:*L8"9& ME;\*(G>/'.\>"Z&L+1R\+6F)U+
M37MD!QPXJ2KX/=BP5E+D-=40/AR> <00#[5&J:MC"RD&>+CM+*_;)I=\.1Z$
M/D.K(Z>X,,4K-J"1CO>N'_Q\J[,UP<,M(([05Q[I(C=2ZUEF8#&Z:&*5KQNR
M6^;D=^X+:=)7QU?2=87-;51'$K1P/8<=A5[UWQ%E:6]G,U;#7TCHGND8,QDY
M\%KNIK9[JVB:!@;Y0,/A+N3P<CU'AZUNS"V> 'WKV_I4'40O@D+7C=R/(JE+
M)O7',.:^2STU5'3W"E=32RYZL[0<Q^.(!'/N4A'0?BJ9U>T^YL$Q83'3U,4T
MCFC)8P'SG >'R$J6@M[9&,?&0YCP'-<-X(/ KNIKS,>\FG+WI"HJ'TLU'.\R
M1TNP(G'B 0?-/;C''L*N7BU4LM;1S.C+)))VMD<TD!X ) <.!WM SQ4EI&WM
M]S_*WG+JIW6$=@&YH]GRDK&U6]T=L,< '63S,BC<[WCB<AWB"-W>N*;>_.UK
MX3-2"8XP=X(W]ZPJ)\=/;*^.5I?2TLA8QG'S2UKMD>MQ [-W8I2I:0R-O=V*
M(.T)3:@1L5$S90[F&G:>X?YHSO['=RI$IE?IXI*&VT=+&X-J)MSY..#C+W;^
M)/+/:L^WTD-,#U3"'$8+G$N)WYXGO7F[,#/(WM_G63-:WLP[<[Y"?8%GTL8<
MQWPN2K,D+8,E42-S:>&0 ]KW#?Z@#[<+(H'"-\D#O-.T7L'(M/''KSN5J@!;
MY7 ?2;(79[0[?_V]2]O_ )VG ]+K!CV'/R94)7FGK)W//!F6-_>5>&YI5EHV
M:F5HWM.'>!/_ ,*]R[L[T'M$10ESSI0E,%\TY,V,R.C;6/#!Q<1%G"U*&66K
MJ81'5OJ:E[FE^P\]6&9\[+0=D-QD#.\[M^=ZW+I%^Z?2OC5?LPL>EI75$YIJ
M1H8YQVI'M& P'WQ[^SM/=E;:<XJY]2LVM&&90VF2HM\5133!KW[6TV3):[#B
M [(W@D 9XYX]JN-LM>3YSZ1H[0YSODV1^E;!!$R"&.*(;,<;0UH[ -P5Q4W3
M#796>Z,M]GBI91-*\SSM]%Q&&L_LC]YR5)HL.Z5K:&F,A&W(X[,;,XVG?-S)
M[%'=;B(5K+A2T;FMJ)=E[AD-:TN=CMP 3CO6L3U0N%7+4%XD:R1S(L<&-!QN
M[R-Y/'>O/G.>^25YDED.7O/,_-R [%C2-%-*^H8/,?\ SP'Z_B.?=X+2M<<L
M+7W<0REBQ#J:R1@&&3?7!_:&YP]>X^U9.1L[6T-G&<YW8[5$SW:EEV1 9'.#
M@8Y-@[!=R /?O&>&_BKLX2CY&,+0][6EYPT..-H]@[5CO<RGJYY9'-9&80YS
MCN #2<D^IP4!7.@FKZIU8Z-P<!U?6$8ZDM!!&>6<Y/;ZEEQ0U5RM#-@.D='&
M_,A!.0)!U;G8WD.V-Y\3P28Q&45G,S"0HKI#5S=4&31/(VF"5H&V.9&\]VXX
M/<KU./K\SNWA_F</T-"A**"LJZZF$%(_;CD#SY[7<,Y'FD\02,G P3X*7U)2
MSVVD?$QSR7LC<9(\Y(! DV>>1O/;@J)QG$+5B=LS,+CJZD94BG=50B<G9ZLO
M&UGLQVI6RNCBV(M\TGFL^=:W"(IVLIZ39ZD/:Y[HQYD;0X$DD;L[O$E;' QT
ME2^:1I!;YK6GWO\ WY>.T%-HQPK2<QF5VGB;!"V-O+B>TJXK<4\,KWLBFBD>
MSTFL>"6^('!7$2]4U3+;CUE,2(\C:A]Z_?R'(]A'/CE;D1@E:'%,^2H#X2 &
M;VO(SLGX6.9[,\./8LB,R1/VX9YV2<=L2$D^.<@^M9S7/9K6^V,2W1%&6>Y&
ML#H9PUM2P9.SP>WX0_>.7K"DUFVB<\PQ+G1,KJ8QN.Q(T[4;Q[UW;X<B.PK5
MB'LD?%,W8FC.'M_01V@\BMT6'<+=!7!IEVF2,]&1APX=W>.XJU;85O3<U621
ML3-IW@ .)*QHHG5#Q-/Z/O&<O'^./R*4N]NBH_)V OD,I=M228R0,'8    /
M$]NRL=:1.YA,;>$#>WNEKA2RN+:?JA(& X$IR0<]H&!NX>=OY*+H(XSJK3LM
M,U@@;<HHR8P USMB4XW<<#]9;;/3PU#0VHACE:#D"1@< >W>HRXR-&HM*0,'
MHW2-QQN#1U<N!Z]_L5K3[N%:1[\2ZZB(N9V"(B B(@(B("(B B(@+S)&R5A9
M*QKV'BUPR"O2(->K]'VJI!,,3J.0^^ISLC_*?-^1:O<M(7.CRZFZNMB'P/,D
M_P IW'U'U+I**]=2U>TL[:5;=X<6=EDKHI&NCE;QC>TM</4=Z+K]PMU'<8NK
MKJ>.=@X;;=X[P>(]2U.YZ'QE]JJB/_LU'G#U.&\>O*WKKQ/WG-?IIC[K3Z8[
M'F!SA'O+69\T'N'+U*3HB7.R^3<S@"5A7"@K+:XBX4LD ^&?.8?\0W>W!5ML
MP+1NSWA+TBW-4Z>I-/=NV $$ @Y"HYH<,. //>HRFK'LC P".6>2RH:L22-:
M6[.>>5SS68=46B8RO5!V8)"!R6)!2![ Y[B,[\!9_ =R*(G"<,6O.S &@#!.
M%M=AVO<>EVSD[/'NR<?(M7JHG3M$<3'22\0UHR<<ULFG(:B"V-94@M.T2UIX
MAO\ \Y4^#RDT55152*JHB JJB("T7I8M,E9:H*^!A<ZD)$@''8=C?ZB![2MZ
M7E[@T;P23N#1O+NY('SM;*&HN=;%2T49DFD. !R[SW+Z)TO9HK):8*2/!<QH
M#G=IXGY23ZU<M5JIZ)SI64T$,K]Y;$P- ]G$]ZDE,RB($1%"1$1 1$0$1$!$
M1!#'[LF_D!_:!3*AC]V3?R _M IE6MX7OX_ 1$55!4=P]:JO,F=@@<3N0>*A
MI,;QG&01GL6+1OV=II;LYP_U'A\WJ69( 68._.Y8,+7,GF8YVT0&[)Y[._'[
MU,(6IVRFYR]3*86B)FT6@$DY=CCN[5C4NU%4S0R/+W;0EZS&"X.)XXYC'+EA
M9U(WKYIZAWHD]6T#L:3^_/R+"QLW&J:-^VUD@/,#>W'R9]91"+%&;G-/6>42
MP,DPUC(L;VM) <<@[SO]6% U,3XZF:"5PD>QK7-DQ@N:<XSWY:?D4_89#'6U
ME!([+H7%\8(P>K<21XX[>]8NHH6LDAJBW C>62. X,(/'N#MG?R]JWT[[91X
M:K50DY618+ VK$%?6.S"2)(H /2'O7./RX'=GL676TSR8XX=GK9GB-A.\#()
MR>T  GU+8J.F;2TL-/&261,:P$\2 ,+;6U9B,0B(8.H7T[+%7>6EIA=$YN#Q
M<X@X [\XPN/VT%LE6P[PV0;^_&_Y5T'4C'UMXD:]OF4K0R,'M< XN]>0/4>U
M:+#'U%5709SU<[M_CO\ WJM:XIGU9ZJ^O.F;BRAU#'/*[$+RZ-[NP'G[<+TH
MBLC$<SFMW#B%:L9X<\\<NMU3P6D@Y'<M<N,FSD@[PI!LC!0P"''5B-NSCLQN
M4'<Y-Q5]&O+GZB_"E-='3N=#,<R 9:[M"C+R^1[8Y("!/!(V6/\ M!1%=4/A
ME$D9PYIR"K\55Y8V)Y\P/.#W;\%>C71B8Y[/"U>JM2T3'?+K6EZZ.[V:LJ*3
M/UZE> T\6NP06GO!7R&X8W'BOJGHL'DUN@D=N;62/EP>0<< ?](]J^=^D*RO
ML&L;M;W-(8R=SHN^-QVFGV$+/Z+M$7O7\'U7,TC*"H*VHMU9%54<KHJB)VTQ
MXX@K?^E&[W9E;8;O2W>X=7<;9%.V03%KFOR0]F6XW CAWKG!X%?1DN@;7<^A
M6VRU5;F:WP2S03!PPW;=DL/K^5=?4VBEJS/F<?JQO-*3NF,S$9_*/_MRS2'2
MQJ;3M:Z66OJ+E 6X,-5*Y[?$9*ITJTD-[CI]<6<'W.N;A'50\3250'G,/<[&
MT#_V6@O&"1G/>NH= K*&JKKK1W^:9MCD:QT\9SU#G@G8VSP'/'#@L;TBL[JQ
MC_W^^&EYKIQ.I_?3\OB]?0]226.ZW#4MRE%)IRGA,-3/(XADCSZ,8'OG9(..
M2P_HA=86+5=XHGV!H?U+"))]G&T?X_0L/ILK8X[U3V:TU$IT[2,ZRCAV=F/S
MB[:<W<-K?D;6_@N9/6<4][?/?_S]RE8U<:GY_GV_3\.[JOT+S'.Z4V.:-S**
M9SO#+1^DA?0NFKE3U%K=1L\VHIG.#F=VT<.':"N0?0OVIU'1:BU-,W9:(Q14
MY/OCD.=CUB,+I6E*4B[SN:TD1P[!=V.<X''C@9]G:O/UXBUK3Z8=+E-\J*VA
MZ1]3FWV^2N<X[3VQYRQN&G;W ]JW1NJ^D.HIXVQ:.C!: #+,2-H]N"X*W36N
MK^JYJ?,$L<,]#ADSV$1[6S$1YW#B/TKJ%NJ&5UGAJ8]S)1M-]O#VY7)F9A;R
MY?03=*-0QE!3LM5NZMFT"_8)QDY.?/R<\=W->*+0NLKI6U$=VU8ZG$1#'&E#
MM^1M$#&QNWCCVKI]*&F]$O<&B.F);GWV7^<?5LM_S+Q2L>_3U7,P.=-4,DDR
M.+B[.,>K 'J3"'.[=T1V>:=[ZBHK[D#@"HFE#&DY.T0!YQ[M^%TFPZ7T]8LR
M6^U45*6#/6; <[_.[)^59M'LOBC,.#&6@LQV8W*[L"2X4['M#FM:]^'<,C9
M/RE52\VMNS5F1XW5)<]H(]$Y)SZVX]BD9CL,,@.'-&X]O<L>5A<[+';+VNRU
MPY'YEZ=)UL5-(X8!?YP[#@C]/[D0NP-V8F@\0-_BKS.)[EX:O<?!WBH2]+1^
MFVAJKET6W^CM]-+554L<89#$TN<[$K"< <=P)6\*G:@^8Z>NNIZ+V:3'1G<Y
M[D:4TPK9:7 #R3B3.SG(SD;^(7K56A-24'1'HJTOH:FLN%/<I)YH:=IE\G8_
M:(:2,\,[^625]-*B83EPW5E#>M&]-<NLJ:R5MYM%=3=5(*)FW)$[8#<;/BQI
M[""=^5B:,TE>]6:BUYJ.YVZ>RP7NAFH:2&J&S)]<:&AQ'$ !K<]I)QP7?51,
M&7SEHV_ZUT1HYVDJ315QGO4,[^HJ3$7TY#W[1)(W'B<;\<,D+.Z6]*Z@U16]
M'T%WH))IG!T=SDM\9,<&V]F=^_&!G>>PKORHF#+B_1E'J;1M=7Z)O5NJJRTA
MLCK=<X(28P""=EQ'#/?O!R-X(*TBUZ6OS/H?+U;7V:O;<)+LR5E,8'=8Y@V,
MN#<9(W%?3Z(C+AW2G8KM6] ^G;=1VVKGKX6T@DIXXBZ1FS$0<M&_<5@:WLM]
ML^JM":HM%N]TJFBMT%-/;P\-F!:P@^;QWA[AD X+=Z[^M)Z0>CJVZRJ:&ODJ
MJNW7>A^QZZD< ]HSD YXX.\<"-^_>B8ER2U7*ZW;Z)&RUE[M+[3/)3'JZ1[P
M][(Q#( 7$<R<G'(87T>M!T3T:4>G+_/?JZZ7"]WR5G5^5UK@2QNX' [<#&23
MNW#"WY(1*BIS5512@7E>E10*<E155$%"J*I5$%$1$%%0JJH4$K1?8S/XYHE%
M]C,_CFBA>%Y$1 7D'#\=J]+SGZYCN08]=GR>7'-I'SJPS$E>S'G-CCR.P$\/
MD'\965,X1A[W>BT%Q\%C6J-T=+M28!?AV.P8  4H6+IF5T=.<_778</Q!O/[
MAZU;OU/%46:L,D8>.H>=GM(!(^5>*YSI*QDC"6]3(U@W^D7$$Y[MD>T]RSH_
M/VHW'+7 C!1#$='_ "*#9=M@- V\\=RAWTK3=GLC&&SPN?(!\($ .\2"1_A'
M8I&Q1"ECK*"64OBIY=B+;XM86M<!GGC) \%1NS#>:5Y< VH:8'9X9&7-]?I#
MUJT3B1@V@.%"R"08DIOY._' EH R/$8/K6/<HO*;I20' :R-\PS[X[FX'@"2
M?$*2LH9&V9DP^N,GE$H_&+R<^L$'P(5-01F"+RJ-H+J0^4-;\( $.;ZVEWKP
MD6Q.3PXY=WOJ=17%\Y.::9U/$SDQH[NT\<JTMVZ5-/044<>H:)Y8^66.*HC]
M[*';@X=CAN]2TE;Q;=&7+>)B>5FKC=+#LL(SG..U8%%53450)H';+V[B#P([
M"I51%40:B3'#*UI/AE:&V05@KZ)LV '<'-!X%0MQ'%6;#UCJ\,C>6MV27@<P
M.2D+A'Q75HSR\[JJHBWT+7A]2_>YKBUH[-W'Y5GV25E+J"V.?N!F+"3P\YI:
M/E5^VTY90N+AZ;RX>'#]RCKM$>JV8P3,]P;$UO$OSNQZUT:LQ?3M$O,T8G3Z
MBEZQY_WPZLKM- ^>398/$]BL1!PB8)""\-&T>_&]2EGE: ^,[GDY'>O&M.(?
M55C,XE(QL#&-8W@T8"U'I6J&Q:1EB<1MU,T<3!W[6T?D:MP6@],%.YUIMM4#
MYL-5L.']MIW_ /3\JRIS:&]^*SAS:%CI9XV1C+W.#6^).Y=ZM#7-I//XD\EP
MNVS-I[C2S/\ 0CE:X^ *[W1R,EI8GQ$%A:,$<%OU$\0PZ>.97E&WG.Q%V9*D
ME:J(6SQ%CMW,'L*YJSB71:,QAI-Y=4T%13WNA ?-0,>)(2/YV%V-L \B ,A3
M<\D5QO-BEB<9*0$3;N +VGJR>_<?X*PKY(RWT%;)4D!D43B[OW</7^]>]$4<
ME.+3;ZCTFTT=8]IXM=L!@!\!\I6UO5EIY[-PJXR)<XW$;E%V%@GN506M)IJ5
M\L<9Y;3BTN \"'#UX4U5.#I/-][N)7FWTL5'1O$#=AKG.( [7$DGVDK*);X8
MM>]ONQ1L<0#L2;/:3YO[L^Q2T+0:<;7!0$/\LO+)<.$,,1,9/_$)<07> V3C
MQSV*;V.LHYX]HMVFEN>S(240M6B1LU&Z-N<1/<UF?@Y.SCNQA9$>ZMCVMPV'
M >.1^X+$HWOB;!,&@1U,;.'O7;/Z"!\BR9FO+0Z/^<8=IN>!.#N^500O4WG&
M0C<'/) ^3]V?6K^,$'LW+%II&.>>K<"UXVP.8/,?QVK,Y(F!$10D1$0%':A^
MT=P'_P";R?J%2*CM0C-DN'Y-)^J5->ZU/O0K;/M51?W#/U0K5&T/JW,WEE.2
M&]Q.-WJ&0KUL/_A-%_<,_5"N4\0@A<&D\2<GF2<J95MWE@WV78C: T.(<'EF
M<;36^<[U8'Z%E0/!PW!P[>"HVM?)/+((FAT<L;J8/)P-MW[@1@^/<LJGFZV)
ML@!:<X+3R(."/:"H5AAV<RQU%7;*EF!%F2%XWAT;G''K!R/8K=='L5E#UH^M
M-G =CX3@6M/AEP]H5+O5OH[I!5M $#V=3)OWYSD?O\=XXX6360^41N8Y[F.R
M'![>+7 Y#AX$ J<^3X,:"$.O-P.YNRZ.#QPT.R>_ZYCU!1NO&TU%8JB>K>W9
MB:2T._XA<"TL\7 D>O/)93*UK[E3F3+*J=ABJ8@TX$C=[7^! =O_ +*@^EVF
MG?8;95-:YU/2S]9. ,X:6D!Q'8"?E4QS9%IQ67-*)KV4<+9,[88 <JZ\ L<#
MPQO56D.:"T@@[P1S0@.:0>!W%=+C>M(U#8JJ>)P\Z5HV3X9W*:K).*UVT1NA
MO4;6;QAWLP5-5CN*UB,R]#H8S58HI&"O;UG$@AO<5E5)SE14#'2UL8;[UP<3
MV *3G.]6MW>W2,->:67+45)3N>'L=41Q.'XH.\?(5U9:51V9TVF*J\4< ?46
M:X=>'L&#)$0U\C">>R2?E6Y0RLFACEB.U'(T/:>T$9"YYMF7S6K&+VGUF7M3
M]("*6(.X[(4;;J43$O?Z#3P[2IA87GPOI5QRT'I?IF.M5NJ\?78JGJL_BO:<
MCVM"T733WLOE%U<CH]J0-<0<9!.\>M;GTP5AZNUT &YSW5+C_9&R!_U%:CI*
MF%5J&CC/)VWCM+02/EPNC1^YRPUOONV4./)(L?!5YS0X8< 1V$+Q!'U4+&?!
M&%<7)/=UQV05SBB$[XPT%CFX<WEOXA6NCUK38JFFD>"+;4RT^T>(C:<MS_A(
M'J63=(RVI+CP< 05K\T\5EOU-7DEE+7!U'6M;_Q 6$L=CX0(QZUM'W>&,3ML
MW;3[7P65LFP6"5[I(V'WC'.+FCV']W)15]9UM1%#)G#V;,'8)'/#7.\6M=D>
M)4Q0NE;:Z2&H:!*R-H?CX6-ZC:[ZY?K<)#B"!S7'O+RX#V.8SUN643RV\-@J
MF_669QE1]MMY%WJJV8M>7-:R+M8P#>/6XD^Q9]7GKSGLW*D3RQCF@#SN:C*4
M;?)732T,$1Q+),'-:#CS6@DN/<-WZ.:FJ4XVARXJ#IPQ]3#4M&T^:=Y8[MB:
MS9SGLVMX_M=ZFX'!CM_/<B(85 X,JQ42$[<^VQY_&#L!OL&[UK.J07-+HVDN
M:X.:!QW'YLJQ1P>4VB3) =.7/!/O23N]F KU-,)F;6"UP.'-/(H+D3VNF+V'
M+)0'-/AN(_0LL;PL2* !X+7N #B[9W8!/%98W#"A, 1!P1$M)UO3-J]7Z4BD
M<]K3Y626'!_FPIZDI8:2+JJ>,,9G)QO)/:3Q)[RHC57W;:3_ /UO]D%.J8!$
M1 6LWXN-WQ)G#(1U8/>3M'VAOL"S=05KHV-I('%LLHVGN:<%C/G/ >L\EK4]
M$UP:ZF=U$S#EKF\/!PY@^U7I'EEJ6C[K*51E6*6<R'JYF]5.WTF9R".UIYC^
M"M;DD\N8ZHKG;3,D]6\^9$ 2,8X9',G?G/+<MJQES6G;W2]?"T4TM$]_503@
MB-Y&6QGCLN_%[NS([%'1T-?6S,I(J=HE<YI<X2!S0 0<C&_&[B0,>.XS>DH7
MO9;8R#Z;I@'>]BRX@>QS6X[UO444<+2V&-D;3O(8T ?(J3>:\0UKI1?F4)]+
M%((XF-DD:V, ;.RUPR!Q&T#LY[E+4-'#11%E.TC)RYSCESCVDK(199=$1$"M
M5-/#4Q&.HC;(S.<.' ]H[#WJZBA+ I[10PRLD$+GN:<MZR1SP#V@.)&>]:1?
M6RPV^>%Y>'1R 5&,AVP79+O C?GLRNC+$K;?35NR9V>>WT7M):YOK'Z."M6V
M)4O3=&(<MHGQFOI!;S&^5CPTMBP0(SZ6<<!C>.\!3TLAJ7]3#O9[YW$$?O'Z
M?#*V46"GC8[,D\S0"1"2UK7'L.R ?E6E75[S'21AY;%4;3I2WS2YX PS=P'I
M;NQF.&Y:[M\\.?9[*.4TR,1L#6@@#MY]ZJM>L[V4=P=#%LL@?&7R,&X1D$8=
MW9SCOP.PK8G1AC0ZK8[SQF.ESLOD'PGGWK/E/R&;>[PBGO\ *[;9HX:N.KE?
ML01[36D DRN(P6M X@<2>1 [\;#07*GK7N9$7LE:,ED@P<=H[0M8.TYYDE(,
MF WS1AK6C@UHY =GM3+VO9+"X-FC.TQQY'L/<>!\52:YY:UO%>([-T16*&I9
M64D4\8(#QDM/%IX$'O!W*^LFZQ64L57 Z&=NTP[]QP0>1!Y%:W7T,]!DOS-3
M\IFC>W^V!P\1N\%M:*8F85M6+=VCNF:& L(D+O1:TYVO#YU$.C<RZ:5?*09Y
MKO')(1VF*3 \ ,#U+I+*:G8][V01->\8<X, +O%:7J&UNH+YI0Q2!],;O&&M
M</.;]:EW9YCY?%6F^5(T\=G3$1%FU$1$!$1 1$0$1$!$1 1$0$1$!$1!1P#F
MD. (/$%0-QTE:JPN='":24[]NG.R,][?1/L4^BF)F.R)B)XESNMT?<Z3+J.2
M*LC[/YM_L.X^T*"J#4T$H\L@EIG [NN86CU'@?45V%4<UKVEK@' \01E7C4G
MSRSG2C_K.'('5CYCEY!8>S@LZGJ\>;+PQN("WJJTS9ZEQ=);X6N/%T68S[6X
M4=+HF@=NAJJV$=@D#OU@4FU9\8*UO7O.4?IM\,]=)(V5NTQFRUG-V>)\-RV5
M00T,R-X?#=:IC@<@[#,CV *<AH:JF@:U\_E9'%SFACC^XJMHK_U6K-O^T*HO
M'6MVMEV6/^"\8*]JJXB(@JJ+P)6EQ:S+W?!8,G_LK\=+-+OD/5,[ <N/KX!3
MA&5H%SWF.%NV_GV-\2LVEI6PY<X[<IXN(^0=@5V*)D+ R-H:T=B]H8$1%"1$
M1 1$0$1$!$1 1$00Q^[)OY ?V@4RH8_=DW\@/[0*95K>%[^/P$1%505'>B>Y
M57F3T'>""A.6 ]JCYG]5)4.=G:V!LXYCN[\GY0I%V]BC:AAGKHHQN:QNVX]O
MG# ]K5,(9$,9BHHX\ %K0#A85L.W+/.1NF>0,_!;N'R@GUK,N,_4TSWM <YH
MR!W\E&V^$TYJH=LN#) -_P (M!<1V9))1#S4Q1,U#1N< UW42!I[3EN[]Z]U
M$?UUP(&_EVJUJ2F%1:#4ASFU%)F:.1O%A''U$;CXK.G?')$QS' G<01V*<IA
MI_4]19V5D6]E'-)+&#[Z-KGM#?\ (<#U+8-G>L%\8;;*ZF:"[R.=DPCQEQAV
MFOW#F/2 _LX4W1N9+'LC9<'C::X;P0K6ME$.?ZB?+!;=05S!BJA<X 8]!H #
M'>SSO7W+0J:)L4(#27$^<YQ.2XGB25V6IIF>ZT396MDAK6FDF8X9#L->YI_7
M!_M#L7+=1VF.PZDJ[932.?3,8R6(..3&'9\PGNQN[EK2V8PPU8\L%1M?$\2&
M0G+3\BDECUQ IG9YXPM*SB6$]E^Q7:2%T=),X&G)PTGBS_ME2%QSYRU1;)1Q
MO-KB=(\O+AG)Y#D%T:<XER:]<QE!SP=?4LB)V0]V"5EN@93]6UK?K;.2NPTS
MI;A'@;FG:)[ %DUD0\XG@N^MO#P=:D]X;5HJ<2Z9MY8<.B9U;L<G-)'\>*B^
MFS2+M3V.*_6N+;N= PMJ(F#+I8N.[O;O([B>Q>^CV.1M%738(IIILQ9]]@8<
MX=Q/Z%NENJG4E0'@G8.YP[0O)K>='4W4\/K-&\VI$VC&8?'!68+Q<6V\T+:V
M<4A_X6V=E=]Z2NB"&^/EN^DC%!62>?+2..S'*>UA]Z3V</!<!O-HN%EJW4MV
MHYZ2H'O)6%N?#M'>%[>EU5->,UGGT6MI1/WHRPJ<QMJ8G3C:B#VEX[6YWKJ?
M2GK'3E5HRWV31S'4T3WMFJV,&SMN:, .(XX[/#L7)W<%:?S5;Q$]_"+:6Z\7
MSV_O_P!^KZ'Z"QI2Z:&?3ZGDI):BE?(U@J7 .CC=O+6GCC.3CO[UQ5^G3J'7
M\]FTK'UT4U06PGWK&9WN/8T<2L[1/1YJ/5TS?<RDDAHG;GUD^61 >/%W@,KZ
M<Z/-"6G0EM=#;QU]PF %16/&'/[@/>M'(>W*X-;7KI9Q.9GQZ&EH36\WF?7_
M 'Y]<=H8-7IR.R:.MVG+#+L/MY;,'D;II1DG;'8XDGNW=BENCFLBN-GFG9%L
M/,[G/!XM)QN]7#_"JW",4CWOFD^M@%Y>[D.9*\]&L 9I%U7L;'EL\M0 ..'/
M.,^H!>;:?=;5F9MRS=2;4M!/3QNS)4GJ(QVEV[V 9)[@5D62-IT[1",!K1$W
M([P-_P JP=3N,%N%1&[9F8XM81^,US3^G/J4]'&RFH8H&M  8&@#@ %3/"_E
M 7H.?-1TT(!J)C(T;\;+#&X.)[AEOB<+8)]F"E<1A@:WV!6H::.2J9(YC3(T
M%H=S .,CY L6_3R-@J(Z=NU*Z&1P)X,:T><X^T8"9.R]I\AU!2%N1B, @\<@
M8(]H*OW*5L-32N:TE[7ESL<FX()]I"\T,#*>&*&+.PP  \2>_P#>KE3#UM>8
MMHCKH"TGX.RX$'VN*@9<C<'(X%6(SFWLC/$NZMWCG>?T^U(97O:YLN!(QVRX
M#AGN[E0CJWN:]V(9=^3[Q_(HEFM&[*],W9'+BK5,_;C:[M&]76\5 ]+5^D&T
MZ@N]ECI]*7EMGKFS![IW-SM,P06\#S(/J6T*B#YAT_/TE7K7MXTK#K9\=5;6
MN<^=[ 6/V2T;ALY]\%-](>J=56W4FF]$NU+!:I'TD;JV]2- $LAVLNR?1'FX
MW8R3O(5_HT/_ /DCKC?_ ,.7]>-2/3'J+3,6JZ2RZ_TP^6U/CVJ>[M>[:;D;
MPW9 =@'<0">1PH626@J7I"LNK(J2ZW*+4NEIV$^Z.VP.B=LD@C?M'> "-XP<
M@J.Z,]:UU3TG:[M^H;TWW/HZA[*2*ID8QL8$SVX;G'(!:!H.2AH^F>TTO19<
M+G56.0!U<R8.$;6^=MY! R ,8)&=K@2LG16B++KCI:Z0J>_,FDCI:V62,0RE
MA!,[P<X\%(WFVZON5;]$34V6FNQGL I-MD$;FNBVNI:XD$<]HGFM8TW5:[UM
MKC5ENMFLJBV06RJ>&-,(D&R9'M#1PQ@-5O1&GK?I7Z)>6SVALC*."B<YC9'[
M;LN@:X[_ !)4+H[0\.M]>=(,#KC6T-12U$KX'4TFR'/=+(!M[MXR!PQS4#H_
M0OK._7#56HM*:GJHKC4VLNV*V-H;M;+]AP.  >((W9X@Y6_:VUG9=&4,-3?*
MA[#._8AAB87RRN[&M'Z>&\=JY9]#"Z@H&ZALE31MI=3TD^*MSG$NEC#B!C/P
M79!QVM/-2/3EJNKL^I--6R*2AM=-59D=>JJD;4&F(=C# 00#N!/B.&%*,<MS
MT;TBV+5EQJ+=0&LIKE W;=25T!AE+>T \>([]ZA[[TT:0LUVJ+?+/654M,XL
MGDI*?K(XW X(+LC@>S*Y7H.L97?1#4DE/?ZB_!U+*SW0FC$76D0O]$  ;(.X
M'N*KT3ZHT_H:QZRLVMHS'<C.X24LD)<ZJ;L%O5@XQO.>.!YV4,-TZ9NDVA@T
M+3NTS=*EM;<VMFI*JE! #&R /!=[T\1CBKE!KVVZGZ);F'7:[4-7;J&G%=<(
MH3UK'D@%S,.&T26D'>-Q43JIE'=OH=:ZITYIR:ST3YFU#*1WG.V!*W:E\#C/
M@,\%XK-7V74'T/MUM]JJ3)66VU4S*J,QN;L':8WB1@[VG@2@W73.MK+9[-HV
MV5ERN5;)>(@VCKJJ$YG.UCZX23AV2!Q/$+8KUK&U6C4]IT_5.G?=+G_,1PQ%
MX SC+CR&X^PKDMYT\^]?0W:>KJ($7"STK*^![>(#2=O'^'?XM"]]#]35ZUUI
M?ND"NIG2>1TK:.C@!_X@C&UL]^X_G4,-QN?3-I.AK:JG:^XUD=*_8GJJ2E,D
M$3LXWOSV]GJRM>Z<ND>"CT=1QZ9N=3%7W%L=52U5,"&F':(=Y_(]W%<VJ-8R
M7W1%^EN&I:>SS2N>QFG+;;F1]:<#>]V,XXY.<@-/@I^X4DU9]"E1&GC=*89N
MM?LC):P5#\GP&4,-NJM>VG4_1572-O-YM<M!%2,K*Z" B82.('F8<-K)!R<C
M<5M,FMK%I'0MAK;O=*FIBJ*6(4\CXRZHJO,!VBW)W[P3D[L\5SO6&L+)J7H%
MK*:SU)DJ*"GH8ZECHW,+';31Q(P=[3PRH;5CA:JGHAO]S8\V.FH*9DLFR7-8
MX8<<CMP0>_9/8AAV31O21I[5MPEM]MEJ8+C&W:-+60F*1S>9 R<_I4-7=-6C
MZ*2MBDFKW5%),Z!\+*8EQ+207#?C9!'$D<0M-CNE%K'Z(RQW#2TGE=)14H\J
MJHV$-W"3.21^,UO_ ,+*^AWAADUCT@/?'&]WEH9D@'S3++D>!P/8AB'5M(:H
MM6KK.+E8YS-3[9C<'-V7QO&"6N'(X(/K4TN&_0M8;1:KC9@,;6LPT<!N</W!
M=R165%0JJH4$K1?8S/XYHE%]C,_CFBA>%Y$1 5!Z1/<JJ@])R"T_?G*LUDK8
M*5[\9#&EY [@KT@PL&8&I>^+<(6N >>;N!QX;PI0PJJD>R8]9,[;D8Z9^QP#
MF8+2!V#AWK*B>YT<<GHN+0XXY'"]U4#Y(Q+"1UT9RT'@1S:>XC]QY+!MLF8^
MJ&2QC&.83Q#3G#3WC9(1$,2ZL=;;E'<''$$SFLJ'YW-&-D$]V=G?R\"5F5<+
M*JEDA<?->W<X<CQ#AW@X(\%?NP+Z2GIF;^OD:P./+?D_(#\BL>15M#F""F%3
M3M)ZIS) TM;G<T@]G#(Y<D%JC@K9;E+-4&GQ)&UKS'GSG-SAV"-V03NR> [%
M74[@ZAG:XD18:R5PXB,N >1W[)*S+34==US3&^-\;MB1C\9:X;\;MQW$'(4%
MK&YT]%0O?6'8I9,F4CB6#BUHYN=N:/$GDD=R>(0W3-<*=[+5:(9 ZJ$XJ)(V
M^\C:UP!/9DG<N?*L]3-<+A6W&L;LU%9*97-SG8;P:S/< %1=-8VQARWMNG(=
MX/[E"/;LO<TG@<*;4+*"V1X=QSO6M&5D_I*BZPSU;B?,^MM':3Q_<IF.A945
M#A)O8T9([4T=1RQ6>264$,F?M,!'+&,^O]RNU4KZ:4R1\>!!YA:4GG$.;6KQ
MF7BJC !   ' *UI"D947:OK90'.IW"GAS[W=EQ\3D!7IY&RQ"1GHN&5@V.XQ
M6F\5$=4X,I*TM<V0^BR0#&">0(Y]RTUHF=/AS]--8U^?R;LJM):X%IP0<@JB
M+A>JV.-VU&UW: 5H/2_6L;;:"W@@S33B<CL8P$9]I'L*WVF<)(HW#<"!ZEPJ
MO=<-1ZKG8QAEN%14.IXHB<"-K20!W  9/K*STJ^]F?#?4MBN(\HF0RD%L#"Y
MPP7'&0P$@ GUD#UKZ%ML1AH88W8R&C@,!:Y5: 99>C^\PT\CJNZ31LFDEV<9
M,;@\-:.0\T^U9UJO0J;?33L:V2*6-KVD'?@C@K7M[3LI2OL^Z>16::H94,VF
M'>.(/$*\L.SHB<M3UA2>64%R@=N+HBYA[' 9:?: LW1=<:N>CKI,.EJHL2'G
MOBB=GP!R/\06=>8FNB:\M!]Z[O!6J:;F?I_4E%:\EU#4/>ZD+M^QD#;B)\6L
M(/8,+7O5C'NVPZ1.PLD.>#MX*QIJA['-AIV.EJ'#:8P<!^,X\A_ RLZK=EC,
M#<=^5C61G6FIK"<]8_JF$<-AA(&/$EQSX+.&RQ2P=35B':VA2P-BS\(N.2?D
M'RK,J!*ZBJ!%D$L(&.W"PV.,MXFE:?-,6'#EN<0W]#SZPI%\C*:E,C]H@XW
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MB]_V8WCM4,UI;,RJ ^L23R1-'9G9&?6YA]JA5F7"*&:TSLK&MZ@L.<]F./\
M'8HJW3OIJ>&GN4NS.8V/8^4AID:6@G?S(.0>? \U+UD!J[9/3QN&VYI&_D5E
M4<T-SH62/B:>3XWC.P\<6D'F"G@85$^.5X<V1KV<BTY!*\W>>*!DDDYS&UN'
M#&<YW8 YDYQCGE>((H1J&K=2L8R*.)C9M@  R;SP'/9(SXA:QTC7A]NM4;:;
M9\MJIVB NX-V3M%Q'<!\H2(S."9Q&7*K8/Y)Z.RTO<6M^"-HX"RE;IXA# R,
M$D-&,GB>]9-)325=0R&!NT]W#YUU.)6S0F6Z32\&PQ[/B3E95:<94TVWQ4$)
M:P9D(&V_FX_,H2=CIZ@1-XN/'L':MJ2]7H:XAETK&1T498,%P#B>TJY8K0=1
MZCBMKGR,HXV&>K=&<'9SAK,\MH_("K%5(]A@I*.)T]5*1%!"WB]WS#B2NK:'
MTRS3EM<V1XGN%01)4S_"=V#L:. "RU;[8^+IZG6VQ[.O>4#K.N@M%KCTGIJF
MB;554)86M'FTT)W.D=WG)QVGY<2D@92TL-/'G8B8V-N>P#"L7*(P])%^Z[TY
MZ>GDA)YL +3C_$%F+*L8AXUYS++M]3U#]EW\VX[^[O4TM:6QQ@AC1Q. %34C
MRTTIXPY[TPQLZBSR[NM$SV?X2W)^4!:3IVI?2WRADB+0\RA@VC@'.[]ZD^D*
M_1WB][-.\>0T(=&Q_)[R?.<.[< /!+'IZ>)MFO5>V2*":X-AAC>W!+=EQVSG
MM( 'AWK>GNTQ+"_O7G#LL;MJ-KNT KTO+"US1L$%N-V%Z7([%JIC9) \2#(
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MKX/?ZD1!1DB&>)I/5BHV01V'!/RDA9<E+B3;@<(S@-+2W+3CAN[4\F;%1=3
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MZ5M/_@*U?%(_F5VFT]9J6=D]+:+=#,PY;)'3,:YI[B!D()-$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!1[&O:6O:'-/(C*QS0T_O8]C^P2W]"R
M40PQ?((OA2_G"JBAIQQC#O[9+OTK)1,HQ"C6M8W#0&CL 541$B(B B(@(B("
M(B B(@(B("(B"&/W9-_(#^T"F5#'[LF_D!_:!3*M;PO?Q^ B(JJ"H[@JJC_1
M[T%'G=A6FX#LDJZ\9"Q*B3JH]H-VG$AK1G&23A$,:IB\MG?3.($(:'R#F[).
M!W#=O6%0AS)87;;G&>)SGEQSM%C@UKO8?D"D((BUSG2.!DD(VB.  X =P4=<
M(WT4H,9&R-N2+/#.,NC/<[!(/(A6CT0S9(/*H9*=V^.1I:X9QD'<H:T2&EJ*
MBVU)#98R'Q#.Y\9&,M[-X/F\L]F%.TV'O8[> 1D*.FHGW*Y5CXW-CFI1&V(D
M9&WO<<]Q! ]9402K/%**F&JI'QMJ(@YOUP$M>QV,M.-_$ Y[E<L-))1T4;)W
ML<(@6M+00-G)P-_8,#U*Q435E+"^:JMTK8HP3(^.1KPT#B0,@D>K/<I1LN*,
M.P.&!WH(I\L3+[1RU3PRG9'-*'$X#7@#>?!A?\JY%?[E%>=3W6YTVT::=[&P
MN<,;36-#=K'82"5/=)%X?)6.LU.-EW5$2.^"QX&3ZQYH\7=RU1H#0 !@ 8 6
MVG7'+#5MGA58EQ;F$.YM*RUC5["Z#+=^R<K:O=A/9'1,,LK(V\7.#1XE;S-1
MLI:9L,>=A@P,K5+#;YKE<8HH0[9:0Y[Q[QH/%;[<H_26L3B<,=2N:L(4D<%.
M!&-[@"YW:H6YP"HFI*1Q(94U#(7D?!)W_H4G3U)VW4\AR,98>SN4;=V/<P.A
M<&SQ/$L3CR<TY"Z(BTUF(>;:U*WK:W:);ZQC8V-9&T-8T8:T#  [%51MAO$%
MWIB^,&.>/ FA=Z3#^\=A4DO/QA[<3$QF$O9GNZAPR?-=N5G5]QH:+3]347BD
M@K:=@ ;!,T.$CB<!HR#^CM7NSO\ -DC[#M+G73!/.+S00R;1I&TYDC:.#I-H
M@^O&S[5E$9OAONVTRQ1](%PGB8_1)\JF>&,CIW8VG'D,.:%N>CM/Z0EM\%RM
M>F**G+\[!FC;(\8..)SV+-Z.=!16>."Z74&6[/9D,)\VG#AZ('-V-Q/L47IF
M6:T&X69Q EH*A[=EPXQN)<QP[B#\BTMJ3;,5F?U1$S7FS=W2N(P-S1N "\+"
MHZX3.V) &OY8X%9JYYB8[M8F)YA#WJ%LKPV5NU%(PL<#S',?*L/H[!;H^ECS
MGJ)98#OXELCM_LPIJY,VZ1^[>WS@M/AD]P;_  5,1V;?<91#4Q^]9*?0E Y9
M.X^(6D>]5G]V[8]0,#F0ES@-ELKAD9V7"-S@[U;&/!Q4^<STL4N-D[.2T\0H
M^EHV7&ON4%07>;3"*/'!C9 X.=XY;CP'>5EV:J=/:897@=9L N X9Y_+E4\+
MQW6Y)&0Q/DD=LL8-HGL"QIF3&GJ*J2,Q;;!3PM>/.:'N <]PY<MW=OXKW.SR
MFJIJ3/FO<9) ..PW?["[9'K*RK\\>02QN!(>UQ.#@[N&.\DM&>]()>HF!C6L
M9G#0 %[ILMNK^M])T(V2>YQR/E:J4S''9;([+P!M$<RJQN\HN;.K!V8 =MW>
M1@-\<'/L[5$)*CS*AU1'NA)#9>S/#:]6X'_LLAA[%<I/L<-/%I+3[5;J*>&.
M"1S(F,>!YI:W!SR^52B%YOHJK>*\\  O4? GO4)>E155$&/%14L55)4Q4T#*
MB3<^5L8#W>)QDI74=+70&"NIH:F$[S',P/:?45D*BD8ENMU#;8G1VZCIJ2-Q
MR6P1-8"?4%Z@HJ6GGFFIZ:"*:8YDD9&&N>>UQ R>/-9"(,<45**LU8IH!5D;
M)FZL;9'9M8SA4IZ.EII99:>F@ADE.9'QQAI>?QB./'FLA408[**ECJWU4=+
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M(ZIFT!G&0&XXGEP6Z:ATS4G2&AZ.^:"JKS%16J&&6IM]5U==13!@!:&C&6Y
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MP=_,>(4]T;5(JM#69_6-D<VG;&X@YP6[B#WC"UW5^FI+#%77W3\O5PLS45=
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M-E>ITO\ QP^@Z",:$?FME2ND]U[#AN<VGJ7-/81!(0?:%%%2ND_MR?R6J_\
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M7 "].I)/*\XV_P":W;7^+;^5)ZJ<SQZ_)G-WSQ)IJ]QL:]]HKVL=-Y.TN@<
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M2.PB(N9(B(@AC]V3?R _M IE0Q^[)OY ?V@4RK6\+W\?@(B*J@B(@(B("(B
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M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B L&_\
MVBN7Y-)^J5G+!O\ ]HKE^32?JE37O"U/O0]V?[4T7]PS]4++6)9_M31?W#/U
M0LM)[HMWD1$4($1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M 'L6-1:5OUPI(ZJALU?44THVF2Q0.<UP[00-ZGVE/6%)M'J@2O)6R'1.I_\
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M#Z@6L/AVOXP[_2J?4!UC\.U_&'?Z5]8(GVAJ_!#Y-^H!K'X=K^,._P!*I_\
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ME:KT*?T6Z=_)_P#W%;5>?M17?W#_ -4K5>A3^BW3OY/_ .XH-V1$0$1$!$1
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M$=ITI=Q<F;)J:JHC>YV>8;G>[)[ ,!;KJ:,-MED@N^EIKG0-I6!\\&3/ [9
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MKZFFEAT.(H97F*ZTSG[+"=@!IR3V!=!7-JUKB)KPM B(L4B(B B(@(B("(B
MB(@(B("(B B(@Y;JZ5U9TIQVNLU'<+-;1:!4#R:L$ =+UI;Q<"#N]>Y2U)/;
MM)6>Z7B*_P!WU%! QAFCDK&5)B;M>D  ,;B2>X+7M<^Y-/TLQ56I;3)7VPV<
M1L_D+JEHEZXD;@TX.,^WO6S:-GTG=(KE;]/V<T4<T6*EIMSJ9LC3EN"2T!W$
M[N]=]XQIUG$XQ&?3]5([RFM0:GHK-9Z2X.;)4LK)8H::.#!=,Z3T0W) X;_
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ME;Y;;Y)(.KFGBB>"USF<G.;M#'@HNNI+M:M*4.MJ6AJ'WR>KJ*F>G:TF015
M+6MQC/F[,1X<BMXZ>DYC//,=_/C]D;I="=K^V"QRW,05;X_+74%-$Q@=)5R@
MX^M@'>"0=YQP*O6/5[;A=GVFXVRMM%S,)GBAJMDB5@W$M<TD'',<5I&J-*55
MIT7HSR=M<66:9LE;Y#_/M#VG;D9N.2'$GAP)69I6"VW365'64-1J>Z>00REM
M;7'9@B+V[)8-IK2YQ'(<,).EI[)M'Q_C]3,Y1%+>+D>BO3-4:^J-3+?6Q22F
M4[3V>42#9)SDC  PMUBN]OMVI]85'6726:@IHIZB%\@="&[!(ZIO(D#?GFM$
MI*&K'1-I>$TE0)F7]KW1]4[::WRF0Y(QD#O4Y<J2I=?^DYS:>8MFMD38B&'#
MSU3]S>T^"TO6LS:/C/\ _J$0DF]*-+Y#3722QWB.Q3;(-Q?$WJV;6[)&=K9!
MW;6,=F5.ZGU?3V6IH:*FHZJZ7*M:7P4M( 7%@XO)) #>\K6KO2SN^A_%,VGE
M-1[BQ-ZH,.WM!C=VSQRL:LDFTUJW3VH:VCJYK9)9FV^:2"%TCJ:3+7 N:!D
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M%G_M4REN)E-XQ:8$1%"HB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MYK7##@".PA7KK[9CCC&$;7$*ZGI:O16O[I05EVN3JFG9"ZKJX&QLJ-C@8]D
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M>LWEAP/-SD# Y%7.CNYT]'I&\:9J^MAO4!K7OIWQ.!V2YQ!!Q@@@A=:#6MX
M#=C<$V1G.!GMPKVZB+9S'I\D17#B%N<ZSV/HNU!603/ME!321519&7& R1[+
M7D#?C(XJ8I+_ $.H.FFRU%K;(^FCME0P5+HG,;*<@D-R!D#/'M*W?5MAK+L*
M&>TW22VUU%(7QD-VXI 1@MD9D!PQ[.2P=/Z5KX=2&_:AN45=7LIS2T\=/!U,
M4+"<NP,DDD@;\K7VU+5FT]\3'ZY^'Q]48EI^B]2T.E++>+!>&U,=XAK*@QTK
M8'N?4![B6&/ W@Y6NTE%5P]''1[<^LK*6EMU1*:J:GCVY(&O+FB39(.X<]W
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MC_TVM!N['?5JL#PT[/N54!S@-WIMW$K?DP,YP,]J+"]]T1\(PF(P(B*B1$1
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M/2/G^YU^H?O"U_''_P"VG7ZA^\+7\<?_ +:(FZ/0WQZ1\_W.OU#]X6OXX_\
MVTZ_4/WA:_CC_P#;1$W? WQZ1\_W.OU#]X6OXX__ &TZ_4/WA;/CC_\ ;1$W
M? WQZ1\_W.OU#]X6OXX__;3K]0_>%K^./_VT1-WP-\>D?/\ <Z_4/WA:_CC_
M /;3K]0_>%K^./\ ]M$3='H;X](^?[G7ZA^\+9\<?_MIU^H?O"V?''_[:(FZ
M/0WQZ1\_W.OU#]X6OXX__;3K]0_>%L^./_VT1-WP-\>D?/\ <Z_4/WA:_CC_
M /;3K]0_>%K^./\ ]M$3='H;X](^?[G7ZA^\+7\<?_MIU^H?O"U_''_[:(F[
MX&^/2/G^YU^H?O"U_''_ .VG7ZA^\+7\<?\ [:(F[X&^/2/G^YU^H?O"U_''
M_P"VG7ZA^\+7\<?_ +:(F[X&^/2/G^YU^H?O"U_''_[:=?J'[PM?QQ_^VB)N
M^!OCTCY_N=?J'[PM?QQ_^VG7ZA^\+7\<?_MHB;O@;X](^?[G7ZA^\+9\<?\
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(=1$2(B(/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g762905g73h34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g73h34.jpg
M_]C_X  02D9)1@ ! 0$!P@'"  #_[1VT4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 <(    !  $!P@    $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              8%   *7P         !
M                          $             "E\   8%
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   8%     %)G:'1L
M;VYG   *7P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   &!0    !29VAT;&]N9P  "E\    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     $X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M      $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%1
M81,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"
MHW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W
M1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%
M,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55
M-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=W
MAY>GM\?_V@ , P$  A$#$0 _ /1O\N3_ -IO/Z<'^JI?Y7+1_,-<"=WTB"/;
MMV\.;_A%=47D@0.28"2FI/6 \2*'-!$QN!(]N[G^VIXO[1W_ *T:MD'Z$[B?
MS?Y/T?I_RU'[=6,W["[U1<=6PT%I9MW>LY[6[:Z][?1_2?X5&-E0N%!O N+=
MXJENXM!V[]D;MB-']J@0;HW29)0&X.VDR")![Z*:"E))*O=D&K4AQ:7;!L8Z
MPC^4[TYVM24!;825)G4&N!]MS8$D''M^[Z"0ZA7.W],#KI]GMX!VS_-H\)3P
MGLW4E3=GUM )]77C]7M\OY'\M$Q\C[1NV;VEL2+*G,Y$^WU-N[^RE15PGLV$
ME#;9^\/N_P!J1+VD2003!T@ZH(9%#M]3TW^G'J0=F[B?S=R(56S#FBK]2;4Z
MV=1>YS6[8.OZ)KW;MVU$(0_Y6B2: [3V@&.?=[Y_=_DJ(/5(._[/,:%NX:[A
M,AW_  >]4+>M9=-MM-U_3&75$34;[ 0(.X/?Z?\ /.=L_1;/8Q"LZM=?C6UV
M7=*L861>/M%FSTW'T7[OT?MWN?Z7\A2B,NP17BZ#G]1!(-F-IWD@G]X;2[VJ
M=+LC7UG5EP(CTC,?U]5S-M?266O975T@U^[WF^PM:#]#=4&_SKF;_P":_P"W
M*_T:V.BUT,KN=0W%#'/:-V)8^UI+1+FV>L/T;V^IN]-G^D3I1H?V(?_0]54+
M-(<> 9/Y%7NIZDZYSJ<FNNHCVUNI+B#$:V>LS\_W?S:>JKJ J8+<BMUH'Z1S
M:B&ETGZ#?5=M;_:1K2[!\%(BZX9=F0,)Y>UHI:\6,AS)?9N:POV[?H_\)^D5
M;.PVYN5BY>5TZRR[ <+,9[+FM(>8W_0LKWL_XSV*Y8VZAHL>:[& @.:&;3!.
MV6NW.^C*M>G7^Z/N"(E6H7 @; ?B@%UI:VQU?IN&CZR02-Q:/I,):K*%>W]$
M0T=QH/B$5 H+"RS8 8+B3#6CDE5LG[,:9S(:T6$B7EHF#^<S;^:K%OTZOZ__
M 'UZ!E4/M9L!V>_=N@D$1MV_HWU.[HBNJO)K"KI-A#6[7N)V@"QY,F&0$]S.
MF5V%ES2VR!INLT!&WVN;[6^WZ28=/NGW6RUQ][=EFK9W;0?M!V(F3A.NR#<'
M[00/8:W'CQVV,W)WIOYBKBEW*\X/3W"0*#8"&ASW&0(_KJVRQSPUS6@M=!#@
M>Q[J-+K&UAMKC8_67AFWX>W53]0?NN^Y,*M3NTNK9K\05N9O$;K'-8QKS:&#
M7#I:^RIWVJ[=ZF/Z7^@4<"ZQ];F&BQEC367WV0&W6.:WU7U[?TC=FW;9ZF-C
M?I/\"KQ+'%I<PDM,M);P8VRW^RY,UK0&UU,V,:9@#:!^=]'^4Y&Q54KILHF_
M]UG^<?\ R"37[V;HCD$'L08<$0H-?T'?UW_]44$+.JJ))+&DDR26@F?'A5\F
M_'Q0V:PY[I#&-:T&/I/U(]K57OS\VO,=7$T-<-1BY+CL$;P+:@ZE]CO\&]!Z
MA;3F"K:,BAX(:UUF-:6'U'&L,?[?9[V?3_<_XQ.@8V.+9;*ZTW3XV3C7O+#2
MRJQHW $,((D<.VM_DH\ 0&@-;.@: !S_ "5EOZ/FLL-IR:B "7%S7".[C^>W
MLK/3Z/39ZS;6W5WM8ZLUZL+?I-L8[\[U&O4LHQWC+Z+(F6Q'U?_1]55?*NR:
M@#30+@1K[PR#+0WZ:L(=S2ZN&B2"TQXP0[^"04U<V^PXK6;&C*LVD8^XD^TA
MS_=779_G^GL1#GU-(:YCV.=HP/:6[CX-<[V[OY"SLV[;BOO-WI>O=Z5\M+7.
MJ-GV;TZ+/T;JGU5>_P#K^I_75:KJO0\6J^C*Z@<G'> RCU'OM>6UCTW_ )KG
M.M;D^I^G_G/^V4\0)%@7X ()UJFSU;K%56,]V16W[,W5X,N+B#-=;-C?:][_
M ,_Z"YO*Z_UE^17?]L-0DN;76T!@$[?<S;NL_P"NK1ZO5]HZ#]J>U[]XK<VL
M ASFN+&VV65M]_LW^]853*KZ38&EQ),D.B#W:6;7;5-BC&KKP9\8 AQGO7@]
M1T/ZR-Z@&8^1_2J'RYQ 9OJVEHRW5[O9^D>RBWT_4_3?\'9^CVWYM+7BINZV
MTB16P28XW$G:QC?Z[EY]T9SZ^N8[*MX;D.%=E38<XM(=OW%[?H55^^YWL]BZ
MNOKW3,+*OQLGU*\EUQ8'&MVQT>REM=S6N9LV[?I?X1,R8ZEZ1TO1;F !L4 0
MZ)RW[YM#L:O=M:YP:YLSM_2/8^ST]SOH[UQG5_JIUN_JF;D/PAU)M]KGT7'+
M=3MK<!Z5/I?\ NDZ?U_ NLMZ=U"W'HS3:^O[+ZDE[7.=Z4-MV[_4K_Z:U,$N
M.*R27;9:''DAKBQKC_6:U-C*6,W6X6QE5UY/FMOU)ZVX$-Z(W7Z+OMYW#1_/
MNV?2=7_VS_PBWOJ=T;K'0&=1MSFG'HR[*Q@]/;:+W!XW[B'N_1-=:UU;-_\
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M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M 0 X0DE-!"(      2Y-30 J    "  ' 1(  P    $  0   1H !0    $
M  !B 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R 3(  @
M !0   "0AVD !     $   "D    T    <(    !   !P@    %!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#(T.C W.C,Q(# T.C$Y.C4S   #
MH $  P    '__P  H ( !     $   I?H , !     $   8%          8!
M P #     0 &   !&@ %     0   1X!&P %     0   28!*  #     0 "
M   " 0 $     0   2X" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!-D5X:68  $U- "H    (  <!$@ #
M     0 !   !&@ %     0   &(!&P %     0   &H!*  #     0 "   !
M,0 "    '@   '(!,@ "    %    )"':0 $     0   *0   #0   !P@
M  $   '"     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C0Z
M,#<Z,S$@,#0Z,3DZ-3,   .@ 0 #     ?__  "@ @ $     0  "E^@ P $
M     0  !@4         !@$#  ,    !  8   $:  4    !   !'@$;  4
M   !   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
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M#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L
M0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@$ P;J P$B  (1 0,1 ?_$ !T
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M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$01$0"H4E0K *"I4%
M1$1(%"E0BH4*5'6J@B(@*"I4% 4*5'4@A$R,XSQ1%$4X/84P>PHCBB 9/!3@
M]A]2H@J%)3=/84$*%.Z<<B@!/(%$0N*Y[I[#ZEQQQQCBK!"%"Y;I[#ZE"*A0
M>:Y8..Y<3S5!$QCF$Y\D1"A3YU" H4J.WN2 4*0,\E.Z>P^I5(<$4X(ZBF#V
M%!Q1201S!4*JA0IP3R4!$05"Y%I["HP>PI CJ4*<$C@"FZ>PJB%"E1@]B0CB
MBD\"H(QSX) XHB$8YJB$1$1"(BH[*5YCJ&.';@^99U5T<PK$%RU&Z-)ZBU-5
M:?VL5=49)I**,L9-$"2.C+&@X'40<'S^=;7O%4V;2];54DF6/I'R1O:>HL)!
M"US[FT]XVMZBM]8TF"HHMQV.8\F/!'>#@J-,7&IL]%J'2%W>>EIZ>5U&YWPV
M;KB0/1Q'I[%S;6#9/7NCV=,JZV5\C873.<YSBX[H)/6JSIZTW/:0^>ZWJY3T
MUL$CHX:>G..74.KAPXD$E>_0_P#J5N&/S55^U9S8SCQ"H\?G)<^??*(JMTI[
MELSNE#4TMQFK+'4R]'+#-Q+>[SXR01CEQ6<VVU<L6E*22EF>P/J6^5&XMR-U
MQZEQV[X\4:?//PMN/FN7@VMY.SNR9Y[T6?HB@]4>S!TD#'LU)<V/<T.&3D ^
MM=NSJ[7:FU+=-,7NI-8^D8'PS$<=T8Z^L$.:>/+BO%6ZXU9:[6:FJTPR&FC:
MT&5[R0,X )QZ%[]E]FK)JNKU5=IHGU5R;^3;$<AK"1]P&.K"*K%1JB>P[6[C
M)432OH'3"&5A<2UK2UN"!U8/'UK<M?60T-#/5U+]R"%AD>[L &5J%MECU!K[
M6UNEQF2$&-WQ7C<+3ZUXAJ*OU+8+7H_#V7*2?P>J?CBV./CD]_#C_-[T&0V8
MWRLO>T2Y553+*(IJ=[V1.<=UK=YH;@<N2V7JZ[ML>G:ZX..'11GH^]YX-'K(
M5$TK1Q6_:_<J.G&[#!;V1L'<&QKGM=J1<[I9=,Q2!O3RB:H). UG$ GT;Q]
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M ZNIMUTL?OHW\G8](*K6RBF@&GJVMNDL!GNLKWRM?(T%S.([>LEQ]*X[*9O
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M1;+/>[=0T_ACA^Y/+CN\1D$.(YA9C:'83?=/2MIVDU]-^7IG-X.R.;0>\?:
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M')<M7R;H(B+DV(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(B"(B"$1%8!0I4%$$1$(%"E<444*4
M51"!$0%!4J"@*.I2HZD$(B(HB(JB.M$[40"H0H@*%*A$%Q7)<58($1%50H*E
M04!0I1$0H*E04!0I4) ^>]!4%/=-L6KZ&MC$E-4,JXY&]H,@"RVS39C<K7K*
M6JO["ZWVPN%O+I YLKBXX<&@G  R<''$A;!L6@K59-5U^H*2:L=6UF_OLD>T
MQMWW!QP T'F.U6Q>W4XJ><4Z3$0Y5IW:)_!U_A1JOS-_Q'JJZ8TK1ZOVHZ@M
MUQEFBA;+43!T) .1+CK![5O71NA;7I*ON-7;)JR22NQT@G>TAN"3PP!V]:Z]
M.Z M-@U-77VBGK7UE7O[[)7M+&[[MXX :#S':ND\56+7M6>L1A(IRB):8I-/
MV_06UNDHK[2LJ[3,X&EGGY-WCY+R!P):X8(/G5D_";HIC'8J]H)B:987GL<<
M.&?/Q]2V3KG1%JUG#2LNKJF)]*YSHY:=P:X!V,@Y!&. ]2R%3IZ@K=.QV2YL
M?7T38FQ$SG+W;HP'$C'E<.868XJ-U-2>L=3P^4U86ZSZ2UEIFGGN]9136UN[
M49=4]'T;MT@YP001DC"UEL#IH)-H]^J[5&YMKBBD9$3G@UT@W!D]>&GU*S2;
M"M-NJ=]M==&0YR8M]A_YMW]BV!I?3ELTQ;_ [-3"&(NWWDDN=([M<3S*DZNG
M33M2DS.?L;;6F)F.CY]LVDZ76&U74UOK:B:GCCGJ)@Z( G(EQCCYULW3VQO3
MEIKF550ZIN+V'>:RHP& ]1+0./IX*P6'0MKL>I[A?J2:L?65N_TC)'-+&[[M
MXX  /,=95I35XJUN5)Y8*:41SF.;1OX3(#IM,MZCX0/MC6(VF[*J73>FV76R
MS54XC<WPALN#NM<.#A@#D>!\ZW!K?0]LUB^@==9JN(T1?T?@[FC>WMW.<@_%
M"L5730U='-2U,8DIYHS$]A^$TC!'J5IQ4Z=*17RSGZI.EF;3/FK&S.OL]3HB
MBJ;-!#14C6'IH@<"*0>_WB?7D]6%J2_&X[7=<34EI>V*TVYCQ%*_W@'QSWO<
M!Z!W%;/M>S2UVO3]ULU)<KJVBN6[TV9&;S<'X)W.&1P/<LQHS25LTA;I*.TB
M5S97]))+,X%[SR&< # '+@I75IIS:].<^2S6;1$3T:XV(:FJ*"KGT9?FF"JI
MWO\ !A(<$'.71?K<.W)[E9-JVT&'2=$ZCH7-EO<[/(;S$#3\-W?V#KY\N>0U
M-LZL^H+_ !7F:>NH[C'N_E*5[6[Q;[UQRT\1@#/<%XM4[*K'J2^5-UKJJXQU
M-1@O;$]@;P '#+2>I7?HWU(O;]8^)B\5Q"G[*]-4,E3XT:ON=%47.=PE@BGJ
MF%S#^<>"??=@ZOU;JCD9*QLD;VR,>,M>TY#AV@]:U?\ B.TS^FW?Z2/V%L6R
MVV&SVBCMU*Z1T%+&(F&0@N(';CK6>(O6\[HG/Z%(F(QA[$1.I>9M"(BH@<U8
MAR5='-6(<ERU/)N@B(N38B(@(B("(B B(@(B("(B B(@(B("(B BX5$T5/"^
M:>1L<3!O.>XX ':2L)&VKOI$DO345KR<1<62U ZBXCBQO=S/7CDK$9YM5KGG
M/1ZJF]4[9Y::C;)6U<?!\5.-[</4'N]ZWTG*X1&]U+<O%'0 _!(,[AZ<M'ZU
MDJ2F@HX&PTL+(8F\F,;@!=JN8CHNZ(Z0Q?N?7N]_>9P?_APQ ?:TJ/<VN^6Z
MSZ*'V%E44W2F^?Y$,5[FUWRW6?10^PGN;7?+=9]%#["RJ*[I-\_R(8KW-KOE
MNL^BA]A/<VN^6ZSZ*'V%E43=)OG^1#%>YM=\MUGT4/L)[FUWRW6?10^PLJB;
MI-\_R(8KW-KOENL^BA]A/<VN^6ZSZ*'V%E43=)OG^1#%>YM=\MUGT4/L)[FU
MWRW6?10^PLJB;I-\_P B&*]S:[Y;K/HH?83W-KOENL^BA]A95$W2;Y_D0Q7N
M;7?+=9]%#[">YM=\MUGT4/L+*HFZ3?/\B&*]S:[Y;K/HH?83W-KOENL^BA]A
M95$W2;Y_D0Q7N;7?+=9]%#[">YM=\MUGT4/L+*HFZ3?/\B&*]S:[Y;K/HH?8
M4^!W./C%=0_NGIVG/S2U91$W2;Y_D0P_AMTI9,5EO;40#G-2/R1_\MW'U$KW
M6ZXTMP8]U),'EAW7L(+7L/8YIX@]Q7J6/N-IIZU_3#>@K ,,J83NR-]/6.XY
M"9B>JYK/7DR"+$4-QG@JFT%W#6U#OW&=@(CJ.W'Q7</>^K/'&74F,):LU$1%
M&1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1=5540TE.^>
MJE9#"P9<][L >E#J[46"9=;A<7N]R* -IARJJTF-K^]C -YP\^[W97$VF\RN
MWIM0/9_)IZ5C0/G;Q6MO>73P\>U.&?18'W%N?\8Z[Z&+V4]Q;G_&.N^AB]E-
ML=S97WH^_P"S/(L#[BW/^,==]#%[*>XMS_C'7?0Q>RFV.YLK[T??]F>18'W%
MN?\ &.N^AB]E/<6Y_P 8Z[Z&+V4VQW-E?>C[_LSR+ ^XMS_C'7?0Q>RGN+<_
MXQUWT,7LIMCN;*^]'W_9GD6!]Q;G_&.N^AB]E/<6Y_QCKOH8O93;'<V5]Z/O
M^S/(L#[BW/\ C'7?0Q>RGN+<_P",==]#%[*;8[FROO1]_P!F>18'W%N?\8Z[
MZ&+V4]Q;G_&.N^AB]E-L=S97WH^_[,\BP/N+<_XQUWT,7LI[BW/^,==]#%[*
M;8[FROO1]_V9Y%@?<6Y_QCKOH8O93W%N?\8Z[Z&+V4VQW-E?>C[_ +,\BP/N
M+<_XQUWT,7LI[BW/^,==]#%[*;8[FROO1]_V9Y%@?<6Y_P 8Z[Z&+V4]Q;G_
M !CKOH8O93;'<V5]Z/O^S/(L#[BW/^,==]#%[*>XMS_C'7?0Q>RFV.YLK[T?
M?]F>18'W%N?\8Z[Z&+V4]Q;G_&.N^AB]E-L=S97WH^_[,\BP/N+<_P",==]#
M%[*>XMS_ (QUWT,7LIMCN;*^]'W_ &9Y%@?<6Y_QCKOH8O93W%N?\8Z[Z&+V
M4VQW-E?>C[_LSR+ ^XMS_C'7?0Q>RGN+<_XQUWT,7LIMCN;*^]'W_9GD6!]Q
M;G_&.N^AB]E/<6Y_QCKOH8O93;'<V5]Z/O\ LSR+ ^XMS_C'7?0Q>RGN+<_X
MQUWT,7LIMCN;*^]'W_9GD6!]Q;G_ !CKOH8O93W%N?\ &.N^AB]E-L=S97WH
M^_[,\BP/N+<_XQUWT,7LI[BW/^,==]#%[*;8[FROO1]_V9Y%@?<6Y_QCKOH8
MO93W%N?\8Z[Z&+V4VQW-E?>C[_LSR+ ^XMS_ (QUWT,7LI[BW/\ C'7?0Q>R
MFV.YLK[T??\ 9GD6!]Q;G_&.N^AB]E/<6Y_QCKOH8O93;'<V5]Z/O^S/(L#[
MBW/^,==]#%[*>XMS_C'7?0Q>RFV.YLK[T??]F>18'W%N?\8Z[Z&+V4]Q;G_&
M.N^AB]E-L=S97WH^_P"S/(L#[BW/^,==]#%[*>XMS_C'7?0Q>RFV.YLK[T??
M]F>18'W%N?\ &.N^AB]E/<6Y_P 8Z[Z&+V4VQW-E?>C[_LSR+ ^XMS_C'7?0
MQ>RGN+<_XQUWT,7LIMCN;*^]'W_9GD6!]Q;G_&.N^AB]E/<6Y_QCKOH8O93;
M'<V5]Z/O^S/(L#[BW/\ C'7?0Q>RGN+<_P",==]#%[*;8[FROO1]_P!F>18'
MW%N?\8Z[Z&+V4]Q;G_&.N^AB]E-L=S97WH^_[,\BP/N+<_XQUWT,7LI[BW/^
M,==]#%[*;8[FROO1]_V9Y%@#9;ICR=1UH/?#$?\ [5S9#?Z-IW:JCN8^+*PP
M/^<W(^Q-L=S9'E:/NSB+%6R]P5<PIJB*6AK\$FFJ  XXZVD$AP[VDK*J3$QU
M8FLUG$B(BB"(B B(B"(B 5"(K *"I4% 1$1(%"E0BH4=JE054$1$!05*ZYY8
MX(W232,CC;S<]P:!Z2@YJ.I=%)6TE:TFCJH*@#F8I _'J*[7/8UP:Y[0X\@3
MQ*N!*+IBJZ:69T,51"^9OOF-D!</.$-73"H%.:B$3GE$7C>/HYIB5=R(O(VZ
M4#JCH&UU(9\XZ,3-WL^;.4B,H]2*G[7;Q76'0-SN-JGZ"LB=$&2;H=NYD:#P
M/#D2J9>M8WVGV%VJ_P -<6W>>5K)*CHV\1OO'+&.31U+O30M>L6CSG#$WB)P
MW&5"KNSJY55WT-9J^X2]+5SP!TDF -XY(S@<%8'/8S&^]K<\LG&5RM6:S-9\
MFHG,9<E"Z?"Z8U'@XJ(>G_-](-[U<TEJZ:&5L4U1#'*[WK'R $^8*8'<N*Y+
MQS7&AAG$,U;2QS'_ &;YFAWJ)RD1D>I%Y[A*Z&W54T1P]D+WM//B&DA:XV#:
MGN^I[)=)[Y5FJEAJ&L8XL:W#2W.. "Z5TYM2;QTC_:3:(G#9ZXE>>IKZ.D>U
ME564T#W<FRRM:3Z"5Z 0X M(+3Q!!X%8PHH7155M+1@&LJJ>GWN72R-9GUE=
ML4C)HVOB>V1CN(<TY!](3 Y*%#7L<2&O:2.8!R0CGM#@TN:''D">)02H6K-<
M:KO-LVMZ=LU%6=';:IL)FAZ-IW]Y[@>)&>0'(K:$LD<,;I)GLCC;S<]P 'I*
MZ6TYI$3/FS%HF9AS4+II:NFJVEU)4P3M',Q2!X'J*[EA80BX=+'TACZ1G2 9
M+-X;V/,NJGKJ2ID='35=/-(WWS8Y6N(\X!3".]$)P"3R"\U/7T=3*8J>LIII
M&\V1RM<X>@%6%>A0I7F@KJ2=[V05=/*]GOFLE:XM\X!X(.\J%#)&2MWHGL>W
MM:X$?8O//7T=/*(JBLIHI3R9)*UKO42K$#T]2A0YS6LWW.:UG/>)P,>=:NT+
MJZY7':7J6V7&X1OMM*9?!V.#&AN)0!AW,\.];IIS>)F/))M$-I*%2=HEMU/<
M9K:_2M\I[;$W>Z823]'TA)&Z1P.]PSP[U= X ACGM,F.(SQ/H2:XB)SU,I4(
MXAH)<0 .LG"C>;N[V\-W&<YX>M8@0BZ*>LI:E[F4U53S/;S;'*UQ'G *[U1"
M=2(B(1$5$#FK$.2KHYJQ#DN6KY-T$1%R;$1$!$1 1$0$1$!$1 1$0$1$!$1
M1%B=1U#Q3PT-.7-J*Y_0-<WFQN,O?Z&@^DA6(S.%K&Z</,R/W>KS-, ZTTLF
M(6?GY6GB\_R6D8 ZR">Q9]=5)3Q4E+%3TS!'#$T,8T<@!R"[4F<K:V>G01$4
M9$717UD%!1S5=7((X(F[SW$9P%2F;18_"\2VR9E'G]UZ0%X':6?LSE;IIVO[
M,9<]36T]/$7G&5\1==-/%4T\<]/(V2&1H>Q[3D.!Y$+L6'01$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0>>XT4-PI'TU2TF-V#D'!:0<@@]1!P05XK)5S])-;
M[@<UM, >DY":,D[KQW\"".H]Q"RJP^HXG11PW2 D34)+W ?#B/[HT^@9\[0M
M5Y\FZ<_5EF$7&-[98VR1N#F. <UPY$'K7)98$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1!U5=1%24LM14O$<,32][CR '$E82WT4UVJ&7.[
ML<R-K@^DHR>$0QP>\=;SV<F\N?%+R&76^4=I<2Z"$"MJ6CDX!V(VGN+@3C^1
MWJP+?LQ\73V*\NLB(BPYB(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B(/)=+=3W*FZ&J:2 0YCVG=<QPY.:1Q!"\-FK*F&K?:KJX/JF-+X
M9QP%1&#C..IPR 1W@CG@9E8;55&Z:WBKIFDUU [PFG(YD@'+?,YN1Z>Y:K.?
M5ETI.?4GHS*+HH*N*OH:>KIG;T,\;9&'M!&0N]9<YC'*1$1 1$1!$1!"(BL
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M1>-T0B(J('-6(<E71S5B')<M3R;H(B+DV(B("(B B(@(B("(B B(@(B("(B
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M]N@-WN>!C*(45$(B(B$1%1 YJQ#DJZ.:L0Y+EJ^3=!$1<FQ$1 1$0$1$!$1
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MT]]L44-=,Z(-DI.D DP&[I\G.<$=8Y$+"W&LNUPVEZ<GO5 *![G-$-/OAY#
MXY)(ZR<^I7W5NB:>^W&"YTU9-;KI" &U,(R2!G (SWGBNC3^A10WQEXN]UJ;
MM7QMQ$Z88#.!&<9/:?6NM=6L5S/7&'>G$:<4B9GG$8Z3G]E5OFFY[1K*ON$^
MGO=ZU5I+PQK0YT3CQ/#SY]![EGM VZJ-PJZV73-!9:4QED :S$YR>1X\!P[
MM@(N4ZTS7#SVXJUJ;9CX>?\ XU_L:M-?:;/7QW*DEII'U <UL@P2-T#*\&D=
M-5[Z[6L%=32TL-PWF12O'!P+I.([>86ST4G6F9F>Z3Q-IFTX]K'V:CT_6ZGT
MM8YK$=-5%5*US^AJ(CO1^42<D@<LG/4O1;]"W&+9A7VR1K1<ZB5M2V'>& 6E
MN&D\LD-]96U$6IUYZQ&/-J>+MUK$1.<S\9AIXUFJZO1K].LTS/&8H!"^H><
ML;\4'FXXQP)6=M5/?;7LTMM-26>"LJF%XJ*.J''<+W'@,X)XCAWK8B*3K9Y8
M\\I;BLQB*QC.?-I">PU=VOMMFT_I>KL$\<@=/.\EK!QY@''+CRY\L+=-9PHI
M\\3T;OU%=RXRL$D3V.Y.!:5F^I-\?!G5UYU<9CHT=LSO=[LUDJG6ZR/NE%)-
MSB=Y3)-T9R "<$8ZEG-*Z*N-7IS4;KJSP2MNW&-CO@D.+P2.K+CRYX"O.C=,
MTVEK?-24D\LS))3*72XR#@#'#S+/+K?7YSMAWUN+S:TZ<=9CG\FD;?;:R@M@
MMU5H&.LNL9+6U;F!T;QGFXCGZ_4O=M)H9*#9M:X*JDI:*;PG>EAI1B-A(>>'
M?CGWK<"P.LM,T^J;8RBJYI86,DZ0.BQG.".OSI77S:)DIQF=2LVC$9SYM?W^
MOU7?=/QV Z;E9)((P^I#\QO#2""#R&< \U9-4Z4JJG9M3V:C(EJZ5D9#<XZ0
MMY@9\Y5W@C$,,<;<EK&AHSW+FL3J]-L8QS<IXF8QLB(Q.?U:WME3?J_1]SLU
M?89J5\%N,,,F]GIG;I;@#M]*Q53I&Z5NRJW4C*61ERI)W3>#NP'$%SOMP<^A
M;=1(UICI'GDCBIK.:Q$<\M.ZGK-5ZHTV* Z;J*<0ECII''C*1P&ZT@=?'KY+
MUZHTC<JW26F9J6CZ:NMT#&34C\>4W )&.OB,$=Y6UT5C7F,;8QAJ.+FN-E8C
M$Y:DH;?)<KI1Q4&@:.@I@X&HFK8N0SQW>6?M6VQP&$1<[WWN.KK3J8Y=/G_L
M1$6'$1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$&'TK_H%5_7:G_%<LPL/
MI7_0*K^NU/\ BN686K=9;U/;D1$66!$1$$1$$(B*P"@J5!0$1$2!0I4(J%!4
MJ"J@B(@*"I4% 4*5'4@A$1%%5=H&N+9HJWQSW'?EJ)B1!3Q^^?CF>X#M5J6J
M]J^JZ"@U!;;12:<I;[J%X:Z 5$8(AWCY.">.21GJ YY7;0IOO$3&6+3B'30[
M9&0W.EIM4:>KK)!4C,<\^<8[<%H..\<EA?PH"'46F7-(+3+.01UC$:K.VD:R
M?9K?-K*2V1QNF<(*:GP9&G=.22!RZN9ZEE=OA+M(:#).283D_P#RXE]'2TJ5
MU-.]?//2<PX6M,Q:)>C\)/\ @]H_^;)_<C6U-;:SMFC+/%57-SGR2C=@IX_?
MRD#CCL ZRM5_A)_P?T?YI/[D:X;:&LJ-JFD8*X!U$6P M?[T@S>5G[,K%-.-
M2FG%NGK+-IK:TQ\&<M^W"G\+IFWNPUMMHJCC'4N<7 CXV-T9'FRM@ZHU=:=.
M:>;>:R?I*20-Z#H?*,Q<,M#?...54OPB(:9VSJ1TK6;\53%T!(X@\00/1E8.
MCTA-K?8?IND%6RGK(-Z2%TV=UV'O:&GK W<<>/)<O#TKUKJ8VQG$M9M$S'5[
M*;;0(9:66^Z9N-MM=5^Y5CLN:1V@;HWAYBNC;KK6ECTT^R4]-)4,NM+'415;
M'?DPWI 1U<?>_:L+7:FUMI"UPTFN-.TEVLT99$)) QS>'O?*;D9X<-X*Z;1;
MC27;8;75UL9T='/30OBC  W!TK!NX' 8QCT+ILI34I:*\L^4YA,S-9C*L[$M
MH,/@-BTE[F5)E'2,\*#AN<7/?G&._'-6O6&T^DLU\]Q+1;:F]7<'#X*;/D'&
M2. )) Y@#@O;L/(.RVP8.0&R@_3/6E-F=5J9FM;]/IRWT===7;_3"JD#"P&3
MB1DCKQE7PZ:FI>V.GQZSDB9K6L=VY]!;1Z'5-=/;)Z2:V7B'.]23GB['/!P.
M(ZP1E>*^;6[+9-37*SW*GJ8S1MXS-PX2.W00T#OSS/#@JE!I?6UQVG6G45UM
M5OH7Q2Q].8*F/RF#(+B-XDDM./4O%14%)<?PD[A!7T\=1"U[Y!'(W+=YL(()
M'7@\5(T='=,]8QGE/F;KXQ\5GKM?V#5NSJ_5]QLU3-;J.6&.6F=-NND+GC=(
M<WE@\59]*WNQVO9G0W>"$VRR1PN>V)[S(YGED8SS<2[]:QNV^GAI]EEY;3PQ
M1-+X"1&P-!/3,[%K763Y&_@^Z0:PN$;ISOXY'C+C*E-.NK2,<HFW?X$VFLS\
M(65^W:G$QE9IZL=;@_<\(,H'[,9[LK:FG;Y0:BM,-RM,W34LN0"1@M(YM(ZB
M%@-&T=LEV4VRFK60>Y<EO:9P[ 9@MR]Q/5QR<]J]>@*+3=#:)HM'S12T)F+G
MF.8RC?P,\2>'#"XZOAXG968F);KN\Y1K_6%-HRTPU]732U+99A"&1N .2"<Y
M/F5%K=NMKAJ8A36FLGI"&[TY>&8<1D@ CCCESXKM_"6_@;;_ .O-_N/7;>:&
MF/X/;(^@CW([=%.T;O*3@=[SY)X]ZZZ6GI;*VO&<SCJS:;9F(\DZBVUV2WRQ
MMM-+/=6;C7R2L=T;8\\@<@\?V\%>-):IMNI[&+I;Y=V%N1*V3@87 9(=Z..>
M6%1MB5%33;(ZEDL$;FU+J@3 M_=,9 SVX"H^RJ25FS#:((2[+(6EH'5EKP?L
M"MM#3F+16,368CYYG"1:8F,^:Y7/;12BX5$%@LM9=H(!E]1&2T8ZR!NDX[SA
M7/06MK9K.ADEMQ?%4PX$U-)[]F>1':.\*K?@Y1PLT%+)"&B9]9()'#F<!N,^
MC]:IVS3-+MGU/'; !"V.L#&LY<'Y;CTX5OHZ<[ZUC$U\^Z5M/*9\UNU5MCM]
MIODELM=NGNDD+BR5\;]T!PYAO EV.U4.GU#2ZHVXV.Z43)(XY7PM='(/*8YK
M,$'MXA9W\&=D3JC4L\@!K086AQ]\&DR%WK(&?,%Y+]%!%^$C0BG:QN]- ^0-
MX>68P23WG@?2NM:Z>G>VG6.<1/-,S:(M/=LV?7-)#M#CTDZDG-4]H/3APW!F
M,R<N?(87/:#K6ET514=164LU2*F1T;6Q. Q@9R<K7=S(;^$Y2EQP"U@&?ZJ0
MO1^$TX>XMB;D;QJ)2!W;K5QKH4G4TZ^4QF?NN^=MI[.C\(RI;6:5TS51@AD[
MWRM!Y@.C:1^M;&U)JJW:2TU35US<X[S&,BA9[^5V[R'[3U+5VW;_ %?Z*_HA
M_@QJV;2-36ZU4UCMTEBI[[=ZF-II:>>,.:S.&YXC.2>  [.:ULW4TZXSSDSB
M9GY/'3[86PS4CK[INXVRWU?&*J?DM</C %HWAQ'(KHVY:PIH+#)8XJ:2<7*E
MCJ(ZMCOR8;OY'GR&_:%5MKCM:3:8II]5MME+1&I:(J2 @R!^Z[K&> &>OK5O
MU 2?P=8\DG_V?3_WV+<:>G6:7B.LXY2FZ9S5BMBVO(64=ETK[FU!E+I&^%!P
MW.)<_ECT<U:-9[4+?8+O[DT-%/=;FUV[)#"<!A^+G!R>X#@O;L-(=LULPSEH
M=*#]*Y438B!+M(U9/5 &M;TA:7>^&9?*Q]BS:M+7O>8]GX]9R5F8K6,]5RT/
MM+M^I;DZUU-+-;+J,[L$YSOXY@' P[N(7+4VTRTZ;U1)9KG!4-Z.(2.J&8<T
M99O !O,D\!YRJ'M5 AVT:=EI?)J7FF<\MYEW2D#/H 'F7/55'3UWX1=%35D+
M)Z=XA+HWC+78AR,CKX@)&CIS.['*:S.%FUL8\\MA: UY1:TDN#:&EGI_ ]PD
MRN!W@[>QRY>]5O75!3P4X(IX(H0<9$; W/J7:O'>:S.:QB'2/BA$3J61"(BH
M@<U8AR5='-6(<ERU/)N@B(N38B(@(B("(B B(@(B("(B B(@(B("PNFOW>]_
M\0?_ '&+-+"Z:_=[W_Q!_P#<8M1TENOLRS2(BRP(B("(B#7VU>W2%E)=(VET
M<+70S$<=T$@M=YLY!\X6M)G<"M\:J8R335U9(\1L=2R N/5Y)XKY_FD);DC!
M(Y=B^EPEYFDU[/@_U33BNI%X\_\ 3;FR*@?3:<FJY' BMF,C .IK?(X]^6E7
MA5#9.QK=%4KFR[Y?)(XCXAWSY/V?:K>O!J3F\R^QP\1&E6([0(B+#L(B("(B
M NNHACJ()(9FAT4C2US3U@\UV(@T!K[34FG;@&M+I**;)AD//O:>\?:J+4]:
MW_M?M4]PT['/2L=(ZDDZ1[6\]P@@GT<"M 5/6OK\+??7,OKZ.I.IIYGJQ%9R
M*V-^#QJ=]%J&JL574AM'5,,L#7G $HQD#SCJ[EKFLY%5RO.'Y'->Z=*-;3FD
M^;AKQF'WFB^??P9]:W&MKZO3=QFDJ8(X344\DCBYT>" 69/5QR.Q?02_/ZVE
M.C>:2^>(B+D"(B B(@Q=I_?:]_UB/_!8LHL5:?WVO?\ 6(_\%BRJMNK5^OT_
M B(HR(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(,-8?WRO_ /76
M_P"#$LRL-8?WRO\ _76_X,2S*U;JWJ=?I^!$198>2YW*CM=,:BXU,5/"#C>D
M=CBNBSWZUWG?]RZZ&I+/?!CN(]"I.T*>VU.JK91LM$UXO43=Z*G,VY"UIR<N
M!X'EGS!5JE%=1[5[*:NW4=JGF&'04;PYI80_WV.&3C[ O171B:Y\^KVTX6+4
MS,XG$SY?CK^K;%1J*T4\U5#/<::.6E ,S7/P6#O]87;9[U;KS&^2UUD-2UAP
M[</$><+5]JM-%=ML5\CN-.RHBBS*V-XRTN 8 2.OF5W6V@I[+ML926Q@IZ::
M!Q=$WWO&,N('=D X2=*N,9YXRL\-3$Q$SG&?@V'<]2V:UU3::X7&G@G=\!SN
M(\_9Z56M':BK[IKJ_P!!/4,EH*89@:UHX#>QS'/@JWLMM-!?KKJ2JO5-%65(
MF W9F[V[O%V3@]? #/5A=VRVDIZ#:#J6DHO]&A861C.< 2<O1R6ITZUBT><0
MW.AIZ=;UZS$1_KHVC<KA26RD=57"HCIZ=I ,CS@ G@%C9=66&*K93276E;,_
M!#=_MY<>06!VS_P%J/Z>+^\J_<=+V2/9,VM92PBJ%*RH%2!Y9D.,Y/6#G&.2
MQ33K-8FWG.''2T*6I%KS/.<<FS+E=:"V,B?<*N*G;*[<C+W8WCV!<*.]6VLK
M9:.DKJ>:IB!+XV/!+0#@K2NJ99*C9?I)TSBY_22,!// +FC[ %=-7Z9M6F-$
MW:JLE)X/5F!L#I@]Q<YCGM#N9ZPK.C6,1,\YG#<\+2L1$S.9F8^DX6E^KK R
MM\$==J03[V[N[_7V9Y+Q[0=0MLFG:B2FK(8;A(S-,'8)?Q&2 >? JHT.F[,[
M9"^K-' ZI-(^H-06C?$@S\+F,$8QR7@AIXJ[8H:NM@9+4T8DCIYGMRYC>EQP
M/V>A:C2IG/QPU7A].+1,9Q%L2ONA-34]ZM-%'/70378P[\T;<!P(YG Y=2]]
M=JJQT%9X)5W2EBJ <%A?Q![^Q5'35#26W9L;U;J2!EU%OD/A#&C?)P>OT#U*
MGZ+I*RJTO5LI]+4]U;4O>U];)4,:\''5GB,<_3E/"K:9GR/1].]K6SB(G'E#
M:VMJJH9II]1:[M36]^^PBJE(+-TGEG!YKTTMVIJ"T6PW>Y4[IZAC&";.&S/(
M'%OG6K*^@N5LV.U-'=F!CHZUG0@/:_R"YIY@GK+N";1&A^C-%,)(#HV-R.]C
M0D:,3BN?.5KPU;8IGEF8S^C:D.J+)-<? (KG3.J][=Z,/XD]F>65F%J':UIN
MU6?3%OJ+71QTL\4S8P^,8<X;I/E'K.0#D\5M*S2OGL]#+*XNDD@C<XGK):"2
MN5Z1%8M5YM72I%*WI/*>[S7?4=HL\K8[G<(*>1PR&/=QQY@O;05U+<*9M10S
MQSP.Y/C=D+5-.^FNFI+M5:7TRV[REY;-5W"H_)AV>.ZUV<#APQU+P[/JBHHK
M3KKH-V%\,6^UD1RV-_Y0>2>[ X]P72="-OQY.\\)&S,3SC';S^'DVC6ZLL5%
M6.I:JZTL=0TX<PNY'O[%Y=<Z@BL^FZBHIZV&*LDB)I22';[NX<CS5/V;:9L=
MRT%+/<::%\LSI1+4/ WXPTD AQ][@#*Y5MEL4>S&X^YU8R[Q48D=!4/+7&%Q
MQD-(Y=OI3PZ1;'/E)X.E74V\YQ.)Y+%H75$5ZT]31U%RIW7IT+W2-X!S2"0"
M6^;"XZ.O+J33U16:BU!15S&S[@J8B QO >2< <<Y/I7CV:6BW,T31W)E' *]
M]/*U\X:-\^4X<_0%@=EMIBOFSJ\V^8#$U0X-/Q7!C"T^@X5FM?6[96U-/U_*
M(F.W>>C:[ZJ!E&:MTS!3!G2&4GR=W&<Y[,+QMOUK=:S<17T_@()'3;_DY'4M
M-C4E3/LW;IWB;LZJ% (\^5N Y ]?D*PZLH[1:Z/35ADMLUUN4+<P4T<QC8YQ
MQO.?U')!]&5/ Q.)_D,^AQ6=MNN9^D>;8%HU%:+Q(Z.V7""HD:,EC'<<=N"J
M7?\ 7/@VO+924MSIQ: "VKX AKAO @NYCD%4[KX?1[0-/RU5JHK/4.EC BI'
MAV6%^,NQPS@D>99?5=FML>U6Q4C:*!M-5 OGC#!NR.)?DD=9SA:KI5K//SAU
MIP^G2W/G$Q,^4_SX-HQ7:@EMONA'60FAP3T^\-W .#Q\Z\EKU/9;K4FGM]RI
MYYOB-=Q/FSS6O]K5'34ATO:*>-M+:Y*A^_'&-UOOF#/_ #.]:ZML=FMMEM5K
MK+120T=7%/N,= W<) :2"<<R"!QYK%=*ML<^KEI\-2^WG/K9Q^G=LZJO-NI*
MYM'55L$-2YAD$;W@$M ))\W ^I<*6_6NJHIZNGKZ>2E@.))0\;K#WE:PUE0P
MWC:G8Z.X,+H:BFCZ5@);GWYQZPK!K+0$,VFO M,PQ4KFU J'0EYW9B&EN"2>
M"GATC&9ZL^!I1MBUIB9^BU6K4MFNU08+=<:>>8#.XUW$^8'FLNM,255);[K:
M6ZNTFRV21/ AK*.3<;O C!(;S X=96YUG4I%<8<]?1C3QCI/R_,"(BY/.(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(,7J2]TU@M;ZVKRYH(:UC
M>;W'J"Z]*7^GU):O#:6-\;0\QN8_J<._KYK1>W"ONU+J:=]TCE90 [E&_=_)
MEN 3@]N<YZUM[9/055OT);(J]D;)WM=+AG'R7N+FY/6<$+U7T(IHQ>>LN]J4
MKIQW6Y$1>5P$1$&'TK_H%5_7:G_%<LPL/I7_ $"J_KM3_BN686K=9;U/;D1$
M66!$1$$1$$%$16 4*5!0$1$2!0I4(J%"E05801$0%!4J"@*.I2HZD$(B(HM:
M[3=FTVI;Q27RQ7'W/O-.&MWWYW7!IRT@CB"/3E;*1=-/4MIVW58FL6C$M(W[
M9'J34U(V?4.IXZJZL<&QYC/11QX.0  .)..H<NM6/:+LXJM5633M#37""G?:
MV;CWR,)$GDL;D8Y>]^U;*[477TK4S$YZ=$\.K76U/9]4ZSMMEI:6OAIC;]X.
M=*PG?R&CACE[W[5[-IVS^EUM;:=O3^"W&EX05&[D8/-KAV''H*O)4+-=>]=N
M)Z=/U6:1.?BTE-LIU7?I**FU9JEE3:Z5P+61@N=CEPR!QQPR<X5VUML]H=1:
M5HK/23/M_N>!X)(S+@SAC#AGB"!Y\\5=U"U;B=29B<XPD4B&EZ[9OKB^T<-J
MU#JVGEM,;@2&QESSCE\$9/G*V1+I6W/T8[3 $C;=X/X.#GR@.8=GMSQ\ZL"X
MJ6U[WQY8[<BM(AJ716S'4&E[U1R0:IZ2T03=(^E:Q[.D;U@MR0,KMU)LRN$6
MJY-1:(N[+5739,L<C<M+G>^(.#P//!'-;54+7I.I-MT_@\.N,-9:*V:55#J9
M^H]5W8W2[YWH]S(8QV,;QY9X< , !>FW:!JZ7:S5ZL?6T[J24/Q &G?&]&&<
M>I;$4'FI/$7F9F9ZQC]"*1"N;0M/2:ITE76>"H93RU!C+9'M) W7M=Q \RQU
M+H2FEV;4ND[O*)Q#&6]/$,;K]YS@]H/9GKY\5=%"Q&K:M=L3YY_5=L9RT<-D
M^KV6UUCBU7#[A$_N6'CAG/O?/QQO86T]%Z8HM)6**V6\O>T$ODE?[Z1YYN/9
MRY=2SRA;U.(OJ1BS-:17HI6U?1]3K.PT]#1U4--)%4"8NE!((W7#'#SKT5VE
MIZC9L=--J8A4>!,I>F+3N;S0...>."MJA9C5M$17MS7;"I;/-+3Z8T:++55,
M4TV]*3)&#NC?)[>*Q.R_9_-I2W7NCNM33UL5Q+06Q!P&X X$'/;O+8:A6=:\
M[OCU2*PTW%LNU-IZMK!HK4XH[?4NR8I<AP'4"0""1V\"K5LQV?0:+BJ)Y:GP
MVZU/"2HW2T-;G.ZT'OXDGGW*\HMWXC4O&V9Z_=(I$3EIZZ;*KO0:EJ;IHF^M
MMK*DDOC=O-+,G):" =YN>(SR798MDM=;=8VV_5-\;62PR">I,C';\LG'.#V<
M1S_\EMQ%KTK4QC/P/#JUMM,V<U&I+O2WNQU[:"[P!K2Y^0UVZ?)<'#B'#S'/
M#L5:O6R;4VH*:.>^ZFBJ[DQP:SI XQQQ\<X.,Y)QU#EUK=JA*<3J4B(CR)TZ
MRUYM"V?U.J=-V*V4]?!3R6UH:Y\C"0_\FUO#'+WJY[1-GQU-';:JWUQHKQ;V
MM9%,0=US1Q&<<00>((5_*A9KKWKC$]/]KLB6G;ULOU/J6A;XR:ICJ:N @4[>
MC/1L!]\3@ DG ZEL"BTS#XC0:;N3Q/"*04LCV<,X'OF]G'B/,K%U*$MKWM$1
M/D12(YM5:+V:WS3%ZI)(=3=):89NDDI6M>SI1CD6Y(R>"[=4;-:YVJ'ZAT?=
MQ:Z^8ETS7@[I<>9:0#P/6""MH*%KTC4FV[*;(QAK/2&S>JI-3'46K+HVZW1I
M#HPT'=:X# <2<9P.0P %[;AH:JJ=JM+JMM9 VEB:P& M=ODMC+/-SXJ^H5/'
MO,S.?+'Z&V(C#B41%R:0G4B(B$1%1 YJQ#DJZ.:L0Y+EJ>3=!$1<FQ$1 1$0
M$1$!$1 1$0$1$!$1 1$0%A=-?N][_P"(/_N,6:6%TU^[WO\ X@_^XQ:CI+=?
M9EFD1%E@1$0$1$&+U5!)4Z:NL$##)+)32-8P<W$M. OG2IF!:7 \.>5]/K U
M&C]/U-P-;/:J=]27;Q<0<$]I'(GT+OHZWAQ,=WAXSA)XC$Q.,,=LGIY:?1-'
MTT?1F1SY6@\"6EQP3YQ^Q6]&@- #0 !P "+C,YG+V4KLK%>PB(HT(B("(B B
M(@XRL$D3V.]ZX%I]*^4[_;Y[5<:BAJXW,EA<6D$8R.HCN(XKZN6#U+I6T:C:
MSW5I1)(P89*UQ:]H[,CJ7IX;7C2F<])>C0UO"F8GI+Y+K.16<AV1:ONENIZV
MFH86QSC>;'+,&/#>HD'E^ON7T!9=F>FK56,JXZ1]1/&[>8ZHD+PP]H')71>R
M_P#49KRTH^JZNONY5:RV,[,AH:&JJ[C-%4W>J:&.=$#NQ,Y[H)YY/,XZ@MFH
MB^;J:EM2TVMU>81$6 1$0$1$&+M/[[7O^L1_X+%E%B[3^^U[_K$?^"Q916W5
MJ_7Z?@1$49$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$&&L/[Y7
M_P#KK?\ !B696&L/[Y7_ /KK?\&)9E:MU;U.OT_ B(LL*KJK1=/?+C!<J>MJ
M;=<HANBHISQ([_65X[?L\HZ2^4-V?<*VHK:<[[WS.WC,[!&3GEP/(=BNR+I&
MK>(QEVCB-2*[8GDKMMTI34&K*^_,J)G3U;=UT3@-UOO>77\%)-*T[]9QZC-1
M,*AD?1]%@;A\DMSV\BK$BF^W?X,^-?.<^6/T46Z[.*6IN\U?;KG6VQTY)F93
M.P'DG)\V5D-)Z)H=,W2KK*&>=_A$8CZ.0@AH!SG/,DE6I%9U;S&)EJ>(U)KM
MF>2D;96.?H:H#&N<>FBX-&?A+"6K9O!<[/;99;K<8:.2&.62BWLLWB 3C/+)
MSZUM)%:ZMJUVU;IQ-]/3V4Y<U5U'HBWWFTV^W-DEI*:A=F)L6#PQC!RK'7T<
M%?134E9&V6GF:6/8[D05WHL3:9\W&=2TQ$3/1KH[+H UU-'?+FRUN?O&C#O(
MY\O^@KG'8[?'8O<=E.T6_HS%T63R//CSSQSGM6216VI:W66KZ^I?&Z5.TQH2
MGL%>9H+C6ST^XZ/P65P,>'<^'6O#-LT@;)4LMEYN%OH*DYEI(7>0[N\ROZ*^
M+?.<M>DZN=V55J]#VV720T_3.EIJ7?;(9&8+RX'.3GGE<;WH>CNUKL]#+55$
M<=MW0QS<9>  ./#N5L12-2T>;,:^I'//Q8'6.F8-3VIE#4SRP,9() ^/&<@$
M=?G68HJ=M)1P4S"7-AC;&">9 &%W(L[IQAB;VFL5\H42?9S RXU$]KO%QMM/
M4G,U-3OPUW;QZOV+)Z4T70:<DN7@TLLT5: UT4N"&M&]P[_?=:M"+<ZMYC$R
MZ6XC4M&V9Y->5&RZFZ69EOO%PH;?,<OI(G98>[CU>?*MM!IVV4-A=9X*9O@+
MVELC"22_/,D\\E99%+:EK=9+Z^I>,6E3-/Z IK'<#/27.O-/NO:*9S_R8WAC
MEUK*:,TQ3Z6MTM'2SRSLDE,I=(!D' &.'F6?1+:EK=92^OJ7S%IZJDS0=M9K
M#Q@:^02[YDZ# W-\C&]V\^/G7?J_1]-J.:FJ?"9Z*OIOW.I@/E =BLR)XELQ
M.>AX^IF+9YQR42/9O2FXT-PJ[K7U5=3R"1\TK@XRX((!SR QU=JR^KM'T.I7
M4\M1)-3U=/PCJ(78<!G./6K(BOBWSG*SQ&I,Q;/.%3GT-0U>FXK3<*FJJS$]
MTD=5*_,K''L/9W+'4.S:G%;!/>+M7W:.G_<H:AWDM^W[%?42-6\>:QQ.K$3$
M2KM?I2FK-745_?43-GI6;C8@!NNX.''K^$O1JK3=%J2@;35W2-=&[?BEC=AT
M;NT+-(L[[<IST8\6^8G/3HHE+LZB?6T\][O-PNT=.<Q0U#O);]ZO:(EKS;J:
MFK;4]J1$19<Q$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$736R214<\D+=^5D;G
M,;VD X"$<W<B^?H-?WNWWF.LJ:R6>'?'34[L;I;U@#J/8MU:;U':]24CZBSU
M39V,=NO&"US#V$'B%VU-"VG&9Z.VKH6TNK+K&W^]4=BH#5W![A'G= 8W+G'L
M 6257VE4#:[1]>=T.DIV=.PYQ@MY_9E<Z1$VB)8TXB;1%NC,6&\45]MS*VVR
M]) XD<1@M(Y@CJ*R"^4-/:QGTAJ*EK>FG\ #_P#.H(SGI&$8/ \,CGZ%]44%
M5'74-/5TY)AGC;*PD8.ZX9"[\1P\Z,Q/E+6M2*6Q#S7NR6R^TK::\4-/6P->
M'M9,P. <.M>]C6L8UK &M:,  8 "E%Y\SC#D(B* B(@P^E?] JOZ[4_XKEF%
MA]*_Z!5?UVI_Q7+,+5NLMZGMR(B++ B(B"(B 5"(K *"I4("(B) H4J$5"@J
M5"L((B("@J5!0%'4I4=2"$1$41$1$(B*B"B%$!0I4(@N*Y+BK (B*JA05*@H
M"(H1!0I4("A2H2 4*5"J0A$1!"(BJH4*5"(@J%)4('4H4]2A4%"E0D(XHB)
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M.7AT=/Q+VW1G'\\N:X:4UC2:@GJZ44\]'7TO&6GF R!G!(([U@H=J-/512^
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M%#3M:27[YRXDD >2.LI70O;,8Z9^QEL9%48=?VE^GZFZ/951NIJ@4DM(Z/\
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MW^CC]M/=V;Y#N_T<?MIMD\.S-(L+[NS?(=W^CC]M2VZ7&9V(+%4L!^'4S1L
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MN<,CAD<0K2BEM:UOM]L_N1#6EGTG=YM66VZUEKM%E=1EQGGMLA+JW(QNN;@
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MMK:G_&<LPM6ZRWJ>W(B(LL"!$1!$1 4(BL H*E04!$1$@4*5"*J6F/X;:O\
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M?]7=E_HW?WW*W*H[)?\ 5W9?Z-W]]RMRUJ^W;YNO$?Y;_.?R(B+#B(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MA][N!,L-&=V/I"7%\F.>3U-'VX[%NY9U:12=L2Y\3I5TK;(G,^8B(N3S"(B
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MDQB;UQ$^;'C3YQU?-IY*-UQ&0TX[<+<NPC0E#>H9KY>(6U,,4O14].\98YP
M)<X=?, #ES6?K=LNGZ.\.H8+.^6W1OZ-U0P-:,#@2UF.(]/%;MQ,[YIIUW8Z
MEM3GBL/G@\EQPM\[7]/:5NFFY-06&KMT%=&QLIC@D8WPACB.; >#AG/+/,%6
M'8!34[]G3))*>%[_  J;+G1@DXQUD*6XR(TO$QYXPYSJ<LOF,KBOH>U[8].7
M*X045=IX4\$[Q&Z5[8Y&MR< EN[R6 _" T3;++%1WJS4[*5M1,89X(QAF\02
M'-'5R.0.')6O$SOBFI7$ST9W]VEL'"XE?75\O-!I#9_0W::UPU+&0T\?1L8U
MI.\T#.2%@]'ZRTMM'J:FSUFGX8INB+VQS1L>'M'/#@ 6D9ZO6N4<;::S?9RC
MXL39\O*"MHWJ%FRG:NTTT3:BVEK9!%,T/)@?S;QZP0<'N'>M@[8M&4FK],TV
MH]+0LFJHX@]HIV8\)A/'D/A#U\QV+K/$Q$US'*WFSE\UD9Y+B5]1Z>LMMV4;
M.*FY7B""HN3VB28/:"72D89"T\> /,CO*UML=TY3[0-;76Z7Z-DD%.14R4[
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M'>XYZNHKZ<1!\_?C>US_ !6B^J3_ 'K;NSN]W#4&E::XWBC%'62.>'0ACF
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M/$T,CCC:&M:T<@ .00>2P6:@L%KAMUIIVT]+$.#1Q)/6YQ/%SB>))XDK((B
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M,!Q'I&0M2Z8VP36PQB^UH?2;P:[I\&09^*1Q<>[F5M&#73:VG;-:M.ZAKX7
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M--;+?3T5#$V&EIV".-C>0 7I1%@$1$!$1 1$0%5M!>^U)_QFH_4Q6E5?0?\
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M3-' _&"R2I8<YCPYA(<#D$=2LUJKVUD6'$"9OOAV]X2U<<X'N4%2H*P"(B)
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MJCJX&RQ'(/,=8/8N-JX'>B(L) H4J$54M,?PVU?_ #Z;_#*M954TQ_#;5_\
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MDFD;LX^5'+:YW'^=)&QWV/*V>QS7M#F.#FGD0<@K2XE<[\&BG?\ "I((0/\
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MHG,BW,AT1WG<^1!/5@^I:[:]W1L+6.WFXQPX>2<?M]:8+7N!9\!S1NG/ ?\
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MKR6FB\+F)?\ N3#Y7?W*S@   # "\%[>3I B(N0\%QO5MMKV,KZV"![N37O
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MQ"JZOI9W6IM$P@U%RF;0Q-C)R!)P>_N#8]]W7R7*P%MZU)?:VD:!3FH;00.
MX".G!:XCNZ1TGJ"ZK]=Y*6XW"Z,:U\=GB%)11_GJ^<- ;Z YC>[??V%7'2-B
MCT_8Z2@8X2/AB:Q\G6]W6[SDY)[RN.[GE65IH&4\+8XQ@#[>]=B(L B(@\59
M:J&M?OU5-'([M(XE>J&*.")L<+&QQM&&M:, #S+P7B^VVS[GNC5LA<_DWB2>
M_ XX7LHZJ"LIV5%)*R:%XRU[#D%7$XRW._;&>CN6+N5AM]?(99H0R?\ .QG=
M=Z>WTK*+7NO::>LN4C*BHDCIHV-="P.+03UGO.5:3B>N&M'2\6VW.'KN^BX'
ML<8W-?GETC!^L+6&IK#)0R/=N.#1[YIX[OIZPMQZ#?6U&F(?=-SWR;SFL>_W
MSHP?))^]8?73:6&CS4[W2DEL;6MR7]H\R]&GJVK;;/-Z]"]J7FG7#0]1'@E>
M-W-9JZPM9*\QAPCSP#AQ'<5C'0DM+AR'/N7T:R^O'.'5&["]4+^I><,*[XFE
M:RYVIE=;1J*&:!E->6.DW?);4MXN ZMX=?GY^=9<6VEJ!OTM732,/6) /6#Q
M"H$#2LC %PFD9S')X]32QT6Z:FI:2,F2HA>_J8QP<?L6-+MXD_8O% UQY!96
MDI7.YA6.7F^;K4EU-C<_D%W1VV27DTGT+-T-O\DO?AK&C+G.X !>&Y7/G#;R
M60 8,@&'/^X+,6F9Q#RQRZL?/010@]/(R,]A/'U<UCIZF" 8IFDN^/CCZ">7
MH7.1O KPS-YKI%<]7KTM3LQ]5*Y[G$\,_;Z5CWCB5D)F\2O,Z/@5TCD]U+9=
M+J6H;2"L$;A3[^X)!\9>4G).5F+5-0,BJXKF)W-<W,09R#N\+&4M/+554=/2
MQNDED=NL8.9*L2FG>\7M6\<O*?\ 3IZEF=):8KM476.EI6/CI0<SU)'!C>O'
M:5M/2VRVGI8HY;O+OU&,EL?5W9/W>E;#MENI;9!T-%"V-AXG'$D]I*\FIQE:
MQBG5ROQGE2/U19K92V>V04%OB$5-"W=:T?:3VD\U[$1?-F<\Y>%J[4&LKY-5
MR&S=%3TD3BUI='ONDP>9SR\P5IT#J9VHJ"854;8JZF<&2M9[UP/)P\_'AW%8
MRXZ>K:9LL-)3"HB>XECFN ('8<K)Z$TY)8X*J:J+?"ZIP+FM.0QHY#/6>)/I
M7JM;3MIS&,3Y/%73U*:L3%IF)Z]OT6A>.XT;:F,^2"[&"".#AV%1>JB>EM55
M-2,:^H8PE@<,C/:>X<U@M#W6Z7"2X0W4PRB LZ.>)FZ'9SEO/JP/6O/6LS6;
M1/1Z9OBT5QU4J$1V2DH^FA+QIJL=053<^4+?,0Z-_;NQ@QG/_P -_>MJQT%+
M'$8Q"QS2<G?&]D^E5+7%+36RZ0WZH@$EOJ8O<R[-QD.@><,D/<QSCD_%>X]2
M]NAZRJCIJFQW5^_<K26PF3/[O"?W*7SEHP?Y37+.71[:JS.DGD+)6MBD.2".
M+<\\+JDLI RRI+G-.6AS?UD+.$KK<58O*, ;7.W+NDBWCPW<G'KQ^Q5_4]0+
M/;9A+&U\L[BV/AEKW'CD]P';V#M5UE=S50UW9ZJ[4]*^B#7R4Y?F,G!<'8Y9
MX9&[]JW6TYYI;..36LTTDTKY:B1TDCCE[W'B5Z]%4<[KZ:OHBUE/O9WQ@AQ!
M &.WBL[IK3-3X>RHN=/T4,1WFQO(R]XY<!U \>/<K%;(C65,L[6;L$LG28SG
MJ'$]Y(SCJRNLVB'E\.9Q,O7J"9PIXJ4.##4DM<[KW0,D#O/+S92S8$KVA@]Z
M,'L[EC]353#4TL8!<[IF 8[G<3]H7=._P2RUT[I#&Z6,PPD<R\@AN._)7*(Q
M5USFZO-#;[M-<=\RTE !NE@RT%HY9_GDJYWC)I<;H=O'''J5<T?!':I9J2E!
MZ)QC+B>)<2",_9GTK,ZK>YEGFW20<'U8XJS'K1!$>K.>K24^S^].MTE51B"1
MDA?)&&R>4-[&.!'/F,]A6/K]%ZDI9XHVVR5[W-<]HBW7AI:SR>(Y;KL@ \\Y
MXK;?NU)#3,A;%'EA&#RX \!A=S-30B9QDIWAA:!P()S]R^A7B=2/++>V'SU6
M4[X9JF.KB<PP'==&]N',#&XP>O>)>/-@KJ\&+((62AS6AK2=YO' '2$X/,G)
M ')?1M>RR3TL-?614TLC7->'.:"_>R,]_5R[ESJH++J(.=5PT]<(@6-#A@M#
MA@XY'CR6XXSO4VOFE]/N2ET1W3&W<<P.."?*<]H=SS@8..TKI9.6M=(YACEE
MPYF[\(EI:S!Y- !YYSR6SM5;,*^"7?LT@K&5$A:8<[CXV%Y<?*/ MQPSSY*@
M7:@EIJE])5Q&*2($/B>,;APX =C6M: >LG*]--6MXY2F&2T_JF\Z>HV4-EJP
MV*H(P.C;(UCL-WY,GGQR.S@MG[-=;NOG@]CK8BVM9 7&;I-XR-&,;W#WY!R<
M=A6CZB !LLC'N?NGR0[)!CX;C#RXG(.%DM+4%;?;W;[;:IW,N-7/Y$AX=$X8
M+Y-T=3&M=C/,\,+EK:=)K-I6);\J:ZIN8NT^_(9[I,W3UJ?CCN N-1,,=0\O
MC_\ !':ML4-)!0T5/24D;8J>"-L4;&\FM:, >H*E:)H(*B[F6CC<+/8H3:K>
MYW^T?D=/+GKXM8P'M:_M5[7PG01$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 7CO-!'=+16T$X!BJH7PN!'4YI'[5[$0:7H[A44.B]!WRL)=56&O]R;
M@3Q+6%SJ60GNWA&_U%;;JKM;Z5C'U%9 QLG%GE@[P[1VK7TUL94:HUKH^L&Y
M17ZD]TJ1WQ7.:(I<=X>UC_[2KNC[@VY6\5$NZVN<<548X%DC26R#'8'M?^OK
M733I%NKEJZDTC,-OOOMJ9T>]<:4;XRW\H.([5RJKS;:1X;45U/&XC>P7CEV^
M;O6L;=N^#G=W2_>/2X^/GCG_ *Y+HM_0U-NFCII(W F2-[HR" [)'V?J77P(
M[O-Z5;LO1UG3]/PHJDTN?W;AG'QMS.<?;W+D_6=)TX$5)52TV?W=H;@CM#2=
MXCT>;*U5==9V.FI:N.IK6BH8Q[70QC><2 <[O41SXKJH]>:?J+*VI-<(B8SF
M)S2'@@<0!UKIZ/YX9](OW;=FUG;8Y/R;*F:G'$U$;!N =O$@D>8+KDUK1M<X
M"BK2#PC.ZT=(>S&]D>D#O6IJ#5UDK].15$=?#%NM;F*0[KLM(\G'7G'5VKNK
M]9V&&@AKVW&*1C3OAC.+W-((/D]V<^A/1XZ8/2+MBU>L:ET?0PT;89Y3ADO2
M![6#&22,#CCEU+ 7"OJY>@]T*V2>G:\N/2-: UV.#N '?YLA:]U1M)M-/;C)
M:'FLK8]V5C2TM:P$XR[/:#C'>J;K+:35WFS5-!3TK*-CF,Z5[7[Q=O8.Z.P8
MSZEUT^'GRC#$VOJ<IEMG4E^I-/PBLJ90\2%L70,(+WDG +?-DY[EJK5NTBHN
M-5"ZQOEML(,D3I"X!TQW>!)'( G[51)I'3=+)%*XR28=$7$Y 9Q+?.,#SX77
M+N20N#VL\J S.QPW7YQD>?AD+U4T:UZ\RM.[:NQF\R4LUR?<8Y9G3!O2U)=O
M/#P7'!SS!!!!"VQ9+M#=HII*>.1C8G!IWP..>1X+1>RQDSXJZJ) IG[D;69R
M=YK0"?4MEZ4KHK;<I:>>01T]0T$%W(.'+)]:\>M'KRZ>SR;/M,C>@+"\;V]P
M:2L1>XGT%>^J;O&FG<WI6XX-/+?'9U9'9Q[5R:>1![P0LS2GPNBQ/Q.<$_M7
MEGU9R[UG?&U\OZ_O=KNFU&_MU''5R45.UUOH_!R,P.9Y(?@D9&=XD9ZUF*>V
M7&Q4<VE]-WBUSNN89X;*:J-G2AS<L8T/.0 ''B.)+NX*N[=-/26/:+7S;I\%
MN3O#(7XX'>]\/.'9^Q<=3S6.KLNF9;5533W9M(*>O8^/=:TMX,P>LX..O@T+
MZO#1NBN''7C$RL.CJ2*W5L]LAA?'K6.I+*9\K!) TMZF]CS@X<00.'+FK5LM
MJZ^+:%6T%VWS/6B5M5&['[JS+\G'#(P>7:O!162O%/%0T=.YVNX*9KYCO-.Y
M2\F[IY=(&[HSSW3SRO?L1MM36ZDJ;Q-O.BI6/#I'GBZ608QWG!<3Z%Z^(M6=
M&]I[?^?IV>#1K/BUB.Z]Z\T]3WNU5%O='&USV!\#WC(CD')P]*^98]'Z@AN-
M30"USU%5;Y#'(Z+BU[7@DD$\,X.0>\+[&JH&SQ$.;EP!W3V%4LO$-QJHI2UK
MI"V9N3C(P&^L%OVA?%X?6FL8?1UJ[7RB*5]OF?2U;'Q24U1O31R1D.+>378[
M >KO5DT;H*]ZAIZB>)T$,44V8YIR=U[N._C X@\,K?M+2V^KN577MA@EJ,B
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M0) T%KF9Y;S7 $9P>KBJ9K+3FD=.:BJ]?ZIJJFHF+1&REFW)&%VZ&M$;,9)
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M"-T+MX-RW'87-YY!&> *L73:W0BT>+WKG46U#5.G+%J""WTE&\N9)+3->86
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M742R23,:^,R%PD#C@@@GCP7:GK1MR^G2;:^CMZ8_TR==K"_4THK>CI_ LYZ
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MTU8=120OK:>*I<6%W2LD(?(T@#B6G)&,>;JPM9O<NML[Z=_212.C<WCO-=C
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MVU+&XP&F:&.1W_,7'TJ-+-;J"DMM**>W4L-+3@EW1PL#6Y/,X'65Z'$-!).
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M":HN][+'7>K:&=&SBRDA!);"P]>,Y<[K/<!CIT[I^H?6P7G4#(1<8X^CI:.
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M\7_YZ?3\OT']/X'PH\34]K\?]=5HIZN[70ZCOL!@JW,,=#1O.310'GGJZ5_
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M4)".*%2H2!Q*(45$(B=2(A$140.:L0Y*NCFK$.2Y:ODW01$7)L1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!>6X6ZBN4/0W&CIJN+XD\39&
M^HA>I$%3.@;1%,9;5-<[2XG);05TD4?T>2ST;J[_ ' O,7^CZLN#CV5--3R#
M_E8T_:K*B"JNL-^<<G4%&>]UJ83_ 'U6=HU3J;2FFA7TNH(G/-1%#N,M\;
MYV">)*V@M<;?_P#5\\]E93_WT&=GT<ZL&[<]1Z@JF?%;5"F!'8>A:PE>ZT:2
ML-H<'T-JI63#_;O;TDI\\CLN/K6<1 1$0$1$!>22V4,DXF?1T[I0<[QC!.>U
M>M$6)F.@L9+J"TQ7$4$EQIFU9=NB(O&=[L\_<LF>1P<%:CN^G)3 ZF;1S2UK
MG$<&'RCGGO?;E;I$3/-Z.'T:ZLSNG#;BPMXT_%<99)!,^%TH DW6@YQPZ^16
M1MD,M/;J6&H?OS1Q-:]W:0.)7I6>CC6\Z<YK*JW6]P:5@IJ&DH)JB*&,%^ZX
M#<9RSWDX*LM+.RJIHIX3F.5@>TGL(RO/<+51W#'A<._PP>)&1V'',+V,8V-C
M6,:&L:,  8 "LS$Q\6KVI-8QU\TKRU5OI*N1KZFFBE>WD7MRO4BRYQ,QT ,#
M Y(B(@B(@+IJZ2"LBZ.IB9*SL<%W(BQ..<.FCI*>CA$5+"R*/GNL&/2NY$1)
MG/.1$1 1$0$1$!$1 1%3-?W*X1OI[=:Y'P/E:9))F>^ S@ =GG6J5WSAC4OL
MKG&5S1:;L>I;IIZ]0MNM=/4VZ5P9+T[B\Q_R@>?#L6W:&LIZ^E94T4\<\#QE
MLD;L@KIJZ$Z>)ZQ/FY:'$UULUQBT=8>6]7NWV6-C[E4MA#SAHP7.=VX XKUT
M=3#6TL532RME@E:',>TY#@J_K2T"KII*YH8^2G@<-QXSD<^'>M:$WNQTD,]%
M<JB../RVP[YZ+GDC=Y8*WIZ5-2N,XEC6UM32F9VYK\.L-XHO'9JPW"TT=8Z,
MQ.GA9(6'X)(SA>Q>>8Q.)>JLQ:(F \EJZJMT-'/60U>1,'N<"?A DD%;1714
MT=-5 "IIXI@.72,#L>M:K;:3$9SC+5^SJV2R:N?7PL(I((GL?)U%SL8;W]OJ
M6UUP@AC@C$<$;(XQR:P8 ]"YK6KJSJ3EQT-&-&LQ'G.1$1<G<1$0$1$!$1!K
M?8U_I6M/^-S?J"V0M;[&O]*UI_QN;]06R$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$%?U;IB&_Q4\T4[Z"
M[T;NDH[A"T&2!W6./OF$<'-/ CT%4V8.O=YHZ&_O.G]=40>:"OISB*N8.>[G
MA(P\"Z)W%O,=JVDL9J"Q6[4% :2ZTS9HP=]CO>OB>.3V.'%KAU$'*# V'5DS
M+A%9-701VV^O)$3FY\&K0/A0//,XXEA.\.\<5;"5K:[155FH1:M=4;]2:9)_
M)W41&2>F^*9V-&>'5*SCPR0.:[J*HO>G*)M7;JB36.F7G>8^&025L##\4\IV
MCSA_\Y!?W%=+RL=9-06N_0/EM-9'4=&<21CR9(CV/8<.8>X@+VO*L,3+JD/-
M>20\UWR'FO+(5TB'.TO/*>:\<IYKTRE>.4\UUK#SVEY)BO%*>:]4QYKQ3'FN
MU8>:TO+*>:\,QYKU2GFO%,>:[5AY[2\DQYKPS'FO5,>:\4IYKO6'FM9YI2O'
M*>:]$IYKQRGFNU8>>UGGD*\DIYKLJIHX8GR32-CC:,ESS@#TK):4TA?]93?^
MRH'4-LQEUSJXRUA'_P )AXR'OX-[^I6^K32C-Y-+1U->=NG&5=DD>^IAI*6&
M:JK:AV[#3P-+Y)#W =7:>0ZUMS0^SJDTK%!J?7<K'W&'C!1,\N*G>> P/]I+
MQX'J/(=:L>F['8M!L-)8:1UWU&]H;/4.(,KNO,DG*-G\D>@%9FEM<AJ_#[O.
M*VX GHSC$=..R-O5_./$KY/$<7;6]6.57Z#@_P"GTX?UK<[?CY/(::KO]9%7
M7V+H:6!^_26_/!IZI)NIS^QO)O>5EW'))/-=AYJ6TTTGO(W><\%YHY/H/,5U
MGK65CM;S^Z2!O<!E>J*W4[/?-+S_ "DW1 KH:7.PP%Q[ ,KT16RJE_V>X.UQ
MPK(R-D8PQK6CN&%R4F_886*QLYS3./<T87NI[=2P<6PM+NUW$_:O6BSNF0
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M".*(B0.)1"BHA.I$1$(B*B!S5B')5T<U8AR7+5\FZ"(BY-B(B B(@(B("(B
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M]>[RVTM3M+T3'FO#,>:AU952'$=AU&X_\)G;_>:%P=1:CJ1BATI=GD\C4&*
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M/L7L1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M8J]'#1RR]*@J5!7S7K$1$1"A2H0%"E0D H4J%4A"(B"$1%50H4J$1!4*2H2
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M]Z[BO*"HCDPTL/O?U)R*D1CDL\^;L:5R!74#A<P48=@4@K@"N0*@Y J0N"Y
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M?-_DGJ](7S>)X2='UJ\X:B<KNB(O&HB(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(B"(B"$1%8!05*@HCJJJ>&KII*>JB
M9-!(TM?&\9#@>HA?-&U?9W4:;J_#K<))+>]V8Y1SB.>#'']3NOES7TXO/7T=
M/<*.:DK8FS4TS2R2-PX.!7HX;B+:%LQT:K;'*>CY%M&M:RF!@NT0N,(X?E3B
M5GF?U_VLJQTE78+RP&EK&4TYYP56(W#^U[T^M6^_;$9I*N1]JKZ5].YQ+(ZI
MA#F#LWAG/J"]%AV)MB:3=[F&CJBHV8'I<X?L7U+<5P\QNB<2W%*^\I=3IF8
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M-6(<E71S5B')<M7R;H(B+DV(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M/VP:$;>Q?J4W,R]&;7PZ4-WL;W/.,<>2WSK+6T%OV5:9O#M.6BI96N ;1RQ
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MD#BB(J(1$1$(B*B!S"L0Y*NCFK$.2Y:GDW01$7)L1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MKZO]+CUK2S+&A<FKB%R:OM.<N^FB=//'"S&_(X,;GEDG"LNNM$W;1-9!!>!
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M(B(A$3J5$#FK$.2KHYJQ#DN6KY-T$1%R;$1$!$1 1$0$1$!$1 1$0$1$!$1
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MVRBH0_W_ (- V/>\^Z!E8&OTM57+:3;[]7SPOMELI7,HZ8 EPG></D=U>]P
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MW[_B+_[C%G5J_5TU/:$1%ES$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MU0I_<VXQ5YRS>Z0,SY/,8SGF@U9>]=-N>MM245UU-=;!0VN44M%%;*9SW2R
M9=)*[<=D9P WAP77<==ZEGV0T5=2UYBO<=[CMOAII^C;4LZ0AKRQPX!S2W(\
MZOE1HN\VK4MXN^CKQ2T8O#FR5E/6TQG8)6C'21X<T@XY@Y!2]Z K;QHZW6>X
M:@FJZVGN$5?+6SQ F0L?O%@:" UO4.>.]!AKI%J'1&J-+U$NJ*Z\6^Z5HH*R
MFK&,QOO8XA\>Z!N@%O)5NXZ\%XU7J6&YZINUAI;=4FDM\%MI7/WG-'E2RD,=
MO#>Y-X< MLZSTR[44UAD;5"G]S+C'7D%F]T@:UPW>8Q[[FL$_15[L]^O5PT;
M>J6CAO,@GJJ>MI3,V.;&#)$6N;C(QD'(R$%.EUEJNX[);5<H35BH9<3272MH
M:3,W@S'.!FCC<.!(#>KAD\%:=E=WAN-RKVVO6$M]MC8VD4EPCW:VFDSQ+CAI
M+3WMX'K67DTO?HM-V^DH-65@N])*9GUM3"V1M2222R1G#R..  01@<5Y=-Z*
MKXM;2:KU%<*6HN?@AHXXJ&F,,36%V\2[+G.<[([41?$1$!$1 6FMJ5S-FVSZ
M&KFT%9<#%1U@\&HV!\K\LQP!('#.3QY+<JJEYTDZX[0M.ZF%8V-MJAGB-/T>
M3)TC=W.]GACS%!2Y(;KKS:'I6\0:>K['06)\LL]1<6MCDGWV@"-C6DDCAQ)X
M)HM^IKW57N\UVJJJ*UVJ[54<=!#3Q_E8XGGR7O(SC' 8Z@MOJM:,TN-/4%UI
M9JAM4ROKZBL/D;H:)79W.9SCEE!K"UOU?>]FE1KINJZNFNCHI*VFH8V,\#9$
MTDB-S"W+B0/?9SQ7JU9K"ZUEKT7=*FHNUITW<J(U%?56B#I963%K2QI.'%C.
M+CD ]BR4.S34-%INHTG;=40Q:8FWV#I*/>JXHG$DQM?O!IYD9+<JS5FE[O;J
M:T1:.O3*&"WTPI/ ZR#IX)F#&''!:X.&.8../)%5:+PB_P"S"^NH-;2W*EBZ
M5\-7%$P3]$&',$^6\3G/' .,+IT?2W2Q[&8KG%JP4[IK73NIWW)C/!Z $#.-
MT NX' SGB!S5HTEH,VQNI*B\5K*JOU 1X6::+H8F-#"P!C<G' G)).2L*-FE
MYGT8--7'4L,]%1] ZW2-H0U\3H7AS.D\HB08 !& @JEGUI/0ZTTI36?4=]O5
M'<ZDTE?[J4ACA<2W(? XL;CB#Y(SP5DM$>HM=:AU/5PZHKK-06VN?045-1L9
MC?8!O/DW@=X$GDO?4Z#U%>=0Z;NVHM044ALM3T\5-241CC>,8).7D[QP./(#
M/#BJRZOIK/K75L-FUI2:;WZD35M#=Z1I(>6#,T!+QD.&#Q!X]2# 72]7>^;"
M+C/J&K\+N$.H64[GAH  94L&&@=0XX5ZVBWJ.EU)3TMPU97VVB%*UT=!98'2
MU;Y"3E\A#'89C  P,G*K>S31DNJ-BDMM%5+2PU5X=6T]1/'O.EB;,'-<1D>^
M#>??E7FHT5>K=JR[7K2MYI*4WAL0K(ZVD,^XZ-I:UT9#FXX'WIR,H*#5Z\U
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ML%%8+%;GV^STKM_=D?O/>[)/'TDGF<DJF- &<!0%R":>G73C;5SU+S><V<@
M>87)K1DX'/FH;R7(+;C,.3  , #"Y  # '!0WDN05ASF$AK<<@N8 R.')0%R
M"KE,.0 SR7-@ S@+@%V-1AR#1G.!E<@ ,X"@*4ASM"6M'8N> >87%JYA5RER
MP">(RNUJZQS78U1AR"]MHHW7&Z4E'&,NGE:ST9XGU97BY!;9V::7DMS'7.XQ
M[E5*W=AC=SC8>9/83]@\Z\_$Z\:%)M/7R>G@N%MQ6K%(Z>?R7T-:T!K!AH&
M.Y0I4+\P_>"A2H2 1%"J0A$1!"(BJH4*5"(@J%)4('4H4]2A4%"E0D(XHB)
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M6C!L=O@_[?;/G/\ 94_B?O?Z?;/G/]E;Q17^XZ_?[)_;=#M/U:/_ !07L?\
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M,1:,U^C/(B+#F(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MU<;M<;A%355'5U1F95L/[HX1GWN[VCEE;PK:F*CI)ZFH<6PPL,CR&EQ  R>
MXE!W(M<4.T^1U3;WW;2MYM-HN$S(*>X5.YN[S_>;[ =YF]RXCK&5WWW:1X#J
MJOT[;-.W6[W2EBCFW*7<#7-<"22YQ :!@<^9/#K0; 14_3.O[;=[#=+C6Q3V
MF6TN>VXTE6 )*8M&>..8(X@CFM:[2]I=RN.SJNEAT[J"Q059A-%<GN#0_P#*
ML/'<=O1[S0<9X'EUH-](NIC]RD$CLG#-X]_!:KIMLKJVR"\VW1M^J[3'O>$U
M,8CQ#NN(=@$Y?@#)QP&<<P4&V451U!KVW6VU6FJM\,]WJKN ;=1T@'25(+=X
MD9P T-XDGDNC3NO8[C)=:2Z6>NLUWM]/X5)156Z7218/EQN:=UPR,=Q075%4
M[-K:ENFSANL(Z2HCI#225?@[BWI,,WLCGC/DK$WC:C1VVETQ*VT7*KDO].Z>
MF@IF!\@(8'!A&>).\!D<!Q)X(-A(J!<MH[J*BM$9TW=I+_<P]T5G:&=,QC#@
MO>[.ZUO+B3UKW:4U[17DW6GN5)462Z6IG2UM%6XWHHR,B0.!(<TCK""XHM35
M&V84UDGOL^D+]'I\,+H*]S6!LWQ?)SO-#C@!QX<1VJR7_7T=O%II[9:*Z[W>
MY4_A45#2[H<R+ )?(YQ#6C) R>9Y(+JBI%MVB4=5I^_5U3;ZNBN-CC=)76R?
M=$T>&EPP0<$. R"#A87\;T<=/27.KTO>Z73506 W:5K1&S?P XLSO;F2!O8Q
MUA!M%%2C7T!VL10"6X&K?9C,,3_YKT?2@9W,^_X^^[%A:G:VT,J[A;M+WFXZ
M;I9',ENU.&&,AIP][&$[SF@@\0.HH-EQ5$,SY&12QO?&=U[6N!+3V'L78M4:
MCI+9;=;:+U=IWHX?=FL\%JWP#=;61RQ.<U[P.9!:"">*VN@(B("(B B(@(B(
M"(B B(@(B("I-QVK:(MU?445=J*CAJJ=YBEC<'9:X'!!X=JNRT+H?55!8[CK
M&GK-/7BYO??:EXDHK:ZH8!D#=+@, \.7>$&[+)>+??;='7V>M@K:.3WLT+PY
MI_\ ->Y:/TE27JQZ3UC>(S2:.ANMR$]*RZ ,;1PG <_<Y!YZFG'$!=^B]7U=
M+M#M5CCU14:HMUT@F<9JBD$)@DC <"QP: ]I&1CCC@@VKI^_V[4$%5+:9^FC
MIJA]+*=PMW9&'#AQ'VK*+1U\UC?*#91JR[4=8([A1WV:F@D$;1NQBH#0W&,'
MAPR>*RMZ=K#1=?9;S<M3^ZU'65\5'6V]U*R../IG;H,3AY7DDCF3G'%!MQ$1
M 1$0$1$!8#6<$HMS+G1Y\,MKO"68^&T#RV>9S<^G"SZB1C9&.8\ M<,$'K"M
M9Q.6J6VVB40R,FB9)&X.8]H<TCK!Y+DL'H:0RZ2M>]S9"(\]N[Y/[%G$M&)F
M"]=MICL(B*,B(B B(@(B("(B B(@+4FTC:A>=-Z[H],V*P0W6IJJ=LL8=,6.
M<XE_D@8QR9E;;7S5MD-V'X05@\7.@]V/!(Q3=/[S>_*\_1E%A=-.[7KDS6%'
MI[7.F9+%4UV!32"3?:YQ. #PY$\,@GCS6UW7&B;TV]5TXZ'A)F0>1Y^Q:6M6
MSC6FIM;VG4.T2X4#8[6]KH::D&2[!W@. P!G!)R3P5-T=HJV:WVQZ[HKV:@T
ME/,^;HX9"P/<97 %V.>../.@^FJVY4-#3-J*VLIZ>!V,22R!K3GEQ)7)U?2-
MI&U3JJ 4SL;LID&X<\L'DOEC4D515[:ZJS/TV[4=)::44U%:9JCHV-B:QH#_
M "N?,GOSGJ64V>:/NUWL>OM.5]$VDMT\8GH:-U7'4>"5 <XM W7$MZ@3@9PA
MA]+RU,$5/T\LT;(, ](YP#<'EQ735W*AHZ1M55UE/!3.QB620-:<\N).%\GR
MZAK=8[/=&[/H3*+L:YU-6L(.]'%$[R"X=P.?_EK)ZZAFJ-MXL;=/&_V^UT<<
M-%9GSB*/<$0.\,\#S)QW#L0P^H8JNFEI!515$3Z8MWNE:\%N.W/+"\\MZM<(
M@,MQHV"<XBWIFCI#G'D\>/%?-6CZ*\VJP[3J2HH/<ZS2VV:6.@\-CG%+)Y0W
M<-<2.!(R0/>CL7AL6@K)<?P?*[4E5#(Z\0B9\4QD=B,,D(#0W.,'!SPYDE##
M?.V'6TNAM(2W.@CI:BN$D;603N(!:YV"< YX+E==3W2IV>,N^F&6VHO+H()3
M!/,!$POP7 G>&.9QDA:*UC007G\'6Q:HN37U%]I@RCCJGO<7=%TSFX(S@\ .
M)XJR:JTS8;%^#U<:NPPL9/<::BEJW-E+]]P<"#Q)QQ<[D@WAIVX54FEJ"NU#
MX)2UCZ=LE3T3QT3'8XX=D\/25[K=<:*Y1&6W5=/51@X+H9 \ ^<+Y7U/(^Y4
MVR'3MPJ)(K%4T-.^=@=NM>2\-.?1P'9O*S26NCT5^$AI^W:3C-'15L %521/
M)806R9R,_P D.[L90PW]-=[=!%-+-7TD<<)W9'.E: P]A.>"]5//%4P,FII6
M2PO&6O8X.:X=H(7S'LLT59=9:ZVA1W^G?40TU6\QQB1S '.EE\K@1D@-X9[2
MK/\ @IU-0RFU3:'3R245!6-$#''.YG>!QV9W0?/GM0;RKJN"AHIZNKD$=/!&
MZ21YY-:!DGU!:XV':@OVK:6^7^\5#S;*FK++;3F-K1'$TG)! R<Y XGX)7F_
M")O$[=+4NF+4[-WU#4,I(F \>CW@7GS<FGN<5L+2EE@T[INVVBE $5' V($#
M&2!Q/I.3Z41[GU=,RH%.^HB;.6[PC+P'8[<=G!0VNI'TKJEM3 :9N=Z4/&Z,
M<\GDOG+:K9(=1?A'VBTU4TT-/544;)70NW7%GY4EN>P@8/<5X]M5DAT>_26D
M+%35,EAJ:A]5+1FH+?"Y3(P;A>>7/AV9SU(N'TK0W2@KX'ST-;35$,?OY(I6
MN:WSD'@N^GJ8*F$34\T<L1SY;'!PX=X7S+IRRWBCVK6KP/2L>F+76Q^#5]N%
MPB>V>(M<"[<WLGT \O.L9XSU6S"R:^T-F0RMF MKLD'<EX$CS,+7<.LE##ZJ
MBKJ26G?415,#X&9WI&O!:,=I7"W7.AN3'OMU9353&'#G02!X![\%?+FTJRU6
MC=#:#TJR.0T];(ZHN$+9.B%3,2P]&YW( ;Q SP& >I>_3]KOEIVKZ=J[1I1N
ME*:1S8:NC9<8G-J(R3EQ9O GMX \1E$P^E'7*A:V8NK*<"$[LA,@\@]AX\%Q
MK[K;[=&R2OKJ:F8_WKII6L#O-D\5\R[/]#6K7.T[7M+?34NI*:KDD;%%*6!S
MW32#>..> #CSE9;:'HRY0[1I;G#9*?65FCI&T[+::H=)2M:T-QN9SD$9! .=
MX]:&'T<R1CXA(Q[71D9#@<@CMRO'17>VUU1)!15])43Q^_CBF:YS?. >"^=+
M7JS1<.QR]4;/&&@@=5M@DMS*HNE#W D,C>>#8R&.SRY'([:AJ>EJ--UNCJZ@
MTLW2LO3 Q3-KNDJ*IH+/*D QCGZ<D(8?0=-KVMEVU56BS1TPH8:05 J 7=(7
M;C78YXQY2V(5HN@__>TN7_#1_A1K>A5A)$1$2!0I4(J%'6I4*P@B(@(44%!J
M;\(\_P#[*6AO6;DS _L/6UV_N;?,%I_:T_W=VBZ.TU%Y8;-X5.T<>&<\?[+'
M'TK</5PY*0J$1%01$51"(B 5"D\E" H4J$07%<EQ5@$10JHH*E0>: B(B(4%
M2H* H4J$@%"E0JD(1$00B(JJ%"E0B(*A25"!U*%/4H5!0I4)".*(B0.)1$5$
M(B(B$1.I40.:L0Y*NCFK$.2Y:ODW01$7)L1$0$1$!$1 1$0$1$!$1 1$08"\
M?PMT_P#S*G^ZQ9]8"\?PMT__ #*G^ZQ9];MTC^><NE_9K\O]R(B+#F(B("(B
M M=R4\WX_8:CH9?!Q8',Z7<.YO=..&]RSW+8B(-2Z8NK;#K_ %;8;K17**:]
M7+PBCJ(Z9SX7L?$QN=\<&X+3G*P&AM9NT'H-NE+G8+M/J2@,D$5''2/?'5DO
M):YL@!;NG/$GO6^40:KJ8:^?:WH6JK+<::06>IZ=D0+XX'G<\C?QCN7:::?_
M "C&U @F\'\7RPR[AW-[I>6]RSW+9Z(-?;7G"F=H^OD(;!2WZG,KCP#0\/C!
M/I<%A-=7QNGMLUEN,U%55=*RRSMG--'TCX6&5GY3='$@' ...#E;+U%9*#45
MEJK5=X!44-2W=DC)(Z\@@CB"" 05@[!H2ALEVMM?35MPGDH:*6AC%5-TI+'R
M!_E.(R2, #CR042PR3:MU_J75EOHJR"RLLIMT$E3"Z)]3)Q<2UA\K Y9PLGH
M>R5ER_!WI;.R)T-;4VE\+&3-+"'.#L @\EM5$'SG>-7"JV(U&D(;)?#J"GM[
M:2H@-$\-BZ/ <\OY%OD\,9)R."N-KI*ENU;14KJ>811Z8<Q[S&=UCLM\DGJ/
M<MMH@UI7TTY_"$M50()33BPS,,H8=P.Z5O#/+/<L1LUKSIK6&J=-W>AN$5;=
M+O-54DS:9[H)(WMR#T@&!R//K6XD0:$T;J3Q/T/7Z)N-HN\NH:=]5#%%3TCW
MQU D>]S'MDQNAN'<22,8*BCI[93;)M"MU39;T88(<MN5 US9[?)C@2&^6 [E
MP!'+*WXB#4^R:\7.HN&I#)7W6OTG31QNHJV[PF*;?PXR-!(!<T#'$A938"'/
MV9T54[E5U-54M_FNG>0?5Q5FUEI:BU;;8Z"Z3UT=()-][*6H=#THP1N/(YM.
M>2RUNHJ:VT-/14$+(*6G8(XHF##6- P $'H1$0$1$&M=NU//4V73K::"68MO
MM&YPC878:'')..0[U%JIIQ^$%?:AT$HIW6.G8V4L.X3TAR [EGN6RT0:XTU3
M3LVOZ^F=!*V&6EH@R0L(:\B(YP>15/-%5_Y*SZ7P6H\*Z)WY'HG;_P#I9/O<
M9Y<5O=$&E-97FNH-8PTFIJN_V[2WN?$ZD=:(GYFFQY;97L:7#'4W@J=#;JH[
M,-KC(;7=(!43QNIH*IKWSN80TC).2XXXGB<+Z<1%:BVF4E1+IG9TR*FFD?%=
M: O#8R2P!O$G X =ZR^I*>9^V_1L[()70,H*P/E#"6M) P">06QD1&EMGE%4
MQ[%M8P34L[)I*FYEL;XR'.!+L8!&3E=>I**J?^#=8Z9E+.ZI;3T =$(R7C#V
M9RW&5NU$&EM:WRHIMH=TH]6UFHZ*P"&(VQEGBDW*DEOY3??&"[>WLC=X#"Q&
MS^PW&NV3[2+9!;ZNGJZRKJFT]/5Y$AS&W=!<??'JSD\>M?0"(/G_ %!>FZAV
M)Q6NBMUUCN-K?;X*F">CD80X/ .[D>4!NGB.7!6&XU_B)M?OU]O='6OLU[HZ
M=D%72T[IQ')$W=+'AH)&>8.,+;Z(/GB]TEPNVSK:OJ!ELK*>GOCHC0T\D)$\
MC(\-WRSF-[.>W@KGM5I*B;8?%!#3S23B*B_)LC+G##X\\!QX+:B(/'>8'5-G
MKH(QE\L#V-'>6D!:WT8R34OX.]-16T!]5)9W436$X_*M86;I[.(6U%6=/:)M
M.GK]<+I:#5TYKLNFI1.XT^^3DO$?(./:$%6V95U!JC9YXJ5M#<*>HH[<RBKH
MJNE?$ 2TL.ZXC#N1/#N56V,6J[W+53&W][9J31D4EII7@Y;+.7',@[Q%N-6]
MI6E\3VM<6%P(#AS'>L'HC3%+I*PQVNCFGJ )))I:B<@R32/<7.<X@ 9R?L0:
MGTMK.BTEKO:&;M17%U)/= 6U-+3.G:'AGO'!N2#CB.&.?%8B325\NFSN]WJ&
MAJX)*S4(OL-"W\G4FG;PX#CB3'E +=VF]+TMANM^KZ:>>22\50JI6R8PQP;C
M#<#EY\K/HK15@%EU1JFQ,H9M=7=U'.VM<^XO,<%&YO(OWVC)XD8;E;5UYJ0:
M3TO67?P&IKWP[K64],PN<]SC@<@<#)XGJ"L"(CYRV>:PM;=0/U%K&GOMPU36
M.$46[:IN@H(R>$<>1PY\7?\ F3O#7<]XIM(7:;3,39KPRG<:9CAG+L=0ZSV#
MK*SJ(/F/4%51WRUV;W-?K&\76.OI)*N6X,F;%3_E&[PW" S.> #0<#)SP6TM
M*TT[-N&L9WP2M@?;J)K)',(:XC?R >16RD0:,N.F[A?KEMGMU)#(R:N;3"F<
M]I:V5P@!P">!R>'I6,VA:YAU-LIEL5KLE[-T:RF;4PR4$C13='(S>)<1@\1@
M8R>/9E?0R(/.\'W/<,'/18QZ%K38_2SP;!X()Z>6.?H*T=$]A:[C++C@>/'@
MMIH@^;76.MI-+;,=0U0O-/;[;0/I:XVX.;54PD;AKPW!.,\'<,X*M^AJ&W:@
MOEXKK2=4UA9;GT++G>GD1NZ0YW&-<T/." 2<86XT0?/%BU*;+L?J="55FO+]
M34M'443J>.C>YAR7D2"3WNYND'.<]@*S=KHJH:@V*N=2SAL%NJ!,3&<1GP4#
M#N'DG/:MV(@U=KFJ?I3:=:M55M%65-FEMTENFEI(3*ZF>9&O:YS6\=TX(R%@
MJ.@J]?:EUM?;92U%):JVR>Y%'-61F%T\GE$O#3Q#03C)6[ET5])%74-125+2
MZ">-T3P#@EI&#Q'+F@^=]7ZXCGV&UVF7V2[P7FFM[*:ICFI'-B@$>[O2&0^2
M6^3PP222."RNIJ,VO4&F[_<9[]2V6IL<-$^KLV\9()&^4!(&@G<<'=0YA6M^
MRVMJ;(S3MPU=<:K3#=UII'P1B5\;2"(W38R1P'5G"V9!$RG@CAA:&QQM#&M'
M4 , (K1UOME'6:3V@WNTTVI9WUEM?3,K+N[+ZP-C=@LCP'  \,D<>I9?:#25
M$GX-DU-'33/J/<NF'0MC)?D&/(W<9SP6W41&IZ&WU,^TZW@PS,C=I/H#*6$-
M:\O;P)Y9[N:P.B-9C0.A(])W.QW>HU);C+!'20TCWQU1=(YS'-D W=TAPR3R
MX\%O9$&LM>32U-=LVH:J&.FN4UTCJ)*6)V\(Q'"]SP#@9 .!E;-59H-$VFDU
M=4ZE=X54W:8.:R2IG=(V!KN;8FG@P'N5F0$1$!$1 1$0$1$!$1 1$0$1$!5/
M9_IFITV=0&KFAE]T;I-71]'GR6/Q@'(Y\%;$05#:7I>LU+;;<;544T-QMM;'
M74[:MA?!(YN1NO XXPX\1R.%@*+1VK*[7]@U+J2OLX9;8YXA1T+) UK7MQD.
M</*)//., #&>*V<B#5-YV:7*NV>:AT_'6T;:JY7:2X1R.WMQK'3"0-/#.<#L
MYJW;0].5&IK504M)-%"^GN--6.,N<%L<@<0,=9 X*T(@#DB(@(B("(B B(@K
M^@?X)T'F=_>*L"K^@?X)T'F=_>*L"W?VI=-7_);YR+K\(AZ?H>ECZ;&>CWAO
M8\R[%IJ8AOX2\1) '@/,_P!$5AS;E1<>EC^.WUITL?QV^M!R1<>EC^.WUITL
M?QV^M!R1<>EC^.WUITL?QV^M!R1<>EC^.WUITL?QV^M!R1<>EC^.WUITL?QV
M^M!R53NN@;/<]<6_5=2ZJ]U*%H9$&R 1D#>QEN./OSUJU=+'\=OK3I8_CM]:
M#DJIIG0=GT[J>\WZWFJ-==3FH$LF\P>47>2,<.)[U:>EC^.WUITL?QV^M!2=
M:[+]/ZNNL5TK?#:2YQM#/"J&<Q2%HR #P(ZSQYKWZ#T)8]#TM1#8H)&R5)#I
MYYI"^24C.,GNR> QS*L_2Q_';ZTZ6/X[?6@IUFV;:?M&MJS5-'%.+G4[Y<'2
M9C87^^+6XX$\>OK*XZWV9V#6%Q@N-P%92W*%NXVKHIS%)N\>!."#S/5GBKGT
ML?QV^M.EC^.WUH*/8-EFFK%8;O:J"&HW;K$8:NIDEWII&D'X6.'OCR'6O9;M
MGUFH-!3:0@-6;5*V1KBZ7,OEN+CY6.T]BMG2Q_';ZTZ6/X[?6@JM+L_L4&A&
MZ0DAEJ+,&D;LTF7^_P!_.\,<0[B,*OVW8KI:WV.\VFG?<O!+J(A/O5 +F]&X
MN;NG=X<2>U;*Z6/X[?6G2Q_';ZT%)OFR_3=[TM:[#7PSNIK9&(Z69LN[-&
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M>::$O&],&C+MT=>!Q7M6A-+VVZ6G4>QFAO\ O>Z$-+<&O:YV\6#H#NM)[0W
M]"RFN-7:HL]5=JN75&E[2RE<XT=I>SPB:I8T9&^X.!87=@'!!N=%I[5&TBXR
M6'1=30U%+I^"_P 1FGN59$9XJ8A@(CQD#+B>!.!@>K)U.H=36C9GJ:[5USLM
MSJ:&%\M#<* ;T<S0,^7'D@$'L)!0;.1:0NFJ=HM@M=AOU;4V6OI+N^*G%O;
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M9Y8XW%L$.Z1NQAQR3@ \<<RK!M0TC<]1[-H+';/!S71OI2>D>6LQ&YI=QQV
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MWYNX_4)O939;L>%?M+/HL!XV6[\W<?J$WLIXV6[\W<?J$WLILMV/"OVEGT6
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g762905g78p09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g78p09.jpg
M_]C_X  02D9)1@ ! 0$!] 'T  #_[2Q04&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0']            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             &(0  "/$          0
M       !              CQ   &(0                     !
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M;&]N9P  !B$     4F=H=&QO;F<   CQ     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
M  =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L
M;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U
M='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT
M3W5T<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M       ! 0 X0DE-!!0       0    %.$))300,     "(A     0   *
M  !N   !X   SD   "(% !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(               $  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MHV-;8^KZ7]97,2]]^.VY]1I<Z?T;B"0 2&F6>WWM]Z)-]$"-=7F<>@?LFHM
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MK6^VO^HNG56K&&-B6,W%[W!S[;#RYY'N=_Y'^0K2BD;-T!X!=T86_1']9O\
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
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M,C@   .@ 0 #     ?__  "@ @ $     0  "/&@ P $     0  !B$
M    !@$#  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H  ,
M   !  (   (!  0    !   !+@("  0    !              !(     0
M $@    !.$))30/]       (          #_X0$V17AI9@  34T *@    @
M!P$2  ,    !  $   $:  4    !    8@$;  4    !    :@$H  ,    !
M  (   $Q  (    >    <@$R  (    4    D(=I  0    !    I    -
M  'T     0   ?0    !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C R-#HP.#HP,2 P.#HT.3HR.    Z !  ,    !__\  * "  0    !   (
M\: #  0    !   &(0         & 0,  P    $ !@   1H !0    $   $>
M 1L !0    $   $F 2@  P    $  @   @$ !     $   $N @( !     $
M             $@    !    2     '_X4![:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E
M:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E
M.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V
M-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR
M9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R
M,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O
M;#X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C0M,#@M,#%4,#@Z,C K
M,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A
M=&4^,C R-"TP."TP,50P.#HT.3HR."LP-3HS,#PO>&UP.DUO9&EF>41A=&4^
M"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C0M,#@M,#%4,#@Z-#DZ
M,C@K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C
M.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H
M;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^
M"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#
M;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX
M;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @
M(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12
M968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D,V
M-S T148Y0C,T1D5&,3%"14,W.#E!.3(S1C P03E"/"]X;7!-33I);G-T86YC
M94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.D,R-S T
M148Y0C,T1D5&,3%"14,W.#E!.3(S1C P03E"/"]X;7!-33I$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z
M0S(W,#1%1CE",S1&148Q,4)%0S<X.4$Y,C-&,#!!.4(\+WAM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC<F5A=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z0S(W,#1%1CE",S1&148Q
M,4)%0S<X.4$Y,C-&,#!!.4(\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C0M,#@M,#%4,#@Z,C K,#4Z,S \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S
M/F9R;VT@:6UA9V4O<&YG('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T
M;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.D,S-S T148Y0C,T1D5&,3%"14,W.#E!.3(S1C P
M03E"/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(T+3 X+3 Q5# X.C0X.C4U*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M0S4W,#1%1CE",S1&148Q,4)%0S<X.4$Y,C-&,#!!.4(\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C0M,#@M
M,#%4,#@Z-#DZ,C@K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@
M9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E
M+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.D,V-S T148Y0C,T1D5&,3%"14,W.#E!.3(S1C P
M03E"/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(T+3 X+3 Q5# X.C0Y.C(X*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.D,U-S T
M148Y0C,T1D5&,3%"14,W.#E!.3(S1C P03E"/"]S=%)E9CII;G-T86YC94E$
M/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.D,R-S T
M148Y0C,T1D5&,3%"14,W.#E!.3(S1C P03E"/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD
M:60Z0S(W,#1%1CE",S1&148Q,4)%0S<X.4$Y,C-&,#!!.4(\+W-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O
M;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X
M.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_
M>'!A8VME="!E;F0](G<B/S[_VP!#  8$!08%! 8&!08'!P8("A *"@D)"A0.
M#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_VP!#
M 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" .M!5T# 2(  A$! Q$!_\0 '0 !
M  (" P$!              4&! <! @,("?_$ &(0  $# P$$! @&"PP'!@8
M!P$  @,$!1$&!Q(A,1-!46$4(C(U<72!D152<Z&RLP@6(S0V0E5RL</2)#-#
M5F*"DI.4P='3%U.BH^'B\#<X5&/"\1@E)G6#M$1V162$)T;_Q  ; 0$! 0$!
M 0$!             @$#! 4&!__$ #01 0 " 0,!!@0$!@,! 0     ! A$#
M$C$A!!,R05%QD;'!\")AH=$%%$)2@>$5(S/Q8O_:  P# 0 "$0,1 #\ ^J41
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%Y5=3!1T[YZJ9D,+!ESWNP
M![5S4SQTU/+/.\,BB:7O<>30!DE0ELHGW6:.ZW:,X\JDI'CQ8&]3R.N0CCG\
M7.!UD[$><JK7/6>'HV]U%5QM=IJJB+JFF(@8?0'>-[=U=O#+W^2*7^W?\BF4
M6YCT;NK_ &_-#>&7S\D4O]N_Y$\,O?Y(I?[=_P BF43,>ANC^V/U_=#>&7S\
MD4O]N_Y$\,OGY(I?[=_R*91,QZ&Z/[8_7]T-X9?/R12_V[_D3PR^?DBE_MW_
M "*91,QZ&Z/[8_7]T-X9?/R12_V[_D3PR^?DBE_MW_(IE$S'H;H_MC]?W0WA
ME\_)%+_;O^1/#+Y^2*7^W?\ (IE$S'H;H_MC]?W0WAE\_)%+_;O^1/#+Y^2*
M7^W?\BF43,>ANC^V/U_=#>&7S\D4O]N_Y$\,OGY(I?[=_P BF43,>ANC^V/U
M_=#>&7O\D4O]N_Y$\,OGY(I?[=_R*91,QZ&Z/[8_7]T-X9>_R12_V[_D3PR^
M?DBE_MW_ "*91,QZ&Z/[8_7]T-X9?/R12_V[_D3PR^?DBE_MW_(IE$S'H;H_
MMC]?W0WAE[_)%+_;O^1/#+Y^2*7^W?\ (IE$S'H;H_MC]?W0WAE\_)%+_;O^
M1/#+Y^2*7^W?\BF43,>ANC^V/U_=#>&7S\D4O]N_Y$\,OGY(I?[=_P BF43,
M>ANC^V/U_=#>&7S\D4O]N_Y$-=>V\39H'#L96@GYV ?.IE$S'H;H_MC]?W0\
M%_@\(93W&">W5+SAC:D#=>>QKVDM)[LY[E,+RJJ:&KIWP543)H7C#F/;D$=X
M4-;W2V:XQVVHD?+0SY\#ED.7,<!DQ.)Y\.+3SP"#RXL1/#<1:.G*>1$4N8B(
M@(B("(B B(@(B("(B B(@(BB[S='TLD5)0Q"HN4X)CB)PUK1S>\]31\_(+8C
M+:Q-IQ#)N5RI+; ):Z=L32=UH.2YQ[&@<2>X*-%?>*_C;K='20GE-7N.\1VB
M-O'^D6GN7O:K*REF-96RFMN;AAU3(/)'Q8V_B-[ASZ\J66YB..J\UKQU0@M=
MVEXU-^E8>REIXV-_VPX_.N?@6K_C!=?=!_EJ:1-TL[R?N(0OP+5_Q@NON@_R
MT^!:O^,%U]T'^6II$W2=Y/W$(7X%J_XP77W0?Y:? M7_ !@NON@_RE-(FZ3O
M+?<0A?@6K_C!=?=!_E)\"U?\8+K[H/\ +4TB;I.\M]Q"%^!:O^,%U]T'^4GP
M+5_Q@NON@_RE-(FZ3O+?<0A?@6K_ (P77W0?Y:? M7_&"Z^Z#_+4TB;I.\M]
MQ"%^!:O^,%U]T'^6GP+5_P 8+K[H/\I32)ND[RWW$(7X%J_XP77W0?Y2? M7
M_&"Z^Z#_ "E-(FZ3O+?<0A?@6K_C!=?=!_E)\"U?\8+K[H/\M32)ND[RWW$(
M7X%J_P",%U]T'^4GP+5_Q@NON@_RU-(FZ3O)^XA"_ M7_&"Z^Z#_ "T^!:O^
M,%U]T'^6II$W2=Y;[B$+\"U?\8+K[H/\I/@6K_C!=?=!_E*:1-TG>6^XA"_
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M7L!P7-!]*#LBZ](SX[?>N7.#1EQ  ZR@Y1=62,D&8WM<.XY79 1$0$1$!$1
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M&3U-8/)FJI-]S?1P SWJUHB"(T_IZBL3ZYU!TN:R8SR[[M[QCV=@4NB("(B
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M<[QRYO ;P:>S*#6^D;#-J38'I^BI;C:Z>OIKU)-1TU<_--5N9(_$&#Y33O9
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MJB)O OW>J>+B,<R 6GD$&S46/;JVFN5!3UM#,R>EJ&"2*1AR'-(R"%D("(B
ML#4/F"Y^K2_1*SU@:A\P7/U:7Z)6UYA5/%#UM/FNC^19]$+*6+:?-='\BSZ(
M64D\LMS(B(L8(B("(B B(@(B("(B B(@A-/><]0^O#ZB)3:A-/><]0^O#ZB)
M3:JW*]3GX?(1$4H$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!0FG/O\ U!Z_
M^JC4VH33GW_J#U_]5&JKQ*Z^&WWYIM$6!?ZIU%8KC5,/CPT\DC?2&DA9$9G"
M8C,X86GAX;5UUW?Q$SS!3Y_%A82/]IP<[T$=BG%B6BE;16JCI6>3#"QGN&%E
MI:<RV\YGH(B+$M#.T[:]0;;-;LN]RK:!D,-(6&FK33%Y,?$$@C>Y>Q7)VG;1
MI[0^KF6>ZUE>9[?*Z055>:DLW8WXQDG=YG/;P[%-W_9QI'4%REN%ZL%%65LF
M ^65I)=@8'7V!>EBV?Z5L+:UMGL='2-K83!4"-I^Z1GFT\>2"L;.;?2'['^A
MIS3QF":TR/D9N\'ES7$D]Y)6NH9F#9EL:JKL[-HBN#/"G2>0WRQ&7=PPOH>A
MM-#06B.UT=-'%;XXNA9 WR0S&-WT+#^U>R?:VW3YME,ZRM9T8I'-S&&YSR/?
MQ0:VVW5=LDU/LXA9+3ON7PY ]@:07B'>&\?S2=Q9>@Y((-MNT.*X.8RY3>"O
MIND(WG4XB .[W XSA6BU;--'6ET3K?I^BB?%.RI8_!+FR,SNNWB<\,G Y+.U
M3HK3FJGPR:@M%-6RPC$<CP0]H[ X$''<@T_,V2MKMMTFGONE))21L:Z#BU\X
MB=TF[C@3SRIRLNNFC]C9NB>B-*;*(61APSX1T> W'/?Z3VYXK95/88+)IFHM
MFDJ:CMCA&_P=HBS&V0C@YPZ^.,K2-3IJOGM=921[*:>#5M7"^EDNL;X6TC7/
M:6NG;XWB\"3@#*#RO1K(M.;&)XJBDIJ=C T35L9?3QSF$=&7@$?RL<>!5NJ;
M7=:C:?I&;4>IK!\*4CII(*6BI7LFGC,9#VDEQ\7''CV%7RUZ1M[-#6[3-XIX
M+C24]+'3R-F9EKRUH&<=7$<%SI?0^F]+SRSV&STU'/(-U\K07/([-YQ)QW(*
M;L0IX1>MHU0(V=._450QS\<2T'(&>SQC[U1YX)X]"[;:.UM<UL=Q>YD<?#=:
M0TOP/S05OZU6:WVE]:^VTD=.ZMG=4U!8/WR5W-Q[RNMNLEMMLUPEH:.&&2OE
M,U46C]^>1C+O8@UEM"KK"_['B<P2TKJ*6W11TC6D<9<-W T?&#L>C!6 Q\EM
MVK[-9KU(('RZ>?3%\IQO3AK=YN3UY/SJ^4>S#1=%=67*ETY01U;'](QP8=UK
MNT-SN@^@*:U/IFS:HH6T>H+=!74[7;[6RCBUW:".(/H0:[O5?2U7V1NFX*:>
M.66FM50)FL=G<+B2 >PX&<*+HJ&XV*TW^Y;/]16&[Z;?43U53;[E'P8\Y,C.
MD:<]7)P6R[%H;3-AJ*:HL]EI*2>F:]L4D;?& ?Y7'F<X'$K#NNS/1MUN4M?7
MZ>HI:J5V_*[!:)'=KF@@./I"#.V=7FGU!HBS7.CH1005%.US:9H ;%CAAN/Q
M>'#N5 TG46V'[(G7+*M\++A)2THIND(#G-$3-\-S_,SZ%MVG@BIJ>."GC9%#
M&T,9&QN&M:.   Y!:R;LY@O.T36-=JFTTU99J\4CJ-TC@3OQQ[KB,'>:>KJR
M@J%UWJ[5NU^33!Z2$V6.*5U.>#JD,=D#'-V[D>E=**&Z7#8I3,J=2:3I=*RV
MYD#C)1R;T0W<8)W_ -\![O*');NTWIVT::MW@-AM\%#2;Q<8XFXWCVD\R>\J
M#_T8Z+^%?A+[7*#POI.ESN'=W_C;GDY]B#6^JVT%KU=L=9?:V&JI(()&&JD&
MZR1W1L$;SGEEVZ>/<K!M%FIJC:_LXBMSXY+I%-423=$<N;3]'QWL=1XXSWJ6
MU[I"?46OM(U<M#!5V2C95QUS92TMW9(]UHW3Y63V<E/Z6T-IK2M1-/I^STU%
M/*-U\C 2XCLR22!W(*=IFHIZ7;WKF.IEBA=-14+HFR.#=\!A!(SSXE0%9'4R
MZLVV,H0\U3K=3B,,\HGP8\EM346C-.:CJZ>JOEFHZVI@QT<LK/&;@Y SSQE2
M%'9K=172NN-+2115U<&"IF:/&EW!AN?0."#5M%<-.#[&QI?+1^ BS=$YF1^_
M]'C=Q\?I/;E4RL-9%I?8I/!44M-$UI:)ZV,OIV3F-O1EX!''RL<>!6Y!LPT6
M+G+<!INW^%2[Q<[<.,N!!(;R!XGB IF?3%DJ-.LL,]LII;.Q@C;2/9EC6CEC
M/9V\T&MY[9=9]J&E)M1ZFT_\*4G3/AI:.ED9-/$6$.:<N/B]?'L*W JYI?0^
MF]+3RSV&T4U'42C=?*T%SR.S><2<=RL: B(@(B("(B B(@A-3M-*VFN\8\>A
M?F3'XT+L"0'T##O2T*;!! (.05Y54#*FEF@D&62L+'#M!&"H_2DSI].V]TIS
M(V(1O/:YOBGYP57-5SUI[)5$12@1$0$1$!$1 1$0$1$!$1 1$00]Y\]V#Y>7
MZEZF%#WGSW8/EY?J7J853Q"[<1[?61$12@6/<JVGMMOJ:VME;#2T\;I99'<F
MM R3\RR%0]9__4^JK?I)GC6^%K;C=\<G1M=]QA/Y[VY(^*P]J",M5>;?;;CM
M!U%3R&X7!C8;;0X^Z1P./W"!H_UDCB"[O(')JM&A;!/;*:HN-Y<V;4%S<)JV
M5O$-^+"SL8P<!V\3S*BZ%OVVZ[FK7^-9=.R.IZ5OXLU:1B1_>(QX@_E.?V*]
MH"(O"JK*:D,0JIXX>E=N,Z1P;O.[!GK0B,\/=$'$9')$!$1 1$0$1$!$1 1$
M0$1$!$1 5!NC?M(U1\+0C=TY>)FQW&/\6EJ7'=94#L:\X:_OW7=JORQKI04U
MTMM505\39J2IB=#+&[DYKA@CW%!2+&/M*U@;$X[NG[P]\]L/XM/4>5)3CN=X
MSVC\X=BV M84-MGONF[MHJZ53V7RR/8ZBKCY9:/&IJ@=I&-UW>UW:KAH2_NU
M'INGK:B(05S"ZGK*?_4U##NR,]XX=Q""?1$0%@:A\P7/U:7Z)6>L#4/F"Y^K
M2_1*VO,*IXH>MI\UT?R+/HA92Q;3YKH_D6?1"RDGEEN9$1%C!$1 1$0$1$!$
M1 1$0$1$$)I[SGJ'UX?41*;4)I[SGJ'UX?41*;56Y7J<_#Y"(BE B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(A.!D\E0ZO:QI2FJ9835SR&-Q:71P.+21V'
MK'>KIIVOX8RYZFK33\<X7Q%K[_2]I3_Q%7_9G*P6+65DO=JJ[C15G[FI,F<R
M,+#&,9R055M'4K&;5E.GVC2U+;:6B96%%1CM3TSG]_J3_P#X[D_TI:9'\-5?
MV=RSN;^CV_RNM_;/P7E%A6:Z4EYMT5=;I>EIY.3L$$$<P0>16:HF,=)<9B8G
M$B+JY[&%H<YK2XX:"<9/<NRQ@B(@(B("+'DKJ2.GDJ)*J!D$9W7R.D :TYQ@
MGD.*]V.:]C7,<'-<,@@Y!"#E$1 1$0$71TT;9FQ.D8)7 EK"X9(',@+N@(B(
M"(B B(@(B("(B B(@(B("A-.??\ J#U_]5&IM0FG/O\ U!Z_^JC55XE=?#;[
M\TVH;67X+W/Y$A3*AM9?@O<ODBE/%!I^./=,CD$0<@BE B(@KEAU73WC5>H;
M%%32QS68PB25Q&[)TC=X8Z^'>K&M%6G2[-4;8]H<%9<;A36^)](9(*.<PF9Q
MB\4N>WQL#!X \2>/)9VD+Q<-(UNTBQOKJFYTFGJ1M?0.JWE\C6NB>_HW.YD
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M 7$M?D.WH]T=6,<.2^AK#/3U-EH9Z*K=6TTD#'1U+CDRMQP<3@<3SY(,Y$1
M1$0$1$!$1 1$0$1$!0FG/O\ U!Z_^JC4VH33GW_J#U_]5&JKQ*Z^&WWYIM0V
MLOP7N7R14RH;67X+W+Y(I3Q0:?CCW3(Y!$'((I0(B("(B J/M<T<-6Z<(IF
MW.C)EIC\;XS/:/G 5X172\Z=HM7F$:FG&I6:6XE\324CHWNCD:YKVDM<UPP0
M1S!"Q0]]'4Q5%.[<FA>)&.'4X'(/S+Z,VL[.'78R7BP1#P_&9Z=O#I_Y3?Y7
MZ?3S^=;DQ\,DD<K'1R,):YCQ@M(ZB.I?H^S:U=>N8?F+=GU.SZNVW'E+Z^T#
MJRBUA8(;A1N:)@ VH@SXT4G6#W=AZPK&OB+1FKKCHV_QW&VO);G=G@)\29G6
MT_W'J*^Q=(ZCH-56*FNMKDWH)1XS3Y4;NMCAU$+XW;.R3H6S'AE^ET=3?6)G
ME,(B+Q.HB(@(OEO6^K=5[1=J,VD=*W*6W4$,TD ,4KH@[H\[\CW-\8C@<#ER
M[5YZBT-M*V<NI;E8+]<KQ&YX:]E-TLI:[F-^)Q<'-/;^A!]4(M)[3M3WFM^Q
M_CO,L5;8[O*^%LT;2^"1CA+NNQR< <9'<58?L=*^KN.RV@J+C5U%74&:8&6>
M0R/($AP,DDH-EHJ=MBJJBBV8:EJ:.>6GJ(Z-Y9+$\L<T]H(XA?.^RW26LMH-
MFJ[A1ZXN-$RGJ/!RR6IG<7'=:[.0_P#E(/KE%\Q;.-9:LT?M69HS5-RDN=-+
M.*9QED,I8YS<L>Q[O&P<MR#V]H7TZ@(J?M1UW1Z TZ+E64\U3+*_H:>%@P'R
M8)PYW)HP#Q]P*^4]1:YUO<]1VZY76XW*WLK7,EIH()7P1=#OX!:T$9&0>)YH
M/MQ$'((@(B("*O7_ %?:[/,*8O?5W!W!M)2MZ24GO Y>U1'@FJ=2\:^<6"VN
M_@*<[U0\=[_Q?8KC3G&9Z0[5T9F-UND?FFK_ *LM-E<(JFHZ6K=P92TXZ25Q
M[-T<O;A0W2:MU'^],9IZWN_&?]TJ7#T<F_I4]8-,VJQ-/P?2-$SO+G?X\C_2
MX\5,K=U:^&/BW?2G@C,^L_M_]4.ZZ.M5HL-?5ADE7<-P$U=4[I)"<CB">7L5
M\4-K+\&:_P#,'T@IE9:TVC,IO>UZQ-ISS]!$10Y"(B B(@(B("(B H36/FB/
MUNF^N8IM0FL?-$?K=-]<Q53Q0O2\<>Z;1$4H$1$!$1 1$0$1$$/>?/=@^7E^
MI>IA0]Y\]V#Y>7ZEZF%4\0NW$>WUD1$4H4BU@6_:U?J5_P"]W>W05S >1=$3
M$_YG1?,N^R,FGTDZT//W6S5<]N<#U-8\]'_NRQ>>T,_!=ZTKJ(<&4E;X%4N[
M(*@;A)[A((BH6_72LTCKVYQ4,49BOU/'61ODXL9-%]SEX#&26=#PR.1[..Q&
M9Q V!>KY066.-UPGW#(2&,:TO>['/#0"<#M5-O\ KIU1,R#3TS6L:P/FEDB.
M^TDG#0UV,<LY(ZQCM5+U%J&:2Y1U=\EBW'1=$R2-A:UFZ2XY&3C.>?\ )53N
M^HG"X/DM!#^B8&/#V\)#S'/'('@>\KUZ79IMY(FRZW&ZU]XK7,NL_3=%&TQM
M8"QF"3Q+<XWLCGV8QCBH!]ZH;;555-43/):XO:,%Y.1EPSUG)//M5*J;I5UM
M2^=U0Z.8C,;FY8-P'BT@<1QSGTY6#ESX).#B0ULS#^,PN))]./GY+W4[)_=*
M)LL$VJ*UL4C*1D3(YRY\3R"2"XD[N<XSQX'M6(V_7%E"VFIYL0O;N,<YOC-(
M)RTGJX#&?^"C& .WQ#NDB03,;R:YN.H^GCZ5W;$\1M#"PF-V_'D^5SR#[^:]
M,:-(\DYEY3EL@+HV$=)$[#>UXY>T<4J"UV^Z([V]$9 1UN' .'>!S7H3T-(0
MUS'M;@QGGAN1Q/H[5R^8;DKL,^YR-W<_BYQXQ]Y.>Q=,,;5T5J0W$T]$^*)C
M&P[K',=G>+1_>.KN5YMY8)RV4MZ-S2UP=R(/45IFRRBDHX*B!@#X)M_ ZSGC
M[PMJV^KCKJ*&IA!#)&Y /,=H7Q-2L9F(<ZSB75]-)9JNGHGR=)0S MII'>4P
MCB(G'KX9P>!PT@YYK/A932QST]:P/@F9N.:>1X_]<5[FC%VL]31U#L,<-V-^
M,NC=U.'>#@A1%MJ9*F*5M3'T53!*Z"9O5OMYD=QR"/2N4=>DND]/Q0[T-T;9
M;M+9JYYD>_$E+-(>,T9SP)Y%PX@]O ]:E*^U05].,0QS0/PXQR $9]!4?J.T
MB[Z;8Y@!JJ)_A$)(XDL.2S/5O 8]W8I735PI[G9X*JDDWXGYY\"TYY$=JF9Q
MUA<1GI/#2&MK ;'>,LCC%-,Y[X]WAT?'BW'N57A>UL8=%#XPAW@UI_%_%'I/
M'YUO[:#;&U&GZY[8NE?N[[6XXM<..0?8?T+1<%IN#!3/;2R1].TAI(\7+CEK
M?0,GFOK=D[1%J8M/",3$X8HD>Z&7HB'.;&W#VCBXD9R!V=B/G#HISEKVMW0P
M.Y$'&''NR?F4Q-IFOHS#CHW&1H@:YCL[KCUNR!U_W]J];GIBHH*0RP.94^(V
M$1AI&,\!Z<D@+OW]/5N)0CWD,E,;2UK91O%O,@$;QPNCI26&1QWA%*9'-_D8
M.".WA@^]24EBKJ9XBDB,?A 9#&_(/CXQDXY'B/<I>?2+88V.?5%T9+&2@,QN
MM!_%X]_7_P $MKTCS,2JNX3#NEKC/&\,=CCO;SAGAU@@\O\ !9%3;ZFG9$VH
MIYVN=(&1[[3ES"0"T]O#JY\E='V.GM]72U5##/*\3 .A;F1TA(W<@<\C@?8K
M ZVU]=N^"V^I=T+VRN,D9CP >(;O 9<>6!WKA;M?I'1L5:YH+-425E)2UK)J
M=KI26.>.): 3C/;C^Y;-V1V&EI]H%9/2M<(;?;@TESLXDFD)^C%G^<O>V:?F
MO-?3Q5='50T<4G2RR2L="1@' :3@YR1RZL^@^MDJ/@#93J+4%&7OJ;Q.]U 7
MX+W!Y;!3#@!G.&._G%>'M/:)O&'2M<+5LH_=5KO-Y/'X6NM341GMB:_HH_\
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M=GU)J*_:5J:?:E;*1]5X5F.!\<;FF,!I:2&DC.]O+2GV430W:AIYK0 !1P@
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MYVHDBJI6X;( [=<".76"#PZ\C@M:V_2!UGMPV@445WKK7- 7RLDHY=PN=EH
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M:.3?1W+V1!BQ6VAAJWU4-%31U3_*F;$T/=Z78RO=D,4<DDC(V-?(07N#0"[
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M 1$00VLOP9K_ ,P?2"F5#:R_!FO_ #!](*95?TKGP1[S]!$12@1$0$1$!$1
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ME^"]R^2*4\4&GXX]TR.01!R"*4"(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B"&UE^#-?^8/I!3*AM9?@S7_F#Z04RJ_I7/@CWGZ"(
MBE B(@(B("(B B(@*$UCYHC];IOKF*;4)K'S1'ZW3?7,54\4+TO''NFT1%*!
M$1 1$0$1$!$1!#WGSW8/EY?J7J84/>?/=@^7E^I>IA5/$+MQ'M]9$1%*!$1
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MZA]>'U$2FU5N5ZG/P^0B(I0(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M5U);*NWU56YC"XQQ!F"X@<<#(69M(O\ ;-3OV<W&Q53:RB.IH&=*UK@,@G/
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MR<#>.,K25PN]SN%9''<:^::/HR8PP]%@@C.0S )XCCU8]^$UYKZJJ%;*ZM?
MX1M,[ND<QNZ"&\?2>/,]>4C1]95N;QNUQI[5;YJRL<6PQCCNC)<2<  =9)P
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M/YN<H,I[&OQOM:[!R,C.#VKI/!%4,W)XHY69SNO:'#YUZ(@X8QL; QC0UH&
M , +RBI*>*5TL4$3)'<WM8 3[5[(@X#&AY>&M#R,%V.)7D*6G$_3B"+IO]9N
M#>]_->R("(B H33GW_J#U_\ 51J;4)IS[_U!Z_\ JHU5>)77PV^_--J&UE^"
M]R^2*F5%:KB=-IFZL8"7FFD+0.LAI(^<)3Q0:?CCW2HY!%YTLK9Z:&5ARU[
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MW+(8Y7'<C)&2X-!QO'@,]@"OMDV?&FO])>+[J&ZWVLHVEM(VJ<UD<.1@NW&
M NQUE3&EM*TNG;C?JREGFE?=ZOPN5LF,,=C&&X'+TH-9V'25DU)MJV@NOUOA
MKV4W@@BBG&\QI=" 7;O+>P, ]62L+91L_P!.76X:UHKO0-N%);+I-;J&*J<7
MMI8<[V(\^227<QQX!;:LNE:6TZIOU]AGF?47@Q&6-^-UG1MW1N\,\>]-*Z6I
M=.5E]J*6>:5UWKG5THDQACW  AN!RX=:#0[*^LCV%4]G;63LI7ZD-E=*'^.V
MEZ5WB[WH&/1P5JVMZ2L6B;!9K]I2W4]KNMON%/'#)3#<=*QSMUS'_&!!ZU=Z
M79I96:.N6FZMT]50UU5+5N<\@/C>]V]EI X8/)8-%LP#[C;JC46I;Q?J>W2"
M:EI:QS!&UX\ES]T O(ZB4$"ZS4&L=NU_IM3TT==26:WT_@5).-Z,&3)>_=/
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M]_Z@]?\ U4:JO$KKX;??FFT1%*!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M;:O>BKA501Q.I21PEBQS /XJ#8%FOMNO,UPCME4RH=05!I:C=!PR4 $MSUD
MCDI):+^QTM-WI[YK6>KO\E530WFHIYJ=U.QHGFQ&>G)'$''#='!;T0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!0F
MG/O_ %!Z_P#JHU-J$TY]_P"H/7_U4:JO$KKX;??FFT1%*!$1 1$0$1$!$1 1
M%P3@H.477)3>.$'9%TWBF\4'=%TWBN-X]J#T1>>\>U<;Y[4P/5%Y;[NU-]W:
MMP/5%X[[NU<=([M3 ]T7ATCNU<=(_M3#<,A%C]*_M^9<=*_M^9,&&2BQNE?V
M_,N.E?V_,F##*18G3/\ C?,G32?&^9,&&6BP^FD^-\RXZ>3XWS)@PS46%T\G
MQOF7'3R?&^9,-VRSD6#X1+\;YEU\(E^-\P3!ME((H_PF7XWS!<&IE^-\P3!M
ME(HHWPF7XWS!>T59QQ*!CM"8-LLQ$''DBQ(B(@(B("(B B(@(B("(B B(@(B
M((>\^>[!\O+]2]3"A[QY[L'R\OU+U,*IXA=N(]OK(B(I0X>UKVEKVAS7#!!&
M00J"PNT%>!&XN.EZZ3Q2>5%*>K\P_-^F_K'N-%3W&AFHZV)LM/,TM>P]85TM
MCI/#KIWV]+<3RR 00"""#R(14?2];4:<NS=,7F5TD+@3;*I_\(P?P9/QA_UU
M*\++5VRG4ILG'D+A[&R,<R1H<QPPYKAD$=A7**4*+4:.KK!/)6:!K(Z)KG%\
MEHJ<NHI3U[@'&$GM;P[6KHW5MGN4C+/K6VNLMQD.&07#'12N[89_)=["'=RO
MJQ;E;Z.Z4<E)<J6"JII!AT4S ]I]A04*[[-V',MEJ]T'B(9^(]CQQ]X/I52K
M]/W2V$^&44S6#^$:-]G](<O:KW]HM59R7Z*OU7:8QQ\!J/W52'N#7G>8/S'
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MYY"E[3HW35G(-KL%KI7#DZ*E8#[\96!IO:/I+4E<**S7REGJW>3"26.?^:'
M9]BQ+QM7T79[G4V^XWR*&KIGF.6,QO.ZX=60,(+PBB=-:DL^IJ)U78+C3UT#
M3NN="[)8>QPY@^E2R B(@(B("(B B(@(B("P-0^8+GZM+]$K/6!J'S!<_5I?
MHE;7F%4\4/6T^:Z/Y%GT0LI8MI\UT?R+/HA923RRW,B(BQ@B(@(B("(B B(@
M(B("(B"$T]YSU#Z\/J(E-J$T]YSU#Z\/J(E-JK<KU.?A\A$12@1$0$1$!$1
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MGX23;Z(B>N<.L]3/G ]I[%>L     #D JILTM[*;3<=:YQDJK@XU$TCN9.2
M/^NLE6LJ+SUVQY.>I/7;'$.$*(5S<X9MN\A_I66L2W>0_P!*RU,\N=N1$18E
MUD8)(W,=R<,* >TL>YKN8."K"HNZQ;L@D')W ^E565TGR8"(BZ.KTBE?$<QO
M+?0LV"Y=4S?YS5'(%DQ$LF(E8(IHY1F-P*[JNM)!R"01UK+@KY8^#_''?S43
M5$T]$NBQX*R&7AO;KNQW!9"ESF,"(B B(@A[SY[L'R\OU+U,*'O/GNP?+R_4
MO4PJGB%VXCV^LB(BE B(@(B(*'<VG1FI?A2($6&YO#*Q@Y03'E(.P'D?_97P
M$. (((/$$+&N5%!<:">CK(Q)3S,+'M/6"JMH:MGMU74Z7NLA=4T0WJ25W\/3
M_BGTCD?^"ZS^.N?.'>?^VF[SC]8_TN2(BY. B(@JFUBHFI-FNIIZ9[HY64$N
MZYIP1XI'!:=V?6JT4FP>EK9-&NU#/7RRQU+:=C3,&[[P'[QXM#0T8QR7T%=[
M=37:UU=OKF=)2U43H96]K7#!_2M)TFR+6]EH*JR:;URRGT].YWW.6#[JQKO*
M (Y$]Q;D\>""CW.NLU9]CG=F:=I*^DHH+O$WHJRH$SMX[I)! &!QY=N>U9&U
MB>*EMFQ^HJ*=U5#%2QO? Q@<96CH26AIYD\L=ZV9<]CD3=DWVG66N9'.^H94
MRU=0PGI'@Y)('+@  .H <^:[ZGV5UMW.@NAN=/%]K@C$N]&X]-NF,^+V>0>?
M:C6MKM3RZ^V@Z4FT=HJOT\RWU+9:NLGI13 M#V.R=WAP#78ZSO86#'J"WZ=V
MSZ[JKKIN>_P&1XZ.*G;-T.' EYWN &.&5]7K76CMGM18MHVJ=1U-;3U%-> 6
MLIVQD.8"X'QB>!Y(*)]C1;IZS4>J=54=&RW:?KW&*FI6O! <'[V !RW1P_G<
M."^@%KC9AL]K=!WV^-H[C#+IRNDZ:"CW'!\#^KCRQCA_-:MCHP1$0$1$!$1
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M]_Z@]?\ U4:FU":<^_\ 4'K_ .JC55XE=?#;[\TVB(I0(B("(B B(@+A<KA
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M1U-5J>!EIT.!9M*4XZ%]TAC#3,!P+*4<L<P9>7Q<\US&Q^T27HX=ZFT-3G<
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M(*MJ72$=?6B[V2I-HU"P8;61-RV8#\29G*1GIXCJ(5>F\&U=4LM&HX7V#6E
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MCV$'DLE=)Y6PP22OSNL:7''8 D-B<<(O4MSEMM)#X,QCIYY.C89 2UOBEQ)
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M#4/F"Y^K2_1*VO,*IXH>MI\UT?R+/HA92Q;3YKH_D6?1"RDGEEN9$1%C!$1
M1$0$1$!$1 1$0$1$$)I[SGJ'UX?41*;4)I[SGJ'UX?41*;56Y7J<_#Y"(BE
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M86M=(Y@/(N#0=T>G""WHL2TW*BN]O@K[750U='.W>CFB<'-<.XK+0$1$!$1
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M]:QV7W@&6LM<AX28GC[B.#A[01[E<+C>66>MIYC!X1,UI?#&YQ# _( <['/
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MCIBTZ2LL=KL-**:D82XC)<Y[CS<YQXDGM*F4!$1 1$0$1$!$1 1$0$1$!$1
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M>^%U?@=-3RD-#R&[N1G (+>!&1VKBVVO7]\U!35E_K19;= 074U%-^^@'.,
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M3NCM.!Q[N]5N^7%UWNM3<)((H)*AW2/9%G=WL<2 >63QQWJZ:?T%K"T7FDN
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M^XZ>XWN_7.TT3VOI[;5U0= PM\D$!H+@.& 2@V+!OF",RX$FZ-[';CBNZ
M < $0$1$!$1 1$0%":<^_P#4'K_ZJ-3:A-.??^H/7_U4:JO$KKX;??FFT1%*
M!$1 1$0$1$!<+E<("X*Y7!YHR' 3J0)U(UPA (((R#P(1%HZL8V-NZQK6M[
M,+E<KA!PAY(B#A.U%PM:X0HA0<+A<KA(;##N5KM]S8UMRH:6K:WR1/$U^/1D
M);K;0VR-T=NHJ:DC=Q+8(FL!]. LQ<+<SPW=.,.$1"L'"X7*X0<+A<KA!PB%
M$:X75=EU6PV'"X*Y7!1KA"B%"&;;O(?Z5EK$MWD/]*RU,\N=N1$18D1$0$1$
M!$1 1$0$1$!$1 1$00]Y\]V#Y>7ZEZF%#WCSW8/EY?J7J853Q"[<1[?61$12
MA2=K#'4EEH=0PM)EL-9'7OW1Q,'%DP_JWN/\T*J;4Z..EU?:KJ';]!=X!2/
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M(B("(B B(@A-/><]0^O#ZB)3:A-/><]0^O#ZB)3:JW*]3GX?(1$4H$1$!$1
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MIR^S6 \1:*>7[O4-[*B5ODC^0P]?$E7F@HZ:WT<-)0P14]-"T,CBB:&M:!U
M!0(_2^GJ#35L%%;6/PYQDFFE=ORSR'G)(X\7./:5+HB B(@(B("P-0^8+GZM
M+]$K/6!J'S!<_5I?HE;7F%4\4/6T^:Z/Y%GT0LI8MI\UT?R+/HA923RRW,B(
MBQ@B(@(B("(B B(@(B("(B"$T]YSU#Z\/J(E-J$T]YSU#Z\/J(E-JK<KU.?A
M\A$12@1$0$1$!$1 1$0%PYH<"' $'J*Y1!&3V*AEJ8IS$6OC>'@-. 2./$*3
M1%N<LB(C@1$6-$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MRK/%&R&)D<+&LC8 UK6C :!R "#LB(@(B("(B B(@(B("(B H33GW_J#U_\
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M[SY[L'R\OU+U,*%OYZ*X6.H/D,JRQQ[-^-[1\Y ]JFE4\0NW$??F(B*4"(B
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M$+X7\C;;LW=/9O\ Q]MNS?T]O]JCLEAEAT;!TL;F;\KWMWAC+2>!5Q0# P.
M1>[3ILK%?1]#3IW=(KZ*'J?08U3KZWW._"DJ]/T%&^.*@E9O[\[SQ>X$8P&X
MQWA8.L]D>GKEIZI@TY:;7:+P"V6EK(:<,,<C7!PXM&<'&/:ME(K6T9J2CO\
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MSM5CCI[]=WW:XESGRU+HQ&,DYW6M')HY!32("(B B(@(B("(B B(@(B("(B
MB(@*$TY]_P"H/7_U4:FU":<^_P#4'K_ZJ-57B5U\-OOS3:(BE B(@(B("(B
MB(@(B("(B!A,(B!@)A$0,!,#L1$# [$P.P(B!@=@3 [ B(&!V!,#L"(@8'8$
MP.P(B#C='8$W1V!<H@XW1V!-T=@]RY1!QNM[![DW6]@]RY1!QNM^*/<FZWXH
M]RY1!QNM^*/<FXWXH]RY1!QN-^*/<FXWXH]RY1!QN-^*/<N41 1$0$1$!$1
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M;EI:X8(*]6G.Z'AU:;9<^$RS9Z$M9'G&^1DGT!-UW743D]S@/[EYQC=8UHX
M !="R3)Q,X#\T*\.7LR!+T+"9)BX9YO(1M0)!EC@X=H.5X,@:';QR]_QG<2/
M1V+,H;=+5U36T\3GS/X8:.)0Q$L8/Q61N?G=W2UI['$_WJS:>H/":]C8V?=)
M2 YW7@?W!9UHT9633-\(88(@?&<[GCN"OUJL]':P?!8SOD8+W'+L=G<N5[Q'
M#OIZ5IY9T,;88F1Q@!C1@!=D1>=[!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 4)IOC6WYW4:\X]D48_N4VXAK27'
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M3;7U32*%^ IORW=OZQG["? 4WY;NW]8S]A,1ZFVOJFD4+\!3?EN[?UC/V$^
MIORW=OZQG["8CU-M?5-+AS@UI<X@-',DXPH;X!D_&O5V([.E:/T-7#=+VQS@
MZJCGK7 Y_==0^8?T7'=^9,1ZFVOG+B?44,DCH+-$^Z5(X'H#]R8?Y<ODCT<3
MW+O;K1*:MMPO,S:JN;GHFM&(J?/Q >OJ+CQ/<."EX8HX8VQPL;&QO -:, >Q
..=DW8Z0;XB,5$1%*'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g762905g95p90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g95p90.jpg
M_]C_X  02D9)1@ ! 0$!: %H  #_X7',:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ
M-C0U,3DL(#(P,C O,#@O,C4M,3<Z-30Z,# @(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(@H@(" @
M(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S
M+S$N,2\B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T
M4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V52968C(@H@(" @(" @(" @("!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O
M8F4N8V]M+W1I9F8O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z97AI9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\B"B @(" @(" @(" @('AM;&YS
M.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@
M(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS
M=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C
M(@H@(" @(" @(" @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O9R\B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A=&]R/2)H
M='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@(" @(" @
M(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$U+C P/"]P9&8Z
M4')O9'5C97(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL
M=7-T<F%T;W(@,C4N," H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C0M,#@M,#)4,3 Z,#$Z,#DK,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^
M,C R-"TP."TP,E0Q,#HP,3HP,RLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @
M(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C0M,#@M,#)4,3 Z,#$Z,#DK
M,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z5&AU;6)N
M86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ,38\+WAM<$=);6<Z:&5I
M9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO
M>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM
M86=E/B\Y:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA
M1SEW241-=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!
M04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G
M549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!
M-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P
M645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!
M9$%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!
M04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F
M(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!
M9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A-
M>%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO
M34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD
M6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI
M-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R
M839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH
M26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I
M63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F
M(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q
M=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I7
M5VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T51
M35)!1#A!:C,K02]04"]!1DQU<"\X05-(8V8F(WA!.S@P6C$S-6Y&+T]J.'<V
M<G<U9'AD+V=0>GHO,4QU<"\Y261X+WI2:BM:>&9Z;R]-3#1C=31U+W=(-34O
M-FPS52\K:T\T+W=#84UF>D\F(WA!.TPK9$@U:&9$;#-&,RM!+U!0+U5U-FXO
M,&@S2"]!1%)J*UIX9GIO+TU,-&-U-'4O=T@U-2\V;#-5+W=$<$1U4"MA369Z
M3TPK9$@U:&8F(WA!.T1L,T8S*T$O4% X03%,=7 O=T132&-F.#!9+VUC6#@V
M4'I#*TA,=4MD84(U93AX861A,VM.+S5%=F16935A27A04&$S84=*67<U64LF
M(WA!.UDQ5G8S:DUN23$K>4-/.5)4;'EW:U)745)R>D1/15-/8V):32MN-D5I
M46U,.'%T5VQ:9WAU:VLK=DIX8FPX26IC0G%R5')64C%P,G(F(WA!.VU.>%,O
M=T)7:CEJ8E5F-6A99G(S:R]Z2F4V=%!C-E8U3S%05$Q#5&HV3FHY6'5P=E1O
M9T1F=D=J0E!*9U<K;DUV1FYG26=3;D5N=G,F(WA!.TY-;T5N649,+W=$069N
M;B]!2VPS52\X07!$=5 K84US+TTT=C4P9FU'4&AY-VDW+T%!2#4U+S9L,U4O
M*VM/-"\U;W@O331V-3!F;48F(WA!.SA/6&-89C1$.#@O.5,W<68O4TAC9C@P
M62]M8U@X-E!Z0RM(3'5,=CA"*V5F*W!D,5 O<$1U4#A!;6I(.'II+VY2*UE8
M=S5D>&0O9U F(WA!.WIZ+S%,=7 O.4ED>"]W03!9+VUC6#@V4'I#*TA,=4M)
M<U!)=FY:8G1'8GDY<6%Q2S%*<S=G1&]F.&I+<S)O>&U*.55F;4A',65'6G@F
M(WA!.VM!2#5E86(O04]$4$](+U9I,40O04M22B]W1&UJ34AX660T*V)P4'EM
M8BM:3#5&,RM$4$](+U9I,40O<$5N+S5O>#A72&50;78U5$XF(WA!.R]-;#AI
M-R]";FY$+T%+<U=O9CA!4TI0+T%-,%DK3$1V2'I8.'!M+VU3*U)D+V=Z>F@O
M,5ET42\V4DHO*V%-9D9H,VHU<BM5>F9Z2F8F(WA!.TEU+W=:-7<O-G-7;V8Y
M26LO=T1Z4FHT<T\X9DYF>6UB*UI,-48S*T103T@O0499=%$O-E)*+SA!;6I(
M>%ED-"MA+VQ-,SAY6'E,270F(WA!.T4P<39T3DTK<39N-49V.$%58F=33S8S
M2'!815(K2E%&0C12.&E!93-,2UIY<S)*9T]F9VAW=W%E1U5J,S!F,4DY8D=X
M24-V*UA7;W$F(WA!.T%J9EI&,E-824E"2DMG,$HT.3EU=WE&;BME1S)O9C9H
M3#=6+S%B5&A-2D8O3%!506\T+T%7=3)',69'4#59-R]!3W%$-T4K:2]W0S0F
M(WA!.VPY<F])<F1B93-J;B],83AL:VAI5TXU46QY<&1H.7!M-'AJ8VIP-&4K
M2G8K945G>&]!-$IF22]Q4TAZ1C5D,4LY;70R,&9Y9G%/;5(F(WA!.U)X.$IK
M359X35I(<51Z<7E#;3)7-#5G9E9)1G=T5&=L36IG>%-J.$-L4#A!9WIZ:"]W
M0E=,55 K:U-F+T%*;WEZ>%ED-"MB:F9L33,F(WA!.SAY6'E,=CA!0FYN1"]Q
M>&%H+S!I5"\X04Y'4&EW-W@X,2]+6G8U:W9K6&8T33@T9CE73%50*VM39B]M
M:DAX660T*V$O;$TS.'E8>4PF(WA!.W8X1V5C4#A!<7AA:"]W0DEK+SA!>E)J
M-'-/.&9.9GEM8BM:3#5&,RM$4$](+U9I,40O<$5N+S5O>#A72&50;78U5$XO
M36PX:3<O0FXF(WA!.VY$+W%X86@O,&E4+T%03D=0:7<W>#@Q+TM:=C5K=FM8
M,5AM:V4U45=T,F0S9F%.9C)6;F1.6EAL,6)443(Q-G1E54UK:UI62E)1<6$F
M(WA!.V]X-61C35125C12-7%U9GIG,$Q86#!F5'1B,6TX,'DR36%Y,S0P.4QH
M;6HT1C9X4V-0,VI+:E5K<7<K244Q-T1-9TE%5U%'0DI23V<F(WA!.S9X*UHP
M5$)T579T8C%A,W5B8C%8=$8P,#)J>"MJ9$M/2WI2<TI"2E V3%)#<6EI4'HR
M-#!X;$=(4V@X5D)+07-R=CA!3T-45C=,5&0F(WA!.TTQ;E<T-T]3-'19=G)D
M.7 V;%5J:T%&>DI),'!M;$Y(24E6>71"56)D34I%2W-G3%IE-"M53DLQ>E,Y
M0F=S=&,Q339X<5-.23 Q*U4F(WA!.SE0;GIK6FQ(1W K>41435-:0D]W<&M%
M-7E#6%EQ-T98;'5T*U)V>DHP*T\K=CE(.#989C%E3DQM8U=$=R]82E=54U-Y
M4E)23DMZ;FLF(WA!.W-43$=+9%-+-6M2>5%/>$1':3@W2&U0.#5O:&-M5%=D
M8CE+,UEE;B]!3&A536IJ-$9!64YW<%8S+UI::58K2VY43"M#2&-0;7AS<'@F
M(WA!.V]L,RM:;'HY4S!35%AT9&IU6C=X9E$Q1V930W-A:5 Q=5-3>6U8;'=C
M3W)(:W!P>$A92$EY14]D1#5P<W959DM(;'IZ=G!/<#-C=74F(WA!.RM:>G)U
M;GE2;$Q3,V4R:F=K:DEL6FQ:;FHK,&5$54]W+T%::GIL16I957E!6F)L4UA9
M<7=V>GIB+VUR2G%D<$HU3G5R1TMY5U O4V\F(WA!.W(T5D130U1F;VI0=6YG
M=S<Y-DA,8V9"6'%18E-I;B]/47!J2'AE6&QF:G9T8VXT="]F<#!Y6#=R>E)U
M>4QY3R\U:7,R;TPU>E-Y6&DF(WA!.UEF<41704E6=5-&<'$X;F1Q2WI"0E5$
M;U1K36Y$+T-K5W%E9F]04&,R:U%,-4MU8F$Q,5)B;%=N93A!84YR9C S1$M+
M<2LO<49$:FHF(WA!.S1B.5-M,DQP1"]Z:TI&<&1U;VTP3V4Y3'E'-&MM179)
M1#EG1# Q:E1J565&8456<6-S+V18,5AD1$Y$+T%--4ET34I&;C!&158U0UDF
M(WA!.TM314UP5E%G2C1C<59"3WAR=64Q040K-C@P8G,T.&LS2&TV-#!#3UAZ
M8F%W,F5S;5-8,4QE,TMS9VHU;C Y,6555C0O-5@T-51K16(F(WA!.SE02DE5
M4%!.;C4W=7)+,UAY9F8R,6AD23!J6$0S35EK1'%);3E.04-R5353.%%7-T1F
M9G!H>&U0.%-L:C)L+SAR-B]3;'%.4B]16#8F(WA!.TU%,%EU,FI%+W%M1V\Y
M4FM&44]62S!'5%!H,71A-W,S,$-05UDY1G,P,7533V)6;&E56'-S27!',&YC
M<4M,*W)+<%9E,TI+4'E+=DPF(WA!.VIA+S@U1%=Q<C96-6\R;V,T,TUN<DLP
M8DI)5F9G13E.14)#;&PV.5-V9V-Y3'AE8DAD4"]!0W=N-7%(5V]:4$UZ-F-U
M;6DR;44X5F@F(WA!.WE+;30Y8RMK>2MQ=G%5.4@O2RM9<FM*.$9B2D9S>7EP
M3$504$9N*UIK.3%B4RM4.5%S-U-#2TUM-'0W=4U0-C!N<7@P6&QX2E)F4S4F
M(WA!.VUO4%AB=E57-'I$*TI"=$E76"]N25-56$--,FA12S-Q:4-327EM4F9G
M8WAC4S9S:"M0:5!I6#9-;BLV.#!B=E)D3E,K5%1R5DPK4DHF(WA!.V(Y65EX
M9'EX:6E.349!:UI246)&<3 R>6<X.6U40TY3.#1F;&QP='I.8EAU<S-S53A%
M<VM%<4,T,58V4WA&438Q4FU";UA(5$UU1VPF(WA!.WI31F=F8S%N3$5D5S=J
M>F8K5V1V8V96-71A=D5L-4)!1&,V<E)M4$1:5S5C5U W>&5H>$=L>D58=R]C
M<'E22%8Q,S5T+TQA,'9R:7@F(WA!.VTQ82]&>F%/.&1Y<7IA<S9O,&9,;E8P
M3$I294163F%#:'AJ<&-P04E!,R]Q<6-K5GEE82]Y,F4T:'0P,6TX85,T8FI$
M4S4Q47%4>%8F(WA!.S8X*UA%1&DT3E-A65!Y=5=R<C=K*TI&;$@K2$Y0+S,Y
M92\X05-F92\Y5G-X=4ES,V8T8S O=T0S.64O.4HY-R]!3E9S94EQ-R]$;6XF
M(WA!.R]W0R]R,R]P4'9F*W$R4$5666DO;E@X<DEJ<4-82&U'94=84W!*64PU
M2F(S55DR5U<S25=6541/1$M62G K-S5E,E<X12LW;C=K5T8F(WA!.V$U.#-F
M;%9B2T=L.#!+1EEQ0G@Q839F9&U+1#=->#=G+U)V,'=#12LW-T9S3&\O3E@U
M6%-4;49033-*>$=:4U)Q=#-W-$)78S!F,74F(WA!.T91<45K5G%/+U59.$4K
M-S=&<TIX;SA(;&)7<E0V-7!'<%A&+V%C=4AR=V%L95-*>4%$1F%R3C%O=WE%
M:5)Z2#)+:G8X3V%F+T%,*W8F(WA!.V8K:RLY+S9R64])<&0O:'I4+SA!9C$W
M+T%.2CDW+S%7>#1I<G8X3V%F+W8V.2\V5#<S+W%T:GA&5VTX=39F5F8S,3=U
M9"\X050W,W<F(WA!.U O1C)0159B+W=!3V%F.$$W*W9F*VLK.2]W0W$R4$56
M9"]H>E0O.$%F,3<O04Y*.3<O,5=X-&ER=CA/868O=C8Y+S94-S,O<71J>$8F
M(WA!.U=L.'4V95)V3F4Y5"]W068Y-S0O.%IS94EQ,R]!26,P+W=$,SEE+SE*
M.3<O04Y6<V5)<3<O1&UN+W=#+W(S+W!0=F8K<3)0159A8GDF(WA!.S=P.58O
M9EAU-3,O,"LY.$0O=T%863A25G8O1&UN+S<K=F8X07!0=F8K<3)0159D+VAZ
M5"]!4&8Q-R\P;C-V.$$Q5W@T:7)V.$]A9B\F(WA!.T%,*W9F*VLK.2\V<EDX
M4E9P4$QU;FQ&2FUV86M$+VHO04PS+T%+<EDX4E9V+T1M;B]W0R]R,R]P4'9F
M*W$R4$569"]H>E0O.2]8=B\F(WA!.T%%;C-V+U9B2&E+=$AY-W O340Q<C)L
M1"]W068Y-S=F.%A9.%)6=B]!035P+W=$=C8Y+S94-S,O04MR63A25C,K2$Y0
M+W="+UAV.$$F(WA!.S!N,W8O5F)(:4MU+W<U<"\K+W(S+W!0=F8K<3)01599
M=&8R9DAZ0E V9FMI2S=K17I854XY>6EJ5GE3=C<Q;4MS=G%.2DAY;V9I<'@F
M(WA!.TY/=5IS5#90-WEU;$Y*-2]3:CE',%<Q,6$T=5IT8SAP,FQG.$QP2F)T
M24E:;60S;UAB-%%10W9P;TLY+W=Y=DIK35%/1UI+66DK650F(WA!.W!02S-L
M,59U5B]2.$Q#-VUE-75E83@K8S!O6EAC.'$Y4DDS,VYX>6YX<#=B.&UZ:$-L
M8V544$MK.5!6,'$R2E=26E994FA71&]146$F(WA!.W)1+W-I=FE.:G1H1V]Y
M1'%58TE4;DM75'-69&ER>'963%A513%R56)36#AR<EA727 W:5<U9W4Q94Y&
M:U8U2#53>7E32DEN3U%)<C@F(WA!.T%A*S%306-K2&(V<5ER5FAV-6]G3%0X
M;G)E2F)P55)M;6UT27=%3"MS<&MJ-$)V9TEQ=S))8EE6=S,O5%@T24XY2S%'
M-C!K,G@O2BLF(WA!.S)J;617:&YE2S1G=#9.2'EH:TUF15)3<6IR.6MQ.6%'
M=GA5,U!&=CEA+T)M=C5:+W!Y=W0T.4=K.&Y$>35P<4Q,3DI/=#1T=W)81%,F
M(WA!.R]%06@U>4506&M#>C=$8G=Y<DQ2,W4P:&YU57!D:7)S5E%U;S)K;#-B
M*VA(8WDR8DUW26YT*T%K1DXY=E574F0O=T16=WA.1FA/2FLF(WA!.TM"23EY
M5B\T679F*W!I,50O9W)4+W-N>7IX0B].2#(O<F%0>3AV-3@O=T19+W=$174O
M=WAE+SA!57AA<"]W049A9CA!6E!J-&<O;6HF(WA!.S=F,7(K6&PO4&XO<V8K
M2F0O:&DY+W=#<&DQ5"]!24LP+W=#>69(>$(O3D@R+W)8.'9,*V90+UDO.%,P
M=FQI.7 O=T%P1G%N52]T5VXF(WA!.VHO>D0T*TE0-6\K,SEA+VPU9GHU+W=#
M>"]W0TIB+W=X92\X055X87 O=T%&868X05I0:C1G+VUJ-V8Q<BM8;"]0;B]S
M9BM*9"]H:3DF(WA!.R]W0W!I,50O04E+,"]W0WEF2'A"+TY(,B]R6#AV3"MF
M4"]9+SA3,#-L:3EQ=B]/>&%P,2]M=%!!+W=$3'9J-&<O;6HW9C%R*UAL+U F
M(WA!.VXO<V8K2F(O04U-6'8O57AA<"]W5G O,E0T*TE0-6\K,SEA+VPU9GHU
M+S=(+VE6+VQF>3EE84Q"8U(S3W%4-FPV,')324HK4$=-1FDF(WA!.V%,458S
M<G8R.$%-1U-9;'E&37109VQJ0G52;'8Q5'9+,TEA:BMW=GE'2W0T<3=&5VHY
M<V9)+W=X5G9&6%EQ-T97<5 T:C=V-V-69%(F(WA!.R]%9F0O8FER<5 T:C=V
M-V-69%(O169D+V)I<G%0-&HW=C=C5F12+T5F9"]B:7)Q4#1J-W8W8U97;T@T
M3'5/9S=F,C1Q=6\O:5!U+W0F(WA!.WA6,4@X4CDS.75+=6\O:5!U+W1X5C%(
M.%(Y,SEU2W5O+VE0=2]T>%8Q2#A2.3,Y=4MR5T0Q6&-D9D0R4'9I<39J*TDK
M-RLS1EA59G@F(WA!.T@S9C(T<39J*TDK-RLS1E9Q0C9D4C%08C,K94MR<5 T
M:C=V-V-69%(O169D+V)I<3%G.58S2%AW.6HW-'%U;R]I4'4O='A6,4@X4CDF
M(WA!.S,Y=4MU;R]I4'4O='A686=F9W4T-D1T+V)I<39J*TDK-RLS1EA59GA(
M,V8R-'%T269M3G@P4&(U92M+<G%0-&HW=C=C5F12+T5F9"\F(WA!.V)I<G%0
M-&HW=C=C5F5-83DU62]+-C8X=UAS=7(V=&1X4R]8<FEE-6=D1'A::DEN<6]R
M4F]X-$0P-E8X1'-D<S-/3$QN14)W>$A)3TPF(WA!.TE1=F-R+S!&*U8Y>'%L
M>G%V-E=V+U=D1$MK3$EW-5)X<$AX36)'3&MY+T-!05<S3S-B0C1M8U)%945F
M:C1P.48S84%V.4$O2S-63E<F(WA!.W5,-BLX=UAP=4PK.'5*-#1%:6)G<E1&
M=4)!.4]8;'A*05)Q-V=$86U4:FMZ>&I1:4YG1T(T0V5A-C0X;B]L4D%I4$YQ
M9#E).3E*2D8F(WA!.T9C;%)61$%D*U$T3'E.6E5C,55S>DPO3E59:DYN4$E$
M6DI%06IF3%DO3&IY-35G9S%#,3%Y95)M-4)O-4QC5F5O2TQ6;VM3:69V4S0F
M(WA!.T)8;V\V54%-37=Z6DE562]A>6I+151Z974V9'%.;G%.;$9F5V-N<3)S
M-#524V-76&M+,')29W W6G%:=TU44C5U44-#3$-)>4M8>G@F(WA!.W)D=#5+
M:#AX-FAB3C5Q.'E78SDY93-Z9E9,3S1H14UC=VUE5U));S%B;DAZ:T1Q;DI1
M5W!8;U%4;7A-<4=W655I8FQ0>3!/<EAI4V8F(WA!.VU(<FPQ23@P;W5R6513
M=D-I5S=L-6MC1TQI-F9U=4I#,4Q656ET9'=$2W9P0V1K3F]D-35'2&U/>3%+
M,2]-3%96,#-44TQO-DY01F,F(WA!.W5J>&]7=5%!,%(Y35(P*T%*=W)S5C=G
M65IC5E9W:$-T<&\O2W(Y2E)"=E R=&%Q.$5O=3-G;$TX:U-H16]V2D1$4V]-
M-$,P,S5';% F(WA!.T%%>G(V46]P2FA:+VQ06B\V6$8U,SAW4G%"2%I7*V]B
M9T-'3D5U;3E0;D=*4%1137!+:&%K=#A)27)K-VUF-%%U,V5M9C%J.')5:%<F
M(WA!.TIF>D\Q.$\Q=55"1#-::S1)-C-N<45#0W1E1$-H.$]N435(,2]W03!,
M=#-V469++S545T=N4C9:9#)0;5A6-VDQ=#)H=7)E3C=G96HF(WA!.TE056MN
M25I!<2]"2TIZ>4=5>GI897=:04TX,45A9V)F+V-E65)D8VAW3G='361/.5%H
M1&1-<&I85D4W<F)M;&9(>C,O04PX,'8O9TPF(WA!.VHO;79**VIZ86%Y+S!F
M=&1X.#DO-S@P=B]G3&HO;79(,&5A,6PO;R]A-VHU-R\S-7!F.$%W1G@O>EAJ
M-E!.87DO=T)(-U=L6'HQ5&$F(WA!.U13*W O67502"]8>#E(;71:9C90,F]4
M5E8O36]7;RMO=G!P=5!55%I6;$AW.&AY-4=2:4].3W1.+T1*4CA/.3=A.'8U
M:794=S,X5U0F(WA!.U<S,6HV=D@Y6C1F5T]).6(P-CA/9%!I-#AT-E8V5GEO
M=5=,<F9M=F)Q=GHO04E(06QV1EA9<3=&5V\O<TPX:&ER94MU>%9O+V)(>5 F
M(WA!.SA-5F)X5C)+=7A61'HR5G)C1D=N=&]::D<S3TUY2T=+=%-N2F%R<V%(
M<FMH26IK545+;U-H0D-,561$.#9E,W1G=$LP=U)K9VU'36LF(WA!.T=O2D$V
M-V4S<TUB2W1M2E-+1TY#3W8X041W>'17:D)'4E%W>&M$8V10;#19,E98:FU"
M44M+9E K>D%R9%@X0CDO=T1::7%G=')!>%<F(WA!.U$R.%)K1D-(24A+=7AR
M5VYI;RLW1&%T+U994&DO=T)(:2M,;'DR1R]-,65U,S=69"](1S%B1G1#3VM%
M63)P<T(P2%1T:F%R9G%6='DF(WA!.TPO5F]U5$-J3GA&4TYU<#0K,DYQ,SE5
M9S1#4#9V1G=!2VA+0VQ$<U)3;G1J87)465=:-C)S2C)++UI8;U9#169:-F-"
M>"M7,DYQ:4LF(WA!.W8T1#<O=T-Z07$Q:3E6,DA8>#EJ-UEQ=7$O9U!V+W-X
M5C%8.$(Y+SEM2W5Q+V=0=B]S>%9A:&5N4614,SDO;&EQ-G(K02LO*WI&6%8F
M(WA!.V9W2#,O=T)M2W)73#%8661F2#)0=&EQ-G(K02LO=T1S>%8Q6#A".2\Y
M;4MU<2]G4'8O<WA686AF9W5W-D1V.$$R67%U<2]G4'8O<W@F(WA!.U8Q6#A"
M.2\Y;4MR4U@U:EED1#,K6'1I<39R*T$K+SA!<WA6,5@X0CDO=T1::7)Q=C1$
M-R]!3WI&6&U7<39:9%1A<&8O0494>C@R;DLF(WA!.U=U1D9T3$LS-VU2<$9O
M<2MP24%21T)X;T]L93%C,E5*9U)&-#<U3D5U9C%*+W=#5'15,#=3.41A,3%(
M>E)$<DYX8G1*2DQE=DE054LF(WA!.T)1-V9#5V1I1G(R-UI2;GAY;$MX1&A:
M46M!3GIA8TPU=CAR1VXK-6$P57-Z4F=.36EN:W8R9U%X0C)P;%@U9DHO3DQ,
M>$DY-V-V;7HF(WA!.WDQ1C904%5O04HR9%EM-6=G;5!I6#-'=T%$:'%N86AR
M,'=$0DTY0VYJ:C-T2'IF-5=$<6@Q5S%$3U-Q9WEQ2VM-1CAF13=E4%AO1&@F
M(WA!.R],-5 U<%)X>#<P>G1R;3)U;U9N='!5;F=E=D-73F<V1VAO84UT461X
M;%)I46%,34<Q5$%R>%<V6%=$<5!M0S%J+TY71%144&5Z3&(F(WA!.S)L>456
M<F8Q2E9947A03S9%*VM%368W;S!"<C!.4FU50TM(<%DO1E-V<'9-161H2$TO
M-711=3!->4$S;'1A>%-W+W9)2TQ'-6@U<6$F(WA!.T9/5S4W9VUH9&-)<2]P
M6#1Q3C@O;E=/,V545%!Z93!A-FUU2EDV3&-Y5W--64%4:65$<CE9;V%P.6Q6
M04\U-CE58U!70E@T=E5)4$\F(WA!.U!L=E,Y4&AS.50Q*S%U=%5S;S!G=B]3
M:U-79')I2D-*4UE)875'2FIC:V-.<4AW>DA-0U1S13)U9R]-:GE&3F%F5VPQ
M-GE60GIR2$HF(WA!.TUS57=-6#(Q345N1U5-4#53=&9V>#A/6&-T=%<O=T-:
M4&M/-'4U8E-06$Q54WA!33=/+W!X54QC1C1Y=GAJ8FM4.%!&:E5B:F)(=S4F
M(WA!.V1Y,G5J+TU4>4UZ=6HV-5IW3VY+<3--<3(U4$AQ5CEB:'E&4&EQ3G5*
M0C9%179H>3=L=$=(>DAP.3%"32MI>7AA,5!B3T9M=')+-&<F(WA!.UHQ2DQ,
M4FEZ<7$P-'0Y;SEJ:4EB-S=-6GE)1F=8*U!.1"]P-WI"+S%,5C,O04Y*1FPO
M,5AY6$)(*V-0="]5,&504#A!,4]8>FHO>%,F(WA!.S-39&8Q,C@Q<65X=3E#
M;G-B4TY&6F)U4C1M05EI=D4X1UI7+S)"3D\T1TUO4D%S1S%X6G!Y;5%91TDW
M.6U16E4U5%-D4'!0-GII<F4F(WA!.TMU>%9P=7$O4"M">%9V1EA9<3=&5V\O
M<TPX:&ER94MU>%9O+V)(>5 X359B>%8R2W5X5DIB-WEL-5=V<&A.9&%:1$I,
M>F%1=C9:57,F(WA!.WHQ-6,K3D]D83=H<6I,;S9J2D550U=">'A04E9(;'9Y
M,$-P1VPR=TM,-F%F=48R4V]0169$,"M%65!';C-L4$%/-5,O=V@U4S5O-# F
M(WA!.V4Q1'AK1TUI0E)X27!3;$8W57<O;4UN.#1O.$]08W%395=03$5Q;W-M
M;%=Z<D=Z4U)G=TME3'91<W<K2%EK:7!W1%!-9%-V0DAU56HF(WA!.S50.$%+
M0DE*,&$P<71/2BMR<E551D]V2$0K67EF>FHX,3A/4&-M='1$83)S0U<Y=$5)
M64EH>&II:E1I:6=D9V]&0FQ22DIS<V=+5F4F(WA!.UDY+W50.4U#56EF>58U
M3VYK831N,%<P;6UL;$YZ23AK0W-7;&1#:G-A9S$U2WAR-#50:FPS;W!42#5F
M*U%X14EF,$):1T5%2#!Z8DDF(WA!.U9.27A%2V=R43!244XO;C%X.%-8971)
M9&9Y=R],9&94<#5A<TMX531(-G-H231K:V16,S-9;F9$-'-U.6%#351Y4C5+
M:G5P3'1.1',F(WA!.S%U<&UM95=C5WEC,F$T0E=9<S-'<#5H:4<X8TAI4S<Q
M<%%K+TQR>4),9#-.,TPU9G-P6C=T=61W,&QU<FAM<'A*-'-#;W%$=E%B.3@F
M(WA!.V9%;#-R46%0-61E46UU67)H=$-T5$I#1D5935952$1G1E!P+UE,05)+
M2VM6,G@X4UAE=$]K+TQN.'8U0W!K.'8R5'-I4$5R1S-5:THF(WA!.TM#<G)7
M;&%%369L:C1K=3EA0UEA3C5B.'5A1C9O,&)464Y/1GDT830K<E%I4&U61&-E
M6$5#=$]2<#192E-*-7)383AX-R]C9C9:1DPF(WA!.W59.2]U4#A!5$988W@W
M+V-F-EEQ=%)X5'8Q4%DK3TMR=5DY+W50.$%41EAC>#<O8V8V67%T6GA69798
M=U!G8U988W@W+V-F-EEQ-VTF(WA!.U!F-VHO5$988W@W+T%(2"MM2W)58V-&
M-CE",D]+<G59.2]U4#E-5F1Z2'8Y>"]P:7$P=4]9-CE$,E!T:7$W;5!F-VHO
M045X5C--92\F(WA!.S-(*VU+=35J,RLT+S!X5F<Q-35I+TTY9%-U<E,P.'5W
M=$(Y665+>'9:2D(V4FE%<4):2F%38W=$15,Q479886YW;75B2$9H-%%43' F
M(WA!.W4Q1U5U-5AJ.'AF;4E.8E='-#AU;VUL=5A26DDU5FMC3UEY,%A*9S1!
M47-T2&)H=&=/3$1W-U,Y4V5+5CAK<FHX>2]N23EV3DUF3%8F(WA!.V]P:593
M:U1356MK675E6$5#66IA3F4W9%-/=2M72$1P-RMO+VHT365+9F-M1W K6E!Z
M1U<U=78P6C5D4U<P0FA.;3!Z<7)S:GA-.&XF(WA!.TUE;W1'5G="-V1.-C%%
M25EC3D1I;'5Y37!D06UN;$164$]..#$P4$U7;5(V8W%*03%O67I8;5A1*W-R
M9DA*46\T>7)01$A'=4$S>E0F(WA!.T5K.'=Y4$UD;3=&6&Q&>BM9,S5P4C8S
M9C9B<"]L3S(Q3T<Q;FMJ9V5'.6A76#!O<'E/8VM8<4UW3%%.1V%(:GA,5D]X
M07I)1TM&5U,F(WA!.WAS;V4W+TY,.#$W9E0T3'E8>6)A,CA8,6QO<FE78E59
M1E%!4TUN<$%L,31Y06IJ=51V6#1E=TEX479M=&Q&<BM9=C5Q6$8W8U!P6&PF
M(WA!.TLQ,6)427I%:4YB,S!)6EI(4TXS47EH-459<'I)4'=R,D]$=S1D5%,R
M5DEF;68X06UQ>45,-414,6Y:;S=A239J0GEK94Y8.55+;W$F(WA!.U=-8DI2
M;$<O:E1S9D-H+T]7>C-0531B:'IA4E184T,Q:V1537-437)C2%E#<6-X.$IO
M>'!59&-X-EI.1R]S4GAR8WA$;DMB9$MU=3@F(WA!.W=R5TUB-W8X2BM(<FI3
M<6MC.$5R3W-C:74P5&-*07!"2W13=$=P,$\K0E9$5611=$Y0="]R5C(U4T)'
M05IG<D]F:3)(=V]'8G(W65DF(WA!.WA*,D1'8WA%5U5R+T%-8RM74#A!;'%F
M+T%+4C=J+W%N:R]":S O;6]D+S)(.51E;&5D9$,Q5%8U9$MT2&QA-6I14T%T
M1DEQ<W!&5%$F(WA!.W-"4VXK5E0R=WEX4T%S<FHQ54IZ-%)Z.7EE-54U1%-D
M4'!0-GII<F5+=7A6<'5Q+U K0GA6=D9867$W1E=O+W-,.&AI<F5+=7A6;R\F
M(WA!.V)(>5 X359B>%8R2W5X5FE..35&.6$Y;'9,5%A,>7EK;G5';6U32FQ#
M1DI#0S9C4GAR<V]!3%9P-$A-=4]Q;U599S=.4G@W,V%)4&PF(WA!.T)V<61N
M87 U9S%+3DQ0;E(P;E%/+TQJ>#5N:CA15&HX23DO1$DO;4YY94=/-F9$.'EH
M5"M8;&U(;&505V(K3G P4T]5:5ID=VEC1S8F(WA!.W)8.3111V(S1U0O3FXK
M8D9(:&5:6$XU2&M&,$I)9DU/;U%7-6I62EE9-596;61!<7$S34%505)A530Y
M9#8Y45(K849B>&EV:"M:4D\F(WA!.VIE568P6G%N,31A-68S86YL5S%U2F<X
M4C56-FEG<E)M2DAV.4Y9-4Y2>%)R:&E%>'@P8G-S:SE24#5H.2M9>EDW,44O
M;4@S-'%W:E8F(WA!.W9Y:"],+U=B:S-E;S)J>EA$33AG9C9X2W!1>5-M9&=H
M1$%Q4%9D,C1J87).-#5A33!H>5)183!B.&]F2D]J-F)Q96U7675"639Q.%4F
M(WA!.W1X0S%W-4MV0U%Y36II:VUZ+T9U>#-X3V%23G%!1W!V>6(O3'EE,&IT
M2G)34C1)<%IP=W8Q<5IA=D]!1W)W9&1H>$A%9G,Y4G54:C0F(WA!.S!L<%%U
M4'E/+TQ+-%I';'-:1TUC6&]*4S=U1F]N0E5.3TQJ<44S.&%M=4AX-4QW:%AV
M9GE:+TQI.'5R839L<UA783!%26AA3S5N:D$F(WA!.T5#3$A(54LT1W=18CE3
M9"LU=T1.24Q143EP*U)F-5E7<W1V3$A93WHR>G)*1'IU6FU!6F9%8S9.56)'
M=F)#8SAL-%$R+W=#4C,U84TF(WA!.S=V.$%5-6QE4G5B<W0S8T%L:GI"3E)*
M,4EK24]0:GE79VUV;&8X="]*,VQF55<Q1%)O2&AU<%EF<3!J=E!,2T1'078W
M3'-W<BLV6&8F(WA!.TEY>4=1;W%!>78Q12]M2#,U5VQ9;W0Q9&Y524AE;DYH
M449Q0V=Q93E-555V.5)0-6@Y*TM6<4]L4'1$<64O=FEQ-S%%+VU(,S1Q-S$F
M(WA!.T4O;4@S-'%T6C!Q=GA$<C0K>'A69#9I9GI$-SA69#9I9GI$-SA69#9I
M9GI$-SA65V\V8T8K261",WA69#9I9GI$-SA69#9I9GI$-S@F(WA!.U97;# U
M:C1H,%!F-5EQ=3E24#5H.2M+=3E24#5H.2M+=3E24#5H.2M+<$QR4&YB>7)O
M='HY5C%455DW5V9I2$M/1T]Z9$)645)5.64F(WA!.U!7;2]43'-E;FY-6$57
M>$UW3V%N9&5F=DHY=&)'-F9626YT,6)G,&M)85E"=FHV*VM(<"]C=G8W2$-.
M3&M*<6Q-=S!F>D,X:D%63W8F(WA!.U=.2VAA*W5N53%P,SES4#583"].2U!%
M:C-R2E!Z1SAI4GE,1S)U5VA:,EI2>&M$0W%F87%6<4)3=F9%851,+TY+*TI(
M=E9R:GHS-4XF(WA!.W1P6F]R:E=,5T=30U)O6E9K:T,P:U)1-TQV,6]'2%0U
M9&-!,#)1.&]L2FY%9%=R:GHU-4YG:&EM:S%I,4UC-#51<VMG:S5Q2D1%5U4F
M(WA!.TIY2E5/0TLY3FII3DYK3S-#5C0T.39W+VU(-4A6>6HV,V%2=6]Q4DI+
M13<X4U!I<'5#3G@R-S1F>758*V%594I(=EAN>C4U3RMQ>3,F(WA!.U,V=&)V
M8E%R>FML:F)M;T@W=R]S9S$O=4@V94AY=V9L<VPQ4B](.7%E360V;D@K679K
M4U-!5')R=&PV9D5.=DUQ:T$Y2W%A340W158F(WA!.W=N4UIB<FA+4$5J,W5V
M=GI%.&DR1C9L;&5A-UIW,T5I3$EI=$MT0W)/54AX+UHK,'!&2S58-%5U-6Q9
M5W8K6DAK2DI413)V5UA-5G$F(WA!.T)+<&]1,T5I;S)R>3)P,7=E2$QU5S-8
M=C5K95),2T-+-'5.8W1"8GIQ-U%Z<DE*23)%86@R;S9C;'%&24Y+.3A2:FME
M:3)T8CAZ9GDF(WA!.SA69W)E67101$U!47!U27=A2#)R:#A+6&-T<G!0>DDX
M:5)084I,<F1R1S$X44Q53R](;5,W>&0V52M/2FQ.96A'*T1W-61Y,G5S9GHF
M(WA!.T0X:S,W6%,R97-7.#=75G5,>35#16YJ07="16<R*TEF15!S,3-.3W5*
M>'E(4F)75"]M5C5%='DV,T=T5S!-<V)2>'I14TU5;&IE54$F(WA!.V]S:U1!
M3VA03&]W1DXV.41J-%5U-6)B6#AY=GDO6C!J6'I&<#=026]A3E9U27E71%9O
M4E$O=T-4:C15=35B1&LO36IY2$I,4$9&<G0F(WA!.W!,3F)O,'-K56-G9'EI
M<'I,27$Q3#=F>58S,C8W62M(3'57,4M,.#!V>3=K:6%195EB2D93;VM75U99
M;51I-GAN;6HX5U=J4TM0:4@F(WA!.S9J:#A+6&-T:%AB.'AF26$R.&1Y,G8R
M270U6DAH:FQ--D)42D5&85)A,39O<VEL=D%(0C1C=35B47@O3E@X=7A-<U0V
M.6%X<S9L,&$F(WA!.U)J1VI"6$M(:3=G251Y2%-T86(Y35!H4S=L=%5K+TTO
M.'99>6Y0>D):05-'3E5B,5%64'%L;%-J1#1A3G=B9G!T:C15=35B0W%0>D0F
M(WA!.SAK=$%:-'19=#4T>$MK1$=":DU6:VM2<$9$0TU-5BM"1UEK-T%!,399
M4$1L,TQA;$@K84@U9'E&479M4%1W5T-T4G P56=-44)8:U(F(WA!.U1D:#%W
M*T9,=5=W;BMN86I986Q9=S,K;C-%9#%:6$-H-$QI2F=Y3W W9VI)159S56]J
M07)S5F1I<G-69&ER<U9D:7%686HU53AT86XF(WA!.V1I-S%$4S=A-W5G1D%M
M;6E6,F]V,F1Y3S%C=&AN;D550U%'2FE$>D159FQ,>79&8G1B4C9687)B=DM:
M,VE%2V-42U9+8WE+9&5,168F(WA!.TDT;E!/-W-R=VIU46IF;#4U1UI9;"]1
M5FM&:&8Q67=S2W%/9FEE249E;E$W6E X04Y:9C5X4C1C935W+TQV>4E'-411
M3$5.,7(V168F(WA!.SE-9GI76"MC5CA/4&-Q>BM2=DIS-6M-,FE756AL9C%*
M4S!#17,Y1TA)-V)N-'IG1W!Y1"M)<$U).7DU4$I8;$)&5E4P87I656IA1D$F
M(WA!.TE5;TDU0WA:3VY1;5)T=F9"*UEY9GII=D%/-5DS:U1Y63!G:V)23$EU
M16%)3C9#5C1/0T=(5'5#8U U;DHO3TLX164U5W1V2B]L5S(F(WA!.U5P8C94
M85))449+<D-G0E5397%"4VY4;G9K5&YM96-I;VE",%5*9DE8:W%94T-44DQ*
M:$TS<5,O=55(2C9S95)O3W9X;DI$535"+T4F(WA!.U5E2$AU6%AN:V)Y8F5S
M<EAE:5=5-W!8:3=W4FQH54)32S!R4V=Y=GA*9#=+:TAE9FQF.$%L.657>E<P
M,F<R9VE92U S4V5I-#1!0F4F(WA!.TQX;$A79U5F6D]%6EID-C!I3&8X=G9*
M549G=6YR;S%S.6UH8WAW>DHV=U0Q94)K-&5P>C0X>D5P8FHQ27(Q=V5*3'97
M;D0X=F9)=DTF(WA!.U K9TQ$:T%60BMR>#%O,U=U,CEC9D5L,W)3*V9Y2C5,
M;FII:6TP4WEK:F<O=49A0TUH4&IE5#1D='9J;&,O-TDK3U!I4S<Q<%IA+VPF
M(WA!.SDU2G1#5&$V3&%7+TI(:F-24FA!-E-Q16180S!$9W%O*S%8135*9#8P
M<&8X<3 O3#9J9C@V-W O>&M--49V1T-33VA*<#(V+U!F<FHF(WA!.S1S=3EA
M0S0O;'8U05HP8RM8=% U4C$T2#9T2'16:35P=#-::51J-&MU.6%#*S,O3#=Y
M4&),3W1V;U9L1#EA:"MR,T)J:%)3.%968FDF(WA!.WI!5E!X27 K64AG369%
M;#-R4VLS-5HO;#9W9%0U9# O:35*9%)B>&='<$)/=T@K4TUF1FPS<E%6=BM6
M9BM2:DA(161"<T=I:3E5>'@F(WA!.W1B>'-Q*W5!2F%!:6YX055/4&E3-S%P
M<5@X=G9).'-+47EA1EEV2$A89T1!;3-*94(S<%AD4E1(>$ID-C!O4F9L:"M8
M:U9V2&)P-64F(WA!.W-F5&EO1C51<7IF0W9%8VYA<DYT='5C4&EY-S%O2S8O
M;#DU2E=*-%)O=' V36MW=4AJ35E+*W%)+U-R>$]W*T1T,'%397!*=V5*3'8F
M(WA!.U13;5!Y,CAG0FUC95AR04TT06,O5C0Y=W!59TAB9F1!8V9%;#-O<%!R
M3WIT8DLP:'1,4TI93%<S45)W=V]+2W%+2T%!1$EK,FQ7=TLF(WA!.S=&6%EQ
M-T9867$W1EA9<7AV>E1D6$=N96@Y46<P.65C8S=U,395:D)A2E%Y26Q7:G%7
M<69953-P;5)G9TI89#E/5%A-:V-K<E179DTF(WA!.T4Q,41B46%:<&IZ339T
M26EY>'4S,69G<D=12TA$0W!.3V@K;G%B5&EG0EI-=FPQ63A5=DI%5&%V<D)U
M0W1R<$9H2TE1<3-D<VLX5'DF(WA!.V\U;4M'<D1J5&I%07A"5'%A9'-I355+
M,THK6&MN:5!C9UIF33)V5S1K934P2W=#:&U267AC4F=J96E->FM&94Q.5'%"
M4V\S<5%-;4XF(WA!.U!!.'!(-4DT-61Y;VUU*UI:-&)I5TA13$I54DMW<S X
M5$MZ1G=Q<5A5.7AY*V5*=S1X6'%0>5AJ;#-.>"M99DU-;$1(-5IT5U-V1GDF
M(WA!.W0Q05-#2U9&05 R9#8T1&=X+WIJ.&EV2$QU4E9L<3)S6$YR3$LK:3)C
M36E30EEW2F]P5F1$1WA9,4A%5E=52VY827EX44(K;R]*26LF(WA!.U0P45$X
M=V5:8F%/6G(W>3=A8TQC0C5,:4]A34E51'%(64HX6DA&0U0Q3U0X1$=E56HX
M:V-C=6]2,VQR5CE3,4M25S%$4F)7>'1'4G F(WA!.T9U4DQ%-%E64$%+;W)U
M5C,S.$1K33)+3655:50W:W=K5'I$2DEO=$QM1EEK9VM(:6]2=C%F4$U9,D=X
M:5AM2%<Y87-D5VUT8DQ3=% F(WA!.V4Q9T-Y=&-813!-8D=.;%5F64QO>2]'
M5TA):6U:94Q$0U5B2DXK-7%L36<W0E1G,69Z5$IE2D%.2S Q>7E+>&A6-'A/
M05%/5&5N-G F(WA!.RMZ5W1+-S%P56135&EX9UAC=G@X1D5P6'E#<V19.'=V
M6G8X054Y071,=3AI4$=32EIO56-%:#EN:4I0<$94=W%#-V14.#AJ-%=/.34F
M(WA!.T5$,THT<%9S1G)A:#4P4EAD+TQD;V]I84UV5C1W=G!H6$UV>#@K=%98
M:6%51F0X4&@T=C5X4GA3-VQ"+TTO;4M/,FUN:SAR,G%1>',F(WA!.WE.3V)U
M,S12=6%&9E4O-$U,4V]Q4C)Q35 U9DAD8UHK4E(T:W4U1UAE<&5:24IV9S!+
M>FM15%1!471*2$9*2D-':5-%>'-3,WA&<$0F(WA!.S%896Q.:5)K630X6B]I
M4#1T:UI3-VQ+3'I$<FAL.4-B>3%B=UA%;G%2>$DQ,6)%*W%K66M694Y15W)Z
M04E(>C=J0V-%3UEL.6A2>'DF(WA!.S=L4V97=DUC8G!#=FQ*5V0K45-C>7=H
M6$M)6"MW2VQE9D4P<3(S:6-!=S1Z=GAP335D>3E,-WI96DDU5#5:9T5"9FA,
M8BMP2#9O0F,F(WA!.TM'16QE3W<K22]$9SA02"]!1&PT<&1Y:W5T*V%8:TE(
M:W111F]'-5A-27)Y<GA:4U5!<#A/-#8W:D0T3U K9CEI3T]8.#%..4TO4V,F
M(WA!.S)Q,TU&.7!C349L1T@Y0UE)=G@P8T)$>41V6&MT4U%61DYU=&1Q<&E)
M:4-$=7I"3C=P>#E3<W8K5V50+T%)0F8V6E1B3DDO3E8Q8V$F(WA!.UIB,C<V
M9%E7<S=Y=5595&U/36)+4T%/5%(K0E!8=# S,G9W445I8DI95$I(2DMT1C%N
M6' U=E)V9$TP=5-A4U-*66]R931J5BM$4BLF(WA!.W!+,4-:=5IJ-4PX27 Q
M<E=M5S5-54%,0FPX;45:4S8P,6)A.35H;'56<U0U870R=55$1S5K5V5!8T)1
M;&8S3EAC9%4V=#-X;&AX9U@F(WA!.WAB930O96]N3&Q3=&1A;C5S4T):269+
M:TQS=TIA3G T4G=O:&]#>&]$.&9C9'1V.'))>'@T-S-N.6E42UAC<#9:<BMV
M6%5C57)E5F\F(WA!.UAT<&Y12F-W,T5,;T9D,50Y:%I#94Y35TDR04(V65HT
M640K4&8S2TIY4%)99&$X,C(T:CEF>7!$9&5O=U508E-*>'$Y0T%D<&5(0VHF
M(WA!.TMX3S%A8FI$-$]).' Q-S!C8W4U='1B.#-T>650>5EI<6UX4G T=5)9
M8U<R4$924FQ*04ER=CA!9&HT3TPK9CEI.&-V-7%*8E503DTF(WA!.TUS;V9Y
M=$101U1),%!P>7A)46E%0D9A=G%C;69X,GE0:#1Z+T%"+UEN:6PS2S)J86IR
M=#5F4G@S=FQD3$=Z:S5C<FQP;S)-9DAK2TTF(WA!.VY!35-7555P=%$U2$IJ
M9T)T3WHW:WAL26YC36HK<%=8+TQ02"]W04%V.4UX-V)%<#@T9C1F+U)I9G!Z
M;#E6.5@Y,7<U.'96.4XK;D0F(WA!.R])-61D<W4P+TAX96IM=VY68G-E="\X
M06Q66#%I.#1E;'HY2"]43V9R8U!4-&YL5W9W,38X<6(Q<C<U:TAX-D18-DXQ
M;FU,+T%*5G F(WA!.SEF;"MV."]R4$=,-GHV9G%5.4@P4GAR6#EJ,'%C=4<O
M:C-W-'9(<F)L*S%:.$8W;T=,+VQ59C%A8C!V5CE,,%4Y5&HY6B]U=6$X96XF
M(WA!.W9X+VAV:WHK678X07-9+W4Q1S(O-54Q.550,68Q=E(Y4U Q94@Q>FQZ
M-4AH>30O1CEV<%1V:VHK6G9F.4-"-&1F,G)B3"]L56905"\F(WA!.T%.1V5V
M>BMT4C Y4#%+.5=P-FYR9C=R-3EF5#-R5'1J3#AX=GA6>5=0:#=5<6XO;%,O
M>&9Y8VUP>"MS.&57,TQJ>#DV65 X04-F>%,F(WA!.V8S84ES9CA!;%5N<FHP
M2RMR-D5T95AR,3E09W9/=&0O<U5P:UIF;4LS+U%K94=G6B]W1&Q4=C%:=E0Y
M4VYQ:6Y$,4LK<"LX-F5R.$XF(WA!.V9T92]H=E1*:CAZ8D4K1WEZ>5HO9VXV
M-V9F-&5P.5HY3T0Q+W15.4=H.4PP*U<S1'(Y;C9E,EEU;SA7:'@X;3-(=S-S
M:&1F+T%-02\F(WA!.S1I8CE+97 K:U!H.6%N<F5J5#DQ+V5C9F<O,WI8+UDK
M*U-X94QW96YL.%!X,V]L=UAV>E5B=CA!-59:.5IU=G)F<#AV5&HK<RMP-B\F
M(WA!.T0P*TLX3W9W.4]05$I2.&5H6#9&4$(Q42MO+SAQ>2]3<"MT970Y8RMT
M4SE0<E!(,65A*W P*TAJ-FQ0<'E54$@T9'5695-$=U=L5V@F(WA!.V8X<6HY
M8RMJ.6$Y6&UF<2\Q:C$O<SA"+V0X9'5.3VY0-'5V8DQC=C5I=6XR34EE1VUL
M="]Y<3,Q<'58<65P+W@Y+U=F<D9+*W1B,3DF(WA!.U1N.% Y-39693-8=%A+
M<&506#EN;BLQ:T]"2D@O=T-62V976G95*W,X*U(T+W=#.5A(:CA(,D]0-U!,
M*V)E=&8X;DQV.$IR<#EJ1#DF(WA!.S%B2G17+S56=CE1+S!Z;#9(0U1J>#EE
M=%!Q,$A/;D@Y<C!F4S8O<G)M3D1X<C(O4C-N.4YT<W5#=#!H;2]W0U90+U=$
M-FXQ:C V;6XF(WA!.T@Q*TAQ8U4U8V5(-WIL=S0Q+W)83'@K67)P.6I79D1E
M;C9D.54O4CER.50O04XU4%-4-G93=CA!9#A2=S8O-4]A>60R8C5U4T]327DF
M(WA!.TM867$W1E=/*V-V.$QF5C=B+T5(3#!U5&5L>#E4=TA,;#9E+T@W4#1:
M:V%F>$Q003$U3TAQ:T$O-59:.6-F-GA8,2M-=E V>#E9<'<F(WA!.S10-G1E
M5S,K+T]8*U98,GI)+V8Q="MH:#9&3R\O=T-65R]7,SE8,5!6-'0Y:C9X=SE0
M,'I7;C=02"M/1U!J,2]9<#1,465L+SAQ<2\F(WA!.U-+96XY6G(V>2]5+U8Y
M8FAZ-%)6-&-F:G!8:E@Q3SEA8EI/9C5I=6XT=&I(9W1$,S,O2VUV4VQP-B],
M-'50;R]783@K22MX>2M#=GHF(WA!.RM'=EA*4B]-*U@R25!H<W(X:F8T2#4S
M2"M'*UA/;G@X+U9R>&]N5#%D-F9:>D4Q4&DW8V)B:C1F-%=86FE.<G-69&ER
M<U9F+S)1/3T\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H
M=6UB;F%I;',^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC871I;VXO<&]S
M='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @
M(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL
M86YG/2)X+61E9F%U;'0B/F<U.7DR-CPO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SID
M97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE($YA;64Z(" @
M(" @(" @(" @(" @9'-P,# W+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @
M(" @($1E;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" P,BU!=6<M
M,C R-" P.3HQ-#HR-R8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" P,2U!
M=6<M,C R-" R,SHT-#HR-R8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @
M,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" R."XV+C F(WA!.T=R
M87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@
M<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA
M;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!
M.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@
M9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86PM0F]L9$U4)B-X03L@(" @
M(" @(" @07)I86PM271A;&EC350F(WA!.R @(" @(" @("!!<FEA;"U";VQD
M271A;&EC350F(WA!.R @(" @(" @("!!<FEA;$U4)B-X03LF(WA!.U1H92!F
M;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF
M(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE
M.B @(" @(" @(" @(" @(&<U.7DR-BYA:28C>$$[57-E<FYA;64Z(" @(" @
M(" @(" @("!R<C8Q-38S-28C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @
M,#(M075G+3(P,C0@,#DZ-34Z-#,F(WA!.T535"!4:6UE.B @(" @(" @(" @
M(" @,#(M075G+3(P,C0@,# Z,C4Z-#,F(WA!.U-C<FEP="!697)S:6]N.B @
M(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,C4N,"XP
M)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[
M*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N
M<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N
M*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L+4)O;&1-5"8C
M>$$[(" @(" @(" @($%R:6%L+4ET86QI8TU4)B-X03L@(" @(" @(" @07)I
M86PM0F]L9$ET86QI8TU4)B-X03L@(" @(" @(" @07)I86Q-5"8C>$$[)B-X
M03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C
M=6UE;G0Z)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I
M;&4@3F%M93H@(" @(" @(" @(" @("!G-3EY,C8N86DF(WA!.U5S97)N86UE
M.B @(" @(" @(" @(" @<G(V,34V,S4F(WA!.TQO8V%L(%1I;64Z(" @(" @
M(" @(" @(# R+4%U9RTR,#(T(#$P.C P.C4Q)B-X03M%4U0@5&EM93H@(" @
M(" @(" @(" @(# R+4%U9RTR,#(T(# P.C,P.C4Q)B-X03M38W)I<'0@5F5R
M<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @
M(#(U+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X
M03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L
M96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P
M<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P
M<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!!<FEA;"U"
M;VQD350F(WA!.R @(" @(" @("!!<FEA;"U)=&%L:6--5"8C>$$[(" @(" @
M(" @($%R:6%L+4)O;&1)=&%L:6--5"8C>$$[(" @(" @(" @($%R:6%L350F
M(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@
M=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($--64LF(WA!.R8C>$$[+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @
M(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^<G(T
M,30V,S4\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E
M/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(" @(#QX;7!-33I);G-T
M86YC94E$/GAM<"YI:60Z,69B8V8S9C$M-&(Y.2TT-S1F+3AE8C4M9F1D,C5D
M,S4Y-31C/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C
M=6UE;G1)1#YX;7 N9&ED.C%F8F-F,V8Q+31B.3DM-#<T9BTX96(U+69D9#(U
M9#,U.34T8SPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C4T.#1A.#-E+6(Y,6,M93DT-2TX
M83<R+3DP961B-V5B,S9C8CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@
M(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ
M4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HU-#@T83@S92UB.3%C+64Y
M-#4M.&$W,BTY,&5D8C=E8C,V8V(\+W-T179T.FEN<W1A;F-E240^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C0M,#@M,#%4,3,Z-3,Z,#@K
M,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS
M;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z,69B8V8S9C$M-&(Y.2TT-S1F+3AE8C4M9F1D
M,C5D,S4Y-31C/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(T+3 X+3 R5#$P.C Q.C Y*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!);&QU<W1R871O<B R-2XP("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.F0V,60X,V$V+60U,&8M,3$T8RTY9C(W+60S,65F,68R-&0P-SPO<W12
M968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^
M>&UP+F1I9#ID-C%D.#-A-BUD-3!F+3$Q-&,M.68R-RUD,S%E9C%F,C1D,#<\
M+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^>&UP+F1I9#HU-#@T83@S92UB.3%C+64Y-#4M.&$W,BTY
M,&5D8C=E8C,V8V(\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E
M;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@
M(" @(" @(" \=&EF9CI/<FEE;G1A=&EO;CXQ/"]T:69F.D]R:65N=&%T:6]N
M/@H@(" @(" @(" \=&EF9CI84F5S;VQU=&EO;CXS-C W.3,O,3 P,#PO=&EF
M9CI84F5S;VQU=&EO;CX*(" @(" @(" @/'1I9F8Z65)E<V]L=71I;VX^,S8P
M-SDS+S$P,# \+W1I9F8Z65)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.E)E
M<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B @(" @(" @
M(#QE>&EF.D-O;&]R4W!A8V4^-C4U,S4\+V5X:68Z0V]L;W)3<&%C93X*(" @
M(" @(" @/&5X:68Z4&EX96Q81&EM96YS:6]N/C(R-S4\+V5X:68Z4&EX96Q8
M1&EM96YS:6]N/@H@(" @(" @(" \97AI9CI0:7AE;%E$:6UE;G-I;VX^,3 S
M.#PO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B @(" @(" @(#QX;7!44&<Z3E!A
M9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z2&%S5FES
M:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N
M<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN
M=#Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @
M(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W1$:6TZ=SXS."XV-C8V-3<\+W-T1&EM.G<^"B @
M(" @(" @(" @(#QS=$1I;3IH/C$X+C Y-3,Q-CPO<W1$:6TZ:#X*(" @(" @
M(" @(" @/'-T1&EM.G5N:70^4&EC87,\+W-T1&EM.G5N:70^"B @(" @(" @
M(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @(" @(" \>&UP5%!G.D9O;G1S
M/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT3F%M93Y!<FEA;"U";VQD271A;&EC350\+W-T1FYT.F9O
M;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!
M<FEA;#PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&86-E/D)O;&0@271A;&EC/"]S=$9N=#IF;VYT1F%C93X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&
M;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N
M4W1R:6YG/E9E<G-I;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z
M8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.
M86UE/F%R:6%L8FDN='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1.86UE/D%R:6%L350\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;"!-5#PO<W1&;G0Z9F]N
M=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E
M9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P,SPO<W1&;G0Z
M=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O
M<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R:5]?7U]?+G!F8CL@87)I7U]?7U\N
M4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D%R
M:6%L+4)O;&1-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z
M9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/
M<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#<N,# \+W-T1FYT.G9E<G-I
M;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^
M1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&:6QE3F%M93YA<FEA;&)D+G1T9CPO<W1&;G0Z9F]N=$9I;&5.
M86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;"U)=&%L:6--5#PO<W1&;G0Z
M9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY
M/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9A8V4^271A;&EC/"]S=$9N=#IF;VYT1F%C93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z
M9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R
M:6YG/E9E<G-I;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M
M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE
M/F%R:6%L:2YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @
M/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^
M0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M
M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P
M3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P
M5'EP93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @
M(" @(" \:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^061O8F4@26QL=7-T
M<F%T;W(\+VEL;'5S=')A=&]R.D-R96%T;W)3=6)4;V]L/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P &
M! 4&!00&!@4&!P<&" H0"@H)"0H4#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L
M(",F)RDJ*1D?+3 M*# E*"DH_]L 0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\
M$0@#2@=3 P$B  (1 0,1 ?_$ !P  0 " @,!               $!@4' @,(
M ?_$ & 0  $# P$#!@@)"04$" 0""P$  @,$!1$&$B$Q!Q,405%4%1=587&2
MD](B,E-S@9&4T>$()C,U4J&CL<$6(T)$<B1B=+(E-C<X@J*S\#1#=<(85K3#
M\473XF.#A)7$_\0 &@$! 0$! 0$!              $" P0%!O_$ #@1 0 "
M 0($!0$( P " P " P ! A$#$A,A,5$405)AD005(G&!H;'A\#+!T05"(U/Q
M)#-B@L+_V@ , P$  A$#$0 _ *$B(OVKXXB(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(BR>F;+4:AOE+
M:J-\3*BH)#'2DAHPTG?@$\!V+-IBL9DB,\H8Q%M1W(?J, XK;43V<Z_W%0M4
M:=N.F;FZ@N\'-3;.TTM.6O;VM/6-RY:?U&EJSBELRW;3M7G,,0B(N[ B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B N47Z5G^H+BN47Z5G^H*3T2W25@1$7RGYD1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!%:-'Z*N&JH*F6WS4L;8'!KN><X$DC.[ *S%;R3ZAIX'R1
M.HJHM&=B*4[1]&T /WKG.M2LXF>;TT^DUKUWUK,PU^BYRQOBD?'*QS)&$M<U
MPP01Q!"X+H\PB(@(B[Z*G?65D%-&6A\TC8VEW $G RBQ&>4.A%F=5Z>JM,W,
M4-=)#)*8Q+F$DMP21U@=BPRD3%HS"WI-+36T<X$1%61$1 1$0$1$!$62N5DN
M%LHJ*JKZ9T$59M&';W.<&[.3CB!\(<5,Q')J*S,3,1T8U$6P+;R5WJJHXIZJ
MHHZ$RC+8IWG;^D ;CYN*S>]:?Y2WI:&IK3C3C+7Z+.:KTO<M,5;(;G&S9D!,
M<L9RQ^..#_0J+=+)<+72T<]PIGT[*L.=$'[G$#&\CB.(XJQ:LXF)ZI;2O69B
MT=.K&HB[:6GFJJB."FB?+-(X-8Q@R7'L 6F(C+J13;Q;*JT7"2AN$?-U,8:7
MLR#C::' 9'F(4)2)SS@F)K.)ZB(BJ"(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B"NHB+ZS]
M.(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("N?(W_ -I5D_UO_P#3>J8K9R45=-0<H%HJ:V>*GIXWO+Y9
M7AK6_P!VX;R=PWE<?J(SI6B.T_LWI_Y0VCK+DRU!>M=U5WH+C2TE++)&YC^=
M>)&;+6@D -QG(/6NKE'J;/J3E+TK97.CK8X7NCJ]A^X[6/@$M/$;).[AE:XY
M6;C%7Z]N\U#5LJ*21T>P^*3:8[^[:#@C<=Z@\F]3!1ZYLM15S1P01U <^21P
M:UHW[R3P7AI]/?AUU+6YQ7E&,>3M-XW36(ZRO/*+2:'TTZZV2CL]1+>7L#XI
M=MQ9 YV-EHR[.X;^!R3]4JY6'1_)[:[=%J:VSW>\5;-N1K9"UL8Z\;P,9W#B
M3@\%2^5ROIZWE&NM9;JF*H@<83'-"\/:<1,!P1N.""K_ *D;I_E0H+9<&W^C
MM%SIX^;G@JB!N.\XR1G!S@CMZEG%JTTYO,XGG/7KCE^1F)FV(C,=%=U]H:W"
MEL=YTD7MMMWE9 V&4DF)[_B[SDXW$$$G!'%9?5EMT'HM]'8[E::NOJY8A)/6
MLF+7Q@DC: SC.XG9QC&.*B:^U9;+7:].:=TS4-KV6B>.HDJ&[VO>S. "-QR2
M2<;N'G64UO%HW6D])J&HU(RW&.%K*BD<P&9P!)V0W.0[>1G!'#Z9%M3%.),[
M>??/MG'-<5Y[<9Y?RCZRT5I^V:NT504-)FDKW[-2><>>>&6#/'=G)X8XKHY1
MJ/0NEGW2T06>HENLT(DADYQQCIW$8:,EV>K:X'CCAN%CY3:JEIM;<GU1)(RG
MI(W[9=*X-$;-IG$GAN6LN6.NI+CR@U]30U,-53.9$!)"\/:<1M!P1N3Z;?JS
M3=,XQ,]?<U,5SB(_L+-IR#1HM]NI[?IFYZDK) !5SM9(T1.W9P.';CS<2NW4
M6A++;.5JQ6N&!SK57MYQ].Z1WP3\,$!V=K&X'BK)J6XT-TM-HET[K*BL=B@B
M GIHY-B8#L#6_"+L;MG^:AZMOUGJ^532%TI[K0R43(W"243MQ%\8_#W_  ?C
M#BN==34FTS&><6[_ )>WPU-:XY^SA#9-!P<H$NDS8YYZB8G,[YW;,1V-L,:,
MYQCKXY77:=/Z%@UK+HZ2U55;5NVLULTQ&R[9V]@!I'!N[/:L*R[VX<OYN73Z
M7P=SQ/2>=;S6.8QG:SCCN7VW7>W,Y?9;D^OI6V\RR$5)E;S>#"0/A9QQW+4T
MU,=9_P ,]9Z_WR3->T=<?DUYJVULLNIKG;8GN?'33NC8YW$M!W9\^,+$JQ<H
MM3!6:XO51231SP25+G,DC<'-<.T$<575]72F9I$SUP\UN4S@1$71D1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 7*+]*S_4%Q7*+]*S_ %!2>B6Z2L"(B^4_,B(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@VSR1[M
M%ZLQ\F[_ --RI_)O<ZNBUE:Q!-(&3SMAD9M'#FN.#D?3E6KDBKK;#IZ_45RN
M5+0NJO[MIFD:TX+",@$C.,KNL-BTEI>XQ7:KU335[J;X<<4(:278W'#7.)_<
MO%-HBUXF.O\ Q]FE+7IHVK,1MZ\XC'-(O6CZ>_<K573R$QT?,,JYPS<7'<W
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MCZ(^(53Q>:5\CQ>T?[R>+S2OD>+VC_>5K1.+?O)X71]$?$*IXO-*^1XO:/\
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MRR\U&U]0YTA(&P!([)W]BU-/;](UEFU"_3FF]1:GG/.R.O56_FV0NV2=K:&
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M"$P.:+J94P/G= R>)TS1ET8>"X>D<5VH"(B B(@(B("+IJ:JGI6AU3/%"TG
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M:LY$]>:8L7)94T%WJX8*VGDF,E*\?#GVN&R/\61\'Z-^Y3_R2_\ JK?-V/\
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MGJ987EI?42G='D=36!SCYR%L6\ZTI;?=W6:VVZX7BY0QA\T%"QI$#3PVW.(
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M-?O)LKV:T\2&BNY57VI_WIXD-%=RJOM3_O6RT3C7[R;*]FM/$AHKN55]J?\
M>GB0T5W*J^U/^];+1.-?O)LKV:T\2&BNY57VI_WIXD-%=RJOM3_O6RT3C7[R
M;*]FM/$AHKN55]J?]Z>)#17<JK[4_P"];+1.-?O)LKV:T\2&BNY57VI_WIXD
M-%=RJOM3_O6RT3C7[R;*]FM/$AHKN55]J?\ >BV6B<:_>397L(B+FT(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@*#'^N)OFA_-3E!C_7$WS0_FD"<B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B HEV_5T_H_JI:B7;]73^C^J0),/Z%G^D+DN,/Z%G^D+D@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B H-H_0S?/.4Y0;1^AF^><@G(B("(B
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M3ECPUP^" "#M @X!_IBY-=ZVU_JVY6SDZDHZ"V6\[+ZR=H=M[R 22UV-K!P
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M1Z"0IHZU:5FEXS$_Z6])F8F):8Y'M-5M?H'5#)XW0079NQ2M?N&0UWPAYLN
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M@211R1F.1C7QG<6N&0?H2*-D489$QK&#@UHP!]"Q;4B:[8CSRL1SRT%R"_\
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MKJ?HM3$*5S6\[*S99+D9RP]8' J:K,3'4B<B*%%=*66[S6V-Y=50QB60 ;F
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M\$\5.I/V*3VWX+T B>-U/8^Q/IO?Y_AY_P#%3J3]BD]M^">*G4G[%)[;\%Z
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M;14NH^?IGU=2<;6RPM &1UD'.,[LX7*U]*M>O7VUMTK:VC-O-5.*N0/V';>
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M B(@(B("(B B(@(B("@VC]#/\\Y3E!M'Z&?YYR"<B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#N^5/K
M*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#N^5/
MK*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#N^5
M/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#N^
M5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#N
M^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#
MN^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H
M#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63
MH#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?6
M45E(XW*2/I,P(C!VMK>=_!9A08_UQ-\T/YJPAT!W?*GUDZ [OE3ZRG(HJ#T!
MW?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#N^5/K*<B"#T
M!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#N^5/K*<B"#
MT!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#N^5/K*<B"
M#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#N^5/K*<B
M"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#N^5/K*<
MB"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#N^5/K*
M<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#N^5/K
M*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?63H#N^5/
MK*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?64>X4;H
MZ.5YJ9W@#XKG;CO6642[?JZ?T?U51U14+C&T]+J!D#<'+ET!W?*GUE,A_0L_
MTA<E%0>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T!W?*GUE.1!!Z [OE3ZR= =WR
MI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T!W?*GUE.1!!Z [OE3ZR= =W
MRI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T!W?*GUE.1!!Z [OE3ZR= =
MWRI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T!W?*GUE.1!!Z [OE3ZRBV
MZD=)'*14S,Q(X8:[CYUF%!M'Z&;YYRJ'0'=\J?63H#N^5/K*<BBH/0'=\J?6
M3H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J?
M63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\J
M?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4^LIR((/0'=\
MJ?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@P]?2.CZ/FIF?M2M;\)W#SCSJ5
MT!W?*GUDNO\ E?GV_P!5.51!Z [OE3ZR= =WRI]93D45!Z [OE3ZR= =WRI]
M93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T!W?*GUE.1!!Z [OE3ZR= =WRI
M]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T!W?*GUE.1!!Z [OE3ZR= =WR
MI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K)T!W?*GUE.1!!Z [OE3ZR= =W
MRI]93D00>@.[Y4^LHURI'144KS4SO Q\%SL@[UEU#O'ZMF^C^851P90.+ >E
MU/#]I?>@.[Y4^LIL?Q&^@+ZHJ#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y4
M^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[Y
M4^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.[
MY4^LIR((/0'=\J?63H#N^5/K*<B"#T!W?*GUDZ [OE3ZRG(@@] =WRI]9.@.
M[Y4^LIR((/0'=\J?646W4CI(Y2*F9F)'##7<?.LPH-H_0S_/.50Z [OE3ZR=
M =WRI]93D45!Z [OE3ZR= =WRI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/K
M)T!W?*GUE.1!!Z [OE3ZR= =WRI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5/
MK)T!W?*GUE.1!!Z [OE3ZR= =WRI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^5
M/K)T!W?*GUE.1!!Z [OE3ZR= =WRI]93D00>@.[Y4^LG0'=\J?64Y$$'H#N^
M5/K(IR("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B H,?ZXF^:'\U.4&/\ 7$WS0_FD"<B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B HEV_5T_H_JI:B7;]73^C^J0),/Z%G^D+
MDN,/Z%G^D+D@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B H-H_0S?/.4Y
M0;1^AF^><@G(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@@W7_*_/M_
MJIR@W7_*_/M_JIR B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("AWC]6S?
M1_,*8H=X_5LWT?S"0)<?Q&^@+ZOD?Q&^@+Z@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B H-H_0S_ #SE.4&T?H9_GG()R(B B(@(B("(B B(@(B("(B
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MUK?2TBEYBLUV],^:4U;3,1G.6]E3=8\H]@TI5BDKY)YZS <Z"F8'.8#PVLD
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M26NKR>;E8QIC8 0"7DN& ,^=2=.T3C!F%O1:FCY>M).NT=(^.Y14TCMEE;)
M!$1G&U\;:V?/CZ%MEI#F@M((.\$=:EJ6K_E!$Q(B(LJ(B("B7;]73^C^JEJ)
M=OU=/Z/ZI DP_H6?Z0N2XP_H6?Z0N2 B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("@VC]#-\\Y3E!M'Z&;YYR"<B(@(B("(B B(@(B("(B B(@(B("(B
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M2NJ:? W\XQ[R /.1EO\ XEK.LU34:UT)HC1-)(75YJ^8J/,UIV8B?-LO.?\
M0MX:6O5!R<\D^FSJR22CS$(]GFG/<'NVI P@ X.,\>L+6GY/5A@O?*->]4TU
M&^"T4LDO0VO'Q7R..!_X6$Y[,A2EL1:T](G,$^4/1MKH8+9;:6AI&[%/31-A
MC;V-:,#]P6K.6K4]%;;]I^T0:<M]ZU#5/:ZC=6M&S 2\-;OX[W#AD#=O6W%1
M^4GDVM>NC235<]11U])D0U-.1M 9S@@\1G>.!"\VG,1;-FYZ<FCN5^+50U;I
M&36-5:G54DW]S#;VD"%O.,SM$C)R>&\\"K%RTTT-9R^Z)IJF-LD$C*5KV.&0
MX=(DR".Q6RIY"[-6-IYJZ]WNIND3P\UTLX?(['!N' @ <>WSJSZDY/+=?]:V
M?4U75U;*VV",1QQEHC?L/+QM9!/%QX%=^+6,>T2SMEK#\K&&-HTG,UC6RB69
MFT!@X_NSA=/+0(G\O.CV7<--K+*?=)\0_P!\_.<[L9V<^9;7Y1^3VW:\9;FW
M.JJZ<43WO9T<M&T78SG:!_9"[.470%HUW;XJ>ZB2*> DP5,) ?'GB-XP0=VX
M]BS35K$5B??]28ZM8_E:LHA8;$YPC%PZ2X,X;7-;)VOHSL+=.EO^K-H_X.'_
M ) M8NY [%46WF+C=KM5U>TTBK?(TN8QH(V&@@@-WY^@<%MJWTK*&@IJ2-SG
M,@B;$TNXD-&!GZEB]J[(K$]%B)SEY_\ RJ_UOH[_ %3?\T:?E 4\57RM:'IJ
MA@DAF,4;V$9#FF?!!^A;1Y1.3FVZZJ;9/<JNLIW4!<8Q3EH#MHM)SD']D+GJ
M_D\MVI]46:^5E55Q5-K<QT4<1;L.V7[8VL@GCV$+=-6L17VRDQU:U_*U@B;8
M=/2-C:'LJ)(VD#&&EHW>C<%T?E5 ?V8TL[_$9'Y/;\!JVIRDZ!M^O:&CI;G5
M5=.RED,K33EH))&-^T"NOE#Y.[=KFWVZCN575T\=$XN8:<M!=D ;\@]B:>K6
MNW/EDF)YJ-^5.T-Y.[4&@ >$(^'S4B^<HVI[=:-.Z)MS].T-[O-730]#%8T;
M$)+6#.>.]V!@$<-YW+8?*'H>AUS9*>V7*IJ:>&"83M=3EH<2&N;@Y!W?"*QN
MN.2^SZMLUKHJN>IIY[9&(J>JB(VPT ##AC!^*#U;^'6I2]8BL6\LK,3S:0Y=
M8M6]*TW+K*HM EDDDZ/34#3_ '(RS)<X[SG=UD;E9>6VGBJ^7?0]/4,;)#**
M5CV.&0X&I?D%6FLY"+-<*6/PI>[Y67!K@>FRSAS]D X8 X$!N_/;YU:-1\G5
MOO\ J^R:BK:VL;6VH1"-K"P,D+'EX+ALYWD[\$+?%K&/;*;9:M_*3I89]?:*
MBEC:YDQ$3QCXS>=:,>C>?K7;^51#'%5Z+=$QK'"69@+1C#08L#T!;/UOR>6[
M5][L]SKZJKAFMCMJ)L):&N^$'?"R#UCJ7+E%Y/;=KI]K=<JJKIS;WO?'T<M&
MT7;.<Y!_9"S35K&W/EDF.K57+;3Q5?+OH>GJ&-DAE%*Q['#(<#4OR"OGY2=+
M#/K[144L;7,F(B>,?&;SK1CT;S]:VIJ?D\MVH=9V?4E555<=7;.;YJ*,MV';
M$A>-K()XGJ*:WY/+=J^]V>YU]55PS6QVU$V$M#7?"#OA9!ZQU)75K$U]H)CJ
MUA^51#'%5Z+=$QK'"69@+1C#08L#T!6/E=U13T>MK%9;7INVW;4\NQ)35-:T
M;-/EYV<'<>+2>( \^5;N47D]MVNGVMURJJNG-O>]\?1RT;1=LYSD']D*)RC\
MF-KUM6TEPFJJJWW2E:&1U5,1G9!) (/822""#O4KJ5Q6+>65Q/-I?7T.I6<K
M>B':NJ[9)7R5-.8V4#2&PLY\8!)&3OSVJQ<IS1_^)/1PP,&*FSY_[V56SQ(6
M9U705\UXO4UVI9A.ZMEF#WRN!:6@[0.X;.[':<D[EEN4KDLMNN;C1W&>MJZ"
MOIF<VV6#!VF@DC(/6"3@@]:WQ:9C\)A,2H'Y1X UQH(#<.>/_JQJ)RDB"?\
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M1 1$0%!C_7$WS0_FIR@Q_KB;YH?S2!.18[4-[H-/6BHN=WJ&T]' ,N>=Y/8
M.LD[@%2#RB7PT9NC-!7<V4-YPSNGC;/S?[7,9VN&_BM129YPF6R$5;J=:V6#
M11U4:DOM'-"5KV-RYV3LAH'[6U\'':JU4\HM[H*(W2Z:$NM-96MYQ]0*F)\L
M;/VG0C> !O._<D4M)F&R454U3K:ALFD*;4%/&ZX4]4Z%M,R)VR9C(1LXSPW;
M_H5J<X-87/(  R3V*3$QS5]15_0>IH]7Z=BO%/2R4T$LDC(VR.!+@UQ;M;NT
M@JP),8G$@B(H"(L!K+4L6F:*AFDIWU,E96Q4,,3'!I<^0D#CV8)5B,SB!GT1
M% 18C56H*+35I=<+CSACYQD3&1-VGR/<<-:!VDJ/=]2Q6_55BL0IWS5%T$SP
M]K@!"V-H)+NW.<!6*S)EG9(V2QN9(UKV.&'-<,@CL(6,I--6.CJ14TEEMD%0
M#D2Q4L;7@^D#*RJ)F8$6Y6VANE.(+G1TU9 ';0CJ(FR-SVX((SO*[*2EIZ*G
M9!1P14\#-S8XF!C6^@#<NY%,@B(@(B("(H5[NE+9;15W*X2&.DI8S+*X#)#1
MV#K*=1-11;56MN-LI*V..2-E3"R9K)!AS0X @''7O4I 1$0$6 K-2Q4^M+?I
MQM.^2HJJ62K=*' ")C3@9'7D[DT7J6+55MJ:ZFIWPP1U<M-&7N!YT,.-L8ZB
M<_4KMG&4RSZ(L!7ZEBI=96O3K:=\M16T\M2Z0. $+&;@2.O)W)$9Z*SZ+%V.
MYU%QDN(J+;4T+*:J=3Q.GW=(:W']XT?LG.Y9128P"(B B(@(B("(B B(@(B(
M"(B B(@(B("B7;]73^C^JEJ)=OU=/Z/ZI \Z5NC=125D[V6>K<QTCG AG$$E
M=/\ 8K4GD:L]1>FH?T+/](7)>V/KKQY/AS_X/2F<[I_1YC_L5J3R-6>HG]BM
M2>1JSU%Z<17QU^T'V%H^J?T>8_[%:D\C5GJ)_8K4GD:L]1>G$3QU^T'V%H^J
M?T>8_P"Q6I/(U9ZB?V*U)Y&K/47IQ$\=?M!]A:/JG]'F/^Q6I/(U9ZB?V*U)
MY&K/47IQ$\=?M!]A:/JG]'F/^Q6I/(U9ZB?V*U)Y&K/47IQ$\=?M!]A:/JG]
M'F/^Q6I/(U9ZB?V*U)Y&K/47IQ$\=?M!]A:/JG]'F/\ L5J3R-6>HG]BM2>1
MJSU%Z<1/'7[0?86CZI_1YC_L5J3R-6>HG]BM2>1JSU%Z<1/'7[0?86CZI_1Y
MC_L5J3R-6>HG]BM2>1JSU%Z<1/'7[0?86CZI_1YC_L5J3R-6>HG]BM2>1JSU
M%Z<1/'7[0?86CZI_1YC_ +%:D\C5GJ)_8K4GD:L]1>G$3QU^T'V%H^J?T>8_
M[%:D\C5GJ+C'H[4,@)CM%6X X.&=:]/*#:/T,WSSD\=?M!]A:7JG]'G'^Q6I
M/(U9ZB?V*U)Y&K/47IQ$\=?M!]A:/JG]'F/^Q6I/(U9ZB?V*U)Y&K/47IQ$\
M=?M!]A:/JG]'F/\ L5J3R-6>HG]BM2>1JSU%Z<1/'7[0?86CZI_1YC_L5J3R
M-6>HG]BM2>1JSU%Z<1/'7[0?86CZI_1YC_L5J3R-6>HG]BM2>1JSU%Z<1/'7
M[0?86CZI_1Y7NNG;O::=L]RM]130N=L!\C< G!./W%8I;]Y:J6>MTU14])#)
M/.^M8&QQM+B?@/Z@J[I#DF<_8J=2R;#>(I(G;S_J<.'H'UKTT^JKLWW?,UO_
M !=XU^%HQF.\M<6"P7*_U7,6NE?,X?&?P8SSN=P"] Z TU5Z;MG,5MSEJW.
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MY>6\0WJ6+1%HFTQRF,Y]VHF8Y?W#ZS45[N=1=G6*GMKH;?,^ P5#W\_*6\2
M-S0>K*QNLZRZ7@:8I*>EAINGS-F=3U.VUX?'ESFO 'Q.&_BL=>)(+I1])%IN
M5!K1H '1*>1F9.&2[XI9YR>"SM7)4Q:]T^^Z4\[Q'0%C98HBYG2'D-=O&X#
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M 1$0$1$!$1 1$0%!C_7$WS0_FIR@Q_KB;YH?S2!.1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MZQZ;?3LO5>VE=.TNC!C>[: X_%![0M%<K^O;3K"CMD-JCJV/IYG/?S[ T8(
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M+G1.8<YCC9L !F#QP>OL"KM[Y5]7:8NMMFU5I6FH;'7OQ'LS;<S&[LY()&T
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M B(@*#:/T,_SSE.4&T?H9_GG()R(B B(@(B("(B B(@(B("(B B(@(B("(B
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ME>J;1G*EJVOKCBFJK)!7X'&1\;S$&CSDEH^D*RV_D\MM+J.W7Z>ONM;=Z(2
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M"&DF']"S_2%R7&']"S_2%R0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M 1$0$1$!$1 4&T?H9OGG*<H-H_0S?/.03D1$!$1 1$0$1$!$1 1$0$1$!$1
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MO74Y$$'P9#\I-ZZ>#(?E)O74Y$$'P9#\I-ZZ*<B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@*#'^N)OFA_-3E!C_7$WS0_FD"<B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B H
MEV_5T_H_JI:B7;]73^C^J0),/Z%G^D+DN,/Z%G^D+D@(B("(B B(@(B("(B
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M#!JW2$3:&JHB#41T[ UI;^WLC=NX.'6#YBMP/BC>]KGQL<YO D D+FX!S2'
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MC<;7$0V>5@=$3N&VTAS<^DC'TKMTOI\65UQGFJ355M?/ST\O-B,;AAK6M'
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M>F?EZGV!3@:GID\=]-_]D?*\HJ-XT],_+U/L"GC3TS\O4^P*<#4],GCOIO\
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M\Y3E!M'Z&;YYR"<B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B"#=?\
M*_/M_JIR@W7_ "OS[?ZJ<@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B H
M=X_5LWT?S"F*'>/U;-]'\PD"7'\1OH"^KY'\1OH"^H"(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@*#:/T,_SSE.4&T?H9_GG()R(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B JOJ2T&\5T%=8[G%37FW%S X8D;AW%DC>I6A
M5*LT_=J&^5MSTU74L9K=DU%+61ET9<!C:!;O"ZZ,XG.<2Q?IT=5KO4]3>:>R
M:MM4$5PWSTLS,20RN;GX3,[VN SY_0L34W:>.AU[=^?EYN.3H5.-HX8YK0S+
M1U':>"L_:M/W"2^Q7G4-9!45=/&Z.G@IF%L46UQ.3O)(4)FC:DZ6I[3+50ND
M?7"KJY,'$HVRX@>?XO'L7HBVG$_&>W7,X^(<\6F&&U)99K7H6*OK+A<);W%'
M"R)[:AS0QY+1LAH.#UY)R3O*S5<:G4&JC8Y:F:&@H*9DU7S#RQT\CN#<C>&X
MW[EFM3V:2]&UL$K&4]-6,JI6N!)D#,X:/I*K]PV':PKZJQW>EHKE#$R&M@K8
MSL/;C+7C>-X'9_\ M4U-\>_/\NG]_,FNV?;DZ*.E?:N4 4D-=5.M%#0/K>9D
ME<\1N<=DMR3DC R <XR5A*6Z5=OT=9X:=U1%67^KFJ)I:>,OE9'M9<6 ;]K9
MV5D=*6RKO-)J^J97">6X.-'#6/;AKVM!:7- _P ._=CL5CN6EY76^Q^#*EE/
M<+.T-IY'LVF.&R&N:X<<$ +I-ZUMMM/;]I_W+,5F8S']Y_\ %<IWQT5XM,FG
M*;4#7/J6Q5C:N*8QR1.R"]Q?N!!P<C"M!UG:A=#;P*PU'/<QNIG[.UG'QL8Q
MGK7VUVB[2W>.Y7^OB>^%I9#2T8<R%N>+G9.7'T\%8UY]2])GGS_/^'2E9CIR
M<*B5D$$DTKVQQQM+G/><!H WD^9:HJ);;/:ZVX555J"YUH:^5M=3QS0PQXSC
M8&0T-&[CE;,OUM;=[-6V^21T;:F)T>V.+<]:J=?IO4=RTVZS5=RM\$#8FQ-=
M3Q.VI0W& \D[ANW@#]ROT]JUYS..?Z)J1,](0;I6W6LTKH^D95/CNEQFB<^8
M<=AK=HD]N[9)'6I5PMHM&LM-LH*RNDJZN24U+IJASQ+&UF3M-.X<=V  LZ;!
M(Z_V6N=+&*>VTKXF1 '.VX!I(\V NZ2S22ZQBO$LK#!#2&GBBP<AY=DN^K<M
M<6L<HZ8GYG/\&R?/V5VR4)UFZMNMSJJMM)S[X:&""=T38V,.-OX)WN)SQ7;R
M5P2FDO%=53.J)ZBM='SSN,C(P&-)_>NRBTW?+9#66ZU7*DBM4TCY(WNB<9X=
MK>6M.=GCUGZEG=(V?P#IVCMI>V1\+3M/:-SG$DD_64U=2-LQ6>4XQ'L4K.8F
M883E._VFAM-J;QN%PBB</]P':<?W!8ZQW?P!I6[PQLYRJIKG/1TL/7)(YV6
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MX*IW=ACCYO=_XG@J3;[*QVM-!:5N,;74%HLGA P/'P):G(9DCK+3EP]*OCM
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M28?T+/\ 2%R7&']"S_2%R6%$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M 1$0$1$!$1 1$0%!C_7$WS0_FIR@Q_KB;YH?S2!.1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M7&J=,WRVTNMZ"@%%7NV&3TA.8SD YWG.,C([.!64UEKJOI]31:9TG0Q5MX<
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M6-S>114,K*%KAO.(6X<T=I+@S'G*R+;]RAU5A?J2GH+'34(B-3':Y^<=4/A
MVM\@( >1O QU[U9T^Q$MH(M=ZFY09(M#6"]:?@B?5WNIIZ>FAJ 7!KI"=H'!
M&<8(X\5E>5#4]7I;3D-3;(H)KE55<-'31S ECGO=U@$'@#UK.R>4+E;T6N]7
MZTO5!KVWZ8T];Z6NJZBA=4NYTN:V-VT6M<YP/P6#!)W$G<!O*BRZKU='<*32
MT%/9ZS5CV.J:N=G.-HZ.#:PPN'QG..[=NXA(TY,MG+&QWRW2:@FL<=2'72*
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M?.T;XV_#.R[X1&!\$E=.%,XQYIN;?L=VHKY:J>Y6J;GZ*H!=%)L.;M#)&<.
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M++!%.,M+<AD;'8X@%Q!6HTI\TW-RV"\T&H+3!<[1/TBAGVN;EV',VL.+3N<
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M#GLG8YI<QT8._) /P>.<=N%A3>>4>LM$]\AH;%:Z1C'S1VZO;*:@QMR?AN!
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M!2=&ZDU"_6M=IG53;8:J"@CK62T+'M:\%^R[XQ.1PZ@IPYQDROZ^.(:TN<0
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M;!"V4RMBC$AXO#1D_2O537ILBFI7..G/#E-)W3:LXRU?R3Z8N= ;MJF_Q/\
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MENRT!1T>D]27ZAMEE@U#>(G$/FFEJG-CI_.0YN_=GL[!G*S>C&MOO+EJ.YN
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MD?X.J74D[G,+6\XWB&GK6:QQQQ6,L-H9:8*@<])45-3,:BHGD #I)" ,X&X
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MXD:'9+0-XVG.SZ/0L-IDVFW\H]FI^2RYU-5:JHR/NM"Q[Y*6"/&Y^7?%<3G
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M4_SV[;#_ !$_/;ML/\1-ON96Q%4_SV[;#_$3\]NVP_Q$V^YE;$53_/;ML/\
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MO6.L8*VFTUF?-,Y4J^JMNCJJIH)Y*>=LD8$D9P0"\ JTPDF%A)R2T*F<L?\
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MIG)'14[=/UL_,L,L]9*'N+02X X ]'F\ZK'.2T?)7JB.D)8QESDA&S_@C+V
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M.JFMX.P[X+CY]P&5GA4Z<\XRUOMU]\._D]U8S4#*V*HJ8WUK9Y',C8PMQ""
MT_O[<[U.J=<:<IZQU++=81*UVR[ <YH/87 ;(^M5*P2RT_)KJB:ERV9M158<
MWB!NR?H"MND+;;_[#VZF;!"^EGI&.E!:,/+F@N)\^25K5T].LS:8G&<?WDS2
MUIB(9:NNM#0T]//554<<$[VQQ2$Y:YSOBX([>W@NBQZ@M=]Z1X)JVU/,$-D+
M6N&"<XXC?P/!:GV>F<FMHI9G.DIA>VP1DGC%EP_J5N>FIH*9NS3010MP!B-@
M;N'#@L:NE72CWS/Z-4O-Y]G:B(O,ZB(B B(@(B("(B J-KW5U=IV]VV&GAAD
MHY&<[4ES27-8'@$MP>P]A5Y5#U711W'7]KHIQ_=5%NJ8G>@C"[_3Q6;_ 'HS
M&)<]3.WDN-SKX:"U5-?*X&&")TI(/$ 9W>E4>RZRNM5H>^7:K@IHZZAD<QL8
M80W<&G>,YZSUJ-2ULMXTY8M.3G-6ZK-)6MZQ'3G+\^D!@_\ $HHW:+Y0<>4:
MC^;5Z-/1K6,6CGF/C./U<[7F><=EDHI-:U=#!51S6 -FC;(UKHY<X(S@[U-T
MMJ5]PM]R==X8Z2KMDKHJH,=E@V1G:![, _4JW)0ZPI-*4]9;;^V=K*9CQ3"C
MC:[8V1N:[?D@>;>N5-1T<W)9=Y['-/4RUL,D\\LQS*^3_&'8Z]Q&/YY4M2LQ
MSQUQR\OQ(M,3^3(T%TU/J.'IUH906VVO)Y@U3722RMS\8@' !60T[>KD^[U%
MFO\ 30QUT40GCFI\\U-&3C(SO!SU+OT[.^JT1;Y+,Z#GNAL;%SN2P.#0,.QO
MW$$%8NW7C4%/J^CM%[\%OCJ('S!U(UX(V?\ 4?Z+$Q%MU8B.7SR:CEB<H]NN
MVJ[S6W@6Q]FCIJ*NEI&BH9)M'8.X[CC@0LA8K]<VZC?8M14]*RK,'2(9J0NY
MN1N<$8=O!^[ZZYI6#4,M?J<V.LM\%.+Q4!S:B)SG%V1O!'5C"L]@TY607N6]
M7RO96W%T7,1B./8CB9G) '6<]?I6M6*5S$XZ<NZ4FTXF,L/IV[:NO]"^LHY+
M)%")GQ!LL<FU\$XZBLI8;[=!J26Q:A@I&U?,=)AGI"[8D9G!R';P?N55T';=
M0U.G9Y;-?HZ./I,P9 ^D:\;6UUN._?Z%EN3=C:NYW&MN\]1-J6G_ -FJ63[(
M$3<Y&P&C&R<<?OWZU:5C?TQ';K#-+3.&7L>H*GP_762_-ABK(_[ZFDC!:R>'
MM&2=XZ]_;V+[8M05%XKKA5P,C;I^E!9',6DOJ'M^,YN_XHX<-ZKG*7 _4MS@
MLEDB:^Z4C'3S5&ULB%A:1S9(ZW9&[T>=6?0%SI+AING91P"E=2CH\U-P,+V\
M0>OS_CE<[TK&GQ,<Y_3W_/\ ODW6TS;;G^_PQ=->-5W"UOO%%2VR&D(=)%23
MA_//8,\7 X!.-VY6?3UUCO=EH[C TL94,VMD\6G@1]!!5;OEVJM0U-18M-'#
M!F.NN&/@0 \6,_:?_+]XM-IM\%KMM-0TC2V"!@8W/'=UGSK&KC;SC$_Z]VJ9
MSUS"0^6-AP^1C3V%P",FB>[#)&./8' JEZSI+;/=FNK=*5UVEYIHZ1 ,M R?
M@_&&\?U77I&CMD-Z8^CTC7VN;8=BIF;AH&.'QCQ4X4;-V?V_[_HWSG']_9;+
M_626^QW&LA#3+3T\DK X9!+6DC/U+!\G.I:G4=JG?<8XHJV%X#V1@@%CFAS'
M8)/$']RRFL?^J=Z_X*;_ )"J7IF1ECK].ULCA'1W6TLAF<> EB8'-<?_  Y'
MT+6G2+:4\N?DEK3%X[,K?=6U=)KFW66BBA?32.C94R/!+FN?DAHW[CLC/TK,
M:RO,]HML/@]D<EQJYV4U,R3.R7./$XZ@ 5161/EJ=,76=I$]UN[JL@\0PC$;
M?0&@?6LE?;E4U?*'$:*V5%RI[+%AS(7-&S/(.))/4W]Z[3HUS7$=(Y^^/Y8B
M\XGW6S1UY-]L%/62L$=3OCGC&[8D:<.'F[?I6&?>+]>KO<J73W0*6EM\O,23
MU0<]TDG6&M' #SK&Z-KZBBUO<Z&LH)[=#=<UE/#,0?[P#X>"#C?O/T*:;'17
MROKKKIB\UEMK.>,-280=ATC>.U&[&2L32M+S,]/+SB,_W"Q:;5AD].7>Z/O%
M59[_ $T+:N&(3QU%,'<U,PG'7P(/5Z5952[/=KW;=0.LE]?!<7R4SJFFJ(6\
MVY^SQ:YO $]O\^K)V:^72NKV05FG:JAA(),\DS' 8'# W[URU-.<YC&/Q;I;
MEB6 TS=M7Z@M++A2R6.*)[W-#9(I=KX)(ZCYEEM/7VYNU%4V+4$%*RM9 *F*
M:E+N;DCSLG<[>#G^OTU+D_MNHJC1[)K-?HZ2/;EYNG?2,>,AQXO._>?,LSR:
MMCJZNY7"XS5,VI(_]FJVS[(YH [@P#=LG'[OK]&M2L;^F([=8<Z6F=JZ55QH
MJ25D5564T,K_ (K))6M)] )6*U?>*BSPVM]*V)QJJ^&F?M@GX#R<D8/'<J#I
M&.JNEIJ*^JTG%>)JZ61TM5-51@_&(V0';V@8PNV6"OI=*:?IKFT-=#?H60MY
MYLI;'DEH+FD\,D?0LQ]/6ML3.<?@O$F8;0K*ZDH6!];504[#N!ED# ?K77-<
M:5EMEKF3PR4[&EVVV0;)QU9X>94R[NM]1K"NZ-9:F_W&**..1DACYBF&,@-+
M]P)XGC_,*#I&F:Z;6]#56^"E@;S4G00X2QQN+''=NQQ .X;B/,L1H1MW3/;]
M?U:XDYPNNE+VR_6*GN']W&^1I<^-K]KF]YP#] 4ZDN-%62/CI*RFG>SXS8I6
MN+?2 5JF5IIN2[3T-#3-#KG5105(B(B=,TEWP2_JS@#)60NENN376Z>V:3I[
M/4TL[',J(ZR$9;P+'8QM CM6[?3US//'.<=/+\V8U9QT;(K*ZDH@TUE5!3AY
MPWG9 S)\V2L1IR\SW*\7ZEE$7,T,[(XG,!RYI;G).=ZP=AH*2^:NU-47BFBJ
MY*:9E-#'.T/;''LYW [AGCE=G)[0P6V^ZKI*,8IXZJ/8;G.R"S.S]&<?0N<Z
M=:UM'G$1^N&MTS,=EFU#=Z>Q6BHN%9GFH1\5O%Q.X-'G)5?@?K6O@;5-\$6\
M/&TREE8][@.H/<.!]"Z^5@%M@H9W FFI[A!+4;O_ )8)!S])"LEW=<I:!CK#
M)1=(<X$.J=HQEF#PV=^>"E8BM(G$9F?,GG:8[(>D[U47:&KAN-)T2XT4O,SQ
MM.6$XR'-/80N&O+S46#2U9<:)L3IX2P-$@);O>&G.".HJ)I*\7:KOUYM=[%#
MSM"V$AU*UP:=L$_XCZ%T<K__ &?W/TQ?^JU6*1QZUF.4S'ZDV_\ CF8]W.7^
MW,,;I&G3]06C/--;*TN\P).,K*:8U#3WNPTEQ=LTQG)88WO&YX)!:#U\/J6*
MEMVM)XW127JUP->,&2&F<7M'FR<96&U;IZEMFG]*V2)SW4YNL44C\X<_;#]H
M[N&<E;VTOBLS&?;LF;5Y^7NV!#7T<U.^>&KIY(&9#I&2 M;CM.<!?:.NI*UC
MGT=5!4-;N<8I \#TX*HU^L]OCU/IRQ14L4%IJ'S5,T$8V632,8-D.'7C'!=N
MHK?2635.FZJT4\5)+55)I)XX6AC98R-^6C<<<5C@UG&)ZQF/[^2[Y^&>T]J.
M&\W&ZTL9A;T.;FH]F0.,H R7>C>LH^Y4,=6*5];3-J3PB,K0\_1G*H%@A@MC
M==UM#20,J:.6;F',C + (\AH[!D<%C+-:YZO2,;7:0BK'U4/.NN#ZV(2/<X9
MYS)^$-YX9W+<Z%)F9B<1R[=O>68U)PV7<)JR.YVV.FDHVTTCGB=LSB)' #=S
M8ZSGCYEWU%RH:=CGU%;31-:[8)?*UH#NS>>/F5!CZ:*[D];=2'5K75#9'!X?
MM89@':!(.0 N[2-DMUQO^JZBXTD-4YMP?&QLS0]K!C)(!W G=O\ ,%F=&L1F
MT].WXS#47F9Q']Y-@12,EC:^)[7L<,AS3D$>8J%?;K3V6TU-PK"1# W:('%Q
MX #SDX"IVBZFHM.G[Q';J":O;2W>>"&GC>&ED>X[B>H9_>H^O*ZON>BZB>NM
M$]O9354+WLD>UYD9M;SN\Y"E?I__ )-LSRR3J?=SYLM3S:TN%,VMA;::%KQM
MQTDS7O?CJ#W#@?0LQI.]27JWR/JJ5])64\KH*B$[P'MXEIZPLQ#(R6)DD3@Z
M-[0YKAP(/ JC:\U##5Z8N<-KJ7M=%51T53*T$<WM.P[!X'=NW=JE?_FG;%<?
MZ)^Y&<KA!<J&HJ'04];32SMXQLE:YP^@'*D<]'SW,\XSGMG;V-H;6SPSCL5%
MUSIVTVK1\]7;:2&BJ[>&RT]1$T-D:X. WNXG/#?VKOHYG3\I5%+*-F22Q![A
MV$RY*<*MJ[JSRY_HN^8G$KES\7.NBYUG.M;M%FT,@=I'8H[KI;VR1,=74H?*
M,QM,S<O]&_>JFX@\I%Z /"SM!]8J#H;3%GK.3N%]72PRRU,+W23O:"]I!(&'
M<1LXZNQ7@UBNZT]OU3?,SB/=9]27BHMMTL5/3MC+*ZJYF4O!)#<9W;^*R]97
MTE"&FMJH*<.W-,L@9GT9*UE05<]=:.3R>K<Y\QK'-+G<7!NTT$_0 N5#TNXZ
MHU%52Z<CO;HJIU*PSU$;6PL;P:&/SQXY_%=)^GC&)\L_OCS9C4_7_C:,;V2,
M:^-S7,<,AS3D$*M:OU/';;#55=IJ:.IJH)(VN9MA^SM/#3D Y'%4FL;=;1I+
M45.^G\'4<U5"V&)E2V4T[)'8D;EIW#ANW?&66Y2-,V>@T=SU#104TM*^(,?&
MT-<X%X!#C_BXYW]84IH4K>NZ<YG_ )_TMJ6FLX;'5(\+ZDN.I[U;K0ZU1P6]
MT8S4QO+G;;<_X3YBKNM:T%#=:S7NK?!%W%MV'T_.9IFS;>8]W$[L;_K7/0B)
MW3..4>?XPWJ3/+#+B^7ZSWJVTFHH;=+2W"3F(YZ/;:62=0<'<05:ZRNI*)@?
M6U4%.UQP#+(& GZ5KVQ05-1KAM)K&NFJ;E1 ST#0UK()6G_&  ,N&.![#V+H
MC-7<=::@GET]'>S32-IHFS5$;&P, ZFO_:XY76VC6T_A&>72>?EEBMYB&SXI
M&31MDB>U\;AD.:<@CS%1XKE0RU1IHJVF?4CC$V5I>/HSE:QJ#=K%IC5[HZ,6
MVF<(WTU.RI9*8"\ALF-D_!&#D</,K34Z1T]#8*8.;#0-IN;D;7QEL<C7 CX1
M>>WS]JYSHUKUGKV_+_K47F>D+165E+11B2LJ8:>,G =*\,&?25R;4P/I^D-F
MC=!L[7.!P+<=N>&%K65U5<M>WR1UB9>VT;8H88Y:AC&0M<W)(:[<2X[\KY%1
MU]#:=9LEMS+;;IJ)\L=(VI9*(I-@AV T_!!X\%?#QB,SSY=O/\\IQ9[-BBY4
M)J64XK:8U#P"V/G6[3@>! SE8R^ZCAM5ZM%O>8?]M>\2/?(&\TUK<@D><[E6
M7::M#.3#GQ3Q"I;;Q5BKP.<YT1[8=M\>/5GAN4>MAANMRY/ZFXTL$T]9"\U!
MDC!YS^Y!&UGCO)/TJTT:9[QS_2";VQ\-B5E=243&OK*J"G8[<'2R!@/UKF*B
M T_2!-&8,;7.;0V<=N>&%2;!04E[U?J2HN]/%5/HYF4M/%,T.;%'LYW-.[?Q
MRL-<(F6P:]M-#\&W,HVU#(0?@PO<T[0'8#QPLQH1,[<\^7ZX_P"KQ)QGR;-A
MK:6>=\$-3!),P NC9("YH[2.I8O5];<[;:C76F&*H-.X/GA>TESX_P#%LD'<
M0-_6HVB+';[=9Z"JI::-M9-2L,L^,OD+@'')]*S=SKJ>VV^>LK9!'3PM+GN/
M9]ZYXBM\5YM<YKSY*_=M7TT6GZ2MM0%757##** <7O/:.H-ZURN]VN]$RTVZ
MF@IJB]5H.W(X.;!%LC+G'KQU 9W_ +E0]+M\!ZDI+[<[>VEM-U=(VCRXGH9>
M<MR.#=H?N/4%M.^WBCL=O?67"38C!V6M:,N>X\&M'62N^IIUT[16L9_O3\F*
MVFT3,SAA*&\W>AU'1VC4#*.3IS'NIJBD#FC:8,N:YKB>KK5K51T];:^YWINH
MK]'T>1C#'0T6<F!CN+G?[Y'U?RMRX:V,Q$=?/\6Z9QS$1%R;$1$!$1 1$0$1
M$!$1 6%U7?F6&@CE$+JFKGD$%-3L.#+(> \P\ZS2I.N7"GU9H^KJ#BC94RQN
M<> >YH#,_2%UT:Q:^)8O,Q7D[BW7'-=)YRR<YC:Z)L/]7;SQ_<NR754LN@ZN
M]T]-S%7 QP=!,"0R1IP0>&0LO?A>RV#P ^W-._G>F!Y[,;.S]/'S*EUMYK[O
MR>:K\*-IA44<LE*33@AIV=G?O)/$E=J1&IB9B.L,3.W,99>_Z@NL%%IL6P48
MJ[HYK'&=KBQI+ >HYX^E=-UN6L+'0RW&NBLM91P#:FCI^<9)L]9!.Y8W5+:E
M]#H-M ^..J,D?-NE!+0[FQQ 64K]/ZHO-*^ANUZHHJ&7 F%)3D/>W]G).Y;B
MM*Q7.,<\Y_%G-ISC+G?=17)]RT]2Z?-&!=87S!]6QQ  :'#XI["5U7>Y:OL5
M!+<:UEEK*2#X4T< D8_9SO().%#U?03-UAH^BM%4*"2.&HCBEYL2;#6L&[9.
MX[AA0=3TUWIJZCH=67R:HT]6O$;YJ>!D.'YR&R8&0T]H*M*4G;C'^YYS_I+6
MGFV90U,=;14]5#GFIXVRLSQPX9'\US?-$QV'R,:>PN 2"*."".*%H;%&T,:T
M<  , *CZMH[9->I'UFD:^Z3;+<U,+<M=NX?&'!>33I%[8_O^G>TS6%X9+&\X
M9(QQ[ X%<*VJAHJ.>JJ7AD$+#(]QZ@!DJGZ,I+;!=GNHM*5UHEYHCI$XPTC(
M^#\8[SQ^A9'E*AFGT->&4X)?S.UN_9#@7?N!6N''$BF>O]]TW3MF6/H+AJO4
M%.VOMK+=;+?)\*!M2UTDLC>IQP< %9'3-ZN%1<JRTWVEBAN-,QLHD@R8IHR<
M;3<[QOZE*MT\M7I*DEL3Z;G7TT?,&;)C&X;CC?NWCTK"VV]WRGU8+3?W6SFW
M43JOG*1KQL@.QO+CYCU+I,;XM$1'+Y_EB.6)RM%1=;?33B&IKZ2*8\(Y)FM=
M]1*DS310Q.EFD9'$T9+W.  'I6K:.GHJNQU1M.E9+E33<X\W.X21L?(23E^2
M-K=U8 X+MI+?67GDZTP:=U/4S02"0TE4_#*D-+AL>? QN.Y6?IZQUGSQY?V/
MS(U9[-CTMPHZN)\M+5T\T3/C/CD#@WTD'<L1IG4U/>8;C(YT$+:6IDA YT'+
M&X&V?,<^A5W3\EN&JHH;AI^:R7.IIWPB)NR::I:-[A\$8) \W!8NV45+#H+6
MLL--"R45-7$'M8 0P8PW/8.Q6-"L9B?;]3B3^Z_WBY_[!5MM%;;O"$36N#:B
M4;#,D;WX.0,'^2R$M3%34PFK)H86 #:>]X:W/I*UO?;';[=R4U%52TT;:R:B
MA,L^,OD+GL<<GTK)STT-XY0J.AN<;9J.DM8J8H)!ECI"_9+B.!W;EG@UF,Q/
M*,_I@WSGX7>EJ8*N$2TD\4\1X/C>'#ZPL)KR\U%@TM67&B;$Z>$L#1("6[WA
MIS@CJ*YVFSVNU7ZL=;I603U,37R4,;FA@ .!(&#>.S/!8KE?_P"S^Y^F+_U6
MK&G6LZM8ZQ,PU:9V3/FMCZJ&+ FFBC<6;>'. W#B?0OE'6TM:POHJF"H8#@N
MBD#P#]"I6IK?3W/E TY35L8EIS2S.?&?BOQ@@$=8S@X\R[*.@I;5RHMBML$=
M+!46LODBB:&L<X2  X&[.%>%7;G//&3?.60TCJ>.XV"FK+O4T=-4322,:TO#
M [9>6C )\RR]ZGJX8Z,T$E&POJ6-D-2X@&,YR&8XOX85$Y.]-6FOT7+/744-
M1/.^8&21H<YH#G !I/Q>W=UE0XY7S<GFAWRN+W>%(&Y)Z@^0#]P"ZVT:3J3M
M\IQ^_P#QB+SMC/9=*;4.-47RAKY::GHJ%D#HY'NV#E[23DDX67KJES[145%M
MFI72<TYT,DC_ .ZSC<7$=2IU#9Z"Y\INHI;A!'4&GAIN;CE:'-RYF]V#N)&/
MWK&5L++:_7UKH6AEO;0BH;"WXL3W,.0!U9XX4X5;3$1UQ$_M_P!7?,1S]_\
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M\TL<$3I)I&1QMXN>< ?25S!R,C>%K0W1VJK;I>T/R9:B3G+@T\0V X<'?ZG
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M4T#'QU#&@/<<C.7<3G/7VKJU.^HK-5V*WBV^%*:&@Z4*1TS8V/?G9VCM;G8
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M/$L[JSRRDV:WQVJU4E!"]SXZ>,1M<[B0.U<[G0P7*WU%%5LVZ>=A8\9QN/\
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MG+3G?GM/%2M2V2&_VT453+)$SG&2[4>,Y:<]:G5-;34M))55%1%'3QYVY'.
M:W!P<GT[EVQO;)&U\;@YC@'-<.!!ZU-]XQ.>G[KMKT8S4=DAOM)!3U$LD;89
MV5 +,9);G W]6]?-0V.&]MH!42R1]#JF5;-C'PG-S@'/5O6612+VC&)Z+-8E
M7[YI>*XW*.Y4E94VZYL9S?2*<CX;>QS3N(7+3^F8+56SU\U545]RG;L/J:@@
MN#?V6@;@%GEUU$T5-!)/42-CAC:7O>XX#0-Y)5XMYC;E-E<Y8[35DAL%O=24
M\LDK'2OEVI,9RXY(W+HMFF:*BMEQM[]NIIJZ>2>5LN/\>,@8ZMWI67I:B&KI
MXYZ:1DL,C=ICV'(<.T%=;:^E=7NH6U$1K&LYQT(<-L-[<=B;[S,_J;:\E4.A
M"ZE%ODOUU=:!@=$+F_%'^';QG9\RM])3Q4E-%3TT;8X8FAC&-X- W +M12^I
M:_\ E)%8KT%BM.62&Q4U3#3RR2-GJ'U+B_&078R!CJW+*HLQ:8C"X\Q8C3%A
M@T_1U%/32R2MFJ'U!,F,@NQD;NK<LNB1:8B8[F(SE@]1Z;I[U54%69IJ6MHI
M-N*>'&U_I.1O'_OK*Z;SI:.MN@NE#755MN6QS;YJ?&)&]0<TC!5B1;C5O&,3
MT2:1+ Z>TS3VBIJ:R2IJ*ZXU(#9:JH(+BT?X0!N \RQSM$"%U1%:KS<;=05#
MBZ2EA+2T9X[!(RW/F5O17C7SG*;*XPKU7I"U5%@I;2R.2"&E(?3R1.Q)$\;]
MH.[<DJ+3Z.VZ^EJKS=JVZ]%=MP13[+6-=U.( WGSE6M0[G=*&UQ,DN57!2QO
M.RUTKPT$]F]*ZNITB2:5ZRH<UH-TY3[R8:VIH:F"EA=%/ 1D9 !!!W$'L5LT
M]IN"T5%3625-177&I $M54$%Q X- &X#S+XS5>G'29;>;:'NW9Y]HS].5FXW
MLEC:^)S7L<,M<TY!':"MZFIJ8BLQB,1"4K7.85VRZ3AM-?7R0UE3)0UA>Y]#
M)@Q!SR,D;O-CT*"-"\U!)145]NE-:GDYI&.:0 >+6N(R!YE<D6./?.<KPZ]F
M K=*4%1:+;;8=NFI:&=D\38\;RW.XY[<DE9]$6)O-NLM1$1T$1%E1%\>]K&[
M3W!HX9)POJ B(@(B("(B L74V6&HU#1W=TD@FI8GQ-8,;)#N)/6LHBL6FO1)
MC+!6_3%%0ZFKKW$Z0U%4W9+#C89PVB/.=D973_9*E\%7N@Z1/S=UG?/*[=EA
M=C(;NX;NM6-%OBWZY_L)LKV=-#3MHZ*GIF$N;#&V,$\2 ,?T6+L>G:>RU]QG
MHI91!6OYUU,<<VQ_66]F>S[EFD68O,9CNN(5*313*>HEDL-VK[2R5VT^"!P=
M%D\2&D;E,L.E*.U5SZ^6>JK[D]NR:JJDVG =C1P 5A1;G6O,8F68I6)SAB[#
M98;.ZXF"623IM7)6/V\?!<_&0,=6Y91$7.UIM.9:B,<H8K35DAL%M-'32R2L
M,KY=J3&<N.3P715:<ADU''>Z:HEIJP1&&3FP"V5O5M C?C=]0[%G$6N);,VS
MSE-L8PQ&FK!36&GG9#))//42&6>HF(+Y7'M([%&DTQ"+S77*BJJBDEK8##.R
M+&RXX($F\;G#M^\JP(G$MF9SU-L8PI%OT"^W4S:>@U'>*> $D,C>T#)XG@K;
M:Z1]#00TTE5-5OC!!FF.7OWD[U*16^K:_P#E)6D5Z"(BYM(UTHV7"VU=%*YS
M8ZB)T3G-X@.!&1]:PEUTA17+3%'99IIVQ4H8(Y6D!_P1L]F-X)^M61%NNI:O
M^,LS6)ZL/<;!35DMH?MOB;;)!)"QF,' P ?-A<M/6.&RLK>:EDGEJZAU1++)
MC:+CU;NH++(G$MC;GD;8SEB+Y88+M66RJ?++#44$W.Q/CQD]K3GJ. L;<-'Q
MR7.>X6FYUMJJJ@YFZ.062']HM.[*M**UU;UY1)-(E@=/Z9AM59-73U=5<+E*
MSFW5-2[)#<YV6@;@%GD19M:;3F5B(CE#%:8LD.G[1';Z:626-CG.#I,9^$<]
M7I74[3U.-4-OE/-+!4F+FIF,QL3-ZMH=HW;_ #!9I%>);,SGJFV,85672!BJ
M*I]GO%=;(*IYDF@AV2S:/$MR,M)\R[SH^WMM-MMU.Z6*"AJF5;2""Z1[23EQ
M(WY)WJQHM<:_=-E>RM5>EG&\55QM=UJ[=+5AHJ&Q-8YLA:, X<#@XZUVV+2E
M)9ZFY2PSU,W3VM$XG?M%Q .79XY.T<JP(I.K>8QE=E<Y56BT520V&HLU565=
M70/(,+9" ZGP21L$#CDI%H\RU5+)=[Q77.&E>)(8)MD-#AP<[ RXCSJU(KQK
M\^:<.O97KII@5%U?<K;<:JV5DK!',Z -<V4#AM-<",CM7;IG3=/I]]<ZGJ*B
M=U8]LDCIW;3BX#!.>TG)6<12=6TUVYY+LC.755TT-932T]5&V6"5I:]CAD.!
MZE4V:*FI&&"U:BNU'1=4 >'A@[&DC("N**4U+4Y1)-8GJP^G-.4-@CFZ'SLD
M\Y#IJB=Y?)*1UN/TKLU/98=066HMM3+)%%,6DOCQM#9<'=?H641.);=OSS7;
M&,>0L9?+-#=W6YTTDC.A5;*MFQCX3FYP#GJWK)HLUM-9S!,9Y2Q.HK%37N&
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M3+J&[5;&9S#/("QV01OW>?/T*QHBS:\WG,K$1'01$65$1$!$1 1$0$1$!$1
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M4'_PD].<.AW8P,\00 ""LXBW.M>9SEG96%?M6F(J:MFKKE63W2MEB,'.5 :
MV,\6M:!@9ZUCO[#AE*^WP7NYPV=^0:-KFD!IXM#R-H-\RN*)&M>)SDV54#6U
MG@?<]'VVGYVFIF2R,8Z [+HME@V2#V@@+/6K3(IKJRY7&X55SK8V&.%\^RUL
M33QV6M &3UE6%%9UK36*D:<9RKU+I:&FN]QJV5=0ZEN&T:BB?@Q.<X8)X94#
M^PXZ)X/\-W/P-PZ'M-QL_L;>-K9\W8K@BD:UX\S95AZG3]++<+-5,+H1:@]L
M,3,;)#FAN#Z %F$1<YM,]6HB(Z"(BBB(B B(@(B("(B B(@+C(QDL;HY&M>Q
MX+7-<,@@\00N2(-;\J-GMM);+2ZEMU'"Y]RA8XQPM:7-(=D' X*\T]GM]&YT
MM!04=-/LEHDCA:TCZ0%5>5O]56;_ .J0_P G*YUO/BCG-&&&IYMW-;?Q=O&[
M/FSA>F]K3I5Y]W*L1NG\FJM'W&P6*"6W:NHVT]Z,KW3SU=/S@FRXX(=@[L?1
MU]:N6D;/;Z2XW"XV&NADME:&D4T&#'&\<2"#NZ]V.OS+'V36%GNMLZ-JA]'2
MW*(EE335;0UH<#Q =NPH.BHZ%^OKE/I=NS8^BALY8"(G3[6[8^CL\_:N^I%K
M1>9S$^?;\O\ 3G3$8QS_ '0>3K5EDLELN-+=*]E/.:^5X86./P3@9W ]A7=>
M]16J_:XTCX(K&U/,SR<YAKF[.0W'$#L*R7))!#+8KDZ2*-[O",PRYH/[*:TA
MBBUOHSFHV,S/+G9:!G<U69IQK<ISS\_:?8C=PX[<OW8^KGL]/RJW9U_=1B T
M489TH-+=KX/#/7C*BZ^J=*5ME--8(Z*:\OD8*44$8YP.VAG>T<,966I:.FK>
M5N\LK*:&H8V@C(;*P/ /P-^]<-66XZ0N,.IK#3M92@B.X4L30&NC)^.!U$>;
MS>=6MJ[Z\YSB,=DF)VSVS*^T F;0T[:H@U C:)".MV-_[UA[_=[Q05C(K7I]
M]RA+ XRMJF18=D_!P1Y@<^=9FAJH:ZCAJJ60203,#V/'6"L/?K+<+C5LEHK]
M5VZ-K TQ0L:X$Y/PM_I_<O#3&[[_ .N?]/1;..2';[_J&>M@BJM)RTT#WAKY
MC6L=S8SO=@#?A6B1C)8W1R-:]CP6N:X9!!X@A5B@TW=J:M@FFU17U$<;PYT3
MXF / / ^E6E75VY^[C\L_P"TIG'/_7^FM^5&SVVDMEI=2VZCA<^Y0L<8X6M+
MFD.R#@<%;ZNT6VBM];+1V^DIY>CR#;BA:TXV3NR J_RM_JJS?_5(?Y.5NN_Z
MIK?F'_\ *5UFUN'3GW8B(W6:XT1>;_%HJB-HLL5124L;@Z2:?8=*0XD[#1V<
M,GK5BFUJT6&RWF*ES05L[89RY^#3Y)&?. 0>SJ79R:C')Y;,?(O_ .9RPVC+
M4V]\D++>[&9F3!A/4\2.+3]8"ZWV3:TVCI;'SEFNZ(B(GR_XM.J;X^SLH(Z:
M!M165M2VGBB+MD;^+CY@/YK"W#5EU=J*Y6:RV9E94TFP[;=,&-V"T$DYZ\D
M#T]BQ&A*NHU1J"CK*UC@VR48@<'#C4N):YWJM69TN!XQ=8'KQ2_\A6>'73S%
MHS,1G]8_TNZ;8F)Y3_QWUNIKC)=!:++;(JBY10LEJS+-LPTY<,[.<9<?_?;B
M3I[4<]7=JBSWFB%#=(HQ,UK7[<<T><;33Z>K\5A;36T^G]?:BAN\K*5MQ,4]
M--*=ECPT$%NT=V03P7VDJH;]RG0U=K>)Z.W4;HYJAF]CGN)PT'KXY^@J3IUQ
M,;>6,Y]_[R(M/?SZ.VQ:HH:'01NXM[*2%LKV,I:<YVW[9  \Y.]83E"NM_=H
MNM9>;-#3TU2&!KX9]MT)VVN >,=>,9'6L=1T\TG)3054,;I6T%SZ7(QHR2QK
MW9W?3E9_E*U19ZS0U5%15L%5-5M9S<<;MIP <"2X<6X Z^M=ZTBNK&VN?O?#
M$VF:<YQR7^A_^"I_FV_R5-Y4J>62GM-1)2S5EJIJH25M/$,ES.HXZP-_UJ?<
M=-SW4TU1%?;K0-YAC.:I9=EFX<<=N]1KW=:S2#;+S[Y:RS NBK*J5I?,TGXK
MB1U9\W4O+I1B\36<SV=;3FLQ/1C)ZC1&J[8^@HYJ"DJGMQ"XPB&2)_5C.,[^
MH'>NOE$%THJ72M*P1U8BKJ8<^]^PZ:9N0 1OP#C).5W:RN6BKE9*J6::WU-4
M^,\R8,&<O(^#C&\;\<=W:H%]Z50Z)T7)>7.9+3W&F?.Z3BQHVB-KT#&5Z*1B
M:SSZ])_#R<K=)_TLYN)_M?9:6OME.VX34DDAG:_:,.,Y:TXW@J'#JR\7*X76
MALMGAEFH*E\+Y9I]F/9!PWJR7'!W=6/.N-740U?*9I^>EE9+#)03.8]AR'#?
MO!7;R=#_ *2U<>OPM*N<UK%=TQY1^\MQ,S.(GS_TZ;7J^]7NED%GL;.ETKC'
M5BHGV6,>"1L-/%QW9ZL+LDUR?[#2WYE#B>&402TSW_%?M!IWX\^5RY,OBZD_
M^L3_ -%33#)-R4ZDYIA>671[R!V![,GZMZW&GIVOMQRB8_5G=:*YSY2V;JV\
MNL.FZNZ,A$SH PB,NV0<N#>/TJOZBDYW7NBI",;;:AV/3&%C^4C4]HK]"5-/
M05L-3/4MC+8XG;3F@.:XEP'Q< =:FWS_ *[Z&^;G_P#3"QI:>VN9C$_>_9JU
MLSB/;]V1J+_>:RYUM)I^U0R14;^;DJ*N4QM<_K#0!D^E<;5J2ONMMO$(MK(;
MS;W".2G=-\ YX$.QPP"?H5>I+CX<N=Y-^U-/9VTE2Z&.B@G;3D1C@XN.]V?Z
M>A<^2]U.^ZZN;0NGD@+H3$Z=Q+WMV7X<2=YSQ^D+5M*M:3,QTQW]O-(O,VCG
MU1-)7"HI.2:::X6VFJK=#&YT8?)GG\S.V@X8W8/IRK-=]52VJ>Q4=';.DON$
M!=%$Q^SLN &&[]V-^\]0"J%KKJ:7D0JZ..>-U731/YZ('X3,SDC(\X*S]0/S
MTT'_ ,'-_P"BMWI6;VFT>=OTC+-9G;&)\H_=DJ#4MT@U%26G4-LAI75K7FFF
MIYMMI+1DM.1QQ_1<JW4EQJKW56S3=NAJG4>!4SU$NQ&UQX,&!DE1]8?]>=%_
M.U/_ "-4+3MRI--:EU'0WN=E&ZJJS6P2S'99*QW8[AD<%QBE9C?%>>.GYX;W
M3$XF?/\ TR^EM45-XO=PME;;30ST4;#(TR;1VCQQVC@0?.LCK7_J??/^"F_Y
M"JQHRYT]WY0]1U='DTY@A:QY!&V!NVAGJ/5YE9]:_P#4^^?\%-_R%9O6*ZM8
MB,=&JSFD\^ZJZ.UQIR@TM:Z6KN;(ZB&G:Q[#&\[) X;@NO35VHKSRK5]7;)Q
M/3FVANV&D;P]N>("L6@:6!VC+,YT$3G&F9DE@).Y86DA;XV[G%$&QAUJ ^",
M8RYN]=,TW:F(G.)\_?\ !C[V*Y]DR'5%XO,M3)IFTP5%!!(8Q45,^QS[AQV
M!P\Y4B#6#:C2MSN;:1T59;@]M122.WLD;U9[/.L3R<7JWV;3IM%WJH*&OM\D
MC)HYWAA.7%P<,\1OZEB8LUNF=>WF-CFT5>3T<N&-MK 1M =ARK.E7=-9KB(F
M,3WY_P"XYD7G&<L]3ZMO4MKJKN^QQQ6EE(ZHBD?.-MY W?!X@'?CS+IGUI>F
M6:.^-L48LVRUSRZHQ*6D@%P;CAD[L]6]3;F,<DCP.'@AO_I!1[R,<C8 X>"X
M?^1JE8I,Q]V.N//I\K.[OY9?+CK*[4= R]&R-\ DM.VZ;$_-N. _9X#.1N\Z
MS&HM2NH*BAH;72&ON=<"^&+;V&M8.+W'J"PVMO\ LB?_ ,)3_P V*/73QV76
MUANUP/-VZHM@HN?=\6.3.T,GJSG'UJ5TZ6C.._+OB.1-ICEGLS%%J2XTMZI;
M9J6W14CZS(IJBGEVXWN'^ Y&05'.J[K67NZ6JS6B.>HHI UTLLVQ&&D;B=V<
MDYW#L4/5=PI;_J/35NL\\=7+3UK*V>2!P>V*-G:X;AG[NT*9H@?G9K(]?2H_
M^4ILK%=\UYXZ?G@S,SMB?[A-TWJ@UT5VCN]**"LM9_VIH?MM#<$AP/9@%0*?
M4VH+A1&Z6RPQ/M>]T;9:C9GF8/\ $!C ]"Q;Z.:X7KE&I*89GF@A:P=IYHX'
MT\%CM/BP_P!F8)JS5%WHIZ>(,GI.GECHWM&"UK,9QD;@%N-*G.8CMRYSUC+.
M^W3/?]VS+!=J>]VBFN%$3S,S<@.XM(."#YP00J?RLN@8[33JSFQ3"Y,,O.?%
MV>O.>K"S7)W34U/I6F-#!5T]/*72M95.#I,$\=W4>(]*Q/*E&R6ITM'*UKXW
M72-KFN&00>HA<M*(KKXCIS;O,SIYESK;GH 4LO/&R/CV3EL<3"X^C SGT*-R
M?5IL')[45]U$T5#%+)+3L>/AB(D;( /:<X]*RFK-'4E=;C+9Z:"BNU,>=IIH
M8VL^$/\ "<#>#PWJO7FY3ZRY,*X11$72E<T55,T8<',<"[=YP"?HQU+I7;>D
M1$SB9C.?+^]V9S6<SUQR9>34^H::W^%JNP1-M8;SCXV5&:AD?[1&,<-^%D[Y
MJJ.CI+8;73FX5ETQT.%KMD/& 2XD\  0J95OTR=.NK7:HO4[)(\=#%QS(\D8
MV"S&?-V*75Q0Z?N6C+E+%/3VJ"!].\U&]U.7M^#MD<../H3A4F8Y=^_/ET(O
M;NL5!J"ZT]ZI;=J&V10&L#N8J*60R,VAO+79&0?.NENIKM=JNK;IFUP5%'2R
M&)]34S; D>.(8 /WJ;)JRCEOEOMEI,5QEJ,NE?!*"V!@'QG$9'T*@Z/MUNI*
M>MMUZO\ <K3<*2=X?"*WF&/;G(>T'<<K--.)B;6KB>7+G[\\=5FTQ.(E=8]8
MB32]UN70W15UM+F5%'(_XKQU;0X@]14+^U=^=:&WJ.PQ&TA@E+#48G,>-[PW
M&,=>..%@8XK>=$:PK+4;C+%,-@U59('](+,_";N!QOZ_Z+-QZPLPT"UW2X>D
M"C$'1=K^\YS8V=G9X\>OAC>M3I5C_&N>>//M"1>9ZSY(?*-<ZBNM^FJJUPQS
M4,];3S1O=)LETF\M81C<.T]2SUUU+6T4EOMT-M947ZK89#3MEQ'$T<7.?CA]
M"JEYI)++R?Z09<,QFFN%/)-M?_+!+W'/HSA92ON-);^4.AO<\\9M-?0&EBJP
M<QM>'[6"[@ <<?/Z5=E9K$1&8C=CW3=,3,Y[,M;]25]/>Z>U:DM\5)-5@FFG
M@EVXI".+=XR"H+M77FLN]SM]DLC*J2@G+)'OG#&['5Q_Q'?N\RZ-25]+J#5N
MFZ&SSQU;Z2IZ7420NVFQ,;U%PW;_ +E,T"!X?U@>OPA_0K&RM:[YKSQTY]\-
M9F9VQ*Z-SLC: !Z\(B+Q.XB(@*M:LOE71U=!:;+'%)=J\NV#+\2%C?C/=C]P
M_P#V&RJCWR1MNY3[-759#*6JHWT;)'?%;)M%V">K.0%VT*Q-N?/$2Q><0[:F
MU:NHZ9]53:B975,;=LTLM&QD<F/\((WA-1:AN$.G+%7T\<E#45E;!%-#+'\)
MK7;6TW#AYN/%9?4-'>)Y!-;+Y';:=D?PVOI6RY.\[62=VY4.NNE7>= Z:K;C
M*):E]XC#GAH;G#W@;ANX!=]*.)BTXZ]OQ]L.=IVYB,ML*C5%1?[IK2\6VW7I
MMOIJ..%[6FE9+G;;D[SOXJ\K7!M]QK^4C40MEW?;7,AIR]S8&R[8V-P^%PPN
M7T\1]Z9QT\^?G'XMZGDR N%]T_J&U45YKX+I17%[H6R-@$,D3P-VX'!&_P#]
M]=W56MFDY&7>"YWJ[5-UJJ8$0"1C8V1D\2&CK\Z[:.MU0^Y1QU5HH8Z(OPZ5
MM3EP;VXQQ34BM_\ &8Y=?+X*S->K$:YU?5T(EIK)32E\$T;*FL?'_=Q;3A\%
MN=SG'(] /U93E&NE;:-,OJK;,(:GGHV!Y8'8!=@[CN71RJ?]47_\3!_ZC5T<
MKXVM&R $C-1",CJ^$NFG%;3I\O/_ (Q:9C=S\O\ J0^S:K:QQBU7&]X'P6OM
MT8:3V$@Y4W0E[FO^GV557&QE2R1T,NQ\4N:<9'F*K&K=-7B@M,E71W^\5T4/
MPJBE?/LNDC_Q;+@-QQYBK=HWP8=-T+K$P,H',RQN<D'.\.\^<Y4U,3IYY3S\
MHQA:9W83KA<Z&W!AN%934H?G8,T@9M8XXR=ZC0ZBLL\S(H;O;Y)7N#6L;4,)
M<3P &>*B:LCGD93='T]2WO!=D5$D;.:X<-L'CYNQ86VT]:VX4Q?H*V4C1(W,
M[)X2Z(9^, &YR..Y<Z:=9KF?WC_]:FTQ./\ J\JD4]PO>JJZL-DKH[7:*64P
M"HYD2R3O'$@.W!OG_P#8NSAEI'#(5)Y)96P:?FM,I#:^@J)(YXS\;>XD.]!S
MQ\R:?*EKXS,8+<YB$FC?J*S7NCI;A4&\VVK)9TAE.&24[@,C:#=VR>W_ -GO
ML]ZF?J'545?4-;0VXPNC): (VF,N<2>OAG>L+?*C4=AK[.:C4,57%65T=.Z#
MH<<9V"=YSO/F^E=$O_Q7*?\ \*W_ /1WKMPXM&9QSCR_&/9C=B<?WHO[[A21
MV[I[ZB,4?-B7GB?@[)W@Y[%PK;I0T- *VLJX8:5P!$KW8!SPQVJH7:1C>1L.
M+@&FV1-!\Y:T#]ZZ#&RIU9HZGK6M?3,MSI86/WM,H:.KK(&]<ZZ,3F9\IG](
M:G4G]ERL][MMYC>^UUL-2&?&V';V^D<0H,FL=/1U9IGWBC$P.R1M[@>S:X?O
M42_G3]ON-765I+*]UODYQD1<UTD X\-V>H$[U5;EX1DY/J@4UEM=NLHI"^,3
MS&24M(RT@ 8VSN.\\2K31I;GSQ/X?V4M>8;(N=SHK72=)N%5%3P9QMR.P">P
M=JC6W4-IN3XF4%PIYWRAQ8UCLD[/'=YLA4JV!E7J31D=>!)3MLPE@#]X=-LM
MR=_$AN]9"OIZ2'E7M3Z=D;:F2BE,P:,9Q\4GS\?J3@UCE/7$S^Z\29YK#<]3
MV6UU0IKA<Z:"?K8YV\>G'#Z5-FN5%!2PU,M5"VGF<UL<FT-EY=\7!\ZJ?);3
MT]3INIJ*F*.6MJ:F;IA>T.<7;1&R[/5C&[SJH3Q1R:-KJ)F76Z/47,4XSN$6
MT-P\V\K4?3UFTUSTG$IQ)B,]VSJ#4UEN%<:.BN=+-4C.(VOWG''';]"S"I.O
M:.GII-*OIX(HG1W>GC86-#=EI)RT8ZMPW+)5U;JAEQD91VBAEHP_#)7U.RXM
M[<87*=*)B)KY]VHO,9B7&Q76KJM9:CH)Y0ZEHQ!S+-D#9VF$NW\3O[5F+Y*^
M&SUDD57'1O;$2VHD;M-C/[1!X@*M:7_[1-8>BE_Y"LIK[_J7>O\ A7_R5M6.
M)6(__P ?VA*S.V9_%#FNU9%J72]$RJ9-3UE-*^=S6#$I:P$.'8,[]RL,%QI)
MZZ>C@J(Y*J  RQM.2S/#/8M;7V.Y2U^B(K))%%7/M\K622<&9B;D^G&<>=2K
M/4QP<F5Y;;X7T]VIHI65K7',O/8.T\GB<C)!^Y=;:$36)C\/UGG+-=28F8_O
M1;SJNQ"X="\+4G2=K8V.<'QNS/#/F6:6KZ6W7:;0,=*VCTXRU/HP[GGS2 @%
MN></P<!W7GM5\TJV9NG+:VIJ(JF5L# 9HG;39,#<X'KR.M<M72K2,UENEYMU
M5NMJ+]<=;7&UVV\MM]-34\<H!I62Y+N/'>C[A?M.WVTT]WN$%TH;C-T</%.(
M9(GGAN!P0H-107"OY3+RVV75]M>VDA+GMA;+MCLP[@LY;])2B[4UQO=XJ;K4
M4N33M?&V..,G_%LCB5VF:5B-V,8Z8Y].^/\ ;$;IF<=V5N^HK19Y617.X4]/
M*X9#'.^%CMP.I27W2A9;3<75</0=G:Y\/!9C.,Y6O-*B]S7?4M30TMIGG=<)
M(I7UDCQ(UHW-;@-/P<</P46JHYZ'06L89I[>YAGVQ!12E[:=Q<W:9O QO W+
M/AJYBN>?+]3BSC.&P8-3V2>X] ANE*^K)V1&'\3V \"?,L97:OIJ;6U/9GU%
M,R PDR.<?A"4D!K/I!S]*@:THK=3\F,@IV1LAIX(Y*9[=Q#\C9<#VGMZ\K[$
M'OY1[.ZI8.>=9RZ3(_Q;8RI33IB;?C^BS:W3\%BM-4XUEWZ1<X*F*&7=&UH;
MT9N,EKCU]N2J[JW6U$RPU;]/76FDKXGQC#<.."\ X!W'<>(5:O[Y&6W7(82V
M)]RA9,X;L1DM!^[Z58N5*WVZ/1 +(88^CR0BF+6@8RX# \VSE;KI4B]=W/,Q
M^T?]9F\S6<?WJM]VNM!:*<3W.KAIHB< R.QD]@'6EINU!=Z<SVRKAJ8@<$QN
MS@]A'4J/>Q<9^5!K:.&@GEI[>'T[*U[FM&7_  GMP#\+J]"EV.CN,6OGU5>^
MSTTLU'B:EI)G%\@#O@R%I:/1E<IT:Q3.>>,M[YSA=ZB5E/!)-*=F.-I>XXS@
M 9*I5IU57W76E-2LI9:2TR4TDL0F8&OGP0-O!WM'8.OCZ+PJC7_]J-J_^G2_
M\X6-';.Z)CREJ^>6)6Y4*EGU#>M2W^EH[ZVAIJ"9C&,Z(R7(<W/$X/4KZM9V
MFS37766K3!=J^W\W41@BE>&A^6GCD'AC]ZUH8Q:9[=L^<,ZF>4,H:^^Z?U%:
M:.[7""Z45R>Z$.%.(9(W@;C@;B-ZLUXOMKLP9X4KH*8O^*U[MY\X'%4?3-&V
MW:[?1ZEGJ:VZ-87VZKGE+F/C/$-;_A=QSQZ_I^6\7B;7FIIZ"GMD]3$^.(&M
MD>UT<>S\'8P#N/$KK;2K:>?E&>V>;-;S$?FV'05U+<*1M30U$4].[A)&X$+&
MT^J[%4UXHH+K2/J2=D,#^)[ >!*H%P@N-MLVMW\];8Y)8XG24E!*YW,..YY(
M(&-II)^A7&NMVGV:,@CN#(HK3#'&\2-RW9X8<"W?DG&\;SE8G1I7KF<]OPCY
MZK%YEEKQ?;79@SPI704Q?\5KW;SYP.*[H+I0U%M=<(*N&2B:PO=,UP+0 ,DD
M^;"U_;#=ZC7.I*BW4]MJ)XG11M-;(]KXXMG+=D!IW'B?.D%'5T=!KSI,ML9S
MM&^1])12N<(9.:=DD$#&T-_T*S]/6(QGGR_7'_3B3V7$:LL)JXZ47:D,\F-E
MNWQSPW\,^98_46KJ>T:GM-MEJ*:.&;G'53Y#OB 9EGHR[^2Q\5!;!R0[!CAZ
M.;=SQ=@?I=C.U_JVON4*F,L]YY.)*P;4[Z6<O+AO)Y@;RK72T\S//EG](E)O
M;'Q^ZZ7C4%ILY8VYU\%,YXRUKW?"([<#?CSJ1%=*&6VNN$57"^A:TO,[7 M
M'$Y\RJNBHHJC4^K*FK8U]>RLYD%XR6P@?  [ ?WX6$J6,IG\H])0@-H64S9-
MAGQ62NB.WC^JS&A69V^<8_7'_5XD]5_H+]:[A724=%703U,;=MT;'9(&[?\
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MBG@J6M;40QRM:X.:'M#L$<",]:['-#FEK@"TC!!X%?40=<,,4$+8H(F1Q-&
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M[=P7UECHH[S47.-CFU%3$(IV@_ E X%S>!/5E9-%G?;NNV%4=H.T$&(25[:
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F 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g762905g98o86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g98o86.jpg
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M=8*2PN'P\1<E)C0U4V.S1%6B)SA4A(63TD5DE*3#_\0 &@$!  ,! 0$
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M=;\N6\D+VLVR+L\[5J>JTX/9F!L==#&T\1DN(<T?S26GCR.%OOY5D@EL6FI
M" ^:1PSZM:M)MM#=^V?M)_.<](ZGM3',;,\9+(86_P"##O%QY^9)P MX_*Q
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M-V/#/X %9<^$G%O5Q\^EL+^+7MU]$1><W$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MOE)BGC#FGW6>!"["BUG-KB^GKYVIV_B[F+;K;0VR$Q6VBIJ2(G)9!$V-I/P
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M*Q=DE]NE0TOBI*J:8M'5V(H\ ?$\*%TO>^T#M2K:\VZ]0V:WTY:'B$;=N[.
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M .1-_P#P7T@BC3T?_E^I^\_V<OTUV?WBW=F%\TW75U+/7USY#','O<QH<Q@
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MV46I-+-DH^ZG9%54S9'.CGC.>H)//'WYZA-&W6GN:QI<]P:T<DDX 5,<T4C
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M+;<+1K2CU7;;?)<J;N/9:VFB;NDVYR'-'CX?3URK-;JBYW^HI*'1]CJZ1[I
M:BLKZ,,CB9XC!SD_V<>G3$5=ITT#4E#5R=JND:F*FGDI8(9Q+,V,EC"6. W$
M# RO.VVAJZ_25-%04L]3**Z)Q9#&7N  =DX'@N@(FTZ<]US;KE;-7VS5MHHY
M*]L$)I:REB_C'1DG#FCQ/O?</51FK+Y7ZYMGY@T]9;G VJ>T5-56P=TR%@<"
M1U.3Q_9E=51-HTYIK^T5MJETE=+1135\%C/=RPQ#,ACVM&0/@T_4*%[2;W<M
M9:7DIK'I^[-IHI&2S25%.6N<<X#&-&2[DY)\ %V5%,I<6G:QN=^LM?;*V@HY
M+A90TLK::"(.F''#AXD>GISU6DWR"GUC>;1_<QINMMU5#5,FJ+C-2^SAC!U'
M'VCT/GQZE=G11+HLV+F^H*:XZ7U])J>BM]1<;970""LBIF[I8RW&'!OB,-'W
M].%TA$ETFS;E&I:JN[1Y*&T6RU7"CM+)VS5E761=UP,^ZT>)Y^N/#E3%RH:I
MW;1:*QE+.:-EM=&Z<1GNVNS)P7= >1QZK?T3:.T1$4+"(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(OGWM"[1;SJ#4+K!HY\T
M<'>&$/ISB2H<.I#O!OP\.25C?]#NL7P>U/N5)[5C=W9J7E^?+=MQGYX]5WSH
MI,9>7.8[^&/U=W\,V^BT7SIV=Z]OFFM4LL.IYIY:5TPIY&U+MSZ=Y. 0X\[>
MG&<8Y"Z+V^5511Z$$M)/+!)[7&-\3RTXP[C(5,^CRPY<>.WWZJ9RRXW+[.C(
MOF'1^E-9ZKM!N-LO;VP"1T6)JV5KL@ G@ ^85NZ5FNNSJ[TWM]QJ2'^]&'SF
M:"8#J,'_ '$96W_Q\N5PQY)<OLK];QNSP^HD6OV_55'4:)BU+49AI#3>T2-Z
MEI'5H\SD$#S7");UK'M2OLU+:I9*:B9[W<LE,<43,\%[ARX_7QP%S\/29<F]
MW4GNU?+DF.M>=OI=%\RW[0NL=#TAN]/<=\,1!DDHIWYC]7 @9'U]5UCL<UQ+
MJZSSQ7';^=*(M$KFC E:<X?CP/!!Q^]6Y>D[,/J89=T1CR;O;9JNA(OEG4L]
M[N?:?<[3;KI51/GN$D,334/:QOO''3H/DMC=V8=H+ 7-OC'$<@-N$N?P6MZ'
M'&2Y\DFU9S6^H^@T7SKV<:WU#8M:PV#4=345$,M0*22.I?O=#(3M!#CSC./'
M&"OHI<W4=/EP9:MWMIAG,YL1$7.N(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B*/N]TCML0<YCI)'?98W\5,ERNH6Z2"*(MMZ94U+J>9HC
MEZ@9S\E+!P/0IEC<?%1++Z>HB*$M4UY5%E'W,9&XC):?$+1K3$2YTLC,.Z@Y
MSPMA[1IZ:G+JBLJFP1L&&DGJ2N=PZ[LM(>Y<^9X.!WC(O='QSS]R[N_'CX=;
M\U'%TO-SY;X\+9/T=%M +I@MXH&XB'P7-]&ZELMUF+**NC?(WDL<"TCY$+IM
M+CNA@^"X?C:^>.6%[<IJKI&1@KGVM:<^UN#"&[@,Y\5T%0&J;2:^(20D-E:/
M'H0MN#.89[K'DEL\.=V^04+]LW0G(<%T*Q3M?&TM<"T]"N77VZ4-FD?%=:ED
M,K?U0=Q^@5BR:LOM;&:?3%K=AQ]VIK"&,9ZX\5OU..%_'+Y7Z;@YL_<UC][X
MG]7=R]K8R][@UH&22< +4-0]HVGK._N6U9N%:>!34([YY/KC@?5:];]$W6_G
MO-9ZBJ:IA_\ A*)QAAQY<8S]%O-ATM9+#$UEHME-3X_7#,O/Q<>3]5P^77V\
M''^:]U_3Q/\ >_V:>R\:\U,QWYHM<&GZ-WV:BORZ8CT9X?,*]2]E]'5U J]6
M7*MOM7UVS/+(FG^:UJZ&B:/YK+'QQ28_M[_W]L6V6ZCM=,VGMU+#30-Z,B:&
MC_>LI$4N:VV[HB(B!$1 1$0$1$!$1 1$0$1$!$4?J&Z162R5MRG:Y\=+$9"U
MO5V.@^902"+FM/>=?5=E9?:6EL3Z.2+VAE$#(Z9T>,@9Z;L?\9X6;J+6EPMN
MF;)?F6_N*6>9C*^"IC<)(6DX)'3Q!Y(YRU3I'<WU%!ZRO[-/Z6KKLW9(8H\P
M@]'O=PT<>&2/DM6U'K6\V&BTJZ>@@J*RZ!PGIXP0=^&[6,R>#EP!)RDFRV1T
M585UNE%:H8Y;A4QP,DD;$S<>7O/1H'B5SZ^:FUKIB".ZWZAM$UJ,C6S14CG]
M[""<#D\$_496'VU2724Z>DI#0FW/K870%^_O#.=V-WALQCIRIF*+DZ'?M0T5
MDJK93UHE+[C4-IH=C<C>2 ,\\#E2ZY'VI5-RHJ?1=5=H:>>Y07(2OBHB[8\M
M<"&MW<\@ <^*S[[J/7&G:,7F[V^SR6MKF]]34[WF6)I.!EQXSR!D9"=IW.FH
MM5U=K"*R6:AJ:.G=65MQ<UE%3@X,CG $$^0Y'U"@[A>]<Z?HOSM>Z*SU=N9A
MU1!1N>)86^)!/!QX]?IRHD3MO-WNE%9Z%U7<ZF.GIVD#<\]2>@ ZD^@6+J74
M-%IV"EFN E+*FH;3,[MNX[W9QGGIPN==ME;5W'2%MK;>^D?9:B2*4.=N[XO.
MXMQX;<=?'*G]4Z@ONGK#:9KI!:IKA4W!E/((6O=$&.W8+=V#NX4R([F^HM1U
MMJJJM-?;[/8Z-E;>Z_)B9([#(V#J]WIP?H?G%OU#JK3MRM[-54MNJK=6RB#V
MBWA^87GIN#NHZ_0_!1I.W0D1%"1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!1.KZF2CTI>JJ$D2PT4TC"/
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MS=!*R1OFQP(667'EA^::6EE]+B(BHD1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MR_@>)Y6P6R6&KBP,QU.3W>TY#L>'HN[LPLU8XMUNUE[6:B%S8]14398R<=_
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MY:>I47$[,8*R*>=T)!:5O+M2S3>@ZW,93[(8I<, =&0<YQR3Z95IQBAD=-)
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M,C/ZQ\@M,=V*W4843B  \G/P4M14CI-CSWK&!WO/ Y!\,*>M-I@<'Q!D9G+
MZ-V[(SY+-KQ)2.$37-DD<]KV2.P TCKE)X\*WSY1KY9/9JVF#Y74^S@O Y/B
M5J$QR]V,*>OER>ZHFC#P&O WM8<C/BM;<1N\U&56PB0M&#4!N6AQ(VEW3/JM
MMH)G1RFH[AI=G#SORWZ>"T)CB"<$A2=+<YX(8P&,QGAQ;R?0J,<IZIECYVVZ
MHP*2:1U+''([WVX=R.?):QJ&(^T"8O:Y[VAQ#.@\E1+<I:B9HG V9^RQNT%9
M4Q+,@4\8$H^R?>+0%?6XKO51%D&+U1_XUOXKM]1(/S)5 GC8N)V@#\]T>/\
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M%-T&%K4.3:Z<'J<+8Z'HH&6B(B1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M.D&\M<8@X!Q;U"E)K?%2RF.H;(T##CO<!P1PML;DQNMK[[BTO='3N?L?TW^
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MM:/,DI9J$N[5]%HD_:QI&*8QBXR/P<;F4[RW\%L]BU!:[]1.J[161U4+/M;
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M70=,_P![=J_R2+^H$6=MK222))$10D1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M8L5&QG@%D!C0.BJ1!28VGP0,:.@52("8'DB(& $1$!$1 185WN=-:Z5T]4_
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MM4;^0T+/@M3&C[(5FSUC98VD$$'E3K""T$+D=Z K[4U[#AH6MU=A)<<-70R
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M5_VI'GJX_=\@%-(FR30B(H2(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B N8]HUZ%14.
MI8G'NH#SCHYRZ/7S&GH:B8#)8PN'R"^>[]4/EEW.=DN))73TV'==N'K>6X8]
ML^6%4S<EO7/*Q'X>2<<KTXP50)"!T7?IX^-VH ZC'U6A7ZF?;+J7Q@MBD.YI
M'WA;\22<YY6/6TL-;3NAJ&AS3]1\%KQ9W"[:\>?9EOX:Y154=3"QX$60??\
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M X<^:KI28UD@GQQE,JPQW!,A'7@JXUWJ"/--(N.E9Z*D@;56T]<JCA$18<"
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MIE6E8D@ (W9R>@5&TY.#P.JS7L.=SL<+QC2(SD8)\E.VDS\,4 ],*] S+^G
M62UNTC R3XE5M&"5&U+R'08\U4&X:>5[G'*ISPJL@)TRGQ3U0>. (ZJVT8>K
MAZ+P  Y\U*97H&#PK4@&P@]3T5TNP[A6'$F0^]P$B<5C/N_ *F/<YSG <A6S
MC+AG/*KB=MX:>O4J^G1K7I+6JX2T=6V5APYI!P/$+M.G;FVII8I&GAS05P-L
MA,O7@!='T/6.%#$#QR?'U7!U>$DV]+HLKK5=:C=N;E5+!MLN]@6<N%WB(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("UCM&TW4:ITX;=25$=/*96R;W@XP,\<?%;.BMCE<;N*<G
M'CR8W#+U7S/K;LWN.E++^<JFY03Q]ZV+9&' Y.>>?@J=#=G5PU;9WW"EN4-/
M&V9T.R0.)R #GCXKJ?;]_>%_^;C_  <K/Y/7]XT_^72?U&+T/YC/Z/?\[?/?
MR'#_ #OT=?AUOVG-!6AFB=/"VW:YTAE?,^5KR_8"" .-WP6Q5-YME-/'!4W&
MCAFD +(Y)VM<X'H0">5QO\I+_OMB_P 7-^+53I7LJEU#;;??+Q=7][4EDSH3
M'NW19&!NSP2T<<<<+'Z6.6,Y>3+6W9.JY./DO2\''OMU\_#N%340TT+IJF:.
M&)O5\C@UH^96!3:BLM5,(::[VZ:4G 9'4L<3\ "N?]I6AK[JF_T\GM]+#8H=
MK1&7D.C'ZS]N,$]?'IA<_P"T?2.F=/VZ*2R7TU5>) U].^9DAVX.7>Z!C!QU
M5>/@PSU.[S5^IZWFX;EE,/PS[W6_V?2CB&M+G$  9)/@L:FN%%5;_9JRGFV#
M+N[E:[:/,X/"T?LRN51<^ROO*R5TLL44T.]YR2&YQD^@P/DN,]E]AJ=3W>IM
M$=;+24,D7>U9CZO8TX#?J[QX\><)CT\O=W77:GE_B%Q^GV8[[X^EZ2^6JLJ3
M3TESH9YQ_@XIV.=] <J07S1VJ:)@T35VV>U5=2^*HW%IE(WQO9@Y!:!YCP\%
MT?6.H+D>QBDN5/(]M7500MGF9P6AW#G#RR>/FF73S\-POBG'_$,I>3'FQU<)
MOQY;[5:ALU),8:J[V^&4'!9)4L:X?$$K/IJB&JA;+331S1.Z/C<'-/S"^:="
MVK0URMNW45WK*.Z.<002&1@9X(=M(Z>971NRO1=?I^[S5M'?:*LLLNYO=P.+
M^\'ZKCC@.''3/B$Y.##"7SYGZ>T=-U_+S98_@EE^UW9^\=2ED9%&Z25[6,:,
MN<XX 'F2H^"\VRX,GCM]QHZJ1K"2V&=KR/D"N*]NE]K;CJB'3E)(X4\0C#HV
MG DE?R,^> 6X^)4O4]CK+79#6VR[5C;Y31F5KFD"-S@,[6@#(\LY2<&,QESR
MU:G+KN3/DSPX<-S'WY_X:_\ D\O<[6=:'.)'L3^I_GL7>Y;C10U'<2UE,R?(
M'=NE:'9/3C.5P+\G?^_*M_R%_P#78K7:/_+4S_**3\&+?FXOJ\UF_AP]%U5Z
M;H\<I-[RT^BI9&0QNDE>UD;1ESG'  \R5:I*VEK XTE3!.&XW=U('8^.%"=H
MO]XE_P#\CD_JE<Y_)LXIM0$]-T'X/7)CQ;X[GOT];DZJX=1AP:_-+Y=BJZJG
MHX3-63Q00CJ^5X:T?,K&M]YMEQ>66^XT=4\<EL,[7D?(%?/;GUO:EVANI9:I
M\- USW1@<B*%OD/VCQSYGT4_J;L?KK9/15.CJFIGE#_?[V5D;XB.0\.X^G5:
M_P OACK'/+5<D_B'-R;SX>/NPEU[\W]H[HHZLOMIH9^XK;I0T\W_ )<M0QCO
MH2M'[0=27C3?9Q2NK',COM3MIGR1.R&G!W/!\\#Y$^BT+079_:=06$W2_7MT
M%14.<8V,F8'#!(W/W9))(/''QY5<."7'OSOAKS==E.2</#CO+6[NZU_^OH2*
M1DL;9(GM?&X9:YIR"/0JQ-<*."<035=/'.<8C?*T..>G&<KA793=JK3.OIM,
MRU8J;?-*^%I:[+-X!+7M\LXP?CZ*,[;Y98.TDRT[BV:.*%S'#J'#D'ZJTZ7?
M)V;^-LLOXIKI_K3'S+JQ]!B[VTUYH1<*,UH.#!WS>\S_ $<Y6<N3Z0[)/S7>
M+9>+C<C45,+N_FA,?'>8)&'9YP[!SCG"Z/>;W;;+")+I60TS79VA[N78ZX'B
ML<\,9=87;MX.;DN%SY\>W_7X2*+1G:\EN)#-,6.NN.3COI&]U$/F>OW*VZS:
MQO;B;G>(;33N_P !1-W.QZNX^Y/I6?FNC^:QR_PI<OV]?[WPVZZ7BW6J+O+E
M6P4S?_4> 3\EJL_:"VKE=#IFTUEWD'Z[&ED8^9"S+3V?V&@<)9J8UU3U,U4[
M><_#HMKBC9$P,B8UC!T#1@)OCQ_4US\GNS']O-_M_1HS;?K2^,S7W&FLL#N>
MZI6;Y /(NSU67;^SRR03^T5[9[I5$>]+6R=YGY=%N"*/JY>IX_9,Z3C]Y_BO
MZ^?_ ,6J6F@I86PTL,<,3>C(VAH'R"NHBS=,FO$%XYP:TN<<- R2O5%ZHJ/9
MK!6R#KW9 ^?"F3=TC*ZEKEFNKO\ G:^$QX[B ;&_SN3RM'K:DO<Z-IP!]ZOW
M6I?)5/&2 .,!1Q;R<\Y7J\>$QCP>3DN5MJDO: ?,^2,.<X'IE.Z._)Z#R5!:
M1G!)\UHSFF1@'&.JK;TZ*F(<9'15E0RH.,Y5.>/4]%X2!D^BHWG#<-Y0D>N/
MN''&/%4.^T,<KTGWMN.!RJ7GDD$@ *8O&,\]<>"IC7I)((/1>,Z=%9O\+@\@
MK\1\#T"Q6@DK(8/<)QT*A3**^23R.JNCDXRK#SAQ\SY*]&X9P.5#.Q<QC*$#
M'"\W#IXH\@-P.JAG%F=OV<G(\EAR@-) 6:[@@E8,Q!>XA6C?B4-Z]%6<$#S5
ML'KA>@^O*EMIDTK</SY*2;TZ*-HSF7;]5*-!\%#GY/:Y'R%4T<<=5;!+>,JX
M#C)"AE7JH<?%>%X/H%0X\@^ 2)D7&=,GJJPJ&D$?%>A$56J7'Z(<GP5MSB"6
MGQZ%(2/207@ 9 "];[SR<\*T'8<,^>"KS!P0$3?#W:'.R1E#G/H%6%YZ!%=J
M-O!/B?%><G@'A>O=G'.$)\BB8]'&/-5-5J,@N)&5=1%%YYKWD*DGA01[U'54
MYP<'H@&>G"](!&'*4O <. "]><= K3VG;D<.'0KQK_=S@Y*2)U\O7/:UQW.(
MXZ+#J:@-:8XQSXE7IW'+G8!\ HR0D$@GWE9MQX_+P2%I/B@F!XY5@O'(\0I6
MS6I]:T32';$3T'4JF?-CA[=F'%<_3RAC?._#&DY71=-0F&..,>"CK;; P!L;
M !\%N5CMI&TD+S>;F^I?T>AP\,XXVNS ]V,^2EUB4$/=L"RU@V$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$'..W[^\+_\ -Q_@Y6?R>O[QI_\ +I/ZC%N>KM-T>J;3^;KB
M^=D'>-DS"X-=D9QU!\U3H_3-%I2U/M]MDJ)(72F8F=P<[) '@!QP%T?4Q^CV
M?.WG_P MG_.?7_RZTY1^4E_WVQ?XN;\6KK6B1C1UC __  ,'_MA1VM=#6S5\
MM))=)JN,TS7-9W#VMSNQG.6GR6PVRBCMUMI:* N,5-$V%A><DAH &?7A,^27
MBQPGN)X>GSPZKDY;ZRUI\^:_N=1J'M-=9KM<)**T153:<#=AC&\9<1TR?,],
M^067VI::TGIG3D,-I>);M+*W#G3]X_NP#DD#@#IX+I>M.S:S:JK/;9W3TM:0
M&NE@(]\#IN!!R?51]!V/Z;IK=4TTWM51+. #4/> ^/!!]SC Z>1XRNC'J,),
M?-FOAYW)_#^?++DEQF7=ZRM]?II8[(#_ /9/-Z>T?O6E_DY?WT7/_(_]MJZ_
MI?25#INRU-KH9ZN2EG<YQ[Y[7.:7- ."&CR6%HSL_M.D:^>KMDU;))-%W3A.
M]KAC(/&&CGA97FQUG/NZ<>CY>[@M_P D\M)_*2_[C8O\9-^#5/T%\MMB[)++
M->Z2:JH9J9D#XXXP\'(/V@2!CA;#K71ENU?%21W26JC;3.<YG</:W.[&<Y:?
M)9]+I^@ATY%8Y8C4V]D(AV3X)<T>> .?4*OU<?IXXWXK3^5Y9U')RXZ_%-3^
MGPY!;M$Z+UA;W5]BN4]HDW$/III&O[O!\6DYP1S]K"UOL_?5V#M0IK;:J\5D
M#JGN)7P']'-'XG'3@9/IA=%K>Q*Q33N?35M?3L)SW>YKP/@2,_7*VC1F@++I
M.1T] R6:L<W::B=P<X#R&  /HM[U&$QLW;OXKBP_A_+ER89=DPLOFR^_]''N
MV&*6S]J++F]A,4A@J8SX.V  CZL^\+L%VUWI^'3,]RAN=+*'0DQ1-D!D<XCA
MNWJ#GKY*2U9I>V:IMXI;M"7!IS'(P[7QGS:?W=%J-B['K!;*]E542U5?W;MS
M(IRW9GPR .?P]%E]3CSPQF?N.F=-U/!RYWAU<<_/GXK0?R=_[\ZW_(7_ -=B
MQNU>04/:[[5."(FOIILXZM ;D_\ TE=ATEV?VG2]WGN-NFK7SS1NC<V9[2T
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M)C87M>6-+V]'$<A5(B"F2-DC=LC6N;UPX95OV2F-3[1[/#[1T[W8-WUZJ\B
ML?V&D]I]H]E@[_KWG=C=]>JR$0%:@IH( X00QQAW+@QH&?CA7406*>BI:9[G
MTU-!"YWVC'&&D_'"NQQLC!$;&L!.2&C'*J1 6.:*E-3[0:6#VC_S>[&[Z]5D
M(@I$; \O#&AY&"[')2.-D;=L;&L;Y-& JD04MC8U[GM8T/=U<!R5ZYH<TM<
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M$E<BKGL<3AP+CR5T/M.DSJ>O,O#1@<^6%S!Y#I''U7;QS6+RN?+\5>84W;(
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M$A9UEMX(&6K;*2B:QO1<7MW>F-:Z$1-'"F ,#"\:T-& O4!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MZ!CHB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M!$1 1$0$1$!$1 1$0$1$!$1 1$0>.^R58<B(A2U9$?1$05(B(D1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
C1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g762905g99m62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g99m62.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_[1<X4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'D
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !D     $  0&0
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             $?0  "4\          0
M                   !              E/   $?0
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   $?0    !29VAT;&]N9P
M"4\    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  !'T     4F=H=&QO;F<   E/     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !- * # 2(  A$! Q$!_]T !  *_\0!/P
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M_]H # ,!  (1 Q$ /P#T6:>CT-:&Y.2RZY[B6M?D.:ZS?D6.=Z;7/93O:_\
MZY9Z3$S>MX[W;1CY?( )Q;V@EP<?SZF_N;7;OY"-U3#=F8;J6!ILD%@>Y[63
M]%V_[.^NSZ#GK&;]6\O;M=5A:2?^U#A)VGAU_P!/3^?3A1WW4Z6/UW&O%/ZM
MFU.O( ;9B7MVEQ#1ZS_2]*KZ7N<ZSV*[9DTUM<YQ.UGTB 2)\-%E871+:;L=
MUM= KIG1C[RX1M=5L]2PM_G![_46GDXE64&BPN&W5I:8@_O1]% UT4C=U3#:
MPNWET?FAIG\B6-U/&R+/1&YEO[KFGP+O:_Z#N%5MZ9CBST:\B+G-+FU.+=Q
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
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M-3<   .@ 0 #     ?__  "@ @ $     0  "4^@ P $     0  !'T
M    !@$#  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H  ,
M   !  (   (!  0    !   !+@("  0    !              !(     0
M $@    !.$))30/]       (          #_X0$V17AI9@  34T *@    @
M!P$2  ,    !  $   $:  4    !    8@$;  4    !    :@$H  ,    !
M  (   $Q  (    >    <@$R  (    4    D(=I  0    !    I    -
M  &0     0   9     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C R-#HP.#HP,2 P,SHR-CHU-P   Z !  ,    !__\  * "  0    !   )
M3Z #  0    !   $?0         & 0,  P    $ !@   1H !0    $   $>
M 1L !0    $   $F 2@  P    $  @   @$ !     $   $N @( !     $
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M 0$! 0$! 0$              0(#! 4&_\0 ,1$! 0 " 0,# P(%! ,! 0
M  $"$0,2(3$$05$3,F$B,Q1Q@:'!!4*Q\)'1X2-B_]H # ,!  (1 Q$ /P#U
M21W7FK*+1NGY+K<&OD8U[6,B8J;SW*O),^E21'F_I%W:74.M;+I.W*KUB<U'
MHU<[TTCD1$5/(B)^LIW]/Q?4SDOAG*ZBVMFNT6W:\;7)0034TM(K=Z.54551
MV<*F.S@38\I:0679=MK]3*J55I)7-I7R+P1T<FZK7+YEQ\BGJTUZGBG'E+CX
MOA,,K9W  >9L
M
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M4T<4CN]S6HBK\J&<?,KL  @
M
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M37"MIJFBJ521K8LHK9$PBKQ[T3Z#7)RX<O%KQ9X)C9DLX 'A=
M
M
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M6FV4MOH8TCIJ:-(XV]R(99\O.RY6SP[3P  RH
M
M
M                                               #/>  1<\@
M
M
M
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MZIQ1.P#= TK-0TSG85DB&?3U\$Z>(]$7N7F!E@(N0
M
M
M
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MRUQLU=  -(
M
M
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M>\(R(F)&QK&HB-:F$1#D?&YQQYGT
M
M
M
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M8G)J)P0[$
M
M
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MQ.>5SP^D@=#9+G!71*Y'QMSA7L=R0G$;7-:C'>-CDJ\U,S+Y3+&8^'< #;(
M
M
M
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M<]@3EQ!L;CN':A]!  !0
M
M
M
M
M
M
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MJTMI^W:7L=-:++"L%!3HJ1QJ]7JF555XJJKS50-J
M
M                   !$=HVIZO3-%2344,$KII%8Y)D541$3/#"H63=TENI
MM+@4KZ[-Z_X*W?JO_F'KLWKA_H5N_5?_ #&_IY,?4Q74#XQ<M1>]#Z<W0
M
M
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MCEXIZ$PGH G0
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M !@
M                                    '7U$76];U3.L_+W4S\IV  #C
M(QDC%;(UKVKS1R913D .,;&QL1L;6M:G)&IA$.0 '7'!%$YSHHHV.=S5K415
M.P
M                                          !6FW+_ &3;/\=WV2RR
MM-N7^R;9_CN^R;X_NC&?VU3H[4\X':GG0]+S/5<?X-OF0Y'&/\&WS(<CQO8
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MDC?(JHN/.I:Q>3VQ^"  .:@
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M_P#VYOYRE^B7#'3[6=3P0MW8HJ:6-C<YPU)T1$^1 /7
M
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M9*[<CJ)J:2.%Z]F'JF$\ZX+"8]LC&O8Y',<F4<BY14[R7&X^8KZ #(
M                             <8XV1HJ1L:Q%7*[J8RO><@
M        "HBHJ*F47L  XQL9&Q&1M:QB<FM3"(<@
M                        '&3>ZMW5XW\+NYY9.1C72L;;[95UCVJYM/$^
M56IVHU%7'T >-MCEATWJ#:=JB':8YCZQCI7,AJYEB:^3K%WE545.*)R3/)3=
M[ Z>*BZ0M[I='ROETW&V9KG(Y7-6),;G'M\;@BF!L[TGZ_FL]0WS5E;)34]/
MNM;%1(QC_&SN)E47@B)S5%55-OLEK*[9?MQJ= LJ&5MIK)MW?<Q&O15CWV.X
M=O!$5.0'J\&BUW9JC4&C[Q::*H2FJ:RF?#',N?$<J<%X<3S<G1MUC^>$/ZTW
M\0/5P/&.OMBNJ=&Z3K[]6:I2H@I$:KHHWRHYV7(W@JKY2Z^B=/+4;(X7U$LD
MK_#9TWI'*Y?;)VJ!<8                     1?:E[FVJ/^6U'[MQ*"+[4
MO<VU1_RVH_=N IOH4_BGJ3X\S]VAZ,/.?0I_%/4GQYG[M#T8
M                     /)?13]V'5G^#/\ OT/6AY+Z*GNPZL_P9_WZ >M
M
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MTC8BKE5[U7RJN5])C/*=.HL;( '!0
M
M          .NI@CJ:>6"=J/BE:K'M7M14PJ'8 /*T^RG:/LVU+7U^S2LBJ;?
M5JK49XJN1BKE&O8],+N\D<B_6278WLAU#3ZWDUOM"JHY+JJNDB@:[><KW)A7
M/5$1$PBX1J'H0   !6724]Q?4?Z$7[UII>B/[D$/QZH^TANNDI[B^H_T(OWK
M32]$?W((?CU1]I +G                     #&N=#3W*W55#6QI+2U,3H9
M6+[YKDPJ?(ID@"*[.]"6;0-IGH+#'(V.>99I'R.WG.7DG'N1$1"5
M                          "%:.V::=TCJ.ZWNST\D=;<57?S(JM8U51R
MM:WDB*Y,DU
M                                          #XYK7M5KD1S53"HO)4
M/H IW7FSR>&N;5:?A=+#42;KH&X^].5>:?W?J)SH32-/IJCWG8EN$J??9L<D
M_);Y"4@U<[9IF8278 #+0
M
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MC>Q'29XL\9.*X7);X
M
M                  XR21QHBR/:Q%Y;RX.16>W-$6TVS*(OW]WV2XS=TF5U
M-K&\*I_[>+]=!X53_P!O%^NAY6W&_DI\@1C<IXJ<T[#K]+\N7U?P]7@XQ_@V
M^9#D<78
M
M                      !6724]Q?4?Z$7[UII>B/[D$/QZH^TANNDI[B^H
M_P!"+]ZTTO1']R"'X]4?:0"YP                     \I]+CW0]'?H?\
MFM/5AY3Z7'NAZ._0_P#-:!ZHIO\ 5XOT4^H[#KIO]7B_13ZCL
M
M                                                       !6FW+
M_9-L_P =WV2RRM-N7^R;9_CN^R;X_NC&?VU3H[4\X"<T\YZ7F>JX_P &WS(<
MCC'^#;YD.1XWL
M
M                 (MJ+:#I/3LBQWF_T--*G.-9-YWR)E0)2"O[=MFV?W"7
MJZ?4]%OJN$21'QY_61"<4%=2W"F;44%1%40.XMDB>CFKZ4 R        5ETE
M/<7U'^A%^]::7HC^Y!#\>J/M(;KI*>XOJ/\ 0B_>M-+T1_<@A^/5'VD N<
M                   /*?2X]T/1WZ'_ )K3U8>5.EQ[H>COT/\ S6@>IZ;_
M %>+]%/J.PZZ;_5XOT4^H[
M
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M06^2J5=U&I+A'+W(J\%]"E';1X:G1FQK3%A@<Z&:XN=-6*SAO<-Y6+^LB?\
M21?4%5H*31D-+8K7=8=00M8J5<D:HDCLIO;WC*F.>,)W&L/2XY3>[WO_ ':7
MDKV""%;&KQ4WO9Y:JJO<Y]2QJPO>_P!L[<7&5\N":GCRQZ<KC?9TEW-@ ,J
M                                          "&[5M?T&SS2[[K71NJ
M)GNZJFIFKA99.[/8B<U4\_Z=VX:]O.N=-T]9316ZSW2MCC8SP3A+&KD1VZ]W
MMN?- /60*3TUMKZW:Y=M&WVE;##X6^"@JD\7BB<&O1>_"X5/)P+L
M HC:E:]J&MM55UBL#VV;2T"M8M:DBQNJ,M17<EWG(BJJ81$3AS-38NBO9HF(
MZ_:@N%7*O%R4K&PMSYW(Y5/1IY2UKKS7NTG6EUL&SJ2>BM5N56R2P2=6KT:J
MHKWR<VHJ\FHO8!,ZGHNZ.?"YM/<KY%*O)[IHW(GHW$(VNPC6FAJEUQV<ZI=-
M(BY6ED3J.L3N=Q5CO3@T6@[UK6HV':EK;)<+I5WNCNT;UEZYTLC(F-R_&]G*
M<.*=I>6P3:!+M T4E97M:VZ4DG@]5NIA'.YHY$[,I].0)5H&MO-QTA;:K5%&
MVBO3XU\*@:W=1CD<J<$RO-$1>?:;\       K+I*>XOJ/]"+]ZTTO1']R"'X
M]4?:0W724]Q?4?Z$7[UII>B/[D$/QZH^T@%S@                    !Y3
MZ7'NA:._0_\ -:>K#RGTN/="T=^A_P":T#U13?ZO%^BGU'8==-_J\7Z*?4=@
M
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M:B+Q5$/7A1.R2LV.Z6N45)I.\PU5XK'=2R>=KWS/S[U';B(B>;!>P
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M5,^7B?F?<8V,B3<8UJKGVJ8/TBTA^*EE^)0?80\_)AT9=-:EVVP ,
M
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M]R<\+S1O9GCD](=%V@OU!LXB;?*Z.>F=*[P2GYR4S47"L>O?E%7=[,^@"X
M        !&]:Z89J&AQ#,ZGKHT^]2M<J?]+L<T*"NL%;1UDE)<>N;-$["LD<
MJ^E,]GE/4)%]=:1I]2T2N3$=PB:O4R__ $N\GU'3#/7:N>>&^\>>@9-QH:BV
MULU)6QK%41.W7-7ZT\A)= Z-FU)4]=4(Z*V1KA\B<%>OY+?XG>V2;<)+;IWZ
M TQ7ZCJDGGJ*B*V1.P]^^[,B_DM_S7L+TI8(Z6GC@@:C(HVHUK>Y$.-'2PT5
M+'3TL;8H(VHUC&\D0[CS99=3TXX],  9:
M
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MI_\ N M72$E?-I>U27E'I<G4T:U"/:C7=9NIO91.2Y-L8=EN4%XM-'<:/?\
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M@_=H?F_=/P*>D_2#2'XJ67XE!]A#YGJ/W*Z8^&V !P4
M
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MVM5>Y?H-W1TL-%2QT]+$V*"--UK&IA$0[@7=\)J>0 $4
M
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MM5LI:"B:K::FC;%&U5RJ-1,)Q,LT&@+ZNIM%V:].:C7UM,R5S4['*G'Z<F_
M'GG:_P!'V6_Z@GU!H^NCHJZ=W634TF6M63\MCT]JJ]J&[GTAKAVW]M^965'W
M)I(U>I\-<C,=5NK]ZSCVQ6>H]F&V"JO]RGH;G6MI):A[X42[R-1&*Y<<,\.
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M\W[I^!3TGZ0:0_%2R_$H/L(?-]1^Y73'PVP ."@
M
M              !I-56".^4L3HY'4URI'=;15;/;02?YM7DYJ\TR;L 1_2E_
M=<EJ;=<HVTU]H,-JX$]JN?:R,7M8[&4[4Y+A397BVMN5%+!UTM-*]BL;40X2
M6-%Y[JJBXRG UFK-/NNG@]?;9FTE\H<NI:G'!<\XI.U8W83*>1%YH=VEK^R]
MTTK9H5H[G2NZNKHGKE\+_P#-JIA4<G!47S@0FBFJ]-W=MNA@BCCC8O4VZ)^*
M:DHT<N]4U,BIETCD:["97BGG4^Z?O<=A6>YT%-4LT-53KN22-QX,Y5XS,;G/
M4.=O9SR7"HFZO"=ZELT%[MRT]5&DS6N25L+W*D<KF\6MD1/;-SC*$#I;G46"
MJKO5ESIZ5SD9<*B>-W5S2*W#*6B@YN3"XRF<X[57@%H-<CFHYJHK53**G)4/
MI7-GNM-HZ\OLSJM); NZL;GNR^V/?Q;#+W,7"[JKC=RC5YH6,
M
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M#\5++\2@^PA\SU'[E=,?#;  X*
M
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M\33[#+M9];4:ZA;(Q]RI%\&BH$;N,MD6/%9&WMRG-_;RX8P!;@
M
M                                                 !UU-/#51+%4
MPQS1+S9(U'(OH4[ !KO4*T_!=!\W9_ >H5I^"Z#YNS^!EUM73T-)+4UDT<%/
M$U7/DD=AK43M533W/6%@MFFFZ@K;I!'9WHBLJ>*M?GENHG%>78!L(K/;(9&R
M16ZC9(U<M<V!J*B^1<&<1'1&TC2NMI98=.7:.JGB3>?"YCHWHG?AR(JIYB7
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M>D_2#2'XJ67XE!]A#YGJ/W*ZX^&V !P4
M
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MI7+A)V9\YW,D:],L5')WHH',!.(
M
M    \Y],6XU;J#3%@@E6.GN-2Y9>/!RM5J-SWHBNR5]TAH7VBGT3L_MU9-5Q
MT%*CG[W!7RO=AN43AR5<>12]^D)LVJMH&G*1UGECCO%ND66G215:CT7VS=Y.
M2\$5%[T*LV8[(-9W7:+2:CVAJY(Z!S),U#TDDG<Q$1C41.&ZF$7/D\H&BU+H
MVGV2;7=".L-752/J>K69DKD5R.5VX_DB<%1>1[&/.UKV9:DU'MXKM2:IDE6R
M6RK5:)9UXRM;Q8UC>QB*N<^0]$@"%[9=0U&EMFE]NU"[<JX8=V)WY+G.1J+Z
M,DT(QM-TRNK]"7BQL>UDM5#B-SN2/1=YN?2B >'[OH&^R;.&;0+C5I4TU3/N
M*V1SI)E17*F^JKV*OUF;JK9-<-/Z2LNI:BXP5=AK^K5\U/&JNID>F>+57CVI
MP5.)<VSC2&K+KL;U?HK4M%)3/I/$MS)HMW+N+TP[DYN\B85.\INNOVO;CI>C
MV;S6RK='33(UM/X([KG*BJJ-5<<D5?J ]O:)@IJ72%F@H*I*NDCI(VQ5")CK
M&HU,.QV9-T1W9S99].Z%L=HK'[]31TK(I'(N?&1.)(@!Y0UWLXUWL]UE<K_L
MW;55-MKU5SXZ9J/>Q'*JJQ\?-S47BBHG#)ZO/)=_O>U[9G?[E5+%65^GW5+Y
M6I(Q:F!K%<JHF_[9G/R(! ])6S:FZTUVF]/V>[TM'<)5?4YIU@1RN3"HZ1V$
M1N$/5VP[0"[/=%QV^ID;+<:AZU%4YOM4>O!&IWHB(B9('H?I-:=NRL@U+1S6
M>I5<=:UW6P>=7<%;Z4])>%EO%MOE"RMLU=35U(_E+3R(]OFRG;Y ,X
M %9=)3W%]1_H1?O6FEZ(_N00_'JC[2&ZZ2GN+ZC_ $(OWK32]$?W((?CU1]I
M +G          'B;I8^[,OQ*G^MQ5Y:'2Q]V9?B5/];BKSW^D^VL9  /6R
M                #"NGX%/2?I!I#\5++\2@^PA^;]T_ IZ3](-(?BI9?B4'
MV$/F>H_<KICX;8 '!0
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M!A>J2N5FKH !I
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M $(OWK32]$?W((?CU1]I#==)3W%]1_H1?O6FEZ(_N00_'JC[2 7.
M  /$W2Q]V9?B5/\ 6XJ\M#I8^[,OQ*G^MQ5Y[_2?;6,@ 'K8    !%  4  $
M  %  1  %&%=/P*>D_2#2'XJ67XE!]A#\W[I^!3TGZ0:0_%2R_$H/L(?,]1^
MY77'PVP ."@
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MEM4=OIT<B9J%3QE7ZB?BDMEW*SZ&GCI*2*"%N['&U&HAW!JY3N4"=D
M
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MF_=/P*>D_2#2'XJ67XE!]A#YGJ/W*Z8^&V !P4
M
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MS^][YWG,Q.0
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MZ0:0_%2R_$H/W:'S/4?N5TQ\-L #@H
M
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MW  TR
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MQKC\MG%GR*IZIZ/FN;KKW1<UQOL5.RJAJ70(Z!BM21$1%WL*J\>/8!9P
M   *RZ2GN+ZC_0B_>M-+T1_<@A^/5'VD-UTE/<7U'^A%^]::7HC^Y!#\>J/M
M(!<X          \3=+'W9E^)4_UN*O+0Z6/NS+\2I_K<5>>_TGVUC( !ZV0
M$  %  $0 !5       !&%=/P*>D_2#2'XJ67XE!]A#\X+I^!3TGZ/Z0_%2R_
M$H/L(?,]1^Y77'PVP ."@
M
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MP/J G8  4
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M[B^H_P!"+]ZTTO1']R"'X]4?:0W724]Q?4?Z$7[UII>B/[D$/QZH^T@%S@
M       #Q-TL?=F7XE3_ %N*O+0Z6/NS+\2I_K<5>>_TGVUC( !ZV0 $  %
M    $  %     &%=/P*>D_2#2'XJ67XE!]A#\W[I^!3TGZ0:0_%2R_$H/W:'
MS/4?N5TQ\-L #@H
M                                                           J
M(J848               /BM:J85J*GE0^=6S*+N-RG+@<@
M
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MUL=2ZW5-8Z-V\UE34N>S*=[>2^DMF"&.GA9#!&R.)B(UK&)A&HG)$0#F
M   "LNDI[B^H_P!"+]ZTTO1']R"'X]4?:0W724]Q?4?Z$7[UII>B/[D$/QZH
M^T@%S@         #Q-TL?=F7XE3_ %N*O+0Z6/NS+\2I_K<5>>_TGVUC( !Z
MV  !0            1  %5A73\"GI/T@TA^*EE^)0?NT/S@NGX%/2?H_I#\5
M++\2@^PA\SU'[E=,?#;  X*
M
M
M
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M_=H?G!=/P*>D_1_2'XJ67XE!]A#YGJ/W*Z8^&V !P4
M
M                             QZ>NI:FHG@@J(I)H';LK&N17,7&>*>D
MU6M+\S3UAGJUPLZIU<#5]\]47'H[3SS3W"KIZ[PV"HDCJ]Y7=:U<*JKS-X8=
M48RSZ7J,%5:4VHHNY3ZB9NKP1*J)O#SN;_#Y"SZ.J@K:9D])*R:%Z9:]BY12
M7&X^5QRF7AW  RT    =554PTE.^>JE9%"Q,N>]<(@':8]374M+-!#4U$44L
M[MR)CG(BO7N1.TK35>U%C=^GTZQ'NY+4RM\7_I;V^DJ^IN%955WAM1422U2.
M1R2N7*HJ+E#ICQV^7/+DD\/48(_H:_,U!8(*E53PEB=7.WN>G;YEYD@,6:[-
MR[[@ (H
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M;JX5R-:J8;GO)+L5VYU.K=1KIO55NBH;N[>2%\#7-:YS4RYCFN55:["*H%\
M "LNDI[B^H_T(OWK32]$?W((?CU1]I#==)3W%]1_H1?O6FEZ(_N00_'JC[2
M7.          /$W2Q]V9?B5/];BKRT.EC[LR_$J?ZW%7GO\ 2?;6,@ 'K9
M                !A73\"GI/T@TA^*EE^)0?80_-^Z?@4])^D&D/Q4LOQ*#
M]VA\SU'[E=,?#;  X*
M
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M@ "                 # NUXM]H;3K<JN&G\(E2&%'NPLCUY-:G:IGC0
M           ,"*\6^6\S6F*KA?<88DFDIVNRYC%7"*J=F<H:^R:LMMYU!>+-
M1+-X9:G-;4;[,-R[.,+V\BZHWX (
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MZ-_X6Z?LD_B75=+?276W5%!<:=E31U#%CEBD3+7M7FBD.]9_9_\ FG:_V?\
M]P*5VO;=M,ZOV>W>QVV"O95U36(Q98T1O![7+E<]R*3[HC^Y!#\>J/M(:S;Q
MLWT?8ME5]N-GT[;Z2NA;'U<T4>'-S(U%POF4V?1']R"'X]4?:0"YP
M  !XFZ6/NS+\2I_K<5>6ATL?=F7XE3_6XJ\]WI/MK&0 #V,@
M      PKI^!3TGZ0:0_%2R_$H/L(?F_=/P*>D_2#2'XJ67XE!^[0^9ZC]RNF
M/AM@ <%
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M]T6T1-E%-CMJIOK0^;&.&T':ACX2B^J09S']4D\)%N  \[0
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MZH^T@%S@         #Q-TL?=F7XE3_6XJ\M#I8^[,OQ*G^MQ5Y[_ $GVUC(
M!ZV0         $  %  !   85T_ IZ3](-(?BI9?B4'V$/S?NGX%/2?I!I#\
M5++\2@^PA\SU'[E=<?#;  X*
M
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M1$D>KUR[GQ4^6#2ULL-TO%PMT<C:F[2MFJE=(KD<Y,XPB\O;*;P$ZJ  (
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M;BZ>JA9UCHI(7QNW<HF?&3EE4)J
M                                       JHB*JKA$[0(YKW4#=/V":
M=KD\+E3JX&YYN7M]',\[R/=)(Y\CE<]RJYRKS55YJ2?:)J)=07][H7JM%3YB
MA3/!>/%WI^I$(L>GCQZ8\V>6Z%B['M.^'7)UWJ6?Z/2.W8LIP=)CGZ.'I4@E
MJH)[G<(**D;O33.W6_Q]"'I6Q6N"S6JGH:5$2.)J)G'%R]KE\JDY,M32\>.[
MMG  \[T              4UMBT[X)<&WFF9]XJ51DR(G!LF."^E$^4N4PKU;
M8+O;*BAJV[T4S=U?(O8OH4UCETW;.6/5-/+Y]:JM<CFJJ.1<HJ<T4R[O;Y[5
M<JBAJDQ-"]6JO8O<J>13#/4\ST1L_P!0IJ&P1RR.3PR'[W.WRIR7TIQ)*>>-
MGVH5T]?XY97+X',G53IY.QWH7Z,GH=JHYJ*U45%XHJ=IYL\>FO1AEU0 !AL/
MCW-8U7/5&M:F555PB(?2O]O5;4T&RN^R4:N:]\21.<U<*C7+A?H^LUC.JR#J
MK-L^C*:KFA2NJ*B.%VY)44]+))"U?TT3"^@VFJM;6RCT+/?;=4OJZ::)S:>:
MCC67#U:NZJHG%,+SSR[3LV<V&U4&@+314E-3/I9*9KG^(BI*KDRJN[\JJ\RK
M]EK? :+:U9J152U4,\R4T>?%CRV1%1/0UOR'68XW>O9&'T;Z'3]RGAND\5SF
MU7B:>:JE:_J7(K\<'+P5<*GIR>B)'MC8Y\CD:QJ9<YRX1$[U*TZ-_N16;]*;
M]ZXS=O57/1;)]034CW,EZIC-YO-&N>U%^A5')^ODU^2=HZG;8]&+7/IFW&5T
M22=4M6VG>M.CLXXR8QCR\B';%]2V_3.SF^WBY+*M#'=9=Y\#.L5$5W!<)V>4
ML30NG[1ZV=IM[*.G=0U%OC65NXF'JZ-%<Y>]<KS(#L.L5)=-FFJ+$_#J.>MJ
MJ5KN>&\6H[T<%+.CILGX%STE;3U=OBK:>5KJ66-)6R9X*U4SDT-BUS8;SIJI
MO]/5K#:*=[XWU%2WJV^+C*IGFG'TE+6S6E;:-A=SLLKW>K]#6+8X43VSE>OB
MK^KO)_TH=FV"SS:9T+H'2U+3LGB?4L94PM=N,J94W5W7+Y7*O$3AF]7Y3:QZ
M3;+HRHJXX5KZB"*5VY'4STLD<+U[,/5,>E<%AL<U[4<Q4<U4RBHN45"C-3U&
ML;MI&LLM7LZMT%O6G=&UWAK42G1&\'M\7AN\_06'L>AN--LXLM/>7-=6PQNC
M<YLB2(K4>[=\9."^+@QGA)-Q6!M:AT]*NF_NFJ:Z#=N4:TG@J(N]-E,([*+X
MIN-2:\L&F[M';[W6>"S/IW52/>U=S<:N%X]_<G-2%=(3GHO_ )U#]:&OVBV^
MEN72 T9!70,G@\%>]8WIEJJUSE3*=O$UCA+)O\B8Z>VLZ3OMXBM=+6S0UDWX
M%M53OB27]%7)@A&MMHK+=MLLE.^6Z)::&&9M3310/5)95:]$<C4]NB93CR0R
M^D914U/!H^M@@BBJH[Q#&V5C41R-5%7&>[*)P,K5/^\GHS_EM1]F4UCCC]T]
MY43C4VN;#IFV4E;>JQ:=M6B+!"L;EFDRF<(Q./G[C$TKM)TUJ:XK;Z"LDBN&
M[O-IJN%T,CT_NHY./F3B0BT4\-ZZ26H/59K)_4N@C\#BE1'(S*,RYJ+V\5X^
M4X])>GAH+5IZ^43607BGND4<4\:(CW-5KE5N4XJG!/\ TIF<>.YC[U=KJ(KJ
M_7^G])U$-+=JMZULJ;S*:GB=-*J=ZM:G!/.2HIK66GM26O:74ZLT<VW7::2F
M;#56^=Z)+&B8PK>[.[SX=O,Y\>,RO<J?:/UWI_5TD\-EK5?50)F6FFC=%*Q.
M]6N3..*<4('L1D9#JW:?+,]K(V77><]RX1J(LF55>XZ-#ZFM=QVGQ+J+2M9I
MS64U,Z*-SGJD50Q,JO#AE>"\51?:\^!5=X;J.6X;2&V>&1]BANBSW5(7JV26
M-'N\1%1,XQO*OD.^/'YQ\>/^4V]&T.K['JVS7YM"^KDMM+%)%/5MA5K')A4=
MU;E]LN$7EY.\T^D-0:6T=LBMMRH*FNDTY$KF12S1[TR[TKDXHB)[Y5[.1L;1
M46:JV1NFTS%'#:G6V3JHF8\3Q%RUW]Y%SGRY*>N/'HBV]/\ XB?^*<9QPE[?
MDVM6X;9=%T-<^FEN,LC8W]7)414[WPL=W*]$Q\F2?457!74<-51S,GIIF(^.
M1BY:YJ\E12#7.P6NFV.5=%%04R4[;0KMWJTXN2+.\OESQSSR=71[>Z39%I]7
MN5RHR1J9[DD=@QECCT[Q658@ .2@
M                                                    "LNDI[B^
MH_T(OWK32]$?W((?CU1]I#==)3W%]1_H1?O6FEZ(_N00_'JC[2 7.
M   /$W2Q]V9?B5/];BKRT.EC[LR_$J?ZW%7GO])]M8R  >MD  0  4
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M*YSK="JJJY5?%0"9
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MGJNM*  R
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M\3*'X\W[#ST+L5]R;27_ "V'[*'GKI&_B90_'F_8>>A=BON3:2_Y;#]E )H
M
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M!+98Z&B:F.IB1J^?FOTE Z$M_JEJRVPJW>C;*DKT_NM7*_4>CSCRWV=>*>:
M XNP
M
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MI&_B90_'F_8>>A=BON3:2_Y;#]E )H
M                                 "L]JNE;A>;K05%II5F>YCHY5WD:
MC<*F%55\ZFGM>R>OFPZXUT-,G:R-O6.^7*(7(#<Y+)J,7"6[0JU[-+!1*CIH
MYJQZ<^O=P7T(B$KH+=1V^/JZ&E@IV=T3$;]1E S;;Y:DD\  (H
M        !C5UOHZ^/JZZE@J&=TK$=]9D@"%W39K8*U5=#'+1N7EU#L)\BHI$
M+ILGKH4<ZW5\52G8R1NX[Y<JA<8-S/*,7#&JQV5Z3N%GO5=57:F6%S(DCB7>
M1R.WERJHJ>9/E+. ,Y9=5W6L<>F:@ "*
M
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MA$/]M'^LA[O263&[K.3M!U^$0_VT?ZR'SPB'^VC_ %D/5UX_+&J[0=7A$/\
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M]0Q-YT<$[7.1._',D
M
M
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M                                               !\543F?4XH
M
M?-Y,X/H
M
M        KK:5LHM>O;W;+G<:VJIY:!,,;#C#O&1W'/F+%--==4V*TUD=)<[O
M14M3(N&Q2S(UR^@#<,;N,:U.2)@^G&-[)8VOC<U[')E'-7**AR
M                       %?[5]EULVD-MZ76LJJ;P-7*SJ,<=[&<Y\Q8!I
MKKJJPVFL927.[T-+4O\ :Q2S(UR^@#9T5.VEI(:=BJK8F(Q%7FJ(F#N.,4C)
M8VR1/:]CDRUS5RBIWHIR
M          !0 ,>2LIXUP^=C5\JG9'*R1,QO8]/(H'8          !\WF_E)
M\IJ[Y7+31]5#QFDY>1"+NJ58_*S2.7.."\E G<CVL8YR\D3*D7JM022R*VF5
M&,_*[S'AN$[HU9UJJQ4QAQI)V.A=A%7@OO0)%2WVHC=AVZ]GEYDAH*R.LC1T
M;D5<<6]Q7#*@V%NN,D,S7->L:IV?E 6""/OU%C"-@5W#BN>T^Q:AWG86F<B>
M<#?@P:6XPU"HB.5'KR:IFHN4 ^@
M  <7.:Q%<Y41.]0.0,9*VF5V$J(\]V3(:J+Q145.] /H          93&<I@
M^(YJ\G)\I&;W<%ED6*%RMAC]LY%YJ:F*L<Q_BRR*O?G@!,;G7,H:997\>Q/.
M1M]\J97*Y'HQ$7@TZ:V>:LI>KD>C\+E,\S2/>Z-RY5V/H EU#?GJYK:I&;JK
MC>3L)!#(V5B.8Y'-7DJ%:1U"IQ1,JG9WFZLEW=3N5'.5S%YL[@)H"/+J/BN*
M9<><[J>_-DQOPN;Y0-V#'IJJ.H15C=G'/R&0
M
M                               $7VGZA=I70-[O,6.NIJ=5BS^6OBM^
ME4/*>RK9!+M/TQ?M2W6[53;@Z5[:=<([K943+ED5>*HJJB<,'H7I+L>_8QJ!
M&9X)$JX3L21N30]$21B;(ERJ>)7SJ[R>U C/0]U36SPWK2UPF?*VAQ-3[[E7
MJV[VZYB>3/'TJ>DSR+T2V.DVLZEFC_ I339],R8/70
M              &GU@ZZLTO=%T[$DUW6G>E*USD:G6*F$7*\."\3RS9NC_6U
MFF;[?=H=UJ+5=FK(]G6/8]JX3._(]57>15SP14/751/%30NEJ)8XHF^V?(Y&
MHGG52I]L6S^3:Q;J-]BU/!3TM*V1N[%]^CG?GDY6NPB)CN4"%]#.^72ML]\M
M=6^66VT3HW4SGJJI&KL[S&JO9P1<=F?*>D#S?T5M7NIZVXZ$KK=24U51*][9
MZ9N%E<U=UZ/_ "E_O=IZ0
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MI%<M-$KTPY6HJIY3CAEE<M5USPQQX\,IYL[NT '5P
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ME4+(.7'EE=[=_48889:P\:  =7G
M
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MC3-M=2PK/,GWZ1$X=R&\..ZN]E%]!R
M
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M;^"21+PSW*B\47R*!LP1[66L[!HVA;5ZDN45%$]<,145SWKY&M154KF#I)Z
MEJTA=-<XH\XZ]](NYY^"J[Z +G!J]-Z@M6I;9'<+%70UM&_E)&OT*B\47R*:
MN;7FGX-:QZ3J*UT5\D8CXX7PO1KT5,INOQNKPSV]@$H
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M5XHI$VU=KL5';VHL;.LE_+>F3:(W"87CY3ZB)D^@
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M1M8B<W8XKZ3+1#ZF$Y
M
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M%-]$V:279'3MDSNQ54S&97LRB_YER
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M5GFM[)73N7K<^*B+PQYCG+9Y;RQQGA(6=O')].+,\<G(Z3NY
M
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M5$T7A,K5YHY_'ZL%AGQC48QK6(B-:F$1.Q#Z
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M?%133/AQQCR^@Y)YCZG( ?.T^@
M   &>(      /FZF<X/H (G,XJQ%]LB*G<J'(<0.E]/!N.18F;J\_%3B:FLL
MK<*^C7<SS:O%#><3YQQW E0"XL6FD:R1BM5>33=6"\1)&RFG<C<<&.7DOD4R
M-1VF>XOIE@5OBNP]57&&FF=I6K;),V*5.K:N8L^^\YBY6.LQQRGE-,I[;.$/
MJ<5XH1S3]MNE(KNOF1L:*GWMR[V?225#4NV+)!$P<=U>/'S'(^84K+XG!>2?
M(<DY #8)V@
M
M
M                                             A&N?QTT'\>G_P##
MO)N0C7/XZ:#^/3_^'>3<Z9?;C_WWJ0 !S4
M
M
M
M
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MCCR7EDLQM\"5@ZZ>3KJ>*56JW?:CMU>:93D=A
M
M
M
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M6QN1?J-GTF/Q8T__ ,Y@^IY9)O''7D6^ #RM
M
M
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MM])6P35M#CPF%CLNBSRWD[!8KW;;]1+66:MAK:5'K'UL+MYN\G-/I0;R\JV
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MBIE%'?R/H ( !A+=:%+NEJ6JB2XK#UZ4ZN\=8\XWL=V0,T
M
M
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M'$>FR_3/6YWO H^?=C@3$XY35L4 !
M
M
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MDCSG=SW9&.>K-^R:?;1;X+5:J.WTC=VGI8FPQI_=:F$^HRP#"@
M
M
@                                        _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
